{"studies": [{"protocolSection": {"identificationModule": {"nctId": "NCT07000786", "orgStudyIdInfo": {"id": "EUmetriosis"}, "organization": {"fullName": "Université Catholique de Louvain", "class": "OTHER"}, "briefTitle": "EUmetriosis: Insights Into the Pathogenesis of Endometriosis", "officialTitle": "EUmetriosis: Insights Into the Pathogenesis of Endometriosis", "acronym": "EUmetriosis"}, "statusModule": {"statusVerifiedDate": "2025-06", "overallStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2025-05-12", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2029-12-31", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2029-12-31", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2025-05-12", "studyFirstSubmitQcDate": "2025-06-02", "studyFirstPostDateStruct": {"date": "2025-06-03", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2025-06-02", "lastUpdatePostDateStruct": {"date": "2025-06-03", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Université Catholique de Louvain", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "This study investigates epigenetic changes in menstrual effluent and plasma from women with endometriosis to identify potential non-invasive diagnostic biomarkers for the disease."}, "conditionsModule": {"conditions": ["Endometriosis"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "DIAGNOSTIC", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 60, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Epigenetics characterization", "type": "EXPERIMENTAL", "interventionNames": ["Procedure: Endometrial biopsy or menstrual cup and blood sample"]}], "interventions": [{"type": "PROCEDURE", "name": "Endometrial biopsy or menstrual cup and blood sample", "description": "Enrolled patients will give their menstrual effluent either via a menstrual cup or via a pipelle biopsy. They will also undergo a blood draw.", "armGroupLabels": ["Epigenetics characterization"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Epigenetic analysis", "description": "Histone post-translational modifications", "timeFrame": "Throughout the entire study, approximately during 3,5 years"}, {"measure": "Epigenetic analysis", "description": "miRNA", "timeFrame": "Throughout the entire study, approximately during 3,5 years"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Premenopausal\n* In spontaneous menstrual cycle (no hormonal treatments for the last 3 months)\n* Healthy or with a clear diagnosis of endometriosis via ultrasound, MRI or laparoscopy\n\nExclusion Criteria:\n\n* HIV or Hepatitis positive\n* Pregnancy", "healthyVolunteers": true, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "56 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Marie-Madeleine Dolmans, MD, PhD", "role": "CONTACT", "phone": "+32 (0)2 764 5287", "email": "marie-madeleine.dolmans@uclouvain.be"}], "locations": [{"facility": "Cliniques universitaires Saint-Luc", "status": "RECRUITING", "city": "Brussels", "zip": "1200", "country": "Belgium", "contacts": [{"name": "Marie-Madeleine Dolmans, MD, PhD", "role": "CONTACT", "phone": "+32 (0)2 764 5287", "email": "marie-madeleine.dolmans@uclouvain.be"}, {"name": "Marie-Madeleine Dolmans, MD, PhD", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 50.85045, "lon": 4.34878}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D052576", "term": "Menstrual Hygiene Products"}, {"id": "D001800", "term": "Blood Specimen Collection"}], "ancestors": [{"id": "D053566", "term": "Feminine Hygiene Products"}, {"id": "D004864", "term": "Equipment and Supplies"}, {"id": "D013048", "term": "Specimen Handling"}, {"id": "D019411", "term": "Clinical Laboratory Techniques"}, {"id": "D019937", "term": "Diagnostic Techniques and Procedures"}, {"id": "D003933", "term": "Diagnosis"}, {"id": "D011677", "term": "Punctures"}, {"id": "D013514", "term": "Surgical Procedures, Operative"}, {"id": "D008919", "term": "Investigative Techniques"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT04319653", "orgStudyIdInfo": {"id": "2018_28"}, "secondaryIdInfos": [{"id": "2019-A00560-57", "type": "OTHER", "domain": "ID-RCB number, ANSM"}], "organization": {"fullName": "University Hospital, Lille", "class": "OTHER"}, "briefTitle": "Development of a Pelvic Cavity Characterization Algorithm Through the Acquisition of MRI Images and Pressure Measurement by an Intravaginal Probe", "officialTitle": "Development of a Pelvic Cavity Characterization Algorithm Through the Acquisition of MRI Images and Pressure Measurement by an Intravaginal Probe", "acronym": "MI-IRM"}, "statusModule": {"statusVerifiedDate": "2022-03", "overallStatus": "UNKNOWN", "lastKnownStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2021-04-13", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2024-04", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2024-04", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2020-03-20", "studyFirstSubmitQcDate": "2020-03-23", "studyFirstPostDateStruct": {"date": "2020-03-24", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2022-03-01", "lastUpdatePostDateStruct": {"date": "2022-03-02", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "University Hospital, Lille", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The conditions such as childbirth or endometriosis can lead to a change in the mobility of the pelvic organs (bladder, vagina, rectum and uterus). The purpose of the study is to study in a personalized way each woman the characteristics of the tissues of their pelvis and to be able to personalize the treatments (surgery, injection, rehabilitation, etc.). Women requiring pelvic MRI may participate in the study. The pelvic dynamic MRI will be done with an intravaginal probe which will be inserted by the patient herself as well as gel in the anus and vagina which will allow to obtain the data on the characteristics of the pelvic tissues of each woman with a 3D reconstruction."}, "conditionsModule": {"conditions": ["Pelvic Floor Disorders"], "keywords": ["Geometrical reconstruction", "Pelvic Floor Disorders", "FE models", "Pelvic system", "MRI"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "DIAGNOSTIC", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 50, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Dynamic pelvic MRI", "type": "EXPERIMENTAL", "interventionNames": ["Device: Dynamic pelvic MRI with intravaginal probe with pressure sensor"]}], "interventions": [{"type": "DEVICE", "name": "Dynamic pelvic MRI with intravaginal probe with pressure sensor", "description": "Dynamic pelvic MRI with intravaginal probe and intravaginal and intrarectal opacification gel", "armGroupLabels": ["Dynamic pelvic MRI"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "3D reconstruction of the pelvic cavity", "description": "Characterization of the pelvic cavity through a double assessment: a pelvic MRI sequence and an intravaginal pressure probe.", "timeFrame": "at 1 month"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\nAll:\n\n* Understanding of the French language\n* Signature of informed consent\n* Insured social patient\n\nFor pregnant women:\n\n* Primiparous women\n* with no severe maternal-fetal pathology\n* with no scheduled caesarean section at the time of the MRI\n\nFor women with prolapse:\n\n\\- Requires pelvic MRI\n\nExclusion Criteria:\n\n* Minor\n* Person who does not have social security\n* Person with ongoing vaginal infection\n* Pregnant woman during the first or third trimester of pregnancy\n* Pregnant woman with broken water pocket\n* Bi-cicatricial uterus\n* IVF\n* Person wearing a pace maker or any intra-body metal implant (if \"tube\" MRI)\n* Claustrophobic person (if \"tube\" MRI)", "healthyVolunteers": false, "sex": "FEMALE", "genderBased": true, "genderDescription": "The recruitment of patients will be done during a consultation within the Obstetric Gynecology Department CHU of Lille to select those requiring a pelvic MRI.", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Michel COSSON, MD,PhD", "role": "CONTACT", "phone": "03 20 44 65 84", "phoneExt": "+33", "email": "michel.cosson@chru-lille.fr"}], "overallOfficials": [{"name": "Michel COSSON, MD,PhD", "affiliation": "University Hospital, Lille", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Hôpital Jeanne de Flandres, CHU", "status": "RECRUITING", "city": "Lille", "country": "France", "contacts": [{"name": "Michel Cosson, MD,PhD", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 50.63391, "lon": 3.05512}}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D059952", "term": "Pelvic Floor Disorders"}], "ancestors": [{"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D011248", "term": "Pregnancy Complications"}, {"id": "D052801", "term": "Male Urogenital Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT01833013", "orgStudyIdInfo": {"id": "9113"}, "organization": {"fullName": "University Hospital, Montpellier", "class": "OTHER"}, "briefTitle": "Infertility and Endometriosis Cohort", "officialTitle": "Infertility and Endometriosis : a Prospective Cohort Study", "acronym": "EndoFertil"}, "statusModule": {"statusVerifiedDate": "2013-04", "overallStatus": "UNKNOWN", "lastKnownStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2013-04"}, "primaryCompletionDateStruct": {"date": "2018-04", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2018-10", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2013-04-11", "studyFirstSubmitQcDate": "2013-04-11", "studyFirstPostDateStruct": {"date": "2013-04-16", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-01-08", "lastUpdatePostDateStruct": {"date": "2015-01-09", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "University Hospital, Montpellier", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "Nowadays, one in six couples consults for fertility problems. If the standard examination and tests do not reveal any cause of infertility, the woman may undergo a laparoscopic exploration which reveals endometriosis in more than 50% of cases.\n\nEndometriosis is an inflammatory disease defined as the presence of endometrial tissue out of the uterine cavity. It is frequent (1 in 10 women) and associated with a high economic burden (22 billion dollars in 2002 in the USA) and important decrease in quality of life. Physiopathological mechanisms and risk factors for endometriosis are not well identified.\n\nA woman with endometriosis is 20 times more at risk of infertility. Fecundity rate of a 25-year-old couple is about 15 to 20% in the general population and only 2 to 10% in case of endometriosis.\n\nThere are many manifestations of this disease (infertility, pelvic pain) and the anatomo-clinical correlation is not good. The presently used international classification (American Fertility Society revised in 1985, AFSr) does not predict the chance of pregnancy. New scores such as the Endometriosis Fertility Index (EFI) have been proposed to do so, but need to be validated. Treatment for endometriosis-related infertility is not consensual.\n\nA prospective cohort study would give access to clinical data of patients followed in our center, so as to identify clinical factors predicting pregnancy and to help treatment decision for women with endometriosis suffering from infertility."}, "conditionsModule": {"conditions": ["Endometriosis", "Infertility"], "keywords": ["Endometriosis", "Cohort study", "fertility", "pregnancy", "assisted reproductive technics", "laparoscopy"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 200, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "endometriosis cohort", "type": "OTHER", "description": "females suffer from endometriosis", "interventionNames": ["Other: live birth date and quality of life assessment"]}], "interventions": [{"type": "OTHER", "name": "live birth date and quality of life assessment", "armGroupLabels": ["endometriosis cohort"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "live birth date", "description": "Assessment of the number of live birth in the 3 years following the laparoscopic exploration making the diagnosis of endometriosis", "timeFrame": "3 years"}], "secondaryOutcomes": [{"measure": "Quality of life", "description": "Assessment of the quality of life relating to infertility and endometriosis in the 3 years following laparoscopic exploration making the diagnosis of endometriosis.", "timeFrame": "3 years"}, {"measure": "pain symptoms", "description": "Assessment of the pain symptoms relating to infertility and endometriosis in the 3 years following laparoscopic exploration making the diagnosis of endometriosis.", "timeFrame": "3 years"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion criteria:\n\n* Woman from 18 to 41 years old.\n* Dealing with infertility,\n* With a normal pelvic echography and hysterosalpingography, a normal hormonal status and a partner with a normal sperm.\n* For whom a laparoscopic exploration finds endometriosis.\n* Consenting to participate to the study.\n\nExclusion criteria:\n\n* Any contraindication for general anesthesia or for laparoscopy.\n* Any contraindication for pregnancy.\n* Follow-up is impossible.\n* Consent is impossible.", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "41 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Herve Dechaud, MD,PhD", "role": "CONTACT", "phone": "+33467336532", "email": "h-dechaud@chu-montpellier.fr"}, {"name": "claire chauveton, pharmD", "role": "CONTACT", "phone": "+33467330924", "email": "c-chauveton@chu-montpellier.fr"}], "overallOfficials": [{"name": "Herve Dechaud, MD,PhD", "affiliation": "University Hospital, Montpellier", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "University Hospital Montpellier", "status": "RECRUITING", "city": "Montpellier", "state": "Herault", "zip": "34295", "country": "France", "contacts": [{"name": "Herve Dechaud, MD,PhD", "role": "CONTACT", "phone": "+33467336532", "email": "h-dechaud@chu-montpellier.fr"}, {"name": "claire chauveton, PharmD", "role": "CONTACT", "phone": "+33467330924", "email": "c-chauveton@chu-montpellier.fr"}, {"name": "Herve Dechaud, MD,PhD", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 43.61093, "lon": 3.87635}}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}, {"id": "D007246", "term": "Infertility"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT05013242", "orgStudyIdInfo": {"id": "MS.19.09.791.R1"}, "organization": {"fullName": "Mansoura University", "class": "OTHER"}, "briefTitle": "Goserline Acetate VS Dienogest in Endometriosi", "officialTitle": "Goserline Acetate Versus Dienogest in Treatment of Pain Associated With Endometriosis"}, "statusModule": {"statusVerifiedDate": "2021-08", "overallStatus": "UNKNOWN", "lastKnownStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2020-12-25", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2021-11-25", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2021-12-25", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2021-04-20", "studyFirstSubmitQcDate": "2021-08-18", "studyFirstPostDateStruct": {"date": "2021-08-19", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2021-10-12", "lastUpdatePostDateStruct": {"date": "2021-10-20", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Mansoura University", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false, "isUsExport": false}, "descriptionModule": {"briefSummary": "clinical trial aims to evaluate efficacy of dienogest (DNG) in comparison to goserline acetate in complete 12 week treatment of pain in women suffer from chronic pelvic pain diagnosed as endometriosis by laparoscopy and histopathology.", "detailedDescription": "The study will be a clinical trial study of 12-week trial of GnRH (zoladex 3.75mg) injection once every 4 weeks and Visanne (dienogest 2mg) oral once daily for 12 weeks in patients confirmed endometriosis by laparoscopic surgery.\n\nPretreatment assessment, the patients will be questioned about their pelvic symptoms (dysmenorrhea, nonmenstrual pelvic pain, and deep dyspareunia) after taking full history and examination , The study will investigate and evaluate possible early, long side effects and efficacy of treatment to controlling the pain."}, "conditionsModule": {"conditions": ["Endometriosis"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "SINGLE", "whoMasked": ["INVESTIGATOR"]}}, "enrollmentInfo": {"count": 40, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "group use GnRH", "type": "ACTIVE_COMPARATOR", "description": "GnRH (zoladex 3.75mg) injection once every 4 weeks", "interventionNames": ["Drug: Zoladex"]}, {"label": "Group use Visanne (dienogest 2mg) oral once daily for 12 weeks", "type": "ACTIVE_COMPARATOR", "description": "Visanne (dienogest 2mg) oral once daily for 12 weeks", "interventionNames": ["Drug: Visanne"]}], "interventions": [{"type": "DRUG", "name": "Zoladex", "description": "evaluate efficacy of Zoladex in complete 12 week treatment of pain in women suffer from chronic pelvic pain diagnosed as endometriosis", "armGroupLabels": ["group use GnRH"], "otherNames": ["Gnrh"]}, {"type": "DRUG", "name": "Visanne", "description": "valuate efficacy of Dienogest in complete 12 week treatment of pain in women suffer from chronic pelvic pain diagnosed as endometriosis", "armGroupLabels": ["Group use Visanne (dienogest 2mg) oral once daily for 12 weeks"], "otherNames": ["Dienogest"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "number of patients with pain symptoms reduction", "description": "number of patients with endometriosis-associated pain symptoms reduction", "timeFrame": "12 week"}], "secondaryOutcomes": [{"measure": "assessment change in pain severity", "description": "pain severity assessment after treatment by visual analogue scale as determined by measuring the distance (mm) on the 10-cm line between the \"no pain\" anchor and the patient's mark providing a range of scores from 0-100", "timeFrame": "12 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Non pregnant women confirmed to have endometriosis by histopathology and not received any hormonal treatment yet. Also, medical treatment was the proper choice for treatment of each case.\n\nExclusion Criteria:\n\n* Women suspect pregnancy.\n* Breast feeding women.\n* Previous use of hormonal agents (progestin less than 6 months, danazol less than 3 month, oral contraceptive pills less than 1 month before screening).\n* Women with other gynecological pathology interfere with treatment we will use.\n* Using of corticosteroids.\n* Family history of osteoporosis.", "healthyVolunteers": true, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "45 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "safaa M ismael, resident", "role": "CONTACT", "phone": "00201281857175", "email": "roses_lover_2007@hotmail.com"}, {"name": "alaa mosbah, prosfeesor", "role": "CONTACT", "email": "alaamosbah@hotmail.com"}], "overallOfficials": [{"name": "Alaa Mosbah", "affiliation": "Mansoura university faculity of medicine , obstetric and gyneclogy department", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Mansoura University", "status": "RECRUITING", "city": "Al Mansurah", "state": "Dakahlia Governorate", "zip": "35111", "country": "Egypt", "geoPoint": {"lat": 31.03637, "lon": 31.38069}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D017273", "term": "Goserelin"}, {"id": "D007987", "term": "Gonadotropin-Releasing Hormone"}, {"id": "C023635", "term": "dienogest"}], "ancestors": [{"id": "D010906", "term": "Pituitary Hormone-Releasing Hormones"}, {"id": "D007028", "term": "Hypothalamic Hormones"}, {"id": "D036361", "term": "Peptide Hormones"}, {"id": "D006728", "term": "Hormones"}, {"id": "D006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D009479", "term": "Neuropeptides"}, {"id": "D010455", "term": "Peptides"}, {"id": "D000602", "term": "Amino Acids, Peptides, and Proteins"}, {"id": "D009842", "term": "Oligopeptides"}, {"id": "D009419", "term": "Nerve Tissue Proteins"}, {"id": "D011506", "term": "Proteins"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT05024227", "orgStudyIdInfo": {"id": "CHGH-IRB:(864)110-10"}, "organization": {"fullName": "National Taipei University of Nursing and Health Sciences", "class": "OTHER"}, "briefTitle": "The Effect of Nursing Education Intervention on Women's Health Literacy of Plasticizers", "officialTitle": "Discussion on the Effect of Nursing Education Intervention on Women's Health Literacy of Plasticizers"}, "statusModule": {"statusVerifiedDate": "2022-02", "overallStatus": "UNKNOWN", "lastKnownStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2021-09-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2022-05-30", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2022-07-01", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2021-08-23", "studyFirstSubmitQcDate": "2021-08-23", "studyFirstPostDateStruct": {"date": "2021-08-27", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2022-02-17", "lastUpdatePostDateStruct": {"date": "2022-02-21", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Chia Jung Hsieh", "investigatorTitle": "PhD, RN, Associate Professor", "investigatorAffiliation": "National Taipei University of Nursing and Health Sciences"}, "leadSponsor": {"name": "National Taipei University of Nursing and Health Sciences", "class": "OTHER"}, "collaborators": [{"name": "Cheng-Hsin General Hospital", "class": "OTHER"}]}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "Environmental hormone (environmental hormone), also known as \"endocrine disrupting chemicals\" (EDCS), is a pollutant that affects the endocrine system and causes diseases and dysfunction throughout the life cycle. Many daily products are ubiquitous, and the most common are phthalates (plasticizers); in recent years, many scientific research reports have determined the adverse health effects of phthalates, including: Infertility (Den Hond et al. al., 2015), testicular hypoplasia (Fisher, 2004), obesity (Dirtu et al., 2013), diabetes (Fénichel \\& Chevalier, 2017), hyperglycemia (Williams et al., 2016), asthma (Wang et al., 2016) al., 2015), endometriosis and high abortion rate (Roy et al., 2015), polycystic ovary syndrome (Vagi et al., 2014), prostate cancer (Chuang et al., 2020), and Breast cancer (Chen et al., 2020; Fu et al., 2017; Holmes et al., 2014; López-Carrillo et al., 2010), etc. In 2011, the Taiwan Food and Drug Administration detected di（2-ethylhexyl）phthalate (DEHP) and dibutyl phthalate (DBP) in foods, food supplements, and beverages, and determined that the Taiwanese population has a high content of phthalates (Yang et al., 2013). It pointed out that exposure to plasticizers in the uterus will have lifelong effects and even endanger the health of the next generation, indicating that there is a significant positive correlation between the concentration of metabolites in the urine of pregnant women and the urine of their children (Lin et al., 2011; Wu et al., 2013), even related to children's autism (Carter \\& Blizard, 2016; Rossignol et al., 2014).\n\nHowever, so far there is still a lack of research on environmental hormone-plasticizers to improve health literacy or develop interventional research. Therefore, this study hopes to track the health literacy of their plasticizers and provide nursing education interventions (including e-health platform assistance) for women. Randomized controlled trials (English: randomized controlled trial, RCT) will be used to test nursing education interventions using a double-blind trial system. (Including e-health platform assistance) Effectiveness, in order to provide simple and fast self-health monitoring and management for the people, and it is expected that the case can early prevent the occurrence of related diseases and ensure the safety of the living environment.", "detailedDescription": "Environmental hormone (environmental hormone), also known as \"endocrine disrupting chemicals\" (EDCS), is a pollutant that affects the endocrine system and causes diseases and dysfunction throughout the life cycle. Many daily products are ubiquitous, and the most common are phthalates (plasticizers); in recent years, many scientific research reports have determined the adverse health effects of phthalates, including: Infertility (Den Hond et al. al., 2015), testicular hypoplasia (Fisher, 2004), obesity (Dirtu et al., 2013), diabetes (Fénichel \\& Chevalier, 2017), hyperglycemia (Williams et al., 2016), asthma (Wang et al., 2016) al., 2015), endometriosis and high abortion rate (Roy et al., 2015), polycystic ovary syndrome (Vagi et al., 2014), prostate cancer (Chuang et al., 2020), and Breast cancer (Chen et al., 2020; Fu et al., 2017; Holmes et al., 2014; López-Carrillo et al., 2010), etc. In 2011, the Taiwan Food and Drug Administration detected DEHP and DBP in foods, food supplements, and beverages, and determined that the Taiwanese population has a high content of phthalates (Yang et al., 2013). It pointed out that exposure to plasticizers in the uterus will have lifelong effects and even endanger the health of the next generation, indicating that there is a significant positive correlation between the concentration of metabolites in the urine of pregnant women and the urine of their children (Lin et al., 2011; Wu et al., 2013), even related to children's autism (Carter \\& Blizard, 2016; Rossignol et al., 2014).\n\nHealth literacy is an important factor in determining public and personal health, and is regarded as the core of patient-centered care. Relevant studies have indicated that a lack of health literacy has the following results: higher mortality, poor self-management skills, lower satisfaction with medical and disease communication, poor awareness of diseases, higher hospitalization and emergency medical use rates, easier incorrect medication, low utilization of preventive health care services (such as screening), high prevalence of chronic diseases (such as cardiovascular disease, diabetes, and obesity, etc.), and high health care costs (Berkman, Sheridan, Donahue, Halpern, \\& Crotty, 2011; Berkman, Sheridan, Donahue, Halpern, Viera, et al., 2011; DeWalt et al., 2004). However, so far there is still a lack of research on environmental hormone-plasticizers to improve health literacy or develop interventional research. Therefore, this study hopes to track the health literacy of their plasticizers and provide nursing education interventions (including e-health platform assistance) for women. Randomized controlled trials (RCT) will be used to test nursing education interventions using a double-blind trial system. (Including e-health platform assistance) Effectiveness, in order to provide simple and fast self-health monitoring and management for the people, and it is expected that the case can early prevent the occurrence of related diseases and ensure the safety of the living environment."}, "conditionsModule": {"conditions": ["Endocrine Disrupting Chemicals", "Health Literacy"], "keywords": ["nursing education intervention", "health literacy", "plasticizers"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "PREVENTION", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 100, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Experimental: nursing education interventions", "type": "EXPERIMENTAL", "description": "nursing education interventions (including e-health platform assistance)", "interventionNames": ["Behavioral: Experimental: nursing education interventions (including e-health platform assistance)"]}, {"label": "No Intervention: Routine care", "type": "NO_INTERVENTION", "description": "Only the original form of nursing education leaflets are given"}], "interventions": [{"type": "BEHAVIORAL", "name": "Experimental: nursing education interventions (including e-health platform assistance)", "description": "Nursing education intervention: Researchers use teaching, consultation and other methods to give individual cases planned learning to meet individual needs, providing 1. What is an environmental hormone-plasticizer; 2. Common types of environmental hormones (such as plasticizers) and Uses 3. Environmental hormones-sources of plasticizers 4. Environmental hormones-plasticizers harm to the human body 5. How to avoid the common environmental hormones-plasticizers and other related health education in life, and use the electronic platform to assist nursing education conduct.", "armGroupLabels": ["Experimental: nursing education interventions"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Basic Demographic Health Assessment Form", "description": "Number, age, gender, marriage, current living area, height, weight, blood pressure, pulse, waist circumference, BMI, education level, past medical history, work-related, living habits, weight control, eating habits; B. Emotional state; C. Female Related questions: menstrual history, fertility status, medication, supplement status, disease history, etc.", "timeFrame": "baseline, pre-intervention(T0)"}, {"measure": ".The Environmental Hormone-Plasticizer Health Literacy Scale", "description": "It is divided into three areas of environmental hormone health literacy: Health care, Disease prevention and Health promotion. The answers are based on a Likert 4-point scale, ranging from \"very difficult\" (1) to \"very easy\" (4). A higher total score, indicates better environmental hormone-plasticizer health literacy. The total score range is 0-40.", "timeFrame": "baseline, pre-intervention(T0)"}, {"measure": "The Environmental Hormone-Plasticizer Health Literacy Scale", "description": "It is divided into three areas of environmental hormone health literacy: Health care, Disease prevention and Health promotion. The answers are based on a Likert 4-point scale, ranging from \"very difficult\" (1) to \"very easy\" (4). A higher total score, indicates better environmental hormone-plasticizer health literacy. The total score range is 0-40.", "timeFrame": "three month after intervention(T1)"}, {"measure": "The Environmental Hormone-Plasticizer Health Literacy Scale", "description": "It is divided into three areas of environmental hormone health literacy: Health care, Disease prevention and Health promotion. The answers are based on a Likert 4-point scale, ranging from \"very difficult\" (1) to \"very easy\" (4). A higher total score, indicates better environmental hormone-plasticizer health literacy. The total score range is 0-40.", "timeFrame": "six month after intervention(T2)"}], "secondaryOutcomes": [{"measure": "The System Usability Scale", "description": "System Usability Scale ( SUS) has ten items, created by John Brooke in 1986 (Brooke, 1986), and is widely used to quickly test standardized questionnaires (objectivity, universality, Repeatable and quantifiable) (Brooke, 2013). Using Likert's five-point scale, questions 1, 3, 5, 7, and 9 are positive questions, and questions 2, 4, 6, 8, and 10 are negative questions. After calculating the scores for each question, multiply all the scores by 2.5 to get the total score.", "timeFrame": "six month after intervention(T2)] for Experimental arm"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* (1) Females who are 20 years or older (inclusive); (2) Clear consciousness and no mental disorders; (3) Those who can communicate with others in Mandarin or Taiwanese, are willing to participate in this research after explanation, and sign the consent form.\n\nExclusion Criteria:\n\n* (1) Diagnosed with mental illness, (2) Cognitive impairment, (3) Under 20 years old, (4) Male.", "healthyVolunteers": true, "sex": "FEMALE", "genderBased": true, "minimumAge": "20 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Chia-Jung Hsieh, PhD", "role": "CONTACT", "phone": "+886(2)2822-7101", "phoneExt": "3135", "email": "chiajung@ntunhs.edu.tw"}, {"name": "Ya-Ling Shih, master", "role": "CONTACT", "phone": "+886 968498086", "email": "tiffanysyl@yahoo.com.tw"}], "overallOfficials": [{"name": "Chia-Jung Hsieh, PhD", "affiliation": "National Taipei University of Nursing and Health Sciences", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Cheng Hsin General Hospital", "status": "RECRUITING", "city": "Taipei", "state": "Taipei City", "zip": "11219", "country": "Taiwan", "contacts": [{"name": "Chia-Jung Hsieh, PhD", "role": "CONTACT", "phone": "0228227101", "phoneExt": "3135", "email": "chiajung@ntunhs.edu.tw"}, {"name": "Ya-Ling Shih, master", "role": "CONTACT", "phone": "+886 968498086", "email": "tiffanysyl@yahoo.com.tw"}], "geoPoint": {"lat": 25.05306, "lon": 121.52639}}]}, "referencesModule": {"references": [{"pmid": "31785779", "type": "BACKGROUND", "citation": "Chuang SC, Chen HC, Sun CW, Chen YA, Wang YH, Chiang CJ, Chen CC, Wang SL, Chen CJ, Hsiung CA. Phthalate exposure and prostate cancer in a population-based nested case-control study. Environ Res. 2020 Feb;181:108902. doi: 10.1016/j.envres.2019.108902. Epub 2019 Nov 8."}, {"pmid": "25493439", "type": "BACKGROUND", "citation": "Den Hond E, Govarts E, Willems H, Smolders R, Casteleyn L, Kolossa-Gehring M, Schwedler G, Seiwert M, Fiddicke U, Castano A, Esteban M, Angerer J, Koch HM, Schindler BK, Sepai O, Exley K, Bloemen L, Horvat M, Knudsen LE, Joas A, Joas R, Biot P, Aerts D, Koppen G, Katsonouri A, Hadjipanayis A, Krskova A, Maly M, Morck TA, Rudnai P, Kozepesy S, Mulcahy M, Mannion R, Gutleb AC, Fischer ME, Ligocka D, Jakubowski M, Reis MF, Namorado S, Gurzau AE, Lupsa IR, Halzlova K, Jajcaj M, Mazej D, Tratnik JS, Lopez A, Lopez E, Berglund M, Larsson K, Lehmann A, Crettaz P, Schoeters G. First steps toward harmonized human biomonitoring in Europe: demonstration project to perform human biomonitoring on a European scale. Environ Health Perspect. 2015 Mar;123(3):255-63. doi: 10.1289/ehp.1408616. Epub 2014 Dec 11."}, {"pmid": "15016950", "type": "BACKGROUND", "citation": "Fisher JS. Environmental anti-androgens and male reproductive health: focus on phthalates and testicular dysgenesis syndrome. Reproduction. 2004 Mar;127(3):305-15. doi: 10.1530/rep.1.00025."}, {"pmid": "28951174", "type": "BACKGROUND", "citation": "Fu Z, Zhao F, Chen K, Xu J, Li P, Xia D, Wu Y. Association between urinary phthalate metabolites and risk of breast cancer and uterine leiomyoma. Reprod Toxicol. 2017 Dec;74:134-142. doi: 10.1016/j.reprotox.2017.09.009. Epub 2017 Sep 23."}, {"pmid": "24916567", "type": "BACKGROUND", "citation": "Jacobs RJ, Lou JQ, Ownby RL, Caballero J. A systematic review of eHealth interventions to improve health literacy. Health Informatics J. 2016 Jun;22(2):81-98. doi: 10.1177/1460458214534092. Epub 2014 Jun 10."}, {"pmid": "25960783", "type": "BACKGROUND", "citation": "Wang IJ, Karmaus WJ, Chen SL, Holloway JW, Ewart S. Effects of phthalate exposure on asthma may be mediated through alterations in DNA methylation. Clin Epigenetics. 2015 Mar 15;7(1):27. doi: 10.1186/s13148-015-0060-x. eCollection 2015."}, {"pmid": "27100621", "type": "BACKGROUND", "citation": "Williams MJ, Wiemerslage L, Gohel P, Kheder S, Kothegala LV, Schioth HB. Dibutyl Phthalate Exposure Disrupts Evolutionarily Conserved Insulin and Glucagon-Like Signaling in Drosophila Males. Endocrinology. 2016 Jun;157(6):2309-21. doi: 10.1210/en.2015-2006. Epub 2016 Apr 21."}, {"pmid": "28800814", "type": "BACKGROUND", "citation": "Benjamin S, Masai E, Kamimura N, Takahashi K, Anderson RC, Faisal PA. Phthalates impact human health: Epidemiological evidences and plausible mechanism of action. J Hazard Mater. 2017 Oct 15;340:360-383. doi: 10.1016/j.jhazmat.2017.06.036. Epub 2017 Jun 19."}, {"pmid": "24952638", "type": "BACKGROUND", "citation": "Sharma S, Ashley JM, Hodgson A, Nisker J. Views of pregnant women and clinicians regarding discussion of exposure to phthalate plasticizers. Reprod Health. 2014 Jun 21;11:47. doi: 10.1186/1742-4755-11-47."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT00073801", "orgStudyIdInfo": {"id": "040056"}, "secondaryIdInfos": [{"id": "04-N-0056"}], "organization": {"fullName": "National Institutes of Health Clinical Center (CC)", "class": "NIH"}, "briefTitle": "Pelvic Pain in Women With Endometriosis", "officialTitle": "The Neural Immune Mechanisms and Genetic Influences on Chronic Pelvic Pain in Women With Endometriosis"}, "statusModule": {"statusVerifiedDate": "2025-02-28", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2004-04-22", "type": "ACTUAL"}, "studyFirstSubmitDate": "2003-12-08", "studyFirstSubmitQcDate": "2003-12-08", "studyFirstPostDateStruct": {"date": "2003-12-09", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2025-10-04", "lastUpdatePostDateStruct": {"date": "2025-10-07", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "National Institute of Neurological Disorders and Stroke (NINDS)", "class": "NIH"}}, "oversightModule": {"isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "This study will examine pelvic pain associated with endometriosis and explore better approaches to treatment. In women with endometriosis, uterine tissue grows outside the uterus. Standard treatments - altering hormone levels to prevent endometrial tissue growth or surgically removing endometrial tissue - treat pelvic pain only temporarily. This study will investigate the role of sex hormones, immune chemicals, stress hormones, and genes in pelvic pain and determine how the nerve, muscle, and skeletal systems are involved in this pain.\n\nWomen between 18 and 50 years of age who:\n\n1. have endometriosis and chronic pelvic pain, and\n2. have chronic pelvic pain without endometriosis, and\n3. have neither endometriosis nor chronic pelvic pain and are willing to have a tubal ligation (Healthy Volunteer group),\n\nmay be eligible for this study. Candidates are screened with a questionnaire to obtain information about their pain and previous treatments and related medical or social issues. Participants will undergo the following tests and procedures:\n\n1. Medical history and physical examination, including pelvic exam, blood tests, urinalysis, and diaphragm fitting.\n2. Questionnaires about pain, quality of life, sexuality, psychological attitudes, spiritual experiences, and history of headache and depression.\n3. At-home monitoring for 4 to 6 weeks of pain symptoms, menstruation and spotting, medicines taken, and urine collections to test for \"LH\" surge. LH is the hormone that causes the ovary to release a mature egg.\n4. Pre-laparoscopy evaluation to include:\n\n   * Examination of menstrual blood collected in a diaphragm for 4 hours.\n   * Blood sampling to measure adrenal and pituitary hormones. For this test, corticotrophin-releasing hormone (CRH) is injected through an IV needle. Up to five blood samples are drawn, starting before the injection until 45 minutes after it. Blood is also collected at this time for genetic analysis.\n   * In-depth pain assessment to identify trigger points in muscles associated with pelvic pain, regions of skin sensitivity, and bone pain. Some women will undergo microdialysis, which uses an acupuncture-type needle to collect chemicals from two different muscles.\n   * Blood sampling twice a week for 1 month to measure changes in blood substances during the menstrual cycle.\n   * Blood sampling after the LH surge to measure progesterone levels.\n   * Cervicovaginal lavage (washing of the cervix with saline and collecting the fluid) to obtain secretions for research.\n   * Ultrasound of the ovaries and uterus. This examination uses a probe inserted into the vagina that emits sound waves that are used to form pictures of the internal structures. A small piece of uterine lining is also obtained for examination and research purposes.\n   * A visit with the members of the Pain and Palliative care service to evaluate the pain in anticipation of offering other treatments for pain after surgery.\n   * Surgery:\n\nCPP + Endo or CPP only: Laparoscopy to look for and remove endometrial tissue. This procedure is done under general anesthetic. A viewing instrument called a laparoscope is passed through an incision in the belly button to look for endometriosis. If it is found, two or more incisions are made in the abdomen for other instruments to remove the tissue. A small piece of uterine lining is also obtained for examination and research purposes.\n\nHealthy Volunteers: Laparoscopy to perform the tubal ligation. A tubal ligation, commonly known as \"getting your tubes tied,\" is a surgical procedure for women to sterilize them. This procedure closes the fallopian tubes, stopping the egg from traveling from the ovary to the uterus and preventing sperm from reaching the fallopian tube to fertilize an egg. In a tubal ligation, fallopian tubes are cut, burned, or blocked with rings, bands or clips. The surgery is effective immediately. Tubal ligations are 99.5% effective as birth control. This procedure is done under general anesthetic. A viewing instrument called a laparoscope is passed through an incision in the belly button to perform a tubal ligation. Two or more incisions are made in the abdomen for other instruments to perform the procedure. During the laparoscopy, we will look for and remove endometrial tissue. A small piece of uterine lining is also obtained for examination and research purposes.\n\n-Follow-up evaluations. Two weeks after surgery, patients return to NIH to discuss the surgical findings and treatment options. Follow-up visits are then scheduled at 1, 3, and 6 months after surgery to complete questionnaires and determine if the treatment is working. Blood samples are drawn at each visit....", "detailedDescription": "Chronic pelvic pain associated with endometriosis is poorly understood. This study is an effort to better understand pelvic pain and identify novel medical approaches for treating it. Endometriosis is a very common disease of women in their reproductive years, in which endometrial tissue grows outside the uterus. In a recent epidemiologic study, we have shown strong associations among endometriosis, fibromyalgia, and autoimmune disorders. Currently, it is believed that endometriosis causes chronic pelvic pain. Yet, some women with endometriosis do not have any pain and others have pain in areas unrelated to endometriosis disease location. The standard approaches to treating endometriosis pain have been to medically alter hormone levels to prevent endometriosis tissue growth or to surgically remove endometriosis lesions. Pelvic pain is only temporarily treated by either approach, which suggests that the current classification of pain, based on disease and treatment with hormones or surgery is not adequate. The feeling of pain involves many complex processes. Generally, women suffer more frequently from chronic, long-term, painful conditions than men. This suggests that women process pain differently because of differences in sex hormone levels and genes expressed in a sexually dimorphic fashion, as well as in central nervous and immune system function differences. We will examine the relations among sex hormones, pain processing, immune system substances and pain related genes. We will also examine changes in levels of hormonal and immune substances in the blood, endometriosis lesions and normal endometrial tissue. Myofascial pain has been noted in women with endometriosis and chronic pelvic pain. We will study how the nerve, muscle and skeletal systems are involved in pelvic pain by performing an in depth pain assessment. Finally, stress plays an important role generating and perpetuating chronic pain. We will examine how the hormones related to the stress response may be altered in pelvic pain."}, "conditionsModule": {"conditions": ["Endometriosis", "Chronic Pelvic Pain"], "keywords": ["Myofascial Dysfunction", "Sensitization", "Healthy Volunteers", "Overlapping Pain Conditions", "Hypothalamic-Pituitary-Adrenal Axis", "Natural History"]}, "designModule": {"studyType": "OBSERVATIONAL", "designInfo": {"observationalModel": "COHORT", "timePerspective": "PROSPECTIVE"}, "enrollmentInfo": {"count": 78, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Chronic Pelvic Pain and Endometriosis", "description": "Women with chronic pelvic pain and endometriosis found at study surgery"}, {"label": "Chronic Pelvic Pain and No Endometriosis", "description": "Women with chronic pelvic pain and NO endometriosis found at study surgery"}, {"label": "Healthy Volunteers", "description": "Women without no chronic pelvic pain and no symptoms of endometriosis"}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "To evaluate the menstrual dynamics of systemic cytokine expression in endometriosis, and to measure the expression of pro-inflammatory cytokines, stem cells, immunologic activity, and neurotransmittors in endometriosis lesions and the endometriu...", "description": "menstrual effluent by collecting menses over a four- hour period on day one to three of the menstrual cycle; Menstrual cycle variation in systemic secretion of inflammatory mediators (IL-6) and hormones, estradiol and progesterone;Mid-luteal cervical secretions and endometrium for measurement of pro and anti-inflammatory effectors", "timeFrame": "Day 1-3 of the menstrual cycle; by twice weekly blood draws between 8 and 9 AM (14 ml/time) over a four-week period; Mid-luteal cervical secretions and endometrium"}], "secondaryOutcomes": [{"measure": "To evaluate the relation between chronic pelvic pain and the HPA axis in women", "description": "CRH stimulation testing. The HPA assessments will include the measurement of morning levels of serum ACTH and cortisol and the serum levels of ACTH and cortisol after CRH stimulation test.", "timeFrame": "Follicular phase of the menstrual cycle"}, {"measure": "To evaluate whether routine Pain and Palliative Care services of medication adjustment, psychosocial and spiritual counseling, and mind- body techniques offered post- operatively contribute to relief from pain", "description": "analysis of records from Pain and Palliative care", "timeFrame": "post-operative over six months"}, {"measure": "To investigate the influence of genetic polymorphisms in pain pathways, pro-inflammatory cytokines, and mediators of sensitization on chronic musculoskeletal pain in women.", "description": "linkage association and with haplotype mapping genomic on DNA that was freshly isolated and stored at 70 degrees C", "timeFrame": "preoperative evaluation"}, {"measure": "to quantitatively and qualitatively characterize the musculoskeletal components of chronic pelvic pain associated with endometriosis by a standardized neuromusculo-skeletal evaluation.", "description": "Identification of myofascial trigger points in muscles associated with pelvic pain and use pressure algometry to measure pressure pain threshold (the minimal pressure that causes pain; Identification of regions of cutaneous allodynia using Semmes-Weinstein monofilaments across abdominal and pelvic dermatomes. Identification of regions of cutaneous hyperalgesia with a Wartenberg pinwheel across abdominal and pelvic dermatomes. Identification of regions of periosteal tenderness using pressure algometry over bony prominences.", "timeFrame": "Follicular phase of the menstrual Cycle"}]}, "eligibilityModule": {"eligibilityCriteria": "* INCLUSION CRITERIA:\n\nWomen between the ages of 18 and 50 years, who have their reproductive organs. Those undergoing tubal ligation must be at least 21 years old.\n\nExcellent health other than a three-month history of pelvic pain and documented endometriosis at laparoscopy. Chronic medications may be acceptable at the discretion of the Principal Investigator (PI). Use of antidepressants, medications for migraines and headaches, allergy medications, and treatment of bowel symptoms such as irritable bowel disease will be allowed.\n\nDo not desire pregnancy for the duration of the study.\n\nAre using abstinence, mechanical (condoms, diaphragms) or sterilization methods of contraception and are willing to continue using them throughout the study.\n\nWilling and able to give informed consent.\n\nWilling and able to comply with study requirements.\n\nBMI \\< than 32 kg/m\\^2.\n\nHistory of regular cyclic menses.\n\nEXCLUSION CRITERIA:\n\nWomen with other causes of chronic pelvic pain including infectious, gastrointestinal, psychologic disorders, fibromyalgia and chronic fatigue syndrome.\n\nSignificant abnormalities in the physical or laboratory examination including renal and liver function more than twice the normal range.\n\nHysterectomy or bilateral salpingo-oophorectomy.\n\nPregnancy.\n\nLactation.\n\nUse of hormonal contraception, selective estrogen receptor modulators, progestins, estrogens, steroids, or ovulation induction in the last 3 months.\n\nOther medical or surgical treatment for endometriosis in the last 6 months.\n\nUntreated abnormal pap smear or other gynecologic condition.\n\nManic-depressive illness or untreated major depression.\n\nHIV infection.", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "50 Years", "stdAges": ["ADULT"], "studyPopulation": "We plan to study women of reproductive age with chronic pelvic pain, some of whom have endometriosis and some who do not. Healthy women without chronic pelvic pain and not known to have endometriosis will serve as controls. In the event that endometriosis is found at laparoscopy in the control group, we will include these patients in the study as a separate subset of controls. Controls may choose to complete the study, including laparoscopy with a tubal ligation, complete the study without laparoscopy, or participate in an abbreviated study that includes only screening and chronic stress testing. All women will be protected from pregnancy by non-hormonal contraception such as barrier contraception, abstinence or surgical sterilization for the duration of the study.", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"overallOfficials": [{"name": "Avindra Nath, M.D.", "affiliation": "National Institute of Neurological Disorders and Stroke (NINDS)", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "National Institutes of Health Clinical Center", "city": "Bethesda", "state": "Maryland", "zip": "20892", "country": "United States", "geoPoint": {"lat": 38.98067, "lon": -77.10026}}]}, "referencesModule": {"references": [{"pmid": "9780254", "type": "BACKGROUND", "citation": "Al-Harthi L, Spear GT, Hashemi FB, Landay A, Sha BE, Roebuck KA. A human immunodeficiency virus (HIV)-inducing factor from the female genital tract activates HIV-1 gene expression through the kappaB enhancer. J Infect Dis. 1998 Nov;178(5):1343-51. doi: 10.1086/314444."}, {"pmid": "10954915", "type": "BACKGROUND", "citation": "Al-Harthi L, Wright DJ, Anderson D, Cohen M, Matity Ahu D, Cohn J, Cu-Unvin S, Burns D, Reichelderfer P, Lewis S, Beckner S, Kovacs A, Landay A. The impact of the ovulatory cycle on cytokine production: evaluation of systemic, cervicovaginal, and salivary compartments. J Interferon Cytokine Res. 2000 Aug;20(8):719-24. doi: 10.1089/10799900050116426."}, {"pmid": "10097000", "type": "BACKGROUND", "citation": "Berkley KJ. Sex differences in pain. Behav Brain Sci. 1997 Sep;20(3):371-80; discussion 435-513. doi: 10.1017/s0140525x97221485."}, {"pmid": "25730237", "type": "DERIVED", "citation": "Stratton P, Khachikyan I, Sinaii N, Ortiz R, Shah J. Association of chronic pelvic pain and endometriosis with signs of sensitization and myofascial pain. Obstet Gynecol. 2015 Mar;125(3):719-728. doi: 10.1097/AOG.0000000000000663."}], "seeAlsoLinks": [{"label": "NIH Clinical Center Detailed Web Page", "url": "https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2004-N-0056.html"}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT03343067", "orgStudyIdInfo": {"id": "M16-383"}, "organization": {"fullName": "AbbVie", "class": "INDUSTRY"}, "briefTitle": "A Study to Evaluate Safety and Efficacy of Elagolix in Participants With Endometriosis With Associated Moderate to Severe Pain", "officialTitle": "A Study to Evaluate Safety and Efficacy of Elagolix Alone or Elagolix With Hormonal Add-Back in Subjects With Endometriosis With Associated Moderate to Severe Pain"}, "statusModule": {"statusVerifiedDate": "2019-07", "overallStatus": "TERMINATED", "whyStopped": "The study was terminated early for business reasons, not for safety concerns.", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2017-12-27", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2018-10-23", "type": "ACTUAL"}, "completionDateStruct": {"date": "2018-10-23", "type": "ACTUAL"}, "studyFirstSubmitDate": "2017-11-13", "studyFirstSubmitQcDate": "2017-11-13", "studyFirstPostDateStruct": {"date": "2017-11-17", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2019-10-22", "resultsFirstSubmitQcDate": "2019-11-08", "resultsFirstPostDateStruct": {"date": "2019-11-27", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2019-11-08", "lastUpdatePostDateStruct": {"date": "2019-11-27", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AbbVie", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false, "isUsExport": false}, "descriptionModule": {"briefSummary": "This is a Phase 3, dose-escalation study designed to evaluate the safety and efficacy of both elagolix alone and elagolix plus estradiol/norethindrone acetate (E2/NETA) over 24 months in the management of endometriosis with associated moderate to severe pain in premenopausal women."}, "conditionsModule": {"conditions": ["Endometriosis"], "keywords": ["Endometriosis associated pain", "Elagolix", "Non-menstrual pelvic pain (NMPP)", "Dysmenorrhea (DYS)"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 11, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Arm A", "type": "EXPERIMENTAL", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 24 (Double-Blind): Efficacy responders to elagolix 150 mg QD at Month 3 and continue treatment through Month 24", "interventionNames": ["Drug: elagolix"]}, {"label": "Arm C", "type": "EXPERIMENTAL", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 24 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group and continue treatment through Month 24.", "interventionNames": ["Drug: elagolix", "Drug: estradiol/norethindrone acetate (E2/NETA)"]}, {"label": "Arm D", "type": "EXPERIMENTAL", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 150 mg QD treatment group\n\nMonth 7 Through Month 24 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 6 and assigned to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group and continue treatment through Month 24.", "interventionNames": ["Drug: elagolix", "Drug: estradiol/norethindrone acetate (E2/NETA)"]}, {"label": "Arm B", "type": "EXPERIMENTAL", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 150 mg QD treatment group\n\nMonth 7 Through Month 24 (Double-Blind): Efficacy responders to elagolix 150 mg QD at Month 6 and continue treatment through Month 24.", "interventionNames": ["Drug: elagolix"]}], "interventions": [{"type": "DRUG", "name": "elagolix", "description": "Tablets", "armGroupLabels": ["Arm A", "Arm B", "Arm C", "Arm D"]}, {"type": "DRUG", "name": "estradiol/norethindrone acetate (E2/NETA)", "description": "Capsules", "armGroupLabels": ["Arm C", "Arm D"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Proportion of Responders at Month 6 Based on DYS Pain Scale", "description": "Proportion of responders at Month 6 based upon the scale for DYS pain scale (ranging from 0 \\[none\\] to 3 \\[severe\\]) using the daily e-Diary, as well as no increased analgesic rescue use for endometriosis-associated pain.", "timeFrame": "Month 6"}, {"measure": "Proportion of Responders at Month 6 Based on NMPP Pain Scale", "description": "Proportion of responders at Month 6 based upon the scale for NMPP pain scale (ranging from 0 \\[none\\] to 3 \\[severe\\]) using the daily e-Diary, as well as no increased analgesic rescue use for endometriosis-associated pain.", "timeFrame": "Month 6"}], "secondaryOutcomes": [{"measure": "Change From Baseline in DYS at Month 6", "description": "The DYS pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.", "timeFrame": "Month 0 (baseline), Month 6"}, {"measure": "Change From Baseline in NMPP at Month 6", "description": "The NMPP pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.", "timeFrame": "Month 0 (baseline), Month 6"}, {"measure": "Change From Baseline in Dyspareunia at Month 6", "description": "The dyspareunia pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.", "timeFrame": "Month 0 (baseline), Month 6"}, {"measure": "Change From Baseline in Daily Diary Endometriosis-Associated Pain Score Via Numeric Rating Scale (NRS) at Month 6", "description": "The NRS for overall endometriosis-associated pain ranges from 0 (none) to 10 (worst pain ever), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.", "timeFrame": "Month 0 (baseline), Month 6"}, {"measure": "Change From Baseline in Rescue Analgesic Use Across Both Classes of Rescue Analgesics (NSAIDs/Opioids) at Month 6", "description": "Based on average pill counts and assessed using the daily e-Diary. Permitted non-steroidal anti-inflammatory drugs (NSAIDs) included naproxen, ibuprofen, diclofenac, and celecoxib. Permitted opioids included hydrocodone + acetaminophen and codeine phosphate + acetaminophen.", "timeFrame": "Month 0 (baseline), Month 6"}, {"measure": "Percentage of Participants With 30% or More Reduction From Baseline Based on the 35 Day Mean of the Daily Diary Endometriosis-Associated Pain Score Via NRS at Month 6", "description": "The NRS for overall endometriosis-associated pain ranges from 0 (none) to 10 (worst pain ever), recorded in a daily eDiary and averaged monthly based on a 35-day window.", "timeFrame": "Month 6"}, {"measure": "Proportion of Responders Over Time", "description": "As assessed by change and percent change from baseline in average pain score and rescue analgesic use monthly for DYS, NMPP, dyspareunia, and Daily Diary endometriosis-associated pain score via NRS, respectively.", "timeFrame": "Month 0 (baseline), Months 1, 2, 3, 4, 5, 6"}, {"measure": "Proportion of Responders Over Time (Not Taking Into Consideration of Analgesic Use)", "description": "As assessed by change and percent change from Baseline in average pain score and rescue analgesic use monthly for DYS, NMPP, dyspareunia, and Daily Diary endometriosis-associated pain score via NRS, respectively.", "timeFrame": "Month 0 (baseline), Months 1, 2, 3, 4, 5, 6"}, {"measure": "Change From Baseline Over Time in Monthly Average DYS Pain Score", "description": "The DYS pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.\n\nThe analysis was based on a 28-day window. If a participant prematurely discontinued during the open-label period, based on the analysis window, some data might fall into Month 4 analysis.", "timeFrame": "Month 0 (baseline), Months 1, 2, 3, 4, 5, 6"}, {"measure": "Change From Baseline Over Time in Monthly Average NMPP Pain Score", "description": "The NMPP pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.", "timeFrame": "Month 0 (baseline), Months 1, 2, 3, 4, 5, 6"}, {"measure": "Change From Baseline Over Time in Monthly Average Dyspareunia Pain Score", "description": "The dyspareunia pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.", "timeFrame": "Month 0 (baseline), Months 1, 2, 3, 4, 5, 6"}, {"measure": "Change From Baseline Over Time in Monthly Average Daily Diary Endometriosis-Associated Pain Score Via NRS", "description": "The NRS for overall endometriosis-associated pain ranges from 0 (none) to 10 (worst pain ever), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.", "timeFrame": "Month 0 (baseline), Months 1, 2, 3, 4, 5, 6"}, {"measure": "Percent Change From Baseline to Each Month During the Treatment Period for DYS", "description": "The DYS pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.", "timeFrame": "Month 0 (baseline), Months 1, 2, 3, 4, 5, 6"}, {"measure": "Percent Change From Baseline to Each Month During the Treatment Period for NMPP", "description": "The NMPP pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.", "timeFrame": "Month 0 (baseline), Months 1, 2, 3, 4, 5, 6"}, {"measure": "Percent Change From Baseline to Each Month During the Treatment Period for Dyspareunia", "description": "The dyspareunia pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.", "timeFrame": "Month 0 (baseline), Months 1, 2, 3, 4, 5, 6"}, {"measure": "Percent Change From Baseline to Each Month During the Treatment Period for Daily Diary Endometriosis-Associated Pain Score Via NRS", "description": "The NRS for overall endometriosis-associated pain ranges from 0 (none) to 10 (worst pain ever), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.", "timeFrame": "Month 0 (baseline), Months 1, 2, 3, 4, 5, 6"}, {"measure": "Change From Baseline Over Time in Daily Rescue Analgesic Use Across Both Classes of Rescue Analgesics", "description": "Based on average pill counts and assessed using a daily e-Diary. Permitted non-steroidal anti-inflammatory drugs (NSAIDs) included naproxen, ibuprofen, diclofenac, and celecoxib. Permitted opioids included hydrocodone + acetaminophen and codeine phosphate + acetaminophen.", "timeFrame": "Month 0 (baseline), Months 1, 2, 3, 4, 5, 6"}, {"measure": "Number of Analgesic Use Responders and Non-Responders Over Time", "description": "Based only on reduction of rescue analgesics used. Responders were defined as:\n\n* participants with no analgesic use at screening and no analgesic use added\n* participants with NSAID only use at screening and NSAID dose stopped, decreased, or stable (\\<15% increase) and no opioid use added\n* participants with opioid only use at screening and opioid dose stopped, decreased, or stable (\\<15% increase), opioid dose stopped and NSAID substituted (any dose), opioid dose decreased and NSAID added (any dose)\n* participants with NSAID + opioid use at screening and any of the following: NSAID dose stopped + opioid analgesic use stopped, decreased, or stable (\\<15% increase); NSAID dose decreased + opioid analgesic use stopped, decreased, or stable (\\<15% increase); NSAID dose stable (\\< 15% increase) + opioid analgesic use stopped, decreased, or stable (\\<15% increase); NSAID dose increased by \\>15% + opioid analgesic use stopped; NSAID dose increased by \\>15% + opioid analgesic dose decreases.", "timeFrame": "Months 1, 2, 3, 4, 5, 6"}, {"measure": "Patient Global Impression of Change (PGIC) Scores Over Time", "description": "The PGIC is a 7-point response scale where participants rate their endometriosis related pain as: very much improved (1), much improved (2), minimally improved (3), not changed (4), minimally worse (5), much worse (6), very much worse (7).", "timeFrame": "Months 1, 2, 3, 4, 5, 6"}, {"measure": "Overall Endometriosis-Associated Pain Via NRS (7-Day Recall) Scores Over Time", "description": "The endometriosis-associated pain questionnaire is an 11-point NRS assessing overall endometriosis-associated pain over a 7-day recall period. Participants assessed their endometriosis-associated pain on a scale of 0 to 10, with 0 = no pain and 10 = worst pain ever.", "timeFrame": "Month 0 (baseline), Months 1, 2, 3, 4, 5, 6"}, {"measure": "Endometriosis Health Profile-30 (EHP-30) Scores Over Time: Pain", "description": "The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Domains used in the study included Pain, Control and Powerlessness, Well-Being, Social Support, Self-Image, and Sexual Intercourse. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.", "timeFrame": "Month 0 (baseline), Months 3, 6"}, {"measure": "EHP-30 Scores Over Time: Control and Powerlessness", "description": "The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Domains used in the study included Pain, Control and Powerlessness, Well-Being, Social Support, Self-Image, and Sexual Intercourse. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.", "timeFrame": "Month 0 (baseline), Months 3, 6"}, {"measure": "EHP-30 Scores Over Time: Emotional Well-Being", "description": "The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Domains used in the study included Pain, Control and Powerlessness, Well-Being, Social Support, Self-Image, and Sexual Intercourse. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.", "timeFrame": "Month 0 (baseline), Months 3, 6"}, {"measure": "EHP-30 Scores Over Time: Social Support", "description": "The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Domains used in the study included Pain, Control and Powerlessness, Well-Being, Social Support, Self-Image, and Sexual Intercourse. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.", "timeFrame": "Month 0 (baseline), Months 3, 6"}, {"measure": "EHP-30 Scores Over Time: Self-Image", "description": "The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Domains used in the study included Pain, Control and Powerlessness, Well-Being, Social Support, Self-Image, and Sexual Intercourse. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.", "timeFrame": "Month 0 (baseline), Months 3, 6"}, {"measure": "EHP-30 Scores Over Time: Sexual Intercourse", "description": "The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Domains used in the study included Pain, Control and Powerlessness, Well-Being, Social Support, Self-Image, and Sexual Intercourse. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.", "timeFrame": "Month 0 (baseline), Months 3, 6"}, {"measure": "EuroQol-5D 5 Level (EQ-5D-5L) Scores Over Time: Mobility", "description": "The EQ-5D-5L is a health state utility instrument with 5 items that comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which is rated on 5 levels of severity (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems) and a separate visual analog scale (VAS) indicating a participant's rating of their current health status (health today) on a scale of from 0 (worst health imaginable) to 100 (best health imaginable).", "timeFrame": "Month 0 (baseline), Months 3, 6"}, {"measure": "EQ-5D-5L Scores Over Time: Self-Care", "description": "The EQ-5D-5L is a health state utility instrument with 5 items that comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which is rated on 5 levels of severity (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems) and a separate visual analog scale (VAS) indicating a participant's rating of their current health status (health today) on a scale of from 0 (worst health imaginable) to 100 (best health imaginable).", "timeFrame": "Month 0 (baseline), Months 3, 6"}, {"measure": "EQ-5D-5L Scores Over Time: Usual Activities", "description": "The EQ-5D-5L is a health state utility instrument with 5 items that comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which is rated on 5 levels of severity (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems) and a separate visual analog scale (VAS) indicating a participant's rating of their current health status (health today) on a scale of from 0 (worst health imaginable) to 100 (best health imaginable).", "timeFrame": "Month 0 (baseline), Months 3, 6"}, {"measure": "EQ-5D-5L Scores Over Time: Pain/Discomfort", "description": "The EQ-5D-5L is a health state utility instrument with 5 items that comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which is rated on 5 levels of severity (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems) and a separate visual analog scale (VAS) indicating a participant's rating of their current health status (health today) on a scale of from 0 (worst health imaginable) to 100 (best health imaginable).", "timeFrame": "Month 0 (baseline), Months 3, 6"}, {"measure": "EQ-5D-5L Scores Over Time: Anxiety/Depression", "description": "The EQ-5D-5L is a health state utility instrument with 5 items that comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which is rated on 5 levels of severity (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems) and a separate visual analog scale (VAS) indicating a participant's rating of their current health status (health today) on a scale of from 0 (worst health imaginable) to 100 (best health imaginable).", "timeFrame": "Month 0 (baseline), Months 3, 6"}, {"measure": "EQ-5D-5L VAS Scores Over Time: Health Today", "description": "The EQ-5D-5L is a health state utility instrument with 5 items that comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which is rated on 5 levels of severity (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems) and a separate VAS indicating a participant's rating of their current health status (health today) on a scale of from 0 (worst health imaginable) to 100 (best health imaginable).", "timeFrame": "Month 0 (baseline), Months 3, 6"}, {"measure": "Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP) Scores Over Time: Percent Work Missed Due to Problem", "description": "Absenteeism is presented as the mean percentage of work time missed due to health problem (as reported on the WPAI:SHP), and is calculated as: 100\\*number of hours of work missed due to health problem / (number of hours of work missed due to health problem + number of hours worked). WPAI is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity.", "timeFrame": "Month 0 (baseline), Month 6"}, {"measure": "WPAI:SHP Scores Over Time: Percent Impairment While Working Due to Problem", "description": "Presenteeism (the extent to which health problem decreased productivity) is presented as the mean percentage of impairment while working due to health problem, and is calculated as: 100\\*scale value of question 5 on the WPAI (between 0 and 10) / 10. WPAI:SHP is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity.", "timeFrame": "Month 0 (baseline), Month 6"}, {"measure": "WPAI:SHP Scores Over Time: Percent Overall Work Impairment Due to Problem", "description": "The mean percentage of overall work impairment due to health problem (based on the WPAI questionnaire) is presented, and is calculated as: Absenteeism (%) + extent to which health problem decreased productivity (%)\\* \\[number of hours worked / (number of hours of work missed due to health problem + number of hours worked)\\]. WPAI is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity.", "timeFrame": "Month 0 (baseline), Month 6"}, {"measure": "WPAI:SHP Scores Over Time: Percent Activity Impairment Due to Problem", "description": "Activity impairment due to health problem (the extent to which health problem affected the ability to perform usual daily activities) is presented as the mean percentage of activity impairment, and is calculated as 100\\*scale value of WPAI question 6 (between 0 and 10) / 10. WPAI is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity.", "timeFrame": "Month 0 (baseline), Month 6"}, {"measure": "Health Endometriosis Treatment Satisfaction Questionnaire (ETSQ) Scores Over Time", "description": "The 6-item ETSQ was developed to assess patient-reported satisfaction with effects on endometriosis pain, dysmenorrhea, dyspareunia, amount of bleeding tolerability and overall treatment satisfaction. The ETSQ has a 7 point response scale. The range for this scale is 0 to 36, with lower ETSQ scores reflecting lower levels of satisfaction with endometriosis treatment.", "timeFrame": "Month 0 (baseline), Months 3, 6"}, {"measure": "PROMIS Fatigue Short Form 6a Scores Over Time", "description": "The PROMIS Fatigue Short Form 6a is self-administered and composed of 6 questions to evaluate fatigue. Possible scores range from 6 to 30, 6 = not at all (no fatigue), and 30 = very much (most fatigue).", "timeFrame": "Month 0 (baseline), Month 6"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Participant is a premenopausal female 18 to 49 years of age (inclusive) at the time of Screening.\n* Participant has a documented surgical diagnosis (e.g., laparoscopy or laparotomy) of endometriosis established by visualization or histology within 10 years prior to entry into Washout or Screening,\n* Participant must agree to use only those rescue analgesics permitted by the protocol during the Screening and Treatment Periods for her endometriosis-associated pain.\n* Participant must have the following documented in the e-Diary during the last 35 days prior to Study Day 1:\n\n  1. At least 2 days of \"moderate\" or \"severe\" DYS, AND either,\n  2. At least 2 days of \"moderate\" or \"severe\" NMPP and an average NMPP score of at least 1.0, OR\n  3. At least 4 days of \"moderate\" or \"severe\" NMPP and an average NMPP score of at least 0.5.\n\nExclusion Criteria:\n\n* Participant has chronic pelvic pain that is not caused by endometriosis that requires chronic analgesic therapy, which would interfere with the assessment of endometriosis-associated pain.\n* Participant is using any systemic corticosteroids for over 14 days within 3 months prior to Screening or is likely to require treatment with systemic corticosteroids during the course of the study. Over-the-counter and prescription topical, inhaled or intranasal corticosteroids are allowed.\n* Participant has a history of major depression or post-traumatic stress disorder (PTSD) within 2 years prior to screening or other major psychiatric disorder at any time\n* Participant has a history of suicide attempts or answered \"yes\" to questions 4 or 5 on the suicidal ideation portion of the Columbia-Suicide Severity Rating Scale (C-SSRS) at Screening or prior to study drug dosing on Day 1.\n* Participant has any condition that would interfere with obtaining adequate dual energy x-ray absorptiometry (DXA) measurements\n* Screening DXA results of the lumbar spine (L1 - L4), femoral neck or total hip bone mineral density (BMD) corresponding to less than 2 or more standard deviations below normal (Z-score \\< -2.0 for participants \\< 40 years of age, T-score for participants \\>= 40 years of age).\n* Participant has either\n\n  1. a newly diagnosed, clinically significant medical condition that requires therapeutic intervention (e.g., new onset hypertension) that has not been stabilized 30 days prior to enrollment on Day 1 OR\n  2. a clinically significant medical condition that is anticipated to required intervention during the course of study participation (e.g., anticipated major elective surgery) OR\n  3. an unstable medical condition that makes the participant an unsuitable candidate for the study in the opinion of the Investigator\n* Participant has any conditions contraindicated with use of E2/NETA", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "49 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "AbbVie Inc.", "affiliation": "AbbVie", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Pinnacle Research Group /ID# 202016", "city": "Anniston", "state": "Alabama", "zip": "36207", "country": "United States", "geoPoint": {"lat": 33.65983, "lon": -85.83163}}, {"facility": "Noble Clinical Research /ID# 170628", "city": "Tucson", "state": "Arizona", "zip": "85704", "country": "United States", "geoPoint": {"lat": 32.22174, "lon": -110.92648}}, {"facility": "Lynn Institute of the Ozarks /ID# 165052", "city": "Little Rock", "state": "Arkansas", "zip": "72205", "country": "United States", "geoPoint": {"lat": 34.74648, "lon": -92.28959}}, {"facility": "SC Clinical Research /ID# 165049", "city": "Garden Grove", "state": "California", "zip": "92844", "country": "United States", "geoPoint": {"lat": 33.77391, "lon": -117.94145}}, {"facility": "Marvel Clinical Research /ID# 169633", "city": "Huntington Beach", "state": "California", "zip": "92647", "country": "United States", "geoPoint": {"lat": 33.6603, "lon": -117.99923}}, {"facility": "Health care Affiliates Medical Group /ID# 165048", "city": "Santa Ana", "state": "California", "zip": "92704", "country": "United States", "geoPoint": {"lat": 33.74557, "lon": -117.86783}}, {"facility": "Western States Clinical Res /ID# 169809", "city": "Wheat Ridge", "state": "Colorado", "zip": "80033-2896", "country": "United States", "geoPoint": {"lat": 39.7661, "lon": -105.07721}}, {"facility": "Nova Clinical Research, LLC /ID# 202227", "city": "Bradenton", "state": "Florida", "zip": "34209-4616", "country": "United States", "geoPoint": {"lat": 27.49893, "lon": -82.57482}}, {"facility": "Midland Florida Clinical Research Center /ID# 201327", "city": "DeLand", "state": "Florida", "zip": "32720-0920", "country": "United States", "geoPoint": {"lat": 29.02832, "lon": -81.30312}}, {"facility": "Southeastern Integrated Med /ID# 203109", "city": "Gainesville", "state": "Florida", "zip": "32607", "country": "United States", "geoPoint": {"lat": 29.65163, "lon": -82.32483}}, {"facility": "Care Partners Clinical Researc /ID# 168395", "city": "Jacksonville", "state": "Florida", "zip": "32277", "country": "United States", "geoPoint": {"lat": 30.33218, "lon": -81.65565}}, {"facility": "LCC Medical Research Institute /ID# 168888", "city": "Miami", "state": "Florida", "zip": "33126", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "A Premier Clinical Research of Florida, LLC /ID# 201887", "city": "Orange City", "state": "Florida", "zip": "32763-2833", "country": "United States", "geoPoint": {"lat": 28.94888, "lon": -81.29867}}, {"facility": "GCP Clinical Research, LLC /ID# 169774", "city": "Tampa", "state": "Florida", "zip": "33609-4044", "country": "United States", "geoPoint": {"lat": 27.94752, "lon": -82.45843}}, {"facility": "Triple O Research Institute /ID# 201128", "city": "West Palm Beach", "state": "Florida", "zip": "33407-3100", "country": "United States", "geoPoint": {"lat": 26.71534, "lon": -80.05337}}, {"facility": "Bingham Memorial Hospital /ID# 170110", "city": "Blackfoot", "state": "Idaho", "zip": "83221", "country": "United States", "geoPoint": {"lat": 43.19047, "lon": -112.34498}}, {"facility": "Leavitt Womens Healthcare /ID# 169495", "city": "Idaho Falls", "state": "Idaho", "zip": "83404-8322", "country": "United States", "geoPoint": {"lat": 43.46658, "lon": -112.03414}}, {"facility": "Quad Clinical Research, LLC /ID# 168294", "city": "Chicago", "state": "Illinois", "zip": "60605", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Quad Clinical Research, LLC /ID# 170629", "city": "Chicago", "state": "Illinois", "zip": "60605", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Women's Health Care, PC /ID# 165033", "city": "Newburgh", "state": "Indiana", "zip": "47630-8940", "country": "United States", "geoPoint": {"lat": 37.94449, "lon": -87.40529}}, {"facility": "Delricht Research /ID# 200219", "city": "New Orleans", "state": "Louisiana", "zip": "70115", "country": "United States", "geoPoint": {"lat": 29.95465, "lon": -90.07507}}, {"facility": "Quad Clinical Research, LLC /ID# 200180", "city": "St Louis", "state": "Missouri", "zip": "63108-3204", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Montana Health Research Inst /ID# 170624", "city": "Billings", "state": "Montana", "zip": "59102", "country": "United States", "geoPoint": {"lat": 45.78329, "lon": -108.50069}}, {"facility": "Excel Clinical Research /ID# 170620", "city": "Las Vegas", "state": "Nevada", "zip": "89109", "country": "United States", "geoPoint": {"lat": 36.17497, "lon": -115.13722}}, {"facility": "Northwell health system /ID# 200162", "city": "Manhasset", "state": "New York", "zip": "11030-3816", "country": "United States", "geoPoint": {"lat": 40.79788, "lon": -73.69957}}, {"facility": "Radiant Research, Inc /ID# 200045", "city": "Akron", "state": "Ohio", "zip": "44311", "country": "United States", "geoPoint": {"lat": 41.08144, "lon": -81.51901}}, {"facility": "Central Ohio Clinical Research /ID# 170750", "city": "Columbus", "state": "Ohio", "zip": "43213-3399", "country": "United States", "geoPoint": {"lat": 39.96118, "lon": -82.99879}}, {"facility": "Optimed Research /ID# 167642", "city": "Columbus", "state": "Ohio", "zip": "43235", "country": "United States", "geoPoint": {"lat": 39.96118, "lon": -82.99879}}, {"facility": "VitaLink Research /ID# 168401", "city": "Greenville", "state": "South Carolina", "zip": "29601", "country": "United States", "geoPoint": {"lat": 34.85262, "lon": -82.39401}}, {"facility": "VitaLink Research /ID# 170625", "city": "Greenville", "state": "South Carolina", "zip": "29601", "country": "United States", "geoPoint": {"lat": 34.85262, "lon": -82.39401}}, {"facility": "Fusion Clinical Research of Spartanburg /ID# 200010", "city": "Spartanburg", "state": "South Carolina", "zip": "29301-5642", "country": "United States", "geoPoint": {"lat": 34.94957, "lon": -81.93205}}, {"facility": "Centex Studies, Inc /ID# 169897", "city": "Houston", "state": "Texas", "zip": "77058-2705", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "America's Adv. Wellness Center /ID# 170005", "city": "Houston", "state": "Texas", "zip": "77080", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "ClinRx Research, LLC /ID# 201189", "city": "Plano", "state": "Texas", "zip": "75024-5280", "country": "United States", "geoPoint": {"lat": 33.01984, "lon": -96.69889}}, {"facility": "Progressive Clinical Research /ID# 205565", "city": "San Antonio", "state": "Texas", "zip": "78229", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Eastern Virginia Med School /ID# 165016", "city": "Norfolk", "state": "Virginia", "zip": "23507-1627", "country": "United States", "geoPoint": {"lat": 36.84681, "lon": -76.28522}}, {"facility": "Seattle Reproductive Medicine /ID# 171079", "city": "Seattle", "state": "Washington", "zip": "98109", "country": "United States", "geoPoint": {"lat": 47.60621, "lon": -122.33207}}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.", "infoTypes": ["STUDY_PROTOCOL", "SAP", "CSR", "ANALYTIC_CODE"], "timeFrame": "Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.", "accessCriteria": "Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.", "url": "https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "The study was terminated early for business reasons, not for safety concerns. There are no subject data past Treatment Month 6.", "groups": [{"id": "FG000", "title": "Group A", "description": "Day 1 through Month 3 (open-label): elagolix 150 mg QD\n\nParticipants discontinued prematurely during the open-label period."}, {"id": "FG001", "title": "Group B", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Efficacy responders to elagolix 150 mg QD Month 3 continued on elagolix 150 mg QD\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via a Numeric Rating Scale (NRS) in the electronic diary. Efficacy responder: ≥ 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}, {"id": "FG002", "title": "Group C", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via NRS in the electronic diary. Incomplete efficacy responder: \\< 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window"}], "periods": [{"title": "Open Label Period: Day 1 to Month 3", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}]}, {"title": "Double Blind Period: Month 3 to Month 6", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Study Terminated by Sponsor", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Group A", "description": "Day 1 through Month 3 (open-label): elagolix 150 mg QD\n\nParticipants discontinued prematurely during the open-label period."}, {"id": "BG001", "title": "Group B", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Efficacy responders to elagolix 150 mg QD Month 3 continued on elagolix 150 mg QD\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via a Numeric Rating Scale (NRS) in the electronic diary. Efficacy responder: ≥ 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}, {"id": "BG002", "title": "Group C", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via NRS in the electronic diary. Incomplete efficacy responder: \\< 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "11"}]}], "measures": [{"title": "Age, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "20 to < 25 years", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "2"}]}]}, {"title": "25 to < 30 years", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "1"}]}]}, {"title": "30 to < 35 years", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "2"}]}]}, {"title": "35 to < 40 years", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "1"}]}]}, {"title": "40 to < 45 years", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "4"}]}]}, {"title": "45 to < 50 years", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "1"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "11"}]}], "categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "11"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "11"}]}], "categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "3"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "8"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "11"}]}], "categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "3"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "6"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "2"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}]}]}, {"title": "Dysmenorrhea (DYS) Pain Scale", "description": "The DYS pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary. A minimum of 45 days of daily e-Diary entries were required to be completed during the Screening Period.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "score on a scale", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "0.641", "spread": "0.1689"}, {"groupId": "BG001", "value": "0.429", "spread": "0.1030"}, {"groupId": "BG002", "value": "0.600", "spread": "NA", "comment": "1 participant analyzed"}, {"groupId": "BG003", "value": "0.579", "spread": "0.1696"}]}]}]}, {"title": "Non-Menstrual Pelvic Pain (NMPP) Pain Scale", "description": "The NMPP pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary. A minimum of 45 days of daily e-Diary entries were required to be completed during the Screening Period.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "score on a scale", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "1.053", "spread": "0.4534"}, {"groupId": "BG001", "value": "0.914", "spread": "0.4721"}, {"groupId": "BG002", "value": "2.400", "spread": "NA", "comment": "1 participant analyzed"}, {"groupId": "BG003", "value": "1.138", "spread": "0.5893"}]}]}]}, {"title": "Dyspareunia Pain Scale", "description": "The dyspareunia pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary. A minimum of 45 days of daily e-Diary entries were required to be completed during the Screening Period.", "populationDescription": "1 subject did not complete assessment", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "score on a scale", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "0.539", "spread": "0.9064"}, {"groupId": "BG001", "value": "0.043", "spread": "0.0202"}, {"groupId": "BG002", "value": "3.000", "spread": "NA", "comment": "1 participant analyzed"}, {"groupId": "BG003", "value": "0.686", "spread": "1.1187"}]}]}]}, {"title": "Daily Diary Endometriosis-Associated Pain Score Via Numeric Rating Scale (NRS)", "description": "The NRS for overall endometriosis-associated pain ranges from 0 (none) to 10 (worst pain ever), recorded in a daily eDiary. A minimum of 45 days of daily e-Diary entries were required to be completed during the Screening Period.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "score on a scale", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "5.176", "spread": "1.9302"}, {"groupId": "BG001", "value": "3.638", "spread": "1.5692"}, {"groupId": "BG002", "value": "7.371", "spread": "NA", "comment": "1 participant analyzed"}, {"groupId": "BG003", "value": "4.956", "spread": "1.9663"}]}]}]}, {"title": "Rescue Analgesic Use Across Both Classes of Rescue Analgesics (NSAIDs/Opioids)", "description": "Based on average pill counts and assessed using the daily e-Diary. Participants were allowed to take protocol-specified analgesic rescue medication for endometriosis-associated pain and recorded use daily in the e-Diary. A minimum of 45 days of daily e-Diary entries were required to be completed during the Screening Period. Permitted non-steroidal anti-inflammatory drugs (NSAIDs) included naproxen, ibuprofen, diclofenac, and celecoxib. Permitted opioids included hydrocodone + acetaminophen and codeine phosphate + acetaminophen.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "pills/day", "classes": [{"title": "NSAID", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "2.388", "spread": "2.7765"}, {"groupId": "BG001", "value": "0.581", "spread": "0.9330"}, {"groupId": "BG002", "value": "0.743", "spread": "NA", "comment": "1 participant analyzed"}, {"groupId": "BG003", "value": "1.745", "spread": "2.3655"}]}]}, {"title": "Opioid", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "0.241", "spread": "0.3750"}, {"groupId": "BG001", "value": "0.057", "spread": "0.0990"}, {"groupId": "BG002", "value": "0.571", "spread": "NA", "comment": "1 participant analyzed"}, {"groupId": "BG003", "value": "0.221", "spread": "0.3270"}]}]}, {"title": "NSAID + Opioid", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "2.629", "spread": "2.6903"}, {"groupId": "BG001", "value": "0.638", "spread": "0.8918"}, {"groupId": "BG002", "value": "1.314", "spread": "NA", "comment": "1 participant analyzed"}, {"groupId": "BG003", "value": "1.966", "spread": "2.3196"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Proportion of Responders at Month 6 Based on DYS Pain Scale", "description": "Proportion of responders at Month 6 based upon the scale for DYS pain scale (ranging from 0 \\[none\\] to 3 \\[severe\\]) using the daily e-Diary, as well as no increased analgesic rescue use for endometriosis-associated pain.", "populationDescription": "Analysis was intended to be based on a receiver operating characteristic (ROC) threshold, which could not be calculated, since only 1 participant had a Month 6 assessment for this endpoint at the time of study termination.", "reportingStatus": "POSTED", "timeFrame": "Month 6", "groups": [{"id": "OG000", "title": "Group A", "description": "Day 1 through Month 3 (open-label): elagolix 150 mg QD\n\nParticipants discontinued prematurely during the open-label period."}, {"id": "OG001", "title": "Group B", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Efficacy responders to elagolix 150 mg QD Month 3 continued on elagolix 150 mg QD\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via a Numeric Rating Scale (NRS) in the electronic diary. Efficacy responder: ≥ 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}, {"id": "OG002", "title": "Group C", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via NRS in the electronic diary. Incomplete efficacy responder: \\< 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"type": "PRIMARY", "title": "Proportion of Responders at Month 6 Based on NMPP Pain Scale", "description": "Proportion of responders at Month 6 based upon the scale for NMPP pain scale (ranging from 0 \\[none\\] to 3 \\[severe\\]) using the daily e-Diary, as well as no increased analgesic rescue use for endometriosis-associated pain.", "populationDescription": "Analysis was intended to be based on ROC threshold, which could not be calculated, since only 1 participant had a Month 6 assessment for this endpoint at the time of study termination.", "reportingStatus": "POSTED", "timeFrame": "Month 6", "groups": [{"id": "OG000", "title": "Group A", "description": "Day 1 through Month 3 (open-label): elagolix 150 mg QD\n\nParticipants discontinued prematurely during the open-label period."}, {"id": "OG001", "title": "Group B", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Efficacy responders to elagolix 150 mg QD Month 3 continued on elagolix 150 mg QD\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via a Numeric Rating Scale (NRS) in the electronic diary. Efficacy responder: ≥ 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}, {"id": "OG002", "title": "Group C", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via NRS in the electronic diary. Incomplete efficacy responder: \\< 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in DYS at Month 6", "description": "The DYS pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.", "populationDescription": "Participants with an assessment at baseline and given time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "Month 0 (baseline), Month 6", "groups": [{"id": "OG000", "title": "Group A", "description": "Day 1 through Month 3 (open-label): elagolix 150 mg QD\n\nParticipants discontinued prematurely during the open-label period."}, {"id": "OG001", "title": "Group B", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Efficacy responders to elagolix 150 mg QD Month 3 continued on elagolix 150 mg QD\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via a Numeric Rating Scale (NRS) in the electronic diary. Efficacy responder: ≥ 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}, {"id": "OG002", "title": "Group C", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via NRS in the electronic diary. Incomplete efficacy responder: \\< 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG001", "value": "-0.23", "spread": "NA", "comment": "1 participant analyzed"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in NMPP at Month 6", "description": "The NMPP pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.", "populationDescription": "Participants with an assessment at baseline and given time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "Month 0 (baseline), Month 6", "groups": [{"id": "OG000", "title": "Group A", "description": "Day 1 through Month 3 (open-label): elagolix 150 mg QD\n\nParticipants discontinued prematurely during the open-label period."}, {"id": "OG001", "title": "Group B", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Efficacy responders to elagolix 150 mg QD Month 3 continued on elagolix 150 mg QD\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via a Numeric Rating Scale (NRS) in the electronic diary. Efficacy responder: ≥ 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}, {"id": "OG002", "title": "Group C", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via NRS in the electronic diary. Incomplete efficacy responder: \\< 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG001", "value": "-0.13", "spread": "0.061"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Dyspareunia at Month 6", "description": "The dyspareunia pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.", "populationDescription": "Participants with an assessment at baseline and given time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "Month 0 (baseline), Month 6", "groups": [{"id": "OG000", "title": "Group A", "description": "Day 1 through Month 3 (open-label): elagolix 150 mg QD\n\nParticipants discontinued prematurely during the open-label period."}, {"id": "OG001", "title": "Group B", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Efficacy responders to elagolix 150 mg QD Month 3 continued on elagolix 150 mg QD\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via a Numeric Rating Scale (NRS) in the electronic diary. Efficacy responder: ≥ 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}, {"id": "OG002", "title": "Group C", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via NRS in the electronic diary. Incomplete efficacy responder: \\< 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG001", "value": "0.29", "spread": "NA", "comment": "1 participant analyzed"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Daily Diary Endometriosis-Associated Pain Score Via Numeric Rating Scale (NRS) at Month 6", "description": "The NRS for overall endometriosis-associated pain ranges from 0 (none) to 10 (worst pain ever), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.", "populationDescription": "Participants with an assessment at baseline and given time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "Month 0 (baseline), Month 6", "groups": [{"id": "OG000", "title": "Group A", "description": "Day 1 through Month 3 (open-label): elagolix 150 mg QD\n\nParticipants discontinued prematurely during the open-label period."}, {"id": "OG001", "title": "Group B", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Efficacy responders to elagolix 150 mg QD Month 3 continued on elagolix 150 mg QD\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via a Numeric Rating Scale (NRS) in the electronic diary. Efficacy responder: ≥ 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}, {"id": "OG002", "title": "Group C", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via NRS in the electronic diary. Incomplete efficacy responder: \\< 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG001", "value": "-1.36", "spread": "0.020"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Rescue Analgesic Use Across Both Classes of Rescue Analgesics (NSAIDs/Opioids) at Month 6", "description": "Based on average pill counts and assessed using the daily e-Diary. Permitted non-steroidal anti-inflammatory drugs (NSAIDs) included naproxen, ibuprofen, diclofenac, and celecoxib. Permitted opioids included hydrocodone + acetaminophen and codeine phosphate + acetaminophen.", "populationDescription": "Participants with an assessment at baseline and given time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pills/day", "timeFrame": "Month 0 (baseline), Month 6", "groups": [{"id": "OG000", "title": "Group A", "description": "Day 1 through Month 3 (open-label): elagolix 150 mg QD\n\nParticipants discontinued prematurely during the open-label period."}, {"id": "OG001", "title": "Group B", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Efficacy responders to elagolix 150 mg QD Month 3 continued on elagolix 150 mg QD\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via a Numeric Rating Scale (NRS) in the electronic diary. Efficacy responder: ≥ 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}, {"id": "OG002", "title": "Group C", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via NRS in the electronic diary. Incomplete efficacy responder: \\< 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "0"}]}], "classes": [{"title": "NSAID: Change at Month 6", "categories": [{"measurements": [{"groupId": "OG001", "value": "0.63", "spread": "0.606"}]}]}, {"title": "Opioid: Change at Month 6", "categories": [{"measurements": [{"groupId": "OG001", "value": "0.09", "spread": "0.121"}]}]}, {"title": "NSAID + Opioid: Change at Month 6", "categories": [{"measurements": [{"groupId": "OG001", "value": "0.71", "spread": "0.485"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With 30% or More Reduction From Baseline Based on the 35 Day Mean of the Daily Diary Endometriosis-Associated Pain Score Via NRS at Month 6", "description": "The NRS for overall endometriosis-associated pain ranges from 0 (none) to 10 (worst pain ever), recorded in a daily eDiary and averaged monthly based on a 35-day window.", "populationDescription": "Participants with both baseline and post-baseline values for Daily Diary Endometriosis-Associated Pain Score via NRS.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Month 6", "groups": [{"id": "OG000", "title": "Group A", "description": "Day 1 through Month 3 (open-label): elagolix 150 mg QD\n\nParticipants discontinued prematurely during the open-label period."}, {"id": "OG001", "title": "Group B", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Efficacy responders to elagolix 150 mg QD Month 3 continued on elagolix 150 mg QD\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via a Numeric Rating Scale (NRS) in the electronic diary. Efficacy responder: ≥ 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}, {"id": "OG002", "title": "Group C", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via NRS in the electronic diary. Incomplete efficacy responder: \\< 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG001", "value": "50.0"}]}]}]}, {"type": "SECONDARY", "title": "Proportion of Responders Over Time", "description": "As assessed by change and percent change from baseline in average pain score and rescue analgesic use monthly for DYS, NMPP, dyspareunia, and Daily Diary endometriosis-associated pain score via NRS, respectively.", "populationDescription": "Analysis was intended to be based on ROC threshold, which could not be calculated for this endpoint due to low enrollment at the time of study termination.", "reportingStatus": "POSTED", "timeFrame": "Month 0 (baseline), Months 1, 2, 3, 4, 5, 6", "groups": [{"id": "OG000", "title": "Group A", "description": "Day 1 through Month 3 (open-label): elagolix 150 mg QD\n\nParticipants discontinued prematurely during the open-label period."}, {"id": "OG001", "title": "Group B", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Efficacy responders to elagolix 150 mg QD Month 3 continued on elagolix 150 mg QD\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via a Numeric Rating Scale (NRS) in the electronic diary. Efficacy responder: ≥ 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}, {"id": "OG002", "title": "Group C", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via NRS in the electronic diary. Incomplete efficacy responder: \\< 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Proportion of Responders Over Time (Not Taking Into Consideration of Analgesic Use)", "description": "As assessed by change and percent change from Baseline in average pain score and rescue analgesic use monthly for DYS, NMPP, dyspareunia, and Daily Diary endometriosis-associated pain score via NRS, respectively.", "populationDescription": "Analysis was intended to be based on ROC threshold, which could not be calculated for this endpoint due to low enrollment at the time of study termination.", "reportingStatus": "POSTED", "timeFrame": "Month 0 (baseline), Months 1, 2, 3, 4, 5, 6", "groups": [{"id": "OG000", "title": "Group A", "description": "Day 1 through Month 3 (open-label): elagolix 150 mg QD\n\nParticipants discontinued prematurely during the open-label period."}, {"id": "OG001", "title": "Group B", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Efficacy responders to elagolix 150 mg QD Month 3 continued on elagolix 150 mg QD\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via a Numeric Rating Scale (NRS) in the electronic diary. Efficacy responder: ≥ 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}, {"id": "OG002", "title": "Group C", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via NRS in the electronic diary. Incomplete efficacy responder: \\< 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Change From Baseline Over Time in Monthly Average DYS Pain Score", "description": "The DYS pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.\n\nThe analysis was based on a 28-day window. If a participant prematurely discontinued during the open-label period, based on the analysis window, some data might fall into Month 4 analysis.", "populationDescription": "Participants with an assessment at baseline and given time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "Month 0 (baseline), Months 1, 2, 3, 4, 5, 6", "groups": [{"id": "OG000", "title": "Group A", "description": "Day 1 through Month 3 (open-label): elagolix 150 mg QD\n\nParticipants discontinued prematurely during the open-label period."}, {"id": "OG001", "title": "Group B", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Efficacy responders to elagolix 150 mg QD Month 3 continued on elagolix 150 mg QD\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via a Numeric Rating Scale (NRS) in the electronic diary. Efficacy responder: ≥ 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}, {"id": "OG002", "title": "Group C", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via NRS in the electronic diary. Incomplete efficacy responder: \\< 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "0"}]}], "classes": [{"title": "Change at Month 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.05", "spread": "0.655"}, {"groupId": "OG001", "value": "-0.04", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Change at Month 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.18", "spread": "0.124"}, {"groupId": "OG001", "value": "-0.26", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Change at Month 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.50", "spread": "0.263"}, {"groupId": "OG001", "value": "-0.34", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Change at Month 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.69", "spread": "NA", "comment": "1 participant analyzed"}, {"groupId": "OG001", "value": "-0.06", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Change at Month 5", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "-0.16", "spread": "0.141"}]}]}, {"title": "Change at Month 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "-0.23", "spread": "NA", "comment": "1 participant analyzed"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline Over Time in Monthly Average NMPP Pain Score", "description": "The NMPP pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.", "populationDescription": "Participants with an assessment at baseline and given time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "Month 0 (baseline), Months 1, 2, 3, 4, 5, 6", "groups": [{"id": "OG000", "title": "Group A", "description": "Day 1 through Month 3 (open-label): elagolix 150 mg QD\n\nParticipants discontinued prematurely during the open-label period."}, {"id": "OG001", "title": "Group B", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Efficacy responders to elagolix 150 mg QD Month 3 continued on elagolix 150 mg QD\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via a Numeric Rating Scale (NRS) in the electronic diary. Efficacy responder: ≥ 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}, {"id": "OG002", "title": "Group C", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via NRS in the electronic diary. Incomplete efficacy responder: \\< 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "classes": [{"title": "Change at Month 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.13", "spread": "0.252"}, {"groupId": "OG001", "value": "-0.07", "spread": "0.508"}, {"groupId": "OG002", "value": "0.39", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Change at Month 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.48", "spread": "0.394"}, {"groupId": "OG001", "value": "-0.30", "spread": "0.167"}, {"groupId": "OG002", "value": "0.29", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Change at Month 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.70", "spread": "0.828"}, {"groupId": "OG001", "value": "-0.30", "spread": "0.092"}, {"groupId": "OG002", "value": "0.54", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Change at Month 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.34", "spread": "NA", "comment": "1 participant analyzed"}, {"groupId": "OG001", "value": "-0.34", "spread": "0.029"}, {"groupId": "OG002", "value": "0.46", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Change at Month 5", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "-0.27", "spread": "0.256"}]}]}, {"title": "Change at Month 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "-0.13", "spread": "0.061"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline Over Time in Monthly Average Dyspareunia Pain Score", "description": "The dyspareunia pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.", "populationDescription": "Participants with an assessment at baseline and given time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "Month 0 (baseline), Months 1, 2, 3, 4, 5, 6", "groups": [{"id": "OG000", "title": "Group A", "description": "Day 1 through Month 3 (open-label): elagolix 150 mg QD\n\nParticipants discontinued prematurely during the open-label period."}, {"id": "OG001", "title": "Group B", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Efficacy responders to elagolix 150 mg QD Month 3 continued on elagolix 150 mg QD\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via a Numeric Rating Scale (NRS) in the electronic diary. Efficacy responder: ≥ 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}, {"id": "OG002", "title": "Group C", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via NRS in the electronic diary. Incomplete efficacy responder: \\< 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "1"}]}], "classes": [{"title": "Change at Month 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.50", "spread": "0.741"}, {"groupId": "OG001", "value": "0.30", "spread": "NA", "comment": "1 participant analyzed"}, {"groupId": "OG002", "value": "-0.29", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Change at Month 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.44", "spread": "1.071"}, {"groupId": "OG001", "value": "0.06", "spread": "NA", "comment": "1 participant analyzed"}, {"groupId": "OG002", "value": "-0.37", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Change at Month 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.20", "spread": "NA", "comment": "1 participant analyzed"}, {"groupId": "OG001", "value": "0.07", "spread": "0.101"}, {"groupId": "OG002", "value": "-0.03", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Change at Month 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.23", "spread": "NA", "comment": "1 participant analyzed"}, {"groupId": "OG001", "value": "0.09", "spread": "0.040"}, {"groupId": "OG002", "value": "-0.03", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Change at Month 5", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "0.09", "spread": "0.081"}]}]}, {"title": "Change at Month 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "0.29", "spread": "NA", "comment": "1 participant analyzed"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline Over Time in Monthly Average Daily Diary Endometriosis-Associated Pain Score Via NRS", "description": "The NRS for overall endometriosis-associated pain ranges from 0 (none) to 10 (worst pain ever), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.", "populationDescription": "Participants with an assessment at baseline and given time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "Month 0 (baseline), Months 1, 2, 3, 4, 5, 6", "groups": [{"id": "OG000", "title": "Group A", "description": "Day 1 through Month 3 (open-label): elagolix 150 mg QD\n\nParticipants discontinued prematurely during the open-label period."}, {"id": "OG001", "title": "Group B", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Efficacy responders to elagolix 150 mg QD Month 3 continued on elagolix 150 mg QD\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via a Numeric Rating Scale (NRS) in the electronic diary. Efficacy responder: ≥ 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}, {"id": "OG002", "title": "Group C", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via NRS in the electronic diary. Incomplete efficacy responder: \\< 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "classes": [{"title": "Change at Month 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.86", "spread": "1.975"}, {"groupId": "OG001", "value": "-0.89", "spread": "1.159"}, {"groupId": "OG002", "value": "-0.84", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Change at Month 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.40", "spread": "2.106"}, {"groupId": "OG001", "value": "-2.02", "spread": "0.758"}, {"groupId": "OG002", "value": "-1.40", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Change at Month 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.70", "spread": "3.616"}, {"groupId": "OG001", "value": "-1.81", "spread": "0.430"}, {"groupId": "OG002", "value": "-1.34", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Change at Month 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-6.43", "spread": "NA", "comment": "1 participant analyzed"}, {"groupId": "OG001", "value": "-1.43", "spread": "1.078"}, {"groupId": "OG002", "value": "-1.06", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Change at Month 5", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "-1.40", "spread": "0.961"}]}]}, {"title": "Change at Month 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "-1.36", "spread": "0.020"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline to Each Month During the Treatment Period for DYS", "description": "The DYS pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.", "populationDescription": "Participants with an assessment at baseline and given time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent change of units on a scale", "timeFrame": "Month 0 (baseline), Months 1, 2, 3, 4, 5, 6", "groups": [{"id": "OG000", "title": "Group A", "description": "Day 1 through Month 3 (open-label): elagolix 150 mg QD\n\nParticipants discontinued prematurely during the open-label period."}, {"id": "OG001", "title": "Group B", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Efficacy responders to elagolix 150 mg QD Month 3 continued on elagolix 150 mg QD\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via a Numeric Rating Scale (NRS) in the electronic diary. Efficacy responder: ≥ 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}, {"id": "OG002", "title": "Group C", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via NRS in the electronic diary. Incomplete efficacy responder: \\< 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "0"}]}], "classes": [{"title": "Percent Change at Month 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.67", "spread": "109.961"}, {"groupId": "OG001", "value": "-7.89", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Percent Change at Month 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-27.45", "spread": "17.119"}, {"groupId": "OG001", "value": "-75.00", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Percent Change at Month 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-62.92", "spread": "24.159"}, {"groupId": "OG001", "value": "-85.71", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Percent Change at Month 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-80.00", "spread": "NA", "comment": "1 participant analyzed"}, {"groupId": "OG001", "value": "-16.67", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Percent Change at Month 5", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "-40.48", "spread": "33.672"}]}]}, {"title": "Percent Change at Month 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "-57.14", "spread": "NA", "comment": "1 participant analyzed"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline to Each Month During the Treatment Period for NMPP", "description": "The NMPP pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.", "populationDescription": "Participants with an assessment at baseline and given time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage change of units on a scale", "timeFrame": "Month 0 (baseline), Months 1, 2, 3, 4, 5, 6", "groups": [{"id": "OG000", "title": "Group A", "description": "Day 1 through Month 3 (open-label): elagolix 150 mg QD\n\nParticipants discontinued prematurely during the open-label period."}, {"id": "OG001", "title": "Group B", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Efficacy responders to elagolix 150 mg QD Month 3 continued on elagolix 150 mg QD\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via a Numeric Rating Scale (NRS) in the electronic diary. Efficacy responder: ≥ 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}, {"id": "OG002", "title": "Group C", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via NRS in the electronic diary. Incomplete efficacy responder: \\< 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "classes": [{"title": "Percent Change at Month 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-11.81", "spread": "26.677"}, {"groupId": "OG001", "value": "4.22", "spread": "53.238"}, {"groupId": "OG002", "value": "16.07", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Percent Change at Month 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-37.53", "spread": "31.150"}, {"groupId": "OG001", "value": "-34.21", "spread": "18.044"}, {"groupId": "OG002", "value": "11.90", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Percent Change at Month 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-38.26", "spread": "42.319"}, {"groupId": "OG001", "value": "-38.03", "spread": "20.343"}, {"groupId": "OG002", "value": "22.62", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Percent Change at Month 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-71.21", "spread": "NA", "comment": "1 participant analyzed"}, {"groupId": "OG001", "value": "-44.49", "spread": "20.725"}, {"groupId": "OG002", "value": "19.05", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Percent Change at Month 5", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "-28.40", "spread": "33.641"}]}]}, {"title": "Percent Change at Month 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "-17.23", "spread": "16.044"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline to Each Month During the Treatment Period for Dyspareunia", "description": "The dyspareunia pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.", "populationDescription": "Participants with an assessment at baseline and given time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage change of units on a scale", "timeFrame": "Month 0 (baseline), Months 1, 2, 3, 4, 5, 6", "groups": [{"id": "OG000", "title": "Group A", "description": "Day 1 through Month 3 (open-label): elagolix 150 mg QD\n\nParticipants discontinued prematurely during the open-label period."}, {"id": "OG001", "title": "Group B", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Efficacy responders to elagolix 150 mg QD Month 3 continued on elagolix 150 mg QD\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via a Numeric Rating Scale (NRS) in the electronic diary. Efficacy responder: ≥ 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}, {"id": "OG002", "title": "Group C", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via NRS in the electronic diary. Incomplete efficacy responder: \\< 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "classes": [{"title": "Percent Change at Month 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.14", "spread": "18.180"}, {"groupId": "OG001", "value": "-15.27", "spread": "26.791"}, {"groupId": "OG002", "value": "-9.52", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Percent Change at Month 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "6.60", "spread": "15.719"}, {"groupId": "OG001", "value": "-15.26", "spread": "21.840"}, {"groupId": "OG002", "value": "-12.38", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Percent Change at Month 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "60.88", "spread": "65.632"}, {"groupId": "OG001", "value": "-21.63", "spread": "24.719"}, {"groupId": "OG002", "value": "-0.95", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Percent Change at Month 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "106.25", "spread": "NA", "comment": "1 participant analyzed"}, {"groupId": "OG001", "value": "-12.67", "spread": "20.433"}, {"groupId": "OG002", "value": "-0.95", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Percent Change at Month 5", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "-14.86", "spread": "16.002"}]}]}, {"title": "Percent Change at Month 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "-18.08", "spread": "25.571"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline to Each Month During the Treatment Period for Daily Diary Endometriosis-Associated Pain Score Via NRS", "description": "The NRS for overall endometriosis-associated pain ranges from 0 (none) to 10 (worst pain ever), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.", "populationDescription": "Participants with an assessment at baseline and given time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage change of score on a scale", "timeFrame": "Month 0 (baseline), Months 1, 2, 3, 4, 5, 6", "groups": [{"id": "OG000", "title": "Group A", "description": "Day 1 through Month 3 (open-label): elagolix 150 mg QD\n\nParticipants discontinued prematurely during the open-label period."}, {"id": "OG001", "title": "Group B", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Efficacy responders to elagolix 150 mg QD Month 3 continued on elagolix 150 mg QD\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via a Numeric Rating Scale (NRS) in the electronic diary. Efficacy responder: ≥ 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}, {"id": "OG002", "title": "Group C", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via NRS in the electronic diary. Incomplete efficacy responder: \\< 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "classes": [{"title": "Percent Change at Month 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-14.10", "spread": "37.146"}, {"groupId": "OG001", "value": "-19.61", "spread": "35.468"}, {"groupId": "OG002", "value": "-11.34", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Percent Change at Month 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-37.82", "spread": "18.066"}, {"groupId": "OG001", "value": "-56.25", "spread": "4.507"}, {"groupId": "OG002", "value": "-18.99", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Percent Change at Month 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-43.98", "spread": "35.509"}, {"groupId": "OG001", "value": "-53.05", "spread": "13.803"}, {"groupId": "OG002", "value": "-18.22", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Percent Change at Month 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-70.98", "spread": "NA", "comment": "1 participant analyzed"}, {"groupId": "OG001", "value": "-38.00", "spread": "31.275"}, {"groupId": "OG002", "value": "-14.34", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Percent Change at Month 5", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "-35.81", "spread": "9.326"}]}]}, {"title": "Percent Change at Month 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "-33.56", "spread": "11.357"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline Over Time in Daily Rescue Analgesic Use Across Both Classes of Rescue Analgesics", "description": "Based on average pill counts and assessed using a daily e-Diary. Permitted non-steroidal anti-inflammatory drugs (NSAIDs) included naproxen, ibuprofen, diclofenac, and celecoxib. Permitted opioids included hydrocodone + acetaminophen and codeine phosphate + acetaminophen.", "populationDescription": "Participants with an assessment at baseline and given time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pills/day", "timeFrame": "Month 0 (baseline), Months 1, 2, 3, 4, 5, 6", "groups": [{"id": "OG000", "title": "Group A", "description": "Day 1 through Month 3 (open-label): elagolix 150 mg QD\n\nParticipants discontinued prematurely during the open-label period."}, {"id": "OG001", "title": "Group B", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Efficacy responders to elagolix 150 mg QD Month 3 continued on elagolix 150 mg QD\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via a Numeric Rating Scale (NRS) in the electronic diary. Efficacy responder: ≥ 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}, {"id": "OG002", "title": "Group C", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via NRS in the electronic diary. Incomplete efficacy responder: \\< 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "classes": [{"title": "NSAID: Change at Month 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.84", "spread": "0.796"}, {"groupId": "OG001", "value": "0.09", "spread": "0.388"}, {"groupId": "OG002", "value": "-0.67", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "NSAID: Change at Month 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.15", "spread": "0.785"}, {"groupId": "OG001", "value": "-0.17", "spread": "0.834"}, {"groupId": "OG002", "value": "0.63", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "NSAID: Change at Month 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.96", "spread": "1.030"}, {"groupId": "OG001", "value": "-0.43", "spread": "1.091"}, {"groupId": "OG002", "value": "-0.71", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "NSAID: Change at Month 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.69", "spread": "NA", "comment": "1 participant analyzed"}, {"groupId": "OG001", "value": "0.01", "spread": "0.845"}, {"groupId": "OG002", "value": "-0.63", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "NSAID: Change at Month 5", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "0.23", "spread": "1.197"}]}]}, {"title": "NSAID: Change at Month 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "0.63", "spread": "0.606"}]}]}, {"title": "Opioid: Change at Month 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.12", "spread": "0.552"}, {"groupId": "OG001", "value": "-0.06", "spread": "0.099"}, {"groupId": "OG002", "value": "-0.43", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Opioid: Change at Month 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.17", "spread": "0.263"}, {"groupId": "OG001", "value": "-0.03", "spread": "0.049"}, {"groupId": "OG002", "value": "-0.51", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Opioid: Change at Month 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.17", "spread": "0.242"}, {"groupId": "OG001", "value": "0.02", "spread": "0.016"}, {"groupId": "OG002", "value": "-0.49", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Opioid: Change at Month 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.34", "spread": "NA", "comment": "1 participant analyzed"}, {"groupId": "OG001", "value": "-0.01", "spread": "0.044"}, {"groupId": "OG002", "value": "-0.40", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Opioid: Change at Month 5", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "-0.05", "spread": "0.082"}]}]}, {"title": "Opioid: Change at Month 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "0.09", "spread": "0.121"}]}]}, {"title": "NSAID + Opioid: Change at Month 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.72", "spread": "1.178"}, {"groupId": "OG001", "value": "0.03", "spread": "0.436"}, {"groupId": "OG002", "value": "-1.10", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "NSAID + Opioid: Change at Month 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.33", "spread": "0.767"}, {"groupId": "OG001", "value": "-0.20", "spread": "0.830"}, {"groupId": "OG002", "value": "-1.14", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "NSAID + Opioid: Change at Month 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.13", "spread": "1.273"}, {"groupId": "OG001", "value": "-0.41", "spread": "1.107"}, {"groupId": "OG002", "value": "-1.20", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "NSAID + Opioid: Change at Month 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.03", "spread": "NA", "comment": "1 participant analyzed"}, {"groupId": "OG001", "value": "-0.00", "spread": "0.863"}, {"groupId": "OG002", "value": "-1.03", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "NSAID + Opioid: Change at Month 5", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "0.18", "spread": "1.217"}]}]}, {"title": "NSAID + Opioid: Change at Month 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "0.71", "spread": "0.485"}]}]}]}, {"type": "SECONDARY", "title": "Number of Analgesic Use Responders and Non-Responders Over Time", "description": "Based only on reduction of rescue analgesics used. Responders were defined as:\n\n* participants with no analgesic use at screening and no analgesic use added\n* participants with NSAID only use at screening and NSAID dose stopped, decreased, or stable (\\<15% increase) and no opioid use added\n* participants with opioid only use at screening and opioid dose stopped, decreased, or stable (\\<15% increase), opioid dose stopped and NSAID substituted (any dose), opioid dose decreased and NSAID added (any dose)\n* participants with NSAID + opioid use at screening and any of the following: NSAID dose stopped + opioid analgesic use stopped, decreased, or stable (\\<15% increase); NSAID dose decreased + opioid analgesic use stopped, decreased, or stable (\\<15% increase); NSAID dose stable (\\< 15% increase) + opioid analgesic use stopped, decreased, or stable (\\<15% increase); NSAID dose increased by \\>15% + opioid analgesic use stopped; NSAID dose increased by \\>15% + opioid analgesic dose decreases.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Months 1, 2, 3, 4, 5, 6", "groups": [{"id": "OG000", "title": "Group A", "description": "Day 1 through Month 3 (open-label): elagolix 150 mg QD\n\nParticipants discontinued prematurely during the open-label period."}, {"id": "OG001", "title": "Group B", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Efficacy responders to elagolix 150 mg QD Month 3 continued on elagolix 150 mg QD\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via a Numeric Rating Scale (NRS) in the electronic diary. Efficacy responder: ≥ 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}, {"id": "OG002", "title": "Group C", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via NRS in the electronic diary. Incomplete efficacy responder: \\< 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "classes": [{"title": "Month 1: Responder", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "1"}]}]}, {"title": "Month 1: Non-Responder", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Month 2: Responder", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "1"}]}]}, {"title": "Month 2: Non-Responder", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Month 3: Responder", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "1"}]}]}, {"title": "Month 3: Non-Responder", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Month 4: Responder", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "1"}]}]}, {"title": "Month 4: Non-Responder", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Month 5: Responder", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Month 5: Non-Responder", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Month 6: Responder", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Month 6: Non-Responder", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Patient Global Impression of Change (PGIC) Scores Over Time", "description": "The PGIC is a 7-point response scale where participants rate their endometriosis related pain as: very much improved (1), much improved (2), minimally improved (3), not changed (4), minimally worse (5), much worse (6), very much worse (7).", "populationDescription": "Participants with an assessment at given time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "Months 1, 2, 3, 4, 5, 6", "groups": [{"id": "OG000", "title": "Group A", "description": "Day 1 through Month 3 (open-label): elagolix 150 mg QD\n\nParticipants discontinued prematurely during the open-label period."}, {"id": "OG001", "title": "Group B", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Efficacy responders to elagolix 150 mg QD Month 3 continued on elagolix 150 mg QD\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via a Numeric Rating Scale (NRS) in the electronic diary. Efficacy responder: ≥ 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}, {"id": "OG002", "title": "Group C", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via NRS in the electronic diary. Incomplete efficacy responder: \\< 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "classes": [{"title": "Month 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.9", "spread": "1.35"}, {"groupId": "OG001", "value": "2.3", "spread": "0.58"}, {"groupId": "OG002", "value": "2.0", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Month 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.0", "spread": "0.00"}, {"groupId": "OG001", "value": "1.3", "spread": "0.58"}, {"groupId": "OG002", "value": "2.0", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Month 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.0", "spread": "NA", "comment": "1 participant analyzed"}, {"groupId": "OG001", "value": "2.0", "spread": "1.00"}, {"groupId": "OG002", "value": "5.0", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Month 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "2.0", "spread": "1.00"}, {"groupId": "OG002", "value": "2.0", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Month 5", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "2.5", "spread": "0.71"}]}]}, {"title": "Month 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "1.0", "spread": "NA", "comment": "1 participant analyzed"}]}]}]}, {"type": "SECONDARY", "title": "Overall Endometriosis-Associated Pain Via NRS (7-Day Recall) Scores Over Time", "description": "The endometriosis-associated pain questionnaire is an 11-point NRS assessing overall endometriosis-associated pain over a 7-day recall period. Participants assessed their endometriosis-associated pain on a scale of 0 to 10, with 0 = no pain and 10 = worst pain ever.", "populationDescription": "Participants with an assessment at given time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "Month 0 (baseline), Months 1, 2, 3, 4, 5, 6", "groups": [{"id": "OG000", "title": "Group A", "description": "Day 1 through Month 3 (open-label): elagolix 150 mg QD\n\nParticipants discontinued prematurely during the open-label period."}, {"id": "OG001", "title": "Group B", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Efficacy responders to elagolix 150 mg QD Month 3 continued on elagolix 150 mg QD\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via a Numeric Rating Scale (NRS) in the electronic diary. Efficacy responder: ≥ 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}, {"id": "OG002", "title": "Group C", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via NRS in the electronic diary. Incomplete efficacy responder: \\< 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "8.2", "spread": "1.79"}, {"groupId": "OG001", "value": "9.0", "spread": "1.00"}, {"groupId": "OG002", "value": "7.0", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Month 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "5.7", "spread": "3.04"}, {"groupId": "OG001", "value": "7.7", "spread": "1.15"}, {"groupId": "OG002", "value": "8.0", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Month 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.5", "spread": "0.71"}, {"groupId": "OG001", "value": "2.7", "spread": "1.15"}, {"groupId": "OG002", "value": "5.0", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Month 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "9.0", "spread": "NA", "comment": "1 participant analyzed"}, {"groupId": "OG001", "value": "5.3", "spread": "2.31"}, {"groupId": "OG002", "value": "8.0", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Month 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "3.3", "spread": "0.58"}, {"groupId": "OG002", "value": "7.0", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Month 5", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "8.0", "spread": "0.00"}]}]}, {"title": "Month 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "4.0", "spread": "NA", "comment": "1 participant analyzed"}]}]}]}, {"type": "SECONDARY", "title": "Endometriosis Health Profile-30 (EHP-30) Scores Over Time: Pain", "description": "The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Domains used in the study included Pain, Control and Powerlessness, Well-Being, Social Support, Self-Image, and Sexual Intercourse. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.", "populationDescription": "Participants with an assessment at given time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "Month 0 (baseline), Months 3, 6", "groups": [{"id": "OG000", "title": "Group A", "description": "Day 1 through Month 3 (open-label): elagolix 150 mg QD\n\nParticipants discontinued prematurely during the open-label period."}, {"id": "OG001", "title": "Group B", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Efficacy responders to elagolix 150 mg QD Month 3 continued on elagolix 150 mg QD\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via a Numeric Rating Scale (NRS) in the electronic diary. Efficacy responder: ≥ 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}, {"id": "OG002", "title": "Group C", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via NRS in the electronic diary. Incomplete efficacy responder: \\< 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "59.42", "spread": "11.694"}, {"groupId": "OG001", "value": "47.73", "spread": "14.193"}, {"groupId": "OG002", "value": "59.09", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Month 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "38.07", "spread": "26.529"}, {"groupId": "OG001", "value": "17.42", "spread": "22.422"}, {"groupId": "OG002", "value": "38.64", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Month 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "27.27", "spread": "NA", "comment": "1 participant analyzed"}]}]}]}, {"type": "SECONDARY", "title": "EHP-30 Scores Over Time: Control and Powerlessness", "description": "The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Domains used in the study included Pain, Control and Powerlessness, Well-Being, Social Support, Self-Image, and Sexual Intercourse. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.", "populationDescription": "Participants with an assessment at given time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "Month 0 (baseline), Months 3, 6", "groups": [{"id": "OG000", "title": "Group A", "description": "Day 1 through Month 3 (open-label): elagolix 150 mg QD\n\nParticipants discontinued prematurely during the open-label period."}, {"id": "OG001", "title": "Group B", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Efficacy responders to elagolix 150 mg QD Month 3 continued on elagolix 150 mg QD\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via a Numeric Rating Scale (NRS) in the electronic diary. Efficacy responder: ≥ 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}, {"id": "OG002", "title": "Group C", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via NRS in the electronic diary. Incomplete efficacy responder: \\< 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "71.43", "spread": "19.159"}, {"groupId": "OG001", "value": "56.94", "spread": "19.691"}, {"groupId": "OG002", "value": "41.67", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Month 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "36.46", "spread": "32.874"}, {"groupId": "OG001", "value": "26.39", "spread": "21.382"}, {"groupId": "OG002", "value": "25.00", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Month 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "8.33", "spread": "NA", "comment": "1 participant analyzed"}]}]}]}, {"type": "SECONDARY", "title": "EHP-30 Scores Over Time: Emotional Well-Being", "description": "The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Domains used in the study included Pain, Control and Powerlessness, Well-Being, Social Support, Self-Image, and Sexual Intercourse. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.", "populationDescription": "Participants with an assessment at given time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "Month 0 (baseline), Months 3, 6", "groups": [{"id": "OG000", "title": "Group A", "description": "Day 1 through Month 3 (open-label): elagolix 150 mg QD\n\nParticipants discontinued prematurely during the open-label period."}, {"id": "OG001", "title": "Group B", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Efficacy responders to elagolix 150 mg QD Month 3 continued on elagolix 150 mg QD\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via a Numeric Rating Scale (NRS) in the electronic diary. Efficacy responder: ≥ 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}, {"id": "OG002", "title": "Group C", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via NRS in the electronic diary. Incomplete efficacy responder: \\< 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "29.76", "spread": "8.815"}, {"groupId": "OG001", "value": "50.00", "spread": "8.333"}, {"groupId": "OG002", "value": "45.83", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Month 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "18.75", "spread": "12.500"}, {"groupId": "OG001", "value": "23.61", "spread": "17.347"}, {"groupId": "OG002", "value": "37.50", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Month 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "25.00", "spread": "NA", "comment": "1 participant analyzed"}]}]}]}, {"type": "SECONDARY", "title": "EHP-30 Scores Over Time: Social Support", "description": "The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Domains used in the study included Pain, Control and Powerlessness, Well-Being, Social Support, Self-Image, and Sexual Intercourse. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.", "populationDescription": "Participants with an assessment at given time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "Month 0 (baseline), Months 3, 6", "groups": [{"id": "OG000", "title": "Group A", "description": "Day 1 through Month 3 (open-label): elagolix 150 mg QD\n\nParticipants discontinued prematurely during the open-label period."}, {"id": "OG001", "title": "Group B", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Efficacy responders to elagolix 150 mg QD Month 3 continued on elagolix 150 mg QD\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via a Numeric Rating Scale (NRS) in the electronic diary. Efficacy responder: ≥ 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}, {"id": "OG002", "title": "Group C", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via NRS in the electronic diary. Incomplete efficacy responder: \\< 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "48.21", "spread": "21.565"}, {"groupId": "OG001", "value": "45.83", "spread": "19.094"}, {"groupId": "OG002", "value": "50.00", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Month 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "17.19", "spread": "11.831"}, {"groupId": "OG001", "value": "16.67", "spread": "28.868"}, {"groupId": "OG002", "value": "18.75", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Month 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "25.00", "spread": "NA", "comment": "1 participant analyzed"}]}]}]}, {"type": "SECONDARY", "title": "EHP-30 Scores Over Time: Self-Image", "description": "The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Domains used in the study included Pain, Control and Powerlessness, Well-Being, Social Support, Self-Image, and Sexual Intercourse. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.", "populationDescription": "Participants with an assessment at given time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "Month 0 (baseline), Months 3, 6", "groups": [{"id": "OG000", "title": "Group A", "description": "Day 1 through Month 3 (open-label): elagolix 150 mg QD\n\nParticipants discontinued prematurely during the open-label period."}, {"id": "OG001", "title": "Group B", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Efficacy responders to elagolix 150 mg QD Month 3 continued on elagolix 150 mg QD\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via a Numeric Rating Scale (NRS) in the electronic diary. Efficacy responder: ≥ 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}, {"id": "OG002", "title": "Group C", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via NRS in the electronic diary. Incomplete efficacy responder: \\< 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "50.00", "spread": "22.048"}, {"groupId": "OG001", "value": "36.11", "spread": "31.549"}, {"groupId": "OG002", "value": "75.00", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Month 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "43.75", "spread": "41.597"}, {"groupId": "OG001", "value": "8.33", "spread": "14.434"}, {"groupId": "OG002", "value": "8.33", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Month 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "16.67", "spread": "NA", "comment": "1 participant analyzed"}]}]}]}, {"type": "SECONDARY", "title": "EHP-30 Scores Over Time: Sexual Intercourse", "description": "The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Domains used in the study included Pain, Control and Powerlessness, Well-Being, Social Support, Self-Image, and Sexual Intercourse. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.", "populationDescription": "Participants with an assessment at given time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "Month 0 (baseline), Months 3, 6", "groups": [{"id": "OG000", "title": "Group A", "description": "Day 1 through Month 3 (open-label): elagolix 150 mg QD\n\nParticipants discontinued prematurely during the open-label period."}, {"id": "OG001", "title": "Group B", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Efficacy responders to elagolix 150 mg QD Month 3 continued on elagolix 150 mg QD\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via a Numeric Rating Scale (NRS) in the electronic diary. Efficacy responder: ≥ 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}, {"id": "OG002", "title": "Group C", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via NRS in the electronic diary. Incomplete efficacy responder: \\< 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "1"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "70.00", "spread": "22.361"}, {"groupId": "OG001", "value": "62.50", "spread": "31.820"}, {"groupId": "OG002", "value": "60.00", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Month 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "45.00", "spread": "23.452"}, {"groupId": "OG001", "value": "45.00", "spread": "42.426"}, {"groupId": "OG002", "value": "60.00", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Month 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "30.00", "spread": "NA", "comment": "1 participant analyzed"}]}]}]}, {"type": "SECONDARY", "title": "EuroQol-5D 5 Level (EQ-5D-5L) Scores Over Time: Mobility", "description": "The EQ-5D-5L is a health state utility instrument with 5 items that comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which is rated on 5 levels of severity (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems) and a separate visual analog scale (VAS) indicating a participant's rating of their current health status (health today) on a scale of from 0 (worst health imaginable) to 100 (best health imaginable).", "populationDescription": "Participants with an assessment at given time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "Month 0 (baseline), Months 3, 6", "groups": [{"id": "OG000", "title": "Group A", "description": "Day 1 through Month 3 (open-label): elagolix 150 mg QD\n\nParticipants discontinued prematurely during the open-label period."}, {"id": "OG001", "title": "Group B", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Efficacy responders to elagolix 150 mg QD Month 3 continued on elagolix 150 mg QD\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via a Numeric Rating Scale (NRS) in the electronic diary. Efficacy responder: ≥ 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}, {"id": "OG002", "title": "Group C", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via NRS in the electronic diary. Incomplete efficacy responder: \\< 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.4", "spread": "0.53"}, {"groupId": "OG001", "value": "1.0", "spread": "0.00"}, {"groupId": "OG002", "value": "1.0", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Month 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.3", "spread": "0.50"}, {"groupId": "OG001", "value": "1.0", "spread": "0.00"}, {"groupId": "OG002", "value": "2.0", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Month 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "1.0", "spread": "NA", "comment": "1 participant analyzed"}]}]}]}, {"type": "SECONDARY", "title": "EQ-5D-5L Scores Over Time: Self-Care", "description": "The EQ-5D-5L is a health state utility instrument with 5 items that comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which is rated on 5 levels of severity (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems) and a separate visual analog scale (VAS) indicating a participant's rating of their current health status (health today) on a scale of from 0 (worst health imaginable) to 100 (best health imaginable).", "populationDescription": "Participants with an assessment at given time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "Month 0 (baseline), Months 3, 6", "groups": [{"id": "OG000", "title": "Group A", "description": "Day 1 through Month 3 (open-label): elagolix 150 mg QD\n\nParticipants discontinued prematurely during the open-label period."}, {"id": "OG001", "title": "Group B", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Efficacy responders to elagolix 150 mg QD Month 3 continued on elagolix 150 mg QD\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via a Numeric Rating Scale (NRS) in the electronic diary. Efficacy responder: ≥ 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}, {"id": "OG002", "title": "Group C", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via NRS in the electronic diary. Incomplete efficacy responder: \\< 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.0", "spread": "0.00"}, {"groupId": "OG001", "value": "1.0", "spread": "0.00"}, {"groupId": "OG002", "value": "1.0", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Month 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.0", "spread": "0.00"}, {"groupId": "OG001", "value": "1.0", "spread": "0.00"}, {"groupId": "OG002", "value": "1.0", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Month 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "1.0", "spread": "NA", "comment": "1 participant analyzed"}]}]}]}, {"type": "SECONDARY", "title": "EQ-5D-5L Scores Over Time: Usual Activities", "description": "The EQ-5D-5L is a health state utility instrument with 5 items that comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which is rated on 5 levels of severity (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems) and a separate visual analog scale (VAS) indicating a participant's rating of their current health status (health today) on a scale of from 0 (worst health imaginable) to 100 (best health imaginable).", "populationDescription": "Participants with an assessment at given time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "Month 0 (baseline), Months 3, 6", "groups": [{"id": "OG000", "title": "Group A", "description": "Day 1 through Month 3 (open-label): elagolix 150 mg QD\n\nParticipants discontinued prematurely during the open-label period."}, {"id": "OG001", "title": "Group B", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Efficacy responders to elagolix 150 mg QD Month 3 continued on elagolix 150 mg QD\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via a Numeric Rating Scale (NRS) in the electronic diary. Efficacy responder: ≥ 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}, {"id": "OG002", "title": "Group C", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via NRS in the electronic diary. Incomplete efficacy responder: \\< 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.0", "spread": "0.82"}, {"groupId": "OG001", "value": "1.3", "spread": "0.58"}, {"groupId": "OG002", "value": "1.0", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Month 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.5", "spread": "0.58"}, {"groupId": "OG001", "value": "1.7", "spread": "1.15"}, {"groupId": "OG002", "value": "2.0", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Month 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "1.0", "spread": "NA", "comment": "1 participant analyzed"}]}]}]}, {"type": "SECONDARY", "title": "EQ-5D-5L Scores Over Time: Pain/Discomfort", "description": "The EQ-5D-5L is a health state utility instrument with 5 items that comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which is rated on 5 levels of severity (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems) and a separate visual analog scale (VAS) indicating a participant's rating of their current health status (health today) on a scale of from 0 (worst health imaginable) to 100 (best health imaginable).", "populationDescription": "Participants with an assessment at given time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "Month 0 (baseline), Months 3, 6", "groups": [{"id": "OG000", "title": "Group A", "description": "Day 1 through Month 3 (open-label): elagolix 150 mg QD\n\nParticipants discontinued prematurely during the open-label period."}, {"id": "OG001", "title": "Group B", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Efficacy responders to elagolix 150 mg QD Month 3 continued on elagolix 150 mg QD\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via a Numeric Rating Scale (NRS) in the electronic diary. Efficacy responder: ≥ 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}, {"id": "OG002", "title": "Group C", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via NRS in the electronic diary. Incomplete efficacy responder: \\< 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.7", "spread": "0.76"}, {"groupId": "OG001", "value": "2.7", "spread": "0.58"}, {"groupId": "OG002", "value": "4.0", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Month 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.0", "spread": "1.15"}, {"groupId": "OG001", "value": "1.7", "spread": "0.58"}, {"groupId": "OG002", "value": "3.0", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Month 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "1.0", "spread": "NA", "comment": "1 participant analyzed"}]}]}]}, {"type": "SECONDARY", "title": "EQ-5D-5L Scores Over Time: Anxiety/Depression", "description": "The EQ-5D-5L is a health state utility instrument with 5 items that comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which is rated on 5 levels of severity (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems) and a separate visual analog scale (VAS) indicating a participant's rating of their current health status (health today) on a scale of from 0 (worst health imaginable) to 100 (best health imaginable).", "populationDescription": "Participants with an assessment at given time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "Month 0 (baseline), Months 3, 6", "groups": [{"id": "OG000", "title": "Group A", "description": "Day 1 through Month 3 (open-label): elagolix 150 mg QD\n\nParticipants discontinued prematurely during the open-label period."}, {"id": "OG001", "title": "Group B", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Efficacy responders to elagolix 150 mg QD Month 3 continued on elagolix 150 mg QD\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via a Numeric Rating Scale (NRS) in the electronic diary. Efficacy responder: ≥ 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}, {"id": "OG002", "title": "Group C", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via NRS in the electronic diary. Incomplete efficacy responder: \\< 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.0", "spread": "0.00"}, {"groupId": "OG001", "value": "1.3", "spread": "0.58"}, {"groupId": "OG002", "value": "1.0", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Month 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.0", "spread": "0.00"}, {"groupId": "OG001", "value": "1.0", "spread": "0.00"}, {"groupId": "OG002", "value": "1.0", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Month 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "1.0", "spread": "NA", "comment": "1 participant analyzed"}]}]}]}, {"type": "SECONDARY", "title": "EQ-5D-5L VAS Scores Over Time: Health Today", "description": "The EQ-5D-5L is a health state utility instrument with 5 items that comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which is rated on 5 levels of severity (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems) and a separate VAS indicating a participant's rating of their current health status (health today) on a scale of from 0 (worst health imaginable) to 100 (best health imaginable).", "populationDescription": "Participants with an assessment at given time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "Month 0 (baseline), Months 3, 6", "groups": [{"id": "OG000", "title": "Group A", "description": "Day 1 through Month 3 (open-label): elagolix 150 mg QD\n\nParticipants discontinued prematurely during the open-label period."}, {"id": "OG001", "title": "Group B", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Efficacy responders to elagolix 150 mg QD Month 3 continued on elagolix 150 mg QD\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via a Numeric Rating Scale (NRS) in the electronic diary. Efficacy responder: ≥ 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}, {"id": "OG002", "title": "Group C", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via NRS in the electronic diary. Incomplete efficacy responder: \\< 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "79.7", "spread": "15.16"}, {"groupId": "OG001", "value": "53.3", "spread": "35.12"}, {"groupId": "OG002", "value": "72.0", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Month 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "72.8", "spread": "17.63"}, {"groupId": "OG001", "value": "85.0", "spread": "15.00"}, {"groupId": "OG002", "value": "70.0", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Month 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "94.0", "spread": "NA", "comment": "1 participant analyzed"}]}]}]}, {"type": "SECONDARY", "title": "Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP) Scores Over Time: Percent Work Missed Due to Problem", "description": "Absenteeism is presented as the mean percentage of work time missed due to health problem (as reported on the WPAI:SHP), and is calculated as: 100\\*number of hours of work missed due to health problem / (number of hours of work missed due to health problem + number of hours worked). WPAI is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity.", "populationDescription": "Participants with an assessment at given time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent of work time missed", "timeFrame": "Month 0 (baseline), Month 6", "groups": [{"id": "OG000", "title": "Group A", "description": "Day 1 through Month 3 (open-label): elagolix 150 mg QD\n\nParticipants discontinued prematurely during the open-label period."}, {"id": "OG001", "title": "Group B", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Efficacy responders to elagolix 150 mg QD Month 3 continued on elagolix 150 mg QD\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via a Numeric Rating Scale (NRS) in the electronic diary. Efficacy responder: ≥ 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}, {"id": "OG002", "title": "Group C", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via NRS in the electronic diary. Incomplete efficacy responder: \\< 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "0"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.16", "spread": "0.205"}, {"groupId": "OG001", "value": "0.08", "spread": "0.144"}]}]}, {"title": "Month 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "spread": "0.000"}, {"groupId": "OG001", "value": "0.00", "spread": "NA", "comment": "1 participant analyzed"}]}]}]}, {"type": "SECONDARY", "title": "WPAI:SHP Scores Over Time: Percent Impairment While Working Due to Problem", "description": "Presenteeism (the extent to which health problem decreased productivity) is presented as the mean percentage of impairment while working due to health problem, and is calculated as: 100\\*scale value of question 5 on the WPAI (between 0 and 10) / 10. WPAI:SHP is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity.", "populationDescription": "Participants with an assessment at given time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent impairment while working", "timeFrame": "Month 0 (baseline), Month 6", "groups": [{"id": "OG000", "title": "Group A", "description": "Day 1 through Month 3 (open-label): elagolix 150 mg QD\n\nParticipants discontinued prematurely during the open-label period."}, {"id": "OG001", "title": "Group B", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Efficacy responders to elagolix 150 mg QD Month 3 continued on elagolix 150 mg QD\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via a Numeric Rating Scale (NRS) in the electronic diary. Efficacy responder: ≥ 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}, {"id": "OG002", "title": "Group C", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via NRS in the electronic diary. Incomplete efficacy responder: \\< 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "0"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.57", "spread": "0.273"}, {"groupId": "OG001", "value": "0.53", "spread": "0.153"}]}]}, {"title": "Month 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.30", "spread": "0.265"}, {"groupId": "OG001", "value": "0.30", "spread": "NA", "comment": "1 participant analyzed"}]}]}]}, {"type": "SECONDARY", "title": "WPAI:SHP Scores Over Time: Percent Overall Work Impairment Due to Problem", "description": "The mean percentage of overall work impairment due to health problem (based on the WPAI questionnaire) is presented, and is calculated as: Absenteeism (%) + extent to which health problem decreased productivity (%)\\* \\[number of hours worked / (number of hours of work missed due to health problem + number of hours worked)\\]. WPAI is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity.", "populationDescription": "Participants with an assessment at given time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent overall work impairment", "timeFrame": "Month 0 (baseline), Month 6", "groups": [{"id": "OG000", "title": "Group A", "description": "Day 1 through Month 3 (open-label): elagolix 150 mg QD\n\nParticipants discontinued prematurely during the open-label period."}, {"id": "OG001", "title": "Group B", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Efficacy responders to elagolix 150 mg QD Month 3 continued on elagolix 150 mg QD\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via a Numeric Rating Scale (NRS) in the electronic diary. Efficacy responder: ≥ 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}, {"id": "OG002", "title": "Group C", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via NRS in the electronic diary. Incomplete efficacy responder: \\< 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "0"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.61", "spread": "0.307"}, {"groupId": "OG001", "value": "0.56", "spread": "0.194"}]}]}, {"title": "Month 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.30", "spread": "0.265"}, {"groupId": "OG001", "value": "0.30", "spread": "NA", "comment": "1 participant analyzed"}]}]}]}, {"type": "SECONDARY", "title": "WPAI:SHP Scores Over Time: Percent Activity Impairment Due to Problem", "description": "Activity impairment due to health problem (the extent to which health problem affected the ability to perform usual daily activities) is presented as the mean percentage of activity impairment, and is calculated as 100\\*scale value of WPAI question 6 (between 0 and 10) / 10. WPAI is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity.", "populationDescription": "Participants with an assessment at given time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage impairment of activity", "timeFrame": "Month 0 (baseline), Month 6", "groups": [{"id": "OG000", "title": "Group A", "description": "Day 1 through Month 3 (open-label): elagolix 150 mg QD\n\nParticipants discontinued prematurely during the open-label period."}, {"id": "OG001", "title": "Group B", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Efficacy responders to elagolix 150 mg QD Month 3 continued on elagolix 150 mg QD\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via a Numeric Rating Scale (NRS) in the electronic diary. Efficacy responder: ≥ 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}, {"id": "OG002", "title": "Group C", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via NRS in the electronic diary. Incomplete efficacy responder: \\< 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.66", "spread": "0.237"}, {"groupId": "OG001", "value": "0.67", "spread": "0.058"}, {"groupId": "OG002", "value": "0.70", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Month 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.40", "spread": "0.346"}, {"groupId": "OG001", "value": "0.30", "spread": "NA", "comment": "1 participant analyzed"}, {"groupId": "OG002", "value": "0.70", "spread": "NA", "comment": "1 participant analyzed"}]}]}]}, {"type": "SECONDARY", "title": "Health Endometriosis Treatment Satisfaction Questionnaire (ETSQ) Scores Over Time", "description": "The 6-item ETSQ was developed to assess patient-reported satisfaction with effects on endometriosis pain, dysmenorrhea, dyspareunia, amount of bleeding tolerability and overall treatment satisfaction. The ETSQ has a 7 point response scale. The range for this scale is 0 to 36, with lower ETSQ scores reflecting lower levels of satisfaction with endometriosis treatment.", "populationDescription": "Participants with an assessment at given time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "Month 0 (baseline), Months 3, 6", "groups": [{"id": "OG000", "title": "Group A", "description": "Day 1 through Month 3 (open-label): elagolix 150 mg QD\n\nParticipants discontinued prematurely during the open-label period."}, {"id": "OG001", "title": "Group B", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Efficacy responders to elagolix 150 mg QD Month 3 continued on elagolix 150 mg QD\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via a Numeric Rating Scale (NRS) in the electronic diary. Efficacy responder: ≥ 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}, {"id": "OG002", "title": "Group C", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via NRS in the electronic diary. Incomplete efficacy responder: \\< 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "19.71", "spread": "4.536"}, {"groupId": "OG001", "value": "18.00", "spread": "0.000"}, {"groupId": "OG002", "value": "18.00", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Month 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "22.25", "spread": "9.430"}, {"groupId": "OG001", "value": "25.47", "spread": "6.652"}, {"groupId": "OG002", "value": "25.00", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Month 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "31.00", "spread": "NA", "comment": "1 participant analyzed"}]}]}]}, {"type": "SECONDARY", "title": "PROMIS Fatigue Short Form 6a Scores Over Time", "description": "The PROMIS Fatigue Short Form 6a is self-administered and composed of 6 questions to evaluate fatigue. Possible scores range from 6 to 30, 6 = not at all (no fatigue), and 30 = very much (most fatigue).", "populationDescription": "Participants with an assessment at given time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "Month 0 (baseline), Month 6", "groups": [{"id": "OG000", "title": "Group A", "description": "Day 1 through Month 3 (open-label): elagolix 150 mg QD\n\nParticipants discontinued prematurely during the open-label period."}, {"id": "OG001", "title": "Group B", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Efficacy responders to elagolix 150 mg QD Month 3 continued on elagolix 150 mg QD\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via a Numeric Rating Scale (NRS) in the electronic diary. Efficacy responder: ≥ 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}, {"id": "OG002", "title": "Group C", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via NRS in the electronic diary. Incomplete efficacy responder: \\< 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "22.1", "spread": "4.10"}, {"groupId": "OG001", "value": "19.3", "spread": "6.11"}, {"groupId": "OG002", "value": "27.0", "spread": "NA", "comment": "1 participant analyzed"}]}]}, {"title": "Month 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "15.3", "spread": "7.77"}, {"groupId": "OG001", "value": "11.0", "spread": "NA", "comment": "1 participant analyzed"}, {"groupId": "OG002", "value": "21.0", "spread": "NA", "comment": "1 participant analyzed"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "From first dose of study drug up to 6 months, plus 30 days.", "eventGroups": [{"id": "EG000", "title": "Group A", "description": "Day 1 through Month 3 (open-label): elagolix 150 mg QD\n\nParticipants discontinued prematurely during the open-label period.", "deathsNumAffected": 0, "deathsNumAtRisk": 7, "seriousNumAffected": 0, "seriousNumAtRisk": 7, "otherNumAffected": 3, "otherNumAtRisk": 7}, {"id": "EG001", "title": "Group B", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Efficacy responders to elagolix 150 mg QD Month 3 continued on elagolix 150 mg QD\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via a Numeric Rating Scale (NRS) in the electronic diary. Efficacy responder: ≥ 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window.", "deathsNumAffected": 0, "deathsNumAtRisk": 3, "seriousNumAffected": 0, "seriousNumAtRisk": 3, "otherNumAffected": 3, "otherNumAtRisk": 3}, {"id": "EG002", "title": "Group C", "description": "Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD\n\nMonth 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group\n\nThe efficacy responder status of each participant was determined based on the responses to the Daily Diary endometriosis-associated pain score via NRS in the electronic diary. Incomplete efficacy responder: \\< 30% decrease (improvement) from Baseline based on the average of the Daily Diary for endometriosis-associated pain score via NRS over a 35 day window.", "deathsNumAffected": 0, "deathsNumAtRisk": 1, "seriousNumAffected": 0, "seriousNumAtRisk": 1, "otherNumAffected": 1, "otherNumAtRisk": 1}], "otherEvents": [{"term": "EAR DISCOMFORT", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 1}]}, {"term": "ABDOMINAL PAIN UPPER", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 1}]}, {"term": "DIARRHOEA", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 7}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 1}]}, {"term": "NAUSEA", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 7}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 1}]}, {"term": "VOMITING", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 7}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 1}]}, {"term": "CHILLS", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 7}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 1}]}, {"term": "FATIGUE", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 7}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 1}]}, {"term": "ANAPHYLACTIC REACTION", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 1}]}, {"term": "DRUG HYPERSENSITIVITY", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 1}]}, {"term": "GARDNERELLA INFECTION", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 1}]}, {"term": "ORAL HERPES", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 1}]}, {"term": "URINARY TRACT INFECTION", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 7}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 1}]}, {"term": "VAGINAL INFECTION", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 7}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 1}]}, {"term": "POLYDIPSIA", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 7}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 1}]}, {"term": "HEADACHE", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 7}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 1}]}, {"term": "IRRITABILITY", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 7}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 1}]}, {"term": "ADNEXA UTERI PAIN", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 1}]}, {"term": "DYSMENORRHOEA", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 1}]}, {"term": "MENSTRUATION DELAYED", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 1}]}, {"term": "PELVIC PAIN", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 1}]}, {"term": "THROAT TIGHTNESS", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 1}]}, {"term": "DERMATITIS ALLERGIC", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 7}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 1}]}, {"term": "NIGHT SWEATS", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 7}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 1}]}, {"term": "HOT FLUSH", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 1}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Due to early study termination at Treatment Month 6 with low subject enrollment, no clinically or statistically meaningful efficacy conclusions can be made. The study was terminated early for business reasons, not for safety concerns."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection."}, "pointOfContact": {"title": "Global Medical Services", "organization": "AbbVie", "email": "abbvieclinicaltrials@abbvie.com", "phone": "800-633-9110"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2017-09-29", "uploadDate": "2019-11-08T15:42", "filename": "Prot_SAP_000.pdf", "size": 1599466}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04", "removedCountries": ["Canada"]}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}, {"id": "D004412", "term": "Dysmenorrhea"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}, {"id": "D008599", "term": "Menstruation Disturbances"}, {"id": "D010335", "term": "Pathologic Processes"}, {"id": "D013568", "term": "Pathological Conditions, Signs and Symptoms"}, {"id": "D017699", "term": "Pelvic Pain"}, {"id": "D010146", "term": "Pain"}, {"id": "D009461", "term": "Neurologic Manifestations"}, {"id": "D012816", "term": "Signs and Symptoms"}]}, "interventionBrowseModule": {"meshes": [{"id": "C539351", "term": "elagolix"}, {"id": "D004958", "term": "Estradiol"}, {"id": "D000077563", "term": "Norethindrone Acetate"}], "ancestors": [{"id": "D004963", "term": "Estrenes"}, {"id": "D004962", "term": "Estranes"}, {"id": "D013256", "term": "Steroids"}, {"id": "D000072473", "term": "Fused-Ring Compounds"}, {"id": "D011083", "term": "Polycyclic Compounds"}, {"id": "D045166", "term": "Estradiol Congeners"}, {"id": "D012739", "term": "Gonadal Steroid Hormones"}, {"id": "D042341", "term": "Gonadal Hormones"}, {"id": "D006728", "term": "Hormones"}, {"id": "D006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D009640", "term": "Norethindrone"}, {"id": "D009652", "term": "Norpregnenes"}, {"id": "D009650", "term": "Norpregnanes"}, {"id": "D009654", "term": "Norsteroids"}]}}, "hasResults": true}, {"protocolSection": {"identificationModule": {"nctId": "NCT03690830", "orgStudyIdInfo": {"id": "RCB n°2018-A01871-54"}, "organization": {"fullName": "University Hospital, Angers", "class": "OTHER_GOV"}, "briefTitle": "Use of Metabolomics for the Identification of Endometrial Biomarkers for IRPL and RIF After in Vitro Fertilization", "officialTitle": "Use of Metabolomics for the Identification of Endometrial Biomarkers for Recurrent Pregnancy Loss and Reccurent Implantation Failure Following in Vitro Fertilization.", "acronym": "ENDOMETAB"}, "statusModule": {"statusVerifiedDate": "2018-09", "overallStatus": "UNKNOWN", "lastKnownStatus": "NOT_YET_RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2019-01-01", "type": "ESTIMATED"}, "primaryCompletionDateStruct": {"date": "2021-01-01", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2021-01-01", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2018-09-17", "studyFirstSubmitQcDate": "2018-09-28", "studyFirstPostDateStruct": {"date": "2018-10-01", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2018-09-28", "lastUpdatePostDateStruct": {"date": "2018-10-01", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "University Hospital, Angers", "class": "OTHER_GOV"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "It is a case-control study composed of 3 groups : 2 cases groups (RIF and IRPL) already composed as part of a pre-existing research project and 1 control group including patients undergoing ART for male factor infertility.\n\nThe purpose of this study is to compare the 2 case group with the control group to identify metabolomics signatures.", "detailedDescription": "The investigators have designed a unicentric, case-control, retro- and prospective study to compare the endometrial metabolomics profile in three groups of patients. The two case groups (RIF and IRPL) are already composed and the endometrial and blood samples already taken as part of a pre-existing research project. The current protocol concerns the control group that includes patients undergoing ART for male factor infertility.\n\nThe study will include three groups. The first group is composed of patients with a history of RIF following IVF-ET. RIF is defined as failure to obtain a clinical pregnancy (fetal cardiac activity at 6-7 weeks gestational age (GA)) following at least 3 different transfers of at least 4 good quality embryos (fresh or frozen).\n\nThe second group comprises patients with a history of IRPL, defined as three or more consecutive pregnancy losses that occurred before 14 weeks gestational age. Early pregnancy losses diagnosed before ultrasonographic confirmation will be included.\n\nThe third group will include patients undergoing ART for male factor infertility.\n\nThe study protocol will be presented and explained to all eligible patients in the control group during the routine consultation before treatment. Patients who agree to participate will contact the department to program the inclusion visit with one of the attending physicians in the department, during which the blood and endometrial samples will be taken. The inclusion visit will take place at the department of reproductive medicine of Angers University Hospital around day 21 of the menstrual cycle (in the middle of the implantation window, which occurs between day 19 and 23 of the cycle, day 1 being the first menstruation day).\n\nThe metabolomics analysis will be performed according to the same protocol for all samples (study and control groups)"}, "conditionsModule": {"conditions": ["Recurrent Pregnancy Loss", "Recurrent Implantation Failure"], "keywords": ["Metabolomic", "Endometrial biomarkers", "Infertility"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "NON_RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": "Two case groups (Recurrent Implantation Failure and idiopathic recurrent pregnancy loss ) One control group (patients undergoing Assisted ReproductiveTechnologies (ART) for male factor infertility)", "primaryPurpose": "OTHER", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 40, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Case group RIF", "type": "EXPERIMENTAL", "description": "blood samples, analyzing endometrial cells", "interventionNames": ["Other: metabolomics analysis"]}, {"label": "Case group IRPL", "type": "EXPERIMENTAL", "description": "blood samples, analyzing endometrial cells", "interventionNames": ["Other: metabolomics analysis"]}, {"label": "Control group", "type": "ACTIVE_COMPARATOR", "description": "blood samples, analyzing endometrial cells", "interventionNames": ["Other: metabolomics analysis"]}], "interventions": [{"type": "OTHER", "name": "metabolomics analysis", "description": "collect blood samples and endometrial cells", "armGroupLabels": ["Case group IRPL", "Case group RIF", "Control group"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Analyze the endometrial samples with mass spectrometry using the Biocrates kit (measures 188 metabolites)", "description": "To compare the metabolomics profile of the endometrium in patients with RIF or IRPL following IVF-ET to patients undergoing Assisted Reproductive Technologies (ART) for male factor infertility to see if there is any significant difference, qualitative or quantitative or both in the metabolites.", "timeFrame": "1 day"}], "secondaryOutcomes": [{"measure": "Analyze the blood sample with standard biological examination and the endometrial sample with mass spectrometry using the Biocrates kit", "description": "To compare the metabolomics profiles based on endometrial cells to profiles based on blood samples, and to compare the profiles between the 2 groups (RIF and IRPL). If any difference, analyze the mecanisms behind it.", "timeFrame": "1 day"}, {"measure": "Analyze the endometrial samples with mass spectrometry using the Biocrates kit", "description": "To analyze the endometrial metabolomics profile according to the etiology of infertility in the group of patients with RIF following IVF-ET (endometriosis, low ovarian reserve, polycystic ovarian syndrome…).", "timeFrame": "1 day"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Age between 18 (included) and 40 years (excluded).\n* Patients who agreed to participate and signed the consent form\n* Patients undergoing ART for male factor infertility: male partner with severe oligoasthenospermia or azoospermia.\n* Patients without any prior history of infertility or risk factors for infertility other than the male factor.\n* Patients with a normal basic infertility workup prior to ART (Day 3 serum FSH, LH, Estradiol and AMH; Antral follicle count; hysterosonography or hysterosalpingography)\n\nExclusion Criteria:\n\n* Non-French speaking patients.\n* Major patients that are wards of the nation.\n\n  * Patients deprived of their liberty on criminal charges or for civil reasons.\n  * Patients under psychiatric care.\n  * Patients under legal protection.\n  * Patients unable to sign consent forms.\n* Patients not covered by social security (which covers all treatments administered).\n* Patients currently participating in other interventional research projects.", "healthyVolunteers": false, "sex": "FEMALE", "genderBased": true, "genderDescription": "women pregnancy", "minimumAge": "18 Years", "maximumAge": "39 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Pierre-Emmanuel BOUET, MD", "role": "CONTACT", "phone": "+33(0)241354213", "email": "PierreEmmanuel.Bouet@chu-angers.fr"}], "locations": [{"facility": "Angers University hospital", "city": "Angers", "state": "Maine Et Loire", "zip": "49000", "country": "France", "geoPoint": {"lat": 47.47156, "lon": -0.55202}}]}, "ipdSharingStatementModule": {"ipdSharing": "YES"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D007246", "term": "Infertility"}], "ancestors": [{"id": "D000091662", "term": "Genital Diseases"}, {"id": "D000091642", "term": "Urogenital Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT06820450", "orgStudyIdInfo": {"id": "RC24_0498"}, "organization": {"fullName": "Nantes University Hospital", "class": "OTHER"}, "briefTitle": "Pilot Study to Characterize the Endometriosis Steroidome and Its Link to Endocrine Disruptors and Vaginal Dysbiosis", "officialTitle": "STERONLINE: Steroidome and Exposome of Endometriosis Single-center Case-control Study", "acronym": "STERONLINE"}, "statusModule": {"statusVerifiedDate": "2025-02", "overallStatus": "NOT_YET_RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2025-07-15", "type": "ESTIMATED"}, "primaryCompletionDateStruct": {"date": "2026-03-15", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2027-03-15", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2025-02-05", "studyFirstSubmitQcDate": "2025-02-05", "studyFirstPostDateStruct": {"date": "2025-02-11", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2025-05-23", "lastUpdatePostDateStruct": {"date": "2025-05-29", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Nantes University Hospital", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "Endometriosis is a systemic, steroid-dependent, inflammatory disease characterized by the growth of endometrial-like tissue outside the uterus, affecting approximately 10 % of women of childbearing age. The etiology and pathophysiology of endometriosis is not completely understood to support effective treatment and prevention strategies. Despite the steroid dependency, little is known concerning the underlying metabolism of estrogen and other tightly related steroids. Moreover, shortening the long diagnostic delays is a major priority in endometriosis research.", "detailedDescription": "The main aim of the study will be to develop a global steroidomics analytical strategy \" fit-for-purpose\" to improve the knowledge of endometriosis pathophysiology and boost the identification of diagnostic biomarkers.\n\nTherefore, in a first step, a new analytical method will be developed adapting state-of-the-art liquid chromatography coupled to high resolution mass spectrometry (LC-HRMS) approaches for steroids and its metabolites towards endometriosis research. The investigators will ensure the characterization of established steroids and its metabolites known to be relevant to endometriosis, but also expand the panel with non-targeted methods to identify phase-1 and -2 metabolites potentially informing of novel steroidogenic pathways in serum and urine.\n\nIn a second phase, a case-control study will be conducted to apply the strategy in a sample of women with and without endometriosis. In a third step, the investigators will explore statistical differences in steroid profiles among endometriosis groups and evaluate the discriminative performance.\n\nThe proposed method has large applications in endometriosis research and large potential to provide novel clues about the still poorly understood steroid metabolism disruption undergoing in endometriosis. Ultimately, non-invasive biomarker discovery in urine could revolutionize endometriosis diagnosis and management, allowing for earlier detection and personalized treatment strategies, ultimately improving the lives of individuals affected by this often overlooked but debilitating condition.\n\nIn parallel, the role of dysbiosis of the vaginal microbiota on hormonal alterations linked to endometriosis will be studied."}, "conditionsModule": {"conditions": ["Endometriosis"], "keywords": ["Steroidome", "exposome", "LC-HRMS"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "CASE_CONTROL", "timePerspective": "PROSPECTIVE"}, "bioSpec": {"retention": "SAMPLES_WITHOUT_DNA", "description": "A 10 ml blood sample (2 x 5 ml tubes) and a 20 ml urine sample for steroid profile analysis; A vaginal swab to characterise your microbiota."}, "enrollmentInfo": {"count": 135, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Group 1. Controls (n=45)", "description": "* Women with no laparoscopically confirmed signs of deep endometriosis.\n* No clinico-biological criteria in favour of a diagnosis of endometriotic disease, nor any radiological signs (ultrasound or MRI) suggestive of endometriosis.\n\nA blood test (2 x 5 ml dry tubes) and a 20 ml urine sample will be taken to analyze steroid profiles, as well as a vaginal sample to characterize the microbiota.", "interventionNames": ["Other: Blood test", "Other: urine sample", "Other: vaginal sample"]}, {"label": "Group 2. Deep endometriosis (n = 90)", "description": "* 45 patients with endometriome\n* 45 patients without endometriome Deep endometriosis confirmed by surgery or MRI Newly diagnosed women (less than 12 months).\n* Severe, deep-seated endometriotic pathology with surgical indication (clinical examination, imaging tests, pre-operative findings).\n\nA blood test (2 x 5 ml dry tubes) and a 20 ml urine sample will be taken to analyze steroid profiles, as well as a vaginal sample to characterize the microbiota.", "interventionNames": ["Other: Blood test", "Other: urine sample", "Other: vaginal sample"]}], "interventions": [{"type": "OTHER", "name": "Blood test", "description": "A blood test (2 x 5 ml dry tubes) will be taken to analyze steroid profiles", "armGroupLabels": ["Group 1. Controls (n=45)", "Group 2. Deep endometriosis (n = 90)"]}, {"type": "OTHER", "name": "urine sample", "description": "a 20 ml urine sample will be taken to analyze steroid profiles", "armGroupLabels": ["Group 1. Controls (n=45)", "Group 2. Deep endometriosis (n = 90)"]}, {"type": "OTHER", "name": "vaginal sample", "description": "to characterize the microbiota.", "armGroupLabels": ["Group 1. Controls (n=45)", "Group 2. Deep endometriosis (n = 90)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Identify steroid profiles associated with endometriosis", "description": "Statistical associations between steroids and the presence of endometriosis.", "timeFrame": "Sampling at inclusion visit"}], "secondaryOutcomes": [{"measure": "Identify biomarkers of environmental chemical exposure associated with endometriosis and steroid profiles.", "description": "Statistical difference between environmental chemical and steroid exposure profiles between subgroups of the study populations.", "timeFrame": "Sampling at inclusion visit"}, {"measure": "Identify the role of vaginal microbiota dysbiosis on hormonal alteration in endometriosis", "description": "Presence of a specific bacterial community in the vaginal microbiota", "timeFrame": "Sampling at inclusion visit"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Women aged 18 to 45\n* Free, informed and written consent from the patient to participate in the study\n* Good understanding of the French language\n* Patient affiliated to or benefiting from a social security or similar scheme\n\nSpecific inclusion criteria for each group:\n\nGroup 1. Controls.\n\n* Women with no laparoscopically confirmed signs suggestive of deep endometriosis.\n* No clinico-biological criteria in favour of a diagnosis of endometriotic disease, nor any radiological signs (ultrasound or MRI) suggestive of endometriosis.\n\nGroup 2. Cases of deep endometriosis.\n\n* Newly diagnosed women (less than 12 months).\n* Severe, deep endometriotic pathology with surgical indication (clinical examination, imaging tests, pre-operative findings).\n\nExclusion Criteria:\n\n* Intercurrent diagnosis of pregnancy.\n* Presence of other hormone-dependent pathologies (e.g. breast cancer, PCOS).\n* Acute infection.", "healthyVolunteers": false, "sex": "FEMALE", "genderBased": true, "minimumAge": "18 Years", "maximumAge": "45 Years", "stdAges": ["ADULT"], "studyPopulation": "The STERONLINE study population will be made up of women aged between 18 years and 45 years\n\n* 45 patients with endometrioma\n* 45 patients without endometrioma", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"centralContacts": [{"name": "Stéphane PLOTEAU, PU-PH", "role": "CONTACT", "phone": "02.40.08.76.84", "phoneExt": "+33", "email": "Stéphane.ploteau@chu-nantes.fr"}]}, "ipdSharingStatementModule": {"ipdSharing": "YES"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D006403", "term": "Hematologic Tests"}], "ancestors": [{"id": "D019411", "term": "Clinical Laboratory Techniques"}, {"id": "D019937", "term": "Diagnostic Techniques and Procedures"}, {"id": "D003933", "term": "Diagnosis"}, {"id": "D008919", "term": "Investigative Techniques"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT00757952", "orgStudyIdInfo": {"id": "PINE-A-14183"}, "secondaryIdInfos": [{"id": "CDR0000614811", "type": "REGISTRY", "domain": "PDQ (Physician Data Query)"}, {"id": "UCSF-H105-31440-01"}], "organization": {"fullName": "Pine Street Foundation", "class": "OTHER"}, "briefTitle": "Early Detection of Ovarian Cancer: GC/FT-ICR Mass Spectrometry and Canine Olfaction", "officialTitle": "Early Detection of Epithelial Ovarian Cancer Using Exhaled Breath Markers: GC/FT-ICR Mass Spectrometry and Canine Olfaction."}, "statusModule": {"statusVerifiedDate": "2016-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-11"}, "primaryCompletionDateStruct": {"date": "2012-12", "type": "ACTUAL"}, "completionDateStruct": {"date": "2012-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-09-22", "studyFirstSubmitQcDate": "2008-09-22", "studyFirstPostDateStruct": {"date": "2008-09-23", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-03-28", "lastUpdatePostDateStruct": {"date": "2016-03-30", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Michael McCulloch", "investigatorTitle": "Principal Investigator", "investigatorAffiliation": "Pine Street Foundation"}, "leadSponsor": {"name": "Pine Street Foundation", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "RATIONALE: Studying samples of exhaled breath from patients with ovarian epithelial cancer, polycystic ovarian syndrome, or endometriosis and from healthy participants in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors find and diagnose ovarian epithelial cancer sooner, when it may be easier to treat.\n\nPURPOSE: This clinical trial is studying exhaled breath biomarkers to see how well they find ovarian epithelial cancer in patients with newly diagnosed ovarian epithelial cancer, polycystic ovarian syndrome, or endometriosis and in healthy participants.", "detailedDescription": "OBJECTIVES:\n\n* Identify patterns of exhaled compounds in breath samples from patients with newly diagnosed ovarian epithelial cancer that are significantly and reproducibility different from those of healthy volunteers using gas chromatography Fourier transform ion cyclotron resonance mass spectrometry (GC/FT-ICR MS).\n* Train five canines to discriminate between exhaled breath samples from patients with newly diagnosed ovarian epithelial cancer and healthy volunteers.\n* Use both canine olfaction and GC/FT-ICR MS to distinguish between exhaled breath samples from patients with newly diagnosed ovarian epithelial cancer and patients with polycystic ovarian syndrome or endometriosis.\n* Repeat breath sampling in patients with newly diagnosed ovarian epithelial cancer throughout the course of diagnosis and therapy.\n\nOUTLINE: Exhaled breath samples are collected from patients and healthy volunteers. The samples are analyzed by gas chromatography Fourier transform ion cyclotron resonance mass spectrometry (GC/FT-ICR MS) to determine chemical compositions, identities, and predictive patterns of biomarkers in exhaled breath condensate. GC/FT-ICR MS and trained canine olfaction are used to distinguish between exhaled breath samples from patients with ovarian epithelial cancer, patients with polycystic ovarian syndrome or endometriosis, and healthy volunteers.\n\nPatients and healthy volunteers complete questionnaires about BRCA 1 and BRCA 2 status (if known), alcohol use, smoking (including duration and type of cigarettes), physical activity (duration and type), socioeconomic status, education, county of residence, age at menopause (if applicable), age at menarche, presence of first- and second-degree family history of breast cancer or ovarian epithelial cancer, body mass index (height and weight), and co-morbidities."}, "conditionsModule": {"conditions": ["Ovarian Cancer"], "keywords": ["ovarian epithelial cancer"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "CASE_CONTROL", "timePerspective": "PROSPECTIVE"}, "enrollmentInfo": {"count": 109, "type": "ACTUAL"}}, "armsInterventionsModule": {"interventions": [{"type": "OTHER", "name": "Fourier transform ion cyclotron resonance mass spectrometry"}, {"type": "OTHER", "name": "chromatography"}, {"type": "OTHER", "name": "diagnostic laboratory biomarker analysis"}, {"type": "OTHER", "name": "questionnaire administration"}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Identification of patterns of exhaled compounds in breath samples using gas chromatography Fourier transform ion cyclotron resonance mass spectrometry (GC/FT-ICR MS)", "timeFrame": "2009-2012"}, {"measure": "Diagnostic accuracy of GC/FT-ICR MS in distinguishing between exhaled breath samples from patients with ovarian epithelial cancer, patients with polycystic ovarian syndrome or endometriosis, and healthy volunteers", "timeFrame": "2009-2012"}, {"measure": "Diagnostic accuracy of canine scent detection in distinguishing between exhaled breath samples from patients with ovarian epithelial cancer and healthy volunteers", "timeFrame": "2009-2012"}]}, "eligibilityModule": {"eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Meets one of the following criteria:\n\n  * Histologically confirmed ovarian epithelial cancer\n\n    * Newly diagnosed disease\n  * Diagnosis of polycystic ovarian syndrome or endometriosis\n  * Healthy volunteer meeting all of the following criteria:\n\n    * No prior ovarian cancer (including invasive ovarian epithelial cancer, fallopian tube cancer, or primary papillary serous carcinoma of the peritoneum)\n    * No prior breast cancer (including ductal carcinoma in situ \\[DCIS\\])\n    * No prior ovarian or breast cancer (including DCIS) in any first- or second-degree relative\n    * BRCA1 or BRCA2 mutation negative (if known) OR no first- or second-degree relative with a BRCA1 or BRCA2 mutation (if known)\n* No prior diagnosis of cancer\n\nPATIENT CHARACTERISTICS:\n\n* Lives in California and close to the study sampling centers\n* Reads and writes English, Spanish, or Chinese\n* Non-smoker\n* Willing to provide breath samples\n* No alcohol intake within the past 3 days\n\nPRIOR CONCURRENT THERAPY:\n\n* At least 3 days since prior Cox-2 inhibitors, vitamin E, omega-3 fatty acids, antioxidants, bromelain, coenzyme Q10, curcumin, or vitamin A", "healthyVolunteers": true, "sex": "FEMALE", "minimumAge": "21 Years", "maximumAge": "120 Years", "stdAges": ["ADULT", "OLDER_ADULT"], "studyPopulation": "1. Histologically confirmed ovarian epithelial cancer.\n2. Polycystic Ovarian Syndrome or Endometriosis\n3. Healthy Controls", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"overallOfficials": [{"name": "Michael McCulloch, MPH, PhD", "affiliation": "Pine Street Foundation", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Pine Street Foundation", "city": "San Anselmo", "state": "California", "zip": "94960-2674", "country": "United States", "geoPoint": {"lat": 37.97465, "lon": -122.56164}}, {"facility": "UCSF Helen Diller Family Comprehensive Cancer Center", "city": "San Francisco", "state": "California", "zip": "94115", "country": "United States", "geoPoint": {"lat": 37.77493, "lon": -122.41942}}, {"facility": "California Pacific Medical Center - California Campus", "city": "San Francisco", "state": "California", "zip": "94118", "country": "United States", "geoPoint": {"lat": 37.77493, "lon": -122.41942}}, {"facility": "University of Maine", "city": "Orono", "state": "Maine", "zip": "04469", "country": "United States", "geoPoint": {"lat": 44.88312, "lon": -68.67198}}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D010051", "term": "Ovarian Neoplasms"}, {"id": "D000077216", "term": "Carcinoma, Ovarian Epithelial"}], "ancestors": [{"id": "D004701", "term": "Endocrine Gland Neoplasms"}, {"id": "D009371", "term": "Neoplasms by Site"}, {"id": "D009369", "term": "Neoplasms"}, {"id": "D010049", "term": "Ovarian Diseases"}, {"id": "D000291", "term": "Adnexal Diseases"}, {"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D005833", "term": "Genital Neoplasms, Female"}, {"id": "D014565", "term": "Urogenital Neoplasms"}, {"id": "D000091662", "term": "Genital Diseases"}, {"id": "D004700", "term": "Endocrine System Diseases"}, {"id": "D006058", "term": "Gonadal Disorders"}, {"id": "D002277", "term": "Carcinoma"}, {"id": "D009375", "term": "Neoplasms, Glandular and Epithelial"}, {"id": "D009370", "term": "Neoplasms by Histologic Type"}]}, "interventionBrowseModule": {"meshes": [{"id": "D002845", "term": "Chromatography"}], "ancestors": [{"id": "D002623", "term": "Chemistry Techniques, Analytical"}, {"id": "D008919", "term": "Investigative Techniques"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT01953250", "orgStudyIdInfo": {"id": "S-54351"}, "organization": {"fullName": "Universitaire Ziekenhuizen KU Leuven", "class": "OTHER"}, "briefTitle": "Functional Outcome in Patients That Underwent Laparoscopic Sigmoid and/or Rectum Resection", "officialTitle": "To Assess the Functional Outcome in Patients That Underwent Laparoscopic Sigmoid and/or Rectum Resection"}, "statusModule": {"statusVerifiedDate": "2012-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-06"}, "primaryCompletionDateStruct": {"date": "2013-06", "type": "ACTUAL"}, "completionDateStruct": {"date": "2013-06", "type": "ACTUAL"}, "studyFirstSubmitDate": "2013-02-19", "studyFirstSubmitQcDate": "2013-09-25", "studyFirstPostDateStruct": {"date": "2013-09-30", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2013-09-25", "lastUpdatePostDateStruct": {"date": "2013-09-30", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Universitaire Ziekenhuizen KU Leuven", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "Questionnaire To assess the functional outcome in patients that underwent laparoscopic sigmoid and/or rectum resection.", "detailedDescription": "A questionnaire will be sent to every patient by mail. The questionnaire that will be used is the COREFO questionnaire (ColoRectal Functional Outcome).\n\nDepending on the amount of responses, we will try to make connections between peri-operative data and functional outcome after considerable period of follow-up. Peri-operative factors include grade of endometriosis, surgical technique and post-operative complications."}, "conditionsModule": {"conditions": ["Endometriosis"], "keywords": ["Deep infiltrating endometriosis", "Laparoscopic sigmoid resection", "laparoscopic rectum resection", "Colorectal surgery"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "COHORT", "timePerspective": "PROSPECTIVE"}, "enrollmentInfo": {"count": 143, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Infiltrating endometriosis", "description": "272 patients that underwent laparoscopic sigmoid and/or rectum resection with the indication of deep infiltrating endometriosis, in the department of Abdominal Surgery, University Hospital Leuven, between the year 1997 and September 2011."}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "ColoRectal Functional Outcome", "description": "Operation: between 1997 and 2011 Questionnaire to assess the colorectal function sent once in 2012", "timeFrame": "1 day"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patients that underwent laparoscopic sigmoid and/or rectum resection with the indication of deep infiltrating endometriosis\n\nExclusion Criteria:\n\n\\-", "healthyVolunteers": false, "sex": "FEMALE", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"], "studyPopulation": "272 patients that underwent laparoscopic sigmoid and/or rectum resection with the indication of deep infiltrating endometriosis", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"overallOfficials": [{"name": "André JL D'Hoore, PhD", "affiliation": "University Clinics Gasthuisberg Department of Abdominal Surgery", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "University Clinics Gasthuisberg", "city": "Leuven", "state": "Flemish Brabant", "zip": "3000", "country": "Belgium", "geoPoint": {"lat": 50.87959, "lon": 4.70093}}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT05722314", "orgStudyIdInfo": {"id": "ENDOMED FIGUIER"}, "organization": {"fullName": "University Hospital, Clermont-Ferrand", "class": "OTHER"}, "briefTitle": "ENDOMED: Evaluation of the Evolution of Endometriosis Lesions on Imaging Under Medical Treatment", "officialTitle": "ENDOMED: Evaluation of the Evolution of Endometriosis Lesions on MRI Before and After Medical Treatment.", "acronym": "ENDOMED"}, "statusModule": {"statusVerifiedDate": "2022-11", "overallStatus": "UNKNOWN", "lastKnownStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2022-09-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2022-09-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2024-11-01", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2022-12-22", "studyFirstSubmitQcDate": "2023-02-01", "studyFirstPostDateStruct": {"date": "2023-02-10", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-02-01", "lastUpdatePostDateStruct": {"date": "2023-02-10", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "University Hospital, Clermont-Ferrand", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "Endometriosis is a difficult disease to diagnose because the symptoms are varied, unspecific and inconsistent from one patient to another. Magnetic resonance imaging is the gold standard for the diagnosis, staging and follow-up of this pathology. Moreover, the management of endometriosis can be medical or surgical depending on the severity and location of the lesions and the patient's expectations. The recommendations of the National College of Obstetricians and Gynecologists and the French National Health Authority are medical treatment first in a certain number of situations. These patients undergoing medical treatment then require close clinical and radiological follow-up in order to evaluate the effectiveness of the treatment and the evolution of the disease. The literature describes the appearance of endometriosis lesions on pelvic MRI quite well for the establishment of the diagnosis, but there are few data on the evolution and imaging description of these lesions when hormonal treatment is in progress. Thus, we decided to evaluate and describe the evolution of endometriosis lesions on magnetic resonance imaging under medical treatment and to examine a correlation between this radiological evolution and the clinical evolution of the patients.", "detailedDescription": "D-0 Consultation: The patient is referred to one of the gynecologists in our department to assess a suspected endometriosis.\n\nIf the symptomatology is suggestive of endometriosis and the patient has not yet had an MRI, it will be performed in the department. In all cases, the inclusion MRI will be performed or reviewed by the department's referring radiologists.\n\nThe patient is then offered to participate in the NoEndo (national observatory of endometriosis) project. Via this application, the patient will be able to fill in questionnaires evaluating her quality of life and pain (SF 36, EHP 30, EHP 5, FSFI, GIQLI).\n\nIn addition, the patient's history, age, BMI, type and duration of treatment and clinical examination will be collected via the NoEndo application. The initial therapeutic choice between hormonal treatment (with details of the choice of the molecule and dosage) or first management in MAP (medical assistance for procreation) (with details of the therapeutic sequence chosen) or therapeutic abstention (with details of the reason) will be collected in the NoEndo application.\n\nM-6 Consultation: At 6 months of treatment, the patient will be seen in consultation, to assess her tolerance to the treatment undertaken. She will be asked to fill in the questionnaires evaluating her quality of life and pain. Any change in treatment or therapeutic strategy will be notified.\n\nPatient compliance and whether or not amenorrhea was achieved will be recorded. M-12 MRI: At 12 months, the patient will have a new MRI check-up in our reference center at the CHU of Clermont-Ferrand according to the same modalities as the first examination and according to the service protocol.\n\nM-12 Consultation: We will see the patient again in consultation, to evaluate again her tolerance of the treatment as well as her compliance. We will evaluate her pain as well as the results of the quality of life questionnaires that she will have filled out beforehand via the NoEndo application. We will also analyze the results of the MRI.\n\nWe will then discuss with the patient the various possible management options for the future: continuation of medical treatment, PMA course, surgery.\n\nIf the patient is or has been pregnant before the one-year MRI, the information will be notified and the surveillance MRI may be delayed."}, "conditionsModule": {"conditions": ["Endometriosis Pelvic"], "keywords": ["Endometriosis", "hormonal treatment", "Endometrioma", "MRI", "Deep Endometriosis", "rectovaginal nodule"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "CASE_ONLY", "timePerspective": "PROSPECTIVE"}, "enrollmentInfo": {"count": 100, "type": "ESTIMATED"}}, "outcomesModule": {"primaryOutcomes": [{"measure": "Evolution of lesions", "description": "To compare endometriosis lesions on pelvic MRI before and after one year of hormonal treatment. The size, appearance and location of the lesions will be compared", "timeFrame": "2 years"}], "secondaryOutcomes": [{"measure": "Clinical evaluation", "description": "Evaluate the clinical evolution of patients undergoing medical treatment, based on the evolution of the Medical Outcomes Study Short Form (MOS SF-36) score, generalist quality of life questionnaire used in endometriosis", "timeFrame": "2 years"}, {"measure": "Clinical evaluation 2", "description": "Evaluate the clinical evolution of patients undergoing medical treatment, based on the evolution of the Endometriosis Health Profile 30 (EHP-30) score, quality of life questionnaire specialized for endometriosis.", "timeFrame": "2 years"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* No history of endometriosis surgery\n* Diagnosis of endometriosis suspected by an MRI performed or reviewed in a reference center\n* Presence of symptomatology requiring medical treatment\n\nExclusion Criteria:\n\n* Pregnant or postmenopausal patient\n* Not speaking French, not affiliated to the french social security system\n* Minors or under guardianship\n* Need for surgical management in the first instance\n* Contraindication to MRI (claustrophobia, renal insufficiency, gadolinium allergy, intracorporeal presence of metallic implant)", "healthyVolunteers": false, "sex": "FEMALE", "genderBased": true, "genderDescription": "female", "minimumAge": "18 Years", "maximumAge": "49 Years", "stdAges": ["ADULT"], "studyPopulation": "Patients whose MRI results are in favor of deep endometriosis, taking medical treatment or included in a MAP program or in whom it is agreed to withhold treatment (by patient choice, refusal of initial medical or surgical management, desire for spontaneous pregnancy, etc.).", "samplingMethod": "PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"centralContacts": [{"name": "Lise Laclautre", "role": "CONTACT", "phone": "334.73.754.963", "email": "promo_interne_drci@chu-clermontferrand.fr"}], "overallOfficials": [{"name": "Claire Figuier", "affiliation": "University Hospital, Clermont-Ferrand", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "CHU clermont-ferrand", "status": "RECRUITING", "city": "Clermont-Ferrand", "country": "France", "contacts": [{"name": "Lise Laclautre", "role": "CONTACT"}, {"name": "Claire FIGUIER", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 45.77969, "lon": 3.08682}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT01982526", "orgStudyIdInfo": {"id": "2011-84"}, "organization": {"fullName": "Kanuni Sultan Suleyman Training and Research Hospital", "class": "OTHER"}, "briefTitle": "Role of Anti Mullerian Hormone for Ovarian Reserve Determination of Preoperative and Postoperative Endometrioma Patients", "officialTitle": "Role of Anti Mullerian Hormone for Ovarian Reserve Determination of Preoperative and Postoperative Endometrioma Patients"}, "statusModule": {"statusVerifiedDate": "2018-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-05"}, "primaryCompletionDateStruct": {"date": "2013-05", "type": "ACTUAL"}, "completionDateStruct": {"date": "2016-05", "type": "ACTUAL"}, "studyFirstSubmitDate": "2013-11-06", "studyFirstSubmitQcDate": "2013-11-12", "studyFirstPostDateStruct": {"date": "2013-11-13", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2018-08-08", "lastUpdatePostDateStruct": {"date": "2018-08-10", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Ergul Demircivi Bor", "investigatorTitle": "Medical Doctor", "investigatorAffiliation": "Kanuni Sultan Suleyman Training and Research Hospital"}, "leadSponsor": {"name": "Kanuni Sultan Suleyman Training and Research Hospital", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "Ovarian reserve influenced by many factor but especially cysts like endometrioma. Anti mullerian hormone is recent marker for ovarian reserve. The investigators are searching ovarian reserve pre and post operatively by using antimullerian hormone of endometrioma patient who are operated for their cysts.", "detailedDescription": "long term results of the postoperative follow up for the endometrioma patients"}, "conditionsModule": {"conditions": ["Endometrioma", "Surgery"], "keywords": ["Ovarian reserve", "Antimullerian hormone"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": true, "targetDuration": "2 Years", "designInfo": {"observationalModel": "COHORT", "timePerspective": "PROSPECTIVE"}, "bioSpec": {"retention": "SAMPLES_WITHOUT_DNA", "description": "We are collecting serum samples of pre and post operative endometroma patients and measuring anti müllerian hormone levels."}, "enrollmentInfo": {"count": 30, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Endmetrioma surgery"}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Long term postoperative ovarian reserve outcomes of endometrioma patients by examining antimullerian hormone.", "timeFrame": "2 years"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Ultrasonographical symptomatic and benign cysts which has surgery indication.\n\nExclusion Criteria:\n\n* Over 42 years old, systemic endocrine disorder, history of ovarian surgery", "healthyVolunteers": true, "sex": "FEMALE", "minimumAge": "17 Years", "maximumAge": "42 Years", "stdAges": ["CHILD", "ADULT"], "studyPopulation": "Females who are administring gynecology clinic suffering from symptomatic benign ovarian cysts.", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"locations": [{"facility": "Kanuni Sultan Suleyman Education and Research Hospital", "city": "Istanbul", "zip": "34303", "country": "Turkey (Türkiye)", "geoPoint": {"lat": 41.01384, "lon": 28.94966}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT07213050", "orgStudyIdInfo": {"id": "Percutaneous Thermal Ablation"}, "organization": {"fullName": "Assiut University", "class": "OTHER"}, "briefTitle": "Percutaneous Thermal Ablation (Radiofrequency and Microwave) in the Treatment of Anterior Abdominal Wall Masses: An Evaluation of Efficacy and Safety.", "officialTitle": "Percutaneous Thermal Ablation (Radiofrequency and Microwave) in the Treatment of Anterior Abdominal Wall Masses: An Evaluation of Efficacy and Safety."}, "statusModule": {"statusVerifiedDate": "2025-10", "overallStatus": "NOT_YET_RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2025-11-01", "type": "ESTIMATED"}, "primaryCompletionDateStruct": {"date": "2026-11-01", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2026-12-01", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2025-10-01", "studyFirstSubmitQcDate": "2025-10-01", "studyFirstPostDateStruct": {"date": "2025-10-08", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2025-10-01", "lastUpdatePostDateStruct": {"date": "2025-10-08", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "MOHAMED ALI IBRAHIM ABOLOYOUN SAYED", "investigatorTitle": "residant doctor at Assiut university hospital", "investigatorAffiliation": "Assiut University"}, "leadSponsor": {"name": "Assiut University", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The anterior abdominal wall is a common site for metastatic deposits (e.g., from colorectal, ovarian, or hepatocellular carcinoma), desmoid tumors (aggressive fibromatosis), and endometriomas. Surgical resection has been the traditional standard of care. However, surgery in this region can be complex due to the proximity of vital structures, the need for large tissue resection, and high recurrence rates. Furthermore, patients often present with significant comorbidities or have recurrent disease after previous surgeries, making them poor surgical candidates While established in organs like the liver and lungs, their application specifically for abdominal wall lesions is a growing and evidence-supported field that warrants further systematic study to standardize protocols and confirm long-term outcomes.\n\nPercutaneous thermal ablation, including microwave ablation (MWA) and radiofrequency ablation (RFA), is an increasingly used minimally invasive treatment for anterior abdominal wall lesions such as metastatic tumors and benign lesions like abdominal wall endometriosis. These techniques deliver thermal energy through percutaneous probes to induce coagulative necrosis, offering an effective alternative to surgery with lower morbidity and shorter recovery times.\n\nRFA uses high-frequency electrical currents to generate heat and ablate tumors. It is well established for treating abdominal wall recurrences, particularly from colorectal cancer, with effective local control and symptom relief.\n\nUltrasound-guided MWA has demonstrated excellent safety and efficacy for abdominal wall lesions. Studies report significant lesion volume reduction, pain relief, and low complication rates in patients with abdominal wall endometriosis and metastases. The ability to visualize the ablation zone in real-time with ultrasound enhances precision and protects adjacent structures."}, "conditionsModule": {"conditions": ["Anterior Abdominal Wall Masses"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 30, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "study group", "type": "ACTIVE_COMPARATOR", "description": "Patients with biopsy-proven metastases to the anterior abdominal wall (e.g.,from colorectal, breast, ovarian cancer)", "interventionNames": ["Procedure: Radiofrequency", "Procedure: Microwave"]}], "interventions": [{"type": "PROCEDURE", "name": "Radiofrequency", "description": "achieve a target temperature of 90-110°C for 4-12 minutes, ensuring an ablative margin of at least 0.5-1.0 cm around the tumor.", "armGroupLabels": ["study group"]}, {"type": "PROCEDURE", "name": "Microwave", "description": "Antennas will be placed under imaging guidance, and ablation will be performed for 5-10 minutes per antenna activation to achieve the desired margin.", "armGroupLabels": ["study group"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Technical Success", "description": "complete coverage of the target lesion by the ablation zone with an adequate margin on the immediate post-procedure CT scan", "timeFrame": "baseline"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* 1\\. Patients with biopsy-proven metastases to the anterior abdominal wall (e.g., from colorectal, breast, ovarian cancer). 2. Patients with biopsy-proven desmoid tumors (aggressive fibromatosis). 3. Patients with symptomatic abdominal wall endometriomas. 4. Lesion size ≤ 5 cm in greatest diameter. 5. Patients deemed unfit for surgery due to comorbidities, or who refuse surgical intervention. 6. Platelet count \\> 50,000/µL and INR \\< 1.5.\n\nExclusion Criteria:\n\n* 1\\. Uncorrectable coagulopathy. 2. Lesion size \\> 5 cm. 3. Unlimited diffuse peritoneal carcinomatosis. 4. Skin or bowel wall involvement with no safe percutaneous pathway for ablation (as determined on pre-procedural CT) 5. Life expectancy \\< 3 months.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "interventionBrowseModule": {"meshes": [{"id": "D008872", "term": "Microwaves"}], "ancestors": [{"id": "D011846", "term": "Radio Waves"}, {"id": "D060733", "term": "Electromagnetic Radiation"}, {"id": "D055590", "term": "Electromagnetic Phenomena"}, {"id": "D060328", "term": "Magnetic Phenomena"}, {"id": "D055585", "term": "Physical Phenomena"}, {"id": "D011827", "term": "Radiation"}, {"id": "D011840", "term": "Radiation, Nonionizing"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT04046081", "orgStudyIdInfo": {"id": "AC18127"}, "organization": {"fullName": "University of Edinburgh", "class": "OTHER"}, "briefTitle": "A Clinical Trial to Evaluate Dichloroacetate (DCA) as a Treatment for Endometriosis-associated Pain", "officialTitle": "A Single-arm Open Label Exploratory Clinical Trial to Evaluate Dichloroacetate (DCA) as a Possible Treatment for Endometriosis-associated Pain", "acronym": "EPiC"}, "statusModule": {"statusVerifiedDate": "2024-06", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2019-11-19", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2021-09-30", "type": "ACTUAL"}, "completionDateStruct": {"date": "2021-09-30", "type": "ACTUAL"}, "studyFirstSubmitDate": "2019-07-31", "studyFirstSubmitQcDate": "2019-08-02", "studyFirstPostDateStruct": {"date": "2019-08-06", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2024-06-11", "lastUpdatePostDateStruct": {"date": "2024-06-13", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "University of Edinburgh", "class": "OTHER"}, "collaborators": [{"name": "University of Nottingham", "class": "OTHER"}, {"name": "Ferring Pharmaceuticals", "class": "INDUSTRY"}, {"name": "University of Birmingham", "class": "OTHER"}]}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "This is a single-arm open label exploratory clinical trial to evaluate dichloroacetate (DCA) as a possible treatment for treatment of endometriosis-associated pain", "detailedDescription": "Endometriosis is a chronic condition usually affecting women throughout their reproductive lives. It is defined as a growth of endometrial-like tissue (womb lining) outside the uterus (womb) and is associated with chronic pelvic pain that can be frequent and severe, resulting in tiredness, lower quality of life and difficulties in getting pregnant. Current treatments are unsatisfactory and there is an unmet need for new medical treatment for endometriosis. Research findings from our laboratory have shown that women with endometriosis have more lactate in their pelvis. In laboratory models of endometriosis, we have tested dichloroacetate (DCA), a compound used to treat metabolic disorders in children. Our results showed that DCA could stop the growth and survival of endometriosis cells and reduce lactate production. In our study we plan to investigate if we can we can recruit and retain women into a trial using this treatment. We will recruit 30 women aged 18 or over, with pelvic pain and a diagnosis of endometriosis within the last three years. Participants will complete informed consent, be willing to comply with the treatment and use contraception throughout the trial. We will recruit patients over six months at Royal Infirmary of Edinburgh. Women who consent will take a daily dose of DCA capsules for 12 weeks."}, "conditionsModule": {"conditions": ["Endometriosis"], "keywords": ["Endometriosis", "Dichloroacetate"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "OTHER", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 30, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Dichloroacetate", "type": "OTHER", "description": "Open label study", "interventionNames": ["Drug: Dichloroacetate"]}], "interventions": [{"type": "DRUG", "name": "Dichloroacetate", "description": "6.25 mg/kg BD for 6 weeks increasing to 12.5 mg/kg BD for 6 weeks", "armGroupLabels": ["Dichloroacetate"], "otherNames": ["DCA"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "To determine whether it is possible to achieve acceptable recruitment and retention rates within defined inclusion/exclusion criteria.", "description": "The proportion of screened women who are eligible for the trial determined from the screening logs", "timeFrame": "Screening"}, {"measure": "To determine whether it is possible to achieve acceptable recruitment and retention rates within defined inclusion/exclusion criteria.", "description": "The proportion of eligible patients recruited to the study recorded on the screening logs", "timeFrame": "Screening"}, {"measure": "To determine whether it is possible to achieve acceptable recruitment and retention rates within defined inclusion/exclusion criteria.", "description": "The proportion of recruited patients who answer their average NRS scores at visits 3 and 5, complete the assessment tools (questionnaires) and attend for designated blood testing", "timeFrame": "Throughout the treatment (Week 1- 12)"}], "secondaryOutcomes": [{"measure": "To determine the acceptability to patients of the proposed methods of recruitment, treatment, questionnaires and follow up.", "description": "Assessed by acceptability questionnaire at the end of study asking questions about participants' satisfaction with the methods of recruitment, treatment, questionnaires and follow up", "timeFrame": "Week 16"}, {"measure": "To assess whether dichloroacetate is well-tolerated in women with endometriosis.", "description": "Self-reported side effects during and after the treatment", "timeFrame": "Throughout the treatment up to week 16"}, {"measure": "To determine participants' compliance with treatment and to assess the tools used to measure it.", "description": "Assessed by self-report using treatment diaries to measure number of doses taken", "timeFrame": "Throughout the treatment (Week 1- 12)"}, {"measure": "To determine participants' compliance with treatment and to assess the tools used to measure it.", "description": "Assessed by measuring levels of systemic dichloroacetate from blood samples using mass spectrometry", "timeFrame": "Throughout the treatment (Week 1- 12)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Women aged 18 or over\n* Weight between 50 and 100kg\n* Pre-menopausal\n* Superficial peritoneal endometriosis (ASRM Stage I or II) at laparoscopy, performed within the last three years (and \\>2 weeks from surgery)\n* Pelvic pain for longer than six months\n* Average pain score of ≥ 4 over the four weeks prior to treatment\n* Willing to comply with the treatment\n* Willing to use contraception throughout the trial\n* Willing and able to complete informed consent\n\nExclusion Criteria:\n\n* Evidence of ovarian endometrioma or deep endometriosis (based upon current surgical staging or most recent imaging)\n* Women who are pregnant or actively trying to get pregnant\n* Known allergy or hypersensitivity to any excipient of DCA\n* Breastfeeding\n* Clinical evidence of pre-existing neuropathy\n* Diabetes\n* History of liver disease\n* History of kidney disease\n* Taking part in a CTIMP or other interventional non-CTIMP studies\n* Patient on combination antiretroviral therapy\n* History of malabsorption syndrome or substantial amount of small bowels or stomach removed", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Andrew W Horne, Prof", "affiliation": "University of Edinburgh", "role": "STUDY_CHAIR"}], "locations": [{"facility": "Royal Infirmary of Edinburgh", "city": "Edinburgh", "country": "United Kingdom", "geoPoint": {"lat": 55.95206, "lon": -3.19648}}]}, "referencesModule": {"references": [{"pmid": "33712086", "type": "DERIVED", "citation": "Leow HW, Koscielniak M, Williams L, Saunders PTK, Daniels J, Doust AM, Jones MC, Ferguson GD, Bagger Y, Horne AW, Whitaker LHR. Dichloroacetate as a possible treatment for endometriosis-associated pain: a single-arm open-label exploratory clinical trial (EPiC). Pilot Feasibility Stud. 2021 Mar 12;7(1):67. doi: 10.1186/s40814-021-00797-0."}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Selected anonymised data collected or generated by the study will be shared with commercial collaborators once the study is finished.", "infoTypes": ["STUDY_PROTOCOL", "SAP", "CSR"], "timeFrame": "Completion of the trial, published online, available indefinitely.", "accessCriteria": "Anonymized results will be shared with other researchers."}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D003999", "term": "Dichloroacetic Acid"}], "ancestors": [{"id": "D062845", "term": "Chloroacetates"}, {"id": "D000085", "term": "Acetates"}, {"id": "D000144", "term": "Acids, Acyclic"}, {"id": "D002264", "term": "Carboxylic Acids"}, {"id": "D009930", "term": "Organic Chemicals"}, {"id": "D006843", "term": "Hydrocarbons, Chlorinated"}, {"id": "D006846", "term": "Hydrocarbons, Halogenated"}, {"id": "D006838", "term": "Hydrocarbons"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT04265781", "orgStudyIdInfo": {"id": "19738"}, "organization": {"fullName": "Bayer", "class": "INDUSTRY"}, "briefTitle": "Study on the Safety of Drug BAY1817080 at Different Doses and the Way the Body Absorbs and Eliminates the Drug in Japanese Healthy Adult Male Participants", "officialTitle": "Phase 1 Dose Escalation Study to Investigate Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of BAY 1817080 in Japanese Healthy Adult Male Participants in a Single-center, Randomized, Single-blind, Placebo-controlled Design"}, "statusModule": {"statusVerifiedDate": "2023-01", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2020-02-15", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2020-09-20", "type": "ACTUAL"}, "completionDateStruct": {"date": "2020-09-20", "type": "ACTUAL"}, "studyFirstSubmitDate": "2020-02-10", "studyFirstSubmitQcDate": "2020-02-10", "studyFirstPostDateStruct": {"date": "2020-02-12", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-01-24", "lastUpdatePostDateStruct": {"date": "2023-01-26", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Bayer", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "Researchers in this study want to learn about the safety of drug BAY1817080 at different doses and the resulting blood levels of the study drug in Japanese healthy adult male participants. Study drug BAY1817080 is a drug under development with a goal to suppress pain and chronic cough. It works by binding to and blocking proteins expressed on the sensory nerves of the womb tissue, bladder or airway which are oversensitive in the patients with endometriosis (a condition where the tissue that usually grows inside the womb grows outside of the womb), overactive bladder (a condition that causes a sudden urge to urinate often or more frequently) and long-standing cough with or without clear causes.\n\nParticipants in this study will receive either the study drug or placebo tablets (a placebo looks like the test drug but does not have any medicine in it). The dosage will be either one single dose of study drug/placebo received on only one day or multiple doses of study drug/placebo received twice daily for 13 days plus one dose in the morning of the 14th day. The total study duration for each participant will be usually no more than 42 days. Blood samples will be collected from the participants to monitor the safety and measure the blood level of the study drug."}, "conditionsModule": {"conditions": ["Endometriosis Related Pain", "Overactive Bladder", "Diabetic Neuropathic Pain", "Refractory or Unexplained Chronic Cough"], "keywords": ["Refractory or unexplained chronic cough", "Healthy volunteers", "P2X3 receptor antagonist"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "SEQUENTIAL", "primaryPurpose": "BASIC_SCIENCE", "maskingInfo": {"masking": "SINGLE", "whoMasked": ["PARTICIPANT"]}}, "enrollmentInfo": {"count": 36, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Dose escalation BAY1817080", "type": "EXPERIMENTAL", "description": "Participants receive dose 1 to 3 of BAY1817080 as a single dose on Day 1.", "interventionNames": ["Drug: BAY1817080"]}, {"label": "Dose expansion BAY1817080", "type": "EXPERIMENTAL", "description": "Participants receive the highest dose 3 of BAY1817080 twice daily (BID) from Day 1 until Day 13 and a single dose on Day 14.", "interventionNames": ["Drug: BAY1817080"]}, {"label": "Dose escalation Placebo", "type": "PLACEBO_COMPARATOR", "description": "Participants receive placebo tablets orally as a single dose on Day 1.", "interventionNames": ["Drug: Matching Placebo"]}, {"label": "Dose expansion Placebo", "type": "PLACEBO_COMPARATOR", "description": "Participants receive placebo tablets as BID multiple doses from Day 1 until Day 13 and as a single dose on Day 14.", "interventionNames": ["Drug: Matching Placebo"]}], "interventions": [{"type": "DRUG", "name": "BAY1817080", "description": "Three different doses over the course of study", "armGroupLabels": ["Dose escalation BAY1817080", "Dose expansion BAY1817080"]}, {"type": "DRUG", "name": "Matching Placebo", "description": "Matching Placebo to BAY1817080", "armGroupLabels": ["Dose escalation Placebo", "Dose expansion Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Frequency of treatment-emergent adverse events (TEAE) after single dose of BAY1817080", "timeFrame": "Up to 14 days"}, {"measure": "Severity of treatment-emergent adverse events after single dose of BAY1817080", "timeFrame": "Up to 14 days"}, {"measure": "Frequency of treatment-emergent adverse events after multiple doses of BAY1817080", "timeFrame": "Up to 27 days"}, {"measure": "Severity of treatment-emergent adverse events after multiple doses of BAY1817080", "timeFrame": "Up to 27 days"}], "secondaryOutcomes": [{"measure": "Maximum plasma concentration of BAY1817080 after single dose (Cmax)", "timeFrame": "At 0 hour before study drug administration and up to 15 hours after study drug administration at Day 1 and at 0 hours on Day 2 to Day 10"}, {"measure": "Area under the concentration-time curve of BAY1817080 after single dose (AUC)", "description": "In the case of extrapolated portion of AUC exceeding20% \\[%AUC(tlast-∞) \\>20%\\], the parameter AUC(0-tlast) may be evaluated as main parameter", "timeFrame": "At 0 hour before study drug administration and up to 15 hours after study drug administration at Day 1 and at 0 hours on Day 2 to Day 10"}, {"measure": "Maximum plasma concentration of BAY1817080 after multiple doses (Cmax,md)", "timeFrame": "At 0 hours before drug administration and up to 12 hours after drug administration on Day 1, at 0 hours from Day 2 to Day 9 and from Day 11 to Day 12, at 0 and 12 hours on Day 13, at 0 hours until 15 hours on Day 14, and at 0 hours from Day 15 to Day 23"}, {"measure": "Area under the concentration-time curve of BAY1817080 after multiple dose (AUCτ,md)", "timeFrame": "At 0 hours before drug administration and up to 12 hours after drug administration on Day 1, at 0 hours from Day 2 to Day 9 and from Day 11 to Day 12, at 0 and 12 hours on Day 13, at 0 hours until 15 hours on Day 14, and at 0 hours from Day 15 to Day 23"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Participant must be 20 to 45 years of age inclusive, at the time of signing the informed consent.\n* Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, vital signs, laboratory tests, and ECG.\n* Non-smoker for at least 6 months and with a pack year history of equal to or less than 5 years\n* Race: Japanese.\n* BMI: above or equal 18.0 and below or equal 30.0 kg/m² at the screening visit.\n* Contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n* Men of reproductive potential must agree to use adequate contraception when sexually active. This applies for the time period between signing of the ICF and 90 days after the last administration of study intervention.\n\nExclusion Criteria:\n\n* Any findings from the medical examination (including medical history, physical examination, vital signs, laboratory tests and ECG) deviating from normal and deemed by the investigator to be of clinical relevance\n* Relevant diseases potentially interfering with the study objectives within the 4 weeks before screening or between screening and randomization\n* Any febrile illness within the four weeks before screening or between screening and randomization\n* Any known presence or history of severe allergies, non-allergic drug reactions, or multiple drug allergies\n* Known or suspected malignant tumors or carcinoma in situ\n* Any history of malignant tumors\n* Any known or suspected benign tumors of the liver and/or pituitary gland\n* Known liver disease: existing acute or chronic progressive liver disease, e.g. disturbance of bilirubin excretion (Dubin-Johnson and Rotor syndromes); disturbances of bile secretion and flow (cholestasis); presence or history of liver tumors (benign or malignant). Note: According to this criterion there must have been an interval of at least 6 months between the subsidence of any viral hepatitis (normalization of liver parameters) and the screening visit.", "healthyVolunteers": true, "sex": "MALE", "minimumAge": "20 Years", "maximumAge": "45 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "Hakata Clinic", "city": "Fukuoka", "zip": "812-0025", "country": "Japan", "geoPoint": {"lat": 33.6, "lon": 130.41667}}]}, "referencesModule": {"references": [{"pmid": "38907175", "type": "DERIVED", "citation": "Li X, Haranaka M, Li H, Liu P, Chen H, Klein S, Reif S, Francke K, Friedrich C, Okumura K. P2X3 Receptor Antagonist Eliapixant in Phase I Clinical Trials: Safety and Inter-ethnic Comparison of Pharmacokinetics in Healthy Chinese and Japanese Participants. Clin Pharmacokinet. 2024 Jun;63(6):901-915. doi: 10.1007/s40262-024-01387-y. Epub 2024 Jun 21."}], "seeAlsoLinks": [{"label": "Click here to find information for studies related to Bayer products. To find this study enter the ClinicalTrials.gov identifier (NCT) number or Bayer Study Identifier (ID) in the search field.", "url": "http://clinicaltrials.bayer.com/"}]}, "ipdSharingStatementModule": {"ipdSharing": "NO", "description": "There are no current plans to share data. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal."}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D053201", "term": "Urinary Bladder, Overactive"}], "ancestors": [{"id": "D001745", "term": "Urinary Bladder Diseases"}, {"id": "D014570", "term": "Urologic Diseases"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D052801", "term": "Male Urogenital Diseases"}, {"id": "D059411", "term": "Lower Urinary Tract Symptoms"}, {"id": "D020924", "term": "Urological Manifestations"}, {"id": "D012816", "term": "Signs and Symptoms"}, {"id": "D013568", "term": "Pathological Conditions, Signs and Symptoms"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT06093243", "orgStudyIdInfo": {"id": "2023_RIPH_012_Connaiss-Endo"}, "organization": {"fullName": "Université de Reims Champagne-Ardenne", "class": "OTHER"}, "briefTitle": "Women's Knowledge About Endometriosis", "officialTitle": "Women's Knowledge About Endometriosis", "acronym": "Connaiss-Endo"}, "statusModule": {"statusVerifiedDate": "2023-10", "overallStatus": "UNKNOWN", "lastKnownStatus": "NOT_YET_RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2023-12-01", "type": "ESTIMATED"}, "primaryCompletionDateStruct": {"date": "2024-02-01", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2024-05-01", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2023-10-09", "studyFirstSubmitQcDate": "2023-10-16", "studyFirstPostDateStruct": {"date": "2023-10-23", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-10-16", "lastUpdatePostDateStruct": {"date": "2023-10-23", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Université de Reims Champagne-Ardenne", "class": "OTHER"}}, "oversightModule": {"isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "In the world, 10% of women of childbearing age have endometriosis with diagnostic mostly between 25 and 30 years old.\n\nEndometriosis is the leading cause of infertility in our country. A diagnosis delay of approximately 6.7 years is observed for endometriosis.", "detailedDescription": "The aim of the study will be to describe knowledge of women about endometriosis."}, "conditionsModule": {"conditions": ["Endometriosis"], "keywords": ["Women", "knowledge", "endometriosis"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "CASE_ONLY", "timePerspective": "CROSS_SECTIONAL"}, "enrollmentInfo": {"count": 500, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "\"women of childbearing age\" group", "description": "women of childbearing age with or without endometriosis", "interventionNames": ["Other: data collection"]}], "interventions": [{"type": "OTHER", "name": "data collection", "description": "data collection", "armGroupLabels": ["\"women of childbearing age\" group"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "knowledge score on endometriosis symptoms", "description": "14 questions with yes/no answers, about symptoms of endometriosis (pain, nausea and vomiting, prolonged heavier period flow,…).\n\nA correct answer earns 1 point and a wrong answer earns 0 points. The knowledge score will therefore be between 0 and 14, the higher the score the better the knowledge.", "timeFrame": "Day 0"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* women older than 18\n* women of childbearing age\n* with or without gynecological history\n* agreed to participate in the study\n\nExclusion Criteria:\n\nNone", "healthyVolunteers": true, "sex": "FEMALE", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"], "studyPopulation": "women of childbearing age with or without endometriosis", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"centralContacts": [{"name": "Barbe Coralie, Dr", "role": "CONTACT", "phone": "0326913665", "phoneExt": "+33", "email": "coralie.barbe1@univ-reims.fr"}], "locations": [{"facility": "Université de Reims Champagne Ardenne", "city": "Reims", "zip": "51100", "country": "France", "geoPoint": {"lat": 49.26526, "lon": 4.02853}}]}, "ipdSharingStatementModule": {"ipdSharing": "UNDECIDED"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D003625", "term": "Data Collection"}], "ancestors": [{"id": "D004812", "term": "Epidemiologic Methods"}, {"id": "D008919", "term": "Investigative Techniques"}, {"id": "D017531", "term": "Health Care Evaluation Mechanisms"}, {"id": "D011787", "term": "Quality of Health Care"}, {"id": "D017530", "term": "Health Care Quality, Access, and Evaluation"}, {"id": "D011634", "term": "Public Health"}, {"id": "D004778", "term": "Environment and Public Health"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT02471443", "orgStudyIdInfo": {"id": "15DEV0009"}, "organization": {"fullName": "Royal Surrey County Hospital NHS Foundation Trust", "class": "OTHER"}, "briefTitle": "Laparoscopic Surgery for Severe Recto-vaginal Endometriosis", "officialTitle": "Laparoscopic Surgery for Severe Recto-vaginal Endometriosis: A Prospective Cohort Study"}, "statusModule": {"statusVerifiedDate": "2019-03", "overallStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2004-05"}, "primaryCompletionDateStruct": {"date": "2025-01", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2040-01", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2015-06-06", "studyFirstSubmitQcDate": "2015-06-10", "studyFirstPostDateStruct": {"date": "2015-06-15", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2019-03-25", "lastUpdatePostDateStruct": {"date": "2019-03-26", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Mr Andrew Kent", "investigatorTitle": "Consultant Gynaecologist", "investigatorAffiliation": "Royal Surrey County Hospital NHS Foundation Trust"}, "leadSponsor": {"name": "Royal Surrey County Hospital NHS Foundation Trust", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "To determine the quality of life following the radical excision of recto-vaginal endometriosis.", "detailedDescription": "Patients undergoing surgery for severe endometriosis with bowel involvement were asked to complete pre-operative and post operative questionnaires at 2, 6 and 12 months, then 5, 10, 15, 20 and 25 years post operatively.\n\nQuality of life measured using the EHP-30 and EQ-5D questionnaires. Bowel symptoms were measured using GIQLI. Dysmenorrhoea, dyspareunia, dyschezia and chronic pain were measured using a visual analogue scale."}, "conditionsModule": {"conditions": ["Endometriosis Rectovaginal Septum"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "COHORT", "timePerspective": "PROSPECTIVE"}, "enrollmentInfo": {"count": 1000, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Surgery for severe endometriosis", "description": "Consecutive patients undergoing excisional surgery for severe endometriosis with bowel involvement", "interventionNames": ["Procedure: Surgery for severe endometriosis"]}], "interventions": [{"type": "PROCEDURE", "name": "Surgery for severe endometriosis", "description": "Consecutive patients undergoing excisional surgery for severe endometriosis with bowel involvement", "armGroupLabels": ["Surgery for severe endometriosis"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Quality of life measured using the Endometriosis Health Profile 30 (EHP-30) and EuroQol-5 dimension (EQ-5D) questionnaires.", "description": "Recruitment is continuous", "timeFrame": "1 year post operative"}, {"measure": "Bowel symptoms measured using the Gastro-intestinal Quality of Life Index (GIQLI).", "description": "Recruitment is continuous", "timeFrame": "1 year post operative"}, {"measure": "Dysmenorrhoea measured using a visual analogue scale (VAS).", "description": "Recruitment is continuous", "timeFrame": "1 year post operative"}, {"measure": "Dyspareunia measured using a visual analogue scale (VAS).", "description": "Recruitment is continuous", "timeFrame": "1 year post operative"}, {"measure": "Dyschezia measured using a visual analogue scale (VAS).", "description": "Recruitment is continuous", "timeFrame": "1 year post operative"}, {"measure": "Chronic pain measured using a visual analogue scale (VAS).", "description": "Recruitment is continuous", "timeFrame": "1 year post operative"}], "secondaryOutcomes": [{"measure": "Quality of life measured using the EHP-30 and EQ-5D questionnaires.", "timeFrame": "2 months, 6 months, 5 years, 10 years, 15 years, 20 years, 25 years follow up post operative"}, {"measure": "Bowel symptoms were measured using GIQLI.", "timeFrame": "2 months, 6 months, 5 years, 10 years, 15 years, 20 years, 25 years follow up post operative"}, {"measure": "Dysmenorrhoea measured using a visual analogue scale.", "timeFrame": "2 months, 6 months, 5 years, 10 years, 15 years, 20 years, 25 years follow up post operative"}, {"measure": "Dyspareunia measured using a visual analogue scale.", "timeFrame": "2 months, 6 months, 5 years, 10 years, 15 years, 20 years, 25 years follow up post operative"}, {"measure": "Dyschezia measured using a visual analogue scale.", "timeFrame": "2 months, 6 months, 5 years, 10 years, 15 years, 20 years, 25 years follow up post operative"}, {"measure": "Chronic pain measured using a visual analogue scale.", "timeFrame": "2 months, 6 months, 5 years, 10 years, 15 years, 20 years, 25 years follow up post operative"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* All women undergoing planned surgery for severe endometriosis with bowel involvement.\n\nExclusion Criteria:\n\n* Patients who declined to complete questionnaires for whatever reason and/or have their anonymous data analysed.", "healthyVolunteers": true, "sex": "FEMALE", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"], "studyPopulation": "Consecutive patients who underwent surgery for endometriosis with bowel involvement.", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"centralContacts": [{"name": "Andrew Kent, TD MD FRCOG", "role": "CONTACT", "email": "kenta@doctors.org.uk"}], "overallOfficials": [{"name": "Andrew Kent, TD MD FRCOG", "affiliation": "Royal Surrey County Hospital/Nuffield Health Guildford Hospital", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Royal Surrey County Hospital NHS Trust", "status": "RECRUITING", "city": "Guildford", "state": "Surrey", "zip": "GU2 7XX", "country": "United Kingdom", "contacts": [{"name": "Andrew Kent, TD MD FRCOG", "role": "CONTACT", "email": "kenta@doctors.org.uk"}], "geoPoint": {"lat": 51.23536, "lon": -0.57427}}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "interventionBrowseModule": {"meshes": [{"id": "D013514", "term": "Surgical Procedures, Operative"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT02511626", "orgStudyIdInfo": {"id": "Endo_QOL"}, "organization": {"fullName": "University of Zurich", "class": "OTHER"}, "briefTitle": "Quality of Life in Endometriosis - a Case Control Study", "officialTitle": "Quality of Life in Endometriosis - a Case Control Study Using Internationally Validated Questionnaires"}, "statusModule": {"statusVerifiedDate": "2022-09", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-01"}, "primaryCompletionDateStruct": {"date": "2016-12", "type": "ACTUAL"}, "completionDateStruct": {"date": "2019-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2015-07-20", "studyFirstSubmitQcDate": "2015-07-27", "studyFirstPostDateStruct": {"date": "2015-07-30", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2022-09-27", "lastUpdatePostDateStruct": {"date": "2022-09-28", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "University of Zurich", "class": "OTHER"}, "collaborators": [{"name": "Triemli Hospital", "class": "OTHER"}, {"name": "Cantonal Hospital of St. Gallen", "class": "OTHER"}, {"name": "Kantonsspital Baden", "class": "OTHER"}, {"name": "Kantonsspital Winterthur KSW", "class": "OTHER"}, {"name": "Kantonsspital Schaffhausen", "class": "UNKNOWN"}, {"name": "Charite University, Berlin, Germany", "class": "OTHER"}, {"name": "University Hospital, Aachen", "class": "OTHER"}, {"name": "Vivantes Kliniken Berlin", "class": "UNKNOWN"}, {"name": "Medical University of Graz", "class": "OTHER"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "Endometriosis, one of the most common diseases of women during their reproductive period., may present a chronic disabling disease with major impact on women's life. Therapeutic options are limited and recurrence of disease symptoms is frequent.\n\nThe current study investigates the quality of life and several risk factors for the development of endometriosis as well as satisfaction with medical support in a minimum of 600 women with different stages of endometriosis and the same number of control women matched for age (± 3 years) and nationality. To evaluate specific features of endometriosis-associated pain a second group of 100 women with chronic abdominal/pelvic pain not related to endometriosis is investigated. Recruitment takes place in different university clinics, and districts hospitals in Switzerland, Germany. And Austria. Control women i.e. women without any evidence for endometriosis presenting for annual routine gynaecological controls are collected at the same places.\n\nA composition of different internationally validated questionnaires as well as specific questions on dealing with endometriosis is used to collect information on the quality of life and potential risk factors for endometriosis. Questions on sexuality and partnership are also distributed to women's partners. All diagnosis of endometriosis and classification of ASRM (American Society for Reproductive Medicine) disease stages are based on woman's medical charts.", "detailedDescription": "With a prevalence of 7-10% endometriosis is one of the most common diseases of women during their reproductive period. There is a broad range of clinical symptoms of endometriosis, which may vary between an incidental asymptomatic finding and a chronic severely painful disease. Symptoms are nearly independent from disease stage and current therapeutic options do not permit to reliably reduce symptoms to an acceptable level. Independent from the therapy chosen, about 20% of women re-develop clinical symptoms in the first year and another 50% within a period of five years.\n\nThe currently provided medical support concentrates on surgical and medical i.e. hormonal options. Although it seems evident that endometriosis-associated pain will have a serious impact on the daily life of women attaint and there is a broad literature on the effect of other chronic pain diseases on patients' lives, comparable data for endometriosis are rare. Also, support models to allow women to integrate a chronic endometriosis into their daily life are currently lacking. To provide a reliable basis for the development of better holistic support models, the current study collects data on different aspects of the quality of life in a minimum of 600 women with different stages of endometriosis and a minimum of 600 control women matched for age (± 3 years) and nationality. To evaluate which features of the quality of life are specific for endometriosis a second control group of 100 women with chronic abdominal/pelvic pain not related to endometriosis is investigated. Recruitment takes place in different university clinics, and districts hospitals in Switzerland, Germany and Austria. Control women i.e. women without any evidence for endometriosis presenting for annual routine gynaecological controls are collected at the same places.\n\nA composition of different internationally validated questionnaires as well as specific questions on dealing with endometriosis is used to collect information on the quality of life and potential risk factors for endometriosis. The questionnaire includes basic socio-demographic data, life style parameters, a general as well as gynaeco-obstetric history including detailed questions on the diagnosis, treatment and current symptoms of endometriosis. In addition questionnaires on pain (modified version of the Brief Pain Inventory (BPI), Pain Disability Index (PDI), resources (SOC), stress perception (PSQ20), professional development, satisfaction with medical support, adverse childhood experiences (modified version of the childhood trauma questionnaire (CTQ), daily life, partnership (Partnerschaftsfragebogen, PFB), sexuality (modified version of the Brief Index of Sexual Functioning and Global sexual functioning) and anxiety/depression (PHQ, GAD) have to be completed by study participants. Socio-demographic questions, questions on partnership as well as on the estimated impact of endometriosis on partnership /sexuality were also given to study participants' partners. In addition to the current quality of life potential risk factors for the development of endometriosis e.g. traumatic childhood experiences are evaluated as well as satisfaction with medical support are evaluated.\n\nAll diagnosis of endometriosis and classification of ASRM disease stages are based on woman's medical charts."}, "conditionsModule": {"conditions": ["Endometriosis", "Quality of Life", "Pain", "Sexuality", "Anxiety", "Depression", "Infertility"], "keywords": ["endometriosis", "quality of life", "professional activity", "pain", "infertility", "sexuality", "partnership", "anxiety", "depression", "stress", "childhood trauma", "medical support", "dyspareunia"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "CASE_CONTROL", "timePerspective": "CROSS_SECTIONAL"}, "enrollmentInfo": {"count": 1267, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Case group", "description": "Women with a surgically confirmed diagnosis of endometriosis"}, {"label": "Control group 1", "description": "Women without any evidence of endometriosis (= no clinical symptom and/or no surgical evidence of endometriosis)"}, {"label": "Control group 2", "description": "Women without endometriosis (surgically confirmed) but chronic abdominal/pelvic pain due to other reasons (e.g. Crohn's disease, colitis etc)"}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Quality of life i.e. pain, infertility, partnership, sexuality, depression, anxiety, stress, medical support, comorbidities and risk factors in the development of endometriosis: childhood trauma, life style factors, menstrual history", "description": "The outcome measures are assessed with internationally validated questionnaires i.e. modified version of the Brief Pain Inventory and Pain Disability Index, modified Form des Childhood Trauma Questionnaire, Brief Symptom Inventory, partnership questionnaire (PFB), modified version of the Brief Index of Sexual Functioning und Global sexual functioning, Hospital Anxiety and Depression Scale (HADS) as well as the questionnaire on life satisfaction (FLZ)", "timeFrame": "The questionnaire is answered once after at inclusion in the study, different questions cover different time periods ranging from childhood (0-17 years) to the actual situation (last 4 weeks/ 24hours) as specified in the questionnaire"}], "secondaryOutcomes": [{"measure": "Prevalences of diseases such as dyspareunia, sexual disorders or adverse childhood experiences in the control group.", "description": "Measurements with internationally validated questionnaires and womens' medical history according to medical charts", "timeFrame": "Once at inclusion in the study"}, {"measure": "Comorbidity of chronic pain.", "description": "Measurements with internationally validated questionnaires and womens' medical history according to medical charts", "timeFrame": "Once at inclusion in the study"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\nfemale \\>18 years fluent German\n\n* Cases: diagnosis of endometriosis Control 1: no endometriosis, no chronic pain Control 2: no endometriosis, chronic abdominal/pelvic pain\n\nExclusion Criteria:\n\n* male (Except for partner questionnaires)\n* \\<18years\n* not fluent in German", "healthyVolunteers": true, "sex": "FEMALE", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"], "studyPopulation": "Female Age \\>18\n\nCase group: women with endometriosis Healthy volunteers in control group", "samplingMethod": "PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"overallOfficials": [{"name": "Brigitte Leeners, Prof. Dr.", "affiliation": "Clinic for Reproductive Endocrinology, University Hospital Zurich, Switzerland", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Clinic for Reproductive Endocrinology, University Hospital Zurich", "city": "Zurich", "zip": "8091", "country": "Switzerland", "geoPoint": {"lat": 47.36667, "lon": 8.55}}]}, "referencesModule": {"references": [{"pmid": "40815907", "type": "DERIVED", "citation": "Candan A, Kohl Schwartz A, Birchler K, Leeners B. Psychosomatic comorbidity in endometriosis: A multi-center, cross-sectional study identifying an underestimated factor in current medical support. J Psychosom Res. 2025 Sep;196:112346. doi: 10.1016/j.jpsychores.2025.112346. Epub 2025 Aug 9."}, {"pmid": "39469237", "type": "DERIVED", "citation": "El Hadad S, Schwartz ASK, Gassner C, Haeberlin F, von Orelli S, Imesch P, Leeners B. Partnership and relationship happiness in endometriosis related chronic pelvic pain: a multicenter case-control study. Front Psychol. 2024 Oct 14;15:1382067. doi: 10.3389/fpsyg.2024.1382067. eCollection 2024."}, {"pmid": "37693279", "type": "DERIVED", "citation": "El-Hadad S, Lasser D, Sachs MK, Schwartz ASK, Haeberlin F, von Orelli S, Eberhard M, Leeners B. Dysmenorrhea in adolescents requires careful investigation of endometriosis-an analysis of early menstrual experiences in a large case-control study. Front Reprod Health. 2023 Aug 25;5:1121515. doi: 10.3389/frph.2023.1121515. eCollection 2023."}, {"pmid": "30782670", "type": "DERIVED", "citation": "Sperschneider ML, Hengartner MP, Kohl-Schwartz A, Geraedts K, Rauchfuss M, Woelfler MM, Haeberlin F, von Orelli S, Eberhard M, Maurer F, Imthurn B, Imesch P, Leeners B. Does endometriosis affect professional life? A matched case-control study in Switzerland, Germany and Austria. BMJ Open. 2019 Jan 9;9(1):e019570. doi: 10.1136/bmjopen-2017-019570."}, {"pmid": "29947766", "type": "DERIVED", "citation": "Ramin-Wright A, Schwartz ASK, Geraedts K, Rauchfuss M, Wolfler MM, Haeberlin F, von Orelli S, Eberhard M, Imthurn B, Imesch P, Fink D, Leeners B. Fatigue - a symptom in endometriosis. Hum Reprod. 2018 Aug 1;33(8):1459-1465. doi: 10.1093/humrep/dey115."}, {"pmid": "29947745", "type": "DERIVED", "citation": "Liebermann C, Kohl Schwartz AS, Charpidou T, Geraedts K, Rauchfuss M, Wolfler M, von Orelli S, Haberlin F, Eberhard M, Imesch P, Imthurn B, Leeners B. Maltreatment during childhood: a risk factor for the development of endometriosis? Hum Reprod. 2018 Aug 1;33(8):1449-1458. doi: 10.1093/humrep/dey111."}, {"pmid": "29079275", "type": "DERIVED", "citation": "Kohl Schwartz AS, Wolfler MM, Mitter V, Rauchfuss M, Haeberlin F, Eberhard M, von Orelli S, Imthurn B, Imesch P, Fink D, Leeners B. Endometriosis, especially mild disease: a risk factor for miscarriages. Fertil Steril. 2017 Nov;108(5):806-814.e2. doi: 10.1016/j.fertnstert.2017.08.025."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}, {"id": "D010146", "term": "Pain"}, {"id": "D019529", "term": "Sexuality"}, {"id": "D001008", "term": "Anxiety Disorders"}, {"id": "D003863", "term": "Depression"}, {"id": "D007246", "term": "Infertility"}, {"id": "D004414", "term": "Dyspareunia"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}, {"id": "D009461", "term": "Neurologic Manifestations"}, {"id": "D012816", "term": "Signs and Symptoms"}, {"id": "D013568", "term": "Pathological Conditions, Signs and Symptoms"}, {"id": "D012725", "term": "Sexual Behavior"}, {"id": "D001519", "term": "Behavior"}, {"id": "D001523", "term": "Mental Disorders"}, {"id": "D001526", "term": "Behavioral Symptoms"}, {"id": "D005832", "term": "Genital Diseases, Male"}, {"id": "D012735", "term": "Sexual Dysfunction, Physiological"}, {"id": "D052801", "term": "Male Urogenital Diseases"}, {"id": "D020018", "term": "Sexual Dysfunctions, Psychological"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT01767090", "orgStudyIdInfo": {"id": "1707-CL-0011"}, "secondaryIdInfos": [{"id": "2012-002791-14", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Astellas Pharma Inc", "class": "INDUSTRY"}, "briefTitle": "A Study to Assess the Effectiveness and Safety of Different Doses of ASP1707 Compared to Placebo for Endometriosis Associated Pelvic Pain", "officialTitle": "A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Assess the Efficacy, Safety, and Dose-Response Relationship of ASP1707 in Subjects With Endometriosis Associated Pelvic Pain for 12 Weeks, Followed by a 12-Week Double-blind Extension Without Placebo Control, Including a 24-Week Open-Label Leuprorelin Acetate Treatment Group for Bone Mineral Density Assessment"}, "statusModule": {"statusVerifiedDate": "2024-10", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-12-04", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2015-05-13", "type": "ACTUAL"}, "completionDateStruct": {"date": "2015-07-30", "type": "ACTUAL"}, "studyFirstSubmitDate": "2012-12-18", "studyFirstSubmitQcDate": "2013-01-10", "studyFirstPostDateStruct": {"date": "2013-01-14", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2024-10-21", "lastUpdatePostDateStruct": {"date": "2024-10-23", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Astellas Pharma Europe B.V.", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The main objective for this study is to assess the efficacy and dose-response relationship of ASP1707 in reduction of endometriosis associated pelvic pain. The secondary objectives are to assess the safety, tolerability, Pharmacokinetics of ASP1707, dose response relationship of ASP1707 in reduction of E2 (Estradiol), 24-week efficacy of ASP1707 in reduction of endometriosis associated pain and 24-week safety and tolerability of ASP1707."}, "conditionsModule": {"conditions": ["Endometriosis"], "keywords": ["Phase 2", "Double-blind", "Pelvic pain", "ASP1707", "Placebo-controlled", "Endometriosis"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 912, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Applicable to first 12 week period (Part One); subjects in this arm will be randomized to one of the ASP1707 dose levels for the second 12 week period (Part Two)", "interventionNames": ["Drug: Placebo"]}, {"label": "ASP1707 lowest dose", "type": "EXPERIMENTAL", "description": "Subjects in this arm will be dosed with ASP1707 once daily for a total of 12 weeks (Part One) and continue taking the assigned dose for a further 12 weeks during the extension phase of the study (Part Two) for a total of 24 weeks", "interventionNames": ["Drug: ASP1707"]}, {"label": "ASP1707 low dose", "type": "EXPERIMENTAL", "description": "Subjects in this arm will be dosed with ASP1707 once daily for a total of 12 weeks (Part One) and continue taking the assigned dose for a further 12 weeks during the extension phase of the study (Part Two) for a total of 24 weeks", "interventionNames": ["Drug: ASP1707"]}, {"label": "ASP1707 medium dose", "type": "EXPERIMENTAL", "description": "Subjects in this arm will be dosed with ASP1707 once daily for a total of 12 weeks (Part One) and continue taking the assigned dose for a further 12 weeks during the extension phase of the study (Part Two) for a total of 24 weeks", "interventionNames": ["Drug: ASP1707"]}, {"label": "ASP1707 high dose", "type": "EXPERIMENTAL", "description": "Subjects in this arm will be dosed with ASP1707 once daily for a total of 12 weeks (Part One) and continue taking the assigned dose for a further 12 weeks during the extension phase of the study (Part Two) for a total of 24 weeks", "interventionNames": ["Drug: ASP1707"]}, {"label": "Leuprorelin acetate", "type": "ACTIVE_COMPARATOR", "description": "Subjects in this arm will be treated with leuprorelin acetate for a total of 24 weeks", "interventionNames": ["Drug: Leuprorelin acetate"]}], "interventions": [{"type": "DRUG", "name": "ASP1707", "description": "Oral", "armGroupLabels": ["ASP1707 high dose", "ASP1707 low dose", "ASP1707 lowest dose", "ASP1707 medium dose"]}, {"type": "DRUG", "name": "Placebo", "description": "Oral", "armGroupLabels": ["Placebo"]}, {"type": "DRUG", "name": "Leuprorelin acetate", "description": "subcutaneous", "armGroupLabels": ["Leuprorelin acetate"], "otherNames": ["Prostap® SR"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change from baseline to the end of 12 weeks treatment of pain score for overall pelvic pain", "timeFrame": "Baseline & Week 12"}, {"measure": "Change from baseline to the end of 12 weeks treatment of pain score for dysmenorrhea", "timeFrame": "Baseline & Week 12"}, {"measure": "Change from baseline to the end of 12 weeks treatment of pain score for non-menstrual pelvic pain", "timeFrame": "Baseline & Week 12"}], "secondaryOutcomes": [{"measure": "Change from baseline to the end of 24 weeks treatment of pain score for overall pelvic pain", "timeFrame": "Baseline & Week 24"}, {"measure": "Change from baseline to the end of 24 weeks treatment of pain score for dysmenorrhea", "timeFrame": "Baseline & Week 24"}, {"measure": "Change from baseline to the end of 24 weeks treatment of pain score for non-menstrual pelvic pain", "timeFrame": "Baseline & Week 24"}, {"measure": "Change from baseline to the end of treatment (EoT) of the dyspareunia score", "timeFrame": "Baseline, Week 12 & Week 24"}, {"measure": "Occurrence of response at the EoT for pain score for overall pelvic pain, dysmenorrhea, non-menstrual pelvic pain and dyspareunia", "timeFrame": "Week 12 & Week 24"}, {"measure": "Change from baseline to the EoT of the mean scores of the modified Biberoglu and Behrman (B&B) symptom and sign domains", "timeFrame": "Baseline, Week 12 & Week 24"}, {"measure": "Change from baseline to the EoT of the use of protocol defined rescue medication", "timeFrame": "Baseline, Week 12 & Week 24"}, {"measure": "Change from baseline to the EoT of the mean Pain Interference score of the Brief Pain Inventory", "timeFrame": "Baseline, Week 12 & Week 24"}, {"measure": "Patient Global Impression of Change (PGIC) at the End of Treatment", "timeFrame": "Week 12 & Week 24"}, {"measure": "Change from baseline to the EoT in the Endometriosis Health Profile (EHP)-5 score", "timeFrame": "Baseline, Week 12 & Week 24"}, {"measure": "Change from baseline to the EoT of the Female Sexual Function Index (FSFI) score (sexual well-being)", "timeFrame": "Baseline, Week 12 & Week 24"}, {"measure": "Change from baseline to the EoT of the Beck's Depression Inventory (BDI)-II score", "timeFrame": "Baseline, Week 12 & Week 24"}, {"measure": "Change from baseline to the EoT in the EuroQol (EQ-5D-5L) score", "timeFrame": "Baseline, Week 12 & Week 24"}, {"measure": "Safety and tolerability of ASP1707 measured by Adverse Events (AEs), bleeding patterns, Bone Mineral Density (BMD)", "timeFrame": "Up to Week 42"}, {"measure": "Pharmacodynamic profile of ASP1707 measured by Serum Estradiol (E2) levels", "timeFrame": "Up to Week 26"}, {"measure": "Pharmacokinetic profile of ASP1707", "description": "Both CL/F, V/F, AUCtau, Cmax, Ctrough", "timeFrame": "Up to Week 24"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Pre menopausal female adults with confirmed length and regular menstrual cycle\n* Surgically diagnosed endometriosis\n* Moderate to severe endometriosis related pain\n\nExclusion Criteria:\n\n* Hormonal contraceptives or other drugs with effects on gynecological endocrinology\n* Surgery for endometriosis within the 4 weeks prior to entry\n* Uterine myoma\n* Abnormal vaginal bleeding\n* Hysterectomy or bilateral oophorectomy\n* Pelvic infection\n* Relevant abnormalities at gynecological exam at screening\n* Disease with chronic abdominal pain of non-endometriosis origin\n* Pituitary adenoma", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "45 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Clinical Study Manager", "affiliation": "Astellas Pharma Europe B.V.", "role": "STUDY_CHAIR"}], "locations": [{"facility": "Site: 1006", "city": "Brussels", "zip": "1200", "country": "Belgium", "geoPoint": {"lat": 50.85045, "lon": 4.34878}}, {"facility": "Site: 1002", "city": "Genk", "zip": "3600", "country": "Belgium", "geoPoint": {"lat": 50.965, "lon": 5.50082}}, {"facility": "Site: 1003", "city": "Ghent", "zip": "9000", "country": "Belgium", "geoPoint": {"lat": 51.05, "lon": 3.71667}}, {"facility": "Site: 1001", "city": "Leuven", "zip": "3000", "country": "Belgium", "geoPoint": {"lat": 50.87959, "lon": 4.70093}}, {"facility": "Site: 1005", "city": "Liège", "zip": "4000", "country": "Belgium", "geoPoint": {"lat": 50.63373, "lon": 5.56749}}, {"facility": "Site: 1105", "city": "Plovdiv", "country": "Bulgaria", "geoPoint": {"lat": 42.15387, "lon": 24.75001}}, {"facility": "Site: 1104", "city": "Sofia", "zip": "1000", "country": "Bulgaria", "geoPoint": {"lat": 42.69751, "lon": 23.32415}}, {"facility": "Site: 1107", "city": "Sofia", "zip": "1330", "country": "Bulgaria", "geoPoint": {"lat": 42.69751, "lon": 23.32415}}, {"facility": "Site: 1106", "city": "Sofia", "zip": "1504", "country": "Bulgaria", "geoPoint": {"lat": 42.69751, "lon": 23.32415}}, {"facility": "Site: 1102", "city": "Sofia", "country": "Bulgaria", "geoPoint": {"lat": 42.69751, "lon": 23.32415}}, {"facility": "Site: 1103", "city": "Stara Zagora", "zip": "6000", "country": "Bulgaria", "geoPoint": {"lat": 42.43205, "lon": 25.64262}}, {"facility": "Site: 1390", "city": "Berlin", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Site: 1304", "city": "Dresden", "country": "Germany", "geoPoint": {"lat": 51.05089, "lon": 13.73832}}, {"facility": "Site: 1302", "city": "Erlangen", "country": "Germany", "geoPoint": {"lat": 49.59099, "lon": 11.00783}}, {"facility": "Site: 1311", "city": "Karlsruhe", "country": "Germany", "geoPoint": {"lat": 49.00937, "lon": 8.40444}}, {"facility": "Site: 1306", "city": "Lübeck", "country": "Germany", "geoPoint": {"lat": 53.86893, "lon": 10.68729}}, {"facility": "Site: 1422", "city": "Kecskemét", "state": "Bacs-Kiskun Megye", "zip": "6000", "country": "Hungary", "geoPoint": {"lat": 46.90618, "lon": 19.69128}}, {"facility": "Site: 1401", "city": "Budapest", "zip": "1135", "country": "Hungary", "geoPoint": {"lat": 47.49835, "lon": 19.04045}}, {"facility": "Site: 1407", "city": "Budapest", "country": "Hungary", "geoPoint": {"lat": 47.49835, "lon": 19.04045}}, {"facility": "Site: 1408", "city": "Debrecen", "zip": "4012", "country": "Hungary", "geoPoint": {"lat": 47.53167, "lon": 21.62444}}, {"facility": "Site: 1406", "city": "Pécs", "country": "Hungary", "geoPoint": {"lat": 46.07617, "lon": 18.22814}}, {"facility": "Site: 1403", "city": "Szekszárd", "zip": "7100", "country": "Hungary", "geoPoint": {"lat": 46.34723, "lon": 18.71189}}, {"facility": "Site: 1402", "city": "Székesfehérvár", "country": "Hungary", "geoPoint": {"lat": 47.18995, "lon": 18.41034}}, {"facility": "Site: 2018", "city": "Aomori", "zip": "036 8203", "country": "Japan", "geoPoint": {"lat": 40.81667, "lon": 140.73333}}, {"facility": "Site: 2017", "city": "Chiba", "zip": "299 0111", "country": "Japan", "geoPoint": {"lat": 35.6, "lon": 140.11667}}, {"facility": "Site: 2005", "city": "Fujisawa", "zip": "252 0804", "country": "Japan", "geoPoint": {"lat": 35.34926, "lon": 139.47666}}, {"facility": "Site: 2034", "city": "Hyōgo", "zip": "666 0195", "country": "Japan", "geoPoint": {"lat": 43.36667, "lon": 144.43333}}, {"facility": "Site: 2039", "city": "Hyōgo", "country": "Japan", "geoPoint": {"lat": 43.36667, "lon": 144.43333}}, {"facility": "Site: 2040", "city": "Hyōgo", "country": "Japan", "geoPoint": {"lat": 43.36667, "lon": 144.43333}}, {"facility": "Site: 2032", "city": "Kagoshima", "country": "Japan", "geoPoint": {"lat": 31.56667, "lon": 130.55}}, {"facility": "Site: 2015", "city": "Kanagawa", "zip": "213 8507", "country": "Japan", "geoPoint": {"lat": 37.58333, "lon": 139.91667}}, {"facility": "Site: 2035", "city": "Kanagawa", "country": "Japan", "geoPoint": {"lat": 37.58333, "lon": 139.91667}}, {"facility": "Site: 2013", "city": "Kawagoe", "zip": "350-8550", "country": "Japan", "geoPoint": {"lat": 35.90861, "lon": 139.48528}}, {"facility": "Site: 2029", "city": "Kawasaki", "zip": "210 0024", "country": "Japan", "geoPoint": {"lat": 35.52056, "lon": 139.71722}}, {"facility": "Site: 2024", "city": "Kawasaki", "zip": "212 0058", "country": "Japan", "geoPoint": {"lat": 35.52056, "lon": 139.71722}}, {"facility": "Site: 2033", "city": "Kochi", "zip": "783 8505", "country": "Japan", "geoPoint": {"lat": 33.55, "lon": 133.53333}}, {"facility": "Site: 2031", "city": "Kumamoto", "zip": "861 8520", "country": "Japan", "geoPoint": {"lat": 32.80589, "lon": 130.69181}}, {"facility": "Site: 2010", "city": "Kurashiki", "zip": "710 0824", "country": "Japan", "geoPoint": {"lat": 34.58333, "lon": 133.76667}}, {"facility": "Site: 2006", "city": "Kyoto", "zip": "602 8566", "country": "Japan", "geoPoint": {"lat": 35.02107, "lon": 135.75385}}, {"facility": "Site: 2036", "city": "Nagano", "country": "Japan", "geoPoint": {"lat": 36.65, "lon": 138.18333}}, {"facility": "Site: 2037", "city": "Nagano", "country": "Japan", "geoPoint": {"lat": 36.65, "lon": 138.18333}}, {"facility": "Site: 2038", "city": "Nagano", "country": "Japan", "geoPoint": {"lat": 36.65, "lon": 138.18333}}, {"facility": "Site: 2002", "city": "Nagaoka", "zip": "940 2085", "country": "Japan", "geoPoint": {"lat": 37.45, "lon": 138.85}}, {"facility": "Site: 2007", "city": "Nagasaki", "zip": "850 0003", "country": "Japan", "geoPoint": {"lat": 32.75, "lon": 129.88333}}, {"facility": "Site: 2011", "city": "Nara", "zip": "631 0805", "country": "Japan", "geoPoint": {"lat": 34.68505, "lon": 135.80485}}, {"facility": "Site: 2027", "city": "Sapporo", "zip": "060 0001", "country": "Japan", "geoPoint": {"lat": 43.06667, "lon": 141.35}}, {"facility": "Site: 2001", "city": "Sapporo", "zip": "060 0031", "country": "Japan", "geoPoint": {"lat": 43.06667, "lon": 141.35}}, {"facility": "Site: 2030", "city": "Sapporo", "zip": "060 0061", "country": "Japan", "geoPoint": {"lat": 43.06667, "lon": 141.35}}, {"facility": "Site: 2004", "city": "Tokyo", "zip": "101 0062", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}, {"facility": "Site: 2020", "city": "Tokyo", "zip": "107 0052", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}, {"facility": "Site: 2014", "city": "Tokyo", "zip": "113 8431", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}, {"facility": "Site: 2009", "city": "Tokyo", "zip": "113 8603", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}, {"facility": "Site: 2003", "city": "Tokyo", "zip": "1130033", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}, {"facility": "Site: 2028", "city": "Tokyo", "zip": "141 0022", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}, {"facility": "Site: 2025", "city": "Tokyo", "zip": "157 0061", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}, {"facility": "Site: 2016", "city": "Tokyo", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}, {"facility": "Site: 2012", "city": "Yokohama", "zip": "225 0024", "country": "Japan", "geoPoint": {"lat": 35.43333, "lon": 139.65}}, {"facility": "Site: 1501", "city": "Bialystok", "zip": "15-464", "country": "Poland", "geoPoint": {"lat": 53.13333, "lon": 23.16433}}, {"facility": "Site: 1505", "city": "Bialystok", "country": "Poland", "geoPoint": {"lat": 53.13333, "lon": 23.16433}}, {"facility": "Site: 1512", "city": "Gdansk", "country": "Poland", "geoPoint": {"lat": 54.35227, "lon": 18.64912}}, {"facility": "Site: 1504", "city": "Katowice", "zip": "40-724", "country": "Poland", "geoPoint": {"lat": 50.2597, "lon": 19.02173}}, {"facility": "Site: 1508", "city": "Lublin", "zip": "20-333", "country": "Poland", "geoPoint": {"lat": 51.25058, "lon": 22.57009}}, {"facility": "Site: 1507", "city": "Lublin", "zip": "20-632", "country": "Poland", "geoPoint": {"lat": 51.25058, "lon": 22.57009}}, {"facility": "Site: 1502", "city": "Warsaw", "zip": "02-066", "country": "Poland", "geoPoint": {"lat": 52.22977, "lon": 21.01178}}, {"facility": "Site: 1509", "city": "Warsaw", "country": "Poland", "geoPoint": {"lat": 52.22977, "lon": 21.01178}}, {"facility": "Site: 1525", "city": "Warzawa", "country": "Poland"}, {"facility": "Site: 1604", "city": "Brasov", "country": "Romania", "geoPoint": {"lat": 45.64861, "lon": 25.60613}}, {"facility": "Site: 1607", "city": "Bucaresti", "country": "Romania"}, {"facility": "Site: 1602", "city": "Bucharest", "zip": "11475", "country": "Romania", "geoPoint": {"lat": 44.43225, "lon": 26.10626}}, {"facility": "Site: 1601", "city": "Bucharest", "country": "Romania", "geoPoint": {"lat": 44.43225, "lon": 26.10626}}, {"facility": "Site: 1606", "city": "Bucharest", "country": "Romania", "geoPoint": {"lat": 44.43225, "lon": 26.10626}}, {"facility": "Site: 1603", "city": "Târgu Mureş", "country": "Romania", "geoPoint": {"lat": 46.54245, "lon": 24.55747}}, {"facility": "Site: 1701", "city": "Bucuresti", "country": "Ukraine"}, {"facility": "Site: 1702", "city": "Bucuresti", "country": "Ukraine"}, {"facility": "Site: 1705", "city": "Bucuresti", "country": "Ukraine"}, {"facility": "Site: 1707", "city": "Bucuresti", "country": "Ukraine"}, {"facility": "Site: 1713", "city": "Donetsk", "country": "Ukraine", "geoPoint": {"lat": 48.023, "lon": 37.80224}}, {"facility": "Site: 1716", "city": "Donetsk", "country": "Ukraine", "geoPoint": {"lat": 48.023, "lon": 37.80224}}, {"facility": "Site: 1708", "city": "Kyiv", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Site: 1703", "city": "Targu Mures", "country": "Ukraine"}, {"facility": "Site: 1717", "city": "Zaporizhzhya", "country": "Ukraine", "geoPoint": {"lat": 47.85167, "lon": 35.11714}}, {"facility": "Site: 1807", "city": "London", "zip": "SE5 9RS", "country": "United Kingdom", "geoPoint": {"lat": 51.50853, "lon": -0.12574}}, {"facility": "Site: 1804", "city": "Norwich", "zip": "NR47UY", "country": "United Kingdom", "geoPoint": {"lat": 52.62783, "lon": 1.29834}}, {"facility": "Site: 1808", "city": "Sheffield", "zip": "S10 2SF", "country": "United Kingdom", "geoPoint": {"lat": 53.38297, "lon": -1.4659}}, {"facility": "Site: 1806", "city": "Southampton", "zip": "SO16 5YA", "country": "United Kingdom", "geoPoint": {"lat": 50.90395, "lon": -1.40428}}]}, "referencesModule": {"references": [{"pmid": "31067329", "type": "DERIVED", "citation": "D'Hooghe T, Fukaya T, Osuga Y, Besuyen R, Lopez B, Holtkamp GM, Miyazaki K, Skillern L. Efficacy and safety of ASP1707 for endometriosis-associated pelvic pain: the phase II randomized controlled TERRA study. Hum Reprod. 2019 May 1;34(5):813-823. doi: 10.1093/humrep/dez028."}], "seeAlsoLinks": [{"label": "Link to results on the Astellas Clinical Study Results website", "url": "https://astellasclinicalstudyresults.com/study.aspx?ID=305"}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.", "infoTypes": ["STUDY_PROTOCOL", "SAP", "CSR"], "timeFrame": "Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.", "accessCriteria": "Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.", "url": "https://www.clinicaltrials.astellas.com/transparency/"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}, {"id": "D017699", "term": "Pelvic Pain"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}, {"id": "D010146", "term": "Pain"}, {"id": "D009461", "term": "Neurologic Manifestations"}, {"id": "D012816", "term": "Signs and Symptoms"}, {"id": "D013568", "term": "Pathological Conditions, Signs and Symptoms"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000708087", "term": "opigolix"}, {"id": "D016729", "term": "Leuprolide"}], "ancestors": [{"id": "D007987", "term": "Gonadotropin-Releasing Hormone"}, {"id": "D010906", "term": "Pituitary Hormone-Releasing Hormones"}, {"id": "D007028", "term": "Hypothalamic Hormones"}, {"id": "D036361", "term": "Peptide Hormones"}, {"id": "D006728", "term": "Hormones"}, {"id": "D006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D009479", "term": "Neuropeptides"}, {"id": "D010455", "term": "Peptides"}, {"id": "D000602", "term": "Amino Acids, Peptides, and Proteins"}, {"id": "D009842", "term": "Oligopeptides"}, {"id": "D009419", "term": "Nerve Tissue Proteins"}, {"id": "D011506", "term": "Proteins"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT04614246", "orgStudyIdInfo": {"id": "20584"}, "secondaryIdInfos": [{"id": "2020-003131-16", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Bayer", "class": "INDUSTRY"}, "briefTitle": "Study to Gather Information How Well Three Different Doses of BAY1817080 Given Twice Daily Over 12 Weeks Work in Comparison to an Inactive Pill (Placebo) and Elagolix in Women Suffering From Pain Related to a Condition Where the Tissue That Usually Grows Inside the Womb Grows Outside of the Womb", "officialTitle": "A Randomized, Double-blind, Open for Active Comparator, Parallel-group, Multicenter Phase 2b Study to Assess the Efficacy and Safety of Three Different Doses of P2X3 Antagonist (BAY1817080) Versus Placebo and Elagolix 150 mg in Women With Symptomatic Endometriosis", "acronym": "SCHUMANN"}, "statusModule": {"statusVerifiedDate": "2023-07", "overallStatus": "TERMINATED", "whyStopped": "Study terminated by Sponsor", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2021-01-29", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2022-01-17", "type": "ACTUAL"}, "completionDateStruct": {"date": "2022-05-03", "type": "ACTUAL"}, "studyFirstSubmitDate": "2020-11-02", "studyFirstSubmitQcDate": "2020-11-02", "studyFirstPostDateStruct": {"date": "2020-11-03", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2023-01-13", "resultsFirstSubmitQcDate": "2023-05-28", "resultsFirstPostDateStruct": {"date": "2023-05-31", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-07-28", "lastUpdatePostDateStruct": {"date": "2023-08-01", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Bayer", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to assess safety and efficacy of BAY 1817080 compared to elagolix and placebo in women with symptomatic endometriosis. Study details include:\n\n* Study duration: 155 up to 285 days\n* Treatment duration: 84 days\n* Visit frequency: 3 laboratory every 2 weeks for participants on BAY 1817080 or placebo"}, "conditionsModule": {"conditions": ["Endometriosis"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "maskingDescription": "Double blind to placebo and open-label for active comparator", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 215, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "BAY1817080 150 mg", "type": "EXPERIMENTAL", "description": "Participants will receive 150 mg of BAY1817080 twice daily over a 12-week intervention period", "interventionNames": ["Drug: BAY1817080"]}, {"label": "BAY1817080 75 mg", "type": "EXPERIMENTAL", "description": "Participants will receive 75 mg of BAY1817080 twice daily over a 12-week intervention period", "interventionNames": ["Drug: BAY1817080"]}, {"label": "BAY1817080 25 mg", "type": "EXPERIMENTAL", "description": "Participants will receive 25 mg of BAY1817080 twice daily over a 12-week intervention period", "interventionNames": ["Drug: BAY1817080"]}, {"label": "Elagolix", "type": "ACTIVE_COMPARATOR", "description": "Participants will receive 150 mg of Elagolix once daily over a 12-week intervention period", "interventionNames": ["Drug: Elagolix"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Participants will receive placebo matching BAY1817080 twice daily over a 12-week intervention period", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "BAY1817080", "description": "Tablet, oral administration", "armGroupLabels": ["BAY1817080 150 mg", "BAY1817080 25 mg", "BAY1817080 75 mg"]}, {"type": "DRUG", "name": "Elagolix", "description": "Tablet, oral administration", "armGroupLabels": ["Elagolix"]}, {"type": "DRUG", "name": "Placebo", "description": "Tablet, oral administration", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Absolute Change in Mean Worst Endometriosis Associated Pelvic Pain (EAPP), Primary Per Protocol Set (pPPS)", "description": "The worst EAPP was measured daily on the 0-10 Numerical Rating Scale (NRS) by item 1 of the Endometriosis Symptom Diary (ESD). In question 1, participants were asked to rate the pain in the target area during the past 24 hours, where 0= no pain and 10= worst imaginable pain and responses were recorded in ESD. The absolute change in mean worst EAPP was from baseline (last 28 days before the first intake of study drug) to end of intervention (last 28 days ending with the last intake of study drug planned on Day 84 \\[+3\\]). The time frame of 28 days captures a menstrual cycle on average.", "timeFrame": "change from baseline to week 12"}], "secondaryOutcomes": [{"measure": "Least Squares Mean (SE) Changes in Worst EAPP From Baseline to Week 12, Per Protocol Set", "description": "The worst EAPP was measured daily on the 0-10 Numerical Rating Scale (NRS) by item 1 of the Endometriosis Symptom Diary (ESD). In question 1, participants were asked to rate the pain in the target area during the past 24 hours, where 0= no pain and 10= worst imaginable pain and responses were recorded in ESD. The absolute change in mean worst EAPP was from baseline (last 28 days before the first intake of study drug) to end of intervention (last 28 days ending with the last intake of study drug planned on Day 84 \\[+3\\]). The time frame of 28 days captures a menstrual cycle on average.", "timeFrame": "change from baseline to week 12"}, {"measure": "Number of Participants With Treatment-emergent Adverse Events (TEAE)", "description": "A treatment-emergent AE (TEAE) was defined as any event arising or worsening after the start of study drug administration until 14 days after the last study medication intake.", "timeFrame": "up to 14 days after the last study medication intake"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Participant must be ≥ 18 years of age at the time of signing the informed consent\n* Visually-confirmed endometriosis: detection of endometriotic lesions during laparoscopy or laparotomy (with or without pathological diagnosis) within 10 years but no less than 8 weeks from Visit 1a (surgically diagnosed endometriosis). For Japan only and limited to no more than half of all randomized Japanese participants: the diagnosis can be based on previous imaging (i.e. endometriosis lesion detected by ultrasound or MRI). If the participant was diagnosed by ultrasound, the lesion must be visualized again by ultrasound at the screening visit. If the participant was diagnosed by MRI, the diagnosis must have been made within 12 months before Visit 1a (clinically diagnosed endometriosis).\n* Both sub-criteria regarding pain symptoms must be fulfilled:\n\n  * At Visit 1a, participant presents self-reported moderate to severe pain which - based on the judgement of the investigator - carries a reasonable likelihood to translate into a severity of pain symptoms sufficient to fulfil the eligibility criterion and be caused by endometriosis, and\n  * During the screening period at least 24 daily ESD entries during the 28 consecutive days starting on the first day with menstrual bleeding at or after Visit 1a and entries in the ESD item 1a ('worst pain' on the daily numerical rating scale) sum up to 98 or more.\n* Willingness to use standardized rescue pain medications for EAPP (i.e. ibuprofen, acetaminophen and tramadol) and not use any prophylactic pain medication, according to investigator's instruction\n* Ability to swallow the study intervention, i.e., the different kinds of tablets, as complete units\n* Good general health (except for findings related to endometriosis) as proven by medical history, physical and gynecological examinations and laboratory test results\n* Normal or clinically insignificant cervical cytology not requiring further follow-up:\n\n  * A cervical cytology sample has to be obtained during screening, or\n  * A documented normal result has to be available from cervical cytology conducted within 12 months prior to Visit 1a.\n  * Human papilloma virus (HPV) testing in participants with atypical squamous cells of unknown significance (ASCUS) will be used as an adjunctive test automatically. Participants with ASCUS can be included if they are negative for high-risk HPV strains.\n\nExclusion Criteria:\n\n* Current pregnancy or less than 3 months since delivery, abortion or stop of lactation before Visit 1a\n* Hypersensitivity to any ingredient of the study intervention and/or the standardized rescue medications\n* Known osteoporosis\n* History of a low trauma fracture\n* Contraindications for elagolix or the standardized rescue medications\n* Current malignancy or history of cancer (exception: basal cell or squamous cell carcinoma of the skin) within the last 5 years prior to Visit 1a\n* Any other diseases or conditions that according to the investigator can compromise the function of the body systems and could result in altered absorption, excessive accumulation, impaired metabolism, or altered excretion of the study intervention (e.g. extremely low body weight, chronic bowel disease, Crohn's disease and ulcerative colitis)\n* Menopause or signs of menopausal transition, such as absence of regular menstrual cycles based on investigator's judgment (absence of information regarding menstrual bleeding pattern e.g. due to long term use of hormonal contraception is not an exclusion criterion)\n* Any disease or condition that may worsen during the study period according to the assessment and opinion of the investigator\n* Abnormal uterine bleeding in terms of regularity or heaviness (with the exception of heavy menstrual bleeding that does not require treatment)\n* Any findings that require further diagnostic procedures to avoid harm to the participant (e.g. ovarian tumors of uncertain origin or pelvic masses of unclear etiology)\n* Any serious or unstable diseases or medical conditions, including psychiatric disorders, that might interfere with the conduct of the study or the interpretation of the result, including for example:\n\n  * history of hysterectomy and/or bilateral oophorectomy\n  * any conditions considered to contribute significantly to pelvic pain by the investigator, e.g. fibromyalgia, uterine fibroids, irritable bowel syndrome or other bowel disorders\n  * any other underlying diseases requiring regular use of pain medication (e.g. migraine)\n  * history of or current anxiety or depression unless stable with or without medical treatment ≥ 6 months before Visit 1a\n* Major surgery scheduled during the study period\n* Non-responsiveness of EAPP to earlier treatment with GnRH-agonists or GnRH-antagonists, based on the judgement of the investigator\n* SARS-CoV-2- positive virus RNA test within 4 weeks prior to Visit 1a reported by participant, regardless of whether the participant had symptoms\n* History of COVID-19 infection with persistent/ongoing symptoms\n* Contact with SARS-CoV-2- positive or COVID-19 patient within the last 4 weeks prior to Visit 1a\n* Intake of medication prohibited due to potential drug-drug interaction\n* Use of other treatments that might interfere with the conduct of the study or the interpretation of the results, including:\n\n  * hormonal medications\n  * other treatments intended for endometriosis/pelvic pain during participation in the study, including the use of herbal products or traditional Chinese medicine for symptom relief, with the exception of the standardized rescue pain medications\n* Simultaneous participation in another clinical trial with investigational medicinal product(s). Participation in another trial 3 months prior to Visit 1a that might have an impact on the study objectives, at the discretion of the investigator\n* Previous assignment to study intervention (randomization) in this study (allowing previously randomized participants to be re-included into the study may lead to bias)\n* Laboratory values outside the inclusion range (specified in the laboratory manual) and considered clinically relevant", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "Accel Research Sites - Cahaba Medical Care", "city": "Birmingham", "state": "Alabama", "zip": "35218", "country": "United States", "geoPoint": {"lat": 33.52066, "lon": -86.80249}}, {"facility": "University of Alabama at Birmingham", "city": "Birmingham", "state": "Alabama", "zip": "35294-0026", "country": "United States", "geoPoint": {"lat": 33.52066, "lon": -86.80249}}, {"facility": "Mobile Ob-Gyn, PC", "city": "Mobile", "state": "Alabama", "zip": "36608-6703", "country": "United States", "geoPoint": {"lat": 30.69436, "lon": -88.04305}}, {"facility": "Precision Trials, AZ, LLC", "city": "Phoenix", "state": "Arizona", "zip": "85032", "country": "United States", "geoPoint": {"lat": 33.44838, "lon": -112.07404}}, {"facility": "Diagnamics, Inc.", "city": "Encinitas", "state": "California", "zip": "92024", "country": "United States", "geoPoint": {"lat": 33.03699, "lon": -117.29198}}, {"facility": "West Coast OB/GYN Associates", "city": "San Diego", "state": "California", "zip": "92123", "country": "United States", "geoPoint": {"lat": 32.71571, "lon": -117.16472}}, {"facility": "Advanced Women's Health Institute", "city": "Greenwood Village", "state": "Colorado", "zip": "80111", "country": "United States", "geoPoint": {"lat": 39.61721, "lon": -104.95081}}, {"facility": "Office of Dr. James A. Simon, MD", "city": "Washington D.C.", "state": "District of Columbia", "zip": "20036", "country": "United States", "geoPoint": {"lat": 38.89511, "lon": -77.03637}}, {"facility": "Helix Biomedics, LLC", "city": "Boynton Beach", "state": "Florida", "zip": "33435", "country": "United States", "geoPoint": {"lat": 26.52535, "lon": -80.06643}}, {"facility": "Alliance for Multispecialty Research, LLC - Fort Meyers", "city": "Fort Myers", "state": "Florida", "zip": "33912", "country": "United States", "geoPoint": {"lat": 26.62168, "lon": -81.84059}}, {"facility": "Suncoast Clinical Research Center, Inc.", "city": "New Port Richey", "state": "Florida", "zip": "34652", "country": "United States", "geoPoint": {"lat": 28.24418, "lon": -82.71927}}, {"facility": "A Premier Medical Research of Florida, LLC", "city": "Orange City", "state": "Florida", "zip": "32763", "country": "United States", "geoPoint": {"lat": 28.94888, "lon": -81.29867}}, {"facility": "Physician Care Clinical Research", "city": "Sarasota", "state": "Florida", "zip": "34239", "country": "United States", "geoPoint": {"lat": 27.33643, "lon": -82.53065}}, {"facility": "Medisense, Inc.", "city": "Atlanta", "state": "Georgia", "zip": "30363", "country": "United States", "geoPoint": {"lat": 33.749, "lon": -84.38798}}, {"facility": "Augusta University Medical Center", "city": "Augusta", "state": "Georgia", "zip": "30912", "country": "United States", "geoPoint": {"lat": 33.47097, "lon": -81.97484}}, {"facility": "Paramount Research Solutions-College Park", "city": "College Park", "state": "Georgia", "zip": "30349", "country": "United States", "geoPoint": {"lat": 33.65344, "lon": -84.44937}}, {"facility": "Journey Medical Research", "city": "Snellville", "state": "Georgia", "zip": "30078", "country": "United States", "geoPoint": {"lat": 33.85733, "lon": -84.01991}}, {"facility": "Clinical Research Prime", "city": "Idaho Falls", "state": "Idaho", "zip": "83404", "country": "United States", "geoPoint": {"lat": 43.46658, "lon": -112.03414}}, {"facility": "Southern Clinical Research Associates LLC", "city": "Metairie", "state": "Louisiana", "zip": "70001", "country": "United States", "geoPoint": {"lat": 29.98409, "lon": -90.15285}}, {"facility": "Continental Clinical Solutions, LLC", "city": "Towson", "state": "Maryland", "zip": "21204", "country": "United States", "geoPoint": {"lat": 39.4015, "lon": -76.60191}}, {"facility": "Wayne State University Physicians Group", "city": "Detroit", "state": "Michigan", "zip": "48201", "country": "United States", "geoPoint": {"lat": 42.33143, "lon": -83.04575}}, {"facility": "Essential Women's Health Associates", "city": "Las Vegas", "state": "Nevada", "zip": "89113", "country": "United States", "geoPoint": {"lat": 36.17497, "lon": -115.13722}}, {"facility": "Bosque Womens Care", "city": "Albuquerque", "state": "New Mexico", "zip": "87109", "country": "United States", "geoPoint": {"lat": 35.08449, "lon": -106.65114}}, {"facility": "SUNY Downstate Medical Center", "city": "Brooklyn", "state": "New York", "zip": "11203", "country": "United States", "geoPoint": {"lat": 40.6501, "lon": -73.94958}}, {"facility": "Carolina Women's Research & Wellness Center", "city": "Durham", "state": "North Carolina", "zip": "27713", "country": "United States", "geoPoint": {"lat": 35.99403, "lon": -78.89862}}, {"facility": "Lyndhurst Clinical Research", "city": "Winston-Salem", "state": "North Carolina", "zip": "27103", "country": "United States", "geoPoint": {"lat": 36.09986, "lon": -80.24422}}, {"facility": "Clinical Inquest Center, Ltd.", "city": "Beavercreek", "state": "Ohio", "zip": "45432", "country": "United States", "geoPoint": {"lat": 39.70923, "lon": -84.06327}}, {"facility": "Aventiv Research - Dublin", "city": "Dublin", "state": "Ohio", "zip": "43016", "country": "United States", "geoPoint": {"lat": 40.09923, "lon": -83.11408}}, {"facility": "Centricity Research formerly Aventiv - Dublin", "city": "Dublin", "state": "Ohio", "zip": "43016", "country": "United States", "geoPoint": {"lat": 40.09923, "lon": -83.11408}}, {"facility": "HWC Women's Research Center", "city": "Englewood", "state": "Ohio", "zip": "45322", "country": "United States", "geoPoint": {"lat": 39.87756, "lon": -84.30217}}, {"facility": "University Hospitals Landerbrook Health Center", "city": "Mayfield Heights", "state": "Ohio", "zip": "44124", "country": "United States", "geoPoint": {"lat": 41.51922, "lon": -81.4579}}, {"facility": "Palmetto Clinical Research", "city": "Summerville", "state": "South Carolina", "zip": "29485", "country": "United States", "geoPoint": {"lat": 33.0185, "lon": -80.17565}}, {"facility": "Chattanooga Medical Research, LLC", "city": "Chattanooga", "state": "Tennessee", "zip": "37404", "country": "United States", "geoPoint": {"lat": 35.04563, "lon": -85.30968}}, {"facility": "ClinSearch, LLC", "city": "Chattanooga", "state": "Tennessee", "zip": "37421", "country": "United States", "geoPoint": {"lat": 35.04563, "lon": -85.30968}}, {"facility": "Medical Research Center of Memphis, LLC", "city": "Memphis", "state": "Tennessee", "zip": "38120", "country": "United States", "geoPoint": {"lat": 35.14953, "lon": -90.04898}}, {"facility": "International Clinical Research-Tennessee LLC.", "city": "Murfreesboro", "state": "Tennessee", "zip": "37130", "country": "United States", "geoPoint": {"lat": 35.84562, "lon": -86.39027}}, {"facility": "Discovery Clinical Trials - Dallas", "city": "Dallas", "state": "Texas", "zip": "75230", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "UT Health Women's Research Center at Memorial City", "city": "Houston", "state": "Texas", "zip": "77024", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Biopharma Informatic, Inc.", "city": "Houston", "state": "Texas", "zip": "77043", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Centex Studies, Inc.", "city": "Houston", "state": "Texas", "zip": "77058", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Centex Studies, Inc.", "city": "Houston", "state": "Texas", "zip": "77090", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Advances in Health", "city": "Pearland", "state": "Texas", "zip": "77584", "country": "United States", "geoPoint": {"lat": 29.56357, "lon": -95.28605}}, {"facility": "Tidewater Clinical Research, Inc.", "city": "Norfolk", "state": "Virginia", "zip": "23456", "country": "United States", "geoPoint": {"lat": 36.84681, "lon": -76.28522}}, {"facility": "Eastern Virginia Medical School | OB/GYN Clinical Research Center", "city": "Norfolk", "state": "Virginia", "zip": "23507", "country": "United States", "geoPoint": {"lat": 36.84681, "lon": -76.28522}}, {"facility": "Eastern Virginia Medical School", "city": "Norfolk", "state": "Virginia", "zip": "23507", "country": "United States", "geoPoint": {"lat": 36.84681, "lon": -76.28522}}, {"facility": "Virginia Physicians For Women", "city": "North Chesterfield", "state": "Virginia", "zip": "23235", "country": "United States", "geoPoint": {"lat": 37.38, "lon": -77.59}}, {"facility": "Seattle Clinical Research Center", "city": "Seattle", "state": "Washington", "zip": "98105", "country": "United States", "geoPoint": {"lat": 47.60621, "lon": -122.33207}}, {"facility": "Medizinische Universität Graz", "city": "Graz", "state": "Styria", "zip": "8036", "country": "Austria", "geoPoint": {"lat": 47.06733, "lon": 15.44197}}, {"facility": "Universitätsklinikum AKH Wien", "city": "Vienna", "zip": "1090", "country": "Austria", "geoPoint": {"lat": 48.20849, "lon": 16.37208}}, {"facility": "AZ Jan Palfijn Gent", "city": "Ghent", "state": "Oost-Vlaanderen", "zip": "9000", "country": "Belgium", "geoPoint": {"lat": 51.05, "lon": 3.71667}}, {"facility": "CU Saint-Luc/UZ St-Luc", "city": "Bruxelles - Brussel", "zip": "1200", "country": "Belgium"}, {"facility": "Ziekenhuis Oost-Limburg", "city": "Genk", "zip": "3600", "country": "Belgium", "geoPoint": {"lat": 50.965, "lon": 5.50082}}, {"facility": "UZ Gent", "city": "Ghent", "zip": "9000", "country": "Belgium", "geoPoint": {"lat": 51.05, "lon": 3.71667}}, {"facility": "MC Asklepii OOD", "city": "Dupnitsa", "zip": "2600", "country": "Bulgaria", "geoPoint": {"lat": 42.26478, "lon": 23.11723}}, {"facility": "Spec. Hospital for Active Treatment of Oncological Diseases", "city": "Sofia", "zip": "1233", "country": "Bulgaria", "geoPoint": {"lat": 42.69751, "lon": 23.32415}}, {"facility": "Medical Center Panaceya", "city": "Sofia", "zip": "1606", "country": "Bulgaria", "geoPoint": {"lat": 42.69751, "lon": 23.32415}}, {"facility": "MHAT Niamed", "city": "Stara Zagora", "zip": "6000", "country": "Bulgaria", "geoPoint": {"lat": 42.43205, "lon": 25.64262}}, {"facility": "SHOGAT Prof Dimitar Stamatov", "city": "Varna", "zip": "9000", "country": "Bulgaria", "geoPoint": {"lat": 43.21912, "lon": 27.91024}}, {"facility": "The Ottawa Hospital", "city": "Ottawa", "state": "Ontario", "zip": "K1H 7W9", "country": "Canada", "geoPoint": {"lat": 45.41117, "lon": -75.69812}}, {"facility": "The Ottawa Hospital | The Ottawa Hospital Research Institute - Neurology - Ottawa Stroke Program", "city": "Ottawa", "state": "Ontario", "zip": "K1Y4E9", "country": "Canada", "geoPoint": {"lat": 45.41117, "lon": -75.69812}}, {"facility": "The Ottawa Hospital", "city": "Ottawa", "state": "Ontario", "zip": "K1Y4E9", "country": "Canada", "geoPoint": {"lat": 45.41117, "lon": -75.69812}}, {"facility": "Clinique OVO", "city": "Montreal", "state": "Quebec", "zip": "H4P 2S4", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"facility": "Alpha Recherche Clinique LB9", "city": "Québec", "zip": "G2J 0C4", "country": "Canada", "geoPoint": {"lat": 46.81228, "lon": -71.21454}}, {"facility": "First Affiliated Hospital of Guangzhou Medical University", "city": "Guangzhou", "state": "Guangdong", "zip": "510120", "country": "China", "geoPoint": {"lat": 23.11667, "lon": 113.25}}, {"facility": "Guangzhou Women and Children's Medical Center", "city": "Guangzhou", "state": "Guangdong", "zip": "510623", "country": "China", "geoPoint": {"lat": 23.11667, "lon": 113.25}}, {"facility": "Wuhan Tongji Reproductive Medicine Hospital", "city": "Wuhan", "state": "Hubei", "zip": "430013", "country": "China", "geoPoint": {"lat": 30.58333, "lon": 114.26667}}, {"facility": "The Second Affiliated Hospital of Nanjing Medical university", "city": "Nanjing", "state": "Jiangsu", "zip": "210000", "country": "China", "geoPoint": {"lat": 32.06167, "lon": 118.77778}}, {"facility": "The Second Affiliated Hospital of Nanjing Medical university", "city": "Nanjing", "state": "Jiangsu", "zip": "210011", "country": "China", "geoPoint": {"lat": 32.06167, "lon": 118.77778}}, {"facility": "Women's Hospital School of Medicine Zhejiang University", "city": "Hangzhou", "state": "Zhejiang", "zip": "310006", "country": "China", "geoPoint": {"lat": 30.29365, "lon": 120.16142}}, {"facility": "Beijing Obstetrics and Gynecology Hospital,Capital Med.Uni.", "city": "Beijing", "zip": "100026", "country": "China", "geoPoint": {"lat": 39.9075, "lon": 116.39723}}, {"facility": "Peking University First Hospital", "city": "Beijing", "zip": "100034", "country": "China", "geoPoint": {"lat": 39.9075, "lon": 116.39723}}, {"facility": "Fakultni nemocnice Brno", "city": "Brno", "zip": "625 00", "country": "Czechia", "geoPoint": {"lat": 49.19522, "lon": 16.60796}}, {"facility": "Gynekologie Meda s.r.o. - Lidicka", "city": "Brno střed", "zip": "60200", "country": "Czechia", "geoPoint": {"lat": 49.19343, "lon": 16.60712}}, {"facility": "GYN-MIKA s.r.o.", "city": "České Budějovice", "zip": "370 01", "country": "Czechia", "geoPoint": {"lat": 48.97447, "lon": 14.47434}}, {"facility": "GynCare MUDr. Michael Svec s.r.o.", "city": "Pilsen", "zip": "326 00", "country": "Czechia", "geoPoint": {"lat": 49.74747, "lon": 13.37759}}, {"facility": "Centrum gynekologicke rehabilitace", "city": "Písek", "zip": "39701", "country": "Czechia", "geoPoint": {"lat": 49.3088, "lon": 14.1475}}, {"facility": "GYNERA", "city": "Prague", "zip": "156 00", "country": "Czechia", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"facility": "Gynekologie Studentsky dum s.r.o.", "city": "Prague", "zip": "160 00", "country": "Czechia", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"facility": "Fakultní nemocnice Bulovka", "city": "Prague", "zip": "180 81", "country": "Czechia", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"facility": "Dr. Smrhova-Kovacs", "city": "Tábor", "zip": "39003", "country": "Czechia", "geoPoint": {"lat": 49.41441, "lon": 14.6578}}, {"facility": "Parnu Hospital", "city": "Pärnu", "zip": "80010", "country": "Estonia", "geoPoint": {"lat": 58.38588, "lon": 24.49711}}, {"facility": "Clinic Elite", "city": "Tartu", "zip": "50407", "country": "Estonia", "geoPoint": {"lat": 58.38062, "lon": 26.72509}}, {"facility": "HUS / Naistenklinikka", "city": "Helsinki", "zip": "00029", "country": "Finland", "geoPoint": {"lat": 60.16952, "lon": 24.93545}}, {"facility": "Lääkärikeskus Gyneko", "city": "Oulu", "zip": "90100", "country": "Finland", "geoPoint": {"lat": 65.01236, "lon": 25.46816}}, {"facility": "Universitätsklinikum Heidelberg", "city": "Heidelberg", "state": "Baden-Wurttemberg", "zip": "69120", "country": "Germany", "geoPoint": {"lat": 49.40768, "lon": 8.69079}}, {"facility": "Praxisklinik am Rosengarten", "city": "Mannheim", "state": "Baden-Wurttemberg", "zip": "68165", "country": "Germany", "geoPoint": {"lat": 49.4891, "lon": 8.46694}}, {"facility": "Praxis f. Gynäkologie und Geburtshilfe", "city": "Bernburg", "state": "Saxony-Anhalt", "zip": "06406", "country": "Germany", "geoPoint": {"lat": 51.79464, "lon": 11.7401}}, {"facility": "emovis GmbH", "city": "Berlin", "zip": "10629", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Charité - Campus Virchow-Klinikum (CVK)", "city": "Berlin", "zip": "13353", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "ARETAIEION University Hospital", "city": "Athens", "zip": "11528", "country": "Greece", "geoPoint": {"lat": 37.98376, "lon": 23.72784}}, {"facility": "University General Hospital of Patras | Univ Obs & Gynae Cli", "city": "Pátrai", "zip": "26504", "country": "Greece", "geoPoint": {"lat": 38.2462, "lon": 21.73508}}, {"facility": "Cortex Study Center", "city": "Budapest", "zip": "1026", "country": "Hungary", "geoPoint": {"lat": 47.49835, "lon": 19.04045}}, {"facility": "SZTE ÁOK Szent Györgyi Albert Klinikai Kozpont", "city": "Szeged", "zip": "6725", "country": "Hungary", "geoPoint": {"lat": 46.253, "lon": 20.14824}}, {"facility": "Fondazione Policlinico Universitario Agostino Gemelli IRCCS", "city": "Rome", "state": "Lazio", "zip": "00168", "country": "Italy", "geoPoint": {"lat": 41.89193, "lon": 12.51133}}, {"facility": "IRCCS Ospedale Policlinico San Martino", "city": "Genoa", "state": "Liguria", "zip": "16132", "country": "Italy", "geoPoint": {"lat": 44.40478, "lon": 8.94439}}, {"facility": "Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico", "city": "Milan", "state": "Lombardy", "zip": "20122", "country": "Italy", "geoPoint": {"lat": 45.46427, "lon": 9.18951}}, {"facility": "ASST Sette Laghi", "city": "Varese", "state": "Lombardy", "zip": "21100", "country": "Italy", "geoPoint": {"lat": 45.82058, "lon": 8.82511}}, {"facility": "A.O.U. Careggi", "city": "Florence", "state": "Tuscany", "zip": "50134", "country": "Italy", "geoPoint": {"lat": 43.77925, "lon": 11.24626}}, {"facility": "A.O.U.I. Verona", "city": "Verona", "state": "Veneto", "zip": "37126", "country": "Italy", "geoPoint": {"lat": 45.43854, "lon": 10.9938}}, {"facility": "Aiiku Ladies Clinic", "city": "Funabashi", "state": "Chiba", "zip": "274-0071", "country": "Japan", "geoPoint": {"lat": 35.70129, "lon": 139.98648}}, {"facility": "Tokyo Bay Urayasu Ichikawa Medical Center", "city": "Urayasu", "state": "Chiba", "zip": "279-0001", "country": "Japan", "geoPoint": {"lat": 35.65879, "lon": 139.90055}}, {"facility": "Sou Clinic", "city": "Yotsukaidō", "state": "Chiba", "zip": "284-0001", "country": "Japan", "geoPoint": {"lat": 35.65, "lon": 140.16667}}, {"facility": "Teine Keijinkai Hospital", "city": "Sapporo", "state": "Hokkaido", "zip": "006-8555", "country": "Japan", "geoPoint": {"lat": 43.06667, "lon": 141.35}}, {"facility": "Social Medical Corporation Tokeidai Memorial Hospital", "city": "Sapporo", "state": "Hokkaido", "zip": "060-0031", "country": "Japan", "geoPoint": {"lat": 43.06667, "lon": 141.35}}, {"facility": "Nishikawa Women's Health Clinic", "city": "Sapporo", "state": "Hokkaido", "zip": "060-0061", "country": "Japan", "geoPoint": {"lat": 43.06667, "lon": 141.35}}, {"facility": "Hitachi General Hospital", "city": "Hitachi", "state": "Ibaraki", "zip": "317-0077", "country": "Japan", "geoPoint": {"lat": 36.6, "lon": 140.65}}, {"facility": "Ibaraki Prefectural Central Hospital", "city": "Kasama", "state": "Ibaraki", "zip": "309-1793", "country": "Japan", "geoPoint": {"lat": 36.38333, "lon": 140.26667}}, {"facility": "Fujisawa City Hospital", "city": "Fujisawa", "state": "Kanagawa", "zip": "251-8550", "country": "Japan", "geoPoint": {"lat": 35.34926, "lon": 139.47666}}, {"facility": "Yokosuka Kyosai Hospital", "city": "Yokosuka", "state": "Kanagawa", "zip": "238-8558", "country": "Japan", "geoPoint": {"lat": 35.28361, "lon": 139.66722}}, {"facility": "Kurashiki Medical Clinic", "city": "Kurashiki", "state": "Okayama-ken", "zip": "710-0824", "country": "Japan", "geoPoint": {"lat": 34.58333, "lon": 133.76667}}, {"facility": "Suita Tokushukai Hospital", "city": "Suita", "state": "Osaka", "zip": "565-0814", "country": "Japan", "geoPoint": {"lat": 34.76143, "lon": 135.51567}}, {"facility": "Omi Medical Center", "city": "Kusatsu", "state": "Shiga", "zip": "525-8585", "country": "Japan", "geoPoint": {"lat": 35.01667, "lon": 135.96667}}, {"facility": "Kashiwazaki ladies clinic", "city": "Saitama", "state": "Tokyo", "zip": "330-0855", "country": "Japan"}, {"facility": "NTT Medical Center Tokyo", "city": "Shinagawa-ku", "state": "Tokyo", "zip": "141-8625", "country": "Japan"}, {"facility": "Toyama Rosai Hospital", "city": "Uozu", "state": "Toyama", "zip": "937-0042", "country": "Japan", "geoPoint": {"lat": 36.8, "lon": 137.4}}, {"facility": "JCHO Tokuyama Central Hospital", "city": "Shūnan", "state": "Yamaguchi", "zip": "745-8522", "country": "Japan", "geoPoint": {"lat": 34.08053, "lon": 131.82564}}, {"facility": "Japanese Red Cross Kumamoto Hospital", "city": "Kumamoto", "zip": "861-8520", "country": "Japan", "geoPoint": {"lat": 32.80589, "lon": 130.69181}}, {"facility": "Saiseikai Nagasaki Hospital", "city": "Nagasaki", "zip": "850-0003", "country": "Japan", "geoPoint": {"lat": 32.75, "lon": 129.88333}}, {"facility": "Nagasaki University Hospital", "city": "Nagasaki", "zip": "852-8501", "country": "Japan", "geoPoint": {"lat": 32.75, "lon": 129.88333}}, {"facility": "Latvian Maritime Medicine Center", "city": "Riga", "zip": "LV-1005", "country": "Latvia", "geoPoint": {"lat": 56.946, "lon": 24.10589}}, {"facility": "Vitols and Vitols Ltd", "city": "Riga", "zip": "LV-1006", "country": "Latvia", "geoPoint": {"lat": 56.946, "lon": 24.10589}}, {"facility": "I.Vasaraudzes Private Practice", "city": "Riga", "zip": "LV-1011", "country": "Latvia", "geoPoint": {"lat": 56.946, "lon": 24.10589}}, {"facility": "I.Dinsbergas Physician Practice", "city": "Riga", "zip": "LV-1013", "country": "Latvia", "geoPoint": {"lat": 56.946, "lon": 24.10589}}, {"facility": "JSC Seimos gydytojas family medical center", "city": "Vilnius", "zip": "LT-01118", "country": "Lithuania", "geoPoint": {"lat": 54.68916, "lon": 25.2798}}, {"facility": "V. Jonaitienes private gynecology clinic", "city": "Vilnius", "zip": "LT-01123", "country": "Lithuania", "geoPoint": {"lat": 54.68916, "lon": 25.2798}}, {"facility": "JSC Gyvenk Silciau Medical Center Maxmeda", "city": "Vilnius", "zip": "LT-03225", "country": "Lithuania", "geoPoint": {"lat": 54.68916, "lon": 25.2798}}, {"facility": "Kirkeparken Spesialistpraksis", "city": "Fredrikstad", "zip": "1605", "country": "Norway", "geoPoint": {"lat": 59.2181, "lon": 10.9298}}, {"facility": "Oslo Universitetssykehus HF, Ullevål", "city": "Oslo", "zip": "0450", "country": "Norway", "geoPoint": {"lat": 59.91273, "lon": 10.74609}}, {"facility": "Sykehuset i Vestfold HF, Tønsberg", "city": "Tønsberg", "zip": "3116", "country": "Norway", "geoPoint": {"lat": 59.26754, "lon": 10.40762}}, {"facility": "Gabinet Ginekologiczny Janusz Tomaszewski", "city": "Bialystok", "zip": "15-244", "country": "Poland", "geoPoint": {"lat": 53.13333, "lon": 23.16433}}, {"facility": "MICS Centrum Medyczne Torun", "city": "Bydgoszcz", "zip": "85-065", "country": "Poland", "geoPoint": {"lat": 53.1235, "lon": 18.00762}}, {"facility": "CLINICAL MEDICAL RESEARCH Sp. z o. o.", "city": "Katowice", "zip": "40-156", "country": "Poland", "geoPoint": {"lat": 50.2597, "lon": 19.02173}}, {"facility": "NZOZ MEDEM Wilk Sp. j.", "city": "Katowice", "zip": "40-301", "country": "Poland", "geoPoint": {"lat": 50.2597, "lon": 19.02173}}, {"facility": "Vita Longa Sp. z o.o.", "city": "Katowice", "zip": "40-748", "country": "Poland", "geoPoint": {"lat": 50.2597, "lon": 19.02173}}, {"facility": "Prywatny Gabinet Lekarski Ginekologia, Poloznictwo i Ultr.", "city": "Lodz", "zip": "90-602", "country": "Poland", "geoPoint": {"lat": 51.77058, "lon": 19.47395}}, {"facility": "Specjalistyczny Gabinet Ginekologiczno-Polozniczy", "city": "Lublin", "zip": "20-400", "country": "Poland", "geoPoint": {"lat": 51.25058, "lon": 22.57009}}, {"facility": "NZOZ NOVITA, Specjalistyczne Gabinety Lekarskie S.C", "city": "Lublin", "zip": "20-632", "country": "Poland", "geoPoint": {"lat": 51.25058, "lon": 22.57009}}, {"facility": "VitroLive Sp. z o.o.", "city": "Szczecin", "zip": "70-483", "country": "Poland", "geoPoint": {"lat": 53.42894, "lon": 14.55302}}, {"facility": "MTZ Clinical Research Sp z o.o.", "city": "Warsaw", "zip": "02-106", "country": "Poland", "geoPoint": {"lat": 52.22977, "lon": 21.01178}}, {"facility": "Medical Concierge Centrum Medyczne", "city": "Warsaw", "zip": "02-798", "country": "Poland", "geoPoint": {"lat": 52.22977, "lon": 21.01178}}, {"facility": "ULMUS, s r.o.", "city": "Hlohovec", "zip": "920 01", "country": "Slovakia", "geoPoint": {"lat": 48.43174, "lon": 17.8031}}, {"facility": "GA Lucenec s.r.o", "city": "Lučenec", "zip": "984 01", "country": "Slovakia", "geoPoint": {"lat": 48.33249, "lon": 19.66708}}, {"facility": "Virina sano, s.r.o. Gynekologicko porodnicka ambulancia", "city": "Veľký Krtíš", "zip": "990 01", "country": "Slovakia", "geoPoint": {"lat": 48.21059, "lon": 19.35043}}, {"facility": "Hospital de Basurto", "city": "Bilbao", "state": "Vizcaya", "zip": "48013", "country": "Spain", "geoPoint": {"lat": 43.26271, "lon": -2.92528}}, {"facility": "Hospital de la Santa Creu i de Sant Pau | Ginecologia", "city": "Barcelona", "zip": "08041", "country": "Spain", "geoPoint": {"lat": 41.38879, "lon": 2.15899}}, {"facility": "Hospital Universitario 12 de Octubre", "city": "Madrid", "zip": "28041", "country": "Spain", "geoPoint": {"lat": 40.4165, "lon": -3.70256}}, {"facility": "Hospital General Universitario de Valencia", "city": "Valencia", "zip": "46014", "country": "Spain", "geoPoint": {"lat": 39.47391, "lon": -0.37966}}]}, "referencesModule": {"references": [{"pmid": "38890641", "type": "DERIVED", "citation": "Parke S, Gude K, Roth K, Messina F. Efficacy and safety of eliapixant in endometriosis-associated pelvic pain: the randomized, placebo-controlled phase 2b SCHUMANN study. BMC Womens Health. 2024 Jun 19;24(1):353. doi: 10.1186/s12905-024-03188-8."}, {"pmid": "34978027", "type": "DERIVED", "citation": "Fletcher MC. Selectivity of the P2X3 receptor antagonist Eliapixant, and its potential use in the treatment of endometriosis. Purinergic Signal. 2022 Mar;18(1):1-3. doi: 10.1007/s11302-021-09831-5. Epub 2022 Jan 3. No abstract available."}], "seeAlsoLinks": [{"label": "Click here to find information for studies related to Bayer products. To find this study enter the ClinicalTrials.gov identifier (NCT) number or Bayer Study Identifier (ID) in the search field.", "url": "https://clinicaltrials.bayer.com/"}, {"label": "Click here to find information about studies related to Bayer Healthcare products conducted in Europe.", "url": "http://www.clinicaltrialsregister.eu/"}]}, "ipdSharingStatementModule": {"ipdSharing": "NO", "description": "Availability of this study's data will be determined according to Bayer's commitment to the EFPIA/PhRMA \"Principles for responsible clinical trial data sharing\". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal."}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "A total of 215 participants were randomized to 5 treatment arms (44 to eliapixant, 44 to eliapixant, 43 to eliapixant, 43 to placebo, and 41 to Elagolix).", "recruitmentDetails": "This multinational study was conducted between 29 JAN 2021 First Patient First Visit (FPFV) and 03 MAY 2022 Last Patient Last Visit (LPLV) in 20 countries/regions: Austria, Belgium, Bulgaria, Canada, China, Czech Republic, Estonia, Finland , Germany, Greece, Hungary, Italy, Japan, Lithuania, Latvia, Norway, Poland, Slovakia, Spain, United States", "groups": [{"id": "FG000", "title": "Eliapixant (BAY1817080) 25 mg", "description": "25mg eliapixant twice daily for 12 weeks"}, {"id": "FG001", "title": "Eliapixant (BAY1817080) 75 mg", "description": "75mg eliapixant twice daily for 12 weeks"}, {"id": "FG002", "title": "Eliapixant (BAY1817080) 150 mg", "description": "150mg eliapixant twice daily for 12 weeks"}, {"id": "FG003", "title": "Placebo", "description": "Placebo for eliapixant twice daily for 12 weeks"}, {"id": "FG004", "title": "Elagolix 150mg", "description": "150mg Elagolix once daily for 12 weeks"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "44"}, {"groupId": "FG001", "numSubjects": "44"}, {"groupId": "FG002", "numSubjects": "43"}, {"groupId": "FG003", "numSubjects": "43"}, {"groupId": "FG004", "numSubjects": "41"}]}, {"type": "Valid for Safety Analysis Set (SAF)", "achievements": [{"groupId": "FG000", "numSubjects": "39"}, {"groupId": "FG001", "numSubjects": "38"}, {"groupId": "FG002", "numSubjects": "38"}, {"groupId": "FG003", "numSubjects": "37"}, {"groupId": "FG004", "numSubjects": "38"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "28"}, {"groupId": "FG001", "numSubjects": "22"}, {"groupId": "FG002", "numSubjects": "22"}, {"groupId": "FG003", "numSubjects": "24"}, {"groupId": "FG004", "numSubjects": "24"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "22"}, {"groupId": "FG002", "numSubjects": "21"}, {"groupId": "FG003", "numSubjects": "19"}, {"groupId": "FG004", "numSubjects": "17"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "1"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "3"}]}, {"type": "Other reason", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "4"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "Study terminated by sponsor", "reasons": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "15"}, {"groupId": "FG002", "numSubjects": "12"}, {"groupId": "FG003", "numSubjects": "13"}, {"groupId": "FG004", "numSubjects": "9"}]}, {"type": "Pregnancy", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Full analysis set (FAS) includes all 215 participants who were randomized to 5 treatment arms.", "groups": [{"id": "BG000", "title": "Eliapixant (BAY1817080) 25 mg", "description": "25mg eliapixant twice daily for 12 weeks"}, {"id": "BG001", "title": "Eliapixant (BAY1817080) 75 mg", "description": "75mg eliapixant twice daily for 12 weeks"}, {"id": "BG002", "title": "Eliapixant (BAY1817080) 150 mg", "description": "150mg eliapixant twice daily for 12 weeks"}, {"id": "BG003", "title": "Placebo", "description": "Placebo for eliapixant twice daily for 12 weeks"}, {"id": "BG004", "title": "Elagolix 150mg", "description": "150mg Elagolix once daily for 12 weeks"}, {"id": "BG005", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "44"}, {"groupId": "BG001", "value": "44"}, {"groupId": "BG002", "value": "43"}, {"groupId": "BG003", "value": "43"}, {"groupId": "BG004", "value": "41"}, {"groupId": "BG005", "value": "215"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "44"}, {"groupId": "BG001", "value": "44"}, {"groupId": "BG002", "value": "43"}, {"groupId": "BG003", "value": "43"}, {"groupId": "BG004", "value": "41"}, {"groupId": "BG005", "value": "215"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "44"}, {"groupId": "BG001", "value": "44"}, {"groupId": "BG002", "value": "43"}, {"groupId": "BG003", "value": "43"}, {"groupId": "BG004", "value": "41"}, {"groupId": "BG005", "value": "215"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "31"}, {"groupId": "BG001", "value": "31"}, {"groupId": "BG002", "value": "30"}, {"groupId": "BG003", "value": "29"}, {"groupId": "BG004", "value": "39"}, {"groupId": "BG005", "value": "160"}]}]}, {"title": "Black or african american", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "2"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "5"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "11"}, {"groupId": "BG003", "value": "12"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "48"}]}]}, {"title": "Not reported", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "2"}, {"groupId": "BG005", "value": "2"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Absolute Change in Mean Worst Endometriosis Associated Pelvic Pain (EAPP), Primary Per Protocol Set (pPPS)", "description": "The worst EAPP was measured daily on the 0-10 Numerical Rating Scale (NRS) by item 1 of the Endometriosis Symptom Diary (ESD). In question 1, participants were asked to rate the pain in the target area during the past 24 hours, where 0= no pain and 10= worst imaginable pain and responses were recorded in ESD. The absolute change in mean worst EAPP was from baseline (last 28 days before the first intake of study drug) to end of intervention (last 28 days ending with the last intake of study drug planned on Day 84 \\[+3\\]). The time frame of 28 days captures a menstrual cycle on average.", "populationDescription": "The Elagolix arm was not included in the primary per protocol set (pPPS) simply because it's not part of the primary objective which was \"to assess the dose-response relationship and demonstrate efficacy of BAY 1817080 compared to placebo in women with symptomatic endometriosis\".", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "change from baseline to week 12", "groups": [{"id": "OG000", "title": "Eliapixant (BAY1817080) 25 mg", "description": "Eliapixant 25 mg BID"}, {"id": "OG001", "title": "Eliapixant (BAY1817080) 75 mg", "description": "Eliapixant 75 mg BID"}, {"id": "OG002", "title": "Eliapixant (BAY1817080) 150 mg", "description": "50 mg Eliapixant BID"}, {"id": "OG003", "title": "Placebo", "description": "Placebo for Eliapixant BID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "31"}, {"groupId": "OG001", "value": "31"}, {"groupId": "OG002", "value": "31"}, {"groupId": "OG003", "value": "30"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "31"}, {"groupId": "OG001", "value": "31"}, {"groupId": "OG002", "value": "31"}, {"groupId": "OG003", "value": "30"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "6.40", "spread": "1.66"}, {"groupId": "OG001", "value": "6.13", "spread": "1.77"}, {"groupId": "OG002", "value": "6.95", "spread": "1.38"}, {"groupId": "OG003", "value": "6.14", "spread": "1.96"}]}]}, {"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "20"}, {"groupId": "OG003", "value": "26"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.57", "spread": "2.10"}, {"groupId": "OG001", "value": "4.15", "spread": "2.49"}, {"groupId": "OG002", "value": "5.15", "spread": "2.42"}, {"groupId": "OG003", "value": "4.29", "spread": "1.71"}]}]}, {"title": "Week 12: Change from Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "20"}, {"groupId": "OG003", "value": "26"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.56", "spread": "1.35"}, {"groupId": "OG001", "value": "-2.12", "spread": "2.66"}, {"groupId": "OG002", "value": "-1.88", "spread": "2.03"}, {"groupId": "OG003", "value": "-1.89", "spread": "1.91"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "80% confidence interval (CI) for change in mean worst EAPP from baseline to Week 12", "nonInferiorityType": "OTHER", "statisticalMethod": "Mixed Models Analysis", "paramType": "LS-Mean", "paramValue": "-1.63", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.13", "ciUpperLimit": "-1.14", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.38"}, {"groupIds": ["OG001"], "groupDescription": "80% confidence interval (CI) for change in mean worst EAPP from baseline to Week 12", "nonInferiorityType": "OTHER", "statisticalMethod": "Mixed Models Analysis", "paramType": "LS-Mean", "paramValue": "-2.13", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.66", "ciUpperLimit": "-1.61", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.41"}, {"groupIds": ["OG002"], "groupDescription": "80% confidence interval (CI) for change in mean worst EAPP from baseline to Week 12", "nonInferiorityType": "OTHER", "statisticalMethod": "Mixed Models Analysis", "paramType": "LS-Mean", "paramValue": "-1.96", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.48", "ciUpperLimit": "-1.43", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.41"}, {"groupIds": ["OG003"], "groupDescription": "80% confidence interval (CI) for change in mean worst EAPP from baseline to Week 12", "nonInferiorityType": "OTHER", "statisticalMethod": "Mixed Models Analysis", "paramType": "LS-Mean", "paramValue": "-1.94", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.44", "ciUpperLimit": "-1.45", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.38"}]}, {"type": "SECONDARY", "title": "Least Squares Mean (SE) Changes in Worst EAPP From Baseline to Week 12, Per Protocol Set", "description": "The worst EAPP was measured daily on the 0-10 Numerical Rating Scale (NRS) by item 1 of the Endometriosis Symptom Diary (ESD). In question 1, participants were asked to rate the pain in the target area during the past 24 hours, where 0= no pain and 10= worst imaginable pain and responses were recorded in ESD. The absolute change in mean worst EAPP was from baseline (last 28 days before the first intake of study drug) to end of intervention (last 28 days ending with the last intake of study drug planned on Day 84 \\[+3\\]). The time frame of 28 days captures a menstrual cycle on average.", "populationDescription": "Per protocol set (PPS): includes 183 participants, which is 85.1% of the FAS population.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "change from baseline to week 12", "groups": [{"id": "OG000", "title": "Eliapixant (BAY1817080) 25 mg", "description": "Eliapixant 25 mg BID"}, {"id": "OG001", "title": "Eliapixant (BAY1817080) 75 mg", "description": "Eliapixant 75 mg BID"}, {"id": "OG002", "title": "Eliapixant (BAY1817080) 150 mg", "description": "50 mg Eliapixant BID"}, {"id": "OG003", "title": "Placebo", "description": "Placebo for Eliapixant BID"}, {"id": "OG004", "title": "Elagolix 150 mg", "description": "Elagolix 150 mg OD"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "37"}, {"groupId": "OG002", "value": "36"}, {"groupId": "OG003", "value": "36"}, {"groupId": "OG004", "value": "37"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.60", "spread": "0.40"}, {"groupId": "OG001", "value": "-2.07", "spread": "0.42"}, {"groupId": "OG002", "value": "-1.97", "spread": "0.42"}, {"groupId": "OG003", "value": "-1.89", "spread": "0.40"}, {"groupId": "OG004", "value": "-2.69", "spread": "0.41"}]}]}], "analyses": [{"groupIds": ["OG000", "OG003"], "groupDescription": "Difference of least square-mean (95% Confidence Interval, CI) - Eliapixant arms vs Placebo arm (pairwise comparison) - change in mean worst EAPP from baseline to Week 12 - pPPS", "nonInferiorityType": "OTHER", "nonInferiorityComment": "mixed model repeated measures", "paramType": "Difference of least square-mean", "paramValue": "0.29", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.77", "ciUpperLimit": "1.35", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.54"}, {"groupIds": ["OG001", "OG003"], "groupDescription": "Difference of least square-mean (95% Confidence Interval, CI) - Eliapixant arms vs Placebo arm (pairwise comparison) - change in mean worst EAPP from baseline to Week 12 - pPPS", "nonInferiorityType": "OTHER", "nonInferiorityComment": "mixed model repeated measures (MMRM)", "paramType": "Difference of least square-mean", "paramValue": "-0.18", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.27", "ciUpperLimit": "0.91", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.55"}, {"groupIds": ["OG000", "OG003"], "groupDescription": "Difference of least square-mean (95% Confidence Interval, CI) - Eliapixant arms vs Placebo arm (pairwise comparison) - change in mean worst EAPP from baseline to Week 12 - pPPS", "nonInferiorityType": "OTHER", "nonInferiorityComment": "mixed model repeated measures (MMRM)", "paramType": "Difference of least square-mean", "paramValue": "-0.08", "ciPctValue": "98", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.17", "ciUpperLimit": "1.02", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.56"}, {"groupIds": ["OG000", "OG003"], "groupDescription": "Difference of least square-mean (80% Confidence Interval, CI) - Eliapixant arms vs Placebo arm (pairwise comparison) - change in mean worst EAPP from baseline to Week 12 - pPPS", "nonInferiorityType": "OTHER", "nonInferiorityComment": "mixed model repeated measures (MMRM)", "paramType": "Difference of least square-mean", "paramValue": "0.29", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.4", "ciUpperLimit": "0.98", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.54"}, {"groupIds": ["OG001", "OG003"], "groupDescription": "Difference of least square-mean (80% Confidence Interval, CI) - Eliapixant arms vs Placebo arm (pairwise comparison) - change in mean worst EAPP from baseline to Week 12 - pPPS", "nonInferiorityType": "OTHER", "nonInferiorityComment": "mixed model repeated measures (MMRM)", "paramType": "Difference of least square-mean", "paramValue": "-0.18", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.89", "ciUpperLimit": "0.53", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.55"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Difference of least square-mean (80% Confidence Interval, CI) - Eliapixant arms vs Placebo arm (pairwise comparison) - change in mean worst EAPP from baseline to Week 12 - pPPS", "nonInferiorityType": "OTHER", "nonInferiorityComment": "mixed model repeated measures (MMRM)", "paramType": "Difference of least square-mean", "paramValue": "-0.08", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.79", "ciUpperLimit": "0.64", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.56"}]}, {"type": "SECONDARY", "title": "Number of Participants With Treatment-emergent Adverse Events (TEAE)", "description": "A treatment-emergent AE (TEAE) was defined as any event arising or worsening after the start of study drug administration until 14 days after the last study medication intake.", "populationDescription": "Safety analysis set (SAF) includes 190 participants (88.4%) since 25 participants (11.6%) did not receive any study intervention and was excluded from SAF.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "up to 14 days after the last study medication intake", "groups": [{"id": "OG000", "title": "Eliapixant (BAY1817080) 25 mg", "description": "Eliapixant 25 mg BID"}, {"id": "OG001", "title": "Eliapixant (BAY1817080) 75 mg", "description": "Eliapixant 75 mg BID"}, {"id": "OG002", "title": "Eliapixant (BAY1817080) 150 mg", "description": "50 mg Eliapixant BID"}, {"id": "OG003", "title": "Placebo", "description": "Placebo for Eliapixant BID"}, {"id": "OG004", "title": "Elagolix 150 mg", "description": "Elagolix 150 mg OD"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "39"}, {"groupId": "OG001", "value": "38"}, {"groupId": "OG002", "value": "38"}, {"groupId": "OG003", "value": "37"}, {"groupId": "OG004", "value": "38"}]}], "classes": [{"title": "Any TEAE", "categories": [{"measurements": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "21"}, {"groupId": "OG002", "value": "29"}, {"groupId": "OG003", "value": "27"}, {"groupId": "OG004", "value": "28"}]}]}, {"title": "Any drug related TEAE", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "10"}, {"groupId": "OG003", "value": "10"}, {"groupId": "OG004", "value": "13"}]}]}, {"title": "Any serious TEAE", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "2"}, {"groupId": "OG003", "value": "1"}, {"groupId": "OG004", "value": "1"}]}]}, {"title": "Any drug related serious TEAE", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "1"}]}]}, {"title": "Any TEAE with outcome death", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}]}, {"title": "Any TEAE resulting in permanent discontinuation of studly drug", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "2"}, {"groupId": "OG004", "value": "1"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "2", "timeFrame": "From start of study drug administration until 14 days after the last study medication intake with an average of 14 weeks. While for the all-cause mortality that occurred at any time during the study before the last contact, up to 285 days.", "description": "A treatment-emergent AE (TEAE) was defined as any event arising or worsening after the start of study drug administration until 14 days after the last study medication intake.", "eventGroups": [{"id": "EG000", "title": "Eliapixant (BAY1817080) 25 mg", "description": "25 mg Eliapixant twice daily for 12 weeks", "deathsNumAffected": 0, "deathsNumAtRisk": 39, "seriousNumAffected": 0, "seriousNumAtRisk": 39, "otherNumAffected": 23, "otherNumAtRisk": 39}, {"id": "EG001", "title": "Eliapixant (BAY1817080) 75 mg", "description": "75 mg Eliapixant twice daily for 12 weeks", "deathsNumAffected": 0, "deathsNumAtRisk": 38, "seriousNumAffected": 2, "seriousNumAtRisk": 38, "otherNumAffected": 20, "otherNumAtRisk": 38}, {"id": "EG002", "title": "Eliapixant (BAY1817080) 150 mg", "description": "75 mg Eliapixant twice daily for 12 weeks", "deathsNumAffected": 0, "deathsNumAtRisk": 38, "seriousNumAffected": 2, "seriousNumAtRisk": 38, "otherNumAffected": 29, "otherNumAtRisk": 38}, {"id": "EG003", "title": "Placebo", "description": "Placebo for 12 weeks", "deathsNumAffected": 0, "deathsNumAtRisk": 37, "seriousNumAffected": 1, "seriousNumAtRisk": 37, "otherNumAffected": 27, "otherNumAtRisk": 37}, {"id": "EG004", "title": "150 mg Elagolix", "description": "150 mg Elagolix once daily for 12 weeks", "deathsNumAffected": 0, "deathsNumAtRisk": 38, "seriousNumAffected": 1, "seriousNumAtRisk": 38, "otherNumAffected": 28, "otherNumAtRisk": 38}], "seriousEvents": [{"term": "Abdominal pain lower", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Carbuncle", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Liver function test increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Ovarian cyst ruptured", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Endometriosis ablation", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Hypertensive crisis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}]}], "otherEvents": [{"term": "Anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Coagulopathy", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Leukopenia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 2, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Neutropenia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Bone marrow oedema", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Ear pain", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}]}, {"term": "Ear swelling", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Eustachian tube dysfunction", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Abdominal discomfort", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}]}, {"term": "Abdominal distension", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}]}, {"term": "Angular cheilitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}]}, {"term": "Dental caries", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Dyspepsia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Food poisoning", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Gastritis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Gastrooesophageal reflux disease", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 6, "numAffected": 5, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 2, "numAffected": 1, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 2, "numAffected": 2, "numAtRisk": 38}]}, {"term": "Toothache", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}]}, {"term": "Asthenia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Discomfort", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}]}, {"term": "Influenza like illness", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Injection site pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Injection site reaction", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 2, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Malaise", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Oedema", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 3, "numAffected": 3, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Peripheral swelling", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Vaccination site pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 6, "numAffected": 4, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 7, "numAffected": 4, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Vaccination site swelling", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Immunisation reaction", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 3, "numAffected": 2, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 2, "numAffected": 1, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Bacterial vaginosis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 2, "numAffected": 2, "numAtRisk": 38}]}, {"term": "Carbuncle", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Cystitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Ear infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}]}, {"term": "Genital herpes", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Hordeolum", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}]}, {"term": "Laryngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Lice infestation", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 3, "numAffected": 2, "numAtRisk": 38}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Pulpitis dental", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Tonsillitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 2, "numAffected": 2, "numAtRisk": 38}]}, {"term": "Vaginal infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}]}, {"term": "COVID-19", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}]}, {"term": "Activated partial thromboplastin time abnormal", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Activated partial thromboplastin time prolonged", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 4, "numAffected": 4, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 6, "numAffected": 5, "numAtRisk": 38}]}, {"term": "Alanine aminotransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Amylase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Aspartate aminotransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Blood fibrinogen decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 3, "numAffected": 3, "numAtRisk": 38}]}, {"term": "Blood fibrinogen increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}]}, {"term": "Blood glucose abnormal", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Full blood count abnormal", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}]}, {"term": "Gamma-glutamyltransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Haemoglobin decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}]}, {"term": "Lipase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Lymphocyte count decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Neutrophil count increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Prothrombin time abnormal", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Prothrombin time prolonged", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "White blood cell count increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Platelet count increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Coagulation test abnormal", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}]}, {"term": "Coronavirus test positive", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Liver function test increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "SARS-CoV-2 test positive", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Dehydration", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}]}, {"term": "Gout", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}]}, {"term": "Metabolic syndrome", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}]}, {"term": "Decreased appetite", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}]}, {"term": "Myalgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Tenosynovitis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Spinal pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 2, "numAffected": 1, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Uterine leiomyoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}]}, {"term": "Anosmia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Cervicobrachial syndrome", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Dysgeusia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 3, "numAffected": 2, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 15, "numAffected": 7, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 11, "numAffected": 7, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 9, "numAffected": 6, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 17, "numAffected": 9, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 15, "numAffected": 8, "numAtRisk": 38}]}, {"term": "Hypogeusia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Migraine", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 4, "numAffected": 2, "numAtRisk": 38}]}, {"term": "Paraesthesia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Somnolence", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Psychogenic seizure", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Taste disorder", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Anxiety", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Depressed mood", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}]}, {"term": "Irritability", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}]}, {"term": "Mood altered", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}]}, {"term": "Nightmare", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Panic attack", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Sleep disorder", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}]}, {"term": "Bladder pain", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Amenorrhoea", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}]}, {"term": "Cervix disorder", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Dysmenorrhoea", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Fibrocystic breast disease", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Intermenstrual bleeding", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Oligomenorrhoea", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Pelvic pain", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Vaginal haemorrhage", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 2, "numAffected": 1, "numAtRisk": 38}]}, {"term": "Adnexa uteri cyst", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Haemorrhagic ovarian cyst", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}]}, {"term": "Genital haemorrhage", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}]}, {"term": "Heavy menstrual bleeding", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Epistaxis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Alopecia", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Dermatitis atopic", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Eczema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}]}, {"term": "Eczema asteatotic", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Rash", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}]}, {"term": "Hypertensive crisis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}]}, {"term": "Varicose vein", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}]}, {"term": "Hot flush", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (25.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 37}, {"groupId": "EG004", "numEvents": 7, "numAffected": 7, "numAtRisk": 38}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "LTE60", "restrictiveAgreement": true}, "pointOfContact": {"title": "Therapeutic Area Head", "organization": "Bayer AG", "email": "clinical-trials-contact@bayer.com", "phone": "1-888-8422937"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2022-01-27", "uploadDate": "2023-01-13T05:45", "filename": "Prot_000.pdf", "size": 1391953}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2022-07-01", "uploadDate": "2023-01-13T05:45", "filename": "SAP_001.pdf", "size": 829648}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04", "submissionTracking": {"firstMcpInfo": {"postDateStruct": {"date": "2023-02-09", "type": "ACTUAL"}}}}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C539351", "term": "elagolix"}]}}, "hasResults": true}, {"protocolSection": {"identificationModule": {"nctId": "NCT02975440", "orgStudyIdInfo": {"id": "17773"}, "organization": {"fullName": "Bayer", "class": "INDUSTRY"}, "briefTitle": "Drug-drug Interaction Study Between Orally Administered Rifampicin and Vilaprisan", "officialTitle": "Non-randomized, Non-blinded, Non-placebo-controlled Study to Investigate the Influence of Repeated Daily Administration of 600 mg Rifampicin Given Once Daily Over 11 Days on the Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of 4 mg Vilaprisan in Healthy Postmenopausal Women."}, "statusModule": {"statusVerifiedDate": "2017-06", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2016-11-10", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2017-01-27", "type": "ACTUAL"}, "completionDateStruct": {"date": "2017-04-11", "type": "ACTUAL"}, "studyFirstSubmitDate": "2016-11-04", "studyFirstSubmitQcDate": "2016-11-23", "studyFirstPostDateStruct": {"date": "2016-11-29", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-06-30", "lastUpdatePostDateStruct": {"date": "2017-07-02", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Bayer", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "This study will be conducted in a single center, open-label study with a single group fixed sequence design to evaluate the effect of repeated oral administration of 600 mg RIF(Rifampicin) given once daily over 11 days on the single oral dose pharmacokinetics of VPR(Vilaprisan) and on MDZ(Midazolam) as a reference (probe) substance."}, "conditionsModule": {"conditions": ["Endometriosis"], "keywords": ["Vilaprisan", "PK", "rifampicin", "midazolam,", "CYP3A4 induction", "drug-drug interaction"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "BASIC_SCIENCE", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 12, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Treatment", "type": "EXPERIMENTAL", "description": "Treatment A (Period 1): a single oral dose of 4 mg Vilaprisan and 1 mg Midazolam Treatment B (Period 2): 600 mg Rifampicin once daily (qd) for 7 days followed by administration of a single oral dose of 4 mg Vilaprisan and 1 mg Midazolam followed by 600 mg Rifampicin 12 hours after Vilaprisan and Midazolam administration and continued dosing of 600 mg Rifampicin once daily for 3 days", "interventionNames": ["Drug: Rifampicin", "Drug: Midazolam", "Drug: BAY1002670_Vilaprisan"]}], "interventions": [{"type": "DRUG", "name": "Rifampicin", "description": "11 single oral doses of 600 mg Rifampicin resulting in a total dose of 6600 mg Rifampicin.", "armGroupLabels": ["Treatment"]}, {"type": "DRUG", "name": "Midazolam", "description": "2 single oral doses of 1 mg Midazolam resulting in a total dose of 2 mg Midazolam", "armGroupLabels": ["Treatment"]}, {"type": "DRUG", "name": "BAY1002670_Vilaprisan", "description": "2 single oral doses of 4 mg Vilaprisan resulting in a total dose of 8 mg Vilaprisan", "armGroupLabels": ["Treatment"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "AUC of Vilaprisan in plasma with co-medication Rifampicin", "timeFrame": "blood sampling for pharmacokinetics of Vilaprisan (LC-MS/MS) at the following time points post administration of Vilaprisan and Midazolam: 0.5,1,1.5,2,2.5,3,3.5,4,4.5,5,6,8,12,15 hour, thereafter daily sampling up to 14 days"}, {"measure": "Cmax of Vilaprisan in plasma with co-medication Rifampicin", "timeFrame": "blood sampling for pharmacokinetics of Vilaprisan (LC-MS/MS) at the following time points post administration of Vilaprisan and Midazolam: 0.5,1,1.5,2,2.5,3,3.5,4,4.5,5,6,8,12,15 hour, thereafter daily sampling up to 14 days"}, {"measure": "AUC of Vilaprisan in plasma without co-medication Rifampicin", "timeFrame": "blood sampling for pharmacokinetics of Vilaprisan (LC-MS/MS) at the following time points post administration of Vilaprisan and Midazolam: 0.5,1,1.5,2,2.5,3,3.5,4,4.5,5,6,8,12,15 hour, thereafter daily sampling up to 14 days"}, {"measure": "Cmax of Vilaprisan in plasma without co-medication Rifampicin", "timeFrame": "blood sampling for pharmacokinetics of Vilaprisan (LC-MS/MS) at the following time points post administration of Vilaprisan and Midazolam: 0.5,1,1.5,2,2.5,3,3.5,4,4.5,5,6,8,12,15 hour, thereafter daily sampling up to 14 days"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Healthy female postmenopausal subjects\n* Age: 45 to 65 years (inclusive)\n* Body mass index (BMI) : ≥20 and ≤32 kg/m²\n* Race: White\n\nExclusion Criteria:\n\n* Any finding of the medical examination (including blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance\n* Relevant diseases within the last 4 weeks prior to the first drug administration\n* Existing chronic diseases requiring medication\n* Known or suspected malignant tumors (including history of malignant tumors, with a status after treatment), known or suspected benign tumors of the liver and pituitary (including after treatment)\n* Incompletely cured pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination and effects of the study drugs will not be normal\n* Regular use of medicines\n* Repeated use of drugs during 1 week before first study drug administration which might affect absorption (e.g. laxatives, loperamide, metoclopramide, antacids, H2-receptor antagonists)", "healthyVolunteers": true, "sex": "FEMALE", "minimumAge": "45 Years", "maximumAge": "65 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Bayer Study Director", "affiliation": "Bayer", "role": "STUDY_DIRECTOR"}], "locations": [{"city": "Berlin", "zip": "13353", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D012293", "term": "Rifampin"}, {"id": "D008874", "term": "Midazolam"}], "ancestors": [{"id": "D012294", "term": "Rifamycins"}, {"id": "D006576", "term": "Heterocyclic Compounds, 4 or More Rings"}, {"id": "D000072471", "term": "Heterocyclic Compounds, Fused-Ring"}, {"id": "D006571", "term": "Heterocyclic Compounds"}, {"id": "D047029", "term": "Lactams, Macrocyclic"}, {"id": "D047028", "term": "Macrocyclic Compounds"}, {"id": "D011083", "term": "Polycyclic Compounds"}, {"id": "D001569", "term": "Benzodiazepines"}, {"id": "D001552", "term": "Benzazepines"}, {"id": "D006574", "term": "Heterocyclic Compounds, 2-Ring"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT00090389", "orgStudyIdInfo": {"id": "U19AT002022", "type": "NIH", "link": "https://reporter.nih.gov/quickSearch/U19AT002022"}, "organization": {"fullName": "National Center for Complementary and Integrative Health (NCCIH)", "class": "NIH"}, "briefTitle": "Acupuncture for Women's Health Conditions", "officialTitle": "New England School of Acupuncture (NESA) Acupuncture Research Collaborative"}, "statusModule": {"statusVerifiedDate": "2008-01", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2005-01"}, "primaryCompletionDateStruct": {"date": "2007-05", "type": "ACTUAL"}, "completionDateStruct": {"date": "2007-05", "type": "ACTUAL"}, "studyFirstSubmitDate": "2004-08-25", "studyFirstSubmitQcDate": "2004-08-25", "studyFirstPostDateStruct": {"date": "2004-08-26", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2008-01-23", "lastUpdatePostDateStruct": {"date": "2008-01-25", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"leadSponsor": {"name": "National Center for Complementary and Integrative Health (NCCIH)", "class": "NIH"}}, "descriptionModule": {"briefSummary": "The purpose of this study is to evaluate the safety and effectiveness of acupuncture in treating women's health conditions.", "detailedDescription": "This trial comprises three studies. In the first two studies, women will be randomly assigned to receive either real or sham acupuncture therapy. Study 1 will include women with various forms of cancer. White blood cell counts will be used to assess the effects of acupuncture on participants' immune responses. Study 2 will include women with unspecified pelvic pain and endometriosis; a self-report pain scale will be used to assess the effects of acupuncture on participants' symptoms. Study 3 will evaluate the validity and reliability of diagnoses made by Chinese medicine practitioners. In this study, a group of Chinese medicine practitioners will diagnose the same group of patients; consistency of the diagnoses will be evaluated."}, "conditionsModule": {"conditions": ["Ovarian Neoplasms", "Endometriosis", "Pelvic Pain", "Uterine Neoplasms"], "keywords": ["Acupuncture", "Medicine, Chinese Traditional"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "SINGLE"}}, "enrollmentInfo": {"count": 50}}, "armsInterventionsModule": {"interventions": [{"type": "PROCEDURE", "name": "Chinese Acupuncture"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria for Study 1:\n\n* Newly diagnosed ovarian cancer; primary peritoneal cancer; papillary serous cancer of the endometrium; or mixed mesodermal tumor of the uterus, ovary, or fallopian tube\n* Currently undergoing chemotherapy\n* Meet certain laboratory test requirements\n\nInclusion Criteria for Study 2:\n\nCurrently closed to recruitment\n\n* Diagnosed with endometriosis or unspecified pelvic pain\n\nExclusion Criteria for Studies 1 and 2:\n\n* Use of white blood cell boosters\n* Prior radiotherapy with the exception of whole-breast irradiation for breast cancer\n* Prior myelotoxic chemotherapy\n* History of symptomatic cardiac or psychiatric disorder\n* Use of a pacemaker\n* Use of herbs or herbal supplements\n* Prior use of acupuncture\n* Enrollment in other research studies", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Peter Wayne, PhD", "affiliation": "New England School of Acupuncture", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Dana Farber Cancer Institute", "city": "Boston", "state": "Massachusetts", "zip": "02115", "country": "United States", "geoPoint": {"lat": 42.35843, "lon": -71.05977}}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D010051", "term": "Ovarian Neoplasms"}, {"id": "D004715", "term": "Endometriosis"}, {"id": "D017699", "term": "Pelvic Pain"}, {"id": "D014594", "term": "Uterine Neoplasms"}], "ancestors": [{"id": "D004701", "term": "Endocrine Gland Neoplasms"}, {"id": "D009371", "term": "Neoplasms by Site"}, {"id": "D009369", "term": "Neoplasms"}, {"id": "D010049", "term": "Ovarian Diseases"}, {"id": "D000291", "term": "Adnexal Diseases"}, {"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D005833", "term": "Genital Neoplasms, Female"}, {"id": "D014565", "term": "Urogenital Neoplasms"}, {"id": "D000091662", "term": "Genital Diseases"}, {"id": "D004700", "term": "Endocrine System Diseases"}, {"id": "D006058", "term": "Gonadal Disorders"}, {"id": "D010146", "term": "Pain"}, {"id": "D009461", "term": "Neurologic Manifestations"}, {"id": "D012816", "term": "Signs and Symptoms"}, {"id": "D013568", "term": "Pathological Conditions, Signs and Symptoms"}, {"id": "D014591", "term": "Uterine Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT04464187", "orgStudyIdInfo": {"id": "P18-954"}, "organization": {"fullName": "AbbVie", "class": "INDUSTRY"}, "briefTitle": "A Study to Evaluate Pregnancy Outcomes in Females Treated With Oral Elagolix Tablets and Capsules", "officialTitle": "Prospective Registry to Evaluate Pregnancy Outcomes in Women Treated With Elagolix"}, "statusModule": {"statusVerifiedDate": "2025-09", "overallStatus": "TERMINATED", "whyStopped": "Company Decision", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2022-01-06", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2025-07-11", "type": "ACTUAL"}, "completionDateStruct": {"date": "2025-07-11", "type": "ACTUAL"}, "studyFirstSubmitDate": "2020-07-07", "studyFirstSubmitQcDate": "2020-07-07", "studyFirstPostDateStruct": {"date": "2020-07-09", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2025-09-09", "lastUpdatePostDateStruct": {"date": "2025-09-15", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AbbVie", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false, "isUsExport": false}, "descriptionModule": {"briefSummary": "Orilissa is a drug approved for the management of moderate to severe pain associated with endometriosis. Oriahnn is approved for heavy menstrual bleeding due to uterine fibroids. Elagolix-containing products should not be taken by women who are pregnant or suspected to be pregnant but pregnancies are expected as the medicine does not completely stop ovulation and women may inadvertently continue taking Elagolix-containing products until their pregnancy is confirmed.\n\nThis study will assess pregnancy outcomes (maternal, fetal, and infant) of participants with and without exposure to Elagolix-containing products for their endometriosis or other conditions based on approved indications and prescribing patterns of Elagolix. Around 584 participants will be enrolled (292 participants exposed to Elagolix and 292 without exposure) in the United States.\n\nParticipants will not receive Elagolix-containing products as part of this study but will be followed for maternal and fetal outcomes up to 1 year after delivery.\n\nThere may be a higher burden for participants in this study compared to standard of care. Participants will be asked to provide additional information by questionnaire during each trimester of pregnancy, and at 0-6 weeks, 26 weeks, and 1 year after delivery. Contact Bloom Pregnancy Call Center at 1-833-782-7241 or bloompregnancyregistry@iqvia.com or visit https://www.bloompregnancyregistry.com/."}, "conditionsModule": {"conditions": ["Endometriosis", "Uterine Fibrioids"], "keywords": ["Endometriosis", "Pregnancy", "Orlissa", "Elagolix", "Uterine fibriods", "Oriahnn"]}, "designModule": {"studyType": "OBSERVATIONAL", "designInfo": {"observationalModel": "COHORT", "timePerspective": "PROSPECTIVE"}, "enrollmentInfo": {"count": 173, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Participants exposed to Elagolix-containing products", "description": "Pregnant participants exposed to Elagolix from 14 days after last menstrual period (LMP) or at any point during pregnancy."}, {"label": "Participants not exposed to Elagolix-containing products", "description": "Pregnant participants with endometriosis, uterine fibroids, or other conditions based on approved indications and prescribing patterns of Elagolix-containing products not exposed to Elagolix from 14 days after LMP or at any point during pregnancy."}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Rate of major congenital malformations", "description": "Defined as an abnormality in structural development that is medically or cosmetically significant, present at birth, and persists in postnatal life unless or until repaired.", "timeFrame": "Approximately 2 years (1 year post-delivery)"}], "secondaryOutcomes": [{"measure": "Rate of minor congenital malformations", "description": "Defined as a defect that occurs infrequently in the population but that has neither cosmetic nor functional significance to the child and is identified in the infant up to 1 year of age.", "timeFrame": "Approximately 2 years (1 year post-delivery)"}, {"measure": "Rate of spontaneous abortion", "description": "Defined as non-deliberate embryonic or fetal death that occurs prior to 20 weeks gestation post-last menstrual period.", "timeFrame": "Up to 9 months"}, {"measure": "Rate of elective or therapeutic pregnancy termination", "description": "Rate of elective or therapeutic pregnancy termination.", "timeFrame": "Up to 9 months"}, {"measure": "Rate of stillbirth", "description": "Defined as non-deliberate fetal death that occurs at or after 20 weeks gestation but prior to delivery.", "timeFrame": "Up to 9 months"}, {"measure": "Rate of preterm birth", "description": "Defined as live birth prior to 37 weeks gestation as counted from last menstrual period or based on ultrasound used for conception dating.", "timeFrame": "Up to 9 months"}, {"measure": "Rate of maternal placental issues", "description": "Rate of maternal placental issues, including placenta previa and placental abruption.", "timeFrame": "Up to 9 months"}, {"measure": "Rate of small for gestation age infants", "description": "Defined as birth size (weight, length, or head circumference) less than or equal to the 10th percentile for sex and gestational age using National Center for Health Statistics (NCHS) pediatric growth curves for full-term infants. Prenatal growth curves specific to preterm infants will be used for premature infants.", "timeFrame": "Up to 9 months"}, {"measure": "Rate of postnatal growth deficiency or failure to thrive", "description": "Rate of postnatal growth deficiency or failure to thrive as diagnosed by his/her treating physician using criteria such as a significant weight or weight-for-height deceleration.", "timeFrame": "Approximately 2 years (1 year post-delivery)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\nParticipants exposed to Elagolix:\n\n* Currently pregnant.\n* Documentation that the participant was exposed to elagolix-containing product from 14 days after last menstrual period (LMP) or at any time during pregnancy.\n* Consents to participate in the study. If the participant is a minor, consent will be obtained according to local regulations.\n\nInternal Comparator:\n\n* Currently pregnant with endometriosis, uterine fibroids, or other conditions based on approved indications and prescribing patterns of elagolix-containing product.\n* Documentation that the participant was not exposed to elagolix-containing product from 14 days after LMP or any time during pregnancy.\n* Consents to participate in the study. If the participant is a minor, consent will be obtained according to local regulations.\n\nExclusion Criteria:\n\n-None.", "healthyVolunteers": false, "sex": "FEMALE", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"], "studyPopulation": "Pregnant women with or without exposure to Orilissa for their endometriosis or other indications for prescribing of the medication.", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"overallOfficials": [{"name": "ABBVIE INC.", "affiliation": "AbbVie", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Iqvia /Id# 240918", "city": "Durham", "state": "North Carolina", "zip": "27703-8426", "country": "United States", "geoPoint": {"lat": 35.99403, "lon": -78.89862}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "Related Info.", "url": "https://www.bloompregnancyregistry.com/"}]}, "ipdSharingStatementModule": {"ipdSharing": "UNDECIDED"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT01121991", "orgStudyIdInfo": {"id": "IMP 25244"}, "organization": {"fullName": "EMD Serono", "class": "INDUSTRY"}, "briefTitle": "A Prospective Study to Evaluate the Addition of Subcutaneous Recombinant Human-Luteinizing Hormone With Recombinant Human-Follicle Stimulating Hormone on Follicular Development in Women Undergoing Ovarian Stimulation for Assisted Reproductive Technologies", "officialTitle": "A Phase III, Multicentre, Open-label Prospective Study to Evaluate the Addition of Subcutaneous Recombinant Human-Luteinizing Hormone (Luveris) With r-hFSH on Follicular Development in Women Undergoing Ovarian Stimulation for ART"}, "statusModule": {"statusVerifiedDate": "2013-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2004-09"}, "primaryCompletionDateStruct": {"date": "2005-09", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-05-10", "studyFirstSubmitQcDate": "2010-05-11", "studyFirstPostDateStruct": {"date": "2010-05-12", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-02-17", "resultsFirstSubmitQcDate": "2011-02-17", "resultsFirstPostDateStruct": {"date": "2011-03-18", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2013-08-02", "lastUpdatePostDateStruct": {"date": "2013-08-07", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "Irene Kavanagh, Medical Research Manager", "oldOrganization": "EMD Serono Canada Inc., an affiliate of Merck KGaA, Darmstadt, Germany"}, "leadSponsor": {"name": "EMD Serono", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "In-vitro fertilization (IVF) of human oocytes followed by the replacement of embryo in the uterine cavity has become a well established treatment for female infertility attributable to damaged fallopian tubes, endometriosis or unexplained causes where alternative forms of therapy have failed. The most commonly used protocols of follicular stimulation now employs follicle stimulating hormone (FSH) and long-acting agonists of gonadotropin releasing hormone (GnRH) to prevent the occurrence of a mid-cycle luteinizing hormone (LH) surge and to ensure the induction of well-synchronized larger cohort of ovarian follicles.\n\nThe results of a number of studies have demonstrated that in the majority of clinical situations, FSH administration alone is sufficient to achieve successful follicular development. A study had shown that in subjects receiving recombinant human-follicle stimulating hormone (r-hFSH) and recombinant human-luteinizing hormone (r-hLH), pregnancy rates were similar in the younger and older age groups, however, in women receiving r-hFSH alone, there was a significant decline in pregnancy rates for women 35 and older. This particular study also went on to show that the subgroup of women 35 and older, may benefit from supplementary r-hLH. A number of studies have been conducted to assess the safety and efficacy of r-hLH administered concomitantly with r-hFSH in the presence of developing follicles to reduce the rate of growth of intermediate and small follicles while allowing the dominant follicle to continue to progress.\n\nThis was a Phase III, open-label, multicentre study to evaluate safety and efficacy of addition of Recombinant Human-Luteinizing Hormone (Luveris) to a standard assisted reproductive technologies (ART) protocol.", "detailedDescription": "Luteinizing hormone is a heterodimeric glycoprotein composed of a non-covalent association of an α and a β subunit. Prior to the generation of human-LH (hLH) through recombinant technology, hLH had only been available for therapeutic use as human menopausal gonadotropins (hMG), a co-extracted, purified preparation of hLH and hFSH from urine of post menopausal women. Recombinant Human-Luteinizing Hormone (Luveris) has been found to be well tolerated in human pharmacokinetic and pharmacodynamic studies at doses of up to 40,000 IU in healthy female volunteers without any Serious Adverse Event (SAE) experience being reported.\n\nOBJECTIVES\n\n* To evaluate safety and efficacy of addition of Recombinant Human-Luteinizing Hormone (Luveris) to a standard ART procedure.\n\nIn this study, subjects were first treated with a GnRH agonist to induce pituitary desensitization according to centre's standard practice followed by administration of r-hFSH. All subjects were then treated with Recombinant Human -Luteinizing Hormone (Luveris)150 IU per day subcutaneous (s.c.) from Day 6 of stimulation of their ART treatment cycle, continuing at the same dose until injection of hCG upto and including day of last FSH dose."}, "conditionsModule": {"conditions": ["Infertility", "Ovarian Stimulation"], "keywords": ["Infertility", "Ovarian Stimulation", "Luveris", "Lutropin alpha", "Controlled ovarian stimulation", "Reproductive techniques, assisted"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 55, "type": "ACTUAL"}}, "armsInterventionsModule": {"interventions": [{"type": "DRUG", "name": "Recombinant Human-Luteinizing Hormone (Luveris)", "description": "Recombinant Human-Luteinizing Hormone (Luveris) was administered once daily subcutaneously at a starting dose of 150 IU per day beginning on stimulation Day 6."}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Mean Number of Metaphase II Oocytes Per Participant Who Underwent Ovum Pick up for Intra-cytoplasmic Sperm Injection (ICSI)", "description": "Mean number of metaphase II oocytes was calculated for each participant undergoing ovum pick up for ICSI. ICSI is an in-vitro fertilization procedure in which a single sperm is injected directly into an egg under a microscope. Metaphase II stage of the oocyte was classified as the time at which the first polar body was observed microscopically. Metaphase II oocytes are a sub-group of the total number of oocytes.", "timeFrame": "On the day of ovum pick up (Day 1 or 2 after human chorionic gonadotropin [hCG] administration)."}, {"measure": "Mean Number of Mature Oocytes Per Participant Who Underwent Ovum Pick up for In Vitro Fertilization (IVF)", "description": "Mean number of oocytes undergoing ovum pick up for IVF were calculated for each participant. IVF is a process by which egg cells are fertilized by sperm outside the body, in-vitro.", "timeFrame": "On the day of ovum pick up (Day 1 or 2 after hCG administration)."}], "secondaryOutcomes": [{"measure": "Mean Number of Oocytes Retrieved Per Number of Follicles Aspirated on the Day of Ovum Pick up", "description": "Mean number of oocytes retrieved per number of follicles aspirated on the day of ovum pick up was calculated. Oocyte retrieval is a technique used in in vitro fertilization in order to remove oocytes from the ovary of the female, enabling fertilization outside the body.", "timeFrame": "On day of ovum pick up (Day 1 or 2 after hCG administration)"}, {"measure": "Number of Participants With Confirmed Pregnancies: Biochemical Pregnancies and Clinical Pregnancies", "description": "Biochemical pregnancy: A positive pregnancy test defined as hCG level \\>10 IU/L in a sample taken at least 14 days after Day 3 embryo transfer or 12 days after Day 5/6 embryo transfer with no further ultrasound confirmation of the existence of a gestational sac in the uterus. Clinical pregnancy: Existence of at least one ultrasonography confirmed gestational sac in the uterus, with or without heartbeat.", "timeFrame": "Post-hCG days 15-20 and post-hCG days 35-42."}, {"measure": "Number of Participants With Multiple Pregnancies", "description": "Multiple pregnancy is a pregnancy where more than one fetus develops simultaneously in the womb. There are two types of twinning-identical and fraternal. Identical twins represent the splitting of a single fertilized zygote (union of two gametes or male/female sex cells that produce a developing fetus) into two separate individuals.", "timeFrame": "Post-hCG Day 35-42."}, {"measure": "Number of Live Births", "description": "A live birth occurs when a fetus, whatever its gestational age, exits the maternal body and subsequently shows any sign of life, such as voluntary movement, heartbeat, or pulsation of the umbilical cord, for however brief a time and regardless of whether the umbilical cord or placenta are intact.", "timeFrame": "Post-hCG days 15-20 to pregnancy follow up."}, {"measure": "Pregnancy Loss Per Clinical Pregnancy", "description": "Preclinical miscarriage: Spontaneous cessation of a biochemical pregnancy. Early spontaneous abortion: Any spontaneous abortion occurring after confirmation of clinical pregnancy and before completion of 12 weeks of gestation. Late spontaneous abortion: any spontaneous abortion occurring between completion of 12 weeks of gestation and prior to a viable stage. Pregnancy loss per clinical pregnancy was measured as a percentage.", "timeFrame": "Post-hCG days 35-42."}, {"measure": "Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Adverse Events (AEs) Leading to Study Drug Discontinuation.", "description": "AEs: Any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug. TEAEs: AEs that occur during treatment with the study drug. It also included incidences of mild, moderate and severe ovarian hyperstimulation syndrome (OHSS). SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Participants who discontinued from the study due to AE were also recorded.", "timeFrame": "From stimulation Day 1 (S1) to post-hCG days 35-42 (safety visit)."}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Female subjects who underwent ovarian stimulation for ART (IVF/ICSI) using r-hFSH.\n* Subjects who in the opinion of the treating investigator met any of the following criteria to require r-LH supplementation during the ovarian stimulation:\n\n  * were selected for a GnRH agonist protocol to induce pituitary desensitization\n  * previous poor ovarian response to r-hFSH alone\n  * aged 35 to 40 years\n  * elevated baseline hormone parameters that were predictive of poor ovarian response\n* Female subjects aged between 18-40 years\n* Subjects with uterine cavity able to sustain embryo implantation or pregnancy\n* Subject who had no known infection with human immunodeficiency virus, hepatitis B or C virus\n* Subjects who were willing to participate and comply with the protocol for the duration of the study\n* Subjects who had given informed consent, prior to any study-related procedure not part of normal medical care\n\nExclusion Criteria:\n\n* Subjects with clinically significant systemic disease (e.g. insulin-dependent diabetes, epilepsy, severe migraine, intermittent porphyria, hepatic, renal or cardiovascular disease, severe corticosteroid-dependent asthma)\n* Any contraindication to being pregnant and/or carrying a pregnancy to term\n* Subjects with abnormal gynecological bleeding of undetermined origin\n* Subjects with known allergy to gonadotrophin preparations\n* Subjects with any medical condition for which the use of gonadotrophin preparations was contraindicated\n* Subjects who had previously entered into this study or simultaneously participated in another clinical drug trial\n* Subjects with any active substance abuse or history of drug, medication or alcohol abuse in the past 5 years\n* Subjects who had refused or were unable to comply with protocol", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "40 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Responsible", "affiliation": "EMD Serono Canada Inc.", "role": "STUDY_DIRECTOR"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "55 participants were enrolled in the study, 3 participants discontinued prior to study drug administration as they did not meet the eligibility criteria.", "recruitmentDetails": "Participants were recruited in 4 study centers in Canada from September 2004 to October 2005.", "groups": [{"id": "FG000", "title": "Recombinant Human-Luteinizing Hormone (Luveris)", "description": "All participants received Luveris 150 International Unit (IU) per day, subcutaneously (s.c) from stimulation day 6 (Day S6) of their assisted reproductive technology (ART) treatment cycle, continuing at the same dose until injection of hCG upto and including day of last FSH dose."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "Number of participants treated", "numSubjects": "52"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "46"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}]}], "dropWithdraws": [{"type": "Lack of Ovarian Response", "reasons": [{"groupId": "FG000", "numSubjects": "2"}]}, {"type": "No Oocytes Retrieved", "reasons": [{"groupId": "FG000", "numSubjects": "3"}]}, {"type": "No Fertilization", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Recombinant Human-Luteinizing Hormone (Luveris)", "description": "All participants received Luveris 150 International Unit (IU) per day, subcutaneously (s.c) from stimulation day 6 (Day S6) of their assisted reproductive technology (ART) treatment cycle, continuing at the same dose until injection of hCG upto and including day of last FSH dose."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "52"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "34.6", "spread": "3.6"}]}]}]}, {"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "<35 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "22"}]}]}, {"title": ">=35 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "30"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "52"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "3"}]}]}, {"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "47"}]}]}, {"title": "Hispanic", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}]}]}, {"title": "Aboriginal", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Canada", "categories": [{"measurements": [{"groupId": "BG000", "value": "52"}]}]}]}, {"title": "Smoking", "description": "Consumption of cigarettes is inclusive of cigarillos and cigars.", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "0 cigarettes per day", "categories": [{"measurements": [{"groupId": "BG000", "value": "50"}]}]}, {"title": "6-20 cigarettes per day", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}]}]}, {"title": ">20 cigarettes per day", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Mean Number of Metaphase II Oocytes Per Participant Who Underwent Ovum Pick up for Intra-cytoplasmic Sperm Injection (ICSI)", "description": "Mean number of metaphase II oocytes was calculated for each participant undergoing ovum pick up for ICSI. ICSI is an in-vitro fertilization procedure in which a single sperm is injected directly into an egg under a microscope. Metaphase II stage of the oocyte was classified as the time at which the first polar body was observed microscopically. Metaphase II oocytes are a sub-group of the total number of oocytes.", "populationDescription": "Analysis population includes those participants undergoing ICSI whose oocytes were assessed for maturity (Metaphase II) using a microscope.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Metaphase II Oocytes", "timeFrame": "On the day of ovum pick up (Day 1 or 2 after human chorionic gonadotropin [hCG] administration).", "groups": [{"id": "OG000", "title": "Recombinant Human-Luteinizing Hormone (Luveris)", "description": "All participants received Luveris 150 International Unit (IU) per day, subcutaneously (s.c) from stimulation day 6 (Day S6) of their assisted reproductive technology (ART) treatment cycle, continuing at the same dose until injection of hCG upto and including day of last FSH dose."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "9.5", "spread": "4.2"}]}]}]}, {"type": "PRIMARY", "title": "Mean Number of Mature Oocytes Per Participant Who Underwent Ovum Pick up for In Vitro Fertilization (IVF)", "description": "Mean number of oocytes undergoing ovum pick up for IVF were calculated for each participant. IVF is a process by which egg cells are fertilized by sperm outside the body, in-vitro.", "populationDescription": "Analysis population includes those participants undergoing IVF whose oocytes were assessed for maturity. Mature oocytes can be considered as Metaphase II oocytes.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "oocytes", "timeFrame": "On the day of ovum pick up (Day 1 or 2 after hCG administration).", "groups": [{"id": "OG000", "title": "Recombinant Human-Luteinizing Hormone (Luveris)", "description": "All participants received Luveris 150 International Unit (IU) per day, subcutaneously (s.c) from stimulation day 6 (Day S6) of their assisted reproductive technology (ART) treatment cycle, continuing at the same dose until injection of hCG upto and including day of last FSH dose."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "7.5", "spread": "6.8"}]}]}]}, {"type": "SECONDARY", "title": "Mean Number of Oocytes Retrieved Per Number of Follicles Aspirated on the Day of Ovum Pick up", "description": "Mean number of oocytes retrieved per number of follicles aspirated on the day of ovum pick up was calculated. Oocyte retrieval is a technique used in in vitro fertilization in order to remove oocytes from the ovary of the female, enabling fertilization outside the body.", "populationDescription": "ITT population: all participants who received at least one dose of the study drug and underwent vaginal ovum pick up.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "oocytes per aspirated follicle", "timeFrame": "On day of ovum pick up (Day 1 or 2 after hCG administration)", "groups": [{"id": "OG000", "title": "Recombinant Human-Luteinizing Hormone (Luveris)", "description": "All participants received Luveris 150 International Unit (IU) per day, subcutaneously (s.c) from stimulation day 6 (Day S6) of their assisted reproductive technology (ART) treatment cycle, continuing at the same dose until injection of hCG upto and including day of last FSH dose."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.9", "spread": "0.2"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Confirmed Pregnancies: Biochemical Pregnancies and Clinical Pregnancies", "description": "Biochemical pregnancy: A positive pregnancy test defined as hCG level \\>10 IU/L in a sample taken at least 14 days after Day 3 embryo transfer or 12 days after Day 5/6 embryo transfer with no further ultrasound confirmation of the existence of a gestational sac in the uterus. Clinical pregnancy: Existence of at least one ultrasonography confirmed gestational sac in the uterus, with or without heartbeat.", "populationDescription": "ITT population: all participants who received at least one dose of the study drug.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Post-hCG days 15-20 and post-hCG days 35-42.", "groups": [{"id": "OG000", "title": "Recombinant Human-Luteinizing Hormone (Luveris)", "description": "All participants received Luveris 150 International Unit (IU) per day, subcutaneously (s.c) from stimulation day 6 (Day S6) of their assisted reproductive technology (ART) treatment cycle, continuing at the same dose until injection of hCG upto and including day of last FSH dose."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "52"}]}], "classes": [{"title": "Participants with confirmed biochemical pregnancy", "categories": [{"measurements": [{"groupId": "OG000", "value": "22"}]}]}, {"title": "Participants with confirmed clinical pregnancy", "categories": [{"measurements": [{"groupId": "OG000", "value": "14"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Multiple Pregnancies", "description": "Multiple pregnancy is a pregnancy where more than one fetus develops simultaneously in the womb. There are two types of twinning-identical and fraternal. Identical twins represent the splitting of a single fertilized zygote (union of two gametes or male/female sex cells that produce a developing fetus) into two separate individuals.", "populationDescription": "ITT population: all participants who received at least one dose of the study drug.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Post-hCG Day 35-42.", "groups": [{"id": "OG000", "title": "Recombinant Human-Luteinizing Hormone (Luveris)", "description": "All participants received Luveris 150 International Unit (IU) per day, subcutaneously (s.c) from stimulation day 6 (Day S6) of their assisted reproductive technology (ART) treatment cycle, continuing at the same dose until injection of hCG upto and including day of last FSH dose."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "52"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4"}]}]}]}, {"type": "SECONDARY", "title": "Number of Live Births", "description": "A live birth occurs when a fetus, whatever its gestational age, exits the maternal body and subsequently shows any sign of life, such as voluntary movement, heartbeat, or pulsation of the umbilical cord, for however brief a time and regardless of whether the umbilical cord or placenta are intact.", "populationDescription": "ITT population: all participants who received at least one dose of the study drug.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Live births", "timeFrame": "Post-hCG days 15-20 to pregnancy follow up.", "groups": [{"id": "OG000", "title": "Recombinant Human-Luteinizing Hormone (Luveris)", "description": "All participants received Luveris 150 International Unit (IU) per day, subcutaneously (s.c) from stimulation day 6 (Day S6) of their assisted reproductive technology (ART) treatment cycle, continuing at the same dose until injection of hCG upto and including day of last FSH dose."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "52"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "13"}]}]}]}, {"type": "SECONDARY", "title": "Pregnancy Loss Per Clinical Pregnancy", "description": "Preclinical miscarriage: Spontaneous cessation of a biochemical pregnancy. Early spontaneous abortion: Any spontaneous abortion occurring after confirmation of clinical pregnancy and before completion of 12 weeks of gestation. Late spontaneous abortion: any spontaneous abortion occurring between completion of 12 weeks of gestation and prior to a viable stage. Pregnancy loss per clinical pregnancy was measured as a percentage.", "populationDescription": "Participants with confirmed clinical pregnancies.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of pregnancy loss", "timeFrame": "Post-hCG days 35-42.", "groups": [{"id": "OG000", "title": "Recombinant Human-Luteinizing Hormone (Luveris)", "description": "All participants received Luveris 150 International Unit (IU) per day, subcutaneously (s.c) from stimulation day 6 (Day S6) of their assisted reproductive technology (ART) treatment cycle, continuing at the same dose until injection of hCG upto and including day of last FSH dose."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "7.14"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Adverse Events (AEs) Leading to Study Drug Discontinuation.", "description": "AEs: Any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug. TEAEs: AEs that occur during treatment with the study drug. It also included incidences of mild, moderate and severe ovarian hyperstimulation syndrome (OHSS). SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Participants who discontinued from the study due to AE were also recorded.", "populationDescription": "ITT population: all participants who received at least one dose of the study drug.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Number of participants", "timeFrame": "From stimulation Day 1 (S1) to post-hCG days 35-42 (safety visit).", "groups": [{"id": "OG000", "title": "Recombinant Human-Luteinizing Hormone (Luveris)", "description": "All participants received Luveris 150 International Unit (IU) per day, subcutaneously (s.c) from stimulation day 6 (Day S6) of their assisted reproductive technology (ART) treatment cycle, continuing at the same dose until injection of hCG upto and including day of last FSH dose."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "52"}]}], "classes": [{"title": "TEAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "15"}]}]}, {"title": "SAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}]}]}, {"title": "Discontinuation due to AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "AEs are collected on an ongoing basis from day of written informed consent. All new AEs must be recorded until the post-treatment safety, on day 35-42 post-hCG administration. AEs are classified as pre-treatment, treatment-emergent and post-treatment.", "description": "Pre-Treatment:Medical conditions present at the initial study visit that did not worsen in severity or frequency during the study;Treatment-Emergent: If the onset date of the AE was on or after the first dose date of the study medication; Post-Treatment: If the onset date of the AE was post-hCG Days 15- 42 for participants who completed the study.", "eventGroups": [{"id": "EG000", "title": "Recombinant Human-Luteinizing Hormone (Luveris)", "description": "All participants received Luveris 150 International Unit (IU) per day, subcutaneously (s.c) from stimulation day 6 (Day S6) of their assisted reproductive technology (ART) treatment cycle, continuing at the same dose until injection of hCG upto and including day of last FSH dose.", "seriousNumAffected": 3, "seriousNumAtRisk": 52, "otherNumAffected": 15, "otherNumAtRisk": 52}], "seriousEvents": [{"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 9.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 52}]}, {"term": "Metrorrhagia", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 9.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 52}]}, {"term": "Post procedural hemorrhage", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 9.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 52}]}], "otherEvents": [{"term": "Local tolerability of injections", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 9.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 52}]}, {"term": "Abdominal distension", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 9.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 52}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 9.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 52}]}, {"term": "Diarrhea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 9.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 52}]}, {"term": "Flatulence", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 9.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 52}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 9.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 52}]}, {"term": "Injection site pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 9.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 52}]}, {"term": "Vulvovaginal mycotic infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 9.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 52}]}, {"term": "Post procedural nausea", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 9.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 52}]}, {"term": "Procedural pain", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 9.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 52}]}, {"term": "Procedural vomiting", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 9.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 52}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 9.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 52}]}, {"term": "Loss of consciousness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 9.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 52}]}, {"term": "Intra-uterine death", "organSystem": "Pregnancy, puerperium and perinatal conditions", "sourceVocabulary": "MedDRA 9.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 52}]}, {"term": "Anxiety", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 9.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 52}]}, {"term": "Dysuria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 9.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 52}]}, {"term": "Genital pruritus female", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 9.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 52}]}, {"term": "Ovarian Hyperstimulation Syndrome", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 9.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 52}]}, {"term": "Ecchymosis", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 9.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 52}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true}, "pointOfContact": {"title": "Medical Responsible", "organization": "EMD Serono Canada Inc., an affiliate of Merck KGaA, Darmstadt, Germany", "email": "david.sciberras@emdserono.com", "phone": "+1-888-737-6668", "phoneExt": "5248"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D007246", "term": "Infertility"}, {"id": "D006379", "term": "Helping Behavior"}], "ancestors": [{"id": "D000091662", "term": "Genital Diseases"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D012919", "term": "Social Behavior"}, {"id": "D001519", "term": "Behavior"}]}, "interventionBrowseModule": {"meshes": [{"id": "D037101", "term": "Luteinizing Hormone, beta Subunit"}], "ancestors": [{"id": "D007986", "term": "Luteinizing Hormone"}, {"id": "D006065", "term": "Gonadotropins, Pituitary"}, {"id": "D006062", "term": "Gonadotropins"}, {"id": "D036361", "term": "Peptide Hormones"}, {"id": "D006728", "term": "Hormones"}, {"id": "D006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D010908", "term": "Pituitary Hormones, Anterior"}, {"id": "D010907", "term": "Pituitary Hormones"}, {"id": "D010455", "term": "Peptides"}, {"id": "D000602", "term": "Amino Acids, Peptides, and Proteins"}]}}, "hasResults": true}, {"protocolSection": {"identificationModule": {"nctId": "NCT02438735", "orgStudyIdInfo": {"id": "2015-7/12"}, "organization": {"fullName": "Uludag University", "class": "OTHER"}, "briefTitle": "Endometrioma Related Reduced Ovarian Reserve", "officialTitle": "The Effect Of The Presence Of Endometriomas On Ovarian Reserve", "acronym": "ERROR"}, "statusModule": {"statusVerifiedDate": "2017-12", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2015-04"}, "primaryCompletionDateStruct": {"date": "2017-08-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2017-08-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2015-05-06", "studyFirstSubmitQcDate": "2015-05-07", "studyFirstPostDateStruct": {"date": "2015-05-08", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-12-16", "lastUpdatePostDateStruct": {"date": "2017-12-19", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "GÜRKAN UNCU,PROF. MD", "investigatorTitle": "prof.md", "investigatorAffiliation": "Uludag University"}, "leadSponsor": {"name": "Uludag University", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "Prior studies have shown surgical excision of endometriomas are associated with a decline in ovarian reserve as assessed by serum anti-Mullerian Hormone (AMH) levels. However, the natural history of serum AMH levels in the presence of untreated endometriomas are unknown. Purpose of this study is to determine whether the presence of endometriomas cause a faster decline in serum AMH levels than in healthy women over a six months period.", "detailedDescription": "The study is a prospective cohort study. Women diagnosed with endometriomas by transvaginal or transabdominal ultrasound or MRI will be recruited from a tertiary care endometriosis clinic. Age matched healthy controls will be recruited from the staff of the same hospital. A priorly published historical group of women who underwent endometrioma excision will be a second comparator."}, "conditionsModule": {"conditions": ["Endometriosis"], "keywords": ["ovarian endometriomas", "AMH", "ovarian reserve"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "COHORT", "timePerspective": "PROSPECTIVE"}, "bioSpec": {"retention": "SAMPLES_WITHOUT_DNA", "description": "Serum Anti-mullerian hormone (AMH)"}, "enrollmentInfo": {"count": 80, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Endometrioma", "description": "Reproductive aged women diagnosed with endometrioma. Conservative follow up for six months.", "interventionNames": ["Other: Conservative follow up"]}, {"label": "Healthy Controls", "description": "Women with regular menstrual cycles and without ovarian pathology will be recruited from physicians, nurses and other staff of the same hospital.\n\nControls will be matched for age with the women in the endometrioma group. They will be conservatively followed up for six months.", "interventionNames": ["Other: Conservative follow up"]}, {"label": "Historical controls who underwent surgical excision", "description": "20 women who underwent surgical excision of endometrioma in the same clinic had serum AMH levels measured preoperatively and on post operative sixth month. Their values will be compared with that of endometrioma group. These data were priorly published in detail (Uncu et al. 2013).", "interventionNames": ["Procedure: laparoscopic endometrioma excision"]}], "interventions": [{"type": "PROCEDURE", "name": "laparoscopic endometrioma excision", "armGroupLabels": ["Historical controls who underwent surgical excision"]}, {"type": "OTHER", "name": "Conservative follow up", "armGroupLabels": ["Endometrioma", "Healthy Controls"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in Serum Anti- mullerian hormone (AMH) level", "timeFrame": "at recruitment and six months later"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Reproductive age\n* Endometrioma without indication for surgery or treatment with combined contraceptive, progestin or other hormonal intervention.\n\nExclusion Criteria:\n\n* Menstrual cycle irregularity\n* Polycystic ovarian syndrome\n* Women who were pregnant or contemplating pregnancy in the next six months\n* History of ovarian surgery\n* Using medication which could affect ovarian function during six months before recruitment\n* Indication for surgical excision", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "40 Years", "stdAges": ["ADULT"], "studyPopulation": "The decision to include a healthy control group was taken five months after starting recruitment of women with endometrioma. Only 12 women with endometriomas had been recruited until then and none of them had six month serum AMH level measured.\n\nSince healthy controls were reluctant to undergo transvaginal ultrasound examination, antral follicle counts were not measured as another marker of ovarian reserve for healthy controls and some women in the endometrioma group.", "samplingMethod": "PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"overallOfficials": [{"name": "gürkan uncu", "affiliation": "Uludag University School of Medicine", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Uludag University Scholl of medicine", "city": "Bursa", "state": "Turkey/bursa", "country": "Turkey (Türkiye)", "geoPoint": {"lat": 40.19559, "lon": 29.06013}}]}, "referencesModule": {"references": [{"pmid": "23624580", "type": "BACKGROUND", "citation": "Uncu G, Kasapoglu I, Ozerkan K, Seyhan A, Oral Yilmaztepe A, Ata B. Prospective assessment of the impact of endometriomas and their removal on ovarian reserve and determinants of the rate of decline in ovarian reserve. Hum Reprod. 2013 Aug;28(8):2140-5. doi: 10.1093/humrep/det123. Epub 2013 Apr 26."}, {"pmid": "29935810", "type": "DERIVED", "citation": "Kasapoglu I, Ata B, Uyaniklar O, Seyhan A, Orhan A, Yildiz Oguz S, Uncu G. Endometrioma-related reduction in ovarian reserve (ERROR): a prospective longitudinal study. Fertil Steril. 2018 Jul 1;110(1):122-127. doi: 10.1016/j.fertnstert.2018.03.015. Epub 2018 Jun 20."}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT06885125", "orgStudyIdInfo": {"id": "DANTE Study"}, "organization": {"fullName": "Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico", "class": "OTHER"}, "briefTitle": "Dietary Intervention to Improve Fertility in Women With Endometriosis Undergoing IVF", "officialTitle": "Randomized Controlled Study on the Effect of a DietAry interveNtion in Ameliorating fertiliTy Parameters in Women With endomEtriosis Undergoing IVF (The DANTE Study)", "acronym": "DANTE"}, "statusModule": {"statusVerifiedDate": "2025-01", "overallStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2025-03-24", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2029-06-30", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2029-12-31", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2025-02-05", "studyFirstSubmitQcDate": "2025-03-17", "studyFirstPostDateStruct": {"date": "2025-03-20", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2025-03-26", "lastUpdatePostDateStruct": {"date": "2025-03-27", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico", "class": "OTHER"}, "collaborators": [{"name": "UNIVERSITE CATHOLIQUE DE LOUVAIN", "class": "UNKNOWN"}, {"name": "Cliniques universitaires Saint-Luc- Université Catholique de Louvain", "class": "OTHER"}, {"name": "University of Edinburgh", "class": "OTHER"}, {"name": "STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM", "class": "UNKNOWN"}, {"name": "UNIWERSYTET MEDYCZNY W LUBLINIE", "class": "UNKNOWN"}, {"name": "SVEUCILISTE U ZAGREBU MEDICINSKI FAKULTET", "class": "UNKNOWN"}, {"name": "University College Cork", "class": "OTHER"}, {"name": "Endometriosis UK", "class": "UNKNOWN"}, {"name": "Wageningen University", "class": "OTHER"}, {"name": "Endometriose Stichting", "class": "UNKNOWN"}, {"name": "Belgian Volition SRL", "class": "UNKNOWN"}, {"name": "ASSOCIATION OF PEOPLE WITH ENDOMETRIOSIS I AM 1 IN 10", "class": "UNKNOWN"}]}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The goal of this randomized controlled trial is to assess whether a 12-week anti-inflammatory diet can improve fertility outcomes in women with endometriosis undergoing In Vitro Fertilization (IVF).\n\nThe main questions are:\n\n* Does the anti-inflammatory diet reduce the rate of inadequate ovarian response to hormonal stimulation (retrieval of ≤3 oocytes)?\n* Does it improve secondary outcomes such as embryo quality, pregnancy rates, inflammation markers, and quality of life?\n\nResearchers will compare two groups:\n\n* Women receiving standard IVF protocols.\n* Women undergoing the same IVF protocol plus the anti-inflammatory diet.\n\nParticipants will:\n\n* Be randomized into one of the two groups.\n* Follow dietary counseling sessions and complete dietary assessments (diet group).\n* Provide biological samples (e.g., plasma, vaginal and fecal swabs, and follicular fluid) before and after the dietary intervention to evaluate potential differences in inflammation, hormonal levels, and microbiome composition between the two groups and across timepoints (pre- and post-diet).\n* Complete questionnaires on quality of life, sexual function, and symptomatology severity before and after the intervention to assess differences between the two groups and across timepoints.", "detailedDescription": "Women who agree to participate in the study will be randomized into two groups: one group will receive standard IVF protocols, and the other will undergo a 12-week anti-inflammatory diet followed by the standard IVF protocol. In both groups, participants' dietary habits will be monitored throughout the study period to detect any variations. The primary outcome will be to compare the rate of inadequate ovarian response to hormonal stimulation (defined as the retrieval of ≤3 oocytes according to the Poseidon 2016 criteria) in infertile women with endometriosis."}, "conditionsModule": {"conditions": ["Endometriosis"], "keywords": ["IVF", "endometriosis", "anti-inflammatory diet"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "maskingDescription": "The treatment will be kept blind for both the medical and laboratory personnel performing the in vitro fertilization procedures. The allocation branch will be revealed to the data manager at the end of data collection related to the primary outcome.", "whoMasked": ["CARE_PROVIDER", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 438, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Anti-Inflammatory Diet", "type": "EXPERIMENTAL", "description": "Patients will follow a 12-week anti-inflammatory diet, followed by the standard IVF treatment protocol.", "interventionNames": ["Dietary Supplement: anti-inflammatory diet"]}, {"label": "Controls", "type": "NO_INTERVENTION", "description": "Patients will undergo the standard IVF treatment protocol without any dietary intervention."}], "interventions": [{"type": "DIETARY_SUPPLEMENT", "name": "anti-inflammatory diet", "description": "The anti-inflammatory diet consists of a 12-week plant-based diet, followed by guidance and monitoring from a nutritionist.", "armGroupLabels": ["Anti-Inflammatory Diet"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Inadequate ovarian response", "description": "Rate of inadequate ovarian response to hormonal stimulation (defined as the retrieval of ≤3 oocytes according to the Poseidon 2016 criteria) in infertile women with endometriosis who follow an anti-inflammatory diet compared to those who do not follow any specific diet.", "timeFrame": "During the oocyte retrieval procedure"}], "secondaryOutcomes": [{"measure": "Adherence to the intervention", "description": "Adherence to the intervention using 24 hour recall.", "timeFrame": "3 months"}, {"measure": "Fertilisation rate", "description": "Fertilisation rate per aspirated oocyte retrieved. Defined as the appearance of 2 pronuclei (PN)", "timeFrame": "The day after oocyte retrieval"}, {"measure": "Embryo quality", "description": "Good quality blastocysts according to Gardner classification", "timeFrame": "Up to six days after oocyte pick-up"}, {"measure": "Cumulative pregnancy rates", "description": "All clinical pregnancies achieved by IVF, including the transfer of fresh embryos and all cryopreserved-thawed embryos from the stimulation cycle.", "timeFrame": "12 months"}, {"measure": "Miscarriage rate", "description": "Spontaneous or planned abortions.", "timeFrame": "24 months"}, {"measure": "Cumulative Live Birth Rate", "description": "All live birth achieved by IVF, including the transfer of fresh embryos and all cryopreserved-thawed embryos from the stimulation cycle.", "timeFrame": "24 months"}, {"measure": "Microbiome composition", "description": "The difference in microorganism species distribution according to 16S RNA sequencing analysis between the control group and the study group, as well as before and after the diet in the study group. Both the vaginal and gut microbiome will be analyzed.", "timeFrame": "4 months"}, {"measure": "Concentration of Steroid Hormones", "description": "The difference between the steroid cascade in follicular fluids of women following the diet and those not following the diet, specifically focusing on the following hormones: Aldosterone, Cortisol, Cortisone, 11-DeoxyCortisol, 21-DeoxyCortisol, Corticosterone, 11-Deoxycorticosterone, DHEAS, DHEA, Estradiol, Androstenedione, Testosterone, DHT, 17-OHProgesterone, and Progesterone.", "timeFrame": "4 months"}, {"measure": "Inflammation Index", "description": "The difference in the inflammation index between the control group and the study group, as well as pre- and post-diet changes within the study group, will be evaluated using a composite blood-based inflammation index called the INFLA-score. This index is based on four circulating biomarkers-C-reactive protein (CRP) levels, blood platelet count (Plt), white blood cell count (WBC), and granulocyte-to-lymphocyte ratio (GLR)-and captures both serum and cellular-circulating inflammation.", "timeFrame": "4 months"}, {"measure": "Quality of life (using 30-item Endometriosis Health Profile)", "description": "Quality of life differences between the control group and the study group, as well as pre- and post-diet changes within the study group, will be evaluated using the Endometriosis Health Profile-30 (EHP-30) questionnaire. The EHP-30 consists of 30 items divided into five subscales: 'pain,' 'control and powerlessness,' 'social support,' 'emotional well-being,' and 'self-image.' Each subscale is standardized on a scale from 0 to 100, where lower scores indicate better quality of life.", "timeFrame": "4 months"}, {"measure": "Sexual function (using Female Sexual Function Index)", "description": "Sexual function differences between the control group and the study group, as well as pre- and post-diet changes within the study group, will be evaluated using the Female Sexual Function Index (FSFI), a questionnaire with a score range from 2 to 36, where higher scores indicate better sexual function.", "timeFrame": "4 months"}, {"measure": "Symptomatology severity (using Numeric Rating Scale)", "description": "Symptomatology severity differences between the control group and the study group, as well as pre- and post-diet changes within the study group, will be evaluated using Numeric Rating Scale (NRS, min 0-max 10), where higher scores indicate worse symptom severity.", "timeFrame": "4 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Age \\< 40 years\n* Pregnancy seeking for more than 12 months\n* Regular menstrual cycle, i.e. mean cycle interval between 21 and 35 days\n* Ultrasonographic diagnosis of ovarian endometriomas or deep peritoneal endometriosis.\n* Antral Follicle Counts (AFC) ≥ 5 (no other cause of reduced ovarian reserve).\n* Absence of ureteral stenosis or intestinal subocclusive symptoms\n\nExclusion Criteria:\n\n* Contraindication to pregnancy\n* Hydrosalpinx\n* Endometriomas with a mean diameter \\> 4 cm\n* Submucosal fibroids or large intramural or subserosal fibroids (≥ 5 cm).\n* Doubtful sonographic findings that do not allow to reliably rule out malignancy.\n* severe male factor (\\<1 million sperm/ml)", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "39 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Paola Vigano', PhD", "role": "CONTACT", "phone": "+390255034302", "email": "paola.vigano@policlinico.mi.it"}, {"name": "Marco Reschini, MSc", "role": "CONTACT", "phone": "+390255034303", "email": "marco.reschini@policlinico.mi.it"}], "locations": [{"facility": "Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico", "status": "RECRUITING", "city": "Milan", "zip": "20122", "country": "Italy", "contacts": [{"name": "Paola Vigano', PhD", "role": "CONTACT", "phone": "+390255034302", "email": "paola.vigano@policlinico.mi.it"}, {"name": "Marco Reschini, MSc", "role": "CONTACT", "phone": "+390255034303", "email": "marco.reschini@policlinico.mi.it"}], "geoPoint": {"lat": 45.46427, "lon": 9.18951}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT00485355", "orgStudyIdInfo": {"id": "07-150"}, "organization": {"fullName": "The Cleveland Clinic", "class": "OTHER"}, "briefTitle": "Study Comparing Conventional vs. Robotic-assisted Laparoscopic Hysterectomy", "officialTitle": "A Prospective Randomized Trial Comparing Conventional vs. Robotic Assisted Laparoscopic Hysterectomy"}, "statusModule": {"statusVerifiedDate": "2013-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-06"}, "primaryCompletionDateStruct": {"date": "2012-12", "type": "ACTUAL"}, "completionDateStruct": {"date": "2012-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-06-11", "studyFirstSubmitQcDate": "2007-06-11", "studyFirstPostDateStruct": {"date": "2007-06-12", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2014-02-18", "lastUpdatePostDateStruct": {"date": "2014-02-19", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "The Cleveland Clinic", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to compare two ways of performing laparoscopic hysterectomy - robotic-assisted vs. conventional laparoscopy.", "detailedDescription": "Compared to abdominal hysterectomy, the advantages of laparoscopic hysterectomy are decreased postoperative intravenous analgesia requirements, shorter length of hospital stay, quicker return to work and daily activities. Longer operating times have been shown to be offset by shorter hospital stays, with similar hospital costs overall. Compared to abdominal hysterectomy, laparoscopic hysterectomy is associated with less blood loss, fewer abdominal wall infections, or febrile episodes. The increased visualization allows for concomitant evaluation and excision of adhesions or endometriosis, as well as facilitating oophorectomy.\n\nRobotic systems were developed in order to facilitate laparoscopy by more ergonomic movements that are easier to perform and more precise. The da Vinci Surgical System (Intuitive Surgical Inc., Sunnyvale, CA, USA) has endowrist instruments that have seven degrees of movement and mimic the human wrist. It can also filter out tremors and other unintentional hand motions that may result from prolonged holding of instruments. The surgeon seated at a console commands the laparoscope and two laparoscopic surgical instruments.\n\nIn the literature, several case series have described the use of robotic-assisted hysterectomy. Two of these series included patients that were undergoing surgery for suspected malignancy, and hence has a different patient population that we are going to enroll.Overall these studies have demonstrated the feasibility of using robot-enhanced technology in order to perform hysterectomy in series of approximately 10-20 patients, with a similar rate of complications compared to classical laparoscopy.\n\nThe objective of this study is to conduct a prospective randomized controlled trial of robotic assisted versus traditional hysterectomy in the treatment of patients who have benign indications for hysterectomy, e.g. menorrhagia, symptomatic fibroid uteri, etc. Our primary outcome is operative time from incision to either closure or, in the case of concomitant prolapse or incontinence procedures, the completion of the hysterectomy portion of the case, i.e. closure of vaginal cuff and achievement of hemostasis from the hysterectomy. Secondary outcomes include intra-operative, peri-operative, and post-operative complications; post-operative patient outcomes as measured by the Short Form 36 (SF-36) questionnaire. Patient scores on this questionnaire before and after surgery can be used to calculate the quality adjusted life years (QALYs), which can then be used in the cost utility analysis. Patients' overall narcotic use and quality of life will also be assessed after surgery with diaries at different intervals. The diaries will consist of a daily narcotic/pain medication diary, a weekly assessment of return to normal activity, and assessments at 2, 4, and 6 weeks of surgical pain and ability to perform functional activities."}, "conditionsModule": {"conditions": ["Uterine Fibroids, Menorrhagia, Endometriosis"], "keywords": ["hysterectomy", "Laparoscopy", "robotics"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 27, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "1", "type": "ACTIVE_COMPARATOR", "description": "Conventional Laparoscopic Hysterectomy", "interventionNames": ["Procedure: conventional laparoscopic hysterectomy"]}, {"label": "2", "type": "ACTIVE_COMPARATOR", "description": "Robotic Assisted Laparoscopic Hysterectomy", "interventionNames": ["Procedure: robotic assisted laparoscopic hysterectomy"]}], "interventions": [{"type": "PROCEDURE", "name": "conventional laparoscopic hysterectomy", "description": "Total laparoscopic hysterectomy", "armGroupLabels": ["1"]}, {"type": "PROCEDURE", "name": "robotic assisted laparoscopic hysterectomy", "description": "Robotic assisted laparoscopic hysterectomy with DaVinci robot", "armGroupLabels": ["2"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Operative time from incision to either closure or, in the case of concomitant prolapse or incontinence procedures, the completion of the hysterectomy portion of the case, i.e. closure of vaginal cuff and achievement of hemostasis from the hysterectomy.", "timeFrame": "Intra-operative time"}], "secondaryOutcomes": [{"measure": "Peri-operative complications; comparison of costs; qualify of life issues; post-operative pain and narcotic use; return to normal activity", "timeFrame": "6 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* women who are 18 years of age or greater who are to undergo laparoscopic hysterectomy for benign indications. Other concomitant laparoscopic or anti-incontinence procedures (e.g., excision of endometriosis or mid-urethral sling procedures) will be performed at the primary surgeon's discretion.\n\nExclusion Criteria:\n\n* suspected malignancy, medical illness precluding laparoscopy, inability to give informed consent, morbid obesity (BMI\\>40), or need for concomitant bowel resection.", "healthyVolunteers": true, "sex": "FEMALE", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Marie FR Paraiso, MD", "affiliation": "The Cleveland Clinic", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Cleveland Clinic", "city": "Cleveland", "state": "Ohio", "zip": "44195", "country": "United States", "geoPoint": {"lat": 41.4995, "lon": -81.69541}}]}, "referencesModule": {"references": [{"pmid": "23395927", "type": "RESULT", "citation": "Paraiso MF, Ridgeway B, Park AJ, Jelovsek JE, Barber MD, Falcone T, Einarsson JI. A randomized trial comparing conventional and robotically assisted total laparoscopic hysterectomy. Am J Obstet Gynecol. 2013 May;208(5):368.e1-7. doi: 10.1016/j.ajog.2013.02.008. Epub 2013 Feb 8."}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D007889", "term": "Leiomyoma"}, {"id": "D008595", "term": "Menorrhagia"}, {"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D009379", "term": "Neoplasms, Muscle Tissue"}, {"id": "D018204", "term": "Neoplasms, Connective and Soft Tissue"}, {"id": "D009370", "term": "Neoplasms by Histologic Type"}, {"id": "D009369", "term": "Neoplasms"}, {"id": "D014592", "term": "Uterine Hemorrhage"}, {"id": "D014591", "term": "Uterine Diseases"}, {"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}, {"id": "D006470", "term": "Hemorrhage"}, {"id": "D010335", "term": "Pathologic Processes"}, {"id": "D013568", "term": "Pathological Conditions, Signs and Symptoms"}, {"id": "D008599", "term": "Menstruation Disturbances"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT03633799", "orgStudyIdInfo": {"id": "CMDOC-0042"}, "organization": {"fullName": "Sebela Pharmaceuticals Inc.", "class": "INDUSTRY"}, "briefTitle": "Evaluation of Efficacy, Safety and Tolerability of VeraCept IUS", "officialTitle": "A Phase 3, Prospective, Multi-Center, Single-Arm, Open-Label Study to Evaluate VeraCept®, a Long-Acting Reversible Intrauterine Contraceptive for Contraceptive Efficacy, Safety, and Tolerability"}, "statusModule": {"statusVerifiedDate": "2025-08", "overallStatus": "ACTIVE_NOT_RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2018-08-22", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2022-09-22", "type": "ACTUAL"}, "completionDateStruct": {"date": "2027-09-22", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2018-07-19", "studyFirstSubmitQcDate": "2018-08-14", "studyFirstPostDateStruct": {"date": "2018-08-16", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2025-07-01", "resultsFirstSubmitQcDate": "2025-08-05", "resultsFirstPostDateStruct": {"date": "2025-08-22", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2025-08-05", "lastUpdatePostDateStruct": {"date": "2025-08-22", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Sebela Women's Health Inc.", "class": "INDUSTRY"}, "collaborators": [{"name": "Syneos Health", "class": "OTHER"}]}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "To assess the contraceptive efficacy (prevention of pregnancy) of VeraCept", "detailedDescription": "Study Design:\n\nProspective, multi-center, single-arm, open-label, Phase 3 clinical study to 3 years with extension up to 8 years\n\nNumber of Subjects:\n\nApproximately 1,605 subjects will be enrolled into the study\n\nStudy Population:\n\nPost-menarcheal, pre-menopausal women up to age 45 years, who are at risk for pregnancy and who desire a long-term intrauterine contraceptive for birth control will be eligible for this study.\n\nPrimary Endpoint:\n\nThe primary endpoint is the contraceptive efficacy through 3 years of use, as assessed by the Pearl Index.\n\nSecondary endpoints:\n\nContraceptive Efficacy:\n\n* Pearl Index at Years 4, 5, 6, 7 and 8 as well as cumulatively through Years 4, 5, 6, 7 and 8.\n* Pregnancy percentage by life table analysis (Kaplan-Meier) at Years 1, 2, 3, 4, 5, 6, 7 and 8\n* The cumulative Pearl Index for Years 6 to 8 will be calculated as well as the cumulative pregnancy percentage for Years 6 to 8 using a life table analysis (Kaplan-Meier) only for the EP population.\n\nStudy drug placement:\n\n* Ease of VeraCept placement\n* Placement success\n\nSafety:\n\n* Serious adverse events (SAEs)\n* Adverse events (AEs)\n* Pelvic infection (pelvic inflammatory disease (PID) or endometritis)\n* Ectopic pregnancies\n* Uterine perforations\n* Dysmenorrhea\n* Abdominal pain\n* Expulsion rates at Years 1, 2, 3, 4, 5, 6, 7 and 8\n\nTolerability:\n\n* Bleeding and spotting patterns\n* Insertion pain assessed immediately after insertion\n* Continuation rates at Years 1, 2, 3, 4, 5, 6, 7 and 8\n* Reasons for discontinuation\n\nReturn to fertility\n\n● Pregnancy rate in subjects who request VeraCept removal specifically to become pregnant. Subjects who desire pregnancy after having VeraCept removed will be followed for either 1 year, until they decide to no longer try to conceive or they become pregnant, whichever comes first."}, "conditionsModule": {"conditions": ["Women at Risk for Pregnancy"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "interventionModelDescription": "VeraCept Intrauterine System (IUS)", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 1620, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "VeraCept", "type": "EXPERIMENTAL", "description": "VeraCept® Intrauterine Contraceptive", "interventionNames": ["Drug: VeraCept"]}], "interventions": [{"type": "DRUG", "name": "VeraCept", "description": "VeraCept Intrauterine Contraceptive is a hormone free, low dose, copper-releasing birth control method", "armGroupLabels": ["VeraCept"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Contraceptive Efficacy Through 3 Years of Use", "description": "Contraceptive efficacy through 3 years of use, as assessed by the Pearl Index. The Pearl Index is calculated as the number of on-treatment pregnancies per 100 woman-years of exposure. On-treatment pregnancy is defined as the estimated conception date being on or after the insertion date (must be a successful insertion) and no more than 7 days after the study drug is removed or expelled. One women year is defined as comprising thirteen 28-day cycles. A lower Pearl Index indicates greater contraceptive effectiveness.", "timeFrame": "3 years"}], "secondaryOutcomes": [{"measure": "Contraceptive Efficacy at Years 4, 5, 6, 7 and 8", "description": "Pearl Index will be calculated for Years 4, 5, 6, 7, and 8 as well as cumulatively through Years 4, 5, 6, 7, and 8", "timeFrame": "Years 4, 5, 6, 7, and 8 and cumulatively through Years 4, 5, 6, 7, and 8"}, {"measure": "Cumulative Pregnancy Percentage", "description": "A life table analysis (using Kaplan-Meier) of pregnancies will be performed for the EP population to present the cumulative pregnancy percentage", "timeFrame": "Years 1 through 3"}, {"measure": "Ease of VeraCept Placement", "description": "Ease of VeraCept placement will be summarized for the ITT population as reported by the investigator (Very easy, Easy, Neither Easy nor Hard, Hard, Very Hard). (First Attempt)", "timeFrame": "Visit 1 (Day 1) / VeraCept placement"}, {"measure": "VeraCept Placement Success", "description": "The number and percentage of subjects with either a successful or unsuccessful placement will be summarized for the ITT", "timeFrame": "Visit 1 (Day 1) / VeraCept placement"}, {"measure": "Bleeding and Spotting Patterns", "description": "Bleeding and spotting patterns will be summarized for the first year of treatment by the number of days in each 28-day cycle with bleeding or spotting, bleeding only, and spotting only", "timeFrame": "Through year 1"}, {"measure": "Insertion Pain Assessed Immediately After Insertion (First Attempt)", "description": "Insertion pain summarized for subjects at first attempt as reported by the subjects", "timeFrame": "Visit 1 (Day 1), immediately after insertion"}, {"measure": "Cumulative VeraCept Discontinuation Rates", "description": "Cumulative VeraCept discontinuation rates will be summarized using Kaplan-Meier methods for the Safety population.", "timeFrame": "Years 1 through 3"}, {"measure": "Cumulative VeraCept Expulsion Rates", "description": "Cumulative VeraCept expulsion rates will be summarized using Kaplan-Meier methods for the Safety population.", "timeFrame": "Years 1 through 3"}, {"measure": "Return to Fertility. Only for Subjects Requesting VeraCept Removal to Become Pregnant.", "description": "The number and percentage of subjects with each return to fertility response will be summarized for the Safety population.", "timeFrame": "Subjects will be followed for either 1 year, until they decide to no longer try to conceive or they become pregnant, whichever comes first."}, {"measure": "Safety Adverse Events of Special Interest: Pelvic Infection (PID or Endometriosis), Uterine Perforations, and Abdominal Pain", "timeFrame": "3 years"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Post-menarcheal, pre-menopausal females up to 45 years of age at the time of informed consent/assent and in good general health;\n2. History of regular menstrual cycles defined as occurring every 21-35 days when not using hormones or prior to recent pregnancy or spontaneous or induced abortion;\n3. Sexually active with a male partner who has not had a vasectomy;\n4. Reasonably expect to have coitus at least once monthly during the study period;\n5. In a mutually monogamous relationship of at least 3 months duration;\n6. Seeking to avoid pregnancy for the duration of the study;\n7. Willing to use the study drug as the sole form of contraception;\n8. Willing to accept a risk of pregnancy;\n9. Subjects must be in compliance with cervical cancer screening guidelines per the American Society for Colposcopy and Cervical Pathology (ASCCP) guidelines without evidence of disease. Subjects who are age 21-24 y/o, at time of informed consent, must have a normal Papanicolaou test (Pap), atypical squamous cells of undetermined significance (ASC-US), or low-grade squamous intraepithelial lesion (LSIL). Subjects who are 25 or older at the time of informed consent with ASC-US results, must also have a negative high-risk human papilloma virus (HPV) test result within the appropriate screen timeframe per American Society for Colposcopy and Cervical Pathology (ASCCP) guidelines, and prior to the study IUS insertion. Alternatively, the subject must have had a colposcopy performed within the appropriate screen timeframe, and prior to the study IUS insertion that showed no evidence of dysplasia requiring treatment per ASCCP guidelines, or treatment was performed and follow-up at least 6 months after the treatment showed no evidence of disease by clinical evaluation;\n10. Able and willing to comply with all study tests, procedures, assessment tools (including e-diary) and follow-up;\n11. Able and willing to provide and document informed consent and Authorization for Release of Protected Health Information (PHI). Unemancipated subjects under 18 years old must provide assent and have written parental consent documented on the consent form consistent with local legal requirements;\n12. Plan to reside within a reasonable driving distance of a research site for the duration of the study.\n13. Subject agrees not to self-remove VeraCept\n\nExclusion Criteria:\n\n1. Known or suspected pregnancy; or at risk for pregnancy from unprotected intercourse earlier in current cycle;\n2. Subject who anticipates separation from her partner for more than a 6-month period during use of VeraCept;\n3. A previously inserted intrauterine system (IUS) that has not been removed by the time the study IUS is placed;\n4. History of previous IUS complications, such as perforation, expulsion, or pregnancy with IUS in place;\n5. Pain with current IUS;\n6. Injection of hormonal contraceptive (e.g., Depo-Provera) within the last 10 months and has not had 2 normal menstrual cycles since the last injection;\n7. Planned use of any non-contraceptive estrogen, progesterone or testosterone any time during study participation;\n8. Exclusively breastfeeding before return of menses; lactating women will be excluded unless they have had 2 normal menstrual periods prior to enrollment;\n9. Unexplained abnormal uterine bleeding (suspicious for a serious condition), including bleeding 4 weeks post-septic abortion or puerperal sepsis;\n10. Severely heavy or painful menstrual bleeding;\n11. Suspected or known cervical, uterine or ovarian cancer, or unresolved clinically significant abnormal Pap smear requiring evaluation or treatment;\n12. Any history of gestational trophoblastic disease with or without detectable elevated ß-human chorionic gonadotropin (ß-hCG) levels, or related malignant disease;\n13. Any congenital or acquired uterine anomaly that may complicate study drug placement, such as:\n\n    * Submucosal uterine leiomyoma\n    * Asherman's syndromes\n    * Pedunculated polyps\n    * Bicornuate uterus\n    * Didelphus or uterine septa\n14. Any distortions of the uterine cavity (e.g. fibroids), that, in the opinion of the investigator, are likely to cause issues during insertion, retention or removal of the IUS;\n15. Known anatomical abnormalities of the cervix such as severe cervical stenosis, prior trachelectomy or extensive conization that, in the opinion of the investigator would prevent cervical dilation and study drug placement;\n16. Untreated or unresolved acute cervicitis or vaginitis;\n17. Known or suspected human immunodeficiency virus (HIV) infection or clinical AIDS;\n18. Subjects who have an established immunodeficiency;\n19. Known intolerance or allergy to any components of VeraCept including intolerance or allergy to nickel, titanium, or copper, and including Wilson's Disease;\n20. Currently participating or planning future participation in a research study of an investigational drug or device during the course of this investigational study. Subject must have waited at least 30 days from exiting their last study prior to informed consent in this study;\n21. Subject has been enrolled in a previous VeraCept or LevoCept study; 21a. Subject has been enrolled in a previous VeraCept or LevoCept study where VeraCept or LevoCept placement was successful or attempted (replaces exclusion #21 for PK sub-study subjects only);\n22. Known or suspected alcohol or drug abuse within 12 months prior to the screening visit;\n23. Any general health, mental health or behavioral condition that, in the opinion of the investigator, could represent an increased risk for the subject or would render the subject less likely to provide the needed study information;\n24. Study staff or a member of the immediate family of study staff.\n25. Subject is \\<4 weeks post-pregnancy (postpartum, spontaneous or induced abortion)", "healthyVolunteers": true, "sex": "FEMALE", "genderBased": true, "genderDescription": "Only women who are at risk for pregnancy will be eligible for this study", "maximumAge": "45 Years", "stdAges": ["CHILD", "ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "David Turok, MD, MPH", "affiliation": "University of Utah", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "MomDoc Women's Health Research", "city": "Scottsdale", "state": "Arizona", "zip": "85251", "country": "United States", "geoPoint": {"lat": 33.50921, "lon": -111.89903}}, {"facility": "Copperstate OB/GYN Associates", "city": "Tucson", "state": "Arizona", "zip": "85712", "country": "United States", "geoPoint": {"lat": 32.22174, "lon": -110.92648}}, {"facility": "Essential Access Health", "city": "Berkeley", "state": "California", "zip": "94710", "country": "United States", "geoPoint": {"lat": 37.87159, "lon": -122.27275}}, {"facility": "Essential Access Health", "city": "Los Angeles", "state": "California", "zip": "90010", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Empire Clinical Research", "city": "Pomona", "state": "California", "zip": "91767", "country": "United States", "geoPoint": {"lat": 34.05529, "lon": -117.75228}}, {"facility": "University of California, Davis Health System", "city": "Sacramento", "state": "California", "zip": "95817", "country": "United States", "geoPoint": {"lat": 38.58157, "lon": -121.4944}}, {"facility": "M3 Wake Research (formerly Women's Health Care Research)", "city": "San Diego", "state": "California", "zip": "92111", "country": "United States", "geoPoint": {"lat": 32.71571, "lon": -117.16472}}, {"facility": "M3 Wake Research (formerly Medical Center for Clinical Research)", "city": "San Diego", "state": "California", "zip": "92120", "country": "United States", "geoPoint": {"lat": 32.71571, "lon": -117.16472}}, {"facility": "Stanford University, Medical Center, Obstetrics and Gynecolocy", "city": "Stanford", "state": "California", "zip": "94305", "country": "United States", "geoPoint": {"lat": 37.42411, "lon": -122.16608}}, {"facility": "Velocity Clinical Research (formerly Downtown Women's Health Care)", "city": "Englewood", "state": "Colorado", "zip": "80110", "country": "United States", "geoPoint": {"lat": 39.64777, "lon": -104.98776}}, {"facility": "Altus Research, Inc", "city": "Lake Worth", "state": "Florida", "zip": "33461", "country": "United States", "geoPoint": {"lat": 26.61708, "lon": -80.07231}}, {"facility": "Emory University School of Medicine", "city": "Atlanta", "state": "Georgia", "zip": "30308", "country": "United States", "geoPoint": {"lat": 33.749, "lon": -84.38798}}, {"facility": "Soapstone Center for Clinical Research", "city": "Decatur", "state": "Georgia", "zip": "30034", "country": "United States", "geoPoint": {"lat": 33.77483, "lon": -84.29631}}, {"facility": "Clinical Research Prime", "city": "Idaho Falls", "state": "Idaho", "zip": "83404", "country": "United States", "geoPoint": {"lat": 43.46658, "lon": -112.03414}}, {"facility": "Women's Health Advantage", "city": "Fort Wayne", "state": "Indiana", "zip": "46825", "country": "United States", "geoPoint": {"lat": 41.1306, "lon": -85.12886}}, {"facility": "Indiana University", "city": "Indianapolis", "state": "Indiana", "zip": "46202", "country": "United States", "geoPoint": {"lat": 39.76838, "lon": -86.15804}}, {"facility": "Praetorian Pharmaceutical Research", "city": "Marrero", "state": "Louisiana", "zip": "70072", "country": "United States", "geoPoint": {"lat": 29.89937, "lon": -90.10035}}, {"facility": "University of Michigan Von Voigtlander Women's Hospital", "city": "Ann Arbor", "state": "Michigan", "zip": "48109", "country": "United States", "geoPoint": {"lat": 42.27756, "lon": -83.74088}}, {"facility": "Planned Parenthood North Central States - Minneapolis", "city": "Minneapolis", "state": "Minnesota", "zip": "55408", "country": "United States", "geoPoint": {"lat": 44.97997, "lon": -93.26384}}, {"facility": "Planned Parenthood Great Rivers (formerly Planned Parenthood of the St. Louis Region and Southwest Missouri)", "city": "Manchester", "state": "Missouri", "zip": "63088", "country": "United States", "geoPoint": {"lat": 38.597, "lon": -90.50929}}, {"facility": "Rex Garn Mabey Jr., MD", "city": "Las Vegas", "state": "Nevada", "zip": "89128", "country": "United States", "geoPoint": {"lat": 36.17497, "lon": -115.13722}}, {"facility": "Capital Health Lawrence OBGYN Research (formerly Lawrence OB/Gyn Clinical Research)", "city": "Lawrenceville", "state": "New Jersey", "zip": "08648", "country": "United States", "geoPoint": {"lat": 40.29733, "lon": -74.7296}}, {"facility": "Columbia University Medical Center, Division of Family Planning", "city": "New York", "state": "New York", "zip": "10032", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "Duke University Medical Center", "city": "Durham", "state": "North Carolina", "zip": "27710", "country": "United States", "geoPoint": {"lat": 35.99403, "lon": -78.89862}}, {"facility": "University of Cincinnati/Reproductive Medicine Research", "city": "Cincinnati", "state": "Ohio", "zip": "45267", "country": "United States", "geoPoint": {"lat": 39.12711, "lon": -84.51439}}, {"facility": "The Ohio State University Ob/Gyn Research Office", "city": "Columbus", "state": "Ohio", "zip": "43210", "country": "United States", "geoPoint": {"lat": 39.96118, "lon": -82.99879}}, {"facility": "OHSU Women's Health Research Unit", "city": "Portland", "state": "Oregon", "zip": "97239", "country": "United States", "geoPoint": {"lat": 45.52345, "lon": -122.67621}}, {"facility": "University of Pennsylvania/Penn Family Planning and Pregnancy Loss Center", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19104", "country": "United States", "geoPoint": {"lat": 39.95238, "lon": -75.16362}}, {"facility": "Clinical Research of Philadelphia", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19114", "country": "United States", "geoPoint": {"lat": 39.95238, "lon": -75.16362}}, {"facility": "Magee-Womens Hospital, Center for Family Planning Research", "city": "Pittsburgh", "state": "Pennsylvania", "zip": "15213", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "Medical Research South, LLC", "city": "Charleston", "state": "South Carolina", "zip": "29407", "country": "United States", "geoPoint": {"lat": 32.77632, "lon": -79.93275}}, {"facility": "Chattanooga Medical Research", "city": "Chattanooga", "state": "Tennessee", "zip": "37404", "country": "United States", "geoPoint": {"lat": 35.04563, "lon": -85.30968}}, {"facility": "The Jackson Clinic, PA", "city": "Jackson", "state": "Tennessee", "zip": "38305", "country": "United States", "geoPoint": {"lat": 35.61452, "lon": -88.81395}}, {"facility": "Advanced Research Associates", "city": "Corpus Christi", "state": "Texas", "zip": "78414", "country": "United States", "geoPoint": {"lat": 27.80058, "lon": -97.39638}}, {"facility": "Advances In Health", "city": "Pearland", "state": "Texas", "zip": "77584", "country": "United States", "geoPoint": {"lat": 29.56357, "lon": -95.28605}}, {"facility": "Wasatch Clinical Research", "city": "Salt Lake City", "state": "Utah", "zip": "84107", "country": "United States", "geoPoint": {"lat": 40.76078, "lon": -111.89105}}, {"facility": "University of Utah Healthcare Health Sciences Center", "city": "Salt Lake City", "state": "Utah", "zip": "84132", "country": "United States", "geoPoint": {"lat": 40.76078, "lon": -111.89105}}, {"facility": "Tidewater Physicians for Women", "city": "Norfolk", "state": "Virginia", "zip": "23502", "country": "United States", "geoPoint": {"lat": 36.84681, "lon": -76.28522}}, {"facility": "Eastern Virginia Medical", "city": "Norfolk", "state": "Virginia", "zip": "23507", "country": "United States", "geoPoint": {"lat": 36.84681, "lon": -76.28522}}, {"facility": "Seattle Clinical REsearch Center (formerly Seattle Women's Health)", "city": "Seattle", "state": "Washington", "zip": "98104", "country": "United States", "geoPoint": {"lat": 47.60621, "lon": -122.33207}}, {"facility": "University of Washington Medical Center", "city": "Seattle", "state": "Washington", "zip": "98117", "country": "United States", "geoPoint": {"lat": 47.60621, "lon": -122.33207}}]}, "referencesModule": {"references": [{"pmid": "39581486", "type": "DERIVED", "citation": "Creinin MD, Gawron LM, Roe AH, Blumenthal PD, Boraas CM, Hou MY, McNicholas C, Schreifels MJ, Peters K, Culwell K, Turok DK; Copper 175mm(2) IUD Phase 3 Clinical Investigator Group. Three-year efficacy, safety, and tolerability outcomes from a phase 3 study of a low-dose copper intrauterine device. Contraception. 2025 Mar;143:110771. doi: 10.1016/j.contraception.2024.110771. Epub 2024 Nov 22."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "VeraCept", "description": "VeraCept® Intrauterine Contraceptive\n\nVeraCept: VeraCept Intrauterine Contraceptive is a hormone free, low dose, copper-releasing birth control method"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "1620"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "689"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "931"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "349"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "288"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "97"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "9"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "4"}]}, {"type": "Pregnancy", "reasons": [{"groupId": "FG000", "numSubjects": "20"}]}, {"type": "other", "reasons": [{"groupId": "FG000", "numSubjects": "39"}]}, {"type": "ongoing within third year of study", "reasons": [{"groupId": "FG000", "numSubjects": "106"}]}, {"type": "unsuccessful study drug placement", "reasons": [{"groupId": "FG000", "numSubjects": "19"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "VeraCept", "description": "VeraCept® Intrauterine Contraceptive\n\nVeraCept: VeraCept Intrauterine Contraceptive is a hormone free, low dose, copper-releasing birth control method"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "1620"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "27.6", "spread": "5.77"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "1620"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "308"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "1312"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "18"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "86"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "10"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "238"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "1196"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "62"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "10"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Contraceptive Efficacy Through 3 Years of Use", "description": "Contraceptive efficacy through 3 years of use, as assessed by the Pearl Index. The Pearl Index is calculated as the number of on-treatment pregnancies per 100 woman-years of exposure. On-treatment pregnancy is defined as the estimated conception date being on or after the insertion date (must be a successful insertion) and no more than 7 days after the study drug is removed or expelled. One women year is defined as comprising thirteen 28-day cycles. A lower Pearl Index indicates greater contraceptive effectiveness.", "populationDescription": "Evaluable for pregnancy population", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Pearl Index", "timeFrame": "3 years", "groups": [{"id": "OG000", "title": "VeraCept", "description": "VeraCept® Intrauterine Contraceptive\n\nVeraCept: VeraCept Intrauterine Contraceptive is a hormone free, low dose, copper-releasing birth control method"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1397"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.06", "lowerLimit": "0.67", "upperLimit": "1.61"}]}]}]}, {"type": "SECONDARY", "title": "Contraceptive Efficacy at Years 4, 5, 6, 7 and 8", "description": "Pearl Index will be calculated for Years 4, 5, 6, 7, and 8 as well as cumulatively through Years 4, 5, 6, 7, and 8", "reportingStatus": "NOT_POSTED", "timeFrame": "Years 4, 5, 6, 7, and 8 and cumulatively through Years 4, 5, 6, 7, and 8", "denomUnitsSelected": "Participants"}, {"type": "SECONDARY", "title": "Cumulative Pregnancy Percentage", "description": "A life table analysis (using Kaplan-Meier) of pregnancies will be performed for the EP population to present the cumulative pregnancy percentage", "populationDescription": "evaluable for pregnancy population", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Probability", "timeFrame": "Years 1 through 3", "groups": [{"id": "OG000", "title": "VeraCept", "description": "VeraCept® Intrauterine Contraceptive\n\nVeraCept: VeraCept Intrauterine Contraceptive is a hormone free, low dose, copper-releasing birth control method"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1397"}]}], "classes": [{"title": "Year 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.013"}]}]}, {"title": "Year 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.024"}]}]}, {"title": "Year 3", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.028"}]}]}]}, {"type": "SECONDARY", "title": "Ease of VeraCept Placement", "description": "Ease of VeraCept placement will be summarized for the ITT population as reported by the investigator (Very easy, Easy, Neither Easy nor Hard, Hard, Very Hard). (First Attempt)", "populationDescription": "Number of subjects in ITT population with available information regarding ease of placement at first attempt.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Visit 1 (Day 1) / VeraCept placement", "groups": [{"id": "OG000", "title": "VeraCept", "description": "VeraCept® Intrauterine Contraceptive\n\nVeraCept: VeraCept Intrauterine Contraceptive is a hormone free, low dose, copper-releasing birth control method"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1609"}]}], "classes": [{"categories": [{"title": "very easy", "measurements": [{"groupId": "OG000", "value": "844"}]}, {"title": "easy", "measurements": [{"groupId": "OG000", "value": "502"}]}, {"title": "neither easy nor hard", "measurements": [{"groupId": "OG000", "value": "160"}]}, {"title": "hard", "measurements": [{"groupId": "OG000", "value": "77"}]}, {"title": "very hard", "measurements": [{"groupId": "OG000", "value": "26"}]}]}]}, {"type": "SECONDARY", "title": "VeraCept Placement Success", "description": "The number and percentage of subjects with either a successful or unsuccessful placement will be summarized for the ITT", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Visit 1 (Day 1) / VeraCept placement", "groups": [{"id": "OG000", "title": "VeraCept", "description": "VeraCept® Intrauterine Contraceptive\n\nVeraCept: VeraCept Intrauterine Contraceptive is a hormone free, low dose, copper-releasing birth control method"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1620"}]}], "classes": [{"categories": [{"title": "successful first attempt of placement", "measurements": [{"groupId": "OG000", "value": "1549"}]}, {"title": "successful second attempt of placement", "measurements": [{"groupId": "OG000", "value": "52"}]}, {"title": "failed placement", "measurements": [{"groupId": "OG000", "value": "7"}]}, {"title": "second attempt not tried", "measurements": [{"groupId": "OG000", "value": "12"}]}]}]}, {"type": "SECONDARY", "title": "Bleeding and Spotting Patterns", "description": "Bleeding and spotting patterns will be summarized for the first year of treatment by the number of days in each 28-day cycle with bleeding or spotting, bleeding only, and spotting only", "populationDescription": "evaluable for cycle control population", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "days", "timeFrame": "Through year 1", "groups": [{"id": "OG000", "title": "VeraCept", "description": "VeraCept® Intrauterine Contraceptive\n\nVeraCept: VeraCept Intrauterine Contraceptive is a hormone free, low dose, copper-releasing birth control method"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1587"}]}], "classes": [{"title": "cycle 1: bleeding or spotting", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1401"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "11.2", "spread": "4.93"}]}]}, {"title": "cycle 1: bleeding only", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1401"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "6.4", "spread": "3.44"}]}]}, {"title": "cycle 1: spotting only", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1401"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.8", "spread": "3.37"}]}]}, {"title": "cycle 2: bleeding or spotting", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1271"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "7.8", "spread": "3.76"}]}]}, {"title": "cycle 2: bleeding only", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1271"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "5.1", "spread": "2.57"}]}]}, {"title": "cycle 2: spotting only", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1271"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.7", "spread": "2.56"}]}]}, {"title": "cycle 3: bleeding or spotting", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1162"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "7.6", "spread": "3.73"}]}]}, {"title": "cycle 3: bleeding only", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1162"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "5.0", "spread": "2.69"}]}]}, {"title": "cycle 3: spotting only", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1162"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.5", "spread": "2.43"}]}]}, {"title": "cycle 4: bleeding or spotting", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1102"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "7.3", "spread": "3.77"}]}]}, {"title": "cycle 4: bleeding only", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1102"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.9", "spread": "2.66"}]}]}, {"title": "cycle 4: spotting only", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1102"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.4", "spread": "2.54"}]}]}, {"title": "cycle 5: bleeding or spotting", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1036"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "7.2", "spread": "3.63"}]}]}, {"title": "cycle 5: bleeding only", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1036"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.8", "spread": "2.60"}]}]}, {"title": "cycle 5: spotting only", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1036"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.4", "spread": "2.33"}]}]}, {"title": "cycle 6: bleeding or spotting", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "946"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "7.0", "spread": "3.48"}]}]}, {"title": "cycle 6: bleeding only", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "946"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.8", "spread": "2.64"}]}]}, {"title": "cycle 6: spotting only", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "946"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.2", "spread": "2.27"}]}]}, {"title": "cycle 7: bleeding or spotting", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "875"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "7.2", "spread": "3.79"}]}]}, {"title": "cycle 7: bleeding only", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "875"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.7", "spread": "2.73"}]}]}, {"title": "cycle 7: spotting only", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "875"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.4", "spread": "2.52"}]}]}, {"title": "cycle 8: bleeding or spotting", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "857"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "7.0", "spread": "3.54"}]}]}, {"title": "cycle 8: bleeding only", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "857"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.7", "spread": "2.43"}]}]}, {"title": "cycle 8: spotting only", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "857"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.3", "spread": "2.51"}]}]}, {"title": "cycle 9: bleeding or spotting", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "797"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "6.9", "spread": "3.60"}]}]}, {"title": "cycle 9: bleeding only", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "797"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.6", "spread": "2.58"}]}]}, {"title": "cycle 9: spotting only", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "797"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.2", "spread": "2.36"}]}]}, {"title": "cycle 10: bleeding or spotting", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "745"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "6.9", "spread": "3.40"}]}]}, {"title": "cycle 10: bleeding only", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "745"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.6", "spread": "2.44"}]}]}, {"title": "cycle 10: spotting only", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "745"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.3", "spread": "2.19"}]}]}, {"title": "cycle 11: bleeding or spotting", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "724"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "6.8", "spread": "3.48"}]}]}, {"title": "cycle 11: bleeding only", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "724"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.5", "spread": "2.38"}]}]}, {"title": "cycle 11: spotting only", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "724"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.2", "spread": "2.60"}]}]}, {"title": "cycle 12: bleeding or spotting", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "703"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "6.8", "spread": "3.38"}]}]}, {"title": "cycle 12: bleeding only", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "703"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.7", "spread": "2.55"}]}]}, {"title": "cycle 12: spotting only", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "703"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.2", "spread": "2.24"}]}]}, {"title": "cycle 13: bleeding or spotting", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "676"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "6.9", "spread": "3.50"}]}]}, {"title": "cycle 13: bleeding only", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "676"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.6", "spread": "2.50"}]}]}, {"title": "cycle 13: spotting only", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "676"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.2", "spread": "2.40"}]}]}]}, {"type": "SECONDARY", "title": "Insertion Pain Assessed Immediately After Insertion (First Attempt)", "description": "Insertion pain summarized for subjects at first attempt as reported by the subjects", "populationDescription": "Number of subjects in ITT population with available information regarding device placement pain at first attempt.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Visit 1 (Day 1), immediately after insertion", "groups": [{"id": "OG000", "title": "VeraCept", "description": "VeraCept® Intrauterine Contraceptive\n\nVeraCept: VeraCept Intrauterine Contraceptive is a hormone free, low dose, copper-releasing birth control method"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1600"}]}], "classes": [{"categories": [{"title": "no pain", "measurements": [{"groupId": "OG000", "value": "85"}]}, {"title": "some pain", "measurements": [{"groupId": "OG000", "value": "363"}]}, {"title": "moderately painful", "measurements": [{"groupId": "OG000", "value": "661"}]}, {"title": "painful", "measurements": [{"groupId": "OG000", "value": "406"}]}, {"title": "very painful", "measurements": [{"groupId": "OG000", "value": "85"}]}]}]}, {"type": "SECONDARY", "title": "Cumulative VeraCept Discontinuation Rates", "description": "Cumulative VeraCept discontinuation rates will be summarized using Kaplan-Meier methods for the Safety population.", "populationDescription": "safety population", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Probability", "timeFrame": "Years 1 through 3", "groups": [{"id": "OG000", "title": "VeraCept", "description": "VeraCept® Intrauterine Contraceptive\n\nVeraCept: VeraCept Intrauterine Contraceptive is a hormone free, low dose, copper-releasing birth control method"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1601"}]}], "classes": [{"title": "Year 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.195"}]}]}, {"title": "Year 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.329"}]}]}, {"title": "Year 3", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.419"}]}]}]}, {"type": "SECONDARY", "title": "Cumulative VeraCept Expulsion Rates", "description": "Cumulative VeraCept expulsion rates will be summarized using Kaplan-Meier methods for the Safety population.", "populationDescription": "safety population", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Probability", "timeFrame": "Years 1 through 3", "groups": [{"id": "OG000", "title": "VeraCept", "description": "VeraCept® Intrauterine Contraceptive\n\nVeraCept: VeraCept Intrauterine Contraceptive is a hormone free, low dose, copper-releasing birth control method"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1601"}]}], "classes": [{"title": "Year 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.025"}]}]}, {"title": "Year 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.040"}]}]}, {"title": "Year 3", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.051"}]}]}]}, {"type": "SECONDARY", "title": "Return to Fertility. Only for Subjects Requesting VeraCept Removal to Become Pregnant.", "description": "The number and percentage of subjects with each return to fertility response will be summarized for the Safety population.", "populationDescription": "Number of subjects requesting VeraCept removal to become pregnant with known fertility outcomes", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Subjects will be followed for either 1 year, until they decide to no longer try to conceive or they become pregnant, whichever comes first.", "groups": [{"id": "OG000", "title": "VeraCept", "description": "VeraCept® Intrauterine Contraceptive\n\nVeraCept: VeraCept Intrauterine Contraceptive is a hormone free, low dose, copper-releasing birth control method"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "51"}]}], "classes": [{"categories": [{"title": "pregnancy occurred", "measurements": [{"groupId": "OG000", "value": "37"}]}, {"title": "pregnancy did not occur", "measurements": [{"groupId": "OG000", "value": "14"}]}]}]}, {"type": "SECONDARY", "title": "Safety Adverse Events of Special Interest: Pelvic Infection (PID or Endometriosis), Uterine Perforations, and Abdominal Pain", "populationDescription": "safety population", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "3 years", "groups": [{"id": "OG000", "title": "VeraCept", "description": "VeraCept® Intrauterine Contraceptive\n\nVeraCept: VeraCept Intrauterine Contraceptive is a hormone free, low dose, copper-releasing birth control method"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1601"}]}], "classes": [{"title": "uterine perforation", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}]}]}, {"title": "pelvic infection (PID or endometriosis)", "categories": [{"measurements": [{"groupId": "OG000", "value": "19"}]}]}, {"title": "abdominal pain", "categories": [{"measurements": [{"groupId": "OG000", "value": "111"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "3 years", "eventGroups": [{"id": "EG000", "title": "VeraCept", "description": "VeraCept™ Intrauterine Contraceptive\n\nVeraCept: VeraCept Intrauterine Contraceptive is a hormone free, low dose, copper-releasing birth control method", "deathsNumAffected": 3, "deathsNumAtRisk": 1620, "seriousNumAffected": 52, "seriousNumAtRisk": 1620, "otherNumAffected": 1551, "otherNumAtRisk": 1601}], "seriousEvents": [{"term": "pyelonephritis", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 1620}]}, {"term": "cellulitis", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 1620}]}, {"term": "pneumonia", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 1620}]}, {"term": "sepsis", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 1620}]}, {"term": "anxiety", "organSystem": "Psychiatric disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 1620}]}, {"term": "depression", "organSystem": "Psychiatric disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 1620}]}, {"term": "suicidal ideation", "organSystem": "Psychiatric disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 1620}]}, {"term": "intentional overdose", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 1620}]}, {"term": "ectopic pregnancy", "organSystem": "Pregnancy, puerperium and perinatal conditions", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 1620}]}, {"term": "ruptured ectopic pregnancy", "organSystem": "Pregnancy, puerperium and perinatal conditions", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 1620}]}, {"term": "appendicitis", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1620}]}, {"term": "bacterial colitis", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1620}]}, {"term": "COVID-19", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1620}]}, {"term": "infectious mononucleosis", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1620}]}, {"term": "pelvic inflammatory disease", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1620}]}, {"term": "tonsillitis", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1620}]}, {"term": "urinary tract infection", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1620}]}, {"term": "drug use disorder", "organSystem": "Psychiatric disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1620}]}, {"term": "intentional self-injury", "organSystem": "Psychiatric disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1620}]}, {"term": "psychotic disorder", "organSystem": "Psychiatric disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1620}]}, {"term": "substance use disorder", "organSystem": "Psychiatric disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1620}]}, {"term": "substance-induced psychotic disorder", "organSystem": "Psychiatric disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1620}]}, {"term": "suicide attempt", "organSystem": "Psychiatric disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1620}]}, {"term": "accidental overdose", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1620}]}, {"term": "road traffic accident", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1620}]}, {"term": "tibia fracture", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1620}]}, {"term": "uterine perforation", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1620}]}, {"term": "abdominal pain", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1620}]}, {"term": "food poisoning", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1620}]}, {"term": "gastric stenosis", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1620}]}, {"term": "pancreatitis acute", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1620}]}, {"term": "cholecystitis", "organSystem": "Hepatobiliary disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1620}]}, {"term": "cholecystitis acute", "organSystem": "Hepatobiliary disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1620}]}, {"term": "cholelithiasis", "organSystem": "Hepatobiliary disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1620}]}, {"term": "hepatitis", "organSystem": "Hepatobiliary disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1620}]}, {"term": "hemiparesis", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1620}]}, {"term": "migraine", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1620}]}, {"term": "seizure", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1620}]}, {"term": "syncope", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1620}]}, {"term": "haemorrhagic ovarian cyst", "organSystem": "Reproductive system and breast disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1620}]}, {"term": "ovarian cyst ruptured", "organSystem": "Reproductive system and breast disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 1620}]}, {"term": "uterine haemorrhage", "organSystem": "Reproductive system and breast disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1620}]}, {"term": "pituitary tumour benign", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1620}]}, {"term": "uterine leiomyoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1620}]}, {"term": "anaemia", "organSystem": "Blood and lymphatic system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1620}]}, {"term": "choledochal cyst", "organSystem": "Congenital, familial and genetic disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1620}]}, {"term": "chest pain", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1620}]}, {"term": "anaphylactic reaction", "organSystem": "Immune system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1620}]}, {"term": "diabetic complication", "organSystem": "Metabolism and nutrition disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1620}]}, {"term": "hypoclycaemia", "organSystem": "Metabolism and nutrition disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1620}]}, {"term": "tenosynovitis", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1620}]}, {"term": "device breakage", "organSystem": "Product Issues", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1620}]}, {"term": "asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1620}]}, {"term": "hypertension", "organSystem": "Vascular disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1620}]}], "otherEvents": [{"term": "heavy menstrual bleeding", "organSystem": "Reproductive system and breast disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3117, "numAffected": 1246, "numAtRisk": 1601}]}, {"term": "dysmenorrhoea", "organSystem": "Reproductive system and breast disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2775, "numAffected": 1172, "numAtRisk": 1601}]}, {"term": "pelvic discomfort", "organSystem": "Reproductive system and breast disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1161, "numAffected": 552, "numAtRisk": 1601}]}, {"term": "intermenstrual bleeding", "organSystem": "Reproductive system and breast disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 864, "numAffected": 491, "numAtRisk": 1601}]}, {"term": "pelvic pain", "organSystem": "Reproductive system and breast disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 559, "numAffected": 324, "numAtRisk": 1601}]}, {"term": "dyspareunia", "organSystem": "Reproductive system and breast disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 160, "numAffected": 128, "numAtRisk": 1601}]}, {"term": "vaginal discharge", "organSystem": "Reproductive system and breast disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 103, "numAffected": 87, "numAtRisk": 1601}]}, {"term": "urinary tract infection", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 338, "numAffected": 235, "numAtRisk": 1601}]}, {"term": "bacterial vaginosis", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 350, "numAffected": 219, "numAtRisk": 1601}]}, {"term": "nasopharyngitis", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 279, "numAffected": 196, "numAtRisk": 1601}]}, {"term": "vulvovaginal mycotic infection", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 298, "numAffected": 192, "numAtRisk": 1601}]}, {"term": "upper respiratory tract infection", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 184, "numAffected": 132, "numAtRisk": 1601}]}, {"term": "COVID-19", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 128, "numAffected": 124, "numAtRisk": 1601}]}, {"term": "procedural pain", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 317, "numAffected": 292, "numAtRisk": 1601}]}, {"term": "post procedural haemorrhage", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 268, "numAffected": 267, "numAtRisk": 1601}]}, {"term": "post procedural discomfort", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 98, "numAffected": 97, "numAtRisk": 1601}]}, {"term": "nausea", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 168, "numAffected": 123, "numAtRisk": 1601}]}, {"term": "headache", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 216, "numAffected": 117, "numAtRisk": 1601}]}, {"term": "back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 128, "numAffected": 101, "numAtRisk": 1601}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": true}, "pointOfContact": {"title": "Elizabeth Gray, Manager, Clinical Operations", "organization": "Sebela Women's Health", "email": "Elizabeth.gray@sebelapharma.com", "phone": "760-593-8383"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2023-06-30", "uploadDate": "2025-07-01T21:54", "filename": "Prot_000.pdf", "size": 1567319}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2018-06-25", "uploadDate": "2025-07-01T21:53", "filename": "SAP_001.pdf", "size": 1061338}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04", "submissionTracking": {"firstMcpInfo": {"postDateStruct": {"date": "2025-07-20", "type": "ACTUAL"}}}}}, "hasResults": true}, {"protocolSection": {"identificationModule": {"nctId": "NCT06908655", "orgStudyIdInfo": {"id": "APHP241481"}, "secondaryIdInfos": [{"id": "2024-A00538-39", "type": "OTHER", "domain": "Agence nationale de sécurité du médicament et des produits de santé"}, {"id": "24.05788.000362", "type": "OTHER", "domain": "Commission Nationale des Recherche Impliquant la Personne Humaine"}], "organization": {"fullName": "Assistance Publique - Hôpitaux de Paris", "class": "OTHER"}, "briefTitle": "Diffusion Endometriosis MRI to Detect and Quantify Symptomatic Neurological Impairment in Pelvic Endometriosis", "officialTitle": "Diffusion Endometriosis MRI to Detect and Quantify Symptomatic Neurological Impairment in Pelvic Endometriosis", "acronym": "TENDANSE"}, "statusModule": {"statusVerifiedDate": "2025-02", "overallStatus": "NOT_YET_RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2025-04-01", "type": "ESTIMATED"}, "primaryCompletionDateStruct": {"date": "2027-04-30", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2027-04-30", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2025-03-13", "studyFirstSubmitQcDate": "2025-03-26", "studyFirstPostDateStruct": {"date": "2025-04-03", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2025-03-26", "lastUpdatePostDateStruct": {"date": "2025-04-03", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Assistance Publique - Hôpitaux de Paris", "class": "OTHER"}, "collaborators": [{"name": "Imagine Institute", "class": "OTHER"}, {"name": "Sauver la vie Fundation", "class": "UNKNOWN"}]}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "This research focuses on evaluating the ability of diffusion tensor imaging (DTI) to detect nerve damage in pelvic endometriosis. The primary objective is to visualize pelvic nerve plexuses to better understand the mechanisms of endometriosis-related neuropathic pain. Secondary objectives include comparing nerve damage between women with and without endometriosis.\n\nTo answer this question, it is planned to include 110 women with symptoms compatible with endometriosis, in Paris hospitals (Hôpital Cochin and HEGP). This research is funded by Assistance Publique - Hôpitaux de Paris. The expected duration of the research is 2 years, with individual participation of 3 months.\n\nThe research process will be as follows:\n\n* Visit 0 (V0): Initial consultation to assess your state of health, complete pain questionnaires (EHP5, EHP30, DN4, EVA), and obtain your informed consent. Prescription of MRI.\n* Visit 1 (V1): MRI with diffusion tensor imaging (DTI) within 60 days of V0. The MRI examination will be 10 minutes longer than the usual MRI. An intramuscular injection of glucagon hydrochloride will be given as part of the treatment.\n* Visit 2 (V2): Follow-up consultation at 3 months, where the results of the standard MRI sequences will be discussed.\n\nResearch constraints and modalities:\n\n* The addition of the DTI sequence extends the routine MRI by 10 minutes.\n* You must attend each scheduled appointment. If you are unable to attend, please inform your doctor.\n* No additional medications, treatments or samples are required for this study. You will be expected to follow your usual endometriosis treatments, with no specific restrictions on the drugs used, but please report any use of alternative medicine to your doctor.\n\nNo additional hospitalization is planned."}, "conditionsModule": {"conditions": ["Endometriosis"], "keywords": ["endometriosis", "tractography", "pelvic nervous tract"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "interventionModelDescription": "This is a prospective, non-randomized, multicenter, diagnostic study.", "primaryPurpose": "DIAGNOSTIC", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 110, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Patients with symptoms compatible with possible endometriosis", "type": "EXPERIMENTAL", "description": "Patients will have an initial gynecological surgery consultation to determine the indication for MRI to diagnose and/or assess pelvic endometriosis. MRI will be performed at the HEGP, comprising a T2-weighted isotropic thin-section (3D) cube sequence (1 mm3), and a T1-weighted isotropic 3D DIXON sequence (1 mm3), for a total duration of 20 minutes (including set-up). Patients will also have a pelvic ultrasound if they have not already had one at a center specializing in endometriosis.\n\nThey will have a further consultation after the MRI, so that the gynecological surgeon can discuss therapeutic management. All these procedures are performed as part of routine management.", "interventionNames": ["Other: MRI"]}], "interventions": [{"type": "OTHER", "name": "MRI", "description": "The procedure to be investigated will be to perform a diffusion tensor sequence during the MRI indicated as part of the treatment. The diffusion tensor sequence takes 10 minutes to acquire, for a total examination time of 30 minutes instead of 20 minutes, including set-up.", "armGroupLabels": ["Patients with symptoms compatible with possible endometriosis"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "At least one measurable parameter (yes/no) on tractography in patients with or without endometriosis.", "description": "Evaluate the ability of the diffusion tensor sequence to visualize normal or pathological pelvic nerve plexuses (hypogastric and sciatic) in pelvic endometriosis. These parameters will be measured on MRI tractography images.", "timeFrame": "3 months"}, {"measure": "Proportion of patients with at least one relevant parameter evaluated by MRI-based tractography, in patients with or without endometriosis", "description": "Number of patients (with or without endometriosis) in whom at least one parameter could be evaluated, divided by the total number of patients (with or without endometriosis) who attended an MRI-based tractography.\n\nParameters expected to be evaluable with MRI-based tractography:\n\n* total volume\n* lengths\n* number of branches\n* tortuosity MRI will be exploited by independant readers, blinded from patients'clinical characteristics and diagnosis", "timeFrame": "Between 7 and 60 days after inclusion"}], "secondaryOutcomes": [{"measure": "Proportion of patients with an individual relevant parameter evaluated by MRI-based tractography, in patients with or without endometriosis", "description": "Number of patients (with or without endometriosis) in whom the individual parameter could be evaluated, divided by the total number of patients (with or without endometriosis) who attended an MRI-based tractography.\n\nIndividual parameters expected to be evaluable with MRI-based tractography:\n\n* total volume\n* lengths\n* number of branches\n* tortuosity", "timeFrame": "Between 7 and 60 days after inclusion"}, {"measure": "Total volume evaluated by MRI-based tractography", "description": "MRI stands for \"Magnetic Resonance Imaging\".\n\nIn patients with vs without endometriosis: comparisons between patients with vs without endometriosis.\n\nIn patients with endometriosis: comparisons according to (i) presence of endometriosis lesions (yes vs no), (ii) pain type (neuropathic vs other), (iii) endometriosis phenotype (endometriom vs deep endometriosis), (iv) localisation of lesions (pelvic wall vs sacro-rectus-genitourinary blade vs iliac incisure), all subgroups evaluated at inclusion.", "timeFrame": "Between 7 and 60 days after inclusion"}, {"measure": "Length of branches evaluated by MRI-based tractography.", "description": "MRI stands for \"Magnetic Resonance Imaging\".\n\nIn patients with vs without endometriosis: comparisons between patients with vs without endometriosis.\n\nIn patients with endometriosis: comparisons according to (i) presence of endometriosis lesions (yes vs no), (ii) pain type (neuropathic vs other), (iii) endometriosis phenotype (endometriom vs deep endometriosis), (iv) localisation of lesions (pelvic wall vs sacro-rectus-genitourinary blade vs iliac incisure), all subgroups evaluated at inclusion.", "timeFrame": "Between 7 and 60 days after inclusion"}, {"measure": "Number of branches evaluated by MRI-based tractography.", "description": "MRI stands for \"Magnetic Resonance Imaging\".\n\nIn patients with vs without endometriosis: comparisons between patients with vs without endometriosis.\n\nIn patients with endometriosis: comparisons according to (i) presence of endometriosis lesions (yes vs no), (ii) pain type (neuropathic vs other), (iii) endometriosis phenotype (endometriom vs deep endometriosis), (iv) localisation of lesions (pelvic wall vs sacro-rectus-genitourinary blade vs iliac incisure), all subgroups evaluated at inclusion.", "timeFrame": "Between 7 and 60 days after inclusion"}, {"measure": "Tortuosity evaluated by MRI-based tractography.", "description": "MRI stands for \"Magnetic Resonance Imaging\".\n\nIn patients with vs without endometriosis: comparisons between patients with vs without endometriosis.\n\nIn patients with endometriosis: comparisons according to (i) presence of endometriosis lesions (yes vs no), (ii) pain type (neuropathic vs other), (iii) endometriosis phenotype (endometriom vs deep endometriosis), (iv) localisation of lesions (pelvic wall vs sacro-rectus-genitourinary blade vs iliac incisure), all subgroups evaluated at inclusion.", "timeFrame": "Between 7 and 60 days after inclusion"}, {"measure": "Proportion of patients with nerve lesions, in patients with endometriosis", "description": "Qualitative assessment of the presence of\n\n* localised lesions\n* diffuse lesions along the plexus", "timeFrame": "Baseline"}, {"measure": "Inter-reader reproductibilty of nerve lesions, in patients with endometriosis", "description": "Cohen's Kappa for reproducibility between 2 readers who performed the qualitative assessment of the presence of\n\n* localised lesions\n* diffuse lesions along the plexus", "timeFrame": "Baseline"}, {"measure": "Fractional Anisotropy, in patients with vs without endometriosis", "description": "Comparisons between patients with vs without endometriosis.\n\nIndividual parameters :\n\n* mean diffusity\n* axial diffusity\n* radial diffusity", "timeFrame": "Between 7 and 60 days after inclusion"}, {"measure": "Scores at EHP5 Quality of Life questionnaires, in patients with endometriosis", "description": "EHP-5 stands for \"Endometriosis Health Profiles in 5 items\". The higher the worse between 0 and 100.\n\nSum of answer at each item divided by the number of answered items. Individual item of the EHP-5.", "timeFrame": "Baseline"}, {"measure": "Scores at EHP30 Quality of Life questionnaires, in patients with endometriosis", "description": "EHP-30 stands for \"Endometriosis Health Profiles in 30 core-items\". The higher the worse between 0 and 100.\n\nSum of score at each scale divided by the number of answered scales. Individual score at each scale of the EHP-30.", "timeFrame": "Baseline"}, {"measure": "DN4-based and visual analog scale for pain assessment, in patients with endometriosis", "description": "DN4 stands for \" Douleur Neuropathique en 4 questions \" or \" Neuropathic pain in 4 questions \". The higher the worse between 0 and 10.\n\nVAS stands for \"Visual Analog Scale\". The higher the worse between 0 and 10. Score at each part of DN4 pain questionnaire.\n\nScore at part 4 on deep pain augmented by 3 items: (i) search for sensation of vice, tightness, heaviness, (ii) search for sensation of digestive or bladder spasm, (iii) pelvic floor muscle tension Individual item of DN4 pain questionnaire. Individual VAS assessing the maximum pain in the 3 months preceding the MRI, on :\n\n* dysmenorrhea\n* deep dyspareunia\n* non-cyclic chronic pelvic pains\n* digestive pains\n* urinary pains", "timeFrame": "Baseline"}, {"measure": "VAS for pain assessement at the end of MRI-based diffusion tensor sequence, in patients with vs without endometriosis", "description": "VAS stands for \"Visual Analog Scale\". The higher the worse between 0 and 10.\n\nMRI stands for \"Magnetic Resonance Imaging\".", "timeFrame": "Between 7 and 60 days after inclusion"}, {"measure": "Total examination duration and MRI-based sequence acquisition duration, in patients with vs without endometriosis", "timeFrame": "Between 7 and 60 days after inclusion"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Women aged ≥ 18 years\n* Non-menopausal (menopause defined as absence of menstrual periods for 12 consecutive months)\n* Referred to the department for clinical suspicion of endometriosis on questioning Or known endometriosis\n* Requiring specialized MRI by a specialist in endometriosis and adenomyosis imaging for diagnosis or follow-up of endometriosis.\n* Patient affiliated to social security\n* Patient with signed informed consent\n* Patient with a good understanding of the French language\n\nExclusion Criteria:\n\n* Pregnant or breast-feeding women\n* Contraindication to MRI: ocular metallic foreign body, pacemaker, mechanical heart valve, old vascular clips on cerebral aneurysm;\n* Claustrophobic patients\n* Contraindication to glucagen injection (anti-peristaltic);\n* Previous pelvic surgery;\n* Patient having participated in a therapeutic clinical trial involving a new molecule within 30 days prior to inclusion;\n* suffering from a severe chronic disease (cancer, HIV, renal failure, ongoing liver or biliary disorders, chronic inflammatory digestive disease, arthritis or other chronic respiratory disorders) or gastrointestinal disorders deemed incompatible with the conduct of the study by the investigator;\n* Vulnerable patients (legal protection, guardianship, curatorship);\n* Patients receiving State Medical Aid.", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "90 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Cléo Bourgeois", "role": "CONTACT", "phone": "0156095638", "phoneExt": "+33", "email": "cleo.bourgeois@aphp.fr"}], "overallOfficials": [{"name": "Louis Marcellin", "affiliation": "Assistance Publique - Hôpitaux de Paris", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "C01 - Cochin Port Royal", "city": "Paris", "zip": "75014", "country": "France", "contacts": [{"name": "Louis Marcellin", "role": "CONTACT", "phone": "0158413661", "phoneExt": "+33", "email": "louis.marcellin@aphp.fr"}, {"name": "Louis Marcellin", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 48.85341, "lon": 2.3488}}, {"facility": "C02-HEGP gynecology", "city": "Paris", "zip": "75015", "country": "France", "contacts": [{"name": "Anne-Sophie Bats", "role": "CONTACT", "phone": "0156093586", "phoneExt": "+33", "email": "anne-sophie.bats@aphp.fr"}, {"name": "Anne-Sophie Bats", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 48.85341, "lon": 2.3488}}, {"facility": "C03- HEGP radiology", "city": "Paris", "zip": "75015", "country": "France", "contacts": [{"name": "Laure Fournier", "role": "CONTACT", "phone": "0156093851", "email": "laure.fournier@aphp.fr"}, {"name": "Laure Fournier", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 48.85341, "lon": 2.3488}}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Individual participant data (IPD) that underlie results in publication could be shared. IPD detailed in the protocol of a planned metaanalysis could be shared", "infoTypes": ["STUDY_PROTOCOL", "ICF"], "timeFrame": "Two years after the last publication", "accessCriteria": "Data sharing must be accepted by the sponsor and the PI based on a scientific project and scientific involvement of the PI team. Collaboration will be fostered. The founder could be involved in the decision. Teams wishing obtain IPD must meet the sponsor and IP team to present scientifics (and commercial) purpose, IPD needed, format of data transmission, and timeframe. Technical feasibility and financial support will be discussed before mandatory contractualization. Processing of shared data must comply with European General Data Protection Regulation (GDPR)."}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT01581359", "orgStudyIdInfo": {"id": "ENDOFIV-010"}, "secondaryIdInfos": [{"id": "2010-022216-39", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Instituto de Investigacion Sanitaria La Fe", "class": "OTHER"}, "briefTitle": "The Effect of Pre-treatment With GnRH Analogues Prior in Vitro Fertilization in Patients With Endometriosis", "officialTitle": "A Comparative Study, Randomized, Blinded, About the Effect of Pre-treatment With GnRH Analogues Versus Placebo in Infertile Patients With Endometriosis Undergoing in Vitro Fertilization Treatment", "acronym": "ENDOFIV"}, "statusModule": {"statusVerifiedDate": "2014-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-03"}, "primaryCompletionDateStruct": {"date": "2015-03", "type": "ACTUAL"}, "completionDateStruct": {"date": "2015-05", "type": "ACTUAL"}, "studyFirstSubmitDate": "2012-03-20", "studyFirstSubmitQcDate": "2012-04-18", "studyFirstPostDateStruct": {"date": "2012-04-20", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-10-21", "lastUpdatePostDateStruct": {"date": "2015-10-22", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Instituto de Investigacion Sanitaria La Fe", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The purpose of this study is to determine whether the administration of an analogue of gonadotropin-releasing hormone (GnRH) during the three months prior to the performing of an IVF may improve the response to ovarian stimulation, implantation rate and clinical pregnancy rate in patients with endometriosis/ endometriomas.", "detailedDescription": "Endometriosis is defined as the presence of ectopic endometrial tissue which induces a local inflammatory reaction. Usually, this tissue is located at any level in the pelvic region, but extrapelvic locations have been described. It is a chronic disease whose cause is unknown, although a genetic predisposition has been proven. It is estimated that endometriosis affects 7-15% of women of fertile age, and up to 30-40% of women with endometriosis have infertility.\n\nAssisted reproduction techniques (ART) are the treatment of many causes of infertility, including endometriosis. The results of assisted reproduction in women with endometriosis appear to be somewhat worse than those obtained from women without endometriosis. Some authors have proven a significant reduction in implantation and pregnancy rates in these patients.\n\nThe worst pregnancy rate and implantation is believed to be originated in a poor oocyte quality, which can lead to a lower rate of fertilization. This poor oocyte quality produce poorer quality embryos with a reduced capacity to implant, particularly in severe endometriosis.\n\nOn the other hand, endometrial receptivity does not appear to contribute to the reduction of results of ART in these women.\n\nIn an attempt to improve ART outcomes in women with endometriosis, different strategies have been proposed prior to the cycle realization, with different results.\n\nSurgical resection of endometriomas (endometriosis cysts) before the cycle of IVF/ICSI may adversely affect the results. On the other hand, careful laparoscopic cystectomy appears not to affect the ovarian response to stimulation.\n\nIn addition to surgical approaches, have been tried different medical treatments to improve the results of IVF / intracytoplasmatic sperm injection (ICSI) in women with endometriosis. It has been suggested that treatment with Danazol prior to IVF may improve results. Similarly, prolonged treatment with GnRH analogues few months before IVF could improve the implantation and pregnancy rates. Unfortunately, many of these studies were not randomized and / or controlled so that the true value of therapy with GnRH analogues before IVF in women with endometriosis still needs to be valued. A recent meta-analysis showed that a 3-6 month treatment with GnRH analogues before IVF increased 4 times the odds of clinical pregnancy in women with endometriosis. Nevertheless, these results were concluded from 165 patients and 78 pregnancies, included in 3 clinical trials, which was not specifically to patients with endometriomas.\n\nThe lack of studies with proper design, suggests that there is insufficient evidence at present to establish firm recommendations in this regard. This study will contribute to increasing scientific evidence to recommend or not pretreatment with GnRH agonists before IVF en patients with endometriosis."}, "conditionsModule": {"conditions": ["Endometriosis", "Infertility"], "keywords": ["Endometriosis", "GnRH treatment", "Infertility", "IVF"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 200, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "GnRHa", "type": "ACTIVE_COMPARATOR", "description": "Triptorelin acetate 3,75 mg subcutaneous injection administered on days 1, 28 and 56 after menstrual cycle.", "interventionNames": ["Drug: Triptorelin acetate"]}, {"label": "Physiological serum", "type": "PLACEBO_COMPARATOR", "description": "physiological serum subcutaneous injection with same delivery device and same volume that active comparator ) administered on days 1, 28 and 56 after menstrual cycle.", "interventionNames": ["Drug: Triptorelin acetate"]}], "interventions": [{"type": "DRUG", "name": "Triptorelin acetate", "description": "* Triptorelin acetate Dosing regimen: 1 subcutaneous injection of 3,75 mg/28 days, total of 3 doses\n* Placebo Dosing regimen: subcutaneous injection of the same volume of physiological serum/28 days, total of 3 doses", "armGroupLabels": ["GnRHa", "Physiological serum"], "otherNames": ["Gonapeptyl Depot 3,75"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Clinical pregnancy rate by started cycle", "description": "Number of pregnancies with fetal hearth beat on ultrasound exam divided by total number of started cycle", "timeFrame": "2 weeks after biochemical diagnosis of pregnancy"}], "secondaryOutcomes": [{"measure": "Number of oocytes retrieved, total and metaphase II", "timeFrame": "In the moment of oocyte retrieval"}, {"measure": "Embryo quality", "description": "* A Class: high quality; 4 equal cells, \\<11% fragmentation, display no irregularities (vacuoles and multinucleation) and normal zona pellucida.\n* B Class: good quality; 2 or 5 cells and \\<26% fragmentation or 4 cells and 12-25% fragmentation, same or similar size (cells even number), display no irregularities and normal zona pellucida.\n* C Class: intermediate quality; no multinucleation , 3 or 6 cells with \\<36% fragmentation or 2, 4 and 5 cells with 25-35% fragmentation or inequal size blastomeres or absence/low vacuoles cells or anormal zona pellucida.", "timeFrame": "Two-three days after oocyte recovery and IVF"}, {"measure": "Number and size of endometrioma(s)", "description": "Total number in each ovary, uni or bilateral cysts and maximum diameter (mm) of the biggest endometrioma", "timeFrame": "Day of the Basal ultrasound"}, {"measure": "Rate of pregnancy to term in patients with endometriosis / endometriomas", "description": "Number of deliveries at 37th to 41st weeks of pregnancy divided by total number of pregnancies", "timeFrame": "37 weeks after cycle"}, {"measure": "Miscarriage rate", "description": "Number of pregnancy losses divided by total number clinical pregnancies", "timeFrame": "22nd week of pregnancy"}, {"measure": "Rate of healthy and live births", "description": "Number of healthy and live births divided by total number of started cycle", "timeFrame": "37th to 41st weeks of pregnancy"}, {"measure": "Fertilization rate", "description": "Number of cleavage embryos divided by total number of metaphase II oocytes", "timeFrame": "Two days after oocyte recovery and IVF"}, {"measure": "Total dose of gonadotropins and days of treatment", "description": "Total dose of gonadotropins in IU, and total days on treatment", "timeFrame": "Day of the administration of human chorionic gonadotropin (hCG)"}, {"measure": "Cancellation rate and causes", "description": "Number of cancelled cycles divided by total number or started cycles", "timeFrame": "Last day of gonadotropin treatment"}, {"measure": "Ovarian Hyperstimulation Syndrome (OHSS) incidence", "description": "Number of patients diagnosed of OHSS divided by ended cycles. Classification in mild, moderate and severe", "timeFrame": "One month after hCG"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Infertile women with endometriosis diagnosed by surgery in the previous year to their inclusion in the study with signs of residual disease and/or by the existence of ovarian endometrioma in vaginal ecography who are susceptible to IVF treatment.\n* BMI \\< 28 Kg/m2\n* Age \\< 40 years old\n* Signed informed consent to perform IVF and participation in this study\n\nExclusion Criteria:\n\n* Follicle stimulating hormone (FSH) 2nd-5th cycle day \\> 12 IU/L\n* Liver disease (sALAT\\> 80 IU/L)\n* Kidney disease (creatinine \\> 130 nmol/L)\n* Other relevant disease that contraindicates a pregnancy", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "40 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "ANA Mª MONZÓ, MD, PhD", "affiliation": "Hospital Universitario La Fe", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Human Reproduction Unit of the La Fe University and Politechnic Hospital", "city": "Valencia", "state": "Valencia", "zip": "46026", "country": "Spain", "geoPoint": {"lat": 39.47391, "lon": -0.37966}}]}, "referencesModule": {"references": [{"pmid": "3091408", "type": "BACKGROUND", "citation": "Matson PL, Yovich JL. The treatment of infertility associated with endometriosis by in vitro fertilization. Fertil Steril. 1986 Sep;46(3):432-4. doi: 10.1016/s0015-0282(16)49581-6."}, {"pmid": "8046030", "type": "BACKGROUND", "citation": "Simon C, Gutierrez A, Vidal A, de los Santos MJ, Tarin JJ, Remohi J, Pellicer A. Outcome of patients with endometriosis in assisted reproduction: results from in-vitro fertilization and oocyte donation. Hum Reprod. 1994 Apr;9(4):725-9. doi: 10.1093/oxfordjournals.humrep.a138578."}, {"pmid": "8774295", "type": "BACKGROUND", "citation": "Arici A, Oral E, Bukulmez O, Duleba A, Olive DL, Jones EE. The effect of endometriosis on implantation: results from the Yale University in vitro fertilization and embryo transfer program. Fertil Steril. 1996 Mar;65(3):603-7. doi: 10.1016/s0015-0282(16)58162-x."}, {"pmid": "9447453", "type": "BACKGROUND", "citation": "Cahill DJ, Wardle PG, Maile LA, Harlow CR, Hull MG. Ovarian dysfunction in endometriosis-associated and unexplained infertility. J Assist Reprod Genet. 1997 Nov;14(10):554-7. doi: 10.1023/a:1022568331845."}, {"pmid": "1442943", "type": "BACKGROUND", "citation": "Inoue M, Kobayashi Y, Honda I, Awaji H, Fujii A. The impact of endometriosis on the reproductive outcome of infertile patients. Am J Obstet Gynecol. 1992 Jul;167(1):278-82. doi: 10.1016/s0002-9378(11)91675-5."}, {"pmid": "7851586", "type": "BACKGROUND", "citation": "Dmowski WP, Rana N, Michalowska J, Friberg J, Papierniak C, el-Roeiy A. The effect of endometriosis, its stage and activity, and of autoantibodies on in vitro fertilization and embryo transfer success rates. Fertil Steril. 1995 Mar;63(3):555-62. doi: 10.1016/s0015-0282(16)57425-1."}, {"pmid": "7615119", "type": "BACKGROUND", "citation": "Olivennes F, Feldberg D, Liu HC, Cohen J, Moy F, Rosenwaks Z. Endometriosis: a stage by stage analysis--the role of in vitro fertilization. Fertil Steril. 1995 Aug;64(2):392-8. doi: 10.1016/s0015-0282(16)57740-1."}, {"pmid": "7618453", "type": "BACKGROUND", "citation": "Tanbo T, Omland A, Dale PO, Abyholm T. In vitro fertilization/embryo transfer in unexplained infertility and minimal peritoneal endometriosis. Acta Obstet Gynecol Scand. 1995 Aug;74(7):539-43. doi: 10.3109/00016349509024386."}, {"pmid": "9154777", "type": "BACKGROUND", "citation": "Huang HY, Lee CL, Lai YM, Chang MY, Chang SY, Soong YK. The outcome of in vitro fertilization and embryo transfer therapy in women with endometriosis failing to conceive after laparoscopic conservative surgery. J Am Assoc Gynecol Laparosc. 1997 May;4(3):299-303. doi: 10.1016/s1074-3804(05)80219-1."}, {"pmid": "12418061", "type": "BACKGROUND", "citation": "Hickman TN. Impact of endometriosis on implantation. Data from the Wilford Hall Medical Center IVF-ET Program. J Reprod Med. 2002 Oct;47(10):801-8."}, {"pmid": "12057720", "type": "BACKGROUND", "citation": "Barnhart K, Dunsmoor-Su R, Coutifaris C. Effect of endometriosis on in vitro fertilization. Fertil Steril. 2002 Jun;77(6):1148-55. doi: 10.1016/s0015-0282(02)03112-6."}, {"pmid": "2862417", "type": "BACKGROUND", "citation": "Wardle PG, Mitchell JD, McLaughlin EA, Ray BD, McDermott A, Hull MG. Endometriosis and ovulatory disorder: reduced fertilisation in vitro compared with tubal and unexplained infertility. Lancet. 1985 Aug 3;2(8449):236-9. doi: 10.1016/s0140-6736(85)90289-2."}, {"pmid": "9740433", "type": "BACKGROUND", "citation": "Hull MG, Williams JA, Ray B, McLaughlin EA, Akande VA, Ford WC. The contribution of subtle oocyte or sperm dysfunction affecting fertilization in endometriosis-associated or unexplained infertility: a controlled comparison with tubal infertility and use of donor spermatozoa. Hum Reprod. 1998 Jul;13(7):1825-30. doi: 10.1093/humrep/13.7.1825."}, {"pmid": "9822979", "type": "BACKGROUND", "citation": "Bergendal A, Naffah S, Nagy C, Bergqvist A, Sjoblom P, Hillensjo T. Outcome of IVF in patients with endometriosis in comparison with tubal-factor infertility. J Assist Reprod Genet. 1998 Oct;15(9):530-4. doi: 10.1023/a:1022526002421."}, {"pmid": "9493063", "type": "BACKGROUND", "citation": "Pal L, Shifren JL, Isaacson KB, Chang Y, Leykin L, Toth TL. Impact of varying stages of endometriosis on the outcome of in vitro fertilization-embryo transfer. J Assist Reprod Genet. 1998 Jan;15(1):27-31. doi: 10.1023/a:1022574221115."}, {"pmid": "11808845", "type": "BACKGROUND", "citation": "Norenstedt SN, Linderoth-Nagy C, Bergendal A, Sjoblom P, Bergqvist A. Reduced developmental potential in oocytes from women with endometriosis. J Assist Reprod Genet. 2001 Dec;18(12):644-9. doi: 10.1023/a:1013111200251."}, {"pmid": "2863700", "type": "BACKGROUND", "citation": "O'Shea RT, Chen C, Weiss T, Jones WR. Endometriosis and in-vitro fertilisation. Lancet. 1985 Sep 28;2(8457):723. doi: 10.1016/s0140-6736(85)92957-5. No abstract available."}, {"pmid": "2863565", "type": "BACKGROUND", "citation": "Yovich JL, Yovich JM, Tuvik AI, Matson PL, Willcox DL. In-vitro fertilisation for endometriosis. Lancet. 1985 Sep 7;2(8454):552. doi: 10.1016/s0140-6736(85)90485-4. No abstract available."}, {"pmid": "10711831", "type": "BACKGROUND", "citation": "Garrido N, Navarro J, Remohi J, Simon C, Pellicer A. Follicular hormonal environment and embryo quality in women with endometriosis. Hum Reprod Update. 2000 Jan-Feb;6(1):67-74. doi: 10.1093/humupd/6.1.67."}, {"pmid": "9627305", "type": "BACKGROUND", "citation": "Pellicer A, Valbuena D, Bauset C, Albert C, Bonilla-Musoles F, Remohi J, Simon C. The follicular endocrine environment in stimulated cycles of women with endometriosis: steroid levels and embryo quality. Fertil Steril. 1998 Jun;69(6):1135-41. doi: 10.1016/s0015-0282(98)00085-5."}, {"pmid": "9757870", "type": "BACKGROUND", "citation": "Pellicer A, Albert C, Mercader A, Bonilla-Musoles F, Remohi J, Simon C. The follicular and endocrine environment in women with endometriosis: local and systemic cytokine production. Fertil Steril. 1998 Sep;70(3):425-31. doi: 10.1016/s0015-0282(98)00204-0."}, {"pmid": "11885559", "type": "BACKGROUND", "citation": "Smith MP, Keay SD, Margo FC, Harlow CR, Wood PJ, Cahill DJ, Hull MG. Total cortisol levels are reduced in the periovulatory follicle of infertile women with minimal-mild endometriosis. Am J Reprod Immunol. 2002 Jan;47(1):52-6. doi: 10.1034/j.1600-0897.2002.1o122.x."}, {"pmid": "12571183", "type": "BACKGROUND", "citation": "Cunha-Filho JS, Lemos NA, Freitas FM, Kiefer K, Faller M, Passos EP. Insulin-like growth factor (IGF)-1 and IGF binding protein-1 and -3 in the follicular fluid of infertile patients with endometriosis. Hum Reprod. 2003 Feb;18(2):423-8. doi: 10.1093/humrep/deg077."}, {"pmid": "10831550", "type": "BACKGROUND", "citation": "Carlberg M, Nejaty J, Froysa B, Guan Y, Soder O, Bergqvist A. Elevated expression of tumour necrosis factor alpha in cultured granulosa cells from women with endometriosis. Hum Reprod. 2000 Jun;15(6):1250-5. doi: 10.1093/humrep/15.6.1250."}, {"pmid": "9591505", "type": "BACKGROUND", "citation": "Nakahara K, Saito H, Saito T, Ito M, Ohta N, Takahashi T, Hiroi M. Ovarian fecundity in patients with endometriosis can be estimated by the incidence of apoptotic bodies. Fertil Steril. 1998 May;69(5):931-5. doi: 10.1016/s0015-0282(98)00038-7."}, {"pmid": "10685541", "type": "BACKGROUND", "citation": "Toya M, Saito H, Ohta N, Saito T, Kaneko T, Hiroi M. Moderate and severe endometriosis is associated with alterations in the cell cycle of granulosa cells in patients undergoing in vitro fertilization and embryo transfer. Fertil Steril. 2000 Feb;73(2):344-50. doi: 10.1016/s0015-0282(99)00507-5."}, {"pmid": "9090558", "type": "BACKGROUND", "citation": "Sung L, Mukherjee T, Takeshige T, Bustillo M, Copperman AB. Endometriosis is not detrimental to embryo implantation in oocyte recipients. J Assist Reprod Genet. 1997 Mar;14(3):152-6. doi: 10.1007/BF02766132."}, {"pmid": "8745306", "type": "BACKGROUND", "citation": "Pellicer A, Oliveira N, Ruiz A, Remohi J, Simon C. Exploring the mechanism(s) of endometriosis-related infertility: an analysis of embryo development and implantation in assisted reproduction. Hum Reprod. 1995 Dec;10 Suppl 2:91-7. doi: 10.1093/humrep/10.suppl_2.91."}, {"pmid": "12484492", "type": "BACKGROUND", "citation": "Ho HY, Lee RK, Hwu YM, Lin MH, Su JT, Tsai YC. Poor response of ovaries with endometrioma previously treated with cystectomy to controlled ovarian hyperstimulation. J Assist Reprod Genet. 2002 Nov;19(11):507-11. doi: 10.1023/a:1020970417778."}, {"pmid": "12592242", "type": "BACKGROUND", "citation": "Aboulghar MA, Mansour RT, Serour GI, Al-Inany HG, Aboulghar MM. The outcome of in vitro fertilization in advanced endometriosis with previous surgery: a case-controlled study. Am J Obstet Gynecol. 2003 Feb;188(2):371-5. doi: 10.1067/mob.2003.13."}, {"pmid": "11726578", "type": "BACKGROUND", "citation": "Canis M, Pouly JL, Tamburro S, Mage G, Wattiez A, Bruhat MA. Ovarian response during IVF-embryo transfer cycles after laparoscopic ovarian cystectomy for endometriotic cysts of >3 cm in diameter. Hum Reprod. 2001 Dec;16(12):2583-6. doi: 10.1093/humrep/16.12.2583."}, {"pmid": "12372472", "type": "BACKGROUND", "citation": "Marconi G, Vilela M, Quintana R, Sueldo C. Laparoscopic ovarian cystectomy of endometriomas does not affect the ovarian response to gonadotropin stimulation. Fertil Steril. 2002 Oct;78(4):876-8. doi: 10.1016/s0015-0282(02)03326-5."}, {"pmid": "11591395", "type": "BACKGROUND", "citation": "Donnez J, Wyns C, Nisolle M. Does ovarian surgery for endometriomas impair the ovarian response to gonadotropin? Fertil Steril. 2001 Oct;76(4):662-5. doi: 10.1016/s0015-0282(01)02011-8."}, {"pmid": "12821063", "type": "BACKGROUND", "citation": "Wyns C, Donnez J. [Laser vaporization of ovarian endometriomas: the impact on the response to gonadotrophin stimulation]. Gynecol Obstet Fertil. 2003 Apr;31(4):337-42. doi: 10.1016/s1297-9589(03)00069-9. French."}, {"pmid": "15136074", "type": "BACKGROUND", "citation": "Garcia-Velasco JA, Mahutte NG, Corona J, Zuniga V, Giles J, Arici A, Pellicer A. Removal of endometriomas before in vitro fertilization does not improve fertility outcomes: a matched, case-control study. Fertil Steril. 2004 May;81(5):1194-7. doi: 10.1016/j.fertnstert.2003.04.006."}, {"pmid": "1757743", "type": "BACKGROUND", "citation": "Dicker D, Goldman JA, Feldberg D, Ashkenazi J, Levy T. Transvaginal ultrasonic needle-guided aspiration of endometriotic cysts before ovulation induction for in vitro fertilization. J In Vitro Fert Embryo Transf. 1991 Oct;8(5):286-9. doi: 10.1007/BF01139786."}, {"pmid": "12441659", "type": "BACKGROUND", "citation": "Suganuma N, Wakahara Y, Ishida D, Asano M, Kitagawa T, Katsumata Y, Moriwaki T, Furuhashi M. Pretreatment for ovarian endometrial cyst before in vitro fertilization. Gynecol Obstet Invest. 2002;54 Suppl 1:36-40; discussion 41-2. doi: 10.1159/000066293."}, {"pmid": "8495784", "type": "BACKGROUND", "citation": "Dicker D, Ashkenazi J, Feldberg D, Levy T, Dekel A, Ben-Rafael Z. Severe abdominal complications after transvaginal ultrasonographically guided retrieval of oocytes for in vitro fertilization and embryo transfer. Fertil Steril. 1993 Jun;59(6):1313-5. doi: 10.1016/s0015-0282(16)55997-4."}, {"pmid": "7836533", "type": "BACKGROUND", "citation": "Yaron Y, Peyser MR, Samuel D, Amit A, Lessing JB. Infected endometriotic cysts secondary to oocyte aspiration for in-vitro fertilization. Hum Reprod. 1994 Sep;9(9):1759-60. doi: 10.1093/oxfordjournals.humrep.a138789."}, {"pmid": "7593536", "type": "BACKGROUND", "citation": "Nargund G, Parsons J. Infected endometriotic cysts secondary to oocyte aspiration for in-vitro fertilization. Hum Reprod. 1995 Jun;10(6):1555. doi: 10.1093/humrep/10.6.1555-a. No abstract available."}, {"pmid": "9226514", "type": "BACKGROUND", "citation": "Younis JS, Ezra Y, Laufer N, Ohel G. Late manifestation of pelvic abscess following oocyte retrieval, for in vitro fertilization, in patients with severe endometriosis and ovarian endometriomata. J Assist Reprod Genet. 1997 Jul;14(6):343-6. doi: 10.1007/BF02765839."}, {"pmid": "9830238", "type": "BACKGROUND", "citation": "Wei CF, Chen SC. Pelvic abscess after ultrasound-guided aspiration of endometrioma: a case report. Zhonghua Yi Xue Za Zhi (Taipei). 1998 Oct;61(10):603-7."}, {"pmid": "9392913", "type": "BACKGROUND", "citation": "Kim CH, Chae HD, Kang BM, Chang YS, Mok JE. The immunotherapy during in vitro fertilization and embryo transfer cycles in infertile patients with endometriosis. J Obstet Gynaecol Res. 1997 Oct;23(5):463-70. doi: 10.1111/j.1447-0756.1997.tb00874.x."}, {"pmid": "9653702", "type": "BACKGROUND", "citation": "Tei C, Miyazaki T, Kuji N, Tanaka M, Sueoka K, Yoshimura Y. Effect of danazol on the pregnancy rate in patients with unsuccessful in vitro fertilization-embryo transfer. J Reprod Med. 1998 Jun;43(6):541-6."}, {"pmid": "2507576", "type": "BACKGROUND", "citation": "Oehninger S, Brzyski RG, Muasher SJ, Acosta AA, Jones GS. In-vitro fertilization and embryo transfer in patients with endometriosis: impact of a gonadotrophin releasing hormone agonist. Hum Reprod. 1989 Jul;4(5):541-4. doi: 10.1093/oxfordjournals.humrep.a136941."}, {"pmid": "2113929", "type": "BACKGROUND", "citation": "Dicker D, Goldman GA, Ashkenazi J, Feldberg D, Voliovitz I, Goldman JA. The value of pre-treatment with gonadotrophin releasing hormone (GnRH) analogue in IVF-ET therapy of severe endometriosis. Hum Reprod. 1990 May;5(4):418-20. doi: 10.1093/oxfordjournals.humrep.a137114."}, {"pmid": "2116489", "type": "BACKGROUND", "citation": "Dale PO, Tanbo T, Abyholm T. Endometriosis-associated infertility treated by long-term gonadotropin-releasing hormone agonist administration and assisted fertilization. J In Vitro Fert Embryo Transf. 1990 Jun;7(3):180-1. doi: 10.1007/BF01135686."}, {"pmid": "1627925", "type": "BACKGROUND", "citation": "Nakamura K, Oosawa M, Kondou I, Inagaki S, Shibata H, Narita O, Suganuma N, Tomoda Y. Menotropin stimulation after prolonged gonadotropin releasing hormone agonist pretreatment for in vitro fertilization in patients with endometriosis. J Assist Reprod Genet. 1992 Apr;9(2):113-7. doi: 10.1007/BF01203749."}, {"pmid": "8163038", "type": "BACKGROUND", "citation": "Curtis P, Jackson A, Bernard A, Shaw RW. Pretreatment with gonadotrophin releasing hormone (GnRH) analogue prior to in vitro fertilisation for patients with endometriosis. Eur J Obstet Gynecol Reprod Biol. 1993 Dec 30;52(3):211-6. doi: 10.1016/0028-2243(93)90074-m."}, {"pmid": "8092234", "type": "BACKGROUND", "citation": "Marcus SF, Edwards RG. High rates of pregnancy after long-term down-regulation of women with severe endometriosis. Am J Obstet Gynecol. 1994 Sep;171(3):812-7. doi: 10.1016/0002-9378(94)90103-1."}, {"pmid": "8530675", "type": "BACKGROUND", "citation": "Chedid S, Camus M, Smitz J, Van Steirteghem AC, Devroey P. Comparison among different ovarian stimulation regimens for assisted procreation procedures in patients with endometriosis. Hum Reprod. 1995 Sep;10(9):2406-11. doi: 10.1093/oxfordjournals.humrep.a136308."}, {"pmid": "9532465", "type": "BACKGROUND", "citation": "Ruiz-Velasco V, Allende S. Goserelin followed by assisted reproduction: results in infertile women with endometriosis. Int J Fertil Womens Med. 1998 Jan-Feb;43(1):18-23."}, {"pmid": "16437491", "type": "BACKGROUND", "citation": "Sallam HN, Garcia-Velasco JA, Dias S, Arici A. Long-term pituitary down-regulation before in vitro fertilization (IVF) for women with endometriosis. Cochrane Database Syst Rev. 2006 Jan 25;2006(1):CD004635. doi: 10.1002/14651858.CD004635.pub2."}]}}, "annotationSection": {"annotationModule": {"unpostedAnnotation": {"unpostedResponsibleParty": "Instituto de Investigacion Sanitaria La Fe", "unpostedEvents": [{"type": "RELEASE", "date": "2020-08-19"}, {"type": "RESET", "date": "2020-09-04"}]}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04", "submissionTracking": {"estimatedResultsFirstSubmitDate": "2020-08-19", "submissionInfos": [{"releaseDate": "2020-08-19", "resetDate": "2020-09-04"}]}}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}, {"id": "D007246", "term": "Infertility"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D017329", "term": "Triptorelin Pamoate"}], "ancestors": [{"id": "D007987", "term": "Gonadotropin-Releasing Hormone"}, {"id": "D010906", "term": "Pituitary Hormone-Releasing Hormones"}, {"id": "D007028", "term": "Hypothalamic Hormones"}, {"id": "D036361", "term": "Peptide Hormones"}, {"id": "D006728", "term": "Hormones"}, {"id": "D006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D009479", "term": "Neuropeptides"}, {"id": "D010455", "term": "Peptides"}, {"id": "D000602", "term": "Amino Acids, Peptides, and Proteins"}, {"id": "D009842", "term": "Oligopeptides"}, {"id": "D009419", "term": "Nerve Tissue Proteins"}, {"id": "D011506", "term": "Proteins"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT05619757", "orgStudyIdInfo": {"id": "69HCL22_0547"}, "organization": {"fullName": "Hospices Civils de Lyon", "class": "OTHER"}, "briefTitle": "Compliance and Endometriosis", "officialTitle": "Compliance With Medical Treatment for Endometriosis : a Cross-sectional Study"}, "statusModule": {"statusVerifiedDate": "2024-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2022-11-17", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2023-05-17", "type": "ACTUAL"}, "completionDateStruct": {"date": "2023-05-17", "type": "ACTUAL"}, "studyFirstSubmitDate": "2022-11-09", "studyFirstSubmitQcDate": "2022-11-09", "studyFirstPostDateStruct": {"date": "2022-11-17", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2024-05-17", "lastUpdatePostDateStruct": {"date": "2024-05-20", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Hospices Civils de Lyon", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "Endometriosis is defined as the presence of hormone-dependent endometrial tissue outside the uterine cavity. It is a chronic, painful and often disabling pathology during the normal activities of daily life. It affects 10% of women of childbearing age. It is therefore a real public health issue.\n\nThe latest recommendations from the HAS and the CNGOF now recommend primary medical management of endometriosis in painful women who do not wish to become pregnant. It should be remembered that until very recently, the teams resigned themselves to carrying out surgical interventions in order to support the diagnosis (this is histological and requires a biopsy) and to treat the patient if possible. Sometimes, this treatment was not possible from the outset, as the lesions appeared to be inaccessible, and additional hormonal treatment was therefore required. The current concept is to propose to patients a first hormonal suppressive treatment before a possible surgery. This therapeutic de-escalation should be considered in the light of the physiopathology of endometriosis, which is essentially based on the ovarian cycles, and indirectly on menstruation, which must then be suspended. However, a good number of patients are initially reluctant to undergo any kind of hormonal therapy, either because they have had a bad experience with hormonal contraception (intolerance) or because of a fear related to the possible complications of hormonal therapy with third or fourth generation pills, for example (thromboembolic risk). There is also a health alert at present concerning macro progestins in relation to the risk of meningioma. Acceptance of the principle of instituting amenorrhea in order to relieve patients suffering from endometriosis requires prior information. In investigator's daily practice, they frequently deplore non-compliance, which is detrimental to the proper management of the disease. The effectiveness of hormonal treatment, which will institute a quiescence of hormonal activity, is not immediate. An analgesic and anti-inflammatory treatment is then added. Investigators propose to compare the compliance of three drug strategies: analgesics alone, hormone therapy alone or hormone therapy and analgesics."}, "conditionsModule": {"conditions": ["Endometriosis"], "keywords": ["Endometriosis", "Pain", "Drug treatments", "Hormonal treatment", "Compliance", "Amenorrhea", "Recommendations", "Menstruation", "Quality of life", "Efficiency"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "OTHER", "timePerspective": "CROSS_SECTIONAL"}, "enrollmentInfo": {"count": 58, "type": "ACTUAL"}}, "armsInterventionsModule": {"interventions": [{"type": "BEHAVIORAL", "name": "Compliance with medical treatment for endometriosis", "description": "During their scheduled consultation at the Hôpital Femme Mère Enfant (HFME), women who meet the eligibility criteria will be presented with the study and given the written information note. If they agree to participate, the investigator will give them a QR code redirecting them to the online self-questionnaire.\n\nPatients will be included once they log in and complete the questionnaire."}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Compliance measured by the Morisky Medication Adherence Scales (MMAS-8).", "description": "This self-administered questionnaire validated in French has 8 items each scored 0 or 1. A high score indicates high compliance: high compliance (score = 8), average compliance (score of 6 to \\< 8) and low compliance (score \\< 6). Patients with a score greater than or equal to 6 will be considered as compliant. This questionnaire has been validated in French.", "timeFrame": "10 minutes"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Be a woman with diagnosed painful endometriosis\n* Have a prescription for medication (analgesics alone, hormone therapy alone or hormone therapy and analgesics).\n* Speak and understand French\n* Be a woman over 18 years old until menopause\n* Agree to participate in the study\n\nExclusion Criteria:\n\n\\- Be a woman who has already had surgery for endometriosis", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"], "studyPopulation": "This study will include women with painful endometriosis who have never had endometriosis surgery. In addition, patients must speak and understand French and be over 18 years old.", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"locations": [{"facility": "Service de Gynécologie-Obstétrique, Sénologie et Oncologie, Hôpital Femme Mère Enfant, Hospices Civils de Lyon", "city": "Bron", "zip": "69500", "country": "France", "geoPoint": {"lat": 45.73865, "lon": 4.91303}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}, {"id": "D010146", "term": "Pain"}, {"id": "D010349", "term": "Patient Compliance"}, {"id": "D000568", "term": "Amenorrhea"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}, {"id": "D009461", "term": "Neurologic Manifestations"}, {"id": "D012816", "term": "Signs and Symptoms"}, {"id": "D013568", "term": "Pathological Conditions, Signs and Symptoms"}, {"id": "D010342", "term": "Patient Acceptance of Health Care"}, {"id": "D000074822", "term": "Treatment Adherence and Compliance"}, {"id": "D015438", "term": "Health Behavior"}, {"id": "D001519", "term": "Behavior"}, {"id": "D008599", "term": "Menstruation Disturbances"}, {"id": "D010335", "term": "Pathologic Processes"}]}, "interventionBrowseModule": {"meshes": [{"id": "D003187", "term": "Compliance"}], "ancestors": [{"id": "D004548", "term": "Elasticity"}, {"id": "D055595", "term": "Mechanical Phenomena"}, {"id": "D055585", "term": "Physical Phenomena"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT03573336", "orgStudyIdInfo": {"id": "15792"}, "secondaryIdInfos": [{"id": "2013-004768-72", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Bayer", "class": "INDUSTRY"}, "briefTitle": "Assess Safety and Efficacy of Vilaprisan in Subjects With Endometriosis", "officialTitle": "A Randomized, Double-blind, Parallel-group, Multicenter Phase 2b Study to Assess the Efficacy and Safety of Two Different Doses of Vilaprisan (BAY1002670) Versus Placebo in Women With Symptomatic Endometriosis", "acronym": "VILLENDO"}, "statusModule": {"statusVerifiedDate": "2022-04", "overallStatus": "TERMINATED", "whyStopped": "Due to a change in the development program, the study was closed prematurely.", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2018-07-04", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2019-03-18", "type": "ACTUAL"}, "completionDateStruct": {"date": "2020-11-26", "type": "ACTUAL"}, "studyFirstSubmitDate": "2018-06-19", "studyFirstSubmitQcDate": "2018-06-19", "studyFirstPostDateStruct": {"date": "2018-06-29", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2020-12-21", "resultsFirstSubmitQcDate": "2021-01-19", "resultsFirstPostDateStruct": {"date": "2021-01-22", "type": "ACTUAL"}, "dispFirstSubmitDate": "2020-03-17", "dispFirstSubmitQcDate": "2021-01-19", "dispFirstPostDateStruct": {"date": "2021-01-22", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2022-04-13", "lastUpdatePostDateStruct": {"date": "2022-05-04", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Bayer", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false, "isUsExport": false}, "descriptionModule": {"briefSummary": "The primary objective of this study was to assess the efficacy and safety of two doses of vilaprisan compared to placebo in women with symptomatic endometriosis.\n\nThe secondary objective of this study was to evaluate the safety and tolerability of two different doses of vilaprisan in women with symptomatic endometriosis.\n\nWith the implementation of protocol version 4.0 dated 11-Dec-2018, no new subjects were enrolled. The objectives above cannot be reached as only limited data is available from subjects recruited before the temporary pause."}, "conditionsModule": {"conditions": ["Endometriosis"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 8, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Vilaprisan (BAY1002670) 2 mg", "type": "EXPERIMENTAL", "description": "Premenopausal women 18 years and older with endometriosis with randomized ratio = 1:1:1 Vilaprisan: 2 mg", "interventionNames": ["Drug: Vilaprisan (BAY1002670)"]}, {"label": "Vilaprisan (BAY1002670) 4 mg", "type": "EXPERIMENTAL", "description": "Premenopausal women 18 years and older with endometriosis with randomized ratio = 1:1:1 Vilaprisan: 4 mg", "interventionNames": ["Drug: Vilaprisan (BAY1002670)"]}, {"label": "Placebo group", "type": "PLACEBO_COMPARATOR", "description": "Premenopausal women 18 years and older with endometriosis with randomized ratio = 1:1:1", "interventionNames": ["Drug: Matching Placebo"]}], "interventions": [{"type": "DRUG", "name": "Vilaprisan (BAY1002670)", "description": "Intake orally, once daily", "armGroupLabels": ["Vilaprisan (BAY1002670) 2 mg", "Vilaprisan (BAY1002670) 4 mg"]}, {"type": "DRUG", "name": "Matching Placebo", "description": "Intake orally, once daily", "armGroupLabels": ["Placebo group"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Mean Worst Pelvic Pain (Measured on a Numerical Rating Scale [NRS], Recorded in the Daily Endometriosis Symptom Diary [ESD])", "description": "Pain intensity was assessed on 11-point (0-10) NRS by ESD item 1. In ESD item 1, participants were asked to rate the worst pain in the target area during the past 24 hours, where 0= no pain and 10= worst imaginable pain and responses were recorded in ESD. Mean 'worst pelvic pain' was calculated as the sum of the participant's daily assessments of the ESD item 1 (\"worst pain\" during the last 24 hours) during a study period divided by number of days with pain assessment in that study period. This was summarized by study period. No inferential statistical analysis was performed.", "timeFrame": "Screening period (up to a maximum of 75 days) + treatment period (up to a maximum of 168 days)"}], "secondaryOutcomes": [{"measure": "Mean Worst Pelvic Pain (Measured on a Numerical Rating Scale [NRS], Recorded in the Daily Endometriosis Symptom Diary [ESD]) on Days With/Without Vaginal Bleeding", "description": "Pain intensity was assessed on 11-point (0-10) NRS by ESD item 1. In ESD item 1, participants were asked to rate the worst pain in the target area during the past 24 hours, where 0= no pain and 10= worst imaginable pain and responses were recorded in ESD. Mean 'worst pelvic pain' on bleeding/non-bleeding days was calculated as the sum of the participant's daily assessments of the ESD item 1 (\"worst pain\" during the last 24 hours) on bleedings/non-bleeding days during a study period divided by number of bleeding/non-bleeding days with pain assessment in that study period. This was summarized by study period. No inferential statistical analysis was performed.", "timeFrame": "Screening period (up to a maximum of 75 days) + treatment period (up to a maximum of 168 days)"}, {"measure": "Mean Number of Tablets of Rescue Pain Medication 1 (Ibuprofen 200 mg) Taken Daily for Endometriosis-associated Pelvic Pain (EAPP)", "description": "Mean number of tablets of rescue pain medication 1 (Ibuprofen 200 mg) taken daily for EAPP was calculated as the sum of the tablets taken for EAPP during a study period divided by the number of days in that study period. This was summarized by study period. No inferential statistical analysis was performed.", "timeFrame": "Screening period (up to a maximum of 75 days) + treatment period (up to a maximum of 168 days)"}, {"measure": "Mean Number of Tablets of Rescue Pain Medication 2 (Tramadol 50 mg) Taken Daily for Endometriosis-associated Pelvic Pain (EAPP)", "description": "Mean number of tablets of rescue pain medication 2 (Tramadol 50 mg) taken daily for EAPP was calculated as the sum of the tablets taken for EAPP during a study period divided by the number of days in that study period. This was summarized by study period. No inferential statistical analysis was performed.", "timeFrame": "Screening period (up to a maximum of 75 days) + treatment period (up to a maximum of 168 days)"}, {"measure": "The Number of Participants With Treatment Emergent Adverse Events (TEAEs)", "description": "An adverse event (AE) is any untoward medical occurrence (i.e. any unfavorable and unintended sign \\[including abnormal laboratory findings\\], symptom or disease) in a patient or clinical investigation subject after providing written informed consent for participation in the study. TEAE is defined as AE that is observed or reported after the first administration of study drug or if it starts before the first administration of study drug and the intensity/grade worsens on treatment) in this study.", "timeFrame": "Up to 6 months"}, {"measure": "Number of Participants With Clinical Significant Abnormal Endometrial Histology Findings", "description": "Number of participants with endometrial histology findings, e.g. hyperplasia, malignant neoplasm or endometrial polyps", "timeFrame": "Up to 6 months"}, {"measure": "Number of Participants With Clinical Significant Abnormal Ultrasound Examinations", "description": "Ultrasound examinations (evaluated for efficacy and safety) will be performed by a qualified expert in performing gynecologic ultrasound exams. If possible, the same examiner should conduct all examinations of a subject throughout the study and the same ultrasound machine (per site) should be used throughout the study. Preferably the safety evaluation should be performed by transvaginal ultrasound (TVU). However, if deemed appropriate, transabdominal or transrectal ultrasound examinations can be performed instead. The chosen method should be used consistently throughout the study.", "timeFrame": "Up to 6 months"}, {"measure": "Number of Participants With Clinical Significant Abnormal Bone Mineral Density Measurements", "description": "A Dual-energy X-ray absorptiometry (DEXA) scan of the lumbar spine (lumbar anterior-posterior, L1-L4) and the hip/femoral neck were performed.", "timeFrame": "Up to 6 months"}, {"measure": "Number of Participants With Clinical Significant Abnormal Laboratory Values", "description": "Clinical laboratory values including the values of hematology, general chemistry, urinalysis, coagulation, hormones, immunology and vitamins.", "timeFrame": "Up to 6 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Signed and dated informed consent\n* Pre-menopausal women 18 years (inclusive) and above at the time of Visit 1\n* Women with endometriosis confirmed by laparoscopy or laparotomy OR diagnosed based on imaging\n* Moderate to severe endometriosis-associated pelvic pain (EAPP)\n* Adherence to screening period diary entries\n* Willingness to use only standardized pain medication if needed\n* Good general health (except for findings related to endometriosis)\n* Normal or clinically insignificant cervical cytology not requiring further follow-up\n* An endometrial biopsy performed at the screening phase without significant histological disorder\n* Use of an acceptable non-hormonal method of contraception\n* Willingness / ability to comply with electronic diary entry for the duration of study participation\n\nExclusion Criteria:\n\n* Pregnancy or lactation (less than 3 months since delivery, abortion, or lactation before Visit 1)\n* Hypersensitivity to any ingredient of the study treatments\n* Laboratory values outside the inclusion range before randomization, and considered clinically relevant\n* Any diseases or conditions that can compromise the function of the body systems and could result in altered absorption, excessive accumulation, impaired metabolism, or altered excretion of the study drug including elevated liver enzymes\n* Any diseases or conditions that might interfere with the conduct of the study or the interpretation of the results\n* Undiagnosed abnormal genital bleeding\n* Abuse of alcohol, drugs, or medicines (e.g. laxatives) as evaluated by the investigator\n* Use of other treatments that might interfere with the conduct of the study or the interpretation of the results\n* Endometriosis-specific treatments for symptom relief except rescue pain medication according to protocol\n* Simultaneous participation in another clinical trial with investigational medicinal product(s). Participation in another trial prior to study entry that might have an impact on the study objectives, at the discretion of the investigator\n* Inability to cooperate with the study procedures for any reason\n* Previous assignment to treatment (e.g. randomization) during this study (allowing previously randomized subjects to be re-included into the study may lead to bias)\n* Hypersensitivity to any ingredient of standardized pain medication\n* Wish for pregnancy during the study\n* Regular use of pain medication due to other underlying diseases\n* Non-responsiveness of EAPP to GnRH-a (Gonadotropin-releasing hormone agonists)", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Bayer Study Director", "affiliation": "Bayer", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Office of Dr. James A. Simon, MD", "city": "Washington D.C.", "state": "District of Columbia", "zip": "20036", "country": "United States", "geoPoint": {"lat": 38.89511, "lon": -77.03637}}, {"facility": "Helix Biomedics, LLC", "city": "Boynton Beach", "state": "Florida", "zip": "33435", "country": "United States", "geoPoint": {"lat": 26.52535, "lon": -80.06643}}, {"facility": "Solutions Through Advanced Research, Inc.", "city": "Jacksonville", "state": "Florida", "zip": "32256", "country": "United States", "geoPoint": {"lat": 30.33218, "lon": -81.65565}}, {"facility": "Southern Clinical Research Associates LLC", "city": "Metairie", "state": "Louisiana", "zip": "70001", "country": "United States", "geoPoint": {"lat": 29.98409, "lon": -90.15285}}, {"facility": "Unified Women's Clinical Research - Morehead City", "city": "Morehead City", "state": "North Carolina", "zip": "28557", "country": "United States", "geoPoint": {"lat": 34.72294, "lon": -76.72604}}, {"facility": "Unified Women's Clinical Research", "city": "Winston-Salem", "state": "North Carolina", "zip": "27103", "country": "United States", "geoPoint": {"lat": 36.09986, "lon": -80.24422}}, {"facility": "Medizinische Universität Graz", "city": "Graz", "state": "Styria", "zip": "8036", "country": "Austria", "geoPoint": {"lat": 47.06733, "lon": 15.44197}}, {"facility": "Kepler Universitätsklinikum Campus IV", "city": "Linz", "state": "Upper Austria", "zip": "4020", "country": "Austria", "geoPoint": {"lat": 48.30639, "lon": 14.28611}}, {"facility": "Universitätsklinikum AKH Wien", "city": "Vienna", "zip": "1090", "country": "Austria", "geoPoint": {"lat": 48.20849, "lon": 16.37208}}, {"facility": "KABEG Landeskrankenhaus Villach", "city": "Villach", "zip": "9500", "country": "Austria", "geoPoint": {"lat": 46.61028, "lon": 13.85583}}, {"facility": "Queen's University", "city": "Kingston", "state": "Ontario", "zip": "K7L 2V7", "country": "Canada", "geoPoint": {"lat": 44.22976, "lon": -76.48098}}, {"facility": "Ottawa Hospital-Riverside Campus", "city": "Ottawa", "state": "Ontario", "zip": "K1H 7W9", "country": "Canada", "geoPoint": {"lat": 45.41117, "lon": -75.69812}}, {"facility": "Clinique OVO", "city": "Montreal", "state": "Quebec", "zip": "H4P 2S4", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"facility": "Gynekologie MEDA s.r.o.", "city": "Brno", "zip": "602 00", "country": "Czechia", "geoPoint": {"lat": 49.19522, "lon": 16.60796}}, {"facility": "GynCare MUDr. Michael Svec s.r.o.", "city": "Pilsen", "zip": "326 00", "country": "Czechia", "geoPoint": {"lat": 49.74747, "lon": 13.37759}}, {"facility": "VL-Medi Oy", "city": "Helsinki", "zip": "00510", "country": "Finland", "geoPoint": {"lat": 60.16952, "lon": 24.93545}}, {"facility": "Satakunnan keskussairaala", "city": "Pori", "zip": "28500", "country": "Finland", "geoPoint": {"lat": 61.48072, "lon": 21.78518}}, {"facility": "A.O.U.I. Verona", "city": "Verona", "state": "Veneto", "zip": "37126", "country": "Italy", "geoPoint": {"lat": 45.43854, "lon": 10.9938}}, {"facility": "Tokeidai Memorial Clinic", "city": "Sapporo", "state": "Hokkaido", "zip": "060-0031", "country": "Japan", "geoPoint": {"lat": 43.06667, "lon": 141.35}}, {"facility": "Ishikawa Prefectural Central Hospital", "city": "Kanazawa", "state": "Ishikawa-ken", "zip": "920-8530", "country": "Japan", "geoPoint": {"lat": 36.6, "lon": 136.61667}}, {"facility": "Japanese Red Cross Kumamoto Hospital", "city": "Kumamoto", "zip": "861-8520", "country": "Japan", "geoPoint": {"lat": 32.80589, "lon": 130.69181}}, {"facility": "Toyama Prefectural Central Hospital", "city": "Toyama", "zip": "930-8550", "country": "Japan", "geoPoint": {"lat": 36.7, "lon": 137.21667}}, {"facility": "Centrum Medyczne Chodzki", "city": "Lublin", "zip": "20-093", "country": "Poland", "geoPoint": {"lat": 51.25058, "lon": 22.57009}}]}, "referencesModule": {"references": [{"pmid": "38983729", "type": "DERIVED", "citation": "Taylor HS, Dong L, Haikonen J, Oppelt P, Tamussino K, Wenzl R, Faustmann T, Groettrup-Wolfers E, Ren X, Seitz C. Vilaprisan for the treatment of symptomatic endometriosis: results from a terminated phase 2b randomized controlled trial. F S Rep. 2024 Mar 11;5(2):189-196. doi: 10.1016/j.xfre.2024.03.002. eCollection 2024 Jun."}], "seeAlsoLinks": [{"label": "Click here to find results for studies related to Bayer products", "url": "https://clinicaltrials.bayer.com/"}, {"label": "Click here to find information about studies related to Bayer Healthcare products conducted in Europe", "url": "https://www.clinicaltrialsregister.eu/"}]}, "ipdSharingStatementModule": {"ipdSharing": "NO", "description": "Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA \"Principles for responsible clinical trial data sharing\". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal."}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "With the implementation of protocol version 4.0 dated 11-Dec-2018, no new participants were enrolled. The objectives of this study cannot be reached as only limited data is available from participants recruited before the treatment stopped. Overall, 48 participants were screened, of whom 8 participants were randomized and received the study treatment.", "recruitmentDetails": "Study was conducted at 7 study centers worldwide, between 04-Jul-2018 (first participant first visit) and 26-Nov-2020 (last participant last visit).", "groups": [{"id": "FG000", "title": "Vilaprisan (BAY1002670) 2 mg", "description": "Premenopausal women 18 years and older with endometriosis received the treatment of Vilaprisan 2 mg."}, {"id": "FG001", "title": "Vilaprisan (BAY1002670) 4 mg", "description": "Premenopausal women 18 years and older with endometriosis received the treatment of Vilaprisan 4 mg"}, {"id": "FG002", "title": "Placebo", "description": "Premenopausal women 18 years and older with endometriosis received placebo."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "2"}]}, {"type": "Treated", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "2"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "2"}]}], "dropWithdraws": [{"type": "Study terminated", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Vilaprisan (BAY1002670) 2 mg", "description": "Premenopausal women 18 years and older with endometriosis received the treatment of Vilaprisan 2 mg."}, {"id": "BG001", "title": "Vilaprisan (BAY1002670) 4 mg", "description": "Premenopausal women 18 years and older with endometriosis received the treatment of Vilaprisan 4 mg"}, {"id": "BG002", "title": "Placebo", "description": "Premenopausal women 18 years and older with endometriosis received placebo."}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "8"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "8"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "8"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "1"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "7"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "8"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Mean Worst Pelvic Pain (Measured on a Numerical Rating Scale [NRS], Recorded in the Daily Endometriosis Symptom Diary [ESD])", "description": "Pain intensity was assessed on 11-point (0-10) NRS by ESD item 1. In ESD item 1, participants were asked to rate the worst pain in the target area during the past 24 hours, where 0= no pain and 10= worst imaginable pain and responses were recorded in ESD. Mean 'worst pelvic pain' was calculated as the sum of the participant's daily assessments of the ESD item 1 (\"worst pain\" during the last 24 hours) during a study period divided by number of days with pain assessment in that study period. This was summarized by study period. No inferential statistical analysis was performed.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Full Range", "unitOfMeasure": "Scores on a scale", "timeFrame": "Screening period (up to a maximum of 75 days) + treatment period (up to a maximum of 168 days)", "groups": [{"id": "OG000", "title": "Vilaprisan (BAY1002670) 2 mg", "description": "Premenopausal women 18 years and older with endometriosis received the treatment of Vilaprisan 2 mg."}, {"id": "OG001", "title": "Vilaprisan (BAY1002670) 4 mg", "description": "Premenopausal women 18 years and older with endometriosis received the treatment of Vilaprisan 4 mg"}, {"id": "OG002", "title": "Placebo", "description": "Premenopausal women 18 years and older with endometriosis received placebo."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "4"}, {"groupId": "OG002", "value": "2"}]}], "classes": [{"title": "Screening period", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.0", "lowerLimit": "5.3", "upperLimit": "6.8"}, {"groupId": "OG001", "value": "5.8", "lowerLimit": "4.0", "upperLimit": "7.1"}, {"groupId": "OG002", "value": "5.6", "lowerLimit": "5.5", "upperLimit": "5.7"}]}]}, {"title": "Treatment period", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.0", "lowerLimit": "2.0", "upperLimit": "4.0"}, {"groupId": "OG001", "value": "3.8", "lowerLimit": "1.9", "upperLimit": "5.6"}, {"groupId": "OG002", "value": "5.0", "lowerLimit": "4.1", "upperLimit": "5.9"}]}]}]}, {"type": "SECONDARY", "title": "Mean Worst Pelvic Pain (Measured on a Numerical Rating Scale [NRS], Recorded in the Daily Endometriosis Symptom Diary [ESD]) on Days With/Without Vaginal Bleeding", "description": "Pain intensity was assessed on 11-point (0-10) NRS by ESD item 1. In ESD item 1, participants were asked to rate the worst pain in the target area during the past 24 hours, where 0= no pain and 10= worst imaginable pain and responses were recorded in ESD. Mean 'worst pelvic pain' on bleeding/non-bleeding days was calculated as the sum of the participant's daily assessments of the ESD item 1 (\"worst pain\" during the last 24 hours) on bleedings/non-bleeding days during a study period divided by number of bleeding/non-bleeding days with pain assessment in that study period. This was summarized by study period. No inferential statistical analysis was performed.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Full Range", "unitOfMeasure": "Scores on a scale", "timeFrame": "Screening period (up to a maximum of 75 days) + treatment period (up to a maximum of 168 days)", "groups": [{"id": "OG000", "title": "Vilaprisan (BAY1002670) 2 mg", "description": "Premenopausal women 18 years and older with endometriosis received the treatment of Vilaprisan 2 mg."}, {"id": "OG001", "title": "Vilaprisan (BAY1002670) 4 mg", "description": "Premenopausal women 18 years and older with endometriosis received the treatment of Vilaprisan 4 mg"}, {"id": "OG002", "title": "Placebo", "description": "Premenopausal women 18 years and older with endometriosis received placebo."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "4"}, {"groupId": "OG002", "value": "2"}]}], "classes": [{"title": "Screening period: Worst Pain on days with vaginal bleeding", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.5", "lowerLimit": "4.6", "upperLimit": "8.4"}, {"groupId": "OG001", "value": "6.9", "lowerLimit": "4.9", "upperLimit": "8.4"}, {"groupId": "OG002", "value": "7.0", "lowerLimit": "6.9", "upperLimit": "7.0"}]}]}, {"title": "Screening period: Worst Pain on days without vaginal bleeding", "categories": [{"measurements": [{"groupId": "OG000", "value": "5.9", "lowerLimit": "5.5", "upperLimit": "6.3"}, {"groupId": "OG001", "value": "5.5", "lowerLimit": "3.7", "upperLimit": "6.7"}, {"groupId": "OG002", "value": "5.3", "lowerLimit": "5.1", "upperLimit": "5.6"}]}]}, {"title": "Treatment period: Worst Pain on days with vaginal bleeding", "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "No participant had pain on vaginal bleeding days in the treatment period."}, {"groupId": "OG001", "value": "5.4", "lowerLimit": "3.8", "upperLimit": "7.0"}, {"groupId": "OG002", "value": "6.0", "lowerLimit": "5.1", "upperLimit": "6.9"}]}]}, {"title": "Treatment period: Worst Pain on days without vaginal bleeding", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.0", "lowerLimit": "2.0", "upperLimit": "4.0"}, {"groupId": "OG001", "value": "3.7", "lowerLimit": "1.8", "upperLimit": "5.6"}, {"groupId": "OG002", "value": "4.7", "lowerLimit": "4.0", "upperLimit": "5.5"}]}]}]}, {"type": "SECONDARY", "title": "Mean Number of Tablets of Rescue Pain Medication 1 (Ibuprofen 200 mg) Taken Daily for Endometriosis-associated Pelvic Pain (EAPP)", "description": "Mean number of tablets of rescue pain medication 1 (Ibuprofen 200 mg) taken daily for EAPP was calculated as the sum of the tablets taken for EAPP during a study period divided by the number of days in that study period. This was summarized by study period. No inferential statistical analysis was performed.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Full Range", "unitOfMeasure": "Tablets", "timeFrame": "Screening period (up to a maximum of 75 days) + treatment period (up to a maximum of 168 days)", "groups": [{"id": "OG000", "title": "Vilaprisan (BAY1002670) 2 mg", "description": "Premenopausal women 18 years and older with endometriosis received the treatment of Vilaprisan 2 mg."}, {"id": "OG001", "title": "Vilaprisan (BAY1002670) 4 mg", "description": "Premenopausal women 18 years and older with endometriosis received the treatment of Vilaprisan 4 mg"}, {"id": "OG002", "title": "Placebo", "description": "Premenopausal women 18 years and older with endometriosis received placebo."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "4"}, {"groupId": "OG002", "value": "2"}]}], "classes": [{"title": "Screening period", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.61", "lowerLimit": "0.35", "upperLimit": "0.86"}, {"groupId": "OG001", "value": "1.01", "lowerLimit": "0", "upperLimit": "2.14"}, {"groupId": "OG002", "value": "1.03", "lowerLimit": "0.31", "upperLimit": "1.74"}]}]}, {"title": "Treatment period", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.09", "lowerLimit": "0.01", "upperLimit": "0.17"}, {"groupId": "OG001", "value": "0.16", "lowerLimit": "0.05", "upperLimit": "0.42"}, {"groupId": "OG002", "value": "0.81", "lowerLimit": "0.33", "upperLimit": "1.30"}]}]}]}, {"type": "SECONDARY", "title": "Mean Number of Tablets of Rescue Pain Medication 2 (Tramadol 50 mg) Taken Daily for Endometriosis-associated Pelvic Pain (EAPP)", "description": "Mean number of tablets of rescue pain medication 2 (Tramadol 50 mg) taken daily for EAPP was calculated as the sum of the tablets taken for EAPP during a study period divided by the number of days in that study period. This was summarized by study period. No inferential statistical analysis was performed.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Full Range", "unitOfMeasure": "Tablets", "timeFrame": "Screening period (up to a maximum of 75 days) + treatment period (up to a maximum of 168 days)", "groups": [{"id": "OG000", "title": "Vilaprisan (BAY1002670) 2 mg", "description": "Premenopausal women 18 years and older with endometriosis received the treatment of Vilaprisan 2 mg."}, {"id": "OG001", "title": "Vilaprisan (BAY1002670) 4 mg", "description": "Premenopausal women 18 years and older with endometriosis received the treatment of Vilaprisan 4 mg"}, {"id": "OG002", "title": "Placebo", "description": "Premenopausal women 18 years and older with endometriosis received placebo."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "4"}, {"groupId": "OG002", "value": "2"}]}], "classes": [{"title": "Screening period", "categories": [{"measurements": [{"groupId": "OG000", "value": "0", "lowerLimit": "0", "upperLimit": "0"}, {"groupId": "OG001", "value": "0", "lowerLimit": "0", "upperLimit": "0"}, {"groupId": "OG002", "value": "0.17", "lowerLimit": "0", "upperLimit": "0.34"}]}]}, {"title": "Treatment period", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.01", "lowerLimit": "0", "upperLimit": "0.03"}, {"groupId": "OG001", "value": "0.01", "lowerLimit": "0", "upperLimit": "0.05"}, {"groupId": "OG002", "value": "0.02", "lowerLimit": "0.01", "upperLimit": "0.02"}]}]}]}, {"type": "SECONDARY", "title": "The Number of Participants With Treatment Emergent Adverse Events (TEAEs)", "description": "An adverse event (AE) is any untoward medical occurrence (i.e. any unfavorable and unintended sign \\[including abnormal laboratory findings\\], symptom or disease) in a patient or clinical investigation subject after providing written informed consent for participation in the study. TEAE is defined as AE that is observed or reported after the first administration of study drug or if it starts before the first administration of study drug and the intensity/grade worsens on treatment) in this study.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Up to 6 months", "groups": [{"id": "OG000", "title": "Vilaprisan (BAY1002670) 2 mg", "description": "Premenopausal women 18 years and older with endometriosis received the treatment of Vilaprisan 2 mg."}, {"id": "OG001", "title": "Vilaprisan (BAY1002670) 4 mg", "description": "Premenopausal women 18 years and older with endometriosis received the treatment of Vilaprisan 4 mg"}, {"id": "OG002", "title": "Placebo", "description": "Premenopausal women 18 years and older with endometriosis received placebo."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "4"}, {"groupId": "OG002", "value": "2"}]}], "classes": [{"title": "Non-serious TEAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "2"}]}]}, {"title": "SAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Deaths", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Clinical Significant Abnormal Endometrial Histology Findings", "description": "Number of participants with endometrial histology findings, e.g. hyperplasia, malignant neoplasm or endometrial polyps", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Up to 6 months", "groups": [{"id": "OG000", "title": "Vilaprisan (BAY1002670) 2 mg", "description": "Premenopausal women 18 years and older with endometriosis received the treatment of Vilaprisan 2 mg."}, {"id": "OG001", "title": "Vilaprisan (BAY1002670) 4 mg", "description": "Premenopausal women 18 years and older with endometriosis received the treatment of Vilaprisan 4 mg"}, {"id": "OG002", "title": "Placebo", "description": "Premenopausal women 18 years and older with endometriosis received placebo."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "4"}, {"groupId": "OG002", "value": "2"}]}], "classes": [{"title": "Endometrial hyperplasia", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Malignant neoplasm", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Endometrial polyps", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Clinical Significant Abnormal Ultrasound Examinations", "description": "Ultrasound examinations (evaluated for efficacy and safety) will be performed by a qualified expert in performing gynecologic ultrasound exams. If possible, the same examiner should conduct all examinations of a subject throughout the study and the same ultrasound machine (per site) should be used throughout the study. Preferably the safety evaluation should be performed by transvaginal ultrasound (TVU). However, if deemed appropriate, transabdominal or transrectal ultrasound examinations can be performed instead. The chosen method should be used consistently throughout the study.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Up to 6 months", "groups": [{"id": "OG000", "title": "Vilaprisan (BAY1002670) 2 mg", "description": "Premenopausal women 18 years and older with endometriosis received the treatment of Vilaprisan 2 mg."}, {"id": "OG001", "title": "Vilaprisan (BAY1002670) 4 mg", "description": "Premenopausal women 18 years and older with endometriosis received the treatment of Vilaprisan 4 mg"}, {"id": "OG002", "title": "Placebo", "description": "Premenopausal women 18 years and older with endometriosis received placebo."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "4"}, {"groupId": "OG002", "value": "2"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Clinical Significant Abnormal Bone Mineral Density Measurements", "description": "A Dual-energy X-ray absorptiometry (DEXA) scan of the lumbar spine (lumbar anterior-posterior, L1-L4) and the hip/femoral neck were performed.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Up to 6 months", "groups": [{"id": "OG000", "title": "Vilaprisan (BAY1002670) 2 mg", "description": "Premenopausal women 18 years and older with endometriosis received the treatment of Vilaprisan 2 mg."}, {"id": "OG001", "title": "Vilaprisan (BAY1002670) 4 mg", "description": "Premenopausal women 18 years and older with endometriosis received the treatment of Vilaprisan 4 mg"}, {"id": "OG002", "title": "Placebo", "description": "Premenopausal women 18 years and older with endometriosis received placebo."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "4"}, {"groupId": "OG002", "value": "2"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Clinical Significant Abnormal Laboratory Values", "description": "Clinical laboratory values including the values of hematology, general chemistry, urinalysis, coagulation, hormones, immunology and vitamins.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Up to 6 months", "groups": [{"id": "OG000", "title": "Vilaprisan (BAY1002670) 2 mg", "description": "Premenopausal women 18 years and older with endometriosis received the treatment of Vilaprisan 2 mg."}, {"id": "OG001", "title": "Vilaprisan (BAY1002670) 4 mg", "description": "Premenopausal women 18 years and older with endometriosis received the treatment of Vilaprisan 4 mg"}, {"id": "OG002", "title": "Placebo", "description": "Premenopausal women 18 years and older with endometriosis received placebo."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "4"}, {"groupId": "OG002", "value": "2"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Adverse event data were collected from first study medication intake until last visit of the subject (516 days on average).", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "Premenopausal women 18 years and older with endometriosis received placebo", "deathsNumAffected": 0, "deathsNumAtRisk": 2, "seriousNumAffected": 0, "seriousNumAtRisk": 2, "otherNumAffected": 2, "otherNumAtRisk": 2}, {"id": "EG001", "title": "Vilaprisan (BAY1002670) 2 mg", "description": "Premenopausal women 18 years and older with endometriosis received the treatment of Vilaprisan 2 mg.", "deathsNumAffected": 0, "deathsNumAtRisk": 2, "seriousNumAffected": 1, "seriousNumAtRisk": 2, "otherNumAffected": 2, "otherNumAtRisk": 2}, {"id": "EG002", "title": "Vilaprisan (BAY1002670) 4 mg", "description": "Premenopausal women 18 years and older with endometriosis received the treatment of Vilaprisan 4 mg", "deathsNumAffected": 0, "deathsNumAtRisk": 4, "seriousNumAffected": 3, "seriousNumAtRisk": 4, "otherNumAffected": 3, "otherNumAtRisk": 4}], "seriousEvents": [{"term": "Retinal detachment", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 4}]}, {"term": "Adrenal adenoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 4}]}, {"term": "Endometriosis", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 4}]}, {"term": "Endometriosis ablation", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}]}], "otherEvents": [{"term": "Dry eye", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 4}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 4}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 4}]}, {"term": "Toothache", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 3, "numAffected": 1, "numAtRisk": 4}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}]}, {"term": "Fungal skin infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 4}]}, {"term": "Gingivitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 2, "numAffected": 1, "numAtRisk": 4}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 3, "numAffected": 1, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 4}]}, {"term": "Pyelitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}]}, {"term": "Tonsillitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 4}]}, {"term": "Vaginal infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}]}, {"term": "Vulvovaginal mycotic infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}]}, {"term": "Procedural pain", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 4}]}, {"term": "Cortisol increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 4}]}, {"term": "Intraocular pressure increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}]}, {"term": "Weight increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 4}]}, {"term": "Bone density decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}]}, {"term": "Iron deficiency", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 4}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 2, "numAffected": 1, "numAtRisk": 4}]}, {"term": "Bone pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 4}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 20, "numAffected": 2, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 6, "numAffected": 1, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 27, "numAffected": 2, "numAtRisk": 4}]}, {"term": "Anxiety", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 4}]}, {"term": "Depressed mood", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 4}]}, {"term": "Mood altered", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 4}]}, {"term": "Adjustment disorder", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 4}]}, {"term": "Vaginal discharge", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}]}, {"term": "Vulvovaginal dryness", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 4}]}, {"term": "Adenomyosis", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}]}, {"term": "Acne", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 4}]}, {"term": "Hyperhidrosis", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}]}, {"term": "Hot flush", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 2, "numAffected": 1, "numAtRisk": 4}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "No inferential statistical analysis was performed due to a small population."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true}, "pointOfContact": {"title": "Therapeutic Area Head", "organization": "Bayer", "email": "clinical-trials-contact@bayer.com", "phone": "(+)1-888-84 22937"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2020-02-17", "uploadDate": "2020-12-18T01:02", "filename": "Prot_001.pdf", "size": 2008999}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2020-01-15", "uploadDate": "2020-12-18T01:02", "filename": "SAP_000.pdf", "size": 208602}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04", "removedCountries": ["Bulgaria", "Chile", "China", "Denmark", "Germany", "Hungary", "Israel", "Portugal", "Spain", "Sweden", "Switzerland", "Taiwan"], "submissionTracking": {"firstMcpInfo": {"postDateStruct": {"date": "2021-01-15", "type": "ACTUAL"}}}}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C586669", "term": "vilaprisan"}]}}, "hasResults": true}, {"protocolSection": {"identificationModule": {"nctId": "NCT01769781", "orgStudyIdInfo": {"id": "CR013-01"}, "organization": {"fullName": "Centre for Endocrinology and Reproductive Medicine, Italy", "class": "NETWORK"}, "briefTitle": "Anastrazole Plus GnRH-agonist in the Treatment of Endometriosis Recurrence", "officialTitle": "Treatment of Patients With Endometriosis Recurrence With Aromatase Inhibitor (Anastrazole) Plus GnRH-agonist (Luprolide)."}, "statusModule": {"statusVerifiedDate": "2016-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2013-01"}, "primaryCompletionDateStruct": {"date": "2015-07", "type": "ACTUAL"}, "completionDateStruct": {"date": "2015-07", "type": "ACTUAL"}, "studyFirstSubmitDate": "2013-01-15", "studyFirstSubmitQcDate": "2013-01-16", "studyFirstPostDateStruct": {"date": "2013-01-17", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-04-25", "lastUpdatePostDateStruct": {"date": "2016-04-27", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Fabio Scarpellini", "investigatorTitle": "PRINCIPAL INVESTIGATOR", "investigatorAffiliation": "Centre for Endocrinology and Reproductive Medicine, Italy"}, "leadSponsor": {"name": "Centre for Endocrinology and Reproductive Medicine, Italy", "class": "NETWORK"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The aromatase inhibitor (anastrazole) plus long acting GnRH agonist leuprolide acetate will be tested for the treatment of women with endometriosis recurrence compared with classical GnRH analog treatment. Pain symptom disappearance and disease free time during follow-up will be the outcomes for establishing which medical treatment is the best in endometriosis recurrence treatment.", "detailedDescription": "Endometriosis is a chronic disease affecting 5-10% of women in reproductive age, showing recurrence after surgery at least in 20-50% after 5 years of follow-up. Aromatase inhibitor plus GnRH analog may be more effective than GnRH agonist alone in the treatment of endometriosis recurrence."}, "conditionsModule": {"conditions": ["Endometriosis"], "keywords": ["endometriosis recurrence", "pelvic pain", "aromatase inhibitor"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "SINGLE", "whoMasked": ["PARTICIPANT"]}}, "enrollmentInfo": {"count": 70, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "anastrazole", "type": "EXPERIMENTAL", "description": "women with endometriosis recurrence will be treated with Leuprolide acetate 11,25mg plus anastrazole 1mg/day for three months", "interventionNames": ["Drug: anastrazole"]}, {"label": "GnRH analog alone", "type": "ACTIVE_COMPARATOR", "description": "women with endometriosis recurrence will be treated with leuprolide acetate 11.25mg", "interventionNames": ["Drug: GnRH analog alone"]}], "interventions": [{"type": "DRUG", "name": "anastrazole", "description": "combined treatment with aromatase inhibitor (anastrazole) plus GnRH analog (leuprolide acetate) for three months", "armGroupLabels": ["anastrazole"]}, {"type": "DRUG", "name": "GnRH analog alone", "description": "treatment for three months with GnRH analog (leuprolide acetate) alone", "armGroupLabels": ["GnRH analog alone"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "disease free time", "description": "time without pain symptoms due to the disease recurrence", "timeFrame": "24 months"}], "secondaryOutcomes": [{"measure": "time of pain disappearance", "description": "time needed during treatment to improve pain symptoms", "timeFrame": "24 months"}], "otherOutcomes": [{"measure": "reduction of endometriosis lesions", "description": "endometriosis lesions regression during treatment evidenced by MRI scan", "timeFrame": "24 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* women affected by endometriosis showing recurrence of pain symptoms, previous surgery for endometriosis\n\nExclusion Criteria:\n\n* presence of other systemic diseases", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "50 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "marco sbracia, md", "affiliation": "CERM-HUNGARIA", "role": "STUDY_CHAIR"}], "locations": [{"facility": "Cerm-Hungaria", "city": "Rome", "zip": "00153", "country": "Italy", "geoPoint": {"lat": 41.89193, "lon": 12.51133}}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}, {"id": "D017699", "term": "Pelvic Pain"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}, {"id": "D010146", "term": "Pain"}, {"id": "D009461", "term": "Neurologic Manifestations"}, {"id": "D012816", "term": "Signs and Symptoms"}, {"id": "D013568", "term": "Pathological Conditions, Signs and Symptoms"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000077384", "term": "Anastrozole"}, {"id": "D007987", "term": "Gonadotropin-Releasing Hormone"}], "ancestors": [{"id": "D009570", "term": "Nitriles"}, {"id": "D009930", "term": "Organic Chemicals"}, {"id": "D014230", "term": "Triazoles"}, {"id": "D001393", "term": "Azoles"}, {"id": "D006573", "term": "Heterocyclic Compounds, 1-Ring"}, {"id": "D006571", "term": "Heterocyclic Compounds"}, {"id": "D010906", "term": "Pituitary Hormone-Releasing Hormones"}, {"id": "D007028", "term": "Hypothalamic Hormones"}, {"id": "D036361", "term": "Peptide Hormones"}, {"id": "D006728", "term": "Hormones"}, {"id": "D006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D009479", "term": "Neuropeptides"}, {"id": "D010455", "term": "Peptides"}, {"id": "D000602", "term": "Amino Acids, Peptides, and Proteins"}, {"id": "D009842", "term": "Oligopeptides"}, {"id": "D009419", "term": "Nerve Tissue Proteins"}, {"id": "D011506", "term": "Proteins"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT03717870", "orgStudyIdInfo": {"id": "SAFE-1"}, "organization": {"fullName": "Università degli Studi dell'Insubria", "class": "OTHER"}, "briefTitle": "Surgery and ART For Endometrioma", "officialTitle": "Evaluation of Reproductive Outcomes After Different Management of Ovarian Endometrioma Prior to Assisted Reproduction Technology (ART): Laparoscopic Enucleation Vs Prolonged Pituitary Downregulation With Gonadotropin Releasing Hormone (GnRH)-Agonists"}, "statusModule": {"statusVerifiedDate": "2021-04", "overallStatus": "NOT_YET_RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2023-10", "type": "ESTIMATED"}, "primaryCompletionDateStruct": {"date": "2025-10", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2027-10", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2018-10-22", "studyFirstSubmitQcDate": "2018-10-23", "studyFirstPostDateStruct": {"date": "2018-10-24", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2021-04-28", "lastUpdatePostDateStruct": {"date": "2021-04-29", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Antonio Simone Laganà", "investigatorTitle": "Principal Investigator", "investigatorAffiliation": "Università degli Studi dell'Insubria"}, "leadSponsor": {"name": "Università degli Studi dell'Insubria", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "Endometriosis is an estrogen-dependent chronic disease, characterized by the presence of endometrial-like tissue, glands and stroma outside the uterine cavity. Although endometriosis is classified in four stage (minimal, mild, moderate, severe), from the clinical point of view it is possible to subdivide among peritoneal superficial lesions, ovarian endometriomas and Deep Infiltrating Endometriosis (DIE).\n\nAccording to the European Society for Human Reproduction and Embryology (ESHRE) Guideline on the management of women with endometriosis, it is recommended to clinicians that in infertile women with endometrioma larger than 3 cm, cystectomy should be considered prior to Assisted Reproduction Technology (ART) to improve endometriosis-associated pain or the accessibility of follicles. They further recommend that clinicians counsel women with endometrioma regarding the risks of reduced ovarian function after surgery, the possible loss of the ovary, and consider that the decision to proceed with surgery should be taken carefully if the woman has had previous ovarian surgery.\n\nIn addition, this Guideline suggests that clinicians can prescribe prolonged (3-6 months) pituitary downregulation with Gonadotropin Releasing Hormone-agonists (GnRH-a) prior to ART, in order to increase live birth rate by four-fold.\n\nDespite these recommendations, to date there is not robust evidence to choose between the two strategies prior to ART in order to improve reproductive outcomes.\n\nFor this reason, the aim of the current study will be to compare reproductive outcomes in infertile women affected by ovarian endometrioma, undergoing laparoscopic enucleation or prolonged pituitary downregulation with GnRH-a, prior to ART."}, "conditionsModule": {"conditions": ["Ovarian Endometrioma", "Infertility, Female"], "keywords": ["Endometrioma", "Infertility", "Laparoscopy", "GnRH-a", "Assisted Reproduction Technology", "Reproductive outcomes"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": "Randomized Controlled Trial", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 100, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Surgery", "type": "EXPERIMENTAL", "description": "Laparoscopic enucleation of ovarian endometrioma (stripping of the peripheral capsule and coagulation using the lowest energy source available).", "interventionNames": ["Procedure: Laparoscopic enucleation of ovarian endometrioma.", "Procedure: Assisted Reproductive Technology (ART)"]}, {"label": "Prolonged pituitary downregulation", "type": "ACTIVE_COMPARATOR", "description": "Treatment with GnRH-a (triptorelin, goserelin, and leuprolide), with add-back therapy (combined oral contraceptive) for 3-6 months.", "interventionNames": ["Procedure: Prolonged pituitary downregulation", "Procedure: Assisted Reproductive Technology (ART)"]}], "interventions": [{"type": "PROCEDURE", "name": "Laparoscopic enucleation of ovarian endometrioma.", "description": "Laparoscopic enucleation of ovarian endometrioma (stripping of the peripheral capsule and coagulation using the lowest energy source available).", "armGroupLabels": ["Surgery"]}, {"type": "PROCEDURE", "name": "Prolonged pituitary downregulation", "description": "Treatment with GnRH-a (triptorelin, goserelin, and leuprolide), with add-back therapy (combined oral contraceptive) for 3-6 months.", "armGroupLabels": ["Prolonged pituitary downregulation"]}, {"type": "PROCEDURE", "name": "Assisted Reproductive Technology (ART)", "description": "Fresh ART cycle: ovarian stimulation, oocyte retrieval, in vitro fertilization and embryo transfer.", "armGroupLabels": ["Prolonged pituitary downregulation", "Surgery"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Clinical pregnancy with fetal heartbeat", "description": "Ultrasound-confirmed intrauterine pregnancy with fetal heartbeat", "timeFrame": "Within 8 weeks from embryo transfer"}], "secondaryOutcomes": [{"measure": "Biochemical pregnancy", "description": "Positive HCG serum testing", "timeFrame": "Within 8 weeks from embryo transfer"}, {"measure": "Miscarriage", "description": "Ultrasound-confirmed abortion", "timeFrame": "Within 12 weeks from embryo transfer"}, {"measure": "Live birth rate", "description": "Delivered fetus after 28 gestational weeks", "timeFrame": "Within 41 weeks from embryo transfer"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Indication for ART: compromised tubal function, male factor infertility, other treatments have failed and/or prolonged infertility of more than 4 years.\n* Age between 18 and 35 years.\n* Ultrasound diagnosis of one ovarian endometriotic cyst with a diameter of 30 mm or more, according to the International Ovarian Tumor Analysis (IOTA)-criteria for reliable diagnosis of endometriomas in premenopausal women.\n\nExclusion Criteria:\n\n* Any comorbidity other than ovarian endometrioma.\n* Deep Infiltrating Endometriosis.\n* Previous ovarian surgery.\n* Bilateral endometriomas.\n* The use of donor oocytes/sperm.\n* ART with preimplantation genetic testing, as the number of embryos suitable. for transfer or cryopreservation is significantly lower compared to normal ART.", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "35 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Antonio Simone Laganà, M.D.", "role": "CONTACT", "phone": "+393296279579", "email": "antoniosimone.lagana@asst-settelaghi.it"}], "overallOfficials": [{"name": "Antonio Simone Laganà, M.D.", "affiliation": "Università degli Studi dell'Insubria", "role": "PRINCIPAL_INVESTIGATOR"}]}, "ipdSharingStatementModule": {"ipdSharing": "UNDECIDED"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}, {"id": "D007247", "term": "Infertility, Female"}, {"id": "D007246", "term": "Infertility"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D027724", "term": "Reproductive Techniques, Assisted"}], "ancestors": [{"id": "D012099", "term": "Reproductive Techniques"}, {"id": "D013812", "term": "Therapeutics"}, {"id": "D008919", "term": "Investigative Techniques"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT05339451", "orgStudyIdInfo": {"id": "K 2022-2797"}, "organization": {"fullName": "Region Stockholm", "class": "OTHER_GOV"}, "briefTitle": "Blood and Tissue Markers for Improving Diagnosis and Prognosis of Endometriosis. (ENDOBIO)", "officialTitle": "Blood and Tissue Markers for Improving Diagnosis and Prognosis of Endometriosis. a Prospective Multicenter Nationwide Study. (ENDOBIO)", "acronym": "ENDOBIO"}, "statusModule": {"statusVerifiedDate": "2025-02", "overallStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2023-05-04", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2025-12-31", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2026-12-31", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2022-04-05", "studyFirstSubmitQcDate": "2022-04-14", "studyFirstPostDateStruct": {"date": "2022-04-21", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2025-02-20", "lastUpdatePostDateStruct": {"date": "2025-02-24", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Region Stockholm", "class": "OTHER_GOV"}, "collaborators": [{"name": "Karolinska Institutet", "class": "OTHER"}, {"name": "Södersjukhuset (Stockholm South General Hospital)", "class": "UNKNOWN"}, {"name": "Akademiska University Hospital, Uppsala, Sweden", "class": "UNKNOWN"}]}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false, "isUsExport": false}, "descriptionModule": {"briefSummary": "Endometriosis is a chronic, benign, estrogen-dependent disease characterized by endometrial tissue that is implanted outside the uterus into the ovaries, intestines, or peritoneum but also outside the pelvis. It is a common disease that affects 7-10% of women around the world. The most common symptoms are pain and infertility. The diagnosis is histological after removal of lesions with laparoscopy (sensitivity 94%, specificity 79%), and treatment is symptomatic.\n\nAt present, there is not a laboratory test that allows early and adequate diagnosis of endometriosis and therefore it can take up to 10 years for a patient to be diagnosed and patients often suffer from the disease.\n\nThe purpose of our study is to investigate biomarkers associated with endometriosis and prove their use in the diagnosis and staging of endometriosis. The biomarkers will be studied even in relationship to clinical manifestations of the disease, as markers of relapse and as fertility markers. Meanwhile, quality of life of patients with advanced stages of endometriosis postoperatively will be studied."}, "conditionsModule": {"conditions": ["Endometriosis"], "keywords": ["endometriosis", "biomarkers"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "COHORT", "timePerspective": "PROSPECTIVE"}, "enrollmentInfo": {"count": 345, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Severe/Deep infiltrating endometriosis", "description": "Endometriosis stage III/IV according to rASRM.", "interventionNames": ["Diagnostic Test: Blood biomarkers"]}, {"label": "Minimal/mild endometriosis", "description": "Endometriosis stage I/II according to rASRM", "interventionNames": ["Diagnostic Test: Blood biomarkers"]}, {"label": "Controls", "description": "Women operated for other benign gynecological diseases and have no signs of endometriosis perioperatively.", "interventionNames": ["Diagnostic Test: Blood biomarkers"]}], "interventions": [{"type": "DIAGNOSTIC_TEST", "name": "Blood biomarkers", "description": "Blood biomarkers in plasma and serum.", "armGroupLabels": ["Controls", "Minimal/mild endometriosis", "Severe/Deep infiltrating endometriosis"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Measurement of blood biomarkers panel for the diagnosis of endometriosis with sensitivity 94%", "description": "Blood biomarkers as endometriosis diagnostic tests", "timeFrame": "Preoperative"}, {"measure": "Change in blood biomarkers levels 3-6 months postoperative in patients with severe endometriosis.", "description": "Blood biomarkers as a relapse marker", "timeFrame": "3-6 months postoperative in the severe/DIE group"}, {"measure": "Measurement of blood biomarkers panel for the diagnosis of endometriosis with specificity 79%", "description": "Blood biomarkers as endometriosis diagnostic tests", "timeFrame": "Preoperative"}], "secondaryOutcomes": [{"measure": "Quality of life of patients undergoing surgery for DIE", "description": "Endometriosis Health Profile 30 Questionnaire", "timeFrame": "Preoperative and 3-6 months postoperative in the severe/DIE group"}, {"measure": "Achieved pregnancy postoperative", "description": "Positive pregnancy test", "timeFrame": "One year postoperative"}]}, "eligibilityModule": {"eligibilityCriteria": "IInclusion Criteria:\n\n* women of reproductive age (18-45) who are operated because of suspected endometriosis (dysmenorrhea, dyspareunia, infertility, etc.) (patient group)\n* women of reproductive age (18-45) who are operated for other benign gynecological causes with laparoscopy (ovarian cysts, sterilization, fibroids, etc.) and are found without macroscopic endometriosis perioperatively and confirmed with blind biopsies (control group\n* talk swedish or english in order to complete questionnaires and give informed consent for their participation in the study.\n\nExclusion Criteria:\n\n* BMI\\> 40\n* postmenopausal women\n* premature ovarian failure\n* pelvic inflammatory disease (PID)\n* current or previous malignancy\n* pregnancy and 6 months postpartum\n* corticosteroids in the last 3 months\n* pituitary, kidney, liver, adrenal disease\n* endometrial hyperplasia or endometrial polyp\n* cardiovascular or systemic inflammatory diseases.", "healthyVolunteers": true, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "45 Years", "stdAges": ["ADULT"], "studyPopulation": "Participants will be recruited in several gynecological clinics around Sweden. A total of 345 women of reproductive age will be included in the study according to the power calculation. 115 patients who are operated on due to deep infiltrating endometriosis or rASRM III-IV in national endometriosis centers in Sweden, 115 patients who are diagnosed during surgery with early-stage endometriosis (rASRM I-II) and 115 patients who are controls, who are operated on for others benign gynecological diseases (fibroids, ovarian cysts, chronic abdominal pain, sterilization) and have no signs of endometriosis perioperatively.", "samplingMethod": "PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"centralContacts": [{"name": "Anastasia Drakou, MSc", "role": "CONTACT", "phone": "0046 735500118", "email": "anastasia.drakou@regionstockholm.se"}, {"name": "Kenny Rodriguez-Wallberg, Professor", "role": "CONTACT", "email": "kenny.rodriguez-wallberg@ki.se"}], "overallOfficials": [{"name": "Kenny Rodriguez-Wallberg, Professor", "affiliation": "Karolinska Institutet", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Karolinska Universitetssjukhus Huddinge", "status": "RECRUITING", "city": "Stockholm", "state": "Huddinge", "country": "Sweden", "contacts": [{"name": "Anastasia Drakou", "role": "CONTACT"}], "geoPoint": {"lat": 59.32938, "lon": 18.06871}}, {"facility": "Södersjukhuset Kvinnokliniken", "status": "RECRUITING", "city": "Stockholm", "state": "Stockholm County", "country": "Sweden", "contacts": [{"name": "Malin Brunes, PhD", "role": "CONTACT"}], "geoPoint": {"lat": 59.32938, "lon": 18.06871}}, {"facility": "Akademiska Uppsala", "status": "NOT_YET_RECRUITING", "city": "Uppsala", "country": "Sweden", "contacts": [{"name": "Christine Asciutto, PhD", "role": "CONTACT"}], "geoPoint": {"lat": 59.85882, "lon": 17.63889}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT01636505", "orgStudyIdInfo": {"id": "ECK011170"}, "organization": {"fullName": "European Hospital", "class": "OTHER"}, "briefTitle": "The Results of Preimplantation Genetic Diagnosis and Preimplantation Genetic Screening of Embryos Obtained From GnRH-agonist Long and GnRH-antagonist Ovarian Stimulation Protocol"}, "statusModule": {"statusVerifiedDate": "2012-07", "overallStatus": "UNKNOWN", "lastKnownStatus": "NOT_YET_RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-09"}, "primaryCompletionDateStruct": {"date": "2013-02", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2013-09", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2012-07-05", "studyFirstSubmitQcDate": "2012-07-09", "studyFirstPostDateStruct": {"date": "2012-07-10", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2012-07-09", "lastUpdatePostDateStruct": {"date": "2012-07-10", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "European Hospital", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The aim of this study is to performed a randomized controlled trial to evaluate the rate of genetic and chromosomal abnormalities in embryos obtained from GnRH-agonist long and GnRH-antagonist ovarian stimulation protocols.\n\nPatients will be prospectively randomized in two groups: the first undergoing controlled ovarian stimulation in GnRH-agonist long protocol and the second following GnRH-antagonist ovarian stimulation regimen.\n\nThe end-points of the study include the number of genetically and chromosomally abnormal embryos, the pregnancy, the implantation and the healthy baby birth rate.\n\nThe patients included in PGS program were selected on the base of advanced maternal age, repeated pregnancy lost and implantation failure whereas the patients who were know to carry sex-linked or monogenic disorders were considered for PGD strategy.\n\nThe uterine abnormalities, endometriosis and endocrinal diseases were considered to be the exclusion factors."}, "conditionsModule": {"conditions": ["Embryo's Genetic and Chromosomal Quality"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "SCREENING", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 200, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "short protocol", "type": "ACTIVE_COMPARATOR", "description": "gnrh agonist versus gnrh antagonist", "interventionNames": ["Drug: ghrh antagonist (cetrotide/orgalutran)"]}, {"label": "long protocol", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: gnrh agonist (suprefact)"]}], "interventions": [{"type": "DRUG", "name": "ghrh antagonist (cetrotide/orgalutran)", "description": "cetrotide/orgalutran 0.25 mg", "armGroupLabels": ["short protocol"]}, {"type": "DRUG", "name": "gnrh agonist (suprefact)", "description": "suprefact 5.5 ml", "armGroupLabels": ["long protocol"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "The results of Preimplantation Genetic Diagnosis and Preimplantation Genetic Screening of embryos obtained from GnRH-agonist long and GnRH-antagonist ovarian stimulation protocol", "description": "difference in embryos' genetic and chromosomal quality using two different ovarian stimulation protocol", "timeFrame": "one year"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* patients carrier genetic disease\n* advanced maternal Age\n* repeated IVF failure\n* recurrent pregnancy loss\n\nExclusion Criteria:\n\n* uterine abnormalities\n* endometriosis\n* endocrinal diseases", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "46 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "European Hospital", "city": "Rome", "zip": "00148", "country": "Italy", "contacts": [{"name": "Ermanno Greco, MD", "role": "CONTACT", "phone": "06-65975643", "email": "ergreco@virgilio.it"}, {"name": "Ermanno greco, MD", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 41.89193, "lon": 12.51133}}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "interventionBrowseModule": {"meshes": [{"id": "C062876", "term": "cetrorelix"}, {"id": "C061018", "term": "ganirelix"}, {"id": "D007987", "term": "Gonadotropin-Releasing Hormone"}, {"id": "D002064", "term": "Buserelin"}], "ancestors": [{"id": "D010906", "term": "Pituitary Hormone-Releasing Hormones"}, {"id": "D007028", "term": "Hypothalamic Hormones"}, {"id": "D036361", "term": "Peptide Hormones"}, {"id": "D006728", "term": "Hormones"}, {"id": "D006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D009479", "term": "Neuropeptides"}, {"id": "D010455", "term": "Peptides"}, {"id": "D000602", "term": "Amino Acids, Peptides, and Proteins"}, {"id": "D009842", "term": "Oligopeptides"}, {"id": "D009419", "term": "Nerve Tissue Proteins"}, {"id": "D011506", "term": "Proteins"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT04318275", "orgStudyIdInfo": {"id": "CT004-AMY004JG"}, "organization": {"fullName": "Biofourmis Singapore Pte Ltd.", "class": "INDUSTRY"}, "briefTitle": "Objective Pain Measurement Using a Wearable Biosensor and a Mobile Platform in Patients With Endometriosis", "officialTitle": "An Early Feasibility Study to Explore a Novel Objective Pain Measurement Using a Wearable Biosensor and a Novel Mobile Platform in Patients With Endometriosis (OPINE)", "acronym": "OPINE"}, "statusModule": {"statusVerifiedDate": "2022-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2020-11-06", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2021-10-28", "type": "ACTUAL"}, "completionDateStruct": {"date": "2022-02-22", "type": "ACTUAL"}, "studyFirstSubmitDate": "2019-12-22", "studyFirstSubmitQcDate": "2020-03-20", "studyFirstPostDateStruct": {"date": "2020-03-23", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2022-05-18", "lastUpdatePostDateStruct": {"date": "2022-05-19", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Biofourmis Singapore Pte Ltd.", "class": "INDUSTRY"}, "collaborators": [{"name": "Chugai Pharmaceutical", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false, "isUsExport": true}, "descriptionModule": {"briefSummary": "This study aims to explore a novel objective measurement for endometriosis-related pain. A variety of pain symptoms are associated with endometriosis, including dysmenorrhea, dyspareunia, dysuria, dyschezia and chronic pelvic pain. However, a clear characterization of pain typology and topology in populations with endometriosis, other gynecologic pathology, or a normal pelvis is lacking. Understanding the precise nature of the relationship between pain and endometriosis is important for the clinical management of affected women, given the body of evidence indicating that medical and surgical management for pain associated with endometriosis has been shown to be effective. Evaluating the relationship between pain and endometriosis, however, is challenging given that pain is difficult to measure and the mechanism by which endometriosis causes pain is not well understood. While previous studies have provided important data on the incidence of pelvic pain and endometriosis, little research has been done to assess both the typology and topology of pelvic pain, pain beyond the pelvis, endometriosis diagnosis, or severity of pain using operative findings and a standardized classification system.", "detailedDescription": "BACKGROUND ON ENDOMETRIOSIS\n\nA variety of pain symptoms are associated with endometriosis, including dysmenorrhea, dyspareunia, dysuria, dyschezia and chronic pelvic pain. However, a clear characterization of pain typology and topology in populations with endometriosis, other gynecologic pathology, or a normal pelvis is lacking. Understanding the precise nature of the relationship between pain and endometriosis is important for the clinical management of affected women, given the body of evidence indicating that medical and surgical management for pain associated with endometriosis has been shown to be effective. Evaluating the relationship between pain and endometriosis, however, is challenging given that pain is difficult to measure and the mechanism by which endometriosis causes pain is not well understood. While previous studies have provided important data on the incidence of pelvic pain and endometriosis, little research has been done to assess both the typology and topology of pelvic pain, and pain beyond the pelvis, and endometriosis diagnosis and severity using operative findings and a standardized classification system.\n\nHistorically, pain has been measured using subjective scales to determine the presence of pain and its severity. Common scales include the numeric rating scale (NRS), visual analog scale (VAS), and visual response scale (VRS). While this is important information, self-reporting is a problematic metric for both diagnostic and research purposes as it depends on pain history, cognitive and behavioral factors, and can vary over time. Other measures used in clinical practice, such as the Biberoglu and Behrman (B\\&B) score, incorporate both patient and clinician assessments of pain. However, patients describe symptomatology and gynecologists evaluate tenderness and induration during physical examination with an exceedingly high risk of bias and inconsistent reproducibility. Over the past few years, significant advances have been made in the development of valid biomarkers or surrogate markers for the presence and severity of pain. Measurement of various physiology parameters like heart rate, heart rate variability and electrodermal activity have shown to be associated with the presence of pain and can aid clinical interpretation.\n\nSTUDY RATIONALE\n\nSeveral ratings, such as the numeric rating scale (NRS) are mainly used in clinical trials to determine the presence and severity of pain associated with endometriosis. Patient Reported Outcomes (PRO) such as NRS can be problematic as they are subjective, containing recall bias, and can vary over time. Thus, a more accurate and objective measurement of pain is needed to evaluate the efficacy of treatment with pain associated with endometriosis."}, "conditionsModule": {"conditions": ["Endometriosis"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "CASE_ONLY", "timePerspective": "PROSPECTIVE"}, "enrollmentInfo": {"count": 90, "type": "ACTUAL"}}, "outcomesModule": {"primaryOutcomes": [{"measure": "The concordance between Pain Index and NRS scores during the study period. (Categorised into none, mild, moderate and severe pain)", "description": "Pain Index will be generated via vital sign collected from subjects and processed by Biofourmis's propriety algorithm. Both pain index and NRS will be categorised into None (0), Mild (1-3), Moderate (4-6), and Severe (7-10) pain.\n\nConcordance will be measured using unweighted Kappa Statistic for multiple categories with 95% CI. Percentage agreement between the categories will be also calculated by taking the number of concordant pairs divided by the total number of pain episodes.", "timeFrame": "12 weeks"}], "secondaryOutcomes": [{"measure": "The correlation between 11-point Pain Index (0-10) and 11-point NRS score (0-10).", "description": "The generated Pain Index will be classified into 11 points (0-10) in accordance with the raw NRS score.\n\nCorrelation between the 11-point Pain Index and raw NRS score will be measured using Spearman correlation.", "timeFrame": "12 weeks"}], "otherOutcomes": [{"measure": "Exploratory Endpoint 1: Correlation between Quality of Life (EQ-5D-5L and EHP-30), Productivity (HRPQ), PROMIS-Fatigue with Sleep Quality and Stress Values calculated using Biofourmis's propriety algorithm.", "description": "The Pearson correlation and its statistical significance between the various Quality of Life measures and the Sleep Quality and Stress Values (calculated using Biofourmis's propriety algorithm) will be presented in a matrix table.", "timeFrame": "12 weeks"}, {"measure": "Exploratory Endpoint 2: Trend of Quality of Life over the study period", "description": "The trend of Quality of life measures will be presented using line charts.", "timeFrame": "12 weeks"}, {"measure": "Exploratory Endpoint 3: Trend of Pain Index and NRS categories over the study period", "description": "The trend of Pain Index and NRS categories (None, Mild, Moderate, Severe) will be presented using bar graphs.", "timeFrame": "12 weeks"}, {"measure": "Exploratory Endpoint 4: Effect of concomitant medication usage on the NRS categories", "description": "Effects of concomitant medication usage will be measured as an increment or decrement in NRS pain categories (None, Mild, Moderate, Severe), based on the highest pain reported by patient before taking the medication and the pain report after medication usage.", "timeFrame": "12 weeks"}, {"measure": "Exploratory Endpoint 5: Effect of concomitant medication usage on the Pain Index categories", "description": "Effects of concomitant medication usage will be measured as an increment or decrement in Pain Index categories (None, Mild, Moderate, Severe), based on the highest pain reported by patient before taking the medication and the Pain Index generated based on the pain report after medication usage.", "timeFrame": "12 weeks"}, {"measure": "Exploratory Endpoint 6: Correlation between EQ-5D-5L and physiological parameters.", "description": "The correlation between EQ-5D-5L and physiological parameters will be presented as scatterplots with the Pearson correlation and statistical significance.", "timeFrame": "12 weeks"}, {"measure": "Exploratory Endpoint 7: Correlation between EHP-30 and physiological parameters.", "description": "The correlation between EHP-30 and physiological parameters will be presented as scatterplots with the Pearson correlation and statistical significance.", "timeFrame": "12 weeks"}, {"measure": "Exploratory Endpoint 8: Correlation between Productivity (HRPQ) and physiological parameters.", "description": "The correlation between Productivity (HRPQ) and physiological parameters will be presented as scatterplots with the Pearson correlation and statistical significance.", "timeFrame": "12 weeks"}, {"measure": "Exploratory Endpoint 9: Correlation between PROMIS-Fatigue and physiological parameters.", "description": "The correlation between PROMIS-Fatigue and physiological parameters will be presented as scatterplots with the Pearson correlation and statistical significance.", "timeFrame": "12 weeks"}, {"measure": "Exploratory Endpoint 10: Change in Pain Index, NRS categories over the menstrual cycle.", "description": "Changes in Pain Index, NRS categories (None, Mild, Moderate, Severe) over the menstrual cycle will be summarized by plotting bar graphs across menstrual cycle.", "timeFrame": "12 weeks"}, {"measure": "Exploratory Endpoint 11: Change in physiological parameters over the menstrual cycle.", "description": "Changes in physiological parameters over the menstrual cycle will be summarized using boxplots across menstrual cycle.", "timeFrame": "12 weeks"}, {"measure": "Exploratory Endpoint 12: Change in Pain Index, NRS categories by the type of lesions", "description": "Changes in Pain Index, NRS categories (None, Mild, Moderate, Severe) over the lesion types will be summarized using bar graphs across the menstrual cycle.", "timeFrame": "12 weeks"}, {"measure": "Exploratory Endpoint 13: Change in physiological parameters by the type of lesions", "description": "Changes in physiological parameters over the lesion types will be summarized using boxplots across the menstrual cycle.", "timeFrame": "12 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion criteria:\n\n1. Able to give a written Informed Consent Form.\n2. Patient who is willing to comply with study restrictions including E4® device management (wearing and charging the device) and Femme Rhythm Patient App Management (pairing E4® device and the patient Femme Rhythm App, and carrying the smartphone for answering questionnaires and data reporting)\n3. Female patients aged ≥ 21 and \\< 50 years.\n4. Patient who meets either A or B or both in the following criteria: A. Confirmed diagnosis of endometriosis (laparoscopy/laparotomy) performed WITHIN 10 YEARS prior to the study participation.\n\n   B. Current clinical diagnosis (endometriotic cysts or deep infiltrating endometriosis detected by TVUS, TRUS or MRI) WITHIN 6 MONTHS prior to the study participation.\n5. Patient who meets either A or B in the following criteria:\n\n   A. Patient is NOT treated with hormonal agents for endometriosis WITHIN 4 WEEKS prior to study participation, and have regular menses (i.e. 21-38 days) within 38 days prior to the study participation.\n\n   B. Patient started hormonal agents for endometriosis, including combined oral contraceptives MORE THAN 8 WEEKS prior to the study participation, or progestins, danazol, GnRH agonists, GnRH antagonists or Progesterone and Levonorgestrel Releasing IUDs MORE THAN 12 WEEKS prior to the study participation, AND stable use of the medication is expected during the study period\n6. Patient has a moderate to severe endometriosis- associated pelvic pain using the Monthly Assessment of Endometriosis Pain within 28 days prior to study participation\n\nExclusion criteria:\n\n1. Patient is pregnant, or breast feeding or is planning a pregnancy during participation of the study or is less than 6 months postpartum, post-abortion, or post-pregnancy before participation.\n2. Patient has chronic pelvic pain that is not caused by endometriosis that requires chronic analgesic or other chronic therapy, or that would interfere with the assessment of endometriosis related pain (e.g., pelvic inflammatory disease).\n3. Patient has more than five surgical histories in pelvic area.\n4. Patient has a skin disease or condition that would interfere with the collection or interpretation of physiological data obtained through E4®\n5. Patient required neuromodulator (a long-acting or immediate release narcotic, or gabapentin) during 3 months prior to the study participation.\n6. Patient has a planned surgery during the study.\n7. Patient had a surgery within 4 weeks prior to the study participation.\n8. Patient has a planned trip overseas during the study participation.\n9. Any other reason that, in the judgment of the investigator, would render the subject unsuitable for the study participation.", "healthyVolunteers": false, "sex": "FEMALE", "genderBased": true, "genderDescription": "Female on self-representation and confirmed diagnosis of endometriosis by TVUS or MRI.", "minimumAge": "21 Years", "maximumAge": "50 Years", "stdAges": ["ADULT"], "studyPopulation": "124 study participants, aged between 21 to 50 years old, female, who is confirmed diagnosis of endometriosis.", "samplingMethod": "PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"overallOfficials": [{"name": "Maulik Majmudar, M.D.", "affiliation": "Biofourmis Inc.", "role": "STUDY_CHAIR"}], "locations": [{"facility": "Mayo Clinic", "city": "Phoenix", "state": "Arizona", "zip": "85054", "country": "United States", "geoPoint": {"lat": 33.44838, "lon": -112.07404}}, {"facility": "Mayo Clinic", "city": "Rochester", "state": "Minnesota", "zip": "55905", "country": "United States", "geoPoint": {"lat": 44.02163, "lon": -92.4699}}, {"facility": "National University Hospital", "city": "Singapore", "zip": "119074", "country": "Singapore", "geoPoint": {"lat": 1.28967, "lon": 103.85007}}, {"facility": "Singapore General Hospital", "city": "Singapore", "zip": "169608", "country": "Singapore", "geoPoint": {"lat": 1.28967, "lon": 103.85007}}, {"facility": "KK Women's and Children's Hospital", "city": "Singapore", "zip": "229899", "country": "Singapore", "geoPoint": {"lat": 1.28967, "lon": 103.85007}}, {"facility": "Taichung Veterans General Hospital", "city": "Taichung", "zip": "40705", "country": "Taiwan", "geoPoint": {"lat": 24.1469, "lon": 120.6839}}, {"facility": "Taipei Veterans General Hospital", "city": "Taipei", "zip": "11217", "country": "Taiwan", "geoPoint": {"lat": 25.05306, "lon": 121.52639}}]}, "referencesModule": {"references": [{"pmid": "16172113", "type": "BACKGROUND", "citation": "Fauconnier A, Chapron C. Endometriosis and pelvic pain: epidemiological evidence of the relationship and implications. Hum Reprod Update. 2005 Nov-Dec;11(6):595-606. doi: 10.1093/humupd/dmi029. Epub 2005 Sep 19."}, {"pmid": "18715240", "type": "BACKGROUND", "citation": "Ballard KD, Seaman HE, de Vries CS, Wright JT. Can symptomatology help in the diagnosis of endometriosis? Findings from a national case-control study--Part 1. BJOG. 2008 Oct;115(11):1382-91. doi: 10.1111/j.1471-0528.2008.01878.x. Epub 2008 Aug 19."}, {"pmid": "16730874", "type": "BACKGROUND", "citation": "Cox L, Ayers S, Nala K, Penny J. Chronic pelvic pain and quality of life after laparoscopy. Eur J Obstet Gynecol Reprod Biol. 2007 Jun;132(2):214-9. doi: 10.1016/j.ejogrb.2006.04.020. Epub 2006 May 30."}, {"pmid": "17103271", "type": "BACKGROUND", "citation": "Kang SB, Chung HH, Lee HP, Lee JY, Chang YS. Impact of diagnostic laparoscopy on the management of chronic pelvic pain. Surg Endosc. 2007 Jun;21(6):916-9. doi: 10.1007/s00464-006-9047-1. Epub 2006 Nov 14."}, {"pmid": "19342028", "type": "BACKGROUND", "citation": "Ballard K, Lane H, Hudelist G, Banerjee S, Wright J. Can specific pain symptoms help in the diagnosis of endometriosis? A cohort study of women with chronic pelvic pain. Fertil Steril. 2010 Jun;94(1):20-7. doi: 10.1016/j.fertnstert.2009.01.164. Epub 2009 Apr 1."}, {"pmid": "21775836", "type": "BACKGROUND", "citation": "Hsu AL, Sinaii N, Segars J, Nieman LK, Stratton P. Relating pelvic pain location to surgical findings of endometriosis. Obstet Gynecol. 2011 Aug;118(2 Pt 1):223-230. doi: 10.1097/AOG.0b013e318223fed0."}, {"pmid": "22569716", "type": "BACKGROUND", "citation": "Renner SP, Boosz AS, Burghaus S, Maihofner C, Beckmann MW, Fasching PA, Jud SM. Visual pain mapping in endometriosis. Arch Gynecol Obstet. 2012 Sep;286(3):687-93. doi: 10.1007/s00404-012-2369-4. Epub 2012 May 9."}, {"pmid": "9130884", "type": "BACKGROUND", "citation": "Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertil Steril. 1997 May;67(5):817-21. doi: 10.1016/s0015-0282(97)81391-x. No abstract available."}, {"pmid": "25180023", "type": "BACKGROUND", "citation": "Bourdel N, Alves J, Pickering G, Ramilo I, Roman H, Canis M. Systematic review of endometriosis pain assessment: how to choose a scale? Hum Reprod Update. 2015 Jan-Feb;21(1):136-52. doi: 10.1093/humupd/dmu046. Epub 2014 Sep 1."}, {"pmid": "30446474", "type": "BACKGROUND", "citation": "Yong PJ, Williams C, Bodmer-Roy S, Ezeigwe C, Zhu S, Arion K, Ambacher K, Yosef A, Wong F, Noga H, Britnell S, Yager H, Bedaiwy MA, Brotto LA, Albert AY, Lisonkova S, Allaire C. Prospective Cohort of Deep Dyspareunia in an Interdisciplinary Setting. J Sex Med. 2018 Dec;15(12):1765-1775. doi: 10.1016/j.jsxm.2018.10.005. Epub 2018 Nov 13."}, {"pmid": "24630080", "type": "BACKGROUND", "citation": "Practice Committee of the American Society for Reproductive Medicine. Treatment of pelvic pain associated with endometriosis: a committee opinion. Fertil Steril. 2014 Apr;101(4):927-35. doi: 10.1016/j.fertnstert.2014.02.012. Epub 2014 Mar 13."}, {"pmid": "22560852", "type": "BACKGROUND", "citation": "Rotondi MA, Donner A. A confidence interval approach to sample size estimation for interobserver agreement studies with multiple raters and outcomes. J Clin Epidemiol. 2012 Jul;65(7):778-84. doi: 10.1016/j.jclinepi.2011.10.019. Epub 2012 May 4."}, {"pmid": "26269529", "type": "BACKGROUND", "citation": "Schliep KC, Mumford SL, Peterson CM, Chen Z, Johnstone EB, Sharp HT, Stanford JB, Hammoud AO, Sun L, Buck Louis GM. Pain typology and incident endometriosis. Hum Reprod. 2015 Oct;30(10):2427-38. doi: 10.1093/humrep/dev147. Epub 2015 Aug 11."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT00455845", "orgStudyIdInfo": {"id": "15/2007"}, "organization": {"fullName": "Mahidol University", "class": "OTHER"}, "briefTitle": "The Effectiveness of Lng IUD for Treatment of the Patient Undergone Conservative Surgery for Pelvic Endometriosis", "officialTitle": "A Double Blind Randomized Controlled Trial to Study the Effectiveness of a Levonorgestrel Releasing Intrauterine Device for the Treatment of Pelvic Pain or Dysmenorrhea in the Patients Undergone Conservative Surgery for Pelvic Endometriosis"}, "statusModule": {"statusVerifiedDate": "2007-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-04"}, "primaryCompletionDateStruct": {"date": "2009-12", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-04-03", "studyFirstSubmitQcDate": "2007-04-03", "studyFirstPostDateStruct": {"date": "2007-04-04", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2011-03-01", "lastUpdatePostDateStruct": {"date": "2011-03-02", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "Associate Prof. Prasong Tanmahasamut", "oldOrganization": "Mahidol University"}, "leadSponsor": {"name": "Mahidol University", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "this study is to determine whether the frequency and severity of pelvic pain or dysmenorrhea are reduced in women with symptomatic endometriosis in whom a Lng IUD is inserted after operative laparoscopy compare with those treated with laparoscopic surgery only", "detailedDescription": "Endometriosis is a common cause of chronic pelvic pain.Laparoscopic surgery is often the treatment of choice for symptomatic disease and results are usually satisfactory but symptoms recur in 10-20% of treated women per year. Postoperative medical therapy has been controversial. Whereas some studies have observed a long pain free interval or higher pregnancy rates when surgical treatment is followed by an interval of medical suppressive treatment, numerous others have found no differences between the prevalence of recurrent pain or pregnancy rates 1-3 years after surgery treatment in women who did and did not receive postoperative medical treatment.Endometriosis is generally a localized disease but is currently managed with systemic medical therapies. The use of drugs administered locally and specifically aimed at pelvic organs could limit the metabolic impact without reducing antalgic efficacy.An intrauterine device releasing levonorgestrel, a potent 19-nortestosterone derivative progestin, can induce amenorrhea with a different modality with respect to standard regimens. The levonorgestrel intrauterine device (Lng-IUD) provides an alternative means of administering progestins.Some researchers reported the effectiveness of the Lng IUD in the patients with endometriosis.The primary objective of this study is to determine whether the frequency and severity of dysmenorrhea are reduced in women with symptomatic endometriosis in whom a Lng IUD is inserted after operative laparoscopy compare with those treated with laparoscopic surgery only.\n\nThe secondary objective is to compare about pain, bleeding, satisfaction and quality of life score between both groups"}, "conditionsModule": {"conditions": ["Endometriosis", "Pelvic Pain", "Dysmenorrhea"], "keywords": ["Endometriosis", "Lng IUD"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "PREVENTION", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 54, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "1 levonorgestrel IUD", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Device: Levonorgestrel IUD"]}, {"label": "2 control", "type": "NO_INTERVENTION", "interventionNames": ["Device: Levonorgestrel IUD"]}], "interventions": [{"type": "DEVICE", "name": "Levonorgestrel IUD", "description": "levonorgestrel IUD", "armGroupLabels": ["1 levonorgestrel IUD", "2 control"], "otherNames": ["Minera IUD"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "the frequency and severity of pelvic pain or dysmenorrhea", "timeFrame": "12 months"}], "secondaryOutcomes": [{"measure": "compare about pain, bleeding, satisfaction and quality of life score between both groups", "timeFrame": "12 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* women diagnosed endometriosis stage I-IV according to the revised American Society of Reproductive Medicine classification\n* Moderate or severe pelvic pain or dysmenorrhea\n* Undergoing conservative laparoscopic surgery\n\nExclusion Criteria:\n\n* Patients who have uterine or adnexal anomalies other than endometriosis (chronic pelvic inflammatory disease, leiomyomas, endometrial polyps, genital malformations, pelvic varices)\n* using treatments for endometriosis other than paracetamol,nonsteroid anti-inflammatory drugs or narcotic derivative in the 3 months before study entry\n* Unable to perform conservative surgery\n* Patients who have contraindications to Lng IUD as defined by the World Health Organization (2004).\n* Patients who are unwilling to tolerate menstrual changes.\n* Plan to have children within 1 year\n* Unable to evaluate pain with visual analogue scale\n* unwilling to participate this project", "healthyVolunteers": true, "sex": "FEMALE", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Prasong Tanmahasamut, M.D.", "affiliation": "Mahidol University", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Mahidol University", "city": "Bangkoknoi", "state": "Bangkok", "zip": "10700", "country": "Thailand"}]}, "referencesModule": {"references": [{"pmid": "22314873", "type": "DERIVED", "citation": "Tanmahasamut P, Rattanachaiyanont M, Angsuwathana S, Techatraisak K, Indhavivadhana S, Leerasiri P. Postoperative levonorgestrel-releasing intrauterine system for pelvic endometriosis-related pain: a randomized controlled trial. Obstet Gynecol. 2012 Mar;119(3):519-26. doi: 10.1097/AOG.0b013e31824264c3."}]}}, "annotationSection": {"annotationModule": {"unpostedAnnotation": {"unpostedResponsibleParty": "Mahidol University", "unpostedEvents": [{"type": "RELEASE", "date": "2015-09-28"}, {"type": "RESET", "date": "2015-10-29"}, {"type": "RELEASE", "date": "2016-11-07"}, {"type": "RESET", "date": "2017-01-03"}, {"type": "RELEASE", "date": "2018-03-20"}, {"type": "RESET", "date": "2018-11-01"}, {"type": "RELEASE", "date": "2019-07-08"}, {"type": "RESET", "date": "2019-08-15"}]}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04", "submissionTracking": {"estimatedResultsFirstSubmitDate": "2015-09-28", "submissionInfos": [{"releaseDate": "2015-09-28", "resetDate": "2015-10-29"}, {"releaseDate": "2016-11-07", "resetDate": "2017-01-03"}, {"releaseDate": "2018-03-20", "resetDate": "2018-11-01"}, {"releaseDate": "2019-07-08", "resetDate": "2019-08-15"}]}}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}, {"id": "D017699", "term": "Pelvic Pain"}, {"id": "D004412", "term": "Dysmenorrhea"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}, {"id": "D010146", "term": "Pain"}, {"id": "D009461", "term": "Neurologic Manifestations"}, {"id": "D012816", "term": "Signs and Symptoms"}, {"id": "D013568", "term": "Pathological Conditions, Signs and Symptoms"}, {"id": "D008599", "term": "Menstruation Disturbances"}, {"id": "D010335", "term": "Pathologic Processes"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT04454424", "orgStudyIdInfo": {"id": "20331"}, "organization": {"fullName": "Bayer", "class": "INDUSTRY"}, "briefTitle": "Study on the Safety of BAY1817080, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug in Participants With Impaired Liver Function or Normal Liver Function", "officialTitle": "An Open-label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of BAY 1817080 in Participants With Impaired Hepatic Function (Classified as Child-Pugh A, B or C) in Comparison to Matched Controls With Normal Hepatic Function"}, "statusModule": {"statusVerifiedDate": "2023-01", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2020-07-23", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2021-06-24", "type": "ACTUAL"}, "completionDateStruct": {"date": "2021-12-15", "type": "ACTUAL"}, "studyFirstSubmitDate": "2020-06-29", "studyFirstSubmitQcDate": "2020-06-29", "studyFirstPostDateStruct": {"date": "2020-07-01", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-01-19", "lastUpdatePostDateStruct": {"date": "2023-01-20", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Bayer", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "BAY1817080 is currently under clinical development to treat pain related to unexplained chronic cough or chronic cough not affected by a treatment (refractory and/or unexplained chronic cough, RUCC), or a condition where the bladder is unable to hold urine normally (overactive bladder, OAB) or a condition in which tissue similar to the tissue that normally lines the inside of the womb grows outside the womb (endometriosis).\n\nIn this study researchers want to learn more about the safety of BAY1817080, how it is tolerated and the way the body absorbs, distributes and gets rid of the study dug given as tablet in participants with mild, moderate or severe hepatic impairment and participants with normal liver function matched for age-, gender-, weight and race.\n\nThe study will enroll 36 male and female participants in the age between 18 and 79 years. Participants with mild or moderate hepatic impairment and the matching participants will take multiple oral doses of study drug depending on the study plan. Participants with severe hepatic impairment and the matching participants will take a single oral dose of study drug during the study. Data from this study will provide researcher important information for further development of the study drug in particular on dose recommendation for patients with hepatic impairment."}, "conditionsModule": {"conditions": ["Endometriosis Related Pain", "Overactive Bladder", "Diabetic Neuropathic Pain", "Refractory or Unexplained Chronic Cough"], "keywords": ["Pharmacokinetics", "Safety", "Tolerability", "Specific population", "Subjects with hepatic impairment"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "NON_RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "BASIC_SCIENCE", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 37, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Arm A: Child-Pugh A", "type": "EXPERIMENTAL", "description": "Participants with mildly impaired hepatic function (Child-Pugh A)", "interventionNames": ["Drug: BAY1817080", "Drug: Midazolam"]}, {"label": "Arm B: Child-Pugh B", "type": "EXPERIMENTAL", "description": "Participants with moderately impaired hepatic function (Child-Pugh B)", "interventionNames": ["Drug: BAY1817080", "Drug: Midazolam"]}, {"label": "Arm C: Child-Pugh C", "type": "EXPERIMENTAL", "description": "Participants with severely impaired hepatic function (Child-Pugh C)", "interventionNames": ["Drug: BAY1817080", "Drug: Midazolam"]}, {"label": "Arm D: Normal hepatic (Matched A and B)", "type": "EXPERIMENTAL", "description": "Participants with normal hepatic function matched to Arm A and B", "interventionNames": ["Drug: BAY1817080", "Drug: Midazolam"]}, {"label": "Arm E: Normal hepatic (Matched to C)", "type": "EXPERIMENTAL", "description": "Participants with normal hepatic function matched to Arm C", "interventionNames": ["Drug: BAY1817080", "Drug: Midazolam"]}], "interventions": [{"type": "DRUG", "name": "BAY1817080", "description": "Study intervention BAY1817080 will be administered orally with tablet(s).", "armGroupLabels": ["Arm A: Child-Pugh A", "Arm B: Child-Pugh B", "Arm C: Child-Pugh C", "Arm D: Normal hepatic (Matched A and B)", "Arm E: Normal hepatic (Matched to C)"]}, {"type": "DRUG", "name": "Midazolam", "description": "Midazolam will be administered intravenously with dose of 0.1 mg on Day 1.", "armGroupLabels": ["Arm A: Child-Pugh A", "Arm B: Child-Pugh B", "Arm C: Child-Pugh C", "Arm D: Normal hepatic (Matched A and B)", "Arm E: Normal hepatic (Matched to C)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "AUCu after single dose of BAY1817080", "description": "AUCu: Area under the Curve unbound", "timeFrame": "On day 1"}, {"measure": "Cmax,u after single dose of BAY1817080", "description": "Cmax,u: maximum observed drug concentration in measured matrix after single dose administration (unbound)", "timeFrame": "On day 1"}], "secondaryOutcomes": [{"measure": "Number of subjects with treatment-emergent adverse events", "timeFrame": "from dosing up to 14 days after end of treatment with study medication"}, {"measure": "AUC (0-12)md,u after multiple dose of BAY1817080", "description": "AUC (0-12)md,u: Area Under the Curve from 0-12 hours at steady state for the multiple dose (unbound)", "timeFrame": "From day 6 to day 13"}, {"measure": "Cmax,md,u after multiple dose of BAY1817080", "description": "Cmax,md,u: Maximum observed drug concentration at steady state for multiple dose (unbound)", "timeFrame": "From day 6 to day 13"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Participant must be 18 to 79 years of age inclusive, at the time of signing the informed consent.\n* Participants with a medical history of chronic (For Hepatically Impaired Participants only):\n\n  * documented liver cirrhosis confirmed by histopathology, laparoscopy, fibroscan, CT, MRI or ultrasound, AND\n  * hepatic impairment (Child-Pugh A or B or C), AND\n  * stable liver disease, i.e. same Child-Pugh class for at least 2 months prior to screening.\n* Body mass index (BMI) within the range 18 to 38 kg/m\\^2 (both inclusive).\n* Male or female.\n* Women of childbearing potential (WOCBP) must agree to use contraception for the duration of the study. This applies for the time period between signing of the Informed Consent Form until at least 30 days after the last dose of the study drug.\n* Capable of giving signed informed consent as described in study protocol which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.\n\nExclusion Criteria:\n\n* Any relevant disease (other than those related to hepatic impairment for the hepatic impaired participants) within 4 weeks prior to study drug administration including infections and acute gastro-intestinal diseases (vomiting, diarrhea, constipation) requiring medical treatment.\n* Renal failure with an estimated glomerular filtration rate (eGFR) ≤ 35 mL/min, according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.\n* Use of strong CYP3A4 and P-glycoprotein inhibitors from 2 weeks before study treatment until last day of blood sampling for pharmacokinetics after study drug administration.\n* Use of CYP3A4 and P-glycoprotein inducers from 2 weeks before study treatment until last day of blood sampling for pharmacokinetics after study drug administration.\n* Use of drugs which may affect absorption (e.g. loperamide, metoclopramide), and systemic administration of any broad-spectrum antibiotic within 1 week before first study drug administration, unless the drug is part of the mandatory dosing regimen for treatment of hepatic impairment or related conditions.\n* Indication or evidence for long QT syndrome; Participants in control arm only: QT interval corrected using Fridericia's method (QTcF) \\> 450 msec.\n* Ascites qualitatively estimated as severe ascites by physical examination, with need of paracentesis; or a recent history of paracentesis.\n* Alkaline phosphatase (AP) ≥4 times the upper limit of normal (ULN).\n* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) in conjunction with gamma-glutamyl transpeptidase (GGT) ≥4 times the ULN (an isolated elevation of GGT above 4 times ULN will not exclude the participant).\n* International Normalized Ratio (INR) \\> 2.7.\n* Inability to provide informed consent: Participants with psychiatric disorders, including hepatic encephalopathy \\>grade 2, e.g. number connection test \\>80 seconds.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "79 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "Clinical Pharmacology of Miami, LLC", "city": "Miami", "state": "Florida", "zip": "33014", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Orlando Clinical Research Center", "city": "Orlando", "state": "Florida", "zip": "32806", "country": "United States", "geoPoint": {"lat": 28.53834, "lon": -81.37924}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "Click here to find information for studies related to Bayer products. To find this study enter the ClinicalTrials.gov identifier (NCT) number or Bayer Study Identifier (ID) in the search field.", "url": "http://clinicaltrials.bayer.com/"}]}, "ipdSharingStatementModule": {"ipdSharing": "NO", "description": "Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA \"Principles for responsible clinical trial data sharing\". This pertains to scope, timepoint and process of data access.\n\nAs such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.\n\nInterested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal."}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D053201", "term": "Urinary Bladder, Overactive"}], "ancestors": [{"id": "D001745", "term": "Urinary Bladder Diseases"}, {"id": "D014570", "term": "Urologic Diseases"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D052801", "term": "Male Urogenital Diseases"}, {"id": "D059411", "term": "Lower Urinary Tract Symptoms"}, {"id": "D020924", "term": "Urological Manifestations"}, {"id": "D012816", "term": "Signs and Symptoms"}, {"id": "D013568", "term": "Pathological Conditions, Signs and Symptoms"}]}, "interventionBrowseModule": {"meshes": [{"id": "D008874", "term": "Midazolam"}], "ancestors": [{"id": "D001569", "term": "Benzodiazepines"}, {"id": "D001552", "term": "Benzazepines"}, {"id": "D006574", "term": "Heterocyclic Compounds, 2-Ring"}, {"id": "D000072471", "term": "Heterocyclic Compounds, Fused-Ring"}, {"id": "D006571", "term": "Heterocyclic Compounds"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT06525155", "orgStudyIdInfo": {"id": "PMR0123"}, "organization": {"fullName": "Rumah Sakit Pusat Angkatan Darat Gatot Soebroto", "class": "OTHER"}, "briefTitle": "Effect GnRH Agonist Administration in Endometriosis Cyst Patients", "officialTitle": "Effect of GnRH Agonist Administration on Decreasing VAS, Estradiol, and Anti Mullerian Hormone in Endometriosis Cyst Patients"}, "statusModule": {"statusVerifiedDate": "2024-11", "overallStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2024-01-02", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2025-02", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2025-02", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2024-07-24", "studyFirstSubmitQcDate": "2024-07-24", "studyFirstPostDateStruct": {"date": "2024-07-29", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2024-11-21", "lastUpdatePostDateStruct": {"date": "2024-11-25", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Surya Adi Pramono", "investigatorTitle": "Principal Investigator", "investigatorAffiliation": "Rumah Sakit Pusat Angkatan Darat Gatot Soebroto"}, "leadSponsor": {"name": "Rumah Sakit Pusat Angkatan Darat Gatot Soebroto", "class": "OTHER"}, "collaborators": [{"name": "Dexa Medica Group", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "Endometriosis is a chronic disease that affects 10-15% of women of childbearing age. The most common symptom is pelvic pain. One of the treatment options that has been proven effective in treating endometriosis symptoms, including endometriosis pain, is triptorelin. Triptorelin has also received a distribution permit in Indonesia for the treatment of endometriosis.\n\nHowever, patient compliance in using this drug is very low due to high medical costs and side effects of the drug. Standard treatment with triptorelin is generally given every 4 weeks. A previous preliminary study showed that triptorelin could be given at 6-week interval and provided treatment results that were no different from those at 4-week interval. This is certainly better, because with longer interval doses it can reduce medical costs, reduce side effects due to hormone suppression and can increase patient compliance in undergoing treatment. Therefore, in this study triptorelin will be given to 2 groups and observed for 18 weeks. The first group will be given triptorelin twice before surgery, each with an interval of 6 weeks, at baseline and week-6. Then triptorelin will be given again once after surgery at week-12. In the second group, triptorelin will be given once after surgery at week-12. In this study, the effect of triptorelin on the treatment of endometriosis will be measured based on the improvement in the degree of pain felt by the subjects using a visual analogue scale (VAS) at baseline, week-6, week-12 (prior to surgery) and week-18; Anti Mullerian Hormone (AMH) levels, and estradiol levels before triptorelin administration (at baseline) and prior to surgery (week-12). The condition of the uterus and cysts will also be evaluated at the time of surgery.", "detailedDescription": "There will be 2 groups of treatment; each group will consist of 16 subjects with study period for 18 weeks.\n\nTreatment I : twice before surgery (baseline and week-6) and once after surgery at week-12 Treatment II : once after surgery at week-12\n\nThe eligible subjects will be allocated to receive study medication (Treatment 1 or Treatment 2) in an open label study. They will be asked to come to the hospital every 6-week interval throughout the study period.\n\nSubjects will be evaluated based on the improvement in the degree of pain felt by the subjects using a visual analogue scale (VAS) on each visit throughout the study period (at baseline, week-6, week-12 prior to surgery and week-18), and Anti Mullerian Hormone (AMH) levels and estradiol levels at baseline and week-12 (prior to surgery). The condition of the uterus and cysts will also be evaluated at the time of surgery at week-12."}, "conditionsModule": {"conditions": ["Endometriosis"], "keywords": ["Triptorelin embonate", "Endometriosis cyst"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "NON_RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 32, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Treatment 1", "type": "EXPERIMENTAL", "description": "Triptorelin Embonate, 3 times dosing", "interventionNames": ["Drug: Triptorelin Embonate"]}, {"label": "Treatment 2", "type": "EXPERIMENTAL", "description": "Triptorelin Embonate, 1 time dosing", "interventionNames": ["Drug: Triptorelin Embonate"]}], "interventions": [{"type": "DRUG", "name": "Triptorelin Embonate", "description": "Treatment 1: 3.75 mg twice before surgery (baseline and week-6) and once after surgery at week-12", "armGroupLabels": ["Treatment 1"], "otherNames": ["Pamorelin"]}, {"type": "DRUG", "name": "Triptorelin Embonate", "description": "Treatment 2: 3.75 mg once after surgery at week-12", "armGroupLabels": ["Treatment 2"], "otherNames": ["Pamorelin"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Anti Mullerian Hormones (AMH) levels", "description": "Hormone which is produced by ovarian follicles indirectly represent remaining ovarian reserves.", "timeFrame": "Baseline, week-12 (prior to surgery)"}], "secondaryOutcomes": [{"measure": "Visual Analogue Scale (VAS)", "description": "Pain intensity measurement tool and presented in the form of a horizontal line and given a number 0-10.", "timeFrame": "Baseline, week-6, week-12, week-18"}, {"measure": "Estradiol levels", "description": "Estradiol is a sex hormone that has proinflammatory and anti-apoptotic effects on endometrial cells which can exacerbate endometriosis.", "timeFrame": "Baseline, week-12 (prior to surgery)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Female subjects aged 18 to 40 years.\n* The subjects was diagnosed with endometriosis cysts.\n* Willing to participate in research and sign informed consent before all research-related activities begin.\n* Regular menstruation (within 25 - 35 day intervals) in the last 3 months before the study was conducted.\n\nExclusion Criteria:\n\n* The patient used hormonal contraception in the last 3 months prior to the study.\n* Using a GnRH agonist within the past 3 months.\n* Using the hormone progesterone within the last 3 months\n* Pregnancy, breastfeeding females\n* History of osteoporosis\n* History of blood clotting disorders\n* History of heart and blood vessel disorders", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "40 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Surya A Pramono, Sp.OG., Subsp.FER, MD", "role": "CONTACT", "phone": "+6282145122104", "email": "suryaadipramono230781@gmail.com"}], "overallOfficials": [{"name": "Surya A Pramono, Sp.OG., Subsp.FER, MD", "affiliation": "Rumah Sakit Pusat Angkatan Darat Gatot Soebroto", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Department of Obstetrics and Gynecology Central Army Hospital Gatot Soebroto", "status": "RECRUITING", "city": "Jakarta", "zip": "10410", "country": "Indonesia", "contacts": [{"name": "Surya A Pramono, Sp.OG., Subsp.FER", "role": "CONTACT", "phone": "+6282145122104", "email": "suryaadipramono230781@gmail.com"}], "geoPoint": {"lat": -6.21462, "lon": 106.84513}}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D017329", "term": "Triptorelin Pamoate"}], "ancestors": [{"id": "D007987", "term": "Gonadotropin-Releasing Hormone"}, {"id": "D010906", "term": "Pituitary Hormone-Releasing Hormones"}, {"id": "D007028", "term": "Hypothalamic Hormones"}, {"id": "D036361", "term": "Peptide Hormones"}, {"id": "D006728", "term": "Hormones"}, {"id": "D006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D009479", "term": "Neuropeptides"}, {"id": "D010455", "term": "Peptides"}, {"id": "D000602", "term": "Amino Acids, Peptides, and Proteins"}, {"id": "D009842", "term": "Oligopeptides"}, {"id": "D009419", "term": "Nerve Tissue Proteins"}, {"id": "D011506", "term": "Proteins"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT01553201", "orgStudyIdInfo": {"id": "120083"}, "secondaryIdInfos": [{"id": "12-N-0083"}], "organization": {"fullName": "National Institutes of Health Clinical Center (CC)", "class": "NIH"}, "briefTitle": "Botulinum Toxin for Pelvic Pain in Women With Endometriosis", "officialTitle": "The Effectiveness of Botulinum Toxin on Persistent Pelvic Pain in Women With Endometriosis"}, "statusModule": {"statusVerifiedDate": "2018-09", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2014-07-30", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2018-07-31", "type": "ACTUAL"}, "completionDateStruct": {"date": "2019-07-24", "type": "ACTUAL"}, "studyFirstSubmitDate": "2012-03-10", "studyFirstSubmitQcDate": "2012-03-13", "studyFirstPostDateStruct": {"date": "2012-03-14", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2020-06-30", "resultsFirstSubmitQcDate": "2020-06-30", "resultsFirstPostDateStruct": {"date": "2020-07-08", "type": "ACTUAL"}, "dispFirstSubmitDate": "2019-04-19", "dispFirstSubmitQcDate": "2019-06-03", "dispFirstPostDateStruct": {"date": "2019-06-06", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2020-07-15", "lastUpdatePostDateStruct": {"date": "2020-07-28", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "National Institute of Neurological Disorders and Stroke (NINDS)", "class": "NIH"}}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "Background:\n\n\\- Some women with endometriosis have chronic pelvic pain. This pain may be caused by spasms of the pelvic floor muscles. These spasms can be detected by an examination. Studies suggest that botulinum toxin can help treat problems caused by muscle spasms. Researchers want to see if botulinum toxin injections into the pelvic floor muscles can decrease pain and spasms in women with pelvic pain.\n\nObjectives:\n\n\\- To see if botulinum toxin can relieve pain from pelvic floor spasm in women with pelvic pain.\n\nEligibility:\n\n\\- Women between 18 and 50 years of age with pain associated with pelvic muscle spasm and endometriosis. Pain must be persistent (lasting for at least 3 months).\n\nDesign:\n\n* Participants will keep a pain diary and record their pain medication use for a month before the first visit.\n* Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. Participants will also answer questions about their pain levels and quality of life.\n* Participants will receive either botulinum toxin or a placebo (salt water) injection. The injection will be given into the pelvic floor muscles through the vaginal wall. Participants will take a muscle relaxant like Valium and have anesthetic cream put on the vaginal wall before the injection.\n* After the injection, participants will keep a pain diary for another month.\n* At a 1-month followup visit, participants will answer questions about their pain. If the pain has not improved, all participants may have a botulinum toxin injection (no placebo) into the pelvic floor muscles as before.\n* Participants will have followup visits for up to a year after the initial 1-month followup visit.", "detailedDescription": "Chronic pelvic pain associated with endometriosis is poorly understood. Some women with chronic pelvic pain have muscle spasm of their pelvic muscles. Muscle spasm may be a significant part of pain in women with endometriosis and other types of chronic pelvic pain. Botulinum toxin injection is widely used to treat conditions associated with excessive muscle activity and spasm. Studies of botulinum toxin injected into pelvic muscles of women with pelvic pain have shown a decrease pain and spasm, but too few women have been studied to conclude its effectiveness. We expect to show that botulinum toxin injection in women with pelvic pain will relieve some of their pelvic pain.\n\nEligible subjects will be otherwise healthy women who have chronic pelvic pain and a history of endometriosis. Subjects will be randomized to either botulinum toxin injection or placebo (salt water) injection. After one month, we will evaluate the presence of the pain and all women will be offered botulinum toxin injection. We will also evaluate the need for reinjection."}, "conditionsModule": {"conditions": ["Endometriosis", "Chronic Pelvic Pain", "Pelvic Muscle Spasm", "Quality of Life"], "keywords": ["Quality of Life", "Endometriosis", "Botulinum Toxin A", "Pelvic Floor Muscle Spasm", "Chronic Pelvic Pain"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1", "PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 30, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Botulinum toxin (BoNT)", "type": "EXPERIMENTAL", "description": "OnabotulinumtoxinA 100 Units diluted in 4cc saline, one time intramuscular administration", "interventionNames": ["Drug: Botulinum toxin (BoNT)"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Saline, 4cc, one time intramuscular administration", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Botulinum toxin (BoNT)", "description": "OnabotulinumtoxinA 100 Units diluted in 4cc saline, one time intramuscular administration", "armGroupLabels": ["Botulinum toxin (BoNT)"]}, {"type": "DRUG", "name": "Placebo", "description": "Saline, 4cc, one time intramuscular administration", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Participants With Improvement in Pain", "description": "Self reported improvement in pain symptoms - a binary measurement of improvement/no improvement", "timeFrame": "1 month"}]}, "eligibilityModule": {"eligibilityCriteria": "* INCLUSION CRITERIA:\n* Female gender\n* Age between 18 and 55\n* History of endometriosis at surgery\n* Persistent pelvic pain for at least 3 months\n* Pelvic floor spasm\n* Negative pregnancy test (in women who have not had a hysterectomy)\n* Willing to use reliable method of contraception for the month after botulinum toxin injection including oral contraceptives, IUD, and barrier with spermicide.\n* Willing and able to give informed consent\n* Willing and able to comply with study requirements\n\nEXCLUSION CRITERIA:\n\n* Women with other causes of chronic pelvic pain including infectious, gastrointestinal, psychological disorders, fibromyalgia and chronic fatigue syndrome based on review of medical history within 1 year of first study visit,\n* Untreated severe cervical dysplasia or other gynecologic condition clinically significant abnormalities on physical or laboratory examinations that require evaluation or treatment or that would make participation unsafe\n* Hysterectomy and bilateral salpingo-oophorectomy\n* Pregnancy\n* Lactation\n* Allergy to albumen or botulinum toxin\n* Presence of antibodies to botulinum toxin or loss of response to previous injections for any indication\n* A known neuromuscular junction disorder such as myasthenia gravis or Eaton-Lambert syndrome\n* History of urinary or fecal incontinence\n* Known pelvic prolapse\n\n  * Eligibility will be based on a physical exam at NIH at the first study visit, as well as history and available medical records within 1 year before the study visit. Negative test results will be documented to confirm study eligibility. If the Pap and the GC and chlamydia tests were not done outside of the NIH within the previous year, or if documentation of the negative test results is not available, we will await the results of the screening tests done at the NIH before administering the study medication.", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "55 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Barbara I Karp, M.D.", "affiliation": "National Institute of Neurological Disorders and Stroke (NINDS)", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "National Institutes of Health Clinical Center, 9000 Rockville Pike", "city": "Bethesda", "state": "Maryland", "zip": "20892", "country": "United States", "geoPoint": {"lat": 38.98067, "lon": -77.10026}}]}, "referencesModule": {"references": [{"pmid": "17012454", "type": "BACKGROUND", "citation": "Abbott JA, Jarvis SK, Lyons SD, Thomson A, Vancaille TG. Botulinum toxin type A for chronic pain and pelvic floor spasm in women: a randomized controlled trial. Obstet Gynecol. 2006 Oct;108(4):915-23. doi: 10.1097/01.AOG.0000237100.29870.cc."}, {"pmid": "15990116", "type": "BACKGROUND", "citation": "Bhidayasiri R, Truong DD. Expanding use of botulinum toxin. J Neurol Sci. 2005 Aug 15;235(1-2):1-9. doi: 10.1016/j.jns.2005.04.017."}, {"pmid": "15201348", "type": "BACKGROUND", "citation": "Jankovic J. Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry. 2004 Jul;75(7):951-7. doi: 10.1136/jnnp.2003.034702."}, {"pmid": "33326662", "type": "DERIVED", "citation": "Phan VT, Stratton P, Tandon HK, Sinaii N, Aredo JV, Karp BI, Merideth MA, Shah JP. Widespread myofascial dysfunction and sensitisation in women with endometriosis-associated chronic pelvic pain: A cross-sectional study. Eur J Pain. 2021 Apr;25(4):831-840. doi: 10.1002/ejp.1713. Epub 2021 Jan 8."}, {"pmid": "31289238", "type": "DERIVED", "citation": "Tandon HK, Stratton P, Sinaii N, Shah J, Karp BI. Botulinum toxin for chronic pelvic pain in women with endometriosis: a cohort study of a pain-focused treatment. Reg Anesth Pain Med. 2019 Jul 8:rapm-2019-100529. doi: 10.1136/rapm-2019-100529. Online ahead of print."}], "seeAlsoLinks": [{"label": "NIH Clinical Center Detailed Web Page", "url": "https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2012-N-0083.html"}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Botulinum Toxin (BoNT)", "description": "OnabotulinumtoxinA 100 Units diluted in 4cc saline, one time intramuscular administration"}, {"id": "FG001", "title": "Placebo", "description": "Saline, 4cc, one time intramuscular administration"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "15"}, {"groupId": "FG001", "numSubjects": "15"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "15"}, {"groupId": "FG001", "numSubjects": "15"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "One subject in the placebo arm completed the study but her data was censored (i.e. not analyzed) on recommendation by the DSMB statistician, as she was one of a sister pair.", "groups": [{"id": "BG000", "title": "Botulinum Toxin (BoNT)", "description": "OnabotulinumtoxinA 100 Units diluted in 4cc saline, one time intramuscular administration"}, {"id": "BG001", "title": "Placebo", "description": "Saline, 4cc, one time intramuscular administration"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "15"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "29"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "15"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "29"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "15"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "29"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "4"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "14"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "25"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "3"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "13"}, {"groupId": "BG002", "value": "23"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "2"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Participants With Improvement in Pain", "description": "Self reported improvement in pain symptoms - a binary measurement of improvement/no improvement", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "1 month", "groups": [{"id": "OG000", "title": "Botulinum Toxin (BoNT)", "description": "OnabotulinumtoxinA 100 Units diluted in 4cc saline, one time intramuscular administration"}, {"id": "OG001", "title": "Placebo", "description": "Saline, 4cc, one time intramuscular administration"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "4"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "1 month", "eventGroups": [{"id": "EG000", "title": "Botulinum Toxin (BoNT)", "description": "OnabotulinumtoxinA 100 Units diluted in 4cc saline, one time intramuscular administration", "deathsNumAffected": 0, "deathsNumAtRisk": 15, "seriousNumAffected": 0, "seriousNumAtRisk": 15, "otherNumAffected": 7, "otherNumAtRisk": 15}, {"id": "EG001", "title": "Placebo", "description": "Saline, 4cc, one time intramuscular administration", "deathsNumAffected": 0, "deathsNumAtRisk": 15, "seriousNumAffected": 0, "seriousNumAtRisk": 15, "otherNumAffected": 2, "otherNumAtRisk": 15}], "otherEvents": [{"term": "Muscular weakness", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Migraine", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Urinary hesitation", "organSystem": "Renal and urinary disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 15}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}]}, {"term": "Micturition urgency", "organSystem": "Renal and urinary disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}]}, {"term": "Pelvic pain", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 15}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": true, "restrictiveAgreement": false}, "pointOfContact": {"title": "Barbara Karp, MD", "organization": "National Institute of Neurological Disorders & Stroke", "email": "karpb@ninds.nih.gov", "phone": "301-496-0150"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2019-07-22", "uploadDate": "2020-07-13T12:31", "filename": "Prot_SAP_001.pdf", "size": 7158837}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D001905", "term": "Botulinum Toxins"}], "ancestors": [{"id": "D008666", "term": "Metalloendopeptidases"}, {"id": "D010450", "term": "Endopeptidases"}, {"id": "D010447", "term": "Peptide Hydrolases"}, {"id": "D006867", "term": "Hydrolases"}, {"id": "D004798", "term": "Enzymes"}, {"id": "D045762", "term": "Enzymes and Coenzymes"}, {"id": "D045726", "term": "Metalloproteases"}, {"id": "D001426", "term": "Bacterial Proteins"}, {"id": "D011506", "term": "Proteins"}, {"id": "D000602", "term": "Amino Acids, Peptides, and Proteins"}, {"id": "D001427", "term": "Bacterial Toxins"}, {"id": "D014118", "term": "Toxins, Biological"}, {"id": "D001685", "term": "Biological Factors"}]}}, "hasResults": true}, {"protocolSection": {"identificationModule": {"nctId": "NCT06799767", "orgStudyIdInfo": {"id": "Endo-RAD"}, "organization": {"fullName": "IRCCS Azienda Ospedaliero-Universitaria di Bologna", "class": "OTHER"}, "briefTitle": "Radiological Diagnostics in Patients With Deep Endometriosis", "officialTitle": "Implementation Of Radiological Diagnostics In Patients With Deep Endometriosis"}, "statusModule": {"statusVerifiedDate": "2024-11", "overallStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2021-04-07", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2025-02-01", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2025-04-30", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2024-11-28", "studyFirstSubmitQcDate": "2025-01-28", "studyFirstPostDateStruct": {"date": "2025-01-29", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2025-01-28", "lastUpdatePostDateStruct": {"date": "2025-01-29", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "IRCCS Azienda Ospedaliero-Universitaria di Bologna", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false, "isUsExport": false}, "descriptionModule": {"briefSummary": "Endometriosis is a benign, chronic, recurrent disease characterised by the presence of endometrial glands and stroma outside the uterine cavity. A non-negligible proportion of patients, 2-37%, are affected by deep endometriosis (DIE), defined as the pathology's involvement of the muscular tunic propria of the abdomino-pelvic organs.\n\nFrom a therapeutic point of view, a medical or surgical approach is possible. The choice is influenced by several factors, such as the patient's age, reproductive desire, the extent of symptoms, the size and location of the endometriosis lesions, and the presence of organ damage. Although the surgical approach brings satisfactory results in terms of symptom reduction and improved fertility, the risk of complications can be very high, especially in the case of DIE, as bladder, rectal and sexual function can be compromised due to iatrogenic damage to the autonomic fibres that innervate the pelvic organs. Recently, the concept of 'nerve-sparing' surgery has been extended to gynaecology, and in particular to surgery for the treatment of endometriosis, showing encouraging results in terms of both symptom control and functional outcome.\n\nIn recent years, nuclear magnetic resonance imaging (NMR) has been increasingly helpful in the diagnosis of endometriosis and adenomyosis and is increasingly used in pre-operative planning.", "detailedDescription": "Endometriosis is a benign, chronic, recurrent condition characterised by the presence of endometrial glands and stroma outside the uterine cavity. Although most frequently localised at the ovarian level (17 - 44%), a proportion of 2-37% of patients are affected by deep endometriosis (DIE), which involves the muscular tunic propria of the abdomino-pelvic organs. The most commonly affected sites are the rectovaginal septum, utero-sacral ligaments, rectum and sigma, ureters, parameters, hypogastric nerves, bladder and pre-vesical peritoneum.\n\nIn recent years, nuclear magnetic resonance imaging (NMR) has been increasingly helpful in the diagnosis of endometriosis and adenomyosis and is increasingly used in pre-operative planning together with transvaginal and/or transabdominal ultrasound. Recently, new techniques have been developed, such as Diffusion Tensor Imaging (DTI), Diffusion Weighted Imaging (DWI) and Dynamic Contrast Enhanced (DCE), whose gynaecological applications are currently in their infancy.\n\nThe study aims to evaluate the diagnostic accuracy and applicability of new MRI techniques in patients with deep endometriosis and candidates for surgical treatment.\n\nIn particular, the techniques that the investigators intend to investigate are: augmented reality, tractography, 3D-modelling, radiomics.\n\nThe use of these innovative methods, based on MRI techniques, may make it possible not only to plan an even more personalised treatment approach, selecting patients who could benefit from different treatments (such as presacral neurectomy, nerve root infiltration neurostimulation and the use of effective analgesics for neuropathic pain), but also to facilitate the localisation of endometriotic lesions during laparoscopic surgery, allowing the surgeon to assess their relationship with the main nerve and vascular structures of the pelvis and increasingly facilitating the nerve-sparing approach."}, "conditionsModule": {"conditions": ["Deep Endometriosis"], "keywords": ["deep endometriosis", "radiological diagnostics", "tractography", "augmented reality", "3D-modelling", "radiomics"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "COHORT", "timePerspective": "PROSPECTIVE"}, "enrollmentInfo": {"count": 94, "type": "ESTIMATED"}}, "outcomesModule": {"primaryOutcomes": [{"measure": "Diagnostics and the applicability of new MRI techniques: tractography", "description": "Assessing sacral plexus root abnormalities by DTI-RMN and analysing the correlation between DTI abnormalities and the presence and severity of typical endometriosis symptoms (chronic pelvic pain, dysmenorrhoea, dyspareunia, ovulatory pain, dyschezia and dysuria) through Numerical Rating Scale (NRS), that is 0 \"no pain,\" 10 \"worst pain imaginable\".", "timeFrame": "During the first visit after enrollment"}, {"measure": "Diagnostic accuracy and applicability of new MRI techniques: augmented reality", "description": "Evaluate the diagnostic accuracy and precision of fiber tractography (FT) in reconstructing the course of the ureters bilaterally and mapping the hypogastric nerve bilaterally by comparing images obtained on MRI with in vivo surgical dissection", "timeFrame": "During the first visit after enrollment"}, {"measure": "Diagnostic accuracy and applicability of new MRI techniques: 3D-modelling", "description": "Evaluate the diagnostic accuracy of 3D models of endometriosis nodules of the rectum and sigma obtained by MRI", "timeFrame": "During the first visit after enrollment"}, {"measure": "Diagnostic accuracy and applicability of new MRI techniques: radiomics", "description": "Develop a pattern-recognition system based on MRI techniques for the histological nature (stromal vs. fibrotic) of the endometriosis nodules examined. Confirmation will be obtained on the basis of the definitive histological examination after surgery", "timeFrame": "During the first visit after enrollment"}], "secondaryOutcomes": [{"measure": "Diagnostics and the applicability of new MRI techniques: tractography", "description": "Assessing the correlation between DTI abnormalities and the location of endometriotic lesions found during surgery", "timeFrame": "During surgery"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Clinical and ultrasound diagnosis of deep endometriosis, with or without ovarian endometriosis, with indication for MRI for further diagnosis and subsequent candidate for laparoscopic surgical treatment of the pathology\n* Age between 18 and 40 years\n* Obtaining informed consent\n\nExclusion Criteria:\n\n* Previous abdominal surgery\n* Personal history of malignancy (current or previous)\n* Chronic inflammatory bowel disease (Crohn's disease, Ulcerative Rectocolitis, Indeterminate Colitis), interstitial cystitis\n* Personal history of Pelvic Inflammatory Disease (PID), active or previous\n* Previous radiotherapy/chemotherapy\n* Radiculopathy, herniated discs, spinal abnormalities and pathologies\n* Laparotomic conversion during surgery", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "40 Years", "stdAges": ["ADULT"], "studyPopulation": "Patients with a clinical and ultrasound diagnosis of deep endometriosis who are candidates for MRI for further diagnosis", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"centralContacts": [{"name": "Renato Seracchioli, MD", "role": "CONTACT", "phone": "+390512143944", "email": "renato.seracchioli@aosp.bo.it"}, {"name": "Linda Bertoldo, MD", "role": "CONTACT", "email": "lindabertoldodrssa@gmail.com"}], "overallOfficials": [{"name": "Renato Seracchioli, MD", "affiliation": "IRCCS Azienda Ospedaliero-Universitaria di Bologna", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "IRCCS Azienda Ospedaliero-Universitaria di Bologna", "status": "RECRUITING", "city": "Bologna", "state": "Bologna", "zip": "40138", "country": "Italy", "contacts": [{"name": "Renato Seracchioli, MD", "role": "CONTACT", "phone": "+390512143944", "email": "renato.seracchioli@aosp.bo.it"}, {"name": "Linda Bertoldo, MD", "role": "CONTACT", "email": "lindabertoldodrssa@gmail.com"}, {"name": "Renato Seracchioli, MD", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 44.49381, "lon": 11.33875}}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT03875820", "orgStudyIdInfo": {"id": "CCR4642"}, "secondaryIdInfos": [{"id": "2017-001035-39", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Institute of Cancer Research, United Kingdom", "class": "OTHER"}, "briefTitle": "Phase I Trial of Defactinib and VS-6766.", "officialTitle": "FRAME: A Phase I Trial of the Combination of Defactinib (VS-6063) (FAK Inhibitor) and VS-6766 (RO5126766) (CH5126776) (a Dual RAF/MEK Inhibitor) in Patients With Advanced Solid Tumours", "acronym": "FRAME"}, "statusModule": {"statusVerifiedDate": "2023-07", "overallStatus": "UNKNOWN", "lastKnownStatus": "ACTIVE_NOT_RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2017-12-12", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2023-04-30", "type": "ACTUAL"}, "completionDateStruct": {"date": "2023-10-31", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2018-11-15", "studyFirstSubmitQcDate": "2019-03-12", "studyFirstPostDateStruct": {"date": "2019-03-15", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-07-07", "lastUpdatePostDateStruct": {"date": "2023-07-10", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Institute of Cancer Research, United Kingdom", "class": "OTHER"}, "collaborators": [{"name": "Verastem, Inc.", "class": "INDUSTRY"}]}, "oversightModule": {"isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "This is a multi-centre, investigator-initiated, dose escalation, Phase I trial of the combination of the FAK inhibitor, Defactinib (VS-6063), and the dual RAF/MEK inhibitor, VS-6766 (RO5126766) in patients with advanced solid tumours. VS-6766 (RO5126766) is the same compound as CH5126766.\n\nThere are two parts to this study, the dose escalation phase and the dose expansion phase. In the dose escalation phase, cohorts of 3 to 6 patients will be enrolled to determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D). This will be followed by a dose expansion phase to further characterise the safety and tolerability and to assess the pharmacodynamic activity of the combination.", "detailedDescription": "This is a multi-centre, investigator-initiated, dose escalation, Phase I trial of the combination of the FAK inhibitor, Defactinib, and the dual RAF/MEK inhibitor, VS-6766 in patients with advanced solid tumours.\n\nThere are two parts to this study, the dose escalation phase and the dose expansion phase. In the dose escalation phase, cohorts of 3 to 6 patients were enrolled to determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D). Up to 24 patients with solid tumours were treated in the dose escalation phase of this study.\n\nThe dose escalation phase is now closed to recruitment.\n\nThis will be followed by a dose expansion phase of 86 patients to further characterise the safety and tolerability and to assess the pharmacodynamic activity of the combination.\n\nThe dose expansion phase is made up of 7 cohorts:\n\n* 20 patients with KRAS mutant non-small-cell lung cancer (NSCLC);\n* 7 patients with solid tumours (enriched for those with RAS mutations) willing to undergo biopsies at three time points throughout the study;\n* 20 patients with low grade serous ovarian cancer (LGSOC);\n* 10 patients with colorectal cancer (CRC);\n* 10 patients with KRAS G12V mutant NSCLC;\n* 10 patients with RAS/RAF mutant endometrioid subtype of gynaecological cancers (ovarian, endometrial, endometriosis related) and\n* 10 patients with pancreatic cancer.\n\nThe following cohorts are still open to recruitment:\n\n* Patients with low grade serous ovarian cancer (LGSOC);\n* Patients with KRAS G12V mutant NSCLC;\n* Patients with RAS/RAF mutant endometrioid subtype of gynaecological cancers (ovarian, endometrial, endometriosis-related) and\n* Patients with pancreatic cancer.\n\nPatients will take the two investigational medicinal products (IMPs) as follows:\n\nVS-6766 will be administered orally twice a week on Monday/Thursday or Tuesday/Friday at least one hour prior or two hours after a meal. The starting dose of VS-6766 will be 3.2mg once a day, twice a week and can be escalated to a maximum of 4mg once a day, twice a week.\n\nDefactinib will be administered orally twice a day immediately after a meal. The starting dose of Defactinib will be 200mg twice daily and can be escalated to a maximum of 400mg twice daily.\n\nA cycle length is 4 weeks (28 days). Combination dosing (VS-6766 and Defactinib) will commence on Cycle 1 Day 1 for 3 weeks followed by one week without either drug in week 4 (i.e. 3 weeks on, 1 week off).\n\nFor patients consenting to optional biopsies, a run-in dose of VS-6766 will be administered on a single day anywhere between Days -7 to Day -3 in order to facilitate pharmacodynamic (PD) biomarker analysis. Therefore, for patients undergoing biopsies the first cycle will be 5 weeks long and subsequent cycles will consist of 4 weeks.\n\nIf this schedule is not tolerated, alternative schedules may be explored following discussion by the Safety Review Committee."}, "conditionsModule": {"conditions": ["NSCLC", "Low Grade Serous Ovarian Cancer", "Endometrioid Carcinoma", "Pancreatic Cancer"], "keywords": ["KRAS G12V", "RAS", "RAF"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "NON_RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": "The dose escalation phase will enrol patients with advanced RAS mutant solid tumours.\n\nIn the dose expansion phase, patients are assigned to one of the following cohorts based on their diagnosis:\n\n* KRAS mutant NSCLC cohort\n* LGSOC cohort\n* RAS mutant CRC cohort\n* Advanced RAS mutant solid tumour cohort - patients in this cohort must have biopsiable disease, be willing and consent to undergo biopsies at three time-points.\n* KRAS G12V mutant NSCLC cohort\n* RAS/RAF mutant endometrioid cohort\n* Pancreatic cohort", "primaryPurpose": "HEALTH_SERVICES_RESEARCH", "maskingInfo": {"masking": "NONE", "maskingDescription": "Non-randomised: Participants are expressly assigned by phase of study and diagnosis."}}, "enrollmentInfo": {"count": 87, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Dose Escalation Phase", "type": "EXPERIMENTAL", "description": "Escalating doses of VS-6766 (RO5126766) and Defactinib (VS-6063) were evaluated in patients with advanced solid tumours to establish the recommended phase II dose. Dose escalation followed a 3+3 design with a maximum of four patient cohorts.\n\nThis arm is now complete.", "interventionNames": ["Drug: VS-6766", "Drug: Defactinib"]}, {"label": "Dose Expansion KRAS mutant NSCLC Cohort", "type": "EXPERIMENTAL", "description": "The dose expansion phase will evaluate the recommended phase II dose of the combination of VS-6766 (RO5126766) and Defactinib (VS-6063), as decided in the dose escalation phase in patients with KRAS mutant NSCLC (20 patients).\n\nThis arm is now complete.", "interventionNames": ["Drug: VS-6766", "Drug: Defactinib"]}, {"label": "Dose Expansion biopsy cohort", "type": "EXPERIMENTAL", "description": "The dose expansion phase will evaluate the recommended phase II dose of the combination of VS-6766 (RO5126766) and Defactinib (VS-6063), as decided in the dose escalation phase in patients advanced RAS mutant solid tumours with biopsiable disease (6 patients).\n\nThis arm is now complete.", "interventionNames": ["Drug: VS-6766", "Drug: Defactinib"]}, {"label": "Dose Expansion LGSOC cohort", "type": "EXPERIMENTAL", "description": "The dose expansion phase will evaluate the recommended phase II dose of the combination of VS-6766 (RO5126766) and Defactinib (VS-6063), as decided in the dose escalation phase in patients with LGSOC (20 patients).", "interventionNames": ["Drug: VS-6766", "Drug: Defactinib"]}, {"label": "Dose Expansion CRC cohort", "type": "EXPERIMENTAL", "description": "The dose expansion phase will evaluate the recommended phase II dose of the combination of VS-6766 (RO5126766) and Defactinib (VS-6063), as decided in the dose escalation phase in patients with CRC (10 patients).\n\nThis arm is now complete.", "interventionNames": ["Drug: VS-6766", "Drug: Defactinib"]}, {"label": "Dose Expansion KRAS G12V mutant NSCLC cohort", "type": "EXPERIMENTAL", "description": "The dose expansion phase will evaluate the recommended phase II dose of the combination of VS-6766 (RO5126766) and Defactinib (VS-6063), as decided in the dose escalation phase in patients with KRAS G12V mutant NSCLC (10 patients).", "interventionNames": ["Drug: VS-6766", "Drug: Defactinib"]}, {"label": "Dose Expansion RAS/RAF mutant endometrioid cancer cohort", "type": "EXPERIMENTAL", "description": "The dose expansion phase will evaluate the recommended phase II dose of the combination of VS-6766 (RO5126766) and Defactinib (VS-6063), as decided in the dose escalation phase in patients with RAS/RAF mutant endometrioid subtype of gynaecological cancers (ovarian, endometrial, endometriosis-related) (10 patients).", "interventionNames": ["Drug: VS-6766", "Drug: Defactinib"]}, {"label": "Dose Expansion pancreatic cancer", "type": "EXPERIMENTAL", "description": "The dose expansion phase will evaluate the recommended phase II dose of the combination of VS-6766 (RO5126766) and Defactinib (VS-6063), as decided in the dose escalation phase in patients with pancreatic cancer (10 patients).", "interventionNames": ["Drug: VS-6766", "Drug: Defactinib"]}], "interventions": [{"type": "DRUG", "name": "VS-6766", "description": "VS-6766 will be supplied as 0.8mg hypromellose (HPMC) capsules for oral administration. The capsule fill consists of VS-6766 and the inactive ingredients mannitol and magnesium stearate.\n\nVS-6766 will be administered on a twice weekly (Monday and Thursday or Tuesday and Friday) schedule for 3 weeks followed by 1 week off in every 4 week cycle, under fasting conditions (approximately 1 hour prior or 2 hours after a meal). The starting dose, based on the previous Phase I trial will be 3.2 mg given orally as a single daily dose. This can be escalated to a maximum of 4mg (as per dose escalation rules in the protocol).", "armGroupLabels": ["Dose Escalation Phase", "Dose Expansion CRC cohort", "Dose Expansion KRAS G12V mutant NSCLC cohort", "Dose Expansion KRAS mutant NSCLC Cohort", "Dose Expansion LGSOC cohort", "Dose Expansion RAS/RAF mutant endometrioid cancer cohort", "Dose Expansion biopsy cohort", "Dose Expansion pancreatic cancer"], "otherNames": ["RO5126766", "CH5126766"]}, {"type": "DRUG", "name": "Defactinib", "description": "Defactinib is formulated as a white to off-white oval tablet for oral administration and supplied in single unit dose strength of 200 mg in 120 cc (HDPE) bottles. In addition to Defactinib, formulation components include microcrystalline cellulose, lactose monohydrate, sodium starch glycolate, and magnesium stearate.\n\nPatients will receive Defactinib orally immediately after a meal twice daily (approximately every 12 hours) for 3 weeks followed by 1 week off in every 4 week cycle. The starting dose will be 200mg. This can be escalated to a maximum of 400mg (as per dose escalation rules in the protocol).", "armGroupLabels": ["Dose Escalation Phase", "Dose Expansion CRC cohort", "Dose Expansion KRAS G12V mutant NSCLC cohort", "Dose Expansion KRAS mutant NSCLC Cohort", "Dose Expansion LGSOC cohort", "Dose Expansion RAS/RAF mutant endometrioid cancer cohort", "Dose Expansion biopsy cohort", "Dose Expansion pancreatic cancer"], "otherNames": ["VS-6063"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "To establish a dose for Phase II evaluation from the maximum tolerated dose of the combination of VS-6766 and Defactinib.", "description": "To determine the maximum dose at which no more than 1 of 6 patients at the same dose level experience a drug related toxicity (DLT) as specified in the protocol.", "timeFrame": "12 months"}, {"measure": "Measure Adverse Events according to CTCAE v4.0.", "description": "To assess the safety and toxicity profile of VS-6766 and Defactinib. To determine causality and grading severity of each adverse event by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.", "timeFrame": "6 months"}], "secondaryOutcomes": [{"measure": "To characterise the pharmacokinetic profile of VS-6766 in combination with Defactinib.", "description": "Determination of the PK parameter Cmax of VS-6766 and Defactinib when dosed together.", "timeFrame": "12 months"}, {"measure": "To characterise the pharmacokinetic profile of VS-6766 in combination with Defactinib.", "description": "Determination of the PK parameter terminal half-life of VS-6766 and Defactinib when dosed together.", "timeFrame": "12 months"}, {"measure": "To characterise the pharmacokinetic profile of VS-6766 in combination with Defactinib.", "description": "Determination of the PK parameter area under the curve of VS-6766 and Defactinib when dosed together.", "timeFrame": "12 months"}], "otherOutcomes": [{"measure": "To document any possible anti-tumour activity in patients.", "description": "Determination of disease response by RECIST criteria version 1.1 and collection of data related to progression free survival.", "timeFrame": "24 months"}, {"measure": "To study the pharmacodynamic profile of VS-6766 alone and in combination with Defactinib in pre-treatment and post-treatment biopsies and PBMCs.", "description": "Quantification of biomarkers such as p-MEK, p-ERK and p-FAK, E-cadherin and vimentin and enumeration of T cell populations which express CD8, CD4 and CD25.", "timeFrame": "24 months"}, {"measure": "To assess putative predictive biomarkers of response and resistance to the combination of VS-6766 and Defactinib.", "description": "Correlation of antitumour activity of the combination of VS-6766 and Defactinib with the detection of putative predictive biomarkers of response and resistance in archival tumours and plasma DNA.", "timeFrame": "24 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Dose escalation:\n\n   Histologically or cytologically proven solid tumours, refractory to conventional treatment, or for which no conventional therapy exists or is declined by the patient enriching for patients with RAS mutant solid tumours.\n\n   Dose expansion:\n\n   Histologically or cytologically proven advanced non-small-cell lung cancer (NSCLC) with a documented KRAS mutation, refractory to conventional treatment, or for which no conventional therapy exists or is declined by the patient (20 patients).\n\n   OR Histologically or cytologically proven advanced low grade serous ovarian cancer (LGSOC), refractory to conventional treatment, or for which no conventional therapy exists or is declined by the patient (20 patients).\n\n   OR Histologically or cytologically proven advanced colorectal cancer (CRC) with a documented RAS mutation, refractory to conventional treatment, or for which no conventional therapy exists or is declined by the patient (10 patients).\n\n   OR Histologically or cytologically proven RAS mutant solid tumours, refractory to conventional treatment, or for which no conventional therapy exists or is declined by the patient. Patient must have biopsiable disease, be willing and has consented to undergo biopsies at three time-points (6 patients).\n\n   OR Histologically or cytologically proven advanced pancreatic cancer or metastatic pancreatic cancer, refractory to conventional treatment, or for which no conventional therapy exists or is declined by the patient (10 patients).\n\n   OR Endometroid subtype of gynaecological cancers (ovarian, endometrial, endometriosis related) with a documented RAS or RAF mutation, refractory to conventional treatment, or for which no conventional therapy exists or is declined by the patient (10 patients).\n\n   OR Histologically or cytologically proven advanced non-small-cell lung cancer (NSCLC) with a documented KRAS G12V specific mutation, refractory to conventional treatment, or for which no conventional therapy exists or is declined by the patient (10 patients).\n2. Predicted life expectancy of at least 12 weeks\n3. World Health Organisation (WHO) performance status of 0 or 1 (Appendix 1)\n4. Haematological and biochemical indices within the ranges shown below. These measurements must be performed within one week (Day -7 to Day 1) before the patient goes in the trial.\n\n   Haemoglobin (Hb) ≥ 9.0 g/dL Absolute neutrophil count (ANC) ≥ 1.5 x 109/L Platelet count ≥ 100 x 109/L Serum bilirubin ≤ 1.5 x upper limit of normal (ULN) Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST)\n\n   ≤ 2.5 x (ULN) unless raised due to tumour in which case up to 5 x ULN is permissible\n\n   Either:\n\n   Calculated creatinine clearance ≥ 50 mL/min (uncorrected value)\n\n   Or:\n\n   Serum creatinine ≤ 1.5 x ULN\n5. Men and women aged 18 years or over.\n6. Written (signed and dated) informed consent and be capable of co-operating with treatment and follow-up.\n7. Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.\n8. Dose escalation: Measurable disease according to RECIST 1.1 or evaluable disease. All radiology studies must be performed within 28 days prior to registration.\n\n   Dose expansion: Measurable disease according to RECIST 1.1, all radiology studies must be performed within 28 days prior to registration.\n9. Corrected QT interval (QTc) \\< 470 ms (as calculated by the Fridericia correction formula, averaged over 3 ECGs).\n10. Agrees to the use of archival paraffin embedded tissue and has archival tumour tissue available.\n\nExclusion Criteria:\n\n1. Radiotherapy (except for palliative reasons), endocrine therapy, biological therapy, immunotherapy or chemotherapy during the previous four weeks (six weeks for nitrosoureas, Mitomycin-C) before treatment.\n2. Ongoing toxic manifestations of previous treatments. Exceptions to this are alopecia or certain Grade 1 toxicities, which in the opinion of the Investigator and the DDU should not exclude the patient.\n3. Known untreated or active central nervous system (CNS) metastases (progressing or requiring corticosteroids for symptomatic control). Patients with a history of treated CNS metastases are eligible, provided they meet all of the following criteria:\n\n   * Evaluable or measurable disease outside the CNS is present.\n   * Radiographic demonstration of improvement upon the completion of CNS-directed therapy and no evidence of interim progression between the completion of CNS-directed therapy and the baseline disease assessment for at least 28 days.\n4. Ability to become pregnant (or already pregnant or lactating). However, those female patients who have a negative serum or urine pregnancy test before enrolment and agree to use two medically approved forms of contraception (oral, injected or implanted hormonal contraception and condom, have an intra-uterine device and condom, diaphragm with spermicidal gel and condom) from time of consent, during the trial and for six months afterwards are considered eligible.\n5. Male patients with partners of child-bearing potential (unless they agree to take measures not to father children by using one form of medically approved contraception \\[condom plus spermicide\\] during the trial and for six months afterwards). Men with pregnant or lactating partners should be advised to use barrier method contraception (for example, condom plus spermicidal gel) to prevent exposure to the foetus or neonate.\n6. Major surgery within 4 weeks prior to entry to the study (excluding placement of vascular access), or minor surgery within 2 weeks of entry into the study and from which the patient has not yet recovered.\n7. Treatment with warfarin. Patients on warfarin for DVT/PE can be converted to LMWH.\n8. Known history of Gilbert's Syndrome.\n9. Acute or chronic pancreatitis.\n10. At high medical risk because of non-malignant systemic disease including active uncontrolled infection.\n11. Known to be serologically positive for hepatitis B, hepatitis C or human immunodeficiency virus (HIV).\n12. Patients with the inability to swallow oral medications or impaired gastrointestinal absorption due to gastrectomy or active inflammatory bowel disease.\n13. Concurrent ocular disorders:\n\n    1. Patients with history of glaucoma, history of retinal vein occlusion (RVO), predisposing factors for RVO, including uncontrolled hypertension, uncontrolled diabetes\n    2. Patient with history of retinal pathology or evidence of visible retinal pathology that is considered a risk factor for RVO, intraocular pressure \\> 21mm Hg as measured by tonometry, or other significant ocular pathology, such as anatomical abnormalities that increase the risk for RVO.\n    3. Patients with a history of corneal erosion (instability of corneal epithelium), corneal degeneration, active or recurrent keratitis, and other forms of serious ocular surface inflammatory conditions.\n14. Concurrent congestive heart failure, prior history of class III/ IV cardiac disease (New York Heart Association \\[NYHA\\] - refer to Appendix 4), myocardial infarction within the last 6 months, unstable arrhythmias, unstable angina or severe obstructive pulmonary disease.\n15. Patients exposed to strong CYP3A4 and strong CYP2C9 inhibitors within 7 days prior to the first dose.\n\n    N.B. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated list such as http://medicine.iupui.edu/clinpharm/ddis/table.aspx; medical reference texts such as the Physicians' Desk Reference may also provide this information.\n16. Is a participant or plans to participate in another interventional clinical trial, whilst taking part in this Phase I study of VS-6766 in combination with Defactinib. Participation in an observational trial would be acceptable.\n17. Symptoms of COVID-19 and/or documented current COVID-19 infection (the patient can be reassessed for eligibility following a full recovery and negative COVID-19 test).\n18. Any other condition which in the Investigator's opinion would not make the patient a good candidate for the clinical trial.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Udai Banerji, FRCP, PhD", "affiliation": "Institute of Cancer Research, United Kingdom", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "The Christie NHS Foundation Trust", "city": "Manchester", "state": "Greater Manchester", "zip": "M20 4BX", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "The Royal Marsden NHS Foundation Trust", "city": "Sutton", "state": "Surrey", "zip": "SM2 5PT", "country": "United Kingdom", "geoPoint": {"lat": 51.35, "lon": -0.2}}, {"facility": "The Royal Marsden NHS Foundation Trust - Gynecology Unit", "city": "London", "zip": "SW3 6JJ", "country": "United Kingdom", "geoPoint": {"lat": 51.50853, "lon": -0.12574}}, {"facility": "The Newcastle Upon Tyne Hospitals NHS Foundation Trust - Freeman Hospital", "city": "Newcastle", "zip": "NE7 7DN", "country": "United Kingdom", "geoPoint": {"lat": 54.21804, "lon": -5.88979}}, {"facility": "The Royal Marsden NHS Foundation Trust - Gynecology Unit", "city": "Sutton", "zip": "SM2 5PT", "country": "United Kingdom", "geoPoint": {"lat": 51.35, "lon": -0.2}}]}, "referencesModule": {"references": [{"pmid": "40579546", "type": "DERIVED", "citation": "Banerjee S, Krebs MG, Greystoke A, Garces AI, Perez VS, Terbuch A, Shinde R, Caldwell R, Grochot R, Rouhifard M, Ruddle R, Gurel B, Swales K, Tunariu N, Prout T, Parmar M, Symeonides S, Rekowski J, Yap C, Sharp A, Paschalis A, Lopez J, Minchom A, de Bono JS, Banerji U. Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trial. Nat Med. 2025 Sep;31(9):3074-3080. doi: 10.1038/s41591-025-03763-y. Epub 2025 Jun 27."}, {"pmid": "37598000", "type": "DERIVED", "citation": "Fard D, Giraudo E, Tamagnone L. Mind the (guidance) signals! Translational relevance of semaphorins, plexins, and neuropilins in pancreatic cancer. Trends Mol Med. 2023 Oct;29(10):817-829. doi: 10.1016/j.molmed.2023.07.009. Epub 2023 Aug 17."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D018269", "term": "Carcinoma, Endometrioid"}, {"id": "D010190", "term": "Pancreatic Neoplasms"}], "ancestors": [{"id": "D000230", "term": "Adenocarcinoma"}, {"id": "D002277", "term": "Carcinoma"}, {"id": "D009375", "term": "Neoplasms, Glandular and Epithelial"}, {"id": "D009370", "term": "Neoplasms by Histologic Type"}, {"id": "D009369", "term": "Neoplasms"}, {"id": "D016889", "term": "Endometrial Neoplasms"}, {"id": "D014594", "term": "Uterine Neoplasms"}, {"id": "D005833", "term": "Genital Neoplasms, Female"}, {"id": "D014565", "term": "Urogenital Neoplasms"}, {"id": "D009371", "term": "Neoplasms by Site"}, {"id": "D010051", "term": "Ovarian Neoplasms"}, {"id": "D010049", "term": "Ovarian Diseases"}, {"id": "D000291", "term": "Adnexal Diseases"}, {"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}, {"id": "D006058", "term": "Gonadal Disorders"}, {"id": "D004700", "term": "Endocrine System Diseases"}, {"id": "D004067", "term": "Digestive System Neoplasms"}, {"id": "D004701", "term": "Endocrine Gland Neoplasms"}, {"id": "D004066", "term": "Digestive System Diseases"}, {"id": "D010182", "term": "Pancreatic Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C577924", "term": "RO5126766"}, {"id": "C584510", "term": "defactinib"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT06794424", "orgStudyIdInfo": {"id": "ZWG-24-04"}, "organization": {"fullName": "ZIWIG", "class": "INDUSTRY"}, "briefTitle": "Impact of Ziwig Endotest® on the Management of Patients with Clinical Symptoms of Endometriosis Inconsistent with Their Imaging Work-up", "officialTitle": "Impact of Ziwig Endotest® on the Decision and Management of Patients with Chronic Disabling Pelvic Pain Strongly Suggestive of Endometriosis and Presenting with a Negative or Uncertain Baseline Imaging Workup", "acronym": "ENDOBEST"}, "statusModule": {"statusVerifiedDate": "2025-01", "overallStatus": "NOT_YET_RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2025-02-01", "type": "ESTIMATED"}, "primaryCompletionDateStruct": {"date": "2026-09-01", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2026-09-01", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2025-01-20", "studyFirstSubmitQcDate": "2025-01-20", "studyFirstPostDateStruct": {"date": "2025-01-27", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2025-01-29", "lastUpdatePostDateStruct": {"date": "2025-02-03", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "ZIWIG", "class": "INDUSTRY"}, "collaborators": [{"name": "Monitoring Force Group", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false, "isUsExport": false}, "descriptionModule": {"briefSummary": "The goal of this study is to evaluate the impact of Ziiwg Endotest on patient management decisions before and after the test. The main questions it aims to answer are:\n\n* Does the test reduce the intention and number of laparoscopies in women whose decision to undergo laparoscopy was made before the test result was obtained?\n* Does the test change management decisions in women with no prior indication for diagnostic laparoscopy?\n\nStudy will compare the patient management decision before and after the test.\n\nThe acts and procedures performed as part of this research are :\n\n* Aa saliva sampling (Ziwig Endotest) at inclusion\n* A mutidisciplinary meeting post test (if applicable)\n* Completion at inclusion and 6 month of a quality-of-life questionnaire (EHP-5)\n* Completion at inclusion and 6 month of a VAS for pain\n* Completion at inclusion and 6 month of a Likert satisfaction scale\n* A test results Announcement consultation\n* A visit at 6 months."}, "conditionsModule": {"conditions": ["Endometriosis"], "keywords": ["Endometriosis", "Endotest", "Management of endometriosis", "Clinical and radiological discrepancies"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "OTHER", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 2500, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Performing Ziwig Endotest®", "type": "EXPERIMENTAL", "interventionNames": ["Diagnostic Test: Ziwig Endotest®"]}], "interventions": [{"type": "DIAGNOSTIC_TEST", "name": "Ziwig Endotest®", "description": "Saliva sampling for Endometriosis diagnostic", "armGroupLabels": ["Performing Ziwig Endotest®"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in the number of laparoscopies related to the test result in women whose decision to undergo laparoscopy was made in multidiscplinary meeting before the test result was obtained. MCID 20%", "description": "The criterion is estimated after the test result is known.\n\nEach of these criteria is estimated independently at 3 different times:\n\n1. After knowledge of the test result, management decided by the physician who carried out the inclusion consultation or at the PCR.\n2. At the end of the consultation, shared decision\n3. At 6 months: by the adjudication committee: positive opinion\n\nA hierarchical sequential analysis will be carried out independently according to the following scheme:\n\nSequence 1: decisional impact of the test on the management decision, if conclusive compared with MCID (main criterion) → sequence 2: decisional impact of the test on the medical decision shared with the patient, if conclusive compared with MCID → sequence 3: percentage of favorable adjudications, conclusive if higher than MCID (highest level of evidence of clinical utility)", "timeFrame": "After 6 months visits"}, {"measure": "Changes in subject management related to Ziwig Endotest® result) in women with no prior indication for diagnostic laparoscopy. MCID 30%.", "description": "The criterion is estimated after the test result is known.\n\nEach of these criteria is estimated independently at 3 different times:\n\n1. After knowledge of the test result, management decided by the physician who carried out the inclusion consultation or at the PCR.\n2. At the end of the consultation, shared decision\n3. At 6 months: by the adjudication committee: positive opinion\n\nA hierarchical sequential analysis will be carried out independently according to the following scheme:\n\nSequence 1: decisional impact of the test on the management decision, if conclusive compared with MCID (main criterion) → sequence 2: decisional impact of the test on the medical decision shared with the patient, if conclusive compared with MCID → sequence 3: percentage of favorable adjudications, conclusive if higher than MCID (highest level of evidence of clinical utility)", "timeFrame": "After 6 months visits"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Female aged 18 to 43\n2. Strong clinical suspicion of endometriosis based on the following suggestive symptoms: chronic pelvic pain (\\> 6 months) that is suggestive and disabling (ENA ≥ 8, absenteeism or resistance to level 1 analgesics) ± deep dyspareunia or painful hematuria/micturition with menstrual rhythm or painful rectal discharge/defecation with menstrual rhythm.\n3. Endovaginal ultrasound and MRI (unless contraindicated, in which case only one of the 2 examinations is required\\*) less than 1 year old and of sufficient quality , in compliance with the endometriosis protocol recommended by the HAS\\*\\*.\n4. Clinical-radiological discrepancy confirmed by the investigating gynecologist and a referent radiologist at the investigating center, in compliance with the protocol's positivity criteria and the French ENDOVALIRM guidelines (for characterizing deep lesions on MRI) and/or the ESUR 2017 guidelines (for ovarian lesions) and/or the SUR-US 2024 guidelines (for ultrasound).\n5. Woman has dated and signed the consent form.\n6. Speaks and understands French\n7. Affiliated with the French healthcare system\n\nExclusion Criteria:\n\n1. Endometriosis diagnosed according to imaging protocol positivity criteria\n2. Differential diagnosis and/or adenomyosis made\n3. History of isolated dysmenorrhea well controlled by hormonal contraception and no immediate desire for pregnancy,\n4. Absence of pelvic pain strongly suggestive of endometriosis.\n5. Isolated fatigue\n6. Aetiological work-up incomplete or pending before deciding on initial medical decision (infertility work-up in progress, waiting for specialist opinion (algologist, psychologist, etc.), waiting for important test results),\n7. Infertility work-up (current or previous), with no signs suggestive of endometriosis.\n8. Search for recurrence of known endometriosis\n9. Laparoscopy for gynecological reasons other than suspected endometriosis\n10. History of cancer\n11. Pregnant or breast-feeding women\n12. Current bacterial or viral infection or less than one month old\n13. Participation in an interventional study or in the exclusion period of an interventional study", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "43 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "François GOLFIER, Pr", "role": "CONTACT", "phone": "+33 4 78 86 41 78", "email": "francois.golfier@chu-lyon.fr"}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT06439524", "orgStudyIdInfo": {"id": "1111"}, "organization": {"fullName": "Main Line Health", "class": "OTHER"}, "briefTitle": "The Effect of Medical Management Following Excisional Surgery for Endometriosis: A Randomized Controlled Trial", "officialTitle": "The Effect of Medical Management Following Excisional Surgery for Endometriosis: A Randomized Controlled Trial"}, "statusModule": {"statusVerifiedDate": "2025-06", "overallStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2024-08-15", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2026-02-15", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2026-08-15", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2024-02-29", "studyFirstSubmitQcDate": "2024-05-29", "studyFirstPostDateStruct": {"date": "2024-06-03", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2025-06-11", "lastUpdatePostDateStruct": {"date": "2025-06-15", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Main Line Health", "class": "OTHER"}, "collaborators": [{"name": "Pfizer", "class": "INDUSTRY"}, {"name": "Sumitomo Pharma Switzerland GmbH", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false, "isUsExport": true}, "descriptionModule": {"briefSummary": "The goal of this investigator-initiated single-site clinical trial is to compare the overall quality of life of participants taking Relugolix combination therapy (Rel-CT) following excisional surgery for endometriosis to participants that do not take Rel-CT following the same surgery. Rel-CT is an FDA approved form of medical treatment for endometriosis. It is known to work in treating endometriosis pain. However, investigators do not know whether or not there is a benefit to beginning Rel-CT immediately following surgery. This study will test if patients who take Rel-CT after surgery have better quality of life and less chance the endometriosis comes back, requiring additional surgery.\n\nThe main question it aims to answer is:\n\n\\- Does taking Rel-CT following excisional surgery for endometriosis result in higher Endometriosis Health Profile 30 (EHP-30) scores, indicating a positive impact on overall health-related quality of life and well-being?\n\nParticipants will:\n\n* Be randomly assigned to one of two treatment groups. One treatment group will take study drug Rel-CT after having excisional surgery, and the other treatment group will just have the surgery alone.\n* Be asked to complete questionnaires, called the Endometriosis Health Profile 30 (EHP-30) at 4 timepoints. The first time is before surgery, then at follow-up visits at 1 month, 3 months, and 6 months. The survey has 30 questions that ask about pain, control, powerlessness, emotional well-being, social support, and self-image.\n\nResearchers will compare the two treatment groups (Rel-CT and non Rel-CT) to see if there is a change in EHP-30 scores.", "detailedDescription": "The design of this study will be an unblinded randomized controlled trial of medical suppression with once daily Relugolix combination therapy (Rel-CT) following excisional surgery for endometriosis performed by high volume minimally invasive gynecologic surgeons. Women over the age of 18 scheduled to undergo a laparoscopic surgery for endometriosis will be screened and if agree and consented to participate will be randomized to either Rel-CT following surgery or no post-operative hormonal suppression using a block randomization with blocks 2 and 4. The surgeon will not have access to the randomization schedule to reduce selection bias. Inclusion criteria will include: 1) Patients over the age of 18 planning to undergo an elective laparoscopic/robotic procedure for known or suspected endometriosis. Exclusion criteria will include: 1) Patients with known contraindications to REL-CT; 2) Any form of hormonal suppression of endometriosis within the protocol guidelines; 3) Primary language other than English/Spanish; 4) Patients without histologic evidence of endometriosis following their surgical procedure; 5) Patients interested in pregnancy within the 12 months following their surgical procedure.\n\nThe primary outcome will be change in Endometriosis Health Profile 30 (EHP-30) score. A preoperative EHP-30 will be completed by all patients enrolled in the study within 4 weeks of their scheduled surgical procedure and then again postoperatively at 1 month, 3 months, and 6 months. Investigators expect that postoperative use of REL-CT will lead to a clinically meaningful improvement in EHP-30 scores compared to surgery alone. In addition, investigators will gather data on our secondary outcomes: These data could be very helpful in informing providers and patients of the utility of medical suppression of endometriosis using REL-CT following surgery."}, "conditionsModule": {"conditions": ["Endometriosis"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": "The design of this study will be an unblinded randomized controlled trial of medical suppression with once daily Relugolix combination therapy (Rel-CT) following excisional surgery for endometriosis performed by high volume minimally invasive gynecologic surgeons. Researchers will use descriptive statistics to compare the demographics and clinical characteristics of the groups with chi-square and two-sample t-tests. The median differences in EHP-30 from baseline to 6 months will be compared between groups with Mann Whitney U test. The 95% confidence interval of the difference between group medians will be used to measure superiority.", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE", "maskingDescription": "Participants and providers will know if participants are assigned to the treatment arm to take Rel-CT or not."}}, "enrollmentInfo": {"count": 110, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Rel-CT", "type": "ACTIVE_COMPARATOR", "description": "40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate, one tablet daily for 6 months", "interventionNames": ["Drug: 40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate"]}, {"label": "no study drug", "type": "NO_INTERVENTION", "description": "no study drug"}], "interventions": [{"type": "DRUG", "name": "40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate", "description": "if randomized to study drug, participants will take one tablet Rel-CT daily following excisional surgery for endometriosis", "armGroupLabels": ["Rel-CT"], "otherNames": ["Relugolix Combination Therapy (Rel-CT)", "Myfembree"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "This study aims to determine if immediate postoperative medical suppression with Regugolix combination therapy (Rel-CT) following excisional surgery for endometriosis is superior to surgery alone.", "description": "The study will assess quality of life via change in total Endometriosis Health Profile 30 (EHP-30) scores following excisional surgery for endometriosis from baseline to 6 months postoperatively.", "timeFrame": "6 months"}], "secondaryOutcomes": [{"measure": "Change in EHP-30 scores between groups stratified by endometriosis stage", "description": "Comparison of EHP-30 scores according to endometriosis stage of the participant of Rel-CT group to non Rel-Ct treatment group", "timeFrame": "6 months"}, {"measure": "Comparison of EHP-30 subscales", "description": "Comparison of EHP-30 survey subscales in treatment groups.", "timeFrame": "6 months"}, {"measure": "Comparison of EHP-30 by superficial vs deep infiltrating types", "description": "Comparison of EHP-30 scores according to the participant having superficial or deep infiltrating endometriosis post-surgery.", "timeFrame": "6 months"}, {"measure": "Reintervention rates between groups", "description": "Need for surgical reintervention will be assessed between treatment groups.", "timeFrame": "6 months"}, {"measure": "Compliance rates for the study drug and office visits following surgery", "description": "Study drug adherence will be monitored and reported.", "timeFrame": "6 months"}, {"measure": "Rates of concomitant adenomyosis", "description": "Rate of concomitant adenomyosis will be collected and compared between two treatment groups.", "timeFrame": "6 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion criteria\n\n* Age ≥ 18 years\n* Planning to undergo an elective laparoscopic or robotic procedure for known or suspected endometriosis\n\nExclusion criteria\n\n-A known contraindication to REL-CT. Contraindications include:\n\n* High risk of arterial, venous thrombotic, or thromboembolic disorder\n* Pregnancy Known osteoporosis\n* Current or history of breast cancer or other hormone-sensitive malignancies\n* Known hepatic impairment or disease\n* Undiagnosed abnormal uterine bleeding\n* Known hypersensitivity to components of Rel-CT\n* The patient did not discontinue hormonal suppression within the required timeline:\n\nTrans-Dermal, Oral Medication, Patch, or Vaginal Ring: day before surgery\n\nIntrauterine Device or Sub-Dermal Implant: removed at surgery\n\nInjectable Medication: at least 12 weeks before surgery\n\n* Primary language other than English/Spanish\n* Interested in pregnancy within the 6 months following the surgical procedure.\n* If pregnancy test performed during pre-surgical work up is positive, the patient will no longer be a candidate for endometriosis surgery and will therefore not be eligible for the study.\n* Patients without histologic evidence of endometriosis following their surgical procedure will be removed from the study prior to receiving the study intervention.\n* Patients who undergo a surgical intervention more invasive than the planned laparoscopic or robotic excisional surgery, such as open abdominal surgical repair, will be removed from the study prior to receiving the study intervention.", "healthyVolunteers": false, "sex": "FEMALE", "genderBased": true, "genderDescription": "biological female at birth and meeting criteria for endometriosis", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Jordan Klebanoff, MD", "role": "CONTACT", "phone": "610-896-4380", "email": "Klebanoffj@mlhs.org"}, {"name": "Sara Burke, MPH", "role": "CONTACT", "phone": "484-476-2620", "email": "BurkeSa@mlhs.org"}], "overallOfficials": [{"name": "Jordan Klebanoff, MD", "affiliation": "Main Line Health", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Main Line Health", "status": "RECRUITING", "city": "Wynnewood", "state": "Pennsylvania", "zip": "19096", "country": "United States", "contacts": [{"name": "Jordan Klebanoff, MD", "role": "CONTACT"}], "geoPoint": {"lat": 40.00289, "lon": -75.27074}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "Estimating the Mean and Variance from the Median, Range, and the Size of a Sample", "url": "https://bmcmedresmethodol.biomedcentral.com/articles/10.1186/1471-2288-5-13"}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "ICF", "hasProtocol": false, "hasSap": false, "hasIcf": true, "label": "Informed Consent Form", "date": "2025-05-08", "uploadDate": "2025-06-11T10:37", "filename": "ICF_002.pdf", "size": 9767101}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C561634", "term": "relugolix"}, {"id": "D004958", "term": "Estradiol"}, {"id": "D000077563", "term": "Norethindrone Acetate"}], "ancestors": [{"id": "D004963", "term": "Estrenes"}, {"id": "D004962", "term": "Estranes"}, {"id": "D013256", "term": "Steroids"}, {"id": "D000072473", "term": "Fused-Ring Compounds"}, {"id": "D011083", "term": "Polycyclic Compounds"}, {"id": "D045166", "term": "Estradiol Congeners"}, {"id": "D012739", "term": "Gonadal Steroid Hormones"}, {"id": "D042341", "term": "Gonadal Hormones"}, {"id": "D006728", "term": "Hormones"}, {"id": "D006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D009640", "term": "Norethindrone"}, {"id": "D009652", "term": "Norpregnenes"}, {"id": "D009650", "term": "Norpregnanes"}, {"id": "D009654", "term": "Norsteroids"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT04258449", "orgStudyIdInfo": {"id": "2020-6016"}, "organization": {"fullName": "McGill University", "class": "OTHER"}, "briefTitle": "DOvEEgene Fleur: New Uterine Sampling Tool", "officialTitle": "DOvEEgene Fleur: New Uterine Sampling Tool"}, "statusModule": {"statusVerifiedDate": "2025-09", "overallStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2020-12-11", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2026-10-01", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2026-10-01", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2020-02-04", "studyFirstSubmitQcDate": "2020-02-05", "studyFirstPostDateStruct": {"date": "2020-02-06", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2025-09-23", "lastUpdatePostDateStruct": {"date": "2025-09-26", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Dr. Lucy Gilbert", "investigatorTitle": "Professor Department of Obstetrics & Gynecology and Department of Oncology", "investigatorAffiliation": "McGill University"}, "leadSponsor": {"name": "McGill University", "class": "OTHER"}, "collaborators": [{"name": "McGill University Health Centre/Research Institute of the McGill University Health Centre", "class": "OTHER"}, {"name": "GSE Biomedical", "class": "OTHER"}]}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false, "isUsExport": false}, "descriptionModule": {"briefSummary": "This study is related to a previous study from the same group which started in 2014 (NTC02288676, McGill REB A08-M79-13B, MUHC REB 2020-5945) to develop a clinically implementable screening test -DovEEgene: developing and validating a novel molecular test for the early diagnosis of cancer of the endometrium, tubes and ovaries. This study is designed to identify endometrial, tubal and ovarian cancer very early based on identifying cancer-specific mutations (cancer DNA) in a pap sample taken from inside the uterus. The results are particularly encouraging given that control group is challenging with high background mutational burden from benign tumours, endometriosis, germ-line mutations etc.\n\nTo date, all the intrauterine samples were obtained using the commercially available TAO brush™ which is designed to take an endometrial sample. However, when patient tolerability was assessed using a numerical pain scale (NPS) ranging from 0 (no pain) to 10 (severe pain), patients rated the sampling using the TAO brush™ at 3.5 versus 0 for a cervical pap sample. These results were not surprising as the TAO brush™ was designed for dislodging strips of endometrial tissue to use for histopathologic examination. With respect to the investigators objective, which is to collect cancer cells that have exfoliated to the uterus, a sampler that collects these exfoliated cells with as little disturbance as possible to the underlying endometrium is preferred. In this sub-study, the investigators aim to evaluate a new endometrial sampling tool, the DOvEEgene Fleur, which is believe to be superior to the current TAO brush™ in terms of cancer detection, ease of use and patient tolerability. The sampler has been designed using materials/components found in the TAO brush™ and other approved medical devices."}, "conditionsModule": {"conditions": ["Women With Suspected or Confirmed Gynecological Disease"], "keywords": ["Ovarian Cancer", "Endometrial Cancer", "Genomics", "DNA tagging", "Somatic mutations", "Endometrial sampling", "Uterine sampling", "Medical device", "Uterine biofluid"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "CASE_ONLY", "timePerspective": "PROSPECTIVE"}, "enrollmentInfo": {"count": 40, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Case", "description": "Participants must have suspected or confirmed upper genital tract cancer (uterine, tubal and ovarian) and must be scheduled to undergo surgery for tumor removal.", "interventionNames": ["Device: DOvEEgene Fleur Sampling"]}], "interventions": [{"type": "DEVICE", "name": "DOvEEgene Fleur Sampling", "description": "Patients will undergo uterine sampling with DOvEEgene Fleur endometrial sampling device prior to surgical intervention, in addition to standard of care treatment.", "armGroupLabels": ["Case"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Patient related outcomes including pain and acceptability", "description": "Evaluate pain tolerability and acceptability during and after endometrial sample collection. This will be assessed using pain scores reported by participants on numeric pain scale (NPS) ranging from 0 to 10. Final pain scores with the DOvEEgene Fleur will be compared to historical pain scores collected with the TAO brush (Cook Medical).", "timeFrame": "up to 1 year"}], "secondaryOutcomes": [{"measure": "Feasibility of performing sample collection by clinicians", "description": "Ease of use of the DOvEEgene Fleur will be evaluated through a physician feedback form.", "timeFrame": "up to 1 year"}, {"measure": "Quality/quantity of sample collection", "description": "Molecular assessment to verify DOvEEgene Fleur is capable of detecting cancer cells from the uterus.", "timeFrame": "up to 1 year"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Be at least 18 years of age.\n* Have capacity to understand the study.\n* Be able to provide informed consent.\n* If the patient has a recently treated cervical abnormality, she must have had a Pap smear with normal results at least 4 months following treatment by loop electrosurgical excision procedure (LEEP) or cone biopsy.\n* Have suspected or confirmed cancer of the upper genital tract and be undergoing surgery for said tumor removal.\n\nExclusion Criteria:\n\n* Prior hysterectomy.\n* Be pregnant or possibly pregnant.\n* Be nursing, as the device contains phthalates (plasticizers) that \"have not been fully characterized and there may be concern for reproductive and developmental effects\".\n* Have an infected or inflamed cervix.\n* Have a confirmed or suspected pelvic infection.\n* Have a confirmed or suspected vaginal infection.\n* Have had recent history of uterine perforation.\n* Patients with recently treated cervical abnormalities must have a Pap smear with normal results at least 4 months following treatment by loop electrosurgical excision procedure (LEEP) or cone biopsy in order to be eligible.", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"], "studyPopulation": "The participating hospital runs multiple weekly routine gynecologic oncology clinics. The cases include women scheduled to undergo surgery for tumor removal, for either proven or suspected upper genital tract cancer.", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"centralContacts": [{"name": "Dr. Lucy Gilbert, MD,MSc,FRCOG", "role": "CONTACT", "phone": "(514) 934-1934", "phoneExt": "34049", "email": "lucy.gilbert@mcgill.ca"}, {"name": "Dr. Claudia Martins, PhD", "role": "CONTACT", "phone": "(514) 934-1934", "phoneExt": "35249", "email": "claudia.martins@mcgill.ca"}], "locations": [{"facility": "Royal Victoria Hospital (Glen Site)", "status": "RECRUITING", "city": "Montreal", "state": "Quebec", "zip": "H4A 3J1", "country": "Canada", "contacts": [{"name": "Dr. Lucy Gilbert, MD,MSc,FRCOG", "role": "CONTACT", "phone": "(514)934-1934", "phoneExt": "34049", "email": "lucy.gilbert@mcgill.ca"}, {"name": "Dr. Claudia Martins, PhD", "role": "CONTACT", "phone": "(514)934-1934", "phoneExt": "36794", "email": "claudia.martins@mcgill.ca"}], "geoPoint": {"lat": 45.50884, "lon": -73.58781}}]}, "referencesModule": {"references": [{"pmid": "22257524", "type": "BACKGROUND", "citation": "Gilbert L, Basso O, Sampalis J, Karp I, Martins C, Feng J, Piedimonte S, Quintal L, Ramanakumar AV, Takefman J, Grigorie MS, Artho G, Krishnamurthy S; DOvE Study Group. Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project. Lancet Oncol. 2012 Mar;13(3):285-91. doi: 10.1016/S1470-2045(11)70333-3. Epub 2012 Jan 17."}, {"pmid": "23303603", "type": "BACKGROUND", "citation": "Kinde I, Bettegowda C, Wang Y, Wu J, Agrawal N, Shih IeM, Kurman R, Dao F, Levine DA, Giuntoli R, Roden R, Eshleman JR, Carvalho JP, Marie SK, Papadopoulos N, Kinzler KW, Vogelstein B, Diaz LA Jr. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med. 2013 Jan 9;5(167):167ra4. doi: 10.1126/scitranslmed.3004952."}, {"pmid": "28872014", "type": "BACKGROUND", "citation": "Gilbert L, Revil T, Meunier C, Jardon K, Zeng X, Martins C, Arseneau J, Fu L, North K, Schiavi A, Ehrensperger E, Artho G, Lee T, Morris D, Ragoussis J. The empress of subterfuge: cancer of the fallopian tube presenting with malapropism. Lancet. 2017 Sep 2;390(10098):1003-1004. doi: 10.1016/S0140-6736(17)31586-6. No abstract available."}, {"pmid": "29563323", "type": "BACKGROUND", "citation": "Wang Y, Li L, Douville C, Cohen JD, Yen TT, Kinde I, Sundfelt K, Kjaer SK, Hruban RH, Shih IM, Wang TL, Kurman RJ, Springer S, Ptak J, Popoli M, Schaefer J, Silliman N, Dobbyn L, Tanner EJ, Angarita A, Lycke M, Jochumsen K, Afsari B, Danilova L, Levine DA, Jardon K, Zeng X, Arseneau J, Fu L, Diaz LA Jr, Karchin R, Tomasetti C, Kinzler KW, Vogelstein B, Fader AN, Gilbert L, Papadopoulos N. Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. Sci Transl Med. 2018 Mar 21;10(433):eaap8793. doi: 10.1126/scitranslmed.aap8793."}], "seeAlsoLinks": [{"label": "Parent study DOvEEgene: Diagnosing Ovarian and Endometrial Cancer Early Using Genomics (DOvEEgene)", "url": "https://clinicaltrials.gov/ct2/show/NCT02288676"}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D010051", "term": "Ovarian Neoplasms"}, {"id": "D016889", "term": "Endometrial Neoplasms"}], "ancestors": [{"id": "D004701", "term": "Endocrine Gland Neoplasms"}, {"id": "D009371", "term": "Neoplasms by Site"}, {"id": "D009369", "term": "Neoplasms"}, {"id": "D010049", "term": "Ovarian Diseases"}, {"id": "D000291", "term": "Adnexal Diseases"}, {"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D005833", "term": "Genital Neoplasms, Female"}, {"id": "D014565", "term": "Urogenital Neoplasms"}, {"id": "D000091662", "term": "Genital Diseases"}, {"id": "D004700", "term": "Endocrine System Diseases"}, {"id": "D006058", "term": "Gonadal Disorders"}, {"id": "D014594", "term": "Uterine Neoplasms"}, {"id": "D014591", "term": "Uterine Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT05770297", "orgStudyIdInfo": {"id": "KET-683/UN2.F1/ETIK/PPM.00.02"}, "organization": {"fullName": "Indonesia University", "class": "OTHER"}, "briefTitle": "Effect of Propolis Administration for Dysmenorrhea in Endometriosis Patient With Levonorgestrel Implant Therapy", "officialTitle": "Effect of Propolis Administration as Levonorgestrel (LNG) Implant Adjuvant for Dysmenorrhea in Endometriosis: Focus on Clinical Improvement, Oxidative Stress Biomarkers and Inflammation"}, "statusModule": {"statusVerifiedDate": "2023-06", "overallStatus": "UNKNOWN", "lastKnownStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2022-07-12", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2023-06-22", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2023-07-11", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2023-01-24", "studyFirstSubmitQcDate": "2023-03-03", "studyFirstPostDateStruct": {"date": "2023-03-15", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-06-05", "lastUpdatePostDateStruct": {"date": "2023-06-06", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Dr. drg. Dwirini Retno Gunarti, M.S.", "investigatorTitle": "Head of Biochemistry Laboratory", "investigatorAffiliation": "Indonesia University"}, "leadSponsor": {"name": "Indonesia University", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false, "isUsExport": false}, "descriptionModule": {"briefSummary": "The goal of this clinical trial is to investigate the effect of propolis administration on dysmenorrhea in endometriosis patient. the main questions it aims to answer are:\n\n* Does the propolis administration reduce symptoms of dysmenorrhea in endometriosis?\n* Does the propolis administration reduce the amount of oxidative stress biomarkers in endometriosis?\n* Does the propolis administration reduce the amount of Inflammatory biomarkers in endometriosis?\n\nParticipants will be given an intervention in the form of propolis at a dose of 1 drop per 10 kilogram of body weight per administration, twice a day. there will be a control group that will be given an intervention in the form of a placebo containing 70% caramel alcohol dye solution."}, "conditionsModule": {"conditions": ["Endometriosis", "Dysmenorrhea"], "keywords": ["Levonorgestrel implant", "Propolis", "Oxidative stress"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": "Endometriosis patients with menstrual pain who received LNG implant therapy were divided into two groups, each group consisted of 12 samples. The control group only received LNG, the treatment group received LNG with the addition of propolis. Propolis is given 2 times a day, namely in the morning before breakfast and at night before going to bed, with a dose of 1 drop /10 kg body weight (kgBW). Both groups were followed and reassessed after 1 month, 3 months both clinical and laboratory. Prior to receiving therapy, all subjects received education and signed informed consent for their willingness to participate in the study", "primaryPurpose": "SUPPORTIVE_CARE", "maskingInfo": {"masking": "DOUBLE", "maskingDescription": "there will be a comparison group that will receive intervention in the same amount, preparation, and form, but only contain a placebo in the form of a 70% caramel alcohol dye solution. Investigator and participant will not know the contain of intervention that has given.\n\nRandomization of participants was carried out based on the arrival of participants to the obstetrics and gynecology clinic at the Cipto Mangunkusumo Hospital by labeling A for the intervention group and B for the treatment group. then data collection is carried out according to research procedures", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 24, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Propolis", "type": "ACTIVE_COMPARATOR", "description": "the subjects were asked to consume propolis 1 drop/10 kgbw/time given 2 times a day for 12 weeks. the dose will be calculated based on body weight by the certified nutritionist during the interview after the subject signs the informed consent form", "interventionNames": ["Dietary Supplement: Propolis"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "the subjects were asked to consume placebo (glucose-only contained) 1 drop/10 kgbw/time given 2 times a day for 12 weeks. the dose will be calculated based on body weight by the certified nutritionist during the interview after the subject signs the informed consent form", "interventionNames": ["Other: placebo"]}], "interventions": [{"type": "DIETARY_SUPPLEMENT", "name": "Propolis", "description": "intervention will use propolis extract (liquid-based) with 1 drop/10kgBW/times, 2 times in a day for 12 weeks. propolis will be given to intervention group", "armGroupLabels": ["Propolis"]}, {"type": "OTHER", "name": "placebo", "description": "intervention will use placebo with 1 drop/10kgBW/times, 2 times in a day for 12 weeks. propolis will be given control group", "armGroupLabels": ["Placebo"], "otherNames": ["70% caramel alcohol dye solution"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Malondialdehyde (MDA)", "description": "blood biochemical test for oxidative stress biomarker from lipid peroxidation product, using ng/mL numeric scale", "timeFrame": "week 0"}, {"measure": "Malondialdehyde (MDA)", "description": "blood biochemical test for oxidative stress biomarker from lipid peroxidation product, using ng/mL numeric scale", "timeFrame": "week 4"}, {"measure": "Malondialdehyde (MDA)", "description": "blood biochemical test for oxidative stress biomarker from lipid peroxidation product, using ng/mL numeric scale", "timeFrame": "week 12"}, {"measure": "Superoxide dismutase (SOD)", "description": "blood biochemical test for oxidative stress biomarker from lipid peroxidation product, using nmol/mLnumeric scale", "timeFrame": "week 0"}, {"measure": "Superoxide dismutase (SOD)", "description": "blood biochemical test for oxidative stress biomarker from lipid peroxidation product, using nmol/mLnumeric scale", "timeFrame": "week 4"}, {"measure": "Superoxide dismutase (SOD)", "description": "blood biochemical test for oxidative stress biomarker from lipid peroxidation product, using nmol/mLnumeric scale", "timeFrame": "week 12"}, {"measure": "interleukin 6", "description": "will test the outcome with ELISA test from blood sample for inflammatory biomarker, using ng/mL numeric scale", "timeFrame": "week 0"}, {"measure": "interleukin 6", "description": "will test the outcome with ELISA test from blood sample for inflammatory biomarker, using ng/mL numeric scale", "timeFrame": "week 4"}, {"measure": "interleukin 6", "description": "will test the outcome with ELISA test from blood sample for inflammatory biomarker, using ng/mL numeric scale", "timeFrame": "week 12"}, {"measure": "tumor necrosis factor alpha (TNF alfa)", "description": "will test the outcome with ELISA test for inflammatory biomarker, using ng/mL numeric scale", "timeFrame": "week 0"}, {"measure": "tumor necrosis factor alpha (TNF alfa)", "description": "will test the outcome with ELISA test for inflammatory biomarker, using ng/mL numeric scale", "timeFrame": "week 4"}, {"measure": "tumor necrosis factor alpha (TNF alfa)", "description": "will test the outcome with ELISA test for inflammatory biomarker, using ng/mL numeric scale", "timeFrame": "week 12"}, {"measure": "pain scale", "description": "to measure the outcome, the investigators use Visual Analogue Scale for measure the pain from the subject, from 0 to 10. The scale consists of a 10cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be'). the subject will be asked to rate their current level of pain by placing a mark on the line.", "timeFrame": "week 0"}, {"measure": "pain scale", "description": "to measure the outcome, the investigators use Visual Analogue Scale for measure the pain from the subject, from 0 to 10. The scale consists of a 10cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be'). the subject will be asked to rate their current level of pain by placing a mark on the line.", "timeFrame": "week 4"}, {"measure": "pain scale", "description": "to measure the outcome, the investigators use Visual Analogue Scale for measure the pain from the subject, from 0 to 10. The scale consists of a 10cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be'). the subject will be asked to rate their current level of pain by placing a mark on the line.", "timeFrame": "week 12"}, {"measure": "Glutathione", "description": "measure the outcome with blood biochemical test using spectrofotometri in µg/mL numeric scale", "timeFrame": "week 0"}, {"measure": "Glutathione", "description": "measure the outcome with blood biochemical test using spectrofotometri in µg/mL numeric scale", "timeFrame": "week 4"}, {"measure": "Glutathione", "description": "measure the outcome with blood biochemical test using spectrofotometri in µg/mL numeric scale", "timeFrame": "week 12"}, {"measure": "8-hydroxy-2-deoxyiguanosine (8-OHdG)", "description": "measure the outcome with ELISA from blood sample in ng/mL numeric scale", "timeFrame": "week 0"}, {"measure": "8-hydroxy-2-deoxyiguanosine (8-OHdG)", "description": "measure the outcome with ELISA from blood sample in ng/mL numeric scale", "timeFrame": "week 4"}, {"measure": "8-hydroxy-2-deoxyiguanosine (8-OHdG)", "description": "measure the outcome with ELISA from blood sample in ng/mL numeric scale", "timeFrame": "week 12"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Women aged 20-49 years and already menstruating with complaints of menstrual pain referred to the obstetrics and gynecology polyclinic for LNG implant placement\n* Willing to have LNG implant installed after receiving explanation about implants\n* Not receiving hormonal treatment for endometriosis within the last 3 months\n* Can receive drops (propolis) during the study\n\nExclusion Criteria:\n\n* Impaired liver function, degenerative diseases (DM, hypertension and cardiovascular disease), benign tumors, cancer\n* Pregnancy and breastfeeding\n* Hypersensitivity to levonogestrel\n* Thromboembolic disease\n* Experiencing bleeding for unknown reasons\n* History of allergies to honey and its processed products\n* Currently taking supplements/drugs that are not included in the standard management of endometriosis patients at RSCM\n* Have consumed propolis before\n* Received hormonal treatment within the last 3 months", "healthyVolunteers": true, "sex": "FEMALE", "minimumAge": "20 Years", "maximumAge": "49 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Dwirini Retno Gunarti, Dr drg Master of Science", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Cipto Mangunkusumo Hospital", "status": "RECRUITING", "city": "Jakarta", "state": "Jakarta Pusat", "zip": "10430", "country": "Indonesia", "contacts": [{"name": "Dwirini Retno Gunarti, Dr drg Master of Science", "role": "CONTACT", "phone": "08118382301", "email": "drg.yellow@gmail.com"}, {"name": "Eka Rusdianto Gunardi, Dr dr SpOG(K)-FER", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": -6.21462, "lon": 106.84513}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_ICF", "hasProtocol": true, "hasSap": false, "hasIcf": true, "label": "Study Protocol and Informed Consent Form", "date": "2022-02-17", "uploadDate": "2023-03-24T10:46", "filename": "Prot_ICF_001.pdf", "size": 397842}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}, {"id": "D004412", "term": "Dysmenorrhea"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}, {"id": "D008599", "term": "Menstruation Disturbances"}, {"id": "D010335", "term": "Pathologic Processes"}, {"id": "D013568", "term": "Pathological Conditions, Signs and Symptoms"}, {"id": "D017699", "term": "Pelvic Pain"}, {"id": "D010146", "term": "Pain"}, {"id": "D009461", "term": "Neurologic Manifestations"}, {"id": "D012816", "term": "Signs and Symptoms"}]}, "interventionBrowseModule": {"meshes": [{"id": "D011429", "term": "Propolis"}, {"id": "C569050", "term": "caramel coloring"}, {"id": "D000431", "term": "Ethanol"}], "ancestors": [{"id": "D012116", "term": "Resins, Plant"}, {"id": "D001704", "term": "Biopolymers"}, {"id": "D011108", "term": "Polymers"}, {"id": "D046911", "term": "Macromolecular Substances"}, {"id": "D053147", "term": "Plant Exudates"}, {"id": "D001688", "term": "Biological Products"}, {"id": "D045424", "term": "Complex Mixtures"}, {"id": "D000438", "term": "Alcohols"}, {"id": "D009930", "term": "Organic Chemicals"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT04495855", "orgStudyIdInfo": {"id": "21088"}, "organization": {"fullName": "Bayer", "class": "INDUSTRY"}, "briefTitle": "A Study to Learn More About Using Dienogest to Treat Endometriosis in Chinese Participants", "officialTitle": "VISANNE OS/Treatment of Endometriosis With Dienogest in the Real World Clinical Practice", "acronym": "VISANNE OS"}, "statusModule": {"statusVerifiedDate": "2023-12", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2020-10-28", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2022-12-23", "type": "ACTUAL"}, "completionDateStruct": {"date": "2022-12-23", "type": "ACTUAL"}, "studyFirstSubmitDate": "2020-07-14", "studyFirstSubmitQcDate": "2020-07-31", "studyFirstPostDateStruct": {"date": "2020-08-03", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-12-06", "lastUpdatePostDateStruct": {"date": "2023-12-12", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Bayer", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "Endometriosis is a condition that affects women, usually during their reproductive years. In women with endometriosis, the tissue that lines the uterus starts to grow outside of the uterus. This can cause pain during their periods or during sex, and constant pain in the pelvis. Endometriosis can decrease a woman's quality of life and requires long-term treatment to control the symptoms.\n\nFor some women with endometriosis, symptoms can return after they stop treatment. Or, they may not be able to tolerate the current long-term treatment options.\n\nIn this study, researchers will find out more about the safety of long-term treatment with dienogest in a large number of Chinese participants. This study will enroll patients from post-menarche to menopause with clinically or surgically diagnosed endometriosis. All of the participants will take dienogest based on their doctor's instructions. They will then visit their doctor's office 3 times over 6 months. During these visits, their doctors will ask them if they have any health problems and about their quality of life. Their doctors will also do tests to measure the pain caused by their endometriosis and any other symptoms."}, "conditionsModule": {"conditions": ["Endometriosis"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "COHORT", "timePerspective": "PROSPECTIVE"}, "enrollmentInfo": {"count": 968, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Visanne treatment", "description": "Patients from post-menarche to menopause with clinically or surgically diagnosed endometriosis, who have been prescribed Visanne", "interventionNames": ["Drug: Dienogest (Visanne,BAY86_5258)"]}], "interventions": [{"type": "DRUG", "name": "Dienogest (Visanne,BAY86_5258)", "description": "2 mg (once a day), oral, tablet.", "armGroupLabels": ["Visanne treatment"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "The absolute number of AEs reported with Visanne treatment", "description": "AE: Adverse Event", "timeFrame": "From baseline up to 6 months"}, {"measure": "The absolute number of ADRs reported with Visanne treatment", "description": "ADR: Adverse drug reaction", "timeFrame": "From baseline up to 6 months"}, {"measure": "The proportion of AEs reported with Visanne treatment", "description": "Proportion of each AE will be calculated as number of patients with at least one event divided by the total number of patients.", "timeFrame": "From baseline up to 6 months"}, {"measure": "The proportion of ADRs reported with Visanne treatment", "description": "Proportion of each ADR will be calculated as number of patients with at least one event divided by the total number of patients.", "timeFrame": "From baseline up to 6 months"}], "secondaryOutcomes": [{"measure": "Changes in Numeric Rating Scale (NRS) score of Endometriosis Associated Pelvic Pain (EAPP) of Visanne treatment", "description": "NRS: 0-10 integers.\"absence of pain\" corresponds to the value of \"0\" and unbearable pain corresponding to the value of \"10\".", "timeFrame": "From baseline up to 1,3,6 months"}, {"measure": "Endometriosis Health Profile-5 (EHP-5) score changes with Visanne treatment", "description": "EHP-5 contains 11 questions (items): five items including pain, control and powerlessness, emotional well-being, lack of social support, self image from the core questionnaire and six items from the modular questionnaire that may not be applicable to every woman with endometriosis including work, intercourse, and worries about infertility, treatment, and relationship with children and medical professionals. Each item is rated on a four-point scale (never = 0, rarely = 1, sometimes = 2, often = 3, always = 4 and not relevant if not applicable).", "timeFrame": "At baseline and 6 months."}, {"measure": "Patient and physician's satisfaction score on Visanne® treatment", "description": "Satisfaction will be assessed in 5 scales (very satisfied, somewhat satisfied, neither satisfied or dissatisfied, somewhat dissatisfied, very dissatisfied)", "timeFrame": "At 3 and 6 months"}, {"measure": "Changes in Clinical Global Impression (CGI) scale scores of overall symptom development", "description": "CGI scale: very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse", "timeFrame": "At 3 and 6 months"}, {"measure": "Changes in Patient Global Impression (PGI-C) scale scores of overall symptom development", "description": "PGI-C scale: very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse", "timeFrame": "At 3 and 6 months"}, {"measure": "Reasons for discontinuation of using Visanne", "description": "Discontinuation reasons identification:\n\n* AEs (Exclude expected menstruation and treatment ineffective)\n* Dissatisfaction with bleeding profile\n* Absence of symptoms\n* Treatment ineffective\n* Physicians decision\n* Switching to another treatment (another medicine or surgery)\n* Wish to conceive\n* Others", "timeFrame": "From baseline up to 6 months"}, {"measure": "The proportion of participant with amenorrhea, infrequent bleeding, frequent bleeding irregular bleeding, prolonged bleeding upon treatment with Visanne", "timeFrame": "At baseline, 1, 3, and 6 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Signed informed consent.\n* Post-menarcheal age through menopause.\n* Have clinically or surgically diagnosed endometriosis according to routine clinical practice.\n* Decision for the treatment with Visanne was made as per physician's routine treatment practice.\n\nExclusion Criteria:\n\n* Patients participating in an investigational program with interventions outside of routine clinical practice.\n* Any contraindication according to Visanne Chinese label", "healthyVolunteers": false, "sex": "FEMALE", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"], "studyPopulation": "Chinese patients from post-menarche to menopause diagnosed with endometriosis, either surgically or clinically, and prescribed with Visanne by a physician according to China's health authority approved label.", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"locations": [{"facility": "Many locations", "city": "Multiple Locations", "country": "China"}]}, "referencesModule": {"seeAlsoLinks": [{"label": "Click here for access to information about Bayer's transparency standards and Bayer studies.", "url": "https://clinicaltrials.bayer.com/"}]}, "ipdSharingStatementModule": {"ipdSharing": "NO", "description": "Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA \"Principles for responsible clinical trial data sharing\". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.\n\nInterested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal."}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C023635", "term": "dienogest"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT04013126", "orgStudyIdInfo": {"id": "0100-18-emc"}, "organization": {"fullName": "HaEmek Medical Center, Israel", "class": "OTHER"}, "briefTitle": "Endothelial Dysfunction Among Woman With Endometriosis", "officialTitle": "Endothelial Dysfunction Among Woman With Endometriosis After Surgical Treatment"}, "statusModule": {"statusVerifiedDate": "2023-09", "overallStatus": "TERMINATED", "whyStopped": "slow recruitment rate", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2019-08-12", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2023-09-13", "type": "ACTUAL"}, "completionDateStruct": {"date": "2023-09-13", "type": "ACTUAL"}, "studyFirstSubmitDate": "2019-07-04", "studyFirstSubmitQcDate": "2019-07-07", "studyFirstPostDateStruct": {"date": "2019-07-09", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-09-20", "lastUpdatePostDateStruct": {"date": "2023-09-22", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Eyal Rom, MD", "investigatorTitle": "Principal Investigator", "investigatorAffiliation": "HaEmek Medical Center, Israel"}, "leadSponsor": {"name": "HaEmek Medical Center, Israel", "class": "OTHER"}}, "oversightModule": {"isFdaRegulatedDrug": false, "isFdaRegulatedDevice": true, "isUsExport": true}, "descriptionModule": {"briefSummary": "Endometriosis is a chronic disease defined as an ectopic endometrial tissue outside the, and associated with chronic inflammatory state and increased risk of atherosclerosis.\n\nEndothelial dysfunction plays an important and elementary role in the development of atherosclerosis.\n\nThere are number of non-invasive tests for evaluating the endothelial function. One of them is FMD - \"Flow Mediated Dilatation\". Clinical studies proved the efficacy of this method in predicting cardio-vascular events in patients with established heart disease and also as an independent risk factor, better than the traditional ones.\n\nAn alternative method, developed in recent years, is evaluation of peripheral blood vessels tone - \"Peripheral Arterial Tonometry\" - (PAT). It evaluates the pulsatile blood volume of the blood vessels in the fingertips during reactive hyperemia. The obtained value \"reactive hyperemic index\" (RHI) correlates well with FMD as well with coronary arteries endothelial dysfunction.\n\nit well suited as a clinical tool or as a test for a large-scale clinical study.\n\nEndothelial dysfunction has been demonstrated among woman with endometriosis. After surgical removal of endometrial implants there was a substantial improvement in the endothelial function, by imaging (using FMD) and by inflammatory markers\n\nIn this study the investigators will follow the endothelial function among women undergoing endometrial implants surgical removal, before and after the surgery, using PAT technology (ENDOPAT system). Inflammatory markers and quality of life parameters will also be evaluated.\n\nThe follow-up will include one meeting 6 weeks after the procedure The investigators expect an improvement in the endothelial function among women who had endometriosis implants removal.", "detailedDescription": "Endometriosis is a chronic disease defined as an ectopic endometrial tissue outside the uterus, mostly in the pelvis. It is related to major morbidity and infertility. It is also associated with chronic inflammatory state and increased risk of atherosclerosis.\n\nEndothelial dysfunction plays an important and elementary role in the development of atherosclerosis.\n\nThere are number of non-invasive tests for evaluating the endothelial function. One of them is FMD - \"Flow Mediated Dilatation\". It refers to dilation (widening) of an artery when blood flow increases in that artery after An intentional block of the blood flow. Clinical studies proved the efficacy of this method in predicting cardio-vascular events in patients with established heart disease and also as an independent risk factor, better than the traditional ones.\n\nAn alternative method, developed in recent years, is evaluation of peripheral blood vessels tone - \"Peripheral Arterial Tonometry\" - (PAT). It evaluates the pulsatile blood volume of the blood vessels in the fingertips during reactive hyperemia. The obtained value \"reactive hyperemic index\" (RHI) correlates well with FMD as well with coronary arteries endothelial dysfunction.\n\nThe test is performed by attaching two sensors to the patient's fingertips. Using this method requires short training interval, completely user-independent and the accepted result is a quantitive index. Because it takes only 15 minute to complete the test it well suited as a clinical tool or as a test for a large-scale clinical study.\n\nEndothelial dysfunction has been demonstrated among woman with endometriosis. After surgical removal of endometrial implants there was a substantial improvement in the endothelial function, by imaging (using FMD) and by inflammatory markers, so no difference was shown between them and healthy women, 2 years thereafter.\n\nIn a large meta-analysis, evaluating 5,547 patients, every 1% improvement in the FMD scale resulted in a 13% decrease in the rate of cardio-vascular events.\n\nIn a meta-analysis evaluating 5,547 patients a 13% reduction in the risk to cardio-vascular events was demonstrated for every 1% improvement in the FMD score.\n\nIn this study the investigators will follow the endothelial function among women undergoing endometrial implants surgical removal, before and after the surgery, using PAT technology (ENDOPAT system). Inflammatory markers and quality of life parameters will also be evaluated.\n\nThe follow-up will include one meeting 6 weeks after the procedure the investigators expect an improvement in the endothelial function among women who had endometriosis implants removal."}, "conditionsModule": {"conditions": ["Endometriosis"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "NON_RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": "2 groups (treatment, control) each group is evaluated pre and post-surgery", "primaryPurpose": "DIAGNOSTIC", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 22, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "endometriosis", "type": "EXPERIMENTAL", "description": "Women who undergoing surgery for removal of endometriosis implants", "interventionNames": ["Diagnostic Test: • Endothelial function using ENDOPAT system"]}, {"label": "non-endometriosis", "type": "ACTIVE_COMPARATOR", "description": "Women who undergoing surgery for removal of benign masses in the pelvis", "interventionNames": ["Diagnostic Test: • Endothelial function using ENDOPAT system"]}], "interventions": [{"type": "DIAGNOSTIC_TEST", "name": "• Endothelial function using ENDOPAT system", "description": "All of the participants will follow an non-invasive test for endothelial function using ENDOPAT 2000 device before surgery. A consecutive assessment will be held 6 weeks and 2 years post-surgery, using the same method.", "armGroupLabels": ["endometriosis", "non-endometriosis"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change from baseline endothelial function at 6 weeks", "description": "RHI index - \"Reactive Hyperemia Index\"", "timeFrame": "before and 6 weeks after surgery"}, {"measure": "Change from baseline inflammatory markers at 6 weeks", "description": "C-reactive protein", "timeFrame": "before and 6 weeks after surgery"}], "secondaryOutcomes": [{"measure": "Change from baseline pain score at 6 weeks", "description": "visual analog scale (VAS)- scale for patient self-reporting of pain. 0 represents no pain, 1-3 represents mild pain, 4-6 represents moderate pain, 7-10 represents severe pain). a lower pain level 6 weeks after surgery is a better outcome", "timeFrame": "before and 6 weeks after surgery"}, {"measure": "Change from baseline quality of life score at 6 weeks", "description": "The Short Form (SF-36) Health Survey is a 36-item, patient-reported survey of patient health.The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. a higher score 6 weeks after surgery is a better outcome", "timeFrame": "before and 6 weeks after surgery"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Women who undergoing surgery for removal of endometriosis implants\n\nExclusion Criteria:\n\n* Women under 18 or above 60 years of age\n* Women with known vascular disease\n* Women with chronic disease which effect the endothelial function (Diabetes mellitus, Hypertension, Obesity (Defined as BMI≥30), Atherosclerosis, Kidney disease, Collagen disease, Chronic inflammatory disease, and Etc.\n* History of Cardio-vascular event or venous thromboembolism (VTE)\n* Smoking\n* Pregnant women or gave birth in the past 3 months", "healthyVolunteers": true, "sex": "FEMALE", "genderBased": true, "minimumAge": "18 Years", "maximumAge": "60 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Eyal Rom, MD", "affiliation": "haemek medical center", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Haemek Medical Center", "city": "Afula", "country": "Israel", "geoPoint": {"lat": 32.60907, "lon": 35.2892}}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT05291624", "orgStudyIdInfo": {"id": "ULTRASOUND-AAGL2021"}, "organization": {"fullName": "Piazza della Vittoria 14 Studio Medico - Ginecologia e Ostetricia", "class": "OTHER"}, "briefTitle": "Ultrasonographic and Surgical Assessment of Endometriosis by AAGL 2021 Endometriosis Classification", "officialTitle": "Concordance Between Ultrasonographic and Surgical Assessment in Patients With Endometriosis by Using AAGL 2021 Endometriosis Classification: a Single-center Prospective Study", "acronym": "ULTRA-AAGL"}, "statusModule": {"statusVerifiedDate": "2022-09", "overallStatus": "UNKNOWN", "lastKnownStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2022-04-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2022-12-31", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2022-12-31", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2022-03-03", "studyFirstSubmitQcDate": "2022-03-12", "studyFirstPostDateStruct": {"date": "2022-03-22", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2022-09-19", "lastUpdatePostDateStruct": {"date": "2022-09-21", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Simone Ferrero", "investigatorTitle": "Principal Investigator", "investigatorAffiliation": "Piazza della Vittoria 14 Studio Medico - Ginecologia e Ostetricia"}, "leadSponsor": {"name": "Piazza della Vittoria 14 Studio Medico - Ginecologia e Ostetricia", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "In 2021, an international consensus developed a new endometriosis classification system, called AAGL 2021 Endometriosis Classification, for scoring intraoperative surgical complexity and to examine its correlation with patient-reported pain and infertility. Until now, no study has investigated the role of AAGL 2021 Endometriosis Classification in ultrasonographic assessment of patient with endometriosis. This study aims to compare the use of the AAGL 2021 Endometriosis Classification in preoperative (at ultrasound) and intraoperative (at surgery) evaluation of patients with endometriosis."}, "conditionsModule": {"conditions": ["Endometriosis", "Bowel Endometriosis", "Deep Endometriosis", "Ovarian Endometrioma"], "keywords": ["Preoperative Ultrasound", "Endometriosis staging", "Surgical complexity"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "COHORT", "timePerspective": "PROSPECTIVE"}, "enrollmentInfo": {"count": 500, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Patients with preoperative suspicion of endometriosis", "description": "Consecutive patients undergoing ultrasonographic preoperative assessment and subsequent surgical approach for deep endometriosis", "interventionNames": ["Diagnostic Test: AAGL Endometriosis Classification score - ULTRASOUND", "Diagnostic Test: AAGL Endometriosis Classification score - SURGERY"]}], "interventions": [{"type": "DIAGNOSTIC_TEST", "name": "AAGL Endometriosis Classification score - ULTRASOUND", "description": "At baseline, ultrasonographic evaluation of patients by following AAGL Endometriosis Classification", "armGroupLabels": ["Patients with preoperative suspicion of endometriosis"]}, {"type": "DIAGNOSTIC_TEST", "name": "AAGL Endometriosis Classification score - SURGERY", "description": "Within 1 month from enrollment, surgical evaluation of patients by following AAGL Endometriosis Classification", "armGroupLabels": ["Patients with preoperative suspicion of endometriosis"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Reproducibility between ultrasonographic and surgical AAGL staging (minimum value: 0 points, maximum value: 111 points, higher scores mean a higher surgical complexity)", "timeFrame": "Through study completion, an average of 1 month"}, {"measure": "Comparison between total ultrasonographic and surgical AAGL staging score (minimum value: 0 points, maximum value: 111 points, higher scores mean a higher surgical complexity)", "timeFrame": "Through study completion, an average of 1 month"}], "secondaryOutcomes": [{"measure": "Comparison between ultrasonographic and surgical AAGL staging subdomains (minimum value: 0 points, maximum value: 111 points, higher scores mean a higher surgical complexity) score", "timeFrame": "Through study completion, an average of 1 month"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n\\- patients with suspected endometriosis undergoing ultrasonographic preoperative evaluation.\n\nExclusion Criteria:\n\n* patients with suspected or diagnosed malignancy;\n* patients a history of colorectal surgery or a surgery for endometriosis including vaginal resection, full-thickness bowel resection or excision of a endometriotic lesion of the urinary bladder;\n* patients with previous bilateral ovariectomy.", "healthyVolunteers": false, "sex": "FEMALE", "genderBased": true, "minimumAge": "18 Years", "maximumAge": "55 Years", "stdAges": ["ADULT"], "studyPopulation": "Patients with suspected endometriosis undergoing ultrasonographic preoperative evaluation and subsequent surgical approach.", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"centralContacts": [{"name": "Simone Ferrero, MD, PhD", "role": "CONTACT", "phone": "0039 010511525", "email": "simoneferrero@me.com"}, {"name": "Marcello Ceccaroni, MD, PhD", "role": "CONTACT", "email": "issaschool@gmail.com"}], "locations": [{"facility": "Ginecologia - IRCCS Ospedale Sacro Cuore Don Calabria", "status": "RECRUITING", "city": "Negrar", "state": "VR", "zip": "37024", "country": "Italy", "contacts": [{"name": "Marcello Ceccaroni", "role": "CONTACT", "email": "issaschool@gmail.com"}, {"name": "Fabio Barra", "role": "CONTACT", "email": "fabio.barra@icloud.com"}], "geoPoint": {"lat": 45.52918, "lon": 10.93899}}]}, "referencesModule": {"references": [{"pmid": "34583009", "type": "BACKGROUND", "citation": "Abrao MS, Andres MP, Miller CE, Gingold JA, Rius M, Neto JS, Carmona F. AAGL 2021 Endometriosis Classification: An Anatomy-based Surgical Complexity Score. J Minim Invasive Gynecol. 2021 Nov;28(11):1941-1950.e1. doi: 10.1016/j.jmig.2021.09.709. Epub 2021 Sep 25."}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT04296760", "orgStudyIdInfo": {"id": "ENHANCED-ETV-ENDO"}, "organization": {"fullName": "Ospedale Policlinico San Martino", "class": "OTHER"}, "briefTitle": "Rectal Water-contrast Transvaginal Ultrasonography Versus Sonovaginography for the Diagnosis of Posterior Deep Pelvic Endometriosis", "officialTitle": "Rectal Water-contrast Transvaginal Ultrasonography Versus Sonovaginography for the Diagnosis of Posterior Deep Pelvic Endometriosis"}, "statusModule": {"statusVerifiedDate": "2020-11", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2018-01-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2020-11-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2020-11-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2020-03-03", "studyFirstSubmitQcDate": "2020-03-03", "studyFirstPostDateStruct": {"date": "2020-03-05", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2020-11-16", "lastUpdatePostDateStruct": {"date": "2020-11-17", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR_INVESTIGATOR", "investigatorFullName": "Fabio Barra", "investigatorTitle": "MD", "investigatorAffiliation": "Ospedale Policlinico San Martino"}, "leadSponsor": {"name": "Fabio Barra", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "As the surgical treatment of posterior deep endometriosis may be challenging for surgeons and carry significant risks for patients, preoperative assessment of the location, characteristics and presence of nodules of posterior deep endometriosis is important in order to inform the patient about the various treatment possibilities and to allow adequate counseling regarding treatment strategy. The aim of this study is to investigate the accuracy of rectal water-contrast transvaginal ultrasonography (RWC-TVS), and sonovaginography (SVG) in patients with clinical suspicion of posterior deep endometriosis (DIE)."}, "conditionsModule": {"conditions": ["Endometriosis, Rectum", "Endometriosis of Vagina", "Endometriosis Rectovaginal Septum", "Endometriosis Pelvic", "Endometriosis of Colon", "Endometriosis"], "keywords": ["rectosigmoid endometriosis; posterior pelvic deep endometriosis; vaginal endometriosis; rectovaginal endometriosis"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "CASE_ONLY", "timePerspective": "PROSPECTIVE"}, "enrollmentInfo": {"count": 250, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Women with suspicious of deep posterior pelvic endometriosis", "interventionNames": ["Diagnostic Test: Rectal water-contrast transvaginal ultrasonography", "Diagnostic Test: Sonovaginography"]}], "interventions": [{"type": "DIAGNOSTIC_TEST", "name": "Rectal water-contrast transvaginal ultrasonography", "description": "Transvaginal ultrasound scan combined with the introduction of saline solution into the rectum", "armGroupLabels": ["Women with suspicious of deep posterior pelvic endometriosis"]}, {"type": "DIAGNOSTIC_TEST", "name": "Sonovaginography", "description": "Transvaginal ultrasound scan combined with the introduction of saline solution into the vagina", "armGroupLabels": ["Women with suspicious of deep posterior pelvic endometriosis"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Accuracy in diagnosing the presence of the following sites of posterior deep endometriosis: rectovaginal septum, rectosigmoid, uterosacral ligaments, and vagina", "timeFrame": "At maximum 6 months before undergoing laparoscopic surgical approach"}], "secondaryOutcomes": [{"measure": "Accuracy in estimating the deep of infiltration in the intestinal muscolari propria of nodules of rectosigmoid endometriosis", "timeFrame": "At maximum 6 months before undergoing laparoscopic surgical approach"}, {"measure": "Accuracy in estimating the distance between rectosigmoid endometriosis nodules and the anal verge", "timeFrame": "At maximum 6 months before undergoing laparoscopic surgical approach"}, {"measure": "Accuracy in diagnosing the presence of multifocal rectosigmoid endometriosis", "timeFrame": "At maximum 6 months before undergoing laparoscopic surgical approach"}, {"measure": "Accuracy in estimating the largest diameter of endometriosis nodules in the following sites of posterior deep endometriosis: rectovaginal septum, rectosigmoid, uterosacral ligaments, and vagina", "timeFrame": "At maximum 6 months before undergoing laparoscopic surgical approach"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* clinical presentation suggestive of the presence of posterior deep infiltrating endometriosis\n\nExclusion Criteria:\n\n* previous diagnosis of posterior deep infiltrating endometriosis by radiologic imaging (i.e. magnetic resonance, computed tomography)\n* previous surgical diagnosis of posterior deep infiltrating endometriosis", "sex": "FEMALE", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"], "studyPopulation": "Patients with suspicion of posterior deep infiltrating endometriosis, referring to our academic department for diagnostic purposes", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"overallOfficials": [{"name": "Fabio Barra, MD", "affiliation": "Ospedale Policlinico San Martino", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Ospedale Policlinico San Martino", "city": "Genoa", "zip": "1632", "country": "Italy", "geoPoint": {"lat": 44.40478, "lon": 8.94439}}]}, "referencesModule": {"references": [{"pmid": "27060846", "type": "BACKGROUND", "citation": "Leone Roberti Maggiore U, Biscaldi E, Vellone VG, Venturini PL, Ferrero S. Magnetic resonance enema vs rectal water-contrast transvaginal sonography in diagnosis of rectosigmoid endometriosis. Ultrasound Obstet Gynecol. 2017 Apr;49(4):524-532. doi: 10.1002/uog.15934."}, {"pmid": "26935873", "type": "BACKGROUND", "citation": "Ferrero S, Biscaldi E, Vellone VG, Venturini PL, Leone Roberti Maggiore U. Computed tomographic colonography vs rectal water- contrast transvaginal sonography in diagnosis of rectosigmoid endometriosis: a pilot study. Ultrasound Obstet Gynecol. 2017 Apr;49(4):515-523. doi: 10.1002/uog.15905."}]}, "ipdSharingStatementModule": {"ipdSharing": "UNDECIDED"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT04118777", "orgStudyIdInfo": {"id": "123"}, "organization": {"fullName": "University of Tennessee, Chattanooga", "class": "OTHER"}, "briefTitle": "Postoperative Narcotic Use After Laparoscopic Gynecologic Surgery", "officialTitle": "Postoperative Narcotic Use After Laparoscopic Gynecologic Surgery: A Randomized, Double-blind, Placebo-controlled Trial Comparing Continuous Intraperitoneal Infusion of Ropivacaine Versus Saline for Post-operative Pain Control"}, "statusModule": {"statusVerifiedDate": "2021-07", "overallStatus": "WITHDRAWN", "whyStopped": "Misregistered to wrong sponsor.", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2020-05-01", "type": "ESTIMATED"}, "primaryCompletionDateStruct": {"date": "2020-06-30", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2020-07-30", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2019-10-01", "studyFirstSubmitQcDate": "2019-10-04", "studyFirstPostDateStruct": {"date": "2019-10-08", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2021-07-13", "lastUpdatePostDateStruct": {"date": "2021-07-20", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "University of Tennessee, Chattanooga", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "This will be a prospective, randomized, double blinded placebo-controlled study at Erlanger hospital. Eligible patients who provide consent will be randomized into one of two arms receiving continuous intra-peritoneal local anesthetic with 0.2% Ropivacaine or saline.", "detailedDescription": "This will be a prospective, randomized, double blinded placebo-controlled study at Erlanger hospital. Eligible patients who provide consent will be randomized into one of two arms receiving continuous intra-peritoneal local anesthetic with 0.2% Ropivacaine or saline. After inclusion criteria are met and consents are obtained all patients will be sent home with a pain measurement, a pill diary to record the quantity of narcotic tablets taken, and a questionnaire nausea and vomiting symptoms.\n\nAfter placement of the ON-Q pain pump the select-a-flow rate will be set to 6 mL/hr for all study participants. . All study participants will be provided with rescue pain medications as needed. If possible non-narcotic medications such as Tylenol and non-steroidal anti-inflammatory's will be utilized first. If pain persists narcotic medications will be provided. Oxycodone 5 mg will be utilized unless a patient reported allergy exists. All rescue narcotics utilized will be converted into morphine equivalents and documented. All patients will be discharged with Oxycodone 5 mg with 35 tablets which provides pain coverage for 7 days after surgery. In addition to Oxycodone all patients will be discharged with Sprix, a nasal non-steroidal anti-inflammatory medication, as well as Zofran and movantik, a medication for narcotic induced constipation. All patients will be instructed to administer Sprix by placing one puff into each nostril every 6 hours for a total of 5 days after surgery. They will further be instructed to take oral Tylenol 1000 mg every 6 hours for a total of 4 days after surgery. Assigned research personnel will contact all patients to obtain the results of their survey and pill dairy at 48 hours and one week after surgery. Patients will then present for a two-week post-operative visit where study personnel will complete data collection. All study participants who request a narcotic refill within 6 weeks of surgery will be documented."}, "conditionsModule": {"conditions": ["Pelvic Pain", "Endometriosis", "Pelvic Prolapse"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "maskingDescription": "this will be a double-blinded study. Study participants will be randomized into one of two study arms by the pharmacy staff after using a random number generator.", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 0, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "0.2 % Ropivacaine", "type": "ACTIVE_COMPARATOR", "description": "An ON-Q pain pump will be placed into the pelvic cavity and 0.2% Ropivacaine will be continuously administered intraperitoneally at a rate of 6 mL/hr.", "interventionNames": ["Drug: Ropivacaine"]}, {"label": "Saline", "type": "PLACEBO_COMPARATOR", "description": "An ON-Q pain pump will be placed into the pelvic cavity and saline will be continuously administered intraperitoneally at a rate of 6 mL/hr", "interventionNames": ["Drug: Ropivacaine"]}], "interventions": [{"type": "DRUG", "name": "Ropivacaine", "description": "0.2 % Ropivacaine will be continuously administered intraperitoneally at a rate of 6 mL/hr", "armGroupLabels": ["0.2 % Ropivacaine", "Saline"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Amount of rescue narcotics consumed in the postoperative period, calculated as morphine equivalents.", "description": "All rescue oral narcotics taken in the post-operative period will be converted to morphine equivalents and recorded", "timeFrame": "6 weeks after surgery"}], "secondaryOutcomes": [{"measure": "post-operative pain scores", "description": "Pain scores will be obtained via the visual analog scale (VAS). The VAS tool measures pain on a scale from 0 to 10 with 0 being no pain and 10 being unbearable pain.", "timeFrame": "1,2, 4, and 48 hours after surgery. 1 and 2 weeks after surgery"}, {"measure": "nausea and vomiting", "description": "The postoperative nausea and vomiting impact scale will be used to measure the presence and amount of nausea and vomiting. The scale measures the amount of vomiting from 0 ( no vomiting) to 3 ( three or more episodes of vomiting). The second questions measures the presence of nausea and then the amount from o ( no nausea) to 3 ( all of the time).", "timeFrame": "48 hours, 1 week, and 2 weeks after surgery"}, {"measure": "Hospital discharge", "description": "Time to discharge", "timeFrame": "post-operative day zero to two"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. All patients undergoing laparoscopic gynecologic surgery with either the traditional \"straight stick\" or robotic assisted techniques will be considered for eligibility. Eligible patients will include those with pelvic pain and endometriosis as well as those who present for pelvic floor reconstruction. Surgical procedures performed will include excision of endometriosis, lysis of adhesions, hysterectomy, bilateral or unilateral salpingo-oophorectomy, cystectomy, and pelvic reconstruction.\n2. Patients who are 18 years or older\n3. Patients who provide written surgical consent\n4. Patients who are capable and willing to follow up with surveys and complete pain and pill diaries\n\nExclusion Criteria:\n\n1. Patients who are unable or willing to provide consent and complete the follow up surveys and dairies\n2. Patients who are allergic to Ropivacaine\n3. Patients whose minimally invasive procedures were converted to laparotomies", "healthyVolunteers": true, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "65 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "referencesModule": {"references": [{"pmid": "29215508", "type": "BACKGROUND", "citation": "Madsen AM, Stark LM, Has P, Emerson JB, Schulkin J, Matteson KA. Opioid Knowledge and Prescribing Practices Among Obstetrician-Gynecologists. Obstet Gynecol. 2018 Jan;131(1):150-157. doi: 10.1097/AOG.0000000000002407."}, {"pmid": "29112660", "type": "BACKGROUND", "citation": "As-Sanie S, Till SR, Mowers EL, Lim CS, Skinner BD, Fritsch L, Tsodikov A, Dalton VK, Clauw DJ, Brummett CM. Opioid Prescribing Patterns, Patient Use, and Postoperative Pain After Hysterectomy for Benign Indications. Obstet Gynecol. 2017 Dec;130(6):1261-1268. doi: 10.1097/AOG.0000000000002344."}, {"pmid": "28889218", "type": "BACKGROUND", "citation": "Hota LS, Warda HA, Haviland MJ, Searle FM, Hacker MR. Opioid use following gynecologic and pelvic reconstructive surgery. Int Urogynecol J. 2018 Oct;29(10):1441-1445. doi: 10.1007/s00192-017-3474-5. Epub 2017 Sep 9."}, {"pmid": "28403427", "type": "BACKGROUND", "citation": "Brummett CM, Waljee JF, Goesling J, Moser S, Lin P, Englesbe MJ, Bohnert ASB, Kheterpal S, Nallamothu BK. New Persistent Opioid Use After Minor and Major Surgical Procedures in US Adults. JAMA Surg. 2017 Jun 21;152(6):e170504. doi: 10.1001/jamasurg.2017.0504. Epub 2017 Jun 21."}, {"pmid": "28564673", "type": "BACKGROUND", "citation": "Wick EC, Grant MC, Wu CL. Postoperative Multimodal Analgesia Pain Management With Nonopioid Analgesics and Techniques: A Review. JAMA Surg. 2017 Jul 1;152(7):691-697. doi: 10.1001/jamasurg.2017.0898."}, {"pmid": "24185607", "type": "BACKGROUND", "citation": "Perniola A, Fant F, Magnuson A, Axelsson K, Gupta A. Postoperative pain after abdominal hysterectomy: a randomized, double-blind, controlled trial comparing continuous infusion vs patient-controlled intraperitoneal injection of local anaesthetic. Br J Anaesth. 2014 Feb;112(2):328-36. doi: 10.1093/bja/aet345. Epub 2013 Oct 31."}, {"pmid": "24327987", "type": "BACKGROUND", "citation": "Chung D, Lee YJ, Jo MH, Park HJ, Lim GW, Cho H, Nam EJ, Kim SW, Kim JH, Kim YT, Kim S. The ON-Q pain management system in elective gynecology oncologic surgery: Management of postoperative surgical site pain compared to intravenous patient-controlled analgesia. Obstet Gynecol Sci. 2013 Mar;56(2):93-101. doi: 10.5468/OGS.2013.56.2.93. Epub 2013 Mar 12."}, {"pmid": "15385371", "type": "BACKGROUND", "citation": "Gupta A, Perniola A, Axelsson K, Thorn SE, Crafoord K, Rawal N. Postoperative pain after abdominal hysterectomy: a double-blind comparison between placebo and local anesthetic infused intraperitoneally. Anesth Analg. 2004 Oct;99(4):1173-1179. doi: 10.1213/01.ANE.0000130260.24433.A2."}, {"pmid": "17658017", "type": "BACKGROUND", "citation": "Cottam DR, Fisher B, Atkinson J, Link D, Volk P, Friesen C, Link D, Grace B, Trovar R. A randomized trial of bupivicaine pain pumps to eliminate the need for patient controlled analgesia pumps in primary laparoscopic Roux-en-Y gastric bypass. Obes Surg. 2007 May;17(5):595-600. doi: 10.1007/s11695-007-9103-5."}, {"pmid": "19335329", "type": "BACKGROUND", "citation": "Yoost TR, McIntyre M, Savage SJ. Continuous infusion of local anesthetic decreases narcotic use and length of hospitalization after laparoscopic renal surgery. J Endourol. 2009 Apr;23(4):623-6. doi: 10.1089/end.2008.0586."}, {"pmid": "21997148", "type": "BACKGROUND", "citation": "Thornton PC, Buggy DJ. Local anaesthetic wound infusion for acute postoperative pain: a viable option? Br J Anaesth. 2011 Nov;107(5):656-8. doi: 10.1093/bja/aer293. No abstract available."}, {"pmid": "21418466", "type": "BACKGROUND", "citation": "Kahokehr A, Sammour T, Soop M, Hill AG. Intraperitoneal local anaesthetic in abdominal surgery - a systematic review. ANZ J Surg. 2011 Apr;81(4):237-45. doi: 10.1111/j.1445-2197.2010.05573.x. Epub 2010 Nov 17."}, {"pmid": "9215018", "type": "BACKGROUND", "citation": "Williamson KM, Cotton BR, Smith G. Intraperitoneal lignocaine for pain relief after total abdominal hysterectomy. Br J Anaesth. 1997 Jun;78(6):675-7. doi: 10.1093/bja/78.6.675."}, {"pmid": "27924202", "type": "BACKGROUND", "citation": "Lee SH, Sim WS, Kim GE, Kim HC, Jun JH, Lee JY, Shin BS, Yoo H, Jung SH, Kim J, Lee SH, Yo DK, Na YR. Randomized trial of subfascial infusion of ropivacaine for early recovery in laparoscopic colorectal cancer surgery. Korean J Anesthesiol. 2016 Dec;69(6):604-613. doi: 10.4097/kjae.2016.69.6.604. Epub 2016 Sep 28."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D017699", "term": "Pelvic Pain"}, {"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D010146", "term": "Pain"}, {"id": "D009461", "term": "Neurologic Manifestations"}, {"id": "D012816", "term": "Signs and Symptoms"}, {"id": "D013568", "term": "Pathological Conditions, Signs and Symptoms"}, {"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000077212", "term": "Ropivacaine"}], "ancestors": [{"id": "D000813", "term": "Anilides"}, {"id": "D000577", "term": "Amides"}, {"id": "D009930", "term": "Organic Chemicals"}, {"id": "D000814", "term": "Aniline Compounds"}, {"id": "D000588", "term": "Amines"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT03769584", "orgStudyIdInfo": {"id": "2018-01728; sp18Tschudin"}, "organization": {"fullName": "University Hospital, Basel, Switzerland", "class": "OTHER"}, "briefTitle": "Follow-up of Treatment Outcome, Quality of Life, Sexual Life and Partnership After Surgery of Endometriosis", "officialTitle": "Follow-up of Treatment Outcome, Quality of Life, Sexual Life and Partnership After Surgery of Endometriosis"}, "statusModule": {"statusVerifiedDate": "2020-01", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2018-12-15", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2019-04-09", "type": "ACTUAL"}, "completionDateStruct": {"date": "2019-12-31", "type": "ACTUAL"}, "studyFirstSubmitDate": "2018-12-06", "studyFirstSubmitQcDate": "2018-12-06", "studyFirstPostDateStruct": {"date": "2018-12-07", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2020-01-29", "lastUpdatePostDateStruct": {"date": "2020-01-30", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "University Hospital, Basel, Switzerland", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "Follow-up of treatment outcome, quality of life, sexual life and partnership after surgery of endometriosis by means of a questionnaire 1 year after surgical Intervention."}, "conditionsModule": {"conditions": ["Endometriosis"], "keywords": ["quality of life", "treatment outcome", "sexuality", "partnership", "surgery of endometriosis"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "COHORT", "timePerspective": "RETROSPECTIVE"}, "enrollmentInfo": {"count": 31, "type": "ACTUAL"}}, "armsInterventionsModule": {"interventions": [{"type": "OTHER", "name": "Follow-up questionnaire", "description": "Online- Questionnaire investigating Follow-up of Treatment Outcome, Quality of Life, Sexual Life and Partnership After Surgery of Endometriosis"}, {"type": "OTHER", "name": "Follow- up interview", "description": "Semi- structured Interview investigating Follow-up of Treatment Outcome, Quality of Life, Sexual Life and Partnership After Surgery of Endometriosis"}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Endometriosis- associated symptoms assessed by questionnaire", "description": "questionnaire asking for pain (with menstruation, with sexual intercourse, with defecation, with urination) on a Visual Analogue Scale (VAS), ranging from 0 = no pain to 10 = intolerable pain", "timeFrame": "1 year after surgery of endometriosis"}, {"measure": "Treatment outcome of surgery of endometriosis assessed by VAS questionnaire", "description": "questionnaire asking for satisfaction with treatment outcome on a Visual Analogue Scale (VAS), ranging from 0 = absolutely dissatisfied to 10 = absolutely satisfied", "timeFrame": "1 year after surgery of endometriosis"}, {"measure": "Change in Quality of life assessed by questionnaire", "description": "questionnaire asking for Quality of life on a Visual Analogue Scale (VAS), ranging from 0 = very bad to 10 = very good", "timeFrame": "before surgery of endometriosis and 1 year after surgery of endometriosis"}, {"measure": "Change in sexual life assessed by questionnaire", "description": "questionnaire asking for Sexual life on a Visual Analogue Scale (VAS), ranging from 0 = absolutely dissatisfied to 10 = absolutely satisfied", "timeFrame": "before surgery of endometriosis and 1 year after surgery of endometriosis"}, {"measure": "Change in conduct of life assessed by questionnaire", "description": "questionnaire asking for change in conduct of life (partnership, family, professional life, leisure activity, sportive activities) on a 6- item scale (ranging from \"negative\" to \"positive\")", "timeFrame": "before surgery of endometriosis and 1 year after surgery of endometriosis"}, {"measure": "Change in wish for child assessed by questionnaire", "description": "questionnaire asking for change in wish for child on a 3- item scale (ranging from \"yes\" , \"no answer\" to \"no\")", "timeFrame": "before surgery of endometriosis and 1 year after surgery of endometriosis"}], "secondaryOutcomes": [{"measure": "Follow-up of Treatment outcome of surgery of endometriosis assessed by interview", "description": "semi- structured interview to assess comments of study participants that are not depicted in the questionnaires", "timeFrame": "1 year after surgery of endometriosis"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* surgery of endometriosis at Frauenklinik of University Hospital Basel (from 01.01.2017 until 31.12.2017)\n* sufficient German language skills in order to be able to complete questionnaires\n\nExclusion Criteria:\n\n* incapable of consenting", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"], "studyPopulation": "women with endometriosis undergoing surgery of endometriosis at Frauenklinik of University Hospital Basel (from 01.01.2017 until 31.12.2017)", "samplingMethod": "PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"overallOfficials": [{"name": "Sibil Tschudin, PD Dr. med", "affiliation": "Frauenklinik Universitätsspital Basel", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Frauenklinik University Hospital Basel", "city": "Basel", "zip": "4031", "country": "Switzerland", "geoPoint": {"lat": 47.55839, "lon": 7.57327}}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}, {"id": "D019529", "term": "Sexuality"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}, {"id": "D012725", "term": "Sexual Behavior"}, {"id": "D001519", "term": "Behavior"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT06495151", "orgStudyIdInfo": {"id": "E2-22-1998"}, "organization": {"fullName": "Ankara City Hospital Bilkent", "class": "OTHER"}, "briefTitle": "Endometriosis and Complement System", "officialTitle": "Evaluation of Serum and Peritoneal Fluid Mannose-binding Lectin Associated Serine Protease-3, Adipsin, Properdin, and Complement Factor H Levels in Endometriosis Patients"}, "statusModule": {"statusVerifiedDate": "2024-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2022-06-10", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2022-09-12", "type": "ACTUAL"}, "completionDateStruct": {"date": "2022-10-07", "type": "ACTUAL"}, "studyFirstSubmitDate": "2024-07-03", "studyFirstSubmitQcDate": "2024-07-03", "studyFirstPostDateStruct": {"date": "2024-07-10", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2024-07-11", "lastUpdatePostDateStruct": {"date": "2024-07-12", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Merve Didem Eşkin Tanrıverdi", "investigatorTitle": "Medical Doctor", "investigatorAffiliation": "Ankara City Hospital Bilkent"}, "leadSponsor": {"name": "Ankara City Hospital Bilkent", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "Endometriosis is a chronic gynecological condition affecting nearly 10% of women of reproductive age. A definitive diagnosis of endometriosis requires laparoscopy. Studies aim to identify novel biomarkers to aid in the development of effective noninvasive diagnostic methods. Despite several theories, the full understanding of the etiopathogenesis remains elusive. A distorted immune response is thought to play a crucial role in the pathophysiology of endometriosis. This study aimed to evaluate whether the levels of alternative complement molecules change in the blood serum and peritoneal fluid of endometriosis patients compared to healthy subjects.", "detailedDescription": "Endometriosis is a chronic gynecological condition affecting nearly 10% of women of reproductive age. It has been reported to contribute to 21-47% of cases of female infertility and 71-87% of cases involving chronic pelvic pain. The definitive diagnosis of endometriosis requires laparoscopy. While CA-125 has diagnostic value, it is not specific to endometriosis. Therefore, studies are focused on identifying novel biomarkers to aid in the development of effective noninvasive diagnostic methods. Despite numerous theories, the etiopathogenesis of endometriosis remains incompletely understood. A distorted immune response is believed to play a crucial role in the pathophysiology of the condition. Regarding alterations in the classical and lectin-dependent complement systems, C3a, C3c, C4, and C5b-9 have been suggested to hold potential diagnostic value in endometriosis. Alternative pathway is another way for complement activation. This study aimed to investigate whether there are alterations in the levels of alternative complement molecules in both the blood serum and peritoneal fluid of patients diagnosed with endometriosis, comparing these levels to those found in healthy individuals. The research focused on understanding potential differences that could contribute to the pathophysiology of endometriosis, aiming to provide insights into the role of the alternative complement pathway in this gynecological condition."}, "conditionsModule": {"conditions": ["Endometriosis", "Complement System", "Alternative Complement Pathway"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "CASE_CONTROL", "timePerspective": "PROSPECTIVE"}, "bioSpec": {"retention": "SAMPLES_WITHOUT_DNA", "description": "Serum samples were collected via antecubital venous blood sampling. In the study group, serum samples were obtained just before laparoscopy, while peritoneal fluid (PF) samples were collected from the Douglas pouch at the time of trochar insertion into the abdominal cavity. Serum and PF MASP-3, adipsin, properdin, and CFH levels were evaluated."}, "enrollmentInfo": {"count": 58, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Endometriosis group (Study group)", "description": "* The study group included 32 women with endometriosis.\n* The study group consisted of women diagnosed with endometriosis who consecutively underwent laparoscopic endometriosis surgery.", "interventionNames": ["Diagnostic Test: Mannose-binding lectin-associated serine protease-3 (MASP-3) Level", "Diagnostic Test: Adipsin Level", "Diagnostic Test: Properdin Level", "Diagnostic Test: Complement Factor H (CFH) Level", "Diagnostic Test: Cancer Antigen 125 (CA-125) Level"]}, {"label": "Healthy women (Control group)", "description": "* Control group consisted of 26 healthy women.\n* The control group consisted of women who consecutively visited the outpatient clinic for routine gynecologic examinations and had no known diseases.", "interventionNames": ["Diagnostic Test: Mannose-binding lectin-associated serine protease-3 (MASP-3) Level", "Diagnostic Test: Adipsin Level", "Diagnostic Test: Properdin Level", "Diagnostic Test: Complement Factor H (CFH) Level", "Diagnostic Test: Cancer Antigen 125 (CA-125) Level"]}], "interventions": [{"type": "DIAGNOSTIC_TEST", "name": "Mannose-binding lectin-associated serine protease-3 (MASP-3) Level", "description": "Measurement of venous blood serum and peritoneal fluid levels of MASP-3 level by ELISA method.", "armGroupLabels": ["Endometriosis group (Study group)", "Healthy women (Control group)"]}, {"type": "DIAGNOSTIC_TEST", "name": "Adipsin Level", "description": "Measurement of venous blood serum and peritoneal fluid levels of adipsin level by ELISA method.", "armGroupLabels": ["Endometriosis group (Study group)", "Healthy women (Control group)"]}, {"type": "DIAGNOSTIC_TEST", "name": "Properdin Level", "description": "Measurement of venous blood serum and peritoneal fluid levels of properdin level by ELISA method.", "armGroupLabels": ["Endometriosis group (Study group)", "Healthy women (Control group)"]}, {"type": "DIAGNOSTIC_TEST", "name": "Complement Factor H (CFH) Level", "description": "Measurement of venous blood serum and peritoneal fluid levels of CFH level by ELISA method.", "armGroupLabels": ["Endometriosis group (Study group)", "Healthy women (Control group)"]}, {"type": "DIAGNOSTIC_TEST", "name": "Cancer Antigen 125 (CA-125) Level", "description": "Measurement of venous blood serum level of CA-125 level by ELISA method.", "armGroupLabels": ["Endometriosis group (Study group)", "Healthy women (Control group)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Serum and peritoneal fluid mannose-binding lectin-associated serine protease-3 level", "description": "Nanogram/milliliter", "timeFrame": "day 1"}, {"measure": "Serum and peritoneal fluid adipsin level", "description": "Nanogram/milliliter", "timeFrame": "day 1"}, {"measure": "Serum and peritoneal fluid properdin level", "description": "Nanogram/milliliter", "timeFrame": "day 1"}, {"measure": "Serum and peritoneal fluid complement factor H level", "description": "Nanogram/milliliter", "timeFrame": "day 1"}], "secondaryOutcomes": [{"measure": "Serum cancer antigen 125 level", "description": "Unit/milliliter", "timeFrame": "day 1"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosis of endometriosis for study group who underwent laparoscopic endometriosis surgery\n* Healthy women for control group\n\nExclusion Criteria:\n\n* Cardiovascular diseases including hypertension\n* Type 1 or type 2 diabetes mellitus\n* Morbid obesity\n* Primary adrenal insufficiency\n* Uterine fibroids\n* Thyroid dysfunctions including Hashimoto thyroiditis and Grave's disease\n* Hepatic dysfunctions\n* Renal insufficiency\n* Genetic disorders in chromosome constitution or karyotype analysis including monosomy X, trisomy X and gene mutations as BMP15, FMR I, POFIB, and GDF9\n* Neurologic diseases\n* Psychiatric disorders\n* Autoimmune diseases or syndromes including Addison's disease, autoimmune syndromes, scleroderma, Sjogren's syndrome, myasthenia gravis, inflammatory bowel diseases, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus and familial Mediterranean fever\n* History of any malignancy\n* History of exposure to chemotherapeutic agents or radiotherapy", "healthyVolunteers": true, "sex": "FEMALE", "genderBased": true, "genderDescription": "Endometriosis is the presence of endometrial tissue outside the uterus, such as in the ovaries, fallopian tubes, peritoneal membrane, or abdominal cavity, and it is diagnosed exclusively in females.", "minimumAge": "18 Years", "maximumAge": "44 Years", "stdAges": ["ADULT"], "studyPopulation": "Study population includes a total of 58 participants. The study group consists of 32 women with the diagnosis of endometriosis, and the control group consists of 26 healthy women.", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"overallOfficials": [{"name": "Merve Didem Eşkin Tanrıverdi, MD", "affiliation": "Ankara City Hospital Bilkent", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Ankara Bilkent City Hospital", "city": "Ankara", "zip": "06100", "country": "Turkey (Türkiye)", "geoPoint": {"lat": 39.91987, "lon": 32.85427}}]}, "referencesModule": {"references": [{"pmid": "29420391", "type": "BACKGROUND", "citation": "Falcone T, Flyckt R. Clinical Management of Endometriosis. Obstet Gynecol. 2018 Mar;131(3):557-571. doi: 10.1097/AOG.0000000000002469."}, {"pmid": "31488888", "type": "BACKGROUND", "citation": "Chapron C, Marcellin L, Borghese B, Santulli P. Rethinking mechanisms, diagnosis and management of endometriosis. Nat Rev Endocrinol. 2019 Nov;15(11):666-682. doi: 10.1038/s41574-019-0245-z. Epub 2019 Sep 5."}, {"pmid": "32325082", "type": "BACKGROUND", "citation": "Karadadas E, Hortu I, Ak H, Ergenoglu AM, Karadadas N, Aydin HH. Evaluation of complement system proteins C3a, C5a and C6 in patients of endometriosis. Clin Biochem. 2020 Jul;81:15-19. doi: 10.1016/j.clinbiochem.2020.04.005. Epub 2020 Apr 20."}, {"pmid": "17482181", "type": "BACKGROUND", "citation": "Kabut J, Kondera-Anasz Z, Sikora J, Mielczarek-Palacz A. Levels of complement components iC3b, C3c, C4, and SC5b-9 in peritoneal fluid and serum of infertile women with endometriosis. Fertil Steril. 2007 Nov;88(5):1298-303. doi: 10.1016/j.fertnstert.2006.12.061. Epub 2007 May 4."}, {"pmid": "11724962", "type": "BACKGROUND", "citation": "Xu Y, Ma M, Ippolito GC, Schroeder HW Jr, Carroll MC, Volanakis JE. Complement activation in factor D-deficient mice. Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14577-82. doi: 10.1073/pnas.261428398. Epub 2001 Nov 27."}, {"pmid": "20720586", "type": "BACKGROUND", "citation": "Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010 Sep;11(9):785-97. doi: 10.1038/ni.1923. Epub 2010 Aug 19."}, {"pmid": "34682837", "type": "BACKGROUND", "citation": "Poppelaars F, Faria B, Schwaeble W, Daha MR. The Contribution of Complement to the Pathogenesis of IgA Nephropathy: Are Complement-Targeted Therapies Moving from Rare Disorders to More Common Diseases? J Clin Med. 2021 Oct 14;10(20):4715. doi: 10.3390/jcm10204715."}, {"pmid": "34671343", "type": "BACKGROUND", "citation": "Liu M, Luo X, Xu Q, Yu H, Gao L, Zhou R, Wang T. Adipsin of the Alternative Complement Pathway Is a Potential Predictor for Preeclampsia in Early Pregnancy. Front Immunol. 2021 Oct 4;12:702385. doi: 10.3389/fimmu.2021.702385. eCollection 2021."}, {"pmid": "27434652", "type": "BACKGROUND", "citation": "Gursoy Calan O, Calan M, Yesil Senses P, Unal Kocabas G, Ozden E, Sari KR, Kocar M, Imamoglu C, Senses YM, Bozkaya G, Bilgir O. Increased adipsin is associated with carotid intima media thickness and metabolic disturbances in polycystic ovary syndrome. Clin Endocrinol (Oxf). 2016 Dec;85(6):910-917. doi: 10.1111/cen.13157. Epub 2016 Aug 15."}, {"pmid": "34696714", "type": "BACKGROUND", "citation": "Zhang J, Teng F, Pan L, Guo D, Liu J, Li K, Yuan Y, Li W, Zhang H. Circulating adipsin is associated with asymptomatic carotid atherosclerosis in obese adults. BMC Cardiovasc Disord. 2021 Oct 25;21(1):517. doi: 10.1186/s12872-021-02329-3."}, {"pmid": "34566967", "type": "BACKGROUND", "citation": "Barratt J, Weitz I. Complement Factor D as a Strategic Target for Regulating the Alternative Complement Pathway. Front Immunol. 2021 Sep 9;12:712572. doi: 10.3389/fimmu.2021.712572. eCollection 2021."}, {"pmid": "38145036", "type": "BACKGROUND", "citation": "Lei X, Song X, Fan Y, Chen Z, Zhang L. The Role and Potential Mechanism of Complement Factor D in Fibromyalgia Development. J Pain Res. 2023 Dec 19;16:4337-4351. doi: 10.2147/JPR.S439689. eCollection 2023."}, {"pmid": "33505394", "type": "BACKGROUND", "citation": "Agostinis C, Balduit A, Mangogna A, Zito G, Romano F, Ricci G, Kishore U, Bulla R. Immunological Basis of the Endometriosis: The Complement System as a Potential Therapeutic Target. Front Immunol. 2021 Jan 11;11:599117. doi: 10.3389/fimmu.2020.599117. eCollection 2020."}, {"pmid": "37108664", "type": "BACKGROUND", "citation": "Chen LH, Lo WC, Huang HY, Wu HM. A Lifelong Impact on Endometriosis: Pathophysiology and Pharmacological Treatment. Int J Mol Sci. 2023 Apr 19;24(8):7503. doi: 10.3390/ijms24087503."}, {"pmid": "27782323", "type": "BACKGROUND", "citation": "Garred P, Genster N, Pilely K, Bayarri-Olmos R, Rosbjerg A, Ma YJ, Skjoedt MO. A journey through the lectin pathway of complement-MBL and beyond. Immunol Rev. 2016 Nov;274(1):74-97. doi: 10.1111/imr.12468."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO", "description": "IPD are available which may be shared in necessary conditions."}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT06082011", "orgStudyIdInfo": {"id": "ISFMT-SP-004"}, "organization": {"fullName": "Ruijin Hospital", "class": "OTHER"}, "briefTitle": "A Real-World Study to Evaluate the Clinical Performance and Safety of da Vinci SP Surgical System for Single-Port Gynecological Surgeries(SPiM-RWS-GYN)", "officialTitle": "A Real-World Study to Evaluate the Clinical Performance and Safety of da Vinci SP Surgical System for Single-Port Gynecological Surgeries"}, "statusModule": {"statusVerifiedDate": "2023-08", "overallStatus": "UNKNOWN", "lastKnownStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2023-03-28", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2024-10-31", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2024-12-31", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2023-09-19", "studyFirstSubmitQcDate": "2023-10-08", "studyFirstPostDateStruct": {"date": "2023-10-13", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-10-08", "lastUpdatePostDateStruct": {"date": "2023-10-13", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Ruijin Hospital", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": true}, "descriptionModule": {"briefSummary": "Study name：A Real-World Study to Evaluate the Clinical Performance and Safety of da Vinci SP Surgical System for Single-Port Gynecological Surgeries Study purpose：This clinical trial is a real-world study to evaluate the clinical performance and safety of da Vinci SP Surgical System (\"SP single-port robot\" for short) for single-port robotic surgeries of gynecological benign and malignant tumors in the real world, providing a real world evidence for clinical application of the product in the Chinese population.\n\nStudy design：Retrospective + prospective, real-world study\n\nEnglish name: da Vinci SP Surgical System Model and specification: SP1098 Manufacturer: Intuitive Surgical, Inc."}, "conditionsModule": {"conditions": ["Gynecological Surgeries"], "keywords": ["radical hysterectomy", "salpingectomy/oophorectomy", "vaginal hysterectomy", "total hysterectomy", "myomectomy", "ovarian cystectomy", "deep endometriosis resection", "pelvic and abdominal lymphadenectomy", "sentinel lymph node resection by image development", "uterus/vagino-sacral colpopexy", "high uterosacral ligament suspension"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "COHORT", "timePerspective": "CROSS_SECTIONAL"}, "enrollmentInfo": {"count": 15, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "RWS study for SP Gynecological Surgeries", "description": "da Vinci SP Surgical System(SP1098)", "interventionNames": ["Device: da Vinci SP Surgical System"]}], "interventions": [{"type": "DEVICE", "name": "da Vinci SP Surgical System", "description": "Model and specification: SP1098 Manufacturer: Intuitive Surgical, Inc.", "armGroupLabels": ["RWS study for SP Gynecological Surgeries"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Primary efficacy endpoint: Intraoperative conversion rate", "timeFrame": "Intraoperative"}, {"measure": "Primary safety endpoint: Incidence of device related or possibly related complications meeting the Clavien-Dindo Grading System level 3 or above criteria within 30 days after the surgery", "timeFrame": "30 days"}], "secondaryOutcomes": [{"measure": "Intraoperative bleeding volume", "timeFrame": "Intraoperative"}, {"measure": "Intraoperative blood transfusion rate", "timeFrame": "Intraoperative"}, {"measure": "Surgical duration", "timeFrame": "Intraoperative"}, {"measure": "Length of stay (LOS)", "timeFrame": "During the follow-up 1 day before discharge.The LOS is defined as the total inpatient days of each subject from the day of the surgery to the day of discharge (unit: days)."}, {"measure": "Admission to ICU and ICU LOS", "timeFrame": "During the follow-up 1 day before discharge, the admission to ICU and ICU LOS (unit: days) of each subject should be recorded."}, {"measure": "Postoperative pain score", "timeFrame": "during the follow-ups 1 day (24±4 h), 3 days (72±4 h) and 1 month (30±5 days) after the surgery"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Female patients who have received or plan to receive gynecological surgeries with the SP single-port robot such as radical hysterectomy, salpingectomy/oophorectomy, vaginal hysterectomy, total hysterectomy, myomectomy, ovarian cystectomy, deep endometriosis resection, pelvic and abdominal lymphadenectomy, sentinel lymph node resection by image development, uterus/vagino-sacral colpopexy, and high uterosacral ligament suspension.\n2. Patients who voluntarily participate in the study and sign the ICF (or exempt from signature of the ICF as approved by the EC).\n\nExclusion Criteria:\n\n1. Patients with missing data on the primary endpoint in retrospective cases;\n2. Patients having any contraindications of single-port robot surgery;\n3. The intraoperative anatomy demonstrate that minimally invasive surgery is not suitable;\n4. Patients who are considered inappropriate to participate in this Study by investigators.", "sex": "ALL", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"], "studyPopulation": "Subjects who have received or plan to receive single-port gynecological surgeries with the SP single-port robot such as radical hysterectomy, salpingectomy/oophorectomy, vaginal hysterectomy, total hysterectomy, myomectomy, ovarian cystectomy, deep endometriosis resection, pelvic and abdominal lymphadenectomy, sentinel lymph node resection by image development, uterus/vagino-sacral colpopexy, and high uterosacral ligament suspension.", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"centralContacts": [{"name": "Weiwei Feng", "role": "CONTACT", "phone": "13918551061", "email": "wfeng7347@aliyun.com"}], "locations": [{"facility": "Shanghai JiaoTong University School of Medicine affliated Ruijin Hospital", "status": "RECRUITING", "city": "Shanghai", "state": "Shanghai Municipality", "zip": "200011", "country": "China", "contacts": [{"name": "Tianjiao Lyu, PhD", "role": "CONTACT", "phone": "008613482445868", "email": "ltj12196@rjh.com.cn"}, {"name": "Yahui Jiang, PhD", "role": "CONTACT", "phone": "008613918551061", "email": "fww12066@rjh.com.cn"}], "geoPoint": {"lat": 31.22222, "lon": 121.45806}}]}, "ipdSharingStatementModule": {"ipdSharing": "UNDECIDED"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT05069740", "orgStudyIdInfo": {"id": "18369"}, "organization": {"fullName": "Penn State University", "class": "OTHER"}, "briefTitle": "Endometriosis and Microvascular Dysfunction: Role of Inflammation", "officialTitle": "Mechanisms and Interventions Addressing Accelerated Cardiovascular Disease Risk in Endometriosis", "acronym": "Endo3/SA2"}, "statusModule": {"statusVerifiedDate": "2024-11", "overallStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2022-01-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2025-12-31", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2026-12-31", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2021-09-10", "studyFirstSubmitQcDate": "2021-09-24", "studyFirstPostDateStruct": {"date": "2021-10-06", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2024-11-04", "lastUpdatePostDateStruct": {"date": "2024-11-05", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Lacy Alexander", "investigatorTitle": "Professor of Kinesiology", "investigatorAffiliation": "Penn State University"}, "leadSponsor": {"name": "Penn State University", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to better understand the underlying mechanisms associated with elevated cardiovascular disease risk in women with endometriosis, and to measure the effectiveness of emerging endometriosis treatments on outcomes specific to cardiovascular dysfunction.\n\nEpidemiologic data demonstrate a clear association between endometriosis, reproductive risk factors, inflammation and cardiovascular (CV) risk. Circulating factors, low-density lipoprotein (LDL) and oxidized LDL (oxLDL), are two of many biomarkers of cardiovascular and inflammatory disease of endometriosis. An important signaling mechanism through which circulating LDL and oxLDL act is the lectin-like oxidized LDL receptor (LOX-1). LOX-1 signal transduction functionally results in pronounced endothelial dysfunction, a hallmark of CV. The investigators hypothesis that one factor mediating the elevated risk of cardiovascular disease in endometriosis is systemic inflammation and activation of LOX-1 receptor mechanisms.", "detailedDescription": "Endometriosis is an estrogen-dependent gynecological disorder associated with considerable chronic pelvic pain, pain during intercourse, and is a major cause of infertility. This disorder affects 6% - 10% of reproductive age women and can be as high as 35-50% in women experiencing pain or infertility. Endometriosis derives from the presence of endometrium-like tissue in sites outside the uterine cavity. While endometriosis is a local inflammatory syndrome, the inflammatory process is systemic.\n\nEndometriosis is associated with higher risk of hypercholesterolemia and hypertension 8. Epidemiologic data demonstrate a clear association between endometriosis, reproductive risk factors, inflammation and cardiovascular (CV) risk.\n\nEndometriosis a disease of inflammation and increased systemic inflammatory cytokine production, although the precise mechanisms by which localized lesion results in systemic inflammation are incompletely understood. Published data confirm an elevation of several inflammatory cytokines in the circulation of women with endometriosis. Alterations in circulating miRNAs specific to endometriosis are one mechanism causing immune dysfunction and subsequent increased cytokine expression in areas remote from the endometriotic lesions. This aberrant increase in systemic cytokine production is a highly plausible putative link to accelerated vascular dysfunction and atherosclerosis in women with endometriosis.\n\nThe circulating factors LDL and oxidized LDL are two of the many biomarkers of cardiovascular and inflammatory disease of endometriosis. An important signaling mechanism through which circulating LDL and oxLDL act is the lectin-like oxidized LDL receptor (LOX-1). LOX-1 is a ubiquitously expressed scavenger receptor, stimulated by oxLDL, Ang II, and other inflammatory cytokines, and inhibited by estrogen. LOX-1 is the upstream signaling initiator of mechanisms including increased oxidant production, reduced nitric oxide (NO) metabolism, and impaired intracellular trafficking. Thus, LOX-1 signal transduction functionally results in pronounced endothelial dysfunction."}, "conditionsModule": {"conditions": ["Endometriosis"], "keywords": ["skin blood flow", "inflammation", "Lectin-like oxidized LDL receptor (LOX-1)", "intradermal microdialysis"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["EARLY_PHASE1"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "interventionModelDescription": "This is a single blind placebo controled cross over study. Two groups of women complete this study: 1) healthy women between the ages of 18 and 45 years (Controls); 2) women between the ages of 18 and 45 years with endometriosis. Once consented and screening, each subject is randomized to either 5 days of salsalate or placebo. On day 5, each subject participates in a cutaneous microdialysis (MD) and flow mediated dilation (FMD) experiment. After a 2-week washout, the participant returns to repeat the study with the other oral drug (salsalate/placebo). These treatments are blinded to only the investigators. The participants and nurse on staff knows which treatment the subject is taking if there are any questions or safety concerns.", "primaryPurpose": "BASIC_SCIENCE", "maskingInfo": {"masking": "SINGLE", "maskingDescription": "These treatments/placebo are blinded to the investigators. The subjects, physician, and the nurse on staff knows which treatment the subject is taking if there are any questions or safety concerns.", "whoMasked": ["INVESTIGATOR"]}}, "enrollmentInfo": {"count": 24, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Salsalate", "type": "EXPERIMENTAL", "description": "3000 mg/day salsalate (1500 mg twice daily) for 5 days", "interventionNames": ["Drug: Salsalate Pill"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "1 capsule contain microcrystalline cellulose filler (twice daily) for 5 days", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Salsalate Pill", "description": "Salsalate acts as an NFkB inhibitor to reduce systemic inflammation", "armGroupLabels": ["Salsalate"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo for the salsalate intervention", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "cutaneous vascular conductance", "description": "doppler flowmetry used to measure cutaneous vascular conductance (cvc = red cell flux/mean arterial pressure) to assess microvascular endothelial function", "timeFrame": "5 days after treatment"}, {"measure": "brachial artery diameter and blood flow velocity", "description": "continuous ultrasound imaging measurements of brachial artery diameter and blood flow velocity to assess endothelial function", "timeFrame": "5 days after treatment"}, {"measure": "Sera LOX-1 protein expression", "description": "Peripheral Blood Mononuclear Cell Isolation, LOX-1 expression quantified using real time pCR", "timeFrame": "5 days after treatment"}, {"measure": "Biopsy LOX-1 protein expression", "description": "Bio-Rad DC assay, western blot technique used for LOX-1 protein receptor expression", "timeFrame": "5 days after treatment"}], "secondaryOutcomes": [{"measure": "sera reproductive hormone analysis", "description": "analysis of plasma estradiol, progesterone, and sex hormone binding globulin determined through hormone assay", "timeFrame": "5 days after treatment"}, {"measure": "sera cytokine expression analysis", "description": "expression of cytokines CRP, TNF-a, IL-1B, IL-6, IL-8 determined through multiplex assay", "timeFrame": "5 days after treatment"}, {"measure": "skin biopsy biochemical analysis", "description": "the expression of estrogen receptor alpha and beta, the protein pVASP/VASP, and the enzyme peNOS/eNOS is determined using Bio-Rad DC assay, western blot technique", "timeFrame": "5 days after treatment"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Healthy women between the ages of 18 and 45 years (Controls), taking oral contraceptive or with regular menses every 26-34 days\n* Women between the ages of 18 and 45 years with endometriosis (diagnosis by prior laparoscopy by subject's own physician \\<5 years prior, and reported by the subject to the researchers)\n* Tylenol if the subject has acute pain is allowed\n* Contraceptive use is allowed\n\nExclusion Criteria:\n\n* Use of nicotine-containing products (e.g. smoking, chewing tobacco, etc.)\n* Diabetes (HbA1C 6.5%)\n* BP\\>140/90\n* Taking pharmacotherapy that could alter peripheral vascular control (e.g. insulin sensitizing, cardiovascular medications)\n* Pregnancy\n* Breastfeeding\n* Taking illicit and/or recreational drugs\n* Abnormal liver function\n* Rash, skin disease, disorders of pigmentation, known skin allergies\n* Diagnosed or suspected metabolic or cardiovascular disease\n* Persistent unexplained elevations of serum transaminases\n* Known allergy to latex or investigative substances (including salsalate or simvastatin)\n* History of gastrointestinal bleeding", "healthyVolunteers": true, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "45 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Lacy M Alexander, Ph.D.", "role": "CONTACT", "phone": "8148671781", "email": "lma191@psu.edu"}, {"name": "Susan Slimak, RN", "role": "CONTACT", "phone": "814-863-8554", "email": "sks31@psu.edu"}], "locations": [{"facility": "The Pennsylvania State University", "status": "RECRUITING", "city": "University Park", "state": "Pennsylvania", "zip": "16801", "country": "United States", "contacts": [{"name": "Lacy M Alexander, PhD", "role": "CONTACT", "phone": "814-867-1781", "email": "lma191@psu.edu"}], "geoPoint": {"lat": 40.80201, "lon": -77.85639}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}, {"id": "D007249", "term": "Inflammation"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}, {"id": "D010335", "term": "Pathologic Processes"}, {"id": "D013568", "term": "Pathological Conditions, Signs and Symptoms"}]}, "interventionBrowseModule": {"meshes": [{"id": "C014182", "term": "salicylsalicylic acid"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT00938496", "orgStudyIdInfo": {"id": "NIS-OCN-ZOL-2009/1"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Non-Interventional Study of Zoladex in Endometriosis", "officialTitle": "A Non-interventional Study of Postoperative Treatment With Goserelin Acetate (Zoladex) in Moderate to Severe Endometriosis Patient"}, "statusModule": {"statusVerifiedDate": "2014-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-07"}, "primaryCompletionDateStruct": {"date": "2012-02", "type": "ACTUAL"}, "completionDateStruct": {"date": "2012-02", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-07-09", "studyFirstSubmitQcDate": "2009-07-13", "studyFirstPostDateStruct": {"date": "2009-07-14", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2014-02-19", "lastUpdatePostDateStruct": {"date": "2014-02-20", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This is a prospective, open label NIS, which is to assess the efficacy of Zoladex in adjuvant setting after operation in moderate to severe endometriosis patients."}, "conditionsModule": {"conditions": ["Endometriosis"]}, "designModule": {"studyType": "OBSERVATIONAL", "designInfo": {"timePerspective": "PROSPECTIVE"}, "enrollmentInfo": {"count": 408, "type": "ACTUAL"}}, "outcomesModule": {"primaryOutcomes": [{"measure": "Symptom recurrence rate and total recurrence rate", "timeFrame": "18 months"}], "secondaryOutcomes": [{"measure": "Pregnancy rate", "timeFrame": "18 months"}, {"measure": "Zoladex administration time", "timeFrame": "6 months"}, {"measure": "Add-back therapy information", "timeFrame": "18 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Advanced endometriosis confirmed histologically (r-AFS score III-IV) with conservative laparoscopy or laparotomy.\n* Patient who has the indication of Zoladex and has been prescribed Zoladex according to physician's judgement, irrespective of the inclusion in the study.\n* Patient has been already prescribed Zoladex within 1 month after operation.\n\nExclusion Criteria:\n\n* Have used hormone treatment prior to 3 months of recruitment.\n* Involvement in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site).\n* Previous enrolment in the present study.", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"], "studyPopulation": "Study Population Description: Patient with advanced endometriosis confirmed histological (r-AFS score III-IV) with conservative laparoscopy or laparotomy has the indication of Zoladex and has already been prescribed Zoladex according to physician's judgment, irrespective of the inclusion in the study", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"overallOfficials": [{"name": "Zhou Yingfang", "affiliation": "Peking University First Hospital", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Research Site", "city": "Hefei", "state": "Anhui", "country": "China", "geoPoint": {"lat": 31.86389, "lon": 117.28083}}, {"facility": "Research Site", "city": "Beijing", "state": "Beijing Municipality", "country": "China", "geoPoint": {"lat": 39.9075, "lon": 116.39723}}, {"facility": "Research Site", "city": "Guangzhou", "state": "Guangdong", "country": "China", "geoPoint": {"lat": 23.11667, "lon": 113.25}}, {"facility": "Research Site", "city": "Shenzhen", "state": "Guangdong", "country": "China", "geoPoint": {"lat": 22.54554, "lon": 114.0683}}, {"facility": "Research Site", "city": "Harbin", "state": "Heilongjiang", "country": "China", "geoPoint": {"lat": 45.75, "lon": 126.65}}, {"facility": "Research Site", "city": "Changsha", "state": "Hunan", "country": "China", "geoPoint": {"lat": 28.19874, "lon": 112.97087}}, {"facility": "Research Site", "city": "Shenyang", "state": "Liaoning", "country": "China", "geoPoint": {"lat": 41.79222, "lon": 123.43278}}, {"facility": "Research Site", "city": "Shanghai", "state": "Shanghai Municipality", "country": "China", "geoPoint": {"lat": 31.22222, "lon": 121.45806}}, {"facility": "Research Site", "city": "Xi’an", "state": "Shanxi", "country": "China", "geoPoint": {"lat": 35.99785, "lon": 113.52486}}, {"facility": "Research Site", "city": "Chengdu", "state": "Sichuan", "country": "China", "geoPoint": {"lat": 30.66667, "lon": 104.06667}}, {"facility": "Research Site", "city": "Hangzhou", "state": "Zhejiang", "country": "China", "geoPoint": {"lat": 30.29365, "lon": 120.16142}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "CSR-NIS-OCN-ZOL-2009-1.pdf", "url": "http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=980&filename=CSR-NIS-OCN-ZOL-2009-1.pdf"}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT03928288", "orgStudyIdInfo": {"id": "P00031528"}, "organization": {"fullName": "Boston Children's Hospital", "class": "OTHER"}, "briefTitle": "Cabergoline for the Treatment of Chronic Pain Due to Endometriosis", "officialTitle": "Novel, Non-Hormonal Therapy for the Treatment of Chronic Pain Due to Endometriosis in Adolescent and Adult Women"}, "statusModule": {"statusVerifiedDate": "2025-08", "overallStatus": "ACTIVE_NOT_RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2019-12-02", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2025-12", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2026-06", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2019-04-04", "studyFirstSubmitQcDate": "2019-04-23", "studyFirstPostDateStruct": {"date": "2019-04-26", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2025-08-04", "lastUpdatePostDateStruct": {"date": "2025-08-07", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Amy DiVasta, MD", "investigatorTitle": "Associate Professor of Pediatrics", "investigatorAffiliation": "Boston Children's Hospital"}, "leadSponsor": {"name": "Boston Children's Hospital", "class": "OTHER"}, "collaborators": [{"name": "Beth Israel Deaconess Medical Center", "class": "OTHER"}, {"name": "Thomas Jefferson University", "class": "OTHER"}, {"name": "Stanford University", "class": "OTHER"}, {"name": "Children's Hospital Colorado", "class": "OTHER"}, {"name": "Brigham and Women's Hospital", "class": "OTHER"}]}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false, "isUsExport": false}, "descriptionModule": {"briefSummary": "Endometriosis is dependent on angiogenesis (the sprouting of new blood vessels) for its growth and maintenance, but the side effects of currently approved angiogenesis inhibitors make these agents inappropriate for use in reproductive-age patients. This obstacle will be overcome by performing a randomized, double blind clinical trial aimed at repurposing an existing drug, cabergoline, as a safe, alternative angiogenesis inhibitor for adolescents and young women with endometriosis. This trial proposes a novel, non-hormonal, non-surgical therapeutic approach aimed at alleviating the pain and suffering associated with this common chronic disease that currently has limited treatment options.", "detailedDescription": "Endometriosis is a gynecologic condition in which tissue similar to the inside lining of the uterus (the endometrium) grows in locations in the body outside of the uterus. This abnormal growth can cause severe pain, often coinciding with a woman's menstrual period. Endometriosis affects about 10% of all women of reproductive age in the US, and leads to an estimated $22 billion/year in health care costs in the US alone. Endometriosis is a chronic disease that can progress over time, leading to infertility, debilitating pelvic pain, and resulting poor quality of life. Disease management involves not only prompt initiation of therapy, but also the maintenance of therapy for a prolonged length of time. As no cure currently exists, the disease typically progresses until menopause. Current medical management typically consists of hormonal medications and surgery, but these therapies are limited by lack of successful relief of symptoms, cost, or side effects. Many patients have endometriosis pain that is refractory to all available treatments. Safe, well-tolerated, long-duration additions to currently available treatments are sorely needed to ameliorate the chronic course of this disease.\n\nAngiogenesis refers to the generation of new blood vessels from existing vessels. It is required for the growth of new living tissue and has been implicated in the initiation, maintenance, and spread of endometriosis. The investigators hypothesize that medications that inhibit the process of angiogenesis can be used to treat endometriosis. The angiogenesis inhibitor medications that are currently available cause severe side effects such as birth defects that prevent them from being safely used for treating endometriosis in young, otherwise healthy women. In contrast, there is an alternative medication, cabergoline, which has been extensively used in clinical practice for treatment of other endocrine conditions suffered by reproductive-aged women. While cabergoline appears to inhibit angiogenesis, it acts on this process indirectly such that it has very few side effects, making it appropriate for use in young women with endometriosis.\n\nThe investigators will conduct a clinical drug trial to determine whether cabergoline is an effective addition to standard hormonal therapy for decreasing persistent pelvic pain suffered by adolescents and young women with surgically-proven endometriosis. Patients who are interested in participating in our study will be randomized (decided by a flip of a coin) to either receive cabergoline, the investigational medication, or a placebo pill (a sugar pill). It is believed that after 6 months, patients who take cabergoline twice a week will demonstrate decreased pain scores and improved quality of life/ability to perform daily activities as compared to patients who take a placebo pill (sugar pill) twice weekly. During the research study, the investigators will study how pain symptoms, menstrual bleeding, levels of inflammation, risk for future cardiac disease, and measures of pain sensitivity change over time by using well-established, validated tools and techniques that the research team has utilized successfully in previous work."}, "conditionsModule": {"conditions": ["Endometriosis"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 140, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Intervention", "type": "EXPERIMENTAL", "description": "Cabergoline 0.5 mg PO twice weekly for 6 months", "interventionNames": ["Drug: Cabergoline 0.5 MG"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo capsule PO twice weekly for 6 months", "interventionNames": ["Drug: Placebo - Cap"]}], "interventions": [{"type": "DRUG", "name": "Cabergoline 0.5 MG", "description": "Medication", "armGroupLabels": ["Intervention"], "otherNames": ["Dostinex"]}, {"type": "DRUG", "name": "Placebo - Cap", "description": "Placebo capsule", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in pain assessed by the Brief Pain Inventory Interference Scale (BPI) over 6 months", "description": "BPI: A 7-item self-report measure. The items in this scale can be grouped into those that assess physical functioning (general activity; walking ability; normal work, including both work outside the home and housework), those that assess emotional functioning (mood; relations with people; enjoyment of life), and a single item that assesses the extent to which pain interferes with sleep. Either the item asking about the \"worst pain\" or the arithmetic mean of the four severity items can be used as measures of pain severity; the arithmetic mean of the seven interference items can be used as a measure of pain interference. The BPI is anchored between a scale of zero (no pain/interference) to ten (maximum pain/interference). The magnitude of treatment-associated change in BPI Interference Scale scores in open-label and randomized clinical trials ranges from 1 to 3 points, depending on the specific pain conditions and treatments studied.", "timeFrame": "every 6 weeks for 6 months"}, {"measure": "Change in pain severity measured by Visual Analog Scale (VAS) over 6 months", "description": "VAS: A measurement of pain intensity, assessed by a 0 to 10 numerical rating scale, to rate maximum and average pain intensity over the preceding 7 days. Higher scores indicate more severe pain intensity.", "timeFrame": "every 6 weeks for 6 months"}, {"measure": "Change in pain measured by Biberoglu and Behrman patient ratings scale (B&B pain scale) over 6 months", "description": "Biberoglu and Behrman patient ratings scale (B\\&B pain scale): Survey that assesses dyspareunia, dysmenorrhea, and noncyclic pelvic pain. Each is graded on a scale from 0 to 3 (or 4), with higher numbers indicating more severe symptoms.", "timeFrame": "every 6 weeks for 6 months"}], "secondaryOutcomes": [{"measure": "Change in measurements of serum biomarkers of angiogenesis and inflammation over 6 months", "description": "Measurement of serum concentrations of high sensitivity C-reactive protein, interleukins 1B and 8, tumor necrosis factor alpha, and vascular endothelial growth factor", "timeFrame": "every 3 months for 6 months"}, {"measure": "Change in cardiovascular dysfunction measured by pulse wave velocity over 6 months", "description": "Peripheral wave velocity is an ultrasound measurement of the rate at which pressure waves move down a blood vessel. It is collected by using two pressure catheters placed a known distance from one another, the \"Pulse Wave Distance\".", "timeFrame": "baseline and 6 months"}, {"measure": "Change in measures of central hypersensitization measured by quantitative sensory testing at 6 months", "description": "Quantitative sensory testing (QST) is a single, standardized protocolized test that involves measurement of 3 pain threshold tests (cutaneous dynamic brush allodynia, muscular pain threshold, temporal summation test) that will be measured at the abdomen", "timeFrame": "every 3 months for 6 months"}, {"measure": "Incidence of vaginal bleeding over 6 months", "description": "Measurement of the incidence of vaginal bleeding using phone-based survey to document the presence/absence of vaginal bleeding", "timeFrame": "completed daily for 6 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Female with surgically-confirmed endometriosis\n* Age 15 years to 40 years\n* Current use ≥ 2 months duration of hormonal therapy such as combined oral contraceptives, norethindrone acetate, or levonorgestrel intrauterine device\n* Current pelvic pain (score ≥ 3 on Visual Analog Scale, where 0 represents absence of pain and 10 indicates unbearable pain) present for ≥ 14 days/month over the 2 months prior to study enrollment\n* Willingness to comply with visit schedule and protocol\n\nExclusion Criteria:\n\n* Pre-menarche or post-menopause\n* Contraindications to cabergoline (e.g., cardiac valve disorder; pulmonary, pericardial, retroperitoneal fibrotic disorder; hypersensitivity to ergot derivatives; uncontrolled hypertension)\n* Significant mental or chronic systemic illness that might confound pain assessment or the ability to complete the study\n* Pregnant, breastfeeding, or planning to become pregnant in the next 6 months\n* Impaired liver function (ALT \\> 2x normal) or liver disease\n* Breast cancer, current or previous\n* Thromboembolic disease, current or previous\n* Use of other drugs that affect dopamine (e.g., phenothiazines, metoclopramide, butyrophenones)", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "15 Years", "maximumAge": "40 Years", "stdAges": ["CHILD", "ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "Standford University", "city": "Palo Alto", "state": "California", "zip": "94305", "country": "United States", "geoPoint": {"lat": 37.44188, "lon": -122.14302}}, {"facility": "Childrens Hospital Colorado", "city": "Aurora", "state": "Colorado", "zip": "80045", "country": "United States", "geoPoint": {"lat": 39.72943, "lon": -104.83192}}, {"facility": "Beth Israel Deaconess Medical Center", "city": "Boston", "state": "Massachusetts", "zip": "02115", "country": "United States", "geoPoint": {"lat": 42.35843, "lon": -71.05977}}, {"facility": "Brigham and Women's Hospital", "city": "Boston", "state": "Massachusetts", "zip": "02115", "country": "United States", "geoPoint": {"lat": 42.35843, "lon": -71.05977}}, {"facility": "Children's Hospital Boston", "city": "Boston", "state": "Massachusetts", "zip": "02115", "country": "United States", "geoPoint": {"lat": 42.35843, "lon": -71.05977}}, {"facility": "Thomas Jefferson University Hospital", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19107", "country": "United States", "geoPoint": {"lat": 39.95238, "lon": -75.16362}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000077465", "term": "Cabergoline"}], "ancestors": [{"id": "D004873", "term": "Ergolines"}, {"id": "D004876", "term": "Ergot Alkaloids"}, {"id": "D000470", "term": "Alkaloids"}, {"id": "D006571", "term": "Heterocyclic Compounds"}, {"id": "D006576", "term": "Heterocyclic Compounds, 4 or More Rings"}, {"id": "D000072471", "term": "Heterocyclic Compounds, Fused-Ring"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT03083262", "orgStudyIdInfo": {"id": "27975"}, "organization": {"fullName": "St. Louis University", "class": "OTHER"}, "briefTitle": "High Tone Pelvic Floor Dysfunction", "officialTitle": "Retrospective Chart Review to Investigate an Association Between Vulvovaginal Atrophy and High Tone Pelvic Floor Dysfunction (HTPFD)"}, "statusModule": {"statusVerifiedDate": "2017-12", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2017-01-31", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2017-02-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2017-02-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2017-03-03", "studyFirstSubmitQcDate": "2017-03-16", "studyFirstPostDateStruct": {"date": "2017-03-17", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2017-12-05", "lastUpdatePostDateStruct": {"date": "2017-12-07", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Becky Lynn, MD", "investigatorTitle": "Principal Investigator", "investigatorAffiliation": "St. Louis University"}, "leadSponsor": {"name": "St. Louis University", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "Dyspareunia, or painful intercourse, is one of the most commonly reported complaints in postmenopausal women. One common cause of dyspareunia is vaginal atrophy (VVA), which occurs in \\>50% of postmenopausal women. At the time of menopause, a lack of estrogen thins the vaginal mucosa and lessons lubrication, making sex painful. Some women with vaginal atrophy will also have high tone pelvic floor dysfunction (HTPFD) (also known as levator spasm). Successful treatment of the sexual pain requires treatment of both vaginal atrophy and HTPFD.\n\nHow often vaginal atrophy and HTPFD coexist has not been studied. In fact, the prevalence of HTPFD is unknown. This is most likely due to the fact that many clinicians are unaware of its existence or how to diagnose or treat it. Also, sexual symptoms tend to be underreported due to embarrassment or hesitation to seek care. HTPFD frequently coexists with other conditions that cause pain like vaginal atrophy, endometriosis or interstitial cystitis. Treatment includes treating both conditions. If only one is treated, then sexual pain is likely to continue. There are several available treatments for HTPFD that have been studied including physical therapy, botox and intravaginal diazepam.\n\nThis is an area where clinicians may be under treating a condition and limiting the possibility of restoring normal sexual function to many women. Treating only vaginal atrophy without appropriate evaluation and treatment of HTPFD leaves a cohort of women still struggling with sexual pain. With a better understanding of the relationship between HTPFD and vaginal atrophy, the investigators hope to bring awareness concerning the importance of treating both in restoring normal sexual function.", "detailedDescription": "This is a retrospective chart review that will be performed to identify all female patients in the electronic medical records with a diagnosis of vulvovaginal atrophy (VVA).\n\nThe records of these patients with VVA will be examined for demographics, symptoms, answers to standardized questionnaires ( e.g. Female Sexual Function Index - FSFI - that is routinely assessed during clinical evaluation), work-up, diagnosis, and/or treatment of high tone pelvic floor dysfunction (HTPFD). Symptoms of HTPFD include but are not limited to pelvic pressure or pain, and dyspareunia. These data will then undergo statistical analysis."}, "conditionsModule": {"conditions": ["Vulvovaginal Atrophy"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "COHORT", "timePerspective": "RETROSPECTIVE"}, "enrollmentInfo": {"count": 80, "type": "ACTUAL"}}, "armsInterventionsModule": {"interventions": [{"type": "OTHER", "name": "no intervention", "description": "None, there is no intervention"}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "vulvovaginal atrophy", "description": "Charts reviewed for HTPFD", "timeFrame": "3 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* diagnosis of vulvovaginal atrophy (VVA)\n\nExclusion Criteria:\n\n* not meeting the inclusion criteria", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "90 Years", "stdAges": ["ADULT", "OLDER_ADULT"], "studyPopulation": "\\>/= 18 -90 years of age female any ethnic background", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"overallOfficials": [{"name": "Becky K Lynn, MD", "affiliation": "St. Louis University", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "St. Mary's Health Center", "city": "St Louis", "state": "Missouri", "zip": "63117", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT01301885", "orgStudyIdInfo": {"id": "ENDOMET-231/2004"}, "organization": {"fullName": "Turku University Hospital", "class": "OTHER_GOV"}, "briefTitle": "ENDOMET - Novel Diagnostic Tools and Treatments for Endometriosis", "officialTitle": "Novel Diagnostic Tools for Endometriosis and Their Exploitation for Prognosis and Prevention of Complications", "acronym": "ENDOMET"}, "statusModule": {"statusVerifiedDate": "2021-08", "overallStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2005-10"}, "primaryCompletionDateStruct": {"date": "2025-12", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2028-12", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2011-02-21", "studyFirstSubmitQcDate": "2011-02-22", "studyFirstPostDateStruct": {"date": "2011-02-23", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2021-08-09", "lastUpdatePostDateStruct": {"date": "2021-08-16", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Antti Perheentupa", "investigatorTitle": "Associate Professor", "investigatorAffiliation": "Turku University Hospital"}, "leadSponsor": {"name": "Turku University Hospital", "class": "OTHER_GOV"}, "collaborators": [{"name": "University of Turku", "class": "OTHER"}, {"name": "The Finnish Funding Agency for Technology and Innovation (TEKES)", "class": "OTHER_GOV"}, {"name": "VTT Technical Research Centre of Finland", "class": "OTHER"}, {"name": "Finnish Medical Foundation", "class": "NETWORK"}, {"name": "Hormos Medical", "class": "INDUSTRY"}, {"name": "PerkinElmer, Wallac Oy", "class": "INDUSTRY"}, {"name": "Biotop Oy", "class": "INDUSTRY"}, {"name": "Pharmatest Services Ltd", "class": "UNKNOWN"}, {"name": "Drug Discovery Graduate School, Finland", "class": "UNKNOWN"}, {"name": "The National Graduate School of Clinical Investigation, Finland", "class": "UNKNOWN"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "Endometriosis is a chronic disease characterized by the presence of functional endometrial glands and stroma in ectopic locations outside the uterine cavity. The ectopic endometrial tissue responds to estradiol and other hormones similarly to the normal endometrium. Endometriosis is one of the most common benign gynecological conditions, as many as 5-10% of women in the reproductive age may be affected. In addition to pain which may be severe, subfertility is one of the typical problems associated with endometriosis and may be present in up to 40% of those affected. There is lack of a clear correlation between severity of pain and degree of compromised fertility. Different modes of treatment exist. Hormonal treatments are based on the suppression of estrogenic action on endometriosis as well as the endometrium. Unfortunately, discontinuation of the hormonal treatment typically results in a rapid recurrence of the disease. Surgery may alleviate the symptom for different lengths of time, however, curative treatment frequently involves hysterectomy with bilateral oophorectomy. In order to escape this radical treatment, new targeted therapy in the form of novel pharmacological agents would be of crucial importance. Presently, endometriosis can be reliably diagnosed only by laparoscopy. Since this is an invasive surgical procedure, new diagnostic tools would be warmly welcomed. Furthermore, as the progression of the disease is presently impossible to predict, new markers for the \"malignancy\" of each case are desperately needed.\n\nThe aim of the investigators research is to identify expression of endometriosis specific RNAs/proteins. Evaluation of expression profiles in samples of endometriosis and endometrium of patients with careful clinical and surgical classification of endometriosis as well as healthy control women should initially enable to identify novel targets for new therapies and biomarkers. Particularly the different pain symptoms will be recorded annually and evaluated comprehensively. Furthermore, combined with an adequate 10-year follow up (based on a questionnaire, including fertility, received treatments and different pain symptoms; NRS), the study should enable for example to identify markers for endometriosis associated infertility as well as cases where the disease progresses very rapidly or reoccurs. Different forms of effective treatment may thereafter be designed following the identification of such factors."}, "conditionsModule": {"conditions": ["Endometriosis"], "keywords": ["endometriosis", "dysmenorrhea", "infertility", "biomarker", "drug target", "recurrence", "complications", "dyspareunia", "dyschezia", "dysuria", "chronic pelvic pain", "surgical treatment", "long-term follow-up"]}, "designModule": {"studyType": "OBSERVATIONAL", "designInfo": {"observationalModel": "CASE_CONTROL", "timePerspective": "PROSPECTIVE"}, "bioSpec": {"retention": "SAMPLES_WITH_DNA", "description": "serum, peritoneal fluid, endometrium tissue, healthy peritoneum, tissue of endometriosis (peritoneal, ovarian, deep infiltrating.\n\nExtracted DNA, RNA, cDNA and protein from the above samples."}, "enrollmentInfo": {"count": 230, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Endometriosis", "description": "Women (19-48 years of age) with surgically confirmed endometriosis.", "interventionNames": ["Procedure: Laparoscopy/laparotomy"]}, {"label": "Healthy women", "description": "Healthy women (32-48 years of age), symptom free, existence of endometriosis ruled out during laparoscopy for tubal ligation", "interventionNames": ["Procedure: Laparoscopy/laparotomy"]}], "interventions": [{"type": "PROCEDURE", "name": "Laparoscopy/laparotomy", "description": "Surgical treatment of endometriosis (laparotomy/laparoscopy) or laparoscopic sterilisation. Sample collection in both groups.", "armGroupLabels": ["Endometriosis", "Healthy women"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Intra-tissue steroid profiling indicates differential progesterone and testosterone metabolism in the endometrium and endometriosis lesions.", "timeFrame": "During the surgical sample collection"}, {"measure": "Endometrial and endometriotic concentrations of estrone and estradiol are determined by local metabolism rather than circulating levels.", "timeFrame": "During the surgical sample collection"}, {"measure": "Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts.", "timeFrame": "During the surgical sample collection"}, {"measure": "A relational database to identify differentially expressed genes in the endometrium and endometriosis lesions", "timeFrame": "During the surgical sample collection"}], "secondaryOutcomes": [{"measure": "A prospective 5-year follow-up of pain recurrence after surgical treatment of endometriosis", "description": "Questionnaire based evaluation of postoperative pain symptoms", "timeFrame": "5 years (annually) after the completion of patient recruitment"}, {"measure": "Serum HE-4 concentration is not dependent on menstrual cycle or hormonal treatment among endometriosis patients and healthy premenopausal women", "timeFrame": "During surgical sample collection"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* study group: surgically and pathologically verified endometriosis\n* control group: existence of endometriosis ruled out in laparoscopy\n\nExclusion Criteria:\n\n* no other significant disease or medication for other diseases\n* suspicion of malignancy\n* pregnancy\n* acute infection\n* insufficient understanding of Finnish language\n* previous hysterectomy and/or bilateral salpingo-oophorectomy", "healthyVolunteers": true, "sex": "FEMALE", "minimumAge": "19 Years", "maximumAge": "48 Years", "stdAges": ["ADULT"], "studyPopulation": "Endometriosis: Finnish Caucasian women surgically treated for endometriosis; age 19-48, no significant other disease or medication for other diseases\n\nHealthy controls: symptomless Finnish Caucasian women going through laparoscopy for tubal ligation; age 32-48, no significant other disease or medication", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"centralContacts": [{"name": "Antti H Perheentupa, MD PhD", "role": "CONTACT", "phone": "+358-2-3130000", "phoneExt": "30222", "email": "antti.perheentupa@utu.fi"}, {"name": "Kaisa Huhtinen, PhD", "role": "CONTACT", "phone": "+358-2-333 7376", "email": "kaisa.huhtinen@utu.fi"}], "overallOfficials": [{"name": "Antti Perheentupa, MD, PhD", "affiliation": "Department of Obstetrics and Gynecology, Turku University Central Hospital", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Dept of Obstetrics and Gynecology, Helsinki University Hospital", "status": "COMPLETED", "city": "Helsinki", "zip": "00029", "country": "Finland", "geoPoint": {"lat": 60.16952, "lon": 24.93545}}, {"facility": "Dept of Obstetrics and Gynecology, North Carelia Central Hospital", "status": "COMPLETED", "city": "Joensuu", "zip": "80210", "country": "Finland", "geoPoint": {"lat": 62.60118, "lon": 29.76316}}, {"facility": "Dept of Obstetrics and Gynecology, Päijät-Häme Central Hospital", "status": "COMPLETED", "city": "Lahti", "zip": "15850", "country": "Finland", "geoPoint": {"lat": 60.98267, "lon": 25.66151}}, {"facility": "Dept of Obstetrics and Gynecology, Turku University Central Hospital", "status": "RECRUITING", "city": "Turku", "zip": "20520", "country": "Finland", "contacts": [{"name": "Antti Perheentupa, MD, PhD", "role": "CONTACT"}, {"name": "Kaisa Huhtinen, PhD", "role": "SUB_INVESTIGATOR"}, {"name": "Pia Suvitie, MD", "role": "SUB_INVESTIGATOR"}], "geoPoint": {"lat": 60.45148, "lon": 22.26869}}]}, "referencesModule": {"references": [{"pmid": "32859947", "type": "BACKGROUND", "citation": "Gabriel M, Fey V, Heinosalo T, Adhikari P, Rytkonen K, Komulainen T, Huhtinen K, Laajala TD, Siitari H, Virkki A, Suvitie P, Kujari H, Aittokallio T, Perheentupa A, Poutanen M. A relational database to identify differentially expressed genes in the endometrium and endometriosis lesions. Sci Data. 2020 Aug 28;7(1):284. doi: 10.1038/s41597-020-00623-x."}, {"pmid": "29462326", "type": "BACKGROUND", "citation": "Heinosalo T, Gabriel M, Kallio L, Adhikari P, Huhtinen K, Laajala TD, Kaikkonen E, Mehmood A, Suvitie P, Kujari H, Aittokallio T, Perheentupa A, Poutanen M. Secreted frizzled-related protein 2 (SFRP2) expression promotes lesion proliferation via canonical WNT signaling and indicates lesion borders in extraovarian endometriosis. Hum Reprod. 2018 May 1;33(5):817-831. doi: 10.1093/humrep/dey026."}, {"pmid": "19337252", "type": "RESULT", "citation": "Huhtinen K, Suvitie P, Hiissa J, Junnila J, Huvila J, Kujari H, Setala M, Harkki P, Jalkanen J, Fraser J, Makinen J, Auranen A, Poutanen M, Perheentupa A. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer. 2009 Apr 21;100(8):1315-9. doi: 10.1038/sj.bjc.6605011. Epub 2009 Mar 31."}, {"pmid": "19663710", "type": "RESULT", "citation": "Hiissa J, Elo LL, Huhtinen K, Perheentupa A, Poutanen M, Aittokallio T. Resampling reveals sample-level differential expression in clinical genome-wide studies. OMICS. 2009 Oct;13(5):381-96. doi: 10.1089/omi.2009.0027."}, {"pmid": "22426487", "type": "RESULT", "citation": "Hallamaa M, Suvitie P, Huhtinen K, Matomaki J, Poutanen M, Perheentupa A. Serum HE4 concentration is not dependent on menstrual cycle or hormonal treatment among endometriosis patients and healthy premenopausal women. Gynecol Oncol. 2012 Jun;125(3):667-72. doi: 10.1016/j.ygyno.2012.03.011. Epub 2012 Mar 14."}, {"pmid": "22969138", "type": "RESULT", "citation": "Huhtinen K, Desai R, Stahle M, Salminen A, Handelsman DJ, Perheentupa A, Poutanen M. Endometrial and endometriotic concentrations of estrone and estradiol are determined by local metabolism rather than circulating levels. J Clin Endocrinol Metab. 2012 Nov;97(11):4228-35. doi: 10.1210/jc.2012-1154. Epub 2012 Sep 11."}, {"pmid": "25137424", "type": "RESULT", "citation": "Huhtinen K, Saloniemi-Heinonen T, Keski-Rahkonen P, Desai R, Laajala D, Stahle M, Hakkinen MR, Awosanya M, Suvitie P, Kujari H, Aittokallio T, Handelsman DJ, Auriola S, Perheentupa A, Poutanen M. Intra-tissue steroid profiling indicates differential progesterone and testosterone metabolism in the endometrium and endometriosis lesions. J Clin Endocrinol Metab. 2014 Nov;99(11):E2188-97. doi: 10.1210/jc.2014-1913. Epub 2014 Aug 19."}, {"pmid": "25099244", "type": "RESULT", "citation": "Vehmas AP, Muth-Pawlak D, Huhtinen K, Saloniemi-Heinonen T, Jaakkola K, Laajala TD, Kaprio H, Suvitie PA, Aittokallio T, Siitari H, Perheentupa A, Poutanen M, Corthals GL. Ovarian endometriosis signatures established through discovery and directed mass spectrometry analysis. J Proteome Res. 2014 Nov 7;13(11):4983-94. doi: 10.1021/pr500384n. Epub 2014 Aug 20."}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}, {"id": "D004412", "term": "Dysmenorrhea"}, {"id": "D007246", "term": "Infertility"}, {"id": "D012008", "term": "Recurrence"}, {"id": "D004414", "term": "Dyspareunia"}, {"id": "D003248", "term": "Constipation"}, {"id": "D053159", "term": "Dysuria"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}, {"id": "D008599", "term": "Menstruation Disturbances"}, {"id": "D010335", "term": "Pathologic Processes"}, {"id": "D013568", "term": "Pathological Conditions, Signs and Symptoms"}, {"id": "D017699", "term": "Pelvic Pain"}, {"id": "D010146", "term": "Pain"}, {"id": "D009461", "term": "Neurologic Manifestations"}, {"id": "D012816", "term": "Signs and Symptoms"}, {"id": "D020969", "term": "Disease Attributes"}, {"id": "D005832", "term": "Genital Diseases, Male"}, {"id": "D012735", "term": "Sexual Dysfunction, Physiological"}, {"id": "D052801", "term": "Male Urogenital Diseases"}, {"id": "D020018", "term": "Sexual Dysfunctions, Psychological"}, {"id": "D001523", "term": "Mental Disorders"}, {"id": "D012817", "term": "Signs and Symptoms, Digestive"}, {"id": "D059411", "term": "Lower Urinary Tract Symptoms"}, {"id": "D020924", "term": "Urological Manifestations"}]}, "interventionBrowseModule": {"meshes": [{"id": "D010535", "term": "Laparoscopy"}, {"id": "D007813", "term": "Laparotomy"}], "ancestors": [{"id": "D004724", "term": "Endoscopy"}, {"id": "D003949", "term": "Diagnostic Techniques, Surgical"}, {"id": "D019937", "term": "Diagnostic Techniques and Procedures"}, {"id": "D003933", "term": "Diagnosis"}, {"id": "D019060", "term": "Minimally Invasive Surgical Procedures"}, {"id": "D013514", "term": "Surgical Procedures, Operative"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT06426420", "orgStudyIdInfo": {"id": "FTIR-ENDOMETRIOSIS"}, "organization": {"fullName": "Federal University of Espirito Santo", "class": "OTHER"}, "briefTitle": "Endometriosis and ATR-FTIR Spectroscopy", "officialTitle": "Detection of Endometriosis Using ATR-FTIR Spectroscopy"}, "statusModule": {"statusVerifiedDate": "2024-05", "overallStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2022-09-15", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2026-04-29", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2026-04-29", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2024-05-14", "studyFirstSubmitQcDate": "2024-05-17", "studyFirstPostDateStruct": {"date": "2024-05-23", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2024-05-26", "lastUpdatePostDateStruct": {"date": "2024-05-29", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "VALERIO GARRONE BARAUNA", "investigatorTitle": "Professor", "investigatorAffiliation": "Federal University of Espirito Santo"}, "leadSponsor": {"name": "Federal University of Espirito Santo", "class": "OTHER"}, "collaborators": [{"name": "Conselho Nacional de Desenvolvimento Científico e Tecnológico", "class": "OTHER_GOV"}]}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The goal of this study is to explore the use of mid-infrared spectroscopy (ATR-FTIR) as a detection tool for endometriosis in urine.", "detailedDescription": "Endometriosis is a chronic gynecological disease that is considered debilitating and multifactorial. Its diagnosis is invasive and can be prolonged due to non-specific symptoms and erroneous or late investigations, which can lead to delays and impair the provision of adequate treatment.\n\nATR-FTIR Spectroscopy is a non-invasive technique with the capability to identify the chemical composition and molecular changes of samples through its interaction with mid-infrared radiation. The aim of this work is to develop a rapid test for the detection of endometriosis in urine samples using spectroscopy and machine learning algorithms."}, "conditionsModule": {"conditions": ["Endometriosis", "Endometriomas"], "keywords": ["Endometriosis", "Diagnosis", "Spectroscopy", "FTIR", "Urine", "Detection", "Infrared"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "DIAGNOSTIC", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 600, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Pelvic Pain", "type": "EXPERIMENTAL", "description": "Patients referred to the gynecology outpatient clinic, with complain of pelvic pain. Positives and negatives for endometriosis will be outlined by an expert gynecologist according to the following criteria:\n\n* Pelvic MRI (Magnetic Resonance Imaging) report;\n* Gynecologic exam;\n* Clinical symptoms and history;\n\nThe intervention is the use of the ATR-FTIR Spectrometer in patient's urine samples to develop and validate a tool for detecting endometriosis.", "interventionNames": ["Diagnostic Test: FTIR spectroscopy analysis"]}], "interventions": [{"type": "DIAGNOSTIC_TEST", "name": "FTIR spectroscopy analysis", "description": "ATR-FTIR Spectroscopy analysis combined with machine learning algorithms.", "armGroupLabels": ["Pelvic Pain"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Spectroscopy Reliability (diagnostic metrics)", "description": "The primary outcome is the evaluation of specificity, sensitivity and accuracy of the diagnostic. Acceptable diagnostic metrics must be comparable to MRI, which will demonstrate if spectroscopy can discriminate between negative and positive endometriosis patients.", "timeFrame": "1 year"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Female\n* Pelvic pain complain\n\nExclusion Criteria:\n\n* Age under 18 or above 55\n* Lack of informed consent", "healthyVolunteers": false, "sex": "FEMALE", "genderBased": true, "genderDescription": "Biological woman self-identified as woman", "minimumAge": "18 Years", "maximumAge": "55 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Valerio G Barauna, PhD", "role": "CONTACT", "phone": "+5527996892407", "email": "barauna2@gmail.com"}], "overallOfficials": [{"name": "Valerio G Barauna, PhD", "affiliation": "Universidade Federal do Espírito Santo", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "University Hospital Cassiano Antonio Moraes at Federal Univeristy Of Espírito Santo", "status": "RECRUITING", "city": "Vitória", "state": "Espírito Santo", "zip": "29041-295", "country": "Brazil", "contacts": [{"name": "Neide A Boldrini, phD", "role": "CONTACT", "phone": "+552733357100", "email": "neide.boldrini@ebserh.gov.br"}, {"name": "Mara RB Barcelos, phD", "role": "CONTACT", "phone": "+5527999829511", "email": "mararsb@gmail.com"}, {"name": "Neide A Boldrini, phD", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Mara RB Barcelos, phD", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": -20.31944, "lon": -40.33778}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}, {"id": "D004194", "term": "Disease"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}, {"id": "D010335", "term": "Pathologic Processes"}, {"id": "D013568", "term": "Pathological Conditions, Signs and Symptoms"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT06386276", "orgStudyIdInfo": {"id": "00025986"}, "organization": {"fullName": "Casa di Cura Privata 'Malzoni - Villa dei Platani' S.P.A.", "class": "OTHER"}, "briefTitle": "Surgical TReatment of Women With Deep ENDometriosis", "officialTitle": "Surgical TReatment of Women With Deep ENDometriosis Infiltrating the Sigmoid Colon and/or the Rectum. A Monocentric Archive", "acronym": "TrEnd"}, "statusModule": {"statusVerifiedDate": "2024-04", "overallStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2023-10-11", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2028-06-30", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2029-06-30", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2024-04-23", "studyFirstSubmitQcDate": "2024-04-23", "studyFirstPostDateStruct": {"date": "2024-04-26", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2024-04-23", "lastUpdatePostDateStruct": {"date": "2024-04-26", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Francesca Falcone", "investigatorTitle": "Medical Doctor", "investigatorAffiliation": "Casa di Cura Privata 'Malzoni - Villa dei Platani' S.P.A."}, "leadSponsor": {"name": "Casa di Cura Privata 'Malzoni - Villa dei Platani' S.P.A.", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "TrEnd trial is aimed to collect data from consecutive patients undergoing segmental sigmoid colon/rectal resection for deep endometriosis. The main purpose of this project is to gather a large series of cases treated using standardized surgical procedures, allowing a precise evaluation of complications and long-term outcomes."}, "conditionsModule": {"conditions": ["Deep Endometriosis", "Surgery"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": true, "targetDuration": "10 Years", "designInfo": {"observationalModel": "CASE_ONLY", "timePerspective": "OTHER"}, "enrollmentInfo": {"count": 250, "type": "ESTIMATED"}}, "armsInterventionsModule": {"interventions": [{"type": "PROCEDURE", "name": "Colorectal bowel resection", "description": "The TrEnd is a single-institutional retrospective/prospective study, conducted in a high-volume referral centre for the endometriosis diagnosis and management, with the aim of systematically collecting data from consecutive patients undergoing segmental sigmoid colon/rectal resection for deep endometriosis."}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "To document the surgical strategies adopted for treating patients with deep endometriosis undergoing to sigmoid colon/rectal resection", "description": "Percentage", "timeFrame": "10 years"}, {"measure": "To assess the rate of complications", "description": "Rate/percentage", "timeFrame": "10 years"}, {"measure": "To assess the rate of conversion to open surgery", "description": "Rate/percentage", "timeFrame": "10 years"}, {"measure": "To assess the rate of endometriosis-free bowel resection margins", "description": "Rate/percentage", "timeFrame": "10 years"}, {"measure": "To assess the rate of recurrence", "description": "Rate/percentage", "timeFrame": "10 years"}], "secondaryOutcomes": [{"measure": "To assess the intraoperative blood loss", "description": "Median with IQR", "timeFrame": "10 years"}, {"measure": "To assess the operating time", "description": "Median time with IQR", "timeFrame": "10 years"}, {"measure": "To assess the gastrointestinal function recovery", "description": "Median days with IQR", "timeFrame": "10 years"}, {"measure": "To assess the duration of hospital stay", "description": "Median days with IQR", "timeFrame": "10 years"}, {"measure": "To assess the reproductive outcomes", "description": "Rate/percentage of pregnancies, normal full term deliveries, spontaneous and voluntary abortions", "timeFrame": "10 years"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* age \\>/= 18 years;\n* presence of deep endometriotic nodule(s) infiltrating the tunica muscularis of the sigmoid colon/rectum.\n\nExclusion Criteria:\n\n* age \\<18 years:\n* presence of coexisting inflammatory bowel disease;\n* patients who have received previous pelvic radiotherapy.", "sex": "FEMALE", "genderBased": true, "minimumAge": "18 Years", "maximumAge": "55 Years", "stdAges": ["ADULT"], "studyPopulation": "Women undergoing segmental sigmoid colon/rectal resection for deep endometriotic nodules infiltrating the tunica muscularis of the sigmoid colon/rectum preoperatively identified with imaging and surgically treated with segmental resection", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"centralContacts": [{"name": "Mario Malzoni, MD", "role": "CONTACT", "phone": "0825796111", "phoneExt": "+39", "email": "malzonimario@gmail.com"}], "overallOfficials": [{"name": "Mario Malzoni, MD", "affiliation": "malzonimario@gmail.com", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Francesca Falcone, MD", "affiliation": "francescafalcone@malzoni.org", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Casa Di Cura Malzoni Villa Platani Spa", "status": "RECRUITING", "city": "Avellino", "state": "Campania", "zip": "83100", "country": "Italy", "contacts": [{"name": "Francesca Falcone, MD", "role": "CONTACT", "email": "francesca.falcone3@icloud.com"}, {"name": "Mario Malzoni, MD", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Francesca Falcone, MD", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 40.91494, "lon": 14.79103}}]}, "ipdSharingStatementModule": {"ipdSharing": "UNDECIDED"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT01809561", "orgStudyIdInfo": {"id": "MMC13186-12CTIL"}, "organization": {"fullName": "Meir Medical Center", "class": "OTHER"}, "briefTitle": "Telomeres Evaluation in Endometriosis", "officialTitle": "Telomeres Evaluation in Endometriosis"}, "statusModule": {"statusVerifiedDate": "2013-02", "overallStatus": "UNKNOWN", "lastKnownStatus": "NOT_YET_RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2013-05"}, "primaryCompletionDateStruct": {"date": "2015-02", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2015-02", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2013-03-10", "studyFirstSubmitQcDate": "2013-03-10", "studyFirstPostDateStruct": {"date": "2013-03-12", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2013-04-07", "lastUpdatePostDateStruct": {"date": "2013-04-09", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Meir Medical Center", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The purpose of the study is to assess the telomere array of different endometriosis tissue and endometrium from women with endometriosis compared to healthy women.\n\nOur hypothesis is that telomere shortening and high telomerase activity will be found in tissues from women with endometriosis.", "detailedDescription": "The purpose of the study is to assess the telomere array of different endometriosis tissue and endometrium from women with endometriosis compared to healthy women. Our hypothesis is that telomere shortening and high telomerase activity will be found in tissues from women with endometriosis, compared to women without endometriosis.\n\nA prospective study that compares telomeres and telomerase levels in different lesions of endometriosis and endometrial tissue of women with endometriosis and healthy women without endometriosis. The study group will consist of women with suspected endometriosis facing surgical treatment and the control group will consist of healthy women facing gynecologic surgery for different indication.\n\nWe will sample endometrial tissue in both groups. In the study group we additionally will sample endometriosis lesion.\n\nThe samples collected will test for histological diagnosis of endometriosis and verification tests will be done to characterize the telomeres array and telomerase levels and other characteristics for genomic instability such as spontaneous aneuploidy.\n\nexpect telomere shortening and high telomerase activity in endometrial tissue and in endometriosis tissue sample, that won't characterize samples from women without endometriosis."}, "conditionsModule": {"conditions": ["Endometriosis"], "keywords": ["endometriosis", "telomere", "telomerase"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": true, "targetDuration": "6 Weeks", "designInfo": {"observationalModel": "CASE_CONTROL", "timePerspective": "PROSPECTIVE"}, "bioSpec": {"retention": "SAMPLES_WITH_DNA", "description": "whole blood, endometrial tissue biopsy, lesion of endometriosis"}, "enrollmentInfo": {"count": 30, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "endometriosis", "description": "The study group will consist of women with suspected endometriosis facing surgical treatment", "interventionNames": ["Procedure: tissue biopsy during surgical treatment"]}, {"label": "no endometriosis", "description": "The control group will consist of healthy women facing gynecologic surgery for different indication", "interventionNames": ["Procedure: tissue biopsy during surgical treatment"]}], "interventions": [{"type": "PROCEDURE", "name": "tissue biopsy during surgical treatment", "description": "The samples collected will test for histological diagnosis of endometriosis and verification tests will be done to characterize the telomeres array and telomerase levels and other characteristics for genomic instability such as spontaneous aneuploidy.", "armGroupLabels": ["endometriosis", "no endometriosis"], "otherNames": ["endometriosis tissue biopsy only study group", "endometrial tissue biopsy"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "characterize the telomeres array and telomerase levels and other characteristics for genomic instability such as spontaneous aneuploidy in endometriosis tissue.", "timeFrame": "the tissue sample will colect at time of surgery"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* women with suspected endometriosis facing surgical treatment\n\nExclusion Criteria:\n\n* no endometriosis on histology\n* malignant finding on histology", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "15 Years", "maximumAge": "60 Years", "stdAges": ["CHILD", "ADULT"], "studyPopulation": "women facing surgical treatment", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"centralContacts": [{"name": "Merav Sharvit, DR", "role": "CONTACT", "phone": "972-9-7472561", "email": "merav.sharvit@gmail.com"}], "overallOfficials": [{"name": "Ron Schonman, DR", "affiliation": "MeirMc, Israel", "role": "STUDY_CHAIR"}], "locations": [{"facility": "OBGYN department, Meir Medical Center", "city": "Kfar Saba", "state": "Israel", "country": "Israel", "contacts": [{"name": "Merav Sharvit, DR", "role": "CONTACT", "email": "merav.sharvit@gmail.com"}, {"name": "Merav Sharvit, DR", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 32.175, "lon": 34.90694}}]}, "referencesModule": {"references": [{"type": "BACKGROUND", "citation": "Sampson JA. Peritoneal endometriosis due to the menstrual dissemination of endometrial tissue into the peritoneal cavity. Am J Obstet Gynecol 1927 14,422-469."}, {"pmid": "11011865", "type": "BACKGROUND", "citation": "Lapp T. ACOG issues recommendations for the management of endometriosis. American College of Obstetricians and Gynecologists. Am Fam Physician. 2000 Sep 15;62(6):1431, 1434. No abstract available."}, {"pmid": "15381900", "type": "BACKGROUND", "citation": "Wells M. Recent advances in endometriosis with emphasis on pathogenesis, molecular pathology, and neoplastic transformation. Int J Gynecol Pathol. 2004 Oct;23(4):316-20. doi: 10.1097/01.pgp.0000139636.94352.89."}, {"pmid": "11594534", "type": "BACKGROUND", "citation": "Sharpe-Timms KL. Endometrial anomalies in women with endometriosis. Ann N Y Acad Sci. 2001 Sep;943:131-47. doi: 10.1111/j.1749-6632.2001.tb03797.x."}, {"pmid": "1554145", "type": "BACKGROUND", "citation": "Nolan CM. Human immunodeficiency syndrome-associated tuberculosis: a review with an emphasis on infection control issues. Am J Infect Control. 1992 Feb;20(1):30-4. doi: 10.1016/s0196-6553(05)80123-3. No abstract available."}, {"pmid": "9886539", "type": "BACKGROUND", "citation": "Jones RK, Searle RF, Bulmer JN. Apoptosis and bcl-2 expression in normal human endometrium, endometriosis and adenomyosis. Hum Reprod. 1998 Dec;13(12):3496-502. doi: 10.1093/humrep/13.12.3496."}, {"pmid": "11020520", "type": "BACKGROUND", "citation": "Meresman GF, Vighi S, Buquet RA, Contreras-Ortiz O, Tesone M, Rumi LS. Apoptosis and expression of Bcl-2 and Bax in eutopic endometrium from women with endometriosis. Fertil Steril. 2000 Oct;74(4):760-6. doi: 10.1016/s0015-0282(00)01522-3."}, {"pmid": "22807950", "type": "BACKGROUND", "citation": "Higashiura Y, Kajihara H, Shigetomi H, Kobayashi H. Identification of multiple pathways involved in the malignant transformation of endometriosis (Review). Oncol Lett. 2012 Jul;4(1):3-9. doi: 10.3892/ol.2012.690. Epub 2012 Apr 23."}, {"pmid": "16157205", "type": "BACKGROUND", "citation": "Amiel A, Gronich N, Yukla M, Suliman S, Josef G, Gaber E, Drori G, Fejgin MD, Lishner M. Random aneuploidy in neoplastic and pre-neoplastic diseases, multiple myeloma, and monoclonal gammopathy. Cancer Genet Cytogenet. 2005 Oct 1;162(1):78-81. doi: 10.1016/j.cancergencyto.2005.03.006."}, {"pmid": "16843101", "type": "BACKGROUND", "citation": "Amiel A, Yukla M, Gaber E, Leopold L, Josef G, Fejgin M, Lishner M. Random aneuploidy in CML patients at diagnosis and under imatinib treatment. Cancer Genet Cytogenet. 2006 Jul 15;168(2):120-3. doi: 10.1016/j.cancergencyto.2006.02.002."}, {"pmid": "19627485", "type": "BACKGROUND", "citation": "Saini N, Srinivasan R, Chawla Y, Sharma S, Chakraborti A, Rajwanshi A. Telomerase activity, telomere length and human telomerase reverse transcriptase expression in hepatocellular carcinoma is independent of hepatitis virus status. Liver Int. 2009 Sep;29(8):1162-70. doi: 10.1111/j.1478-3231.2009.02082.x. Epub 2009 Jul 17."}, {"pmid": "19419696", "type": "BACKGROUND", "citation": "Svenson U, Roos G. Telomere length as a biological marker in malignancy. Biochim Biophys Acta. 2009 Apr;1792(4):317-23. doi: 10.1016/j.bbadis.2009.01.017. Epub 2009 Feb 7."}, {"pmid": "9542976", "type": "BACKGROUND", "citation": "Yokoyama Y, Takahashi Y, Morishita S, Hashimoto M, Niwa K, Tamaya T. Telomerase activity in the human endometrium throughout the menstrual cycle. Mol Hum Reprod. 1998 Feb;4(2):173-7. doi: 10.1093/molehr/4.2.173."}, {"pmid": "11748987", "type": "BACKGROUND", "citation": "Lehner R, Enomoto T, McGregor JA, Shroyer AL, Haugen BR, Pugazhenthi U, Shroyer KR. Quantitative analysis of telomerase hTERT mRNA and telomerase activity in endometrioid adenocarcinoma and in normal endometrium. Gynecol Oncol. 2002 Jan;84(1):120-5. doi: 10.1006/gyno.2001.6474."}, {"pmid": "17077107", "type": "BACKGROUND", "citation": "Kim CM, Oh YJ, Cho SH, Chung DJ, Hwang JY, Park KH, Cho DJ, Choi YM, Lee BS. Increased telomerase activity and human telomerase reverse transcriptase mRNA expression in the endometrium of patients with endometriosis. Hum Reprod. 2007 Mar;22(3):843-9. doi: 10.1093/humrep/del425. Epub 2006 Oct 31."}, {"pmid": "18456668", "type": "BACKGROUND", "citation": "Hapangama DK, Turner MA, Drury JA, Quenby S, Saretzki G, Martin-Ruiz C, Von Zglinicki T. Endometriosis is associated with aberrant endometrial expression of telomerase and increased telomere length. Hum Reprod. 2008 Jul;23(7):1511-9. doi: 10.1093/humrep/den172. Epub 2008 May 2."}, {"pmid": "6234483", "type": "BACKGROUND", "citation": "Halme J, Hammond MG, Hulka JF, Raj SG, Talbert LM. Retrograde menstruation in healthy women and in patients with endometriosis. Obstet Gynecol. 1984 Aug;64(2):151-4."}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT04610710", "orgStudyIdInfo": {"id": "Horsens MR"}, "organization": {"fullName": "Horsens Hospital", "class": "OTHER"}, "briefTitle": "Impact of Operation on Fertility for Women with Severe Endometriosis", "officialTitle": "Comparing Impact of Operation and Fertility Treatment on Fertility for Women with Deep Infiltrating Endometriosis: a Multicenter Randomized Controlled Trial", "acronym": "EFFORT"}, "statusModule": {"statusVerifiedDate": "2025-03", "overallStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2020-08-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2030-01-31", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2035-07-31", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2020-10-22", "studyFirstSubmitQcDate": "2020-10-29", "studyFirstPostDateStruct": {"date": "2020-10-30", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2025-03-11", "lastUpdatePostDateStruct": {"date": "2025-03-13", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Ulla Breth Knudsen", "investigatorTitle": "Professor", "investigatorAffiliation": "Horsens Hospital"}, "leadSponsor": {"name": "Horsens Hospital", "class": "OTHER"}, "collaborators": [{"name": "Aarhus University Hospital", "class": "OTHER"}, {"name": "Clinique Tivoli Ducos", "class": "OTHER"}]}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false, "isUsExport": false}, "descriptionModule": {"briefSummary": "The EFFORT study compares the impact on fertility of operation or fertility treatment (IVF, in vitro fertilization) in a multicenter randomized controlled trial. The study population consists of women with colorectal deep infiltrating endometriosis and a pregnancy intention. These women will be randomized to either of the two treatment groups: Group A = Operation or Group B = fertility treatment (IVF). Group A will be further divided postoperatively into spontaneous conception or IVF depending on the Endometriosis Fertility Index score."}, "conditionsModule": {"conditions": ["Deep Endometriosis", "Infertility, Female"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": "Randomized Clinical Trail (RCT)", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 352, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Operation", "type": "ACTIVE_COMPARATOR", "description": "Operation for severe endometriosis", "interventionNames": ["Procedure: Operation"]}, {"label": "Fertility treatment", "type": "ACTIVE_COMPARATOR", "description": "Fertility treatment for women with severe endometriosis.", "interventionNames": ["Procedure: Fertility treatment"]}], "interventions": [{"type": "PROCEDURE", "name": "Operation", "description": "Operation for deep infiltrating endometriosis", "armGroupLabels": ["Operation"]}, {"type": "PROCEDURE", "name": "Fertility treatment", "description": "In vitro fertilisation (IVF) and IVF-intracytoplasmic injection (ICSI)", "armGroupLabels": ["Fertility treatment"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Cumulative pregnancy rate (CPR)", "description": "Rate of cumulative pregnancies defined as a fetal heartbeat by ultrasound at gestational week 6 to 8", "timeFrame": "18 months"}, {"measure": "Live birth rate (LBR)", "description": "Rate of live births", "timeFrame": "18 months"}], "secondaryOutcomes": [{"measure": "Non-viable pregnancies", "description": "Number of biochemical pregnancies, miscarriages, missed abortions, extrauterine pregnancies and pregnancies of unknown location (PUL)", "timeFrame": "18 months"}, {"measure": "Ovarian potential", "description": "Concentration of Anti-Müllerian hormone (AMH)", "timeFrame": "Baseline and 9-18 months"}, {"measure": "Time to pregnancy", "description": "Shortest time from intervention date to date of visualisation of the first ongoing pregnancy", "timeFrame": "18 months"}, {"measure": "Postoperative complications", "description": "Rate of complications in accordance to Clavien-Dindo Classification, including anastomotic leakage or stenosis, ureteral lesion or obstruction, pelvic abscess, fistula, bladder or bowel perforation and urinary retention", "timeFrame": "18 months"}, {"measure": "Fertility treatment complications", "description": "Rate of hospital admissions, bleeding, superinfection, worsening of pain or having ovarian hyperstimulation syndrome (OHSS)", "timeFrame": "18 months"}, {"measure": "Pain score", "description": "Numeric Rating Scale (NRS) score from 0 to 10, where 10 implies the worst pain", "timeFrame": "Baseline, 9 and 18 months"}, {"measure": "Quality of Life (QoL)", "description": "Development in Endometriosis Health Profile (EHP-30+23), including section C (sexual function QoL questions) and section F (fertility QoL questions)", "timeFrame": "Baseline, 9 and 18 months"}, {"measure": "Delayed bowel function", "description": "Development in bowel function rated by Low Anterior Resection Syndrome (LARS) score", "timeFrame": "Baseline, 9 and 18 months"}, {"measure": "Delayed bladder function", "description": "Development in urinary tract function rated by International Consultation on Incontinence Questionnaire (ICIQ- FLUTS)", "timeFrame": "Baseline, 9 and 18 months"}, {"measure": "Endometriosis hormonal and inflammatory status", "description": "Concentrations of hormonal and inflammatory markers in blood samples", "timeFrame": "Baseline and 9-18 months"}, {"measure": "Follicles, oocytes, fertilized oocytes, blastocysts, and frozen embryos", "description": "Number of follicles as measured at last scan prior to oocyte pick-up (OPU), number of oocytes at OPU, fertilized oocytes, blastocysts and frozen embryos", "timeFrame": "18 months"}, {"measure": "Blastocyst morphology score", "description": "Gardner scoring system, Steer grading system, Veecks criteria, or other scoring systems of blastocyst morphology", "timeFrame": "18 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Rectosigmoid endometriosis and wish for surgery\n* Pregnancy intention for at least 6 months\n* AMH above 5 pmol/ml\n* Maximum of 2 previous IVF treatments\n* Male partner\n\nExclusion Criteria:\n\n* Endometriosis involving the ureter unilaterally or bilaterally (randomization unethical)\n* BMI above 32\n* Contraindication for IVF (untreated uterine factor infertility, untreated/maltreated systemic or malignant disease, oocyte aspiration severely riskful (e.g. severe abdominal adhesions)\n* No wish for randomization", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "38 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Ulla B Knudsen, Professor", "role": "CONTACT", "phone": "+45 78426592", "email": "ubk@dadlnet.dk"}, {"name": "Maja Raos", "role": "CONTACT", "email": "majaraos@clin.au.dk"}], "locations": [{"facility": "Aarhus University Hospital", "status": "RECRUITING", "city": "Aarhus N", "state": "Central Region", "zip": "8200", "country": "Denmark", "contacts": [{"name": "Mikkel Seyer-Hansen, MD", "role": "CONTACT"}], "geoPoint": {"lat": 56.20367, "lon": 10.17317}}, {"facility": "Horsens Regional Hospital", "status": "RECRUITING", "city": "Horsens", "state": "Central Region", "zip": "8700", "country": "Denmark", "contacts": [{"name": "Ulla B Knudsen, Professor", "role": "CONTACT", "phone": "+45 7842 6592", "email": "ubk@dadlnet.dk"}], "geoPoint": {"lat": 55.86066, "lon": 9.85034}}, {"facility": "The Endometriosis Center, Clinique Tivoli-Ducos", "status": "RECRUITING", "city": "Bordeaux", "country": "France", "contacts": [{"name": "Horace Roman, MD", "role": "CONTACT"}], "geoPoint": {"lat": 44.84124, "lon": -0.58046}}]}, "referencesModule": {"references": [{"pmid": "35410921", "type": "DERIVED", "citation": "Raos M, Roman H, Seyer-Hansen M, Kesmodel US, Knudsen UB. EFFORT study: Comparing impact of operation and assisted reproductive technologies on fertility for women with deep infiltrating endometriosis - study protocol for a multicentre randomised trial. BMJ Open. 2022 Apr 11;12(4):e052877. doi: 10.1136/bmjopen-2021-052877."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D007247", "term": "Infertility, Female"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}, {"id": "D007246", "term": "Infertility"}]}, "interventionBrowseModule": {"meshes": [{"id": "D013514", "term": "Surgical Procedures, Operative"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT05801523", "orgStudyIdInfo": {"id": "AMHstudy"}, "organization": {"fullName": "Institute for the Care of Mother and Child, Prague, Czech Republic", "class": "OTHER"}, "briefTitle": "Laparoscopic Therapy of Endometrioma: Sclerotherapy vs Cystectomy in Patients With Unfinished Reproductive Plans", "officialTitle": "Laparoscopic Therapy of Endometrioma: Sclerotherapy vs Cystectomy in Patients With Unfinished Reproductive Plans"}, "statusModule": {"statusVerifiedDate": "2024-05", "overallStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2023-02-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2024-06-01", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2025-07-01", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2023-03-23", "studyFirstSubmitQcDate": "2023-04-05", "studyFirstPostDateStruct": {"date": "2023-04-06", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2024-05-06", "lastUpdatePostDateStruct": {"date": "2024-05-08", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Katarina Ivankova", "investigatorTitle": "Medical doctor at Endometriosis centre, Institute for the mother and child care", "investigatorAffiliation": "Institute for the Care of Mother and Child, Prague, Czech Republic"}, "leadSponsor": {"name": "Institute for the Care of Mother and Child, Prague, Czech Republic", "class": "OTHER"}, "collaborators": [{"name": "University Hospital Ostrava", "class": "OTHER"}]}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The aim of this prospective randomized study is to compare laparoscopic sclerotherapy to cystectomy in following: AMH dynamics, endometrioma recurrence, complications, pregnancy rate, assisted reproduction methods success rate, live birth rate", "detailedDescription": "Only patients who sign informed consent will be included. Only patients wishing for future pregnancy will be involved in the study. Expected number of enrolled subjects is 160 ( 80 in each arm) Patients with endometrioma and planned surgery to remove it will be randomized either to laparoscopic sclerotherapy with 96% ethanol or cystectomy. First AMH sample will be taken day before surgery. If other endometriosis lesions (deep or superficial) are present, they may be also resected during this surgery.\n\nEthanol sclerotherapy description: classical laparoscopic approach - small (max1cm) fenestration of endometrioma - aspiration of endometrioma contents- foley catheter insertion- ballon inflation inside of the cyst- instillation with 96% ethanol which is left in the cyst for 10min- aspiration of ethanol and flushing with saline.\n\nCystectomy: classical laparoscopic approach- large fenestration of endometrioma - aspiration of endometrioma contents- indentification of ovary/ endometrioma tissue and plane between the ovarian capsule and cyst wall is developed using a mix of blunt and sharp dissection - if bleeding is present it is stopped by cautious bipolar coagulation\n\nvisit 1 - surgery time (AMH day before surgery, age, BMI, endometriosis extent, gravidity/ parity, endometriosis residue after surgery, pain levels) visit 2- 3 months after surgery : Ultrasound, complications, pregnancy, asissted reproduction, pain levels visit 3+4 - 6/12months after surgery: AMH, Ultrasound, complications, pregnancy, asissted reproduction, pain levels visit 5- 24 months after surgery: Ultrasound, complications, pregnancy, asissted reproduction, pain levels"}, "conditionsModule": {"conditions": ["Endometrioma", "Endometriosis"], "keywords": ["laparoscopic", "sclerotherapy", "endometrioma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 160, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "laparoscopic ethanol sclerotherapy", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Procedure: laparoscopic ethanol sclerotherapy"]}, {"label": "laparoscopic cystectomy", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Procedure: laparoscopic cystectomy of endometrioma"]}], "interventions": [{"type": "PROCEDURE", "name": "laparoscopic ethanol sclerotherapy", "description": "ethanol (96%) sclerapy of endometrioma - endometrioma is filled with ethanol via foley catether, left for 10 min and than aspirated, endometrioma is washed with saline", "armGroupLabels": ["laparoscopic ethanol sclerotherapy"]}, {"type": "PROCEDURE", "name": "laparoscopic cystectomy of endometrioma", "description": "cystectomy of endometrioma - removal of endometrioma from ovary surgically", "armGroupLabels": ["laparoscopic cystectomy"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "AMH dynamics", "description": "Measuring AMH level in blood", "timeFrame": "Measuring change in AMH levels immediately before surgery and than at 6 and 12 months after surgery"}, {"measure": "endometrioma recurrence", "description": "recurrence described as endometrioma measuring 20 or more milimeters on ultrasound", "timeFrame": "Measuring change of endometrioma size (in case of recurrence) at 3, 6, 12 and 24 months after surgery"}, {"measure": "complications", "description": "recording all complications related to surgery, classified according Clavien Dindo", "timeFrame": "0-12 months"}], "secondaryOutcomes": [{"measure": "Asissted reproduction methods succes rate", "description": "if patient undergoes assisted reproduction techniques and gets pregnant we check what methodes were used", "timeFrame": "0-24 months after surgery"}, {"measure": "pregnancy rate", "description": "pregnancy rate among study patients", "timeFrame": "0-24 months after surgery"}, {"measure": "deliveries", "description": "number of deliveries after surgery", "timeFrame": "24 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* IOTA benign endometrioma\n* bilateral or unilateral endometrioma measuring 30 or more milimeters\n* patients with unfinished reproductive plans\n\nExclusion Criteria:\n\n* bilateral recurrence of endometrioma\n* recurrent endometrioma if the other ovary is not present or patient had cystectomy on the other ovary\n* suspision for ovarian malignancy\n* signs of inflammatory pelvic disease\n* disagreement with participation in the study", "healthyVolunteers": true, "sex": "FEMALE", "genderBased": true, "minimumAge": "18 Years", "maximumAge": "40 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Katarína Ivánková", "role": "CONTACT", "phone": "+420 296511200", "email": "katarina.ivankova@upmd.eu"}], "overallOfficials": [{"name": "Katarína Ivánková, MUDr.", "affiliation": "Institute for the Care of Mother and Child, Prague, Czech Republic", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Institute for mother and child care", "status": "RECRUITING", "city": "Prague", "zip": "147 00", "country": "Czechia", "contacts": [{"name": "Katarína Ivánková, MUDr.", "role": "CONTACT", "email": "katarina.ivankova@upmd.eu"}, {"name": "Katarína Ivánková, MUDr.", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Zuzana Marvanova, MUDr.", "role": "SUB_INVESTIGATOR"}, {"name": "Lucie Hájková Hympánová, MUDr.", "role": "SUB_INVESTIGATOR"}], "geoPoint": {"lat": 50.08804, "lon": 14.42076}}]}, "referencesModule": {"references": [{"pmid": "29420391", "type": "BACKGROUND", "citation": "Falcone T, Flyckt R. Clinical Management of Endometriosis. Obstet Gynecol. 2018 Mar;131(3):557-571. doi: 10.1097/AOG.0000000000002469."}, {"pmid": "12858105", "type": "BACKGROUND", "citation": "Busacca M, Vignali M. Ovarian endometriosis: from pathogenesis to surgical treatment. Curr Opin Obstet Gynecol. 2003 Aug;15(4):321-6. doi: 10.1097/01.gco.0000084247.09900.4f."}, {"pmid": "28579409", "type": "BACKGROUND", "citation": "Cohen A, Almog B, Tulandi T. Sclerotherapy in the management of ovarian endometrioma: systematic review and meta-analysis. Fertil Steril. 2017 Jul;108(1):117-124.e5. doi: 10.1016/j.fertnstert.2017.05.015. Epub 2017 Jun 1."}, {"pmid": "29935810", "type": "BACKGROUND", "citation": "Kasapoglu I, Ata B, Uyaniklar O, Seyhan A, Orhan A, Yildiz Oguz S, Uncu G. Endometrioma-related reduction in ovarian reserve (ERROR): a prospective longitudinal study. Fertil Steril. 2018 Jul 1;110(1):122-127. doi: 10.1016/j.fertnstert.2018.03.015. Epub 2018 Jun 20."}, {"pmid": "36228863", "type": "BACKGROUND", "citation": "Crestani A, Merlot B, Dennis T, Chanavaz-Lacheray I, Roman H. Impact of Laparoscopic Sclerotherapy for Ovarian Endometriomas on Ovarian Reserve. J Minim Invasive Gynecol. 2023 Jan;30(1):32-38. doi: 10.1016/j.jmig.2022.10.001. Epub 2022 Oct 10."}, {"pmid": "32380241", "type": "BACKGROUND", "citation": "De Cicco Nardone A, Carfagna P, De Cicco Nardone C, Scambia G, Marana R, De Cicco Nardone F. Laparoscopic Ethanol Sclerotherapy for Ovarian Endometriomas: Preliminary Results. J Minim Invasive Gynecol. 2020 Sep-Oct;27(6):1331-1336. doi: 10.1016/j.jmig.2019.09.792. Epub 2020 May 5."}, {"pmid": "19502358", "type": "BACKGROUND", "citation": "Benaglia L, Somigliana E, Vercellini P, Abbiati A, Ragni G, Fedele L. Endometriotic ovarian cysts negatively affect the rate of spontaneous ovulation. Hum Reprod. 2009 Sep;24(9):2183-6. doi: 10.1093/humrep/dep202. Epub 2009 Jun 5."}, {"pmid": "20083485", "type": "BACKGROUND", "citation": "Benaglia L, Somigliana E, Vighi V, Ragni G, Vercellini P, Fedele L. Rate of severe ovarian damage following surgery for endometriomas. Hum Reprod. 2010 Mar;25(3):678-82. doi: 10.1093/humrep/dep464. Epub 2010 Jan 17."}, {"pmid": "35698769", "type": "BACKGROUND", "citation": "Jee BC. Efficacy of ablation and sclerotherapy for the management of ovarian endometrioma: A narrative review. Clin Exp Reprod Med. 2022 Jun;49(2):76-86. doi: 10.5653/cerm.2021.05183. Epub 2022 May 4."}, {"pmid": "26492167", "type": "BACKGROUND", "citation": "Giampaolino P, Bifulco G, Di Spiezio Sardo A, Mercorio A, Bruzzese D, Di Carlo C. Endometrioma size is a relevant factor in selection of the most appropriate surgical technique: a prospective randomized preliminary study. Eur J Obstet Gynecol Reprod Biol. 2015 Dec;195:88-93. doi: 10.1016/j.ejogrb.2015.09.046. Epub 2015 Oct 24."}, {"pmid": "32272240", "type": "BACKGROUND", "citation": "Garcia-Tejedor A, Martinez-Garcia JM, Candas B, Suarez E, Manalich L, Gomez M, Merino E, Castellarnau M, Regueiro P, Carreras M, Martinez-Franco E, Carrarrach M, Subirats N, Barbera J, Gonzalez S, Climent M, Fernandez-Montoli E, Ponce J. Ethanol Sclerotherapy versus Laparoscopic Surgery for Endometrioma Treatment: A Prospective, Multicenter, Cohort Pilot Study. J Minim Invasive Gynecol. 2020 Jul-Aug;27(5):1133-1140. doi: 10.1016/j.jmig.2019.08.036. Epub 2020 Apr 7."}, {"pmid": "33349801", "type": "BACKGROUND", "citation": "Aflatoonian A, Tabibnejad N. Aspiration versus retention ultrasound-guided ethanol sclerotherapy for treating endometrioma: A retrospective cross-sectional study. Int J Reprod Biomed. 2020 Nov 22;18(11):935-942. doi: 10.18502/ijrm.v13i11.7960. eCollection 2020 Nov."}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT04500743", "orgStudyIdInfo": {"id": "Dienogest before IVF"}, "organization": {"fullName": "National Research Centre, Egypt", "class": "OTHER"}, "briefTitle": "Role of Suppression of Endometriosis With Progestins Before IVF-ET", "officialTitle": "Role of Suppression of Endometriosis With Progestins Before IVF-ET: a Non-inferiority Randomized Controlled Trial"}, "statusModule": {"statusVerifiedDate": "2020-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2018-08-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2019-10-31", "type": "ACTUAL"}, "completionDateStruct": {"date": "2020-04-30", "type": "ACTUAL"}, "studyFirstSubmitDate": "2020-07-29", "studyFirstSubmitQcDate": "2020-08-03", "studyFirstPostDateStruct": {"date": "2020-08-05", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2020-08-03", "lastUpdatePostDateStruct": {"date": "2020-08-05", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Mazen Abdel Rasheed", "investigatorTitle": "Principal Investigator", "investigatorAffiliation": "National Research Centre, Egypt"}, "leadSponsor": {"name": "National Research Centre, Egypt", "class": "OTHER"}}, "oversightModule": {"isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false, "isUsExport": false}, "descriptionModule": {"briefSummary": "This study aimed to assess the role of Dienogest pretreatment for endometriosis suppression as compared to Gonadotropin-releasing hormone agonist (GnRHa) in patients with endometriosis pursuing IVF treatment."}, "conditionsModule": {"conditions": ["IVF", "Endometriosis", "Pregnancy Rate", "Progestins", "GnRH-analogue"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 134, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Dienogest", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: Dienogest"]}, {"label": "GnRH analogue", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: leuprorelin acetate"]}], "interventions": [{"type": "DRUG", "name": "Dienogest", "description": "Group B (n=67) who had daily oral Dienogest 2 mg/d for 3 months before starting standard long protocol for IVF", "armGroupLabels": ["Dienogest"]}, {"type": "DRUG", "name": "leuprorelin acetate", "description": "Group A (n=67) who had monthly depot GnRHa for 3 months before ovarian stimulation in IVF treatment (Ultra-long protocol)", "armGroupLabels": ["GnRH analogue"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "the number of retrieved oocytes", "description": "the number of retrieved oocytes as the main concern was the effect of either GnRHa or Dienogest on ovarian responsiveness", "timeFrame": "After the ovarian induction (3 months after the pre treatment with either GnRHa or Dienogest)"}], "secondaryOutcomes": [{"measure": "the fertilization rate", "description": "defined as the number of zygotes with two pronuclei divided by the number of oocytes", "timeFrame": "After the ovarian induction (3 months after the pre treatment with either GnRHa or Dienogest)"}, {"measure": "the number of transferrable embryos", "description": "defined as the number of embryos suitable for transfer in the stimulated cycle or cryopreservation", "timeFrame": "After the ovarian induction (3 months after the pre treatment with either GnRHa or Dienogest)"}, {"measure": "the cost of the treatment", "description": "the cost of the treatment in Egyptian pounds including cost of pretreatment and ovarian stimulation drugs", "timeFrame": "After the ovarian induction (3 months after the pre treatment with either GnRHa or Dienogest)"}, {"measure": "pregnancy rate per cycle started", "description": "defined as patients with positive urinary or serum pregnancy test divided by the number of patients starting the treatment", "timeFrame": "After the ovarian induction (3 months after the pre treatment with either GnRHa or Dienogest)"}, {"measure": "the clinical pregnancy rate per cycle started", "description": "defined as the number of patients with at least one intrauterine gestational sac with identifiable fetal heart pulsations over the total number of patients starting the treatment", "timeFrame": "after women have postive pregnancy test (2 weeks after after the embryo transfer)"}, {"measure": "the miscarriage rate", "description": "defined as patients with identified intrauterine gestational sac without a fetal pole, or a fetal pole with no heart pulsations with no other viable fetuses over the number of patients with positive pregnancy test", "timeFrame": "After occurence of the clinical pregnancy (5 months after after the embryo transfer)"}, {"measure": "patient's quality of life", "description": "patient's quality of life during the pretreatment period as assessed by the Fertility quality of life (FertiQoL) questionnaire with a range of 0 (the worst) to 100 (the best).", "timeFrame": "throughout the pre-treatment with GnRHa or Dienogest as well as the induction of ovulation \"through study completion, an average of 9 months\""}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* confirmed diagnosis of endometriosis\n* body mass index \\< 35 Kg/m2\n\nExclusion Criteria:\n\n* if they have been already on long-term down-regulation of the pituitary gland with GnRHa for control of endometriosis\n* liver or kidney disease\n* evidence of diminished ovarian reserve (e.g. high FSH level \\>12 IU/L or low AMH level \\<1 ng/ml).", "healthyVolunteers": true, "sex": "FEMALE", "minimumAge": "30 Years", "maximumAge": "40 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "Minia Infertility research unit", "city": "Minya", "country": "Egypt", "geoPoint": {"lat": 28.09193, "lon": 30.75813}}]}, "referencesModule": {"references": [{"pmid": "41065045", "type": "DERIVED", "citation": "Chen I, Kives S, Zakhari A, Nguyen DB, Goldberg HR, Choudhry AJ, Le AL, Kowalczewski E, Schroll JB. Progestagens for pain symptoms associated with endometriosis. Cochrane Database Syst Rev. 2025 Oct 9;10:CD002122. doi: 10.1002/14651858.CD002122.pub3."}, {"pmid": "33784989", "type": "DERIVED", "citation": "Khalifa E, Mohammad H, Abdullah A, Abdel-Rasheed M, Khairy M, Hosni M. Role of suppression of endometriosis with progestins before IVF-ET: a non-inferiority randomized controlled trial. BMC Pregnancy Childbirth. 2021 Mar 30;21(1):264. doi: 10.1186/s12884-021-03736-2."}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C023635", "term": "dienogest"}, {"id": "D016729", "term": "Leuprolide"}], "ancestors": [{"id": "D007987", "term": "Gonadotropin-Releasing Hormone"}, {"id": "D010906", "term": "Pituitary Hormone-Releasing Hormones"}, {"id": "D007028", "term": "Hypothalamic Hormones"}, {"id": "D036361", "term": "Peptide Hormones"}, {"id": "D006728", "term": "Hormones"}, {"id": "D006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D009479", "term": "Neuropeptides"}, {"id": "D010455", "term": "Peptides"}, {"id": "D000602", "term": "Amino Acids, Peptides, and Proteins"}, {"id": "D009842", "term": "Oligopeptides"}, {"id": "D009419", "term": "Nerve Tissue Proteins"}, {"id": "D011506", "term": "Proteins"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT04347135", "orgStudyIdInfo": {"id": "19-004345"}, "organization": {"fullName": "Mayo Clinic", "class": "OTHER"}, "briefTitle": "Evaluating Endometriosis With 16α-(18)F-fluoro-17β-estradiol ([F-18] FES) PET/MRI", "officialTitle": "Pilot Study Evaluating Endometriosis With 16α-(18)F-fluoro-17β-estradiol ([F-18] FES) PET/MRI"}, "statusModule": {"statusVerifiedDate": "2024-04", "overallStatus": "WITHDRAWN", "whyStopped": "No Enrollment", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2022-10-07", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2024-04-30", "type": "ACTUAL"}, "completionDateStruct": {"date": "2024-04-30", "type": "ACTUAL"}, "studyFirstSubmitDate": "2020-04-13", "studyFirstSubmitQcDate": "2020-04-13", "studyFirstPostDateStruct": {"date": "2020-04-15", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2024-05-08", "lastUpdatePostDateStruct": {"date": "2024-05-10", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR_INVESTIGATOR", "investigatorFullName": "Annie (Annie) T. Packard", "investigatorTitle": "Principal Investigator", "investigatorAffiliation": "Mayo Clinic"}, "leadSponsor": {"name": "Annie (Annie) T. Packard", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "Researchers are trying to improve the detection of endometriosis using F-18 FES PET/MRI imaging."}, "conditionsModule": {"conditions": ["Endometriosis"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1", "PHASE2"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "DIAGNOSTIC", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 0, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "F-18 FES PET/MRI", "type": "EXPERIMENTAL", "description": "16α-(18)F-fluoro-17β-estradiol (\\[F-18\\] FES)", "interventionNames": ["Drug: F-18 FES"]}], "interventions": [{"type": "DRUG", "name": "F-18 FES", "description": "F-18 FES PET/MRI for detection of endometriosis.", "armGroupLabels": ["F-18 FES PET/MRI"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Detection of Endometriosis", "description": "Comparisons will be made descriptively between conventional MRI imaging, FES PET/MRI imaging and surgical/pathologic findings. Outcome data include number of detected lesions, differences in the accuracy for detection of active disease versus inactive fibrosis, and confidence score.", "timeFrame": "24 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n\\- Premenopausal women (18-50) with endometriosis\n\nExclusion Criteria:\n\n* Postmenopausal women\n* AP diameter when lying supine greater than 32 cm (too large for PET/MRI)\n* Unable to undergo PET/MRI for any reason (metal implants, severe claustrophobia)\n* Unable to receive IV Gadolinium contrast for any reason (renal failure eGFR \\< 60, contrast allergy)\n* Pregnant (Urine test will be provided for all patients)", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "50 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Ann Packard, MD", "affiliation": "Mayo Clinic", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Mayo Clinic in Rochester", "city": "Rochester", "state": "Minnesota", "zip": "55905", "country": "United States", "geoPoint": {"lat": 44.02163, "lon": -92.4699}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "Mayo Clinic Clinical Trials", "url": "https://www.mayo.edu/research/clinical-trials"}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT07004959", "orgStudyIdInfo": {"id": "RCAPHM20_0429"}, "organization": {"fullName": "Assistance Publique Hopitaux De Marseille", "class": "OTHER"}, "briefTitle": "Non-inferiority Trial Comparing Vaginal Ultrasound-guided Ethanol Sclerotherapy and Laparoscopic Cystectomy for the Management of Ovarian Endometriomas (E-STEP)", "officialTitle": "Randomised Controlled Non-inferiority Trial Comparing Vaginal Ultrasound-guided Ethanol Sclerotherapy and Laparoscopic Cystectomy for the Management of Ovarian Endometriomas", "acronym": "E-STEP"}, "statusModule": {"statusVerifiedDate": "2025-05", "overallStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2024-11-19", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2028-03-19", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2028-03-19", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2025-05-26", "studyFirstSubmitQcDate": "2025-05-26", "studyFirstPostDateStruct": {"date": "2025-06-04", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2025-05-26", "lastUpdatePostDateStruct": {"date": "2025-06-04", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Assistance Publique Hopitaux De Marseille", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "Endometriosis is a disease that affects between 6 and 10% of women of childbearing age. It is defined by the presence of endometrial tissue outside the uterine cavity, most often in the ovaries or the peritoneal cavity.\n\nThe standard treatment for endometriomas is laparoscopic intraperitoneal cystectomy. This treatment has been shown to be associated with a lower rate of recurrence of painful symptoms than simple cyst drainage, and with higher pregnancy rates. Nevertheless, cystectomy can lead to a reduction in ovarian reserve due to the removal of adjacent healthy ovarian tissue, particularly when there is no cleavage plane between the ovary and the endometrioma.\n\nOther methods have been developed to manage endometriomas while preserving the ovarian reserve. Endometrioma sclerotherapy is one of the most promising techniques for reducing the risk of recurrence while preserving the ovarian reserve. This technique involves injecting a sclerosing agent into the cystic cavity, which has been drained beforehand, in order to create an abrasion of the cystic epithelium, resulting in inflammation and fibrosis that can lead to the permanent destruction of the cyst.\n\nThe aim of the study is to conduct a single-centre randomised controlled non-inferiority trial comparing sclerotherapy and intraperitoneal cystectomy for the treatment of endometriomas.\n\nThe main hypothesis of the study is that sclerotherapy is not inferior to cystectomy in terms of reducing painful symptoms one year after the operation and that it is superior to cystectomy on one or more of the following criteria: preservation of ovarian reserve, operative complications, post-operative pain, patient acceptability/satisfaction.\n\nThe number of patients to be included will be 64, calculated to demonstrate non-inferiority between sclerotherapy and cystectomy for the primary endpoint.", "detailedDescription": "Endometriosis is a disease that affects between 6 and 10% of women of childbearing age. It is defined by the presence of endometrial tissue outside the uterine cavity, most often in the ovaries or the peritoneal cavity. Endometriomas are ovarian cysts whose lining is composed of ectopic endometrium and which contain a liquid resulting from the accumulation of menstrual debris. Between 17% and 44% of women with endometriosis have one or more ovarian endometriomas (i.e. between 1% and 5% of women). The clinical symptoms of endometriomas include pelvic pain (dysmenorrhoea, chronic pelvic pain or dyspareunia) and/or infertility. The standard treatment for endometriomas is laparoscopic intraperitoneal cystectomy. This treatment has been shown to be associated with a lower rate of recurrence of painful symptoms than simple cyst drainage, and with higher pregnancy rates. Nevertheless, cystectomy can lead to a reduction in ovarian reserve due to the removal of adjacent healthy ovarian tissue, particularly when there is no cleavage plane between the ovary and the endometrioma. Excessive coagulation to ensure haemostasis after cystectomy could also contribute to this reduction in ovarian reserve. Other methods have been developed to manage endometriomas while preserving the ovarian reserve: therapeutic abstention, drainage, laser or plasma energy ablation and sclerotherapy. Endometrioma sclerotherapy is one of the most promising techniques for reducing the risk of recurrence while preserving the ovarian reserve. This technique involves injecting a sclerosing agent into the cystic cavity, which has been drained beforehand, in order to create an abrasion of the cystic epithelium, resulting in inflammation and fibrosis that can lead to the permanent destruction of the cyst. This very simple technique is effective and low-risk for treating endometriomas:\n\n* Recurrence rate between 0 and 62.5% depending on the protocol (recurrence rate after cystectomy between 6 and 67%).\n* Improvement in pain in 68 to 96% of patients.\n* Improvement in ovarian reserve compared with intraperitoneal cystectomy (increase in antral follicle count and AMH and higher number of oocytes harvested during subsequent in vitro fertilisation).\n* Low complication rate: transient abdominal pain (1.8 - 15.3%), transient alcohol intoxication (3.8%).\n\nMost of what is known about serotherapy comes from non-comparative prospective studies and a few randomised trials comparing sclerotherapy with either no treatment or simple drainage of the endometrioma. In addition, most studies have been conducted in the specific context of endometriomas recurring after cystectomy. To date, there is no comparative trial between sclerotherapy and intraperitoneal cystectomy (reference treatment).\n\nWe aim to conduct a single-centre randomised controlled non-inferiority trial comparing sclerotherapy and intraperitoneal cystectomy for the treatment of endometriomas.\n\nThe main hypothesis of the study is that sclerotherapy is not inferior to cystectomy in terms of reducing painful symptoms one year after the operation and that it is superior to cystectomy on one or more of the following criteria: preservation of ovarian reserve, operative complications, post-operative pain, patient acceptability/satisfaction.\n\nThe main objective is to investigate the non-inferiority of sclerotherapy of endometriomas one year after the operation in terms of reduction of painful symptoms compared with laparoscopic cystectomy. The reduction in painful symptoms was defined by the difference in the number of millimetres of VAS for pain between the preoperative consultation and the consultation one year after the operation, according to the answer to the question : \" Indicate the subjective level of your endometriosis-related pain over the last 4 weeks by simply drawing a line through the line\".\n\nThe secondary objectives were to compare the two techniques:\n\n* The evolution of the 3 components of endometriosis-related pain (chronic pelvic pain, dysmenorrhoea and dyspareunia) with a VAS evaluation at 3 months and one year.\n* Subjective evaluation of the evolution of treatment-related symptoms at 3 months and one year (based on self-assessment using the Clinical Global Impression Scale (CGI-S)).\n* Patient satisfaction at 3 months (based on the SSQ-8 questionnaire).\n* The endometrioma recurrence rate at one year (defined as the visualisation of an endometrioma with a maximum diameter greater than 3 cm on the same ovary on ultrasound or pelvic MRI one year after the operation).\n* Pregnancy rate at one year for all patients (defined by at least one analysis of a quantitative plasma HCG level greater than 100 IU/ml in the year following the operation).\n* The one-year pregnancy rate for patients who have expressed a desire to become pregnant within the year (defined by at least one analysis of the quantitative plasma HCG level greater than 100 IU/ml within the year following the procedure). Assessment of ovarian reserve at one year (defined by the AMH value one year after the operation and by the antral follicle count between the 2nd and 5th day of the cycle one year after the operation).\n* Changes in quality of life at 3 months and one year (based on responses to the SF-36 questionnaire).\n* The rate of per- and post-operative complications.\n* Duration of the operation and length of post-operative hospitalisation.\n\nThe number of patients to be included will be 64, calculated to demonstrate non-inferiority between sclerotherapy and cystectomy for the primary endpoint."}, "conditionsModule": {"conditions": ["Ovarian Endometrioma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 64, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Sclerotherapy", "type": "EXPERIMENTAL", "interventionNames": ["Procedure: Vaginal ultrasound-guided ethanol sclerotherapy"]}, {"label": "Intraperitoneal cystectomy", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Procedure: Laparoscopic cystectomy"]}], "interventions": [{"type": "PROCEDURE", "name": "Vaginal ultrasound-guided ethanol sclerotherapy", "description": "Use of an endovaginal ultrasound probe combined with a puncture guide. The technique involves locating the endometriosis cyst, echo-guided drainage via the endovaginal route, sclerotherapy (replacement of 60% of the punctured volume with 95% ethanol left in place for 10 minutes) and then reaspiration of the ethanol.", "armGroupLabels": ["Sclerotherapy"]}, {"type": "PROCEDURE", "name": "Laparoscopic cystectomy", "description": "Conventional laparoscopy, with the laparoscope introduced through a 10mm incision at the umbilicus, and the laparoscopic instruments used through two or three 5mm incisions (suprapubic and right and left fossa iliaca). The surgical technique may vary according to the patient and the surgeon's preferences or habits, but must necessarily include a cystectomy (cyst wall sent for anatomopathology).", "armGroupLabels": ["Intraperitoneal cystectomy"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Difference in the number of millimetres of VAS for pain between the preoperative consultation and the consultation one year after the operation", "description": "The main objective is to investigate the non-inferiority of sclerotherapy of endometriomas one year after the operation in terms of reduction of painful symptoms compared with laparoscopic cystectomy. The reduction in painful symptoms was defined by the difference in the number of millimetres of VAS for pain between the preoperative consultation and the consultation one year after the operation, according to the answer to the question : \" Indicate the subjective level of your endometriosis-related pain over the last 4 weeks by simply drawing a line through the line\".", "timeFrame": "At 12 months"}], "secondaryOutcomes": [{"measure": "Pain components", "description": "The evolution of the 3 components of endometriosis-related pain (chronic pelvic pain, dysmenorrhoea and dyspareunia) with a VAS evaluation at 3 months and one year.", "timeFrame": "At 3 and 12 months"}, {"measure": "Subjective improvement", "description": "Subjective assessment of the evolution of treatment-related symptoms at 3 months and one year (based on self-assessment using the Clinical Global Impression Scale (CGI-S)).", "timeFrame": "At 3 and 12 months"}, {"measure": "Patient satisfaction", "description": "Patient satisfaction at 3 months (according to the SSQ-8 questionnaire)", "timeFrame": "At 3 months"}, {"measure": "Reccurence rate", "description": "The rate of recurrence of endometriomas at one year (defined as the visualisation of an endometrioma with a maximum diameter greater than 3 cm on the same ovary on ultrasound or pelvic MRI one year after the operation).", "timeFrame": "At 12 months"}, {"measure": "Pregnancy rate", "description": "Pregnancy rate at one year for all patients (defined by at least one analysis of the quantitative plasma HCG level greater than 100 IU/ml in the year following the procedure).", "timeFrame": "At 12 months"}, {"measure": "Pregnancy achievement", "description": "Pregnancy rate at one year for patients who have expressed a desire to become pregnant within the year (defined by at least one analysis of the quantitative plasma HCG level greater than 100 IU/ml in the year following the operation). Assessment of ovarian reserve at one year (defined by the AMH value one year after the procedure and by the antral follicle count between the 2nd and 5th day of the cycle one year after the procedure).", "timeFrame": "At 12 months"}, {"measure": "Quality of life", "description": "Changes in quality of life at 3 months and one year (based on responses to the SF-36 questionnaire)", "timeFrame": "At 3 and 12 months"}, {"measure": "Complication rate", "description": "The rate of intra- and post-operative complications.", "timeFrame": "At one month"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patients aged between 18 and 45\n* Endometrioma diagnosed by endovaginal ultrasound or MRI (examinations carried out by a radiologist or gynaecologist) with a typical appearance and whose largest diameter is between 3 and 10 centimetres.\n* Pain (dysmenorrhoea or chronic pelvic pain) with a VAS greater than 30 millimetres, assessed by the question \"Indicate the subjective level of your endometriosis-related pain over the last 4 weeks\".\n\nExclusion Criteria:\n\n* Inability to speak French\n* Refusal to take part in the study\n* Risk factors for impaired ovarian reserve:\n* Ovarian reserve already low (AMH \\<1,5ng/ml or Antral follicle count \\< 7 on the contralateral ovary\n* Bilateral or multiple endometriomas (two or more endometriomas greater than 3 centimetres in diameter).\n* Previous cystectomy\n* Previous major peritoneal surgery causing adhesions.\n* Contraindication to sclerotherapy : allergy to ethanol\n* Contraindications to general anaesthesia\n* Pregnant women, women in labour and nursing mothers", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "45 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Claire MORANDO", "role": "CONTACT", "phone": "0491382183", "email": "claire.morando@ap-hm.fr ; promotion.interne@ap-hm.fr"}], "overallOfficials": [{"name": "Antoine NETTER", "affiliation": "Assistance Publique - Hôpitaux de Marseille", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "gynecology department APHM", "status": "RECRUITING", "city": "Marseille", "state": "France", "zip": "13005", "country": "France", "geoPoint": {"lat": 43.29695, "lon": 5.38107}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT02484196", "orgStudyIdInfo": {"id": "ENDODISP14"}, "organization": {"fullName": "University of Cagliari", "class": "OTHER"}, "briefTitle": "Dyspareunia in Women With Endometriosis: Impact of Surgery on Sexual Health", "officialTitle": "Dyspareunia in Women With Endometriosis: Impact of Surgery on Sexual Health"}, "statusModule": {"statusVerifiedDate": "2021-01", "overallStatus": "UNKNOWN", "lastKnownStatus": "NOT_YET_RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2021-06-01", "type": "ESTIMATED"}, "primaryCompletionDateStruct": {"date": "2021-09-01", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2021-12", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2015-06-23", "studyFirstSubmitQcDate": "2015-06-24", "studyFirstPostDateStruct": {"date": "2015-06-29", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2021-01-31", "lastUpdatePostDateStruct": {"date": "2021-02-02", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Stefano Angioni", "investigatorTitle": "Associate Professor", "investigatorAffiliation": "University of Cagliari"}, "leadSponsor": {"name": "University of Cagliari", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "Endometriosis is a disease that affects different areas of individual functioning, including the area of sexual life. Women with endometriosis have an impairment of desire and sexual arousal, orgasmic capacity reducted because of the pain and deep dyspareunia. The aim of the study is to evaluate the effectiveness of surgery on dyspareunia in women with endometriosis, taking into account other variables involved in determining dyspareunia: the quality of the couple relationship, anxiety and depression, body image, coping strategies and resilience."}, "conditionsModule": {"conditions": ["Dyspareunia", "Endometriosis"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "COHORT", "timePerspective": "PROSPECTIVE"}, "enrollmentInfo": {"count": 100, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Couples", "description": "Women, with their partners, referred to the Obstetrics and Gynecological Department of the University Hospital for surgical treatment of endometriosis.", "interventionNames": ["Behavioral: Questionnaires"]}, {"label": "Women", "description": "Women referred to the Obstetrics and Gynecological Department of the University Hospital for surgical treatment of endometriosis.", "interventionNames": ["Behavioral: Questionnaires"]}], "interventions": [{"type": "BEHAVIORAL", "name": "Questionnaires", "description": "Questionnaires", "armGroupLabels": ["Couples", "Women"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Quality of sexual life", "timeFrame": "Cases were administered and fulfilled the questionnaires at the moment of diagnosis of endometriosis up to 4weeks; Change from baseline were evalueted 2 months after surgery"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Women affected by endometriosis with dyspareunia;\n* Women in waiting list for surgery\n\nExclusion Criteria:\n\n* Severe underlying comorbidities (gynecological, cardiovascular, respiratory, renal, hematological, endocrine, hepatic, gastrointestinal, neurological)\n* Psychiatric diseases\n* Refusal or inability to sign the informed consent\n* Pregnancy\n* Previous gynecological surgery\n* End of couple relationship", "healthyVolunteers": true, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "45 Years", "stdAges": ["ADULT"], "studyPopulation": "Women, and their parteners, affected by endometriosis with dyspareunia, referred to the Obstetrics and Gynecological Department of the University Hospital for the treatment of endometriosis", "samplingMethod": "NON_PROBABILITY_SAMPLE"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004414", "term": "Dyspareunia"}, {"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}, {"id": "D005832", "term": "Genital Diseases, Male"}, {"id": "D012735", "term": "Sexual Dysfunction, Physiological"}, {"id": "D052801", "term": "Male Urogenital Diseases"}, {"id": "D020018", "term": "Sexual Dysfunctions, Psychological"}, {"id": "D001523", "term": "Mental Disorders"}]}, "interventionBrowseModule": {"meshes": [{"id": "D011795", "term": "Surveys and Questionnaires"}], "ancestors": [{"id": "D003625", "term": "Data Collection"}, {"id": "D004812", "term": "Epidemiologic Methods"}, {"id": "D008919", "term": "Investigative Techniques"}, {"id": "D017531", "term": "Health Care Evaluation Mechanisms"}, {"id": "D011787", "term": "Quality of Health Care"}, {"id": "D017530", "term": "Health Care Quality, Access, and Evaluation"}, {"id": "D011634", "term": "Public Health"}, {"id": "D004778", "term": "Environment and Public Health"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT03425604", "orgStudyIdInfo": {"id": "IVIBILBAO"}, "organization": {"fullName": "IVI Bilbao", "class": "OTHER"}, "briefTitle": "Role of Intrauterine Insemination in Patients With Endometriosis I-II", "officialTitle": "Role of Intrauterine Insemination in Patients With Endometriosis I-II"}, "statusModule": {"statusVerifiedDate": "2018-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2011-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2017-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2017-06", "type": "ACTUAL"}, "studyFirstSubmitDate": "2018-02-01", "studyFirstSubmitQcDate": "2018-02-01", "studyFirstPostDateStruct": {"date": "2018-02-07", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2020-02-11", "lastUpdatePostDateStruct": {"date": "2020-02-12", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "IVI Bilbao", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "Intrauterine insemination (IUI) is an ART that provides good results in selected patients, improving their reproductive prognosis. Endometriosis I y II, according to ASRM classification, remains an indication to perform IUI. This indication is on continuous debate, considering that different studies have shown controversial results about it, due to the poor reproductive outcomes in this group of patients"}, "conditionsModule": {"conditions": ["Endometriosis I-II"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "CASE_CONTROL", "timePerspective": "RETROSPECTIVE"}, "enrollmentInfo": {"count": 9979, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Endometriosis I y II, according to ASRM classification", "description": "Cycles were chosen for analysis only when all the following selection criteria were satisfied: \\< 38 years old women, antral follicle count \\> 6, basal FSH \\< 10mUI/ml, BMI\\<30, Infertility time \\<4 years, absence of uterine malformations, endometrial polyps or myomas, absence of known thrombofilia, normal kayotype, \\< 3 previous IUI cycles, no male severe factor associated", "interventionNames": ["Procedure: Intrauterine insemination"]}, {"label": "patients without endometriosis", "description": "Cycles were chosen for analysis only when all the following selection criteria were satisfied: \\< 38 years old women, antral follicle count \\> 6, basal FSH \\< 10mUI/ml, BMI\\<30, Infertility time \\<4 years, absence of uterine malformations, endometrial polyps or myomas, absence of known thrombofilia, normal kayotype, \\< 3 previous IUI cycles, no male severe factor associated", "interventionNames": ["Procedure: Intrauterine insemination"]}], "interventions": [{"type": "PROCEDURE", "name": "Intrauterine insemination", "armGroupLabels": ["Endometriosis I y II, according to ASRM classification", "patients without endometriosis"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "pregnancy rate", "description": "to compare pregnancy rate between Endometriosis I-II patients (according to ASRM classification) vs. control group (patients without endometriosis) going under an IUI cycle", "timeFrame": "2011-2017"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\\< 38 years old women, antral follicle count \\> 6, basal FSH \\< 10mUI/ml, BMI\\<30, Infertility time \\<4 years, absence of uterine malformations, endometrial polyps or myomas, absence of known thrombofilia, normal kayotype, \\< 3 previous IUI cycles, no male severe factor associated\n\n\\-\n\nExclusion Criteria:\n\n* \\> 38 years old", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "38 Years", "stdAges": ["ADULT"], "studyPopulation": "We analyzed the database (SIVIS) containing information on IUI treatment cycles carried out at the IVI-Clinics between 2011 and 2017.", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT05038878", "orgStudyIdInfo": {"id": "GCO 19-1595"}, "organization": {"fullName": "Icahn School of Medicine at Mount Sinai", "class": "OTHER"}, "briefTitle": "An Oral GnRH Antagonist to Treat Mild Autonomous Cortisol Excess (MACE) Due to Adrenal Adenomas in Postmenopausal Women", "officialTitle": "An Oral GnRH Antagonist to Treat Mild Autonomous Cortisol Excess (MACE) Due to Adrenal Adenomas in Postmenopausal Women"}, "statusModule": {"statusVerifiedDate": "2025-03", "overallStatus": "TERMINATED", "whyStopped": "Difficulty recruiting patients", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2021-07-06", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2022-06-24", "type": "ACTUAL"}, "completionDateStruct": {"date": "2022-06-24", "type": "ACTUAL"}, "studyFirstSubmitDate": "2021-08-17", "studyFirstSubmitQcDate": "2021-09-08", "studyFirstPostDateStruct": {"date": "2021-09-09", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2025-02-12", "resultsFirstSubmitQcDate": "2025-03-11", "resultsFirstPostDateStruct": {"date": "2025-03-18", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2025-03-11", "lastUpdatePostDateStruct": {"date": "2025-03-18", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Alice C. Levine", "investigatorTitle": "Professor, Medicine - Endocrinology, Diabetes and Bone Disease", "investigatorAffiliation": "Icahn School of Medicine at Mount Sinai"}, "leadSponsor": {"name": "Icahn School of Medicine at Mount Sinai", "class": "OTHER"}, "collaborators": [{"name": "AbbVie", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The purpose of this research study is to determine if treatment with Elagolix will improve body weight, waist circumference, muscle strength, cortisol secretion, blood glucose, cholesterol, and bone quality as well as mood and quality of life in a female patient with mild hypercortisolism from adrenal overproduction of cortisol. Many people with adrenal nodules, or non-cancerous growths in the adrenal glands, have mildly elevated cortisol levels. Cortisol is a hormone normally made by the adrenal glands. It is increasingly being recognized that even mild elevations in cortisol levels can negatively impact blood glucose levels, serum cholesterol levels, weight and other metabolic parameters. This can lead to an increase in risk for cardiovascular disease. The study team is trying to determine if the medication Elagolix might be an effective treatment for post-menopausal females with mild hypercortisolism. Elagolix is a medication used to treat a medical condition called endometriosis by decreasing the body's production of sex hormones. Growth of adrenal adenomas is thought to be driven by such sex hormones. Therefore, by decreasing production of these hormones, the study team hopes to treat hypercortisolism caused by adrenal adenomas."}, "conditionsModule": {"conditions": ["Mild Autonomous Cortisol Excess"], "keywords": ["mild autonomous cortisol excess (MACE)", "adrenal adenomas", "postmenopausal women", "GnRH antagonist"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 4, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "GnRH antagonist (Elagolix)", "type": "EXPERIMENTAL", "description": "Post-menopausal women with benign appearing adrenal adenomas, absence of clinical features of overt Cushing's signs or symptoms and MACE confirmed on either 24 hr urine free cortisol (UFC), late night salivary cortisol and/or abnormal dexamethasone suppression", "interventionNames": ["Drug: Elagolix"]}], "interventions": [{"type": "DRUG", "name": "Elagolix", "description": "Patients will be given Elagolix 200 mg orally twice daily for a total of 6 months", "armGroupLabels": ["GnRH antagonist (Elagolix)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Participants With Change in Cortisol Level", "description": "Cortisol level after dexamethasone suppression test which measures whether adrenocorticotrophic hormone (ACTH) secretion by the pituitary can be suppressed.\n\nNumber of participants with interval improvement and normalization of late-night salivary results after 6 months of treatment.", "timeFrame": "baseline and 6 months"}, {"measure": "Change in Cortisol Level", "description": "Cortisol level after dexamethasone suppression test which measures whether adrenocorticotrophic hormone (ACTH) secretion by the pituitary can be suppressed.\n\nCortisol secretion as reported below by assessment of pre-treatment and post-treatment of late-night salivary cortisol levels (normal midnight values: \\<0.010 - 0.090)", "timeFrame": "baseline and 6 months"}, {"measure": "Number of Participants With Change in 24 Hour Urine Free Cortisol Level", "description": "24 hour urine free cortisol measurements. The cortisol urine test measures the level of cortisol in the urine. Cortisol is a glucocorticoid (steroid) hormone produced by the adrenal gland.\n\nNumber of participants with improvement in 24-hour urinary free cortisol after treatment (normal 24-hr urinary cortisol is between 6 - 42 ug/24 hr).", "timeFrame": "Baseline and 6 months"}, {"measure": "24 Hour Urine Free Cortisol Level", "description": "24 hour urine free cortisol measurements. The cortisol urine test measures the level of cortisol in the urine. Cortisol is a glucocorticoid (steroid) hormone produced by the adrenal gland.\n\nCortisol secretion as reported below by assessment of pre-treatment and post-treatment of 24-hour urinary cortisol levels (normal 24-hr urinary cortisol is between 6 - 42 ug/24 hr).", "timeFrame": "Baseline and 6 months"}, {"measure": "Number of Participants With Change in Adenoma Size as Compared to Baseline", "description": "All patients will have baseline imaging (CT or MRI) within 6 months to start of treatment and then will have repeat imaging with CT abdomen without contrast at 6 months to determine the effect of elagolix treatment on adrenal adenoma size and imaging characteristics. The images will be reviewed by a dedicated adrenal radiologist for consistency.", "timeFrame": "Baseline and 6 months"}, {"measure": "Change in Adenoma Size as Compared to Baseline", "description": "All patients will have baseline imaging (CT or MRI) within 6 months to start of treatment and then will have repeat imaging with CT abdomen without contrast at 6 months to determine the effect of elagolix treatment on adrenal adenoma size and imaging characteristics. The images will be reviewed by a dedicated adrenal radiologist for consistency.", "timeFrame": "Baseline and 6 months"}], "secondaryOutcomes": [{"measure": "Change in Body Weight as Compared to Baseline", "description": "Mean percent change in body weight is measured in kilograms at 6 months compared to baseline", "timeFrame": "baseline and 6 months"}, {"measure": "Change in Body Weight for Those Participants Who Lost Weight", "description": "Mean percent change in body weight is measured in kilograms at 6 months compared to baseline", "timeFrame": "baseline and 6 months"}, {"measure": "Trunk Fat", "description": "Trunk Fat composition assessed by DEXA scans at baseline and at 6 months.", "timeFrame": "baseline and 6 months"}, {"measure": "Preserved Glucose", "description": "fasting blood sugar", "timeFrame": "baseline and 6 months"}, {"measure": "Number of Participants With Vertebral Fractures", "description": "Number of participants with vertebral fractures to measure rates will be assessed by lateral X-rays of thoracic and lumbar spine.", "timeFrame": "baseline and 6 months"}, {"measure": "The Cushing's Quality of Life Questionnaire", "description": "The Cushing's Quality of Life Questionnaire is converted to a 0-100 scale in which 0 indicates the worse and 100 the best possible quality of life.", "timeFrame": "baseline and 6 months"}, {"measure": "Beck's Depression Scale", "description": "Beck's Depression Scale is scored on a scale of 1 to 40, where the higher score indicates severe or extreme depression.", "timeFrame": "baseline and 6 months"}, {"measure": "State Trait Anxiety Inventory (STAI)", "description": "The State Trait Anxiety Inventory gives a score range from 6-24 with the higher score indicating a higher level of anxiety.", "timeFrame": "baseline and 6 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Post-menopausal women that have incidentally found adrenal adenomas with benign appearing characteristics on imaging (\\<4 cm, non-contrast CT \\<10 HU and/or lipid rich and benign appearing on MRI)\n* Absence of anti-anabolic clinical features of overt Cushing's signs (proximal muscle weakness, \\>three ecchymoses, hyperpigmented striae) and 2 of 3 of the following:\n\n  * Elevated 24 hr urine free cortisol (UFC) above the upper limit of normal (\\>50 mcg/24 hours) in at least two complete 24-hour tests and/or\n  * Late night salivary cortisol more than upper limit of normal in at least two tests and/or\n  * an abnormal dexamethasone suppression defined as post 1mg dexamethasone suppression test serum cortisol concentration of \\>1.8 mcg/ml\n* Clinic status of cessation of menses for 12 mo in a previously cycling woman and reflecting complete or nearly complete permanent cessation of ovarian function and fertility (26).\n* Patients with osteoporosis that are not receiving treatment with either antiresorptive medications (bisphosphonates, denosumab) or anabolic agents (teriparitide, abaloparatide or romosozumab)\n\nExclusion Criteria:", "healthyVolunteers": false, "sex": "FEMALE", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Alice C Levine", "affiliation": "Icahn School of Medicine at Mount Sinai", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Icahn School of Medicine at Mount Sinai", "city": "New York", "state": "New York", "zip": "10029", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO", "description": "Privacy"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "GnRH Antagonist (Elagolix)", "description": "Post-menopausal women with benign appearing adrenal adenomas, absence of clinical features of overt Cushing's signs or symptoms and MACE confirmed on either 24 hr urine free cortisol (UFC), late night salivary cortisol and/or abnormal dexamethasone suppression\n\nElagolix: Patients will be given Elagolix 200 mg orally twice daily for a total of 6 months"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "GnRH Antagonist (Elagolix)", "description": "Post-menopausal women with benign appearing adrenal adenomas, absence of clinical features of overt Cushing's signs or symptoms and MACE confirmed on either 24 hr urine free cortisol (UFC), late night salivary cortisol and/or abnormal dexamethasone suppression\n\nElagolix: Patients will be given Elagolix 200 mg orally twice daily for a total of 6 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "4"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "4"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "64.25", "spread": "5.37"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "4"}]}], "categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "4"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Race and Ethnicity Not Collected", "populationDescription": "Race and Ethnicity were not collected from any participant.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "0"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Participants With Change in Cortisol Level", "description": "Cortisol level after dexamethasone suppression test which measures whether adrenocorticotrophic hormone (ACTH) secretion by the pituitary can be suppressed.\n\nNumber of participants with interval improvement and normalization of late-night salivary results after 6 months of treatment.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "baseline and 6 months", "groups": [{"id": "OG000", "title": "GnRH Antagonist (Elagolix)", "description": "Post-menopausal women with benign appearing adrenal adenomas, absence of clinical features of overt Cushing's signs or symptoms and MACE confirmed on either 24 hr urine free cortisol (UFC), late night salivary cortisol and/or abnormal dexamethasone suppression\n\nElagolix: Patients will be given Elagolix 200 mg orally twice daily for a total of 6 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2"}]}]}]}, {"type": "PRIMARY", "title": "Change in Cortisol Level", "description": "Cortisol level after dexamethasone suppression test which measures whether adrenocorticotrophic hormone (ACTH) secretion by the pituitary can be suppressed.\n\nCortisol secretion as reported below by assessment of pre-treatment and post-treatment of late-night salivary cortisol levels (normal midnight values: \\<0.010 - 0.090)", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "ng/mL", "timeFrame": "baseline and 6 months", "groups": [{"id": "OG000", "title": "GnRH Antagonist (Elagolix)", "description": "Post-menopausal women with benign appearing adrenal adenomas, absence of clinical features of overt Cushing's signs or symptoms and MACE confirmed on either 24 hr urine free cortisol (UFC), late night salivary cortisol and/or abnormal dexamethasone suppression\n\nElagolix: Patients will be given Elagolix 200 mg orally twice daily for a total of 6 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}]}], "classes": [{"title": "Baseline Salivary #1", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.252", "lowerLimit": "0.192", "upperLimit": "0.347"}]}]}, {"title": "Baseline Salivary #2", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.092", "lowerLimit": "0.045", "upperLimit": "0.161"}]}]}, {"title": "6 months Salivary #1", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.092", "lowerLimit": "0.053", "upperLimit": "0.124"}]}]}, {"title": "6 months Salivary #2", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.4355", "lowerLimit": "0.035", "upperLimit": "0.78"}]}]}]}, {"type": "PRIMARY", "title": "Number of Participants With Change in 24 Hour Urine Free Cortisol Level", "description": "24 hour urine free cortisol measurements. The cortisol urine test measures the level of cortisol in the urine. Cortisol is a glucocorticoid (steroid) hormone produced by the adrenal gland.\n\nNumber of participants with improvement in 24-hour urinary free cortisol after treatment (normal 24-hr urinary cortisol is between 6 - 42 ug/24 hr).", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Baseline and 6 months", "groups": [{"id": "OG000", "title": "GnRH Antagonist (Elagolix)", "description": "Post-menopausal women with benign appearing adrenal adenomas, absence of clinical features of overt Cushing's signs or symptoms and MACE confirmed on either 24 hr urine free cortisol (UFC), late night salivary cortisol and/or abnormal dexamethasone suppression\n\nElagolix: Patients will be given Elagolix 200 mg orally twice daily for a total of 6 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}]}, {"type": "PRIMARY", "title": "24 Hour Urine Free Cortisol Level", "description": "24 hour urine free cortisol measurements. The cortisol urine test measures the level of cortisol in the urine. Cortisol is a glucocorticoid (steroid) hormone produced by the adrenal gland.\n\nCortisol secretion as reported below by assessment of pre-treatment and post-treatment of 24-hour urinary cortisol levels (normal 24-hr urinary cortisol is between 6 - 42 ug/24 hr).", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "ug/24 hour", "timeFrame": "Baseline and 6 months", "groups": [{"id": "OG000", "title": "GnRH Antagonist (Elagolix)", "description": "Post-menopausal women with benign appearing adrenal adenomas, absence of clinical features of overt Cushing's signs or symptoms and MACE confirmed on either 24 hr urine free cortisol (UFC), late night salivary cortisol and/or abnormal dexamethasone suppression\n\nElagolix: Patients will be given Elagolix 200 mg orally twice daily for a total of 6 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}]}], "classes": [{"title": "baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "14", "lowerLimit": "13", "upperLimit": "66"}]}]}, {"title": "6 months", "categories": [{"measurements": [{"groupId": "OG000", "value": "23", "lowerLimit": "12", "upperLimit": "32"}]}]}]}, {"type": "PRIMARY", "title": "Number of Participants With Change in Adenoma Size as Compared to Baseline", "description": "All patients will have baseline imaging (CT or MRI) within 6 months to start of treatment and then will have repeat imaging with CT abdomen without contrast at 6 months to determine the effect of elagolix treatment on adrenal adenoma size and imaging characteristics. The images will be reviewed by a dedicated adrenal radiologist for consistency.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Baseline and 6 months", "groups": [{"id": "OG000", "title": "GnRH Antagonist (Elagolix)", "description": "Post-menopausal women with benign appearing adrenal adenomas, absence of clinical features of overt Cushing's signs or symptoms and MACE confirmed on either 24 hr urine free cortisol (UFC), late night salivary cortisol and/or abnormal dexamethasone suppression\n\nElagolix: Patients will be given Elagolix 200 mg orally twice daily for a total of 6 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}]}, {"type": "PRIMARY", "title": "Change in Adenoma Size as Compared to Baseline", "description": "All patients will have baseline imaging (CT or MRI) within 6 months to start of treatment and then will have repeat imaging with CT abdomen without contrast at 6 months to determine the effect of elagolix treatment on adrenal adenoma size and imaging characteristics. The images will be reviewed by a dedicated adrenal radiologist for consistency.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "cm", "timeFrame": "Baseline and 6 months", "groups": [{"id": "OG000", "title": "GnRH Antagonist (Elagolix)", "description": "Post-menopausal women with benign appearing adrenal adenomas, absence of clinical features of overt Cushing's signs or symptoms and MACE confirmed on either 24 hr urine free cortisol (UFC), late night salivary cortisol and/or abnormal dexamethasone suppression\n\nElagolix: Patients will be given Elagolix 200 mg orally twice daily for a total of 6 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}]}], "classes": [{"title": "baseline (MRI) Right", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.78", "spread": "0.26"}]}]}, {"title": "6 months (CT) Right", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.8", "spread": "0.22"}]}]}, {"title": "baseline (MRI) Left", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.33", "spread": "1.27"}]}]}, {"title": "6 months (CT) Left", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.13", "spread": "1.29"}]}]}]}, {"type": "SECONDARY", "title": "Change in Body Weight as Compared to Baseline", "description": "Mean percent change in body weight is measured in kilograms at 6 months compared to baseline", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent change in body weight", "timeFrame": "baseline and 6 months", "groups": [{"id": "OG000", "title": "GnRH Antagonist (Elagolix)", "description": "Post-menopausal women with benign appearing adrenal adenomas, absence of clinical features of overt Cushing's signs or symptoms and MACE confirmed on either 24 hr urine free cortisol (UFC), late night salivary cortisol and/or abnormal dexamethasone suppression\n\nElagolix: Patients will be given Elagolix 200 mg orally twice daily for a total of 6 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.86", "spread": "11.4"}]}]}]}, {"type": "SECONDARY", "title": "Change in Body Weight for Those Participants Who Lost Weight", "description": "Mean percent change in body weight is measured in kilograms at 6 months compared to baseline", "populationDescription": "Data for participants who lost weight", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent change in body weight", "timeFrame": "baseline and 6 months", "groups": [{"id": "OG000", "title": "GnRH Antagonist (Elagolix)", "description": "Post-menopausal women with benign appearing adrenal adenomas, absence of clinical features of overt Cushing's signs or symptoms and MACE confirmed on either 24 hr urine free cortisol (UFC), late night salivary cortisol and/or abnormal dexamethasone suppression\n\nElagolix: Patients will be given Elagolix 200 mg orally twice daily for a total of 6 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-3.86", "spread": "0.6"}]}]}]}, {"type": "SECONDARY", "title": "Trunk Fat", "description": "Trunk Fat composition assessed by DEXA scans at baseline and at 6 months.", "populationDescription": "Data for participants who completed dexa scan at both timepoints", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent of total fat", "timeFrame": "baseline and 6 months", "groups": [{"id": "OG000", "title": "GnRH Antagonist (Elagolix)", "description": "Post-menopausal women with benign appearing adrenal adenomas, absence of clinical features of overt Cushing's signs or symptoms and MACE confirmed on either 24 hr urine free cortisol (UFC), late night salivary cortisol and/or abnormal dexamethasone suppression\n\nElagolix: Patients will be given Elagolix 200 mg orally twice daily for a total of 6 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "44.7", "spread": "3.9"}]}]}, {"title": "6 months", "categories": [{"measurements": [{"groupId": "OG000", "value": "42.6", "spread": "1.6"}]}]}]}, {"type": "SECONDARY", "title": "Preserved Glucose", "description": "fasting blood sugar", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "baseline and 6 months", "groups": [{"id": "OG000", "title": "GnRH Antagonist (Elagolix)", "description": "Post-menopausal women with benign appearing adrenal adenomas, absence of clinical features of overt Cushing's signs or symptoms and MACE confirmed on either 24 hr urine free cortisol (UFC), late night salivary cortisol and/or abnormal dexamethasone suppression\n\nElagolix: Patients will be given Elagolix 200 mg orally twice daily for a total of 6 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "136.5", "spread": "51.9"}]}]}, {"title": "6 months", "categories": [{"measurements": [{"groupId": "OG000", "value": "126.75", "spread": "41.6"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Vertebral Fractures", "description": "Number of participants with vertebral fractures to measure rates will be assessed by lateral X-rays of thoracic and lumbar spine.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "baseline and 6 months", "groups": [{"id": "OG000", "title": "GnRH Antagonist (Elagolix)", "description": "Post-menopausal women with benign appearing adrenal adenomas, absence of clinical features of overt Cushing's signs or symptoms and MACE confirmed on either 24 hr urine free cortisol (UFC), late night salivary cortisol and/or abnormal dexamethasone suppression\n\nElagolix: Patients will be given Elagolix 200 mg orally twice daily for a total of 6 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "6 months", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "The Cushing's Quality of Life Questionnaire", "description": "The Cushing's Quality of Life Questionnaire is converted to a 0-100 scale in which 0 indicates the worse and 100 the best possible quality of life.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "baseline and 6 months", "groups": [{"id": "OG000", "title": "GnRH Antagonist (Elagolix)", "description": "Post-menopausal women with benign appearing adrenal adenomas, absence of clinical features of overt Cushing's signs or symptoms and MACE confirmed on either 24 hr urine free cortisol (UFC), late night salivary cortisol and/or abnormal dexamethasone suppression\n\nElagolix: Patients will be given Elagolix 200 mg orally twice daily for a total of 6 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}]}], "classes": [{"title": "baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "70", "spread": "9.2"}]}]}, {"title": "6 months", "categories": [{"measurements": [{"groupId": "OG000", "value": "83", "spread": "7.0"}]}]}]}, {"type": "SECONDARY", "title": "Beck's Depression Scale", "description": "Beck's Depression Scale is scored on a scale of 1 to 40, where the higher score indicates severe or extreme depression.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "baseline and 6 months", "groups": [{"id": "OG000", "title": "GnRH Antagonist (Elagolix)", "description": "Post-menopausal women with benign appearing adrenal adenomas, absence of clinical features of overt Cushing's signs or symptoms and MACE confirmed on either 24 hr urine free cortisol (UFC), late night salivary cortisol and/or abnormal dexamethasone suppression\n\nElagolix: Patients will be given Elagolix 200 mg orally twice daily for a total of 6 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}]}], "classes": [{"title": "baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "29", "spread": "10.1"}]}]}, {"title": "6 months", "categories": [{"measurements": [{"groupId": "OG000", "value": "22", "spread": "8.3"}]}]}]}, {"type": "SECONDARY", "title": "State Trait Anxiety Inventory (STAI)", "description": "The State Trait Anxiety Inventory gives a score range from 6-24 with the higher score indicating a higher level of anxiety.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "baseline and 6 months", "groups": [{"id": "OG000", "title": "GnRH Antagonist (Elagolix)", "description": "Post-menopausal women with benign appearing adrenal adenomas, absence of clinical features of overt Cushing's signs or symptoms and MACE confirmed on either 24 hr urine free cortisol (UFC), late night salivary cortisol and/or abnormal dexamethasone suppression\n\nElagolix: Patients will be given Elagolix 200 mg orally twice daily for a total of 6 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}]}], "classes": [{"title": "baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "17", "spread": "5.4"}]}]}, {"title": "6 months", "categories": [{"measurements": [{"groupId": "OG000", "value": "12", "spread": "3.8"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "6 months", "description": "There were no adverse events.", "eventGroups": [{"id": "EG000", "title": "GnRH Antagonist (Elagolix)", "description": "Post-menopausal women with benign appearing adrenal adenomas, absence of clinical features of overt Cushing's signs or symptoms and MACE confirmed on either 24 hr urine free cortisol (UFC), late night salivary cortisol and/or abnormal dexamethasone suppression\n\nElagolix: Patients will be given Elagolix 200 mg orally twice daily for a total of 6 months", "deathsNumAffected": 0, "deathsNumAtRisk": 4, "seriousNumAffected": 0, "seriousNumAtRisk": 4, "otherNumAffected": 0, "otherNumAtRisk": 4}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "Dr. Alice C. Levine", "organization": "Icahn School of Medicine at Mount Sinai", "email": "alice.levine@mountsinai.org", "phone": "(212) 241-3422"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2018-08-02", "uploadDate": "2024-12-02T17:03", "filename": "Prot_SAP_000.pdf", "size": 522888}, {"typeAbbrev": "ICF", "hasProtocol": false, "hasSap": false, "hasIcf": true, "label": "Informed Consent Form", "date": "2023-03-01", "uploadDate": "2024-12-02T15:18", "filename": "ICF_001.pdf", "size": 266204}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04", "submissionTracking": {"firstMcpInfo": {"postDateStruct": {"date": "2025-03-06", "type": "ACTUAL"}}}}, "interventionBrowseModule": {"meshes": [{"id": "C539351", "term": "elagolix"}]}}, "hasResults": true}, {"protocolSection": {"identificationModule": {"nctId": "NCT01880918", "orgStudyIdInfo": {"id": "RETROPRESS, CLPR-43-11-01"}, "organization": {"fullName": "novoGI", "class": "INDUSTRY"}, "briefTitle": "A RETROspective Data Collection of comPRESSion Anastomosis Using the ColonRing", "officialTitle": "Multi Center, Observational, Retrospective Data Collection of Patients Treated With the ColonRing in Routine Clinical Practice. This Study to Continue RETROPRESS Study ID NCT01301417"}, "statusModule": {"statusVerifiedDate": "2013-06", "overallStatus": "UNKNOWN", "lastKnownStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-10"}, "primaryCompletionDateStruct": {"date": "2013-06", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2013-07", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2013-06-16", "studyFirstSubmitQcDate": "2013-06-16", "studyFirstPostDateStruct": {"date": "2013-06-19", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2013-06-16", "lastUpdatePostDateStruct": {"date": "2013-06-19", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "novoGI", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The proposed study is a post marketing, observational, retrospective data collection intended to gather and record data on patients treated with the ColonRing device in routine clinical practice at 4-6 centers. The data will assist in future evaluating the performance of the ColonRing device in regards to the creation of a colorectal anastomosis in Low Anterior Resection procedures.\n\nHypothesis: The performance of the ColonRing, determined by the rate of complications, will be within the acceptable range reported in the literature for alternative treatment modalities."}, "conditionsModule": {"conditions": ["Diverticulum, Colon", "Colorectal Neoplasms", "Crohn Disease", "Colitis, Ulcerative", "Colostomy", "Ileostomy - Stoma", "Rectal Prolapse", "Intestinal Polyposis", "Lymphoma", "Endometriosis", "Intestinal Volvulus"], "keywords": ["Compression Anastomosis"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"timePerspective": "RETROSPECTIVE"}, "enrollmentInfo": {"count": 200, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "ColonRing", "description": "The ColonRing device is intended to be used for the creation of intestinal anastomoses in colorectal surgery in both open and laparoscopic surgeries. This indication is within the currently cleared indication of the ColonRing device, which has been cleared by the US FDA and carries the CE Mark for use throughout the alimentary trct for the creation of circular end-to-end, side-to-end or side-to-side anastomosis."}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "The rate of anastomotic leakage.", "description": "Anastomotic leakage is defined as evidence of a defect in the intestinal wall integrity at the anastomotic site leading to a communication between the intra and extra luminal compartments.", "timeFrame": "6 weeks after the procedure"}], "secondaryOutcomes": [{"measure": "Rate of other device related complications and measures during hospitalization and post procedure.", "description": "The Following complications will be examined:\n\nBleeding. Stricture (either clinical evidence of a stricture or the inability to pass a 12 mm sigmoidoscope through the anastomosis in a procedure that does not include a diversion). Septic complication (including wound infection, pelvic infection, peritonitis, abscess) Readmission, re-operation, death within two months of the procedure Extra colonic complications (including urinary infection, urinary retention, DVT, pneumonitis, pulmonary embolism, cardiac, injury to other organs - e.g. spleen, ureter)\n\nThe following post operative measures will be reported:\n\nHospitalization duration (two dates will be recorded: ready for discharge and discharge). The latter noting where the patient was discharged to - e.g. nursing home or home. First day to first postoperative flatus. First day to first postoperative bowel movements. First day of first postoperative toleration of liquids and solids (time to \"keeping them down\")", "timeFrame": "6 weeks after the procedure."}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Patient was \\> 18 years old at time of procedure\n2. Patient underwent a technically successful open or laparoscopic colorectal, Low Anterior Resection procedure with the creation of an anastomosis using the ColonRing™\n3. Patient treated in routine clinical practice\n4. Patient underwent his/her first follow-up visit within two months post-surgery\n\nExclusion Criteria:\n\nNo exclusion criteria have been defined for this data collection.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"], "studyPopulation": "Adult patients who underwent a laparoscopic or open Low Anterior resection with the creation of an anastomosis using the ColonRing in routine clinical practice.", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"locations": [{"facility": "Florida Hospital, Center for Colon & Rectal Surgery", "status": "RECRUITING", "city": "Atlamonte Springs", "state": "Florida", "zip": "32701", "country": "United States", "contacts": [{"name": "Dr. Matthew Albert, MD", "role": "CONTACT", "phone": "407-303-5191"}, {"name": "Leslee Cunnion", "role": "CONTACT", "phone": "407-303-5191", "email": "Leslee.Cunnion@flhosp.org"}, {"name": "Dr. Matthew Albert, MD", "role": "PRINCIPAL_INVESTIGATOR"}]}, {"facility": "18308 Murdock Circle, Suite 108", "status": "RECRUITING", "city": "Port Charlotte", "state": "Florida", "country": "United States", "contacts": [{"name": "Dr. Domingo E. Galliano Jr., MD", "role": "CONTACT", "phone": "941-625-3411", "email": "office@gallianosurgery.com"}, {"name": "Kathleen Lueck", "role": "CONTACT"}, {"name": "Dr. Domingo E. Galiano Jr., MD", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 26.97617, "lon": -82.09064}}, {"facility": "CoxHealth Hospital, Colorectal Department", "status": "RECRUITING", "city": "Springfield", "state": "Missouri", "zip": "65807", "country": "United States", "contacts": [{"name": "Dr. Jose Dominguez, MD", "role": "CONTACT", "phone": "417-875-3211"}, {"name": "Kami Oster", "role": "CONTACT", "phone": "417- 875-3211", "email": "Kami.Oster@coxhealth.com"}, {"name": "Dr. Jose Dominguez, MD", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 37.21533, "lon": -93.29824}}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004241", "term": "Diverticulum, Colon"}, {"id": "D015179", "term": "Colorectal Neoplasms"}, {"id": "D003424", "term": "Crohn Disease"}, {"id": "D003093", "term": "Colitis, Ulcerative"}, {"id": "D012005", "term": "Rectal Prolapse"}, {"id": "D044483", "term": "Intestinal Polyposis"}, {"id": "D008223", "term": "Lymphoma"}, {"id": "D004715", "term": "Endometriosis"}, {"id": "D045822", "term": "Intestinal Volvulus"}], "ancestors": [{"id": "D004240", "term": "Diverticulum"}, {"id": "D000076385", "term": "Diverticular Diseases"}, {"id": "D005759", "term": "Gastroenteritis"}, {"id": "D005767", "term": "Gastrointestinal Diseases"}, {"id": "D004066", "term": "Digestive System Diseases"}, {"id": "D020763", "term": "Pathological Conditions, Anatomical"}, {"id": "D013568", "term": "Pathological Conditions, Signs and Symptoms"}, {"id": "D007414", "term": "Intestinal Neoplasms"}, {"id": "D005770", "term": "Gastrointestinal Neoplasms"}, {"id": "D004067", "term": "Digestive System Neoplasms"}, {"id": "D009371", "term": "Neoplasms by Site"}, {"id": "D009369", "term": "Neoplasms"}, {"id": "D003108", "term": "Colonic Diseases"}, {"id": "D007410", "term": "Intestinal Diseases"}, {"id": "D012002", "term": "Rectal Diseases"}, {"id": "D015212", "term": "Inflammatory Bowel Diseases"}, {"id": "D003092", "term": "Colitis"}, {"id": "D056887", "term": "Pelvic Organ Prolapse"}, {"id": "D011391", "term": "Prolapse"}, {"id": "D009370", "term": "Neoplasms by Histologic Type"}, {"id": "D008232", "term": "Lymphoproliferative Disorders"}, {"id": "D008206", "term": "Lymphatic Diseases"}, {"id": "D006425", "term": "Hemic and Lymphatic Diseases"}, {"id": "D007160", "term": "Immunoproliferative Disorders"}, {"id": "D007154", "term": "Immune System Diseases"}, {"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}, {"id": "D007415", "term": "Intestinal Obstruction"}, {"id": "D014102", "term": "Torsion Abnormality"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT05528601", "orgStudyIdInfo": {"id": "Pre ELEA"}, "organization": {"fullName": "University Hospital Muenster", "class": "OTHER"}, "briefTitle": "Influence of an App on Quality of Life of Women With Endometriosis", "officialTitle": "Observational Study on the Influence of an App-based Self-management Program on the Quality of Life of Women With Endometriosis", "acronym": "pre ELEA"}, "statusModule": {"statusVerifiedDate": "2022-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2022-01-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2022-01-15", "type": "ACTUAL"}, "completionDateStruct": {"date": "2022-01-30", "type": "ACTUAL"}, "studyFirstSubmitDate": "2022-08-18", "studyFirstSubmitQcDate": "2022-08-31", "studyFirstPostDateStruct": {"date": "2022-09-06", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2022-08-31", "lastUpdatePostDateStruct": {"date": "2022-09-06", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Dr. med. Sebastian Daniel Schäfer", "investigatorTitle": "PI", "investigatorAffiliation": "University Hospital Muenster"}, "leadSponsor": {"name": "University Hospital Muenster", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "Comparison of quality of life before and after 14 days of use of Endo App® in endometriosis patients compared to non-users", "detailedDescription": "Introduction: Endometriosis can significantly impair the quality of life of those affected. Multimodal self-help measures are recommended but often difficult to access. Smartphone apps have been shown to improve quality of life for other conditions with chronic pain. The aim of this study was to examine whether there is evidence of beneficial effects of the Endo-App and whether a multicenter randomized controlled trial should be planned to substantiate these effects.\n\nMethods: In a sample of N=106 women affected by endometriosis the present study determined the influence of the use of a smartphone app (Endo-App ®) on their quality of life. Among others, the validated questionnaire Endometriosis Health Profile from Oxford University was used for this purpose."}, "conditionsModule": {"conditions": ["Endometriosis", "Quality of Life"], "keywords": ["endometriosis", "quality of life", "smartphone application"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "NON_RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": "two arm study", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 106, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "users", "type": "EXPERIMENTAL", "description": "app users", "interventionNames": ["Behavioral: use of Endo App®"]}, {"label": "non-users", "type": "NO_INTERVENTION", "description": "app non-users"}], "interventions": [{"type": "BEHAVIORAL", "name": "use of Endo App®", "description": "use of Endo App® smartphone application containing endometriosis relevant exercises and educational material", "armGroupLabels": ["users"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "quality of life of endometriosis patients", "description": "quality of life measured bei Endometriosis Health Profile 30", "timeFrame": "14 days"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* suffering from endometriosis\n* 18 years or older\n* willing and capable of using a smartphone\n\nExclusion Criteria:\n\n* minor under 18 years\n* endometriosis excluded\n* not capable of using a smartphone", "healthyVolunteers": false, "sex": "FEMALE", "genderBased": true, "genderDescription": "applicable for participants with female body", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "University Hospital Münster Germany", "city": "Münster", "state": "North Rhine-Westphalia", "zip": "48149", "country": "Germany", "geoPoint": {"lat": 51.96236, "lon": 7.62571}}]}, "referencesModule": {"references": [{"pmid": "38869629", "type": "DERIVED", "citation": "Rohloff N, Rothenhofer M, Gotz T, Schafer SD. Observational pilot study on the influence of an app-based self-management program on the quality of life of women with endometriosis. Arch Gynecol Obstet. 2024 Aug;310(2):1157-1170. doi: 10.1007/s00404-024-07468-4. Epub 2024 Jun 13."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT04382911", "orgStudyIdInfo": {"id": "20-0328"}, "organization": {"fullName": "University of North Carolina, Chapel Hill", "class": "OTHER"}, "briefTitle": "Evaluation of Endometriosis With 18F-fluoroestradiol PET / MRI", "officialTitle": "Evaluation of Endometriosis With 18F-fluoroestradiol PET / MRI"}, "statusModule": {"statusVerifiedDate": "2022-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2020-08-07", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2022-07-11", "type": "ACTUAL"}, "completionDateStruct": {"date": "2022-07-11", "type": "ACTUAL"}, "studyFirstSubmitDate": "2020-05-06", "studyFirstSubmitQcDate": "2020-05-06", "studyFirstPostDateStruct": {"date": "2020-05-11", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2022-11-04", "resultsFirstSubmitQcDate": "2023-02-06", "resultsFirstPostDateStruct": {"date": "2023-02-09", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-05-25", "lastUpdatePostDateStruct": {"date": "2023-05-30", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "University of North Carolina, Chapel Hill", "class": "OTHER"}, "collaborators": [{"name": "North Carolina Translational and Clinical Sciences Institute", "class": "OTHER"}]}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "Purpose: The primary objective is to evaluate the sensitivity and specificity of 18F-fluoroestradiol (FES) PET/MRI for evaluating endometriosis.\n\nParticipants: A total of 12 participants will be recruited from individuals with clinically suspected endometriosis who are scheduled for planned operative laparoscopy at the University of North Carolina at Chapel Hill (UNC).\n\nProcedures (methods): This is a prospective, one arm, single center study of 12 subjects with clinically suspected endometriosis to demonstrate FES PET/MR's clinical utility for diagnosis of endometriosis. This study will be an evaluation of the radiotracer, FES, which binds to estrogen receptors and has previously been used to study estrogen receptor expression in tumors, to detect endometriosis. Participants will undergo one FES PET/MR scan within 4 weeks prior to their scheduled surgery. Participants will also complete questionnaires regarding their condition, pain, and quality of life.", "detailedDescription": "This is a prospective, one arm, single center study of 12 subjects with clinically suspected endometriosis to demonstrate FES PET-MRI's clinical utility for diagnosis of endometriosis. The primary objective is to evaluate the sensitivity and specificity of 18F-fluoroestradiol (FES) PET/MRI for evaluating endometriosis. Secondary objectives include comparing PET to conventional MRI, using histopathology from laparotomy as the gold standard and evaluating association of uptake values (SUV-max) with Endometriosis Health profile -30 (EHP-30) and pain rating scales, controlling for covariates."}, "conditionsModule": {"conditions": ["Endometriosis"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "DIAGNOSTIC", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 8, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "18F-fluoroestradiol PET / MRI", "type": "EXPERIMENTAL", "description": "All enrolled subjects will receive the tracer and then have a PET/MRI scan.", "interventionNames": ["Drug: 18F-fluoroestradiol"]}], "interventions": [{"type": "DRUG", "name": "18F-fluoroestradiol", "description": "Patients will receive the FES tracer during a PET/MRI scan", "armGroupLabels": ["18F-fluoroestradiol PET / MRI"], "otherNames": ["FES"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Sensitivity of FES PET/MRI for Evaluating Endometriosis (Percentage of Positive Scans)", "description": "The sensitivity of FES PET /MRI is defined as the ability of readers (radiologists) to detect endometriosis among those with histopathologically identified endometriosis in the entire cohort. Sensitivity is calculated by dividing the number of true cases of endometriosis by the overall number of patients with endometriosis identified using the research imaging. The sensitivity data can only be calculated upon completion of study imaging for all participants.", "timeFrame": "day of scan, up to 2 hours"}, {"measure": "Specificity of FES PET/MRI for Evaluating Endometriosis (Percentage of Negative Scans)", "description": "The specificity of FES PET /MRI is defined as the ability of readers (radiologists) to detect that patients do not have endometriosis divided by the number of participants without endometriosis as defined histopathologically in the entire cohort. Specificity is calculated by dividing the number of true negative cases by the overall number of patients without endometriosis identified using the research imaging. The specificity data can only be calculated upon completion of study imaging for all participants.", "timeFrame": "day of scan, up to 2 hours"}], "secondaryOutcomes": [{"measure": "Correlation of the FES PET/MRI Specificity to Conventional MRI", "description": "The investigators will use McNemar's test, constructing the 2x2 table among all patients with a surgical diagnosis of negative to compare specificity for FES PET/MRI (Outcome Measure 2) versus conventional MRI. The specificity of FES PET /MRI is defined as the ability of readers (radiologists) to detect that patients do not have endometriosis divided by the number of participants without endometriosis as defined histopathologically in the entire cohort. Specificity is calculated by dividing the number of true negative cases by the overall number of patients without endometriosis identified using the research imaging. The specificity data can only be calculated upon completion of study imaging for all participants.", "timeFrame": "day of scan, up to 2 hours"}, {"measure": "Mean Standard Uptake Values (SUV-max) for 18F-fluoroestradiol PET / MRI", "description": "The SUV-max is the maximum standardized uptake value for FES within the tissue.", "timeFrame": "day of scan, up to 2 hours"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Age 18 or older\n* Female of childbearing age\n* Clinically suspected (symptomatic) endometriosis.\n* Scheduled for planned operative laparoscopy with no hormone treatment for at least two cycles\n* Able to provide informed consent or assent\n\nExclusion Criteria:\n\n* Male\n* Institutionalized subject (prisoner or nursing home patient)\n* Known history of breast, ovarian or endometrial cancer.\n* Pregnant or breast-feeding women", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Jorge Oldan, MD", "affiliation": "University of North Carolina, Chapel Hill", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "UNC Hospitals", "city": "Chapel Hill", "state": "North Carolina", "zip": "27599", "country": "United States", "geoPoint": {"lat": 35.9132, "lon": -79.05584}}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Deidentified individual data that supports the results will be shared beginning 9 to 36 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with UNC.", "infoTypes": ["STUDY_PROTOCOL"], "timeFrame": "9 to 36 months following publication", "accessCriteria": "The investigator who proposes to use the data has approval from an IRB, IEC, or REB, as applicable, and an executed data use/sharing agreement with UNC."}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "18F-fluoroestradiol PET / MRI", "description": "All enrolled subjects will receive the tracer and then have a PET/MRI scan. A PET/MRI scan is a two-in-one test that combines images from a positron emission tomography (PET) scan and a magnetic resonance imaging (MRI) scan.\n\n18F-fluoroestradiol (FES): Patients will receive 6 mCi of the FES tracer during a PET/MRI scan"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "8"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}]}], "dropWithdraws": [{"type": "unable to be imaged prior to surgery", "reasons": [{"groupId": "FG000", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "18F-fluoroestradiol PET / MRI", "description": "All enrolled subjects will receive the tracer and then have a PET/MRI scan. A PET/MRI scan is a two-in-one test that combines images from a positron emission tomography (PET) scan and a magnetic resonance imaging (MRI) scan\n\n18F-fluoroestradiol: Patients will receive the FES tracer during a PET/MRI scan"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "8"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "8"}]}], "categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "8"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "8"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "35.3", "spread": "7.7"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "8"}]}], "categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "8"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "8"}]}], "categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "8"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "8"}]}], "categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "1"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "1"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "6"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "United States", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "8"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "8"}]}]}]}, {"title": "Pain Rating Scales (Visual Analog Scale - VAS)", "description": "Individuals will be given a 100mm scale and asked to draw a single vertical line corresponding to the level of pain where 0mm is no pain and 100mm is pain as bad as it possibly could be. This line will be measured and the result will be recorded in mm.", "populationDescription": "One participant did not complete the VAS questionnaire.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mm", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "7"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "11.71", "spread": "25.06"}]}]}]}, {"title": "Endometriosis Health Profile-30 (EHP-30)", "description": "The Endometriosis Health Profile-30 (EHP-30), a quality of life questionnaire used in women with endometriosis, includes questions related to pain, control and powerlessness, social support, emotional wellbeing, and self-image. Each scale is standardized on a scale of 0 - 100, where 0 indicates the best health status through to 100 worst health status. Scale scores for each scale are calculated from the total of the raw scores of each item in the scale divided by the maximum possible raw score of all the items in the scale, multiplied by 100.", "populationDescription": "One participant did not complete the EHP-30 questionnaire", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "units on a scale", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "7"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "40.7", "spread": "28.3"}]}]}]}, {"title": "Body Mass Index (BMI)", "description": "Body Mass Index (BMI) is a person's weight in kilograms (or pounds) divided by the square of height in meters (or feet).", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m^2", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "8"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "26.54", "spread": "4.81"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Sensitivity of FES PET/MRI for Evaluating Endometriosis (Percentage of Positive Scans)", "description": "The sensitivity of FES PET /MRI is defined as the ability of readers (radiologists) to detect endometriosis among those with histopathologically identified endometriosis in the entire cohort. Sensitivity is calculated by dividing the number of true cases of endometriosis by the overall number of patients with endometriosis identified using the research imaging. The sensitivity data can only be calculated upon completion of study imaging for all participants.", "populationDescription": "Two of the 8 enrolled subjects were unable to be imaged and therefore are not included in the analysis.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of positive scans", "timeFrame": "day of scan, up to 2 hours", "typeUnitsAnalyzed": "scans", "denomUnitsSelected": "scans", "groups": [{"id": "OG000", "title": "18F-fluoroestradiol PET / MRI", "description": "All enrolled subjects will receive the tracer and then have a PET/MRI scan. A PET/MRI scan is a two-in-one test that combines images from a positron emission tomography (PET) scan and a magnetic resonance imaging (MRI) scan.\n\n18F-fluoroestradiol: Patients will receive the FES tracer during a PET/MRI scan."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}]}, {"units": "scans", "counts": [{"groupId": "OG000", "value": "6"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "67"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "EQUIVALENCE", "nonInferiorityComment": "A 2x2 table was constructed among all patients with histopathologically identified endometriosis (true positive) to compare sensitivity for FES PET/MRI versus sensitivity of conventional MRI.", "pValue": "0.317", "statisticalMethod": "McNemar"}]}, {"type": "PRIMARY", "title": "Specificity of FES PET/MRI for Evaluating Endometriosis (Percentage of Negative Scans)", "description": "The specificity of FES PET /MRI is defined as the ability of readers (radiologists) to detect that patients do not have endometriosis divided by the number of participants without endometriosis as defined histopathologically in the entire cohort. Specificity is calculated by dividing the number of true negative cases by the overall number of patients without endometriosis identified using the research imaging. The specificity data can only be calculated upon completion of study imaging for all participants.", "populationDescription": "The specificity is undefined since the denominator is 0 as all participants had endometriosis.", "reportingStatus": "POSTED", "timeFrame": "day of scan, up to 2 hours", "groups": [{"id": "OG000", "title": "18F-fluoroestradiol PET / MRI", "description": "All enrolled subjects will receive the tracer and then have a PET/MRI scan. A PET/MRI scan is a two-in-one test that combines images from a positron emission tomography (PET) scan and a magnetic resonance imaging (MRI) scan.\n\n18F-fluoroestradiol: Patients will receive the FES tracer during a PET/MRI scan."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Correlation of the FES PET/MRI Specificity to Conventional MRI", "description": "The investigators will use McNemar's test, constructing the 2x2 table among all patients with a surgical diagnosis of negative to compare specificity for FES PET/MRI (Outcome Measure 2) versus conventional MRI. The specificity of FES PET /MRI is defined as the ability of readers (radiologists) to detect that patients do not have endometriosis divided by the number of participants without endometriosis as defined histopathologically in the entire cohort. Specificity is calculated by dividing the number of true negative cases by the overall number of patients without endometriosis identified using the research imaging. The specificity data can only be calculated upon completion of study imaging for all participants.", "populationDescription": "The specificity is undefined since the denominator is 0 as all participants had endometriosis.", "reportingStatus": "POSTED", "timeFrame": "day of scan, up to 2 hours", "groups": [{"id": "OG000", "title": "18F-fluoroestradiol PET / MRI", "description": "All enrolled subjects will receive the tracer and then have a PET/MRI scan. A PET/MRI scan is a two-in-one test that combines images from a positron emission tomography (PET) scan and a magnetic resonance imaging (MRI) scan.\n\n18F-fluoroestradiol: Patients will receive the FES tracer during a PET/MRI scan."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Mean Standard Uptake Values (SUV-max) for 18F-fluoroestradiol PET / MRI", "description": "The SUV-max is the maximum standardized uptake value for FES within the tissue.", "populationDescription": "Two of the eight enrolled subjects were unable to be imaged and therefore are not included in the analysis because SUV-max can only be determined using the research scan.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "SUV-max", "timeFrame": "day of scan, up to 2 hours", "typeUnitsAnalyzed": "scans", "denomUnitsSelected": "scans", "groups": [{"id": "OG000", "title": "18F-fluoroestradiol PET / MRI", "description": "All enrolled subjects will receive the tracer and then have a PET/MRI scan. A PET/MRI scan is a two-in-one test that combines images from a positron emission tomography (PET) scan and a magnetic resonance imaging (MRI) scan.\n\n18F-fluoroestradiol: Patients will receive the FES tracer during a PET/MRI scan."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}]}, {"units": "scans", "counts": [{"groupId": "OG000", "value": "6"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.23", "spread": "3.04"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "nonInferiorityComment": "A random effects linear regression model, modeling SUV-max as a function of the pain rating, while controlling for patient-level covariates (BMI, race, age) was performed. The investigators included physician as a random effect to account for physician-level correlation.", "pValue": "0.24", "statisticalMethod": "Pearson's Correlation Coefficient", "paramType": "Slope", "paramValue": "0.748", "ciNumSides": "TWO_SIDED"}, {"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "nonInferiorityComment": "The investigators will implement a random effects linear regression model, modeling SUV-max as a function of EHP-30, while controlling for patient-level covariates (BMI, race, age). The investigators will include physician as a random effect to account for physician-level correlation.", "pValue": "0.13", "statisticalMethod": "Mixed Models Analysis", "paramType": "Slope", "paramValue": "0.406", "ciNumSides": "TWO_SIDED"}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Assessed for 24 hours following the imaging procedure.", "eventGroups": [{"id": "EG000", "title": "18F-fluoroestradiol PET / MRI", "description": "All enrolled subjects will receive the tracer and then have a PET/MRI scan. A PET/MRI scan is a two-in-one test that combines images from a positron emission tomography (PET) scan and a magnetic resonance imaging (MRI) scan\n\n18F-fluoroestradiol: Patients will receive the FES tracer during a PET/MRI scan", "deathsNumAffected": 0, "deathsNumAtRisk": 6, "seriousNumAffected": 0, "seriousNumAtRisk": 6, "otherNumAffected": 2, "otherNumAtRisk": 6}], "otherEvents": [{"term": "Fatigue", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Patient reported fatigue lasting 4 hours following the procedure.", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}]}, {"term": "Change in smell", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Subject reported change in smell for 4 hours, which was determined to be unrelated.", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}]}, {"term": "headache", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Patient reported a headache that resolved, which was determined to be unrelated.", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "Director, Clinical Research, Department of Radiology", "organization": "University of North Carolina at Chapel Hill", "email": "rad_research@med.unc.edu", "phone": "919-966-4997"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2020-08-27", "uploadDate": "2022-11-02T16:01", "filename": "Prot_SAP_000.pdf", "size": 502332}, {"typeAbbrev": "ICF", "hasProtocol": false, "hasSap": false, "hasIcf": true, "label": "Informed Consent Form", "date": "2021-03-15", "uploadDate": "2023-05-25T15:32", "filename": "ICF_001.pdf", "size": 260967}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04", "submissionTracking": {"firstMcpInfo": {"postDateStruct": {"date": "2022-12-05", "type": "ACTUAL"}}}}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}}, "hasResults": true}, {"protocolSection": {"identificationModule": {"nctId": "NCT06802900", "orgStudyIdInfo": {"id": "E-96317027-514.10-253796352"}, "secondaryIdInfos": [{"id": "E-96317027-514.10-253796352", "type": "OTHER", "domain": "Basaksehir Cam ve Sakura City Hospital"}], "organization": {"fullName": "Başakşehir Çam & Sakura City Hospital", "class": "OTHER_GOV"}, "briefTitle": "Uterine Skeletonization for Deep Infiltrative Endometriosis (DIE) Hysterectomy", "officialTitle": "Assessment of Surgical Techniques and Clinical Outcomes in Patients Undergoing Nerve-Sparing Modified Radical Hysterectomy with Uterine Skeletonization for Deep Infiltrative Endometriosis (DIE)\"", "acronym": "SKELETONDIE"}, "statusModule": {"statusVerifiedDate": "2025-01", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2022-10-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2024-09-17", "type": "ACTUAL"}, "completionDateStruct": {"date": "2024-09-17", "type": "ACTUAL"}, "studyFirstSubmitDate": "2025-01-10", "studyFirstSubmitQcDate": "2025-01-26", "studyFirstPostDateStruct": {"date": "2025-01-31", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2025-01-26", "lastUpdatePostDateStruct": {"date": "2025-01-31", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Baris KAYA", "investigatorTitle": "Associate Professor", "investigatorAffiliation": "Başakşehir Çam & Sakura City Hospital"}, "leadSponsor": {"name": "Başakşehir Çam & Sakura City Hospital", "class": "OTHER_GOV"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false, "isUsExport": false}, "descriptionModule": {"briefSummary": "Endometriosis is characterized by the presence of endometrial glands and stroma outside the uterine cavity, accompanied by chronic inflammation. The most common locations of endometriosis are the ovaries, ovarian fossae, uterosacral ligaments, and the posterior cul-de-sac. Endometriosis lesions may be superficial, ovarian, or deeply infiltrative. Lesions that invade the rectovaginal space and/or the bowel are defined as deep infiltrative endometriosis (DIE). The invasive nature of these implants can lead to infertility, severe menstrual pain (dysmenorrhea), pain during intercourse (dyspareunia), and chronic pelvic pain. In cases of bowel involvement, symptoms such as constipation, painful defecation, and rectal bleeding may occur. When the urinary system is affected, patients may experience painful urination, hematuria, urinary dysfunction, and, in severe cases, renal loss due to ureteral obstruction.Treatment options vary depending on the severity and localization of the disease, the patient's desire for fertility, and their age. Treatment can include medical therapy, surgical therapy, or a combination of both. Surgical approaches to DIE can be conservative or definitive. Conservative surgery involves the removal of symptomatic endometriotic lesions without damaging surrounding structures. Definitive surgery typically includes hysterectomy with bilateral salpingo-oophorectomy and the excision of symptomatic lesions in other areas (e.g., peritoneum, bowel), often described as a radical hysterectomy. Here in this study, the hospital records of the patients who underwent modified radical nerve sapring hysterectomy for deeply infiltrating endometriosis by the gynecologist Baris Kaya,MD will be evaluated. The demographic and clinical characteristics of patients who underwent hysterectomy for endometriosis at our hospital's endometriosis clinic will be retrospectively analyzed. The diagnosis of these patients was already established through routine pelvic examination, transvaginal ultrasonography, and MRI at the endometriosis clinic of Basaksehir Cam ve Sakura City Hospital.", "detailedDescription": "The aim of this study is to contribute to the literature by evaluating the surgical features, intraoperative complications, and postoperative outcomes of patients undergoing nerve-sparing hysterectomy due to endometriosis. Steps of the modified radical hysterectomy for deeply infiltrating endometriosis with uterine skeletonization technique will be clearly stated, Data on patients' age, body mass index (BMI), known comorbidities, mode and number of deliveries, and previous surgeries will be collected, along with preoperative medical treatments. Visual analog scale (VAS) scores for dysmenorrhea, dyspareunia, dysuria, dyschezia, and chronic pelvic pain will be obtained from the HBYS system or patient files. Preoperative imaging findings, including ultrasonography, computed tomography (CT), and MRI, will be reviewed. Surgical data such as operation duration, surgical type (e.g., hysterectomy + salpingo-oophorectomy, excision of parametrial, rectovaginal, or vaginal nodules, and bowel resections), and intraoperative complications (organ injuries, blood transfusions, conversion to open surgery) will be recorded. ENZIAN scores according to the surgical findings will be stated. Early and late postoperative complications (fever, deep vein thrombosis, sepsis, pelvic abscess, genitourinary fistulas, anastomotic leaks, reoperation, vaginal cuff bleeding or abscess, and bladder dysfunction) will also be evaluated according to Clavien-Dindo Clasification. Pathological examination results of the excised specimens will be included."}, "conditionsModule": {"conditions": ["Deep Infiltrating Endometriosis (DIE)", "Nerve Sparing Modified Radical Hysterectomy", "Uterine Skeletonization"], "keywords": ["Deep Infiltrating Endometriosis (DIE)", "Nerve sparing modified radical hysterectomy", "Uterine skeletonization"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "interventionModelDescription": "Retrospective analysis of the prospectively collected data of the surgical technique, intraoperative and postoperative clinical outcomes and complications", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 75, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "\"Evaluation of Uterine Skeletonization-Based Nerve-Sparing Modified Radical Hysterectomy in Deep Inf", "type": "OTHER", "description": "Data on patients' demographics, preoperative treatments, imaging findings (ultrasound, CT, MRI), and surgical details (duration, type, complications) will be collected. Postoperative complications and pathological results of excised specimens will also be evaluated.", "interventionNames": ["Procedure: Clinical Outcomes and Surgical Insights from Nerve-Sparing Hysterectomy with Uterine Skeletonization for Deep Infiltrative Endometriosis"]}], "interventions": [{"type": "PROCEDURE", "name": "Clinical Outcomes and Surgical Insights from Nerve-Sparing Hysterectomy with Uterine Skeletonization for Deep Infiltrative Endometriosis", "description": "In this retrospective study, the patents whom underwent nerve sparing modified radical hysterectomy for deeply infiltrating endometriosis with uterine skeletonization technique will be reviewed. The uterine skeletonization technique was developed by the princible investigator (BK) for DIE modified radical hsyterectomy and performed systematically in Basaksehir Cam ve Sakura City Hospital. The detailed surgical steps, surgical data such as operation duration, surgical type (e.g., hysterectomy + salpingo-oophorectomy, excision of parametrial, rectovaginal, or vaginal nodules, and bowel resections), and intraoperative complications (organ injuries, blood transfusions, conversion to open surgery) will be recorded. Early and late postoperative complications (fever, deep vein thrombosis, sepsis, pelvic abscess, genitourinary fistulas, anastomotic leaks, reoperation, vaginal cuff bleeding or abscess, and bladder dysfunction) will also be evaluated.", "armGroupLabels": ["\"Evaluation of Uterine Skeletonization-Based Nerve-Sparing Modified Radical Hysterectomy in Deep Inf"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "1.Surgical features of the Modified Radical Hysterectomy for DIE with Uterine Sketelonization", "description": "Surgical data such as detailed anatomical surgical steps of the surgery, surgery type (e.g., hysterectomy + salpingo-oophorectomy, excision of parametrial, rectovaginal, or vaginal nodules, and bowel resections)", "timeFrame": "From placing the laparoscopic trocars to the end of the surgery"}, {"measure": "Duration of operation", "description": "Duration of the laparascopic deep infiltrating hysterectomy with uterine skeletonization will be stated which was recorded as minute.", "timeFrame": "From placing the laparoscopic trocars to the end of the surgery"}, {"measure": "Intraoperative complications", "description": "Complications during surgery for deep infiltrating surgery such as bladder, ureter, bowel and nerve injuries will be reviewed.", "timeFrame": "From placing the laparoscopic trocars to the end of the surgery"}], "secondaryOutcomes": [{"measure": "Postoperative complications", "description": "Postoperative complications following surgery of the deep infiltrative endometriosis hysterectomy.\n\nSurgical site infections (SSI), urinary tract infections, or pelvic abscesses. Urogenital or rectovaginal fistulas following surgery. Vaginal Cuff Dehiscence, thromboembolic Events, Bladder or bowel dysfunction due to hypogastric and/or pelvic splanchnic nerve damages. These will also be stated as Clavien Dindo classification.", "timeFrame": "From enrollment to the end of treatment at 12 weeks"}], "otherOutcomes": [{"measure": "Age of the patients", "description": "Patients' age in years will be collected.", "timeFrame": "From enrollment to the end of treatment at 8 weeks"}, {"measure": "Patients' weight", "description": "Patients' weight in kilograms will be collected.", "timeFrame": "From enrollment to the end of treatment at 8 weeks"}, {"measure": "Patients' height", "description": "Patients' height will be stated as meters obtained from medical records.", "timeFrame": "From enrollment to the end of treatment at 8 weeks"}, {"measure": "Patients' BMI", "description": "Body mass index of the patients will be calculated by weight (kg) and height (meter) will be combined to report BMI in kg/m\\^2", "timeFrame": "From enrollment to the end of treatment at 8 weeks"}, {"measure": "Patients' Medical History", "description": "Known comorbidities, mode and number of deliveries, and previous surgeries will be collected, along with preoperative medical treatments from medical records .", "timeFrame": "From enrollment to the end of treatment at 8 weeks"}, {"measure": "Preoperative Imaging", "description": "Preoperative imaging findings, including ultrasonography, computed tomography (CT), and Magnetic Resonance Imaging (MRI) reports, will be reviewed.", "timeFrame": "From enrollment to the end of treatment at 8 weeks"}, {"measure": "Visual analog scale (VAS) scores", "description": "Visual analog scale (VAS) scores for dysmenorrhea, dyspareunia, dysuria, dyschezia, and chronic pelvic pain before and after the surgery will be obtained from the hospital records and patient files.", "timeFrame": "From enrollment to the end of treatment at 12 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\nPatients Aged 30-50\n\nPatients with severe dysmenorrhea (VAS\\>7) dyspareunia (VAS\\>7), and /or diskhezia and/or chronic pelvic pain\n\nPatients with deep infiltrating endometriosis who are unresponsive to medical treatment\n\nOnly patients who underwent nerve sparing hysterectomy by the principal investigator (BK)\n\nExclusion Criteria:\n\nPatients under 30 or over 50 years of age. Patients who did not undergo nerve-sparing hysterectomy or salpingo-oophorectomy.\n\nPatients with incomplete medical records or missing preoperative imaging data. Patients with a history of pelvic or abdominal malignancy. Patients with significant comorbidities such as advanced cardiovascular or respiratory diseases that may affect surgical outcomes.\n\nPatients who responded positively to medical treatment and did not require surgical intervention.\n\nPatients diagnosed with bowel, bladder, or rectovaginal fistulas unrelated to endometriosis.\n\nPatients undergoing emergency surgeries unrelated to endometriosis. Patients unwilling to provide consent for their data to be used in the study.\n\n\\-", "healthyVolunteers": false, "sex": "FEMALE", "genderBased": true, "genderDescription": "endometriosis is a disease of biologically female gender", "minimumAge": "30 Years", "maximumAge": "55 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Baris Kaya, Associate Professor", "affiliation": "Başakşehir Çam & Sakura City Hospital", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Basaksehir Cam ve Sakura City Hospital", "city": "Istanbul", "zip": "34480", "country": "Turkey (Türkiye)", "geoPoint": {"lat": 41.01384, "lon": 28.94966}}]}, "referencesModule": {"references": [{"pmid": "32963921", "type": "BACKGROUND", "citation": "Nezhat C, Nguyen K, Ackroyd E, Roman RA, Rambhatla A, Nezhat A, Asiaii A. Nerve-Sparing Modified Radical Hysterectomy for Severe Endometriosis and Complex Pelvic Pathology. Cureus. 2020 Aug 19;12(8):e9882. doi: 10.7759/cureus.9882."}, {"pmid": "35781108", "type": "BACKGROUND", "citation": "Rosati A, Pavone M, Campolo F, De Cicco Nardone A, Raimondo D, Serracchioli R, Scambia G, Ianieri MM. Surgical and functional impact of nerve-sparing radical hysterectomy for parametrial deep endometriosis: a single centre experience. Facts Views Vis Obgyn. 2022 Jun;14(2):121-127. doi: 10.52054/FVVO.14.2.016."}, {"pmid": "31326949", "type": "BACKGROUND", "citation": "Muallem MZ, Diab Y, Sehouli J, Fujii S. Nerve-sparing radical hysterectomy: steps to standardize surgical technique. Int J Gynecol Cancer. 2019 Sep;29(7):1203-1208. doi: 10.1136/ijgc-2019-000410. Epub 2019 Jul 19."}, {"pmid": "27951614", "type": "BACKGROUND", "citation": "Darwish B, Roman H. Nerve Sparing and Surgery for Deep Infiltrating Endometriosis: Pessimism of the Intellect or Optimism of the Will. Semin Reprod Med. 2017 Jan;35(1):72-80. doi: 10.1055/s-0036-1597305. Epub 2016 Dec 12."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO", "description": "\"Individual Participant Data (IPD) will not be shared due to privacy and confidentiality concerns. Additionally, resource limitations prevent proper preparation and documentation of IPD for external sharing.\""}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT07144904", "orgStudyIdInfo": {"id": "H-57801"}, "organization": {"fullName": "Baylor College of Medicine", "class": "OTHER"}, "briefTitle": "Assessing the Efficacy of Indocyanine Green for Ureter Identification During Robot-Assisted Surgery in Advanced-Stage Endometriosis", "officialTitle": "A Side-Randomized, Self-Controlled Trial Assessing the Efficacy of Indocyanine Green Fluorescence Imaging for Intraoperative Ureter Identification During Robot-Assisted Single-Site Surgery in Advanced-Stage Endometriosis"}, "statusModule": {"statusVerifiedDate": "2025-08", "overallStatus": "NOT_YET_RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2025-10-01", "type": "ESTIMATED"}, "primaryCompletionDateStruct": {"date": "2026-02-01", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2026-03-15", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2025-08-14", "studyFirstSubmitQcDate": "2025-08-20", "studyFirstPostDateStruct": {"date": "2025-08-28", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2025-08-20", "lastUpdatePostDateStruct": {"date": "2025-08-28", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "XIAOMING GUAN", "investigatorTitle": "Division Chief of Minimally Invasive Gynecologic Surgery", "investigatorAffiliation": "Baylor College of Medicine"}, "leadSponsor": {"name": "Baylor College of Medicine", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false, "isUsExport": false}, "descriptionModule": {"briefSummary": "The goal of this side-randomized, self-controlled trial, 1-site study is to explore the efficacy of Indocyanine Green Fluorescence (ICG) for Intraoperative Ureter Identification During Robot-Assisted Single-Site Surgery in Advanced-Stage Endometriosis.\n\nResearchers will perform temporary ureteral stent using indocyanine green fluorescence for intraoperative ureteral identification on either the left or right side of subjects who are undergoing a robotic assisted transumbilical resection of advanced endometriosis.\n\nParticipants will be randomized to receive ICG-assisted ureteral identification on either the left or right side. Randomization will be conducted using a computer-generated block randomization method.\n\nThe primary aim is to determine whether ICG-assisted ureter visualization can reduce operative time for endometriosis resection and ureterolysis, and minimize the risk of ureteral injury.\n\nSecondary objectives are to assess the feasibility and safety of temporary ureteral ICG stenting for intraoperative ureter identification in advanced endometriosis.", "detailedDescription": "Clinic schedules will be screened for possible surgical candidates by the attending surgeons, fellow, and research assistant. Patients will be recruited from the minimally invasive gynecologic surgery clinics of Dr. Guan. Patients who are meet the inclusion and exclusion criteria will undergo recruitment and be offered to participate in the research study. The research study will be introduced by the surgeon (Dr. Guan) during their pre-operative consultation. If the patient is interested in hearing more about the study and possibly participating, then the investigators will interact with the patient in order to explain the study in detail, answer questions, and obtain informed consent. Patients will be able to learn more about the study and provide consent in-person (after their initial surgical consultation is completed but prior to leaving clinic), through remote consent via telephone, or on the day of surgery. This should allow the patient sufficient time to evaluate the risks and benefits of participation and ensure informed consent or informed refusal of participation, minimizing coercion. Participants will be counseled that their consent or refusal to participate will not otherwise alter their routine perioperative care or surgery.\n\nAfter the patient was prepped and draped, a 17F sheathed cystoscope was threaded with a single 5F open-ended 27 cm stent. Twenty-five mg of ICG was diluted with 10 ml of normal saline and placed on the lur-lock of a single open-ended stent. The cystoscope was primed. Time was started once the labia were parted to find the urethra. The cystoscope was advanced into the bladder, and both ureteral openings were visualized before placement of the singular stent. The side randomized by computer to receive ICG was again visualized, and the stent was advanced retrograde to a depth of 15 cm. Five ml of ICG was then injected into the stent. The stent was allowed to sit in the same ureter for 60 seconds before the stent and cystoscope were removed. Once all instruments were removed from the urethra, time was stopped and recorded.\n\nOnce the robot was docked, the camera was positioned to visualize both pelvic sidewalls. At this point, the surgeon remained blinded to the side injected with ICG. Ureter identification was then performed by the both the surgeon and fellows on each side, and the time required to identify each ureter was recorded. After identification, they rated the difficulty of ureteral dissection on each side using a visual analog scale (VAS), where 0 indicated extremely easy and 10 indicated maximal difficulty, based on anatomical complexity and the extent of adhesions.\n\nWhen the surgeon begins pelvic sidewall endometriosis resection, timing will be initiated to record the duration of each step and the total operative time for each side. The side without ICG injection will be addressed first. The procedures will follow a standardized sequence: lysis of adhesions - ureterolysis -endometriosis resection.\n\nFollowing the surgery, the surgeon is required to complete the Surgery Task Load Index (SURG-TLX) for each side.\n\nData regarding the participant's demographics and pre-operative symptoms will be collected through standardized questionnaires administered in clinic that have been validated for use in endometriosis participants. It will also be collected from routine pre-operative data that is standardly recorded in clinical documentation and will be extracted from the electronic medical record (EPIC).\n\nIntra-operative data will be extracted from the electronic medical record (EPIC) or recorded during the OR case by the operating room circulator nurse or research assistant. Post-operative data will be collected from the electronic medical record.\n\nSample Size：Using a paired t-test or Wilcoxon signed-rank test presuming d = 0.5 (a medium Cohen's d effect size), α = 0.05, power = 0.80, and self-control, the total sample size required is 35. Accounting for a 10% dropout, that would be 39 per group. Thus, the investigators will recruit until the investigators have achieved 40 participants per group.\n\nStatistical Analysis: 1. Descriptive statistics were generated. Continuous variables were tested for normality with the Kolmogorov-Smirnov test. Normal distribution variables are shown as mean±standard deviation (SD), with non-normal distribution data described as median \\[inter-quartile range (IQR)\\]. Categorical data are reported as proportions and percentages. 2. Total operative time of each side, and operative time of every procedures, ureter identification time without ICG and VAS score will be compared between two sides using the paired t-test or paired Wilcoxon signed rank test as appropriate. 3. All statistical analysis was carried out using SPSS version 25 (Inc, Chicago, IL, USA). Statistical significance was set at P\\<0.05."}, "conditionsModule": {"conditions": ["Indocyanine Green (ICG)", "Robotic Surgical Procedure", "Deep Infiltrating Endometriosis (DIE)", "Endometriosis Pelvic", "Endometriosis (Diagnosis)", "Endometriosis of the Cul-de-sac", "Ureteral Stent Placement", "Ureteral Injury", "Endometriosis Ovaries"], "keywords": ["ureteral stent placement", "indocyanine green", "endometriosis", "robotic surgery", "ureteral identification"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "interventionModelDescription": "This study will be a side-randomized, self-controlled trial where participant will be randomized to receive ICG-assisted ureteral identification on either the left or right side. Randomization will be conducted using a computer-generated block randomization method. No stratification based on preoperative characteristics is planned.The patient will be blinded to their randomization, and the surgeon will be initially blinded as well. Ureteral ICG stent placement will be performed after anesthesia induction and while the surgeon is scrubbing. The assistant surgeon, surgical staff, research assistants, and statisticians will not be blinded.", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "SINGLE", "maskingDescription": "Participants will be informed that the study involves intraoperative indocyanine green (ICG)-assisted ureter identification and that they will be randomized to receive a temporary ICG ureteral stent on either the left or right side. They will be advised that there is a 50% probability of assignment to either side and that they will remain blinded to their allocation throughout the study. Risks and potential benefits of the procedure will be explained, and written informed consent will be obtained. Each participant will be assigned a unique study number for data de-identification prior to randomization, which will be conducted using a computer-generated sequence in REDCap. The operating surgeon will be informed of the assigned side.", "whoMasked": ["PARTICIPANT"]}}, "enrollmentInfo": {"count": 40, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Arm A: ICG-Assisted Ureteral Identification (Unilateral)", "type": "EXPERIMENTAL", "description": "Participants assigned to this study will undergo intraoperative ureteral identification using indocyanine green (ICG) fluorescence imaging in either left or right side. A temporary ureteral stent will be inserted on the randomized side (left or right) prior to ureterolysis and endometriosis resection. ICG will be administered through the stent to facilitate real-time fluorescence visualization of the ureter during robot-assisted single-site surgery. The contralateral side will serve as the control arm (standard visualization without ICG).", "interventionNames": ["Drug: Indocyanine Green (ICG)-Assisted Ureteral Identification"]}, {"label": "Arm B: Standard Visualization (Contralateral Control)", "type": "ACTIVE_COMPARATOR", "description": "Participants assigned to this study will undergo intraoperative ureteral identification using indocyanine green (ICG) fluorescence imaging in either left or right side. A temporary ureteral stent will be inserted on the randomized side (left or right) prior to ureterolysis and endometriosis resection. ICG will be administered through the stent to facilitate real-time fluorescence visualization of the ureter during robot-assisted single-site surgery. The contralateral side will serve as the control arm (standard visualization without ICG).", "interventionNames": ["Procedure: Standard Ureteral Identification without ICG"]}], "interventions": [{"type": "DRUG", "name": "Indocyanine Green (ICG)-Assisted Ureteral Identification", "description": "A temporary ureteral stent will be placed unilaterally (left or right) prior to robotic procedures in participants undergoing robot-assisted single-site surgery for advanced-stage endometriosis. Indocyanine green (ICG) will be administered through the stent to enable real-time fluorescence imaging for intraoperative ureter identification. The contralateral ureter will be identified using standard visualization techniques without ICG. Side allocation (ICG vs. control) will be determined by computer-generated block randomization.", "armGroupLabels": ["Arm A: ICG-Assisted Ureteral Identification (Unilateral)"]}, {"type": "PROCEDURE", "name": "Standard Ureteral Identification without ICG", "description": "Ureter identification will be performed using standard intraoperative visualization techniques without the use of indocyanine green (ICG) fluorescence imaging. This will be done on the contralateral side to the randomized ICG-assisted ureteral identification during robot-assisted single-site surgery for advanced-stage endometriosis.", "armGroupLabels": ["Arm B: Standard Visualization (Contralateral Control)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Comparison of operative time between the ICG-assisted and standard visualization sides", "description": "Total operative time was calculated for each side, as well as for each individual procedure. The total operative time represents the sum of the operative times for all individual procedures performed.", "timeFrame": "Intraoperative, measured during the surgical procedure on the day of surgery."}], "secondaryOutcomes": [{"measure": "Incidence of ureter or bladder symptoms or complications & Surgical complication rate by Clavien-Dindo classification", "description": "Number and percentage of participants with postoperative ureter or bladder-related symptoms or complications, confirmed by clinical evaluation.Number and percentage of participants experiencing surgical complications, graded according to the Clavien-Dindo classification system.", "timeFrame": "Postoperative, up to 6 weeks after surgery."}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Stage III or IV endometriosis (rASRM classification)\n* Planned robotic transabdominal endometriosis excision with or without hysterectomy.\n\nExclusion Criteria:\n\n\\- Subjects who are part of a vulnerable population will be excluded including those who are prisoners, younger than 18 years old, pregnant, individuals with mental disabilities or cognitive impairment.", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Ann Tims", "role": "CONTACT", "phone": "8328267464", "email": "atims@bcm.edu"}], "overallOfficials": [{"name": "Xiaoming Guan, PhD, MD", "affiliation": "Department Chair of Minimally Invasive Gynecologic Surgery", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Texas Childrens Hospital Pavilion for Women", "city": "Houston", "state": "Texas", "zip": "77030", "country": "United States", "contacts": [{"name": "Xiaoming Guan, PhD, MD", "role": "CONTACT", "phone": "973-330-2602", "email": "guanxiaoming@yahoo.com"}, {"name": "Xiaoming Guan, PhD, MD", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Qiannan Yang, PhD, MD", "role": "SUB_INVESTIGATOR"}], "geoPoint": {"lat": 29.76328, "lon": -95.36327}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}, {"id": "D004194", "term": "Disease"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}, {"id": "D010335", "term": "Pathologic Processes"}, {"id": "D013568", "term": "Pathological Conditions, Signs and Symptoms"}]}, "interventionBrowseModule": {"meshes": [{"id": "D007208", "term": "Indocyanine Green"}], "ancestors": [{"id": "D007211", "term": "Indoles"}, {"id": "D006574", "term": "Heterocyclic Compounds, 2-Ring"}, {"id": "D000072471", "term": "Heterocyclic Compounds, Fused-Ring"}, {"id": "D006571", "term": "Heterocyclic Compounds"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT04081532", "orgStudyIdInfo": {"id": "AC19062"}, "organization": {"fullName": "University of Edinburgh", "class": "OTHER"}, "briefTitle": "The Effectiveness of Laparoscopic Treatment of Superficial Endometriosis for Managing Chronic Pelvic Pain", "officialTitle": "The Effectiveness of Laparoscopic Treatment of Isolated Superficial Peritoneal Endometriosis for Managing Chronic Pelvic Pain in Women: a Randomised Controlled Feasibility Trial", "acronym": "ESPriT1"}, "statusModule": {"statusVerifiedDate": "2024-06", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2019-09-30", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2021-04-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2021-04-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2019-08-15", "studyFirstSubmitQcDate": "2019-09-04", "studyFirstPostDateStruct": {"date": "2019-09-09", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2024-06-11", "lastUpdatePostDateStruct": {"date": "2024-06-13", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "University of Edinburgh", "class": "OTHER"}, "collaborators": [{"name": "NHS Grampian", "class": "OTHER_GOV"}, {"name": "University of Nottingham", "class": "OTHER"}]}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "Endometriosis is a chronic, incurable condition that affects about 10% of women of reproductive age. It is defined as a growth of cells similar to the womb lining outside of the womb in the pelvis, and is associated with chronic pelvic pain, excessive period pain, pain with sexual intercourse and difficulties in getting pregnant. If the disease is found only on the lining of the pelvis it is known as \"superficial peritoneal\" and is usually treated during a laparoscopic surgery by cutting out (excision) or burning off (ablation). However, many women do not find improvement in their symptoms after the surgery and can have complications from the procedure. The aim of this study is to determine if removal of the superficial peritoneal endometriosis improves pain symptoms and quality of life, which method of removal (excision or ablation) is more effective or if surgical removal is of no benefit to the patients and can potentially cause harm. The investigators plan to recruit up to 90 women from four NHS hospitals in Scotland over a period of 12 months. Women who are attending gynaecology departments with pelvic pain who have not previously had a diagnosis of endometriosis via laparoscopy will be approached. Patients will be asked to read an information sheet about the trial. Women who consent to the trial will be randomised during the surgery, if superficial endometriosis is found, to either having the endometriosis removed or not. For this pilot, follow up will be at 3 and 6 months (and obtain permission to continue to follow them up at 12 and 24 months should time and finding permit). Patients who do not consent to take part in the trial will be asked if the investigators can collect data on their demographics and reasons on why they did not wish to take part."}, "conditionsModule": {"conditions": ["Endometriosis", "Pelvic Pain"], "keywords": ["endometriosis", "laparoscopy", "pelvic pain"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "OTHER", "maskingInfo": {"masking": "SINGLE", "maskingDescription": "General Practitioner", "whoMasked": ["PARTICIPANT"]}}, "enrollmentInfo": {"count": 7, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Surgical treatment", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Procedure: surgical removal of superficial peritoneal endometriosis"]}, {"label": "No surgical treatment", "type": "NO_INTERVENTION"}], "interventions": [{"type": "PROCEDURE", "name": "surgical removal of superficial peritoneal endometriosis", "description": "In the active comparator group patients will have endometriosis lesions removed by ablation or excision. Patients randomised to no surgical treatment arm will not have lesions removed and will only be given diagnosis on whether endometriosis was found or not.", "armGroupLabels": ["Surgical treatment"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Proportion of women with suspected SPE undergoing diagnostic laparoscopy that were approached for the study an agreed to randomisation", "description": "The proportion of screened women who are eligible for the trial determined from the screening logs", "timeFrame": "Screening"}], "secondaryOutcomes": [{"measure": "Baseline characteristics of eligible women that agree to be randomised and those that decline participation", "description": "Baseline characteristics including age, social deprivation, ethnicity and duration of pain collected from screened women", "timeFrame": "Screening"}, {"measure": "Proportion of women having laparoscopy for investigation of chronic pelvic pain that are eligible (i.e. have only SPE) for the trial", "description": "The proportion of women undergoing diagnostic laparoscopy who go on to be diagnosed with SPE", "timeFrame": "visit 2 (day of surgery)"}, {"measure": "Effects of treatment and variability in treatment outcomes", "description": "Intraoperative and postoperative complications", "timeFrame": "visit 2 (day of surgery), 30 days post surgery"}, {"measure": "Improvement in quality of life", "description": "Endometriosis Health Profile-30 (EHP-30)", "timeFrame": "30 days post surgery, follow up at 3 and 6 months"}, {"measure": "Improvement in quality of life", "description": "Rome IV criteria", "timeFrame": "day of surgery, follow up at 3 and 6 months"}, {"measure": "Improvement in quality of life", "description": "Pelvic Pain and Urgency/Frequency Patient (PUF) Symptom Scale", "timeFrame": "day of surgery, follow up at 3 and 6 months"}, {"measure": "Improvement in quality of life", "description": "PainDetect TM", "timeFrame": "day of surgery, follow up at 3 and 6 months"}, {"measure": "Improvement in quality of life", "description": "Brief Fatigue Inventory (BFI)", "timeFrame": "day of surgery, follow up at 3 and 6 months"}, {"measure": "Improvement in quality of life", "description": "Pain Catastrophising Questionnaire (PCQ)", "timeFrame": "day of surgery, follow up at 3 and 6 months"}, {"measure": "Improvement in quality of life", "description": "Fibromyalgia Scale", "timeFrame": "day of surgery, follow up at 3 and 6 months"}, {"measure": "Improvement in quality of life", "description": "Measure Yourself Medical Outcome Profile 2 (MYMOP 2)", "timeFrame": "day of surgery, follow up at 3 and 6 months"}, {"measure": "Improvement in quality of life", "description": "Working Productivity and Activity Impairment Questionnaire (WPAIQ)", "timeFrame": "day of surgery, follow up at 3 and 6 months"}, {"measure": "Improvement in quality of life", "description": "EuroQol 5 Dimensions 5 Level Questionnaire (EQ-5D-5L)", "timeFrame": "day of surgery, follow up at 3 and 6 months"}, {"measure": "Effects of treatment and variability in treatment outcomes", "description": "Number of patients who needed analgesia after laparoscopy recorded during follow up.", "timeFrame": "30 days post surgery, follow up at 3 and 6 months"}, {"measure": "Effects of treatment and variability in treatment outcomes", "description": "Number of patients who needed medical management with ovarian suppression after laparoscopy recorded during follow up.", "timeFrame": "30 days post surgery, follow up at 3 and 6 months"}, {"measure": "Effects of treatment and variability in treatment outcomes", "description": "Adverse events (as reported by the participants)", "timeFrame": "Throughout the trial starting from day of surgery until end of followup at 6 months"}, {"measure": "To determine the most acceptable methods of recruitment and assessment tools", "description": "The proportion of completed trial questionnaires", "timeFrame": "Questionnaires collected at Baseline (within a week of surgery), 3 and 6 months follow up"}, {"measure": "To determine the most acceptable methods of assessment tools", "description": "Number of patients who remained blinded for 6 months after the surgery recorded by asking patient if they were told their allocation", "timeFrame": "Throughout the trial until end of follow up at 6 months"}, {"measure": "To determine the most acceptable methods of recruitment, randomisation and assessment tools", "description": "Acceptability of the trial completed at 6 months after surgery will be compared between two arms.", "timeFrame": "6 months follow up"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Undergoing laparoscopy for the investigation of chronic pelvic pain\n* In order to be randomised, isolated superficial peritoneal endometriosis (SPE) must be identified at laparoscopy (macroscopically)\n* Able to give informed consent\n\nExclusion Criteria:\n\n* Previous surgical diagnosis of endometriosis\n* Pregnant or are actively trying for pregnancy within the next six months\n* Deep endometriosis or ovarian endometrioma on imaging or at laparoscopy\n* Peritoneal 'pockets' only noted at laparoscopy", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "55 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Andrew W Horne, Prof", "affiliation": "University of Edinburgh", "role": "STUDY_CHAIR"}], "locations": [{"facility": "Royal Infirmary of Edinburgh", "city": "Edinburgh", "country": "United Kingdom", "geoPoint": {"lat": 55.95206, "lon": -3.19648}}]}, "referencesModule": {"references": [{"pmid": "33413677", "type": "DERIVED", "citation": "Whitaker LHR, Doust A, Stephen J, Norrie J, Cooper K, Daniels J, Hummelshoj L, Cox E, Beatty L, Chien P, Madhra M, Vincent K, Horne AW. Laparoscopic treatment of isolated superficial peritoneal endometriosis for managing chronic pelvic pain in women: study protocol for a randomised controlled feasibility trial (ESPriT1). Pilot Feasibility Stud. 2021 Jan 7;7(1):19. doi: 10.1186/s40814-020-00740-9."}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}, {"id": "D017699", "term": "Pelvic Pain"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}, {"id": "D010146", "term": "Pain"}, {"id": "D009461", "term": "Neurologic Manifestations"}, {"id": "D012816", "term": "Signs and Symptoms"}, {"id": "D013568", "term": "Pathological Conditions, Signs and Symptoms"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT04445025", "orgStudyIdInfo": {"id": "elagolix"}, "organization": {"fullName": "Colorado Center for Reproductive Medicine", "class": "OTHER"}, "briefTitle": "Comparison Elagolix vs Depot Leuprolide Prior to Frozen Embryo Transfers in Patients With Endometriosis", "officialTitle": "The Effect of Elagolix in Comparison to Leuprolide Acetate on in Vitro Fertilization (IVF) Cycle Outcomes After a Transfer of Euploid Embryos to Patients With Surgically Diagnosed Endometriosis: A Pilot Trial"}, "statusModule": {"statusVerifiedDate": "2025-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2020-09-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2024-09-30", "type": "ACTUAL"}, "completionDateStruct": {"date": "2024-12-30", "type": "ACTUAL"}, "studyFirstSubmitDate": "2020-06-18", "studyFirstSubmitQcDate": "2020-06-22", "studyFirstPostDateStruct": {"date": "2020-06-24", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2025-02-19", "lastUpdatePostDateStruct": {"date": "2025-02-20", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Eric Surrey, M.D.", "investigatorTitle": "Medical Director", "investigatorAffiliation": "Colorado Center for Reproductive Medicine"}, "leadSponsor": {"name": "Colorado Center for Reproductive Medicine", "class": "OTHER"}, "collaborators": [{"name": "AbbVie", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false, "isUsExport": false}, "descriptionModule": {"briefSummary": "Patients who have been previously surgically diagnosed with endometriosis and have embryos predicted to be euploid after in vitro fertilization will be divided into 2 groups via randomization. The test group will receive Elagolix for 60 days prior to starting frozen embryo transfer preparation. The control group will be given leuprolide acetate every 28 days x 2 prior to starting the frozen embryo transfer preparation.\n\nComparative implantation rates between two groups of patients will be evaluated", "detailedDescription": "1. Baseline visit prior to initiation of IVF cycle:\n\n   Review nature of study, confirm surgical diagnosis of endometriosis, obtain informed consent, confirm absence of exclusion criteria\n2. Standard IVF and preimplantation genetic screening (prior to study entry):\n\n   Subjects will undergo standard ovarian stimulation, monitoring (serum and ultrasound), oocyte aspiration, in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), embryo culture to the blastocyst stage of development, trophectoderm biopsy, comprehensive chromosomal screening of embryos (CCS) and embryo vitrification as per protocols of CCRM and as determined by the primary CCRM physician.\n3. Initial study entry visit performed within 4 weeks of initial medication administration after confirmation of presence of euploid embryo(s): Complete blood count, chemistry, renal and liver function panels. Computer generated randomization Obtain serum sample for micro RNA evaluation (results will not impact treatment and will only be analyzed retrospectively) Cycle Day2-4 serum FSH, estradiol, LH, progesterone, hCG level and transvaginal ultrasound examination to evaluate endometrial lining and the presence/absence of ovarian cysts All patients will be instructed to avoid pregnancy through use of barrier contraception while on study drug\n4. Initial dosing Once screening evaluation has been cleared by the investigator, subject will be administered Lupron Depot 3.75 mg intramuscularly on cycle day 2-6 or will self-administer elagolix 200 mg orally twice daily beginning 2-6\n5. Week 4 (30 days after initial dosing) Subjects will have repeat FSH, estradiol, LH, progesterone, and hCG levels drawn Subjects will be interviewed by study coordinator regarding presence or absence adverse outcomes/side effects including incidence and severity of hot flushes, vaginal bleeding, headache, nausea and vomiting Unless subject wishes to discontinue trial or is experiencing significant adverse events necessitating drop-out, patients in Lupron group will receive a second dose of Lupron Depot 3.75 mg intramuscularly and those in the elagolix dose will continue 200 mg twice daily oral dosing for an additional 30 days which will be dispensed at this visit\n6. Week 8 (60 days after initial dosing) Subjects will have repeat FSH, estradiol, LH, progesterone and hCG levels as well as CBC and chem panel including liver function tests drawn Serum sample will be obtained for follow-up microarray analysis Transvaginal ultrasound examination will be performed to evaluate endometrial thickness and presence/absence of ovarian cysts Interview with study coordinator regarding presence/absence of adverse events/ side effects as described above\n7. First menses after completion of study drug/ Endometrial preparation for embryo transfer Initiation of standard endometrial preparation with exogenous trans-dermal estradiol in conjunction with oral and/or intramuscular preparations per standard CCRM protocols and as determined by the primary physician to achieve an endometrial thickness of 7.0-15.0 mm with a trilaminar pattern. Standard monitoring with serial ultrasound examination and assessment of serial estradiol, LH and progesterone levels will be performed per CCRM protocols. Once appropriate endometrial development has been achieved after a minimum of 10 days of preparation, both intravaginal and intramuscular progesterone will be added to the estradiol with planned embryo transfer on the sixth day of progesterone administration\n8. Embryo transfer Vitrified euploid embryo(s) selected for transfer will be warmed on the day of transfer which will be performed under ultrasound guidance using standard CCRM protocols. No more than 2 euploid embryos may be transferred and all patients will be encouraged to undergo a single transfer. Indication for a two embryo transfer will be documented. Best quality embryo(s) will be transferred preferentially choosing day 5 euploid blastocysts over day 6 or 7 euploid blastocysts. Embryos will be graded using the classification system of Gardner et al. (see reference section)\n9. Luteal support Subjects will receive standard luteal support with both injectable and intravaginal progesterone with doses adjusted per CCRM guidelines.\n10. Pregnancy diagnosis and monitoring Subjects will have an initial serum hCG level obtained 9 days after embryo transfer in their local clinic. Estradiol and progesterone levels will also be measured if hCG is positive. Repeat hCG level will obtained two days after the first level if the first level was positive. First pregnancy ultrasound will be obtained 2-2.5 weeks after initial positive hCG level unless there is a clinical indication for an earlier evaluation. If all is normal with first pregnancy ultrasound examination, a second ultrasound examination to evaluate pregnancy will be performed 2-2.5 weeks thereafter unless clinical circumstances require earlier evaluation. Progesterone and estradiol supplementation will typically be tapered using CCRM guidelines beginning at 10 weeks of pregnancy and be discontinued entirely no later than the end of the 13th week of pregnancy. Subjects will be referred to their primary obstetricians after the second pregnancy ultrasound examination at 8 weeks of pregnancy\n11. Pregnancy outcome data collection The outcomes of all pregnancies shall be obtained from the patient and recorded. If live birth, all data required by Center for Disease Control will be collected including gestational age, birth weight, immediately diagnosed anomalies and pregnancy complications. The gestational age, management, and pathology reports (if available) from pregnancy loss, ectopic pregnancy and still birth shall also be collected.\n\nAny pregnancies that occur while on study drugs or which occur after completion of the drugs but prior to embryo transfer will be recorded and monitored in the same fashion as described above"}, "conditionsModule": {"conditions": ["Infertility", "Endometriosis"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["EARLY_PHASE1"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": "Test group will receive Elagolix 60 days prior to initiating frozen embryo transfer preparation.\n\nControl group will receive depot leuprolide twice (once every 28 days) prior to initiation frozen embryo transfer preparation.", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 30, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Test group", "type": "EXPERIMENTAL", "description": "Subjects will receive the medication elagolix", "interventionNames": ["Drug: Elagolix 200 MG", "Diagnostic Test: Lab work"]}, {"label": "Control group", "type": "ACTIVE_COMPARATOR", "description": "Subjects will receive leuprolide acetate", "interventionNames": ["Drug: Leuprolide Acetate 3.75 MG/ML", "Diagnostic Test: Lab work"]}], "interventions": [{"type": "DRUG", "name": "Elagolix 200 MG", "description": "Elagolix 200mg twice daily orally for 60 days prior to beginning frozen embryo transfer preparation", "armGroupLabels": ["Test group"]}, {"type": "DRUG", "name": "Leuprolide Acetate 3.75 MG/ML", "description": "Leuprolide Acetate intramuscularly every 28 days (twice) prior to beginning frozen embryo transfer preparation", "armGroupLabels": ["Control group"]}, {"type": "DIAGNOSTIC_TEST", "name": "Lab work", "description": "Serum follicle stimulating hormone (FSH), estradiol, luteinizing hormone (LH), progesterone, human chorionic gonadotropin (hCG), serum for microarray analysis, complete blood count, and chemistry panel with liver functions levels will be drawn via blood draw", "armGroupLabels": ["Control group", "Test group"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Comparison of Implantation Rates", "description": "Implantation rates of both groups will be compared (defined as number of intrauterine gestational sacs with visible cardiac activity noted on ultrasound examination performed 2-3 weeks after initial positive pregnancy test)", "timeFrame": "2-3 weeks after initial positive pregnancy test (approx 14-15 weeks post initiation of treatment)"}], "secondaryOutcomes": [{"measure": "Comparison of Biochemical pregnancy rates", "description": "Comparative biochemical pregnancy rates (positive pregnancy tests with no evidence of intrauterine gestational sac noted at ultrasound performed 2-3 weeks after initial positive pregnancy test) per embryo transfer", "timeFrame": "2-3 weeks after initial positive pregnancy test (approx 14-15 weeks post initiation of treatment)"}, {"measure": "Comparison of hormone levels between the two groups", "description": "FSH, LH, Estradiol, progesterone will compared after 4 weeks and 8 weeks of initiation of treatment", "timeFrame": "4 weeks and 8 weeks after initiation of treatment"}, {"measure": "Comparison of live birth rates and pregnancy loss rates", "description": "At the end of the pregnancy. Live birth rates and pregnancy loss rates will be compared between the two groups", "timeFrame": "10-11 months after initiation of treatment"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Diagnosis of infertility who are candidate for IVF\n2. Surgical diagnosis of endometriosis within 10 years of study entry\n3. Willing to sign/give informed consent and adhere to parameters of study\n4. Normal endometrial cavity as diagnosed by 3D ultrasound and office hysteroscopy examinations at baseline or after correction of underlying clinically relevant cavity abnormalities\n5. Day 2-4 serum FSH level ≤ 12 mIu/mL and/or random serum AMH level ≥ 0.9 ng/mL and/or antral follicular phase follicle count obtained by trans-vaginal ultrasound examination ≥ 5\n6. No contraindication to GnRH agonist or GnRH antagonist use\n7. No prolonged use of GnRH agonist or antagonist (\\> 30 consecutive days) or other treatment for endometriosis within 4 months of study entry\n8. Have at least one euploid embryo available for transfer\n9. Agrees to transfer best quality embryo as determined by CCRM physician and embryology team\n10. Regular menses ranging from 22-36 days\n11. Agrees to use barrier contraception throughout GnRH agonist or antagonist administration\n12. No evidence of untreated hydrosalpinx\n\nExclusion Criteria:\n\n1. Age \\<21 or \\> 42 years at time of initiation of IVF cycle\n2. Day 2-4 FSH level \\>12 mIu/mL or random serum AMH level \\<1.0 ng/mL and antral follicle count obtained by trans-vaginal ultrasound examination \\< 5\n3. Planned use of donor oocytes or embryos\n4. Planned use of gestational carrier\n5. Use of GnRH agonist, GnRH antagonist or other approved medical therapy for endometriosis (with the exception of combination contraceptives) for \\> 30 consecutive days prior to study entry\n6. Unwilling to abide by study parameters or sign informed consent\n7. No documentation of surgical diagnosis of endometriosis with study timeline (10 years of study entry)\n8. Absence of embryos predicted to be euploid available for transfer (embryos with no results may not be included in transfer)\n9. Prior adverse reaction to any GnRH agonist or antagonist\n10. Uncorrected or uncorrectable clinically relevant uterine cavity abnormalities or hydrosalpinx\n11. Acute or chronic renal, pulmonary, hepatic, or cardiac disease\n12. Prior diagnosis of pituitary adenoma or any other intracranial lesion\n13. Menstrual cycles outside the range of inclusion criteria\n14. Diagnosis of polycystic ovary syndrome (PCOS)\n15. Pregnancy prior to study initiation or initiation of endometrial preparation for embryo transfer.\n16. Undiagnosed vaginal bleeding\n17. Clinically relevant adenomyosis as diagnosed by baseline 3D ultrasound exam (and/or MRI if felt to be appropriate)\n18. Bipolar disorder, history of suicidal ideation, any other psychiatric disorder requiring lithium or anti-psychotic medications", "healthyVolunteers": true, "sex": "FEMALE", "genderBased": true, "minimumAge": "21 Years", "maximumAge": "42 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Eric Surrey, MD", "affiliation": "Colorado Center for Reproductive Medicine", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Colorado Center for Reproductive Medicine", "city": "Lone Tree", "state": "Colorado", "zip": "80124", "country": "United States", "geoPoint": {"lat": 39.55171, "lon": -104.8863}}]}, "referencesModule": {"references": [{"pmid": "27179784", "type": "BACKGROUND", "citation": "Cosar E, Mamillapalli R, Ersoy GS, Cho S, Seifer B, Taylor HS. Serum microRNAs as diagnostic markers of endometriosis: a comprehensive array-based analysis. Fertil Steril. 2016 Aug;106(2):402-9. doi: 10.1016/j.fertnstert.2016.04.013. Epub 2016 May 11."}, {"pmid": "21782169", "type": "BACKGROUND", "citation": "Schoolcraft WB, Treff NR, Stevens JM, Ferry K, Katz-Jaffe M, Scott RT Jr. Live birth outcome with trophectoderm biopsy, blastocyst vitrification, and single-nucleotide polymorphism microarray-based comprehensive chromosome screening in infertile patients. Fertil Steril. 2011 Sep;96(3):638-40. doi: 10.1016/j.fertnstert.2011.06.049. Epub 2011 Jul 23."}, {"pmid": "18026832", "type": "BACKGROUND", "citation": "Surrey ES, Minjarez DA, Schoolcraft WB. The incidence of aberrant endometrial alphavbeta(3) vitronectin expression in a high risk infertility population: could prolonged GnRH agonist therapy play a role? J Assist Reprod Genet. 2007 Nov;24(11):553-6. doi: 10.1007/s10815-007-9164-3. Epub 2007 Nov 17."}, {"pmid": "28525302", "type": "BACKGROUND", "citation": "Taylor HS, Giudice LC, Lessey BA, Abrao MS, Kotarski J, Archer DF, Diamond MP, Surrey E, Johnson NP, Watts NB, Gallagher JC, Simon JA, Carr BR, Dmowski WP, Leyland N, Rowan JP, Duan WR, Ng J, Schwefel B, Thomas JW, Jain RI, Chwalisz K. Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist. N Engl J Med. 2017 Jul 6;377(1):28-40. doi: 10.1056/NEJMoa1700089. Epub 2017 May 19."}, {"pmid": "28601378", "type": "BACKGROUND", "citation": "Surrey ES, Katz-Jaffe M, Kondapalli LV, Gustofson RL, Schoolcraft WB. GnRH agonist administration prior to embryo transfer in freeze-all cycles of patients with endometriosis or aberrant endometrial integrin expression. Reprod Biomed Online. 2017 Aug;35(2):145-151. doi: 10.1016/j.rbmo.2017.05.004. Epub 2017 May 17."}, {"pmid": "15037401", "type": "BACKGROUND", "citation": "Gardner DK, Surrey E, Minjarez D, Leitz A, Stevens J, Schoolcraft WB. Single blastocyst transfer: a prospective randomized trial. Fertil Steril. 2004 Mar;81(3):551-5. doi: 10.1016/j.fertnstert.2003.07.023."}, {"pmid": "16437491", "type": "BACKGROUND", "citation": "Sallam HN, Garcia-Velasco JA, Dias S, Arici A. Long-term pituitary down-regulation before in vitro fertilization (IVF) for women with endometriosis. Cochrane Database Syst Rev. 2006 Jan 25;2006(1):CD004635. doi: 10.1002/14651858.CD004635.pub2."}, {"pmid": "12372443", "type": "RESULT", "citation": "Surrey ES, Silverberg KM, Surrey MW, Schoolcraft WB. Effect of prolonged gonadotropin-releasing hormone agonist therapy on the outcome of in vitro fertilization-embryo transfer in patients with endometriosis. Fertil Steril. 2002 Oct;78(4):699-704. doi: 10.1016/s0015-0282(02)03373-3."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D007246", "term": "Infertility"}, {"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D000091662", "term": "Genital Diseases"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}]}, "interventionBrowseModule": {"meshes": [{"id": "C539351", "term": "elagolix"}, {"id": "D016729", "term": "Leuprolide"}], "ancestors": [{"id": "D007987", "term": "Gonadotropin-Releasing Hormone"}, {"id": "D010906", "term": "Pituitary Hormone-Releasing Hormones"}, {"id": "D007028", "term": "Hypothalamic Hormones"}, {"id": "D036361", "term": "Peptide Hormones"}, {"id": "D006728", "term": "Hormones"}, {"id": "D006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D009479", "term": "Neuropeptides"}, {"id": "D010455", "term": "Peptides"}, {"id": "D000602", "term": "Amino Acids, Peptides, and Proteins"}, {"id": "D009842", "term": "Oligopeptides"}, {"id": "D009419", "term": "Nerve Tissue Proteins"}, {"id": "D011506", "term": "Proteins"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT04831619", "orgStudyIdInfo": {"id": "2013/CHU/12"}, "organization": {"fullName": "Centre Hospitalier Universitaire de la Réunion", "class": "OTHER"}, "briefTitle": "Contribution of PET (Positron Emission Tomography) Scans for the Preoperative Assessment of Symptomatic Endometriosis Lesions: TEP-ENDORUN", "officialTitle": "Contribution of PET Scans for the Preoperative Assessment of Symptomatic Endometriosis Lesions: TEP-ENDORUN", "acronym": "TEP-ENDORUN"}, "statusModule": {"statusVerifiedDate": "2022-03", "overallStatus": "UNKNOWN", "lastKnownStatus": "NOT_YET_RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2022-05", "type": "ESTIMATED"}, "primaryCompletionDateStruct": {"date": "2023-05", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2024-09-30", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2021-03-26", "studyFirstSubmitQcDate": "2021-04-02", "studyFirstPostDateStruct": {"date": "2021-04-05", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2022-03-01", "lastUpdatePostDateStruct": {"date": "2022-03-02", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Centre Hospitalier Universitaire de la Réunion", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "Endometriosis is an inflammatory condition that is often treated by surgery. MRI and ultrasound are used for the preoperative morphological assessment. Currently, only surgery allows the exhaustive and qualitative diagnosis of lesions.\n\nThe PET scan, fixing in certain inflammatory pathologies and in certain cases of endometriosis, could refine this assessment by evaluating the location of the lesions."}, "conditionsModule": {"conditions": ["Endometriosis"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "DIAGNOSTIC", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 10, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "PET scanner in addition to MRI", "type": "EXPERIMENTAL", "interventionNames": ["Drug: PET scanner with injection of 18 FDG (18F-2-fluoro-2-deoxy-D-glucose) (radiolabel)"]}], "interventions": [{"type": "DRUG", "name": "PET scanner with injection of 18 FDG (18F-2-fluoro-2-deoxy-D-glucose) (radiolabel)", "description": "A PET scan will be performed in the patients included, in addition to the conventional imaging workup (MRI, endovaginal and pelvic ultrasound).", "armGroupLabels": ["PET scanner in addition to MRI"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "To assess the PET scan in the diagnosis of endometriosis lesions compared to surgery in terms of number of lesions diagnosed and locations.", "description": "Total number of endometriosis lesions diagnosed by the PET scanner", "timeFrame": "at inclusion (before surgery)"}], "secondaryOutcomes": [{"measure": "Compare the results of the PET scanner and MRI for the sensitivity of detection of endometriosis lesions", "description": "number of endometriosis lesions", "timeFrame": "up to 14 weeks (after surgery)"}, {"measure": "Compare the results of the PET scanner and MRI for the sensitivity of detection of endometriosis lesions", "description": "location of endometriosis lesions", "timeFrame": "up to 14 weeks (after surgery)"}, {"measure": "Define a reading threshold of SUV (Standardized Uptake Value) on a PET scanner for the diagnosis of endometriosis", "description": "degree of inflammation of the cells", "timeFrame": "up to 14 weeks (after PET-Scanner)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patient aged over 18 and under 50\n* Patient with symptomatic endometriosis with indication for surgery\n* Showing at least one typical endometriosis lesion on MRI, greater than 5mm\n* Accepting surgical management\n* Having signed an informed consent after information\n* Affiliate or beneficiary of a social security scheme\n\nExclusion Criteria:\n\n* Patient who has received an injection with GnRH (gonadotropin-releasing hormone ) analogues for less than 3 months (because it induces the quiescence of the disease which is no longer stimulated by estrogen secretion)\n* Patient with a history of heavy abdominopelvic surgery\n* Diabetic patient\n* Patient unable to understand the interest of the study\n* Patient already included in another therapeutic trial with an experimental molecule.\n* Persons referred to in articles L1121-5 to L1121-8 of the PHC (public health code) (corresponding to all protected persons: pregnant woman, parturient, nursing mother, person deprived of liberty by judicial or administrative decision, minor, and person making the subject to a legal protection measure: guardianship or curators)\n* Contraindications to PET Scanner (major claustrophobia, contraindication or hypersensitivity to 18-FDG or one of its excipients, contraindication or hypersensitivity to Ultravist® or one of its excipients, etc.)\n* Contraindication to surgery or anesthesia", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "50 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Lucie AUZANNEAU", "role": "CONTACT", "phone": "(0)262 35 99 49", "phoneExt": "+33", "email": "lucie.auzanneau@chu-reunion.fr"}], "locations": [{"facility": "Centre Hospitalier Universitaire Réunion", "city": "Saint-Denis", "zip": "97400", "country": "France", "contacts": [{"name": "Lucie AUZANNEAU", "role": "CONTACT", "phone": "(0)262 35 99 49", "phoneExt": "+33", "email": "lucie.auzanneau@chu-reunion.fr"}, {"name": "Peter VON THEOBALD, PHD", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 48.93564, "lon": 2.35387}}, {"facility": "CHU de la Réunion", "city": "Saint-Pierre", "zip": "97448", "country": "France", "contacts": [{"name": "Lucie AUZANNEAU", "role": "CONTACT", "phone": "(0)262 35 99 49", "phoneExt": "+33", "email": "lucie.auzanneau@chu-reunion.fr"}, {"name": "Malik BOUKERROU, PHD", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 43.29282, "lon": 5.40682}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT06821438", "orgStudyIdInfo": {"id": "US vs MRI in DIE"}, "organization": {"fullName": "Alexandria University", "class": "OTHER"}, "briefTitle": "TVUS vs MRI Efficacy in Diagnosis of Laparoscopically Managed Patients With DIE", "officialTitle": "PREOPERATIVE TRANSVAGINAL ULTRASOUND VERSUS MAGNETIC RESONANCE IMAGING IN DIAGNOSIS OF LAPAROSCOPICALLY MANAGED PATIENTS WITH DEEP INFILTRATING ENDOMETRIOSIS"}, "statusModule": {"statusVerifiedDate": "2025-02", "overallStatus": "NOT_YET_RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2025-02", "type": "ESTIMATED"}, "primaryCompletionDateStruct": {"date": "2025-04", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2025-05", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2025-01-05", "studyFirstSubmitQcDate": "2025-02-09", "studyFirstPostDateStruct": {"date": "2025-02-12", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2025-02-09", "lastUpdatePostDateStruct": {"date": "2025-02-12", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Tamer Hosny", "investigatorTitle": "Principal investigator Dr Tamer Ahmed Hosny", "investigatorAffiliation": "Alexandria University"}, "leadSponsor": {"name": "Alexandria University", "class": "OTHER"}}, "oversightModule": {"isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The purpose of the study is to compare the reliability and accuracy of systematic ultrasonographic scanning using International Deep Endometriosis Analysis group approach versus magnetic resonance imaging (MRI) assessment in diagnosis of patients with deep infiltrative endometriosis in comparison with the intraoperative findings to confirm the accuracy.", "detailedDescription": "Endometriosis is the existence of endometrial glands outside the uterus. About 10%- 12% of women who are menstruating have this benign gynecologic disease with peak age between 25 years and 35 years. However asymptomatic women can develop endometriosis lesions, and half of those suffering from infertility are found to have them. Endometriosis currently poses a significant problem because of its complexity, the range of clinical presentations it might take, and the still unknown physio-pathobiological genesis. There are three types of endometriosis; Deep Infiltrating Endometriosis, ovarian endometrioma, and superficial peritoneal endometriosis.\n\nDeep infiltrating endometriosis is defined as the ectopic growth of endometrial glands and stroma extending more than 5 mm beneath the peritoneal surface. This type needs special and more vigorous management than the other types. It accounts for 15-30% of all the diagnosed endometriosis cases.\n\nOvarian endometrioma which is defined as \"Endometrium-like tissue in the form of ovarian cysts \"chocolate cysts\". it is found in 2-10% of women in reproductive age and half of women receiving infertility treatment.\n\nSuperficial peritoneal endometriosis which is defined as \"Endometrium- like tissue lesions involving the peritoneal surface. The lesions can have different appearances and color e.g. clear, black, etc.\". It represent 15-50% of diagnosed cases.\n\nThis illness can cause crippling pain, infertility, and problems with bowel, sexual, and urine functions. These symptoms can have a major negative impact on a woman's quality of life during her reproductive years.\n\nBecause Deep Infiltrating Endometriosis tends to profoundly infiltrate pelvic systems, including several organs, ligaments, blood arteries, and nerves, it might mimic malignant processes despite being benign. Extensive and intricate dissection inside deep pelvic regions is necessary for the complicated excision of Deep Infiltrating Endometriosis in its aggressive form.\n\nNoninvasive imaging modalities such as magnetic resonance imaging and transvaginal sonography are currently available for the diagnosis of Deep Infiltrating Endometriosis.\n\nRegardless of its location, it is crucial to remember that there is significant variation in the stated sensitivity and specificity of transvaginal ultrasound for Deep Infiltrating Endometriosis detection.\n\nThe diagnosis of pelvic endometriosis is more accurate when an expert operator does an ultrasonography according to International Deep Endometriosis Analysis approach in addition to a pelvic examination and history.\n\nWhen a woman has endometriosis, an ultrasound examination is performed to map the location of the disease, determine its severity, and attempt to explain the underlying symptoms before pursuing medication or surgery.\n\nHowever, discrepancies in examination techniques, ultrasound equipment quality, and operator experience may account for discrepancies in the reported accuracy of the ultrasound diagnosis of Deep Infiltrating Endometriosis across different investigations.\n\nMRI has a great degree of objectivity and the ability to capture pictures in various orientations over a wide field of view. The fusion of many Magnetic Resonance sequences can provide extensive information regarding the sites and histological aspects of endometriosis because of its superior contrast resolution.\n\nThe diagnosis is usually made through surgical visualization, ideally laparoscopy, although the recent guidelines from ESHRE suggest that actual imaging modalities for some types of endometriosis could be sufficient in the diagnosis process.\n\nAt present, there is no curative treatment for endometriosis, and clinical management of symptoms such as pain occurs through medical and/or surgical treatments .\n\nMedical treatment follows the basic principle of suppression of menstrual cycles, resulting in the reduction in inflammation and blocking the effect of estrogens \\[Falcone 2018\\]. Unfortunately, current medical therapies could alleviate symptoms, but they are far from curative treatments and can often lead to side effects that compromise patient compliance.\n\nSurgical treatment aims to remove bulky endometriotic lesions or, in more complex cases, complete excision of the pelvic organs. Neither the medical management nor the surgery turns out to give relief in the long term or is universally acceptable for the patients.\n\nLaparoscopic observation and biopsy are very important in the diagnosis of Deep Infiltrating Endometriosis where the specimens biopsied are sent for histopathological examination for diagnosis of the nature of the lesions and their exact origin."}, "conditionsModule": {"conditions": ["Endometriosis"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "CASE_CONTROL", "timePerspective": "RETROSPECTIVE"}, "enrollmentInfo": {"count": 40, "type": "ESTIMATED"}}, "armsInterventionsModule": {"interventions": [{"type": "PROCEDURE", "name": "Laparoscopy", "description": "Endoscopy"}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "TRANSVAGINAL ULTRASOUND VERSUS MAGNETIC RESONANCE IMAGING IN DIAGNOSIS OF LAPAROSCOPICALLY MANAGED PATIENTS WITH DEEP INFILTRATING ENDOMETRIOSIS", "description": "The purpose of the study is to compare the reliability and accuracy of systematic ultrasonographic scanning using International Deep Endometriosis Analysis group approach versus magnetic resonance imaging (MRI) assessment in diagnosis of patients with deep infiltrative endometriosis in comparison with intraoperative findings to confirm the diagnosis .", "timeFrame": "Baseline"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Known patient with Deep Infiltrating Endometriosis affecting ovaries (endometriomas), rectosigmoid , bladder or any type of endometriosis who suffers from chronic pelvic pain, dysmenorrhea, dyspareunia, dyschasia, dysuria or infertility.\n\nExclusion Criteria:\n\n* Postmenopausal status.\n* Women with malignancy or adnexal lesions other than suspected endometrioma.\n* Those who were pregnant.\n* History of any metallic implants or prosthesis preventing MRI. 5. Virgin cases (No Transvaginal Ultrasound).", "healthyVolunteers": true, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "50 Years", "stdAges": ["ADULT"], "studyPopulation": "Patients with Deep Infiltrating Endometriosis affecting ovaries (endometriomas), rectosigmoid , bladder or any type of endometriosis who suffers from chronic pelvic pain, dysmenorrhea, dyspareunia, dyschasia, dysuria or infertility. All cases included were subjected to the following: History taking, analysis of complaint, physical examination , transvaginal sonography, MRI and laparoscopy. These are done after informed written consents.", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"centralContacts": [{"name": "Rawan El Sawy, Bachelor", "role": "CONTACT", "phone": "01154009283", "phoneExt": "+20-3", "email": "rawanabedmed@gmail.com"}, {"name": "Tamer Hosny, Ph.D", "role": "CONTACT", "phone": "01001594801", "phoneExt": "+20-3"}], "locations": [{"facility": "Alexandria Faculty Of Medicine", "city": "Alexandria", "state": "El Shatby", "zip": "21526", "country": "Egypt", "geoPoint": {"lat": 31.20176, "lon": 29.91582}}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D010535", "term": "Laparoscopy"}], "ancestors": [{"id": "D004724", "term": "Endoscopy"}, {"id": "D003949", "term": "Diagnostic Techniques, Surgical"}, {"id": "D019937", "term": "Diagnostic Techniques and Procedures"}, {"id": "D003933", "term": "Diagnosis"}, {"id": "D019060", "term": "Minimally Invasive Surgical Procedures"}, {"id": "D013514", "term": "Surgical Procedures, Operative"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT06352840", "orgStudyIdInfo": {"id": "HUM00231526"}, "secondaryIdInfos": [{"id": "5K23HD099283-03", "type": "NIH", "link": "https://reporter.nih.gov/quickSearch/5K23HD099283-03"}], "organization": {"fullName": "University of Michigan", "class": "OTHER"}, "briefTitle": "Novel Web-based, Self-directed Intervention for Chronic Pelvic Pain", "officialTitle": "Novel Web-based, Self-directed Intervention for Chronic Pelvic Pain"}, "statusModule": {"statusVerifiedDate": "2025-06", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2024-06-20", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2025-01-23", "type": "ACTUAL"}, "completionDateStruct": {"date": "2025-04-28", "type": "ACTUAL"}, "studyFirstSubmitDate": "2024-04-02", "studyFirstSubmitQcDate": "2024-04-02", "studyFirstPostDateStruct": {"date": "2024-04-08", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2025-06-24", "lastUpdatePostDateStruct": {"date": "2025-06-26", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Sara Till, MD, MPH", "investigatorTitle": "Assistant Professor of Obstetrics and Gynecology", "investigatorAffiliation": "University of Michigan"}, "leadSponsor": {"name": "University of Michigan", "class": "OTHER"}, "collaborators": [{"name": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)", "class": "NIH"}]}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false, "isUsExport": false}, "descriptionModule": {"briefSummary": "The study is being completed to evaluate the effectiveness of a web-based, self-management program for patients with Chronic Pelvic Pain (CPP).\n\nThe overall hypothesis is that patients with chronic pelvic pain that have access to the My Pelvic Plan program will demonstrate improvements in pain, physical function, and quality of life with this integrative self-management approach."}, "conditionsModule": {"conditions": ["Chronic Pelvic Pain", "Endometriosis"], "keywords": ["Quality of life", "Cognitive Behavioral Therapy"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "maskingDescription": "Both participants and outcome assessors will be blinded to study group assignment.", "whoMasked": ["PARTICIPANT", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 69, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Monitoring progress plus usual care", "type": "OTHER", "description": "Participants will have access to the monitoring progress web-based symptom monitoring program.", "interventionNames": ["Behavioral: Control Group website"]}, {"label": "My Pelvic Plan plus usual care", "type": "EXPERIMENTAL", "description": "Participants will have access to My Pelvic Plan program.", "interventionNames": ["Behavioral: My Pelvic Plan Website"]}], "interventions": [{"type": "BEHAVIORAL", "name": "My Pelvic Plan Website", "description": "This is a self-directed program which integrates patient education about conditions that frequently contribute to pelvic pain, as well as instruction on cognitive and behavioral restructuring, self-administration of acupressure, engaging in physical activity, and a brief introduction to pelvic floor physical therapy techniques. Participants will have open access to the program over the 6-month intervention period. The intervention will be comprised of an active (12-week) phase and a maintenance (3-month) phase. Participants will receive a weekly text or email prompt directing patients to a specific module. All participants will receive prompts to the same modules for the first four weeks of the study, then during the next 8 weeks, participants will receive prompts to modules that corresponded to the most impactful symptoms on participant's baseline questionnaires. Following 12-week active phase, all participants will enter the maintenance phase.", "armGroupLabels": ["My Pelvic Plan plus usual care"]}, {"type": "BEHAVIORAL", "name": "Control Group website", "description": "Patients in the control group will undergo an active control intervention in which participants receive open access to a separate website that contains only the Monitoring Progress symptom tracker subpage over the 6-month study period. Control group participation will also be divided into an active (12-week) phase and a maintenance (3-month) phase. Similar to the intervention group, the control group will receive a weekly text (first 12 weeks) or email prompt directing them to a specific module or portion of the respective website. During the maintenance phase of the study, participants will receive monthly prompts to the Monitoring Progress subpage (without prompting to a specific symptom or activity).", "armGroupLabels": ["Monitoring progress plus usual care"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Patient Reported Outcomes Measurement Information System (PROMIS) Pain Interference short form (SF) 4a between groups", "description": "There are four questions that participants will answer from not at all (1) - very much (5). Scores range from 4-20, with higher scores meaning more interference.", "timeFrame": "3 months"}, {"measure": "PROMIS pain intensity 1a between groups", "description": "There is one question that participants will answer no pain (0) - worst pain (10). Lower score means less pain.", "timeFrame": "3 months"}, {"measure": "PROMIS Self Efficacy for Managing Symptoms SF 4a between groups", "description": "There are four questions that participants will answer from I am not all confident (1) - I am very confident (5). Scores range from 4-20, with higher scores meaning more confident.", "timeFrame": "3 months"}], "secondaryOutcomes": [{"measure": "Patient Reported Outcomes Measurement Information System (PROMIS) Pain Interference short form (SF) 4a between groups", "description": "There are four questions that participants will answer from not at all (1) - very much (5). Scores range from 4-20, with higher scores meaning more interference.", "timeFrame": "6 months"}, {"measure": "PROMIS pain intensity 1a between groups", "description": "There is one question that participants will answer no pain (0) - worst pain (10). Lower score means less pain.", "timeFrame": "6 months"}, {"measure": "PROMIS Self Efficacy for Managing Symptoms SF 4a between groups", "description": "There are four questions that participants will answer from I am not all confident (1) - I am very confident (5). Scores range from 4-20, with higher scores meaning more confident.", "timeFrame": "6 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Participants have chronic pelvic pain, defined by the protocol for ≥ 6-month duration, and is non-cyclic, occurring for at least 14 days of each month.\n* Must be currently receiving care within Department of Obstetrics and Gynecology at the University of Michigan for treatment of chronic pelvic pain\n* Access to internet via computer or smartphone\n* English-language proficiency (current version of the website is in English)\n\nExclusion Criteria:\n\n* Underwent gynecologic surgery within 3 months of screening visit\n* Plan to undergo gynecologic surgery within 6 months following screening visit\n* Pregnant (self-reported) at time of screening visit. Will not exclude patients that become pregnant during the course of the study.\n* Severe physical impairment precluding participating in internet-based program (for example, complete blindness or deafness)\n* Current psychiatric disorder with history of psychosis (for example, schizophrenia, schizoaffective disorder, delusional disorder),\n* Current suicidal ideation or suicide attempt within 2 years of screening visit. The study will screen for severe depression and suicidality at each questionnaire time point and have developed a robust triage and referral plan.", "healthyVolunteers": false, "sex": "FEMALE", "genderBased": true, "genderDescription": "Woman (female sex assigned at birth, may include cis-gender, trans-gender, nonbinary)", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Sara Till, MD", "affiliation": "University of Michigan", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "University of Michigan", "city": "Ann Arbor", "state": "Michigan", "zip": "48109", "country": "United States", "geoPoint": {"lat": 42.27756, "lon": -83.74088}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT05726786", "orgStudyIdInfo": {"id": "INCyst"}, "organization": {"fullName": "Centre Hospitalier Universitaire Vaudois", "class": "OTHER"}, "briefTitle": "The Role of Preoperative Immunonutrition on Morbidity and Immune Response After Cystectomy (INCyst Trial)", "officialTitle": "The Role of Preoperative Immunonutrition on Morbidity and Immune Response After Cystectomy - A Multicenter Randomized Controlled Trial (INCyst Trial)", "acronym": "INCyst"}, "statusModule": {"statusVerifiedDate": "2023-09", "overallStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2023-04-10", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2026-08", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2026-10", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2023-01-16", "studyFirstSubmitQcDate": "2023-02-03", "studyFirstPostDateStruct": {"date": "2023-02-14", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-09-01", "lastUpdatePostDateStruct": {"date": "2023-09-05", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Ilaria Lucca", "investigatorTitle": "MD, Principal Investigator", "investigatorAffiliation": "Centre Hospitalier Universitaire Vaudois"}, "leadSponsor": {"name": "Centre Hospitalier Universitaire Vaudois", "class": "OTHER"}, "collaborators": [{"name": "Insel Gruppe AG, University Hospital Bern", "class": "OTHER"}, {"name": "Hôpital Riviera-Chablais, Vaud-Valais", "class": "OTHER"}]}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false, "isUsExport": false}, "descriptionModule": {"briefSummary": "The goal of this clinical trial research study is to evaluate the impact of preoperative oral immunonutrition (IN) on post-operative complications in patients undergoing a cystectomy.\n\nAs a secondary focus, this study will aim to develop a signature that would identify patients that would benefit the most from IN.\n\nThis is a multicentric (Swiss: N=3), prospective, controlled, pragmatic, parallel-group comparative study with block randomization stratified by centers.", "detailedDescription": "Despite standardized surgical technique and the development of new perioperative care protocols, cystectomy morbidity remains a serious challenge for urologists. Most common postoperative complications, such as infections, often lead to longer length of stay and worse survival. Malnutrition has been identified as an independent and modifiable risk factor for both mortality and morbidity. Immunonutrition (IN), containing arginine, ribonucleic acid and omega-3 polyunsaturated fatty acids, aims to improve the nutritional status, immunological function and clinical outcome of surgical patients. Meta-analyses have demonstrated that preoperative IN reduces complications and length of hospital stay after major bowel surgery. Evidence-based data on preoperative oral IN support for cystectomy patients are lacking, which does not allow this treatment to be widely accepted, recommended, or reimbursed by health insurances in most European countries. Uncertainties also remain about the exact mechanism by which IN modulates the host immune response.\n\nComplication rates after cystectomy range from 40-75%. Malnutrition has been identified as an independent and modifiable risk factor for both mortality and morbidity. To date, and in the last 20 years, no single intervention has allowed for a significant reduction in morbidity after cystectomy, which remains one of the highest in surgery. The present adequately powered multicenter RCT has the potential of changing current practice by recommending preoperative IN before cystectomy in case of positive results. If the present RCT demonstrates a benefit in administrating IN prior to cystectomy, urological guidelines will be modified accordingly to this new evidence. IN will then be recommended before cystectomy for the patient's benefit. The investigators truly believe that the proposed study is of high clinical importance with potential impact on perioperative urology guidelines."}, "conditionsModule": {"conditions": ["Bladder Cancer", "Interstitial Cystitis", "Painful Bladder Syndrome", "Neurogenic Bladder", "Hemorrhagic Cystitis", "Endometriosis", "Bladder Disease"], "keywords": ["Cystectomy", "Immunonutrition", "Complication", "Malnutrition"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": "Multicenter, prospective, controlled, pragmatic, parallel-group comparative study with block randomization stratified by centers", "primaryPurpose": "SUPPORTIVE_CARE", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 232, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Immunonutrition", "type": "EXPERIMENTAL", "description": "Seven days of preoperative oral supplementation with an immune-enhanced oral nutrition", "interventionNames": ["Drug: Immunonutrition"]}, {"label": "No immunonutrition (control)", "type": "NO_INTERVENTION", "description": "Standard of care"}], "interventions": [{"type": "DRUG", "name": "Immunonutrition", "description": "Immunonutrition: Oral Impact®, Nestlé Health Science, Switzerland.\n\nIN will be administered as per manufacturer suggestion, i.e. three times a day during 7 days preoperatively. Oral Impact® is a powdered oral feed that provides 309 kcal/bag", "armGroupLabels": ["Immunonutrition"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Infectious complication after cystectomy", "description": "Determination of infectious complications rate at 30 days after surgery (pneumonia, urinary tract infection, surgical site infection, sepsis, shock).", "timeFrame": "30-days afetr surgery"}], "secondaryOutcomes": [{"measure": "Comprehensive Complication Index (CCI)", "description": "Determination of the Comprehensive Complication Index (CCI) at 30 and 90 days after surgery. The range is between 0 (no complication) to 100 (death).", "timeFrame": "30 and 90 days after surgery"}, {"measure": "Mortality rate", "description": "Determination of the mortality rate at 30 and 90 days after surgery", "timeFrame": "30 and 90 days after surgery"}, {"measure": "Complication-free survival rate", "description": "Determination of the post-operative complication-free survival", "timeFrame": "90-days after surgery"}, {"measure": "Treatment compliance rate", "description": "Serum arginine levels will be assessed at enrolment (between Day -30 and Day -10) and at preoperative admission after intake of the allocated nutrition (Day -1) in all patients treated at Lausanne, CHUV.", "timeFrame": "Between Day -30 and Day -10 and at preoperative admission after intake of the allocated nutrition (Day -1)"}], "otherOutcomes": [{"measure": "Cancer-specific survival rate", "description": "Long term overall and cancer-specific survival for bladder cancer patients", "timeFrame": "Postoperative time"}, {"measure": "Quality of life assessment", "description": "Assessment of the quality of life after surgery through a questionnaire (EORTC QLQ-C30)", "timeFrame": "30 and 90 days after surgery"}, {"measure": "Identification of biomarkers predictive of postoperative complications", "description": "Identification of biomarkers predictive of postoperative complications studying the patient's immune and microbiome signature: analysis of immune cells in the blood, analysis of the polyfunctionality of blood T cells, analysis of immune-related proteins in the urine and serum, microbiota analysis, expression of Argininosuccinate synthetase 1", "timeFrame": "Before and after immunonutrition treatement"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patient undergoing open cystectomy (for all reasons)\n* Age ≥18 years\n* Ability and willingness to provide informed consent documented by signature\n\nExclusion Criteria:\n\n* Contraindications to IN, e.g. known hypersensitivity or allergy to lactose, fish oil or soy lecithin\n* Severe diarrhoea requiring medical attention\n* Current treatment with any immunosuppressive drug\n* In standard practice, pregnant or lactating women are systematically rejected by the surgeon for this surgical procedure. Furthermore, during the pre-surgical anaesthesia consultation, the eligibility of each patient for anaesthesia will be assessed according to the usual criteria and recommendations of the anaesthesia service of the CHUV\n* Other clinically significant concomitant disease affecting immunity (e.g., severe renal failure, HIV, SLE, transplant recipient, ...)\n* Inability to follow the procedures of the study, e.g. due psychological disorders, dementia, etc.\n* Participation in another study with investigational drug within the 30 days preceding and during the present study\n* Previous enrolment into the current study\n* Use of IN independently of the study\n* Enrolment of the investigator, his/her family members, employees and other dependent persons\n* Emergency procedure (less than 7 days between screening and surgery)", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Ilaria Lucca, MD", "role": "CONTACT", "phone": "+41213142981", "email": "ilaria.lucca@chuv.ch"}], "locations": [{"facility": "Centre Hospitalier Universitaire Vaudois, CHUV", "status": "RECRUITING", "city": "Lausanne", "state": "Canton of Vaud", "zip": "1011", "country": "Switzerland", "contacts": [{"name": "Ilaria Lucca, MD", "role": "CONTACT", "email": "ilaria.lucca@chuv.ch"}, {"name": "François Crettenand, MD", "role": "CONTACT", "email": "francois.crettenand@chuv.ch"}], "geoPoint": {"lat": 46.516, "lon": 6.63282}}, {"facility": "University Hospital of Bern", "status": "NOT_YET_RECRUITING", "city": "Bern", "country": "Switzerland", "contacts": [{"name": "Bernhard Kiss, MD", "role": "CONTACT", "email": "bernhard.kiss@insel.ch"}], "geoPoint": {"lat": 46.94809, "lon": 7.44744}}, {"facility": "Hospital of Riviera-Chablais", "status": "NOT_YET_RECRUITING", "city": "Rennaz", "country": "Switzerland", "contacts": [{"name": "Thomas Tawadros, PhD", "role": "CONTACT", "email": "thomas.tawadros@rivierachablais.ch"}], "geoPoint": {"lat": 46.3748, "lon": 6.91604}}]}, "referencesModule": {"references": [{"pmid": "39415282", "type": "DERIVED", "citation": "Derre L, Crettenand F, Grilo N, Stritt K, Kiss B, Tawadros T, Domingos-Pereira S, Roth B, Cerantola Y, Lucca I. The role of preoperative immunonutrition on morbidity and immune response after cystectomy: protocol of a multicenter randomized controlled trial (INCyst Trial). Trials. 2024 Oct 17;25(1):687. doi: 10.1186/s13063-024-08536-5."}]}, "ipdSharingStatementModule": {"ipdSharing": "UNDECIDED"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D001749", "term": "Urinary Bladder Neoplasms"}, {"id": "D018856", "term": "Cystitis, Interstitial"}, {"id": "D001750", "term": "Urinary Bladder, Neurogenic"}, {"id": "D000096722", "term": "Cystitis, Hemorrhagic"}, {"id": "D004715", "term": "Endometriosis"}, {"id": "D001745", "term": "Urinary Bladder Diseases"}, {"id": "D044342", "term": "Malnutrition"}], "ancestors": [{"id": "D014571", "term": "Urologic Neoplasms"}, {"id": "D014565", "term": "Urogenital Neoplasms"}, {"id": "D009371", "term": "Neoplasms by Site"}, {"id": "D009369", "term": "Neoplasms"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D014570", "term": "Urologic Diseases"}, {"id": "D052801", "term": "Male Urogenital Diseases"}, {"id": "D003556", "term": "Cystitis"}, {"id": "D009461", "term": "Neurologic Manifestations"}, {"id": "D009422", "term": "Nervous System Diseases"}, {"id": "D012816", "term": "Signs and Symptoms"}, {"id": "D013568", "term": "Pathological Conditions, Signs and Symptoms"}, {"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D000091662", "term": "Genital Diseases"}, {"id": "D009748", "term": "Nutrition Disorders"}, {"id": "D009750", "term": "Nutritional and Metabolic Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000093702", "term": "Immunonutrition Diet"}], "ancestors": [{"id": "D004032", "term": "Diet"}, {"id": "D009747", "term": "Nutritional Physiological Phenomena"}, {"id": "D000066888", "term": "Diet, Food, and Nutrition"}, {"id": "D010829", "term": "Physiological Phenomena"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT05698212", "orgStudyIdInfo": {"id": "HER001"}, "organization": {"fullName": "Hera Biotech, Inc.", "class": "INDUSTRY"}, "briefTitle": "Proof of Concept Study to Eval MetriDx Lab-developed Test to Identify Endometriosis-specific Bio Markers", "officialTitle": "Proof-of-Concept, Obs Study to Evaluate Accuracy of MetriDx Lab Developed Test (LDT) to Accurately Identify Endometriosis-specific Biological Markers Using Micro-fluidic Analysis of Cells Enabling Clinicians to Diagnose Endometriosis"}, "statusModule": {"statusVerifiedDate": "2022-11", "overallStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2022-09-14", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2023-03-25", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2023-04-10", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2022-11-29", "studyFirstSubmitQcDate": "2023-01-24", "studyFirstPostDateStruct": {"date": "2023-01-26", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-01-24", "lastUpdatePostDateStruct": {"date": "2023-01-26", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Hera Biotech, Inc.", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false, "isUsExport": false}, "descriptionModule": {"briefSummary": "This study is testing a way to diagnose endometriosis using a uterine tissue biopsy (similar to a pap smear) as opposed to undergoing laparoscopy surgery. The tissue is sent to lab for cellular analysis with a proprietary AI (artificial intelligence) technology.", "detailedDescription": "This study involves 2 visits to the site and possibly as outpatient surgical center, and the participant will be involved in the for as little as 1 day to as much as 60 days, mainly depending on scheduling of laparoscopy. Eligible participants in the active group will have history of endometriosis and will be having a laparoscopy for diagnosis within the next few weeks. Eligible participants in the control group will have no history of endometriosis but will need or have recently had a laparoscopy surgical procedure for a reasons such as tubal ligation.\n\nThe participant will have an uterine biopsy (similar to a pap smear) in the physician's office before the laparoscopy. The biopsied tissue will be sent to a special lab for analysis and diagnosis of endometriosis by an innovative proprietary procedure that analyses the cells of the tissue collected in the biopsy.\n\nThe results of the biopsy will be compared to the laparoscopy for accuracy."}, "conditionsModule": {"conditions": ["Endometriosis", "Diagnosis"], "keywords": ["endometriosis", "MetriDx", "connexins", "biological markers", "micro-fluidic analysis", "uterine tissue biopsy"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "NON_RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": "Two cohorts defined by confirmed diagnosis of endometriosis and further grouping by staging of endometriosis A third cohort of control participants who have not been suspected or diagnosed with endometriosis", "primaryPurpose": "DIAGNOSTIC", "maskingInfo": {"masking": "SINGLE", "maskingDescription": "The lab associates conducting the diagnosis tests are blinded.", "whoMasked": ["OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 75, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Cohort 1", "type": "ACTIVE_COMPARATOR", "description": "Endometriosis diagnosed at stage 1 or 2", "interventionNames": ["Diagnostic Test: MetriDx"]}, {"label": "Cohort 2", "type": "ACTIVE_COMPARATOR", "description": "Endometriosis diagnosed at stage 3 or 4", "interventionNames": ["Diagnostic Test: MetriDx"]}, {"label": "Cohort 3", "type": "OTHER", "description": "Control--Not suspected of having and absence of endometriosis confirmed by diagnostic test.\n\nThis group has uterine tissue biopsy and laparoscopy for non-endometriosis indication, i.e. tubal ligation", "interventionNames": ["Diagnostic Test: MetriDx"]}], "interventions": [{"type": "DIAGNOSTIC_TEST", "name": "MetriDx", "description": "Biopsied tissue will be analyze by proprietary LDT, MetriDx, and compared to laparoscopy diagnostic report on record", "armGroupLabels": ["Cohort 1", "Cohort 2", "Cohort 3"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Primary Outcome", "description": "Endometriosis diagnosis", "timeFrame": "1 week after laparoscopy"}], "secondaryOutcomes": [{"measure": "Secondary Outcome", "description": "Accurate staging of endometriosis", "timeFrame": "1 week after laparoscopy"}, {"measure": "Tertiary Outcome", "description": "observe and explore any relationship between subject's estrogen and progesterone levels and MetriDx results.", "timeFrame": "1 week after providing menstrual effluent sample"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Able to understand and provide informed consent.\n* Natural born female of childbearing potential.\n* Age between 18 and 50, inclusive.\n* Not pregnant at Visit 0 (screening) or Visit 1 (day of procedure).\n* Free of systemic or pelvic disorder that, in the opinion of the investigator, may interfere with the tissue collection procedure, analysis of the tissue or increase the risk to subject.\n* Must not have received excision or ablation surgical procedure or treatment, such as gonadotropin-releasing hormone (GnRH), for endometriosis within the past 12 months.\n* For Cohort 1 and 2:\n\n  * Suspected of having endometriosis, or previously diagnosed with endometriosis, and currently recommended for laparoscopic surgery by physician.\n  * Must have laparoscopic surgery within 60 days after screening Visit 0 and any time after the endometrial biopsy is obtained on Visit 1 (including the same day), or a laparoscopy on record within the 12 months prior to Visit 0 for diagnosis only.\n  * Surgical report from prior laparoscopy must indicate that endometriosis was not treated with surgical ablation or excision.\n  * Subjects will be assigned to Cohort 1 or 2 based on diagnosis and staging results from laparoscopy.\n* Or for Cohort 3:\n\n  * Not suspected of having endometriosis\n  * no previous diagnosis or symptoms of endometriosis, who have had a laparoscopy for another reason, such as tubal ligation or other abdominal procedure, within the past 12 months prior to screening Visit 0,\n  * or laparoscopy to be completed within 60 days after screening Visit 0 and any time after the endometrial biopsy is obtained on Visit 1 (including the same day).\n  * Surgeon's report must have no supplemental observations of endometriosis lesions or diagnosis. Subjects will be assigned to Cohort 3.\n\nExclusion Criteria:\n\n* Younger than 18 or 51 years or older.\n* Surgical history of hysterectomy.\n* Has received excision or ablation surgical procedure or treatment, such as gonadotropin-releasing hormone (GnRH), for endometriosis within the past 12 months.\n* Cohort 3: Prior diagnosis of endometriosis, or surgical note from prior laparoscopy that indicates endometriosis lesions were observed.\n* Has a BMI 40 or above.\n* Is currently taking a blood thinner medication.\n* Currently, pregnant, breast feeding, or has given birth in the last 6 months.\n* Diagnosed with HIV, AIDS, hepatitis A, B, or C, or has active malignancy.\n* Has a complicating condition that would pose a hazard to tissue handling.\n* Undergoing fertility or hormone therapy treatments.\n* History or evidence of uterine fibroids.\n* History of reproductive cancer.\n* Has a condition that, in the opinion of the investigator, would confound tissue collection or analysis.\n* Has an active pelvic infection or other infections contra-indicated for laparoscopy.\n* Has participated in any interventional clinical trial in the previous 90 days in which an investigational drug was administered.\n* Has a history of alcohol or illegal drug/substance abuse, or suspected alcohol or illegal drug/substance abuse in the past two years.", "healthyVolunteers": true, "sex": "FEMALE", "genderBased": true, "genderDescription": "Natural born female", "minimumAge": "18 Years", "maximumAge": "50 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Janan Van Osdell, MHSA", "role": "CONTACT", "phone": "855-826-6638", "phoneExt": "102", "email": "janan@tammnet.com"}, {"name": "Somer Baburek, MBA", "role": "CONTACT", "phone": "210-683-1069", "email": "somer@herabiotech.com"}], "overallOfficials": [{"name": "Sandra M Hurtado, MD", "affiliation": "University of Texas Physicians Women's Center", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Charles R Kirkham, MD", "affiliation": "Corpus Christi Women's Clinic", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Jacqueline A Robinson, MD", "affiliation": "Valley OB-GYN Clinic", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Valley OB-GYN Clinic, PC", "status": "NOT_YET_RECRUITING", "city": "Saginaw", "state": "Michigan", "zip": "48602", "country": "United States", "contacts": [{"name": "Mackenzie Rittenberg", "role": "CONTACT", "phone": "989-753-8453", "email": "mackenzie.rittenberg@elligodirect.com"}, {"name": "Jackie Lang", "role": "CONTACT", "phone": "989-753-8453", "email": "jacqueline.lang@elligodirect.com"}, {"name": "Jacqueline A Robinsons, MD", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 43.41947, "lon": -83.95081}}, {"facility": "Corpus Christi Women's Center", "status": "RECRUITING", "city": "Corpus Christi", "state": "Texas", "zip": "78412", "country": "United States", "contacts": [{"name": "Jessica Sanchez", "role": "CONTACT", "phone": "361-851-5000", "email": "Jessica.sanchez@elligodirect.com"}, {"name": "Monica Marroquin", "role": "CONTACT", "phone": "361-851-5000", "email": "monica.marroquin@elligodirect.com"}, {"name": "Charles R Kirkham, MD", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 27.80058, "lon": -97.39638}}, {"facility": "University of Texas Physician's Women's Center--Memorial City", "status": "RECRUITING", "city": "Houston", "state": "Texas", "zip": "77024", "country": "United States", "contacts": [{"name": "Lori L Wink, MSN, NP", "role": "CONTACT", "phone": "706-251-8339", "email": "lori.L.wink@uth.tmc.edu"}, {"name": "Sandry Hurtago, MD", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 29.76328, "lon": -95.36327}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04", "submissionTracking": {"estimatedResultsFirstSubmitDate": "2025-10-09", "submissionInfos": [{"releaseDate": "2025-10-09", "resetDate": "2025-10-24", "mcpReleaseN": 1}]}}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}, {"id": "D004194", "term": "Disease"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}, {"id": "D010335", "term": "Pathologic Processes"}, {"id": "D013568", "term": "Pathological Conditions, Signs and Symptoms"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT03890042", "orgStudyIdInfo": {"id": "DAD"}, "organization": {"fullName": "Assiut University", "class": "OTHER"}, "briefTitle": "Dienogest for Treatment of Adenomyotic Uteri", "officialTitle": "Dienogest Versus a Low-dose Combined Oral Contraceptive for Treatment of Adenomyotic Uteri"}, "statusModule": {"statusVerifiedDate": "2020-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2019-03-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2020-07-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2020-08-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2019-03-23", "studyFirstSubmitQcDate": "2019-03-23", "studyFirstPostDateStruct": {"date": "2019-03-26", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2020-08-22", "lastUpdatePostDateStruct": {"date": "2020-08-25", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Mohammed Khairy Ali", "investigatorTitle": "Lecturer", "investigatorAffiliation": "Assiut University"}, "leadSponsor": {"name": "Assiut University", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "Adenomyosis is a common disease in women aged 40-50 years. It associates with dysmenorrhea and menorrhagia. Hysterectomy was considered the main treatment that could definitively cure this disease. Other treatment options are increasingly offered, including hormonal suppression with gonadotropin-releasing hormone agonists or danazol and endometrial ablation. However, deep adenomyosis responds weakly to the above treatment options, which are commonly not considered for long-term management because of the associated side effects.\n\nDienogest is a progestin medication which is used in birth control pills and in the treatment of endometriosis and adenomyosis. Low-dose combined oral contraceptive (COC) pills have been widely used as the primary treatment for menorrhagia. COCs can also be used to induce endometrial atrophy and to decrease endometrial prostaglandin production, which can consequently improve menorrhagia and dysmenorrhea that are associated with adenomyosis"}, "conditionsModule": {"conditions": ["Adenomyosis"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 100, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Dienogest group", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: Dienogest group", "Radiation: Ultrasound", "Other: visual analogue scale"]}, {"label": "Gynera group", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: Gestodene-Ethinyl Estradiol", "Radiation: Ultrasound", "Other: visual analogue scale"]}], "interventions": [{"type": "DRUG", "name": "Dienogest group", "description": "VISANNE 2MG Tablet once daily", "armGroupLabels": ["Dienogest group"]}, {"type": "DRUG", "name": "Gestodene-Ethinyl Estradiol", "description": "Gynera tablet once daily", "armGroupLabels": ["Gynera group"]}, {"type": "RADIATION", "name": "Ultrasound", "description": "ultrasound assessment of uterine volume", "armGroupLabels": ["Dienogest group", "Gynera group"]}, {"type": "OTHER", "name": "visual analogue scale", "description": "visual analogue scale for assessment of pain", "armGroupLabels": ["Dienogest group", "Gynera group"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of women who will improved from the pelvic pain measured by visual analogue scale", "timeFrame": "6 months"}], "secondaryOutcomes": [{"measure": "Uterine volume (cm 3 ) measure by ultrasound", "timeFrame": "6 month"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Women aged 20-40 years\n* Women with ultrasonographic evidence of adenomyosis\n* Woman complains of vaginal bleeding or pelvic pain related to adenomyosis\n\nExclusion Criteria:\n\n* Women with a history of malignancy or histological evidence of endometrial hyperplasia\n* any adnexal abnormality on ultrasound\n* undiagnosed vaginal\n* contraindication to receive Vissane or gynera .", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "20 Years", "maximumAge": "40 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "Women Health Hospital - Assiut university", "city": "Asyut", "zip": "71111", "country": "Egypt", "geoPoint": {"lat": 27.18096, "lon": 31.18368}}]}, "referencesModule": {"references": [{"pmid": "33454995", "type": "DERIVED", "citation": "Hassanin AI, Youssef AA, Yousef AM, Ali MK. Comparison of dienogest versus combined oral contraceptive pills in the treatment of women with adenomyosis: A randomized clinical trial. Int J Gynaecol Obstet. 2021 Aug;154(2):263-269. doi: 10.1002/ijgo.13600. Epub 2021 Feb 11."}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D062788", "term": "Adenomyosis"}], "ancestors": [{"id": "D014591", "term": "Uterine Diseases"}, {"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C055368", "term": "Femovan"}, {"id": "D019220", "term": "High-Energy Shock Waves"}], "ancestors": [{"id": "D000069453", "term": "Ultrasonic Waves"}, {"id": "D013016", "term": "Sound"}, {"id": "D011840", "term": "Radiation, Nonionizing"}, {"id": "D011827", "term": "Radiation"}, {"id": "D055585", "term": "Physical Phenomena"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT05517746", "orgStudyIdInfo": {"id": "19634"}, "secondaryIdInfos": [{"id": "2019-002573-65", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Bayer", "class": "INDUSTRY"}, "briefTitle": "Study on the Safety of the Drug BAY2395840 at Different Doses, the Way the Body Absorbs, Distributes and Excretes the Drug Including the Effect of Its Formulation (Tablet or Liquid) and the Effect of Food on the Absorption, Distribution or Excretion of the Drug in Healthy Male Participants", "officialTitle": "Randomized, Placebo-controlled, Double-blind Study to Investigate the Safety, Tolerability and Pharmacokinetics of Increasing Single and Multiple Oral Doses of BAY 2395840 Including the Relative Bioavailability Between Solution and Tablet Formulation and the Effect of Food on the Pharmacokinetics of BAY 2395840 in Healthy Men"}, "statusModule": {"statusVerifiedDate": "2022-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2019-12-18", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2020-12-17", "type": "ACTUAL"}, "completionDateStruct": {"date": "2021-03-11", "type": "ACTUAL"}, "studyFirstSubmitDate": "2022-08-24", "studyFirstSubmitQcDate": "2022-08-24", "studyFirstPostDateStruct": {"date": "2022-08-26", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2022-08-24", "lastUpdatePostDateStruct": {"date": "2022-08-26", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Bayer", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "Researchers are looking for a better way to treat people who have endometriosis, a condition in which tissue similar to the lining of the uterus starts to grow in places outside of the uterus. The study treatment, BAY2395840, is being developed to help block certain proteins from causing inflammation and pain in people with endometriosis. But, this is the first time that researchers will study BAY2395840 in humans.\n\nIn this study, the researchers will learn how safe BAY2395840 is for the participants to take. They will also learn what happens to BAY2395840 in the body. The study will include about 56 healthy adult men.\n\nAll of the participants will take increasing doses of BAY2395840, or a placebo. A placebo looks like a treatment but does not have any medicine in it. Some of the participants will take their study treatment 1 time under diet 1 conditions. The other participants will take their study treatment 7 times with diet 1 or diet 2.\n\nThe participants will take BAY2395840 or the placebo as tablets or as a liquid by mouth. The participants will stay at the study site for up to 11 days . After that, they will visit the study site 1 more time. Each participant will be in the study for up to about 14 weeks.\n\nDuring the study, the doctors will collect blood and urine samples and check the participants' overall health and heart health. The participants will answer questions about how they are feeling, what medications they are taking, and what adverse events they are having. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments."}, "conditionsModule": {"conditions": ["Endometriosis"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "SEQUENTIAL", "primaryPurpose": "BASIC_SCIENCE", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 63, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Group 1", "type": "EXPERIMENTAL", "description": "Participants received BAY2395840 dose A as tablets under diet 1 conditions (Period 1). After the safety assessment for Period 1 and a washout period of at least 14 days participants were re-dosed with the same BAY2395840 dose A1 as oral solution under diet 1 conditions (Period 2)", "interventionNames": ["Drug: BAY2395840 tablet", "Drug: BAY2395840 oral solution"]}, {"label": "Group 2", "type": "EXPERIMENTAL", "description": "Participants received BAY2395840 dose C as tablets under diet 1 conditions.", "interventionNames": ["Drug: BAY2395840 tablet"]}, {"label": "Group 3", "type": "EXPERIMENTAL", "description": "Participants received BAY2395840 dose E as tablets under diet 1 conditions.", "interventionNames": ["Drug: BAY2395840 tablet"]}, {"label": "Group 4", "type": "EXPERIMENTAL", "description": "Participants received BAY2395840 dose H as tablets under diet 1 conditions", "interventionNames": ["Drug: BAY2395840 tablet"]}, {"label": "Group 5", "type": "EXPERIMENTAL", "description": "Participants received BAY2395840 dose B as tablets on Day 1 after diet 2, on Days 2 to 7 under diet 1 conditions", "interventionNames": ["Drug: BAY2395840 tablet"]}, {"label": "Group 6", "type": "EXPERIMENTAL", "description": "Participants received BAY2395840 dose C as tablets on Day 1 after diet 2, on Days 2 to 7 under diet 1 conditions", "interventionNames": ["Drug: BAY2395840 tablet"]}, {"label": "Group 7", "type": "EXPERIMENTAL", "description": "Participants received BAY2395840 dose I as tablets under diet 1 conditions", "interventionNames": ["Drug: BAY2395840 tablet"]}, {"label": "Group 8", "type": "EXPERIMENTAL", "description": "Participants received BAY2395840 dose G as tablets on Day 1, followed by 3 BAY395840 doses of dose F as tablets on Days 2 to 4 and subsequently 7 further BAY395840 doses of dose G as tablets on Days 5 to 11 under diet 1 conditions", "interventionNames": ["Drug: BAY2395840 tablet"]}, {"label": "Placebo matching Group 1", "type": "PLACEBO_COMPARATOR", "description": "Participants received a dose of placebo as tablets under diet 1 conditions (Period 1). After the safety assessment for Period 1 and a washout period of at least 14 days participants were re-dosed with a single dose of placebo as oral solution under under diet 1 conditions (Period 2)", "interventionNames": ["Drug: Placebo oral solution", "Drug: Placebo tablet"]}, {"label": "Placebo matching Group 2 to 4 and Group 7", "type": "PLACEBO_COMPARATOR", "description": "Participants received a dose of Placebo as tablets under diet 1 conditions", "interventionNames": ["Drug: Placebo tablet"]}, {"label": "Placebo matching Group 5 and 6", "type": "PLACEBO_COMPARATOR", "description": "Participants received Placebo as tablets on Day 1 after diet 2, on Days 2 to 7 under diet 1 conditions", "interventionNames": ["Drug: Placebo tablet"]}, {"label": "Placebo matching Group 8", "type": "PLACEBO_COMPARATOR", "description": "Participants received a dose of Placebo as tablets on Day 1, followed by 3 doses of Placebo as tablets on Days 2 to 4 and subsequently 7 further doses of Placebo as tablets on Days 5 to 11 under diet 1 conditions.", "interventionNames": ["Drug: Placebo tablet"]}], "interventions": [{"type": "DRUG", "name": "BAY2395840 tablet", "description": "tablets, oral administration", "armGroupLabels": ["Group 1", "Group 2", "Group 3", "Group 4", "Group 5", "Group 6", "Group 7", "Group 8"]}, {"type": "DRUG", "name": "BAY2395840 oral solution", "description": "solution, oral administration", "armGroupLabels": ["Group 1"]}, {"type": "DRUG", "name": "Placebo oral solution", "description": "Placebo matching BAY2395840, oral administration", "armGroupLabels": ["Placebo matching Group 1"]}, {"type": "DRUG", "name": "Placebo tablet", "description": "Placebo matching BAY2395840, oral administration", "armGroupLabels": ["Placebo matching Group 1", "Placebo matching Group 2 to 4 and Group 7", "Placebo matching Group 5 and 6", "Placebo matching Group 8"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of participants with treatment-emergent adverse events", "timeFrame": "Up to 14 days after end of treatment with study medication in the respective period."}, {"measure": "Number of participants with treatment-emergent adverse events, categorized by severity.", "timeFrame": "Up to 14 days after end of treatment with study medication in the respective period."}], "secondaryOutcomes": [{"measure": "Maximum observed drug concentration in plasma (Cmax) after single dose of BAY2395840", "timeFrame": "Predose up to 192 hours"}, {"measure": "Area under the concentration vs. time curve from zero to infinity (AUC) in plasma after single dose of BAY2395840", "timeFrame": "Predose up to 192 hours"}, {"measure": "Area under the plasma concentration-time curve from zero to 24 hours AUC (0-24) after single dose of BAY2395840", "description": "AUC from time 0 to 24 hours", "timeFrame": "Pre-dose and up to 24 hours post dose"}, {"measure": "Maximum observed drug concentration in plasma (Cmax) after multiple doses of BAY2395840", "timeFrame": "Predose up to 192 hours"}, {"measure": "Area under the plasma concentration-time curve over the last 24-h dosing interval AUC(0-24)in plasma after multiple doses of BAY2395840", "description": "AUC from time 0 to 24 hours", "timeFrame": "Pre-dose and up to 24 hours post dose"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Male participants of age 18 to 45 years (inclusive), at the time of signing the informed consent.\n* Body mass index (BMI) ≥18 kg/m\\^2 and ≤30 kg/m\\^2.\n* Participants who are overtly healthy.\n* Race: White.\n* Male participants of reproductive potential who are sexually active must agree to use contraception methods.\n\nExclusion Criteria:\n\n* Any findings from the medical examination (including medical history, physical examination, vital signs, laboratory tests and ECG) deviating from normal and deemed to be of clinical relevance by the investigator.\n* Any known disease that was forbidden in the study as specified in study protocol.\n* Any medication or drug use that was forbidden in the study as specified in study protocol.\n* Any abnormal finding in Electrocardiogram (ECG), blood pressure or heart rate.\n* Any clinical relevant deviation from normal range of laboratory parameters at screening.\n* History of COVID-19.\n* Prior contact with SARS-CoV-2 positive person or COVID-19 patient within the last 4 weeks prior admission to the ward.\n* Positive SARS-CoV-2 viral RNA test.", "healthyVolunteers": true, "sex": "MALE", "minimumAge": "18 Years", "maximumAge": "45 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "CRS Clinical Research Services Berlin GmbH", "city": "Berlin", "zip": "13353", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO", "description": "Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA \"Principles for responsible clinical trial data sharing\". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal."}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT03828591", "orgStudyIdInfo": {"id": "ENDO.PS."}, "organization": {"fullName": "IRCCS Azienda Ospedaliero-Universitaria di Bologna", "class": "OTHER"}, "briefTitle": "Endometriosis and Psychological Support", "officialTitle": "The Impact of Psychological Support During the Hospitalization in Women With Endometriosis"}, "statusModule": {"statusVerifiedDate": "2019-05", "overallStatus": "UNKNOWN", "lastKnownStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2019-03-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2019-08", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2019-09", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2019-01-24", "studyFirstSubmitQcDate": "2019-02-01", "studyFirstPostDateStruct": {"date": "2019-02-04", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2019-05-13", "lastUpdatePostDateStruct": {"date": "2019-05-15", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Renato Seracchioli", "investigatorTitle": "principal investigator", "investigatorAffiliation": "IRCCS Azienda Ospedaliero-Universitaria di Bologna"}, "leadSponsor": {"name": "IRCCS Azienda Ospedaliero-Universitaria di Bologna", "class": "OTHER"}}, "oversightModule": {"isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "Endometriosis is a common disease, causing significant pain (dysmenorrhea, dysuria, dyspnea, dyspareunia, and chronic pelvic pain) and infertility, drastically reducing patients' quality of life.\n\nEndometriosis surgery is often a stressful event for the patient. For that reason, psychological support can improve patients' general health state.", "detailedDescription": "Patients with clinical and trans-vaginal / abdominal ultrasound diagnosis of endometriosis, undergoing surgery for the removal of endometriotic lesions are included in the study.\n\nPsychological support is offered to all women one month before and one month after surgery. A group of patients will receive intensive psychological support during hospitalization.\n\nPatients are divided into 2 groups:\n\nGroup A: patients receiving intensive psychological support during hospitalization\n\nGroup B: patients not receiving intensive psychological support during hospitalization\n\nAfter surgery, patients will be included in the post-operative follow-up, as usual in the investigator's clinical practice."}, "conditionsModule": {"conditions": ["Endometriosis"], "keywords": ["Endometriosis", "Psychological support"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "OTHER", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 50, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Group A (intensive support)", "type": "OTHER", "description": "Patients that receive standard and intensive psychological support during hospitalization", "interventionNames": ["Procedure: Intensive psychological support", "Procedure: Standard psychological support"]}, {"label": "Group B (standard support)", "type": "OTHER", "description": "Patients that receive only standard psychological support during hospitalization", "interventionNames": ["Procedure: Standard psychological support"]}], "interventions": [{"type": "PROCEDURE", "name": "Intensive psychological support", "description": "Two meeting with a psychologist during the hospitalization (the first two days after surgery; the second one at the moment of the hospitalization discharge)", "armGroupLabels": ["Group A (intensive support)"]}, {"type": "PROCEDURE", "name": "Standard psychological support", "description": "Two meetings with a psychologist: the first meeting is one month before surgery; the second meeting is one month after surgery", "armGroupLabels": ["Group A (intensive support)", "Group B (standard support)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "General health state", "description": "Measurement of quality of life of patients underwent surgery for endometriosis, using the validated questionnaire Clinical Outcomes In Routine Evaluation, with a total score from 1 (the best outcome) to more than 85 (the worse outcome), where: 1 to 20 is Healthy; 21 to 33 is Low level; 34 to 50 is Mild level; 51 to 67 is Moderate level; 68 to 84 is Moderate to severe level; more than 85 is Severe level. The questionnaire is submitted one month before surgery and at the hospitalization discharge.", "timeFrame": "From one month before surgery until the hospitalization discharge; assessed up to 7 days after surgery"}], "secondaryOutcomes": [{"measure": "Postoperative pain: Numeric Rating Scale", "description": "Evaluation of postoperative pain using Numeric Rating Scale, from 0 to 10 (where 0 is no pain and 10 is the worse pain ever).", "timeFrame": "Postoperative: at the hospitalization discharge (assessed up to 7 days after surgery) and one month after surgery"}, {"measure": "Anxiety and Depression", "description": "Measurement of anxiety and depression of patients underwent surgery for endometriosis, using the validated questionnaire Hospital Anxiety and Depression Scale, from 0 (the best outcome) to 21 (the worse outcome), where: 0 to 7 is Normal; 8 to 10 is Borderline case; 11 to 21 is Abnormal.", "timeFrame": "From one month before surgery until the hospitalization discharge; assessed up to 7 days after surgery"}, {"measure": "Stress", "description": "Measurement of stress in patients underwent surgery for endometriosis, using the validated questionnaire Perceived Stress Scale, from 0 (the best outcome) to 40 (the worse outcome), where scores ranging from 0-13 would be considered low stress; scores ranging from 14-26 would be considered moderate stress; scores ranging from 27-40 would be considered high perceived stress.", "timeFrame": "From one month before surgery until the hospitalization discharge; assessed up to 7 days after surgery"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patients undergoing surgery for endometriosis\n* Patients that have signed an informed consent\n\nExclusion Criteria:\n\n* Patients with active or history of psychological/psychiatric diseases\n* Patients that refuse psychological support", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "50 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Alessandro Arena, MD", "role": "CONTACT", "phone": "0512144385", "email": "alessandroarena1588@gmail.com"}], "locations": [{"facility": "Azienda Ospedaliero-Universitaria Sant'Orsola Malpighi", "status": "RECRUITING", "city": "Bologna", "state": "BO", "zip": "40138", "country": "Italy", "contacts": [{"name": "Alessandro Arena, MD", "role": "CONTACT", "phone": "0512144385", "email": "alessandroarena1588@gmail.com"}, {"name": "Renato Seracchioli, MD", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Alessandro Arena, MD", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Federica Manzara, MD", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Chiara Ferracuti, Psychologist", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Manuela Mastronardi, MD", "role": "SUB_INVESTIGATOR"}], "geoPoint": {"lat": 44.49381, "lon": 11.33875}}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT02762461", "orgStudyIdInfo": {"id": "MMF2016"}, "organization": {"fullName": "University of Aarhus", "class": "OTHER"}, "briefTitle": "Artificial Reproductive Techniques (ART) and Progression of Endometriosis Symptoms", "officialTitle": "Artificial Reproductive Techniques (ART) and Progression of Endometriosis Symptoms"}, "statusModule": {"statusVerifiedDate": "2018-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2016-02", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2018-04", "type": "ACTUAL"}, "completionDateStruct": {"date": "2018-04", "type": "ACTUAL"}, "studyFirstSubmitDate": "2016-04-28", "studyFirstSubmitQcDate": "2016-05-02", "studyFirstPostDateStruct": {"date": "2016-05-05", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2018-04-05", "lastUpdatePostDateStruct": {"date": "2018-04-06", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "University of Aarhus", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This project will investigate worsening of symptoms in endometriosis patients undergoing artificial reproductive techniques (ART). The study compares patients with peritoneal/ovarian and deep infiltrating endometriosis to relevant reference groups. Symptoms are monitored with a questionnaire with the categories quality of life, pain and bowel habits. The EHP-30® questionnaire is included in the questionnaire.", "detailedDescription": "Endometriosis affects up to 10% of all fertile women, and is associated with symptoms like infertility, dysmenorrhea, deep dyspareunia and chronic pelvic pain. 10-25% of endometriosis patients need artificial reproductive techniques (ART) to become pregnant. Endometriosis is estrogen dependent, and in theory this means, that the increased levels of estrogen during fertility treatment will worsen endometriosis symptoms. Endometriosis is a benign disease, and treatment is guided by the patient's symptoms. Worsening of endometriosis symptoms during fertility treatment may result in cessation of the treatment, operation and risk of complications.\n\nThis project will investigate worsening of symptoms in endometriosis patients undergoing artificial reproductive techniques (ART). The study compares endometriosis patients undergoing ART to two relevant reference groups; one group consisting women undergoing ART with infertility because of factors other than endometriosis, and one group consisting women with medically treated endometriosis not undergoing ART. Symptoms of endometriosis during ART will be monitored using a questionnaire that among other questions includes the validated questionnaire Endometriosis Health Profile 30® (EHP-30®). The questionnaire is administered before starting ART and later in the cycle before the patient gets to know if she is pregnant. The questionnaires as well as data collection will be administered electronically in REDCap® which is a secure web application for building and managing online surveys and databases."}, "conditionsModule": {"conditions": ["Endometriosis"], "keywords": ["Fertilization in Vitro", "Sperm Injections, Intracytoplasmic", "Endometriosis"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": true, "targetDuration": "4 Weeks", "designInfo": {"observationalModel": "COHORT", "timePerspective": "PROSPECTIVE"}, "enrollmentInfo": {"count": 154, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Exposed group", "description": "Women with peritoneal/ovarian endometriosis and DIE (rectovaginal and rectosigmoid endometriosis) undergoing ART (IVF or ICSI).", "interventionNames": ["Procedure: IVF or ICSI"]}, {"label": "Reference group 1", "description": "Women with infertility because of factors other than endometriosis, e.g. male factor, undergoing ART (IVF or ICSI).", "interventionNames": ["Procedure: IVF or ICSI"]}, {"label": "Reference group 2", "description": "Women with medically treated endometriosis not undergoing ART."}], "interventions": [{"type": "PROCEDURE", "name": "IVF or ICSI", "armGroupLabels": ["Exposed group", "Reference group 1"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Endometriosis Health Profile 30® (EHP-30®)", "description": "The core instruments have five scale scores covering: Pain (11 questions), control and powerlessness (6 questions), social support (4 questions), emotional well-being (6 questions), self-image (3 questions).", "timeFrame": "Groups undergoing ART: Change from baseline measures before stimulation during ART to ten days after aspiration. Reference group not undergoing ART: Change from baseline measures to four weeks later."}], "secondaryOutcomes": [{"measure": "Pain (NRS scale: 0-10)", "description": "Three categories with frequency, general, and worst perception of pain. In each category the patient has to rate her pain on the NRS scale according to dysmenorrhea, chronic pelvic pain, dyspareunia, defecation and urination pain. In addition there are qualitative questions in the same categories of pain.", "timeFrame": "Groups undergoing ART: Change from baseline measures before stimulation during ART to ten days after aspiration. Reference group not undergoing ART: Change from baseline measures to four weeks later."}, {"measure": "Bowel habits", "description": "Defecation frequency and time, stool consistency and blood in stool. Frequency and general perception of five bowel symptoms (constipation, diarrhea, nauseousness, emesis, and bloatedness) on a scale from 0-10.", "timeFrame": "Groups undergoing ART: Change from baseline measures before stimulation during ART to ten days after aspiration. Reference group not undergoing ART: Change from baseline measures to four weeks later."}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Female\n* \\< 40 years\n* Either undergoing ART (IVF or ICSI) with or without endometriosis or medically treated endometriosis\n\nExclusion Criteria:\n\n* \\> 40 years", "healthyVolunteers": false, "sex": "FEMALE", "maximumAge": "40 Years", "stdAges": ["CHILD", "ADULT"], "studyPopulation": "Women with endometriosis under the age of 40 years.", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"overallOfficials": [{"name": "Mie Mathiasen, Student", "affiliation": "University of Aarhus", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Department of Gynaecology and Obstetrics, Aarhus University Hospital", "city": "Aarhus", "zip": "8000", "country": "Denmark", "geoPoint": {"lat": 56.15674, "lon": 10.21076}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D020554", "term": "Sperm Injections, Intracytoplasmic"}], "ancestors": [{"id": "D005307", "term": "Fertilization in Vitro"}, {"id": "D027724", "term": "Reproductive Techniques, Assisted"}, {"id": "D012099", "term": "Reproductive Techniques"}, {"id": "D013812", "term": "Therapeutics"}, {"id": "D008919", "term": "Investigative Techniques"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT03927651", "orgStudyIdInfo": {"id": "STU00208846"}, "organization": {"fullName": "Northwestern University", "class": "OTHER"}, "briefTitle": "ICG to Assess Ovarian Perfusion", "officialTitle": "Intraoperative Use of Intravenous Indocyanine Green (ICG) to Assess Ovarian Perfusion Using Infrared Imaging: A Feasibility Pilot Study"}, "statusModule": {"statusVerifiedDate": "2023-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2019-06-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2022-11-15", "type": "ACTUAL"}, "completionDateStruct": {"date": "2022-11-15", "type": "ACTUAL"}, "studyFirstSubmitDate": "2019-04-09", "studyFirstSubmitQcDate": "2019-04-24", "studyFirstPostDateStruct": {"date": "2019-04-25", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-04-13", "lastUpdatePostDateStruct": {"date": "2023-04-18", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Magdy Milad, MD", "investigatorTitle": "Chief of Minimally Invasive Gynecologic Surgery in the Department of Obstetrics and Gynecology Albert B. Gerbie, MD, Professor of Obstetrics and Gynecology Professor of Obstetrics and Gynecology (Minimally Invasive Gynecologic Surgery)", "investigatorAffiliation": "Northwestern University"}, "leadSponsor": {"name": "Northwestern University", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false, "isUsExport": true}, "descriptionModule": {"briefSummary": "To assess the feasibility of using intravenous ICG to characterize the vascular perfusion of ovaries during gynecologic surgery", "detailedDescription": "The purpose of this study is to determine the feasibility of intravenous ICG administration to facilitate assessments of ovarian vascular perfusion. Historically, assessment of ovarian perfusion has been performed visually or via ultrasound with Doppler evaluation. In patients with ovarian endometriomas, evidence of ovarian interstitial microvascular injury has been demonstrated similarly by the presence of low flow and high RI. The use of ICG to evaluate ovarian perfusion specifically has not been reported. The use of ICG for intraoperative perfusion assessment of the ovary could provide more information about the health of the ovary and inform the surgical approach to ovarian pathology.\n\nICG will be injected intravenously to assess ovarian perfusion in the presence or absence (control) of pathology. Near infrared fluorescence imaging will be used to illuminate the ICG. The extent of perfusion will be determined using digital imaging software."}, "conditionsModule": {"conditions": ["Fibroid Uterus", "Endometriosis", "Uterus Myoma", "Uterine Fibroid", "Uterine Adenomyosis", "Endometrial Cyst", "Uterine Cyst"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["EARLY_PHASE1"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "DIAGNOSTIC", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 54, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Administration of ICG", "type": "EXPERIMENTAL", "description": "ICG will be injected intravenously to assess ovarian perfusion in the presence or absence (control) of pathology. Near infrared fluorescence imaging will be used to illuminate the ICG. The extent of perfusion will be determined using digital imaging software. ICG will be stored at the NM Investigational Pharmacy and administered intravenously by the anesthesiologist at the direction of the surgeon during surgical procedure.", "interventionNames": ["Drug: ICG"]}], "interventions": [{"type": "DRUG", "name": "ICG", "description": "Indocyanine green (ICG) is a Food and Drug (FDA)-approved tricarbocyanine dye that is fluorescent under near-infrared (NIR) light. ICG solutions for injection often contain sodium iodide. ICG is water soluble and when introduced intravenously, it is bound by plasma proteins, namely albumin. The intravascular half-life of ICG is 3-4 minutes with rapid hepatic clearance.", "armGroupLabels": ["Administration of ICG"], "otherNames": ["Indocyanine green (ICG)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Assessment of ovarian perfusion after ICG administration via fluorescent imaging", "description": "The investigators will be assessing the feasibility of using intravenous ICG to characterize the vascular perfusion of ovaries by imaging. During surgery ICG will be administered intravenously via a peripheral or central line at the direction of the surgeon by the anesthesiologist. The injected amount will be a 3 mL solution of reconstituted ICG that contains a 7.5 mg dose of ICG. This will be followed by a 10 mL bolus of normal saline for injection per the manufacturer's recommendation. The total dose of dye injected should not exceed 2 mg/kg.\n\nVisibility of the ICG fluorescence should occur within 1-2 minutes with a duration of 20-120 minutes.", "timeFrame": "2 years"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patients attending a preoperative visit at the Center for Comprehensive Gynecology who will undergo surgery.\n\nExclusion Criteria:\n\n* Not able to comprehend and sign a written consent\n* Patients with a history of allergy to iodides\n* Patients history of renal failure or uremia, and those on dialysis", "healthyVolunteers": true, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "50 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Magdy Milad, MD,MS", "affiliation": "Northwestern University", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "259 E Erie - Northwestern", "city": "Chicago", "state": "Illinois", "zip": "60611", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}]}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2020-06-08", "uploadDate": "2020-09-22T11:45", "filename": "Prot_000.pdf", "size": 170080}, {"typeAbbrev": "ICF", "hasProtocol": false, "hasSap": false, "hasIcf": true, "label": "Informed Consent Form", "date": "2020-06-08", "uploadDate": "2020-09-22T11:45", "filename": "ICF_001.pdf", "size": 155295}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D007889", "term": "Leiomyoma"}, {"id": "D004715", "term": "Endometriosis"}, {"id": "D047708", "term": "Myofibroma"}, {"id": "D062788", "term": "Adenomyosis"}], "ancestors": [{"id": "D009379", "term": "Neoplasms, Muscle Tissue"}, {"id": "D018204", "term": "Neoplasms, Connective and Soft Tissue"}, {"id": "D009370", "term": "Neoplasms by Histologic Type"}, {"id": "D009369", "term": "Neoplasms"}, {"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}, {"id": "D009372", "term": "Neoplasms, Connective Tissue"}, {"id": "D003240", "term": "Connective Tissue Diseases"}, {"id": "D017437", "term": "Skin and Connective Tissue Diseases"}, {"id": "D014591", "term": "Uterine Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D007208", "term": "Indocyanine Green"}], "ancestors": [{"id": "D007211", "term": "Indoles"}, {"id": "D006574", "term": "Heterocyclic Compounds, 2-Ring"}, {"id": "D000072471", "term": "Heterocyclic Compounds, Fused-Ring"}, {"id": "D006571", "term": "Heterocyclic Compounds"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT07037251", "orgStudyIdInfo": {"id": "0129-23-AAA"}, "organization": {"fullName": "Assuta Ashdod Hospital", "class": "OTHER"}, "briefTitle": "Screening for Fibromyalgia Among Patients With Suspected Endometriosis", "officialTitle": "Screening for Fibromyalgia Among Patients With Suspected Endometriosis"}, "statusModule": {"statusVerifiedDate": "2025-06", "overallStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2024-07-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2027-05", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2027-05", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2024-05-19", "studyFirstSubmitQcDate": "2025-06-23", "studyFirstPostDateStruct": {"date": "2025-06-25", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2025-06-23", "lastUpdatePostDateStruct": {"date": "2025-06-25", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Assuta Ashdod Hospital", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The main purposes of the study are:\n\nTo determine the prevalence of fibromyalgia among patients with suspected endometriosis during their initial visit to an endometriosis clinic.\n\nSecondary aims include staging of endometriosis in these patients according to the AAGL (16,17) endometriosis classification and correlate the prevalence of fibromyalgia with ultrasound and surgical findings. Another aim will be to assess the improvement in symptoms in patients diagnosed with both disorders in comparison to patients with either one separately.\n\nAll women with suspected endometriosis will be asked to complete the questionnaire before their first visit to the doctor's office.\n\nStudy design\n\n* A single center prospective cohort study\n* All patients attending to Endometriosis clinic at Assuta Ashdod University Hospital with suspected endometriosis at initial visit and who will consent and able to sign the consent form for participation.\n* Fibromyalgia will be defined by the ACR Preliminary Diagnostic Criteria, including Widespread Pain Index, Symptoms severity scale and somatic symptoms.\n* The treating physician will blinded to questionnaire results until the end of the visit.\n* At the end of the visit the questionnaire will be analyzed by one of the investigators and if fibromyalgia is found, the patient will also be referred for treatment of this disorder along with the endometriosis treatment.\n* Questionnaires will be coded with numbers from 1 to 150.", "detailedDescription": "Screening for fibromyalgia among patients with suspected endometriosis Introduction Fibromyalgia is a chronic pain syndrome affecting mainly females. Most patients have soft tissue sensitivity and pain, without any abnormality indicating inflammation or damage to those tissues. Therefore, diagnosis of the disease is made promptly by ruling out other conditions and assessing the patients with physical examination and designated thorough questionnaires. For epidemiological purposes the common questionnaire is the London Fibromyalgia Epidemiology Study Screening Questionnaire (LFESSQ) based on pain and fatigue criteria, without referring to tender points. The most recent and practical questionnaire for diagnosing and assessing the severity of the syndrome is the Modified ACR Preliminary Diagnostic Criteria, first published in 2011 and revised in 2016. A patient that fulfills the diagnostic criteria according to the questionere can be diagnosed with this condition without need for other tests.\n\nThe pathophysiology of fibromyalgia is not well understood, however is has been extensitvely studied. It is suggested that changes in central pain modulation cause widespread pain and it is associated withseveral genetic and environmental risk factors. This phenomenon of central sensitization also plays a role in chronic pain in patients with endometriosis.\n\nFibromyalgia and its relation to endometriosis have been studied. Similarly to fibromyalgia, endometriosis is associated with chronic pain and comorbidities. Greenbaum et al. found that endometriosis and fibromyalgia are both associated with autoimmune diseases, such as inflammatory bowel disease and rheumatic arthritis. In addition, both conditions are known to reduce the quality of life and have been associated with depressive symptoms. A study by Nunes et al examined whether there is a difference in the prevalence of fibromyalgia among healthy women or those diagnosed with endometriosis. They did not find any difference in the prevalence between the two groups, however they did identify that the quality of life among women diagnosed with endometriosis was poorer. Another study by Coloma et al. found that there is a higher prevalence of fibromyalgia among women diagnosed with deep infiltrating endometriosis using the LFESSQ, and once again poorer quality of life. Diagnosing fibromyalgia in patients with endometriosis might impact our treatment in these patients, enabling us to better address their pain and offer more focused treatment.\n\nAs far as we know, no study was performed in order to assess the prevalence of fibromyalgia in patients with suspected endometriosis as part of their initial visit.\n\nObjectives:\n\nThe main purposes of the study are:\n\nTo determine the prevalence of fibromyalgia among patients with suspected endometriosis during their initial visit to an endometriosis clinic.\n\nSecondary aims include staging of endometriosis in these patients according to the AAGL endometriosis classification and correlate the prevalence of fibromyalgia with ultrasound and surgical findings. Another aim will be to assess the improvement in symptoms in patients diagnosed with both disorders in comparison to patients with either one separately.\n\nAll women with suspected endometriosis will be asked to complete the questionnaire before their first visit to the doctor's office.\n\nStudy design\n\n* A single center prospective cohort study\n* All patients attending to Endometriosis clinic at Assuta Ashdod University Hospital with suspected endometriosis at initial visit and who will consent and able to sign the consent form for participation.\n* Fibromyalgia will be defined by the ACR Preliminary Diagnostic Criteria, including Widespread Pain Index, Symptoms severity scale and somatic symptoms.\n* The treating physician will blinded to questionnaire results until the end of the visit.\n* At the end of the visit the questionnaire will be analyzed by one of the investigators and if fibromyalgia is found, the patient will also be referred for treatment of this disorder along with the endometriosis treatment.\n* Questionnaires will be coded with numbers from 1 to 150.\n\nInclusion criteria All women with suspected endometriosis in their first visit to endometriosis clinics in Assuta Ashdod Hospital Exclusion criteria Proven fibromyalgia prior to the first visit. Sample size According to previous studies , have used a sample size of 229 patients ,difference between fibromyalgia prevalence in patients with and without endometriosis 6,7% (CI 1.8 -20.5) we assume that 150 eligible cases will be found sufficient ( with 80% power and 5% significance level) Statistical analysis: results will be summarized in Excel table and then analyzed by statistician and the investigators."}, "conditionsModule": {"conditions": ["Fibromyalgia", "Endometriosis"], "keywords": ["fibromialgia", "endometriosis"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "COHORT", "timePerspective": "PROSPECTIVE"}, "enrollmentInfo": {"count": 150, "type": "ESTIMATED"}}, "armsInterventionsModule": {"interventions": [{"type": "OTHER", "name": "there is no intervention", "description": "there is no intervention only observation"}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Occurrence of Fibromyalgia in patients with endometriosis", "description": "Occurrence of Fibromyalgia on first visit to endometriosis clinic", "timeFrame": "within 2 years from the beginning of the study"}], "secondaryOutcomes": [{"measure": "staging of endometriosis in these patients according to the AAGL (16,17) endometriosis classification and correlate the prevalence of fibromyalgia with ultrasound and surgical findings.", "description": "staging of endometriosis in these patients according to the AAGL (16,17) endometriosis classification and correlate the prevalence of fibromyalgia with ultrasound and surgical findings.", "timeFrame": "The questionnaire will be annalized at the end of the study, within 2 years of initial visit"}, {"measure": "To determine the prevalence of fibromyalgia among patients with suspected endometriosis during their initial visit to an endometriosis clinic.", "description": "Patients will fill diagnostic questionnaire for fibromialgia that will be analyzed by rheumatologists. To determine the prevalence of fibromyalgia among patients with suspected endometriosis during their initial visit to an endometriosis clinic.", "timeFrame": "questionnaire for fibromialgia will be filled up to one day from visit to clinic"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* All women with suspected endometriosis in their first visit to endometriosis clinics in Assuta Ashdod Hospital\n\nExclusion Criteria:\n\n* Proven fibromyalgia prior to the first visit.", "healthyVolunteers": false, "sex": "FEMALE", "genderBased": true, "genderDescription": "women", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"], "studyPopulation": "All women with suspected endometriosis in their first visit to endometriosis clinics in Assuta Ashdod Hospital", "samplingMethod": "PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"centralContacts": [{"name": "Oshri Barel, MD", "role": "CONTACT", "phone": "+972559382117", "email": "oshrib@assuta.co.il"}], "locations": [{"facility": "Assuta Ashdod University Hospital", "status": "RECRUITING", "city": "Ashdod", "country": "Israel", "contacts": [{"name": "Oshri Barel, MD", "role": "CONTACT", "phone": "0559382117", "email": "PRIVATEPRACTICE.BAREL@GMAIL.COM"}, {"name": "oshri Barel, MD", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 31.79213, "lon": 34.64966}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D005356", "term": "Fibromyalgia"}, {"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D009135", "term": "Muscular Diseases"}, {"id": "D009140", "term": "Musculoskeletal Diseases"}, {"id": "D012216", "term": "Rheumatic Diseases"}, {"id": "D009468", "term": "Neuromuscular Diseases"}, {"id": "D009422", "term": "Nervous System Diseases"}, {"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT06414720", "orgStudyIdInfo": {"id": "ENDOmiRNA"}, "organization": {"fullName": "University of Udine", "class": "OTHER"}, "briefTitle": "Salivary microRNA in Endometriosis: Correlation With Response to Progestin Therapy", "officialTitle": "Salivary MicroRNA in Endometriosis: Correlation With Progestin Treatment Response: A Prospective Observational Study", "acronym": "ENDOmiRNA"}, "statusModule": {"statusVerifiedDate": "2025-03", "overallStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2024-04-22", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2025-12-01", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2025-12-01", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2024-05-05", "studyFirstSubmitQcDate": "2024-05-09", "studyFirstPostDateStruct": {"date": "2024-05-16", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2025-03-27", "lastUpdatePostDateStruct": {"date": "2025-04-02", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Giuseppe Vizzielli", "investigatorTitle": "Professor", "investigatorAffiliation": "University of Udine"}, "leadSponsor": {"name": "University of Udine", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false, "isUsExport": false}, "descriptionModule": {"briefSummary": "This study aims to analyze the salivary miRNA specific for patients diagnosed with endometriosis, specifically evaluating the miRNA profile of patients who respond versus those who do not respond to progestin therapy. Ninety patients attending the Chronic Pelvic Pain Clinic will be recruited, and they will be asked to provide a saliva sample before starting medical therapy. The response to the therapy will be evaluated after 4 months from the beginning of the therapy itself.", "detailedDescription": "In recent years, scientific literature has focused on the search for new non-invasive diagnostic tools that can identify patients with endometriosis early and easily, thereby reducing diagnostic delay and enabling the immediate initiation of appropriate treatment. Among these, microRNA (miRNA) is emerging as a promising option. Despite recent progress in this field, a predictive biomarker of response to medical therapy or vice versa, resistance to progesterone in endometriosis, has not yet been identified, including among miRNAs. This study aims, therefore, to identify salivary miRNA signatures specific to endometriosis and differentially expressed between responder and non-responder patients to 2 mg dienogest medical therapy. 90 patients diagnosed with endometriosis attending the Obstetrics and Gynecology Clinic at the Santa Maria della Misericordia Hospital in Udine will be enrolled. The investigators will ask them for a salivary sample before starting the progestin therapy. After 4 months from the beginning, the response will be evaluated. The researchers will evaluate the differences between salivary miRNA of the responders vs non-responders."}, "conditionsModule": {"conditions": ["Endometriosis"], "keywords": ["Endometriosis", "miRNA", "Progesterone resistance"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "COHORT", "timePerspective": "PROSPECTIVE"}, "bioSpec": {"retention": "SAMPLES_WITH_DNA", "description": "salivary specimen"}, "enrollmentInfo": {"count": 90, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Endometriosis patients", "description": "Patients diagnosed with endometriosis attending the Obstetrics and Gynecology Clinic at the Santa Maria della Misericordia Hospital in Udine, who have not yet started medical therapy.", "interventionNames": ["Drug: Dienogest 2 MG"]}], "interventions": [{"type": "DRUG", "name": "Dienogest 2 MG", "description": "The patients will be started on progestin therapy after a saliva sample is collected from them for miRNA analysis.", "armGroupLabels": ["Endometriosis patients"], "otherNames": ["zafrilla", "devicius", "endodien", "visanne"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "response to the progestin therapy", "description": "response to 2 mg dienogest therapy evaluated with NRS (numeric rating scale) scale assessed for acyclic pain, dyspareunia, dyschezia, dysmenorrhea, periovulatory pain", "timeFrame": "0 (pre-therapy) - 4 months (after therapy)"}, {"measure": "changes in quality of life", "description": "changes in quality of life assessed with questionnaire SF-36 (Short Form Health Survey 36)", "timeFrame": "0 (pre-therapy) - 4 months (after therapy)"}, {"measure": "differences in salivary miRNoma", "description": "Once it is established which patients are responders and which are non-responders, differential salivary miRNAs between the two groups will be identified via sequencing. The miRNA reverse transcription reaction will be performed using the reverse transcription kit TaqMan MicroRNA (Applied Biosystems). The reverse transcription product will be used for Real-time PCR. The small nucleolar RNA RNU6 will be used as an endogenous control. The protocol of Amplification will be carried out using the LightCycler 480 instrument (Roche). For each miRNA, qPCR will be performed in duplicate. The relative expression levels of miRNAs will be calculated using the 2-ΔΔCt method.", "timeFrame": "sample collection at time 0, analysis after time 4"}]}, "eligibilityModule": {"eligibilityCriteria": "INCLUSION CRITERIA\n\n* Age \\> 18 years\n* Fertile age\n* Clinical-ultrasound diagnosis or histological diagnosis of endometriosis\n* Informed consent\n\nEXCLUSION CRITERIA\n\n* Pregnancy\n* Pre-menarcheal or post-menopausal status\n* Chronic pelvic pain syndrome with or without central sensitization assessed with the Central Sensitization Inventory Test (CSI)\n* Neoplasia, diabetes, BMI \\> 30 kg/m2, coagulopathies, autoimmune diseases, or other conditions that may affect salivary miRNA measurement\n* Currently undergoing progestin therapy", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "45 Years", "stdAges": ["ADULT"], "studyPopulation": "All the patients diagnosed with endometriosis attending the Obstetrics and Gynecology Clinic at the Santa Maria della Misericordia Hospital in Udine, who meet the inclusion criteria.", "samplingMethod": "PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"centralContacts": [{"name": "Matilde Degano, dr", "role": "CONTACT", "phone": "3206173076", "phoneExt": "0039", "email": "matildedegano@rocketmail.com"}, {"name": "Anna Biasioli, dr", "role": "CONTACT", "email": "anna.biasioli@asufc.sanita.fvg.it"}], "overallOfficials": [{"name": "Giuseppe Vizzielli, prof", "affiliation": "University of Udine", "role": "STUDY_CHAIR"}], "locations": [{"facility": "University of Udine", "status": "RECRUITING", "city": "Udine", "state": "UD", "zip": "33100", "country": "Italy", "contacts": [{"name": "Matilde Degano, dr", "role": "CONTACT", "phone": "3206173076", "phoneExt": "0039", "email": "matildedegano@rocketmail.com"}, {"name": "Anna Biasioli, dr", "role": "CONTACT", "email": "anna.biasioli@asufc.sanita.fvg.it"}, {"name": "Daniela Cesselli, prof", "role": "SUB_INVESTIGATOR"}, {"name": "Michela Bulfoni, dr", "role": "SUB_INVESTIGATOR"}], "geoPoint": {"lat": 46.0693, "lon": 13.23715}}]}, "referencesModule": {"references": [{"pmid": "35160066", "type": "BACKGROUND", "citation": "Bendifallah S, Suisse S, Puchar A, Delbos L, Poilblanc M, Descamps P, Golfier F, Jornea L, Bouteiller D, Touboul C, Dabi Y, Darai E. Salivary MicroRNA Signature for Diagnosis of Endometriosis. J Clin Med. 2022 Jan 26;11(3):612. doi: 10.3390/jcm11030612."}, {"pmid": "37108154", "type": "BACKGROUND", "citation": "Zhang P, Wang G. Progesterone Resistance in Endometriosis: Current Evidence and Putative Mechanisms. Int J Mol Sci. 2023 Apr 10;24(8):6992. doi: 10.3390/ijms24086992."}, {"pmid": "37834449", "type": "BACKGROUND", "citation": "Hon JX, Wahab NA, Karim AKA, Mokhtar NM, Mokhtar MH. MicroRNAs in Endometriosis: Insights into Inflammation and Progesterone Resistance. Int J Mol Sci. 2023 Oct 9;24(19):15001. doi: 10.3390/ijms241915001."}]}, "ipdSharingStatementModule": {"ipdSharing": "UNDECIDED"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}, {"id": "C564871", "term": "Progesterone Resistance"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C023635", "term": "dienogest"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT06060756", "orgStudyIdInfo": {"id": "ENDOSAS"}, "organization": {"fullName": "Elsan", "class": "OTHER"}, "briefTitle": "Assessment of the Occurrence of Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) in Women Suffering from Endometriosis", "officialTitle": "Assessment of the Occurrence of Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) in French Women Suffering from Endometriosis.", "acronym": "ENDOSAS"}, "statusModule": {"statusVerifiedDate": "2024-09", "overallStatus": "NOT_YET_RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2024-10", "type": "ESTIMATED"}, "primaryCompletionDateStruct": {"date": "2025-10", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2026-10", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2023-09-25", "studyFirstSubmitQcDate": "2023-09-25", "studyFirstPostDateStruct": {"date": "2023-09-29", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2024-09-02", "lastUpdatePostDateStruct": {"date": "2024-09-05", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Elsan", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false, "isUsExport": false}, "descriptionModule": {"briefSummary": "This observational study aims at establishing the proportion of patients suffering from endometriosis and for whom an Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) diagnosis is established.\n\nThe study participation will be offered to endometriosis patients displaying symptoms that may suggest an underlying OSAHS.\n\nOSAHS diagnosis will be made according to standard of care practice and patients will be followed up to 12 months after initiating the OSAHS treatment to fill in questionnaires assessing the impact of OSAHS treatment on various endometriosis-related symptoms", "detailedDescription": "The overall prevalence of endometriosis varies between 1% and 8% depending on the studies, and endometriosis would affect approximately one in 10 women in France. In 2022, A report was submitted to the President of the French Republic for the development of a national strategy to fight against endometriosis, proposing in particular the development of a national epidemiological database and an \"easily identifiable and accessible diagnosis pathway throughout the territory\".\n\nThe experience at the investigational site has led to note a significant prevalence of obstructive sleep apnea hypopnea syndrome (OSAHS) in the population of patients with endometriosis. There are no published studies on the relationships between OSAHS and endometriosis. However, intermittent hypoxemia and endothelial dysfunction are two important consequences of OSAHS that may be related to endometriosis. Moreover, it is now accepted that OSAHS is correlated with painful bladder syndrome (interstitial cystitis) and the relationship between endometriosis and a decrease in sleep quality as well as chronic fatigue syndrome has also been demonstrated.\n\nFinally, the benefit of Continuous Positive Airway Pressure (CPAP) treatment on endothelial dysfunction has been demonstrated and, empirically, in cooperation with the investigational site's pain unit, a symptomatic improvement in women with endometriosis and OSAHS after initiation of CPAP treatment was observed.\n\nThe study aims at exploring the occurrence of OSAHS in patients with endometriosis followed in the site's dedicated pain unit and the impact of OSAHS treatment when it exists, on the symptoms of endometriosis and quality of life.\n\nOSAHS diagnosis will be made according to standard of care practice in the investigation site. Patients with confirmed diagnosis of OSAHS will be treated according to national recommendations for this disease (CPAP or alternative treatments) and will complete questionnaires at 3, 6 and 12 months after start of OSAHS treatment to assess the impact of OSAHS treatment on various endometriosis-related symptoms."}, "conditionsModule": {"conditions": ["Endometriosis", "Obstructive Sleep Apnea-hypopnea"], "keywords": ["observational", "Endometriosis"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "COHORT", "timePerspective": "PROSPECTIVE"}, "enrollmentInfo": {"count": 80, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Patients with confirmed Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) diagnosis", "description": "Patients from site's pain unit with confirmed OSAHS diagnosis. OSAHS diagnosis will be made according to standard of care practice in the investigation site, through polysomnography and Epworth Sleepiness Scale (ESS).", "interventionNames": ["Other: questionnaires completion"]}], "interventions": [{"type": "OTHER", "name": "questionnaires completion", "description": "Patients will complete the following questionnaires at 3, 6 and 12 months after start of the treatment for Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS):\n\n* Pain-related questionnaire\n* Endometriosis-specific questionnaire\n* Hospital Anxiety and Depression scale\n* Questionnaire McGill on Quality Of Life\n* Insomnia-related questionnaire", "armGroupLabels": ["Patients with confirmed Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) diagnosis"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "the number of patients suffering from endometriosis, followed in the site's dedicated pain unit, and who are diagnosed with Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS)", "description": "The diagnosis of OSAHS will be performed as per standard of care procedures (medical assessment and polysomnography).Patients with confirmed OSAHS diagnosis will be accounted for the study as positive (Yes) for the primary endpoint.\n\nPatients who are not diagnosed with OSAHS will be accounted for the study as Negative (No) for the primary endpoint and will discontinue from the study without being followed up to 12 months in the study", "timeFrame": "12 months"}], "secondaryOutcomes": [{"measure": "Assessment of the impact of Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) treatment on endometriosis-associated pain", "description": "Patients with confirmed OSAHS diagnosis will complete Pain-related questionnaire at 3, 6 and 12 months after start of OSAHS treatment", "timeFrame": "3, 6 and 12 months"}, {"measure": "Assessment of the impact of Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) treatment on endometriosis-specific symptoms", "description": "Patients with confirmed OSAHS diagnosis will complete Endometriosis-specific questionnaire at 3, 6 and 12 months after start of OSAHS treatment", "timeFrame": "3, 6 and 12 months"}, {"measure": "Assessment of the impact of Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) treatment on anxiety and depression", "description": "Patients with confirmed OSAHS diagnosis will complete Hospital Anxiety and Depression scale at 3, 6 and 12 months after start of OSAHS treatment", "timeFrame": "3, 6 and 12 months"}, {"measure": "Assessment of the impact of Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) treatment on quality of life", "description": "Patients with confirmed OSAHS diagnosis will complete the Questionnaire McGill on Quality Of Life at 3, 6 and 12 months after start of OSAHS treatment", "timeFrame": "3, 6 and 12 months"}, {"measure": "Exploration of the correlation between answers to the Insomnia-related questionnaire and the sleep disorders objectified by the nocturnal recordings.", "description": "Patients with confirmed OSAHS diagnosis will complete Insomnia Severity Index questionnaire at 3, 6 and 12 months after start of OSAHS treatment", "timeFrame": "3, 6 and 12 months"}, {"measure": "Exploration of the relationship between cardiological symptoms (palpitations, malaise, chest pain) and the existence of Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS)", "description": "Cardiological symptoms occurrence (palpitations, malaise, chest pain) will be assessed from baseline up to the end of study.", "timeFrame": "12 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Female patients aged between 18 and 50 years of age\n* Confirmed diagnostic of endometriosis (either through imaging procedure (ultrasound or RMI) or diagnostic coelioscopy)\n* Patient suffering from symptoms evocating Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) and justifying a diagnosis process performed within Standard of Care practice\n* Patient who has been informed about the study and has signed the informed consent form prior to any study-specific procedures\n* Patient willing and able to perform all scheduled procedures in accordance with the study protocol\n\nExclusion Criteria:\n\n* Post menopausal patient\n* Ongoing treatment for OSAHS\n* Patient with Chronic Obstructive Pulmonary Disease (COPD) or unstabilized cardiac disorders\n* Concomitant participation in another clinical trial\n* Pregnant or breastfeeding woman\n* Patient under legal protection measure", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "50 Years", "stdAges": ["ADULT"], "studyPopulation": "Patients with confirmed endometriosis, that are followed for pain at the site's dedicated pain unit, and who display OSAHS symptoms.", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"centralContacts": [{"name": "Fabrice Mr THOIN, MD", "role": "CONTACT", "phone": "0491159022", "phoneExt": "+33", "email": "fabrice.thoin@gmail.com"}]}, "ipdSharingStatementModule": {"ipdSharing": "UNDECIDED"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT02894151", "orgStudyIdInfo": {"id": "523/57"}, "organization": {"fullName": "Chulalongkorn University", "class": "OTHER"}, "briefTitle": "Effectiveness of Levonorgestrel-intrauterine System (LNG-IUS) Versus Depot Medroxyprogesterone Acetate (DMPA) in Treatment of Pelvic Pain in Clinically Diagnosed Endometriotic Patients"}, "statusModule": {"statusVerifiedDate": "2016-09", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2015-04"}, "primaryCompletionDateStruct": {"date": "2016-05", "type": "ACTUAL"}, "completionDateStruct": {"date": "2016-05", "type": "ACTUAL"}, "studyFirstSubmitDate": "2016-08-31", "studyFirstSubmitQcDate": "2016-09-03", "studyFirstPostDateStruct": {"date": "2016-09-09", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-09-03", "lastUpdatePostDateStruct": {"date": "2016-09-09", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Chulalongkorn University", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The primary objective : To compare effectiveness of pain control in endometriosis associated pelvic pain between LNG-IUS and DMPA The secondary objective : To compare vaginal bleeding pattern, side effect, continuation rate, satisfaction and quality of life between LNG-IUS and DMPA in treatment of endometriosis associated pelvic pain", "detailedDescription": "The participants were randomized into two treatment groups, by Block Of Four method, LNG-IUS and DMPA group. For the patients in the LNG-IUS group, a LNG-IUS (Mirena) was inserted. The system released the active ingredient LNG for up to five years at a virtually constant rate. For the patients in the Depot MPA Group, 150 mg depot MPA was given intramuscularly once every three months.\n\nAll participants were recieved the individual calendars to record all vaginal bleeding occured during treatment. The amount of bleeding was described relative to normal menstruation of each patient; less than, same as, more than their baseline menses. To use easily, we assigned the symbols to represent quantity of vaginal bleeding as described. Each symbol was recorded every day except no bleeding, which was represented with blank space in the calendar. The bleeding pattern were assessed as bleeding rating score; less than normal menses = 1, same amount of normal menses = 2, more than normal menses = 3. No bleeding was defined as 30 consecutive days with bleeding score 0. The mean bleeding score was calculated by sum of the daily scores in each month period.\n\nFollow-up visits were scheduled three times at months 1, 3 and 6 after initial treatment. At each visit, VAS and bleeding pattern was recorded. Side-effects of the two therapies were checked. Patients were allowed to choose to withdraw from their designated therapy at any time. The follow-up was completed in May 2016 for the last patient.\n\nAt the final visit, 6 months after treatment, all participants in both treatment groups were recorded the datas of blood pressure, body weight, transvaginal ultrasonography, lipid profiles and SF-36 quesionaires. In addition, all50 patients were asked whether they want to continue in the given treatement and the reason of discontinuation including the satisfaction scores during therapy were rated as 1-5 Likert-scale; 1-very dissatisfied, 2- dissatisfied, 3-neither satisfied/dissatisfied, 4-satisfied, 5-very satified."}, "conditionsModule": {"conditions": ["Clinically Diagnosed Endometriotic Patient Was Defined as a Woman Who Has Pelvic Pain and at Least One Evidence of PV or TVS"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 50, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "LNG-IUS", "type": "ACTIVE_COMPARATOR", "description": "LNG IUS was hormonal containing IUD relased LNG at constant rate through out 5 year period.\n\nIt was inserted only first time entry in the study.", "interventionNames": ["Device: LNG-IUS"]}, {"label": "DMPA", "type": "ACTIVE_COMPARATOR", "description": "DMPA was given in trimonthly intramuscular injection.", "interventionNames": ["Drug: Depot medroxyprogesterone acetate"]}], "interventions": [{"type": "DRUG", "name": "Depot medroxyprogesterone acetate", "armGroupLabels": ["DMPA"]}, {"type": "DEVICE", "name": "LNG-IUS", "armGroupLabels": ["LNG-IUS"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change baseline pain score assessed by visual analog scale after 6 month-use of both interventions", "timeFrame": "1year"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* age 18-45year Pelvic pain VAS\\>50 Previous Sexual intercouse\n\nExclusion Criteria:\n\n* other genital tract disease causing pelvic pain Previous hromonal treament 3 month History of DMPA treatment failure WHO eligibility criteria 2009 categorized in 3-4 for DMPA and LNG-IUS user Fertility desire within 1 year Psychoneurosis Pregnant and breast fed women", "healthyVolunteers": true, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "45 Years", "stdAges": ["ADULT"]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT03844412", "orgStudyIdInfo": {"id": "Pro00100678"}, "secondaryIdInfos": [{"id": "1R01HD096331-01", "type": "NIH", "link": "https://reporter.nih.gov/quickSearch/1R01HD096331-01"}], "organization": {"fullName": "Duke University", "class": "OTHER"}, "briefTitle": "Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments", "officialTitle": "Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments"}, "statusModule": {"statusVerifiedDate": "2024-06", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2019-11-04", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2024-03-13", "type": "ACTUAL"}, "completionDateStruct": {"date": "2024-05-30", "type": "ACTUAL"}, "studyFirstSubmitDate": "2019-02-15", "studyFirstSubmitQcDate": "2019-02-15", "studyFirstPostDateStruct": {"date": "2019-02-18", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2024-06-06", "lastUpdatePostDateStruct": {"date": "2024-06-07", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Duke University", "class": "OTHER"}, "collaborators": [{"name": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)", "class": "NIH"}]}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false, "isUsExport": false}, "descriptionModule": {"briefSummary": "Vestibulodynia (VBD) is a complex chronic vulvar pain condition that impairs the psychological, physical, and sexual health of 1 in 6 reproductive aged women in the United States. Here, the investigators plan to conduct a randomized, double-blinded, placebo-controlled clinical trial to 1) compare the efficacy of peripheral (lidocaine/estradiol cream), centrally-targeted (nortriptyline), and combined treatments in alleviating pain and improving patient-reported outcomes and 2) determine cytokine and microRNA biomarkers that predict treatment response in women with distinct VBD subtypes. Positive findings from this study will readily translate to improved patient care, permitting the millions of women with VBD, their partners, and their clinicians to make more informed decisions about pain management.", "detailedDescription": "Vestibulodynia (VBD) is a chronic pelvic pain condition that affects 1 in 6 reproductive aged women, yet remains ineffectively treated by standard trial-and-error approaches. The investigators have identified two distinct VBD subtypes that may benefit from different types of treatment: 1) VBD peripheral (VBD-p) subtype characterized by localized pain specific to the vulvar vestibule, and 2) VBD central (VBD-c) subtype characterized by pain at both vaginal and remote body regions. Preliminary data further demonstrate that VBD-p and VBD-c subtypes differ with respect to patient reported outcomes (e.g., physical and mental health), production of cytokines (intracellular proteins that regulate the activity of pain nerves and inflammatory processes), and expression of microRNAs (small non-coding RNA molecules that regulate gene expression). Women with VBD-p exhibit normal psychological profiles; balanced circulating pro- and anti-inflammatory cytokines; and dysregulation in microRNAs that regulate the expression of genes in estrogen pathways. In contrast, women with VBD-c report decreased functional status and increased somatization; increased pro-inflammatory but not anti-inflammatory cytokines; and dysregulation in microRNAs that regulate the expression of genes relevant to muscle, nerve, and immune cell function. Based on these data, the investigators hypothesize that two VBD-p and VBD-c subtypes will preferentially respond to peripheral, central, or combined treatments and can be distinguished by cytokine and microRNA profiles. These hypotheses will be tested in a phase III clinical trial that evaluates diverse treatment strategies in women with VBD-p and VBD-c. Participants will be randomly assigned to one of four parallel arms: peripheral treatment with 5% lidocaine + 0.5 mg/ml 0.02% estradiol compound cream, 2) central treatment with the tricyclic antidepressant nortriptyline, 3) combined peripheral and central treatments, or 4) placebo. The treatment phase will last 4 months (with a 6-week titration at treatment initiation and 2-week taper period at 4 months), with outcome measures and biomarkers assessed at 4 time points (0, 2, 4, and 6 months). First, the investigators will compare the efficacy of treatments in alleviating pain among women with VBD-p and VBD-c using standardized tampon insertion with a numeric rating scale and self-reported pain on the McGill Pain Questionnaire. Next, the investigators will compare the efficacy of treatments in improving perceived physical, mental, and sexual health among women with VBD-p and VBD-c using standardized questionnaires. Finally, investigators will measure cytokines and microRNAs in women with VBD-p versus VBD-c using multiplex assays and RNA sequencing, and determine the ability of these biomarkers to predict treatment response. Successful completion of the proposed work will provide new insights into the mechanisms that drive pain perception and treatment response in two distinct VBD subtypes, and determine the efficacy of peripheral, central, and combined therapies in reversing this pain. Such findings will readily translate to improved patient care, permitting the millions of women with VBD, their partners, and clinicians to make more informed decisions about pain management."}, "conditionsModule": {"conditions": ["Vestibulodynia", "Temporomandibular Disorder", "Fibromyalgia Syndrome", "Irritable Bowel Syndrome", "Migraines", "Tension Headache", "Endometriosis", "Interstitial Cystitis", "Back Pain", "Chronic Fatigue Syndrome"], "keywords": ["Pelvic pain", "Lidocaine", "Estradiol", "Nortriptyline", "Chronic pain"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "FACTORIAL", "interventionModelDescription": "Two-center, randomized, double-blind, placebo-controlled 2x2 factorial study enrolling 400 women to participate for 24-week duration.", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 223, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "peripheral treatment", "type": "ACTIVE_COMPARATOR", "description": "5% lidocaine/5 mg/ml 0.02% estradiol compound cream", "interventionNames": ["Drug: 5% lidocaine/5 mg/ml 0.02% estradiol compound cream", "Drug: Placebo pill"]}, {"label": "central treatment", "type": "ACTIVE_COMPARATOR", "description": "tricyclic antidepressant nortriptyline pill", "interventionNames": ["Drug: Nortriptyline", "Drug: Placebo cream"]}, {"label": "combined peripheral and central treatments", "type": "ACTIVE_COMPARATOR", "description": "5% lidocaine/5 mg/ml 0.02% estradiol compound cream and tricyclic antidepressant nortriptyline pill", "interventionNames": ["Drug: 5% lidocaine/5 mg/ml 0.02% estradiol compound cream", "Drug: Nortriptyline"]}, {"label": "placebo", "type": "PLACEBO_COMPARATOR", "description": "placebo cream and placebo pill", "interventionNames": ["Drug: Placebo cream", "Drug: Placebo pill"]}], "interventions": [{"type": "DRUG", "name": "5% lidocaine/5 mg/ml 0.02% estradiol compound cream", "description": "Lidocaine/estradiol cream targets peripheral nerves and tissues affected in VBD. Participants will be provided with a diagram and written instructions, detailing how to apply the cream to the vaginal vestibule daily for weeks 1-16. Treatment with lidocaine/estradiol or placebo cream will be terminated at week 16 (end of month 4).", "armGroupLabels": ["combined peripheral and central treatments", "peripheral treatment"]}, {"type": "DRUG", "name": "Nortriptyline", "description": "Nortriptyline is a centrally-acting tricyclic antidepressant that is FDA-approved for treatment of neuropathic pain. Dosing will begin with one 10 mg pill nightly for week 1, then two 10 mg pills nightly for week 2, three 10 mg pills nightly for week 3, four 10 mg pills nightly for week 4, and five for weeks 5 -16. Treatment with nortriptyline or placebo pill will be tapered off over weeks 16-18, decreasing the dose by 10 mg every 4 days. Participants will be provided with a list of drugs to avoid that are known to interact with nortriptyline.", "armGroupLabels": ["central treatment", "combined peripheral and central treatments"]}, {"type": "DRUG", "name": "Placebo cream", "description": "The comparison treatment will be an identical-appearing placebo Moisturel™ cream", "armGroupLabels": ["central treatment", "placebo"], "otherNames": ["Moisturel cream"]}, {"type": "DRUG", "name": "Placebo pill", "description": "The comparison treatment will be an identical-appearing placebo pill", "armGroupLabels": ["peripheral treatment", "placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in pain score during the tampon test", "description": "The Tampon Test will provide a self-reported numeric rating scale of pain with self-tampon insertion, performed by the patient and reported to the research nurse. Participants will be asked to verbally rate the pain on a scale of 0-10, with 0 meaning no pain and 10 meaning the worst possible pain.", "timeFrame": "Baseline, 16 weeks"}, {"measure": "Change in self-reported pain via the Short Form- McGill Pain Questionnaire (SF-MPQ)", "description": "The SF-MPQ will be used to create a summary score. The SF-MPQ measures perceived sensory qualities of pain using 11 describers and affective qualities related to pain using 5 describers. Responses on 4-point scales are summed to compute scores for each section.", "timeFrame": "Baseline, 16 weeks"}, {"measure": "Change in self-reported physical/mental health via SF-12 Health Survey (SF12v2)", "description": "The SF-12 assesses 6 domains: global health, physical functioning, physical roles, emotional functioning, emotional roles and pain interference using an algorithm based on answers to 12 physical and mental health-related questions.", "timeFrame": "Baseline, 16 weeks"}, {"measure": "Change in sexual health via Patient-Reported Outcomes Measurement Information System (PROMIS)", "description": "The PROMIS score is based on a 96-item form developed by the NIH that measures 11 domains of biopsychosocial function and includes an assessment of sexual function measures (e.g., desire, frequency, fear, and pain) related to sexual intercourse.", "timeFrame": "Baseline, 16 weeks"}, {"measure": "Change in inflammation as measured by cytokine expression levels", "description": "Cytokine expression levels will be measured via mesoscale discovery assays.", "timeFrame": "Baseline, 16 weeks"}, {"measure": "Change in regulators of pro-pain and pro-inflammatory genes, as measured by microRNA expression levels", "description": "MicroRNA expression levels will be measured via sequencing read.", "timeFrame": "Baseline, 16 weeks"}], "secondaryOutcomes": [{"measure": "Change in pain level as measured by Vaginal Vestibule Pressure Pain Intensities (PPI)", "description": "Vaginal Vestibule PPIs will be determined using a cotton swab applied to 6 externally-accessed sites (at 12, 10, 7, 6, 5, 2 o'clock on the vestibule) for 1-2 seconds. Upon application of cotton swab at each site, participants will rate their pain intensity on a scale from 0-10.", "timeFrame": "Baseline, 8 weeks, 16 weeks, and 24 weeks"}, {"measure": "Levator Muscle Complex Pressure Pain Thresholds (PPTs)", "description": "Levator Muscle Complex PPTs will be determined using a digital vestibular algometer applied internally to the right, midline, and left puborectalis levator muscles sites (5, 6, and 7 o'clock) just lateral to the perineum.", "timeFrame": "Baseline, 8 weeks, 16 weeks, and 24 weeks"}, {"measure": "Change in pain level as measured by Remote Bodily PPTs", "description": "Remote Bodily PPTs will be determined by applying the algometer to 3 'neutral' non-pelvic body sites (deltoid, shin, and trapezius), right and left, beginning at 1N and increasing until the participant's first sensation of pain. A composite score will be calculated.", "timeFrame": "Baseline, 8 weeks, 16 weeks, and 24 weeks"}, {"measure": "Change in degree of overlapping pain, as measured by COPC follow-up survey", "description": "The COPC survey consists of 2 questions used to determine the change in degree of overlapping pain.", "timeFrame": "Baseline, 8 weeks, 16 weeks, and 24 weeks"}, {"measure": "Change in mood as measured by the Symptom Checklist-27 (SCL-27)", "description": "Symptom Check List 27 (SCL-27) questionnaire will be used to measure a broad range of psychological symptoms (e.g., anxiety and depression).", "timeFrame": "Baseline, 8 weeks, 16 weeks, and 24 weeks"}, {"measure": "Change in somatic awareness via Pennebaker Index of Limbic Languidness (PILL)", "description": "Pennebaker Index of Limbic Languidness (PILL) is used to create a summary score of somatic symptoms (e.g., itchy eyes, dizziness). Symptom frequency is recorded on a five-point Likert scale ranging from \"never\" to \"more than once a week\".", "timeFrame": "Baseline, 8 weeks, 16 weeks, and 24 weeks"}, {"measure": "Change in perceived stress via Perceived Stress Scale (PSS)", "description": "The Perceived stress scale (PSS) is a 10-item scale that measures the impact of personal stress on thoughts and feelings.", "timeFrame": "Baseline, 8 weeks, 16 weeks, and 24 weeks"}, {"measure": "Change in sleep as measured by the sleep scale", "description": "The sleep scale is a 12-item scale that measures amount of sleep and ease/difficulty of initiating and maintaining sleep.", "timeFrame": "Baseline, 8 weeks, 16 weeks, and 24 weeks"}, {"measure": "Change in in pain score during the tampon test at other time points", "description": "Change in pain score during the tampon test will be measured as described above.", "timeFrame": "8 weeks and 24 weeks"}, {"measure": "Change in in pain score via the SF-MPQ at other time points", "description": "Change in pain score via the SF-MPQ will be measured as described above.", "timeFrame": "8 weeks and 24 weeks"}, {"measure": "Change in self-reported health on the SF12v2 at other time points", "description": "Change in self-reported health on the SF12v2 will be measured as described above.", "timeFrame": "8 weeks and 24 weeks"}, {"measure": "Change in self-reported health on the PROMIS at other time points", "description": "Change in self-reported outcomes on the PROMIS will be measured. The PROMIS score is based on a 96-item form developed by the NIH that measures 11 domains of biopsychosocial function and includes an assessment of sexual function measures (e.g., desire, frequency, fear, and pain) related to sexual intercourse.", "timeFrame": "8 weeks and 24 weeks"}, {"measure": "Change in cytokine biomarkers at other time points", "description": "Change in cytokine levels will be measured as described above.", "timeFrame": "8 weeks and 24 weeks"}, {"measure": "Change in microRNA biomarkers at other time points", "description": "Change in microRNA levels will be measured as described above.", "timeFrame": "8 weeks and 24 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria\n\n1. Female\n2. Age 18-50 years\n3. English-literate\n4. Willingness to provide informed consent\n5. Meeting criteria for diagnosis of VBD based on:\n\n   1. self-report of 3 continuous months of insertional (entryway) dyspareunia, and/or pain to touch/tampon insertion\n   2. pain score of ≥ 3 on the tampon insertion test\n\nExclusion Criteria\n\n1. Use of daily topical lidocaine, or estradiol, or lidocaine/estradiol to the vulvar vestibule within the past three months\n2. Use of nortriptyline or other TCA medications within the past three months\n3. Use of pregabalin or gabapentin within the past three months\n4. Presence of active dermatologic vulvar disease or vaginal infection\n5. Untreated atrophic vaginitis (participants may undergo treatment and re-evaluation for enrollment if the condition is resolved)\n6. Previous vestibulectomy\n7. Pregnant or planning on becoming pregnant during the study period. Within the first six months of the postpartum period. Currently breastfeeding/lactating, or within three months of discontinuing breastfeeding/lactation.\n8. Active incarceration\n9. Cancer within the past year.\n10. Chemotherapy and/or radiation treatment within the past year.\n11. Unstable medical condition (e.g., renal impairment, significant hematological disease, cardiovascular disease, hepatic insufficiency, neurological disorder, autoimmune disease, or respiratory illness)\n12. Clear inflammatory states (e.g., morbid obesity)\n13. Use of immunosuppressant medications\n14. History of intolerance to nortriptyline, topical lidocaine, or topical estradiol\n15. Contraindications to use of nortriptyline: current use, or use within the past 3 months, of MAOIs, SSRIs, SNRIs, NDRIs; recent (within the past year) myocardial infarction, active psychotic or suicidal thoughts, narrow angle closure glaucoma\n16. Contraindications to the use of lidocaine or local anesthetics\n17. Contraindications to the use of topical estrogen therapy\n18. Post-menopausal, defined as no menses for 12 consecutive months or surgical removal of both ovaries. (Hysterectomy is not an exclusion)\n19. Have not had Botox of the pelvic floor muscles in the last 12 months, or pelvic nerve blocks in the last three months.\n20. Are not currently enrolled or planning to enroll in another clinical trial during the course of this trial.\n21. Are not currently receiving pelvic physical therapy", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "50 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Andrea Nackley, PhD", "affiliation": "Duke University", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "University of California, Los Angeles", "city": "Los Angeles", "state": "California", "zip": "90095", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "University of North Carolina at Chapel Hill", "city": "Chapel Hill", "state": "North Carolina", "zip": "27278", "country": "United States", "geoPoint": {"lat": 35.9132, "lon": -79.05584}}]}, "referencesModule": {"references": [{"pmid": "36269028", "type": "DERIVED", "citation": "Carey ET, Geller EJ, Rapkin A, Farb D, Cutting H, Akaninwor J, Stirling C, Bortsov A, McNulty S, Merrill P, Zakroysky P, DeLaRosa J, Luo S, Nackley AG. Rationale and design of a multicenter randomized clinical trial of vestibulodynia: understanding pathophysiology and determining appropriate treatments (vestibulodynia: UPDATe). Ann Med. 2022 Dec;54(1):2885-2897. doi: 10.1080/07853890.2022.2132531."}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "The investigators will share data in a manner consistent with NIH's policy NOT-OD-14-124, found at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-14-124.html, released August 28, 2014. Genotypic data (e.g. microRNA and protein expression) and relevant phenotypic data (e.g. pain scores) from 400 participants will be posted on the dbGaP website.", "infoTypes": ["STUDY_PROTOCOL", "SAP", "ICF"], "timeFrame": "The PI expects data release up to 6 months after data submission is initiated or at the time of acceptance of initial publication, whichever occurs first.", "accessCriteria": "Requests to download individual unit-record datasets should be submitted to the PI and require approval from a Data Access Committee convened by the NIH/NICHD.", "url": "http://grants.nih.gov/grants/guide/notice-files/NOT-OD-14-124.html"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04", "submissionTracking": {"estimatedResultsFirstSubmitDate": "2025-02-25", "submissionInfos": [{"releaseDate": "2025-02-25", "resetDate": "2025-03-13", "mcpReleaseN": 15}, {"releaseDate": "2025-08-19", "resetDate": "2025-09-08", "mcpReleaseN": 16}, {"releaseDate": "2025-10-02", "resetDate": "2025-10-17", "mcpReleaseN": 17}]}}, "conditionBrowseModule": {"meshes": [{"id": "D056650", "term": "Vulvodynia"}, {"id": "D013705", "term": "Temporomandibular Joint Disorders"}, {"id": "D005356", "term": "Fibromyalgia"}, {"id": "D043183", "term": "Irritable Bowel Syndrome"}, {"id": "D008881", "term": "Migraine Disorders"}, {"id": "D018781", "term": "Tension-Type Headache"}, {"id": "D004715", "term": "Endometriosis"}, {"id": "D018856", "term": "Cystitis, Interstitial"}, {"id": "D001416", "term": "Back Pain"}, {"id": "D015673", "term": "Fatigue Syndrome, Chronic"}, {"id": "D017699", "term": "Pelvic Pain"}, {"id": "D059350", "term": "Chronic Pain"}], "ancestors": [{"id": "D014845", "term": "Vulvar Diseases"}, {"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}, {"id": "D017271", "term": "Craniomandibular Disorders"}, {"id": "D008336", "term": "Mandibular Diseases"}, {"id": "D007571", "term": "Jaw Diseases"}, {"id": "D009140", "term": "Musculoskeletal Diseases"}, {"id": "D007592", "term": "Joint Diseases"}, {"id": "D009135", "term": "Muscular Diseases"}, {"id": "D009057", "term": "Stomatognathic Diseases"}, {"id": "D012216", "term": "Rheumatic Diseases"}, {"id": "D009468", "term": "Neuromuscular Diseases"}, {"id": "D009422", "term": "Nervous System Diseases"}, {"id": "D003109", "term": "Colonic Diseases, Functional"}, {"id": "D003108", "term": "Colonic Diseases"}, {"id": "D007410", "term": "Intestinal Diseases"}, {"id": "D005767", "term": "Gastrointestinal Diseases"}, {"id": "D004066", "term": "Digestive System Diseases"}, {"id": "D051270", "term": "Headache Disorders, Primary"}, {"id": "D020773", "term": "Headache Disorders"}, {"id": "D001927", "term": "Brain Diseases"}, {"id": "D002493", "term": "Central Nervous System Diseases"}, {"id": "D003556", "term": "Cystitis"}, {"id": "D001745", "term": "Urinary Bladder Diseases"}, {"id": "D014570", "term": "Urologic Diseases"}, {"id": "D052801", "term": "Male Urogenital Diseases"}, {"id": "D010146", "term": "Pain"}, {"id": "D009461", "term": "Neurologic Manifestations"}, {"id": "D012816", "term": "Signs and Symptoms"}, {"id": "D013568", "term": "Pathological Conditions, Signs and Symptoms"}, {"id": "D004679", "term": "Encephalomyelitis"}, {"id": "D000090862", "term": "Neuroinflammatory Diseases"}, {"id": "D002908", "term": "Chronic Disease"}, {"id": "D020969", "term": "Disease Attributes"}, {"id": "D010335", "term": "Pathologic Processes"}]}, "interventionBrowseModule": {"meshes": [{"id": "D009661", "term": "Nortriptyline"}], "ancestors": [{"id": "D003986", "term": "Dibenzocycloheptenes"}, {"id": "D001567", "term": "Benzocycloheptenes"}, {"id": "D011084", "term": "Polycyclic Aromatic Hydrocarbons"}, {"id": "D006841", "term": "Hydrocarbons, Aromatic"}, {"id": "D006844", "term": "Hydrocarbons, Cyclic"}, {"id": "D006838", "term": "Hydrocarbons"}, {"id": "D009930", "term": "Organic Chemicals"}, {"id": "D011083", "term": "Polycyclic Compounds"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT00173212", "orgStudyIdInfo": {"id": "9461700522"}, "secondaryIdInfos": [{"id": "NTUH.95-000357"}], "organization": {"fullName": "National Taiwan University Hospital", "class": "OTHER"}, "briefTitle": "Proliferation of Endometrial Stromal Cells in Adenomyosis"}, "statusModule": {"statusVerifiedDate": "2005-05", "overallStatus": "UNKNOWN", "lastKnownStatus": "ACTIVE_NOT_RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2005-09"}, "completionDateStruct": {"date": "2006-03"}, "studyFirstSubmitDate": "2005-09-12", "studyFirstSubmitQcDate": "2005-09-12", "studyFirstPostDateStruct": {"date": "2005-09-15", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2005-09-12", "lastUpdatePostDateStruct": {"date": "2005-09-15", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"leadSponsor": {"name": "National Taiwan University Hospital", "class": "OTHER"}}, "descriptionModule": {"briefSummary": "Adenomyosis refers to the presence of endometrial glands and stroma that is haphazardly deep within the myometrium. However, the etiology and pathologic mechanism responsible for adenomyosis are not yet very well known. Our previous results revealed that the expression of killer inhibitory receptors on natural killer cells was decreased in eutopic endometrium in women with adenomyosis. It implies that the formation of adenomyosis might be due to abnormal endometrial tissues, but not the aberrant local immunological dysfunction in myometrium. Our further investigation revealed that in vitro coculture of macrophages and endometrial stromal cells (ESCs) increase the expression of IL-6 mRNA in ESC, which might further enhance the proliferation of ESC and subsequently result in the formation of ectopic endometrial implants in adenomyosis.\n\nAbnormal cell proliferation has been generally found in the tumorigenesis, including the formation of endometriosis. Adenomyosis is considered to have a similar pathophysiology with endometriosis, and it must be interesting to examine whether there is abnormal cell proliferation in the eutopic endometrium of adenomyosis. Lipopolysaccharide (LPS) was found to promote proliferation of ESCs via induction of TNF-a and IL-8 expression, whereas IFN-g significantly inhibited ESCs proliferation. Therefore, whether abnormal cell proliferation occurs under the effects of LPS and IFN-g in the eutopic endometrium of adenomyosis needs further clarification.\n\nAdenomyosis preferentially affects women between the ages of 35 and 50 years, and the symptoms subside gradually after menopause. It is well known that there is a close conjunction between estrogen and adenomyosis. Estradiol (E2) was demonstrated to induce endometrial cell proliferation, whereas medroxyprogesterone (MPA) inhibited endometrial cell proliferation via antagonizing estrogenic effects. Experiments to investigate these steroid effects on ESC proliferation in vitro in the eutopic endometrium of adenomyosis are of clinical relevance.\n\nIn this study, we try to collect endometrial tissues from women with and without adenomyosis, and then purify ESCs from endometrium. ESCs are cultured for 2 days with the supplement of LPS, IFN-gamma, Estradiol, MPA and Estradiol+MPA. Quantification of cell proliferation was done with Cell Proliferation Assay Kit and immunocytochemical detection of Ki-67, in an attempt to examine the cell proliferation of ESCs in women with adenomyosis.", "detailedDescription": "Eutopic endometrium was obtained and separated into single endometrial stromal cell (ESC) in women with adenomyosis (study group) and without adenomyosis (control group).\n\nESCs are cultured for 2 days with the supplement of LPS, IFN-gamma, Estradiol, MPA and Estradiol+MPA.\n\nQuantification of cell proliferation was done with Cell Proliferation Assay Kit and immunocytochemical detection of Ki-67."}, "conditionsModule": {"conditions": ["Endometriosis"], "keywords": ["adenomyosis", "cell proliferation", "Immunocytochemistry"]}, "designModule": {"studyType": "OBSERVATIONAL", "designInfo": {"observationalModel": "DEFINED_POPULATION", "timePerspective": "OTHER"}, "enrollmentInfo": {"count": 45}}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* women with adenomyosis\n* at early- to mid-secretory phases\n\nExclusion Criteria:\n\n* postmenopausal\n* malignancy", "healthyVolunteers": true, "sex": "FEMALE", "minimumAge": "35 Years", "maximumAge": "50 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Jehn-Hsiahn Yang, M.D.", "affiliation": "Department of Obstetrics and Gynecology, National Taiwan University Hospital", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "National Taiwan University Hospital", "city": "Taipei", "country": "Taiwan", "geoPoint": {"lat": 25.05306, "lon": 121.52639}}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}, {"id": "D062788", "term": "Adenomyosis"}, {"id": "D006965", "term": "Hyperplasia"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}, {"id": "D014591", "term": "Uterine Diseases"}, {"id": "D010335", "term": "Pathologic Processes"}, {"id": "D013568", "term": "Pathological Conditions, Signs and Symptoms"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT06621342", "orgStudyIdInfo": {"id": "STUDY00149149"}, "organization": {"fullName": "University of Kansas Medical Center", "class": "OTHER"}, "briefTitle": "Platelet Rich Plasma Uterine Infusion", "officialTitle": "Evaluating Cytokine Concentrations in the Endometrium Before and After Autologous Platelet Rich Plasma Uterine Infusion Preceding Frozen Embryo Transfer"}, "statusModule": {"statusVerifiedDate": "2023-01", "overallStatus": "WITHDRAWN", "whyStopped": "Study deferred/stopped by initiator before any study recruitment was initiated.", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2023-02-16", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2023-02-16", "type": "ACTUAL"}, "completionDateStruct": {"date": "2023-02-16", "type": "ACTUAL"}, "studyFirstSubmitDate": "2023-01-24", "studyFirstSubmitQcDate": "2024-09-27", "studyFirstPostDateStruct": {"date": "2024-10-01", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2024-09-27", "lastUpdatePostDateStruct": {"date": "2024-10-01", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "University of Kansas Medical Center", "class": "OTHER"}, "collaborators": [{"name": "Eastern Virginia Medical School", "class": "OTHER"}]}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false, "isUsExport": false}, "descriptionModule": {"briefSummary": "Platelet Rich Plasma (PRP), a rich source of important growth factors, has been shown to significantly affect the body's ability to heal and regenerate tissues. It is an affordable, accessible treatment with little risk of side effects that is being utilized in many areas of regenerative and cosmetic medicine. PRP is also relatively easy to prepare with supplies on hand in most IVF clinics. Specifically relating to reproductive function, PRP has been demonstrated to increase cellular proliferation and decrease fibrosis in damaged rat endometrium. It is hypothesized that infusing the uterus with Platelet Rich Plasma at measured intervals prior to embryo transfer will increase concentrations of implantation-promoting cytokines while reducing concentrations of inflammatory cytokines during the window of implantation.", "detailedDescription": "1\\. Platelet Rich Plasma (PRP), a rich source of important growth factors, has been shown to significantly affect the body's ability to heal and regenerate tissues.7 It is an affordable, accessible treatment with little risk of side effects that is being utilized in many areas of regenerative and cosmetic medicine. PRP is also relatively easy to prepare with supplies on hand in most IVF clinics. PRP has shown great promise in veterinary medicine to regenerate tissues and reduce endometrial inflammation.8 Specifically relating to reproductive function, PRP has been demonstrated to increase cellular proliferation and decrease fibrosis in damaged rat endometrium.6 Endometritis, which is characterized by an increase in inflammatory cells, erosion of the endometrial epithelial layer as well as endometrial edema has been a large cause of infertility in cattle and therefore revenue loss in the cattle industry. A recent study applying uterine infusion of PRP as the intervention demonstrated decreased markers for inflammation in cattle in vivo and as well as decreased inflammatory markers in in vitro cultured endometrial cells exposed to PRP.6 A similar in vitro study was conducted on horses; the authors noticed a decrease in clinical uterine infections in mares along with an increased embryo recovery rate.31 Chronic endometritis is hypothesized to be one of the potential factors involved in recurrent implantation failure in women.32 Using these previous studies in veterinary medicine as a model for potential benefit in human patients, it would be prudent to explore the mechanism of PRP action in humans. It is hypothesized that infusing the uterus with Platelet Rich Plasma at measured intervals prior to embryo transfer will increase concentrations of implantation-promoting cytokines while reducing concentrations of inflammatory cytokines during the window of implantation. TGF-b, IL-6 and LIF are known to be promoters of implantation, while TNF-a and IL-4 are pro-inflammatory factors and can inhibit implantation."}, "conditionsModule": {"conditions": ["Infertility", "Endometriosis"], "keywords": ["implantation failure", "IVF", "Embryo Transfer"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1", "PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": "40 patients will be enrolled in each of the control and test groups, using a confidence interval of 95% and a 5% margin of error Total participants expected = 80.", "primaryPurpose": "SUPPORTIVE_CARE", "maskingInfo": {"masking": "TRIPLE", "maskingDescription": "2\\. It is not possible to blind clinical staff for the procedure. It is not necessary for the integrity of the study to blind participants as we are assessing their pregnancy outcomes. Regardless of which group they are assigned, participants will partake in routine prenatal care, as well as two additional study visits. They will know which group they have been assigned at the time of the procedure based on if they receive the treatment prior to implantation or not.", "whoMasked": ["PARTICIPANT", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 0, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "PRP Experimental", "type": "EXPERIMENTAL", "description": "The treatment group will receive 1 ml of autologous PRP infused into the cervix via Rocket IUI catheter at 72+/- 5 hours and 48 +/- 5 hours prior to embryo transfer. Prior to the first PRP infusion, endometrial secretions will be aspirated as described in a previous study regarding endometrial secretions. An embryo transfer catheter will be introduced trans-cervically. A 2 mL syringe will be used to gradually add suction, aspirating secretions from the endometrium. The outer sheath of the embryo catheter will be positioned in the exterior, and the inner catheter retracted into the outer sheath, to avoid cervical fluid contamination in the collected endometrial secretions. Secretions will be deposited into screw top cryovials by snipping the end of the transfer catheter containing secretion off into the tube. These tubes will then be snap-frozen in liquid nitrogen. Process will be repeated prior to embryo transfer", "interventionNames": ["Biological: PRP Experimental"]}, {"label": "PRP Control", "type": "PLACEBO_COMPARATOR", "description": "Negative control patients will have endometrial secretions aspirated at identical intervals to the test group but will not receive PRP infusions.", "interventionNames": ["Biological: PRP Experimental"]}], "interventions": [{"type": "BIOLOGICAL", "name": "PRP Experimental", "description": "All participants will have 5 2ml tubes of blood collected at 72 +/- 5 hr prior to embryo transfer and again at 48 +/- 5 hour prior to embryo transfer. This blood will be processed to create PRP for the uterine infusion per protocol.", "armGroupLabels": ["PRP Control", "PRP Experimental"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Determine the effect of autologous uterine PRP infusion on factors critical to the implantation process", "description": "Compare differences of the levels TGF- b, IL-6 and LIF in endometrial secretions pre- and post-treatment.", "timeFrame": "18 months"}], "secondaryOutcomes": [{"measure": "Determine the effect of autologous uterine PRP infusions on factors that are deleterious to embryo implantation", "description": "By measuring and comparing levels of TNF-a and IL-4 post uterine infusion with PRP.", "timeFrame": "18 months"}], "otherOutcomes": [{"measure": "Determine if autologous uterine PRP infusion influences implantation rates after frozen embryo transfer.", "description": "Compare implantation rates after frozen embryo transfer post PRP infusion to implantation rates in the control group.", "timeFrame": "18 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patient at REI clinic population\n* Ages 23 to 45\n* Undergo frozen embryo transfers with clinic standard medicated protocols\n* Transferring one or two embryos on day 5 or 6 of development\n\nExclusion Criteria:\n\n* BMI \\>32\n* Low level or high-level mosaic\n* Aneuploid embryos only will be excluded\n* Desiring day 3 or fresh embryo", "healthyVolunteers": true, "sex": "FEMALE", "genderBased": true, "genderDescription": "Patients assigned female at birth, who are capable of becoming pregnant.", "minimumAge": "23 Years", "maximumAge": "45 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Courtney Marsh, MD, MPH", "affiliation": "University of Kansas Medical Center", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "The University of Kansas Medical Center", "city": "Kansas City", "state": "Kansas", "zip": "66160", "country": "United States", "geoPoint": {"lat": 39.11417, "lon": -94.62746}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D007246", "term": "Infertility"}, {"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D000091662", "term": "Genital Diseases"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT02948972", "orgStudyIdInfo": {"id": "2015_02"}, "secondaryIdInfos": [{"id": "2015 A01536-43", "type": "OTHER", "domain": "ID-RCB number, ANSM"}], "organization": {"fullName": "University Hospital, Lille", "class": "OTHER"}, "briefTitle": "Impact of Complete Surgery of Colorectal Deep Infiltrating Endometriosis on Fertility", "officialTitle": "Impact of Complete Surgery of Colorectal Deep Infiltrating Endometriosis on Fertility: Complete Surgery + IVF Versus IVF (ENDOFERT)", "acronym": "ENDOFERT"}, "statusModule": {"statusVerifiedDate": "2020-08", "overallStatus": "UNKNOWN", "lastKnownStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2016-11-17", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2025-05", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2025-05", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2016-10-04", "studyFirstSubmitQcDate": "2016-10-26", "studyFirstPostDateStruct": {"date": "2016-10-31", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2020-09-08", "lastUpdatePostDateStruct": {"date": "2020-09-09", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "University Hospital, Lille", "class": "OTHER"}, "collaborators": [{"name": "Ministry of Health, France", "class": "OTHER_GOV"}]}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The ENDOFERT Study is an open, multicenter, randomized, parallel-group, controlled trial. This study includes patients presenting colorectal DIE and infertility. Patients will be randomized in two parallel-groups; one group underwent complete surgery of colorectal DIE prior to ART and the other group underwent ART alone (ratio 1:1)"}, "conditionsModule": {"conditions": ["Endometriosis", "Infertility"], "keywords": ["deep infiltrating endometriosis", "endometriosis surgery", "In vitro fertilization"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 120, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "complete surgery", "type": "EXPERIMENTAL", "description": "Prior surgery 3 months before IVF followup 1, 6 12 and 24 month after surgery", "interventionNames": ["Procedure: complete surgery", "Procedure: In vitro fertilization without surgery"]}, {"label": "In vitro fertilization without surgery", "type": "ACTIVE_COMPARATOR", "description": "IVF without endometriosis surgery follow up 6, 12 and 24 month after inclusion.", "interventionNames": ["Procedure: In vitro fertilization without surgery"]}], "interventions": [{"type": "PROCEDURE", "name": "complete surgery", "description": "complete surgery of colorectal deep infiltrating endometriosis", "armGroupLabels": ["complete surgery"]}, {"type": "PROCEDURE", "name": "In vitro fertilization without surgery", "description": "IVF without endometriosis surgery", "armGroupLabels": ["In vitro fertilization without surgery", "complete surgery"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Clinical pregnancy after 2 IVF cycles", "description": "Clinical pregnancy is defined as pregnancy at 6 weeks of gestation with ultrasound echographic confirmation.\n\nAn IVF cycle is defined as the transfer of all the embryos created via IVF after 1 oocytes puncture until a pregnancy confirmation or until the failure of the last embryo transfer. 2 embryos are transferred for each transfer steps.\n\nThe length of one cycle depend on the number of embryo transfer steps. It is usually between 2 and 9 months.", "timeFrame": "At the end of the 2nd IVF cycle (therefore at 6 weeks after each embryo transfer)"}], "secondaryOutcomes": [{"measure": "predictive factors", "description": "The expected predictive factors observed according to the fecundity status after 2 IVF cycles\n\nAn IVF cycle is defined as the transfer of all the embryos created via IVF after 1 oocytes puncture until a pregnancy confirmation or until the failure of the last embryo transfer. 2 embryos are transferred for each transfer steps.\n\nThe length of one cycle depend on the number of embryo transfer steps. It is usually between 2 and 9 months.", "timeFrame": "At the end of the 2nd IVF cycle"}, {"measure": "Clinical pregnancy rate after 1st IVF cycle", "description": "Clinical pregnancy is defined as pregnancy at 6 weeks of gestation with ultrasound echographic confirmation.\n\nAn IVF cycle is defined as the transfer of all the embryos created via IVF after 1 oocytes puncture until a pregnancy confirmation or until the failure of the last embryo transfer. 2 embryos are transferred for each transfer steps.\n\nThe length of one cycle depend on the number of embryo transfer steps. It is usually between 2 and 9 months.", "timeFrame": "At the end of the 1st IVF cycle (therefore at 6 weeks after each embryo transfer)"}, {"measure": "Clinical pregnancy rate per embryo transferred", "description": "Clinical pregnancy is defined as pregnancy at 6 weeks of gestation with ultrasound echographic confirmation.\n\nAn IVF cycle is defined as the transfer of all the embryos created via IVF after 1 oocytes puncture until a pregnancy confirmation or until the failure of the last embryo transfer. 2 embryos are transferred for each transfer steps.\n\nThe length of one cycle depend on the number of embryo transfer steps. It is usually between 2 and 9 months.", "timeFrame": "At the end of the 2nd IVF cycle (therefore at 6 weeks after each embryo transfer)"}, {"measure": "The IVF complication", "description": "rate of hyperstimulation, superinfection, worsening of pain and hospitalization related to IVF procedures in each group.", "timeFrame": "24 months after surgery or inclusion in \"IVF without surgery\" group"}, {"measure": "perioperative complications", "description": "Complications rate of perioperative surgical excision according to the CLAVIEN-DINDO grading system and to the Comprehensive Complication Index", "timeFrame": "24 months after surgery"}, {"measure": "The cumulative IVF cycle cancellation rate", "description": "The cumulative IVF cycle cancellation rate in each group.\n\nAn IVF cycle is defined as the transfer of all the embryos created via IVF after 1 oocytes puncture until a pregnancy confirmation or until the failure of the last embryo transfer. 2 embryos are transferred for each transfer steps.\n\nThe length of one cycle depend on the number of embryo transfer steps. It is usually between 2 and 9 months.", "timeFrame": "At the end of the 2nd IVF cycle"}, {"measure": "Endometriosis Health Profile -5 (short form / EHP5)", "description": "Evolution of quality life scores in each group", "timeFrame": "during inclusion, 6, 12 and 24 months after surgery or inclusion in \"IVF without surgery\" group"}, {"measure": "Gastrointestinal Quality of Life Index. (GIQLI)", "description": "Evolution of quality life scores in each group", "timeFrame": "during inclusion, 6, 12 and 24 months after surgery or inclusion in \"IVF without surgery\" group"}, {"measure": "Short Form (36) Health Survey _ SF 36", "description": "Evolution of quality life scores in each group", "timeFrame": "during inclusion, 6, 12 and 24 months after surgery or inclusion in \"IVF without surgery\" group"}, {"measure": "Evaluation of hemorrhagic, digestive, urinary symptoms Dysmenorrhea and pains not related to menstruation", "description": "* Dysmenorrhea and pains not related to menstruation will be evaluated by Visual Analog Scale (VAS)\n* Evolution of the hemorrhagic, digestive and urinary symptoms at 6, 12 and 24 months", "timeFrame": "during inclusion, 6, 12 and 24 months after surgery or inclusion in \"IVF without surgery\" group"}, {"measure": "Knowles Eccersley Scott Symptom (KESS) score", "description": "Evolution of the bowel function score KESS", "timeFrame": "during inclusion, 6, 12 and 24 months after surgery or inclusion in \"IVF without surgery\" group"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Primary and secondary infertility\n* Indication for IVF\n* Persistent pain related to endometriosis with analgesic medical treatment failure\n* Persistent pain including at least one of the following digestive symptoms related to endometriosis: Dyschesia / Sub-occlusive syndrome / Rectal bleeding / Painful defecation\n* Colorectal deep infiltrating endometriosis : Whatever lesion size / With at least rectal serosal involvement / Confirmed by MRI and 1 different investigation: vaginal ultrasound echography or coloscopic CT scan or rectal endoscope ultrasound\n* Eligible for DIE surgery\n\nExclusion Criteria:\n\n* Contraindication to pregnancy or to IVF\n* Viral risk\n* Previous IVF cycle(s)\n* Previous colorectal surgery\n* Need of myomectomy during surgery\n* The use of oocytes donor", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "38 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Pierre Collinet, MD,PhD", "role": "CONTACT", "phone": "+33 320444676", "phoneExt": "+33", "email": "pierre.collinet@chru-lille.fr"}], "overallOfficials": [{"name": "Pierre Collinet, MD, PhD", "affiliation": "University Hospital, Lille", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "CHU", "status": "RECRUITING", "city": "Clermont-Ferrand", "country": "France", "contacts": [{"name": "Michel CANIS, MD", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 45.77969, "lon": 3.08682}}, {"facility": "Hôpital Jeanne de Flandres, CHRU", "status": "RECRUITING", "city": "Lille", "country": "France", "contacts": [{"name": "Pierre Collinet, MD,PhD", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 50.63391, "lon": 3.05512}}, {"facility": "AP-HP, Hôpital Tenon", "status": "RECRUITING", "city": "Paris", "country": "France", "contacts": [{"name": "Marcos BALLESTER, MD", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 48.85341, "lon": 2.3488}}, {"facility": "CHU", "status": "RECRUITING", "city": "Poissy", "country": "France", "contacts": [{"name": "Arnaud FAUCONNIER, MD", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 48.92902, "lon": 2.04952}}, {"facility": "CHU", "status": "RECRUITING", "city": "Rouen", "country": "France", "contacts": [{"name": "Horace ROMAN, MD", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 49.44313, "lon": 1.09932}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}, {"id": "D007246", "term": "Infertility"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D005307", "term": "Fertilization in Vitro"}, {"id": "D013514", "term": "Surgical Procedures, Operative"}], "ancestors": [{"id": "D027724", "term": "Reproductive Techniques, Assisted"}, {"id": "D012099", "term": "Reproductive Techniques"}, {"id": "D013812", "term": "Therapeutics"}, {"id": "D008919", "term": "Investigative Techniques"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT01092494", "orgStudyIdInfo": {"id": "2010-02-020"}, "organization": {"fullName": "Samsung Medical Center", "class": "OTHER"}, "briefTitle": "Postoperative Cyclic Oral Contraceptive Use for the Prevention of Endometrioma Recurrence", "officialTitle": "Efficacy of Postoperative Cyclic Oral Contraceptive Use After Gonadotropin-releasing Hormone Agonist for the Prevention of Endometrioma Recurrence"}, "statusModule": {"statusVerifiedDate": "2010-03", "overallStatus": "UNKNOWN", "lastKnownStatus": "NOT_YET_RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-03"}, "primaryCompletionDateStruct": {"date": "2010-03", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2010-03", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2010-03-23", "studyFirstSubmitQcDate": "2010-03-24", "studyFirstPostDateStruct": {"date": "2010-03-25", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2010-03-24", "lastUpdatePostDateStruct": {"date": "2010-03-25", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "DooSeok Choi", "oldOrganization": "Samsung Medical Center"}, "leadSponsor": {"name": "Samsung Medical Center", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "Ovarian endometriotic cyst (endometrioma) is one of the most common endometriotic lesions, and conservative laparoscopic surgery is the treatment of choice. However, the recurrence after surgery is common.\n\nAs repetitive surgery leads to morbidities and ovarian function decrease, recurrence after surgery frustrates both patients and clinicians. In this aspect, medical treatments have been offered after surgery to prevent or delay the recurrence. Gonadotropin-releasing hormone agonist (GnRHa) is frequently used in women with advanced endometriosis, but the efficacy is rather controversial. On the other hand, it has been demonstrated that oral contraceptives (OCs) could reduce or delay endometrioma recurrence, but data are still limited. Consequently, no one type of postoperative medical therapy has been shown to be superior in reducing the recurrence of endometrioma.\n\nThe rationale of postoperative medical therapy is that it could eradicate microscopic lesions which were not found and not treated sufficiently during surgery. Therefore, the maintenance of strongly suppressed condition induced by postoperative GnRHa treatment by addition of OCs could be a promising treatment to prevent the recurrence, but it has not been widely investigated.\n\nWe performed this retrospective cohort study to evaluate the efficacy of cyclic monophasic low-dose OCs as a maintenance therapy after GnRHa treatment for the suppression of endometrioma recurrence."}, "conditionsModule": {"conditions": ["Endometriosis"], "keywords": ["Endometrioma recurrence", "oral contraceptives", "gonadotropin-releasing hormone agonist"]}, "designModule": {"studyType": "OBSERVATIONAL", "designInfo": {"observationalModel": "COHORT", "timePerspective": "RETROSPECTIVE"}, "enrollmentInfo": {"count": 232, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "OC use", "description": "OC use after postoperative gonadotropin-releasing hormone agonist treatment"}, {"label": "OC non-use", "description": "Only postoperative gonadotropin-releasing hormone agonist treatment"}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "recurrence rate of endometrioma", "timeFrame": "60 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. reproductive aged women who underwent conservative laparoscopic ovarian surgery for endometrioma (ASRM stage III/IV) which was confirmed by pathologic inspection\n2. women who were given postoperative GnRHa injections every 28 days for 3 or 6 months\n3. women with no residual lesion confirmed by ultrasonography after surgery\n4. women who were followed up for over 12 months after surgery.\n\nExclusion Criteria:if they had\n\n1. undergone hysterectomy during an operation\n2. been given GnRHa injections more than 6 times\n3. been given other types of postoperative treatment (progestin or intrauterine device)\n4. a history of previous pelvic surgery for endometriosis\n5. a history of hormonal treatment before surgery\n6. been diagnosed as menopause after surgery\n7. contraindications to OCs\n8. been identified ovarian endometriomas within 6 months of postoperative evaluation", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "15 Years", "maximumAge": "49 Years", "stdAges": ["CHILD", "ADULT"], "studyPopulation": "Reproductive aged women who underwent conservative laparoscopic surgery for ovarian endometrioma and followed up at Samsung Medical Center between January 2000 and December 2007.", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"centralContacts": [{"name": "DooSeok Choi, MD, PhD", "role": "CONTACT", "phone": "82-2-3410-3514", "email": "dooseok.choi@samsung.com"}], "overallOfficials": [{"name": "DooSeok Choi", "affiliation": "Samsung Medical Center", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Samsung Medical Center", "city": "Seoul", "state": "Seoul", "zip": "135-710", "country": "South Korea", "contacts": [{"name": "DooSeok Choi", "role": "CONTACT", "email": "dooseok.choi@samsung.com"}], "geoPoint": {"lat": 37.566, "lon": 126.9784}}]}, "referencesModule": {"references": [{"pmid": "18976968", "type": "BACKGROUND", "citation": "Park HJ, Koo YA, Yoon BK, Choi D. Postoperative long-term maintenance therapy with oral contraceptives after gonadotropin-releasing hormone analog treatment in women with ovarian endometrioma. J Minim Invasive Gynecol. 2009 Jan-Feb;16(1):34-9. doi: 10.1016/j.jmig.2008.09.582. Epub 2008 Oct 30."}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT03373422", "orgStudyIdInfo": {"id": "17472"}, "secondaryIdInfos": [{"id": "2017-000244-18", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Bayer", "class": "INDUSTRY"}, "briefTitle": "A Study to Test Whether Study Drug BAY1128688 Brings Pain Relief to Women With Endometriosis and if so to Get a First Idea Which Dose(s) Work Best", "officialTitle": "A Randomized, Placebo-controlled, Double-blind, Parallel-group, Multi-center, Exploratory Dose-response Study to Assess the Efficacy and Safety of Different Oral Doses of BAY1128688 in Women With Symptomatic Endometriosis Over a 12-week Treatment Period", "acronym": "AKRENDO1"}, "statusModule": {"statusVerifiedDate": "2019-10", "overallStatus": "TERMINATED", "whyStopped": "Study BAY1128688/17472 (AKRENDO 1) was terminated early on 20 July 2018 due to hepatotoxicity", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2017-11-30", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2018-07-23", "type": "ACTUAL"}, "completionDateStruct": {"date": "2018-10-22", "type": "ACTUAL"}, "studyFirstSubmitDate": "2017-11-23", "studyFirstSubmitQcDate": "2017-12-13", "studyFirstPostDateStruct": {"date": "2017-12-14", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2019-10-02", "lastUpdatePostDateStruct": {"date": "2019-10-03", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Bayer", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "Purpose of the study is to test whether study drug BAY1128688 brings relief for pain to women with endometriosis and if so to get a first impression which dose(s) work best."}, "conditionsModule": {"conditions": ["Endometriosis"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 121, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "BAY1128688 (dose 1)", "type": "EXPERIMENTAL", "description": "One BAY1128688 tablet (lowest dose) in the morning, one placebo tablet in the evening", "interventionNames": ["Drug: BAY1128688", "Drug: Placebo"]}, {"label": "BAY1128688 (dose 2)", "type": "EXPERIMENTAL", "description": "One BAY1128688 tablet (first intermediate dose) in the morning, one placebo tablet in the evening", "interventionNames": ["Drug: BAY1128688", "Drug: Placebo"]}, {"label": "BAY1128688 (dose 3)", "type": "EXPERIMENTAL", "description": "One BAY1128688 tablet (second intermediate dose) in the morning, one placebo tablet in the evening", "interventionNames": ["Drug: BAY1128688", "Drug: Placebo"]}, {"label": "BAY1128688 (dose 4)", "type": "EXPERIMENTAL", "description": "One BAY1128688 tablet (second intermediate dose) in the morning and one in the evening", "interventionNames": ["Drug: BAY1128688"]}, {"label": "BAY1128688 (dose 5)", "type": "EXPERIMENTAL", "description": "One BAY1128688 tablet (highest dose) in the morning and one in the evening", "interventionNames": ["Drug: BAY1128688"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "One placebo tablet in the morning and one in the evening", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "BAY1128688", "description": "Various dosing OD (once daily) and BID (twice daily)", "armGroupLabels": ["BAY1128688 (dose 1)", "BAY1128688 (dose 2)", "BAY1128688 (dose 3)", "BAY1128688 (dose 4)", "BAY1128688 (dose 5)"]}, {"type": "DRUG", "name": "Placebo", "description": "Matching placebo tablets", "armGroupLabels": ["BAY1128688 (dose 1)", "BAY1128688 (dose 2)", "BAY1128688 (dose 3)", "Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Absolute change in mean pain of the 7 days with worst EAPP comparing the 28-day baseline cycle (baseline period of daily pain recordings) to the 28-day end of treatment cycle (daily pain recordings during the last 28 days of the treatment period)", "description": "EAPP: endometriosis-associated pelvic pain, measured on the NRS (Numerical Rating Scale) by item 1 of the ESD (Endometriosis Symptom Diary)", "timeFrame": "12 weeks"}], "secondaryOutcomes": [{"measure": "Incidence of treatment-emergent adverse events", "timeFrame": "18 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Women of at least 18 years of age at the time of signing of informed consent\n* Women with endometriosis confirmed by at least one of the two criteria:\n\n  * surgery within the last 10 years\n  * imaging within the last 12 months\n* moderate to severe pelvic pain which will be assessed over a period of 28 days\n* Willingness to use only ibuprofen as rescue pain medication for endometriosis-associated pelvic pain\n* Willingness to use non-hormonal barrier method for contraception (here spermicide-coated condoms) from screening visit until the end of the study (unless adequate contraception is achieved by vasectomy of the partner or use of copper intrauterine device \\[IUD\\] or commitment to abstinence) and refrain from using hormonal contraception\n\nExclusion Criteria:\n\n* Pregnancy or lactation (more than three months since delivery, abortion, or lactation before start of treatment) AND no wish for pregnancy during the study\n* Altered bilirubin metabolism and liver function at Visit 1\n* Requirement to use pain medications for reasons other than endometriosis\n* Contraindications to using ibuprofen\n* Signs of hyperandrogenism\n* Absence of menstrual cycles and/or abnormal vaginal/genital bleeding\n* History of hysterectomy, tubal-ligation or bilateral ovariectomy\n* Uncontrolled thyroid disorder", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Bayer Study Director", "affiliation": "Bayer", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Medizinische Universität Graz", "city": "Graz", "state": "Styria", "zip": "8036", "country": "Austria", "geoPoint": {"lat": 47.06733, "lon": 15.44197}}, {"facility": "Kepler Universitätsklinikum", "city": "Linz", "state": "Upper Austria", "zip": "4020", "country": "Austria", "geoPoint": {"lat": 48.30639, "lon": 14.28611}}, {"facility": "Landeskrankenhaus - Universitätskliniken Innsbruck", "city": "Innsbruck", "zip": "6020", "country": "Austria", "geoPoint": {"lat": 47.26266, "lon": 11.39454}}, {"facility": "Allgemeines Krankenhaus der Stadt Wien", "city": "Vienna", "zip": "1090", "country": "Austria", "geoPoint": {"lat": 48.20849, "lon": 16.37208}}, {"facility": "AZ Jan Palfijn Gent", "city": "Ghent", "state": "Oost-Vlaanderen", "zip": "9000", "country": "Belgium", "geoPoint": {"lat": 51.05, "lon": 3.71667}}, {"facility": "CU Saint-Luc/UZ St-Luc", "city": "Bruxelles - Brussel", "zip": "1200", "country": "Belgium"}, {"facility": "Ziekenhuis Oost-Limburg", "city": "Genk", "zip": "3600", "country": "Belgium", "geoPoint": {"lat": 50.965, "lon": 5.50082}}, {"facility": "CHU de Tivoli", "city": "La Louvière", "zip": "7100", "country": "Belgium", "geoPoint": {"lat": 50.48657, "lon": 4.18785}}, {"facility": "Gynekologie MEDA s.r.o.", "city": "Brno", "zip": "602 00", "country": "Czechia", "geoPoint": {"lat": 49.19522, "lon": 16.60796}}, {"facility": "GYN-F s.r.o.", "city": "Hradec Králové", "zip": "500 03", "country": "Czechia", "geoPoint": {"lat": 50.20923, "lon": 15.83277}}, {"facility": "G-Centrum Olomouc s.r.o. Dr. Skrivanek", "city": "Olomouc", "zip": "772 00", "country": "Czechia", "geoPoint": {"lat": 49.59552, "lon": 17.25175}}, {"facility": "GynCare MUDr. Michael Svec s.r.o.", "city": "Pilsen", "zip": "326 00", "country": "Czechia", "geoPoint": {"lat": 49.74747, "lon": 13.37759}}, {"facility": "Centrum gynekologicke rehabilitace", "city": "Písek", "zip": "39701", "country": "Czechia", "geoPoint": {"lat": 49.3088, "lon": 14.1475}}, {"facility": "Dr. Smrhova-Kovacs", "city": "Tábor", "zip": "39003", "country": "Czechia", "geoPoint": {"lat": 49.41441, "lon": 14.6578}}, {"facility": "Aarhus Universitetshospital, Skejby", "city": "Aarhus N", "zip": "8200", "country": "Denmark", "geoPoint": {"lat": 56.20367, "lon": 10.17317}}, {"facility": "H:S Rigshospitalet", "city": "København Ø", "zip": "DK-2100", "country": "Denmark", "geoPoint": {"lat": 55.70968, "lon": 12.56862}}, {"facility": "HUS / Naistenklinikka", "city": "Helsinki", "zip": "00290", "country": "Finland", "geoPoint": {"lat": 60.16952, "lon": 24.93545}}, {"facility": "Keski-Suomen keskussairaala", "city": "Jyväskylä", "zip": "40620", "country": "Finland", "geoPoint": {"lat": 62.24147, "lon": 25.72088}}, {"facility": "Lääkäriasema Cantti Oy", "city": "Kuopio", "zip": "70110", "country": "Finland", "geoPoint": {"lat": 62.89238, "lon": 27.67703}}, {"facility": "Lääkärikeskus Gyneko", "city": "Oulu", "zip": "90100", "country": "Finland", "geoPoint": {"lat": 65.01236, "lon": 25.46816}}, {"facility": "Centre Hospitalier Universitaire - Angers", "city": "Angers", "zip": "49100", "country": "France", "geoPoint": {"lat": 47.47156, "lon": -0.55202}}, {"facility": "Cochin - Paris", "city": "Paris", "zip": "75674", "country": "France", "geoPoint": {"lat": 48.85341, "lon": 2.3488}}, {"facility": "Vincentius-Diakonissen-Kliniken gAG", "city": "Karlsruhe", "state": "Baden-Wurttemberg", "zip": "76199", "country": "Germany", "geoPoint": {"lat": 49.00937, "lon": 8.40444}}, {"facility": "Praxisklinik am Rosengarten", "city": "Mannheim", "state": "Baden-Wurttemberg", "zip": "68165", "country": "Germany", "geoPoint": {"lat": 49.4891, "lon": 8.46694}}, {"facility": "Klinikum rechts der Isar", "city": "München", "state": "Bavaria", "zip": "81675", "country": "Germany", "geoPoint": {"lat": 48.69668, "lon": 13.46314}}, {"facility": "Praxis Hr. Dr. A. Gerick", "city": "Aachen", "state": "North Rhine-Westphalia", "zip": "52072", "country": "Germany", "geoPoint": {"lat": 50.77664, "lon": 6.08342}}, {"facility": "Praxis Hr. Dr. S. Fiedler", "city": "Aachen", "state": "North Rhine-Westphalia", "zip": "52074", "country": "Germany", "geoPoint": {"lat": 50.77664, "lon": 6.08342}}, {"facility": "Frauenarztpraxis Dr. Wolfgang Clemens", "city": "Stolberg", "state": "North Rhine-Westphalia", "zip": "52222", "country": "Germany", "geoPoint": {"lat": 50.77368, "lon": 6.22595}}, {"facility": "Praxis f. Gynäkologie und Geburtshilfe", "city": "Bernburg", "state": "Saxony-Anhalt", "zip": "06406", "country": "Germany", "geoPoint": {"lat": 51.79464, "lon": 11.7401}}, {"facility": "Frauenarztpraxis Dr. Wetzel", "city": "Blankenburg", "state": "Saxony-Anhalt", "zip": "38889", "country": "Germany", "geoPoint": {"lat": 51.79025, "lon": 10.95509}}, {"facility": "Praxis Hr. Prof. Dr. A. Ebert", "city": "Berlin", "zip": "10787", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Charité Campus Benjamin Franklin (CBF)", "city": "Berlin", "zip": "12200", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Semmelweis University", "city": "Budapest", "zip": "1082", "country": "Hungary", "geoPoint": {"lat": 47.49835, "lon": 19.04045}}, {"facility": "Semmelweis University", "city": "Budapest", "zip": "1085", "country": "Hungary", "geoPoint": {"lat": 47.49835, "lon": 19.04045}}, {"facility": "Bajcsy Zsilinszky Korhaz-Rendelointezet", "city": "Budapest", "zip": "1106", "country": "Hungary", "geoPoint": {"lat": 47.49835, "lon": 19.04045}}, {"facility": "Robert Karoly Magankorhaz", "city": "Budapest", "zip": "1135", "country": "Hungary", "geoPoint": {"lat": 47.49835, "lon": 19.04045}}, {"facility": "NAP - Rendelo, Private Clinic", "city": "Debrecen", "zip": "4028", "country": "Hungary", "geoPoint": {"lat": 47.53167, "lon": 21.62444}}, {"facility": "Debreceni Egyetem Klinikai Kozpont", "city": "Debrecen", "zip": "4032", "country": "Hungary", "geoPoint": {"lat": 47.53167, "lon": 21.62444}}, {"facility": "SZTE ÁOK Szent Györgyi Albert Klinikai Kozpont", "city": "Szeged", "zip": "6725", "country": "Hungary", "geoPoint": {"lat": 46.253, "lon": 20.14824}}, {"facility": "Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz", "city": "Székesfehérvár", "zip": "8000", "country": "Hungary", "geoPoint": {"lat": 47.18995, "lon": 18.41034}}, {"facility": "Casa di Cura Privata Malzoni - Villa dei Platani", "city": "Avellino", "state": "Campania", "zip": "83100", "country": "Italy", "geoPoint": {"lat": 40.91494, "lon": 14.79103}}, {"facility": "A.O.U. di Bologna Policlinico S.Orsola Malpighi", "city": "Bologna", "state": "Emilia-Romagna", "zip": "40138", "country": "Italy", "geoPoint": {"lat": 44.49381, "lon": 11.33875}}, {"facility": "A.S.U. Integrata di Udine", "city": "Udine", "state": "Friuli Venezia Giulia", "zip": "33100", "country": "Italy", "geoPoint": {"lat": 46.0693, "lon": 13.23715}}, {"facility": "Fondazione Policlinico Universitario Agostino Gemelli", "city": "Rome", "state": "Lazio", "zip": "00168", "country": "Italy", "geoPoint": {"lat": 41.89193, "lon": 12.51133}}, {"facility": "IRCCS A.O.U. San Martino IST Ist. Nazionale Ricerca Cancro", "city": "Genoa", "state": "Liguria", "zip": "16132", "country": "Italy", "geoPoint": {"lat": 44.40478, "lon": 8.94439}}, {"facility": "A.O.U. Careggi", "city": "Florence", "state": "Tuscany", "zip": "50134", "country": "Italy", "geoPoint": {"lat": 43.77925, "lon": 11.24626}}, {"facility": "A.O.U. Senese", "city": "Siena", "state": "Tuscany", "zip": "53100", "country": "Italy", "geoPoint": {"lat": 43.31822, "lon": 11.33064}}, {"facility": "A.O.U. Integrata Verona", "city": "Verona", "state": "Veneto", "zip": "37126", "country": "Italy", "geoPoint": {"lat": 45.43854, "lon": 10.9938}}, {"facility": "Flevoziekenhuis", "city": "Almere Stad", "zip": "1315 RA", "country": "Netherlands", "geoPoint": {"lat": 52.37025, "lon": 5.21413}}, {"facility": "Isala", "city": "Zwolle", "zip": "8025 AB", "country": "Netherlands", "geoPoint": {"lat": 52.5125, "lon": 6.09444}}, {"facility": "CLINICAL MEDICAL RESEARCH Sp. z o. o.", "city": "Katowice", "zip": "40-001", "country": "Poland", "geoPoint": {"lat": 50.2597, "lon": 19.02173}}, {"facility": "Vita Longa Sp. z o.o.", "city": "Katowice", "zip": "40-748", "country": "Poland", "geoPoint": {"lat": 50.2597, "lon": 19.02173}}, {"facility": "Prywatny Gabinet Lekarski Ginekologia, Poloznictwo i Ultr.", "city": "Lodz", "zip": "90-602", "country": "Poland", "geoPoint": {"lat": 51.77058, "lon": 19.47395}}, {"facility": "Specjalistyczny Gabinet Ginekologiczno-Polozniczy", "city": "Lublin", "zip": "20-064", "country": "Poland", "geoPoint": {"lat": 51.25058, "lon": 22.57009}}, {"facility": "NZOZ NOVITA, Specjalistyczne Gabinety Lekarskie", "city": "Lublin", "zip": "20-632", "country": "Poland", "geoPoint": {"lat": 51.25058, "lon": 22.57009}}, {"facility": "VitroLive Sp. z o.o.", "city": "Szczecin", "zip": "70-483", "country": "Poland", "geoPoint": {"lat": 53.42894, "lon": 14.55302}}, {"facility": "Twoja Przychodnia - Szczecinskie Centrum Medyczne", "city": "Szczecin", "zip": "71-434", "country": "Poland", "geoPoint": {"lat": 53.42894, "lon": 14.55302}}, {"facility": "NZOZ Zieniewicz Medical", "city": "Warsaw", "zip": "02-201", "country": "Poland", "geoPoint": {"lat": 52.22977, "lon": 21.01178}}, {"facility": "Hospital Clínic i Provincial de Barcelona", "city": "Barcelona", "zip": "08036", "country": "Spain", "geoPoint": {"lat": 41.38879, "lon": 2.15899}}, {"facility": "Hospital Universitario 12 de Octubre", "city": "Madrid", "zip": "28041", "country": "Spain", "geoPoint": {"lat": 40.4165, "lon": -3.70256}}, {"facility": "Hospital Universitario \"La Paz\"", "city": "Madrid", "zip": "28046", "country": "Spain", "geoPoint": {"lat": 40.4165, "lon": -3.70256}}, {"facility": "Hospital Regional de Málaga", "city": "Málaga", "zip": "29010", "country": "Spain", "geoPoint": {"lat": 36.72016, "lon": -4.42034}}, {"facility": "Hospital Universitario Virgen del Rocío", "city": "Seville", "zip": "41013", "country": "Spain", "geoPoint": {"lat": 37.38283, "lon": -5.97317}}, {"facility": "Hospital General Universitario de Valencia", "city": "Valencia", "zip": "46014", "country": "Spain", "geoPoint": {"lat": 39.47391, "lon": -0.37966}}, {"facility": "York Teaching Hospital NHS Foundation Trust", "city": "York", "state": "North Yorkshire", "zip": "YO318HE", "country": "United Kingdom", "geoPoint": {"lat": 53.95763, "lon": -1.08271}}, {"facility": "Liverpool Womens Hospital", "city": "Liverpool", "zip": "L8 7SS", "country": "United Kingdom", "geoPoint": {"lat": 53.41058, "lon": -2.97794}}, {"facility": "Norfolk and Norwich Hospital", "city": "Norwich", "zip": "NR4 7UY", "country": "United Kingdom", "geoPoint": {"lat": 52.62783, "lon": 1.29834}}, {"facility": "Whiston Hospital", "city": "Prescot", "zip": "L35 5DR", "country": "United Kingdom", "geoPoint": {"lat": 53.42948, "lon": -2.80031}}]}, "referencesModule": {"references": [{"pmid": "37422772", "type": "DERIVED", "citation": "Hilpert J, Groettrup-Wolfers E, Kosturski H, Bennett L, Barnes CLK, Gude K, Gashaw I, Reif S, Steger-Hartmann T, Scheerans C, Solms A, Rottmann A, Mao G, Chapron C. Hepatotoxicity of AKR1C3 Inhibitor BAY1128688: Findings from an Early Terminated Phase IIa Trial for the Treatment of Endometriosis. Drugs R D. 2023 Sep;23(3):221-237. doi: 10.1007/s40268-023-00427-5. Epub 2023 Jul 9."}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000729512", "term": "BAY1128688"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT05728281", "orgStudyIdInfo": {"id": "2022-A02714-39"}, "organization": {"fullName": "University Hospital, Angers", "class": "OTHER_GOV"}, "briefTitle": "Impact of Time on Sexual Function (FSFI® Score) After Hysterectomy", "officialTitle": "Recommended Time to Resume Sexual Activity After Hysterectomy: Impact on Sexual Function (FSFI® Score) and Complication Rate ISHYS Study", "acronym": "ISHYS"}, "statusModule": {"statusVerifiedDate": "2025-07", "overallStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2023-06-05", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2026-06-05", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2026-10-05", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2023-02-04", "studyFirstSubmitQcDate": "2023-02-04", "studyFirstPostDateStruct": {"date": "2023-02-15", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2025-07-18", "lastUpdatePostDateStruct": {"date": "2025-07-23", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "University Hospital, Angers", "class": "OTHER_GOV"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "In France, more than 62 000 hysterectomies are performed each year. Female sexual function is the result of multiple psychological, social and physiological factors. There is no information in the current literature about the optimum time between the surgery and the sexual relation resumption. The primary outcome is to assess the impact of advising time between hysterectomy and sexual relation resumption by using FSFI® score. Secondaries outcomes are: to describe and compare post-operative complications in the two groups of the study, to describe the follow-up of the recommendation concerning time between surgery and sexual relation resumption and to describe why this recommendation was not followed. This study is based on 4 questionnaires: FSFI® pre-operative and post-operative, pre-operative questionnaire and post-operative questionnaire. This is a monocentric, comparative, of superiority, randomised and prospective study. Patients are randomised into two groups: sexual relation resumption advised 4 weeks after surgery, or 8 weeks. The inclusion criteria are more than 18 years, francophone, in sexual activity, scheduled for a total hysterectomy for benign indication (menometrorrhagia, fibroma, adenomyosis, endometriosis, pelvic floor disorders, low-grade endometrial cancer), considering vaginal, laparoscopic and abdominal approach, and a written consent. Non-inclusion criteria are illiteracy, cognitive disorders, without social security, deprived liberty by judicial or administrative decision, psychiatric care, patient with legal protection, patient incapable of giving consent. If our conclusions confirmed our hypothesis, it can improve clinical practices by providing additional informations for surgeon and patient, to undergo this surgery as serenely as possible."}, "conditionsModule": {"conditions": ["Time Between Hysterectomy and Resumption of Sexual Relations", "Sexual Function"], "keywords": ["benign gynaecological disease", "hysterectomy", "sexual function", "FSFI® score"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "OTHER", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 142, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Resumption of sexual intercourse recommended 4 weeks after hysterectomy", "type": "OTHER", "interventionNames": ["Other: Recommended time after hysterectomy"]}, {"label": "Resumption of sexual intercourse recommended 8 weeks after hysterectomy", "type": "OTHER", "interventionNames": ["Other: Recommended time after hysterectomy"]}], "interventions": [{"type": "OTHER", "name": "Recommended time after hysterectomy", "description": "Currently there is no consensus on the optimal time to resume sexual activity. Using a randomization, we will therefore compare two groups: one, whose postoperative instructions will indicate a resumption of sexual activity from 4 weeks after the operation and the other from 8 weeks postoperatively. The primary endpoint is the FSFI® score. The patients will answer the FSFI® questionnaire preoperatively and then at 3 months after surgery.", "armGroupLabels": ["Resumption of sexual intercourse recommended 4 weeks after hysterectomy", "Resumption of sexual intercourse recommended 8 weeks after hysterectomy"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "The Female Sexual Function Index score", "description": "Assessment of the impact of the recommended time between hysterectomy and resumption of sexual intercourse on sexual function using the Female Sexual Function Index score", "timeFrame": "one year"}], "secondaryOutcomes": [{"measure": "Postoperative complications", "description": "Describe and compare postoperative complications according to the recommended time between hysterectomy and resumption of sexual intercourse. The postoperative complications studied include dyspareunia, spontaneous pain outside of sexual intercourse, metrorrhagia, infection, and vaginal fundal suture release.", "timeFrame": "one year"}, {"measure": "Follow-up to the recommendation", "description": "Describe the follow-up to the recommendation in terms of time to resume sexual intercourse and describe the reasons for not following the recommendation", "timeFrame": "one year"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patient ≥ 18 years old,\n* Francophone,\n* Sexually active,\n* Receiving a conservative or non-conservative total hysterectomy for benign pathology\\*,\n* Having signed a consent form. All surgical approaches are considered, laparoscopic approach with laparoscopic or vaginal closure, vaginal approach and laparotomy.\n\n  \\*The indications for the procedure selected for this study include:\n* Menometrorrhagia,\n* Fibroids,\n* Adenomyosis,\n* Endometriosis,\n* Pelvic statics disorder,\n* Cervical dysplasia,\n* Endometrial cancer not requiring lymph node dissection or additional treatment.", "healthyVolunteers": true, "sex": "FEMALE", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "University Hospital of Angers", "status": "RECRUITING", "city": "Angers", "country": "France", "contacts": [{"name": "Pierre-Emmanuel BOUET, MD, PhD", "role": "CONTACT", "phone": "+33241354213", "email": "pierreemmanuel.bouet@chu-angers.fr"}], "geoPoint": {"lat": 47.47156, "lon": -0.55202}}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT01184144", "orgStudyIdInfo": {"id": "H-2010-0066"}, "organization": {"fullName": "University of Wisconsin, Madison", "class": "OTHER"}, "briefTitle": "Endometriosis: Immunomodulation", "officialTitle": "Effect of Pioglitazone on Peritoneal Cytokines in Women With Endometriosis"}, "statusModule": {"statusVerifiedDate": "2012-04", "overallStatus": "WITHDRAWN", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-08"}, "primaryCompletionDateStruct": {"date": "2012-05", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2012-05", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2010-08-13", "studyFirstSubmitQcDate": "2010-08-17", "studyFirstPostDateStruct": {"date": "2010-08-18", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-10-01", "lastUpdatePostDateStruct": {"date": "2015-10-02", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "University of Wisconsin, Madison", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to compare the effect of pioglitazone versus no drug on soluble profinflammatory markers in peritoneal fluid of women with endometriosis.", "detailedDescription": "The overall goal of this proposal is to assess modulation of immune mechanisms in endometriosis. Endometriosis is a common ailment affecting approximately five million reproductive-aged American women. We will test the efficacy of a novel immunomodulatory drug (peroxisome proliferator activated receptor gamma, PPAR-gamma, agonist), pioglitazone, to reduce peritoneal fluid cytokine concentrations in women with endometriosis compared with the non-treated controls (randomized controlled trial). Based on prior studies done by the investigator highlighting the major role of cytokines and the immune system in the genesis or propagation of endometriosis, these experiments could lead to improved translational treatment strategies and a better understanding of endometriosis. Acting through PPAR-gamma, TZDs inhibit proinflammatory cytokines as well as NF-kB, an important nuclear transcription factor for the production of many cytokines. Accordingly, since human endometrial epithelial and stromal cells contain PPAR-gamma, we felt i would be useful to evaluate the influence of a PPAR-gamma ligand, pioglitazone, on the concentration of specific peritoneal fluid cytokines.\n\nComparison: After the pre-trial screening, eligible subjects with presumed endometriosis and age 18-45 will be consented and randomly assigned to receive either pioglitazone (30 mg, daily)or no drug for 2 weeks. Peritoneal fluid will be collected at the time of surgery and the volume measured. All patients enrolled in the study will have their surgery during the follicular phase of the cycle in order to minimize differences in volume and cytokine concentration due to the cyclical changes. The primary measure will be the peritoneal fluid concentration comparisons of the two groups assessing six different cytokines."}, "conditionsModule": {"conditions": ["Endometriosis"], "keywords": ["Endometriosis", "Peritoneal fluid", "Cytokines", "Peroxisome Proliferator-Activated Receptors"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2", "PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "DIAGNOSTIC", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 0, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "pioglitazone", "type": "EXPERIMENTAL", "description": "Pioglitazone study drug", "interventionNames": ["Drug: Pioglitazone"]}, {"label": "No drug", "type": "NO_INTERVENTION", "description": "\"Placebo\" like comparitor"}], "interventions": [{"type": "DRUG", "name": "Pioglitazone", "description": "Pioglitazone, 30 mg, by mouth daily for 2 weeks", "armGroupLabels": ["pioglitazone"], "otherNames": ["Actos"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Peritoneal cytokine levels", "timeFrame": "Within 1 year"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Healthy woman age 18 - 45 years.\n2. Regular cycles (24-35 days).\n3. Pelvic pain ≥ 3 months.\n4. Negative pregnancy test.\n5. Non-lactating.\n6. No prior (\\<3 months) use of hormonal therapy.\n7. No history of liver disease.\n8. Suspected endometriosis and scheduled for surgery to confirm this diagnosis\n9. Surgery scheduled in follicular phase.\n10. Consent to participate in the study.\n11. Enrollment into data analysis portion of study if:\n\n    * Endometriosis diagnosed from surgical specimen by routine hematoxylin and eosin staining and histological evaluation.\n\nExclusion Criteria:\n\n1. Major psychiatric conditions or the abuse of alcohol or drugs which would make it difficult for the subject to complete study procedures.\n2. Active or prior infection with hepatitis, human immunodeficiency virus (HIV) infection, or history of high-risk activities (e.g., IV drug abuse) which would increase risk to laboratory personnel. Of note, no testing for hepatitis or HIV will be performed as part of this study and all tissues will be handled and discarded as if they were potentially infected.\n3. Patients with liver dysfunction (elevated liver enzymes \\> 2 times the upper limit of normal).\n4. Presence of pre-existing malignancy, including carcinoma of the breast or uterus.\n5. Women with other causes of chronic pelvic pain including infectious, gastrointestinal, musculoskeletal, neurologic or psychiatric.\n6. Elevated WBC.\n7. NYHA functional class I-IV heart failure.\n8. Diabetes mellitus.\n9. Known pregnancy or positive pregnancy test.", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "45 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Dan I Lebovic, MD", "affiliation": "Univ Wisconsin", "role": "PRINCIPAL_INVESTIGATOR"}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04", "removedCountries": ["United States"]}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000077205", "term": "Pioglitazone"}], "ancestors": [{"id": "D045162", "term": "Thiazolidinediones"}, {"id": "D013844", "term": "Thiazoles"}, {"id": "D013457", "term": "Sulfur Compounds"}, {"id": "D009930", "term": "Organic Chemicals"}, {"id": "D001393", "term": "Azoles"}, {"id": "D006573", "term": "Heterocyclic Compounds, 1-Ring"}, {"id": "D006571", "term": "Heterocyclic Compounds"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT06041347", "orgStudyIdInfo": {"id": "Semmelweis University Szabó G"}, "organization": {"fullName": "Semmelweis University", "class": "OTHER"}, "briefTitle": "Learning Curve for the Visualization of Sacral Plexus on TVS", "officialTitle": "Evaluation of the Learning Curve for the Visualization of Sacral Nerve Roots and Sacral Plexus on Gynecological Transvaginal Ultrasound - PlexUS Study", "acronym": "PlexUS"}, "statusModule": {"statusVerifiedDate": "2023-09", "overallStatus": "NOT_YET_RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2023-10-01", "type": "ESTIMATED"}, "primaryCompletionDateStruct": {"date": "2025-10-01", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2025-12-31", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2023-09-05", "studyFirstSubmitQcDate": "2023-09-14", "studyFirstPostDateStruct": {"date": "2023-09-18", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-09-14", "lastUpdatePostDateStruct": {"date": "2023-09-18", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Semmelweis University", "class": "OTHER"}, "collaborators": [{"name": "Jagiellonian University", "class": "OTHER"}, {"name": "Charles University, Czech Republic", "class": "OTHER"}, {"name": "St John of God Hospital, Vienna", "class": "OTHER"}]}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The purpose of this prospective study was to evaluate the learning curve of TVUS (transvaginal ultrasound) for the visualization of sacral nerve roots and sacral plexus on gynecological transvaginal ultrasound. The investigators aim to evaluate to evaluate the number needed to gain competence or to review the level of competence.", "detailedDescription": "For each patient, the fellows are blinded to the clinical and surgical history. The investigators will be aware that all patients were being evaluated for pelvic pain or endometriosis. The expert sonographer assess the patient and visualized the sacral roots and the sacral plexus first as part of the advanced TVUS examination for endometriosis.\n\nTVUS examination will conducted in six steps eas follows in six successive steps. All women will be asked to empty their bladder prior to examination. TVUS scans will be performed in the lithotomy position in a standardized fashion using a transvaginal probe Step 1: First the probe will inserted into the anterior vaginal fornix. The uterus is examined in the midsagittal view on the longitudinal section to identify the cervix and the uterine cavity. The image is frozen with time displayed on the screen, which was marked as Time 1.\n\nStep 2: The image is unfrozen and at the level of the inner cervical meatus the transducer is rotated 90 degrees counterclockwise to obtain a transverse scan.\n\nStep 3: Then the probe is immediately moved towards the right lateral fornix pointing towards the uterine vessels, which appear as hypoechoic bands. Behind these structures, a thick hyperechoic band - the left uterosacral ligament -appears, starting from the cervix and pointing laterally in a semi horizontal direction. By rotating the probe the uterosacral ligament is then followed from medial to lateral, up to the lateral pelvic wall. The obturator internus muscle covers most of the lateral wall of the pelvis minor, which - in transverse scan - is a hypoechoic thin band just lateral to the uterosacral ligament. On the lateral side of the muscle a continuous bright white band is seen, corresponding to the body of the ischium.\n\nStep 4: Sweeping the probe medially and pushing it superior the hypoechoic obturator internus muscle and the hyperechoic ischium are followed ending at the greater sciatic foramen. At this point transverse and oblique sections of the branches of the anterior division of the internal iliac vessels became visible. Deeper to the vessels the hypoechoic muscle fiber bundles with intervening echogenic perimysium, the piriformis muscle, and a bright white line, the anterior surface of the sacrum are visualized. Between the vessels and the piriformis muscle on conventional gray scale B mode the sacral roots of the sacral plexus (SP) appear in longitudinal section, with a typical \"bundle of straw\" appearance: hypoechoic bands, with echogenic septae. The hypoechoic areas correspond to nerve fascicles, while the hyperechoic septae correspond to the inner and outer epineurium. In transverse section, the nerves have a \"honeycomb\" shape echotexture.\n\nStep 5: Pushing the transducer superior color Doppler and pulse wave Doppler can be used to differentiate blood vessels from the ureter on the lateral pelvic wall and to identify the branching of the internal iliac artery. From the posterior division rises the superior gluteal artery and from the anterior division originates the inferior gluteal artery. Both of them exiting the pelvis between the ischium and the sacrum. The former runs between the lumbosacral trunk and the ventral ramus of the S1 nerve and leaves the pelvis superior to the piriformis muscle. The inferior gluteal artery passes usually posteriorly between S2 and S3 roots, and leaves the pelvis together with the sciatic nerve, inferior to the piriformis muscle near to the transducer. When the sacral plexus was clearly visualized the image was frozen again and Time 2 was marked. The total time required to complete the visualization of the sacral plexus was calculated as Time 2 minus Time 1.\n\nThe diameter of the SP is measured in all patients in a transverse section at the notional intersection of the SP and a vertical line extending from the medial border of the obturator internus muscle. The measurement is taken by placing the caliper on the outer edge of hyperechoic epineurium. The same procedure is then repeated on the contralateral side."}, "conditionsModule": {"conditions": ["Endometriosis", "Nerve Sheath Tumor", "Radiculopathy"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "COHORT", "timePerspective": "PROSPECTIVE"}, "enrollmentInfo": {"count": 480, "type": "ESTIMATED"}}, "armsInterventionsModule": {"interventions": [{"type": "DIAGNOSTIC_TEST", "name": "Transvaginal ultrasound", "description": "Preoperative detection with TVUS of proximity or the involvement of the sacral nerve roots in women diagnosed with deep endometriosis or other benign or malignant pelvic tumors would also contribute to the safety of surgical interventions (e.g laparoscopy, tru-cut biopsy) It aslo provides correct counseling and select the appropriate surgical team and assess the likely operative complexity of the surgery. Until now the diagnosis was based on MRI."}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "The number of scans to gain competency for the visualization of sacral nerve roots and sacral plexus on gynecological transvaginal ultrasound", "description": "The LC-CUSUM test will be used to monitor the performance of sequential interventions. Hereby the Null hypothesis (H0, performance is inadequate) is continuously tested against the alternative hypothesis (H1, performance is adequate). Negative scores for correct interventions and positive scores for incorrect results are calculated as previously reported by Biau et al. (2008a,b). Once the summation score reaches a predefined level (h) the test rejects the null hypothesis in favour of the alternative hypothesis indicating that the performance is adequate. After the literature(Tammaa 2014 and Ong 2020) we have chosen h: 1.25, P0: 0.175 as an unacceptable failure rate, and P1: 0.1, as an acceptable failure rate.", "timeFrame": "12 months"}], "secondaryOutcomes": [{"measure": "inter and intraobserver variability", "description": "The LC-CUSUM test will be used to monitor the performance of sequential interventions. Hereby the Null hypothesis (H0, performance is inadequate) is continuously tested against the alternative hypothesis (H1, performance is adequate). Negative scores for correct interventions and positive scores for incorrect results are calculated as previously reported by Biau et al. (2008a,b). Once the summation score reaches a predefined level (h) the test rejects the null hypothesis in favour of the alternative hypothesis indicating that the performance is adequate. After the literature(Tammaa 2014 and Ong 2020) we have chosen h: 1.25, P0: 0.175 as an unacceptable failure rate, and P1: 0.1, as an acceptable failure rate", "timeFrame": "12 months"}, {"measure": "differences between sonographers of different level of experience in the field of gynecological TVS.", "description": "The LC-CUSUM test will be used to monitor the performance of sequential interventions. Hereby the Null hypothesis (H0, performance is inadequate) is continuously tested against the alternative hypothesis (H1, performance is adequate). Negative scores for correct interventions and positive scores for incorrect results are calculated as previously reported by Biau et al. (2008a,b). Once the summation score reaches a predefined level (h) the test rejects the null hypothesis in favour of the alternative hypothesis indicating that the performance is adequate. After the literature(Tammaa 2014 and Ong 2020) we have chosen h: 1.25, P0: 0.175 as an unacceptable failure rate, and P1: 0.1, as an acceptable failure rate", "timeFrame": "12 months"}, {"measure": "differences between participating centers.", "description": "The LC-CUSUM test will be used to monitor the performance of sequential interventions. Hereby the Null hypothesis (H0, performance is inadequate) is continuously tested against the alternative hypothesis (H1, performance is adequate). Negative scores for correct interventions and positive scores for incorrect results are calculated as previously reported by Biau et al. (2008a,b). Once the summation score reaches a predefined level (h) the test rejects the null hypothesis in favour of the alternative hypothesis indicating that the performance is adequate. After the literature(Tammaa 2014 and Ong 2020) we have chosen h: 1.25, P0: 0.175 as an unacceptable failure rate, and P1: 0.1, as an acceptable failure rate", "timeFrame": "12 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with pelvic pain scheduled for TVS\n\nExclusion Criteria:\n\n* 18 years\n* Women who have never been sexually active\n* (suspected) Pelvic malignancy for example gynecological, intestinal or urological malignancy\n* Premenarche\n* Pregnancy\n* Patients refusal to participate to the study", "healthyVolunteers": true, "sex": "FEMALE", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"], "studyPopulation": "Participants are consecutive patients of the Gynecology and Endometriosis Ambulance of the participating centres.", "samplingMethod": "PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"centralContacts": [{"name": "Gábor Szabó, PhD", "role": "CONTACT", "phone": "+36204554710", "email": "szabo.gabor6@med.semmelweis-univ.hu"}], "overallOfficials": [{"name": "Gábor Szabó, PhD", "affiliation": "Semmelweis University", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Gábor Szabó", "city": "Budapest", "zip": "1088", "country": "Hungary", "geoPoint": {"lat": 47.49835, "lon": 19.04045}}]}, "referencesModule": {"references": [{"pmid": "36938682", "type": "RESULT", "citation": "Szabo G, Madar I, Hudelist G, Aranyi Z, Turtoczki K, Rigo J Jr, Acs N, Liptak L, Fancsovits V, Bokor A. Visualization of sacral nerve roots and sacral plexus on gynecological transvaginal ultrasound: feasibility study. Ultrasound Obstet Gynecol. 2023 Aug;62(2):290-299. doi: 10.1002/uog.26204."}, {"pmid": "37058402", "type": "RESULT", "citation": "Fischerova D, Santos G, Wong L, Yulzari V, Bennett RJ, Dundr P, Burgetova A, Barsa P, Szabo G, Sousa N, Scovazzi U, Cibula D. Imaging in gynecological disease (26): clinical and ultrasound characteristics of benign retroperitoneal pelvic peripheral-nerve-sheath tumors. Ultrasound Obstet Gynecol. 2023 Nov;62(5):727-738. doi: 10.1002/uog.26223."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}, {"id": "D018317", "term": "Nerve Sheath Neoplasms"}, {"id": "D011843", "term": "Radiculopathy"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}, {"id": "D009380", "term": "Neoplasms, Nerve Tissue"}, {"id": "D009370", "term": "Neoplasms by Histologic Type"}, {"id": "D009369", "term": "Neoplasms"}, {"id": "D010524", "term": "Peripheral Nervous System Neoplasms"}, {"id": "D009423", "term": "Nervous System Neoplasms"}, {"id": "D009422", "term": "Nervous System Diseases"}, {"id": "D010523", "term": "Peripheral Nervous System Diseases"}, {"id": "D009468", "term": "Neuromuscular Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT02575248", "orgStudyIdInfo": {"id": "fwa000017585"}, "organization": {"fullName": "Ain Shams University", "class": "OTHER"}, "briefTitle": "Induction of Ovulation by Clomiphene Citrate Following Laparoscopic Surgery for Endometriosis Stage 1 and Stage 2 With and Without Suppression by Dienogest", "officialTitle": "Induction of Ovulation by Clomiphene Citrate Following Laparoscopic Surgery for Endometriosis Stage 1 and Stage 11 With and Without Suppression by Dienogest"}, "statusModule": {"statusVerifiedDate": "2017-06", "overallStatus": "UNKNOWN", "lastKnownStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2014-10"}, "primaryCompletionDateStruct": {"date": "2017-07", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2017-07", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2015-09-05", "studyFirstSubmitQcDate": "2015-10-11", "studyFirstPostDateStruct": {"date": "2015-10-14", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-06-20", "lastUpdatePostDateStruct": {"date": "2017-06-22", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Alhassan Mohammad Khedr", "investigatorTitle": "principal investigator", "investigatorAffiliation": "Ain Shams University"}, "leadSponsor": {"name": "Ain Shams University", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "This study aims at investigating the fertility outcome of endometriosis suppression with dienogest 2mg / day for 3 month followed by induction of ovulation for 3 month in endometriosis patients stage I and II.", "detailedDescription": "Study population: Sample size:\n\nGroup sample sizes of this study is 155 in group one and 155 in group two achieve 80% power to detect a difference between the group proportions of 0.10. The proportion in group one (the treatment group) is assumed to be 0.1000 under the null hypothesis and 0.2000 under the alternative hypothesis. The proportion in group two (the control group) is 0.1000. The test statistic used is .the one-sided Z test with un pooled variance. The significance level of the test was targeted at 0.05\n\nPrimary outcome:\n\nClinical pregnancy rate in endometriosis patients stage I and II undergoing endometriosis suppression with dienogest 2mg / day for 3 month followed by induction of ovulation for 3 month.\n\nSecondary outcome:\n\nOvulation rate in endometriosis patients stage I and II undergoing endometriosis suppression with dienogest 2mg / day for 3 month followed by induction of ovulation for 3 month.\n\nInclusion criteria:\n\nAll women recruited in this study will have the have a definitive diagnosis of endometriosis grade I or grade II via laparoscopy just before randomization.\n\nMethod of Randomization:\n\nA Computerized generated list from the internet https://www.sealedenvelope.com/sirnple-randomiser/vl/lists\n\nAllocation concealment:\n\nClosed envelope method by a nurse not participating in the study Intervention It is a prospective randomized controlled trial. Investigation done after recruitment and before randomization.\n\nThe patients will be randomized in to two groups:\n\nGroup A: patients receive dienogest 2 mg (visanne 2mg sanofi Aventis) daily for three months then followed by induction of ovulation with clomiphene citrate (clomid 5mg sanofi aventis for three months.\n\nGroup B: Patients will undergo induction of ovulation with clomiphene citrate (clomid 50mg sanofi aventis) for three months.\n\nProtocol of induction of ovulation\n\n1. Clomiphen citrate (clomid 50mg sanofi aventis) will be given on day two of the menstrual cycle at a dose of 50 mg twice daily for five days.\n2. Folliculometry will be performed every other day starting from seventh day of the cycle till ovulation occurs using a 6 Mhz transvaginal probe till the follicles reach 18 - 20 mm.\n3. A trigger of ovulation HCG 10000iu is given IM when the follicles reach 18- 22 mm. The couple will be advised to have intercourse after 36 hrs then daily for 7 days.\n4. Prontogest 400 mg (progest 400 mg Sanofi Aventis) daily vaginal suppository as a luteal phase support.\n5. Pregnancy will be diagnosed quantitative B HCG blood test after 2 days missed period.\n6. Clinical pregnancy rate will be diagnosed by TVUS confirmed fetal echo with pulsation at 5-7 weeks gestation.\n\nThe sonographer confirming clinical pregnancy will be blinded to both groups. Statistical Analysis\n\nStatistical Method:\n\nStatistical analysis will be performed using Microsoft Excel version 2010 and statistical package for social sciences ( SPSS ) for windows version l S.O.\n\nContinious data are to be presented as range, mean and standard deviation (if parametric); or range; median and inter quartile range (if non - parametric).\n\nDichotomous or categorical data are to be presented as number and percentage. Difference between independent is to be estimated using independent student's t-test (for parametric continuous variables), Manny whitney test U-test (for non -parametric continuous variables) and Chi-square and test (for categorical variables). Receiver operator characteristics curve is to be constructed to assess the predictability is to be expressed in terms of sensitivity , specificity , positive and negative predictive values. Significance level is at 0.05.\n\nEthical and legal aspects\n\nDelegation of investigator responsibilities:\n\nThe investigator will ensure that all persons assisting with the trial are adequately informed about the protocol, any amendments to the protocol, the study treatments, and their trial-related duties and functions.\n\nPatient information and informed consent:\n\nBefore being admitted to the clinical study, the patient must consent to participate after the nature, scope and possible consequences of the clinical study have been explained in a form understandable to her and a written consent will be obtained.\n\nConfidentiality:\n\nOnly the patient initials will be recorded in the files, and if the patients name appears on any other document, it must be kept in a privacy by the investigators. The investigator will maintain a personal patient identification list (patient initials with the corresponding patient names) to enable records to be identified.\n\nProtocol approval:\n\nBefore the beginning of the study and in accordance with the local regulation followed, the protocol and all the corresponding documents will be declared for Ethical and Research approval by the council of the obstetrics Department, Ain Shams University."}, "conditionsModule": {"conditions": ["Infertility"], "keywords": ["dienogest", "infertility", "endometriosis"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 310, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Group A", "type": "EXPERIMENTAL", "description": "patients diagnosed laparoscopically with Endometriosis Stage 1 and Stage 2", "interventionNames": ["Drug: Dienogest 2mg", "Drug: Clomiphene citrate 5 mg"]}, {"label": "group B", "type": "ACTIVE_COMPARATOR", "description": "patients diagnosed laparoscopically with Endometriosis Stage 1 and Stage 2", "interventionNames": ["Drug: Clomiphene citrate 5 mg"]}], "interventions": [{"type": "DRUG", "name": "Dienogest 2mg", "description": "Dienogest 2mg is given daily for 3 months then followed by Clomiphene citrate 5 mg induction of ovulation for three months", "armGroupLabels": ["Group A"]}, {"type": "DRUG", "name": "Clomiphene citrate 5 mg", "description": "Clomiphene citrate 5 mg for induction of ovulation for three months", "armGroupLabels": ["Group A", "group B"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Clinical pregnancy rate", "description": "fetal life detected by ultrasound", "timeFrame": "2 months"}], "secondaryOutcomes": [{"measure": "Ovulation rate", "description": "ovulation rate is recorded before triggering", "timeFrame": "up to 21 days"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1\\. All women recruited in this study will have the have- a definitive diagnosis of endometriosis grade I or grade II via laparoscopy just before randomization.\n\nExclusion Criteria:\n\n1. Male factor.\n2. Other factors e.g. mullerian duct anomalies, hydrosalpinx.\n3. Age \\> 35 years.\n4. Day 3 FSH \\> 14 mlu/ml or antimullerian hormone \\<1 ng/1.", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "20 Years", "maximumAge": "40 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "sherif Abdelhamid, professor", "role": "CONTACT", "phone": "01001424742"}, {"name": "Noha rabei, professor", "role": "CONTACT", "phone": "01227174996"}], "overallOfficials": [{"name": "laila fareed, lecturer", "affiliation": "01222148471", "role": "STUDY_DIRECTOR"}, {"name": "mostafa fouad, professor", "affiliation": "01226188993", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "AinShamsU", "status": "RECRUITING", "city": "Abbasia", "state": "C", "country": "Egypt", "contacts": [{"name": "alhassan mo khedr, Assistant lecture", "role": "CONTACT", "phone": "01006193797", "email": "hasankhedr@yahoo.com"}]}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D007246", "term": "Infertility"}, {"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D000091662", "term": "Genital Diseases"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}]}, "interventionBrowseModule": {"meshes": [{"id": "C023635", "term": "dienogest"}, {"id": "D002996", "term": "Clomiphene"}], "ancestors": [{"id": "D013267", "term": "Stilbenes"}, {"id": "D001597", "term": "Benzylidene Compounds"}, {"id": "D001555", "term": "Benzene Derivatives"}, {"id": "D006841", "term": "Hydrocarbons, Aromatic"}, {"id": "D006844", "term": "Hydrocarbons, Cyclic"}, {"id": "D006838", "term": "Hydrocarbons"}, {"id": "D009930", "term": "Organic Chemicals"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT05279209", "orgStudyIdInfo": {"id": "4-2021-1512"}, "organization": {"fullName": "Yonsei University", "class": "OTHER"}, "briefTitle": "Catheter-directed Sclerotherapy Versus Surgical Resecction: Randomized Controlled Trial Comparing Ovarian Function and Therapeutic Efficacy After Treatment of Ovarian Endometrioma", "officialTitle": "Catheter-directed Sclerotherapy Versus Surgical Resecction: Randomized Controlled Trial Comparing Ovarian Function and Therapeutic Efficacy After Treatment of Ovarian Endometrioma"}, "statusModule": {"statusVerifiedDate": "2022-03", "overallStatus": "UNKNOWN", "lastKnownStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2021-12-18", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2022-12-17", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2023-12-17", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2022-01-11", "studyFirstSubmitQcDate": "2022-03-14", "studyFirstPostDateStruct": {"date": "2022-03-15", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2022-03-14", "lastUpdatePostDateStruct": {"date": "2022-03-15", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Yonsei University", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The primary purpose of this study is to compare residual ovarian function and therapeutic efficacy of surgical resection and catheter-directed sclerotherapy for ovarian endometrioma", "detailedDescription": "Screening\n\n* History, Physical examination\n* Vital signs\n* Laboratory test (Serum AMH, CA-125, HE-4) / EKG / MRI\n* EHP-30\n\nIntervention\n\n* Surgical enucleation or catheter-directed sclerotherapy\n* Laboratory test / EKG\n* Adverse event monitoring\n\nFollow-up visit #1 (1 month)\n\n* Vital signs\n* Lab test (AMH, CA-125) / Ultrasound\n* Adverse event monitoring\n\nFollow-up visit #2 (6 months)\n\n* Vital signs\n* Lab test (AMH, CA-125) / Ultrasound / Contrast-enhanced MRI\n* EHP-30\n\nFollow-up visit #3 (12months)\n\n* Vital signs\n* Lab test (AMH, CA-125) / Ultrasound\n* EHP-30"}, "conditionsModule": {"conditions": ["Ovarian Endometrioma"], "keywords": ["Endometrioma", "resection", "enucleation", "sclerotherapy", "ovarian function"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 98, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Sclerotherapy", "type": "EXPERIMENTAL", "description": "Patients who receive uterine artery embolization for symptomatic fibroids", "interventionNames": ["Procedure: catheter-directed sclerotherapy"]}, {"label": "Surgery", "type": "ACTIVE_COMPARATOR", "description": "Patients who receive uterine artery embolization for symptomatic fibroids", "interventionNames": ["Procedure: surgical resection"]}], "interventions": [{"type": "PROCEDURE", "name": "catheter-directed sclerotherapy", "description": "Ovarian endometrioma is targeted under transvaginal/transabdominal ultrasound. A guidewire is inserted to the lesion and is exchanged for a catheter. The cystic content is thoroughly aspirated and then sclerotherapy is performed by injecting 99% ethanol.", "armGroupLabels": ["Sclerotherapy"]}, {"type": "PROCEDURE", "name": "surgical resection", "description": "Surgical resection of the ovarian endometrioma is performed under general anesthesia. To preserve the residual ovarian function, enucleation is the primary surgical technique.", "armGroupLabels": ["Surgery"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Serum AMH", "description": "Serum AMH: A measure of ovarian function", "timeFrame": "Serum AMH at 1month after catheter-directed sclerotherapy"}, {"measure": "Serum AMH", "description": "Serum AMH: A measure of ovarian function", "timeFrame": "Serum AMH at 6months after catheter-directed sclerotherapy"}, {"measure": "Serum AMH", "description": "Serum AMH: A measure of ovarian function", "timeFrame": "Serum AMH at 12 months after catheter-directed sclerotherapy"}], "secondaryOutcomes": [{"measure": "Recurrence", "description": "Recurrence of symptoms or development of ovarian endometrioma of 2cm or larger on follow-up imaging (surgery) vs. Recurrence of symptoms or detection of the lesion 50% or larger to the size of the initial lesion on follow-up imaging (sclerotherapy).", "timeFrame": "1, 6, and 12 months"}, {"measure": "hospital stay", "description": "Time from admission to discharge", "timeFrame": "duration of admission (days), up to 5 days"}, {"measure": "serum CA-125", "description": "Serum CA-125 (unit/mL): Surrogate marker for therapeutic efficacy (A reduction in serum CA-125 represents a response to the intervention)", "timeFrame": "1, 6, 12 months"}, {"measure": "EHP-30 (Endometriosis Health Profile-30)", "description": "EHP-30: A measure of quality of life related to ovarian endometrioma (Scale of 0 to 30, A higher score represents adverse impact of daily living by the endometriosis)", "timeFrame": "6 and 12 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1\\. Women with symptomatic fibroids (age: 20 - 60 years old)\n\nExclusion Criteria:\n\n1. Gynecologic malignancy\n2. Ongoing infection or inflammation\n3. Coagulopathy (platelet \\< 50,000 or INR \\> 1.5)\n4. Extraovarian endometriosis\n5. Serum AMH of 5 or higher\n6. Drug allergy\n7. Illiteracy\n8. Pregnancy", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "19 Years", "maximumAge": "60 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Kichang Han", "role": "CONTACT", "phone": "82-10-9722-6315", "email": "wowsaycheese@yuhs.ac"}], "locations": [{"facility": "Yonsei University Health System, Severance Hospital", "status": "RECRUITING", "city": "Seoul", "country": "South Korea", "contacts": [{"name": "Kichang Han", "role": "CONTACT", "phone": "82-10-9722-6315", "email": "wowsaycheese@yuhs.ac"}], "geoPoint": {"lat": 37.566, "lon": 126.9784}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT05179109", "orgStudyIdInfo": {"id": "ROBtrial1"}, "organization": {"fullName": "University of Oulu", "class": "OTHER"}, "briefTitle": "Robotic Versus Laparoscopic Surgery for Deep Endometriosis", "officialTitle": "Robotic Versus Laparoscopic Surgery for Severe Deep Endometriosis: a Prospective, Randomized, Controlled Trial", "acronym": "ROBEndo"}, "statusModule": {"statusVerifiedDate": "2024-12", "overallStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2022-10-03", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2025-12-31", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2026-12-31", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2021-12-07", "studyFirstSubmitQcDate": "2021-12-20", "studyFirstPostDateStruct": {"date": "2022-01-05", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2024-12-03", "lastUpdatePostDateStruct": {"date": "2024-12-06", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Sari Koivurova", "investigatorTitle": "Assistant Chief of Gynecology", "investigatorAffiliation": "University of Oulu"}, "leadSponsor": {"name": "University of Oulu", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The objective of this study is to examine whether robot-assisted laparoscopy is superior compared to conventional laparoscopy as regards to patient outcome.", "detailedDescription": "The objective of this prospective, randomized trial is to examine whether robot-assisted laparoscopy is superior compared to conventional laparoscopy as regards to patient outcome at 6, 12 and 24 months postoperatively, measured by questionnaires concerning the pain symptoms and disease-related quality-of life."}, "conditionsModule": {"conditions": ["Endometriosis", "Deep Endometriosis", "Surgery"], "keywords": ["Endometriosis surgery", "Deep endometriosis surgery", "Robotic surgery"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": "This is a prospective, randomized, controlled clinical trial with an allocation ratio of 1:1.", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 70, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Robot-assisted laparoscopy", "type": "EXPERIMENTAL", "description": "Surgery for deep endometriosis using robot-assisted laparoscopy.", "interventionNames": ["Procedure: Minimally invasive surgery"]}, {"label": "Conventional laparoscopy", "type": "ACTIVE_COMPARATOR", "description": "Surgery for deep endometriosis using conventional laparoscopy.", "interventionNames": ["Procedure: Minimally invasive surgery"]}], "interventions": [{"type": "PROCEDURE", "name": "Minimally invasive surgery", "description": "Minimally invasive surgery for severe deep endometriosis", "armGroupLabels": ["Conventional laparoscopy", "Robot-assisted laparoscopy"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "NRS (Numeric rating scale) Score for pain", "description": "The surgical outcome as regards to pain symptoms (NRS questionnaire), absolute scores and change from baseline for both study groups.", "timeFrame": "Immediately postoperatively (24 hours) and 6, 12 and 24 months postoperatively"}], "secondaryOutcomes": [{"measure": "Intraoperative measures", "description": "Operation time (minutes), blood loss (ml), complications (classified according to Clavien-Dindo) for both study groups.", "timeFrame": "Up to 300 minutes (intraoperative)"}, {"measure": "Factors concerning ERAS (Enhanced recovery after surgery)", "description": "Nausea (yes/no), vomiting (yes/no), peroral intake (minutes from surgery), mobilization (minutes from surgery), bowel movement (minutes from surgery), time of discharge (hours after surgery), complications (classified according to Clavien-Dindo) for both study groups.", "timeFrame": "Up to 7 days (Hospital stay)"}, {"measure": "Cost", "description": "Cost, euros.", "timeFrame": "Primary hospital stay and 24 months, for both study groups."}, {"measure": "Complications", "description": "Complications (classified according to Clavien-Dindo), readmissions to hospital.", "timeFrame": "30 days"}, {"measure": "Endometriosis-related quality-of-life", "description": "Quality-of-life questionnaire (EHP-30, Endometriosis-related health profile) described as absolute scores and change from the baseline. Scale 0-100. Score 0 equals the best outcome and score 100 equals the worst outcome.", "timeFrame": "6, 12 and 24 months"}, {"measure": "General 15 dimensional health-related quality-of-life questionnaire", "description": "Quality-of-life questionnaire (15D, general quality-of-life questionnaire) described as absolute scores and change from baseline for both study groups. Scale 0-1. Score 0 equals the worst outcome and score 1 equals the best outcome.", "timeFrame": "6, 12 and 24 months"}, {"measure": "Sexual quality-of-life questionnaire", "description": "Quality-of-life (FSFI, female sexual function index) described as absolute scores and change from baseline for both study groups. Scale 2,0-36,0. Score 2,0 equals the worst outcome and score 36,0 equals the best outcome.", "timeFrame": "6, 12 and 24 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* ASA (American Society of Anesthesiologists physical status classification) 1-3\n* Diagnosed deep endometriosis (MRI)\n* Patient has symptoms\n* Operative treatment is indicated\n* Patient is able to give informed consent\n\nExclusion Criteria:\n\n* ASA \\> 3\n* Recurring rectosigmoid endometriosis", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "50 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Anna M Terho, MD", "role": "CONTACT", "phone": "+35883153603", "email": "anna.terho@fimnet.fi"}, {"name": "Sari Koivurova, MD, PhD", "role": "CONTACT", "phone": "+35883153082", "email": "sari.koivurova@fimnet.fi"}], "overallOfficials": [{"name": "Sari Koivurova, MD, PhD", "affiliation": "Oulu University Hospital, Department of Obstetrics and Gynecology", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Northern Ostrobothnia Hospital District", "status": "RECRUITING", "city": "Oulu", "zip": "90220", "country": "Finland", "contacts": [{"name": "Koivurova", "role": "CONTACT", "email": "sari.koivurova@fimnet.fi"}], "geoPoint": {"lat": 65.01236, "lon": 25.46816}}]}, "referencesModule": {"references": [{"pmid": "35851028", "type": "DERIVED", "citation": "Terho AM, Makela-Kaikkonen J, Ohtonen P, Uimari O, Puhto T, Rautio T, Koivurova S. Robotic versus laparoscopic surgery for severe deep endometriosis: protocol for a randomised controlled trial (ROBEndo trial). BMJ Open. 2022 Jul 18;12(7):e063572. doi: 10.1136/bmjopen-2022-063572."}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D019060", "term": "Minimally Invasive Surgical Procedures"}], "ancestors": [{"id": "D013514", "term": "Surgical Procedures, Operative"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT06781398", "orgStudyIdInfo": {"id": "ROBOTENDO"}, "organization": {"fullName": "IRCCS Azienda Ospedaliero-Universitaria di Bologna", "class": "OTHER"}, "briefTitle": "Robotic Surgery in the Treatment of Deep Endometriosis: Da Vinci Vs HUGO RAS Comparison", "officialTitle": "Robotic Surgery in the Treatment of Deep Endometriosis: Da Vinci Vs HUGO RAS Compared"}, "statusModule": {"statusVerifiedDate": "2024-10", "overallStatus": "NOT_YET_RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2025-01", "type": "ESTIMATED"}, "primaryCompletionDateStruct": {"date": "2027-07", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2027-10", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2024-12-03", "studyFirstSubmitQcDate": "2025-01-13", "studyFirstPostDateStruct": {"date": "2025-01-17", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2025-01-13", "lastUpdatePostDateStruct": {"date": "2025-01-17", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "IRCCS Azienda Ospedaliero-Universitaria di Bologna", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false, "isUsExport": false}, "descriptionModule": {"briefSummary": "The aim is to clarify whether both surgical approaches represent, equivalently, a good treatment for the management of patients with deep endometriosis who are candidates for surgery, or whether there are any differences between the two methods, and, if so, how they differ", "detailedDescription": "Numerous studies have shown how surgical excision of deep endometriosis nodules improves pain and quality of life. Robotic-assisted laparoscopic surgery has been employed for the treatment of deep endometriosis. While the Da Vinci System is widely used for the surgical treatment of endometriosis, with good results, the available data regarding the benefits of the HUGO RAS System, however, are limited, given the recent introduction of this method in gynecology, and particularly in the treatment of endometriosis. The aim of the study is to investigate whether the robotic surgical approach using HUGO RAS is noninferior to that performed using Da Vinci in terms of operative time (docking + surgical time) in the surgical treatment of patients with endometriosis"}, "conditionsModule": {"conditions": ["Deep Endometriosis"], "keywords": ["endometriosis", "gynaecology", "surgery", "Da Vinci", "HUGO RAS"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "COHORT", "timePerspective": "PROSPECTIVE"}, "enrollmentInfo": {"count": 86, "type": "ESTIMATED"}}, "outcomesModule": {"primaryOutcomes": [{"measure": "The robotic surgical approach using HUGO RAS is noninferior to that performed using Da Vinci in terms of operative time (docking + surgical time) in the surgical treatment of patients with endometriosis", "description": "Compare the two surgical techniques by evaluating the operative time (expressed in minutes), which includes docking and surgical time.\n\nDocking is defined as the time required to move the robotic arms into the operative field, place them in their respective port sites, and insert the robotic instruments into the abdomen.\n\nSurgical time is from the end of docking to suturing the laparoscopic/laparotomy breaches.", "timeFrame": "During surgery"}], "secondaryOutcomes": [{"measure": "Conversion rate to laparoscopy or laparotomy", "description": "Conversion to laparoscopy or laparotomy, based on intraoperative assessment of the clinical picture", "timeFrame": "During surgery"}, {"measure": "Intra-operative and post-operative complication rates; need for complication treatment", "description": "Intraoperative complications (incidental injury to organs and structures, incoercible bleeding) classified by ClassIntra System (iAE); postoperative complications (anemia, postoperative fever, hemoperitoneum, bowel perforation), according to Clavien-Dindo classification; treatment of complications (GRC transfusion, reintervention, interventional procedures)", "timeFrame": "Perioperative and at 3 months"}, {"measure": "Ergonomics for the surgeon", "description": "Ergonomics of the two robotic approaches established through the Rapid Upper Limb Assessment (RULA) system that allows through the compilation of a score, rapid assessment of the load on the neck and upper limb. The risk of work-related disorders is calculated in a score from 1 (low) to 7 (high)", "timeFrame": "During surgery"}, {"measure": "Entity of postoperative pain", "description": "Postoperative pain assessed as maximum value recorded by numeric rating scale (NRS), from 0 to 10, corresponding to 'no pain' and 'worst pain imaginable' respectively", "timeFrame": "Perioperative and at 3 and 12 months"}, {"measure": "Hospitalization time", "description": "Hospitalization time", "timeFrame": "From the day of admission to the day of discharge, an average of 1 year"}, {"measure": "Assessment of pain and quality of life", "description": "Pain assessment and change in quality of life, assessed by administration of NRS scale, from 0 to 10, corresponding to 'no pain' and 'worst pain imaginable' respectively", "timeFrame": "At 3 and 12 months after surgery"}, {"measure": "Assessment of pain and quality of life", "description": "Pain assessment and change in quality of life, assessed by administration of quality of life questionnaire (EHP-30, Endometriosis-related health profile), scored from 0 to 100, with 0 being the best outcome and 100 the worst outcome", "timeFrame": "At 3 and 12 months after surgery"}, {"measure": "Symptomatological and/or anatomical recurrence", "description": "Clinical or anatomical resumption of disease by gynecological examination, recent pathological history, pelvic ultrasound, and possible radiological methods such as nuclear magnetic resonance imaging (NMR)", "timeFrame": "At 12 months after surgery"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Age between 18 and 55 years;\n* Pelvic ultrasound and/or radiologic (MRI/CT scan with rectal insufflation) diagnosis of endometriosis\n* Indication for surgery (symptomatic despite or refractory to medical therapy, and/or with critical bowel stenosis or urinary stenosis, and/or infertile awaiting medically assisted procreation (PMA) treatment or with previous failed assisted fertilization attempts);\n* ASA (American Society of Anesthesiologists physical status classification) class between 1 and 3;\n* Acquisition of consent to undergo surgical treatment;\n* Acquisition of consent for study participation and data processing\n\nExclusion Criteria:\n\n\\- Past or current diagnosis of gynecologic oncologic pathology.", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "55 Years", "stdAges": ["ADULT"], "studyPopulation": "Patients who are candidates for surgery with minimally invasive approach for endometriosis", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"centralContacts": [{"name": "Diego Raimondo, MD", "role": "CONTACT", "phone": "+393290636618", "email": "die.raimondo@gmail.com"}, {"name": "Pierluigi Celerino, MD", "role": "CONTACT", "email": "celerinopierluigi@gmail.com"}], "overallOfficials": [{"name": "Diego Raimondo, MD", "affiliation": "IRCCS Azienda Ospedaliero-Universitaria di Bologna", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "IRCCS Azienda Ospedaliero-Universitaria di Bologna", "city": "Bologna", "state": "Bologna", "zip": "40138", "country": "Italy", "contacts": [{"name": "Diego Raimondo, MD", "role": "CONTACT", "phone": "+393290636618", "email": "die.raimondo@gmail.com"}, {"name": "Pierluigi Celerino, MD", "role": "CONTACT", "email": "celerinopierluigi@gmail.com"}, {"name": "Diego Raimondo, MD", "role": "CONTACT"}], "geoPoint": {"lat": 44.49381, "lon": 11.33875}}, {"facility": "Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore", "city": "Roma", "state": "Roma", "zip": "00168", "country": "Italy", "contacts": [{"name": "Federica Campolo, MD", "role": "CONTACT", "phone": "+390630155629", "email": "campolo.f@gmail.com"}], "geoPoint": {"lat": 44.99364, "lon": 11.10642}}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT03823833", "orgStudyIdInfo": {"id": "2018_48"}, "organization": {"fullName": "University Hospital, Lille", "class": "OTHER"}, "briefTitle": "Oocyte Freezing for Fertility Preservation in Benign Ovarian Tumors", "officialTitle": "Systematic Proposal of Fertility Preservation by Oocyte Freezing in Case of Benign Ovarian Tumors With High Risk of Recurrence", "acronym": "OFBOT"}, "statusModule": {"statusVerifiedDate": "2022-12", "overallStatus": "UNKNOWN", "lastKnownStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2021-07-28", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2022-12", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2022-12", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2019-01-28", "studyFirstSubmitQcDate": "2019-01-28", "studyFirstPostDateStruct": {"date": "2019-01-31", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2022-12-13", "lastUpdatePostDateStruct": {"date": "2022-12-16", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "University Hospital, Lille", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "Benign ovarian cysts are frequent during women's life. They are diagnosed with pelvic pain or fortuitously during an ultra-sonographic exam. In case of persistence,a surgery will be necessary to identify the nature of the cyst and assess its benignity. In some case, cysts are recurrent and multiple surgeries are needed leading to a significant risk of ovarian damage by follicular depletion. Oocyte cryopreservation is no longer considered as an experimental technique of Fertility Preservation since 2013 as it has been recognized to be efficient and safe. According to reproductive medicine scientific committees and the French ethic law, fertility preservation has to be proposed in every situation of infertility risk. To date, there is no cohort study dedicated to fertility preservation by oocyte freezing in this specific subgroup of patients. The purpose of the study is to prospectively evaluate the oocyte number and quality after controlled ovarian hyperstimulation in patients with recurrent ovarian cysts."}, "conditionsModule": {"conditions": ["Endometriosis", "Dermoid Cyst", "Mucinous Cyst"], "keywords": ["Oocyte freezing", "fertility preservation", "ovarian cysts", "benign ovarian tumor", "endometrioma"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "COHORT", "timePerspective": "PROSPECTIVE"}, "enrollmentInfo": {"count": 100, "type": "ESTIMATED"}}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of mature oocytes eligible for cryopreservation", "timeFrame": "After 15 days of controlled ovarian hyperstimulation (COH)"}], "secondaryOutcomes": [{"measure": "Percentage of immature or morphologically abnormal oocytes", "timeFrame": "Real-time, the day of egg retrieval"}, {"measure": "Number of mature follicles (≥15 mm) and intermediary (10-14 mm) during ovarian stimulation", "timeFrame": "The day of HCG triggering at the end of ovarian stimulation"}, {"measure": "Questionnaire on tolerance and complications", "description": "A systematic telephone interview will be carried out 48 to 72 hours after the oocyte puncture to judge the tolerance of the procedure.", "timeFrame": "One week after the egg retrieval"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* women with benign ovarian tumor with high risk of recurrence, i-e, endometrioma, dermoid cysts or mucinous cysts.\n* women with previous surgery and/or high risk of ovarian damage: bilateral cysts, cyst diameter higher than 5 cms\n* Having a social insurance\n* Able to give an informed consent\n\nExclusion Criteria:\n\n* Borderline tumors\n* Undetectable AMH levels\n* Personal history of thrombo-embolic events\n* pregnancy", "healthyVolunteers": false, "sex": "FEMALE", "genderBased": true, "genderDescription": "young women", "minimumAge": "18 Years", "maximumAge": "35 Years", "stdAges": ["ADULT"], "studyPopulation": "Young women with benign ovarian tumors and high risk of further infertility due to surgery", "samplingMethod": "PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"centralContacts": [{"name": "Christine Decanter, MD", "role": "CONTACT", "phone": "320445962", "phoneExt": "+33", "email": "christine.decanter@chru-lille.fr"}], "overallOfficials": [{"name": "Christine Decanter, MD", "affiliation": "University Hospital, Lille", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Hop Jeanne de Flandre Chu Lille", "status": "RECRUITING", "city": "Lille", "zip": "59037", "country": "France", "geoPoint": {"lat": 50.63391, "lon": 3.05512}}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}, {"id": "D003884", "term": "Dermoid Cyst"}, {"id": "D009078", "term": "Mucocele"}, {"id": "D010048", "term": "Ovarian Cysts"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}, {"id": "D003560", "term": "Cysts"}, {"id": "D009369", "term": "Neoplasms"}, {"id": "D013724", "term": "Teratoma"}, {"id": "D009373", "term": "Neoplasms, Germ Cell and Embryonal"}, {"id": "D009370", "term": "Neoplasms by Histologic Type"}, {"id": "D010049", "term": "Ovarian Diseases"}, {"id": "D000291", "term": "Adnexal Diseases"}, {"id": "D006058", "term": "Gonadal Disorders"}, {"id": "D004700", "term": "Endocrine System Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT04256200", "orgStudyIdInfo": {"id": "OGY.AA.07"}, "organization": {"fullName": "American University of Beirut Medical Center", "class": "OTHER"}, "briefTitle": "Efficacy of Dienogest Versus Oral Contraceptive Pills on Pain Associated With Endometriosis", "officialTitle": "Efficacy of Dienogest Versus Oral Contraceptive Pills on Pain Associated With Endometriosis"}, "statusModule": {"statusVerifiedDate": "2021-04", "overallStatus": "UNKNOWN", "lastKnownStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2017-02-07", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2021-11", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2021-12", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2020-01-15", "studyFirstSubmitQcDate": "2020-02-03", "studyFirstPostDateStruct": {"date": "2020-02-05", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2021-04-14", "lastUpdatePostDateStruct": {"date": "2021-04-15", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Antoine Abou Moussa", "investigatorTitle": "Professor of Obstetrics and Gynecology/principal investigator", "investigatorAffiliation": "American University of Beirut Medical Center"}, "leadSponsor": {"name": "American University of Beirut Medical Center", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "Endometriosis is a chronic inflammatory disease, frequently associated with dysmenorrhea, dyspareunia and abdomino-pelvic pain limiting quality of life. Most medical therapies aim to alleviate the severity of symptoms. Recent guidelines recommend the use of either OCPs or progestins as a first-line treatment of pain associated with endometriosis. The effectiveness of both OCPs and dienogest, a fourth-generation progestin, for endometriosis treatment has been demonstrated. The literature is rich with data comparing the use of Visanne or OCPs to placebo or GnRH analogs. However, there are no head to head studies comparing their efficacy in the management of endometriosis associated pain. The study aims to evaluate if Dienogest (Visanne) is not inferior in efficacy to oral contraceptive pills (Yasmin) in controlling pain associated with endometriosis?", "detailedDescription": "Endometriosis is defined as the presence of endometrial tissue outside the uterus, which induces a chronic inflammatory reaction. It is an estrogen-dependent associated with pelvic pain and infertility. It is a relatively common chronic gynecological disease that affects approximately 10% of reproductive aged women. Patients with endometriosis often suffer from dysmenorrhea, dyspareunia, dysuria, and chronic abdominal or pelvic pain, resulting in a severely limited quality of life. The aim of most medical therapies is to alleviate the severity of symptoms. Commonly used hormonal therapies include combined oral contraceptives (OCP), progestogens, gonadotropin-releasing hormone (GnRH) agonists, androgens and antiprogestogens, all of which are considered to have similar efficacy but different tolerability profiles, which are often suboptimal. To date, the most widely used agent for the medical treatment of endometriosis is oral contraceptive (albeit off-label). In particular, evidence supporting the efficacy of estrogen-progestin therapy (EP) in pain control and reducing the risk of recurrence in women undergoing surgery for endometriosis. In recent years, the effectiveness of dienogest, a fourth-generation progestin, for endometriosis treatment has been demonstrated. Dienogest seems to be as effective as gonadotrophin-releasing hormone-a (GnRH-a) in terms of endometriosis-related pelvic pain improvement. The aim of this study is to evaluate the efficacy of Visanne versus OCP treatment of endometriosis associated pelvic pain in a double-blinded randomized controlled pilot study. It is a two armed pilot study; each group will include 50 patients. Women with endometriosis will be randomized to receive either DNG (n=50) or OCPs (n=50). The diagnosis of endometriosis will be by clinical evaluation, laparotomy, laparoscopy, or imaging analysis (combination of magnetic resonance imaging and ultrasonography) of endometriotic ovarian chocolate cysts.The first group will receive Deinogest (Visanne) 2mg/day, orally for 24 weeks. The second group will receive monophasic combined OCP (Yasmin, Ethinyl Estradiol and Drospirenone) daily for 24 weeks. The treating physician and the patients will be blinded to the treatment option. The relief of symptoms and efficacy will be evaluated by questionnaire on follow up visits at 3 and 6 month of the treatment. Data collected will be analyzed and compared between the 2 groups. We hypothesize that there will be no difference in pain scores, efficacy and safety between the two treatments."}, "conditionsModule": {"conditions": ["Endometriosis"], "keywords": ["endometriosis", "oral contraceptive pills", "progestin"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2", "PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER"]}}, "enrollmentInfo": {"count": 100, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Dienogest", "type": "ACTIVE_COMPARATOR", "description": "Deinogest (Visanne) 2mg/day orally for 24 weeks", "interventionNames": ["Drug: Dienogest 2 MG Oral Tablet"]}, {"label": "Oral Contraceptive Pills", "type": "ACTIVE_COMPARATOR", "description": "Oral contraceptive pill (Yasmin, 0.03mg Ethinyl Estradiol and 3mg Drospirenone) orally daily for 24 weeks", "interventionNames": ["Drug: Yasmin"]}], "interventions": [{"type": "DRUG", "name": "Dienogest 2 MG Oral Tablet", "description": "Deinogest (Visanne) 2mg/day, orally for 24 weeks versus combined OCP (Yasmin, 0.03mg", "armGroupLabels": ["Dienogest"], "otherNames": ["Visanne"]}, {"type": "DRUG", "name": "Yasmin", "description": "0.03mg Ethinyl Estradiol and 3mg Drospirenone daily for 24 weeks", "armGroupLabels": ["Oral Contraceptive Pills"], "otherNames": ["combined oral contraceptive"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Endometriosis-associated pelvic pain", "description": "be the absolute change in endometriosis -associated pelvic pain from baseline to end of treatment, assessed by the Visual Analogue Scale (VAS): with \"absence of pain\" corresponding to the value \"0\" and \"unbearable pain\" corresponding to the value \"10\"", "timeFrame": "6 months"}], "secondaryOutcomes": [{"measure": "Impact on Quality of life", "description": "Outcome quality of life will be assessed using Endometriosis Health Profile 30 (EHP30) with each item of this questionnaire can be answered by choosing one of the following (Never, rarely,sometimes, often and always). The endometriosis health profile is a patient-generated questionnaire in which the items were developed from interviews with women with the condition ( Obtained from Oxford University Press) .", "timeFrame": "6 months"}, {"measure": "incidence of side effects", "description": "Incidence of possible side effects including headache, migraine,nausea, vomiting, abdominal pain/discomfort, breast pain or tenderness, mood swings, premenstrual syndrome, decreased libido, fatigue, weight changes and menstrual irregularities", "timeFrame": "6 months"}, {"measure": "Patient Tolerability", "description": "Assessing tolerability to side effects via numerical scale from zero to ten ( zero not bothersome at all , ten maximum possible)", "timeFrame": "6 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patients confirmed or suspected of endometriosis on clinical evaluation (VAS score more than 5 and presence of subjective symptoms), surgical or imaging studies, and not taking any pain killer or other hormonal treatment for the moment\n* Age 20-45\n* Regular menstrual cycles\n* The presence of subjective symptoms during menstruation (at least one from among lower abdominal pain, lumbago, defecation pain, nausea, and headache)\n* The presence of subjective symptoms during non-menstruation (at least one from among lower abdominal pain, lumbago, defecation pain, dyspareunia, and pain on internal examination).\n\nExclusion Criteria:\n\n* Undiagnosed genital bleeding\n* Use of any hormonal therapy for endometriosis within 16 weeks before enrollment\n* A history of severe adverse drug reactions or hypersensitivity to steroid hormone\n* Having undergone surgery therapy or surgical examination for endometriosis within a menstrual cycle before the start of medication\n* Previous failure of treatment with the OCP used in the current study\n* Contraindications to OCP or Dienogest use\n* Smokers \\>35\n* A history or complication of thrombosis/embolism\n* Migraines with aura\n* Depression\n* Patients on anti-epileptics\n* Diabetes Mellitus with vascular involvement\n* Liver diseases\n* Known or suspected sex hormone dependent malignancies\n* Repeat surgery for endometriosis\n* Patient consulting for infertility\n* Pregnant or nursing\n* Planning for pregnancy in near future.", "healthyVolunteers": false, "sex": "FEMALE", "genderBased": true, "genderDescription": "Female", "minimumAge": "20 Years", "maximumAge": "45 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Antoine Abu Musa, M.D.", "role": "CONTACT", "phone": "+9611350000", "phoneExt": "5840", "email": "aa06@aub.edu.lb"}], "overallOfficials": [{"name": "Antoine Abu Musa, MD", "affiliation": "American University of Beirut Medical Center", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "American University of Beirut", "status": "RECRUITING", "city": "Beirut", "country": "Lebanon", "contacts": [{"name": "Antoine Abu Musa, MD", "role": "CONTACT", "phone": "+9611350000", "phoneExt": "4840", "email": "aa06@aub.edu.lb"}], "geoPoint": {"lat": 33.89332, "lon": 35.50157}}]}, "referencesModule": {"references": [{"pmid": "34826668", "type": "DERIVED", "citation": "El Taha L, Abu Musa A, Khalifeh D, Khalil A, Abbasi S, Nassif J. Efficacy of dienogest vs combined oral contraceptive on pain associated with endometriosis: Randomized clinical trial. Eur J Obstet Gynecol Reprod Biol. 2021 Dec;267:205-212. doi: 10.1016/j.ejogrb.2021.10.029. Epub 2021 Oct 30."}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C023635", "term": "dienogest"}, {"id": "D013607", "term": "Tablets"}, {"id": "C534342", "term": "drospirenone and ethinyl estradiol combination"}, {"id": "D003277", "term": "Contraceptives, Oral, Combined"}], "ancestors": [{"id": "D004304", "term": "Dosage Forms"}, {"id": "D004364", "term": "Pharmaceutical Preparations"}, {"id": "D004338", "term": "Drug Combinations"}, {"id": "D003276", "term": "Contraceptives, Oral"}, {"id": "D003271", "term": "Contraceptive Agents, Female"}, {"id": "D003270", "term": "Contraceptive Agents"}, {"id": "D012102", "term": "Reproductive Control Agents"}, {"id": "D045505", "term": "Physiological Effects of Drugs"}, {"id": "D020228", "term": "Pharmacologic Actions"}, {"id": "D020164", "term": "Chemical Actions and Uses"}, {"id": "D045506", "term": "Therapeutic Uses"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT07127783", "orgStudyIdInfo": {"id": "STUDY00028168"}, "organization": {"fullName": "Oregon Health and Science University", "class": "OTHER"}, "briefTitle": "Physical Therapy After Endometriosis Excision", "officialTitle": "The Role of a Postoperative Home Physical Therapy Program for the Treatment of Pelvic Pain in Patients Undergoing Endometriosis Excision"}, "statusModule": {"statusVerifiedDate": "2025-09", "overallStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2025-08-28", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2026-03", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2026-03", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2025-08-11", "studyFirstSubmitQcDate": "2025-08-11", "studyFirstPostDateStruct": {"date": "2025-08-17", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2025-09-30", "lastUpdatePostDateStruct": {"date": "2025-10-06", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Jacqueline Wong", "investigatorTitle": "Principal Investigator", "investigatorAffiliation": "Oregon Health and Science University"}, "leadSponsor": {"name": "Oregon Health and Science University", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false, "isUsExport": false}, "descriptionModule": {"briefSummary": "This is a randomized controlled pilot study comparing a home pelvic floor physical therapy program to routine post-operative care for patients undergoing endometriosis excisional surgery without hysterectomy. Quality of life and endometriosis symptoms will be compared following the recovery period.", "detailedDescription": "This is a randomized controlled pilot study conducted at a single institution comparing a home pelvic floor physical therapy program to routine post-operative care for patients undergoing endometriosis excisional surgery without hysterectomy. Patients will be recruited from a referral gynecological surgery group specializing in the diagnosis and treatment of pelvic pain and endometriosis. The goal is to assess the role of the active recovery program on quality of life and on pain and endometriosis symptoms.\n\nSubjects will be randomized to routine post-operative care or to a home physical therapy program, in which they will receive written instruct ions and videos of exercises to complete immediately after surgery. The home exercise program was developed by the Department of Urogynecology in conjunction with pelvic floor physical therapists, and includes videos created by the education communications division. Quality of life, pain score, and endometriosis symptoms will be assessed at their pre-operative appointment, and at 6 and 12 weeks postoperatively."}, "conditionsModule": {"conditions": ["Endometriosis", "Surgery"], "keywords": ["Active Recovery"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": "Participants will be randomized in a 1:1 ratio to either standard postoperative instructions or the active recovery intervention group.", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 30, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Standard Postoperative Instructions", "type": "ACTIVE_COMPARATOR", "description": "Participants will receive standard postoperative recovery instructions", "interventionNames": ["Behavioral: Standard Postoperative Instructions"]}, {"label": "Active Recovery", "type": "EXPERIMENTAL", "description": "Participants will receive postoperative instructions to follow an active recovery protocol focused on increasing activity level, core strength exercises, and pelvic floor exercises focused on urinary and bowel symptoms. Exercises are to be completed twice per day for the 12 weeks following surgery.", "interventionNames": ["Behavioral: Active Recovery"]}], "interventions": [{"type": "BEHAVIORAL", "name": "Active Recovery", "description": "Participants will receive postoperative instructions to follow an active recovery protocol focused on increasing activity level, core strength exercises, and pelvic floor exercises focused on urinary and bowel symptoms. Exercises are to be completed twice per day for the 12 weeks following surgery.", "armGroupLabels": ["Active Recovery"]}, {"type": "BEHAVIORAL", "name": "Standard Postoperative Instructions", "description": "Standard of care postoperative instructions covering incision care, pain control, dietary instructions, and emergency precautions. Also includes guidelines regarding pelvic rest and lifting restrictions.", "armGroupLabels": ["Standard Postoperative Instructions"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Short Form Survey (SF-36)", "description": "The Short Form Survey (SF-36) is a 36-item survey regarding general health and pain and its impact on quality of life including physical activities, work, social activities, and emotional well-being over the last four weeks. Scores range from 0 to 100 with a higher score representing a more favorable health state.", "timeFrame": "Collected immediately following surgery, 6 weeks following surgery, and 12 weeks following surgery"}, {"measure": "Pelvic Floor Impact Questionnaire (PFIQ)", "description": "The Pelvic Floor Impact Questionnaire (PFIQ) asks about how bladder, bowel, and pelvic symptoms affect the ability to do physical activities as well as their impact on emotional well-being over the last 3 months. Scores range from 0 to 300 with a lower score representing a lesser impact on quality of life.", "timeFrame": "Collected immediately following surgery and 12 weeks following surgery"}], "secondaryOutcomes": [{"measure": "Pain Scores", "description": "Pain measured using a Visual Analog Scale (VAS). This scale asks patients to rate their pelvic pain and dyspareunia over the last 4 weeks. Responses are on a scale from 0 to 10, with 10 being the worst pain.", "timeFrame": "Collected at baseline, 6 weeks following surgery, and 12 weeks following surgery."}, {"measure": "Endometriosis Health Profile (EHP-5)", "description": "The Endometriosis Health Profile (EHP-5) is a 5-item questionnaire asking about the perception of endometriosis symptoms on physical ability, emotional well-being, mood, social isolation, and appearance over the last four weeks. Scores range from 0 to 100 where 0 indicates the best health status.", "timeFrame": "Collected at baseline, 6 weeks following surgery, and 12 weeks following surgery."}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Premenopausal\n* English speaking\n* Undergoing endometriosis excision surgery without hysterectomy at Legacy Health with subspecialty-trained surgeons specializing in endometriosis care\n* History of chronic pelvic pain (defined as \\>= 6 months of pain in the anatomic pelvis)\n* Diagnosis of high tone pelvic floor dysfunction on examiniation\n* Have access to reliable email and phone for study-related communication\n\nExclusion Criteria:\n\n* Non-English speaking\n* Unable to consent\n* Unable to sustain 30 minutes of moderate activity at baseline\n* Uses a mobility assistive device at baseline\n* Chronic opioid use\n* No histologic diagnosis of endometriosis on surgical pathology\n* Need for additional pelvic rest (\\>2 weeks) postoperatively\n* Pregnancy or planning to pursue pregnancy or undergo fertility treatments within 12 weeks postoperatively", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "50 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Women's Health Research Unit Department of Ob/Gyn", "role": "CONTACT", "phone": "503-494-3666", "email": "whru@ohsu.edu"}], "overallOfficials": [{"name": "Jacqueline Wong", "affiliation": "Oregon Health and Science University", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Oregon Health & Science University", "status": "RECRUITING", "city": "Portland", "state": "Oregon", "zip": "97239", "country": "United States", "contacts": [{"name": "Women's Health Research Unit", "role": "CONTACT", "phone": "503-494-3666", "email": "whru@ohsu.edu"}, {"name": "Jacqueline Wong", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 45.52345, "lon": -122.67621}}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT04233983", "orgStudyIdInfo": {"id": "2019-19/12"}, "organization": {"fullName": "Uludag University", "class": "OTHER"}, "briefTitle": "Surgery Before Embryo Transfer in ERROR (Endometrioma Related Reduction in Ovarian Reserve)", "officialTitle": "Surgery Before Embryo Transfer in Endometrioma Related Reduction in Ovarian Reserve"}, "statusModule": {"statusVerifiedDate": "2020-01", "overallStatus": "UNKNOWN", "lastKnownStatus": "NOT_YET_RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2020-02-01", "type": "ESTIMATED"}, "primaryCompletionDateStruct": {"date": "2021-01-01", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2021-03-01", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2020-01-13", "studyFirstSubmitQcDate": "2020-01-16", "studyFirstPostDateStruct": {"date": "2020-01-18", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2020-01-16", "lastUpdatePostDateStruct": {"date": "2020-01-18", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "GÜRKAN UNCU,PROF. MD", "investigatorTitle": "Prof. Dr.", "investigatorAffiliation": "Uludag University"}, "leadSponsor": {"name": "Uludag University", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "This prospective study evaluates the pregnancy results after laparoscopic endometriosis operation in infertile patients with ERROR (endometrioma related reduction in ovarian reserve)", "detailedDescription": "This study consists of two groups. Patients will be randomly enrolled into the groups by ART (assisted reproductive technology) centre nursery. All patients will sign a consent form about procedure.\n\nPatients diagnosed with endometrioma (larger than 3 cm diameter) and ERROR (endometrioma related reduction in ovarian reserve - Antimullerian Hormon \\< 1.2 ng/ml, Antral follicle count \\< 7 , Day3 Follicle Stimulating Hormone \\> 10 IU/dl, Low response to ovarian hyper stimulation \\< 3 oocytes) will be enrolled in study. Patients with age \\>40, with male factor, with undefined adnexal mass, malignity suspicion will be excluded from study.\n\nThe study group consists of patients who will undergo laparoscopic endometriosis surgery after ICSI procedure with freezing all embryos. The patients will wait about 6 months for spontaneous conception, if there is no pregnancy during this period, frozen embryo transfer will be performed. The control group consists of patients who will be performed IVF\\&ICSI procedure with fresh embryo transfer without surgery. If there is no pregnancy, patients will be operated then.\n\nAs the primary; result positive b-hCG rates will be compared between groups.\n\nIn conclusion we will find out whether laparoscopic endometriosis operation improves or worsens the pregnancy results in patients with ERROR."}, "conditionsModule": {"conditions": ["Endometriosis Related Infertility"], "keywords": ["Endometriosis", "Laparoscopy", "Infertility", "Ovarian Reserve", "Endometrioma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": "Prospective Randomised Controlled Trial", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 40, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Study Group", "type": "ACTIVE_COMPARATOR", "description": "The study group consists of ERROR(endometrioma related reduction in ovarian reserve) patients who will undergo laparoscopic endometriosis surgery after ICSI procedure with freezing all embryos. The patients will wait about 6 months for spontaneous conception, if there is no pregnancy during this period, frozen embryo transfer will be performed.", "interventionNames": ["Procedure: Laparoscopic Endometriosis Surgery"]}, {"label": "Control Group", "type": "NO_INTERVENTION", "description": "The control group consists of ERROR(endometrioma related reduction in ovarian reserve) patients who will be performed IVF\\&ICSI procedure with fresh embryo transfer without surgery. If there is no pregnancy, patients will be operated then."}], "interventions": [{"type": "PROCEDURE", "name": "Laparoscopic Endometriosis Surgery", "description": "Patient with ERROR(endometrioma related reduction in ovarian reserve), and endometrioma larger than 3 cm diameter will be operated after IVF\\&ICSI procedure. Operation will be done by senior surgeons of our department. Laparoscopic endometrioma operation procedure consists of excision of endometrioma cyst with its capsule from ovary without using any electric modality to prevent ovarian damage.", "armGroupLabels": ["Study Group"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Positive b-hCG Rate", "description": "Postoperative 6. months positive b-hCG rates will be compared with control group.", "timeFrame": "6 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Presence of Endometrioma at least in one ovary, larger than 3 cm diameter\n* Endometriosis Related Reduction in Ovarian Reserve (ERROR)\n* Presence of endometriosis related infertility\n\nExclusion Criteria:\n\n* Presence of chronic systemic disease\n* Presence of male factor infertility\n* Suspicion of ovarian malignancy or undefined ovarian mass", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "23 Years", "maximumAge": "40 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Kiper Aslan, M.D", "role": "CONTACT", "phone": "+902242952541", "email": "kiperaslan@yahoo.com.tr"}, {"name": "Isil Kasapoglu, Asc. Prof.", "role": "CONTACT", "phone": "+902242952541", "email": "kasapogluisil@hotmail.com"}], "overallOfficials": [{"name": "Gurkan Uncu, Prof.", "affiliation": "Bursa Uludag University School of Medicine ART Center", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Uludag University ART Center", "city": "Bursa", "country": "Turkey (Türkiye)", "geoPoint": {"lat": 40.19559, "lon": 29.06013}}]}, "referencesModule": {"references": [{"pmid": "25085800", "type": "BACKGROUND", "citation": "Muzii L, Di Tucci C, Di Feliciantonio M, Marchetti C, Perniola G, Panici PB. The effect of surgery for endometrioma on ovarian reserve evaluated by antral follicle count: a systematic review and meta-analysis. Hum Reprod. 2014 Oct 10;29(10):2190-8. doi: 10.1093/humrep/deu199. Epub 2014 Aug 1."}, {"pmid": "29935810", "type": "RESULT", "citation": "Kasapoglu I, Ata B, Uyaniklar O, Seyhan A, Orhan A, Yildiz Oguz S, Uncu G. Endometrioma-related reduction in ovarian reserve (ERROR): a prospective longitudinal study. Fertil Steril. 2018 Jul 1;110(1):122-127. doi: 10.1016/j.fertnstert.2018.03.015. Epub 2018 Jun 20."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}, {"id": "D007246", "term": "Infertility"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT05623514", "orgStudyIdInfo": {"id": "HSC-MS-22-0947"}, "organization": {"fullName": "The University of Texas Health Science Center, Houston", "class": "OTHER"}, "briefTitle": "Ultrasound Evaluation for Improving Patient Selection in vNOTES", "officialTitle": "Pre-surgical Ultrasound Evaluation for Improving Patient Selection for vNOTES Approach", "acronym": "PUP-VNOTES"}, "statusModule": {"statusVerifiedDate": "2024-11", "overallStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2022-05-16", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2025-12", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2025-12", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2022-11-10", "studyFirstSubmitQcDate": "2022-11-11", "studyFirstPostDateStruct": {"date": "2022-11-21", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2024-11-12", "lastUpdatePostDateStruct": {"date": "2024-11-14", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Aya Mohr Sasson", "investigatorTitle": "Principle investigator", "investigatorAffiliation": "The University of Texas Health Science Center, Houston"}, "leadSponsor": {"name": "The University of Texas Health Science Center, Houston", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": true}, "descriptionModule": {"briefSummary": "Vaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES) is an emerging field in minimally invasive surgery. International consensus-based statement was recently published to help guide the basis for adopting vNOTES into clinical practice, including regarding patient selection. It was agreed that women with potential adhesions are not appropriate candidates for vNOTES approach including women with suspected adhesions due to history of severe pelvic inflammatory disease (PID) or endometriosis. However, as some pelvic infections might be asymptomatic, pre-operation imaging might be beneficial to complete improved selection of patients. Moreover, women with previous severe PID or endometriosis might still have favorable pelvic to perform the vNOTES approach. Therefore, we aim to compare pre-operation ultrasound evaluation to operative characteristics and outcomes in women undergoing VNOTES approach surgery.", "detailedDescription": "Vaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES) is an emerging field in minimally invasive surgery. It has gained the most popularity compared to other transluminal natural orifices such as mouth, rectum or urinary tract. By incorporating the advantages of endoscopic surgery, the vNOTES approach avoids abdominal wall wounds and trocar-related complications. Recent studies report reduced postoperative pain, accelerated postoperative recovery, and decreased postoperative wound infections, as well as achieving highly satisfying cosmetic results. All these made this technique very appealing to surgeons and patients alike.\n\nThe feasibility and safety of vNOTES in gynecologic surgeries, was first introduced by Ahn et al. in 2012 that performed vNOTES in ten women with benign uterine adnexal disease. Since then, surgeons have developed the technique in various benign gynecologic surgeries indications. There has been an exponential uptake of the number of surgeons performing vNOTES procedures worldwide with no official guidance to ensure the safe implementation of this technique into gynecological practice. The novelty of the technique is still a matter of concern in sub-populations and different indications.\n\nInternational consensus-based statement was recently published based on Delphi consensus of expert panel to help guide the basis for adopting vNOTES into clinical practice with respect to eight key domains including patient selection. It was agreed that women with potential adhesions are not appropriate candidates for vNOTES approach including women with a history of a severe PID that is considered contraindication. 97.4% of the experts agreed that it is not necessary to perform a preoperative vaginal culture if the patient is asymptomatic. However, as some pelvic infections might be asymptomatic such as with chlamydia, pre-operation imaging might be beneficial to complete proper patient selection for the vNOTES approach. Moreover, women with previous severe PID infection might still have favorable pelvic to perform the vNOTES approach Aim: To the best of our knowledge no guidelines have been published regarding the pre-operation evaluation and the imaging characteristics. Due to the aforementioned, the aim of our study is to compare pre-operation ultrasound evaluation to operative characteristics and outcomes.\n\nMaterial and Methods This is a prospective cohort study that will be conducted in a single tertiary medical center. Study population will include all women planned for surgery due to benign indication (adnexectomy/ hysterectomy) that vNOTES approach is considered and have normal vaginal examination (normal mobility of the uterus). Women with history of pelvic radiation, suspected malignancy or combined operations will be excluded from the study.\n\nIntervention:\n\n1. As part of the evaluation at the pre-operation clinics, women will complete vaginal examination to assess for pelvic organs mobility and potential adhesions.\n2. Trans-vaginal examination will be completed to evaluate uterus and adnexal characteristics in addition to sliding sign between the uterus to the rectum for the evaluation of the Douglas space.\n3. Women with normal ultrasound evaluation and a positive sliding sign will continue with surgery via the vNOTES approach. Women with limited mobility demonstrated on ultrasound will be recommended alternative surgical approaches.\n\n3-Swabs will be collected for potential PID pathogens including chlamydia, gonorrhea, trichomonas and mycoplasma.\n\n4-Operation report- will include information regarding pelvic adhesions, location of the adhesions and abdominal screening (Including diaphragm and liver area). For the study group undergoing vNOTES approach surgery - difficulty to complete anterior or posterior colpotomy will be documented.\n\nDouglas space characteristics of the patients undergoing vNOTES approach surgery will be compared to patients that were ruled from vNOTES approach in order to evaluate the association of the presence or absence of sliding sign on pre operation ultrasound to the clinical findings.\n\nDemographic and clinical characteristics will be collected from women's medical files. Operative and post-operative data will be collected including: operation duration, estimated blood loss, operation complications (hypotension, bladder gut or vascular perforation), post-operative complications (hemorrhage, endometritis, vascular - thromboembolic event, ileus)."}, "conditionsModule": {"conditions": ["Surgery"], "keywords": ["vaginal surgery", "trans-vaginal ultrasound examination", "sliding sign"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "DIAGNOSTIC", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 75, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Candidates for vaginal natural orifice trans-luminal surgery approach", "type": "EXPERIMENTAL", "description": "Candidates for benign gynecological surgery in the vaginal natural orifice trans-luminal surgery approach", "interventionNames": ["Combination Product: Trans-vaginal ultrasound"]}], "interventions": [{"type": "COMBINATION_PRODUCT", "name": "Trans-vaginal ultrasound", "description": "Pre-operative trans-vaginal ultrasound in order to evaluate sliding sign between the uterus and the rectum", "armGroupLabels": ["Candidates for vaginal natural orifice trans-luminal surgery approach"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "The rate of adhesions/ complicated entry to the Douglas space reported during surgery.", "timeFrame": "From recruitment in the clinics until one month post operation"}], "secondaryOutcomes": [{"measure": "Organ damage", "description": "Damage caused during the surgery to the bladder, the rectum or blood vessel", "timeFrame": "From operation until one month post-operation"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion criteria:\n\n\\- Women planned to undergo surgery for hysterectomy or adnexal indication with normal vaginal examination, that are considered for vNOTES approach.\n\nExclusion criteria:\n\n* History of radiation to the pelvis\n* Malignancy\n* Combined current vaginal operation (for the treatment of prolapse/ urinary complaints)", "healthyVolunteers": true, "sex": "FEMALE", "genderBased": true, "genderDescription": "Inclusion criteria include only women undergoing vaginal surgery", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Aya Mohr-Sasson, M.D", "role": "CONTACT", "phone": "13462704682", "email": "aya.mohrsasson@uth.tmc.edu"}], "overallOfficials": [{"name": "Aya Mohr-Sasson", "affiliation": "The University of Texas Health Science Center, Houston, TX", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "University of Texas", "status": "RECRUITING", "city": "Houston", "state": "Texas", "zip": "77030", "country": "United States", "contacts": [{"name": "Aya Mohr-Sasson, M.D", "role": "CONTACT", "phone": "346-270-4682", "email": "aya.mohrsasson@uth.tmc.edu"}, {"name": "Sunbola Ashimi", "role": "CONTACT", "email": "sunbola.s.ashimi@uth.tmc.edu"}], "geoPoint": {"lat": 29.76328, "lon": -95.36327}}]}, "referencesModule": {"references": [{"pmid": "28221179", "type": "RESULT", "citation": "Jallad K, Walters MD. Natural Orifice Transluminal Endoscopic Surgery (NOTES) in Gynecology. Clin Obstet Gynecol. 2017 Jun;60(2):324-329. doi: 10.1097/GRF.0000000000000280."}, {"pmid": "31444108", "type": "RESULT", "citation": "Li CB, Hua KQ. Transvaginal natural orifice transluminal endoscopic surgery (vNOTES) in gynecologic surgeries: A systematic review. Asian J Surg. 2020 Jan;43(1):44-51. doi: 10.1016/j.asjsur.2019.07.014. Epub 2019 Aug 20."}, {"pmid": "27880893", "type": "RESULT", "citation": "Baekelandt J, De Mulder PA, Le Roy I, Mathieu C, Laenen A, Enzlin P, Weyers S, Mol BW, Bosteels JJ. Postoperative outcomes and quality of life following hysterectomy by natural orifice transluminal endoscopic surgery (NOTES) compared to laparoscopy in women with a non-prolapsed uterus and benign gynaecological disease: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2017 Jan;208:6-15. doi: 10.1016/j.ejogrb.2016.10.044. Epub 2016 Oct 29."}, {"pmid": "22442743", "type": "RESULT", "citation": "Coomber RS, Sodergren MH, Clark J, Teare J, Yang GZ, Darzi A. Natural orifice translumenal endoscopic surgery applications in clinical practice. World J Gastrointest Endosc. 2012 Mar 16;4(3):65-74. doi: 10.4253/wjge.v4.i3.65."}, {"pmid": "22763314", "type": "RESULT", "citation": "Ahn KH, Song JY, Kim SH, Lee KW, Kim T. Transvaginal single-port natural orifice transluminal endoscopic surgery for benign uterine adnexal pathologies. J Minim Invasive Gynecol. 2012 Sep-Oct;19(5):631-5. doi: 10.1016/j.jmig.2012.04.001. Epub 2012 Jul 3."}, {"pmid": "34237485", "type": "RESULT", "citation": "Kapurubandara S, Lowenstein L, Salvay H, Herijgers A, King J, Baekelandt J. Consensus on safe implementation of vaginal natural orifice transluminal endoscopic surgery (vNOTES). Eur J Obstet Gynecol Reprod Biol. 2021 Aug;263:216-222. doi: 10.1016/j.ejogrb.2021.06.019. Epub 2021 Jun 17."}]}, "ipdSharingStatementModule": {"ipdSharing": "UNDECIDED"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT02400684", "orgStudyIdInfo": {"id": "6017"}, "organization": {"fullName": "University Hospital, Strasbourg, France", "class": "OTHER"}, "briefTitle": "ENDmetriosis and Reserve Ovarienne", "officialTitle": "ENDmetriosis and Reserve Ovarienne", "acronym": "ENDRO"}, "statusModule": {"statusVerifiedDate": "2015-09", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2015-06"}, "primaryCompletionDateStruct": {"date": "2019-03", "type": "ACTUAL"}, "completionDateStruct": {"date": "2019-03", "type": "ACTUAL"}, "studyFirstSubmitDate": "2015-03-23", "studyFirstSubmitQcDate": "2015-03-26", "studyFirstPostDateStruct": {"date": "2015-03-27", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2020-05-28", "lastUpdatePostDateStruct": {"date": "2020-05-29", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "University Hospital, Strasbourg, France", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "Endometriosis is the ectopic implantation of endometrial glands and stroma, and can be ovarian and peritoneal (superficial or deep). There are 4 stages in endometriosis according to severity, and the stage is established on the basis of intra-operative observations. The AFSr classification is currently most used (I-IV,minimal, mild, moderate, severe). Most associated with endometriosis are subfertility and pelvic pain.\n\nIn the surgical management of deep endometriosis, the issue of fertility is pivotal. There is a higher rate of infertility in a population of women with endometriosis as compared to the general population, even though the mechanisms are not yet elucidated. Patients with deep endometriosis can be referred to the surgeon for subfertility, but even when they are referred for chronic pain, future fertility considerations are taken into account in the planning of the surgery, as the patients are often young.\n\nIt is now well documented that ovarian cystectomy is deleterious with regards to the ovarian reserve, and more so in endometriomas than in any other type of benign cysts. The ovarian reserve is the functional potential of the ovaries, reflecting the quantity and quality of remaining follicles. Studies have also relied greatly on the measure of serum anti-mullerian hormone (AMH) to evaluate the effect of cystectomy on ovarian reserve, as AMH is currently the most reliable marker to assess ovarian reserve. A significant difference was found between AMH before and following cystectomy in several studies. The deleterious effect of deep endometriosis surgery which comprises a wide dissection and adhesiolysis of the pelvis in many cases, even when no cystectomy has been performed, is therefore not entirely ruled out. To the best of our knowledge, there are no studies on the effect of deep endometriosis surgery, apart from ovarian surgery, on ovarian reserve.\n\nOur center is very active in the laparoscopic surgical treatment of deep endometriosis, with more than 200 cases every year. The objective of this trial is to assess the effect of deep endometriosis surgery on the ovarian reserve, whether a cystectomy is performed or not, by measuring serum AMH before and after surgery, at 6 months and 1 year post-operatively."}, "conditionsModule": {"conditions": ["Deep Endometriosis Stage III", "Deep Endometriosis Stage IV"], "keywords": ["AFSr classification", "laparoscopy"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": true, "targetDuration": "1 Year", "designInfo": {"observationalModel": "CASE_ONLY", "timePerspective": "PROSPECTIVE"}, "bioSpec": {"retention": "SAMPLES_WITHOUT_DNA", "description": "3 times blood sample retrieval and use serum to measure AMH the primary end point but also FSH, LH, estradiol which are study usually."}, "enrollmentInfo": {"count": 118, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Deep endometriosis", "description": "The population is a female population, above 18 years and under 38 years who have stage III or IV endometriosis (which will remain to be confirmed after inclusion by intra-operative observations), and who undergo operative laparoscopy in our center, with only deep endometriosis without endometriomas.", "interventionNames": ["Biological: blood samples"]}, {"label": "Deep endometriosis and endométriomas", "description": "The population is a female population, above 18 years and under 38 years who have stage III or IV endometriosis (which will remain to be confirmed after inclusion by intra-operative observations), and who undergo operative laparoscopy in our center, with deep endometriosis and endometriomas.", "interventionNames": ["Biological: blood samples"]}], "interventions": [{"type": "BIOLOGICAL", "name": "blood samples", "description": "Evolution of AMH before and after deep endometriosis surgery", "armGroupLabels": ["Deep endometriosis", "Deep endometriosis and endométriomas"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change from baseline in ovarian reserve (determined by AMH) at one year", "timeFrame": "Baseline : before surgery (less than one month) and one year after surgery"}], "secondaryOutcomes": [{"measure": "Percentage of decline in AMH between patients who underwent ovarian cystectomy and those who did not", "timeFrame": "baseline and 1 year after surgery"}, {"measure": "Evolution curve of AMH at 6 months and 1 year post-operatively", "timeFrame": "baseline, 6 months and 1 year after surgery"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* female patient between 18 and 38 years\n* endometriosis stage III or IV in the AFSr classification\n* laparoscopy included deep endometriosis procedures (adhesiolysis, ureterolysis, cystectomy, resection of bowel, urinary or deep peritoneal endometriosis)\n* written informed consent\n\nExclusion Criteria:\n\n* previous adnexectomy or adnexectomy during surgery", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "37 Years", "stdAges": ["ADULT"], "studyPopulation": "Female between 18 and 38 years old Deep endometriosis stage III or IV endometriosis of AFSr classification who undergo laparoscopy", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"overallOfficials": [{"name": "Catherine RONGIERES, MD", "affiliation": "Hôpitaux Universitaires de Strasbourg", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "CMCO - Hôpitaux Universitaires de Strasbourg", "city": "Schiltigheim", "zip": "67303", "country": "France", "geoPoint": {"lat": 48.60749, "lon": 7.74931}}, {"facility": "Hôpital de Hautepierre - Hôpitaux Universitaires de Strasbourg", "city": "Strasbourg", "zip": "67200", "country": "France", "geoPoint": {"lat": 48.58392, "lon": 7.74553}}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "interventionBrowseModule": {"meshes": [{"id": "D001800", "term": "Blood Specimen Collection"}], "ancestors": [{"id": "D013048", "term": "Specimen Handling"}, {"id": "D019411", "term": "Clinical Laboratory Techniques"}, {"id": "D019937", "term": "Diagnostic Techniques and Procedures"}, {"id": "D003933", "term": "Diagnosis"}, {"id": "D011677", "term": "Punctures"}, {"id": "D013514", "term": "Surgical Procedures, Operative"}, {"id": "D008919", "term": "Investigative Techniques"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT02498691", "orgStudyIdInfo": {"id": "P140304"}, "organization": {"fullName": "Assistance Publique - Hôpitaux de Paris", "class": "OTHER"}, "briefTitle": "Perinatal Consequences of Endometriosis", "officialTitle": "Perinatal Consequences of Endometriosis: Multicenter Prospective Comparative Study", "acronym": "ENDOBST"}, "statusModule": {"statusVerifiedDate": "2025-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2016-02-04", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2018-12-30", "type": "ACTUAL"}, "completionDateStruct": {"date": "2019-02-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2015-07-13", "studyFirstSubmitQcDate": "2015-07-14", "studyFirstPostDateStruct": {"date": "2015-07-15", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2025-08-29", "lastUpdatePostDateStruct": {"date": "2025-09-05", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Assistance Publique - Hôpitaux de Paris", "class": "OTHER"}, "collaborators": [{"name": "URC-CIC Paris Descartes Necker Cochin", "class": "OTHER"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "Endometriosis is a benign gynecological disease, characterized by the presence of endometrium-like tissue outside the uterine cavity that affect up to 10-15% of women in reproductive age worldwide, with an extensive impact on women's wellbeing and their reproductive life. Endometriosis lesions are heterogeneous and three phenotypes of the disease are well recognized and are fundamentally different from each other: superficial peritoneal endometriosis (peritoneal implants), ovarian endometrioma (cyst ovarian endometriosis), and deeply infiltrating endometriosis (invasive nodules greater than 5 mm).\n\nThe investigators performed a prospective multicenter comparative study to assess the maternal and fetal risks related to endometriosis during pregnancy, regarding disease phenotype, This study will evaluate with sufficient power the risk of prematurity and obstetrical complications associated with endometriosis according to disease phenotype.\n\nThis study aims to provide new informations to pregnant women with endometriosis, guide the monitoring of pregnancy, optimize management strategies based on the nature of complications and ultimately to improve the health of women and their unborn child", "detailedDescription": "Design selected and justification: the study ENDOBST is a\n\n* exposed / unexposed type\n* in superiority\n* with two comparative groups (endometriosis / without endometriosis)\n* Ratio of distribution of subjects in study groups = 1: 2\n\nENDOBST is a comparative prospective multicenter study presentation exposed - unexposed type. The study aims to compare the outcomes of pregnancy in the whole exposed group to controls and then according to the three disease phenotype (superficial, ovarian, and deep endometriosis).\n\nEndobst aims to test the hypothesis that women with endometriosis have an increased risk of preterm delivery (primary endpoint) and an increased risk of pregnancy complications (secondary endpoints) when compared to diseases-free women. Comparisons will be performed according to disease phenotype.\n\nThese analyzes will be conducted after taking into account factors likely to influence the occurrence of preterm birth such as particularly social characteristics (education level, employment status), age and body mass index of women, pathological medical and obstetrical history and behavioral factors (tobacco).\n\nSecondary analyzes will be conducted to investigate the link between endometriosis, and other adverse pregnancy outcomes (premature rupture of membranes, intrauterine growth restriction), complications related to the surgical treatment endometriosis prior to pregnancy.\n\nRegarding the previous surgical treatment, the subgroup of women operated for their endometriosis will be compared to the subgroup of non-operated endometriosis in women and free subset of women. Particular attention will be paid to the phenotype of endometriosis and the nature of previous surgical treatment for pregnancy to control bias indication inherent in observational studies. These associations will be studied from multivariate regression models."}, "conditionsModule": {"conditions": ["Endometriosis"], "keywords": ["endometriosis", "preterm delivery", "caesarean", "Pregnancy outcomes of women with or without endometriosis"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "NON_RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "OTHER", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 1444, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Type exposed", "type": "EXPERIMENTAL", "description": "endometriosis", "interventionNames": ["Biological: Biological collection"]}, {"label": "Type unexposed", "type": "EXPERIMENTAL", "description": "Without endometriosis", "interventionNames": ["Biological: Biological collection"]}], "interventions": [{"type": "BIOLOGICAL", "name": "Biological collection", "description": "Blood and saliva samples, placenta and cord blood collection", "armGroupLabels": ["Type exposed", "Type unexposed"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of preterm delivery", "description": "Each delivery greater than or equal to 22 weeks and less than 37 weeks", "timeFrame": "at Day 0 until 26 weeks"}], "secondaryOutcomes": [{"measure": "premature rupture of membranes", "timeFrame": "at Day 0 until 26 weeks"}, {"measure": "fetal loss", "timeFrame": "at Day 0 until 11 weeks"}, {"measure": "intrauterine growth restriction", "timeFrame": "at Day 0 until 31 weeks"}, {"measure": "induced or spontaneous preterm birth", "timeFrame": "at Day 0 until 26 weeks"}, {"measure": "preeclampsia", "timeFrame": "at Day 0 until 31 weeks"}, {"measure": "placenta previa", "timeFrame": "at Day 0 until 31 weeks"}, {"measure": "postpartum hemorrhage", "timeFrame": "at 11 weeks until 31 weeks"}, {"measure": "number of caesarean", "timeFrame": "at 11 weeks until 31 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patient major\n* Single Pregnancy\n* Patient followed before 22 SA and giving birth in the maternity ward in the study\n* Affiliated to health care\n\nExclusion Criteria:\n\n* Opposition to the use of personal medical data or medical data of their child for research purposes\n* Pregnant women with multiple pregnancies\n* HIV positive women\n* Patients addressed in the center as part of a transfer in utero.\n* Women whose pregnancy is complicated by a spontaneous miscarriage before 15 weeks", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Charles Chapron, MD, PhD", "affiliation": "Assistance Publique - Hôpitaux de Paris", "role": "STUDY_CHAIR"}, {"name": "Francois Goffinet, MD, PhD", "affiliation": "Assistance Publique - Hôpitaux de Paris", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Hopital Cochin", "city": "Paris", "zip": "75014", "country": "France", "geoPoint": {"lat": 48.85341, "lon": 2.3488}}]}, "referencesModule": {"references": [{"pmid": "35133433", "type": "BACKGROUND", "citation": "Marcellin L, Goffinet F, Azria E, Thomin A, Garabedian C, Sibiude J, Verspyck E, Koskas M, Santulli P, Rousseau J, Ancel PY, Chapron C. Association Between Endometriosis Phenotype and Preterm Birth in France. JAMA Netw Open. 2022 Feb 1;5(2):e2147788. doi: 10.1001/jamanetworkopen.2021.47788."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}, {"id": "D047928", "term": "Premature Birth"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}, {"id": "D007752", "term": "Obstetric Labor, Premature"}, {"id": "D007744", "term": "Obstetric Labor Complications"}, {"id": "D011248", "term": "Pregnancy Complications"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT04249297", "orgStudyIdInfo": {"id": "DYDR5005"}, "organization": {"fullName": "Abbott", "class": "INDUSTRY"}, "briefTitle": "Predictors of Pregnancy Rate in Assisted Reproductive Technology According to Actual Guidelines", "officialTitle": "Multicenter Open-Label Observational Program to Research on Predictors of Pregnancy Rate in Assisted Reproductive Technology in the Russian Population and Kazakhstan Population According to Actual International and National Guidelines (IRIS)", "acronym": "IRIS"}, "statusModule": {"statusVerifiedDate": "2021-12", "overallStatus": "UNKNOWN", "lastKnownStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2020-03-03", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2022-03", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2022-12", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2020-01-29", "studyFirstSubmitQcDate": "2020-01-29", "studyFirstPostDateStruct": {"date": "2020-01-30", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2021-12-22", "lastUpdatePostDateStruct": {"date": "2021-12-28", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Abbott", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "Goals: To explore the association of probability of pregnancy with certain prognostic factors in patients undergoing assisted reproductive technology in Russian population according to international and national guidelines.", "detailedDescription": "Research on significant factors (predictors) of pregnancy rate in In Vitro Fertilization (IVF) and Intracytoplasmatic Sperm Injection (ICSI) cycles in Russian population according to actual national and international guidelines in patients using oral dydrogesterone for luteal phase support in assisted reproductive technology. Investigating the strength of the relationship and assessing coefficients of impact on the pregnancy rate.\n\nCreating a predictive table of Clinical Pregnancy in IVF and ICSI cycles and 4-5 most impact predictors."}, "conditionsModule": {"conditions": ["Infertility"], "keywords": ["dydrogesterone", "Duphaston", "Assisted Reproductive Technology", "In-Vitro Fertilization", "luteal phase support"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "COHORT", "timePerspective": "PROSPECTIVE"}, "enrollmentInfo": {"count": 1150, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "IVF/Dydrogesteron", "description": "Females aged ≥ 18 years, underwent In-Vitro Fertilization with Elective single embryo transfer in fresh cycle, for whom were prescribed treatment with Duphaston® for luteal phase support as part of an Assisted Reproductive Technology", "interventionNames": ["Drug: Duphaston® (Dydrogesteron)"]}], "interventions": [{"type": "DRUG", "name": "Duphaston® (Dydrogesteron)", "description": "No intervention. Description of routine practice only. Prescribed Duphaston® according local marketing authorization and international and Russian In-Vitro Fertilization guidelines for luteal phase support as part of an Assisted Reproductive Technology (1 tablet 3 times a day starting at the day of oocyte retrieval).", "armGroupLabels": ["IVF/Dydrogesteron"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "4-5 predictors with highest impact on the probability of clinical pregnancy as evaluated by a logistic regression model", "description": "Evaluating coefficients of the relationship between pregnancy rate and following variables:\n\n* female age (years),\n* female height (cm) / weight (kg) / Body Mass Index (kg/m2),\n* Antral Follicle Count,\n* Ovarian Sensitivity Index,\n* number of top-quality embryos,\n* pre-implantation genetic testing (performed / not performed),\n* day of embryo transfer,\n* treatment history (number of previous attempts),\n* infertility cause (male factor infertility, endometriosis, endometrial factor, myoma, tubal factor, idiopathic),\n* endometrial thickness,\n* serum Anti-Mullerian hormone level,\n* year, season,\n* race (Caucasian, Asian, Black) as predictors.", "timeFrame": "10 weeks"}], "secondaryOutcomes": [{"measure": "Patient's convenience and global satisfaction", "description": "Patient's convenience and global satisfaction of using medication for luteal phase support assessed by Treatment Satisfaction Questionnaire for Medication (TSQM-9). TSQM-9 is a 9-item instrument consisting of 3 scales: effectiveness scale (3 questions), convenience scale (3 questions) and global satisfaction scale (3 questions). The scores were computed by adding items for each domain. The lowest possible score was subtracted from this composite score and divided by the greatest possible score minus the lowest possible score. This provided a transformed score between 0 and 1 that was then multiplied by 100. TSQM-9 domain scores range from 0 to 100 with higher scores representing higher satisfaction on that domain.", "timeFrame": "2 weeks, 10 weeks"}, {"measure": "The overall pregnancy rate", "description": "The overall pregnancy rate with confirmed clinical pregnancy diagnosed by ultrasonographic visualization of one or more gestational sacs, including ectopic pregnancy", "timeFrame": "10 weeks"}, {"measure": "The rate of positive biochemical pregnancy test", "description": "The rate of positive biochemical pregnancy test (diagnosed by the detection of human chorionic gonadotropin (hCG) in serum or urine on Day 12-14 after embryo transfer).", "timeFrame": "2 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Female, age ≥ 18 years\n* Prescribed Duphaston® according local marketing authorization and international and Russian In Vitro Fertilisation guidelines for luteal phase support as part of an Assisted Reproductive Technologies (1 tablet 3 times a day starting at the day of oocyte retrieval)\n* Elective single embryo transfer in fresh cycle\n* Normal ultrasound at enrollment without evidence of clinically significant abnormality consistent with finding adequate for Assisted Reproductive Technologies with respect to uterus and adnexa (incl. no hydrosalpinx or clinically relevant uterine fibroids)\n* Signed the Patient Authorization for Use/Disclosure of Data\n\nExclusion Criteria:\n\n* Evidence of cardiovascular, respiratory, urogenital, gastrointestinal/hepatic, hematologic/immunologic, HEENT (head, ears, eyes, nose, throat), dermatologic/connective tissue, musculoskeletal, metabolic/nutritional, endocrine, neurologic/psychiatric, allergy, recent major surgery (\\< 3 months), or other relevant diseases as revealed by history, physical examination and/or laboratory assessments which could limit participation in or completion of the study\n* Acute urogenital disease\n* Known allergic reactions to dydrogesterone or other progestogens products\n* Any contraindication or other condition that precludes use of dydrogesterone in a particular patient, in accordance with the precautions listed in the locally approved label (Instructions for the medical use of Duphaston®):\n* Hypersensitivity to dydrogesterone or any of the excipients\n* Diagnosed or suspected progestogen-dependent neoplasms (e.g., meningioma)\n* Undiagnosed vaginal bleeding\n* Hepatic impairment associated with acute or chronic, current or past liver diseases (as long as liver function tests have failed to return to normal)\n* Presence or history of malignant liver tumors\n* Galactose intolerance, lactase deficiency, glucose-galactose malabsorption syndrome\n* Breastfeeding.\n* Presence or history of porphyria\n* Age below 18 years, since safety and efficacy in adolescents aged below 18 years have not been established\n* Spontaneous abortion (miscarriage) or missed abortion in luteal-phase support as part of assisted reproductive technology\n* Participation in any other clinical trial within 30 days prior to program start\n* Mental disability or any other lack of fitness, in the Investigator's opinion, to preclude subjects in or to complete the study\n* Current or recent substance abuse, including alcohol and tobacco (Note: Patients who stopped tobacco usage at least 3 months prior to screening visit would be allowed)\n* History of prior chemotherapy\n* Usage of other progestogens except dydrogesterone\n* Contraindication for pregnancy\n* Refusal or inability to comply with the conditions of this program for any reason, including scheduled clinic visits and laboratory tests.\n* Gestational surrogacy, oocyte or embryo donation", "healthyVolunteers": false, "sex": "FEMALE", "genderBased": true, "minimumAge": "18 Years", "maximumAge": "99 Years", "stdAges": ["ADULT", "OLDER_ADULT"], "studyPopulation": "Females aged ≥ 18 years, underwent In-Vitro Fertilization with Elective single embryo transfer in fresh cycle, for whom were prescribed treatment with Duphaston® for luteal phase support as part of an Assisted Reproductive Technology", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"centralContacts": [{"name": "Aleksander Akimov", "role": "CONTACT", "phone": "74952584280", "phoneExt": "57461", "email": "a.akimov@abbott.com"}], "overallOfficials": [{"name": "Tatiana A Nazarenko, Prof", "affiliation": "Kulakov National Medical Research Center of Obstetrics, Gynecology and Perinatology", "role": "STUDY_CHAIR"}], "locations": [{"facility": "LLP Institute of Reproductive Medicine", "status": "RECRUITING", "city": "Almaty", "zip": "050008", "country": "Kazakhstan", "geoPoint": {"lat": 43.25249, "lon": 76.9115}}, {"facility": "PERSONA International Clinical Center for Reproductology", "status": "RECRUITING", "city": "Almaty", "zip": "050060", "country": "Kazakhstan", "geoPoint": {"lat": 43.25249, "lon": 76.9115}}, {"facility": "Regional Clinical Perinatal Center \"Dar\"", "status": "COMPLETED", "city": "Barnaul", "zip": "656045", "country": "Russia", "geoPoint": {"lat": 53.36199, "lon": 83.72786}}, {"facility": "Clinic of Family Medicine", "status": "COMPLETED", "city": "Chelyabinsk", "zip": "454021", "country": "Russia", "geoPoint": {"lat": 55.1611, "lon": 61.42877}}, {"facility": "Regional Perinatal Center", "status": "COMPLETED", "city": "Chelyabinsk", "zip": "454080", "country": "Russia", "geoPoint": {"lat": 55.1611, "lon": 61.42877}}, {"facility": "ART Department Irkutsk Regional Clinical Hospital", "status": "COMPLETED", "city": "Irkutsk", "zip": "664003", "country": "Russia", "geoPoint": {"lat": 52.29566, "lon": 104.29076}}, {"facility": "Mother and Child", "status": "COMPLETED", "city": "Irkutsk", "zip": "664005", "country": "Russia", "geoPoint": {"lat": 52.29566, "lon": 104.29076}}, {"facility": "Ivanovo Research Institute motherhood and childhood named after VN Gorodkov", "status": "COMPLETED", "city": "Ivanovo", "zip": "153045", "country": "Russia", "geoPoint": {"lat": 56.99988, "lon": 40.97257}}, {"facility": "Mother and Child", "status": "COMPLETED", "city": "Kazan'", "zip": "117335", "country": "Russia", "geoPoint": {"lat": 55.78874, "lon": 49.12214}}, {"facility": "Scandinavia", "status": "COMPLETED", "city": "Kazan'", "zip": "420111", "country": "Russia", "geoPoint": {"lat": 55.78874, "lon": 49.12214}}, {"facility": "Clinic for male and female health 'OXY-center'", "status": "COMPLETED", "city": "Krasnodar", "zip": "350020", "country": "Russia", "geoPoint": {"lat": 45.04534, "lon": 38.98178}}, {"facility": "Clinic of Kuban State Medical University", "status": "COMPLETED", "city": "Krasnodar", "zip": "350072", "country": "Russia", "geoPoint": {"lat": 45.04534, "lon": 38.98178}}, {"facility": "Regional Center for Family Health and Reproduction", "status": "COMPLETED", "city": "Krasnodar", "zip": "350901", "country": "Russia", "geoPoint": {"lat": 45.04534, "lon": 38.98178}}, {"facility": "Mother and Child", "status": "COMPLETED", "city": "Krasnoyarsk", "zip": "660037", "country": "Russia", "geoPoint": {"lat": 56.03742, "lon": 92.93136}}, {"facility": "IVF Center", "status": "COMPLETED", "city": "Lipetsk", "zip": "398007", "country": "Russia", "geoPoint": {"lat": 52.5876, "lon": 39.55151}}, {"facility": "Reproductive Health Clinic 'Biootpima'", "status": "COMPLETED", "city": "Moscow", "zip": "105043", "country": "Russia", "geoPoint": {"lat": 55.75204, "lon": 37.61781}}, {"facility": "Generation NEXT", "status": "COMPLETED", "city": "Moscow", "zip": "109544", "country": "Russia", "geoPoint": {"lat": 55.75204, "lon": 37.61781}}, {"facility": "Medical Center Altra Vita", "status": "COMPLETED", "city": "Moscow", "zip": "117186", "country": "Russia", "geoPoint": {"lat": 55.75204, "lon": 37.61781}}, {"facility": "Kulakov National Medical Research Center of Obstetrics, Gynecology and Perinatology", "status": "COMPLETED", "city": "Moscow", "zip": "117198", "country": "Russia", "geoPoint": {"lat": 55.75204, "lon": 37.61781}}, {"facility": "Family Planning and Reproduction Center", "status": "COMPLETED", "city": "Moscow", "zip": "117209", "country": "Russia", "geoPoint": {"lat": 55.75204, "lon": 37.61781}}, {"facility": "Mother and Child Perinatal Center", "status": "COMPLETED", "city": "Moscow", "zip": "117209", "country": "Russia", "geoPoint": {"lat": 55.75204, "lon": 37.61781}}, {"facility": "NOVA Clinic, Center for Reproduction and Genetics", "status": "COMPLETED", "city": "Moscow", "zip": "119048", "country": "Russia", "geoPoint": {"lat": 55.75204, "lon": 37.61781}}, {"facility": "Medical Center MIRA", "status": "COMPLETED", "city": "Moscow", "zip": "119334", "country": "Russia", "geoPoint": {"lat": 55.75204, "lon": 37.61781}}, {"facility": "Mother and Child Kuntsevo", "status": "COMPLETED", "city": "Moscow", "zip": "121374", "country": "Russia", "geoPoint": {"lat": 55.75204, "lon": 37.61781}}, {"facility": "Center of Reproduction 'Line of Life'", "status": "COMPLETED", "city": "Moscow", "zip": "121471", "country": "Russia", "geoPoint": {"lat": 55.75204, "lon": 37.61781}}, {"facility": "Mother and Child Savelovskaya", "status": "COMPLETED", "city": "Moscow", "zip": "127015", "country": "Russia", "geoPoint": {"lat": 55.75204, "lon": 37.61781}}, {"facility": "Clinic 'IVF Center'", "status": "COMPLETED", "city": "Moscow", "zip": "129075", "country": "Russia", "geoPoint": {"lat": 55.75204, "lon": 37.61781}}, {"facility": "Mother and Child Khodynka", "status": "COMPLETED", "city": "Moscow", "zip": "129090", "country": "Russia", "geoPoint": {"lat": 55.75204, "lon": 37.61781}}, {"facility": "Multidisciplinary Medical Center 'MAK IVF'", "status": "COMPLETED", "city": "Moscow", "zip": "129110", "country": "Russia", "geoPoint": {"lat": 55.75204, "lon": 37.61781}}, {"facility": "Mother and Child Lapino", "status": "COMPLETED", "city": "Moscow", "zip": "143081", "country": "Russia", "geoPoint": {"lat": 55.75204, "lon": 37.61781}}, {"facility": "Volga Regional Medical Center, Clinical Hospital #1", "status": "COMPLETED", "city": "Nizhny Novgorod", "zip": "603000", "country": "Russia", "geoPoint": {"lat": 56.32867, "lon": 44.00205}}, {"facility": "Clinical Hospital 'Avicenna'", "status": "COMPLETED", "city": "Novosibirsk", "zip": "630007", "country": "Russia", "geoPoint": {"lat": 55.02259, "lon": 82.93175}}, {"facility": "Novosibirsk Center for Reproductive Medicine 'Mother and Child'", "status": "COMPLETED", "city": "Novosibirsk", "zip": "630037", "country": "Russia", "geoPoint": {"lat": 55.02259, "lon": 82.93175}}, {"facility": "Reproduction Clinic ' Philosophy of Life'", "status": "COMPLETED", "city": "Perm", "zip": "614107", "country": "Russia", "geoPoint": {"lat": 58.01046, "lon": 56.25017}}, {"facility": "Center for Reproductive Technologies 'EmbryLife'", "status": "COMPLETED", "city": "Saint Petersburg", "zip": "190031", "country": "Russia", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Ava-Peter Reproduction Clinic", "status": "COMPLETED", "city": "Saint Petersburg", "zip": "191186", "country": "Russia", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Scandinavia Reproduction Clinic", "status": "COMPLETED", "city": "Saint Petersburg", "zip": "196211", "country": "Russia", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Reproductive Medicine Clinic ICLINIC", "status": "COMPLETED", "city": "Saint Petersburg", "zip": "197110", "country": "Russia", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Center for Reproductive Medicine", "status": "COMPLETED", "city": "Saint Petersburg", "zip": "197371", "country": "Russia", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Ott Research Institute of Obstetrics, Gynecology and Reproductology", "status": "COMPLETED", "city": "Saint Petersburg", "zip": "199034", "country": "Russia", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Mother and Child St. Petersburg", "status": "COMPLETED", "city": "Saint Petersburg", "zip": "199106", "country": "Russia", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Mother and Child", "status": "COMPLETED", "city": "Samara", "zip": "443072", "country": "Russia", "geoPoint": {"lat": 53.20767, "lon": 50.13553}}, {"facility": "Regional Center for Reproductive Medicine Dynasty", "status": "COMPLETED", "city": "Samara", "zip": "443095", "country": "Russia", "geoPoint": {"lat": 53.20767, "lon": 50.13553}}, {"facility": "Saratov Regional Perinatal Center", "status": "COMPLETED", "city": "Saratov", "zip": "640015", "country": "Russia", "geoPoint": {"lat": 51.54048, "lon": 45.9901}}, {"facility": "Stavropol Regional Clinical Diagnostic Center, ART Department", "status": "COMPLETED", "city": "Stavropol", "zip": "355029", "country": "Russia", "geoPoint": {"lat": 45.03442, "lon": 41.9642}}, {"facility": "Center ART, Siberian State Medical University", "status": "COMPLETED", "city": "Tomsk", "zip": "634050", "country": "Russia", "geoPoint": {"lat": 56.50049, "lon": 84.98216}}, {"facility": "Mother and Child", "status": "COMPLETED", "city": "Tyumen", "zip": "625062", "country": "Russia", "geoPoint": {"lat": 57.15222, "lon": 65.52722}}, {"facility": "Volgograd State Medical University, Clinik #1", "status": "COMPLETED", "city": "Volgograd", "zip": "400079", "country": "Russia", "geoPoint": {"lat": 48.71378, "lon": 44.4976}}, {"facility": "Voronezh Regional Clinical Hospital #1, Perinatal Center", "status": "COMPLETED", "city": "Voronezh", "zip": "394066", "country": "Russia", "geoPoint": {"lat": 51.66833, "lon": 39.19204}}, {"facility": "Research Institute for the Protection of Maternity and Infancy", "status": "COMPLETED", "city": "Yekaterinburg", "zip": "620028", "country": "Russia", "geoPoint": {"lat": 56.85733, "lon": 60.61529}}, {"facility": "Clinical diagnostic center \"Maternal and child health\"", "status": "COMPLETED", "city": "Yekaterinburg", "zip": "620041", "country": "Russia", "geoPoint": {"lat": 56.85733, "lon": 60.61529}}, {"facility": "IVF Center Partus", "status": "COMPLETED", "city": "Yekaterinburg", "zip": "620075", "country": "Russia", "geoPoint": {"lat": 56.85733, "lon": 60.61529}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D007246", "term": "Infertility"}], "ancestors": [{"id": "D000091662", "term": "Genital Diseases"}, {"id": "D000091642", "term": "Urogenital Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D004394", "term": "Dydrogesterone"}], "ancestors": [{"id": "D011245", "term": "Pregnadienes"}, {"id": "D011278", "term": "Pregnanes"}, {"id": "D013256", "term": "Steroids"}, {"id": "D000072473", "term": "Fused-Ring Compounds"}, {"id": "D011083", "term": "Polycyclic Compounds"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT04452123", "orgStudyIdInfo": {"id": "GPKENDO2001"}, "organization": {"fullName": "Charles University, Czech Republic", "class": "OTHER"}, "briefTitle": "Endometrioma Treatment and Ovarian Function", "officialTitle": "Endometrioma Treatment and Ovarian Function", "acronym": "EnTOF"}, "statusModule": {"statusVerifiedDate": "2020-06", "overallStatus": "UNKNOWN", "lastKnownStatus": "NOT_YET_RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2020-07-01", "type": "ESTIMATED"}, "primaryCompletionDateStruct": {"date": "2022-12-31", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2023-12-31", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2020-06-12", "studyFirstSubmitQcDate": "2020-06-27", "studyFirstPostDateStruct": {"date": "2020-06-30", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2020-06-27", "lastUpdatePostDateStruct": {"date": "2020-06-30", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Jan Humplik, MD", "investigatorTitle": "Principal investigator", "investigatorAffiliation": "Charles University, Czech Republic"}, "leadSponsor": {"name": "Charles University, Czech Republic", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "Ovarian endometriosis (endometrioma) can be a cause of subfertility. According to European Society of Human Reproduction and Embryology (ESHRE) guidelines, surgery for endometrioma is recommended when an endometrioma is more than 3 cm in diameter because this management is associated with better spontaneous conception rates. Nevertheless, surgery can also be potentially associated with a risk of destruction of functional ovarian tissue and reduction in ovarian reserve.\n\nAnti-müllerian hormone (AMH) is a member of the Transforming Growth Factor beta family and is expressed by the small (\\<8 mm) pre-antral and early antral follicles. The AMH level reflects the size of the primordial follicle pool, and may be the best biochemical marker of ovarian function across an array of clinical situations Its level in serum is almost stable between 20 and 35 years of the woman´s life, unless using hormonal contraception and / or they suffer with Polycystic ovarian syndrome (PCOS). The level of AMH is also a useful indicator for the prediction chances of success of spontaneous or assisted conceptions. However, there paucity of data regarding changes in serum levels of AMH following surgery for endometrioma.\n\nAn alternative way for estimating ovarian reserve is quantifying ovarian mass with using standard 3D transvaginal ultrasound calculation (OVM) and assessment of antral follicular count.\n\nThe gold standard of endometrioma surgery is laparoscopic excision with suture or gentle coagulation of the rest of ovary or by the use of laparoscopic treatment with argon plasma energy."}, "conditionsModule": {"conditions": ["Endometrioma"], "keywords": ["Endometrioma", "AMH"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 100, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Argon plasma", "type": "EXPERIMENTAL", "description": "Patients with endometrioma treated with laparoscopic argon plasma energy.", "interventionNames": ["Procedure: Laparoscopic argon plasma treatment of endometrioma", "Procedure: Laparoscopic stripping of endometrioma and suture/coagulation of the rest of ovary"]}, {"label": "Stripping and suture/coagulation", "type": "EXPERIMENTAL", "description": "Patients with endometrioma treated with laparoscopic excision with suture or gentle coagulation of the rest of ovary.", "interventionNames": ["Procedure: Laparoscopic argon plasma treatment of endometrioma", "Procedure: Laparoscopic stripping of endometrioma and suture/coagulation of the rest of ovary"]}], "interventions": [{"type": "PROCEDURE", "name": "Laparoscopic argon plasma treatment of endometrioma", "description": "Laparoscopic Argon Plasma vaporising the endometriotic cyst lining only until haemosiderin pigment stained tissue is no longer visible", "armGroupLabels": ["Argon plasma", "Stripping and suture/coagulation"]}, {"type": "PROCEDURE", "name": "Laparoscopic stripping of endometrioma and suture/coagulation of the rest of ovary", "description": "Laparoscopic dissecting of capsule of endometrioma and achieving hemostasis with suture of rest of the ovary or with gentle coagulation.", "armGroupLabels": ["Argon plasma", "Stripping and suture/coagulation"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "AMH", "description": "Changing of anti-müllerian hormon assay postop. in µg/L", "timeFrame": "3 days,3-5 week postop., 3 months postop., 1 year (optional)"}, {"measure": "Antral follicle count (AFC)", "description": "Ultrasound count of Antral follicles after the surgery, counted 3-5. day of menstrual cycle", "timeFrame": "3 months, 1 year"}, {"measure": "Both ovarian volume", "description": "Ultrasound volume of both ovaries in cm\\^3, measured 3-5. day of menstrual cycle", "timeFrame": "3 months, 1 year"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* women with endometrioma 3cm and more in diameter\n\nExclusion Criteria:\n\n* using hormonal contraception or other hormonal treatment last 6 months\n* suffer with polycystic ovarian syndrome", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "20 Years", "maximumAge": "35 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Jan Humplik, MD", "role": "CONTACT", "phone": "420377105254", "email": "humplikj@fnplzen.cz"}], "overallOfficials": [{"name": "Jan Humplik, MD", "affiliation": "Charles university in Pilsen", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Departement of gynecology and obstetrics, University hospital in Pilsen", "city": "Pilsen", "zip": "30408", "country": "Czechia", "contacts": [{"name": "Jan Humplik, MD", "role": "CONTACT", "phone": "420377105240", "email": "humplikj@fnplzen.cz"}], "geoPoint": {"lat": 49.74747, "lon": 13.37759}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D013537", "term": "Sutures"}], "ancestors": [{"id": "D053831", "term": "Surgical Fixation Devices"}, {"id": "D013523", "term": "Surgical Equipment"}, {"id": "D004864", "term": "Equipment and Supplies"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT01125488", "orgStudyIdInfo": {"id": "VGHIRB 97-04-03"}, "organization": {"fullName": "Taipei Veterans General Hospital, Taiwan", "class": "OTHER_GOV"}, "briefTitle": "Maintenance Therapy of Levonorgestrel-releasing Intrauterine System (LNG-IUS) to Prevent the Recurrence of Symptomatic Endometriosis After Conservative Surgery", "officialTitle": "Maintenance Therapy of LNG-IUS in Conjunction With the GnRH Agonist to Prevent the Recurrence of Symptomatic Endometriosis After Conservative Surgery: A Prospective Randomized, Phase III Trial"}, "statusModule": {"statusVerifiedDate": "2010-06", "overallStatus": "UNKNOWN", "lastKnownStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-03"}, "primaryCompletionDateStruct": {"date": "2009-03", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2010-09", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2010-04-26", "studyFirstSubmitQcDate": "2010-05-17", "studyFirstPostDateStruct": {"date": "2010-05-18", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2010-06-06", "lastUpdatePostDateStruct": {"date": "2010-06-08", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "Yi-Jen Chen MD", "oldOrganization": "Department of Obstetrics & Gynecology,Taipei Veterans General Hospital,Taiwan"}, "leadSponsor": {"name": "Taipei Veterans General Hospital, Taiwan", "class": "OTHER_GOV"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The recurrence rates of endometriosis reported in women 5 years after therapy with gonadotropin releasing hormone (GnRH) agonist were 74% for severe disease . No strategies to prevent the recurrence of endometriosis have been uniformly successful. Local progesterone treatment of endometriosis-associated dysmenorrhea with a levonorgestrel-releasing intrauterine system (LNG-IUS) for 12 months has resulted in a significant reduction in dysmenorrhea, pelvic pain and dyspareunia; a high degree of patient satisfaction; and a significant reduction in the volume of rectovaginal endometriotic nodules. LNG-IUS may become a more important option if a long-term medical suppression of endometriosis.\n\nBased on literature review, I hypothesized that maintenance therapy of LNG-IUS in conjunction with the GnRH agonist could lower the recurrence rates endometriosis after conservative surgery. We try to answer the question whether maintenance therapy of LNG-IUS in conjunction with the GnRH agonist could lower the recurrence rates and thus extend the symptom-free interval (menorrhagia and dysmenorrhea) as compared to GnRH agonist alone after conservative surgery in severe endometriosis cases.", "detailedDescription": "Participants:\n\nThis post-surgical medical therapy trial will be undertaken among patients with moderate-severe symptomatic endometriosis (rASRM score \\>16, according to the American Society for Reproductive Medicine) or adenomyosis. Symptomatic endometriosis means menorrhagia or dysmenorrhea. All patients were surgically treated by a conservative approach (means preserve uterus and ovary).\n\nInterventions:\n\nIn all patients, were prescribed 600 mg elemental Ca and 400 IU vitamin D (bid). The first group of patients receive LNG-IUS for 5 years and GnRH agonist (triptorelin 3.75 mg, sc q28day) for 24 weeks.\n\nThe second group of patients receive GnRH agonist (triptorelin 3.75 mg, sc q28day) alone for 24 weeks.\n\nPatients were evaluated every month for 24 weeks, and at 3,6,9,12,15,18,21,24 months after the end of medical treatment.\n\nObjectives and outcomes:\n\nThe main objective of this trial was to assess the clinical efficacy of LNG-IUS maintenance therapy to prevent recurrence of endometriosis. Thus the primary outcome measures of this trial is the recurrence rate of endometriosis.\n\nDuring this trial, recurrence was defined as elevation of CA125 (6) or endometriosis lesion in sonography or symptoms suggesting endometriosis including menorrhagia or dysmenorrhea.\n\nThe pain score diary was based on the visual analogue scale in which patients recorded the occurrence an intensity of their pain daily. VAS consists of a subjective evaluation of the pain on a scale of 10 in which 0 is no pain and 10 the most severe pain (7).\n\nBleeding and menorrhagia were assessed as: 0= no bleeding; 1=spotting (light bleeding not requiring sanitary protection); 2=light bleeding (light bleeding requiring sanitary protection); 3=normal bleeding (bleeding similar to normal menstrual blood flow); and 4=heavy bleeding (bleeding exceeding normal menstrual blood flow). No bleeding was defined as 30 consecutive days with bleeding score 0 (8).\n\nRandomization process:\n\nTreatment allocation was performed in accordance with a computer-generated randomization sequence using numbered, sealed envelopes.\n\nEvaluation of efficacy:\n\nSample size:\n\nIn calculating the sample size required, the primary assessment was the recurrence rates. A 31% recurrence rate after laparoscopic reproductive surgery and post-surgical treatment with a GnRH agonist has been reported (9). We expected a decrease in recurrence rates after laparoscopic conservative surgery and post-surgical treatment with GnRH agonist plus LNG-IUS. A difference of 25% between the allocated treatments was considered significant. To have a 90% chance of detecting such a difference at an overall significant level of 5%, 40 patients for each group were required.\n\nEndpoints:\n\nWe will follow the patients for 2 years, after the end of GnRH agonist medical treatment. Thus the primary outcome measures of this trial is the recurrence rate of endometriosis.\n\nThe main objective of this trial was to assess the clinical efficacy of LNG-IUS maintenance therapy to prevent recurrence of endometriosis.\n\nStatistical analysis plan:\n\nThe cumulative proportion of recurrences by plotting percent recurrences as a function of time was estimated by the method of Kaplan and Meier. The survival curves for each allocated treatment were compared with the log-rank test.\n\nFor quantitative variables with normal distribution, the parametric t-test was used; in the case of the other variables, the non-parametric Mann-Whitney test was applied. For qualitative variables, x2-test or Fisher's exact test were used. For dependent variables with numerical scores referring to long-term measurement, multivariate analysis of variance ( MANOVA) was used."}, "conditionsModule": {"conditions": ["Endometriosis"], "keywords": ["Maintenance therapy", "LNG-IUS", "recurrence,endometriosis", "Recurrence"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "PREVENTION", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 80, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "LNG-IUS", "type": "EXPERIMENTAL", "description": "LNG-IUS insertion during conservative surgery and GnRH agonist 6 doses.", "interventionNames": ["Device: LNG-IUS", "Drug: GnRH agonist (triptorelin)"]}, {"label": "GnRH agonist", "type": "ACTIVE_COMPARATOR", "description": "The second group of patients receive GnRH agonist (triptorelin 3.75 mg, sc q28day) alone for 24 weeks.", "interventionNames": ["Drug: GnRH agonist (triptorelin)"]}], "interventions": [{"type": "DEVICE", "name": "LNG-IUS", "description": "levonorgestrel-releasing intrauterine system (LNG-IUS) 52mg, duration 5 years", "armGroupLabels": ["LNG-IUS"], "otherNames": ["mirena"]}, {"type": "DRUG", "name": "GnRH agonist (triptorelin)", "description": "GnRH agonist (triptorelin 3.75 mg, sc q28day)", "armGroupLabels": ["GnRH agonist", "LNG-IUS"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Recurrence rate of endometriosis", "description": "We will follow the patients for 2 years, after the end of GnRH agonist medical treatment. Number of Participants with recurrence as a Measure of the clinical efficacy of LNG-IUS maintenance therapy to prevent recurrence of endometriosis.", "timeFrame": "2 years"}], "secondaryOutcomes": [{"measure": "the safety of LNG-IUS maintenance therapy to prevent recurrence of endometriosis.", "description": "Number of Participants with Adverse Events as a Measure of Safety and Tolerability.", "timeFrame": "2 years"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with moderate-severe symptomatic endometriosis (rASRM score \\>16) according to the American Society for Reproductive Medicine) or adenomyosis. Symptomatic endometriosis means menorrhagia or dysmenorrhea.\n* All patients were surgically treated by a conservative approach.\n* Levels of serum CA125 is higher than normal range.\n\nExclusion Criteria:\n\n* Further desire for child bearing in future 3 years.\n* Any treatment for endometriosis within the previous 2 months.\n* Any concomitant disease that can be an established cause of chronic pelvic pain and anemia (Thalassemia anemia, inflammation sequela, myoma , and pelvic congestion etc)", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "20 Years", "maximumAge": "45 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Yi-Jen Chen, MD", "role": "CONTACT", "phone": "886-2-28757566", "email": "chenyj@vghtpe.gov.tw"}, {"name": "PH Wang, MD, PhD", "role": "CONTACT", "phone": "886-2-28757566", "email": "phwang@vghtpe.gov.tw"}], "overallOfficials": [{"name": "Yi-Jen Chen, MD", "affiliation": "Department OBS & GYN, Taipei Veterans General Hospital", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Taipei Veterans Genreal Hospital", "status": "RECRUITING", "city": "Taipei", "zip": "11217", "country": "Taiwan", "contacts": [{"name": "Yi-Jen Chen, MD. PhD", "role": "CONTACT", "phone": "886 22 8757566", "email": "chenyj@vghtpe.gov.tw"}, {"name": "Yi-Jen Chen, MD", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 25.05306, "lon": 121.52639}}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}, {"id": "D012008", "term": "Recurrence"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}, {"id": "D020969", "term": "Disease Attributes"}, {"id": "D010335", "term": "Pathologic Processes"}, {"id": "D013568", "term": "Pathological Conditions, Signs and Symptoms"}]}, "interventionBrowseModule": {"meshes": [{"id": "D007987", "term": "Gonadotropin-Releasing Hormone"}, {"id": "D017329", "term": "Triptorelin Pamoate"}], "ancestors": [{"id": "D010906", "term": "Pituitary Hormone-Releasing Hormones"}, {"id": "D007028", "term": "Hypothalamic Hormones"}, {"id": "D036361", "term": "Peptide Hormones"}, {"id": "D006728", "term": "Hormones"}, {"id": "D006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D009479", "term": "Neuropeptides"}, {"id": "D010455", "term": "Peptides"}, {"id": "D000602", "term": "Amino Acids, Peptides, and Proteins"}, {"id": "D009842", "term": "Oligopeptides"}, {"id": "D009419", "term": "Nerve Tissue Proteins"}, {"id": "D011506", "term": "Proteins"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT05714189", "orgStudyIdInfo": {"id": "W20_534 # 20.593"}, "organization": {"fullName": "Amsterdam UMC, location VUmc", "class": "OTHER"}, "briefTitle": "The Effect of Dietary Interventions, or no Intervention, on Pain and Quality of Life in Women Diagnosed With Endometriosis", "officialTitle": "The Effect of Dietary Interventions, or no Intervention, on Pain and Quality of Life in Women Diagnosed With Endometriosis", "acronym": "Dieetstudie"}, "statusModule": {"statusVerifiedDate": "2023-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2021-04-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2022-12-31", "type": "ACTUAL"}, "completionDateStruct": {"date": "2022-12-31", "type": "ACTUAL"}, "studyFirstSubmitDate": "2023-01-26", "studyFirstSubmitQcDate": "2023-01-26", "studyFirstPostDateStruct": {"date": "2023-02-06", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-02-09", "lastUpdatePostDateStruct": {"date": "2023-02-14", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Prof. Velja Mijatovic", "investigatorTitle": "Professor Doctor", "investigatorAffiliation": "Amsterdam UMC, location VUmc"}, "leadSponsor": {"name": "Amsterdam UMC, location VUmc", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "This prospective pilot study was performed to explore the influence of a dietary intervention, the Low FODMAP diet or endometriosis diet, on endometriosis-related pain and Quality of Life (QoL). Participants could choose between adherence to a diet; the Low FODMAP diet or endometriosis diet, or to contribute to the control group and not adhere to a diet.", "detailedDescription": "This prospective pilot study was performed to explore the influence of a dietary intervention, the Low FODMAP diet or endometriosis diet, on endometriosis-related pain and Quality of Life (QoL). Participants could choose between adherence to a diet; the Low FODMAP diet or endometriosis diet, or to contribute to the control group and not adhere to a diet. Women choosing to adhere to a diet were extensively guided by a dietician in training. In addition, both groups are asked to complete three questionnaires over a period of six months; once every two months."}, "conditionsModule": {"conditions": ["Endometriosis"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "NON_RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": "Women could chose to adhere to a diet or the control group. there was no cross-over.", "primaryPurpose": "SUPPORTIVE_CARE", "maskingInfo": {"masking": "NONE", "maskingDescription": "Women were able to choose themselves whether to adhere to a diet, and to which diet, or to adhere to the control group."}}, "enrollmentInfo": {"count": 62, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Intervention group: adherence to Low FODMAP diet", "type": "OTHER", "description": "Women could choose to adhere to the low FODMAP diet, over a period of six months. In the first three months, they received extensive guidance by a dietician in training, in addition to supportive materials such as the Monash app, recipes and grocery lists, in the hope of optimal adherence to the diet. After three months, women were asked to continue the diet independently. In addition, women were asked to complete three questionnaires, one every two months. The questionnaires contained the EHP-30, the GIQLI, and self composed questions on their demographics in the first questionnaire, and their strictness of adherence in the second and third questionnaire. The third questionnaire also contained questions on their satisfaction with the dietary guidance and the dietician in training.", "interventionNames": ["Other: Low FODMAP diet"]}, {"label": "Intervention group: adherence to endometriosis diet", "type": "OTHER", "description": "Women could choose to adhere to the endometriosis diet, over a period of six months. In the first three months, they received extensive guidance by a dietician in training, in addition to supportive materials such as the Monash app, recipes and grocery lists, in the hope of optimal adherence to the diet. After three months, women were asked to continue the diet independently. In addition, women were asked to complete three questionnaires, one every two months. The questionnaires contained the EHP-30, the GIQLI, and self composed questions on their demographics in the first questionnaire, and their strictness of adherence in the second and third questionnaire. The third questionnaire also contained questions on their satisfaction with the dietary guidance and the dietician in training.", "interventionNames": ["Other: Endometriosis diet"]}, {"label": "Control group: no diet adherence", "type": "NO_INTERVENTION", "description": "Women were asked to complete three questionnaires, once every two months. These contained the EHP-30 and GIQLI. The first questionnaire contained questions on their demographics, and whether they applied a diet before."}], "interventions": [{"type": "OTHER", "name": "Low FODMAP diet", "description": "The Low FODMAP diet is an avoidance diet and consist of three phases. In the first phase, all nutrients high in FODMAPs (high-FODMAPS) are eliminated from the daily diet over a period of 2 to 6 weeks to calm down the bowel. The second phase consists of the addition of FODMAP challenges. During this phase the patient continues the Low FODMAP diet, but will reintroduce one high-FODMAP nutrient once every three days to see whether exposure to this high-FODMAP causes IBS symptoms. When this is not the case, the patient can continue eating this high-FODMAP group in their daily diet. In the third and final phase, the diet is fully personalized. This personalization is based on whether the patient tolerated the high-FODMAP nutrient or not during the FODMAP challenges. Only when the high-FODMAP nutrient is not tolerated, it is advised to permanently remove it from the daily diet.", "armGroupLabels": ["Intervention group: adherence to Low FODMAP diet"]}, {"type": "OTHER", "name": "Endometriosis diet", "description": "The endometriosis diet The endometriosis diet is a patient experience based, avoidance diet developed by women diagnosed with endometriosis. Therefore no specific recommendations exist regarding the application of the endometriosis diet. With the endometriosis diet, women avoid nutrients they noticed provoked or aggravated their endometriosis-related symptoms such as red meat, coffee, sugar, lactose and soy.", "armGroupLabels": ["Intervention group: adherence to endometriosis diet"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "pain scores", "description": "The primary outcome focused on pain scores (in VAS, scale 0-10cm) of the endometriosis-related symptoms dysmenorrhea, deep dyspareunia, chronic pelvic pain, dysuria, dyschezia, tiredness and bloating. Pain scores will be measured on a scale between 0 and 10, where 0 represents no pain at all and 10 the worst pain possible.", "timeFrame": "6 months"}], "secondaryOutcomes": [{"measure": "Quality of Life (QoL)", "description": "Secondary outcome focused on QoL, expressed using the EHP-30 questionnaire. Using the EHP-30, a score between 0 and 100 can be measured for 11 different QoL domains. For every domain, a score of 0 represents best health status through to a score of 100 which represents worst health status.", "timeFrame": "6 months"}, {"measure": "Gastro-Intestinal Health", "description": "Secondary outcome focused on gastro-intestinal health, expressed using the GIQLI questionnaire. With the GIQLI, a score between 0 and 144 can be calculated where 0 represents worst possible gastro-intestinal health and 144 best possible gastro-intestinal health.", "timeFrame": "6 months"}, {"measure": "Adhesion to dietary intervention", "description": "with every follow-up visit, women were asked on their dietary adhesion. they were asked how often they made an exception, with what meal (snack/main meal) and what strictness score they gave themselves. Women could score their strictness between 0 and 10 where 0 represented worst possible strictness and 10 best possible strictness", "timeFrame": "6 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Women diagnosed with endometriosis, either through radiologic imaging (transvaginal ultrasound and/or MRI) or laparoscopy\n* A reported pain score of ≥ 3 (Visual Analogue Score (VAS), scale 0-10cm) in one or more of the following symptoms: dysmenorrhea, deep dyspareunia and chronic pelvic pain\n\nExclusion Criteria:\n\n* about to undergo an operation within six months\n* Undergone an operation in the past six weeks\n* a switch in hormonal therapy within six weeks\n* Women that were pregnant or breastfeeding\n* women diagnosed with a malignancy\n* An additional diagnosis with Coeliac Disease (CD) and/or lactose intolerance.\n* Not sufficient in the Dutch or English language.", "healthyVolunteers": false, "sex": "FEMALE", "genderBased": true, "genderDescription": "Women diagnosed with endometriosis", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "Amsterdam AMC", "city": "Amsterdam", "zip": "1081HV", "country": "Netherlands", "geoPoint": {"lat": 52.37403, "lon": 4.88969}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000092622", "term": "FODMAP Diet"}], "ancestors": [{"id": "D000092724", "term": "Elimination Diets"}, {"id": "D004032", "term": "Diet"}, {"id": "D009747", "term": "Nutritional Physiological Phenomena"}, {"id": "D000066888", "term": "Diet, Food, and Nutrition"}, {"id": "D010829", "term": "Physiological Phenomena"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT00160446", "orgStudyIdInfo": {"id": "M99-110"}, "organization": {"fullName": "Abbott", "class": "INDUSTRY"}, "briefTitle": "A Study to Evaluate the Safety and Effectiveness of Three Asoprisnil Doses in the Treatment of Women With Endometriosis", "officialTitle": "A Phase II Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of J867 Administered in Patients With Endometriosis"}, "statusModule": {"statusVerifiedDate": "2008-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2000-05"}, "primaryCompletionDateStruct": {"date": "2001-07", "type": "ACTUAL"}, "completionDateStruct": {"date": "2001-07", "type": "ACTUAL"}, "studyFirstSubmitDate": "2005-09-08", "studyFirstSubmitQcDate": "2005-09-08", "studyFirstPostDateStruct": {"date": "2005-09-12", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2008-05-27", "lastUpdatePostDateStruct": {"date": "2008-05-29", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "Cynthia Mattia-Goldberg", "oldOrganization": "Abbott"}, "leadSponsor": {"name": "Abbott", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The objective of this study is to determine the safety and effectiveness of three doses of asoprisnil, compared to placebo, in the treatment of women with endometriosis.", "detailedDescription": "Endometriosis, the presence of endometrial tissue outside the uterus, is a progressive, estrogen-dependent disease that occurs in menstruating women of reproductive age. Although all major endometriosis therapies are effective for the treatment of pain, no single treatment is superior to others in terms of efficacy. The major drawbacks of the current medical therapies are severe side effects such as hot flushes and osteoporosis. The objective of this study is to determine the safety and efficacy of asoprisnil 5, 10, and 25 mg tablets, compared to placebo, administered daily for 12 weeks to women with endometriosis, by assessing whether asoprisnil administration diminishes the pelvic pain, dysmenorrhea, dyspareunia, excessive bleeding, and analgesic use associated with this disease and lessens the subjects' perceived pain symptoms. Otherwise healthy women with surgically confirmed endometriosis will be enrolled."}, "conditionsModule": {"conditions": ["Endometriosis"], "keywords": ["Pelvic pain", "Dysmenorrhea", "Dyspareunia", "Infertility", "Asoprisnil"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 130, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "1", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Asoprisnil"]}, {"label": "2", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Asoprisnil"]}, {"label": "3", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Asoprisnil"]}, {"label": "4", "type": "PLACEBO_COMPARATOR", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Asoprisnil", "description": "5mg Tablet, oral Daily for 12 weeks", "armGroupLabels": ["1"]}, {"type": "DRUG", "name": "Asoprisnil", "description": "10 mg Tablet, oral Daily for 12 weeks", "armGroupLabels": ["2"]}, {"type": "DRUG", "name": "Asoprisnil", "description": "25 mg Tablet, oral Daily for 12 weeks", "armGroupLabels": ["3"]}, {"type": "DRUG", "name": "Placebo", "description": "Tablet, oral Daily for 12 weeks", "armGroupLabels": ["4"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Pain (dysmenorrhea, dyspareunia, pelvic pain) measured by daily diary", "timeFrame": "Mean change from baseline to Months 1, 2, 3"}], "secondaryOutcomes": [{"measure": "Global efficacy question", "timeFrame": "Final visit"}, {"measure": "Pain (dysmenorrhea, dyspareunia, pelvic pain) pelvic tenderness and induration evaluated during office visits using modified Biberoglu and Behrman grading scale", "timeFrame": "Each monthly visit"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Surgically confirmed endometriosis\n* History of menstrual cycles between 26 and 32 days\n* Otherwise in good health\n* Age 18-40 years, inclusive\n* Subject had pain graded at Screening and Day 1 according to a scale suggested by Biberoglu and Berhman5 in at least one of the following categories:\n\n  1. moderate or severe pelvic pain not related to menstruation, OR\n  2. moderate or severe dysmenorrhea, OR\n  3. moderate or severe pelvic tenderness elicited on pelvic examination accompanied by non-menstrual pelvic pain.\n* Subject agrees to double barrier method of contraception\n\nExclusion Criteria:\n\n* Any abnormal lab or procedure result the study-doctor considers important\n* History of undiagnosed uterine bleeding or gynecological disorder\n* Severe reaction(s) to hormone therapy\n* History of osteoporosis or other metabolic bone disease\n* Subject currently breast feeding", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "40 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Director", "affiliation": "Abbott", "role": "STUDY_CHAIR"}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}, {"id": "D017699", "term": "Pelvic Pain"}, {"id": "D004412", "term": "Dysmenorrhea"}, {"id": "D004414", "term": "Dyspareunia"}, {"id": "D007246", "term": "Infertility"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}, {"id": "D010146", "term": "Pain"}, {"id": "D009461", "term": "Neurologic Manifestations"}, {"id": "D012816", "term": "Signs and Symptoms"}, {"id": "D013568", "term": "Pathological Conditions, Signs and Symptoms"}, {"id": "D008599", "term": "Menstruation Disturbances"}, {"id": "D010335", "term": "Pathologic Processes"}, {"id": "D005832", "term": "Genital Diseases, Male"}, {"id": "D012735", "term": "Sexual Dysfunction, Physiological"}, {"id": "D052801", "term": "Male Urogenital Diseases"}, {"id": "D020018", "term": "Sexual Dysfunctions, Psychological"}, {"id": "D001523", "term": "Mental Disorders"}]}, "interventionBrowseModule": {"meshes": [{"id": "C488516", "term": "asoprisnil"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT01283724", "orgStudyIdInfo": {"id": "13788"}, "secondaryIdInfos": [{"id": "2009-017169-53", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Bayer", "class": "INDUSTRY"}, "briefTitle": "Visanne Study to Assess Safety in Adolescents", "officialTitle": "A Multi-center, Open Label, Single-arm Study to Investigate the Safety and Efficacy of Daily Oral Administration of 2 mg Dienogest Tablets for the Treatment of Endometriosis in Adolescents Over a Treatment Period of 52 Weeks", "acronym": "VISADO"}, "statusModule": {"statusVerifiedDate": "2015-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2011-03"}, "primaryCompletionDateStruct": {"date": "2013-03", "type": "ACTUAL"}, "completionDateStruct": {"date": "2014-06", "type": "ACTUAL"}, "studyFirstSubmitDate": "2011-01-25", "studyFirstSubmitQcDate": "2011-01-25", "studyFirstPostDateStruct": {"date": "2011-01-26", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-08-12", "lastUpdatePostDateStruct": {"date": "2015-08-13", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Bayer", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "A clinical trial which was designed to demonstrate the safety and efficacy of Visanne (approved in endometriosis for adults) in the adolescent population."}, "conditionsModule": {"conditions": ["Endometriosis"], "keywords": ["Endometriosis", "DEXA", "Adolescent", "Safety", "Efficacy", "Post-menarche"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 111, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Dienogest (Visanne, BAY86-5258)", "type": "EXPERIMENTAL", "description": "Subjects received Dienogest tablet orally at a dosage of 2 mg once daily over a period of 52 weeks.", "interventionNames": ["Drug: Dienogest (Visanne, BAY86-5258)"]}], "interventions": [{"type": "DRUG", "name": "Dienogest (Visanne, BAY86-5258)", "description": "Subjects received Dienogest tablet orally at a dosage of 2 mg once daily over a period of 52 weeks.", "armGroupLabels": ["Dienogest (Visanne, BAY86-5258)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Relative change in bone mineral density (BMD) of the lumbar spine as assessed by dual energy X-ray absorptiometry (DEXA)", "description": "The measurement of BMD by DEXA is the gold standard method for investigation of bone mass.", "timeFrame": "Baseline week 52"}], "secondaryOutcomes": [{"measure": "Relative Percent Change From Baseline in Whole Body Bone Mineral Density (BMD) at Week 52 Assessed by Dual-Energy X-ray Absorptiometry (DEXA)", "description": "The measurement of BMD by DEXA is the gold standard method for investigation of bone mass.", "timeFrame": "Baseline, Week 52"}, {"measure": "Change From Baseline in Spinal Lumbar Vertebrae 2 to 4 (L2-L4) Z scores at week 52", "description": "Based on the BMD values and the weight, the age-normalized percentiles (Z-scores) were determined to allow for comparison with historical control groups. \"No difference\" in comparison with the historical control groups was defined as a Z-score between '-0.5' and '0.5', a lower value was defined as a value below '-0.5', and a higher value above '0.5'.", "timeFrame": "Baseline, Week 52"}, {"measure": "Change From Baseline in Whole Body Z-scores at Week 52", "description": "Based on the BMD values and the weight, the age-normalized percentiles (Z-scores) were determined to allow for comparison with historical control groups. \"No difference\" in comparison with the historical control groups was defined as a Z-score between '-0.5' and '0.5', a lower value was defined as a value below '-0.5', and a higher value above '0.5'.", "timeFrame": "Baseline, Week 52"}, {"measure": "Percentage of Responders at Week 24", "description": "Responders were defined as subjects with reduction in pain intensity from baseline of at least 30% in the Visual Analog Scale (VAS) at Week 24. VAS consisted of a 100 unit long straight line, with verbal anchors at either end, representing a continuum of pain intensity. One end of the line with 0 score as \"absence of pain\" while the other end of the line with 100 score as \"unbearable pain\". The assessment of pelvic pain on a VAS was done once every 4 weeks till the end of the treatment (Week 52).", "timeFrame": "Week 24"}, {"measure": "Change From Baseline in Pelvic Pain Over 52 Weeks Using Modified Biberoglu and Behrman Severity Profile", "description": "The cardinal symptoms inlcuded in the modified Biberoglu and Behrman severity profile were pelvic pain, dysmenorrhea, and dyspareunia (the latter only in those subjects having sexual intercourse), analyzed at all visits with symptom severity scores from 0 (none) to 3 (severe). Negative value for change from baseline indicates an improvement. In the listed categories, 'N' signifies those subjects who were evaluable for this measure.", "timeFrame": "Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52"}, {"measure": "Change From Baseline in Dysmenorrhea Over 52 Weeks Using Modified Biberoglu and Behrman Severity Profile", "description": "The cardinal symptoms inlcuded in the modified Biberoglu and Behrman severity profile were pelvic pain, dysmenorrhea, and dyspareunia (the latter only in those subjects having sexual intercourse), analyzed at all visits with symptom severity scores from 0 (none) to 3 (severe). Negative value for change from baseline indicates an improvement. In the listed categories, 'N' signifies those subjects who were evaluable for this measure.", "timeFrame": "Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52"}, {"measure": "Percentage of Subjects With Pelvic Pain Over 52 Weeks Using Modified Biberoglu and Behrman Severity Profile", "description": "In order to judge therapeutic effectiveness and to compare subjects' complaints, a severity profile score of pelvic pain was assessed using a rating scale: missing; 0 = none; 1 = mild (occasional pelvic discomfort); 2 = moderate (noticeable discomfort for most of the cycle); 3 = severe (requires strong analgesics and persists during cycle when not menstruating) based on the subject's self-assessment of symptoms. In the listed categories, 'N' signifies those subjects who were evaluable for this measure.", "timeFrame": "Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52"}, {"measure": "Percentage of Subjects With Dysmenorrhea Over 52 Weeks Using Modified Biberoglu and Behrman Severity Profile", "description": "In order to judge therapeutic effectiveness and to compare subjects' complaints, a severity profile score of dysmenorrhea was assessed using a rating scale: missing; 0 = none; 1 = mild (some loss in work efficiency); 2 = moderate (in bed part of day, occasional loss of work efficiency); 3 = severe (in bed one or more days, incapacitation) based on the subject's self-assessment of symptoms. In the listed categories, 'N' signifies those subjects who were evaluable for this measure.", "timeFrame": "Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52"}, {"measure": "Percentage of Subjects With Dyspareunia Over 52 Weeks Using Modified Biberoglu and Behrman Severity Profile", "description": "In order to judge therapeutic effectiveness and to compare subjects' complaints, a severity profile score of dyspareunia was assessed using a rating scale.", "timeFrame": "Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52"}, {"measure": "Percentage of Subjects With Pelvic Tenderness Over 52 Weeks Using Modified Biberoglu and Behrman Severity Profile", "description": "In order to judge therapeutic effectiveness and to compare subjects' complaints, a severity profile score of pelvic tenderness was assessed using a rating scale: missing; 0 = none (no pain during intercourse); 1 = mild (minimal tenderness on palpation); 2 = moderate (extensive tenderness on palpation); 3 = severe (unable to palpate because of tenderness) based on the gynecological palpation by the attending physician. In the listed categories, 'N' signifies those subjects who were evaluable for this measure.", "timeFrame": "Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52"}, {"measure": "Percentage of Subjects With Induration Over 52 Weeks Using Modified Biberoglu and Behrman Severity Profile", "description": "In order to judge therapeutic effectiveness and to compare subjects' complaints, a severity profile score of induration was assessed using a rating scale: missing; 0 = none (no pain during intercourse); 1 = mild (uterus freely mobile, induration in the cul-de-sac); 2 = moderate (thickened and indurated adnexa and cul-de-sac, restricted uterine mobility); 3 = severe (nodular adnexa and cul-de-sac, uterus frequently frozen) based on the gynecological palpation by the attending physician. In the listed categories, 'N' signifies those subjects who were evaluable for this measure.", "timeFrame": "Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52"}, {"measure": "Percentage of Subjects With Clinical Global Impression (CGI) Scores - Assessed by the Investigator", "description": "The investigator rating scale used in this study was based on the validated CGI scale, which is widely used as a simple tool to assess the overall effect of treatments. The investigator or a sub-investigator rated the total improvement according to the following scale: Score 1 = very much improved; Score 2 =much improved; Score 3 = minimally improved; Score 4 = no change; Score 5 = minimally worse; Score 6 = much worse; Score 7 = very much worse. None of the subjects reported Score 7. In the listed categories, 'N' signifies those subjects who were evaluable for this measure.", "timeFrame": "Weeks 12, 24, 36, and 52"}, {"measure": "Percentage of Subjects With Clinical Global Impression (CGI) Scores -Assessed by the Subject", "description": "The subject rating scale used in this study was based on the validated CGI scale, which is widely used as a simple tool to assess the overall effect of treatments. The subject was asked to rate her satisfaction with the study treatment according to the following scale: Score 1 = very much satisfied; Score 2 = much satisfied; Score 3 = minimally satisfied; Score 4 = neither satisfied nor dissatisfied; Score 5 =minimally dissatisfied; Score 6 = much dissatisfied; Score 7 = very much dissatisfied. In the listed categories, 'N' signifies those subjects who were evaluable for this measure.", "timeFrame": "Weeks 12, 24, 36, 40, and 52"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Female adolescents after menarche (12 - less than 18 years of age) at screening. For Finland: Adolescents aged 12 - 14 years old who present with clinical features of endometriosis will only be enrolled into the study if their diagnosis of endometriosis has been confirmed by laparoscopy.\n* Dysmenorrhea of at least moderate intensity, with or without chronic pelvic pain, for at least 2 cycles in the previous 4 months and one of the following conditions:\n\n  * Clinically suspected endometriosis based on the presence of pelvic pain incompletely relieved by non steroidal anti-inflammatory drugs and/or oral contraceptives\n  * Any abdominal pain associated with ultrasound findings suggestive of endometriosis (abdominal, vaginal or rectal; only after additional specific consent and assent)\n  * Failure of surgical treatment for endometriosis (with cyclic or chronic pelvic pain of at least 4 months duration postsurgery)\n  * Threshold for endometriosis-associated pelvic pain (EAPP) score: at least 30 on a 100 units visual analog scale retrospectively evaluated at screening for the last 4 weeks\n\nExclusion Criteria:\n\n* Absence of endometriosis at laparoscopy\n* Previous application of hormonal agents including oral contraceptives within 2 months, progestins, danazol within 3 months, and Gonadotropin Releasing Hormone (GnRH) agonists within 6 months prior to start of treatment\n* Chronic pelvic pain that might be related to genitourinary disease or to chronic or recurrent gastrointestinal disease, including irritable bowel syndrome (defined as a disease characterized by pain relieved by defecation and irregular defecation patterns lasting at least 3 months)\n* Clinically established need for primary surgical treatment of endometriosis", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "12 Years", "maximumAge": "17 Years", "stdAges": ["CHILD"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Bayer Study Director", "affiliation": "Bayer", "role": "STUDY_DIRECTOR"}], "locations": [{"city": "Sankt Pölten", "state": "Lower Austria", "zip": "3100", "country": "Austria", "geoPoint": {"lat": 48.20762, "lon": 15.63725}}, {"city": "Graz", "state": "Styria", "zip": "8044", "country": "Austria", "geoPoint": {"lat": 47.06733, "lon": 15.44197}}, {"city": "Linz", "state": "Upper Austria", "zip": "4020", "country": "Austria", "geoPoint": {"lat": 48.30639, "lon": 14.28611}}, {"city": "Graz", "zip": "8010", "country": "Austria", "geoPoint": {"lat": 47.06733, "lon": 15.44197}}, {"city": "Innsbruck", "zip": "6020", "country": "Austria", "geoPoint": {"lat": 47.26266, "lon": 11.39454}}, {"city": "Vienna", "zip": "1060", "country": "Austria", "geoPoint": {"lat": 48.20849, "lon": 16.37208}}, {"city": "Vienna", "zip": "1090", "country": "Austria", "geoPoint": {"lat": 48.20849, "lon": 16.37208}}, {"city": "Brno", "zip": "625 00", "country": "Czechia", "geoPoint": {"lat": 49.19522, "lon": 16.60796}}, {"city": "České Budějovice", "zip": "37001", "country": "Czechia", "geoPoint": {"lat": 48.97447, "lon": 14.47434}}, {"city": "Písek", "zip": "39701", "country": "Czechia", "geoPoint": {"lat": 49.3088, "lon": 14.1475}}, {"city": "Prague", "zip": "13000", "country": "Czechia", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"city": "Prague", "country": "Czechia", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"city": "Espoo", "zip": "02100", "country": "Finland", "geoPoint": {"lat": 60.2052, "lon": 24.6522}}, {"city": "Helsinki", "zip": "00100", "country": "Finland", "geoPoint": {"lat": 60.16952, "lon": 24.93545}}, {"city": "Turku", "zip": "20100", "country": "Finland", "geoPoint": {"lat": 60.45148, "lon": 22.26869}}, {"city": "Angers", "zip": "49033", "country": "France", "geoPoint": {"lat": 47.47156, "lon": -0.55202}}, {"city": "Le Kremlin-Bicêtre", "zip": "94275", "country": "France", "geoPoint": {"lat": 48.81471, "lon": 2.36073}}, {"city": "Paris", "zip": "75018", "country": "France", "geoPoint": {"lat": 48.85341, "lon": 2.3488}}, {"city": "Rouen", "zip": "76031", "country": "France", "geoPoint": {"lat": 49.44313, "lon": 1.09932}}, {"city": "Erlangen", "state": "Bavaria", "zip": "91054", "country": "Germany", "geoPoint": {"lat": 49.59099, "lon": 11.00783}}, {"city": "Hamburg", "state": "City state of Hamburg", "zip": "20357", "country": "Germany", "geoPoint": {"lat": 53.55073, "lon": 9.99302}}, {"city": "Oldenburg", "state": "Lower Saxony", "zip": "26121", "country": "Germany", "geoPoint": {"lat": 53.14118, "lon": 8.21467}}, {"city": "Westerstede", "state": "Lower Saxony", "zip": "26655", "country": "Germany", "geoPoint": {"lat": 53.25682, "lon": 7.92737}}, {"city": "Münster", "state": "North Rhine-Westphalia", "zip": "48149", "country": "Germany", "geoPoint": {"lat": 51.96236, "lon": 7.62571}}, {"city": "Lübeck", "state": "Schleswig-Holstein", "zip": "23538", "country": "Germany", "geoPoint": {"lat": 53.86893, "lon": 10.68729}}, {"city": "Berlin", "state": "State of Berlin", "zip": "10117", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"city": "Berlin", "state": "State of Berlin", "zip": "12200", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"city": "Berlin", "state": "State of Berlin", "zip": "12587", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"city": "Berlin", "state": "State of Berlin", "zip": "13509", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"city": "Berlin", "state": "State of Berlin", "zip": "14129", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"city": "Berlin", "state": "State of Berlin", "zip": "14193", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"city": "Benidorm", "state": "Alicante", "zip": "03503", "country": "Spain", "geoPoint": {"lat": 38.53816, "lon": -0.13098}}, {"city": "Vigo", "state": "Pontevedra", "zip": "36209", "country": "Spain", "geoPoint": {"lat": 42.23282, "lon": -8.72264}}, {"city": "Seville", "state": "Sevilla", "zip": "41013", "country": "Spain", "geoPoint": {"lat": 37.38283, "lon": -5.97317}}, {"city": "Valencia", "state": "Valencia", "zip": "46017", "country": "Spain", "geoPoint": {"lat": 39.47391, "lon": -0.37966}}, {"city": "Seville", "zip": "41014", "country": "Spain", "geoPoint": {"lat": 37.38283, "lon": -5.97317}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "Click here to find information about studies related to Bayer Healthcare products conducted in Europe", "url": "http://www.clinicaltrialsregister.eu"}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C023635", "term": "dienogest"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT01301417", "orgStudyIdInfo": {"id": "RETROPRESS"}, "organization": {"fullName": "novoGI", "class": "INDUSTRY"}, "briefTitle": "Data Collection of Patients Treated With the ColonRing™ for the Creation of Circular Compression Anastomosis", "officialTitle": "a RETROspective Data Collection of comPRESSion Anastomosis Using the ColonRing ™", "acronym": "RETROPRESS"}, "statusModule": {"statusVerifiedDate": "2013-06", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2011-02"}, "primaryCompletionDateStruct": {"date": "2011-08", "type": "ACTUAL"}, "completionDateStruct": {"date": "2011-08", "type": "ACTUAL"}, "studyFirstSubmitDate": "2011-02-20", "studyFirstSubmitQcDate": "2011-02-22", "studyFirstPostDateStruct": {"date": "2011-02-23", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2013-06-04", "lastUpdatePostDateStruct": {"date": "2013-06-05", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "novoGI", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The proposed study is a post marketing, observational, retrospective data collection intended to gather and record data on patients treated with the ColonRing™ device in routine clinical practice at a single center. The data will assist in further evaluating the performance of the ColonRing™ device in regards to the creation of a colorectal anastomosis.\n\nHypothesis:The performance of the ColonRing™, determined by the rate of complications, will be within the acceptable range reported in the literature for alternative treatment modalities."}, "conditionsModule": {"conditions": ["Diverticulum, Colon", "Colorectal Neoplasms", "Crohn Disease", "Colitis, Ulcerative", "Colostomy", "Ileostomy - Stoma", "Rectal Prolapse", "Intestinal Polyposis", "Lymphoma", "Endometriosis", "Intestinal Volvulus"], "keywords": ["Compression Anastomosis"]}, "designModule": {"studyType": "OBSERVATIONAL", "designInfo": {"timePerspective": "RETROSPECTIVE"}, "enrollmentInfo": {"count": 171, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "ColonRing™", "description": "Adult Patients who underwent a laparoscopic or open colorectal resection with the creation of an anastomosis using the ColonRing™ in routine clinical practice", "interventionNames": ["Device: ColonRing™"]}], "interventions": [{"type": "DEVICE", "name": "ColonRing™", "description": "Creation of a circular Compression Anastomosis", "armGroupLabels": ["ColonRing™"], "otherNames": ["Compression Anaqstomosis Ring™(CAR™)27"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Rate of anastomotic leakage", "description": "The primary study outcome is the rate of anastomotic leakage. Anastomotic leakage is defined as evidence of a defect in the intestinal wall integrity at the anastomotic site leading to a communication between the intra and extra luminal compartments.", "timeFrame": "2-mo post-op"}], "secondaryOutcomes": [{"measure": "Rate of other device related complications and measures during hospitalization and post procedure:", "description": "The following complications will be examined for relation to the device:\n\nBleeding. Stricture (either clinical evidence of a stricture or the inability to pass a 12 mm sigmoidoscope through the anastomosis in a procedure that does not include a diversion). Septic complication (including wound infection, pelvic infection, peritonitis, abscess).\n\nReadmission, re-operation, death within two months of the procedure. Extra colonic complications (including urinary infection, urinary retention, DVT, pneumonitis, pulmonary embolism, cardiac, injury to other organs - e.g. spleen, ureter)", "timeFrame": "2-mo post-op"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patient was \\> 18 years old at time of procedure\n* Patient underwent an open or laparoscopic colorectal procedure with the creation of an anastomosis using the ColonRing™\n* Patient treated in routine clinical practice following marketing clearance of the device within the cleared intended use\n* Patient underwent his/her first follow-up visit within two months post-surgery\n\nExclusion Criteria:\n\n* No exclusion criteria have been defined for this data collection.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"], "studyPopulation": "Adult Patients who underwent a laparoscopic or open colorectal resection with the creation of an anastomosis using the ColonRing™ in routine clinical practice.", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"overallOfficials": [{"name": "Eran Choman, Msc", "affiliation": "novoGI", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Southern Regional Medical Center", "city": "Riverdale", "state": "Georgia", "zip": "30274", "country": "United States", "geoPoint": {"lat": 33.57261, "lon": -84.41326}}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004241", "term": "Diverticulum, Colon"}, {"id": "D015179", "term": "Colorectal Neoplasms"}, {"id": "D003424", "term": "Crohn Disease"}, {"id": "D003093", "term": "Colitis, Ulcerative"}, {"id": "D012005", "term": "Rectal Prolapse"}, {"id": "D044483", "term": "Intestinal Polyposis"}, {"id": "D008223", "term": "Lymphoma"}, {"id": "D004715", "term": "Endometriosis"}, {"id": "D045822", "term": "Intestinal Volvulus"}], "ancestors": [{"id": "D004240", "term": "Diverticulum"}, {"id": "D000076385", "term": "Diverticular Diseases"}, {"id": "D005759", "term": "Gastroenteritis"}, {"id": "D005767", "term": "Gastrointestinal Diseases"}, {"id": "D004066", "term": "Digestive System Diseases"}, {"id": "D020763", "term": "Pathological Conditions, Anatomical"}, {"id": "D013568", "term": "Pathological Conditions, Signs and Symptoms"}, {"id": "D007414", "term": "Intestinal Neoplasms"}, {"id": "D005770", "term": "Gastrointestinal Neoplasms"}, {"id": "D004067", "term": "Digestive System Neoplasms"}, {"id": "D009371", "term": "Neoplasms by Site"}, {"id": "D009369", "term": "Neoplasms"}, {"id": "D003108", "term": "Colonic Diseases"}, {"id": "D007410", "term": "Intestinal Diseases"}, {"id": "D012002", "term": "Rectal Diseases"}, {"id": "D015212", "term": "Inflammatory Bowel Diseases"}, {"id": "D003092", "term": "Colitis"}, {"id": "D056887", "term": "Pelvic Organ Prolapse"}, {"id": "D011391", "term": "Prolapse"}, {"id": "D009370", "term": "Neoplasms by Histologic Type"}, {"id": "D008232", "term": "Lymphoproliferative Disorders"}, {"id": "D008206", "term": "Lymphatic Diseases"}, {"id": "D006425", "term": "Hemic and Lymphatic Diseases"}, {"id": "D007160", "term": "Immunoproliferative Disorders"}, {"id": "D007154", "term": "Immune System Diseases"}, {"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}, {"id": "D007415", "term": "Intestinal Obstruction"}, {"id": "D014102", "term": "Torsion Abnormality"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT06543550", "orgStudyIdInfo": {"id": "CS.001"}, "organization": {"fullName": "Bio Meds Pharmaceutica Ltda", "class": "INDUSTRY"}, "briefTitle": "Comparison Between the Effects of Implantable Gestrinone and Oral Dienogest in the Treatment of Endometriosis", "officialTitle": "Comparison Between the Effects of Implantable Gestrinone and Oral Dienogest in the Treatment of Endometriosis: Randomized Controlled Clinical Trial"}, "statusModule": {"statusVerifiedDate": "2024-08", "overallStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2024-07-30", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2025-09", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2025-10", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2024-07-31", "studyFirstSubmitQcDate": "2024-08-04", "studyFirstPostDateStruct": {"date": "2024-08-09", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2024-08-04", "lastUpdatePostDateStruct": {"date": "2024-08-09", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Bio Meds Pharmaceutica Ltda", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "This study aims to evaluate the effects of therapy with implantable Gestrinone compared to oral Dienogest in relieving complaints related to endometriosis.", "detailedDescription": "Patient recruitment will be carried out on a prospective basis and based on the group of patients from the private Medical Clinics in 4 cities (Campina Grande - Pb, São Paulo - SP, São José dos Campos - SP and Brasilia-DF). The study will include 70 adult female patients of menstrual age, pre-menopause (18 to 45 years old), who seek medical treatment to alleviate complaints related to endometriosis. The selected patients will be randomly allocated into two groups, in a 1:1 ratio. Control Group (n=35) - treatment with oral Dienogest - and Test Group (n=35) - Implantation of Gestrinone pellets. Follow-up visits will be scheduled after 1 week and 1, 3, 6, 9 and 12 months of initiation of therapy. Therapies will be compared with respect to the effects on the severity of dysmenorrhea, dyspareunia and non-cyclical pelvic pain (Verbal Scale and Visual Analogue Scale), level of Uterine Bleeding assessed by PBAC, systemic effects (hormonal, hepatic, lipid profile, cell concentration red, clotting factor - assessed through blood tests), endometriosis lesions, endometrial thickness (transvaginal ultrasound), body composition (bioimpendance test), quality of life (EHP30) and sexual function (female sexual function index ) - FSFI. Data analysis will be carried out using validated statistical software. Chi-square or Fisher\\&amp;#39;s exact tests will be used to compare qualitative variables, while independent t-tests will be used to compare quantitative variables between the two groups. Analysis of variance with repeated measures will be used to compare the average pain intensity over time. The significance level for all tests will be p\\&lt;0.05."}, "conditionsModule": {"conditions": ["Endometriosis"], "keywords": ["Endometriosis", "Implantable Gestrinone", "Dienogest"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "SINGLE", "whoMasked": ["OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 70, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Implantable Gestrinone", "type": "EXPERIMENTAL", "description": "Implantation of Gestrinone pellets - Eligible patients will undergo implantation of Gestrinone pellets (bio meds Brasil, Florianópolis, Brazil) subcutaneously, in the gluteal region, using aseptic technique under local anesthesia. Patients will use 1.6mg/kg of weight to treat endometriosis. A second implantation procedure will be performed 6 months after the first, allowing evaluation of the effects of the therapy over a period of 12 months.", "interventionNames": ["Drug: Implantable gestrinone"]}, {"label": "Oral Dienogest", "type": "ACTIVE_COMPARATOR", "description": "Patients will receive the medication to be administered orally at 2mg daily for 12 months.", "interventionNames": ["Drug: Oral Dienogest"]}], "interventions": [{"type": "DRUG", "name": "Implantable gestrinone", "description": "1.6mg/kg of weight of gestrinone in pellets (bio meds Brasil, Florianópolis, Brazil) subcutaneously, in the gluteal region.", "armGroupLabels": ["Implantable Gestrinone"], "otherNames": ["Gestrinone pellet"]}, {"type": "DRUG", "name": "Oral Dienogest", "description": "Administered orally at 2 mg daily", "armGroupLabels": ["Oral Dienogest"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Evaluation of dysmenorrhea severity", "description": "Patients will be instructed to rate the intensity of dysmenorrhea at each visit after the first month of treatment, using a modified verbal scale from 0 to 3, as suggested by Biberoglu and Behrman. Patients should also rate the intensity of the symptoms using a 100 mm visual analogue scale.", "timeFrame": "Pre-treatment, 1 week, 1, 3 , 6 and 12 months"}, {"measure": "Evaluation of dyspareunia severity", "description": "Patients will be instructed to rate the intensity of deep dyspareunia at each visit after the first month of treatment, using a modified verbal scale from 0 to 3, as suggested by Biberoglu and Behrman. Patients should also rate the intensity of the symptoms using a 100 mm visual analogue scale.", "timeFrame": "Pre-treatment, 1 week, 1, 3 , 6 and 12 months"}, {"measure": "Evaluation of non-cyclical pelvic pain severity", "description": "Patients will be instructed to rate the intensity of pelvic pain (outside the menstrual period), at each visit after the first month of treatment, using a modified verbal scale from 0 to 3, as suggested by Biberoglu and Behrman. Patients should also rate the intensity of the symptoms using a 100 mm visual analogue scale.", "timeFrame": "Pre-treatment, 1 week, 1, 3 , 6 and 12 months"}, {"measure": "Evaluation of endometriosis foci regression", "description": "Assessment of endometriosis lesions and endometrial thickness on Transvaginal Ultrasound with bowel preparation and/or MRI of the pelvis with bowel preparation - All patients will be referred, at pre-treatment and at 6 and 12 month visits, to undergo transvaginal ultrasound to assess the presence or absence of endometriotic lesions, in addition to controlling the thickness of the endometrium.", "timeFrame": "Pre-treatment, 6 and 12 months"}], "secondaryOutcomes": [{"measure": "Evaluation of quality of life", "description": "The evaluation of the influence of complaints on the impact of endometriosis on patients' quality of life will be carried out using the EHP-30 questionnaires validated for the Portuguese language.", "timeFrame": "Pre-treatment, 6 and 12 months"}, {"measure": "Evaluation of adverse effect", "description": "Evaluation of sings and symptoms. In addition, it will be evaluated at each visit the serum levels of Estradiol, Sex Hormone Binding Globulin (SHBG), Progesterone, Total and free Testosterone, FSH, LH, Hepatic transaminase (TGO, TGP, GGT), Total cholesterol and fractions, Triglycerides, Red cell concentration, Coagulation factors , Homocysteine, Fibrinogen, DHT.", "timeFrame": "Pre-treatment, 1 week, 1, 3 , 6 and 12 months"}, {"measure": "Evaluation of abnormal Uterine Bleeding (AUB)", "description": "The duration and intensity of menstrual flow will be recorded pre-treatment and at each visit after the first month of treatment. Abnormal uterine bleeding will be defined as a PBAC (Pictorial blood loss assessment chart) score greater than 100.", "timeFrame": "Pre-treatment, 1, 3 , 6 and 12 months"}, {"measure": "Evaluation of sexual function", "description": "The assessment of sexual function (desire, excitement, lubrication, orgasm, satisfaction and pain) will be carried out through the application of the Female Sexual Function Index.", "timeFrame": "Pre-treatment, 1 week, 1, 3 , 6 and 12 months"}, {"measure": "Evaluation of body composition", "description": "Body composition will be assessed using the tetrapolar Bioimpedance test with the Indoby device (weight, percentage of lean mass and fat mass)", "timeFrame": "Pre-treatment, 3 , 6 and 12 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Adult female patients of menstrual age, pre-menopause (18 to 45 years old), who seek medical treatment to alleviate complaints related to endometriosis, who are not undergoing other therapies to treat them.\n* Patients must have a diagnosis of Grade 1 or 2 endometriosis assessed by imaging tests (ultrasound with bowel preparation and/or MRI of the pelvis with bowel preparation)14, have a BMI of up to 25kg/m2, and weigh between 50 and 70kg.\n\nExclusion Criteria:\n\n* Pregnant patients (supporting test must be presented)\n* Breastfeeding women, using other hormonal contraceptive methods or copper or silver IUDs, who have polycystic ovaries, and/or hyperandrogenism.\n* Patients using medications that may interfere with androgen metabolism within 4 weeks of screening or during the study.\n* Patients with a history of liver disease, cardiovascular disease (myocardial infarction, unstable angina or heart failure), active hepatitis, liver neoplasia or renal failure\n* Patient who are scheduled for surgical treatment during the study period.", "healthyVolunteers": false, "sex": "FEMALE", "genderBased": true, "genderDescription": "Female", "minimumAge": "18 Years", "maximumAge": "45 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "André V. A. Florentino, Dr", "role": "CONTACT", "phone": "+55 83 982001868", "email": "f.andrevinicius@gmail.com"}], "locations": [{"facility": "Gm Ignacio Atividade Medica LTDA", "status": "RECRUITING", "city": "Brasília", "state": "Federal District", "zip": "70.390-150", "country": "Brazil", "contacts": [{"name": "Giovanna M. Ignácio, Dr", "role": "CONTACT", "phone": "+55 61 99266-1706", "email": "dragiovannamilhomem@gmail.com"}, {"name": "Giovanna M. Ignácio, Dr", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": -15.77972, "lon": -47.92972}}, {"facility": "Instituto Longevite Servicos Medicos LTDA", "status": "RECRUITING", "city": "Campina Grande", "state": "Paraíba", "zip": "58.400-506", "country": "Brazil", "contacts": [{"name": "André V.A. Florentino, Dr", "role": "CONTACT", "phone": "+55 83 3077-8928", "email": "f.andrevinicius@gmail.com"}, {"name": "f.andrevinicius@gmail.com V.A. Florentino, Dr", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": -7.23056, "lon": -35.88111}}, {"facility": "Jpml Clinica Medica LTDA", "status": "RECRUITING", "city": "São José dos Campos", "state": "São Paulo", "zip": "12.246-876", "country": "Brazil", "contacts": [{"name": "Juliana P.M. Lima, Dr", "role": "CONTACT", "phone": "+55 12 3939-6436", "email": "drajulianapaola@gmail.com"}, {"name": "Juliana P.M. Lima, Dr", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": -23.17944, "lon": -45.88694}}, {"facility": "Dra Juliana Bicca Endocrinologia e Medicina Funcional LTDA", "status": "RECRUITING", "city": "São Paulo", "zip": "05.688-021", "country": "Brazil", "contacts": [{"name": "Juliana B. Nascimento, Dr", "role": "CONTACT", "phone": "+55 11 3027-1500", "email": "drajubicca@gmail.com"}, {"name": "Juliana B. Nascimento, Dr", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": -23.5475, "lon": -46.63611}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO", "description": "The patients data will be reported together in the final report."}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C023635", "term": "dienogest"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT04665414", "orgStudyIdInfo": {"id": "Schäfer_Adenomyosis"}, "organization": {"fullName": "University Hospital Muenster", "class": "OTHER"}, "briefTitle": "Diagnosis of Adenomyosis Using Ultrasound, Elastography and MRI", "officialTitle": "Value of Transvaginal Ultrasound, Transvaginal Sonographic Elastography and MRI for the Diagnosis of Adenomyosis"}, "statusModule": {"statusVerifiedDate": "2021-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2017-09-29", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2021-01-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2021-01-31", "type": "ACTUAL"}, "studyFirstSubmitDate": "2020-12-04", "studyFirstSubmitQcDate": "2020-12-10", "studyFirstPostDateStruct": {"date": "2020-12-11", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2021-04-26", "lastUpdatePostDateStruct": {"date": "2021-04-28", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Dr. med. Sebastian Daniel Schäfer", "investigatorTitle": "Head of Gynecology", "investigatorAffiliation": "University Hospital Muenster"}, "leadSponsor": {"name": "University Hospital Muenster", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "comparison of transvaginal ultrasound, transvaginal ultrasound elastography and MRI for the diagnosis of adenomyosis in patients receiving hysterectomy afterwards"}, "conditionsModule": {"conditions": ["Endometriosis", "Adenomyosis"], "keywords": ["adenomyosis", "endometriosis", "MRI", "elastography", "ultrasound", "hysterectomy"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "COHORT", "timePerspective": "PROSPECTIVE"}, "enrollmentInfo": {"count": 103, "type": "ACTUAL"}}, "armsInterventionsModule": {"interventions": [{"type": "DIAGNOSTIC_TEST", "name": "MRI", "description": "preoperative MRI"}, {"type": "DIAGNOSTIC_TEST", "name": "transvaginal ultrasound", "description": "preoperative transvaginal ultrasound"}, {"type": "DIAGNOSTIC_TEST", "name": "transvaginal ultrasound elastography", "description": "preoperative transvaginal ultrasound elastography"}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "sensitivity MRI", "description": "sensitivity MRI", "timeFrame": "through study completion, an average of 1 year"}, {"measure": "specificity MRI", "description": "specificity MRI", "timeFrame": "through study completion, an average of 1 year"}, {"measure": "sensitivity transvaginal ultrasound", "description": "sensitivity transvaginal ultrasound", "timeFrame": "through study completion, an average of 1 year"}, {"measure": "specificity transvaginal ultrasound", "description": "specificity transvaginal ultrasound", "timeFrame": "through study completion, an average of 1 year"}, {"measure": "sensitivity transvaginal ultrasound elastography", "description": "sensitivity transvaginal ultrasound elastography", "timeFrame": "through study completion, an average of 1 year"}, {"measure": "specificity transvaginal ultrasound elastography", "description": "specificity transvaginal ultrasound elastography", "timeFrame": "through study completion, an average of 1 year"}, {"measure": "sensitivity intraoperative ENZIAN FA", "description": "sensitivity intraoperative ENZIAN FA", "timeFrame": "through study completion, an average of 1 year"}, {"measure": "specificity intraoperative ENZIAN FA", "description": "specificity intraoperative ENZIAN FA", "timeFrame": "through study completion, an average of 1 year"}], "secondaryOutcomes": [{"measure": "sensitivity and specificity of single sonographic or MRI criteria or combinations thereof", "description": "sensitivity and specificity of single sonographic or MRI criteria or combinations thereof", "timeFrame": "through study completion, an average of 1 year"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* dysmenorrhea\n* dyspareunia\n* non cyclic lower abdominal pain\n* hypermenorrhea\n* menometrorrhaghia\n* pain while compressing the Uterus during gyn exam\n* Patient wants to participate\n* Patient will receive hysterectomy\n\nExclusion Criteria:\n\n* Patient declines to participate\n* contraindications against MRI\n* contraindications against ultrasound\n* minor\n* cannot give informed consent\n* no hysterectomy planned", "healthyVolunteers": false, "sex": "FEMALE", "genderBased": true, "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"], "studyPopulation": "all patients in accordance with eligibility criteria registered to receive hysterectomy because of a suspicion of adenomyosis according to the above criteria", "samplingMethod": "PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"overallOfficials": [{"name": "se D Schaefer, MD PhD", "affiliation": "University Hospital Muenster, Germany", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "University Hospital Muenster", "city": "Münster", "state": "North Rhine-Westphalia", "zip": "48149", "country": "Germany", "geoPoint": {"lat": 51.96236, "lon": 7.62571}}]}, "ipdSharingStatementModule": {"ipdSharing": "UNDECIDED", "description": "data will be shared upon reasonable request according to regulations"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}, {"id": "D062788", "term": "Adenomyosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}, {"id": "D014591", "term": "Uterine Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT00437658", "orgStudyIdInfo": {"id": "NBI-56418-0603"}, "organization": {"fullName": "AbbVie", "class": "INDUSTRY"}, "briefTitle": "Elagolix Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatment of Endometriosis", "officialTitle": "A Phase II, Randomized, Double-blind, Active-controlled Study to Assess the Safety and Efficacy of NBI-56418 in Subjects With Endometriosis", "acronym": "PETAL"}, "statusModule": {"statusVerifiedDate": "2018-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2006-12-11", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2008-11-24", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-11-24", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-02-16", "studyFirstSubmitQcDate": "2007-02-16", "studyFirstPostDateStruct": {"date": "2007-02-21", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2018-08-09", "resultsFirstSubmitQcDate": "2018-09-14", "resultsFirstPostDateStruct": {"date": "2018-10-12", "type": "ACTUAL"}, "dispFirstSubmitDate": "2012-02-24", "dispFirstSubmitQcDate": "2012-02-24", "dispFirstPostDateStruct": {"date": "2012-02-28", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2018-09-14", "lastUpdatePostDateStruct": {"date": "2018-10-12", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AbbVie", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false, "isUsExport": false}, "descriptionModule": {"briefSummary": "This study is designed to assess the effects of elagolix versus subcutaneous depot medroxyprogesterone acetate (DMPA-SC; also known as depo-provera) on bone mineral density (BMD) during treatment for 24 weeks with a subsequent 24-week post-treatment period."}, "conditionsModule": {"conditions": ["Endometriosis"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 252, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Elagolix 75 mg BID", "type": "EXPERIMENTAL", "description": "Participants received elagolix 75 mg orally twice a day (BID) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12.", "interventionNames": ["Drug: Elagolix", "Drug: Placebo to DMPA-SC"]}, {"label": "Elagolix 150 mg QD", "type": "EXPERIMENTAL", "description": "Participants received elagolix 150 mg orally once a day (QD) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12.", "interventionNames": ["Drug: Elagolix", "Drug: Placebo to DMPA-SC"]}, {"label": "DMPA-SC", "type": "ACTIVE_COMPARATOR", "description": "Participants received placebo to elagolix orally once a day for 24 weeks and DMPA-SC 104 mg by subcutaneous injection at weeks 1 and 12.", "interventionNames": ["Drug: Subcutaneous depot medroxyprogesterone acetate (DMPA-SC)", "Drug: Placebo to Elagolix"]}], "interventions": [{"type": "DRUG", "name": "Elagolix", "description": "Provided as tablets for oral administration", "armGroupLabels": ["Elagolix 150 mg QD", "Elagolix 75 mg BID"], "otherNames": ["NBI-56418", "Orilissa™"]}, {"type": "DRUG", "name": "Subcutaneous depot medroxyprogesterone acetate (DMPA-SC)", "description": "Provided for subcutaneous injection in a prefilled syringe, 104 mg/0.65 mL per syringe.", "armGroupLabels": ["DMPA-SC"], "otherNames": ["depo-subQ provera 104™"]}, {"type": "DRUG", "name": "Placebo to Elagolix", "description": "Matching placebo tablets for oral administration", "armGroupLabels": ["DMPA-SC"]}, {"type": "DRUG", "name": "Placebo to DMPA-SC", "description": "Matching placebo for subcutaneous injection in a pre-filled syringe", "armGroupLabels": ["Elagolix 150 mg QD", "Elagolix 75 mg BID"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Percent Change From Baseline in Bone Mineral Density of the Spine at Week 24", "description": "Bone mineral density (BMD) was measured by dual X-ray absorptiometry (DXA). The percent change from baseline in spine and femur BMD at week 24 was assessed using a one-way analysis of variance (ANOVA) model. The absence of significant bone loss was supported if the lower bounds of the confidence intervals for the mean percent change in BMD were ≥ -2.2% for both the spine and femur at week 24.", "timeFrame": "Baseline and week 24"}, {"measure": "Percent Change From Baseline in Bone Mineral Density of the Femur at Week 24", "description": "Bone mineral density (BMD) was measured by dual X-ray absorptiometry (DXA). The percent change from baseline in spine and femur BMD at week 24 was assessed using a one-way analysis of variance (ANOVA) model. The absence of significant bone loss was supported if the lower bounds of the confidence intervals for the mean percent change in BMD were ≥ -2.2% for both the spine and femur at week 24.", "timeFrame": "Baseline and week 24"}], "secondaryOutcomes": [{"measure": "Percent Change From Baseline in Bone Mineral Density of the Spine at Weeks 12 and 48", "description": "Bone mineral density (BMD) was measured by dual X-ray absorptiometry (DXA). The percent change from baseline in BMD was assessed using a one-way analysis of variance (ANOVA) model.", "timeFrame": "Baseline and weeks 12 and 48"}, {"measure": "Percent Change From Baseline in Bone Mineral Density of the Femur at Weeks 12 and 48", "description": "Bone mineral density (BMD) was measured by dual X-ray absorptiometry (DXA). The percent change from baseline in BMD was assessed using a one-way analysis of variance (ANOVA) model.", "timeFrame": "Baseline and weeks 12 and 48"}, {"measure": "Change From Baseline in N-telopeptide at Weeks 12, 24 and 48", "description": "Blood samples to determine N-telopeptide concentrations were analyzed by a central laboratory using an enzyme-linked immunosorbent assay (ELISA). Change from baseline in N-telopeptide was analyzed using a one-way ANOVA model.", "timeFrame": "Baseline and weeks 12, 24 and 48"}, {"measure": "Percentage of Participants With a Response in the Dysmenorrhea Component of the Composite Pelvic Signs and Symptoms Score (CPSSS) at Week 24", "description": "The CPSSS consists of 5 components that address dysmenorrhea (pain during menstruation), dyspareunia (painful intercourse), non-menstrual pelvic pain, pelvic tenderness, and pelvic induration (hardening). Each component was scored on a scale of 0 to 3 (0 = absent, 1 = mild, 2 = moderate, and 3 = severe). The dysmenorrhea score was based on the participant's response to the question \"Have you had painful menstruation during the last 28 days?\".\n\nParticipants were classified as responders for dysmenorrhea if they reported a 1 point or greater reduction (improvement) from baseline.", "timeFrame": "Baseline and week 24"}, {"measure": "Percentage of Participants With a Response in the Non-menstrual Pelvic Pain Component of the CPSSS at Week 24", "description": "The CPSSS consists of 5 components that address dysmenorrhea, dyspareunia, non-menstrual pelvic pain, pelvic tenderness, and pelvic induration. Each component was scored on a scale of 0 to 3 (0 = absent, 1 = mild, 2 = moderate, and 3 = severe). The non-menstrual pelvic pain score was based on participant's response to the question \"Have you had pelvic pain during the last 28 days?\" Participants were classified as responders for non-menstrual pelvic pain if they reported a 1 point or greater reduction (improvement) from baseline.", "timeFrame": "Baseline and week 24"}, {"measure": "Percentage of Participants With a Response in the Dysmenorrhea Component of the CPSSS Over Time", "description": "The CPSSS consists of 5 components that address dysmenorrhea, dyspareunia, non-menstrual pelvic pain, pelvic tenderness, and pelvic induration. Each component was scored on a scale of 0 to 3 (0 = absent, 1 = mild, 2 = moderate, and 3 = severe). The dysmenorrhea score was based on the participant's response to the question \"Have you had painful menstruation during the last 28 days?\".\n\nParticipants were classified as responders for dysmenorrhea if they reported a 1 point or greater reduction (improvement) from baseline.", "timeFrame": "Baseline and weeks 4, 8, 12, 16, 20, 24, 28, 36, and 48"}, {"measure": "Percentage of Participants With a Response in the Non-menstrual Pelvic Pain Component of the CPSSS Over Time", "description": "The CPSSS consists of 5 components that address dysmenorrhea, dyspareunia, non-menstrual pelvic pain, pelvic tenderness, and pelvic induration. Each component was scored on a scale of 0 to 3 (0 = absent, 1 = mild, 2 = moderate, and 3 = severe). The non-menstrual pelvic pain score was based on participant's response to the question \"Have you had pelvic pain during the last 28 days?\" Participants were classified as responders for non-menstrual pelvic pain if they reported a 1 point or greater reduction (improvement) from baseline.", "timeFrame": "Baseline and weeks 4, 8, 12, 16, 20, 24, 28, 36, and 48"}, {"measure": "Change From Baseline in Total CPSSS During the Treatment Period", "description": "The CPSSS consists of 5 components that address dysmenorrhea, dyspareunia, non-menstrual pelvic pain, pelvic tenderness, and pelvic induration. Each component was scored on a scale of 0 to 3 (0 = absent, 1 = mild, 2 = moderate, and 3 = severe).\n\nDysmenorrhea, dyspareunia, and nonmenstrual pelvic pain scores are based on the participant's assessment, pelvic tenderness and induration were assessed by the investigator based on findings associated with a pelvic examination.\n\nThe total CPSSS has a maximum possible value of 15 (total score range: 0 to 15, where a lower score indicates less signs and symptoms of endometriosis or better functioning).\n\nChange from baseline was analyzed using a mixed-effects repeated measures (MERM) analysis of covariance model which included fixed effects for treatment, time, treatment-by-time interaction, a random effect for patient, and terms for baseline value and the baseline-by-time interaction.", "timeFrame": "Baseline and weeks 4, 8, 12, 16, 20, and 24"}, {"measure": "Change From Baseline in Total CPSSS Excluding Dyspareunia During the Treatment Period", "description": "The CPSSS consists of 5 components that address dysmenorrhea, dyspareunia, non-menstrual pelvic pain, pelvic tenderness, and pelvic induration. Each component was scored on a scale of 0 to 3 (0 = absent, 1 = mild, 2 = moderate, and 3 = severe).\n\nDysmenorrhea, dyspareunia, and nonmenstrual pelvic pain scores are based on the participant's assessment, pelvic tenderness and induration were assessed by the investigator based on findings associated with a pelvic examination.\n\nThe total CPSSS excluding dyspareunia has a maximum possible value of 12 (total score range: 0 to 12, where a lower score indicates less signs and symptoms of endometriosis or better functioning).\n\nChange from baseline was analyzed using a mixed-effects repeated measures (MERM) analysis of covariance model which included fixed effects for treatment, time, treatment-by-time interaction, a random effect for patient, and terms for baseline value and the baseline-by-time interaction.", "timeFrame": "Baseline and weeks 4, 8, 12, 16, 20, and 24"}, {"measure": "Change From Baseline in Dysmenorrhea Component of the CPSSS During the Treatment Period", "description": "The CPSSS consists of 5 components that address dysmenorrhea, dyspareunia, non-menstrual pelvic pain, pelvic tenderness, and pelvic induration. Each component was scored on a scale of 0 to 3 (0 = absent, 1 = mild, 2 = moderate, and 3 = severe).\n\nThe dysmenorrhea score was based on the participant's response to the question \"Have you had painful menstruation during the last 28 days?\".\n\nChange from baseline was analyzed using a mixed-effects repeated measures (MERM) analysis of covariance model which included fixed effects for treatment, time, treatment-by-time interaction, a random effect for patient, and terms for baseline value and the baseline-by-time interaction.", "timeFrame": "Baseline and weeks 4, 8, 12, 16, 20, and 24"}, {"measure": "Change From Baseline in Dyspareunia Component of the CPSSS During the Treatment Period", "description": "The CPSSS consists of 5 components that address dysmenorrhea, dyspareunia, non-menstrual pelvic pain, pelvic tenderness, and pelvic induration. Each component was scored on a scale of 0 to 3 (0 = absent, 1 = mild, 2 = moderate, and 3 = severe).\n\nThe dyspareunia score was based on the participant's response to the question \"Have you had painful intercourse during the last 28 days?\" Change from baseline was analyzed using a mixed-effects repeated measures (MERM) analysis of covariance model which included fixed effects for treatment, time, treatment-by-time interaction, a random effect for patient, and terms for baseline value and the baseline-by-time interaction.", "timeFrame": "Baseline and weeks 4, 8, 12, 16, 20, and 24"}, {"measure": "Change From Baseline in Non-menstrual Pelvic Pain Component of the CPSSS During the Treatment Period", "description": "The CPSSS consists of 5 components that address dysmenorrhea, dyspareunia, non-menstrual pelvic pain, pelvic tenderness, and pelvic induration. Each component was scored on a scale of 0 to 3 (0 = absent, 1 = mild, 2 = moderate, and 3 = severe).\n\nThe non-menstrual pelvic pain score was based on participant's response to the question \"Have you had pelvic pain during the last 28 days?\".\n\nChange from baseline was analyzed using a mixed-effects repeated measures (MERM) analysis of covariance model which included fixed effects for treatment, time, treatment-by-time interaction, a random effect for patient, and terms for baseline value and the baseline-by-time interaction.", "timeFrame": "Baseline and weeks 4, 8, 12, 16, 20, and 24"}, {"measure": "Change From Baseline in Pelvic Tenderness Component of the CPSSS During the Treatment Period", "description": "The CPSSS consists of 5 components that address dysmenorrhea, dyspareunia, non-menstrual pelvic pain, pelvic tenderness, and pelvic induration. Each component was scored on a scale of 0 to 3 (0 = absent, 1 = mild, 2 = moderate, and 3 = severe).\n\nPelvic tenderness was assessed by the investigator based on findings associated with a pelvic examination.\n\nChange from baseline was analyzed using a mixed-effects repeated measures (MERM) analysis of covariance model which included fixed effects for treatment, time, treatment-by-time interaction, a random effect for patient, and terms for baseline value and the baseline-by-time interaction.", "timeFrame": "Baseline and weeks 4, 8, 12, 16, 20, and 24"}, {"measure": "Change From Baseline in Pelvic Induration Component of the CPSSS During the Treatment Period", "description": "The CPSSS consists of 5 components that address dysmenorrhea, dyspareunia, non-menstrual pelvic pain, pelvic tenderness, and pelvic induration. Each component was scored on a scale of 0 to 3 (0 = absent, 1 = mild, 2 = moderate, and 3 = severe).\n\nPelvic induration was assessed by the investigator based on findings associated with a pelvic examination.\n\nChange from baseline was analyzed using a mixed-effects repeated measures (MERM) analysis of covariance model which included fixed effects for treatment, time, treatment-by-time interaction, a random effect for patient, and terms for baseline value and the baseline-by-time interaction.", "timeFrame": "Baseline and weeks 4, 8, 12, 16, 20, and 24"}, {"measure": "Change From Baseline in in Monthly Peak Visual Analog Scale (VAS) for Pelvic Pain", "description": "The VAS for pelvic pain was used as an assessment of pain intensity. The VAS was a horizontal line on which the left extreme was labeled \"no pain\" and the right extreme was labeled \"worst pain ever felt\" scored on a scale from of 0 (no pain) to 100 (worst pain ever felt). Participants indicated the worst level of pain felt over a 24-hour period by ''ticking'' the horizontal line on their e-Diary at approximately the same time each day. Monthly peak VAS for pelvic pain was defined as the maximum VAS pain score reported for an individual participant from the previous visit to the day of the current scheduled visit.\n\nChange from baseline was analyzed using a mixed-effects repeated measures (MERM) analysis of covariance model which included fixed effects for treatment, time, treatment-by-time interaction, a random effect for patient, and terms for baseline value and the baseline-by-time interaction.", "timeFrame": "Baseline and weeks 4, 8, 12, 16, 20, and 24"}, {"measure": "Change From Baseline in in Monthly Mean Visual Analog Scale (VAS) for Pelvic Pain", "description": "The VAS for pelvic pain was used as an assessment of pain intensity. The VAS was a horizontal line on which the left extreme was labeled \"no pain\" and the right extreme was labeled \"worst pain ever felt\" scored on a scale from of 0 (no pain) to 100 (worst pain ever felt). Participants indicated the worst level of pain felt over a 24-hour period by ''ticking'' the horizontal line on their e-Diary at approximately the same time each day. Monthly mean VAS for pelvic pain defined as the average of all VAS pain scores reported for an individual participant from the previous visit to the day of the current scheduled visit.\n\nChange from baseline was analyzed using a mixed-effects repeated measures (MERM) analysis of covariance model which included fixed effects for treatment, time, treatment-by-time interaction, a random effect for patient, and terms for baseline value and the baseline-by-time interaction.", "timeFrame": "Baseline and weeks 4, 8, 12, 16, 20, and 24"}, {"measure": "Change From Baseline in Endometriosis Health Profile-5 (EHP-5) Pain Dimension", "description": "The EHP-5 is an instrument to measure health-related quality of life in women with endometriosis. The EHP-5 consists of two parts:\n\n* A core questionnaire consisting of five questions that measure the areas of pain, control and powerlessness, emotional well-being, social support, and self-image\n* A supplemental questionnaire consisting of six additional questions, five of which were recorded in this study: work, relationship with children, sexual intercourse, feelings about the medical profession and treatment.\n\nEach question was scored on a five point scale (Never = 0, Rarely = 25, Sometimes = 50, Often = 75, Always = 100), where 0 indicates the best health status and 100 worst health status. A negative change from baseline score indicates improvement in quality of life.", "timeFrame": "Baseline and weeks 4, 8, 12, 16, 20, and 24"}, {"measure": "Change From Baseline in EHP-5 Control and Powerlessness Dimension", "description": "The EHP-5 is an instrument to measure health-related quality of life in women with endometriosis. The EHP-5 consists of two parts:\n\n* A core questionnaire consisting of five questions that measure the areas of pain, control and powerlessness, emotional well-being, social support, and self-image\n* A supplemental questionnaire consisting of six additional questions, five of which were recorded in this study: work, relationship with children, sexual intercourse, feelings about the medical profession and treatment.\n\nEach question was scored on a five point scale (Never = 0, Rarely = 25, Sometimes = 50, Often = 75, Always = 100), where 0 indicates the best health status and 100 worst health status. A negative change from baseline score indicates improvement in quality of life.", "timeFrame": "Baseline and weeks 4, 8, 12, 16, 20, and 24"}, {"measure": "Change From Baseline in EHP-5 Emotional Well-being Dimension", "description": "The EHP-5 is an instrument to measure health-related quality of life in women with endometriosis. The EHP-5 consists of two parts:\n\n* A core questionnaire consisting of five questions that measure the areas of pain, control and powerlessness, emotional well-being, social support, and self-image\n* A supplemental questionnaire consisting of six additional questions, five of which were recorded in this study: work, relationship with children, sexual intercourse, feelings about the medical profession and treatment.\n\nEach question was scored on a five point scale (Never = 0, Rarely = 25, Sometimes = 50, Often = 75, Always = 100), where 0 indicates the best health status and 100 worst health status. A negative change from baseline score indicates improvement in quality of life.", "timeFrame": "Baseline and weeks 4, 8, 12, 16, 20, and 24"}, {"measure": "Change From Baseline in EHP-5 Social Support Dimension", "description": "The EHP-5 is an instrument to measure health-related quality of life in women with endometriosis. The EHP-5 consists of two parts:\n\n* A core questionnaire consisting of five questions that measure the areas of pain, control and powerlessness, emotional well-being, social support, and self-image\n* A supplemental questionnaire consisting of six additional questions, five of which were recorded in this study: work, relationship with children, sexual intercourse, feelings about the medical profession and treatment.\n\nEach question was scored on a five point scale (Never = 0, Rarely = 25, Sometimes = 50, Often = 75, Always = 100), where 0 indicates the best health status and 100 worst health status. A negative change from baseline score indicates improvement in quality of life.", "timeFrame": "Baseline and weeks 4, 8, 12, 16, 20, and 24"}, {"measure": "Change From Baseline in EHP-5 Self Image Dimension", "description": "The EHP-5 is an instrument to measure health-related quality of life in women with endometriosis. The EHP-5 consists of two parts:\n\n* A core questionnaire consisting of five questions that measure the areas of pain, control and powerlessness, emotional well-being, social support, and self-image\n* A supplemental questionnaire consisting of six additional questions, five of which were recorded in this study: work, relationship with children, sexual intercourse, feelings about the medical profession and treatment.\n\nEach question was scored on a five point scale (Never = 0, Rarely = 25, Sometimes = 50, Often = 75, Always = 100), where 0 indicates the best health status and 100 worst health status. A negative change from baseline score indicates improvement in quality of life.", "timeFrame": "Baseline and weeks 4, 8, 12, 16, 20, and 24"}, {"measure": "Change From Baseline in EHP-5 Work Dimension", "description": "The EHP-5 is an instrument to measure health-related quality of life in women with endometriosis. The EHP-5 consists of two parts:\n\n* A core questionnaire consisting of five questions that measure the areas of pain, control and powerlessness, emotional well-being, social support, and self-image\n* A supplemental questionnaire consisting of six additional questions, five of which were recorded in this study: work, relationship with children, sexual intercourse, feelings about the medical profession and treatment.\n\nEach question was scored on a five point scale (Never = 0, Rarely = 25, Sometimes = 50, Often = 75, Always = 100), or Not Relevant (no score), where 0 indicates the best health status and 100 worst health status. A negative change from baseline score indicates improvement in quality of life.", "timeFrame": "Baseline and weeks 4, 8, 12, 16, 20, and 24"}, {"measure": "Change From Baseline in EHP-5 Relationship With Children Dimension", "description": "The EHP-5 is an instrument to measure health-related quality of life in women with endometriosis. The EHP-5 consists of two parts:\n\n* A core questionnaire consisting of five questions that measure the areas of pain, control and powerlessness, emotional well-being, social support, and self-image\n* A supplemental questionnaire consisting of six additional questions, five of which were recorded in this study: work, relationship with children, sexual intercourse, feelings about the medical profession and treatment.\n\nEach question was scored on a five point scale (Never = 0, Rarely = 25, Sometimes = 50, Often = 75, Always = 100), or Not Relevant (no score), where 0 indicates the best health status and 100 worst health status. A negative change from baseline score indicates improvement in quality of life.", "timeFrame": "Baseline and weeks 4, 8, 12, 16, 20, and 24"}, {"measure": "Change From Baseline in EHP-5 Intercourse Dimension", "description": "The EHP-5 is an instrument to measure health-related quality of life in women with endometriosis. The EHP-5 consists of two parts:\n\n* A core questionnaire consisting of five questions that measure the areas of pain, control and powerlessness, emotional well-being, social support, and self-image\n* A supplemental questionnaire consisting of six additional questions, five of which were recorded in this study: work, relationship with children, sexual intercourse, feelings about the medical profession and treatment.\n\nEach question was scored on a five point scale (Never = 0, Rarely = 25, Sometimes = 50, Often = 75, Always = 100), or Not Relevant (no score), where 0 indicates the best health status and 100 worst health status. A negative change from baseline score indicates improvement in quality of life.", "timeFrame": "Baseline and weeks 4, 8, 12, 16, 20, and 24"}, {"measure": "Change From Baseline in EHP-5 Medical Profession Dimension", "description": "The EHP-5 is an instrument to measure health-related quality of life in women with endometriosis. The EHP-5 consists of two parts:\n\n* A core questionnaire consisting of five questions that measure the areas of pain, control and powerlessness, emotional well-being, social support, and self-image\n* A supplemental questionnaire consisting of six additional questions, five of which were recorded in this study: work, relationship with children, sexual intercourse, feelings about the medical profession and treatment.\n\nEach question was scored on a five point scale (Never = 0, Rarely = 25, Sometimes = 50, Often = 75, Always = 100), or Not Relevant (no score), where 0 indicates the best health status and 100 worst health status. A negative change from baseline score indicates improvement in quality of life.", "timeFrame": "Baseline and weeks 4, 8, 12, 16, 20, and 24"}, {"measure": "Change From Baseline in EHP-5 Treatment Dimension", "description": "The EHP-5 is an instrument to measure health-related quality of life in women with endometriosis. The EHP-5 consists of two parts:\n\n* A core questionnaire consisting of five questions that measure the areas of pain, control and powerlessness, emotional well-being, social support, and self-image\n* A supplemental questionnaire consisting of six additional questions, five of which were recorded in this study: work, relationship with children, sexual intercourse, feelings about the medical profession and treatment.\n\nEach question was scored on a five point scale (Never = 0, Rarely = 25, Sometimes = 50, Often = 75, Always = 100), or Not Relevant (no score), where 0 indicates the best health status and 100 worst health status. A negative change from baseline score indicates improvement in quality of life.", "timeFrame": "Baseline and weeks 4, 8, 12, 16, 20, and 24"}, {"measure": "Percentage of Participants Using Analgesics During the Treatment Phase", "description": "Analgesic use was collected as part of concomitant medications on a case report form that was administered at each scheduled visit.", "timeFrame": "24 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Be female, aged 18 to 49 years, inclusive\n* Have a total CPSSS of ≥ 6 at screening and baseline (Day 1) in the following categories: dysmenorrhea, dyspareunia, nonmenstrual pelvic pain, pelvic tenderness and induration. The total score must include a total of at least 2 in each of the categories of dysmenorrhea and nonmenstrual pelvic pain.\n* Have had a diagnosis of endometriosis made following laparoscopic visualization of the disease within 8 years of the start of screening with recurrent or persistent symptoms.\n* Have documented negative mammogram results within 12 months of screening if over the age of 40 years.\n* Have menstrual cycles (28 days ±5 days). Assessment of cycle duration should be based on observations in the absence of drugs or conditions that are known to affect the cycle (e.g., oral contraceptives, leuprolide, pregnancy).\n* Have a Body Mass Index (BMI) between 18 and 36 kg/m², inclusive.\n* Agree to use two forms of nonhormonal contraception (e.g. condom with spermicide) during the study.\n\nExclusion Criteria:\n\n* Are currently receiving gonadotropin-releasing hormone (GnRH) agonist, GnRH antagonist, danazol, or have received any of these agents within 6 months of the start of screening.\n* Are currently receiving subcutaneous medroxyprogesterone acetate (DMPA-SC) or intramuscular medroxyprogesterone acetate (DMPA-IM) or have received any of these agents within 3 months of the start of screening.\n* Have been nonresponsive to GnRH agonist or antagonist therapy for the management of endometriosis.\n* Are currently using hormonal contraception or other forms of hormonal therapy or received such treatment within 1 month of the start of screening.\n* Have had surgical treatment for endometriosis (laparoscopy) within 1 month of the start of screening.\n* Have had a hysterectomy or bilateral oophorectomy.\n* Have had prior treatment with NBI-56418.\n* Have uterine fibroids or other pelvic lesions ≥ 5 cm in diameter\n* Have any of the following abnormal cervical smear results at screening (based on the 2001 Bethesda System):\n\n  * Benign endometrial cells (BEC) present, provided subject has irregular uterine bleeding or is over 40 years old\n  * Atypical squamous cells of undetermined significance (ASC-US) present, and human papilloma virus (HPV) reflex testing is positive for high risk types or the testing outcome is unknown\n  * Atypical squamous cells present, and high-grade squamous intraepithelial lesion (ASC-H) cannot be excluded\n  * Atypical glandular cells of uncertain significance (AGUS/AGC): not otherwise specified (NOS), favor neoplasia (FN), favor endocervical, or favor endometrial origin types\n  * Low-grade squamous intraepithelial lesion (LSIL) present\n  * High-grade squamous intraepithelial lesion (HSIL) present\n  * Adenocarcinoma in situ (AIS) / malignant cells present\n* Have BMD with either lumbar spine or femur T-scores below -1.5 at screening as determined by the central DXA facility or have history of pathologic or compression fractures.\n* Have been pregnant within 6 months of screening or currently breast feeding\n* Are using systemic steroids on a chronic or regular basis within 3 months\n* Have unstable medical condition or chronic disease\n* Have chronic pelvic pain that is not caused by endometriosis", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "49 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "AbbVie Inc.", "affiliation": "AbbVie", "role": "STUDY_DIRECTOR"}]}, "ipdSharingStatementModule": {"ipdSharing": "UNDECIDED"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "This study consisted of a 24-week treatment period and a 24-week post-treatment period. Participants were randomized in a 1:1:1 ratio to one of three treatment groups.", "recruitmentDetails": "Participants were randomized at 58 centers in the United States.", "groups": [{"id": "FG000", "title": "Elagolix 150 mg QD", "description": "Participants received elagolix 150 mg orally once a day (QD) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "FG001", "title": "Elagolix 75 mg BID", "description": "Participants received elagolix 75 mg orally twice a day (BID) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "FG002", "title": "DMPA-SC", "description": "Participants received placebo to elagolix orally once a day for 24 weeks and DMPA-SC 104 mg by subcutaneous injection at weeks 1 and 12."}], "periods": [{"title": "Treatment Period (24 Weeks)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "84"}, {"groupId": "FG001", "numSubjects": "84"}, {"groupId": "FG002", "numSubjects": "84"}]}, {"type": "Received Study Drug", "achievements": [{"groupId": "FG000", "numSubjects": "84"}, {"groupId": "FG001", "numSubjects": "84"}, {"groupId": "FG002", "numSubjects": "84"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "56"}, {"groupId": "FG001", "numSubjects": "62"}, {"groupId": "FG002", "numSubjects": "51"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "28"}, {"groupId": "FG001", "numSubjects": "22"}, {"groupId": "FG002", "numSubjects": "33"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "7"}, {"groupId": "FG002", "numSubjects": "14"}]}, {"type": "Non-compliance", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "4"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "7"}, {"groupId": "FG002", "numSubjects": "7"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "3"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "5"}]}, {"type": "Sponsor/Investigator Decision", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}]}]}, {"title": "Post-treatment Period (24 Weeks)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "56"}, {"groupId": "FG001", "numSubjects": "62"}, {"groupId": "FG002", "numSubjects": "51"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "32"}, {"groupId": "FG001", "numSubjects": "54"}, {"groupId": "FG002", "numSubjects": "37"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "24"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "14"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Non-compliance", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "8"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "2"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Sponsor/Investigator Decision", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Elagolix 150 mg QD", "description": "Participants received elagolix 150 mg orally once a day (QD) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "BG001", "title": "Elagolix 75 mg BID", "description": "Participants received elagolix 75 mg orally twice a day (BID) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "BG002", "title": "DMPA-SC", "description": "Participants received placebo to elagolix orally once a day for 24 weeks and DMPA-SC 104 mg by subcutaneous injection at weeks 1 and 12."}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "84"}, {"groupId": "BG001", "value": "84"}, {"groupId": "BG002", "value": "84"}, {"groupId": "BG003", "value": "252"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "32.4", "spread": "7.5"}, {"groupId": "BG001", "value": "31.4", "spread": "6.1"}, {"groupId": "BG002", "value": "30.9", "spread": "6.3"}, {"groupId": "BG003", "value": "31.6", "spread": "6.7"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "84"}, {"groupId": "BG001", "value": "84"}, {"groupId": "BG002", "value": "84"}, {"groupId": "BG003", "value": "252"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Asian", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "2"}]}, {"title": "Black", "measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "10"}, {"groupId": "BG003", "value": "26"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "68"}, {"groupId": "BG001", "value": "70"}, {"groupId": "BG002", "value": "65"}, {"groupId": "BG003", "value": "203"}]}, {"title": "Hispanic", "measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "6"}, {"groupId": "BG003", "value": "18"}]}, {"title": "American Indian or Alaska Native, Caucasian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "1"}]}, {"title": "Black, Caucasian", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "1"}]}, {"title": "Caucasian, Hispanic", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "1"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Percent Change From Baseline in Bone Mineral Density of the Spine at Week 24", "description": "Bone mineral density (BMD) was measured by dual X-ray absorptiometry (DXA). The percent change from baseline in spine and femur BMD at week 24 was assessed using a one-way analysis of variance (ANOVA) model. The absence of significant bone loss was supported if the lower bounds of the confidence intervals for the mean percent change in BMD were ≥ -2.2% for both the spine and femur at week 24.", "populationDescription": "Participants who received at least one dose (i.e., one tablet or injection) of study drug (safety analysis set) with available BMD data at both time points", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "percent change", "timeFrame": "Baseline and week 24", "groups": [{"id": "OG000", "title": "Elagolix 150 mg QD", "description": "Participants received elagolix 150 mg orally once a day (QD) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG001", "title": "Elagolix 75 mg BID", "description": "Participants received elagolix 75 mg orally twice a day (BID) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG002", "title": "DMPA-SC", "description": "Participants received placebo to elagolix orally once a day for 24 weeks and DMPA-SC 104 mg by subcutaneous injection at weeks 1 and 12."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "55"}, {"groupId": "OG001", "value": "62"}, {"groupId": "OG002", "value": "50"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.11", "lowerLimit": "-0.70", "upperLimit": "0.48"}, {"groupId": "OG001", "value": "-1.29", "lowerLimit": "-1.85", "upperLimit": "-0.74"}, {"groupId": "OG002", "value": "-0.99", "lowerLimit": "-1.61", "upperLimit": "-0.37"}]}]}]}, {"type": "PRIMARY", "title": "Percent Change From Baseline in Bone Mineral Density of the Femur at Week 24", "description": "Bone mineral density (BMD) was measured by dual X-ray absorptiometry (DXA). The percent change from baseline in spine and femur BMD at week 24 was assessed using a one-way analysis of variance (ANOVA) model. The absence of significant bone loss was supported if the lower bounds of the confidence intervals for the mean percent change in BMD were ≥ -2.2% for both the spine and femur at week 24.", "populationDescription": "Participants who received at least one dose (i.e., one tablet or injection) of study drug (safety analysis set) with available BMD data at both time points", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "percent change", "timeFrame": "Baseline and week 24", "groups": [{"id": "OG000", "title": "Elagolix 150 mg QD", "description": "Participants received elagolix 150 mg orally once a day (QD) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG001", "title": "Elagolix 75 mg BID", "description": "Participants received elagolix 75 mg orally twice a day (BID) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG002", "title": "DMPA-SC", "description": "Participants received placebo to elagolix orally once a day for 24 weeks and DMPA-SC 104 mg by subcutaneous injection at weeks 1 and 12."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "56"}, {"groupId": "OG001", "value": "64"}, {"groupId": "OG002", "value": "51"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.47", "lowerLimit": "-0.96", "upperLimit": "0.02"}, {"groupId": "OG001", "value": "-1.02", "lowerLimit": "-1.48", "upperLimit": "-0.56"}, {"groupId": "OG002", "value": "-1.29", "lowerLimit": "-1.80", "upperLimit": "-0.77"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Bone Mineral Density of the Spine at Weeks 12 and 48", "description": "Bone mineral density (BMD) was measured by dual X-ray absorptiometry (DXA). The percent change from baseline in BMD was assessed using a one-way analysis of variance (ANOVA) model.", "populationDescription": "Participants who received at least one dose (i.e., one tablet or injection) of study drug (safety analysis set) with available BMD data at each time point", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "percent change", "timeFrame": "Baseline and weeks 12 and 48", "groups": [{"id": "OG000", "title": "Elagolix 150 mg QD", "description": "Participants received elagolix 150 mg orally once a day (QD) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG001", "title": "Elagolix 75 mg BID", "description": "Participants received elagolix 75 mg orally twice a day (BID) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG002", "title": "DMPA-SC", "description": "Participants received placebo to elagolix orally once a day for 24 weeks and DMPA-SC 104 mg by subcutaneous injection at weeks 1 and 12."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "84"}, {"groupId": "OG001", "value": "84"}, {"groupId": "OG002", "value": "84"}]}], "classes": [{"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "68"}, {"groupId": "OG001", "value": "68"}, {"groupId": "OG002", "value": "67"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.39", "lowerLimit": "-0.80", "upperLimit": "0.02"}, {"groupId": "OG001", "value": "-1.05", "lowerLimit": "-1.46", "upperLimit": "-0.64"}, {"groupId": "OG002", "value": "-0.57", "lowerLimit": "-0.98", "upperLimit": "-0.15"}]}]}, {"title": "Week 48", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "34"}, {"groupId": "OG001", "value": "56"}, {"groupId": "OG002", "value": "40"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.20", "lowerLimit": "-0.57", "upperLimit": "0.96"}, {"groupId": "OG001", "value": "-0.49", "lowerLimit": "-1.09", "upperLimit": "0.10"}, {"groupId": "OG002", "value": "-0.56", "lowerLimit": "-1.27", "upperLimit": "0.15"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Bone Mineral Density of the Femur at Weeks 12 and 48", "description": "Bone mineral density (BMD) was measured by dual X-ray absorptiometry (DXA). The percent change from baseline in BMD was assessed using a one-way analysis of variance (ANOVA) model.", "populationDescription": "Participants who received at least one dose (i.e., one tablet or injection) of study drug (safety analysis set) with available BMD data at each time point", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "percent change", "timeFrame": "Baseline and weeks 12 and 48", "groups": [{"id": "OG000", "title": "Elagolix 150 mg QD", "description": "Participants received elagolix 150 mg orally once a day (QD) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG001", "title": "Elagolix 75 mg BID", "description": "Participants received elagolix 75 mg orally twice a day (BID) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG002", "title": "DMPA-SC", "description": "Participants received placebo to elagolix orally once a day for 24 weeks and DMPA-SC 104 mg by subcutaneous injection at weeks 1 and 12."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "84"}, {"groupId": "OG001", "value": "84"}, {"groupId": "OG002", "value": "84"}]}], "classes": [{"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "67"}, {"groupId": "OG001", "value": "70"}, {"groupId": "OG002", "value": "68"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.63", "lowerLimit": "-1.02", "upperLimit": "-0.24"}, {"groupId": "OG001", "value": "-0.54", "lowerLimit": "-0.92", "upperLimit": "-0.17"}, {"groupId": "OG002", "value": "-0.77", "lowerLimit": "-1.16", "upperLimit": "-0.39"}]}]}, {"title": "Week 48", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "57"}, {"groupId": "OG002", "value": "39"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.38", "lowerLimit": "-1.10", "upperLimit": "0.33"}, {"groupId": "OG001", "value": "-0.86", "lowerLimit": "-1.41", "upperLimit": "-0.32"}, {"groupId": "OG002", "value": "-0.76", "lowerLimit": "-1.42", "upperLimit": "-0.10"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in N-telopeptide at Weeks 12, 24 and 48", "description": "Blood samples to determine N-telopeptide concentrations were analyzed by a central laboratory using an enzyme-linked immunosorbent assay (ELISA). Change from baseline in N-telopeptide was analyzed using a one-way ANOVA model.", "populationDescription": "Participants who received at least one dose (i.e., one tablet or injection) of study drug (safety analysis set) with available BMD data at each time point", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "nM bone collagen equivalents (BCE)", "timeFrame": "Baseline and weeks 12, 24 and 48", "groups": [{"id": "OG000", "title": "Elagolix 150 mg QD", "description": "Participants received elagolix 150 mg orally once a day (QD) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG001", "title": "Elagolix 75 mg BID", "description": "Participants received elagolix 75 mg orally twice a day (BID) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG002", "title": "DMPA-SC", "description": "Participants received placebo to elagolix orally once a day for 24 weeks and DMPA-SC 104 mg by subcutaneous injection at weeks 1 and 12."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "84"}, {"groupId": "OG001", "value": "84"}, {"groupId": "OG002", "value": "84"}]}], "classes": [{"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "70"}, {"groupId": "OG001", "value": "68"}, {"groupId": "OG002", "value": "63"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.94", "spread": "0.43"}, {"groupId": "OG001", "value": "0.57", "spread": "0.43"}, {"groupId": "OG002", "value": "0.74", "spread": "0.45"}]}]}, {"title": "Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "61"}, {"groupId": "OG002", "value": "49"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.23", "spread": "0.50"}, {"groupId": "OG001", "value": "-0.30", "spread": "0.48"}, {"groupId": "OG002", "value": "-0.24", "spread": "0.54"}]}]}, {"title": "Week 48", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "52"}, {"groupId": "OG002", "value": "36"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.28", "spread": "0.61"}, {"groupId": "OG001", "value": "-1.53", "spread": "0.48"}, {"groupId": "OG002", "value": "-1.39", "spread": "0.58"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With a Response in the Dysmenorrhea Component of the Composite Pelvic Signs and Symptoms Score (CPSSS) at Week 24", "description": "The CPSSS consists of 5 components that address dysmenorrhea (pain during menstruation), dyspareunia (painful intercourse), non-menstrual pelvic pain, pelvic tenderness, and pelvic induration (hardening). Each component was scored on a scale of 0 to 3 (0 = absent, 1 = mild, 2 = moderate, and 3 = severe). The dysmenorrhea score was based on the participant's response to the question \"Have you had painful menstruation during the last 28 days?\".\n\nParticipants were classified as responders for dysmenorrhea if they reported a 1 point or greater reduction (improvement) from baseline.", "populationDescription": "All randomized participants who received at least one oral dose of study drug, an initial subcutaneous injection, and either reported at least 7 e-diary visual analog scale (VAS) values or provided an assessment of either dysmenorrhea or non-menstrual pelvic pain at week 4 or later during the treatment phase (intent-to-treat) with available data.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline and week 24", "groups": [{"id": "OG000", "title": "Elagolix 150 mg QD", "description": "Participants received elagolix 150 mg orally once a day (QD) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG001", "title": "Elagolix 75 mg BID", "description": "Participants received elagolix 75 mg orally twice a day (BID) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG002", "title": "DMPA-SC", "description": "Participants received placebo to elagolix orally once a day for 24 weeks and DMPA-SC 104 mg by subcutaneous injection at weeks 1 and 12."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "65"}, {"groupId": "OG002", "value": "51"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "86.0"}, {"groupId": "OG001", "value": "73.8"}, {"groupId": "OG002", "value": "86.3"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "NON_INFERIORITY", "nonInferiorityComment": "Statistical non-inferiority was defined when the lower bound of the 95% 2-sided confidence interval for the difference between an elagolix dose and DMPA-SC in the response rate was no less than -20% at week 24 for both dysmenorrhea and non-menstrual pelvic pain.", "pValue": "0.9630", "statisticalMethod": "Pearson chi-squared", "paramType": "Difference in response rates", "paramValue": "-0.3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-13.4", "ciUpperLimit": "12.7", "estimateComment": "Difference in response rate = elogolix - DMPA-SC"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "NON_INFERIORITY", "nonInferiorityComment": "Statistical non-inferiority was defined when the lower bound of the 95% 2-sided confidence interval for the difference between an elagolix dose and DMPA-SC in the response rate was no less than -20% at week 24 for both dysmenorrhea and non-menstrual pelvic pain.", "pValue": "0.1010", "statisticalMethod": "Pearson chi-squared", "paramType": "Difference in response rates", "paramValue": "-12.4", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-26.7", "ciUpperLimit": "1.8", "estimateComment": "Difference in response rate = elogolix - DMPA-SC"}]}, {"type": "SECONDARY", "title": "Percentage of Participants With a Response in the Non-menstrual Pelvic Pain Component of the CPSSS at Week 24", "description": "The CPSSS consists of 5 components that address dysmenorrhea, dyspareunia, non-menstrual pelvic pain, pelvic tenderness, and pelvic induration. Each component was scored on a scale of 0 to 3 (0 = absent, 1 = mild, 2 = moderate, and 3 = severe). The non-menstrual pelvic pain score was based on participant's response to the question \"Have you had pelvic pain during the last 28 days?\" Participants were classified as responders for non-menstrual pelvic pain if they reported a 1 point or greater reduction (improvement) from baseline.", "populationDescription": "All randomized participants who received at least one oral dose of study drug, an initial subcutaneous injection, and either reported at least 7 e-diary visual analog scale (VAS) values or provided an assessment of either dysmenorrhea or non-menstrual pelvic pain at week 4 or later during the treatment phase (intent-to-treat) with available data.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline and week 24", "groups": [{"id": "OG000", "title": "Elagolix 150 mg QD", "description": "Participants received elagolix 150 mg orally once a day (QD) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG001", "title": "Elagolix 75 mg BID", "description": "Participants received elagolix 75 mg orally twice a day (BID) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG002", "title": "DMPA-SC", "description": "Participants received placebo to elagolix orally once a day for 24 weeks and DMPA-SC 104 mg by subcutaneous injection at weeks 1 and 12."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "65"}, {"groupId": "OG002", "value": "51"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "86.0"}, {"groupId": "OG001", "value": "76.9"}, {"groupId": "OG002", "value": "76.5"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "NON_INFERIORITY", "nonInferiorityComment": "Statistical non-inferiority was defined when the lower bound of the 95% 2-sided confidence interval for the difference between an elagolix dose and DMPA-SC in the response rate was no less than -20% at week 24 for both dysmenorrhea and non-menstrual pelvic pain.", "pValue": "0.2048", "statisticalMethod": "Pearson chi-squared", "paramType": "Difference in response rates", "paramValue": "9.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.2", "ciUpperLimit": "24.2", "estimateComment": "Difference in response rates = elagolix - DMPA-SC"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "NON_INFERIORITY", "nonInferiorityComment": "Statistical non-inferiority was defined when the lower bound of the 95% 2-sided confidence interval for the difference between an elagolix dose and DMPA-SC in the response rate was no less than -20% at week 24 for both dysmenorrhea and non-menstrual pelvic pain.", "pValue": "0.9544", "statisticalMethod": "Pearson chi-squared", "paramType": "Difference in response rates", "paramValue": "0.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-15.1", "ciUpperLimit": "16.0", "estimateComment": "Difference in response rates = elagolix - DMPA-SC"}]}, {"type": "SECONDARY", "title": "Percentage of Participants With a Response in the Dysmenorrhea Component of the CPSSS Over Time", "description": "The CPSSS consists of 5 components that address dysmenorrhea, dyspareunia, non-menstrual pelvic pain, pelvic tenderness, and pelvic induration. Each component was scored on a scale of 0 to 3 (0 = absent, 1 = mild, 2 = moderate, and 3 = severe). The dysmenorrhea score was based on the participant's response to the question \"Have you had painful menstruation during the last 28 days?\".\n\nParticipants were classified as responders for dysmenorrhea if they reported a 1 point or greater reduction (improvement) from baseline.", "populationDescription": "All randomized participants who received at least one oral dose of study drug, an initial subcutaneous injection, and either reported at least 7 e-diary VAS values or provided an assessment of either dysmenorrhea or non-menstrual pelvic pain at week 4 or later during the treatment phase (intent-to-treat) with available data at each time point.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline and weeks 4, 8, 12, 16, 20, 24, 28, 36, and 48", "groups": [{"id": "OG000", "title": "Elagolix 150 mg QD", "description": "Participants received elagolix 150 mg orally once a day (QD) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG001", "title": "Elagolix 75 mg BID", "description": "Participants received elagolix 75 mg orally twice a day (BID) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG002", "title": "DMPA-SC", "description": "Participants received placebo to elagolix orally once a day for 24 weeks and DMPA-SC 104 mg by subcutaneous injection at weeks 1 and 12."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "84"}, {"groupId": "OG001", "value": "84"}, {"groupId": "OG002", "value": "83"}]}], "classes": [{"title": "Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "81"}, {"groupId": "OG001", "value": "83"}, {"groupId": "OG002", "value": "83"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "75.3"}, {"groupId": "OG001", "value": "80.7"}, {"groupId": "OG002", "value": "74.7"}]}]}, {"title": "Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "75"}, {"groupId": "OG001", "value": "75"}, {"groupId": "OG002", "value": "73"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "84.0"}, {"groupId": "OG001", "value": "84.0"}, {"groupId": "OG002", "value": "79.5"}]}]}, {"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "71"}, {"groupId": "OG001", "value": "73"}, {"groupId": "OG002", "value": "67"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "73.2"}, {"groupId": "OG001", "value": "82.2"}, {"groupId": "OG002", "value": "82.1"}]}]}, {"title": "Week 16", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "64"}, {"groupId": "OG001", "value": "69"}, {"groupId": "OG002", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "87.5"}, {"groupId": "OG001", "value": "82.6"}, {"groupId": "OG002", "value": "91.2"}]}]}, {"title": "Week 20", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "60"}, {"groupId": "OG001", "value": "68"}, {"groupId": "OG002", "value": "54"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "81.7"}, {"groupId": "OG001", "value": "76.5"}, {"groupId": "OG002", "value": "83.3"}]}]}, {"title": "Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "65"}, {"groupId": "OG002", "value": "51"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "86.0"}, {"groupId": "OG001", "value": "73.8"}, {"groupId": "OG002", "value": "86.3"}]}]}, {"title": "Week 28", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "48"}, {"groupId": "OG001", "value": "61"}, {"groupId": "OG002", "value": "45"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "70.8"}, {"groupId": "OG001", "value": "57.4"}, {"groupId": "OG002", "value": "93.3"}]}]}, {"title": "Week 36", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "40"}, {"groupId": "OG001", "value": "56"}, {"groupId": "OG002", "value": "41"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "52.5"}, {"groupId": "OG001", "value": "44.6"}, {"groupId": "OG002", "value": "80.5"}]}]}, {"title": "Week 48", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "55"}, {"groupId": "OG002", "value": "39"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "63.6"}, {"groupId": "OG001", "value": "58.2"}, {"groupId": "OG002", "value": "66.7"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With a Response in the Non-menstrual Pelvic Pain Component of the CPSSS Over Time", "description": "The CPSSS consists of 5 components that address dysmenorrhea, dyspareunia, non-menstrual pelvic pain, pelvic tenderness, and pelvic induration. Each component was scored on a scale of 0 to 3 (0 = absent, 1 = mild, 2 = moderate, and 3 = severe). The non-menstrual pelvic pain score was based on participant's response to the question \"Have you had pelvic pain during the last 28 days?\" Participants were classified as responders for non-menstrual pelvic pain if they reported a 1 point or greater reduction (improvement) from baseline.", "populationDescription": "All randomized participants who received at least one oral dose of study drug, an initial subcutaneous injection, and either reported at least 7 e-diary VAS values or provided an assessment of either dysmenorrhea or non-menstrual pelvic pain at week 4 or later during the treatment phase (intent-to-treat) with available data at each time point.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline and weeks 4, 8, 12, 16, 20, 24, 28, 36, and 48", "groups": [{"id": "OG000", "title": "Elagolix 150 mg QD", "description": "Participants received elagolix 150 mg orally once a day (QD) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG001", "title": "Elagolix 75 mg BID", "description": "Participants received elagolix 75 mg orally twice a day (BID) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG002", "title": "DMPA-SC", "description": "Participants received placebo to elagolix orally once a day for 24 weeks and DMPA-SC 104 mg by subcutaneous injection at weeks 1 and 12."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "84"}, {"groupId": "OG001", "value": "84"}, {"groupId": "OG002", "value": "83"}]}], "classes": [{"title": "Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "81"}, {"groupId": "OG001", "value": "83"}, {"groupId": "OG002", "value": "83"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "74.1"}, {"groupId": "OG001", "value": "56.6"}, {"groupId": "OG002", "value": "68.7"}]}]}, {"title": "Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "75"}, {"groupId": "OG001", "value": "75"}, {"groupId": "OG002", "value": "73"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "82.7"}, {"groupId": "OG001", "value": "76.0"}, {"groupId": "OG002", "value": "82.2"}]}]}, {"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "71"}, {"groupId": "OG001", "value": "73"}, {"groupId": "OG002", "value": "67"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "74.6"}, {"groupId": "OG001", "value": "82.2"}, {"groupId": "OG002", "value": "71.6"}]}]}, {"title": "Week 16", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "64"}, {"groupId": "OG001", "value": "69"}, {"groupId": "OG002", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "82.8"}, {"groupId": "OG001", "value": "78.3"}, {"groupId": "OG002", "value": "70.2"}]}]}, {"title": "Week 20", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "60"}, {"groupId": "OG001", "value": "68"}, {"groupId": "OG002", "value": "54"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "81.7"}, {"groupId": "OG001", "value": "80.9"}, {"groupId": "OG002", "value": "75.9"}]}]}, {"title": "Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "65"}, {"groupId": "OG002", "value": "51"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "86.0"}, {"groupId": "OG001", "value": "76.9"}, {"groupId": "OG002", "value": "76.5"}]}]}, {"title": "Week 28", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "48"}, {"groupId": "OG001", "value": "61"}, {"groupId": "OG002", "value": "45"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "66.7"}, {"groupId": "OG001", "value": "60.7"}, {"groupId": "OG002", "value": "73.3"}]}]}, {"title": "Week 36", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "40"}, {"groupId": "OG001", "value": "56"}, {"groupId": "OG002", "value": "41"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "67.5"}, {"groupId": "OG001", "value": "60.7"}, {"groupId": "OG002", "value": "68.3"}]}]}, {"title": "Week 48", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "55"}, {"groupId": "OG002", "value": "39"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "66.7"}, {"groupId": "OG001", "value": "56.4"}, {"groupId": "OG002", "value": "71.8"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Total CPSSS During the Treatment Period", "description": "The CPSSS consists of 5 components that address dysmenorrhea, dyspareunia, non-menstrual pelvic pain, pelvic tenderness, and pelvic induration. Each component was scored on a scale of 0 to 3 (0 = absent, 1 = mild, 2 = moderate, and 3 = severe).\n\nDysmenorrhea, dyspareunia, and nonmenstrual pelvic pain scores are based on the participant's assessment, pelvic tenderness and induration were assessed by the investigator based on findings associated with a pelvic examination.\n\nThe total CPSSS has a maximum possible value of 15 (total score range: 0 to 15, where a lower score indicates less signs and symptoms of endometriosis or better functioning).\n\nChange from baseline was analyzed using a mixed-effects repeated measures (MERM) analysis of covariance model which included fixed effects for treatment, time, treatment-by-time interaction, a random effect for patient, and terms for baseline value and the baseline-by-time interaction.", "populationDescription": "All randomized participants who received at least one oral dose of study drug, an initial subcutaneous injection, and either reported at least 7 e-diary VAS values or provided an assessment of either dysmenorrhea or non-menstrual pelvic pain at week 4 or later during the treatment phase (intent-to-treat) with available data at each time point.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and weeks 4, 8, 12, 16, 20, and 24", "groups": [{"id": "OG000", "title": "Elagolix 150 mg QD", "description": "Participants received elagolix 150 mg orally once a day (QD) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG001", "title": "Elagolix 75 mg BID", "description": "Participants received elagolix 75 mg orally twice a day (BID) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG002", "title": "DMPA-SC", "description": "Participants received placebo to elagolix orally once a day for 24 weeks and DMPA-SC 104 mg by subcutaneous injection at weeks 1 and 12."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "84"}, {"groupId": "OG001", "value": "84"}, {"groupId": "OG002", "value": "83"}]}], "classes": [{"title": "Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "81"}, {"groupId": "OG001", "value": "83"}, {"groupId": "OG002", "value": "81"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.9", "spread": "0.29"}, {"groupId": "OG001", "value": "-3.7", "spread": "0.29"}, {"groupId": "OG002", "value": "-3.8", "spread": "0.29"}]}]}, {"title": "Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "74"}, {"groupId": "OG001", "value": "75"}, {"groupId": "OG002", "value": "73"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.9", "spread": "0.30"}, {"groupId": "OG001", "value": "-4.8", "spread": "0.30"}, {"groupId": "OG002", "value": "-4.5", "spread": "0.30"}]}]}, {"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "70"}, {"groupId": "OG001", "value": "72"}, {"groupId": "OG002", "value": "67"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.6", "spread": "0.31"}, {"groupId": "OG001", "value": "-5.1", "spread": "0.30"}, {"groupId": "OG002", "value": "-4.2", "spread": "0.31"}]}]}, {"title": "Week 16", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "64"}, {"groupId": "OG001", "value": "69"}, {"groupId": "OG002", "value": "56"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-5.5", "spread": "0.32"}, {"groupId": "OG001", "value": "-5.4", "spread": "0.31"}, {"groupId": "OG002", "value": "-4.6", "spread": "0.33"}]}]}, {"title": "Week 20", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "60"}, {"groupId": "OG001", "value": "68"}, {"groupId": "OG002", "value": "54"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-5.1", "spread": "0.33"}, {"groupId": "OG001", "value": "-5.3", "spread": "0.31"}, {"groupId": "OG002", "value": "-4.8", "spread": "0.34"}]}]}, {"title": "Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "64"}, {"groupId": "OG002", "value": "50"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-5.5", "spread": "0.34"}, {"groupId": "OG001", "value": "-5.2", "spread": "0.32"}, {"groupId": "OG002", "value": "-5.3", "spread": "0.36"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Within-group analysis of change from baseline in total CPSSS at week 24. Change from baseline was analyzed using a mixed-effects repeated measures (MERM) analysis of covariance model which included fixed effects for treatment, time, treatment-by-time interaction, a random effect for patient, and terms for baseline value and the baseline-by-time interaction.", "nonInferiorityType": "OTHER", "pValue": "< 0.0001", "pValueComment": "P-value for test of null hypothesis that the treatment group least squares mean is equal to zero.", "statisticalMethod": "t-test, 2 sided", "paramType": "Least squares mean", "paramValue": "-5.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-6.2", "ciUpperLimit": "-4.8"}, {"groupIds": ["OG001"], "groupDescription": "Within-group analysis of change from baseline in total CPSSS at week 24. Change from baseline was analyzed using a mixed-effects repeated measures (MERM) analysis of covariance model which included fixed effects for treatment, time, treatment-by-time interaction, a random effect for patient, and terms for baseline value and the baseline-by-time interaction.", "nonInferiorityType": "OTHER", "pValue": "< 0.0001", "pValueComment": "P-value for test of null hypothesis that the treatment group least squares mean is equal to zero.", "statisticalMethod": "t-test, 2 sided", "paramType": "Least squares mean", "paramValue": "-5.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.8", "ciUpperLimit": "-4.5"}, {"groupIds": ["OG002"], "groupDescription": "Within-group analysis of change from baseline in total CPSSS at week 24.\n\nChange from baseline was analyzed using a mixed-effects repeated measures (MERM) analysis of covariance model which included fixed effects for treatment, time, treatment-by-time interaction, a random effect for patient, and terms for baseline value and the baseline-by-time interaction.", "nonInferiorityType": "OTHER", "pValue": "< 0.0001", "pValueComment": "P-value for test of null hypothesis that the treatment group least squares mean is equal to zero.", "statisticalMethod": "t-test, 2 sided", "paramType": "Least squares mean", "paramValue": "-5.3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-6.0", "ciUpperLimit": "-4.6"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Total CPSSS Excluding Dyspareunia During the Treatment Period", "description": "The CPSSS consists of 5 components that address dysmenorrhea, dyspareunia, non-menstrual pelvic pain, pelvic tenderness, and pelvic induration. Each component was scored on a scale of 0 to 3 (0 = absent, 1 = mild, 2 = moderate, and 3 = severe).\n\nDysmenorrhea, dyspareunia, and nonmenstrual pelvic pain scores are based on the participant's assessment, pelvic tenderness and induration were assessed by the investigator based on findings associated with a pelvic examination.\n\nThe total CPSSS excluding dyspareunia has a maximum possible value of 12 (total score range: 0 to 12, where a lower score indicates less signs and symptoms of endometriosis or better functioning).\n\nChange from baseline was analyzed using a mixed-effects repeated measures (MERM) analysis of covariance model which included fixed effects for treatment, time, treatment-by-time interaction, a random effect for patient, and terms for baseline value and the baseline-by-time interaction.", "populationDescription": "All randomized participants who received at least one oral dose of study drug, an initial subcutaneous injection, and either reported at least 7 e-diary VAS values or provided an assessment of either dysmenorrhea or non-menstrual pelvic pain at week 4 or later during the treatment phase (intent-to-treat) with available data at each time point.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and weeks 4, 8, 12, 16, 20, and 24", "groups": [{"id": "OG000", "title": "Elagolix 150 mg QD", "description": "Participants received elagolix 150 mg orally once a day (QD) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG001", "title": "Elagolix 75 mg BID", "description": "Participants received elagolix 75 mg orally twice a day (BID) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG002", "title": "DMPA-SC", "description": "Participants received placebo to elagolix orally once a day for 24 weeks and DMPA-SC 104 mg by subcutaneous injection at weeks 1 and 12."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "84"}, {"groupId": "OG001", "value": "84"}, {"groupId": "OG002", "value": "83"}]}], "classes": [{"title": "Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "81"}, {"groupId": "OG001", "value": "83"}, {"groupId": "OG002", "value": "81"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.4", "spread": "0.25"}, {"groupId": "OG001", "value": "-3.4", "spread": "0.25"}, {"groupId": "OG002", "value": "-3.3", "spread": "0.25"}]}]}, {"title": "Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "74"}, {"groupId": "OG001", "value": "75"}, {"groupId": "OG002", "value": "73"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.1", "spread": "0.26"}, {"groupId": "OG001", "value": "-4.2", "spread": "0.26"}, {"groupId": "OG002", "value": "-3.8", "spread": "0.26"}]}]}, {"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "70"}, {"groupId": "OG001", "value": "72"}, {"groupId": "OG002", "value": "67"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.8", "spread": "0.26"}, {"groupId": "OG001", "value": "-4.4", "spread": "0.26"}, {"groupId": "OG002", "value": "-3.7", "spread": "0.27"}]}]}, {"title": "Week 16", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "64"}, {"groupId": "OG001", "value": "69"}, {"groupId": "OG002", "value": "56"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.6", "spread": "0.27"}, {"groupId": "OG001", "value": "-4.6", "spread": "0.27"}, {"groupId": "OG002", "value": "-3.9", "spread": "0.29"}]}]}, {"title": "Week 20", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "60"}, {"groupId": "OG001", "value": "68"}, {"groupId": "OG002", "value": "54"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.4", "spread": "0.28"}, {"groupId": "OG001", "value": "-4.4", "spread": "0.27"}, {"groupId": "OG002", "value": "-4.1", "spread": "0.30"}]}]}, {"title": "Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "64"}, {"groupId": "OG002", "value": "50"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.6", "spread": "0.29"}, {"groupId": "OG001", "value": "-4.4", "spread": "0.28"}, {"groupId": "OG002", "value": "-4.5", "spread": "0.31"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Within-group analysis of change from baseline in total CPSSS excluding dyspareunia at week 24.\n\nChange from baseline was analyzed using a mixed-effects repeated measures (MERM) analysis of covariance model which included fixed effects for treatment, time, treatment-by-time interaction, a random effect for patient, and terms for baseline value and the baseline-by-time interaction.", "nonInferiorityType": "OTHER", "pValue": "<0.0001", "pValueComment": "P-value for test of null hypothesis that the treatment group least squares mean is equal to zero.", "statisticalMethod": "t-test, 2 sided", "paramType": "Least squares mean", "paramValue": "-4.6", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.1", "ciUpperLimit": "-4.0"}, {"groupIds": ["OG001"], "groupDescription": "Within-group analysis of change from baseline in total CPSSS excluding dyspareunia at week 24.\n\nChange from baseline was analyzed using a mixed-effects repeated measures (MERM) analysis of covariance model which included fixed effects for treatment, time, treatment-by-time interaction, a random effect for patient, and terms for baseline value and the baseline-by-time interaction.", "nonInferiorityType": "OTHER", "pValue": "<0.0001", "pValueComment": "P-value for test of null hypothesis that the treatment group least squares mean is equal to zero.", "statisticalMethod": "t-test, 2 sided", "paramType": "Least squares mean", "paramValue": "-4.4", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.0", "ciUpperLimit": "-3.9"}, {"groupIds": ["OG002"], "groupDescription": "Within-group analysis of change from baseline in total CPSSS excluding dyspareunia at week 24.\n\nChange from baseline was analyzed using a mixed-effects repeated measures (MERM) analysis of covariance model which included fixed effects for treatment, time, treatment-by-time interaction, a random effect for patient, and terms for baseline value and the baseline-by-time interaction.", "nonInferiorityType": "OTHER", "pValue": "< 0.0001", "pValueComment": "P-value for test of null hypothesis that the treatment group least squares mean is equal to zero.", "statisticalMethod": "t-test, 2 sided", "paramType": "Least squares mean", "paramValue": "-4.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.1", "ciUpperLimit": "-3.9"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Dysmenorrhea Component of the CPSSS During the Treatment Period", "description": "The CPSSS consists of 5 components that address dysmenorrhea, dyspareunia, non-menstrual pelvic pain, pelvic tenderness, and pelvic induration. Each component was scored on a scale of 0 to 3 (0 = absent, 1 = mild, 2 = moderate, and 3 = severe).\n\nThe dysmenorrhea score was based on the participant's response to the question \"Have you had painful menstruation during the last 28 days?\".\n\nChange from baseline was analyzed using a mixed-effects repeated measures (MERM) analysis of covariance model which included fixed effects for treatment, time, treatment-by-time interaction, a random effect for patient, and terms for baseline value and the baseline-by-time interaction.", "populationDescription": "All randomized participants who received at least one oral dose of study drug, an initial subcutaneous injection, and either reported at least 7 e-diary VAS values or provided an assessment of either dysmenorrhea or non-menstrual pelvic pain at week 4 or later during the treatment phase (intent-to-treat) with available data at each time point.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and weeks 4, 8, 12, 16, 20, and 24", "groups": [{"id": "OG000", "title": "Elagolix 150 mg QD", "description": "Participants received elagolix 150 mg orally once a day (QD) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG001", "title": "Elagolix 75 mg BID", "description": "Participants received elagolix 75 mg orally twice a day (BID) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG002", "title": "DMPA-SC", "description": "Participants received placebo to elagolix orally once a day for 24 weeks and DMPA-SC 104 mg by subcutaneous injection at weeks 1 and 12."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "84"}, {"groupId": "OG001", "value": "84"}, {"groupId": "OG002", "value": "83"}]}], "classes": [{"title": "Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "81"}, {"groupId": "OG001", "value": "83"}, {"groupId": "OG002", "value": "83"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.4", "spread": "0.11"}, {"groupId": "OG001", "value": "-1.5", "spread": "0.11"}, {"groupId": "OG002", "value": "-1.3", "spread": "0.11"}]}]}, {"title": "Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "75"}, {"groupId": "OG001", "value": "75"}, {"groupId": "OG002", "value": "73"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.6", "spread": "0.11"}, {"groupId": "OG001", "value": "-1.7", "spread": "0.11"}, {"groupId": "OG002", "value": "-1.5", "spread": "0.12"}]}]}, {"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "71"}, {"groupId": "OG001", "value": "73"}, {"groupId": "OG002", "value": "67"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.3", "spread": "0.12"}, {"groupId": "OG001", "value": "-1.7", "spread": "0.12"}, {"groupId": "OG002", "value": "-1.5", "spread": "0.12"}]}]}, {"title": "Week 16", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "64"}, {"groupId": "OG001", "value": "69"}, {"groupId": "OG002", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.6", "spread": "0.12"}, {"groupId": "OG001", "value": "-1.8", "spread": "0.12"}, {"groupId": "OG002", "value": "-1.8", "spread": "0.13"}]}]}, {"title": "Week 20", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "60"}, {"groupId": "OG001", "value": "68"}, {"groupId": "OG002", "value": "54"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.4", "spread": "0.13"}, {"groupId": "OG001", "value": "-1.5", "spread": "0.12"}, {"groupId": "OG002", "value": "-1.4", "spread": "0.13"}]}]}, {"title": "Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "65"}, {"groupId": "OG002", "value": "51"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.5", "spread": "0.13"}, {"groupId": "OG001", "value": "-1.4", "spread": "0.12"}, {"groupId": "OG002", "value": "-1.7", "spread": "0.14"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Within-group analysis of change from baseline in dysmenorrhea at week 24. Change from baseline was analyzed using a mixed-effects repeated measures (MERM) analysis of covariance model which included fixed effects for treatment, time, treatment-by-time interaction, a random effect for patient, and terms for baseline value and the baseline-by-time interaction.", "nonInferiorityType": "OTHER", "pValue": "< 0.0001", "pValueComment": "P-value for test of null hypothesis that the treatment group least squares mean is equal to zero.", "statisticalMethod": "t-test, 2 sided", "paramType": "Least squares mean", "paramValue": "-1.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.7", "ciUpperLimit": "-1.2"}, {"groupIds": ["OG001"], "groupDescription": "Within-group analysis of change from baseline in dysmenorrhea at week 24. Change from baseline was analyzed using a mixed-effects repeated measures (MERM) analysis of covariance model which included fixed effects for treatment, time, treatment-by-time interaction, a random effect for patient, and terms for baseline value and the baseline-by-time interaction.", "nonInferiorityType": "OTHER", "pValue": "< 0.0001", "pValueComment": "P-value for test of null hypothesis that the treatment group least squares mean is equal to zero.", "statisticalMethod": "t-test, 2 sided", "paramType": "Least squares mean", "paramValue": "-1.4", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.6", "ciUpperLimit": "-1.2"}, {"groupIds": ["OG002"], "groupDescription": "Within-group analysis of change from baseline in dysmenorrhea at week 24. Change from baseline was analyzed using a mixed-effects repeated measures (MERM) analysis of covariance model which included fixed effects for treatment, time, treatment-by-time interaction, a random effect for patient, and terms for baseline value and the baseline-by-time interaction.", "nonInferiorityType": "OTHER", "pValue": "< 0.0001", "pValueComment": "P-value for test of null hypothesis that the treatment group least squares mean is equal to zero.", "statisticalMethod": "t-test, 2 sided", "paramType": "Least squares mean", "paramValue": "-1.7", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.9", "ciUpperLimit": "-1.4"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Dyspareunia Component of the CPSSS During the Treatment Period", "description": "The CPSSS consists of 5 components that address dysmenorrhea, dyspareunia, non-menstrual pelvic pain, pelvic tenderness, and pelvic induration. Each component was scored on a scale of 0 to 3 (0 = absent, 1 = mild, 2 = moderate, and 3 = severe).\n\nThe dyspareunia score was based on the participant's response to the question \"Have you had painful intercourse during the last 28 days?\" Change from baseline was analyzed using a mixed-effects repeated measures (MERM) analysis of covariance model which included fixed effects for treatment, time, treatment-by-time interaction, a random effect for patient, and terms for baseline value and the baseline-by-time interaction.", "populationDescription": "All randomized participants who received at least one oral dose of study drug, an initial subcutaneous injection, and either reported at least 7 e-diary VAS values or provided an assessment of either dysmenorrhea or non-menstrual pelvic pain at week 4 or later during the treatment phase (intent-to-treat) with available data at each time point.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and weeks 4, 8, 12, 16, 20, and 24", "groups": [{"id": "OG000", "title": "Elagolix 150 mg QD", "description": "Participants received elagolix 150 mg orally once a day (QD) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG001", "title": "Elagolix 75 mg BID", "description": "Participants received elagolix 75 mg orally twice a day (BID) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG002", "title": "DMPA-SC", "description": "Participants received placebo to elagolix orally once a day for 24 weeks and DMPA-SC 104 mg by subcutaneous injection at weeks 1 and 12."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "84"}, {"groupId": "OG001", "value": "84"}, {"groupId": "OG002", "value": "83"}]}], "classes": [{"title": "Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "62"}, {"groupId": "OG001", "value": "48"}, {"groupId": "OG002", "value": "59"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.6", "spread": "0.11"}, {"groupId": "OG001", "value": "-0.4", "spread": "0.13"}, {"groupId": "OG002", "value": "-0.5", "spread": "0.11"}]}]}, {"title": "Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "53"}, {"groupId": "OG001", "value": "47"}, {"groupId": "OG002", "value": "51"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.9", "spread": "0.12"}, {"groupId": "OG001", "value": "-0.7", "spread": "0.13"}, {"groupId": "OG002", "value": "-0.8", "spread": "0.12"}]}]}, {"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "51"}, {"groupId": "OG001", "value": "46"}, {"groupId": "OG002", "value": "49"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.0", "spread": "0.12"}, {"groupId": "OG001", "value": "-0.8", "spread": "0.13"}, {"groupId": "OG002", "value": "-0.6", "spread": "0.12"}]}]}, {"title": "Week 16", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "45"}, {"groupId": "OG001", "value": "42"}, {"groupId": "OG002", "value": "35"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.2", "spread": "0.13"}, {"groupId": "OG001", "value": "-1.0", "spread": "0.13"}, {"groupId": "OG002", "value": "-0.8", "spread": "0.14"}]}]}, {"title": "Week 20", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "41"}, {"groupId": "OG001", "value": "38"}, {"groupId": "OG002", "value": "33"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.9", "spread": "0.13"}, {"groupId": "OG001", "value": "-1.0", "spread": "0.14"}, {"groupId": "OG002", "value": "-0.8", "spread": "0.14"}]}]}, {"title": "Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "39"}, {"groupId": "OG001", "value": "38"}, {"groupId": "OG002", "value": "30"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.2", "spread": "0.13"}, {"groupId": "OG001", "value": "-1.0", "spread": "0.14"}, {"groupId": "OG002", "value": "-0.8", "spread": "0.15"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Within-group analysis of change from baseline in dyspareunia at week 24. Change from baseline was analyzed using a mixed-effects repeated measures (MERM) analysis of covariance model which included fixed effects for treatment, time, treatment-by-time interaction, a random effect for patient, and terms for baseline value and the baseline-by-time interaction.", "nonInferiorityType": "OTHER", "pValue": "< 0.0001", "pValueComment": "P-value for test of null hypothesis that the treatment group least squares mean is equal to zero.", "statisticalMethod": "t-test, 2 sided", "paramType": "Least squares mean", "paramValue": "-1.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.4", "ciUpperLimit": "-0.9"}, {"groupIds": ["OG001"], "groupDescription": "Within-group analysis of change from baseline in dyspareunia at week 24. Change from baseline was analyzed using a mixed-effects repeated measures (MERM) analysis of covariance model which included fixed effects for treatment, time, treatment-by-time interaction, a random effect for patient, and terms for baseline value and the baseline-by-time interaction.", "nonInferiorityType": "OTHER", "pValue": "< 0.0001", "pValueComment": "P-value for test of null hypothesis that the treatment group least squares mean is equal to zero.", "statisticalMethod": "t-test, 2 sided", "paramType": "Least squares mean", "paramValue": "-1.0", "ciPctValue": "2", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.2", "ciUpperLimit": "-0.7"}, {"groupIds": ["OG002"], "groupDescription": "Within-group analysis of change from baseline in dyspareunia at week 24. Change from baseline was analyzed using a mixed-effects repeated measures (MERM) analysis of covariance model which included fixed effects for treatment, time, treatment-by-time interaction, a random effect for patient, and terms for baseline value and the baseline-by-time interaction.", "nonInferiorityType": "OTHER", "pValue": "< 0.0001", "pValueComment": "P-value for test of null hypothesis that the treatment group least squares mean is equal to zero.", "statisticalMethod": "t-test, 2 sided", "paramType": "Least squares mean", "paramValue": "-0.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.1", "ciUpperLimit": "-0.5"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Non-menstrual Pelvic Pain Component of the CPSSS During the Treatment Period", "description": "The CPSSS consists of 5 components that address dysmenorrhea, dyspareunia, non-menstrual pelvic pain, pelvic tenderness, and pelvic induration. Each component was scored on a scale of 0 to 3 (0 = absent, 1 = mild, 2 = moderate, and 3 = severe).\n\nThe non-menstrual pelvic pain score was based on participant's response to the question \"Have you had pelvic pain during the last 28 days?\".\n\nChange from baseline was analyzed using a mixed-effects repeated measures (MERM) analysis of covariance model which included fixed effects for treatment, time, treatment-by-time interaction, a random effect for patient, and terms for baseline value and the baseline-by-time interaction.", "populationDescription": "All randomized participants who received at least one oral dose of study drug, an initial subcutaneous injection, and either reported at least 7 e-diary VAS values or provided an assessment of either dysmenorrhea or non-menstrual pelvic pain at week 4 or later during the treatment phase (intent-to-treat) with available data at each time point.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and weeks 4, 8, 12, 16, 20, and 24", "groups": [{"id": "OG000", "title": "Elagolix 150 mg QD", "description": "Participants received elagolix 150 mg orally once a day (QD) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG001", "title": "Elagolix 75 mg BID", "description": "Participants received elagolix 75 mg orally twice a day (BID) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG002", "title": "DMPA-SC", "description": "Participants received placebo to elagolix orally once a day for 24 weeks and DMPA-SC 104 mg by subcutaneous injection at weeks 1 and 12."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "84"}, {"groupId": "OG001", "value": "84"}, {"groupId": "OG002", "value": "83"}]}], "classes": [{"title": "Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "81"}, {"groupId": "OG001", "value": "83"}, {"groupId": "OG002", "value": "83"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.9", "spread": "0.09"}, {"groupId": "OG001", "value": "-0.8", "spread": "0.09"}, {"groupId": "OG002", "value": "-0.8", "spread": "0.09"}]}]}, {"title": "Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "75"}, {"groupId": "OG001", "value": "75"}, {"groupId": "OG002", "value": "73"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.1", "spread": "0.09"}, {"groupId": "OG001", "value": "-1.1", "spread": "0.09"}, {"groupId": "OG002", "value": "-1.1", "spread": "0.09"}]}]}, {"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "71"}, {"groupId": "OG001", "value": "73"}, {"groupId": "OG002", "value": "67"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.0", "spread": "0.09"}, {"groupId": "OG001", "value": "-1.1", "spread": "0.09"}, {"groupId": "OG002", "value": "-0.9", "spread": "0.10"}]}]}, {"title": "Week 16", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "64"}, {"groupId": "OG001", "value": "69"}, {"groupId": "OG002", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.2", "spread": "0.10"}, {"groupId": "OG001", "value": "-1.2", "spread": "0.09"}, {"groupId": "OG002", "value": "-0.9", "spread": "0.10"}]}]}, {"title": "Week 20", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "60"}, {"groupId": "OG001", "value": "68"}, {"groupId": "OG002", "value": "54"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.1", "spread": "0.10"}, {"groupId": "OG001", "value": "-1.3", "spread": "0.10"}, {"groupId": "OG002", "value": "-1.0", "spread": "0.11"}]}]}, {"title": "Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "65"}, {"groupId": "OG002", "value": "51"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.2", "spread": "0.10"}, {"groupId": "OG001", "value": "-1.2", "spread": "0.10"}, {"groupId": "OG002", "value": "-1.1", "spread": "0.11"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Within-group analysis of change from baseline in non-menstrual pelvic pain at week 24.\n\nChange from baseline was analyzed using a mixed-effects repeated measures (MERM) analysis of covariance model which included fixed effects for treatment, time, treatment-by-time interaction, a random effect for patient, and terms for baseline value and the baseline-by-time interaction.", "nonInferiorityType": "OTHER", "pValue": "< 0.0001", "pValueComment": "P-value for test of null hypothesis that the treatment group least squares mean is equal to zero.", "statisticalMethod": "t-test, 2 sided", "paramType": "Least squares mean", "paramValue": "-1.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.4", "ciUpperLimit": "-1.0"}, {"groupIds": ["OG001"], "groupDescription": "Within-group analysis of change from baseline in non-menstrual pelvic pain at week 24.\n\nChange from baseline was analyzed using a mixed-effects repeated measures (MERM) analysis of covariance model which included fixed effects for treatment, time, treatment-by-time interaction, a random effect for patient, and terms for baseline value and the baseline-by-time interaction.", "nonInferiorityType": "OTHER", "pValue": "< 0.0001", "pValueComment": "P-value for test of null hypothesis that the treatment group least squares mean is equal to zero.", "statisticalMethod": "t-test, 2 sided", "paramType": "Least squares mean", "paramValue": "-1.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.4", "ciUpperLimit": "-1.0"}, {"groupIds": ["OG002"], "groupDescription": "Within-group analysis of change from baseline in non-menstrual pelvic pain at week 24.\n\nChange from baseline was analyzed using a mixed-effects repeated measures (MERM) analysis of covariance model which included fixed effects for treatment, time, treatment-by-time interaction, a random effect for patient, and terms for baseline value and the baseline-by-time interaction.", "nonInferiorityType": "OTHER", "pValue": "< 0.0001", "pValueComment": "P-value for test of null hypothesis that the treatment group least squares mean is equal to zero.", "statisticalMethod": "t-test, 2 sided", "paramType": "Least squares mean", "paramValue": "-1.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.3", "ciUpperLimit": "-0.8"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Pelvic Tenderness Component of the CPSSS During the Treatment Period", "description": "The CPSSS consists of 5 components that address dysmenorrhea, dyspareunia, non-menstrual pelvic pain, pelvic tenderness, and pelvic induration. Each component was scored on a scale of 0 to 3 (0 = absent, 1 = mild, 2 = moderate, and 3 = severe).\n\nPelvic tenderness was assessed by the investigator based on findings associated with a pelvic examination.\n\nChange from baseline was analyzed using a mixed-effects repeated measures (MERM) analysis of covariance model which included fixed effects for treatment, time, treatment-by-time interaction, a random effect for patient, and terms for baseline value and the baseline-by-time interaction.", "populationDescription": "All randomized participants who received at least one oral dose of study drug, an initial subcutaneous injection, and either reported at least 7 e-diary VAS values or provided an assessment of either dysmenorrhea or non-menstrual pelvic pain at week 4 or later during the treatment phase (intent-to-treat) with available data at each time point.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and weeks 4, 8, 12, 16, 20, and 24", "groups": [{"id": "OG000", "title": "Elagolix 150 mg QD", "description": "Participants received elagolix 150 mg orally once a day (QD) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG001", "title": "Elagolix 75 mg BID", "description": "Participants received elagolix 75 mg orally twice a day (BID) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG002", "title": "DMPA-SC", "description": "Participants received placebo to elagolix orally once a day for 24 weeks and DMPA-SC 104 mg by subcutaneous injection at weeks 1 and 12."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "84"}, {"groupId": "OG001", "value": "84"}, {"groupId": "OG002", "value": "83"}]}], "classes": [{"title": "Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "81"}, {"groupId": "OG001", "value": "83"}, {"groupId": "OG002", "value": "81"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.6", "spread": "0.08"}, {"groupId": "OG001", "value": "-0.7", "spread": "0.08"}, {"groupId": "OG002", "value": "-0.7", "spread": "0.08"}]}]}, {"title": "Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "74"}, {"groupId": "OG001", "value": "75"}, {"groupId": "OG002", "value": "73"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.8", "spread": "0.09"}, {"groupId": "OG001", "value": "-0.8", "spread": "0.08"}, {"groupId": "OG002", "value": "-0.7", "spread": "0.09"}]}]}, {"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "70"}, {"groupId": "OG001", "value": "72"}, {"groupId": "OG002", "value": "67"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.8", "spread": "0.09"}, {"groupId": "OG001", "value": "-0.9", "spread": "0.09"}, {"groupId": "OG002", "value": "-0.7", "spread": "0.09"}]}]}, {"title": "Week 16", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "64"}, {"groupId": "OG001", "value": "69"}, {"groupId": "OG002", "value": "56"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.0", "spread": "0.09"}, {"groupId": "OG001", "value": "-0.9", "spread": "0.09"}, {"groupId": "OG002", "value": "-0.6", "spread": "0.09"}]}]}, {"title": "Week 20", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "60"}, {"groupId": "OG001", "value": "68"}, {"groupId": "OG002", "value": "54"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.0", "spread": "0.09"}, {"groupId": "OG001", "value": "-0.8", "spread": "0.09"}, {"groupId": "OG002", "value": "-0.9", "spread": "0.10"}]}]}, {"title": "Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "64"}, {"groupId": "OG002", "value": "50"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.0", "spread": "0.09"}, {"groupId": "OG001", "value": "-1.0", "spread": "0.09"}, {"groupId": "OG002", "value": "-0.9", "spread": "0.10"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Within-group analysis of change from baseline in pelvic tenderness at week 24. Change from baseline was analyzed using a mixed-effects repeated measures (MERM) analysis of covariance model which included fixed effects for treatment, time, treatment-by-time interaction, a random effect for patient, and terms for baseline value and the baseline-by-time interaction.", "nonInferiorityType": "OTHER", "pValue": "< 0.0001", "pValueComment": "P-value for test of null hypothesis that the treatment group least squares mean is equal to zero.", "statisticalMethod": "t-test, 2 sided", "paramType": "Least squares mean", "paramValue": "-1.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.2", "ciUpperLimit": "-0.8"}, {"groupIds": ["OG001"], "groupDescription": "Within-group analysis of change from baseline in pelvic tenderness at week 24. Change from baseline was analyzed using a mixed-effects repeated measures (MERM) analysis of covariance model which included fixed effects for treatment, time, treatment-by-time interaction, a random effect for patient, and terms for baseline value and the baseline-by-time interaction.", "nonInferiorityType": "OTHER", "pValue": "< 0.0001", "pValueComment": "P-value for test of null hypothesis that the treatment group least squares mean is equal to zero.", "statisticalMethod": "t-test, 2 sided", "paramType": "Least squares mean", "paramValue": "-1.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.1", "ciUpperLimit": "-0.8"}, {"groupIds": ["OG002"], "groupDescription": "Within-group analysis of change from baseline in pelvic tenderness at week 24. Change from baseline was analyzed using a mixed-effects repeated measures (MERM) analysis of covariance model which included fixed effects for treatment, time, treatment-by-time interaction, a random effect for patient, and terms for baseline value and the baseline-by-time interaction.", "nonInferiorityType": "OTHER", "pValue": "< 0.0001", "pValueComment": "P-value for test of null hypothesis that the treatment group least squares mean is equal to zero.", "statisticalMethod": "t-test, 2 sided", "paramType": "Least squares mean", "paramValue": "-0.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.1", "ciUpperLimit": "-0.7"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Pelvic Induration Component of the CPSSS During the Treatment Period", "description": "The CPSSS consists of 5 components that address dysmenorrhea, dyspareunia, non-menstrual pelvic pain, pelvic tenderness, and pelvic induration. Each component was scored on a scale of 0 to 3 (0 = absent, 1 = mild, 2 = moderate, and 3 = severe).\n\nPelvic induration was assessed by the investigator based on findings associated with a pelvic examination.\n\nChange from baseline was analyzed using a mixed-effects repeated measures (MERM) analysis of covariance model which included fixed effects for treatment, time, treatment-by-time interaction, a random effect for patient, and terms for baseline value and the baseline-by-time interaction.", "populationDescription": "All randomized participants who received at least one oral dose of study drug, an initial subcutaneous injection, and either reported at least 7 e-diary VAS values or provided an assessment of either dysmenorrhea or non-menstrual pelvic pain at week 4 or later during the treatment phase (intent-to-treat) with available data at each time point.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and weeks 4, 8, 12, 16, 20, and 24", "groups": [{"id": "OG000", "title": "Elagolix 150 mg QD", "description": "Participants received elagolix 150 mg orally once a day (QD) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG001", "title": "Elagolix 75 mg BID", "description": "Participants received elagolix 75 mg orally twice a day (BID) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG002", "title": "DMPA-SC", "description": "Participants received placebo to elagolix orally once a day for 24 weeks and DMPA-SC 104 mg by subcutaneous injection at weeks 1 and 12."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "84"}, {"groupId": "OG001", "value": "84"}, {"groupId": "OG002", "value": "83"}]}], "classes": [{"title": "Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "81"}, {"groupId": "OG001", "value": "83"}, {"groupId": "OG002", "value": "81"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.4", "spread": "0.08"}, {"groupId": "OG001", "value": "-0.5", "spread": "0.08"}, {"groupId": "OG002", "value": "-0.5", "spread": "0.08"}]}]}, {"title": "Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "74"}, {"groupId": "OG001", "value": "75"}, {"groupId": "OG002", "value": "73"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.7", "spread": "0.08"}, {"groupId": "OG001", "value": "-0.6", "spread": "0.08"}, {"groupId": "OG002", "value": "-0.6", "spread": "0.08"}]}]}, {"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "70"}, {"groupId": "OG001", "value": "72"}, {"groupId": "OG002", "value": "67"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.7", "spread": "0.08"}, {"groupId": "OG001", "value": "-0.8", "spread": "0.08"}, {"groupId": "OG002", "value": "-0.6", "spread": "0.08"}]}]}, {"title": "Week 16", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "64"}, {"groupId": "OG001", "value": "69"}, {"groupId": "OG002", "value": "56"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.9", "spread": "0.09"}, {"groupId": "OG001", "value": "-0.8", "spread": "0.08"}, {"groupId": "OG002", "value": "-0.7", "spread": "0.09"}]}]}, {"title": "Week 20", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "60"}, {"groupId": "OG001", "value": "68"}, {"groupId": "OG002", "value": "54"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.9", "spread": "0.09"}, {"groupId": "OG001", "value": "-0.8", "spread": "0.08"}, {"groupId": "OG002", "value": "-0.8", "spread": "0.09"}]}]}, {"title": "Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "64"}, {"groupId": "OG002", "value": "50"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.9", "spread": "0.09"}, {"groupId": "OG001", "value": "-0.9", "spread": "0.09"}, {"groupId": "OG002", "value": "-0.8", "spread": "0.10"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Within-group analysis of change from baseline in pelvic induration at week 24. Change from baseline was analyzed using a mixed-effects repeated measures (MERM) analysis of covariance model which included fixed effects for treatment, time, treatment-by-time interaction, a random effect for patient, and terms for baseline value and the baseline-by-time interaction.", "nonInferiorityType": "OTHER", "pValue": "< 0.0001", "pValueComment": "P-value for test of null hypothesis that the treatment group least squares mean is equal to zero.", "statisticalMethod": "t-test, 2 sided", "paramType": "Least squares mean", "paramValue": "-0.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.0", "ciUpperLimit": "-0.7"}, {"groupIds": ["OG001"], "groupDescription": "Within-group analysis of change from baseline in pelvic induration at week 24. Change from baseline was analyzed using a mixed-effects repeated measures (MERM) analysis of covariance model which included fixed effects for treatment, time, treatment-by-time interaction, a random effect for patient, and terms for baseline value and the baseline-by-time interaction.", "nonInferiorityType": "OTHER", "pValue": "< 0.0001", "pValueComment": "P-value for test of null hypothesis that the treatment group least squares mean is equal to zero.", "statisticalMethod": "t-test, 2 sided", "paramType": "Least squares mean", "paramValue": "-0.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.1", "ciUpperLimit": "-0.7"}, {"groupIds": ["OG002"], "groupDescription": "Within-group analysis of change from baseline in pelvic induration at week 24. Change from baseline was analyzed using a mixed-effects repeated measures (MERM) analysis of covariance model which included fixed effects for treatment, time, treatment-by-time interaction, a random effect for patient, and terms for baseline value and the baseline-by-time interaction.", "nonInferiorityType": "OTHER", "pValue": "<0.0001", "statisticalMethod": "t-test, 2 sided", "paramType": "Least squares mean", "paramValue": "-0.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.9", "ciUpperLimit": "-0.6"}]}, {"type": "SECONDARY", "title": "Change From Baseline in in Monthly Peak Visual Analog Scale (VAS) for Pelvic Pain", "description": "The VAS for pelvic pain was used as an assessment of pain intensity. The VAS was a horizontal line on which the left extreme was labeled \"no pain\" and the right extreme was labeled \"worst pain ever felt\" scored on a scale from of 0 (no pain) to 100 (worst pain ever felt). Participants indicated the worst level of pain felt over a 24-hour period by ''ticking'' the horizontal line on their e-Diary at approximately the same time each day. Monthly peak VAS for pelvic pain was defined as the maximum VAS pain score reported for an individual participant from the previous visit to the day of the current scheduled visit.\n\nChange from baseline was analyzed using a mixed-effects repeated measures (MERM) analysis of covariance model which included fixed effects for treatment, time, treatment-by-time interaction, a random effect for patient, and terms for baseline value and the baseline-by-time interaction.", "populationDescription": "All randomized participants who received at least one oral dose of study drug, an initial subcutaneous injection, and either reported at least 7 e-diary VAS values or provided an assessment of either dysmenorrhea or non-menstrual pelvic pain at week 4 or later during the treatment phase (intent-to-treat) with available data at each time point.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and weeks 4, 8, 12, 16, 20, and 24", "groups": [{"id": "OG000", "title": "Elagolix 150 mg QD", "description": "Participants received elagolix 150 mg orally once a day (QD) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG001", "title": "Elagolix 75 mg BID", "description": "Participants received elagolix 75 mg orally twice a day (BID) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG002", "title": "DMPA-SC", "description": "Participants received placebo to elagolix orally once a day for 24 weeks and DMPA-SC 104 mg by subcutaneous injection at weeks 1 and 12."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "84"}, {"groupId": "OG001", "value": "84"}, {"groupId": "OG002", "value": "83"}]}], "classes": [{"title": "Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "83"}, {"groupId": "OG001", "value": "84"}, {"groupId": "OG002", "value": "82"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-18.2", "spread": "2.97"}, {"groupId": "OG001", "value": "-14.4", "spread": "2.96"}, {"groupId": "OG002", "value": "-15.4", "spread": "2.98"}]}]}, {"title": "Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "76"}, {"groupId": "OG001", "value": "78"}, {"groupId": "OG002", "value": "74"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-26.3", "spread": "3.06"}, {"groupId": "OG001", "value": "-28.1", "spread": "3.02"}, {"groupId": "OG002", "value": "-27.1", "spread": "3.08"}]}]}, {"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "70"}, {"groupId": "OG001", "value": "73"}, {"groupId": "OG002", "value": "66"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-31.3", "spread": "3.14"}, {"groupId": "OG001", "value": "-32.7", "spread": "3.09"}, {"groupId": "OG002", "value": "-24.9", "spread": "3.20"}]}]}, {"title": "Week 16", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "65"}, {"groupId": "OG001", "value": "67"}, {"groupId": "OG002", "value": "58"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-32.1", "spread": "3.24"}, {"groupId": "OG001", "value": "-37.8", "spread": "3.19"}, {"groupId": "OG002", "value": "-30.8", "spread": "3.38"}]}]}, {"title": "Week 20", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "66"}, {"groupId": "OG002", "value": "54"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-29.0", "spread": "3.40"}, {"groupId": "OG001", "value": "-37.9", "spread": "3.23"}, {"groupId": "OG002", "value": "-31.0", "spread": "3.51"}]}]}, {"title": "Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "55"}, {"groupId": "OG001", "value": "63"}, {"groupId": "OG002", "value": "50"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-32.3", "spread": "3.51"}, {"groupId": "OG001", "value": "-32.9", "spread": "3.31"}, {"groupId": "OG002", "value": "-35.8", "spread": "3.65"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Within-group analysis of change from baseline in peak VAS for pelvic pain at week 24. Change from baseline was analyzed using a mixed-effects repeated measures (MERM) analysis of covariance model which included fixed effects for treatment, time, treatment-by-time interaction, a random effect for patient, and terms for baseline value and the baseline-by-time interaction.", "nonInferiorityType": "OTHER", "pValue": "< 0.0001", "pValueComment": "P-value for test of null hypothesis that the treatment group least squares mean is equal to zero.", "statisticalMethod": "t-test, 2 sided", "paramType": "Least squares mean", "paramValue": "-32.3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-39.2", "ciUpperLimit": "-25.4"}, {"groupIds": ["OG001"], "groupDescription": "Within-group analysis of change from baseline in peak VAS for pelvic pain at week 24. Change from baseline was analyzed using a mixed-effects repeated measures (MERM) analysis of covariance model which included fixed effects for treatment, time, treatment-by-time interaction, a random effect for patient, and terms for baseline value and the baseline-by-time interaction.", "nonInferiorityType": "OTHER", "pValue": "< 0.0001", "pValueComment": "P-value for test of null hypothesis that the treatment group least squares mean is equal to zero.", "statisticalMethod": "t-test, 2 sided", "paramType": "Least squares mean", "paramValue": "-32.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-39.4", "ciUpperLimit": "-26.4"}, {"groupIds": ["OG002"], "groupDescription": "Within-group analysis of change from baseline in peak VAS for pelvic pain at week 24. Change from baseline was analyzed using a mixed-effects repeated measures (MERM) analysis of covariance model which included fixed effects for treatment, time, treatment-by-time interaction, a random effect for patient, and terms for baseline value and the baseline-by-time interaction.", "nonInferiorityType": "OTHER", "pValue": "< 0.0001", "pValueComment": "P-value for test of null hypothesis that the treatment group least squares mean is equal to zero.", "statisticalMethod": "t-test, 2 sided", "paramType": "Least squares mean", "paramValue": "-35.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-43.0", "ciUpperLimit": "-28.6"}]}, {"type": "SECONDARY", "title": "Change From Baseline in in Monthly Mean Visual Analog Scale (VAS) for Pelvic Pain", "description": "The VAS for pelvic pain was used as an assessment of pain intensity. The VAS was a horizontal line on which the left extreme was labeled \"no pain\" and the right extreme was labeled \"worst pain ever felt\" scored on a scale from of 0 (no pain) to 100 (worst pain ever felt). Participants indicated the worst level of pain felt over a 24-hour period by ''ticking'' the horizontal line on their e-Diary at approximately the same time each day. Monthly mean VAS for pelvic pain defined as the average of all VAS pain scores reported for an individual participant from the previous visit to the day of the current scheduled visit.\n\nChange from baseline was analyzed using a mixed-effects repeated measures (MERM) analysis of covariance model which included fixed effects for treatment, time, treatment-by-time interaction, a random effect for patient, and terms for baseline value and the baseline-by-time interaction.", "populationDescription": "All randomized participants who received at least one oral dose of study drug, an initial subcutaneous injection, and either reported at least 7 e-diary VAS values or provided an assessment of either dysmenorrhea or non-menstrual pelvic pain at week 4 or later during the treatment phase (intent-to-treat) with available data at each time point.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and weeks 4, 8, 12, 16, 20, and 24", "groups": [{"id": "OG000", "title": "Elagolix 150 mg QD", "description": "Participants received elagolix 150 mg orally once a day (QD) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG001", "title": "Elagolix 75 mg BID", "description": "Participants received elagolix 75 mg orally twice a day (BID) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG002", "title": "DMPA-SC", "description": "Participants received placebo to elagolix orally once a day for 24 weeks and DMPA-SC 104 mg by subcutaneous injection at weeks 1 and 12."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "84"}, {"groupId": "OG001", "value": "84"}, {"groupId": "OG002", "value": "83"}]}], "classes": [{"title": "Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "83"}, {"groupId": "OG001", "value": "84"}, {"groupId": "OG002", "value": "82"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-10.2", "spread": "1.59"}, {"groupId": "OG001", "value": "-11.7", "spread": "1.58"}, {"groupId": "OG002", "value": "-10.2", "spread": "1.59"}]}]}, {"title": "Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "76"}, {"groupId": "OG001", "value": "78"}, {"groupId": "OG002", "value": "74"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-14.0", "spread": "2.09"}, {"groupId": "OG001", "value": "-17.8", "spread": "2.06"}, {"groupId": "OG002", "value": "-15.9", "spread": "2.10"}]}]}, {"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "70"}, {"groupId": "OG001", "value": "73"}, {"groupId": "OG002", "value": "66"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-17.7", "spread": "2.24"}, {"groupId": "OG001", "value": "-23.4", "spread": "2.19"}, {"groupId": "OG002", "value": "-15.5", "spread": "2.27"}]}]}, {"title": "Week 16", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "65"}, {"groupId": "OG001", "value": "67"}, {"groupId": "OG002", "value": "58"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-17.8", "spread": "2.51"}, {"groupId": "OG001", "value": "-23.6", "spread": "2.45"}, {"groupId": "OG002", "value": "-17.3", "spread": "2.57"}]}]}, {"title": "Week 20", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "66"}, {"groupId": "OG002", "value": "54"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-16.6", "spread": "2.53"}, {"groupId": "OG001", "value": "-24.1", "spread": "2.43"}, {"groupId": "OG002", "value": "-17.1", "spread": "2.59"}]}]}, {"title": "Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "55"}, {"groupId": "OG001", "value": "63"}, {"groupId": "OG002", "value": "50"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-18.2", "spread": "2.57"}, {"groupId": "OG001", "value": "-23.4", "spread": "2.47"}, {"groupId": "OG002", "value": "-17.9", "spread": "2.64"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Within-group analysis of change from baseline in monthly mean VAS for pelvic pain at week 24. Change from baseline was analyzed using a mixed-effects repeated measures (MERM) analysis of covariance model which included fixed effects for treatment, time, treatment-by-time interaction, a random effect for patient, and terms for baseline value and the baseline-by-time interaction.", "nonInferiorityType": "OTHER", "pValue": "< 0.0001", "pValueComment": "P-value for test of null hypothesis that the treatment group least squares mean is equal to zero.", "statisticalMethod": "t-test, 2 sided", "paramType": "Least squares mean", "paramValue": "-18.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-23.3", "ciUpperLimit": "-13.1"}, {"groupIds": ["OG001"], "groupDescription": "Within-group analysis of change from baseline in monthly mean VAS for pelvic pain at week 24. Change from baseline was analyzed using a mixed-effects repeated measures (MERM) analysis of covariance model which included fixed effects for treatment, time, treatment-by-time interaction, a random effect for patient, and terms for baseline value and the baseline-by-time interaction.", "nonInferiorityType": "OTHER", "pValue": "< 0.0001", "pValueComment": "P-value for test of null hypothesis that the treatment group least squares mean is equal to zero.", "statisticalMethod": "t-test, 2 sided", "paramType": "Least squares mean", "paramValue": "-23.4", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-28.3", "ciUpperLimit": "-18.5"}, {"groupIds": ["OG002"], "groupDescription": "Within-group analysis of change from baseline in peak VAS for pelvic pain at week 24. Change from baseline was analyzed using a mixed-effects repeated measures (MERM) analysis of covariance model which included fixed effects for treatment, time, treatment-by-time interaction, a random effect for patient, and terms for baseline value and the baseline-by-time interaction.", "nonInferiorityType": "OTHER", "pValue": "< 0.0001", "pValueComment": "P-value for test of null hypothesis that the treatment group least squares mean is equal to zero.", "statisticalMethod": "t-test, 2 sided", "paramType": "Least squares mean", "paramValue": "-17.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-23.1", "ciUpperLimit": "-12.7"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Endometriosis Health Profile-5 (EHP-5) Pain Dimension", "description": "The EHP-5 is an instrument to measure health-related quality of life in women with endometriosis. The EHP-5 consists of two parts:\n\n* A core questionnaire consisting of five questions that measure the areas of pain, control and powerlessness, emotional well-being, social support, and self-image\n* A supplemental questionnaire consisting of six additional questions, five of which were recorded in this study: work, relationship with children, sexual intercourse, feelings about the medical profession and treatment.\n\nEach question was scored on a five point scale (Never = 0, Rarely = 25, Sometimes = 50, Often = 75, Always = 100), where 0 indicates the best health status and 100 worst health status. A negative change from baseline score indicates improvement in quality of life.", "populationDescription": "All randomized participants who received at least one oral dose of study drug, an initial subcutaneous injection, and either reported at least 7 e-diary VAS values or provided an assessment of either dysmenorrhea or non-menstrual pelvic pain at week 4 or later during the treatment phase (intent-to-treat) with available data at each time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and weeks 4, 8, 12, 16, 20, and 24", "groups": [{"id": "OG000", "title": "Elagolix 150 mg QD", "description": "Participants received elagolix 150 mg orally once a day (QD) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG001", "title": "Elagolix 75 mg BID", "description": "Participants received elagolix 75 mg orally twice a day (BID) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG002", "title": "DMPA-SC", "description": "Participants received placebo to elagolix orally once a day for 24 weeks and DMPA-SC 104 mg by subcutaneous injection at weeks 1 and 12."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "84"}, {"groupId": "OG001", "value": "84"}, {"groupId": "OG002", "value": "83"}]}], "classes": [{"title": "Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "81"}, {"groupId": "OG001", "value": "82"}, {"groupId": "OG002", "value": "83"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-20.7", "spread": "2.4"}, {"groupId": "OG001", "value": "-22.9", "spread": "2.6"}, {"groupId": "OG002", "value": "-18.7", "spread": "2.5"}]}]}, {"title": "Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "74"}, {"groupId": "OG001", "value": "75"}, {"groupId": "OG002", "value": "73"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-22.0", "spread": "3.1"}, {"groupId": "OG001", "value": "-30.0", "spread": "2.5"}, {"groupId": "OG002", "value": "-24.3", "spread": "2.6"}]}]}, {"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "71"}, {"groupId": "OG001", "value": "73"}, {"groupId": "OG002", "value": "67"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-23.2", "spread": "3.1"}, {"groupId": "OG001", "value": "-28.4", "spread": "3.2"}, {"groupId": "OG002", "value": "-25.4", "spread": "3.4"}]}]}, {"title": "Week 16", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "64"}, {"groupId": "OG001", "value": "69"}, {"groupId": "OG002", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-30.9", "spread": "3.1"}, {"groupId": "OG001", "value": "-31.9", "spread": "2.8"}, {"groupId": "OG002", "value": "-29.8", "spread": "3.7"}]}]}, {"title": "Week 20", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "60"}, {"groupId": "OG001", "value": "68"}, {"groupId": "OG002", "value": "53"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-26.3", "spread": "3.8"}, {"groupId": "OG001", "value": "-29.8", "spread": "2.8"}, {"groupId": "OG002", "value": "-28.3", "spread": "3.6"}]}]}, {"title": "Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "65"}, {"groupId": "OG002", "value": "51"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-28.9", "spread": "3.2"}, {"groupId": "OG001", "value": "-28.5", "spread": "3.2"}, {"groupId": "OG002", "value": "-30.9", "spread": "4.1"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in EHP-5 Control and Powerlessness Dimension", "description": "The EHP-5 is an instrument to measure health-related quality of life in women with endometriosis. The EHP-5 consists of two parts:\n\n* A core questionnaire consisting of five questions that measure the areas of pain, control and powerlessness, emotional well-being, social support, and self-image\n* A supplemental questionnaire consisting of six additional questions, five of which were recorded in this study: work, relationship with children, sexual intercourse, feelings about the medical profession and treatment.\n\nEach question was scored on a five point scale (Never = 0, Rarely = 25, Sometimes = 50, Often = 75, Always = 100), where 0 indicates the best health status and 100 worst health status. A negative change from baseline score indicates improvement in quality of life.", "populationDescription": "All randomized participants who received at least one oral dose of study drug, an initial subcutaneous injection, and either reported at least 7 e-diary VAS values or provided an assessment of either dysmenorrhea or non-menstrual pelvic pain at week 4 or later during the treatment phase (intent-to-treat) with available data at each time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and weeks 4, 8, 12, 16, 20, and 24", "groups": [{"id": "OG000", "title": "Elagolix 150 mg QD", "description": "Participants received elagolix 150 mg orally once a day (QD) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG001", "title": "Elagolix 75 mg BID", "description": "Participants received elagolix 75 mg orally twice a day (BID) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG002", "title": "DMPA-SC", "description": "Participants received placebo to elagolix orally once a day for 24 weeks and DMPA-SC 104 mg by subcutaneous injection at weeks 1 and 12."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "84"}, {"groupId": "OG001", "value": "84"}, {"groupId": "OG002", "value": "83"}]}], "classes": [{"title": "Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "81"}, {"groupId": "OG001", "value": "82"}, {"groupId": "OG002", "value": "83"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-19.8", "spread": "2.9"}, {"groupId": "OG001", "value": "-24.7", "spread": "3.0"}, {"groupId": "OG002", "value": "-22.9", "spread": "2.6"}]}]}, {"title": "Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "74"}, {"groupId": "OG001", "value": "75"}, {"groupId": "OG002", "value": "73"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-27.7", "spread": "3.1"}, {"groupId": "OG001", "value": "-33.0", "spread": "3.5"}, {"groupId": "OG002", "value": "-31.2", "spread": "3.5"}]}]}, {"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "71"}, {"groupId": "OG001", "value": "73"}, {"groupId": "OG002", "value": "67"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-30.6", "spread": "3.3"}, {"groupId": "OG001", "value": "-31.2", "spread": "3.8"}, {"groupId": "OG002", "value": "-26.1", "spread": "4.0"}]}]}, {"title": "Week 16", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "64"}, {"groupId": "OG001", "value": "69"}, {"groupId": "OG002", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-34.4", "spread": "3.7"}, {"groupId": "OG001", "value": "-33.3", "spread": "3.8"}, {"groupId": "OG002", "value": "-31.1", "spread": "4.3"}]}]}, {"title": "Week 20", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "60"}, {"groupId": "OG001", "value": "68"}, {"groupId": "OG002", "value": "53"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-32.9", "spread": "3.8"}, {"groupId": "OG001", "value": "-33.1", "spread": "4.2"}, {"groupId": "OG002", "value": "-34.9", "spread": "4.4"}]}]}, {"title": "Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "65"}, {"groupId": "OG002", "value": "51"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-37.3", "spread": "3.8"}, {"groupId": "OG001", "value": "-33.1", "spread": "3.8"}, {"groupId": "OG002", "value": "-35.8", "spread": "5.0"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in EHP-5 Emotional Well-being Dimension", "description": "The EHP-5 is an instrument to measure health-related quality of life in women with endometriosis. The EHP-5 consists of two parts:\n\n* A core questionnaire consisting of five questions that measure the areas of pain, control and powerlessness, emotional well-being, social support, and self-image\n* A supplemental questionnaire consisting of six additional questions, five of which were recorded in this study: work, relationship with children, sexual intercourse, feelings about the medical profession and treatment.\n\nEach question was scored on a five point scale (Never = 0, Rarely = 25, Sometimes = 50, Often = 75, Always = 100), where 0 indicates the best health status and 100 worst health status. A negative change from baseline score indicates improvement in quality of life.", "populationDescription": "All randomized participants who received at least one oral dose of study drug, an initial subcutaneous injection, and either reported at least 7 e-diary VAS values or provided an assessment of either dysmenorrhea or non-menstrual pelvic pain at week 4 or later during the treatment phase (intent-to-treat) with available data at each time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and weeks 4, 8, 12, 16, 20, and 24", "groups": [{"id": "OG000", "title": "Elagolix 150 mg QD", "description": "Participants received elagolix 150 mg orally once a day (QD) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG001", "title": "Elagolix 75 mg BID", "description": "Participants received elagolix 75 mg orally twice a day (BID) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG002", "title": "DMPA-SC", "description": "Participants received placebo to elagolix orally once a day for 24 weeks and DMPA-SC 104 mg by subcutaneous injection at weeks 1 and 12."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "84"}, {"groupId": "OG001", "value": "84"}, {"groupId": "OG002", "value": "83"}]}], "classes": [{"title": "Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "81"}, {"groupId": "OG001", "value": "82"}, {"groupId": "OG002", "value": "83"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-12.7", "spread": "2.5"}, {"groupId": "OG001", "value": "-10.4", "spread": "2.7"}, {"groupId": "OG002", "value": "-5.1", "spread": "2.8"}]}]}, {"title": "Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "74"}, {"groupId": "OG001", "value": "75"}, {"groupId": "OG002", "value": "73"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-20.6", "spread": "2.7"}, {"groupId": "OG001", "value": "-16.0", "spread": "3.1"}, {"groupId": "OG002", "value": "-13.4", "spread": "2.9"}]}]}, {"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "71"}, {"groupId": "OG001", "value": "73"}, {"groupId": "OG002", "value": "67"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-18.0", "spread": "3.0"}, {"groupId": "OG001", "value": "-21.9", "spread": "3.2"}, {"groupId": "OG002", "value": "-14.6", "spread": "2.6"}]}]}, {"title": "Week 16", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "64"}, {"groupId": "OG001", "value": "69"}, {"groupId": "OG002", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-21.1", "spread": "3.3"}, {"groupId": "OG001", "value": "-20.7", "spread": "3.6"}, {"groupId": "OG002", "value": "-14.9", "spread": "3.7"}]}]}, {"title": "Week 20", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "60"}, {"groupId": "OG001", "value": "68"}, {"groupId": "OG002", "value": "53"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-20.8", "spread": "3.7"}, {"groupId": "OG001", "value": "-22.8", "spread": "3.1"}, {"groupId": "OG002", "value": "-18.4", "spread": "3.8"}]}]}, {"title": "Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "65"}, {"groupId": "OG002", "value": "51"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-24.1", "spread": "3.6"}, {"groupId": "OG001", "value": "-23.8", "spread": "3.4"}, {"groupId": "OG002", "value": "-25.5", "spread": "4.2"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in EHP-5 Social Support Dimension", "description": "The EHP-5 is an instrument to measure health-related quality of life in women with endometriosis. The EHP-5 consists of two parts:\n\n* A core questionnaire consisting of five questions that measure the areas of pain, control and powerlessness, emotional well-being, social support, and self-image\n* A supplemental questionnaire consisting of six additional questions, five of which were recorded in this study: work, relationship with children, sexual intercourse, feelings about the medical profession and treatment.\n\nEach question was scored on a five point scale (Never = 0, Rarely = 25, Sometimes = 50, Often = 75, Always = 100), where 0 indicates the best health status and 100 worst health status. A negative change from baseline score indicates improvement in quality of life.", "populationDescription": "All randomized participants who received at least one oral dose of study drug, an initial subcutaneous injection, and either reported at least 7 e-diary VAS values or provided an assessment of either dysmenorrhea or non-menstrual pelvic pain at week 4 or later during the treatment phase (intent-to-treat) with available data at each time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and weeks 4, 8, 12, 16, 20, and 24", "groups": [{"id": "OG000", "title": "Elagolix 150 mg QD", "description": "Participants received elagolix 150 mg orally once a day (QD) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG001", "title": "Elagolix 75 mg BID", "description": "Participants received elagolix 75 mg orally twice a day (BID) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG002", "title": "DMPA-SC", "description": "Participants received placebo to elagolix orally once a day for 24 weeks and DMPA-SC 104 mg by subcutaneous injection at weeks 1 and 12."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "84"}, {"groupId": "OG001", "value": "84"}, {"groupId": "OG002", "value": "83"}]}], "classes": [{"title": "Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "81"}, {"groupId": "OG001", "value": "82"}, {"groupId": "OG002", "value": "83"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-25.3", "spread": "3.0"}, {"groupId": "OG001", "value": "-26.5", "spread": "3.4"}, {"groupId": "OG002", "value": "-19.6", "spread": "2.9"}]}]}, {"title": "Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "74"}, {"groupId": "OG001", "value": "75"}, {"groupId": "OG002", "value": "73"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-31.4", "spread": "3.5"}, {"groupId": "OG001", "value": "-33.7", "spread": "3.9"}, {"groupId": "OG002", "value": "-29.8", "spread": "3.4"}]}]}, {"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "70"}, {"groupId": "OG001", "value": "73"}, {"groupId": "OG002", "value": "67"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-36.8", "spread": "3.7"}, {"groupId": "OG001", "value": "-34.6", "spread": "4.4"}, {"groupId": "OG002", "value": "-28.4", "spread": "3.6"}]}]}, {"title": "Week 16", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "64"}, {"groupId": "OG001", "value": "69"}, {"groupId": "OG002", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-42.2", "spread": "4.0"}, {"groupId": "OG001", "value": "-37.0", "spread": "4.3"}, {"groupId": "OG002", "value": "-32.0", "spread": "3.7"}]}]}, {"title": "Week 20", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "60"}, {"groupId": "OG001", "value": "68"}, {"groupId": "OG002", "value": "53"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-42.1", "spread": "4.2"}, {"groupId": "OG001", "value": "-39.0", "spread": "4.4"}, {"groupId": "OG002", "value": "-34.9", "spread": "3.9"}]}]}, {"title": "Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "65"}, {"groupId": "OG002", "value": "51"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-43.4", "spread": "4.1"}, {"groupId": "OG001", "value": "-40.0", "spread": "4.4"}, {"groupId": "OG002", "value": "-32.8", "spread": "5.1"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in EHP-5 Self Image Dimension", "description": "The EHP-5 is an instrument to measure health-related quality of life in women with endometriosis. The EHP-5 consists of two parts:\n\n* A core questionnaire consisting of five questions that measure the areas of pain, control and powerlessness, emotional well-being, social support, and self-image\n* A supplemental questionnaire consisting of six additional questions, five of which were recorded in this study: work, relationship with children, sexual intercourse, feelings about the medical profession and treatment.\n\nEach question was scored on a five point scale (Never = 0, Rarely = 25, Sometimes = 50, Often = 75, Always = 100), where 0 indicates the best health status and 100 worst health status. A negative change from baseline score indicates improvement in quality of life.", "populationDescription": "All randomized participants who received at least one oral dose of study drug, an initial subcutaneous injection, and either reported at least 7 e-diary VAS values or provided an assessment of either dysmenorrhea or non-menstrual pelvic pain at week 4 or later during the treatment phase (intent-to-treat) with available data at each time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and weeks 4, 8, 12, 16, 20, and 24", "groups": [{"id": "OG000", "title": "Elagolix 150 mg QD", "description": "Participants received elagolix 150 mg orally once a day (QD) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG001", "title": "Elagolix 75 mg BID", "description": "Participants received elagolix 75 mg orally twice a day (BID) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG002", "title": "DMPA-SC", "description": "Participants received placebo to elagolix orally once a day for 24 weeks and DMPA-SC 104 mg by subcutaneous injection at weeks 1 and 12."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "84"}, {"groupId": "OG001", "value": "84"}, {"groupId": "OG002", "value": "83"}]}], "classes": [{"title": "Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "81"}, {"groupId": "OG001", "value": "82"}, {"groupId": "OG002", "value": "83"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-11.1", "spread": "3.3"}, {"groupId": "OG001", "value": "-20.1", "spread": "2.9"}, {"groupId": "OG002", "value": "-11.1", "spread": "3.5"}]}]}, {"title": "Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "74"}, {"groupId": "OG001", "value": "75"}, {"groupId": "OG002", "value": "73"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-19.6", "spread": "3.3"}, {"groupId": "OG001", "value": "-22.7", "spread": "3.3"}, {"groupId": "OG002", "value": "-17.5", "spread": "3.8"}]}]}, {"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "71"}, {"groupId": "OG001", "value": "73"}, {"groupId": "OG002", "value": "67"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-21.1", "spread": "4.0"}, {"groupId": "OG001", "value": "-22.6", "spread": "3.2"}, {"groupId": "OG002", "value": "-18.3", "spread": "4.1"}]}]}, {"title": "Week 16", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "64"}, {"groupId": "OG001", "value": "69"}, {"groupId": "OG002", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-20.3", "spread": "3.6"}, {"groupId": "OG001", "value": "-25.7", "spread": "3.1"}, {"groupId": "OG002", "value": "-18.9", "spread": "3.9"}]}]}, {"title": "Week 20", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "60"}, {"groupId": "OG001", "value": "68"}, {"groupId": "OG002", "value": "53"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-20.8", "spread": "4.3"}, {"groupId": "OG001", "value": "-26.1", "spread": "3.4"}, {"groupId": "OG002", "value": "-19.3", "spread": "4.4"}]}]}, {"title": "Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "65"}, {"groupId": "OG002", "value": "51"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-23.7", "spread": "4.1"}, {"groupId": "OG001", "value": "-26.9", "spread": "3.8"}, {"groupId": "OG002", "value": "-24.5", "spread": "4.9"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in EHP-5 Work Dimension", "description": "The EHP-5 is an instrument to measure health-related quality of life in women with endometriosis. The EHP-5 consists of two parts:\n\n* A core questionnaire consisting of five questions that measure the areas of pain, control and powerlessness, emotional well-being, social support, and self-image\n* A supplemental questionnaire consisting of six additional questions, five of which were recorded in this study: work, relationship with children, sexual intercourse, feelings about the medical profession and treatment.\n\nEach question was scored on a five point scale (Never = 0, Rarely = 25, Sometimes = 50, Often = 75, Always = 100), or Not Relevant (no score), where 0 indicates the best health status and 100 worst health status. A negative change from baseline score indicates improvement in quality of life.", "populationDescription": "All randomized participants who received at least one oral dose of study drug, an initial subcutaneous injection, and either reported at least 7 e-diary VAS values or provided an assessment of either dysmenorrhea or non-menstrual pelvic pain at week 4 or later during the treatment phase (intent-to-treat) with available data at each time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and weeks 4, 8, 12, 16, 20, and 24", "groups": [{"id": "OG000", "title": "Elagolix 150 mg QD", "description": "Participants received elagolix 150 mg orally once a day (QD) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG001", "title": "Elagolix 75 mg BID", "description": "Participants received elagolix 75 mg orally twice a day (BID) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG002", "title": "DMPA-SC", "description": "Participants received placebo to elagolix orally once a day for 24 weeks and DMPA-SC 104 mg by subcutaneous injection at weeks 1 and 12."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "84"}, {"groupId": "OG001", "value": "84"}, {"groupId": "OG002", "value": "83"}]}], "classes": [{"title": "Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "73"}, {"groupId": "OG001", "value": "73"}, {"groupId": "OG002", "value": "75"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-20.5", "spread": "3.2"}, {"groupId": "OG001", "value": "-20.9", "spread": "2.8"}, {"groupId": "OG002", "value": "-21.0", "spread": "2.6"}]}]}, {"title": "Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "66"}, {"groupId": "OG001", "value": "66"}, {"groupId": "OG002", "value": "64"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-21.2", "spread": "3.5"}, {"groupId": "OG001", "value": "-25.8", "spread": "3.1"}, {"groupId": "OG002", "value": "-25.8", "spread": "3.3"}]}]}, {"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "62"}, {"groupId": "OG001", "value": "66"}, {"groupId": "OG002", "value": "58"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-21.8", "spread": "3.8"}, {"groupId": "OG001", "value": "-24.2", "spread": "3.3"}, {"groupId": "OG002", "value": "-25.4", "spread": "3.7"}]}]}, {"title": "Week 16", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "63"}, {"groupId": "OG002", "value": "47"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-24.6", "spread": "3.9"}, {"groupId": "OG001", "value": "-26.6", "spread": "3.2"}, {"groupId": "OG002", "value": "-26.6", "spread": "4.0"}]}]}, {"title": "Week 20", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "54"}, {"groupId": "OG001", "value": "61"}, {"groupId": "OG002", "value": "45"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-24.1", "spread": "4.2"}, {"groupId": "OG001", "value": "-27.5", "spread": "3.1"}, {"groupId": "OG002", "value": "-29.4", "spread": "4.1"}]}]}, {"title": "Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "51"}, {"groupId": "OG001", "value": "58"}, {"groupId": "OG002", "value": "44"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-24.0", "spread": "4.0"}, {"groupId": "OG001", "value": "-26.7", "spread": "3.1"}, {"groupId": "OG002", "value": "-27.8", "spread": "4.2"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in EHP-5 Relationship With Children Dimension", "description": "The EHP-5 is an instrument to measure health-related quality of life in women with endometriosis. The EHP-5 consists of two parts:\n\n* A core questionnaire consisting of five questions that measure the areas of pain, control and powerlessness, emotional well-being, social support, and self-image\n* A supplemental questionnaire consisting of six additional questions, five of which were recorded in this study: work, relationship with children, sexual intercourse, feelings about the medical profession and treatment.\n\nEach question was scored on a five point scale (Never = 0, Rarely = 25, Sometimes = 50, Often = 75, Always = 100), or Not Relevant (no score), where 0 indicates the best health status and 100 worst health status. A negative change from baseline score indicates improvement in quality of life.", "populationDescription": "All randomized participants who received at least one oral dose of study drug, an initial subcutaneous injection, and either reported at least 7 e-diary VAS values or provided an assessment of either dysmenorrhea or non-menstrual pelvic pain at week 4 or later during the treatment phase (intent-to-treat) with available data at each time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and weeks 4, 8, 12, 16, 20, and 24", "groups": [{"id": "OG000", "title": "Elagolix 150 mg QD", "description": "Participants received elagolix 150 mg orally once a day (QD) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG001", "title": "Elagolix 75 mg BID", "description": "Participants received elagolix 75 mg orally twice a day (BID) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG002", "title": "DMPA-SC", "description": "Participants received placebo to elagolix orally once a day for 24 weeks and DMPA-SC 104 mg by subcutaneous injection at weeks 1 and 12."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "84"}, {"groupId": "OG001", "value": "84"}, {"groupId": "OG002", "value": "83"}]}], "classes": [{"title": "Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "42"}, {"groupId": "OG001", "value": "37"}, {"groupId": "OG002", "value": "45"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-16.1", "spread": "4.4"}, {"groupId": "OG001", "value": "-18.9", "spread": "3.8"}, {"groupId": "OG002", "value": "-16.1", "spread": "3.9"}]}]}, {"title": "Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "39"}, {"groupId": "OG001", "value": "36"}, {"groupId": "OG002", "value": "39"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-19.9", "spread": "4.5"}, {"groupId": "OG001", "value": "-20.8", "spread": "3.8"}, {"groupId": "OG002", "value": "-24.4", "spread": "3.9"}]}]}, {"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "35"}, {"groupId": "OG002", "value": "35"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-23.0", "spread": "4.8"}, {"groupId": "OG001", "value": "-20.7", "spread": "4.2"}, {"groupId": "OG002", "value": "-28.6", "spread": "4.8"}]}]}, {"title": "Week 16", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "31"}, {"groupId": "OG001", "value": "32"}, {"groupId": "OG002", "value": "30"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-24.2", "spread": "4.7"}, {"groupId": "OG001", "value": "-26.6", "spread": "4.2"}, {"groupId": "OG002", "value": "-25.8", "spread": "5.0"}]}]}, {"title": "Week 20", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "28"}, {"groupId": "OG002", "value": "28"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-27.8", "spread": "4.3"}, {"groupId": "OG001", "value": "-25.0", "spread": "4.1"}, {"groupId": "OG002", "value": "-28.6", "spread": "5.7"}]}]}, {"title": "Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "29"}, {"groupId": "OG002", "value": "26"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-29.8", "spread": "4.6"}, {"groupId": "OG001", "value": "-23.3", "spread": "4.3"}, {"groupId": "OG002", "value": "-31.7", "spread": "6.0"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in EHP-5 Intercourse Dimension", "description": "The EHP-5 is an instrument to measure health-related quality of life in women with endometriosis. The EHP-5 consists of two parts:\n\n* A core questionnaire consisting of five questions that measure the areas of pain, control and powerlessness, emotional well-being, social support, and self-image\n* A supplemental questionnaire consisting of six additional questions, five of which were recorded in this study: work, relationship with children, sexual intercourse, feelings about the medical profession and treatment.\n\nEach question was scored on a five point scale (Never = 0, Rarely = 25, Sometimes = 50, Often = 75, Always = 100), or Not Relevant (no score), where 0 indicates the best health status and 100 worst health status. A negative change from baseline score indicates improvement in quality of life.", "populationDescription": "All randomized participants who received at least one oral dose of study drug, an initial subcutaneous injection, and either reported at least 7 e-diary VAS values or provided an assessment of either dysmenorrhea or non-menstrual pelvic pain at week 4 or later during the treatment phase (intent-to-treat) with available data at each time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and weeks 4, 8, 12, 16, 20, and 24", "groups": [{"id": "OG000", "title": "Elagolix 150 mg QD", "description": "Participants received elagolix 150 mg orally once a day (QD) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG001", "title": "Elagolix 75 mg BID", "description": "Participants received elagolix 75 mg orally twice a day (BID) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG002", "title": "DMPA-SC", "description": "Participants received placebo to elagolix orally once a day for 24 weeks and DMPA-SC 104 mg by subcutaneous injection at weeks 1 and 12."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "84"}, {"groupId": "OG001", "value": "84"}, {"groupId": "OG002", "value": "83"}]}], "classes": [{"title": "Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "71"}, {"groupId": "OG001", "value": "65"}, {"groupId": "OG002", "value": "69"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-17.3", "spread": "3.3"}, {"groupId": "OG001", "value": "-18.5", "spread": "3.6"}, {"groupId": "OG002", "value": "-17.4", "spread": "3.3"}]}]}, {"title": "Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "62"}, {"groupId": "OG001", "value": "57"}, {"groupId": "OG002", "value": "61"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-25.8", "spread": "3.5"}, {"groupId": "OG001", "value": "-27.2", "spread": "3.8"}, {"groupId": "OG002", "value": "-20.5", "spread": "4.3"}]}]}, {"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}, {"groupId": "OG001", "value": "56"}, {"groupId": "OG002", "value": "55"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-29.1", "spread": "3.7"}, {"groupId": "OG001", "value": "-29.5", "spread": "4.0"}, {"groupId": "OG002", "value": "-20.5", "spread": "4.4"}]}]}, {"title": "Week 16", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "52"}, {"groupId": "OG001", "value": "54"}, {"groupId": "OG002", "value": "43"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-31.7", "spread": "4.3"}, {"groupId": "OG001", "value": "-29.2", "spread": "3.8"}, {"groupId": "OG002", "value": "-23.3", "spread": "5.1"}]}]}, {"title": "Week 20", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "48"}, {"groupId": "OG001", "value": "52"}, {"groupId": "OG002", "value": "41"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-30.7", "spread": "4.4"}, {"groupId": "OG001", "value": "-31.7", "spread": "4.2"}, {"groupId": "OG002", "value": "-25.0", "spread": "5.2"}]}]}, {"title": "Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "46"}, {"groupId": "OG001", "value": "45"}, {"groupId": "OG002", "value": "39"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-35.3", "spread": "4.4"}, {"groupId": "OG001", "value": "-33.9", "spread": "4.4"}, {"groupId": "OG002", "value": "-29.5", "spread": "5.4"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in EHP-5 Medical Profession Dimension", "description": "The EHP-5 is an instrument to measure health-related quality of life in women with endometriosis. The EHP-5 consists of two parts:\n\n* A core questionnaire consisting of five questions that measure the areas of pain, control and powerlessness, emotional well-being, social support, and self-image\n* A supplemental questionnaire consisting of six additional questions, five of which were recorded in this study: work, relationship with children, sexual intercourse, feelings about the medical profession and treatment.\n\nEach question was scored on a five point scale (Never = 0, Rarely = 25, Sometimes = 50, Often = 75, Always = 100), or Not Relevant (no score), where 0 indicates the best health status and 100 worst health status. A negative change from baseline score indicates improvement in quality of life.", "populationDescription": "All randomized participants who received at least one oral dose of study drug, an initial subcutaneous injection, and either reported at least 7 e-diary VAS values or provided an assessment of either dysmenorrhea or non-menstrual pelvic pain at week 4 or later during the treatment phase (intent-to-treat) with available data at each time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and weeks 4, 8, 12, 16, 20, and 24", "groups": [{"id": "OG000", "title": "Elagolix 150 mg QD", "description": "Participants received elagolix 150 mg orally once a day (QD) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG001", "title": "Elagolix 75 mg BID", "description": "Participants received elagolix 75 mg orally twice a day (BID) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG002", "title": "DMPA-SC", "description": "Participants received placebo to elagolix orally once a day for 24 weeks and DMPA-SC 104 mg by subcutaneous injection at weeks 1 and 12."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "84"}, {"groupId": "OG001", "value": "84"}, {"groupId": "OG002", "value": "83"}]}], "classes": [{"title": "Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "70"}, {"groupId": "OG001", "value": "69"}, {"groupId": "OG002", "value": "71"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-13.2", "spread": "3.4"}, {"groupId": "OG001", "value": "-9.1", "spread": "2.6"}, {"groupId": "OG002", "value": "-12.0", "spread": "2.6"}]}]}, {"title": "Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "62"}, {"groupId": "OG001", "value": "63"}, {"groupId": "OG002", "value": "65"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-15.3", "spread": "3.0"}, {"groupId": "OG001", "value": "-14.7", "spread": "3.2"}, {"groupId": "OG002", "value": "-13.5", "spread": "3.2"}]}]}, {"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "60"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-16.7", "spread": "3.4"}, {"groupId": "OG001", "value": "-14.2", "spread": "3.7"}, {"groupId": "OG002", "value": "-15.0", "spread": "3.2"}]}]}, {"title": "Week 16", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "53"}, {"groupId": "OG001", "value": "59"}, {"groupId": "OG002", "value": "49"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-18.9", "spread": "3.6"}, {"groupId": "OG001", "value": "-14.4", "spread": "3.4"}, {"groupId": "OG002", "value": "-17.9", "spread": "3.5"}]}]}, {"title": "Week 20", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "48"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "48"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-18.2", "spread": "3.8"}, {"groupId": "OG001", "value": "-14.6", "spread": "3.2"}, {"groupId": "OG002", "value": "-15.6", "spread": "3.8"}]}]}, {"title": "Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "48"}, {"groupId": "OG001", "value": "57"}, {"groupId": "OG002", "value": "47"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-18.8", "spread": "3.5"}, {"groupId": "OG001", "value": "-14.0", "spread": "3.5"}, {"groupId": "OG002", "value": "-16.0", "spread": "4.1"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in EHP-5 Treatment Dimension", "description": "The EHP-5 is an instrument to measure health-related quality of life in women with endometriosis. The EHP-5 consists of two parts:\n\n* A core questionnaire consisting of five questions that measure the areas of pain, control and powerlessness, emotional well-being, social support, and self-image\n* A supplemental questionnaire consisting of six additional questions, five of which were recorded in this study: work, relationship with children, sexual intercourse, feelings about the medical profession and treatment.\n\nEach question was scored on a five point scale (Never = 0, Rarely = 25, Sometimes = 50, Often = 75, Always = 100), or Not Relevant (no score), where 0 indicates the best health status and 100 worst health status. A negative change from baseline score indicates improvement in quality of life.", "populationDescription": "All randomized participants who received at least one oral dose of study drug, an initial subcutaneous injection, and either reported at least 7 e-diary VAS values or provided an assessment of either dysmenorrhea or non-menstrual pelvic pain at week 4 or later during the treatment phase (intent-to-treat) with available data at each time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and weeks 4, 8, 12, 16, 20, and 24", "groups": [{"id": "OG000", "title": "Elagolix 150 mg QD", "description": "Participants received elagolix 150 mg orally once a day (QD) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG001", "title": "Elagolix 75 mg BID", "description": "Participants received elagolix 75 mg orally twice a day (BID) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG002", "title": "DMPA-SC", "description": "Participants received placebo to elagolix orally once a day for 24 weeks and DMPA-SC 104 mg by subcutaneous injection at weeks 1 and 12."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "84"}, {"groupId": "OG001", "value": "84"}, {"groupId": "OG002", "value": "83"}]}], "classes": [{"title": "Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "52"}, {"groupId": "OG001", "value": "53"}, {"groupId": "OG002", "value": "55"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-27.4", "spread": "5.1"}, {"groupId": "OG001", "value": "-30.2", "spread": "4.5"}, {"groupId": "OG002", "value": "-26.8", "spread": "4.4"}]}]}, {"title": "Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "48"}, {"groupId": "OG001", "value": "50"}, {"groupId": "OG002", "value": "47"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-32.8", "spread": "6.3"}, {"groupId": "OG001", "value": "-37.0", "spread": "4.8"}, {"groupId": "OG002", "value": "-29.8", "spread": "4.8"}]}]}, {"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "45"}, {"groupId": "OG001", "value": "45"}, {"groupId": "OG002", "value": "42"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-35.0", "spread": "6.0"}, {"groupId": "OG001", "value": "-37.2", "spread": "5.5"}, {"groupId": "OG002", "value": "-28.0", "spread": "5.3"}]}]}, {"title": "Week 16", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "38"}, {"groupId": "OG001", "value": "47"}, {"groupId": "OG002", "value": "35"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-36.8", "spread": "6.9"}, {"groupId": "OG001", "value": "-38.3", "spread": "4.6"}, {"groupId": "OG002", "value": "-28.6", "spread": "6.4"}]}]}, {"title": "Week 20", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "46"}, {"groupId": "OG002", "value": "33"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-35.7", "spread": "6.6"}, {"groupId": "OG001", "value": "-34.8", "spread": "5.2"}, {"groupId": "OG002", "value": "-35.6", "spread": "6.3"}]}]}, {"title": "Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "42"}, {"groupId": "OG002", "value": "32"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-35.6", "spread": "7.1"}, {"groupId": "OG001", "value": "-39.3", "spread": "5.0"}, {"groupId": "OG002", "value": "-28.9", "spread": "7.3"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants Using Analgesics During the Treatment Phase", "description": "Analgesic use was collected as part of concomitant medications on a case report form that was administered at each scheduled visit.", "populationDescription": "All randomized participants who received at least one oral dose of study drug, an initial subcutaneous injection, and either reported at least 7 e-diary VAS values or provided an assessment of either dysmenorrhea or non-menstrual pelvic pain at week 4 or later during the treatment phase (intent-to-treat).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "24 weeks", "groups": [{"id": "OG000", "title": "Elagolix 150 mg QD", "description": "Participants received elagolix 150 mg orally once a day (QD) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG001", "title": "Elagolix 75 mg BID", "description": "Participants received elagolix 75 mg orally twice a day (BID) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12."}, {"id": "OG002", "title": "DMPA-SC", "description": "Participants received placebo to elagolix orally once a day for 24 weeks and DMPA-SC 104 mg by subcutaneous injection at weeks 1 and 12."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "84"}, {"groupId": "OG001", "value": "84"}, {"groupId": "OG002", "value": "83"}]}], "classes": [{"title": "Antiinflammatory/Antirheumatics, Non-Steroids", "categories": [{"measurements": [{"groupId": "OG000", "value": "65.5"}, {"groupId": "OG001", "value": "64.3"}, {"groupId": "OG002", "value": "68.7"}]}]}, {"title": "Opioids", "categories": [{"measurements": [{"groupId": "OG000", "value": "23.8"}, {"groupId": "OG001", "value": "25.0"}, {"groupId": "OG002", "value": "33.7"}]}]}, {"title": "Other Analgesics and Antipyretics", "categories": [{"measurements": [{"groupId": "OG000", "value": "45.2"}, {"groupId": "OG001", "value": "46.4"}, {"groupId": "OG002", "value": "34.9"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "From first dose of study drug through 24 weeks after last dose (48 weeks)", "eventGroups": [{"id": "EG000", "title": "Elagolix 150 mg QD", "description": "Participants received elagolix 150 mg orally once a day (QD) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12.", "deathsNumAffected": 0, "deathsNumAtRisk": 84, "seriousNumAffected": 3, "seriousNumAtRisk": 84, "otherNumAffected": 63, "otherNumAtRisk": 84}, {"id": "EG001", "title": "Elagolix 75 mg BID", "description": "Participants received elagolix 75 mg orally twice a day (BID) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12.", "deathsNumAffected": 0, "deathsNumAtRisk": 84, "seriousNumAffected": 3, "seriousNumAtRisk": 84, "otherNumAffected": 59, "otherNumAtRisk": 84}, {"id": "EG002", "title": "DMPA-SC", "description": "Participants received placebo to elagolix orally once a day for 24 weeks and DMPA-SC 104 mg by subcutaneous injection at weeks 1 and 12.", "deathsNumAffected": 0, "deathsNumAtRisk": 84, "seriousNumAffected": 6, "seriousNumAtRisk": 84, "otherNumAffected": 63, "otherNumAtRisk": 84}], "seriousEvents": [{"term": "FOOD POISONING", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "medDRA 6.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 84}]}, {"term": "CHEST PAIN", "organSystem": "General disorders", "sourceVocabulary": "medDRA 6.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 84}]}, {"term": "APPENDICITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "medDRA 6.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 84}]}, {"term": "PNEUMONIA", "organSystem": "Infections and infestations", "sourceVocabulary": "medDRA 6.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 84}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "DEHYDRATION", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "medDRA 6.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "OVARIAN DYSGERMINOMA STAGE I", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "medDRA 6.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "MIGRAINE", "organSystem": "Nervous system disorders", "sourceVocabulary": "medDRA 6.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 84}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "DEPRESSION SUICIDAL", "organSystem": "Psychiatric disorders", "sourceVocabulary": "medDRA 6.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 84}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "PELVIC CONGESTION", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "medDRA 6.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 84}]}, {"term": "PELVIC PAIN", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "medDRA 6.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 84}]}, {"term": "PNEUMOTHORAX", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "medDRA 6.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 84}]}], "otherEvents": [{"term": "ABDOMINAL DISTENSION", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "medDRA 6.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}, {"groupId": "EG002", "numEvents": 7, "numAffected": 6, "numAtRisk": 84}]}, {"term": "DIARRHOEA", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "medDRA 6.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 10, "numAffected": 9, "numAtRisk": 84}, {"groupId": "EG002", "numEvents": 10, "numAffected": 8, "numAtRisk": 84}]}, {"term": "DYSPEPSIA", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "medDRA 6.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 7, "numAffected": 5, "numAtRisk": 84}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 84}]}, {"term": "NAUSEA", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "medDRA 6.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 21, "numAffected": 16, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 16, "numAffected": 13, "numAtRisk": 84}, {"groupId": "EG002", "numEvents": 20, "numAffected": 13, "numAtRisk": 84}]}, {"term": "FATIGUE", "organSystem": "General disorders", "sourceVocabulary": "medDRA 6.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 84}, {"groupId": "EG002", "numEvents": 6, "numAffected": 6, "numAtRisk": 84}]}, {"term": "INFLUENZA", "organSystem": "Infections and infestations", "sourceVocabulary": "medDRA 6.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 7, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 84}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 84}]}, {"term": "NASOPHARYNGITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "medDRA 6.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 9, "numAffected": 9, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 22, "numAffected": 18, "numAtRisk": 84}, {"groupId": "EG002", "numEvents": 11, "numAffected": 9, "numAtRisk": 84}]}, {"term": "SINUSITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "medDRA 6.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 7, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 12, "numAffected": 7, "numAtRisk": 84}, {"groupId": "EG002", "numEvents": 6, "numAffected": 6, "numAtRisk": 84}]}, {"term": "UPPER RESPIRATORY TRACT INFECTION", "organSystem": "Infections and infestations", "sourceVocabulary": "medDRA 6.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 10, "numAffected": 8, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 14, "numAffected": 10, "numAtRisk": 84}, {"groupId": "EG002", "numEvents": 10, "numAffected": 10, "numAtRisk": 84}]}, {"term": "URINARY TRACT INFECTION", "organSystem": "Infections and infestations", "sourceVocabulary": "medDRA 6.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 5, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 10, "numAffected": 8, "numAtRisk": 84}, {"groupId": "EG002", "numEvents": 5, "numAffected": 5, "numAtRisk": 84}]}, {"term": "VAGINAL MYCOSIS", "organSystem": "Infections and infestations", "sourceVocabulary": "medDRA 6.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 5, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 5, "numAffected": 4, "numAtRisk": 84}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 84}]}, {"term": "ARTHRALGIA", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "medDRA 6.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 10, "numAffected": 4, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 13, "numAffected": 9, "numAtRisk": 84}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 84}]}, {"term": "BACK PAIN", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "medDRA 6.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 6, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 11, "numAffected": 10, "numAtRisk": 84}, {"groupId": "EG002", "numEvents": 4, "numAffected": 4, "numAtRisk": 84}]}, {"term": "DIZZINESS", "organSystem": "Nervous system disorders", "sourceVocabulary": "medDRA 6.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 8, "numAffected": 6, "numAtRisk": 84}, {"groupId": "EG002", "numEvents": 9, "numAffected": 8, "numAtRisk": 84}]}, {"term": "HEADACHE", "organSystem": "Nervous system disorders", "sourceVocabulary": "medDRA 6.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 48, "numAffected": 22, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 66, "numAffected": 23, "numAtRisk": 84}, {"groupId": "EG002", "numEvents": 64, "numAffected": 15, "numAtRisk": 84}]}, {"term": "MIGRAINE", "organSystem": "Nervous system disorders", "sourceVocabulary": "medDRA 6.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 4, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 84}, {"groupId": "EG002", "numEvents": 6, "numAffected": 5, "numAtRisk": 84}]}, {"term": "ANXIETY", "organSystem": "Psychiatric disorders", "sourceVocabulary": "medDRA 6.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 6, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 84}, {"groupId": "EG002", "numEvents": 4, "numAffected": 4, "numAtRisk": 84}]}, {"term": "DEPRESSION", "organSystem": "Psychiatric disorders", "sourceVocabulary": "medDRA 6.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 6, "numAffected": 6, "numAtRisk": 84}, {"groupId": "EG002", "numEvents": 4, "numAffected": 4, "numAtRisk": 84}]}, {"term": "INSOMNIA", "organSystem": "Psychiatric disorders", "sourceVocabulary": "medDRA 6.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 11, "numAffected": 7, "numAtRisk": 84}, {"groupId": "EG002", "numEvents": 4, "numAffected": 4, "numAtRisk": 84}]}, {"term": "MOOD SWINGS", "organSystem": "Psychiatric disorders", "sourceVocabulary": "medDRA 6.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 7, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 6, "numAffected": 6, "numAtRisk": 84}, {"groupId": "EG002", "numEvents": 10, "numAffected": 10, "numAtRisk": 84}]}, {"term": "OVARIAN CYST", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "medDRA 6.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 84}]}, {"term": "COUGH", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "medDRA 6.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 7, "numAffected": 6, "numAtRisk": 84}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 84}]}, {"term": "NASAL CONGESTION", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "medDRA 6.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 4, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 6, "numAffected": 6, "numAtRisk": 84}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 84}]}, {"term": "PHARYNGOLARYNGEAL PAIN", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "medDRA 6.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 9, "numAffected": 7, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 8, "numAffected": 7, "numAtRisk": 84}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 84}]}, {"term": "SINUS CONGESTION", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "medDRA 6.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 6, "numAffected": 5, "numAtRisk": 84}, {"groupId": "EG002", "numEvents": 5, "numAffected": 5, "numAtRisk": 84}]}, {"term": "ACNE", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "medDRA 6.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 7, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 84}, {"groupId": "EG002", "numEvents": 7, "numAffected": 7, "numAtRisk": 84}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection."}, "pointOfContact": {"title": "Global Medical Services", "organization": "AbbVie", "phone": "800-633-9110"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04", "removedCountries": ["United States"]}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C539351", "term": "elagolix"}, {"id": "D017258", "term": "Medroxyprogesterone Acetate"}], "ancestors": [{"id": "D008525", "term": "Medroxyprogesterone"}, {"id": "D006908", "term": "Hydroxyprogesterones"}, {"id": "D011374", "term": "Progesterone"}, {"id": "D011282", "term": "Pregnenediones"}, {"id": "D011283", "term": "Pregnenes"}, {"id": "D011278", "term": "Pregnanes"}, {"id": "D013256", "term": "Steroids"}, {"id": "D000072473", "term": "Fused-Ring Compounds"}, {"id": "D011083", "term": "Polycyclic Compounds"}]}}, "hasResults": true}, {"protocolSection": {"identificationModule": {"nctId": "NCT03981991", "orgStudyIdInfo": {"id": "38RC19.130"}, "secondaryIdInfos": [{"id": "2019-A01143-54", "type": "OTHER", "domain": "ID RCB"}], "organization": {"fullName": "University Hospital, Grenoble", "class": "OTHER"}, "briefTitle": "Endometriosis and Quality of Life Assessed by EHP 30", "officialTitle": "Assessment of the Quality of Life for Patients Suffering From Isolated Endometriosic Lesion of Utero-sacral Ligaments Diagnosed by MRI, Before and After Surgical Treatment by Using French Version of Endometriosis Health Profile 30 (EHP30)", "acronym": "ENDOLUS"}, "statusModule": {"statusVerifiedDate": "2020-03", "overallStatus": "UNKNOWN", "lastKnownStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2019-07-31", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2020-11", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2021-06", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2019-06-07", "studyFirstSubmitQcDate": "2019-06-07", "studyFirstPostDateStruct": {"date": "2019-06-11", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2020-03-09", "lastUpdatePostDateStruct": {"date": "2020-03-10", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "University Hospital, Grenoble", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "Assessment of the quality of life for patients suffering from isolated endometriosic lesion of utero-sacral ligaments diagnosed by MRI, before and after surgical treatment by using French version of Endometriosis Health Profile 30 (EHP 30).\n\nThis is prospective, non-controlled, non-randomized, monocentric, observational feasibility study.", "detailedDescription": "Endometriosis is a gynecological pathology affecting women during periods of genital activity, which prevalence is underestimated and varies from 10 to 30%. It is characterized by dysmenorrhea, dyspareunia, chronic pelvic pain or infertility. These various manifestations lead to an alteration of the quality of life.\n\nAmong women consulting for chronic pelvic pain or suspicion of endometriosis, it is recommended to evaluate pain, as well as suggestive symptoms and localizers using validated quality of life questionnaires such as Endometriosis Health Profile 30 (EHP 30).\n\nIn case of chronic pelvic pain and suspicion of a deep lesion, the assessment of disease is based on the interrogation (deep and positional dyspareunia, urinary or digestive catamenial functional signs), pelvic clinical examination by a referral physician, an endovaginal ultrasound by a referral sonographer and pelvic MRI also by a referral radiologist.\n\nHowever, interpretation is not always easy with a high rate of false negatives. In case of absence of pathognomonic iconographic signs and, if there is an impact on patients' quality of life, a diagnostic laparoscopy can be proposed. This procedure can help to affirm or invalidate endometriotic lesions not visible in imaging, allowing either an excision or lesion destruction.\n\nAlthough the beneficial role of surgical management in spontaneous fertility has been demonstrated, the clinical benefit of reducing pain and improving the quality of life in isolated uterine sacral ligament lesions has not been demonstrated by clinical studies with a good level of evidence.\n\nThrough this study, we would like to evaluate the functional benefit on the quality of life in the short and medium term of laparoscopic surgical management in case of suspicion of isolated uterosacral ligament endometriosis documented by standardized pelvic MRI.\n\nAll MRI exams will be analyzed blindly by an expert radiologist."}, "conditionsModule": {"conditions": ["Endometriosis"], "keywords": ["EHP 30", "Endometriosis", "Quality of Life", "Uterosacral Ligament"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "COHORT", "timePerspective": "PROSPECTIVE"}, "enrollmentInfo": {"count": 30, "type": "ESTIMATED"}}, "outcomesModule": {"primaryOutcomes": [{"measure": "Assess the quality of life of patients before and 3 months after laparoscopic treatment of isolated endometriosic lesions of uterosacral ligaments by French version of the EHP 30 questionnaire.", "description": "Overall score and scores by subdomains of EHP 30 questionnaire preoperatively and at 3 months postoperatively.", "timeFrame": "3 months"}], "secondaryOutcomes": [{"measure": "Evolution of EHP 30 score (and its subdomains) preoperatively, and at 1, 3 and 6 months postoperatively.", "description": "Overall score, and scores by subdomains, of EHP 30 questionnaire at 1, 3 and 6 months postoperatively.", "timeFrame": "1 , 3 and 6 months"}, {"measure": "Assess diagnostic performances of MRI for diagnosis of lesions of uterosacral ligaments by correlating MRI's results with those of laparoscopy.", "description": "Uterosacral ligaments (yes / no) on MRI vs. laparoscopy.", "timeFrame": "1 month"}, {"measure": "Correlate, a posteriori, MRI results with findings of laparoscopy and EHP 30 score evolution", "description": "Uterosacral ligaments (yes / no) on MRI vs overall score of EHP 30 questionnaire preoperatively and at 3 months postoperatively.", "timeFrame": "3 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Patient aged from 18 to 50 years\n2. Patient with medical sign proving endometriotic lesion: dysmenorrhea, deep dyspareunia or chronic pelvic pain\n3. Patient with standardized pelvic MRI realized at CHUGA\n4. Patient with an indication for laparoscopic surgical treatment\n5. Patient available to complete the questionnaire based on EHP 30\n6. Patient available for a follow-up of 6 months\n7. Patient able to understand and read French language\n8. Patient affiliated to a social security system or beneficiary of the same.\n9. Patient who agreed to participate to the research\n\nExclusion Criteria:\n\n1. Patient with functional urinary or digestive signs related to endometriotic lesion\n2. Patient with another deep lesion proved by MRI: endometrioma, rectovaginal septum, recto-sigmoid, urinary bladder, ureters, recto-uterine pouch.\n3. Virgin patient\n4. Patient with a contraindication to MRI\n5. History of extensive pelvic surgery related to endometriosis\n6. Pregnancy\n7. Patient who did not receive laparoscopic treatment of uterosacral ligaments\n8. Patient already involved in another clinical research study\n9. Patient in a period of exclusion from another clinical research study\n10. Referred to the Articles L1121-5, L1121-6, and L1121-8 of the Public Health Code (corresponds to protected persons: pregnant woman, parturient, breastfeeding mother, person deprived of liberty by judicial or administrative decision, legally protected subject).", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "50 Years", "stdAges": ["ADULT"], "studyPopulation": "Women during periods of genital activity with medical sign proving endometriotic lesion of utero-sacral ligaments: dysmenorrhea, deep dyspareunia or chronic pelvic pain referred to Obstetrics and Gynecological Department of University Hospital of Grenoble", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"centralContacts": [{"name": "Pierre PITTET", "role": "CONTACT", "phone": "+33 (0)4 76 76 68 72", "email": "ppittet@chu-grenoble.fr"}], "overallOfficials": [{"name": "Thierry MICHY, MD", "affiliation": "University Hospital, Grenoble", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "University Hospital Grenoble", "status": "RECRUITING", "city": "Grenoble", "zip": "38043", "country": "France", "contacts": [{"name": "Thierry MICHY, MD", "role": "CONTACT", "phone": "+33 (0)4 76 76 66 77", "email": "tmichy@chu-grenoble.fr"}, {"name": "Pierre PITTET", "role": "CONTACT", "phone": "+33 (0)4 76 76 68 72", "email": "ppittet@chu-grenoble.fr"}, {"name": "Thierry MICHY, MD", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 45.17869, "lon": 5.71479}}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT04171297", "orgStudyIdInfo": {"id": "S63056"}, "organization": {"fullName": "Universitaire Ziekenhuizen KU Leuven", "class": "OTHER"}, "briefTitle": "Ultrasound Evaluation of the Pelvis in Women with Suspected Endometriosis Scheduled for Laparoscopic Surgery", "officialTitle": "Ultrasound Evaluation of the Pelvis Using the International Deep Endometriosis Analysis (IDEA) Terminology in Women with Suspected Endometriosis Scheduled for Laparoscopic Surgery - IDEA 1 Study", "acronym": "IDEA1"}, "statusModule": {"statusVerifiedDate": "2024-12", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2019-09-25", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2023-12-31", "type": "ACTUAL"}, "completionDateStruct": {"date": "2024-05-17", "type": "ACTUAL"}, "studyFirstSubmitDate": "2019-11-18", "studyFirstSubmitQcDate": "2019-11-18", "studyFirstPostDateStruct": {"date": "2019-11-20", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2024-12-04", "lastUpdatePostDateStruct": {"date": "2024-12-10", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Universitaire Ziekenhuizen KU Leuven", "class": "OTHER"}, "collaborators": [{"name": "University of Sydney", "class": "OTHER"}, {"name": "University of Cagliari", "class": "OTHER"}]}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false, "isUsExport": false}, "descriptionModule": {"briefSummary": "An international multicenter observation study to evaluate the diagnostic accuracy and predictive value of ultrasound using the IDEA terminology in the detection of deep endometriosis in women scheduled for surgery."}, "conditionsModule": {"conditions": ["Gynecologic Disease", "Endometriosis", "Endometriosis, Rectum", "Endometriosis of Colon", "Endometriosis of Vagina", "Endometriosis Rectovaginal Septum", "Endometriosis of Bladder", "Surgery"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "COHORT", "timePerspective": "PROSPECTIVE"}, "enrollmentInfo": {"count": 1866, "type": "ACTUAL"}}, "armsInterventionsModule": {"interventions": [{"type": "PROCEDURE", "name": "Ultrasound evaluation of DE", "description": "To evaluate diagnostic accuracy of ultrasound for the presence of deep endometriosis."}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Presence of deep endometriosis", "description": "The primary objective is to assess the diagnostic value of the ultrasound features in the diagnosis of deep endometriosis. The endpoints are the univariable diagnostic accuracies of ultrasound features (defined by the IDEA consensus statement) for the presence of deep endometriosis at any location: anterior compartment (i.e. bladder and its specific location) or posterior compartment (i.e. rectovaginal septum, uterosacral ligaments, torus uterinus, vaginal fornix and bowel involvement). All recruited patients are included in this analysis. The reference standard for this objective is whether there is deep endometriosis (at any location) or not (binary outcome).", "timeFrame": "1 year"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patients scheduled for radical laparoscopic endometriosis surgery\n\nExclusion Criteria:\n\n* \\<18 years\n* \\>45 years\n* (suspected) Pelvic malignancy for example gynecological, intestinal or urological malignancy\n* Premenarche\n* Menopause\n* Pregnancy\n* Patients refusal for radical surgery (for example refusal for bowel resection/temporary stoma)\n* Surgery performed more than 1 year after ultrasound scan\n* Patients refusal to participate to the study", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "45 Years", "stdAges": ["ADULT"], "studyPopulation": "Women with suspected endometriosis scheduled for laparoscopic surgery.", "samplingMethod": "PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"overallOfficials": [{"name": "Dirk Timmerman, MD, PhD", "affiliation": "UZ Leuven", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Sydney Medical School Nepean", "city": "Sydney", "country": "Australia", "geoPoint": {"lat": -33.86785, "lon": 151.20732}}, {"facility": "UZLeuven", "city": "Leuven", "zip": "3000", "country": "Belgium", "geoPoint": {"lat": 50.87959, "lon": 4.70093}}, {"facility": "University of Cagliari", "city": "Cagliari", "country": "Italy", "geoPoint": {"lat": 39.23054, "lon": 9.11917}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT06795243", "orgStudyIdInfo": {"id": "SICEIA 2024-146"}, "organization": {"fullName": "University of Seville", "class": "OTHER"}, "briefTitle": "Efficacy of Physical Therapy Treatment in Endometriosis and Its Relationship to Adherence Rates.", "officialTitle": "Efficacy of Physical Therapy Treatment in Endometriosis and Its Relationship to Adherence Rates."}, "statusModule": {"statusVerifiedDate": "2025-01", "overallStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2025-05-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2025-12-31", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2026-07-01", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2025-01-11", "studyFirstSubmitQcDate": "2025-01-24", "studyFirstPostDateStruct": {"date": "2025-01-28", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2025-06-11", "lastUpdatePostDateStruct": {"date": "2025-06-15", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Manuel Rebollo Salas", "investigatorTitle": "Principal investigator", "investigatorAffiliation": "University of Seville"}, "leadSponsor": {"name": "University of Seville", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false, "isUsExport": false}, "descriptionModule": {"briefSummary": "The main objective of this study is to know if the application of both therapies, neuroscience pain education plus therapeutic exercise will modify pain, catastrophizing and quality of life in endometriosis.", "detailedDescription": "Endometriosis is a chronic and inflammatory gynecological condition characterized by the growth of endometrial- like tissue within and outside the pelvic cavity (uterus).\n\nWith current means and diagnostic systems, a prevalence of 10% is estimated, although the evidence warns that with the improvement of early diagnosis, these figures will be much higher in the future. One of the main problems with endometriosis is the late diagnosis, which takes an average of seven years. Added to this is the fact that until a definitive diagnosis, patients live in the adolescent stage with symptoms (around 50% with severe pelvic pain) that cause disability and changes in activity and participation in daily life.\n\nAt the social level, endometriosis patients are known to have limitations in academic and work activities, as well as in social participation. All of this causes high economic costs.\n\nChronic pelvic pain can cause the phenomenon of central nervous system sensitization in which pain processing is altered. Pain catastrophizing significantly affects pain disability and vice versa in endometriosis.\n\nConventional medical care is based on hormonal, pharmacological, and / or surgical treatment and is carried out on an individualized basis depending on the severity of the treatment and the patient's needs.\n\nThe multidisciplinary approach to endometriosis has gained relevance in recent decades and has been considered by leaders in the clinical and research sectors. Within the multidisciplinary team, physiotherapy has gained relevance in recent decades.\n\nThe multimodal approach of physiotherapy is the one that the Clinical Practice Guidelines and national and international documents demand with greater relevance. Therapeutic exercise based on the work of the abdominal stabilizing musculature and motor control appears to be effective in the treatment of nonspecific low back pain and in endometriosis-related pain. But there is no 'gold standard' in terms of dosage, considering the individualization of treatments.\n\nIn the biopsychosocial care paradigm, and specifically in the approach to pathologies with primary chronic pain, patients tend to be motivated and accompanied toward self-determination to achieve adherence to treatment through health education strategies, adequate information, and personalized and goal-oriented multimodal treatment.\n\nHowever, today, nonadherence is positioned as a global problem, which is growing as the burden of chronicity of pathologies increases, influencing health outcomes and long-term healthcare costs.\n\nDue to symptomatology especially related to chronic pain in endometriosis and in the context of the biopsychosocial paradigm demanded by the scientific community, the investigators consider pertinent the study of catastrophization and its relationship with quality of life and, therefore, disability, and an intervention that addresses in a multimodal way the physiotherapy treatment for endometriosis.\n\nIt is recognized that physiotherapeutic interventions based on therapeutic exercise programs, both individual and group, are most effective when tailored to the needs of everyone. Part of this customization should focus on the barriers that each patient recognizes to treatment adherence.\n\nFor this reason, the investigators found that studies that support further research to increase the basic understanding of the factors that act as a barrier to adherence in physical therapy treatments could facilitate the development of strategies to overcome nonadherence. And if the investigators follow international recommendations, these systems should address adherence and compliance to treatment from a multidimensional perspective.\n\nTherefore, the investigators believe that measuring compliance and adherence to treatment in this way in patients with endometriosis would allow to know whether adherence to the proposed exercise programs in the target population and their effectiveness are really related or not to the adherence rates to treatment as suggested in recent publications.\n\nIn view of the above, this project aims to examine the relationship between the efficacy of physical therapy treatment in patients diagnosed with endometriosis measured in clinical and quality of life terms with short-term compliance and short- and medium-term adherence rates."}, "conditionsModule": {"conditions": ["Endometriosis", "Endometriosis Related Pain", "Endometriosis, Pain", "Endometriosis-related Pain", "Pain", "Pain Intensity Assessment", "Pain Management", "Pain, Chronic Disease", "Pain Score", "Therapeutic Exercise", "Exercise Adherence", "Adherence, Treatment", "Treatment Adherence and Compliance", "Quality of Life"], "keywords": ["Endometriosis", "Endometriosis Related Pain", "Endometriosis, Pain", "Pain", "Pain Intensity Assessment", "Pain Management", "Pain, chronic disease", "pain score", "therapeutic exercise", "exercise adherence", "Adherence, Treatment", "Treatment Adherence and Compliance", "Quality of life"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "SINGLE", "whoMasked": ["OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 50, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Experimental Group", "type": "EXPERIMENTAL", "description": "Application of a multimodal physical therapy program based on pain education and therapeutic exercise. Sixteen sessions will be carried out. The sessions will be carried out with a frequency of two days a week. Subjects will receive 6 PAIN NEUROSCIENCE EDUCATION (PNE), and 8 weeks (2 times/ week) of therapeutic exercise.", "interventionNames": ["Procedure: PAIN NEUROSCIENCE EDUCATION AND THERAPEUTIC EXERCISE PROGRAM"]}, {"label": "Control Group", "type": "ACTIVE_COMPARATOR", "description": "Usual Care. Application of standard medical treatment. In Spain, the treatment provided is mainly pharmacological, adjusted to the symptomatic profile of theses patients.", "interventionNames": ["Procedure: USUAL CARE"]}], "interventions": [{"type": "PROCEDURE", "name": "PAIN NEUROSCIENCE EDUCATION AND THERAPEUTIC EXERCISE PROGRAM", "description": "PAIN NEUROSCIENCE EDUCATION\n\n1\\. Introduction to the knowledge of pain in the XXI century. Pain as an alarm system.\n\nTypes of pain. Differences between acute and chronic pain. 3. Chronic pain. Concepts of kinesiophobia, catastrophism and fear avoidance, self-determination and neuroplasticity.\n\n4\\. Main pain management tools based on scientific evidence. 5. . Transtheoretical model of change. Adherence to treatment, importance as a determinant in health.\n\n6\\. Messages for home. Strategies of active coping in the maintenance stage.\n\nTHERAPEUTIC EXERCISE PROGRAM 10-min warm-up. Joint mobility exercises with dual task or gamification. 30-min main part. Sequence of balance work between strength and body flexibility dosed according to the specific needs of each participant.\n\n10-min cool down including breathing exercises and motor imagery. Home exercise program: walking (150 minutes in total, 3 days alternating with the face-to-face sessions).", "armGroupLabels": ["Experimental Group"]}, {"type": "PROCEDURE", "name": "USUAL CARE", "description": "The treatment provided is mainly pharmacological, adjusted to the symptomatic profile of theses patients.\n\nConventional medical care is based on hormonal, pharmacological and/or surgical treatment and is carried out on an individualized basis depending on the severity of the disease and the patient's needs, especially in matters of desire to become pregnant. Surgical treatment is carried out when pharmacological therapy (hormonal or anti-inflammatory) is ineffective or involves adverse events.", "armGroupLabels": ["Control Group"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change from Self-report Pain magnitude", "description": "Magnitude of chronic pain: Chronic pain grading scale. Likert-type scale with 8 items that are evaluated between 0 and 10 for items 2, 3, 4, 6, 7 and 8. Item 1 collects the number of days with pain in the last six months. Item 5 rates the impediment to the performance of usual tasks in the last three months, and can be evaluated between none and 90. The higher the score, the greater the chronic pain involvement. If the score is zero, the patient will be rated as having no pain. Chronic pain will be of low interference with grade I (low intensity) or grade II (high intensity) or of high interference with grade III (moderately limiting) or grade IV (severely limiting). Persistence will be graded as non-persistent or persistent pain.", "timeFrame": "At the start of the study (at baseline, 0 week), 1 month and 2 months after the start of the intervention (4 and 8 weeks), 1 month from the last session (12th week), 3 months from the last session (20th week) and 6 months from the last session (32th week"}, {"measure": "Treatment Compliance", "description": "Self-report of the person responsible for managing attendance at the group sessions in the experimental group. Participants who attend 80% or more of the sessions will be considered compliant.", "timeFrame": "From enrollment to the end of treatment at 8 weeks"}, {"measure": "Treatment adherence (Maintenance of the therapeutic exercise program at home )", "description": "Adherence to treatment (experimental group), measured by visual analogue scale (VAS) included in the patient diary, in terms of:\n\nMaintenance of treatment at home: number of days that the proposed exercise is performed (100% being 3 times a week). Each patient will complete the VAS scale weekly. Participants with a score equal to or greater than 80 points out of 100 on the VAS scale will be considered to have high adherence.", "timeFrame": "From the end of the intervention at 8 weeks (starting at week 9) to the end of treatment at 32 weeks"}, {"measure": "Changes from Self-report pain catastrophizing", "description": "Catastrophizing thoughts in the face of pain: Pain Catastrophizing Scale (PCS). Pain catastrophizing is a construct that is related to a negative and exaggerated orientation towards painful stimuli. The scale, validated in Spanish, is a list of 13 statements that describe different thoughts and feelings that may be related to pain in the dimensions of rumination, magnification and hopelessness. The person indicates the degree to which he/she has such thoughts or feelings by rating them between 0 (not at all) and 4 (all the time). The theoretical range of the instrument is between 13 and 62, with higher values indicating a higher index of catastrophizing.", "timeFrame": "At the start of the study (at baseline, 0 week), 1 month and 2 months after the start of the intervention (4 and 8 weeks), 1 month from the last session (12th week), 3 months from the last session (20th week) and 6 months from the last session (32th week"}, {"measure": "Change from Self-report specific quality of life", "description": "Specific quality of life: Endometriosis Health Profile (EHP-30+23) questionnaire Spanish version. The questionnaire is composed of two parts. Part 1 with 30 itmens and part 2 divided into five subscales: pain, control and helplessness, emotional well-being, social support and self-image. For part 1 and each subscale a total score is created as a percentage of the maximum possible score. 0 is considered the best possible health status and 100 the worst.", "timeFrame": "At the start of the study (at baseline, 0 week), 1 month and 2 months after the start of the intervention (4 and 8 weeks), 1 month from the last session (12th week), 3 months from the last session (20th week) and 6 months from the last session (32th week"}, {"measure": "Changes in self-reported general quality of life", "description": "Overall Quality of Life: EUROQOL-5 Dimensions- 3 Levels (EQ-5D-3L). It is a standardized instrument that measures health outcomes and is applicable to a wide range of diseases and treatments. It provides a simple descriptive profile and a single index of health status. The EQ-5D-3L covers 5 dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is assessed in 3 categories (no problems; moderate problems; extreme problems). The assessment consists of measuring each of the 5 domains in one of the 3 categories. In this work we use, as in our reference study, the validated Spanish version of the EQ-5D-3L in its current version for the adult population. EQ-5D © 2025 EuroQol Research Foundation.", "timeFrame": "At the start of the study (at baseline, 0 week), 1 month and 2 months after the start of the intervention (4 and 8 weeks), 1 month from the last session (12th week), 3 months from the last session (20th week) and 6 months from the last session (32th week"}], "secondaryOutcomes": [{"measure": "Exercise-related adverse events", "description": "Possible occurrence of pain, frequency of flares and fatigue, measured qualitatively in narrative text through patient diary.", "timeFrame": "At the start of the study (at baseline, 0 week), 1 month and 2 months after the start of the intervention (4 and 8 weeks), 1 month from the last session (12th week), 3 months from the last session (20th week) and 6 months from the last session (32th week"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Adult women (over 18 years of age) diagnosed with endometriosis.\n* Women with the capacity to carry out a therapeutic program based on muscular exercise.\n* Women with the capacity to understand the requirements of the study.\n\nExclusion Criteria:\n\n* Women undergoing fertility and/or assisted reproduction treatment.\n* Pregnant women.", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Inmaculada Villa-del-Pino", "role": "CONTACT", "phone": "+34679183871", "email": "inmvildel@alum.us.es"}, {"name": "Manuel Rebollo-Salas", "role": "CONTACT", "phone": "+34620399549", "email": "mrebollo@us.es"}], "overallOfficials": [{"name": "Carmen-María Suárez-Serrano", "affiliation": "Departamento de Fisioterapia. Facultad de Enfermería, Fisioterapia y Podología de la Universidad de Sevilla.", "role": "STUDY_CHAIR"}, {"name": "José-Jesús Jiménez-Rejano", "affiliation": "Departamento de Fisioterapia. Facultad de Enfermería, Fisioterapia y Podología de la Universidad de Sevilla.", "role": "STUDY_DIRECTOR"}, {"name": "Manuel Rebollo-Salas", "affiliation": "Departamento de Fisioterapia. Facultad de Enfermería, Fisioterapia y Podología de la Universidad de Sevilla.", "role": "STUDY_DIRECTOR"}, {"name": "Inmaculada Villa-del-Pino", "affiliation": "Centro universitario San Isidoro, adscrito a Universidad Pablo de Olavide, Sevilla.", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Universidad de Sevilla", "status": "RECRUITING", "city": "Seville", "country": "Spain", "contacts": [{"name": "Inmaculada Villa del Pino", "role": "CONTACT", "phone": "679183871", "email": "inmvildel@alum.us.es"}], "geoPoint": {"lat": 37.38283, "lon": -5.97317}}]}, "referencesModule": {"references": [{"pmid": "19007576", "type": "BACKGROUND", "citation": "Garcia Campayo J, Rodero B, Alda M, Sobradiel N, Montero J, Moreno S. [Validation of the Spanish version of the Pain Catastrophizing Scale in fibromyalgia]. Med Clin (Barc). 2008 Oct 18;131(13):487-92. doi: 10.1157/13127277. Spanish."}, {"pmid": "36204486", "type": "BACKGROUND", "citation": "Bordeleau M, Vincenot M, Lefevre S, Duport A, Seggio L, Breton T, Lelard T, Serra E, Roussel N, Neves JFD, Leonard G. Treatments for kinesiophobia in people with chronic pain: A scoping review. Front Behav Neurosci. 2022 Sep 20;16:933483. doi: 10.3389/fnbeh.2022.933483. eCollection 2022."}, {"pmid": "25059910", "type": "BACKGROUND", "citation": "Hamacher D, Hamacher D, Schega L. A cognitive dual task affects gait variability in patients suffering from chronic low back pain. Exp Brain Res. 2014 Nov;232(11):3509-13. doi: 10.1007/s00221-014-4039-1. Epub 2014 Jul 25."}, {"pmid": "35722759", "type": "BACKGROUND", "citation": "Fernandez-Rodriguez R, Alvarez-Bueno C, Cavero-Redondo I, Torres-Costoso A, Pozuelo-Carrascosa DP, Reina-Gutierrez S, Pascual-Morena C, Martinez-Vizcaino V. Best Exercise Options for Reducing Pain and Disability in Adults With Chronic Low Back Pain: Pilates, Strength, Core-Based, and Mind-Body. A Network Meta-analysis. J Orthop Sports Phys Ther. 2022 Aug;52(8):505-521. doi: 10.2519/jospt.2022.10671. Epub 2022 Jun 19."}, {"pmid": "32331323", "type": "BACKGROUND", "citation": "Galan-Martin MA, Montero-Cuadrado F, Lluch-Girbes E, Coca-Lopez MC, Mayo-Iscar A, Cuesta-Vargas A. Pain Neuroscience Education and Physical Therapeutic Exercise for Patients with Chronic Spinal Pain in Spanish Physiotherapy Primary Care: A Pragmatic Randomized Controlled Trial. J Clin Med. 2020 Apr 22;9(4):1201. doi: 10.3390/jcm9041201."}, {"pmid": "32735156", "type": "BACKGROUND", "citation": "Mari-Alexandre J, Garcia-Oms J, Agababyan C, Belda-Montesinos R, Royo-Bolea S, Varo-Gomez B, Diaz-Sierra C, Gonzalez-Canto E, Gilabert-Estelles J. Toward an improved assessment of quality of life in endometriosis: evaluation of the Spanish version of the Endometriosis Health Profile 30. J Psychosom Obstet Gynaecol. 2022 Sep;43(3):251-257. doi: 10.1080/0167482X.2020.1795827. Epub 2020 Jul 31."}, {"pmid": "38007607", "type": "BACKGROUND", "citation": "Jones GL, Budds K, Taylor F, Musson D, Raymer J, Churchman D, Kennedy SH, Jenkinson C. A systematic review to determine use of the Endometriosis Health Profiles to measure quality of life outcomes in women with endometriosis. Hum Reprod Update. 2024 Mar 1;30(2):186-214. doi: 10.1093/humupd/dmad029."}, {"pmid": "26298083", "type": "BACKGROUND", "citation": "Ferrer-Pena R, Gil-Martinez A, Pardo-Montero J, Jimenez-Penick V, Gallego-Izquierdo T, La Touche R. Adaptation and validation of the Spanish version of the graded chronic pain scale. Reumatol Clin. 2016 May-Jun;12(3):130-8. doi: 10.1016/j.reuma.2015.07.004. Epub 2015 Aug 19. English, Spanish."}, {"pmid": "30694929", "type": "BACKGROUND", "citation": "Wheeler CHB, Williams ACC, Morley SJ. Meta-analysis of the psychometric properties of the Pain Catastrophizing Scale and associations with participant characteristics. Pain. 2019 Sep;160(9):1946-1953. doi: 10.1097/j.pain.0000000000001494."}, {"pmid": "38455973", "type": "BACKGROUND", "citation": "Xu Y, Deng Z, Fei F, Zhou S. An overview and comprehensive analysis of interdisciplinary clinical research in endometriosis based on trial registry. iScience. 2024 Feb 20;27(3):109298. doi: 10.1016/j.isci.2024.109298. eCollection 2024 Mar 15."}, {"pmid": "34627209", "type": "BACKGROUND", "citation": "Tennfjord MK, Gabrielsen R, Tellum T. Effect of physical activity and exercise on endometriosis-associated symptoms: a systematic review. BMC Womens Health. 2021 Oct 9;21(1):355. doi: 10.1186/s12905-021-01500-4."}, {"pmid": "37345574", "type": "BACKGROUND", "citation": "Tourny C, Zouita A, El Kababi S, Feuillet L, Saeidi A, Laher I, Weiss K, Knechtle B, Zouhal H. Endometriosis and physical activity: A narrative review. Int J Gynaecol Obstet. 2023 Dec;163(3):747-756. doi: 10.1002/ijgo.14898. Epub 2023 Jun 22."}, {"pmid": "20630793", "type": "BACKGROUND", "citation": "McLean SM, Burton M, Bradley L, Littlewood C. Interventions for enhancing adherence with physiotherapy: a systematic review. Man Ther. 2010 Dec;15(6):514-21. doi: 10.1016/j.math.2010.05.012. Epub 2010 Jul 14."}, {"pmid": "20163979", "type": "BACKGROUND", "citation": "Jack K, McLean SM, Moffett JK, Gardiner E. Barriers to treatment adherence in physiotherapy outpatient clinics: a systematic review. Man Ther. 2010 Jun;15(3):220-8. doi: 10.1016/j.math.2009.12.004. Epub 2010 Feb 16."}, {"pmid": "34555674", "type": "BACKGROUND", "citation": "Nagpal TS, Mottola MF, Barakat R, Prapavessis H. Adherence is a key factor for interpreting the results of exercise interventions. Physiotherapy. 2021 Dec;113:8-11. doi: 10.1016/j.physio.2021.05.010. Epub 2021 Sep 21."}, {"pmid": "37674205", "type": "BACKGROUND", "citation": "Rubi-Carnacea F, Masbernat-Almenara M, Climent-Sanz C, Soler-Gonzalez J, Garcia-Escudero M, Martinez-Navarro O, Valenzuela-Pascual F. Effectiveness of an exercise intervention based on preactivation of the abdominal transverse muscle in patients with chronic nonspecific low back pain in primary care: a randomized control trial. BMC Prim Care. 2023 Sep 6;24(1):180. doi: 10.1186/s12875-023-02140-3."}, {"pmid": "36498220", "type": "BACKGROUND", "citation": "Wojcik M, Szczepaniak R, Placek K. Physiotherapy Management in Endometriosis. Int J Environ Res Public Health. 2022 Dec 2;19(23):16148. doi: 10.3390/ijerph192316148."}, {"pmid": "37467936", "type": "BACKGROUND", "citation": "Artacho-Cordon F, Salinas-Asensio MDM, Galiano-Castillo N, Ocon-Hernandez O, Peinado FM, Mundo-Lopez A, Lozano-Lozano M, Alvarez-Salvago F, Arroyo-Morales M, Fernandez-Lao C, Cantarero-Villanueva I. Effect of a Multimodal Supervised Therapeutic Exercise Program on Quality of Life, Pain, and Lumbopelvic Impairments in Women With Endometriosis Unresponsive to Conventional Therapy: A Randomized Controlled Trial. Arch Phys Med Rehabil. 2023 Nov;104(11):1785-1795. doi: 10.1016/j.apmr.2023.06.020. Epub 2023 Jul 17."}, {"pmid": "36571475", "type": "BACKGROUND", "citation": "Abril-Coello R, Correyero-Leon M, Ceballos-Laita L, Jimenez-Barrio S. Benefits of physical therapy in improving quality of life and pain associated with endometriosis: A systematic review and meta-analysis. Int J Gynaecol Obstet. 2023 Jul;162(1):233-243. doi: 10.1002/ijgo.14645. Epub 2023 Jan 17."}, {"pmid": "27869485", "type": "BACKGROUND", "citation": "Goncalves AV, Barros NF, Bahamondes L. The Practice of Hatha Yoga for the Treatment of Pain Associated with Endometriosis. J Altern Complement Med. 2017 Jan;23(1):45-52. doi: 10.1089/acm.2015.0343. Epub 2016 Nov 21."}, {"pmid": "35488093", "type": "BACKGROUND", "citation": "Mardon AK, Leake HB, Hayles C, Henry ML, Neumann PB, Moseley GL, Chalmers KJ. The Efficacy of Self-Management Strategies for Females with Endometriosis: a Systematic Review. Reprod Sci. 2023 Feb;30(2):390-407. doi: 10.1007/s43032-022-00952-9. Epub 2022 Apr 29."}, {"pmid": "28049214", "type": "BACKGROUND", "citation": "Aredo JV, Heyrana KJ, Karp BI, Shah JP, Stratton P. Relating Chronic Pelvic Pain and Endometriosis to Signs of Sensitization and Myofascial Pain and Dysfunction. Semin Reprod Med. 2017 Jan;35(1):88-97. doi: 10.1055/s-0036-1597123. Epub 2017 Jan 3."}, {"pmid": "38171483", "type": "BACKGROUND", "citation": "Levang SL, Pukall CF. An Investigation of Associations between Pain Catastrophizing and Pain Disability in a Diverse Sample of Persons with Endometriosis. J Obstet Gynaecol Can. 2024 Apr;46(4):102340. doi: 10.1016/j.jogc.2023.102340. Epub 2024 Jan 1."}, {"pmid": "30307628", "type": "BACKGROUND", "citation": "Hemmert R, Schliep KC, Willis S, Peterson CM, Louis GB, Allen-Brady K, Simonsen SE, Stanford JB, Byun J, Smith KR. Modifiable life style factors and risk for incident endometriosis. Paediatr Perinat Epidemiol. 2019 Jan;33(1):19-25. doi: 10.1111/ppe.12516. Epub 2018 Oct 11."}, {"pmid": "35162761", "type": "BACKGROUND", "citation": "Salinas-Asensio MDM, Ocon-Hernandez O, Mundo-Lopez A, Fernandez-Lao C, Peinado FM, Padilla-Vinuesa C, Alvarez-Salvago F, Postigo-Martin P, Lozano-Lozano M, Lara-Ramos A, Arroyo-Morales M, Cantarero-Villanueva I, Artacho-Cordon F. 'Physio-EndEA' Study: A Randomized, Parallel-Group Controlled Trial to Evaluate the Effect of a Supervised and Adapted Therapeutic Exercise Program to Improve Quality of Life in Symptomatic Women Diagnosed with Endometriosis. Int J Environ Res Public Health. 2022 Feb 2;19(3):1738. doi: 10.3390/ijerph19031738."}, {"pmid": "30646891", "type": "BACKGROUND", "citation": "Armour M, Sinclair J, Chalmers KJ, Smith CA. Self-management strategies amongst Australian women with endometriosis: a national online survey. BMC Complement Altern Med. 2019 Jan 15;19(1):17. doi: 10.1186/s12906-019-2431-x."}, {"pmid": "36375827", "type": "BACKGROUND", "citation": "Horne AW, Missmer SA. Pathophysiology, diagnosis, and management of endometriosis. BMJ. 2022 Nov 14;379:e070750. doi: 10.1136/bmj-2022-070750."}, {"pmid": "34617386", "type": "BACKGROUND", "citation": "Parsons BA, Baranowski AP, Berghmans B, Borovicka J, Cottrell AM, Dinis-Oliveira P, Elneil S, Hughes J, Messelink BEJ, de C Williams AC, Abreu-Mendes P, Zumstein V, Engeler DS. Management of chronic primary pelvic pain syndromes. BJU Int. 2022 May;129(5):572-581. doi: 10.1111/bju.15609. Epub 2021 Oct 27."}, {"pmid": "33675228", "type": "BACKGROUND", "citation": "Lara-Ramos A, Alvarez-Salvago F, Fernandez-Lao C, Galiano-Castillo N, Ocon-Hernandez O, Mazheika M, Salinas-Asensio MM, Mundo-Lopez A, Arroyo-Morales M, Cantarero-Villanueva I, Artacho-Cordon F. Widespread Pain Hypersensitivity and Lumbopelvic Impairments in Women Diagnosed with Endometriosis. Pain Med. 2021 Sep 8;22(9):1970-1981. doi: 10.1093/pm/pnaa463."}, {"pmid": "29509818", "type": "BACKGROUND", "citation": "Biggs WS, Carey ET, McIntyre JM. Limited evidence guides empiric Tx of female chronic pelvic pain. J Fam Pract. 2018 Mar;67(3):E1-E9."}], "seeAlsoLinks": [{"label": "Related Info", "url": "https://www.consejo-fisioterapia.org/adjuntos/publicaciones/publicacion_2.pdf"}, {"label": "Related Info", "url": "https://www.aetsa.org/download/publicaciones/Endometriosis_DEF.pdf"}, {"label": "Related Info", "url": "https://www.sspa.juntadeandalucia.es/servicioandaluzdesalud/sites/default/files/sincfiles/wsas-media-mediafile_sasdocumento/2019/guia_endometriosis_2018.pdf"}, {"label": "Related Info", "url": "https://www.sanidad.gob.es/organizacion/sns/planCalidadSNS/pdf/equidad/ENDOMETRIOSIS.pdf"}, {"label": "Related Info", "url": "https://www.ncbi.nlm.nih.gov/books/NBK11822/"}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "All collected IPD.\n\nThe data to be provided will refer to all the variables of the study: independent, dependent and control variables.\n\nDependent (Catastrophic thoughts about pain, magnitude of chronic pain, general quality of life, specific quality of life, adverse events related to exercise ( pain, frequency of flares and fatigue), adherence and compliance to treatment Control variables:\n\n* Age (years).\n* Height: measured in centimeters.\n* Weight: measured in kilograms.\n* BMI: (kg/m2).\n* Work and/or academic activity: measured according to whether the person works, studies or both at the same time.\n* Academic level: measured according to whether the person has compulsory or higher education.\n* Stage of pathology: measured in stages according to the American Society for Reproductive Medicine.\n\nAll this will be carried out preserving the confidentiality of the data of the study participants according to the rules of the Ethics Committee of the University of Seville.", "infoTypes": ["STUDY_PROTOCOL", "ICF"], "timeFrame": "The data will be available in the repository of the University of Seville once the research has been completed and the research report has been written."}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}, {"id": "D010146", "term": "Pain"}, {"id": "D000377", "term": "Agnosia"}, {"id": "D002908", "term": "Chronic Disease"}, {"id": "D000074822", "term": "Treatment Adherence and Compliance"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}, {"id": "D009461", "term": "Neurologic Manifestations"}, {"id": "D012816", "term": "Signs and Symptoms"}, {"id": "D013568", "term": "Pathological Conditions, Signs and Symptoms"}, {"id": "D010468", "term": "Perceptual Disorders"}, {"id": "D019954", "term": "Neurobehavioral Manifestations"}, {"id": "D009422", "term": "Nervous System Diseases"}, {"id": "D020969", "term": "Disease Attributes"}, {"id": "D010335", "term": "Pathologic Processes"}, {"id": "D015438", "term": "Health Behavior"}, {"id": "D001519", "term": "Behavior"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT02031523", "orgStudyIdInfo": {"id": "NO.2-20130301"}, "organization": {"fullName": "Jiangsu Kanion Pharmaceutical Co., Ltd", "class": "INDUSTRY"}, "briefTitle": "Multi-center Clinical Trials of Sanjie Analgesic Capsule in Treating Endometriosis", "officialTitle": "A Randomized, Double-blind, Placebo-controlled Post-marketing Study to Assess the Treatment Effect of Sanjie Analgesic Capsule in Treating Endometriosis - Associated Pain"}, "statusModule": {"statusVerifiedDate": "2013-12", "overallStatus": "UNKNOWN", "lastKnownStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2013-10"}, "primaryCompletionDateStruct": {"date": "2015-10", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2015-12", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2013-12-16", "studyFirstSubmitQcDate": "2014-01-08", "studyFirstPostDateStruct": {"date": "2014-01-09", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2014-11-18", "lastUpdatePostDateStruct": {"date": "2014-11-19", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Jiangsu Kanion Pharmaceutical Co., Ltd", "class": "INDUSTRY"}, "collaborators": [{"name": "Beijing Bionovo Medicine Development Co., Ltd.", "class": "OTHER"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "It is a multi-center, double -blind, placebo -controlled, randomized post-marketing study in Chinese subjects with endometriosis-associated pain to assess treatment effect and safety in the subjects treated with Sanjie Analgesic Capsule versus subjects treated with placebo.", "detailedDescription": "Sanjie Analgesic Capsule is a Chinese Traditional Patent Medicine. It is a botanical extract from the raw materials of the Resina Draconis , Panax Notoginseng, fritillary bulb and coix seed, which are derived from a classic prescription of traditional Chinese medicine.\n\nSanjie Analgesic Capsule was approved by CFDA in 2004, produced by means of modern technology by Jiangsu Kanion Pharmaceutical Co., Ltd. The study is a multi-center, double -blind, placebo-controlled, randomized in Chinese subjects with endometriosis-associated pain to assess treatment effect and safety in the subjects treated with Sanjie Analgesic Capsule versus subjects treated with placebo."}, "conditionsModule": {"conditions": ["Dysmenorrhea"], "keywords": ["endometriosis", "dysmenorrhea", "Sanjie analgesic capsule", "effect/safety"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 400, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Sanjie analgesic capsule", "type": "ACTIVE_COMPARATOR", "description": "every 4 capsules , 3 times a day, on the first day of menstruation to start taking, taking three consecutive menstrual cycle.", "interventionNames": ["Drug: Sanjie analgesic capsule"]}, {"label": "placebo", "type": "PLACEBO_COMPARATOR", "description": "every 4 capsules, 3 times a day, on the first day of menstruation to start taking, taking three consecutive menstrual cycle.", "interventionNames": ["Drug: placebo"]}], "interventions": [{"type": "DRUG", "name": "Sanjie analgesic capsule", "description": "Oral, four each time, 3 times a day, on the first day of menstruation to start taking, taking three consecutive menstrual cycle.or follow the doctor's advice.", "armGroupLabels": ["Sanjie analgesic capsule"], "otherNames": ["Jiangsu Kanion Pharmaceutical Co.,Ltd"]}, {"type": "DRUG", "name": "placebo", "description": "oral，four each time, 3 times a day, on the first day of menstruation to start taking, taking three consecutive menstrual cycle. Or Follow the doctor's advice.", "armGroupLabels": ["placebo"], "otherNames": ["Jiangsu Kanion Pharmaceutical Co.,Ltd"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "dysmenorrhea", "timeFrame": "Baseline, 1,2,3,4 menstrual cycle"}], "secondaryOutcomes": [{"measure": "change of Symptom (CPP Dyspareunia Defecate-pain Anal-bulge )", "timeFrame": "baseline，1,2,3,4 menstrual cycle"}, {"measure": "change of Signs(Pelvic-tenderness Tubercle )", "timeFrame": "baseline，1,2,3,4 menstrual cycle"}, {"measure": "change of Menstrual cycle and quantity", "timeFrame": "baseline，1,2,3,4 menstrual cycle"}, {"measure": "change of serum CA125", "timeFrame": "baseline,3,4 menstrual cycle"}, {"measure": "the size of uterus and endometriosis cyst", "timeFrame": "baseline,3,4 menstrual cycle"}, {"measure": "change of serum endocrinological hormone", "description": "the content of FSH, LH, E2, PRL, P, T", "timeFrame": "baseline,3,4 menstrual cycle"}, {"measure": "change of SF-36 score", "timeFrame": "Baseline,3 menstrual cycle"}, {"measure": "Safety assessments will be based on electrocardiogram, physical examinations, and clinical laboratory tests", "timeFrame": "Baseline,3 menstrual cycle"}, {"measure": "Safety assessments will be based on adverse event reports", "timeFrame": "1,2,3 menstrual cycle"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Subjects have a diagnosis of endometriosis by laparoscopy within 5 years prior to signing ICF, main complain of dysmenorrhea (or menstrual pain or painful periods) and with VAS score of 4 or above; Endometriosis combined with uterine adenomyosis is included.\n* Female between the ages of 18 and 45 years old;\n* Regular menstrual period, menstrual cycle falls in the ranging from 28 to 30 days;\n* No pregnancy planning during taking study medication; use (or have their partner use) an acceptable method of birth control within the projected duration of the study ;\n* Subjects must sign ICF and agree for follow up.\n\nExclusion Criteria:\n\n* Genital cancer or other malignant tumor;\n* Adnexal masses≥5cm;\n* Uterine myoma≥3cm;\n* Suffering from cardiovascular, hepatic, renal or hematopoietic system disease or mental illness;\n* Receiving hormone therapy within 3 months prior to signing ICF;\n* Receiving surgical treatment for endometriosis within 3 months prior to signing ICF;\n* Subjects have a plan of pregnancy, being pregnant, breast-feeding during recent 3 months.", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "45 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Lang Jinghe, Doctor", "affiliation": "Beijing Union Medical College Hospital, Chinese Academy of Medical Sciences", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Beijing ChaoYang Hospital", "status": "RECRUITING", "city": "Beijing", "state": "Beijing Municipality", "zip": "100020", "country": "China", "contacts": [{"name": "Zhang Zhenyu, M.D.", "role": "CONTACT", "email": "zhengyuzhang2000@yahoo.com"}, {"name": "Zhang Zhenyu, M.D.", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 39.9075, "lon": 116.39723}}, {"facility": "Beijing Obstetrics and Gynecology Hospital,Capital Medical University", "status": "RECRUITING", "city": "Beijing", "state": "Beijing Municipality", "zip": "100026", "country": "China", "contacts": [{"name": "Duan Hua, M.D.", "role": "CONTACT", "email": "duanhua888@163.com"}, {"name": "Duan Hua, M.D.", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 39.9075, "lon": 116.39723}}, {"facility": "Peking University First Hospital", "status": "RECRUITING", "city": "Beijing", "state": "Beijing Municipality", "zip": "100034", "country": "China", "contacts": [{"name": "Zhou Yingfang, M.D.", "role": "CONTACT", "email": "zhouyf8853@yahoo.com.cn"}, {"name": "Zhou Yingfang, M.D.", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 39.9075, "lon": 116.39723}}, {"facility": "Peking Union Medical College Hospital", "status": "RECRUITING", "city": "Beijing", "state": "Beijing Municipality", "zip": "100730", "country": "China", "contacts": [{"name": "Leng Jinhua, M.D.", "role": "CONTACT", "email": "lengjenny@vip.sina.com"}, {"name": "Lang Jinghe, Doctor", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 39.9075, "lon": 116.39723}}, {"facility": "The General Hospital of People's Liberation Army", "status": "RECRUITING", "city": "Beijing", "state": "Beijing Municipality", "zip": "100853", "country": "China", "contacts": [{"name": "Guan Zheng, Master", "role": "CONTACT", "email": "GZ9332@yahoo.com.cn"}, {"name": "Guan Zheng, Master", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 39.9075, "lon": 116.39723}}, {"facility": "Hubei Provincal Hospital of TCM", "status": "RECRUITING", "city": "Wuhan", "state": "Hubei", "zip": "430061", "country": "China", "contacts": [{"name": "Zhou zhongming", "role": "CONTACT", "email": "379327931@qq.com"}, {"name": "Zhou Zhongming", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 30.58333, "lon": 114.26667}}, {"facility": "The First Hospital of Hunan University of chinese Medicine", "status": "RECRUITING", "city": "Changsha", "state": "Hunan", "zip": "410000", "country": "China", "contacts": [{"name": "Lin Jie", "role": "CONTACT", "email": "379327931@qq.com"}, {"name": "Lin Jie", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 28.19874, "lon": 112.97087}}, {"facility": "The Maternal and Child Health Hospital of Hunan Province", "status": "RECRUITING", "city": "Changsha", "state": "Hunan", "zip": "41008", "country": "China", "contacts": [{"name": "Gong Yingping", "role": "CONTACT", "phone": "13973139188"}, {"name": "Gong Yingping", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 28.19874, "lon": 112.97087}}, {"facility": "Shengjing Hospital of China Medical University", "status": "RECRUITING", "city": "Shenyang", "state": "Liaoning", "zip": "110004", "country": "China", "contacts": [{"name": "Zhang Shulan, Master", "role": "CONTACT", "email": "zsl0909@sina.com"}, {"name": "Zhang Shulan, Master", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 41.79222, "lon": 123.43278}}, {"facility": "Jinan municipal hospital of Traditional Chinese Medicine", "status": "RECRUITING", "city": "Jinan", "state": "Shandong", "zip": "250012", "country": "China", "contacts": [{"name": "Tang Ye", "role": "CONTACT", "phone": "13589018957"}, {"name": "Tang Ye", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 36.66833, "lon": 116.99722}}, {"facility": "The Second Hospital of Shandong University of Traditional Chinese Medicine", "status": "RECRUITING", "city": "Jinan", "state": "Shandong", "zip": "25001", "country": "China", "contacts": [{"name": "Sun Wei", "role": "CONTACT", "email": "839580089@qq.com"}, {"name": "Sun Wei", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 36.66833, "lon": 116.99722}}, {"facility": "Obstetrics and Gynecology Hospital of Fudan University", "status": "RECRUITING", "city": "Shanghai", "state": "Shanghai Municipality", "zip": "200011", "country": "China", "contacts": [{"name": "Zhang Shaofen, Bachelor", "role": "CONTACT", "email": "zhangshaofen@163.com"}, {"name": "Zhang Shaofen, Bachelor", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 31.22222, "lon": 121.45806}}, {"facility": "Women's Hospital School Of Medicine Zhejiang University", "status": "RECRUITING", "city": "Hangzhou", "state": "Zhejiang", "zip": "310006", "country": "China", "contacts": [{"name": "Lin Jun, Bachelor", "role": "CONTACT", "email": "linjun@zju.edu.cn"}, {"name": "Lin Jun, Bachelor", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 30.29365, "lon": 120.16142}}, {"facility": "Guangxing Hospital Of Zhejiang Chinese Medicine University", "status": "RECRUITING", "city": "Hangzhou", "state": "Zhejiang", "zip": "31007", "country": "China", "contacts": [{"name": "Zhang Qin", "role": "CONTACT", "email": "Zhqin@zjwh.gov.cn"}, {"name": "Zhang Qin", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 30.29365, "lon": 120.16142}}]}, "referencesModule": {"references": [{"pmid": "39046647", "type": "DERIVED", "citation": "Leng JH, Duan H, Guan Z, Zhou YF, Qu H, Xu KH, Zhang SF, Zhang Q, Wang X, Lin KQ, Lang JH. Efficacy and Safety of Sanjie Analgesic Capsule in Patients with Endometriosis-Associated Pain: A Multicenter, 3:1 Randomized, Double-Blind, Placebo-Controlled Trial. Chin J Integr Med. 2024 Sep;30(9):780-787. doi: 10.1007/s11655-024-3756-y. Epub 2024 Jul 24."}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004412", "term": "Dysmenorrhea"}, {"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D008599", "term": "Menstruation Disturbances"}, {"id": "D010335", "term": "Pathologic Processes"}, {"id": "D013568", "term": "Pathological Conditions, Signs and Symptoms"}, {"id": "D017699", "term": "Pelvic Pain"}, {"id": "D010146", "term": "Pain"}, {"id": "D009461", "term": "Neurologic Manifestations"}, {"id": "D012816", "term": "Signs and Symptoms"}, {"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT05245695", "orgStudyIdInfo": {"id": "12-2021"}, "organization": {"fullName": "Aspira Women's Health", "class": "INDUSTRY"}, "briefTitle": "Deep Neural Network Stratification for Use Detecting Endometriosis in Women Affected by Chronic Pelvic Pain (EndoCheck)", "officialTitle": "Deep Neural Network Stratification for the Use in Detecting Endometriosis in Women Affected by Chronic Pelvic Pain (EndoCheck)"}, "statusModule": {"statusVerifiedDate": "2025-06", "overallStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2022-07-12", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2026-06-30", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2026-06-30", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2022-02-01", "studyFirstSubmitQcDate": "2022-02-08", "studyFirstPostDateStruct": {"date": "2022-02-18", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2025-06-23", "lastUpdatePostDateStruct": {"date": "2025-06-25", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Aspira Women's Health", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false, "isUsExport": false}, "descriptionModule": {"briefSummary": "The goal of this observational study is to determine the clinical validity of a deep neural network algorithm that utilizes protein biomarker detection of Endometriosis - \"EndoCheck\" - as an \"aid in diagnosis\" for endometriosis and to show validity as a diagnostic test", "detailedDescription": "The objective is to confirm the clinical performance (sensitivity and specificity) of EndoCheck when compared to laparoscopic surgical assessment as an \"aid in diagnosis\" for endometriosis in subjects who present with chronic pelvic pain.\n\nThe primary endpoint of the study is to optimize the test to achieve the success criteria of at least 94% and 79% sensitivity and specificity, respectively. Secondary endpoints include examining the performance of the test in patients stratified by pain severity and other clinical factors."}, "conditionsModule": {"conditions": ["Endometriosis"], "keywords": ["Endometriosis", "Biomarkers", "Deep neural network"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "CASE_CONTROL", "timePerspective": "PROSPECTIVE"}, "bioSpec": {"retention": "SAMPLES_WITH_DNA", "description": "Serum Cell-free DNA"}, "enrollmentInfo": {"count": 1200, "type": "ESTIMATED"}}, "armsInterventionsModule": {"interventions": [{"type": "OTHER", "name": "Observational study, no intervention", "description": "Observational study, no intervention"}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Sensitivity and Specificity", "description": "The primary endpoint of the study is to optimize the test to achieve the success criteria of at least 94% and 79% sensitivity and specificity, respectively", "timeFrame": "24 months"}], "secondaryOutcomes": [{"measure": "Performance", "description": "Examining the performance of the test in patients stratified by pain severity and other clinical factors.", "timeFrame": "24 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Participant is willing and able to provide written informed consent.\n* Participant is a female aged 14 to 50 years old at time of consent.\n* Participant is scheduled to undergo laparotomy or laparoscopy for symptomology consistent with possible endometriosis\n\nExclusion Criteria:\n\n* Participant is a female in a pre-menarchal state.\n* Participant is pregnant.\n* Participant has an active malignancy.\n* Participant is known to have tested positive for human immunodeficiency virus or hepatitis A, B, or C.\n* Participant has an active pelvic infection or other infections contraindicated for surgery.\n* Participant has participated (±3 months of study enrollment) in a clinical trial where an investigational drug/ device/ procedure was or is planned to be administered.\n* Participant has any general health or behavioral condition that, in the opinion of the investigator, should exclude the participant from participation.\n* Participant is under 14 years old or over 50 years old", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "14 Years", "maximumAge": "50 Years", "stdAges": ["CHILD", "ADULT"], "studyPopulation": "Women scheduled for a gynecologic surgery", "samplingMethod": "PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"centralContacts": [{"name": "Marla Then, CRC", "role": "CONTACT", "phone": "844-277-4721", "email": "mthen@aspirawh.com"}, {"name": "Silvana Franco", "role": "CONTACT", "email": "sfranco@aspirawh.com"}], "overallOfficials": [{"name": "Todd Pappas, PhD", "affiliation": "Aspira Women's Health", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "New Horizons Clinical Trials", "status": "RECRUITING", "city": "Chandler", "state": "Arizona", "zip": "852224", "country": "United States", "contacts": [{"name": "Saira Flores, MD", "role": "CONTACT", "email": "sflores@aoafamily.com"}, {"role": "CONTACT", "phone": "(480) 496-2236"}, {"name": "Monte Swarup", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 33.30616, "lon": -111.84125}}, {"facility": "Velvet Clinical Research", "status": "RECRUITING", "city": "Burbank", "state": "California", "zip": "91506", "country": "United States", "contacts": [{"name": "Monica Torres", "role": "CONTACT", "phone": "3235270907", "email": "mtorres@velvetclinicalresearch.com"}, {"name": "Jose Medrano, MD", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 34.18084, "lon": -118.30897}}, {"facility": "Reproductive Associates of Delaware (RAD)", "status": "RECRUITING", "city": "Newark", "state": "Delaware", "zip": "19713", "country": "United States", "contacts": [{"name": "Eileen Davies", "role": "CONTACT", "email": "edavies@radfertility.com"}, {"name": "Ronald Feinberg", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 39.68372, "lon": -75.74966}}, {"facility": "Midtown OBGYN North", "status": "RECRUITING", "city": "Columbus", "state": "Georgia", "zip": "31909", "country": "United States", "contacts": [{"name": "Rebecca Watkins", "role": "CONTACT", "email": "rebeccaw@midtownob.com"}, {"name": "Serena Tidwell", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 32.46098, "lon": -84.98771}}, {"facility": "Cindy Basinski, MD", "status": "RECRUITING", "city": "Forest Hill", "state": "Indiana", "zip": "47630", "country": "United States", "contacts": [{"name": "Alicia Sollman", "role": "CONTACT", "phone": "812-853-3500", "email": "alicia@drbasinski.com"}, {"name": "Cindy Basinski, MD", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 39.257, "lon": -85.61331}}, {"facility": "Johns Hopkins School of Medicine", "status": "RECRUITING", "city": "Baltimore", "state": "Maryland", "zip": "21205", "country": "United States", "contacts": [{"name": "Samya El Sayed, MD", "role": "CONTACT", "email": "selsaye4@jh.edu"}, {"name": "James Segar, Dr", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 39.29038, "lon": -76.61219}}, {"facility": "Nezhat Surgery for Gynecology/Oncology", "status": "RECRUITING", "city": "Valley Stream", "state": "New York", "zip": "11581", "country": "United States", "contacts": [{"name": "Sharon Cote, MD", "role": "CONTACT", "email": "sharon@farrnezhatmd.com"}, {"name": "Farr Nezhat, MD", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 40.66427, "lon": -73.70846}}, {"facility": "Seven Hills Clinical Research", "status": "RECRUITING", "city": "Cincinnati", "state": "Ohio", "zip": "45242", "country": "United States", "contacts": [{"name": "Brigette Tillman", "role": "CONTACT", "email": "brigette.tillman@axiawh.com"}, {"name": "Gerard Reilly", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 39.12711, "lon": -84.51439}}, {"facility": "May Grant", "status": "RECRUITING", "city": "Lancaster", "state": "Pennsylvania", "zip": "17601", "country": "United States", "contacts": [{"name": "Aelxa Trimble", "role": "CONTACT", "email": "alexamish5@gmail.com"}, {"name": "Kent Meldrum", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 40.03788, "lon": -76.30551}}, {"facility": "Womens Health Services of Central Virginia", "status": "RECRUITING", "city": "Lynchburg", "state": "Virginia", "zip": "24502", "country": "United States", "contacts": [{"name": "Whittney Calohan", "role": "CONTACT", "phone": "434-485-7059", "email": "wcalohan@whscv.com"}, {"name": "Wade Neiman", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 37.41375, "lon": -79.14225}}]}, "referencesModule": {"references": [{"pmid": "15521864", "type": "BACKGROUND", "citation": "Wykes CB, Clark TJ, Khan KS. Accuracy of laparoscopy in the diagnosis of endometriosis: a systematic quantitative review. BJOG. 2004 Nov;111(11):1204-12. doi: 10.1111/j.1471-0528.2004.00433.x. No abstract available."}, {"pmid": "27094925", "type": "BACKGROUND", "citation": "Gupta D, Hull ML, Fraser I, Miller L, Bossuyt PM, Johnson N, Nisenblat V. Endometrial biomarkers for the non-invasive diagnosis of endometriosis. Cochrane Database Syst Rev. 2016 Apr 20;4(4):CD012165. doi: 10.1002/14651858.CD012165."}, {"pmid": "9130884", "type": "BACKGROUND", "citation": "Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertil Steril. 1997 May;67(5):817-21. doi: 10.1016/s0015-0282(97)81391-x. No abstract available."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D019370", "term": "Observation"}], "ancestors": [{"id": "D008722", "term": "Methods"}, {"id": "D008919", "term": "Investigative Techniques"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT00121953", "orgStudyIdInfo": {"id": "2004-1012"}, "secondaryIdInfos": [{"id": "1K23HD043952-01A2", "type": "NIH", "link": "https://reporter.nih.gov/quickSearch/1K23HD043952-01A2"}], "organization": {"fullName": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)", "class": "NIH"}, "briefTitle": "Effect of Rosiglitazone on Peritoneal Cytokines in Women With Endometriosis", "officialTitle": "Endometriosis: Immunomodulation"}, "statusModule": {"statusVerifiedDate": "2012-10", "overallStatus": "WITHDRAWN", "whyStopped": "Due to the recent meta-analysis about CV adverse effects.", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2005-07"}, "primaryCompletionDateStruct": {"date": "2008-05", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-05", "type": "ACTUAL"}, "studyFirstSubmitDate": "2005-07-18", "studyFirstSubmitQcDate": "2005-07-18", "studyFirstPostDateStruct": {"date": "2005-07-21", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2012-10-16", "lastUpdatePostDateStruct": {"date": "2012-10-17", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Dan Lebovic", "investigatorTitle": "Associate Professor", "investigatorAffiliation": "University of Wisconsin, Madison"}, "leadSponsor": {"name": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)", "class": "NIH"}}, "descriptionModule": {"briefSummary": "The purpose of this study is to compare the effect of rosiglitazone versus placebo on soluble proinflammatory markers in peritoneal fluid of women with endometriosis.", "detailedDescription": "The overall goal of this proposal is to assess modulation of immune mechanisms in endometriosis. Endometriosis is a common ailment affecting approximately five million reproductive-aged American women. We will test the efficacy of a novel immunomodulatory drug (peroxisome proliferator activated receptor gamma, PPAR-gamma, agonist), rosiglitazone, to reduce peritoneal fluid cytokine concentrations in women with endometriosis compared with placebo controls (randomized controlled trial). Based on prior studies done by the investigator highlighting the major role of cytokines and the immune system in the genesis or propagation of endometriosis, these experiments could lead to improved translational treatment strategies and a better understanding of endometriosis. Acting through PPAR-gamma, TZDs inhibit proinflammatory cytokines as well as NF-kB, an important nuclear transcription factor for the production of many cytokines. Accordingly, since human endometrial epithelial and stromal cells contain PPAR-gamma, we felt it would be useful to evaluate the influence of a PPAR-gamma ligand, rosiglitazone, on the concentration of specific peritoneal fluid cytokines.\n\nComparison: After the pre-trial screening, eligible subjects with presumed endometriosis and age 18-45 will be consented and randomly assigned to receive either placebo (control) or rosiglitazone, Avandia®, 4 mg daily for 2 weeks. Peritoneal fluid will be collected at the time of surgery and the volume measured. All patients enrolled in the study will have their surgery during the follicular phase of the cycle in order to minimize differences in volume and cytokine concentration due to the cyclical changes. The primary measure will be the peritoneal fluid concentration comparisons of the two groups assessing six different cytokines: interleukin-1 beta, RANTES, tumor necrosis factor-alpha and vascular endothelial growth factor."}, "conditionsModule": {"conditions": ["Endometriosis"], "keywords": ["Endometriosis", "Peritoneal fluid", "Cytokines", "Peroxisome Proliferator-Activated Receptors"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2", "PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "DIAGNOSTIC", "maskingInfo": {"masking": "DOUBLE"}}, "enrollmentInfo": {"count": 0, "type": "ACTUAL"}}, "armsInterventionsModule": {"interventions": [{"type": "DRUG", "name": "Rosiglitazone"}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Peritoneal fluid cytokine concentrations"}], "secondaryOutcomes": [{"measure": "Cytokine quantification"}, {"measure": "Proteomics"}, {"measure": "Gene array analyses"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Healthy women ages 18 - 45 years.\n* Regular menstrual cycles (24-35 days).\n* Pelvic pain ≥3 months\n* Negative pregnancy test\n* Non-lactating\n* No prior (\\<3 months) use of hormonal therapy (\\<6 mos for depoprovera users)\n* No history of liver disease\n* Consent to participate in the study\n* Endometriosis diagnosed from surgical specimen by routine hematoxylin and eosin staining and histological evaluation (within the past 4 years)\n\nExclusion Criteria:\n\n* Major psychiatric conditions or the abuse of alcohol or drugs which would make it difficult for the subject to complete study procedures.\n* Active or prior infection with hepatitis, human immunodeficiency virus (HIV) infection, or history of high-risk activities (e.g., intravenous \\[IV\\] drug abuse) which would increase risk to laboratory personnel. Of note, no testing for hepatitis or HIV will be performed as part of this study and all tissues will be handled and discarded as if they were potentially infected.\n* Patients with liver dysfunction (elevated liver enzymes \\>2 times upper limit of normal).\n* Presence of pre-existing malignancy, including carcinoma of the breast or uterus.\n* Women with other causes of chronic pelvic pain including infectious, gastrointestinal, musculoskeletal, neurologic or psychiatric.\n* Elevated white blood cell (WBC) count.\n* NYHA functional class I-IV heart failure.\n* Diabetes mellitus.\n* Known pregnancy or positive pregnancy test.", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "45 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Dan I. Lebovic, MD, MA", "affiliation": "University of Michigan", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "University of Michigan Health System", "city": "Ann Arbor", "state": "Michigan", "zip": "48109", "country": "United States", "geoPoint": {"lat": 42.27756, "lon": -83.74088}}]}, "referencesModule": {"references": [{"pmid": "15474065", "type": "BACKGROUND", "citation": "Lebovic DI, Kir M, Casey CL. Peroxisome proliferator-activated receptor-gamma induces regression of endometrial explants in a rat model of endometriosis. Fertil Steril. 2004 Oct;82 Suppl 3:1008-13. doi: 10.1016/j.fertnstert.2004.02.148."}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000077154", "term": "Rosiglitazone"}], "ancestors": [{"id": "D045162", "term": "Thiazolidinediones"}, {"id": "D013844", "term": "Thiazoles"}, {"id": "D013457", "term": "Sulfur Compounds"}, {"id": "D009930", "term": "Organic Chemicals"}, {"id": "D001393", "term": "Azoles"}, {"id": "D006573", "term": "Heterocyclic Compounds, 1-Ring"}, {"id": "D006571", "term": "Heterocyclic Compounds"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT05470972", "orgStudyIdInfo": {"id": "35560/6/22"}, "organization": {"fullName": "Tanta University", "class": "OTHER"}, "briefTitle": "Relation Between Ethanol Sclerotherapy for Endometrioma Systemic Immune Milieu", "officialTitle": "Endometrioma Cystic Fluid Aspiration and Retained Ethanol Sclerotherapy Might Improve the Systemic Immune Milieu"}, "statusModule": {"statusVerifiedDate": "2022-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2020-05-21", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2021-11-17", "type": "ACTUAL"}, "completionDateStruct": {"date": "2022-05-19", "type": "ACTUAL"}, "studyFirstSubmitDate": "2022-07-17", "studyFirstSubmitQcDate": "2022-07-20", "studyFirstPostDateStruct": {"date": "2022-07-22", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2022-07-20", "lastUpdatePostDateStruct": {"date": "2022-07-22", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Ahmed Hagars", "investigatorTitle": "Assistant professor of gynecology", "investigatorAffiliation": "Tanta University"}, "leadSponsor": {"name": "Tanta University", "class": "OTHER"}}, "oversightModule": {"isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "Design: Prospective interventional study. 69 women with OE were evaluated clinically and by transvaginal ultrasonography (TUV). AEST procedure was performed and the collected aspirate and pre-procedural blood samples were collected for estimation of cytokines' levels. At 6-m post-procedure, clinical evaluation and TUV were repeated and serum cytokines' levels were re-estimated."}, "conditionsModule": {"conditions": ["Endometriosis"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["EARLY_PHASE1"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 69, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Ovarian Endometrioma", "type": "EXPERIMENTAL", "description": "Ovarian endometrioma (OE) is in women of reproductive age", "interventionNames": ["Drug: Ethanol Injection"]}], "interventions": [{"type": "DRUG", "name": "Ethanol Injection", "description": "The AEST procedure was performed as follows: vaginal walls were cleansed using vaginal povidone-iodine, a 17 gauge, 30-cm length needle was inserted through the posterior vaginal fornix into the pouch of Douglas, and the cyst was aspirated till complete disappearance of the cyst on the ultrasound scanner. The collected cystic fluid was collected into a plastic tube without an anticoagulant. The needle was maintained in its place, the syringe was removed and the cyst was flushed with saline solution until obtaining a clear liquid. Then, 96% ethanol was injected as 60% of the volume of the aspirated fluid to guard against over distension or rupture of the cyst and/or ethanol diffusion into the pelvis. The collected fluid was divided into three sterile tubes for cytological and bacteriological examinations and the study investigations. Patients were allowed to be completely recovered and were discharged home.", "armGroupLabels": ["Ovarian Endometrioma"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "The effect of AEST procedures on patients' cytokines levels.", "description": "The effect of AEST on patients serum levels of tumor necrosis factor-α, interleukin-8 and interleukin-10", "timeFrame": "6 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Women with OE of a mean diameter of \\>3 cm\n\nExclusion Criteria:\n\n* Women with recurrent OE\n* a cyst that was suspicious of being malignant\n* diabetes mellitus\n* polycystic ovary syndrome\n* body mass index (BMI) of \\>30 kg/m2\n* previous surgical interference that resulted in pelvic adhesions", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "21 Years", "maximumAge": "45 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "Tanta university", "city": "Tanta", "state": "El-Gharbyia", "zip": "13511", "country": "Egypt", "geoPoint": {"lat": 30.78847, "lon": 31.00192}}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000431", "term": "Ethanol"}], "ancestors": [{"id": "D000438", "term": "Alcohols"}, {"id": "D009930", "term": "Organic Chemicals"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT03204318", "orgStudyIdInfo": {"id": "MVT-601-3101"}, "secondaryIdInfos": [{"id": "2017-001588-19", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Myovant Sciences GmbH", "class": "INDUSTRY"}, "briefTitle": "SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain", "officialTitle": "SPIRIT 1: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Administered With and Without Low-Dose Estradiol and Norethindrone Acetate in Women With Endometriosis-Associated Pain"}, "statusModule": {"statusVerifiedDate": "2021-06", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2017-12-07", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2020-06-09", "type": "ACTUAL"}, "completionDateStruct": {"date": "2021-04-08", "type": "ACTUAL"}, "studyFirstSubmitDate": "2017-06-27", "studyFirstSubmitQcDate": "2017-06-28", "studyFirstPostDateStruct": {"date": "2017-07-02", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2021-06-25", "lastUpdatePostDateStruct": {"date": "2021-06-28", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Myovant Sciences GmbH", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to determine the benefit and safety of relugolix 40 milligrams (mg) once daily, co-administered with low-dose estradiol (E2) and norethindrone acetate (NETA) compared with placebo for 24 weeks, on dysmenorrhea and on nonmenstrual pelvic pain.", "detailedDescription": "This study is an international phase 3 randomized, double-blind, placebo-controlled efficacy and safety study to evaluate 24 weeks of oral, once-daily relugolix (40 mg) co-administered with either 12 or 24 weeks of low-dose E2 (1.0 mg) and NETA (0.5 mg), compared with placebo.\n\nApproximately 600 women with endometriosis-associated pain will be enrolled and randomized 1:1:1 to Group A - relugolix plus low-dose hormonal add-back therapy, Group B - relugolix monotherapy for 12 weeks followed by co-administration with low-dose hormonal add-back therapy, or Group C - placebo (N = 200 per group).\n\nEligible participants were randomized on Baseline Day 1 to Treatment Group A, B, or C, in the double-blind period.\n\nEligible participants, including those randomized to placebo, were offered the opportunity to enroll in an 80-week open-label extension study where participants received relugolix co-administered with low-dose E2 and NETA. Participants who did not enroll into the extension study had a Follow-Up visit approximately 30 days after the participant's last dose of study drug."}, "conditionsModule": {"conditions": ["Endometriosis Related Pain"], "keywords": ["Endometriosis", "Pain", "Dysmenorrhea"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 638, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Relugolix plus E2/NETA (Group A)", "type": "EXPERIMENTAL", "description": "Relugolix co-administered with E2/NETA for 24 weeks.", "interventionNames": ["Drug: Relugolix", "Drug: Estradiol/norethindrone acetate"]}, {"label": "Relugolix plus Delayed E2/NETA (Group B)", "type": "EXPERIMENTAL", "description": "Relugolix co-administered with E2/NETA placebo for 12 weeks, followed by relugolix co-administered with E2/NETA for 12 weeks.", "interventionNames": ["Drug: Relugolix", "Drug: Estradiol/norethindrone acetate", "Drug: Estradiol/norethindrone acetate placebo"]}, {"label": "Placebo (Group C)", "type": "PLACEBO_COMPARATOR", "description": "Relugolix placebo co-administered with E2/NETA placebo for 24 weeks.", "interventionNames": ["Drug: Estradiol/norethindrone acetate placebo", "Drug: Relugolix placebo"]}], "interventions": [{"type": "DRUG", "name": "Relugolix", "description": "Relugolix 40-mg tablet administered orally once daily.", "armGroupLabels": ["Relugolix plus Delayed E2/NETA (Group B)", "Relugolix plus E2/NETA (Group A)"], "otherNames": ["TAK-385", "MVT-601"]}, {"type": "DRUG", "name": "Estradiol/norethindrone acetate", "description": "Capsule containing co-formulated tablet of E2 (1.0 mg)/NETA (0.5 mg) administered orally once daily.", "armGroupLabels": ["Relugolix plus Delayed E2/NETA (Group B)", "Relugolix plus E2/NETA (Group A)"], "otherNames": ["E2/NETA"]}, {"type": "DRUG", "name": "Estradiol/norethindrone acetate placebo", "description": "E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the E2/NETA capsule in size, shape, color, and odor.", "armGroupLabels": ["Placebo (Group C)", "Relugolix plus Delayed E2/NETA (Group B)"]}, {"type": "DRUG", "name": "Relugolix placebo", "description": "Relugolix (0 mg) placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.", "armGroupLabels": ["Placebo (Group C)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Percentage Of Participants Who Meet The Dysmenorrhea Responder Criteria At Week 24 Or End Of Treatment (EOT)", "description": "Assessed using a Numerical Rating Scale (NRS) score (11-point scale) for pain recorded daily in an electronic diary (e-Diary). The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.", "timeFrame": "Week 24 or EOT"}, {"measure": "Percentage Of Participants Who Meet The Non-Menstrual Pelvic Pain (NMPP) Responder Criteria At Week 24 Or EOT", "description": "Assessed using an NRS score (11-point scale) for pain recorded daily in an e-Diary. The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.", "timeFrame": "Week 24 or EOT"}], "secondaryOutcomes": [{"measure": "Change From Baseline In The Endometriosis Health Profile (EHP)-30 Pain Score At Week 24", "description": "Assessed using the Pain Domain of the EHP-30 questionnaire.", "timeFrame": "Baseline, Week 24"}, {"measure": "Change From Baseline In Dysmenorrhea NRS Score At Week 24 Or EOT", "description": "Assessed using an NRS score (11-point scale) for pain recorded daily in an e-Diary.", "timeFrame": "Baseline, Week 24 or EOT"}, {"measure": "Change From Baseline In NMPP NRS Score At Week 24 Or EOT", "description": "Assessed using an NRS score (11-point scale) for pain recorded daily in an e-Diary.", "timeFrame": "Baseline, Week 24 or EOT"}, {"measure": "Change From Baseline In Overall Pelvic Pain NRS Score At Week 24 Or EOT", "description": "Assessed using an NRS score (11-point scale) for pain recorded daily in an e-Diary.", "timeFrame": "Baseline, Week 24 or EOT"}, {"measure": "Percentage Of Participants Who Are Not Using Opioids For Endometriosis-associated Pain At Week 24 Or EOT", "description": "Assessed based on usage of protocol-specified opioids for endometriosis-associated pain recorded daily in an e-Diary.", "timeFrame": "Week 24 or EOT"}, {"measure": "Change From Baseline In Dyspareunia NRS Scores At Week 24 Or EOT", "description": "Assessed using an NRS score (11-point scale) for dyspareunia recorded daily in an e-Diary.", "timeFrame": "Baseline, Week 24 or EOT"}, {"measure": "Change From Baseline In Analgesic Use For Endometriosis-associated Pain Based On Mean Pill Count At Week 24 Or EOT", "description": "Assessed based on usage of protocol-specified analgesic for endometriosis-associated pain recorded daily in an e-Diary.", "timeFrame": "Baseline, Week 24 or EOT"}, {"measure": "Percentage Of Participants Who Have A Reduction Of At Least 20 Points In The EHP-30 Pain Domain From Baseline To Week 24", "description": "Assessed using the pain domain of the EHP-30 questionnaire.", "timeFrame": "Baseline to Week 24"}, {"measure": "Dysmenorrhea Responder Rate By Month", "description": "The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.", "timeFrame": "Baseline to Week 24"}, {"measure": "NMPP Responder Rate By Month", "description": "The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.", "timeFrame": "Baseline to Week 24"}, {"measure": "Change In Dysmenorrhea NRS Score By Month", "description": "Assessed using an NRS score (11-point scale) for pain recorded daily in an e-Diary.", "timeFrame": "Baseline to Week 24"}, {"measure": "Change In NMPP NRS Score By Month", "description": "Assessed using an NRS score (11-point scale) for pain recorded daily in an e-Diary.", "timeFrame": "Baseline to Week 24"}, {"measure": "Change In Overall Pelvic Pain NRS Score By Month", "description": "Assessed using an NRS score (11-point scale) for pain recorded daily in an e-Diary.", "timeFrame": "Baseline to Week 24"}, {"measure": "Change In Dyspareunia NRS Score By Month", "description": "Assessed using an NRS score (11-point scale) for pain recorded daily in an e-Diary.", "timeFrame": "Baseline to Week 24"}, {"measure": "Change From Baseline In Ibuprofen Use At Week 24 Or EOT", "description": "Assessed using ibuprofen pill counts for endometriosis-associated pain recorded daily in an e-Diary.", "timeFrame": "Baseline, Week 24 or EOT"}, {"measure": "Change From Baseline In Opioid Use At Week 24 Or EOT", "description": "Assessed using opioid pill counts for endometriosis-associated pain recorded daily in an e-Diary.", "timeFrame": "Baseline, Week 24 or EOT"}, {"measure": "Change From Baseline In The Mean Dysmenorrhea Functional Impairment At Week 24 Or EOT", "description": "Assessed using the subject modified Biberoglu and Behrman 5-point scale for dysmenorrhea recorded daily in an e-Diary.", "timeFrame": "Baseline, Week 24 or EOT"}, {"measure": "Change From Baseline In The Mean NMPP Functional Impairment At Week 24 Or EOT", "description": "Assessed using the subject modified Biberoglu and Behrman 4-point scale for pelvic pain recorded daily in an e-Diary.", "timeFrame": "Baseline, Week 24 or EOT"}, {"measure": "Change From Baseline In The Mean Dyspareunia Functional Impairment At Week 24 Or EOT", "description": "Assessed using the subject modified Biberoglu and Behrman 5-point scale for dyspareunia recorded daily in an e-Diary.", "timeFrame": "Baseline, Week 24 or EOT"}, {"measure": "Change From Baseline In Patient Global Assessment (PGA) For Dysmenorrhea Symptom Severity At Week 24", "description": "The PGA for dysmenorrhea is a 1-item questionnaire designed to assess participants' impression of the severity of pain during their menstrual cycle.", "timeFrame": "Baseline, Week 24"}, {"measure": "Percentage Of Participants With Improvement, No Change, Or Worsening From Baseline In PGA For Dysmenorrhea At Week 24", "description": "The PGA for dysmenorrhea is a 1-item questionnaire designed to assess participants' impression of the severity of pain during their menstrual cycle.", "timeFrame": "Week 24"}, {"measure": "Change From Baseline In PGA For NMPP Symptom Severity At Week 24", "description": "The PGA for NMPP is a 1-item questionnaire designed to assess participants' impression of the severity of pain when they are not menstruating.", "timeFrame": "Baseline, Week 24"}, {"measure": "Percentage Of Participants With Improvement, No Change, Or Worsening From Baseline In PGA For NMPP At Week 24", "description": "The PGA for NMPP is a 1-item questionnaire designed to assess participants' impression of the severity of pain when they are not menstruating.", "timeFrame": "Week 24"}, {"measure": "Change From Baseline In PGA For Pain Severity At Week 24", "description": "The PGA for pain severity is a 1-item questionnaire designed to assess participants' impression of how their pain affected their usual activities.", "timeFrame": "Baseline, Week 24"}, {"measure": "Percentage Of Participants With Improvement, No Change, Or Worsening From Baseline In PGA For Pain Severity At Week 24", "description": "The PGA for pain severity is a 1-item questionnaire designed to assess participants' impression of how their pain affected their usual activities.", "timeFrame": "Week 24"}, {"measure": "Change From Baseline In PGA For Function At Week 24", "description": "The PGA for function is a 1-item questionnaire designed to assess participants' impression of how their pain affected their usual activities.", "timeFrame": "Baseline, Week 24"}, {"measure": "Percentage Of Participants With Improvement, No Change, Or Worsening From Baseline In PGA For Function At Week 24", "description": "The PGA for function is a 1-item questionnaire designed to assess participants' impression of how their pain affected their usual activities.", "timeFrame": "Week 24"}, {"measure": "Percentage Of Participants Who Are \"Better\" Or \"Much Better\" On The Patient Global Impression Of Change (PGIC) For Dysmenorrhea At Week 24", "description": "The PGIC for dysmenorrhea is a 1-item questionnaire designed to assess participants' impression of change in the severity of pain during their menstrual cycle.", "timeFrame": "Week 24"}, {"measure": "Percentage Of Participants Who Are \"Better\" Or \"Much Better\" On The PGIC For NMPP At Week 24", "description": "The PGIC for NMPP is a 1-item questionnaire designed to assess participants' impression of change in the severity of pain during their menstrual cycle.", "timeFrame": "Week 24"}, {"measure": "Percentage Of Participants Who Are \"Better\" Or \"Much Better\" On The PGIC For Dyspareunia At Week 24", "description": "The PGIC for dyspareunia is a 1-item questionnaire designed to assess participants' impression of change in the severity of pain during sexual intercourse.", "timeFrame": "Week 24"}, {"measure": "Change From Baseline In The Non-Pain Of The EHP-30 Domains At Week 24", "description": "Assessed using the non-pain domains (Control and Powerlessness, Social Support, Emotional Well-Being, and Self-Image) of the EHP-30 questionnaire.", "timeFrame": "Baseline, Week 24"}, {"measure": "Change From Baseline In The EHP-30 Scale Total Score At Week 24", "description": "Assessed using the total score of the EHP-30 questionnaire.", "timeFrame": "Baseline, Week 24"}, {"measure": "Change From Baseline In The EHP Work Domain Score At Week 24", "description": "The EHP Work domain is a 5-item questionnaire that assesses impact of pain on ability to work.", "timeFrame": "Baseline, Week 24"}, {"measure": "Categorical Change From Baseline In Quality Of Life Assessed By European Quality Of Life Five Dimension Five Level (EQ-5D-5L) Questionnaire At Week 24", "description": "The EQ-5D-5L is a 5-item questionnaire designed to assess quality of life.", "timeFrame": "Baseline, Week 24"}, {"measure": "Change From Baseline To Week 24 In EQ-5D-5L Visual Analogue Scale Score At Week 24", "description": "The EQ-5D-5L is a 5-item questionnaire designed to assess quality of life.", "timeFrame": "Baseline, Week 24"}, {"measure": "Percentage Of Participants Who Meet The Dysmenorrhea Responder Criteria At Week 24 Or EOT For Relugolix Plus Delayed E2/NETA", "description": "Assessed using an NRS score (11-point scale) for pain recorded daily in an e-Diary. The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.", "timeFrame": "Week 24 or EOT"}, {"measure": "Percentage Of Participants Who Meet The NMPP Responder Criteria At Week 24 Or EOT For Relugolix Plus Delayed E2/NETA", "description": "Assessed using an NRS score (11-point scale) for pain recorded daily in an e-Diary. The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.", "timeFrame": "Week 24 or EOT"}, {"measure": "Change From Baseline In The EHP-30 Pain Score At Week 24 For Relugolix Plus Delayed E2/NETA", "description": "Assessed using the Pain Domain of the EHP-30 questionnaire.", "timeFrame": "Baseline, Week 24"}, {"measure": "Percentage Of Participants Who Have A Reduction Of At Least 20 Points In The EHP-30 Pain Domain From Baseline To Week 24 For Relugolix Plus Delayed E2/NETA", "description": "Assessed using the pain domain of the EHP-30 questionnaire.", "timeFrame": "Baseline to Week 24"}, {"measure": "Percentage Change From Baseline In Bone Mineral Density At The Lumbar Spine (L1-L4) At Week 12", "description": "Assessed by dual-energy X-ray absorptiometry (DXA) scan.", "timeFrame": "Baseline, Week 12"}, {"measure": "Percentage Change From Baseline In Bone Mineral Density At Lumbar Spine (L1-L4), Femoral Neck, And Total Hip At Week 24", "description": "Assessed by DXA scan.", "timeFrame": "Baseline, Week 24"}, {"measure": "Percentage Of Participants Experiencing Vasomotor Symptoms At Week 12 Between Group A And B", "timeFrame": "Week 12"}, {"measure": "Change From Baseline In Serum Concentrations Of Luteinizing Hormone, Follicle Stimulating Hormone, Estradiol, And Progesterone", "description": "Blood samples will be collected from participants for hormonal measurements.", "timeFrame": "Baseline, Week 24"}, {"measure": "Pre-dose Relugolix Plasma Concentrations", "description": "Blood samples will be collected from participants for relugolix measurements.", "timeFrame": "Week 4"}, {"measure": "Endometrial Biopsy At Week 24", "description": "Primary diagnosis of endometrial biopsy assessment by pathologist.", "timeFrame": "Week 24"}]}, "eligibilityModule": {"eligibilityCriteria": "Key Inclusion Criteria:\n\n1. Is a premenopausal female aged 18 to 50 years old (inclusive) on the day of signing of the informed consent form.\n2. Has agreed to use only study-specified analgesic medications during the study and is not known to be intolerant to these.\n3. Has a diagnosis of endometriosis and has had, within 10 years prior to signing the informed consent form, surgical or direct visualization and/or histopathologic confirmation of endometriosis, for example, during a laparoscopy or laparotomy.\n4. During the Run-In Period (35 to 70 days prior to treatment period) has a dysmenorrhea NRS score ≥ 4.0 on at least 2 days and\n\n   1. Mean NMPP NRS score ≥ 2.5, or\n   2. Mean NMPP NRS score ≥ 1.25 and NMPP NRS score ≥ 5.0 on ≥ 4 days.\n\nKey Exclusion Criteria:\n\n1. Has a history of chronic pelvic pain that is not caused by endometriosis.\n2. Has any chronic pain or frequently recurring pain condition, other than endometriosis that is treated with opioids or requires analgesics for ≥ 7 days per month.\n3. Has had surgical procedures for treatment of endometriosis within the 3 months prior to the Screening visit.\n4. Has a history of or currently has osteoporosis or other metabolic bone disease.\n5. Has a clinically significant gynecologic condition, other than endometriosis, identified during Screening or Run-In period transvaginal ultrasound or endometrial biopsy.", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "50 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Myovant Medical Monitor", "affiliation": "Myovant Sciences", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Dothan", "city": "Dothan", "state": "Alabama", "zip": "36303", "country": "United States", "geoPoint": {"lat": 31.22323, "lon": -85.39049}}, {"facility": "Mesa", "city": "Mesa", "state": "Arizona", "zip": "85209", "country": "United States", "geoPoint": {"lat": 33.42227, "lon": -111.82264}}, {"facility": "Scottsdale", "city": "Scottsdale", "state": "Arizona", "zip": "85251", "country": "United States", "geoPoint": {"lat": 33.50921, "lon": -111.89903}}, {"facility": "Tucson", "city": "Tucson", "state": "Arizona", "zip": "85704", "country": "United States", "geoPoint": {"lat": 32.22174, "lon": -110.92648}}, {"facility": "Tucson", "city": "Tucson", "state": "Arizona", "zip": "85712", "country": "United States", "geoPoint": {"lat": 32.22174, "lon": -110.92648}}, {"facility": "Canoga Park", "city": "Canoga Park", "state": "California", "zip": "91303", "country": "United States", "geoPoint": {"lat": 34.20112, "lon": -118.59814}}, {"facility": "Long Beach", "city": "Long Beach", "state": "California", "zip": "90806", "country": "United States", "geoPoint": {"lat": 33.76696, "lon": -118.18923}}, {"facility": "San Diego", "city": "San Diego", "state": "California", "zip": "92111", "country": "United States", "geoPoint": {"lat": 32.71571, "lon": -117.16472}}, {"facility": "Greenwood Village", "city": "Greenwood Village", "state": "Colorado", "zip": "80111", "country": "United States", "geoPoint": {"lat": 39.61721, "lon": -104.95081}}, {"facility": "Fort Myers", "city": "Fort Myers", "state": "Florida", "zip": "33912", "country": "United States", "geoPoint": {"lat": 26.62168, "lon": -81.84059}}, {"facility": "Loxahatchee", "city": "Loxahatchee Groves", "state": "Florida", "zip": "33470", "country": "United States", "geoPoint": {"lat": 26.68368, "lon": -80.27977}}, {"facility": "Miami", "city": "Miami", "state": "Florida", "zip": "33126", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Miami", "city": "Miami", "state": "Florida", "zip": "33155", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Orlando", "city": "Orlando", "state": "Florida", "zip": "32808", "country": "United States", "geoPoint": {"lat": 28.53834, "lon": -81.37924}}, {"facility": "Oviedo", "city": "Oviedo", "state": "Florida", "zip": "32765", "country": "United States", "geoPoint": {"lat": 28.67, "lon": -81.20812}}, {"facility": "Plantation", "city": "Plantation", "state": "Florida", "zip": "33324", "country": "United States", "geoPoint": {"lat": 26.13421, "lon": -80.23184}}, {"facility": "Sarasota", "city": "Sarasota", "state": "Florida", "zip": "34239", "country": "United States", "geoPoint": {"lat": 27.33643, "lon": -82.53065}}, {"facility": "Atlanta", "city": "Atlanta", "state": "Georgia", "zip": "30363", "country": "United States", "geoPoint": {"lat": 33.749, "lon": -84.38798}}, {"facility": "Augusta", "city": "Augusta", "state": "Georgia", "zip": "30909", "country": "United States", "geoPoint": {"lat": 33.47097, "lon": -81.97484}}, {"facility": "Norcross", "city": "Norcross", "state": "Georgia", "zip": "30093", "country": "United States", "geoPoint": {"lat": 33.94121, "lon": -84.21353}}, {"facility": "Idaho Falls", "city": "Idaho Falls", "state": "Idaho", "zip": "83404", "country": "United States", "geoPoint": {"lat": 43.46658, "lon": -112.03414}}, {"facility": "Oakbrook", "city": "Oak Brook", "state": "Illinois", "zip": "60523", "country": "United States", "geoPoint": {"lat": 41.83281, "lon": -87.92895}}, {"facility": "Shawnee", "city": "Shawnee Mission", "state": "Kansas", "zip": "66218", "country": "United States", "geoPoint": {"lat": 39.02, "lon": -94.66583}}, {"facility": "New Orleans", "city": "New Orleans", "state": "Louisiana", "zip": "70115", "country": "United States", "geoPoint": {"lat": 29.95465, "lon": -90.07507}}, {"facility": "Jefferson City", "city": "Jefferson City", "state": "Missouri", "zip": "65109", "country": "United States", "geoPoint": {"lat": 38.5767, "lon": -92.17352}}, {"facility": "Las Vegas", "city": "Las Vegas", "state": "Nevada", "zip": "89113", "country": "United States", "geoPoint": {"lat": 36.17497, "lon": -115.13722}}, {"facility": "Port Jefferson", "city": "Port Jefferson", "state": "New York", "zip": "11777", "country": "United States", "geoPoint": {"lat": 40.94649, "lon": -73.06927}}, {"facility": "Durham", "city": "Durham", "state": "North Carolina", "zip": "27713", "country": "United States", "geoPoint": {"lat": 35.99403, "lon": -78.89862}}, {"facility": "Raleigh", "city": "Raleigh", "state": "North Carolina", "zip": "27612", "country": "United States", "geoPoint": {"lat": 35.7721, "lon": -78.63861}}, {"facility": "Winston Salem", "city": "Winston-Salem", "state": "North Carolina", "zip": "27103", "country": "United States", "geoPoint": {"lat": 36.09986, "lon": -80.24422}}, {"facility": "Englewood", "city": "Englewood", "state": "Ohio", "zip": "45322", "country": "United States", "geoPoint": {"lat": 39.87756, "lon": -84.30217}}, {"facility": "Hershey", "city": "Hershey", "state": "Pennsylvania", "zip": "17033", "country": "United States", "geoPoint": {"lat": 40.28592, "lon": -76.65025}}, {"facility": "Philadelphia", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19104", "country": "United States", "geoPoint": {"lat": 39.95238, "lon": -75.16362}}, {"facility": "Memphis", "city": "Memphis", "state": "Tennessee", "zip": "38120", "country": "United States", "geoPoint": {"lat": 35.14953, "lon": -90.04898}}, {"facility": "Murfreesboro", "city": "Murfreesboro", "state": "Tennessee", "zip": "37130", "country": "United States", "geoPoint": {"lat": 35.84562, "lon": -86.39027}}, {"facility": "Austin", "city": "Austin", "state": "Texas", "zip": "78705", "country": "United States", "geoPoint": {"lat": 30.26715, "lon": -97.74306}}, {"facility": "Houston", "city": "Houston", "state": "Texas", "zip": "77030", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Webster", "city": "Webster", "state": "Texas", "zip": "77598", "country": "United States", "geoPoint": {"lat": 29.53773, "lon": -95.11826}}, {"facility": "Salt Lake City", "city": "Salt Lake City", "state": "Utah", "zip": "84107", "country": "United States", "geoPoint": {"lat": 40.76078, "lon": -111.89105}}, {"facility": "Salt Lake City", "city": "Salt Lake City", "state": "Utah", "zip": "84124", "country": "United States", "geoPoint": {"lat": 40.76078, "lon": -111.89105}}, {"facility": "Norfolk", "city": "Norfolk", "state": "Virginia", "zip": "23507", "country": "United States", "geoPoint": {"lat": 36.84681, "lon": -76.28522}}, {"facility": "Richmond", "city": "Richmond", "state": "Virginia", "zip": "23235", "country": "United States", "geoPoint": {"lat": 37.55376, "lon": -77.46026}}, {"facility": "Seattle", "city": "Seattle", "state": "Washington", "zip": "98105", "country": "United States", "geoPoint": {"lat": 47.60621, "lon": -122.33207}}, {"facility": "Ciudad de Buenos Aires", "city": "Ciudad de Buenos Aires", "state": "Buenos Aires", "zip": "C1128AAF", "country": "Argentina"}, {"facility": "San Isidro", "city": "San Isidro", "state": "Buenos Aires", "zip": "B1642CKL", "country": "Argentina", "geoPoint": {"lat": -34.46971, "lon": -58.52111}}, {"facility": "Rosario", "city": "Rosario", "state": "Santa Fe Province", "zip": "S2000PRB", "country": "Argentina", "geoPoint": {"lat": -32.94682, "lon": -60.63932}}, {"facility": "Córdoba", "city": "Córdoba", "zip": "X5000JHQ", "country": "Argentina", "geoPoint": {"lat": -31.40648, "lon": -64.18853}}, {"facility": "Leuven", "city": "Leuven", "state": "Flemish Brabant", "zip": "3000", "country": "Belgium", "geoPoint": {"lat": 50.87959, "lon": 4.70093}}, {"facility": "La Louvière", "city": "La Louvière", "state": "Hainaut", "zip": "7100", "country": "Belgium", "geoPoint": {"lat": 50.48657, "lon": 4.18785}}, {"facility": "Gent", "city": "Ghent", "state": "Oost-vlaanderen", "zip": "9000", "country": "Belgium", "geoPoint": {"lat": 51.05, "lon": 3.71667}}, {"facility": "Brussels", "city": "Brussels", "zip": "1070", "country": "Belgium", "geoPoint": {"lat": 50.85045, "lon": 4.34878}}, {"facility": "Sofia", "city": "Sofia", "state": "Sofia", "zip": "1233", "country": "Bulgaria"}, {"facility": "Sofia", "city": "Sofia", "state": "Sofia", "zip": "1431", "country": "Bulgaria"}, {"facility": "Sofia", "city": "Sofia", "state": "Sofia", "zip": "1504", "country": "Bulgaria"}, {"facility": "Blagoevgrad", "city": "Blagoevgrad", "zip": "2700", "country": "Bulgaria", "geoPoint": {"lat": 42.01457, "lon": 23.09804}}, {"facility": "Pleven", "city": "Pleven", "zip": "5809", "country": "Bulgaria", "geoPoint": {"lat": 43.41791, "lon": 24.61666}}, {"facility": "Sofia", "city": "Sofia", "zip": "1336", "country": "Bulgaria", "geoPoint": {"lat": 42.69751, "lon": 23.32415}}, {"facility": "Sofia", "city": "Sofia", "zip": "1606", "country": "Bulgaria", "geoPoint": {"lat": 42.69751, "lon": 23.32415}}, {"facility": "Stara Zagora", "city": "Stara Zagora", "zip": "6003", "country": "Bulgaria", "geoPoint": {"lat": 42.43205, "lon": 25.64262}}, {"facility": "Varna", "city": "Varna", "zip": "9005", "country": "Bulgaria", "geoPoint": {"lat": 43.21912, "lon": 27.91024}}, {"facility": "Red Deer", "city": "Red Deer", "state": "Alberta", "zip": "T4N 6V7", "country": "Canada", "geoPoint": {"lat": 52.26682, "lon": -113.802}}, {"facility": "Waterloo", "city": "Waterloo", "state": "Ontario", "zip": "N2J1C4", "country": "Canada", "geoPoint": {"lat": 43.4668, "lon": -80.51639}}, {"facility": "Victoriaville", "city": "Victoriaville", "state": "Quebec", "zip": "G6P 6P6", "country": "Canada", "geoPoint": {"lat": 46.05007, "lon": -71.96579}}, {"facility": "Praha 10", "city": "Prague", "state": "Prague", "zip": "100 34", "country": "Czechia", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"facility": "Nachod", "city": "Náchod", "zip": "54701", "country": "Czechia", "geoPoint": {"lat": 50.4167, "lon": 16.16289}}, {"facility": "Olomouc", "city": "Olomouc", "zip": "772 00", "country": "Czechia", "geoPoint": {"lat": 49.59552, "lon": 17.25175}}, {"facility": "Praha 8 - Libeň", "city": "Praha 8 - Libeň", "zip": "180 81", "country": "Czechia"}, {"facility": "Vodnany", "city": "Vodňany", "zip": "389 01", "country": "Czechia", "geoPoint": {"lat": 49.14789, "lon": 14.17513}}, {"facility": "Vysoké Mýto", "city": "Vysoké Mýto", "zip": "566 01", "country": "Czechia", "geoPoint": {"lat": 49.9532, "lon": 16.16169}}, {"facility": "Kuopio", "city": "Kuopio", "state": "Eastern Finland", "zip": "FI-70110", "country": "Finland", "geoPoint": {"lat": 62.89238, "lon": 27.67703}}, {"facility": "Helsinki", "city": "Helsinki", "state": "Southern Finland", "zip": "00260", "country": "Finland", "geoPoint": {"lat": 60.16952, "lon": 24.93545}}, {"facility": "Oulu", "city": "Oulu", "zip": "90100", "country": "Finland", "geoPoint": {"lat": 65.01236, "lon": 25.46816}}, {"facility": "Pécs", "city": "Pécs", "state": "Baranya", "zip": "7624", "country": "Hungary", "geoPoint": {"lat": 46.07617, "lon": 18.22814}}, {"facility": "Békéscsaba", "city": "Békéscsaba", "state": "Bekes County", "zip": "5600", "country": "Hungary", "geoPoint": {"lat": 46.68333, "lon": 21.1}}, {"facility": "Gyula", "city": "Gyula", "state": "Bekes County", "zip": "5700", "country": "Hungary", "geoPoint": {"lat": 46.65, "lon": 21.28333}}, {"facility": "Kecskemét", "city": "Kecskemét", "state": "Bács-Kiskun county", "zip": "6000", "country": "Hungary", "geoPoint": {"lat": 46.90618, "lon": 19.69128}}, {"facility": "Szeged", "city": "Szeged", "state": "Csongrád megye", "zip": "6725", "country": "Hungary", "geoPoint": {"lat": 46.253, "lon": 20.14824}}, {"facility": "Debrecen", "city": "Debrecen", "state": "Hajdú-Bihar", "zip": "4024", "country": "Hungary", "geoPoint": {"lat": 47.53167, "lon": 21.62444}}, {"facility": "Debrecen", "city": "Debrecen", "state": "Hajdú-Bihar", "zip": "4025", "country": "Hungary", "geoPoint": {"lat": 47.53167, "lon": 21.62444}}, {"facility": "Debrecen", "city": "Debrecen", "state": "Hajdú-Bihar", "zip": "4032", "country": "Hungary", "geoPoint": {"lat": 47.53167, "lon": 21.62444}}, {"facility": "Nyíregyháza", "city": "Nyíregyháza", "state": "Szabolcs-Szatmár-Bereg", "zip": "4400", "country": "Hungary", "geoPoint": {"lat": 47.95539, "lon": 21.71671}}, {"facility": "Budapest", "city": "Budapest", "zip": "1027", "country": "Hungary", "geoPoint": {"lat": 47.49835, "lon": 19.04045}}, {"facility": "Budapest", "city": "Budapest", "zip": "1062", "country": "Hungary", "geoPoint": {"lat": 47.49835, "lon": 19.04045}}, {"facility": "Budapest", "city": "Budapest", "zip": "1135", "country": "Hungary", "geoPoint": {"lat": 47.49835, "lon": 19.04045}}, {"facility": "Poznań", "city": "Poznan", "state": "Greater Poland Voivodeship", "zip": "60-535", "country": "Poland", "geoPoint": {"lat": 52.40692, "lon": 16.92993}}, {"facility": "Skórzewo", "city": "Skórzewo", "state": "Greater Poland Voivodeship", "zip": "601-85", "country": "Poland", "geoPoint": {"lat": 52.39085, "lon": 16.78934}}, {"facility": "Kraków", "city": "Krakow", "state": "Lesser Poland Voivodeship", "zip": "31-121", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"facility": "Lublin", "city": "Lublin", "state": "Lublin Voivodeship", "zip": "20-064", "country": "Poland", "geoPoint": {"lat": 51.25058, "lon": 22.57009}}, {"facility": "Lublin", "city": "Lublin", "state": "Lublin Voivodeship", "zip": "20-632", "country": "Poland", "geoPoint": {"lat": 51.25058, "lon": 22.57009}}, {"facility": "Lublin", "city": "Lublin", "state": "Lublin Voivodeship", "zip": "20-880", "country": "Poland", "geoPoint": {"lat": 51.25058, "lon": 22.57009}}, {"facility": "Warszawa", "city": "Warsaw", "state": "Masovian Voivodeship", "zip": "02-066", "country": "Poland", "geoPoint": {"lat": 52.22977, "lon": 21.01178}}, {"facility": "Warszawa", "city": "Warsaw", "state": "Masovian Voivodeship", "zip": "02-929", "country": "Poland", "geoPoint": {"lat": 52.22977, "lon": 21.01178}}, {"facility": "Białystok", "city": "Bialystok", "state": "Podlaskie Voivodeship", "zip": "15-224", "country": "Poland", "geoPoint": {"lat": 53.13333, "lon": 23.16433}}, {"facility": "Katowice", "city": "Katowice", "state": "Silesian Voivodeship", "zip": "02-066", "country": "Poland", "geoPoint": {"lat": 50.2597, "lon": 19.02173}}, {"facility": "Katowice", "city": "Katowice", "state": "Silesian Voivodeship", "zip": "40-081", "country": "Poland", "geoPoint": {"lat": 50.2597, "lon": 19.02173}}, {"facility": "Szczecin", "city": "Szczecin", "state": "West Pomeranian Voivodeship", "zip": "71-434", "country": "Poland", "geoPoint": {"lat": 53.42894, "lon": 14.55302}}, {"facility": "Lódz", "city": "Lódz", "state": "Łódź Voivodeship", "zip": "90-602", "country": "Poland"}, {"facility": "Almada", "city": "Almada", "state": "Lisbon District", "zip": "2805-267", "country": "Portugal", "geoPoint": {"lat": 38.93057, "lon": -9.3448}}, {"facility": "Coimbra", "city": "Coimbra", "zip": "3000-075", "country": "Portugal", "geoPoint": {"lat": 40.20686, "lon": -8.41996}}, {"facility": "Covilhã", "city": "Covilha", "zip": "6200-251", "country": "Portugal", "geoPoint": {"lat": 40.28106, "lon": -7.50504}}, {"facility": "Lisbon", "city": "Lisbon", "zip": "1069-089", "country": "Portugal", "geoPoint": {"lat": 38.72509, "lon": -9.1498}}, {"facility": "Porto", "city": "Porto", "zip": "4099-001", "country": "Portugal", "geoPoint": {"lat": 41.1485, "lon": -8.61097}}, {"facility": "Port Elizabeth", "city": "Port Elizabeth", "state": "Eastern Cape", "zip": "6001", "country": "South Africa", "geoPoint": {"lat": -33.96109, "lon": 25.61494}}, {"facility": "Centurion", "city": "Centurion", "state": "Gauteng", "zip": "0157", "country": "South Africa", "geoPoint": {"lat": -25.85891, "lon": 28.18577}}, {"facility": "Roodepoort", "city": "Roodepoort", "state": "Gauteng", "zip": "1724", "country": "South Africa", "geoPoint": {"lat": -26.1625, "lon": 27.8725}}, {"facility": "Durban", "city": "Durban", "state": "KwaZulu-Natal", "zip": "4001", "country": "South Africa", "geoPoint": {"lat": -29.8579, "lon": 31.0292}}, {"facility": "Cape Town", "city": "Cape Town", "state": "Western Cape", "zip": "7405", "country": "South Africa", "geoPoint": {"lat": -33.92584, "lon": 18.42322}}, {"facility": "Madrid", "city": "Madrid", "zip": "28041", "country": "Spain", "geoPoint": {"lat": 40.4165, "lon": -3.70256}}, {"facility": "Valencia", "city": "Valencia", "zip": "46010", "country": "Spain", "geoPoint": {"lat": 39.47391, "lon": -0.37966}}, {"facility": "Kyiv", "city": "Kyiv", "state": "Kiev City", "zip": "02232", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Kyiv", "city": "Kyiv", "state": "Kiev City", "zip": "04050", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Kyiv", "city": "Kyiv", "state": "Kyiv City", "zip": "01034", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Chernivtsi", "city": "Chernivtsi", "zip": "58001", "country": "Ukraine", "geoPoint": {"lat": 48.29045, "lon": 25.93241}}, {"facility": "Ivano-Frankivsk", "city": "Ivano-Frankivsk", "zip": "76018", "country": "Ukraine", "geoPoint": {"lat": 48.92312, "lon": 24.71248}}, {"facility": "Kharkiv", "city": "Kharkiv", "zip": "61052", "country": "Ukraine", "geoPoint": {"lat": 49.98177, "lon": 36.25475}}, {"facility": "Kiev", "city": "Kiev", "zip": "03148", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Kiev", "city": "Kiev", "zip": "04053", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Kiev", "city": "Kiev", "zip": "04112", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Vinnytsya", "city": "Vinnytsia", "zip": "21101", "country": "Ukraine", "geoPoint": {"lat": 49.2322, "lon": 28.46871}}, {"facility": "Zaporizhzhya", "city": "Zaporizhzhya", "zip": "69065", "country": "Ukraine", "geoPoint": {"lat": 47.85167, "lon": 35.11714}}, {"facility": "Zaporizhzhya", "city": "Zaporizhzhya", "zip": "69068", "country": "Ukraine", "geoPoint": {"lat": 47.85167, "lon": 35.11714}}, {"facility": "Zaporizhzhya", "city": "Zaporizhzhya", "zip": "69071", "country": "Ukraine", "geoPoint": {"lat": 47.85167, "lon": 35.11714}}, {"facility": "Zaporizhzhya", "city": "Zaporizhzhya", "zip": "69663", "country": "Ukraine", "geoPoint": {"lat": 47.85167, "lon": 35.11714}}]}, "referencesModule": {"references": [{"pmid": "37982388", "type": "DERIVED", "citation": "Giudice LC, As-Sanie S, Arjona Ferreira JC, Becker CM, Abrao MS, Lessey BA, Dynowski K, Wilk K, Li Y, Mathur V, Wagman RB, Johnson NP. A Plain Language Summary to learn about relugolix combination therapy for the treatment of pain associated with endometriosis. Pain Manag. 2023 Nov;13(11):631-640. doi: 10.2217/pmt-2023-0052. Epub 2023 Nov 20."}, {"pmid": "37283994", "type": "DERIVED", "citation": "Hunsche E, Gauthier M, Witherspoon B, Rakov V, Agarwal SK. Endometriosis Symptoms and Their Impacts on the Daily Lives of US Women: Results from an Interview Study. Int J Womens Health. 2023 Jun 1;15:893-904. doi: 10.2147/IJWH.S409733. eCollection 2023."}, {"pmid": "35717987", "type": "DERIVED", "citation": "Giudice LC, As-Sanie S, Arjona Ferreira JC, Becker CM, Abrao MS, Lessey BA, Brown E, Dynowski K, Wilk K, Li Y, Mathur V, Warsi QA, Wagman RB, Johnson NP. Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2). Lancet. 2022 Jun 18;399(10343):2267-2279. doi: 10.1016/S0140-6736(22)00622-5."}, {"pmid": "31069056", "type": "DERIVED", "citation": "Rolla E. Endometriosis: advances and controversies in classification, pathogenesis, diagnosis, and treatment. F1000Res. 2019 Apr 23;8:F1000 Faculty Rev-529. doi: 10.12688/f1000research.14817.1. eCollection 2019."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04", "submissionTracking": {"estimatedResultsFirstSubmitDate": "2022-09-02", "submissionInfos": [{"releaseDate": "2022-09-02", "resetDate": "2022-09-29", "mcpReleaseN": 30}, {"releaseDate": "2023-12-05", "resetDate": "2023-12-26", "mcpReleaseN": 31}, {"releaseDate": "2024-04-15", "resetDate": "2024-04-16", "mcpReleaseN": 32}, {"releaseDate": "2024-05-28", "resetDate": "2024-05-31", "mcpReleaseN": 33}, {"releaseDate": "2025-05-07", "resetDate": "2025-05-08", "mcpReleaseN": 34}, {"releaseDate": "2025-05-20", "resetDate": "2025-05-21", "mcpReleaseN": 35}]}}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}, {"id": "D010146", "term": "Pain"}, {"id": "D004412", "term": "Dysmenorrhea"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}, {"id": "D009461", "term": "Neurologic Manifestations"}, {"id": "D012816", "term": "Signs and Symptoms"}, {"id": "D013568", "term": "Pathological Conditions, Signs and Symptoms"}, {"id": "D008599", "term": "Menstruation Disturbances"}, {"id": "D010335", "term": "Pathologic Processes"}, {"id": "D017699", "term": "Pelvic Pain"}]}, "interventionBrowseModule": {"meshes": [{"id": "C561634", "term": "relugolix"}, {"id": "C418365", "term": "estradiol, norethindrone drug combination"}, {"id": "D004958", "term": "Estradiol"}], "ancestors": [{"id": "D004963", "term": "Estrenes"}, {"id": "D004962", "term": "Estranes"}, {"id": "D013256", "term": "Steroids"}, {"id": "D000072473", "term": "Fused-Ring Compounds"}, {"id": "D011083", "term": "Polycyclic Compounds"}, {"id": "D045166", "term": "Estradiol Congeners"}, {"id": "D012739", "term": "Gonadal Steroid Hormones"}, {"id": "D042341", "term": "Gonadal Hormones"}, {"id": "D006728", "term": "Hormones"}, {"id": "D006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT02086318", "orgStudyIdInfo": {"id": "OvAge"}, "organization": {"fullName": "University Magna Graecia", "class": "OTHER"}, "briefTitle": "A New Algorithm to Predict Ovarian Age", "officialTitle": "A New Algorithm to Predict Ovarian Age Combining Clinical, Biochemical and 3D-ultrasonographic Parameters: OvAge", "acronym": "OvAge"}, "statusModule": {"statusVerifiedDate": "2016-12", "overallStatus": "UNKNOWN", "lastKnownStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-01"}, "primaryCompletionDateStruct": {"date": "2018-06", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2018-06", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2014-03-09", "studyFirstSubmitQcDate": "2014-03-11", "studyFirstPostDateStruct": {"date": "2014-03-13", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-12-07", "lastUpdatePostDateStruct": {"date": "2016-12-08", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Fulvio Zullo", "investigatorTitle": "Full Professor Obstetric Gynecology", "investigatorAffiliation": "University Magna Graecia"}, "leadSponsor": {"name": "University Magna Graecia", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "To collect data of clinical, biochemical and 3D-ultrasonographic parameters of a population of fertile women aged 18-55 in order to design a new algorithm able to predict ovarian age and to evaluate the reliability of a multimodal diagnostic evaluation of ovarian age in term of both reproductive prognosis and distance to menopause following the guidelines of the Standards for Reporting of Diagnostic Accuracy initiative (STARD)", "detailedDescription": "The normal process of reproductive aging varies considerably among women. This implies that some women remain highly fertile until the fifth decade of their life, whereas others face the loss of natural fertility already in their mid-thirties. Female reproductive aging seems to be largely based on age related changes in ovarian function. Decreasing numbers of follicles, coinciding with diminished oocyte quality, dictate the gradual changes in menstrual cycle regularity and monthly fecundity which inevitable evolution will be menopause. The mechanisms behind the observed gradual decline of the follicle pool and the reduced oocyte quality are far from being fully understood, although recent knowledge regarding the endocrine, paracrine, genetic, and metabolic factors involved has led to a better understanding of this immensely complex puzzle.\n\nWithin the context of normal female reproductive aging, as already outlined, large individual variation exists in the age at which the various reproductive events occur. This variation has major implications for the preventive management of age-related decreased fertility and general health risks associated with extremely early menopause in conditions such as POF. Moreover, distance from menopause is an important parameter which can lead clinician's choice in the appropriate timing for surgical treatment of benign gynecological pathologies.\n\nAlthough chronological age is the most important predictor of physiological ovarian response to endogenous and exogenous Follicle-stimulating Hormone (FSH), both environmental and genetic factors contribute to biological ovarian ageing, so that chronological and biological age are not always equivalent. Among genetic factors able to determine age at which menopause will occur, the most important are the size of the initial oocyte stock, the proportion that undergoes atresia and the rate of initiation of follicles growth. It has been suggested, moreover, that certain single nucleotide polymorphisms (such as regarding FSH receptors genotype) also affect sensitivity to gonadotrophins and ovarian ageing \\[Alviggi 45\\]. Environmental factors such as diet, cigarette smoking, regimens of chemotherapy or radiotherapy, endometriosis or ovarian surgery may shorten the functional lifespan of a woman's ovaries too.\n\nEven if the continuous follicles loss will only be recognized in the late stages by cycle irregularity, endocrine and ultrasound markers have emerged over the last decade that may express more accurately the follicle number decline over a long time period. Among endocrine parameters, the most studied and used in clinical practice are FSH, Estradiol (E2) and Anti-Mullerian Hormone (AMH).\n\nBasal FSH, extensively studied over the past few decades, provides the most indirect marker of ovarian reserve. FSH levels increase with advancing age, by reducing the negative feedback on FSH release from the pituitary \\[broekm vecchio 10\\]. High FSH levels therefore represent small cohort size. To exclude the possibility that confounding factors, such as E2 levels greater than 50 pg/ml, suppress FSH secretion, this parameters have to be always evaluated together on menstrual cycle days 1-4.\n\nIn women with varying degrees of hypergonadotropism (ranging from imminent ovarian failure to full-blown POF), however, the better parameter to assess the extent of ovarian follicle depletion seems to be represented by AMH (Broekm 109). It is a dimeric glycoprotein with autocrine and paracrine actions in follicle development, exclusively produced by granulose cells of preantral (primary and secondary) and small antral follicles (2-7 mm in diameters). The number of small antral follicles is directly related to the total size of the primordial follicle pool (Broekm 68). With the decrease in the number of antral follicles with age, AMH serum levels also become diminished (Br 66, 95, 104) and will invariably become undetectable near menopause (Br 65). Recent studies have indeed suggested that AMH serum levels represent ovarian quantitative reserve (Br 105-107) and may provide an index of age at menopause.\n\nRegarding ultrasound markers, several studies, recently, demonstrated that Antral Follicle Count (AFC), defined as the total number of antral follicles, sized 2-10 mm, present in both ovaries, represents a better marker than either chronological age or basal FSH for assessing the ovarian biological age \\[alviggi 89\\] and it has also been correlated with the occurrence of the menopausal transition (broekm 66), indicating that this parameter relates strongly with the quantitative aspects of ovarian reserve.\n\nAs for AFC, ovarian volume, measured by vaginal ultrasound, has been associated to the ovarian functional asset and also transvaginal ultrasound with the use of power Doppler is often used to evaluate the blood flow through the ovary in natural cycles. Several studies, moreover, have shown that ovarian flow index at the baseline ultrasound scan are correlated with subsequent follicular response and may be a new indicator for predicting ovarian responsiveness in IVF treatment (Sattar 2005) The added value of ovarian volume and stromal blood flow, however, either individually or together, to AFC and endocrine markers, in the predictability of ovarian age has not been assessed in a multivariate module.\n\nThe challenge of any ovarian reserve tests, anyhow, lies in the possibility of identifying women with a reduced reproductive life span at such an early stage in their lives that adequate action can be taken. Basal endocrine levels and sonographic parameters, however, are usually considered to have low specificity and sensitivity when used both to predict low ovarian reserve in infertile women (Younis 2010) and to prognosticate distance from menopause. Although these simple tests have been extensively investigated in the past they have seldom been looked into in combination. On the contrary, improvement of tests for the identification of women with a reduced ovarian life span will probably come from combining endocrine and imaging evaluations."}, "conditionsModule": {"conditions": ["Infertility", "Polycystic Ovary Syndrome", "Premature Ovarian Failure (POF)", "Ovarian Cysts", "Endometriosis"], "keywords": ["Ovarian reserve", "Ovarian age", "Fertility", "Reproductive prognosis", "Distance to menopause"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "COHORT", "timePerspective": "PROSPECTIVE"}, "enrollmentInfo": {"count": 720, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "OvAge assessment", "description": "Basal serum anti-Mullerian hormone (AMH), Follicle-stimulating hormone (FSH) and estradiol (E2), antral follicle count (AFC), ovarian volume, Vascularization Index (VI), Flow Index (FI) and Vascularization Flow Index (VFI) will be measured in all women between day 1 and day 4 of menstrual cycle", "interventionNames": ["Other: OvAge assessment"]}], "interventions": [{"type": "OTHER", "name": "OvAge assessment", "description": "Basal serum anti-Mullerian hormone (AMH), Follicle-stimulating hormone (FSH) and Estradiol (E2), antral follicle count (AFC), ovarian volume, Vascularization Index (VI), Flow Index (FI) and Vascularization Flow Index (VFI) will be measured in all women between day 1 and day 4 of menstrual cycle. Evaluation can be repeated after every kind of intervention regarding ovaries, both medical or surgical. Evaluation can be repeated also at interval of 3-6-12 months in order to study the modification of ovarian age when time passes.", "armGroupLabels": ["OvAge assessment"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Ovarian Age prediction", "description": "Reliability of a multimodal diagnostic evaluation of ovarian age in term of both reproductive prognosis and distance to menopause", "timeFrame": "One month"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Age between 18 and 55 years\n* Consent to participate to the prospective study\n* Regular menses at 22 to 35 day interval\n\nExclusion Criteria:\n\n* Estrogen or progestin-containing medications in the month before enrollment\n* Gynecological malignancy\n* Hypogonadotropic hypogonadism\n* Assumption of drugs that can cause menstrual irregularity", "healthyVolunteers": true, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "55 Years", "stdAges": ["ADULT"], "studyPopulation": "Healthy women", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"centralContacts": [{"name": "Fulvio Zullo", "role": "CONTACT", "phone": "39337947003", "email": "zullo@unicz.it"}], "overallOfficials": [{"name": "Fulvio Zullo", "affiliation": "Magna Graecia University of Catanzaro", "role": "STUDY_DIRECTOR"}, {"name": "Roberta Venturella, MD", "affiliation": "Magna Graecia University of Catanzaro", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Chair of Obstetrics and Gynecology - University division - UMG", "status": "RECRUITING", "city": "Catanzaro", "state": "CZ", "zip": "88100", "country": "Italy", "contacts": [{"name": "Fulvio Zullo", "role": "CONTACT", "phone": "39337947003", "email": "zullo@unicz.it"}, {"name": "Roberta Venturella, MD", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Daniela Lico, MD", "role": "SUB_INVESTIGATOR"}, {"name": "Elio Gulletta", "role": "SUB_INVESTIGATOR"}, {"name": "Mariapia Falbo", "role": "SUB_INVESTIGATOR"}, {"name": "Alessia Sarica", "role": "SUB_INVESTIGATOR"}, {"name": "Mario Cannataro", "role": "SUB_INVESTIGATOR"}], "geoPoint": {"lat": 38.88247, "lon": 16.60086}}]}, "referencesModule": {"references": [{"pmid": "25881987", "type": "RESULT", "citation": "Venturella R, Lico D, Sarica A, Falbo MP, Gulletta E, Morelli M, Zupi E, Cevenini G, Cannataro M, Zullo F. OvAge: a new methodology to quantify ovarian reserve combining clinical, biochemical and 3D-ultrasonographic parameters. J Ovarian Res. 2015 Apr 8;8:21. doi: 10.1186/s13048-015-0149-z."}, {"pmid": "26335129", "type": "RESULT", "citation": "Venturella R, Morelli M, Lico D, Di Cello A, Rocca M, Sacchinelli A, Mocciaro R, D'Alessandro P, Maiorana A, Gizzo S, Zullo F. Wide excision of soft tissues adjacent to the ovary and fallopian tube does not impair the ovarian reserve in women undergoing prophylactic bilateral salpingectomy: results from a randomized, controlled trial. Fertil Steril. 2015 Nov;104(5):1332-9. doi: 10.1016/j.fertnstert.2015.08.004. Epub 2015 Aug 31."}, {"pmid": "27621194", "type": "RESULT", "citation": "Venturella R, Lico D, Borelli M, Imbrogno MG, Cevenini G, Zupi E, Zullo F, Morelli M. 3 to 5 Years Later: Long-term Effects of Prophylactic Bilateral Salpingectomy on Ovarian Function. J Minim Invasive Gynecol. 2017 Jan 1;24(1):145-150. doi: 10.1016/j.jmig.2016.08.833. Epub 2016 Sep 13."}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D007246", "term": "Infertility"}, {"id": "D011085", "term": "Polycystic Ovary Syndrome"}, {"id": "D016649", "term": "Primary Ovarian Insufficiency"}, {"id": "D010048", "term": "Ovarian Cysts"}, {"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D000091662", "term": "Genital Diseases"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D003560", "term": "Cysts"}, {"id": "D009369", "term": "Neoplasms"}, {"id": "D010049", "term": "Ovarian Diseases"}, {"id": "D000291", "term": "Adnexal Diseases"}, {"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D006058", "term": "Gonadal Disorders"}, {"id": "D004700", "term": "Endocrine System Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT00172588", "orgStudyIdInfo": {"id": "9361701197"}, "organization": {"fullName": "National Taiwan University Hospital", "class": "OTHER"}, "briefTitle": "Evaluation of Endometrial Stromal Cell Apoptosis in Adenomyosis"}, "statusModule": {"statusVerifiedDate": "2004-12", "overallStatus": "UNKNOWN", "lastKnownStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2005-01"}, "completionDateStruct": {"date": "2005-10"}, "studyFirstSubmitDate": "2005-09-12", "studyFirstSubmitQcDate": "2005-09-12", "studyFirstPostDateStruct": {"date": "2005-09-15", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2005-11-25", "lastUpdatePostDateStruct": {"date": "2005-11-28", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"leadSponsor": {"name": "National Taiwan University Hospital", "class": "OTHER"}}, "descriptionModule": {"briefSummary": "Our previous results revealed that the expression of killer inhibitory receptors (KIRs) on NK cells was decreased in eutopic endometrium in women with adenomyosis. It implies that the formation of adenomyosis might be due to abnormal endometrial tissues, but not the aberrant local immunological dysfunction in myometrium. In addition, in vitro coculture of macrophages and endometrial stromal cells (ESC) increase the expression of IL-6 mRNA in ESC, which might further enhance the proliferation of ESC and subsequently result in the formation of ectopic endometrial implants in adenomyosis. Besides, another possible mechanism is the abnormal apoptosis of ESC in adenomyosis. In endometriosis, apoptotic endometrial cells were found to be decreased, which possibly accounts for the formation of endometriosis. However, there have not been reports investigating the apoptosis of ESC in adenomyosis.\n\nIn this study, we try to investigate apoptotic ESC with flow cytometry in women with and without adenomyosis. Annexin V, bcl-2, and caspase-3 were measured to represent the degree of apoptosis in ESC.", "detailedDescription": "Eutopic endometrium was obtained and separated into single endometrial stromal cell (ESC) in women with adenomyosis (study group) and without adenomyosis (control group).\n\nAnnexin V-PE, bcl-2-PE, and caspase-3-PE are stained, and flow cytometry is done to measure the degree of apoptosis in ESC. On the other hand, another half of ESC are cultured for 24h, and also Annexin V-PE, bcl-2-PE, and caspase-3-PE are stained, and flow cytometry is done."}, "conditionsModule": {"conditions": ["Endometriosis"], "keywords": ["adenomyosis", "apoptosis", "flowcytometry"]}, "designModule": {"studyType": "OBSERVATIONAL", "designInfo": {"observationalModel": "DEFINED_POPULATION", "timePerspective": "OTHER"}, "enrollmentInfo": {"count": 40}}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* women with adenomyosis\n* at early- to mid-secretory phases\n\nExclusion Criteria:\n\n* postmenopausal\n* malignancy", "healthyVolunteers": true, "sex": "FEMALE", "minimumAge": "35 Years", "maximumAge": "50 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Jehn-Hsiahn Yang, M.D.", "role": "CONTACT", "phone": "886-2-2312-3456", "phoneExt": "3210", "email": "jhyang@ha.mc.ntu.edu.tw"}], "overallOfficials": [{"name": "Jehn-Hsiahn Yang, M.D.", "affiliation": "Department of Obstetrics and Gynecology, National Taiwan University Hospital", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "National Taiwan University Hospital", "status": "RECRUITING", "city": "Taipei", "country": "Taiwan", "contacts": [{"name": "Jehn-Hsiahn Yang, M.D.", "role": "CONTACT", "phone": "886-2-2312-3456", "phoneExt": "3210", "email": "jhyang@ha.mc.ntu.edu.tw"}, {"name": "Jehn-Hsiahn Yang, M.D.", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 25.05306, "lon": 121.52639}}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}, {"id": "D062788", "term": "Adenomyosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}, {"id": "D014591", "term": "Uterine Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT00973973", "orgStudyIdInfo": {"id": "NBI-56418-0901"}, "organization": {"fullName": "AbbVie", "class": "INDUSTRY"}, "briefTitle": "Efficacy and Safety Study of Elagolix in Women With Endometriosis", "officialTitle": "A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-56418 Sodium in Subjects With Endometriosis"}, "statusModule": {"statusVerifiedDate": "2018-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-10-12", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2010-09-22", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-09-22", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-09-07", "studyFirstSubmitQcDate": "2009-09-07", "studyFirstPostDateStruct": {"date": "2009-09-09", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2018-08-09", "resultsFirstSubmitQcDate": "2018-09-14", "resultsFirstPostDateStruct": {"date": "2018-09-26", "type": "ACTUAL"}, "dispFirstSubmitDate": "2012-02-06", "dispFirstSubmitQcDate": "2012-02-06", "dispFirstPostDateStruct": {"date": "2012-02-08", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2018-09-14", "lastUpdatePostDateStruct": {"date": "2018-09-26", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AbbVie", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false, "isUsExport": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to evaluate elagolix (NBI-56418) compared to placebo for its effects on endometriosis related pelvic pain and its safety.", "detailedDescription": "Participants were randomized (1:1) to 150 mg elagolix once daily or placebo once daily for the first 8 weeks of the study. Following 8 weeks of dosing, participants continued in the study for an additional 16 weeks in an open-label phase where all participants still enrolled in the study received 150 mg elagolix once daily.\n\nThere was no pre-specified primary efficacy end point for this study as there is no single key efficacy outcome measure in this exploratory Phase 2 study. However, the efficacy measures of primary interest included the daily assessment of dysmenorrhea, non-menstrual pelvic pain and dyspareunia on a 4-point scale (0 = none, 1 = mild, 2 = moderate, 3 = severe) using an e-Diary."}, "conditionsModule": {"conditions": ["Endometriosis, Pain"], "keywords": ["Pelvic Pain,NBI-56418,Endometriosis"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 137, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Elagolix 150 mg", "type": "EXPERIMENTAL", "description": "Participants received 150 mg elagolix orally once a day for 8 weeks during the double-blind treatment period and continued to receive 150 mg elagolix for 16 additional weeks during the open-label treatment period.", "interventionNames": ["Drug: Elagolix"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Participants received placebo orally once a day for 8 weeks during the double-blind treatment period and switched to receive 150 mg elagolix for 16 weeks during the open-label treatment period.", "interventionNames": ["Drug: Placebo", "Drug: Elagolix"]}], "interventions": [{"type": "DRUG", "name": "Placebo", "description": "Matching placebo tablets taken orally once a day", "armGroupLabels": ["Placebo"]}, {"type": "DRUG", "name": "Elagolix", "description": "Immediate release (IR) tablets taken orally once a day", "armGroupLabels": ["Elagolix 150 mg", "Placebo"], "otherNames": ["NBI-56418", "Orilissa™"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in the Monthly Mean Dysmenorrhea Score During the Double-blind Treatment Phase", "description": "Participants assessed dysmenorrhea (pain during menstruation) and its impact on their daily activities at approximately the same time each day of their period in an electronic diary (e-Diary) according to the following response options:\n\n* 0 = No discomfort\n* 1 = Mild discomfort but I was easily able to do the things I usually do\n* 2 = Moderate discomfort or pain that made it difficult to do some of the things I usually do\n* 3 = Severe pain that made it difficult to do the things I usually do.\n\nThe monthly mean dysmenorrhea score is the average of the daily values reported during the 4 weeks prior to each visit.", "timeFrame": "Baseline and Weeks 4 and 8"}, {"measure": "Change From Baseline in the Monthly Mean Dysmenorrhea Score During the Open-label and Posttreatment Phases", "description": "Participants assessed dysmenorrhea (pain during menstruation) and its impact on their daily activities at approximately the same time each day of their period in an electronic diary (e-Diary) according to the following response options:\n\n* 0 = No discomfort\n* 1 = Mild discomfort but I was easily able to do the things I usually do\n* 2 = Moderate discomfort or pain that made it difficult to do some of the things I usually do\n* 3 = Severe pain that made it difficult to do the things I usually do.\n\nThe monthly mean dysmenorrhea score is the average of the daily values reported during the 4 weeks prior to each visit, except for the week 30 value which is based on 6 weeks of data.", "timeFrame": "Baseline and Weeks 12, 16, 20, 24, and 30 (6 weeks posttreatment)"}, {"measure": "Change From Baseline in the Monthly Mean Non-menstrual Pelvic Pain Score During the Double-Blind Treatment Phase", "description": "Participants assessed their pelvic pain not related to menses and its impact on their daily activities at approximately the same time each day they were not having their period in an e-Diary according to the following response options:\n\n* 0 = No discomfort\n* 1 = Mild discomfort but I was easily able to do the things I usually do\n* 2 = Moderate discomfort or pain that made it difficult to do some of the things I usually do\n* 3 = Severe pain that made it difficult to do the things I usually do.\n\nThe monthly mean non-menstrual pelvic pain score is the average of the daily values reported during the 4 weeks prior to each visit.", "timeFrame": "Baseline and weeks 4 and 8"}, {"measure": "Change From Baseline in the Monthly Mean Non-menstrual Pelvic Pain Score During the Open-label and Posttreatment Phases", "description": "Participants assessed their pelvic pain not related to menses and its impact on their daily activities at approximately the same time each day they were not having their period in an e-Diary according to the following response options:\n\n* 0 = No discomfort\n* 1 = Mild discomfort but I was easily able to do the things I usually do\n* 2 = Moderate discomfort or pain that made it difficult to do some of the things I usually do\n* 3 = Severe pain that made it difficult to do the things I usually do.\n\nThe monthly mean non-menstrual pelvic pain score is the average of the daily values reported during the 4 weeks prior to each visit, except for the week 30 value which is based on 6 weeks of data.", "timeFrame": "Baseline and Weeks 12, 16, 20, 24, and 30 (6 weeks posttreatment)"}, {"measure": "Change From Baseline in the Monthly Mean Cumulative Pain Score During the Double-Blind Treatment Phase", "description": "Participants assessed dysmenorrhea or non-menstrual pelvic pain at approximately the same time each day in an e-Diary according to the following:\n\n* 0 = No discomfort\n* 1 = Mild discomfort but I was easily able to do the things I usually do\n* 2 = Moderate discomfort or pain that made it difficult to do some of the things I usually do\n* 3 = Severe pain that made it difficult to do the things I usually do.\n\nThe monthly mean cumulative pain score is the average of the daily values for all days (menstrual and non-menstrual) reported during the 4 weeks prior to each visit.", "timeFrame": "Baseline and weeks 4 and 8"}, {"measure": "Change From Baseline in the Monthly Mean Cumulative Pain Score During the Open-label and Posttreatment Phases", "description": "Participants assessed dysmenorrhea or non-menstrual pelvic pain at approximately the same time each day in an e-Diary according to the following:\n\n* 0: No discomfort\n* 1: Mild discomfort, I was easily able to do the things I usually do\n* 2: Moderate discomfort or pain making it difficult to do some of the things I usually do\n* 3: Severe pain making it difficult to do the things I usually do\n\nThe monthly mean cumulative pain score is the average of the daily values for all days (menstrual and non-menstrual) reported during the 4 weeks prior to each visit, except for the week 30 value which is based on 6 weeks of data.", "timeFrame": "Baseline and Weeks 12, 16, 20, 24, and 30 (6 weeks posttreatment)"}, {"measure": "Change From Baseline in the Monthly Mean Dyspareunia Score During the Double-Blind Treatment Phase", "description": "Participants assessed their dyspareunia (pain during sexual intercourse) at approximately the same time every day in an e-Diary according to the following response options:\n\n* 0 = Absent; No discomfort during sexual intercourse\n* 1 = Mild; I was able to tolerate the discomfort during sexual intercourse\n* 2 = Moderate; Intercourse was interrupted due to pain\n* 3 = Severe; I avoided intercourse because of pain\n* Does not apply; I was not sexually active for reasons other than my endometriosis or did not have sexual intercourse\n\nThe monthly mean dyspareunia score is the average of the daily values reported during the 4 weeks prior to each visit. Responses of \"does not apply\" were not included in the calculations.", "timeFrame": "Baseline and weeks 4 and 8"}, {"measure": "Change From Baseline in the Monthly Mean Dyspareunia Score During the Open-label and Posttreatment Phases", "description": "Participants assessed their dyspareunia (pain during sexual intercourse) at approximately the same time every day in an e-Diary according to the following response options:\n\n* 0: Absent; No discomfort during sexual intercourse\n* 1: Mild; I was able to tolerate the discomfort during sexual intercourse\n* 2: Moderate; Intercourse was interrupted due to pain\n* 3: Severe; I avoided intercourse because of pain\n* Does not apply; I was not sexually active for reasons other than my endometriosis or did not have sexual intercourse\n\nThe monthly mean dyspareunia score is the average of the daily values reported during the 4 weeks prior to each visit, except for week 30 which is based on 6 weeks of data. Responses of \"does not apply\" were not included in the calculations.", "timeFrame": "Baseline and Weeks 12, 16, 20, 24, and 30 (6 weeks posttreatment)"}], "secondaryOutcomes": [{"measure": "Percentage of Participants With a Response in Monthly Mean Dysmenorrhea Score at Week 8", "description": "Participants assessed dysmenorrhea (pain during menstruation) and its impact on their daily activities at approximately the same time each day of their period in an e-Diary according to the following response options:\n\n* 0: No discomfort\n* 1: Mild discomfort but I was easily able to do the things I usually do\n* 2: Moderate discomfort or pain that made it difficult to do some of the things I usually do\n* 3: Severe pain that made it difficult to do the things I usually do.\n\nThe monthly mean dysmenorrhea score is the average of the daily values reported during the 4 weeks prior to each time point.\n\nResponse was defined as the percentage of participants with a percent decrease from baseline in the week 8 monthly mean score that was greater than or equal to each specified threshold value (10% through 90% in steps of 10%).", "timeFrame": "Baseline and Week 8"}, {"measure": "Percentage of Participants With a Response in Monthly Mean Non-menstrual Pelvic Pain Score at Week 8", "description": "Participants assessed their pelvic pain not related to menses and its impact on their daily activities at approximately the same time each day they were not having their period in an e-Diary according to the following response options:\n\n* 0 = No discomfort\n* 1 = Mild discomfort but I was easily able to do the things I usually do\n* 2 = Moderate discomfort or pain that made it difficult to do some of the things I usually do\n* 3 = Severe pain that made it difficult to do the things I usually do.\n\nThe monthly mean non-menstrual pelvic pain score is the average of the daily values reported during the 4 weeks prior to each time point.\n\nResponse is defined as the percentage of participants with a percent decrease from baseline in the week 8 monthly mean score that was greater than or equal to each specified threshold value (10% through 90% in steps of 10%).", "timeFrame": "Baseline and Week 8"}, {"measure": "Percentage of Participants With a Response in Monthly Mean Cumulative Pain Score at Week 8", "description": "Participants assessed dysmenorrhea or non-menstrual pelvic pain at approximately the same time every day in an e-Diary according to the following:\n\n* 0 = No discomfort\n* 1 = Mild discomfort\n* 2 = Moderate discomfort or pain\n* 3 = Severe pain\n\nThe monthly mean cumulative pain score is the average of the daily values for all days (menstrual and non-menstrual) in the 4 weeks prior to each time point.\n\nResponse is the percentage of participants with a percent decrease from baseline in the week 8 monthly mean score that was greater than or equal to each specified threshold value (10% through 90% in steps of 10%).", "timeFrame": "Baseline and Week 8"}, {"measure": "Percentage of Participants With a Response in Monthly Mean Dyspareunia Score at Week 8", "description": "Participants assessed their dyspareunia (pain during sexual intercourse) at approximately the same time every day in an e-Diary according to the following response options:\n\n* 0 = Absent; No discomfort during sexual intercourse\n* 1 = Mild; I was able to tolerate the discomfort during sexual intercourse\n* 2 = Moderate; Intercourse was interrupted due to pain\n* 3 = Severe; I avoided intercourse because of pain\n* Does not apply; I was not sexually active for reasons other than my endometriosis or did not have sexual intercourse\n\nThe monthly mean dyspareunia score is the average of the daily values reported during the 4 weeks prior to each time point.\n\nResponse is defined as the percentage of participants with a percent decrease from baseline in the week 8 monthly mean score that was greater than or equal to each specified threshold value (10% through 90% in steps of 10%).", "timeFrame": "Baseline and Week 8"}, {"measure": "Change From Baseline in the Percentage of Days of Any Analgesic Use During the Double-Blind Treatment Phase", "description": "The daily use of endometriosis analgesics was reported by participants daily using the e-Diary. Participants reported whether the medication was over-the-counter (OTC) or prescription, and, if prescription, whether the medication was a narcotic.\n\nThe percentage of days of any analgesic use is defined as the number of days in the 4 weeks prior to each study visit that the participant reported the use of an analgesic, divided by the number of study days in the interval that the participant provided an e-Diary report regarding the use of endometriosis analgesics (including a response of \"none\").", "timeFrame": "Baseline and Weeks 4 and 8"}, {"measure": "Change From Baseline in the Percentage of Days of Any Analgesic Use During the Open-Label and Posttreatment Phases", "description": "The daily use of endometriosis analgesics was reported by participants daily using the e-Diary. Participants reported whether the medication was over-the-counter (OTC) or prescription, and, if prescription, whether the medication was a narcotic.\n\nThe percentage of days of any analgesic use is defined as the number of days in the 4 weeks prior to each study visit (except for week 30 which is based on 6 weeks of data) that the participant reported the use of an analgesic, divided by the number of study days in the interval that the participant provided an e-Diary report regarding the use of endometriosis analgesics (including a response of \"none\").", "timeFrame": "Baseline and Weeks 12, 16, 20, 24, and 30 (6 weeks posttreatment)"}, {"measure": "Change From Baseline in the Percentage of Days of Prescription Analgesic Use During the Double-Blind Treatment Phase", "description": "The daily use of endometriosis analgesics was reported by participants daily using the e-Diary. Participants reported whether the medication was over-the-counter (OTC) or prescription, and, if prescription, whether the medication was a narcotic.\n\nThe percentage of days of prescription analgesic use is defined as the number of days in the 4 weeks prior to each study visit that the participant reported the use of a prescription analgesic, divided by the number of study days in the interval that the participant provided an e-Diary report regarding the use of endometriosis analgesics (including a response of \"none\").", "timeFrame": "Baseline and Weeks 4 and 8"}, {"measure": "Change From Baseline in the Percentage of Days of Prescription Analgesic Use During the Open-Label and Posttreatment Phases", "description": "The daily use of endometriosis analgesics was reported by participants daily using the e-Diary. Participants reported whether the medication was over-the-counter (OTC) or prescription, and, if prescription, whether the medication was a narcotic.\n\nThe percentage of days of prescription analgesic use is defined as the number of days in the 4 weeks prior to each study visit (except for week 30 which is based on 6 weeks of data) that the participant reported the use of a prescription analgesic, divided by the number of study days in the interval that the participant provided an e-Diary report regarding the use of endometriosis analgesics (including a response of \"none\").", "timeFrame": "Baseline and Weeks 12, 16, 20, 24, and 30 (6 weeks posttreatment)"}, {"measure": "Change From Baseline in the Percentage of Days of Narcotic Analgesic Use During the Double-Blind Treatment Phase", "description": "The daily use of endometriosis analgesics was reported by participants daily using the e-Diary. Participants reported whether the medication was over-the-counter (OTC) or prescription, and, if prescription, whether the medication was a narcotic.\n\nThe percentage of days of narcotic analgesic use is defined as the number of days in the 4 weeks prior to each study visit that the participant reported the use of a narcotic analgesic, divided by the number of study days in the interval that the participant provided an e-Diary report regarding the use of endometriosis analgesics (including a response of \"none\").", "timeFrame": "Baseline and Weeks 4 and 8"}, {"measure": "Change From Baseline in the Percentage of Days of Narcotic Analgesic Use During the Open-Label and Posttreatment Phases", "description": "The daily use of endometriosis analgesics was reported by participants daily using the e-Diary. Participants reported whether the medication was over-the-counter (OTC) or prescription, and, if prescription, whether the medication was a narcotic.\n\nThe percentage of days of narcotic analgesic use is defined as the number of days in the 4 weeks prior to each study visit (except for week 30 which is based on 6 weeks of data) that the participant reported the use of a narcotic analgesic, divided by the number of study days in the interval that the participant provided an e-Diary report regarding the use of endometriosis analgesics (including a response of \"none\").", "timeFrame": "Baseline and Weeks 12, 16, 20, 24, and 30 (6 weeks posttreatment)"}, {"measure": "Change From Baseline to the End of the Double-blind Treatment Phase in Composite Pelvic Signs and Symptoms Score (CPSSS) Total Score and Component Scores", "description": "The CPSSS consists of 5 components that address dysmenorrhea, dyspareunia, non-menstrual pelvic pain, pelvic tenderness, and pelvic induration. Each component was scored on a scale of 0 to 3 (0 = absent, 1 = mild, 2 = moderate, and 3 = severe).\n\nDysmenorrhea, dyspareunia, and non-menstrual pelvic pain scores are based on the participant's assessment of symptoms during the past 28 days; pelvic tenderness and induration were assessed by the investigator based on findings associated with a pelvic examination.\n\nThe total CPSSS has a maximum possible value of 15 (total score range: 0 to 15, where a lower score indicates less signs and symptoms of endometriosis or better functioning). Individual component scores range from 0 (absent) to 3 (severe).", "timeFrame": "Baseline and Week 8"}, {"measure": "Change From Baseline to the End of the Open-label Treatment Phase in Composite Pelvic Signs and Symptoms Score (CPSSS) Total Score and Component Scores", "description": "The CPSSS consists of 5 components that address dysmenorrhea, dyspareunia, non-menstrual pelvic pain, pelvic tenderness, and pelvic induration. Each component was scored on a scale of 0 to 3 (0 = absent, 1 = mild, 2 = moderate, and 3 = severe).\n\nDysmenorrhea, dyspareunia, and non-menstrual pelvic pain scores are based on the participant's assessment of symptoms during the past 28 days; pelvic tenderness and induration were assessed by the investigator based on findings associated with a pelvic examination.\n\nThe total CPSSS has a maximum possible value of 15 (total score range: 0 to 15, where a lower score indicates less signs and symptoms of endometriosis or better functioning). Individual component scores range from 0 (absent) to 3 (severe).", "timeFrame": "Baseline and week 24"}, {"measure": "Patient Global Impression of Change During the Double-blind Treatment Phase", "description": "The Patient Global Impression of Change (PGIC) is a questionnaire-based assessment of the change in endometriosis pain since the initiation of study drug. The participant was asked to select from one of seven response categories:\n\n1. Very Much Improved\n2. Much Improved\n3. Minimally Improved\n4. Not Changed\n5. Minimally Worse\n6. Much Worse\n7. Very Much Worse", "timeFrame": "Weeks 4 and 8"}, {"measure": "Patient Global Impression of Change During the Open-Label and Posttreatment Phases", "description": "The Patient Global Impression of Change (PGIC) is a questionnaire-based assessment of the change in endometriosis pain since the initiation of study drug. The participant was asked to select from one of seven response categories:\n\n1. Very Much Improved\n2. Much Improved\n3. Minimally Improved\n4. Not Changed\n5. Minimally Worse\n6. Much Worse\n7. Very Much Worse", "timeFrame": "Weeks 12, 16, 20, 24, and 30 (6 weeks posttreatment)"}, {"measure": "Percentage of Participants With a PGIC Response of Much Improved or Very Much Improved During the Double-blind Treatment Phase", "description": "The Patient Global Impression of Change (PGIC) is a questionnaire-based assessment of the change in endometriosis pain since the initiation of study drug. The participant was asked to select from one of seven response categories:\n\n1. Very Much Improved\n2. Much Improved\n3. Minimally Improved\n4. Not Changed\n5. Minimally Worse\n6. Much Worse\n7. Very Much Worse", "timeFrame": "Weeks 4 and 8"}, {"measure": "Percentage of Participants With a PGIC Response of Much Improved or Very Much Improved During the Open-label Treatment Phase", "description": "The Patient Global Impression of Change (PGIC) is a questionnaire-based assessment of the change in endometriosis pain since the initiation of study drug. The participant was asked to select from one of seven response categories:\n\n1. Very Much Improved\n2. Much Improved\n3. Minimally Improved\n4. Not Changed\n5. Minimally Worse\n6. Much Worse\n7. Very Much Worse", "timeFrame": "Weeks 12, 16, 20, 24, and 30 (6 weeks posttreatment)"}, {"measure": "Change From Baseline to the End of the Double-blind Treatment Phase in Endometriosis Health Profile-5 (EHP-5)", "description": "The EHP-5 is an instrument to measure health-related quality of life in women with endometriosis. The EHP-5 consists of two parts:\n\n* A core questionnaire consisting of five questions that measure the impact of endometriosis in areas of pain, control and powerlessness, emotional well-being, social support, and self-image with five response categories for each item (Never, Rarely, Sometimes, Often, Always)\n* A supplemental questionnaire consisting of six additional questions which assess the impact of endometriosis on the areas of work, relationship with children, sexual intercourse, feelings about the medical profession, treatment, and infertility with the same five response categories plus an additional response category of Not Relevant which was not scored.\n\nThe scores associated with each possible outcome category are as follows: never (0), rarely (25), sometimes (50), often (75), and always (100). A negative change from baseline score indicates improvement in quality of life.", "timeFrame": "Baseline and week 8"}, {"measure": "Change From Baseline to the End of the Open-label Treatment Phase in Endometriosis Health Profile-5 (EHP-5)", "description": "The EHP-5 is an instrument to measure health-related quality of life in women with endometriosis. The EHP-5 consists of two parts:\n\n* A core questionnaire consisting of five questions that measure the impact of endometriosis on areas of pain, control and powerlessness, emotional well-being, social support, and self-image with five response categories for each item (Never, Rarely, Sometimes, Often, Always)\n* A supplemental questionnaire consisting of six additional questions which assess the impact of endometriosis on areas of work, relationship with children, sexual intercourse, feelings about the medical profession, treatment, and infertility with the same five response categories plus an additional response category of Not Relevant which was not scored.\n\nThe scores associated with each possible outcome category are as follows: never (0), rarely (25), sometimes (50), often (75), and always (100). A negative change from baseline score indicates improvement in quality of life.", "timeFrame": "Baseline and week 24"}, {"measure": "Percentage of Days With Uterine Bleeding During the Double- Blind Treatment Phase", "description": "Uterine bleeding was reported daily by participants during the study using the e-Diary.\n\nThe percentage of days a participant reported any bleeding was calculated as the total number of days the participant reported any bleeding ( light, moderate, or heavy) divided by the total number of days the participant had a non-missing e-Diary report of vaginal bleeding in the phase.", "timeFrame": "Screening (8 weeks prior to day 1) and the double-blind treatment phase (Weeks 1-8)"}, {"measure": "Number of Days to First Posttreatment Menses", "description": "Defined as the number of days from the last dose of study drug until the start date of the first post-treatment menses.", "timeFrame": "From last day of study drug up to 6 weeks after the last dose."}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Be female, aged 18 to 49 years, inclusive.\n* Have moderate to severe pelvic pain due to endometriosis.\n* Have a history of regular menstrual cycles.\n* Have been surgically (laparoscopy or laparotomy) diagnosed with endometriosis within 8 years of the start of screening.\n* Have a Body Mass Index (BMI) of 18 to 36 kg/m², inclusive.\n* Agree to use two forms of non-hormonal contraception during the study.\n\nExclusion Criteria:\n\n* Are currently receiving gonadotropin-releasing hormone (GnRH) agonist, a GnRH antagonist other than NBI-56418, or danazol or have received any of these agents within 6 months of the start of screening.\n* Are currently receiving subcutaneous medroxyprogesterone acetate (DMPA-SC) or intramuscular medroxyprogesterone acetate (DMPA-IM) or have received any of these agents within 3 months of the start of screening.\n* Are currently using hormonal contraception or other forms of hormonal therapy or received such treatment within the last month.\n* Have had surgery for endometriosis within the last month.\n* Have had a hysterectomy or bilateral oophorectomy.\n* Are using systemic steroids on a chronic or regular basis within 3 months.\n* Have uterine fibroids ≥ 3 cm in diameter.\n* Have pelvic pain that is not caused by endometriosis.\n* Have unstable medical condition or chronic disease.\n* Have been pregnant within the last six months.\n* Currently breast feeding.", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "49 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "AbbVie Inc.", "affiliation": "AbbVie", "role": "STUDY_DIRECTOR"}]}, "ipdSharingStatementModule": {"ipdSharing": "UNDECIDED"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "The study consisted of up to 8 weeks of screening with data collection to establish baseline pain, an 8-week double-blind placebo-controlled treatment period, a 16-week open-label treatment period with all patients receiving elagolix 150 mg once per day, and a 6-week posttreatment follow-up period.", "recruitmentDetails": "Participants were enrolled at 37 centers in the United States.", "groups": [{"id": "FG000", "title": "Placebo", "description": "Participants received placebo orally once a day for 8 weeks during the double-blind treatment period and switched to receive 150 mg elagolix for 16 weeks during the open-label treatment period."}, {"id": "FG001", "title": "Elagolix 150 mg", "description": "Participants received 150 mg elagolix orally once a day for 8 weeks during the double-blind treatment period and continued to receive 150 mg elagolix for 16 additional weeks during the open-label treatment period."}], "periods": [{"title": "Double-blind Treatment Phase (Weeks 1-8)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "69"}, {"groupId": "FG001", "numSubjects": "68"}]}, {"type": "Received Study Drug", "achievements": [{"groupId": "FG000", "numSubjects": "69"}, {"groupId": "FG001", "numSubjects": "68"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "63"}, {"groupId": "FG001", "numSubjects": "60"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "8"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Protocol Deviation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Sponsor/Investigator Decision", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}]}, {"title": "Open-label Treatment Phase (Weeks 8-24)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "63"}, {"groupId": "FG001", "numSubjects": "60"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "57"}, {"groupId": "FG001", "numSubjects": "55"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "5"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Protocol Deviation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Noncompliance", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Sponsor/Investigator Decision", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Placebo", "description": "Participants received placebo orally once a day for 8 weeks during the double-blind treatment period and switched to receive 150 mg elagolix for 16 weeks during the open-label treatment period."}, {"id": "BG001", "title": "Elagolix 150 mg", "description": "Participants received 150 mg elagolix orally once a day for 8 weeks during the double-blind treatment period and continued to receive 150 mg elagolix for 16 additional weeks during the open-label treatment period."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "69"}, {"groupId": "BG001", "value": "68"}, {"groupId": "BG002", "value": "137"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "33.0", "spread": "0.9"}, {"groupId": "BG001", "value": "32.8", "spread": "0.7"}, {"groupId": "BG002", "value": "32.9", "spread": "0.6"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "69"}, {"groupId": "BG001", "value": "68"}, {"groupId": "BG002", "value": "137"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "2"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black", "measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "13"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "57"}, {"groupId": "BG001", "value": "55"}, {"groupId": "BG002", "value": "112"}]}, {"title": "Hispanic", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "10"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in the Monthly Mean Dysmenorrhea Score During the Double-blind Treatment Phase", "description": "Participants assessed dysmenorrhea (pain during menstruation) and its impact on their daily activities at approximately the same time each day of their period in an electronic diary (e-Diary) according to the following response options:\n\n* 0 = No discomfort\n* 1 = Mild discomfort but I was easily able to do the things I usually do\n* 2 = Moderate discomfort or pain that made it difficult to do some of the things I usually do\n* 3 = Severe pain that made it difficult to do the things I usually do.\n\nThe monthly mean dysmenorrhea score is the average of the daily values reported during the 4 weeks prior to each visit.", "populationDescription": "All randomized participants who received at least 1 dose of study drug and had at least 10 evaluable e-Diary reports during the double-blind period (intent-to-treat population). The analysis includes participants with non-missing data at each time point.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and Weeks 4 and 8", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo orally once a day for 8 weeks during the double-blind treatment period and switched to receive 150 mg elagolix for 16 weeks during the open-label treatment period."}, {"id": "OG001", "title": "Elagolix 150 mg", "description": "Participants received 150 mg elagolix orally once a day for 8 weeks during the double-blind treatment period and continued to receive 150 mg elagolix for 16 additional weeks during the open-label treatment period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "66"}, {"groupId": "OG001", "value": "66"}]}], "classes": [{"title": "Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "66"}, {"groupId": "OG001", "value": "66"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.24", "spread": "0.076"}, {"groupId": "OG001", "value": "-0.49", "spread": "0.076"}]}]}, {"title": "Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "64"}, {"groupId": "OG001", "value": "64"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.37", "spread": "0.107"}, {"groupId": "OG001", "value": "-1.13", "spread": "0.107"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Comparison of Change from Baseline at Week 4", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0262", "statisticalMethod": "ANCOVA", "statisticalComment": "Analysis of covariance (ANCOVA) model including baseline value as a covariate.", "paramType": "LS Mean Difference", "paramValue": "-0.24", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.45", "ciUpperLimit": "-0.03", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.107"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Comparison of change from baseline at week 8", "nonInferiorityType": "SUPERIORITY", "pValue": "< 0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Analysis of covariance (ANCOVA) model, including baseline value as a covariate.", "paramType": "LS Mean Difference", "paramValue": "-0.76", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.06", "ciUpperLimit": "-0.46", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.152"}]}, {"type": "PRIMARY", "title": "Change From Baseline in the Monthly Mean Dysmenorrhea Score During the Open-label and Posttreatment Phases", "description": "Participants assessed dysmenorrhea (pain during menstruation) and its impact on their daily activities at approximately the same time each day of their period in an electronic diary (e-Diary) according to the following response options:\n\n* 0 = No discomfort\n* 1 = Mild discomfort but I was easily able to do the things I usually do\n* 2 = Moderate discomfort or pain that made it difficult to do some of the things I usually do\n* 3 = Severe pain that made it difficult to do the things I usually do.\n\nThe monthly mean dysmenorrhea score is the average of the daily values reported during the 4 weeks prior to each visit, except for the week 30 value which is based on 6 weeks of data.", "populationDescription": "All randomized participants who received at least 1 dose of study drug and had at least 10 evaluable e-Diary reports during the double-blind period (intent-to-treat population) with data on or after Week 12. The analysis includes participants with non-missing data at each time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and Weeks 12, 16, 20, 24, and 30 (6 weeks posttreatment)", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo orally once a day for 8 weeks during the double-blind treatment period and switched to receive 150 mg elagolix for 16 weeks during the open-label treatment period."}, {"id": "OG001", "title": "Elagolix 150 mg", "description": "Participants received 150 mg elagolix orally once a day for 8 weeks during the double-blind treatment period and continued to receive 150 mg elagolix for 16 additional weeks during the open-label treatment period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}, {"groupId": "OG001", "value": "60"}]}], "classes": [{"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}, {"groupId": "OG001", "value": "60"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.768", "spread": "0.118"}, {"groupId": "OG001", "value": "-1.060", "spread": "0.130"}]}]}, {"title": "Week 16", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}, {"groupId": "OG001", "value": "59"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.325", "spread": "0.112"}, {"groupId": "OG001", "value": "-1.022", "spread": "0.137"}]}]}, {"title": "Week 20", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.026", "spread": "0.119"}, {"groupId": "OG001", "value": "-0.991", "spread": "0.121"}]}]}, {"title": "Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.282", "spread": "0.118"}, {"groupId": "OG001", "value": "-1.372", "spread": "0.132"}]}]}, {"title": "Week 30", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "55"}, {"groupId": "OG001", "value": "55"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.547", "spread": "0.104"}, {"groupId": "OG001", "value": "-0.534", "spread": "0.102"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in the Monthly Mean Non-menstrual Pelvic Pain Score During the Double-Blind Treatment Phase", "description": "Participants assessed their pelvic pain not related to menses and its impact on their daily activities at approximately the same time each day they were not having their period in an e-Diary according to the following response options:\n\n* 0 = No discomfort\n* 1 = Mild discomfort but I was easily able to do the things I usually do\n* 2 = Moderate discomfort or pain that made it difficult to do some of the things I usually do\n* 3 = Severe pain that made it difficult to do the things I usually do.\n\nThe monthly mean non-menstrual pelvic pain score is the average of the daily values reported during the 4 weeks prior to each visit.", "populationDescription": "All randomized participants who received at least 1 dose of study drug and had at least 10 evaluable e-Diary reports during the double-blind period (intent-to-treat population). The analysis includes participants with non-missing data at each time point.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and weeks 4 and 8", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo orally once a day for 8 weeks during the double-blind treatment period and switched to receive 150 mg elagolix for 16 weeks during the open-label treatment period."}, {"id": "OG001", "title": "Elagolix 150 mg", "description": "Participants received 150 mg elagolix orally once a day for 8 weeks during the double-blind treatment period and continued to receive 150 mg elagolix for 16 additional weeks during the open-label treatment period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "66"}, {"groupId": "OG001", "value": "66"}]}], "classes": [{"title": "Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "66"}, {"groupId": "OG001", "value": "66"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.05", "spread": "0.061"}, {"groupId": "OG001", "value": "-0.26", "spread": "0.061"}]}]}, {"title": "Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "64"}, {"groupId": "OG001", "value": "64"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.19", "spread": "0.071"}, {"groupId": "OG001", "value": "-0.47", "spread": "0.071"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Comparison of change from baseline at week 4", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0163", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model including baseline value as a covariate.", "paramType": "LS Mean Difference", "paramValue": "-0.21", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.38", "ciUpperLimit": "-0.04", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.086"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Comparison of change from baseline at week 8", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0066", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model including baseline value as a covariate.", "paramType": "LS Mean Difference", "paramValue": "-0.28", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.48", "ciUpperLimit": "-0.08", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.101"}]}, {"type": "PRIMARY", "title": "Change From Baseline in the Monthly Mean Non-menstrual Pelvic Pain Score During the Open-label and Posttreatment Phases", "description": "Participants assessed their pelvic pain not related to menses and its impact on their daily activities at approximately the same time each day they were not having their period in an e-Diary according to the following response options:\n\n* 0 = No discomfort\n* 1 = Mild discomfort but I was easily able to do the things I usually do\n* 2 = Moderate discomfort or pain that made it difficult to do some of the things I usually do\n* 3 = Severe pain that made it difficult to do the things I usually do.\n\nThe monthly mean non-menstrual pelvic pain score is the average of the daily values reported during the 4 weeks prior to each visit, except for the week 30 value which is based on 6 weeks of data.", "populationDescription": "All randomized participants who received at least 1 dose of study drug and had at least 10 evaluable e-Diary reports during the double-blind period (intent-to-treat population) with data on or after Week 12. The analysis includes participants with non-missing data at each time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and Weeks 12, 16, 20, 24, and 30 (6 weeks posttreatment)", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo orally once a day for 8 weeks during the double-blind treatment period and switched to receive 150 mg elagolix for 16 weeks during the open-label treatment period."}, {"id": "OG001", "title": "Elagolix 150 mg", "description": "Participants received 150 mg elagolix orally once a day for 8 weeks during the double-blind treatment period and continued to receive 150 mg elagolix for 16 additional weeks during the open-label treatment period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}, {"groupId": "OG001", "value": "60"}]}], "classes": [{"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}, {"groupId": "OG001", "value": "60"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.355", "spread": "0.087"}, {"groupId": "OG001", "value": "-0.727", "spread": "0.072"}]}]}, {"title": "Week 16", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}, {"groupId": "OG001", "value": "59"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.422", "spread": "0.078"}, {"groupId": "OG001", "value": "-0.763", "spread": "0.079"}]}]}, {"title": "Week 20", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.524", "spread": "0.090"}, {"groupId": "OG001", "value": "-0.759", "spread": "0.082"}]}]}, {"title": "Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.543", "spread": "0.092"}, {"groupId": "OG001", "value": "-0.801", "spread": "0.082"}]}]}, {"title": "Week 30", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "55"}, {"groupId": "OG001", "value": "55"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.326", "spread": "0.104"}, {"groupId": "OG001", "value": "-0.689", "spread": "0.085"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in the Monthly Mean Cumulative Pain Score During the Double-Blind Treatment Phase", "description": "Participants assessed dysmenorrhea or non-menstrual pelvic pain at approximately the same time each day in an e-Diary according to the following:\n\n* 0 = No discomfort\n* 1 = Mild discomfort but I was easily able to do the things I usually do\n* 2 = Moderate discomfort or pain that made it difficult to do some of the things I usually do\n* 3 = Severe pain that made it difficult to do the things I usually do.\n\nThe monthly mean cumulative pain score is the average of the daily values for all days (menstrual and non-menstrual) reported during the 4 weeks prior to each visit.", "populationDescription": "All randomized participants who received at least 1 dose of study drug and had at least 10 evaluable e-Diary reports during the double-blind period (intent-to-treat population). The analysis includes participants with non-missing data at each time point.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and weeks 4 and 8", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo orally once a day for 8 weeks during the double-blind treatment period and switched to receive 150 mg elagolix for 16 weeks during the open-label treatment period."}, {"id": "OG001", "title": "Elagolix 150 mg", "description": "Participants received 150 mg elagolix orally once a day for 8 weeks during the double-blind treatment period and continued to receive 150 mg elagolix for 16 additional weeks during the open-label treatment period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "66"}, {"groupId": "OG001", "value": "66"}]}], "classes": [{"title": "Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "66"}, {"groupId": "OG001", "value": "66"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.11", "spread": "0.058"}, {"groupId": "OG001", "value": "-0.32", "spread": "0.058"}]}]}, {"title": "Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "64"}, {"groupId": "OG001", "value": "64"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.21", "spread": "0.070"}, {"groupId": "OG001", "value": "-0.55", "spread": "0.070"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Comparison of change from baseline at week 4", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0089", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model including baseline value as a covariate.", "paramType": "LS Mean Difference", "paramValue": "-0.22", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.38", "ciUpperLimit": "-0.06", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.082"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Comparison of change from baseline at week 8", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0011", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model including baseline value as a covariate.", "paramType": "LS Mean Difference", "paramValue": "-0.33", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.53", "ciUpperLimit": "-0.14", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.100"}]}, {"type": "PRIMARY", "title": "Change From Baseline in the Monthly Mean Cumulative Pain Score During the Open-label and Posttreatment Phases", "description": "Participants assessed dysmenorrhea or non-menstrual pelvic pain at approximately the same time each day in an e-Diary according to the following:\n\n* 0: No discomfort\n* 1: Mild discomfort, I was easily able to do the things I usually do\n* 2: Moderate discomfort or pain making it difficult to do some of the things I usually do\n* 3: Severe pain making it difficult to do the things I usually do\n\nThe monthly mean cumulative pain score is the average of the daily values for all days (menstrual and non-menstrual) reported during the 4 weeks prior to each visit, except for the week 30 value which is based on 6 weeks of data.", "populationDescription": "All randomized participants who received at least 1 dose of study drug and had at least 10 evaluable e-Diary reports during the double-blind period (intent-to-treat population) with data on or after Week 12. The analysis includes participants with non-missing data at each time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and Weeks 12, 16, 20, 24, and 30 (6 weeks posttreatment)", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo orally once a day for 8 weeks during the double-blind treatment period and switched to receive 150 mg elagolix for 16 weeks during the open-label treatment period."}, {"id": "OG001", "title": "Elagolix 150 mg", "description": "Participants received 150 mg elagolix orally once a day for 8 weeks during the double-blind treatment period and continued to receive 150 mg elagolix for 16 additional weeks during the open-label treatment period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}, {"groupId": "OG001", "value": "60"}]}], "classes": [{"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}, {"groupId": "OG001", "value": "60"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.433", "spread": "0.082"}, {"groupId": "OG001", "value": "-0.781", "spread": "0.070"}]}]}, {"title": "Week 16", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}, {"groupId": "OG001", "value": "59"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.530", "spread": "0.072"}, {"groupId": "OG001", "value": "-0.793", "spread": "0.083"}]}]}, {"title": "Week 20", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.615", "spread": "0.085"}, {"groupId": "OG001", "value": "-0.798", "spread": "0.081"}]}]}, {"title": "Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.655", "spread": "0.088"}, {"groupId": "OG001", "value": "-0.878", "spread": "0.082"}]}]}, {"title": "Week 30", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "55"}, {"groupId": "OG001", "value": "55"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.374", "spread": "0.095"}, {"groupId": "OG001", "value": "-0.666", "spread": "0.085"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in the Monthly Mean Dyspareunia Score During the Double-Blind Treatment Phase", "description": "Participants assessed their dyspareunia (pain during sexual intercourse) at approximately the same time every day in an e-Diary according to the following response options:\n\n* 0 = Absent; No discomfort during sexual intercourse\n* 1 = Mild; I was able to tolerate the discomfort during sexual intercourse\n* 2 = Moderate; Intercourse was interrupted due to pain\n* 3 = Severe; I avoided intercourse because of pain\n* Does not apply; I was not sexually active for reasons other than my endometriosis or did not have sexual intercourse\n\nThe monthly mean dyspareunia score is the average of the daily values reported during the 4 weeks prior to each visit. Responses of \"does not apply\" were not included in the calculations.", "populationDescription": "All randomized participants who received at least 1 dose of study drug and had at least 10 evaluable e-Diary reports during the double-blind period (intent-to-treat population) with non-missing data at each time point. If a participant's responses were all \"does not apply\" for that month the score was treated as missing.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and weeks 4 and 8", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo orally once a day for 8 weeks during the double-blind treatment period and switched to receive 150 mg elagolix for 16 weeks during the open-label treatment period."}, {"id": "OG001", "title": "Elagolix 150 mg", "description": "Participants received 150 mg elagolix orally once a day for 8 weeks during the double-blind treatment period and continued to receive 150 mg elagolix for 16 additional weeks during the open-label treatment period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "53"}]}], "classes": [{"title": "Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "54"}, {"groupId": "OG001", "value": "49"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.07", "spread": "0.087"}, {"groupId": "OG001", "value": "-0.34", "spread": "0.091"}]}]}, {"title": "Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "51"}, {"groupId": "OG001", "value": "48"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.23", "spread": "0.095"}, {"groupId": "OG001", "value": "-0.61", "spread": "0.098"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Comparison of change form baseline at week 4", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0360", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model including baseline value as a covariate.", "paramType": "LS Mean Difference", "paramValue": "-0.27", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.52", "ciUpperLimit": "-0.02", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.127"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Comparison of change from baseline at week 8", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0070", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model including baseline value as a covariate.", "paramType": "LS Mean Difference", "paramValue": "-0.38", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.65", "ciUpperLimit": "-0.11", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.137"}]}, {"type": "PRIMARY", "title": "Change From Baseline in the Monthly Mean Dyspareunia Score During the Open-label and Posttreatment Phases", "description": "Participants assessed their dyspareunia (pain during sexual intercourse) at approximately the same time every day in an e-Diary according to the following response options:\n\n* 0: Absent; No discomfort during sexual intercourse\n* 1: Mild; I was able to tolerate the discomfort during sexual intercourse\n* 2: Moderate; Intercourse was interrupted due to pain\n* 3: Severe; I avoided intercourse because of pain\n* Does not apply; I was not sexually active for reasons other than my endometriosis or did not have sexual intercourse\n\nThe monthly mean dyspareunia score is the average of the daily values reported during the 4 weeks prior to each visit, except for week 30 which is based on 6 weeks of data. Responses of \"does not apply\" were not included in the calculations.", "populationDescription": "Randomized participants who received at least 1 dose of study drug and had at least 10 evaluable e-Diary reports during the double-blind period (intent-to-treat population) with data on or after Week 12 and non-missing data at each time point. If a participant's responses were all \"does not apply\" for that month the score was treated as missing.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and Weeks 12, 16, 20, 24, and 30 (6 weeks posttreatment)", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo orally once a day for 8 weeks during the double-blind treatment period and switched to receive 150 mg elagolix for 16 weeks during the open-label treatment period."}, {"id": "OG001", "title": "Elagolix 150 mg", "description": "Participants received 150 mg elagolix orally once a day for 8 weeks during the double-blind treatment period and continued to receive 150 mg elagolix for 16 additional weeks during the open-label treatment period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "53"}, {"groupId": "OG001", "value": "47"}]}], "classes": [{"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "49"}, {"groupId": "OG001", "value": "46"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.334", "spread": "0.125"}, {"groupId": "OG001", "value": "-0.696", "spread": "0.112"}]}]}, {"title": "Week 16", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "49"}, {"groupId": "OG001", "value": "43"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.453", "spread": "0.114"}, {"groupId": "OG001", "value": "-0.738", "spread": "0.124"}]}]}, {"title": "Week 20", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "41"}, {"groupId": "OG001", "value": "41"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.492", "spread": "0.135"}, {"groupId": "OG001", "value": "-0.778", "spread": "0.121"}]}]}, {"title": "Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "40"}, {"groupId": "OG001", "value": "39"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.633", "spread": "0.155"}, {"groupId": "OG001", "value": "-0.789", "spread": "0.115"}]}]}, {"title": "Week 30", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "44"}, {"groupId": "OG001", "value": "40"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.300", "spread": "0.118"}, {"groupId": "OG001", "value": "-0.730", "spread": "0.118"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With a Response in Monthly Mean Dysmenorrhea Score at Week 8", "description": "Participants assessed dysmenorrhea (pain during menstruation) and its impact on their daily activities at approximately the same time each day of their period in an e-Diary according to the following response options:\n\n* 0: No discomfort\n* 1: Mild discomfort but I was easily able to do the things I usually do\n* 2: Moderate discomfort or pain that made it difficult to do some of the things I usually do\n* 3: Severe pain that made it difficult to do the things I usually do.\n\nThe monthly mean dysmenorrhea score is the average of the daily values reported during the 4 weeks prior to each time point.\n\nResponse was defined as the percentage of participants with a percent decrease from baseline in the week 8 monthly mean score that was greater than or equal to each specified threshold value (10% through 90% in steps of 10%).", "populationDescription": "All randomized participants who received at least 1 dose of study drug and had at least 10 evaluable e-Diary reports during the double-blind period (intent-to-treat population) with non-missing data at baseline and week 8.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo orally once a day for 8 weeks during the double-blind treatment period and switched to receive 150 mg elagolix for 16 weeks during the open-label treatment period."}, {"id": "OG001", "title": "Elagolix 150 mg", "description": "Participants received 150 mg elagolix orally once a day for 8 weeks during the double-blind treatment period and continued to receive 150 mg elagolix for 16 additional weeks during the open-label treatment period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "64"}, {"groupId": "OG001", "value": "64"}]}], "classes": [{"title": "10% Reduction", "categories": [{"measurements": [{"groupId": "OG000", "value": "56.3"}, {"groupId": "OG001", "value": "68.8"}]}]}, {"title": "20% Reduction", "categories": [{"measurements": [{"groupId": "OG000", "value": "43.8"}, {"groupId": "OG001", "value": "68.8"}]}]}, {"title": "30% Reduction", "categories": [{"measurements": [{"groupId": "OG000", "value": "32.8"}, {"groupId": "OG001", "value": "62.5"}]}]}, {"title": "40% Reduction", "categories": [{"measurements": [{"groupId": "OG000", "value": "25.0"}, {"groupId": "OG001", "value": "59.4"}]}]}, {"title": "50% Reduction", "categories": [{"measurements": [{"groupId": "OG000", "value": "15.6"}, {"groupId": "OG001", "value": "54.7"}]}]}, {"title": "60% Reduction", "categories": [{"measurements": [{"groupId": "OG000", "value": "9.4"}, {"groupId": "OG001", "value": "51.6"}]}]}, {"title": "70% Reduction", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.7"}, {"groupId": "OG001", "value": "46.9"}]}]}, {"title": "80% Reduction", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.1"}, {"groupId": "OG001", "value": "43.8"}]}]}, {"title": "90% Reduction", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.1"}, {"groupId": "OG001", "value": "43.8"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With a Response in Monthly Mean Non-menstrual Pelvic Pain Score at Week 8", "description": "Participants assessed their pelvic pain not related to menses and its impact on their daily activities at approximately the same time each day they were not having their period in an e-Diary according to the following response options:\n\n* 0 = No discomfort\n* 1 = Mild discomfort but I was easily able to do the things I usually do\n* 2 = Moderate discomfort or pain that made it difficult to do some of the things I usually do\n* 3 = Severe pain that made it difficult to do the things I usually do.\n\nThe monthly mean non-menstrual pelvic pain score is the average of the daily values reported during the 4 weeks prior to each time point.\n\nResponse is defined as the percentage of participants with a percent decrease from baseline in the week 8 monthly mean score that was greater than or equal to each specified threshold value (10% through 90% in steps of 10%).", "populationDescription": "All randomized participants who received at least 1 dose of study drug and had at least 10 evaluable e-Diary reports during the double-blind period (intent-to-treat population) with non-missing data at baseline and week 8.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo orally once a day for 8 weeks during the double-blind treatment period and switched to receive 150 mg elagolix for 16 weeks during the open-label treatment period."}, {"id": "OG001", "title": "Elagolix 150 mg", "description": "Participants received 150 mg elagolix orally once a day for 8 weeks during the double-blind treatment period and continued to receive 150 mg elagolix for 16 additional weeks during the open-label treatment period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "64"}, {"groupId": "OG001", "value": "64"}]}], "classes": [{"title": "10% Reduction", "categories": [{"measurements": [{"groupId": "OG000", "value": "51.6"}, {"groupId": "OG001", "value": "79.7"}]}]}, {"title": "20% Reduction", "categories": [{"measurements": [{"groupId": "OG000", "value": "40.6"}, {"groupId": "OG001", "value": "68.8"}]}]}, {"title": "30% Reduction", "categories": [{"measurements": [{"groupId": "OG000", "value": "32.8"}, {"groupId": "OG001", "value": "62.5"}]}]}, {"title": "40% Reduction", "categories": [{"measurements": [{"groupId": "OG000", "value": "25.0"}, {"groupId": "OG001", "value": "51.6"}]}]}, {"title": "50% Reduction", "categories": [{"measurements": [{"groupId": "OG000", "value": "25.0"}, {"groupId": "OG001", "value": "32.8"}]}]}, {"title": "60% Reduction", "categories": [{"measurements": [{"groupId": "OG000", "value": "20.3"}, {"groupId": "OG001", "value": "26.6"}]}]}, {"title": "70% Reduction", "categories": [{"measurements": [{"groupId": "OG000", "value": "14.1"}, {"groupId": "OG001", "value": "21.9"}]}]}, {"title": "80% Reduction", "categories": [{"measurements": [{"groupId": "OG000", "value": "9.4"}, {"groupId": "OG001", "value": "10.9"}]}]}, {"title": "90% Reduction", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.7"}, {"groupId": "OG001", "value": "7.8"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With a Response in Monthly Mean Cumulative Pain Score at Week 8", "description": "Participants assessed dysmenorrhea or non-menstrual pelvic pain at approximately the same time every day in an e-Diary according to the following:\n\n* 0 = No discomfort\n* 1 = Mild discomfort\n* 2 = Moderate discomfort or pain\n* 3 = Severe pain\n\nThe monthly mean cumulative pain score is the average of the daily values for all days (menstrual and non-menstrual) in the 4 weeks prior to each time point.\n\nResponse is the percentage of participants with a percent decrease from baseline in the week 8 monthly mean score that was greater than or equal to each specified threshold value (10% through 90% in steps of 10%).", "populationDescription": "All randomized participants who received at least 1 dose of study drug and had at least 10 evaluable e-Diary reports during the double-blind period (intent-to-treat population) with non-missing data at baseline and week 8.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo orally once a day for 8 weeks during the double-blind treatment period and switched to receive 150 mg elagolix for 16 weeks during the open-label treatment period."}, {"id": "OG001", "title": "Elagolix 150 mg", "description": "Participants received 150 mg elagolix orally once a day for 8 weeks during the double-blind treatment period and continued to receive 150 mg elagolix for 16 additional weeks during the open-label treatment period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "64"}, {"groupId": "OG001", "value": "64"}]}], "classes": [{"title": "10% Reduction", "categories": [{"measurements": [{"groupId": "OG000", "value": "51.6"}, {"groupId": "OG001", "value": "76.6"}]}]}, {"title": "20% Reduction", "categories": [{"measurements": [{"groupId": "OG000", "value": "40.6"}, {"groupId": "OG001", "value": "70.3"}]}]}, {"title": "30% Reduction", "categories": [{"measurements": [{"groupId": "OG000", "value": "37.5"}, {"groupId": "OG001", "value": "59.4"}]}]}, {"title": "40% Reduction", "categories": [{"measurements": [{"groupId": "OG000", "value": "23.4"}, {"groupId": "OG001", "value": "46.9"}]}]}, {"title": "50% Reduction", "categories": [{"measurements": [{"groupId": "OG000", "value": "20.3"}, {"groupId": "OG001", "value": "37.5"}]}]}, {"title": "60% Reduction", "categories": [{"measurements": [{"groupId": "OG000", "value": "15.6"}, {"groupId": "OG001", "value": "26.6"}]}]}, {"title": "70% Reduction", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.8"}, {"groupId": "OG001", "value": "18.8"}]}]}, {"title": "80% Reduction", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.1"}, {"groupId": "OG001", "value": "9.4"}]}]}, {"title": "90% Reduction", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0"}, {"groupId": "OG001", "value": "9.4"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With a Response in Monthly Mean Dyspareunia Score at Week 8", "description": "Participants assessed their dyspareunia (pain during sexual intercourse) at approximately the same time every day in an e-Diary according to the following response options:\n\n* 0 = Absent; No discomfort during sexual intercourse\n* 1 = Mild; I was able to tolerate the discomfort during sexual intercourse\n* 2 = Moderate; Intercourse was interrupted due to pain\n* 3 = Severe; I avoided intercourse because of pain\n* Does not apply; I was not sexually active for reasons other than my endometriosis or did not have sexual intercourse\n\nThe monthly mean dyspareunia score is the average of the daily values reported during the 4 weeks prior to each time point.\n\nResponse is defined as the percentage of participants with a percent decrease from baseline in the week 8 monthly mean score that was greater than or equal to each specified threshold value (10% through 90% in steps of 10%).", "populationDescription": "All randomized participants who received at least 1 dose of study drug and had at least 10 evaluable e-Diary reports during the double-blind period (intent-to-treat population) with non-missing data at baseline and week 8. If a participant's responses were all \"does not apply\" for that month the score was treated as missing.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo orally once a day for 8 weeks during the double-blind treatment period and switched to receive 150 mg elagolix for 16 weeks during the open-label treatment period."}, {"id": "OG001", "title": "Elagolix 150 mg", "description": "Participants received 150 mg elagolix orally once a day for 8 weeks during the double-blind treatment period and continued to receive 150 mg elagolix for 16 additional weeks during the open-label treatment period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "47"}, {"groupId": "OG001", "value": "45"}]}], "classes": [{"title": "10% Reduction", "categories": [{"measurements": [{"groupId": "OG000", "value": "44.7"}, {"groupId": "OG001", "value": "73.3"}]}]}, {"title": "20% Reduction", "categories": [{"measurements": [{"groupId": "OG000", "value": "38.3"}, {"groupId": "OG001", "value": "64.4"}]}]}, {"title": "30% Reduction", "categories": [{"measurements": [{"groupId": "OG000", "value": "34.0"}, {"groupId": "OG001", "value": "57.8"}]}]}, {"title": "40% Reduction", "categories": [{"measurements": [{"groupId": "OG000", "value": "27.7"}, {"groupId": "OG001", "value": "53.3"}]}]}, {"title": "50% Reduction", "categories": [{"measurements": [{"groupId": "OG000", "value": "23.4"}, {"groupId": "OG001", "value": "48.9"}]}]}, {"title": "60% Reduction", "categories": [{"measurements": [{"groupId": "OG000", "value": "19.1"}, {"groupId": "OG001", "value": "37.8"}]}]}, {"title": "70% Reduction", "categories": [{"measurements": [{"groupId": "OG000", "value": "19.1"}, {"groupId": "OG001", "value": "31.1"}]}]}, {"title": "80% Reduction", "categories": [{"measurements": [{"groupId": "OG000", "value": "17.0"}, {"groupId": "OG001", "value": "22.2"}]}]}, {"title": "90% Reduction", "categories": [{"measurements": [{"groupId": "OG000", "value": "12.8"}, {"groupId": "OG001", "value": "20.0"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in the Percentage of Days of Any Analgesic Use During the Double-Blind Treatment Phase", "description": "The daily use of endometriosis analgesics was reported by participants daily using the e-Diary. Participants reported whether the medication was over-the-counter (OTC) or prescription, and, if prescription, whether the medication was a narcotic.\n\nThe percentage of days of any analgesic use is defined as the number of days in the 4 weeks prior to each study visit that the participant reported the use of an analgesic, divided by the number of study days in the interval that the participant provided an e-Diary report regarding the use of endometriosis analgesics (including a response of \"none\").", "populationDescription": "All randomized participants who received at least 1 dose of study drug and had at least 10 evaluable e-Diary reports during the double-blind period (intent-to-treat population). The analysis includes participants with non-missing data at each time point.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage of days", "timeFrame": "Baseline and Weeks 4 and 8", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo orally once a day for 8 weeks during the double-blind treatment period and switched to receive 150 mg elagolix for 16 weeks during the open-label treatment period."}, {"id": "OG001", "title": "Elagolix 150 mg", "description": "Participants received 150 mg elagolix orally once a day for 8 weeks during the double-blind treatment period and continued to receive 150 mg elagolix for 16 additional weeks during the open-label treatment period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "66"}, {"groupId": "OG001", "value": "66"}]}], "classes": [{"title": "Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "66"}, {"groupId": "OG001", "value": "66"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-5.78", "spread": "2.782"}, {"groupId": "OG001", "value": "-15.62", "spread": "2.782"}]}]}, {"title": "Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "64"}, {"groupId": "OG001", "value": "64"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-9.19", "spread": "2.763"}, {"groupId": "OG001", "value": "-21.63", "spread": "2.763"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Comparison of change from baseline at week 4", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0137", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model including baseline value as a covariate.", "paramType": "LS Mean Difference", "paramValue": "-9.84", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-17.63", "ciUpperLimit": "-2.05", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.939"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Comparison of change from baseline at week 8", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0019", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model including baseline value as a covariate.", "paramType": "LS Mean Difference", "paramValue": "-12.44", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-20.19", "ciUpperLimit": "-4.70", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.913"}]}, {"type": "SECONDARY", "title": "Change From Baseline in the Percentage of Days of Any Analgesic Use During the Open-Label and Posttreatment Phases", "description": "The daily use of endometriosis analgesics was reported by participants daily using the e-Diary. Participants reported whether the medication was over-the-counter (OTC) or prescription, and, if prescription, whether the medication was a narcotic.\n\nThe percentage of days of any analgesic use is defined as the number of days in the 4 weeks prior to each study visit (except for week 30 which is based on 6 weeks of data) that the participant reported the use of an analgesic, divided by the number of study days in the interval that the participant provided an e-Diary report regarding the use of endometriosis analgesics (including a response of \"none\").", "populationDescription": "All randomized participants who received at least 1 dose of study drug and had at least 10 evaluable e-Diary reports during the double-blind period (intent-to-treat population) with data on or after Week 12. The analysis includes participants with non-missing data at each time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage of days", "timeFrame": "Baseline and Weeks 12, 16, 20, 24, and 30 (6 weeks posttreatment)", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo orally once a day for 8 weeks during the double-blind treatment period and switched to receive 150 mg elagolix for 16 weeks during the open-label treatment period."}, {"id": "OG001", "title": "Elagolix 150 mg", "description": "Participants received 150 mg elagolix orally once a day for 8 weeks during the double-blind treatment period and continued to receive 150 mg elagolix for 16 additional weeks during the open-label treatment period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}, {"groupId": "OG001", "value": "60"}]}], "classes": [{"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}, {"groupId": "OG001", "value": "60"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-14.91", "spread": "3.76"}, {"groupId": "OG001", "value": "-27.70", "spread": "3.49"}]}]}, {"title": "Week 16", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}, {"groupId": "OG001", "value": "59"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-18.34", "spread": "3.33"}, {"groupId": "OG001", "value": "-26.27", "spread": "3.71"}]}]}, {"title": "Week 20", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-19.82", "spread": "4.05"}, {"groupId": "OG001", "value": "-26.35", "spread": "4.27"}]}]}, {"title": "Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-20.63", "spread": "4.17"}, {"groupId": "OG001", "value": "-29.21", "spread": "4.23"}]}]}, {"title": "Week 30", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "55"}, {"groupId": "OG001", "value": "55"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-11.64", "spread": "4.18"}, {"groupId": "OG001", "value": "-21.83", "spread": "4.30"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in the Percentage of Days of Prescription Analgesic Use During the Double-Blind Treatment Phase", "description": "The daily use of endometriosis analgesics was reported by participants daily using the e-Diary. Participants reported whether the medication was over-the-counter (OTC) or prescription, and, if prescription, whether the medication was a narcotic.\n\nThe percentage of days of prescription analgesic use is defined as the number of days in the 4 weeks prior to each study visit that the participant reported the use of a prescription analgesic, divided by the number of study days in the interval that the participant provided an e-Diary report regarding the use of endometriosis analgesics (including a response of \"none\").", "populationDescription": "All randomized participants who received at least 1 dose of study drug and had at least 10 evaluable e-Diary reports during the double-blind period (intent-to-treat population). The analysis includes participants with non-missing data at each time point.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage of days", "timeFrame": "Baseline and Weeks 4 and 8", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo orally once a day for 8 weeks during the double-blind treatment period and switched to receive 150 mg elagolix for 16 weeks during the open-label treatment period."}, {"id": "OG001", "title": "Elagolix 150 mg", "description": "Participants received 150 mg elagolix orally once a day for 8 weeks during the double-blind treatment period and continued to receive 150 mg elagolix for 16 additional weeks during the open-label treatment period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "66"}, {"groupId": "OG001", "value": "66"}]}], "classes": [{"title": "Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "66"}, {"groupId": "OG001", "value": "66"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.92", "spread": "1.929"}, {"groupId": "OG001", "value": "-5.29", "spread": "1.929"}]}]}, {"title": "Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "64"}, {"groupId": "OG001", "value": "64"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.82", "spread": "1.802"}, {"groupId": "OG001", "value": "-7.16", "spread": "1.802"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Comparison of change from baseline at week 4", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0244", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model including baseline value as a covariate.", "paramType": "LS Mean Difference", "paramValue": "-6.21", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-11.61", "ciUpperLimit": "-0.81", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "2.728"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Comparison of change from baseline at week 8", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0141", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model including baseline value as a covariate.", "paramType": "LS Mean Difference", "paramValue": "-6.35", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-11.39", "ciUpperLimit": "-1.30", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "2.549"}]}, {"type": "SECONDARY", "title": "Change From Baseline in the Percentage of Days of Prescription Analgesic Use During the Open-Label and Posttreatment Phases", "description": "The daily use of endometriosis analgesics was reported by participants daily using the e-Diary. Participants reported whether the medication was over-the-counter (OTC) or prescription, and, if prescription, whether the medication was a narcotic.\n\nThe percentage of days of prescription analgesic use is defined as the number of days in the 4 weeks prior to each study visit (except for week 30 which is based on 6 weeks of data) that the participant reported the use of a prescription analgesic, divided by the number of study days in the interval that the participant provided an e-Diary report regarding the use of endometriosis analgesics (including a response of \"none\").", "populationDescription": "All randomized participants who received at least 1 dose of study drug and had at least 10 evaluable e-Diary reports during the double-blind period (intent-to-treat population) with data on or after Week 12. The analysis includes participants with non-missing data at each time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage of days", "timeFrame": "Baseline and Weeks 12, 16, 20, 24, and 30 (6 weeks posttreatment)", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo orally once a day for 8 weeks during the double-blind treatment period and switched to receive 150 mg elagolix for 16 weeks during the open-label treatment period."}, {"id": "OG001", "title": "Elagolix 150 mg", "description": "Participants received 150 mg elagolix orally once a day for 8 weeks during the double-blind treatment period and continued to receive 150 mg elagolix for 16 additional weeks during the open-label treatment period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}, {"groupId": "OG001", "value": "60"}]}], "classes": [{"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}, {"groupId": "OG001", "value": "60"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.34", "spread": "2.70"}, {"groupId": "OG001", "value": "-8.53", "spread": "1.66"}]}]}, {"title": "Week 16", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}, {"groupId": "OG001", "value": "59"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-5.52", "spread": "2.26"}, {"groupId": "OG001", "value": "-7.52", "spread": "1.67"}]}]}, {"title": "Week 20", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-5.21", "spread": "2.78"}, {"groupId": "OG001", "value": "-6.06", "spread": "2.31"}]}]}, {"title": "Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-5.89", "spread": "2.56"}, {"groupId": "OG001", "value": "-7.83", "spread": "1.89"}]}]}, {"title": "Week 30", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "55"}, {"groupId": "OG001", "value": "55"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.72", "spread": "3.07"}, {"groupId": "OG001", "value": "-6.06", "spread": "2.26"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in the Percentage of Days of Narcotic Analgesic Use During the Double-Blind Treatment Phase", "description": "The daily use of endometriosis analgesics was reported by participants daily using the e-Diary. Participants reported whether the medication was over-the-counter (OTC) or prescription, and, if prescription, whether the medication was a narcotic.\n\nThe percentage of days of narcotic analgesic use is defined as the number of days in the 4 weeks prior to each study visit that the participant reported the use of a narcotic analgesic, divided by the number of study days in the interval that the participant provided an e-Diary report regarding the use of endometriosis analgesics (including a response of \"none\").", "populationDescription": "All randomized participants who received at least 1 dose of study drug and had at least 10 evaluable e-Diary reports during the double-blind period (intent-to-treat population). The analysis includes participants with non-missing data at each time point.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage of days", "timeFrame": "Baseline and Weeks 4 and 8", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo orally once a day for 8 weeks during the double-blind treatment period and switched to receive 150 mg elagolix for 16 weeks during the open-label treatment period."}, {"id": "OG001", "title": "Elagolix 150 mg", "description": "Participants received 150 mg elagolix orally once a day for 8 weeks during the double-blind treatment period and continued to receive 150 mg elagolix for 16 additional weeks during the open-label treatment period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "66"}, {"groupId": "OG001", "value": "66"}]}], "classes": [{"title": "Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "66"}, {"groupId": "OG001", "value": "66"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.51", "spread": "1.287"}, {"groupId": "OG001", "value": "-3.63", "spread": "1.287"}]}]}, {"title": "Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "64"}, {"groupId": "OG001", "value": "64"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.19", "spread": "1.369"}, {"groupId": "OG001", "value": "-4.71", "spread": "1.369"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Comparison of change from baseline at week 4", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0893", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model including baseline value as a covariate.", "paramType": "LS Mean Difference", "paramValue": "-3.12", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-6.72", "ciUpperLimit": "0.49", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.821"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Comparison of change from baseline at week 8", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0720", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model including baseline value as a covariate.", "paramType": "LS Mean Difference", "paramValue": "-3.52", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-7.35", "ciUpperLimit": "0.32", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.938"}]}, {"type": "SECONDARY", "title": "Change From Baseline in the Percentage of Days of Narcotic Analgesic Use During the Open-Label and Posttreatment Phases", "description": "The daily use of endometriosis analgesics was reported by participants daily using the e-Diary. Participants reported whether the medication was over-the-counter (OTC) or prescription, and, if prescription, whether the medication was a narcotic.\n\nThe percentage of days of narcotic analgesic use is defined as the number of days in the 4 weeks prior to each study visit (except for week 30 which is based on 6 weeks of data) that the participant reported the use of a narcotic analgesic, divided by the number of study days in the interval that the participant provided an e-Diary report regarding the use of endometriosis analgesics (including a response of \"none\").", "populationDescription": "All randomized participants who received at least 1 dose of study drug and had at least 10 evaluable e-Diary reports during the double-blind period (intent-to-treat population) with data on or after Week 12. The analysis includes participants with non-missing data at each time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage of days", "timeFrame": "Baseline and Weeks 12, 16, 20, 24, and 30 (6 weeks posttreatment)", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo orally once a day for 8 weeks during the double-blind treatment period and switched to receive 150 mg elagolix for 16 weeks during the open-label treatment period."}, {"id": "OG001", "title": "Elagolix 150 mg", "description": "Participants received 150 mg elagolix orally once a day for 8 weeks during the double-blind treatment period and continued to receive 150 mg elagolix for 16 additional weeks during the open-label treatment period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}, {"groupId": "OG001", "value": "60"}]}], "classes": [{"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}, {"groupId": "OG001", "value": "60"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.91", "spread": "2.16"}, {"groupId": "OG001", "value": "-4.79", "spread": "1.25"}]}]}, {"title": "Week 16", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}, {"groupId": "OG001", "value": "59"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.03", "spread": "1.76"}, {"groupId": "OG001", "value": "-3.64", "spread": "1.27"}]}]}, {"title": "Week 20", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.79", "spread": "2.24"}, {"groupId": "OG001", "value": "-5.41", "spread": "1.64"}]}]}, {"title": "Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.12", "spread": "2.20"}, {"groupId": "OG001", "value": "-3.92", "spread": "1.68"}]}]}, {"title": "Week 30", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "55"}, {"groupId": "OG001", "value": "55"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.75", "spread": "2.73"}, {"groupId": "OG001", "value": "-3.56", "spread": "1.69"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to the End of the Double-blind Treatment Phase in Composite Pelvic Signs and Symptoms Score (CPSSS) Total Score and Component Scores", "description": "The CPSSS consists of 5 components that address dysmenorrhea, dyspareunia, non-menstrual pelvic pain, pelvic tenderness, and pelvic induration. Each component was scored on a scale of 0 to 3 (0 = absent, 1 = mild, 2 = moderate, and 3 = severe).\n\nDysmenorrhea, dyspareunia, and non-menstrual pelvic pain scores are based on the participant's assessment of symptoms during the past 28 days; pelvic tenderness and induration were assessed by the investigator based on findings associated with a pelvic examination.\n\nThe total CPSSS has a maximum possible value of 15 (total score range: 0 to 15, where a lower score indicates less signs and symptoms of endometriosis or better functioning). Individual component scores range from 0 (absent) to 3 (severe).", "populationDescription": "All randomized participants who received at least 1 dose of study drug and had at least 10 evaluable e-Diary reports during the double-blind period (intent-to-treat population). The analysis includes participants with non-missing data at baseline and week 8.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo orally once a day for 8 weeks during the double-blind treatment period and switched to receive 150 mg elagolix for 16 weeks during the open-label treatment period."}, {"id": "OG001", "title": "Elagolix 150 mg", "description": "Participants received 150 mg elagolix orally once a day for 8 weeks during the double-blind treatment period and continued to receive 150 mg elagolix for 16 additional weeks during the open-label treatment period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "66"}, {"groupId": "OG001", "value": "66"}]}], "classes": [{"title": "Total Score", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "62"}, {"groupId": "OG001", "value": "63"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.19", "spread": "0.359"}, {"groupId": "OG001", "value": "-4.45", "spread": "0.356"}]}]}, {"title": "Dysmenorrhea Component", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "63"}, {"groupId": "OG001", "value": "63"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.39", "spread": "0.127"}, {"groupId": "OG001", "value": "-1.44", "spread": "0.127"}]}]}, {"title": "Non-menstrual Pelvic Pain Component", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "63"}, {"groupId": "OG001", "value": "63"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.54", "spread": "0.101"}, {"groupId": "OG001", "value": "-0.90", "spread": "0.101"}]}]}, {"title": "Dyspareunia Component", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}, {"groupId": "OG001", "value": "51"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.46", "spread": "0.123"}, {"groupId": "OG001", "value": "-0.74", "spread": "0.121"}]}]}, {"title": "Pelvic Tenderness Component", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "62"}, {"groupId": "OG001", "value": "63"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.41", "spread": "0.102"}, {"groupId": "OG001", "value": "-0.80", "spread": "0.101"}]}]}, {"title": "Pelvic Induration Component", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "62"}, {"groupId": "OG001", "value": "63"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.38", "spread": "0.089"}, {"groupId": "OG001", "value": "-0.66", "spread": "0.088"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Comparison of the change from baseline in CPSSS total score", "nonInferiorityType": "SUPERIORITY", "pValue": "< 0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model including baseline value as a covariate.", "paramType": "LS Mean Difference", "paramValue": "-2.26", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.26", "ciUpperLimit": "-1.26", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.505"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Comparison of change from baseline in CPSSS component of dysmenorrhea score", "nonInferiorityType": "SUPERIORITY", "pValue": "< 0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model including baseline value as a covariate.", "paramType": "LS Mean Difference", "paramValue": "-1.05", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.41", "ciUpperLimit": "-0.69", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.180"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Comparison of change from baseline in CPSSS component of non-menstrual pelvic pain score", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0139", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model including baseline value as a covariate.", "paramType": "LS Mean Difference", "paramValue": "-0.36", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.64", "ciUpperLimit": "-0.07", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.143"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Comparison of change from baseline in CPSSS component of dyspareunia score", "nonInferiorityType": "SUPERIORITY", "pValue": "0.1052", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model including baseline value as a covariate.", "paramType": "LS Mean Difference", "paramValue": "-0.28", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.63", "ciUpperLimit": "0.06", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.173"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Comparison of change from baseline in CPSSS component of pelvic tenderness score", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0081", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model including baseline value as a covariate.", "paramType": "LS Mean Difference", "paramValue": "-0.39", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.67", "ciUpperLimit": "-0.10", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.143"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Comparison of change from baseline in CPSSS component of induration score", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0240", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model including baseline value as a covariate.", "paramType": "LS Mean Difference", "paramValue": "-0.29", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.53", "ciUpperLimit": "-0.04", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.125"}]}, {"type": "SECONDARY", "title": "Change From Baseline to the End of the Open-label Treatment Phase in Composite Pelvic Signs and Symptoms Score (CPSSS) Total Score and Component Scores", "description": "The CPSSS consists of 5 components that address dysmenorrhea, dyspareunia, non-menstrual pelvic pain, pelvic tenderness, and pelvic induration. Each component was scored on a scale of 0 to 3 (0 = absent, 1 = mild, 2 = moderate, and 3 = severe).\n\nDysmenorrhea, dyspareunia, and non-menstrual pelvic pain scores are based on the participant's assessment of symptoms during the past 28 days; pelvic tenderness and induration were assessed by the investigator based on findings associated with a pelvic examination.\n\nThe total CPSSS has a maximum possible value of 15 (total score range: 0 to 15, where a lower score indicates less signs and symptoms of endometriosis or better functioning). Individual component scores range from 0 (absent) to 3 (severe).", "populationDescription": "All randomized participants who received at least 1 dose of study drug and had at least 10 evaluable e-Diary reports during the double-blind period (intent-to-treat population) with data on or after Week 24. The analysis includes participants with non-missing data for each component at baseline and week 24.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and week 24", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo orally once a day for 8 weeks during the double-blind treatment period and switched to receive 150 mg elagolix for 16 weeks during the open-label treatment period."}, {"id": "OG001", "title": "Elagolix 150 mg", "description": "Participants received 150 mg elagolix orally once a day for 8 weeks during the double-blind treatment period and continued to receive 150 mg elagolix for 16 additional weeks during the open-label treatment period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "57"}]}], "classes": [{"title": "Total Score", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "56"}, {"groupId": "OG001", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-5.571", "spread": "0.451"}, {"groupId": "OG001", "value": "-5.404", "spread": "0.384"}]}]}, {"title": "Dysmenorrhea Component", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.544", "spread": "0.175"}, {"groupId": "OG001", "value": "-1.386", "spread": "0.175"}]}]}, {"title": "Non-menstrual Pelvic Pain Component", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.000", "spread": "0.128"}, {"groupId": "OG001", "value": "-1.211", "spread": "0.127"}]}]}, {"title": "Dyspareunia Component", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "41"}, {"groupId": "OG001", "value": "43"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.12", "spread": "0.17"}, {"groupId": "OG001", "value": "-0.77", "spread": "0.16"}]}]}, {"title": "Pelvic Tenderness Component", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "56"}, {"groupId": "OG001", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.000", "spread": "0.120"}, {"groupId": "OG001", "value": "-1.175", "spread": "0.112"}]}]}, {"title": "Pelvic Induration Component", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "56"}, {"groupId": "OG001", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.964", "spread": "0.142"}, {"groupId": "OG001", "value": "-0.807", "spread": "0.121"}]}]}]}, {"type": "SECONDARY", "title": "Patient Global Impression of Change During the Double-blind Treatment Phase", "description": "The Patient Global Impression of Change (PGIC) is a questionnaire-based assessment of the change in endometriosis pain since the initiation of study drug. The participant was asked to select from one of seven response categories:\n\n1. Very Much Improved\n2. Much Improved\n3. Minimally Improved\n4. Not Changed\n5. Minimally Worse\n6. Much Worse\n7. Very Much Worse", "populationDescription": "All randomized participants who received at least 1 dose of study drug and had at least 10 evaluable e-Diary reports during the double-blind period (intent-to-treat population). The analysis includes participants with non-missing data at each time point.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Weeks 4 and 8", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo orally once a day for 8 weeks during the double-blind treatment period and switched to receive 150 mg elagolix for 16 weeks during the open-label treatment period."}, {"id": "OG001", "title": "Elagolix 150 mg", "description": "Participants received 150 mg elagolix orally once a day for 8 weeks during the double-blind treatment period and continued to receive 150 mg elagolix for 16 additional weeks during the open-label treatment period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "66"}, {"groupId": "OG001", "value": "66"}]}], "classes": [{"title": "Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "65"}, {"groupId": "OG001", "value": "66"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.6", "spread": "0.16"}, {"groupId": "OG001", "value": "2.8", "spread": "0.16"}]}]}, {"title": "Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "63"}, {"groupId": "OG001", "value": "63"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.4", "spread": "0.18"}, {"groupId": "OG001", "value": "2.4", "spread": "0.18"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Comparison of Patient Global Impression of Change at week 4", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0012", "statisticalMethod": "ANOVA", "paramType": "LS Mean Difference", "paramValue": "-0.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.2", "ciUpperLimit": "-0.3", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.23"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Comparison of Patient Global Impression of Change at week 8", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0002", "statisticalMethod": "ANOVA", "paramType": "LS Mean Difference", "paramValue": "-1.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.5", "ciUpperLimit": "-0.5", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.26"}]}, {"type": "SECONDARY", "title": "Patient Global Impression of Change During the Open-Label and Posttreatment Phases", "description": "The Patient Global Impression of Change (PGIC) is a questionnaire-based assessment of the change in endometriosis pain since the initiation of study drug. The participant was asked to select from one of seven response categories:\n\n1. Very Much Improved\n2. Much Improved\n3. Minimally Improved\n4. Not Changed\n5. Minimally Worse\n6. Much Worse\n7. Very Much Worse", "populationDescription": "All randomized participants who received at least 1 dose of study drug and had at least 10 evaluable e-Diary reports during the double-blind period (intent-to-treat population) with data on or after Week 12. The analysis includes participants with non-missing data at each time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Weeks 12, 16, 20, 24, and 30 (6 weeks posttreatment)", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo orally once a day for 8 weeks during the double-blind treatment period and switched to receive 150 mg elagolix for 16 weeks during the open-label treatment period."}, {"id": "OG001", "title": "Elagolix 150 mg", "description": "Participants received 150 mg elagolix orally once a day for 8 weeks during the double-blind treatment period and continued to receive 150 mg elagolix for 16 additional weeks during the open-label treatment period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}, {"groupId": "OG001", "value": "60"}]}], "classes": [{"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}, {"groupId": "OG001", "value": "59"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.5", "spread": "0.2"}, {"groupId": "OG001", "value": "2.0", "spread": "0.1"}]}]}, {"title": "Week 16", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "60"}, {"groupId": "OG001", "value": "59"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.4", "spread": "0.2"}, {"groupId": "OG001", "value": "1.8", "spread": "0.1"}]}]}, {"title": "Week 20", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.2", "spread": "0.2"}, {"groupId": "OG001", "value": "2.0", "spread": "0.1"}]}]}, {"title": "Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.0", "spread": "0.2"}, {"groupId": "OG001", "value": "1.8", "spread": "0.1"}]}]}, {"title": "Week 30", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "55"}, {"groupId": "OG001", "value": "53"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.4", "spread": "0.2"}, {"groupId": "OG001", "value": "2.2", "spread": "0.2"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With a PGIC Response of Much Improved or Very Much Improved During the Double-blind Treatment Phase", "description": "The Patient Global Impression of Change (PGIC) is a questionnaire-based assessment of the change in endometriosis pain since the initiation of study drug. The participant was asked to select from one of seven response categories:\n\n1. Very Much Improved\n2. Much Improved\n3. Minimally Improved\n4. Not Changed\n5. Minimally Worse\n6. Much Worse\n7. Very Much Worse", "populationDescription": "All randomized participants who received at least 1 dose of study drug and had at least 10 evaluable e-Diary reports during the double-blind period (intent-to-treat population). The analysis includes participants with non-missing data at each time point.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "percentage of participants", "timeFrame": "Weeks 4 and 8", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo orally once a day for 8 weeks during the double-blind treatment period and switched to receive 150 mg elagolix for 16 weeks during the open-label treatment period."}, {"id": "OG001", "title": "Elagolix 150 mg", "description": "Participants received 150 mg elagolix orally once a day for 8 weeks during the double-blind treatment period and continued to receive 150 mg elagolix for 16 additional weeks during the open-label treatment period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "66"}, {"groupId": "OG001", "value": "66"}]}], "classes": [{"title": "Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "65"}, {"groupId": "OG001", "value": "66"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "18.5", "lowerLimit": "9.0", "upperLimit": "27.9"}, {"groupId": "OG001", "value": "37.9", "lowerLimit": "26.2", "upperLimit": "49.6"}]}]}, {"title": "Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "63"}, {"groupId": "OG001", "value": "63"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "30.2", "lowerLimit": "18.8", "upperLimit": "41.5"}, {"groupId": "OG001", "value": "60.3", "lowerLimit": "48.2", "upperLimit": "72.4"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Comparison of response rates at week 4", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0136", "statisticalMethod": "Pearson chi-squared", "paramType": "Difference", "paramValue": "19.4", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "4.4", "ciUpperLimit": "34.4"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Comparison of response rates at week 8", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0007", "statisticalMethod": "Pearson chi-squared", "paramType": "Difference", "paramValue": "30.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "13.6", "ciUpperLimit": "46.7"}]}, {"type": "SECONDARY", "title": "Percentage of Participants With a PGIC Response of Much Improved or Very Much Improved During the Open-label Treatment Phase", "description": "The Patient Global Impression of Change (PGIC) is a questionnaire-based assessment of the change in endometriosis pain since the initiation of study drug. The participant was asked to select from one of seven response categories:\n\n1. Very Much Improved\n2. Much Improved\n3. Minimally Improved\n4. Not Changed\n5. Minimally Worse\n6. Much Worse\n7. Very Much Worse", "populationDescription": "All randomized participants who received at least 1 dose of study drug and had at least 10 evaluable e-Diary reports during the double-blind period (intent-to-treat population) with data on or after Week 12. The analysis includes participants with non-missing data at each time point.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Weeks 12, 16, 20, 24, and 30 (6 weeks posttreatment)", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo orally once a day for 8 weeks during the double-blind treatment period and switched to receive 150 mg elagolix for 16 weeks during the open-label treatment period."}, {"id": "OG001", "title": "Elagolix 150 mg", "description": "Participants received 150 mg elagolix orally once a day for 8 weeks during the double-blind treatment period and continued to receive 150 mg elagolix for 16 additional weeks during the open-label treatment period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}, {"groupId": "OG001", "value": "60"}]}], "classes": [{"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}, {"groupId": "OG001", "value": "59"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "59.0"}, {"groupId": "OG001", "value": "76.3"}]}]}, {"title": "Week 16", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "60"}, {"groupId": "OG001", "value": "59"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "61.7"}, {"groupId": "OG001", "value": "76.3"}]}]}, {"title": "Week 20", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "71.9"}, {"groupId": "OG001", "value": "71.9"}]}]}, {"title": "Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "73.7"}, {"groupId": "OG001", "value": "86.0"}]}]}, {"title": "Week 30", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "55"}, {"groupId": "OG001", "value": "53"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "69.1"}, {"groupId": "OG001", "value": "73.6"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to the End of the Double-blind Treatment Phase in Endometriosis Health Profile-5 (EHP-5)", "description": "The EHP-5 is an instrument to measure health-related quality of life in women with endometriosis. The EHP-5 consists of two parts:\n\n* A core questionnaire consisting of five questions that measure the impact of endometriosis in areas of pain, control and powerlessness, emotional well-being, social support, and self-image with five response categories for each item (Never, Rarely, Sometimes, Often, Always)\n* A supplemental questionnaire consisting of six additional questions which assess the impact of endometriosis on the areas of work, relationship with children, sexual intercourse, feelings about the medical profession, treatment, and infertility with the same five response categories plus an additional response category of Not Relevant which was not scored.\n\nThe scores associated with each possible outcome category are as follows: never (0), rarely (25), sometimes (50), often (75), and always (100). A negative change from baseline score indicates improvement in quality of life.", "populationDescription": "All randomized participants who received at least 1 dose of study drug and had at least 10 evaluable e-Diary reports during the double-blind period (intent-to-treat population). The analysis includes participants with non-missing data at baseline and week 8 for each question.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and week 8", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo orally once a day for 8 weeks during the double-blind treatment period and switched to receive 150 mg elagolix for 16 weeks during the open-label treatment period."}, {"id": "OG001", "title": "Elagolix 150 mg", "description": "Participants received 150 mg elagolix orally once a day for 8 weeks during the double-blind treatment period and continued to receive 150 mg elagolix for 16 additional weeks during the open-label treatment period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "63"}, {"groupId": "OG001", "value": "63"}]}], "classes": [{"title": "Pain", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "63"}, {"groupId": "OG001", "value": "63"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-12.3", "spread": "3.2"}, {"groupId": "OG001", "value": "-29.0", "spread": "3.0"}]}]}, {"title": "Control and Powerlessness", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "63"}, {"groupId": "OG001", "value": "63"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-12.7", "spread": "3.2"}, {"groupId": "OG001", "value": "-35.3", "spread": "3.7"}]}]}, {"title": "Emotional Well-being", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "63"}, {"groupId": "OG001", "value": "63"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-10.3", "spread": "2.9"}, {"groupId": "OG001", "value": "-17.1", "spread": "3.1"}]}]}, {"title": "Social Support", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "63"}, {"groupId": "OG001", "value": "63"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-13.1", "spread": "3.5"}, {"groupId": "OG001", "value": "-27.8", "spread": "3.9"}]}]}, {"title": "Self-image", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "63"}, {"groupId": "OG001", "value": "63"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-7.1", "spread": "3.3"}, {"groupId": "OG001", "value": "-23.4", "spread": "3.5"}]}]}, {"title": "Work", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "54"}, {"groupId": "OG001", "value": "54"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-13.0", "spread": "3.4"}, {"groupId": "OG001", "value": "-26.4", "spread": "3.4"}]}]}, {"title": "Relationship with Children", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "23"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-19.0", "spread": "4.8"}, {"groupId": "OG001", "value": "-31.5", "spread": "5.5"}]}]}, {"title": "Sexual Intercourse", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "56"}, {"groupId": "OG001", "value": "52"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-14.3", "spread": "2.9"}, {"groupId": "OG001", "value": "-22.6", "spread": "3.8"}]}]}, {"title": "Medical Profession", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "55"}, {"groupId": "OG001", "value": "50"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-9.5", "spread": "2.9"}, {"groupId": "OG001", "value": "-11.5", "spread": "3.3"}]}]}, {"title": "Frustration with Treatment", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "48"}, {"groupId": "OG001", "value": "48"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-20.8", "spread": "5.1"}, {"groupId": "OG001", "value": "-36.5", "spread": "4.6"}]}]}, {"title": "Concerns with Infertility", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "47"}, {"groupId": "OG001", "value": "48"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-10.6", "spread": "3.6"}, {"groupId": "OG001", "value": "-14.1", "spread": "3.3"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to the End of the Open-label Treatment Phase in Endometriosis Health Profile-5 (EHP-5)", "description": "The EHP-5 is an instrument to measure health-related quality of life in women with endometriosis. The EHP-5 consists of two parts:\n\n* A core questionnaire consisting of five questions that measure the impact of endometriosis on areas of pain, control and powerlessness, emotional well-being, social support, and self-image with five response categories for each item (Never, Rarely, Sometimes, Often, Always)\n* A supplemental questionnaire consisting of six additional questions which assess the impact of endometriosis on areas of work, relationship with children, sexual intercourse, feelings about the medical profession, treatment, and infertility with the same five response categories plus an additional response category of Not Relevant which was not scored.\n\nThe scores associated with each possible outcome category are as follows: never (0), rarely (25), sometimes (50), often (75), and always (100). A negative change from baseline score indicates improvement in quality of life.", "populationDescription": "All randomized participants who received at least 1 dose of study drug and had at least 10 evaluable e-Diary reports during the double-blind period (intent-to-treat population) with data on or after Week 12. The analysis includes participants with non-missing data at baseline and week 24 for each question.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and week 24", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo orally once a day for 8 weeks during the double-blind treatment period and switched to receive 150 mg elagolix for 16 weeks during the open-label treatment period."}, {"id": "OG001", "title": "Elagolix 150 mg", "description": "Participants received 150 mg elagolix orally once a day for 8 weeks during the double-blind treatment period and continued to receive 150 mg elagolix for 16 additional weeks during the open-label treatment period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}, {"groupId": "OG001", "value": "60"}]}], "classes": [{"title": "Pain", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-30.3", "spread": "3.9"}, {"groupId": "OG001", "value": "-36.4", "spread": "2.9"}]}]}, {"title": "Control and Powerlessness", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-35.1", "spread": "4.3"}, {"groupId": "OG001", "value": "-39.5", "spread": "3.5"}]}]}, {"title": "Emotional Well-being", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-22.8", "spread": "4.0"}, {"groupId": "OG001", "value": "-23.7", "spread": "3.3"}]}]}, {"title": "Social Support", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-29.8", "spread": "4.5"}, {"groupId": "OG001", "value": "-37.7", "spread": "4.1"}]}]}, {"title": "Self-image", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-20.6", "spread": "4.3"}, {"groupId": "OG001", "value": "-25.9", "spread": "3.9"}]}]}, {"title": "Work", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "48"}, {"groupId": "OG001", "value": "48"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-27.6", "spread": "4.4"}, {"groupId": "OG001", "value": "-37.0", "spread": "3.1"}]}]}, {"title": "Relationship with Children", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "20"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-39.6", "spread": "5.4"}, {"groupId": "OG001", "value": "-40.0", "spread": "4.2"}]}]}, {"title": "Sexual Intercourse", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "49"}, {"groupId": "OG001", "value": "46"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-30.1", "spread": "3.9"}, {"groupId": "OG001", "value": "-27.2", "spread": "4.0"}]}]}, {"title": "Medical Profession", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "49"}, {"groupId": "OG001", "value": "46"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-16.8", "spread": "4.5"}, {"groupId": "OG001", "value": "-19.6", "spread": "3.9"}]}]}, {"title": "Frustration with Treatment", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "43"}, {"groupId": "OG001", "value": "45"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-40.1", "spread": "5.5"}, {"groupId": "OG001", "value": "-40.6", "spread": "4.4"}]}]}, {"title": "Concerns with Infertility", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "42"}, {"groupId": "OG001", "value": "45"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-20.8", "spread": "5.0"}, {"groupId": "OG001", "value": "-22.8", "spread": "3.8"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Days With Uterine Bleeding During the Double- Blind Treatment Phase", "description": "Uterine bleeding was reported daily by participants during the study using the e-Diary.\n\nThe percentage of days a participant reported any bleeding was calculated as the total number of days the participant reported any bleeding ( light, moderate, or heavy) divided by the total number of days the participant had a non-missing e-Diary report of vaginal bleeding in the phase.", "populationDescription": "Participants who received at least one dose of randomized, double-blind study drug (safety analysis set) with non-missing data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage of days", "timeFrame": "Screening (8 weeks prior to day 1) and the double-blind treatment phase (Weeks 1-8)", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo orally once a day for 8 weeks during the double-blind treatment period and switched to receive 150 mg elagolix for 16 weeks during the open-label treatment period."}, {"id": "OG001", "title": "Elagolix 150 mg", "description": "Participants received 150 mg elagolix orally once a day for 8 weeks during the double-blind treatment period and continued to receive 150 mg elagolix for 16 additional weeks during the open-label treatment period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "69"}, {"groupId": "OG001", "value": "68"}]}], "classes": [{"title": "Screening", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "69"}, {"groupId": "OG001", "value": "68"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "24.29", "spread": "0.96"}, {"groupId": "OG001", "value": "22.98", "spread": "1.12"}]}]}, {"title": "Double-Blind Treatment Phase (Weeks 1-8)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "68"}, {"groupId": "OG001", "value": "67"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "23.91", "spread": "1.62"}, {"groupId": "OG001", "value": "14.00", "spread": "1.03"}]}]}]}, {"type": "SECONDARY", "title": "Number of Days to First Posttreatment Menses", "description": "Defined as the number of days from the last dose of study drug until the start date of the first post-treatment menses.", "populationDescription": "Participants who received at least one dose of randomized, double-blind study drug (safety analysis set) with non-missing post-treatment data.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "days", "timeFrame": "From last day of study drug up to 6 weeks after the last dose.", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo orally once a day for 8 weeks during the double-blind treatment period and switched to receive 150 mg elagolix for 16 weeks during the open-label treatment period."}, {"id": "OG001", "title": "Elagolix 150 mg", "description": "Participants received 150 mg elagolix orally once a day for 8 weeks during the double-blind treatment period and continued to receive 150 mg elagolix for 16 additional weeks during the open-label treatment period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "56"}, {"groupId": "OG001", "value": "58"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "22.0", "lowerLimit": "1", "upperLimit": "40"}, {"groupId": "OG001", "value": "25.0", "lowerLimit": "3", "upperLimit": "45"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "From the first dose of any study drug through week 24. The Placebo treatment group includes data for the 8-week double-blind treatment phase. The Elagolix treatment group included data for the total 24-week treatment period for participants initially randomized to elagolix, and 16-week open-label treatment period for participants initially randomized to placebo.", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "Participants received placebo orally once a day for 8 weeks during the double-blind treatment period.", "deathsNumAffected": 0, "deathsNumAtRisk": 69, "seriousNumAffected": 3, "seriousNumAtRisk": 69, "otherNumAffected": 13, "otherNumAtRisk": 69}, {"id": "EG001", "title": "Elagolix", "description": "Participants initially randomized to elagolix received 150 mg elagolix orally once a day for 8 weeks during the double-blind treatment period and continued to receive 150 mg elagolix for 16 additional weeks during the open-label treatment period.\n\nParticipants originally randomized to placebo were switched to receive 150 mg elagolix for 16 weeks during the open-label treatment period.", "deathsNumAffected": 0, "deathsNumAtRisk": 131, "seriousNumAffected": 1, "seriousNumAtRisk": 131, "otherNumAffected": 49, "otherNumAtRisk": 131}], "seriousEvents": [{"term": "ABDOMINAL PAIN LOWER", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (6.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 131}]}, {"term": "CONVULSION", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (6.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 69}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 131}]}, {"term": "ABORTION SPONTANEOUS", "organSystem": "Pregnancy, puerperium and perinatal conditions", "sourceVocabulary": "MedDRA (6.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 69}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 131}]}, {"term": "DEPRESSION SUICIDAL", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (6.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 69}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 131}]}], "otherEvents": [{"term": "NAUSEA", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (6.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 69}, {"groupId": "EG001", "numEvents": 13, "numAffected": 13, "numAtRisk": 131}]}, {"term": "NASOPHARYNGITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (6.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 69}, {"groupId": "EG001", "numEvents": 7, "numAffected": 7, "numAtRisk": 131}]}, {"term": "SINUSITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (6.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 69}, {"groupId": "EG001", "numEvents": 9, "numAffected": 8, "numAtRisk": 131}]}, {"term": "UPPER RESPIRATORY TRACT INFECTION", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (6.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 69}, {"groupId": "EG001", "numEvents": 10, "numAffected": 8, "numAtRisk": 131}]}, {"term": "HEADACHE", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (6.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 69}, {"groupId": "EG001", "numEvents": 20, "numAffected": 13, "numAtRisk": 131}]}, {"term": "HOT FLUSH", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (6.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 69}, {"groupId": "EG001", "numEvents": 13, "numAffected": 13, "numAtRisk": 131}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection."}, "pointOfContact": {"title": "Global Medical Services", "organization": "AbbVie", "phone": "800-633-9110"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04", "removedCountries": ["United States"]}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}, {"id": "D010146", "term": "Pain"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}, {"id": "D009461", "term": "Neurologic Manifestations"}, {"id": "D012816", "term": "Signs and Symptoms"}, {"id": "D013568", "term": "Pathological Conditions, Signs and Symptoms"}]}, "interventionBrowseModule": {"meshes": [{"id": "C539351", "term": "elagolix"}]}}, "hasResults": true}, {"protocolSection": {"identificationModule": {"nctId": "NCT07035522", "orgStudyIdInfo": {"id": "7.499.295"}, "secondaryIdInfos": [{"id": "86719325.4.0000.0177", "type": "OTHER", "domain": "CEP UTFPR"}], "organization": {"fullName": "Universidade Federal do Paraná", "class": "OTHER"}, "briefTitle": "Ozone Therapy for Women With Endometriosis", "officialTitle": "Evaluation of the Effects of Ozone Therapy on Endometriosis"}, "statusModule": {"statusVerifiedDate": "2025-06", "overallStatus": "NOT_YET_RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2025-06-18", "type": "ESTIMATED"}, "primaryCompletionDateStruct": {"date": "2025-12-20", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2025-12-20", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2025-06-02", "studyFirstSubmitQcDate": "2025-06-16", "studyFirstPostDateStruct": {"date": "2025-06-25", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2025-06-16", "lastUpdatePostDateStruct": {"date": "2025-06-25", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Henrique Cunha Carvalho", "investigatorTitle": "Evaluation of the effects of ozone therapy on endometriosis", "investigatorAffiliation": "Universidade Federal do Paraná"}, "leadSponsor": {"name": "Universidade Federal do Paraná", "class": "OTHER"}, "collaborators": [{"name": "Philozon Geradores de Ozonio LTDA", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false, "isUsExport": false}, "descriptionModule": {"briefSummary": "To evaluate the action of ozone therapy as an adjuvant treatment in patients with endometriosis. Secondary Objective: To evaluate the efficacy of ozone therapy for pelvic analgesia in women with endometriosis; To compare the imaging diagnostic techniques of transvaginal ultrasound with infrared thermography in the pre-treatment (before), fourth, seventh and post-treatment (10th session) periods; To evaluate the application of the consolidated questionnaire (EHP-30) in the changes in the quality of life of the participants immediately after the intervention.", "detailedDescription": "Endometriosis is a chronic gynecological condition characterized by the abnormal presence of endometrial glands and stroma outside the uterus, accompanied by chronic inflammation. It is found mainly in girls and women of reproductive age, and according to data from the World Health Organization, it occurs in approximately 10% of women of reproductive age (190 million) worldwide. Effective management of endometriosis requires rapid diagnosis to allow early multidisciplinary intervention that aligns with the patient's needs and priorities. The etiopathogenesis is not yet well established, but evidence indicates that the combination of genetic, hormonal and immunological factors may contribute to the formation and development of ectopic foci of endometriosis. The clinical picture is quite variable. It may be asymptomatic, refer only to infertility or have symptoms such as severe dysmenorrhea, deep dyspareunia, chronic pelvic pain, ovulatory pain, urinary or perimenstrual evacuation symptoms and chronic fatigue. Uncertainty and delays in diagnosis contribute to disturbances in the emotional system, impacting on quality of life. The objective of this research project is to evaluate the effectiveness of ozone therapy and the assessment by means of diagnostic imaging examinations using transvaginal ultrasound and infrared thermography, before, during and after the intervention, aiming at a comparative investigation of possible evidence of the evolution of patients diagnosed with endometriosis who did not respond to conventional treatments, as well as to apply a consolidated questionnaire that assesses changes in the quality of life of the participants after the intervention. This study is part of an experimental research project and will be carried out in a private clinic, Clínica Fernanda Ferraz - Fisioterapia Integrativa LTDA. The clinic is located at Travessa João Turin, 37, room 603 - Água Verde, Curitiba-PR. The target population of this study will be composed of women between the ages of 25 and 45, with a diagnosis based on a report of endometriosis (all stages will be treated). A convenience sample will be used, recruited through advertisements on social networks. A total of 40 participants will be selected for the study, divided equally into two groups: Group A (ozone therapy) and Group B (control group - conventional clinical treatment). This study will contribute to a deeper understanding of the effects of ozone therapy on endometriosis. It is expected that a statistically significant analysis will be observed that will highlight important differences in imaging in transvaginal ultrasound and thermographic examinations, as well as in symptoms and quality of life. Based on the literature review and the biochemical properties of both techniques (ozone therapy and clinical approach), it is likely that one of the approaches will demonstrate a statistically superior advantage over the other. In addition, the research aims to investigate whether the quality of life of the participants will improve, and in some cases, with potential positive results on infertility."}, "conditionsModule": {"conditions": ["Endometriosis", "Ozone Therapy", "Thermography"], "keywords": ["ozone", "ozone therapy", "ultrasound", "thermography"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 40, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Ozone therapy on endometriosis", "type": "EXPERIMENTAL", "description": "The participants will undergo anamnesis, including clinical and epidemiological aspects for this research, including the capture of thermographic images. The participants will have previously undergone the transvaginal ultrasound examination; These participants will undergo 10 sessions, within the pre-established protocol with ozone. The selected participants will be allocated into two groups: Group A (ozone therapy) and Group B (control group - conventional treatment). Each group will consist of 20 participants. - Group A (Ozone Therapy): The participants in this group will undergo ozone therapy sessions, according to the established protocol, and will receive treatment in the pelvic cavity with an initial injection of ozonated water, followed by an injection of ozone gas. The application of ozone will be done according to standardized and referenced techniques. - Group B (Clinical treatment): The participants in this group will be monitored to compare the results.", "interventionNames": ["Other: Ozone therapy"]}], "interventions": [{"type": "OTHER", "name": "Ozone therapy", "description": "The study also aims to analyze the efficacy of ozone therapy in participants affected by endometriosis, enriching the knowledge base in the field of women's health/gynecology. The expected results will contribute to improving current therapeutic approaches, informing clinical decisions and encouraging future research. Understanding the technique and its clinical applicability will help health professionals to offer personalized and effective treatments. In addition, the insights obtained can direct new investigations, such as the optimization of protocols or the exploration of innovative therapeutic combinations for even more satisfactory results. Based on the literature review and the biochemical properties of both techniques (ozone therapy and clinical approach), it may be possible that one of the approaches demonstrates a statistically superior advantage over the other. In addition, the research aims to investigate whether the quality of life of these participants will improve and i", "armGroupLabels": ["Ozone therapy on endometriosis"], "otherNames": ["thermography", "ultrasound"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "EHP-30 - Endometriosis Health Profile Questionnaire", "description": "The EHP-30 (Endometriosis Health Profile-30) is a disease-specific, patient-reported outcome measure designed to assess the health-related quality of life (HRQoL) in individuals with endometriosis on various aspects, including physical, emotional, and social well-being.", "timeFrame": "EHP-30 will be applied at pre (baseline), through study completion, an average of 2 months."}], "secondaryOutcomes": [{"measure": "Thermographic images", "description": "Thermography, a non-invasive imaging technique that detects infrared radiation to map skin surface temperature, will be applied as a tool to assess the physiological response to ozone therapy in endometriosis. Ozone therapy, known for its anti-inflammatory and analgesic properties, may influence local blood flow and immune activity. Thermographic imaging allows visualization of these changes by capturing temperature variations in the abdominal or pelvic regions before (baseline), during (4 and 7th session) and after treatment (10th session). In endometriosis, affected areas often exhibit thermal asymmetry or increased heat due to inflammation. Post-ozone therapy, thermography can reveal reductions in localized hyperthermia, suggesting decreased inflammation and improved circulation. This method provides a visual, quantifiable means to monitor treatment response over time, offering a complementary assessment tool alongside symptom tracking.", "timeFrame": "Infra-red images will be captured at pre (baseline), through study completion, an average of 2 months."}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Women with a clinical diagnosis of endometriosis (ultrasonography / transvaginal exam)\n* 25-45 years old\n\nExclusion Criteria:\n\n* Pregnancy\n* G6PD positive\n* Addicted\n* HIV and hepatitis positive\n* Cancer\n* Anticoagulant sensitive\n* Endometrial surgery history", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "25 Years", "maximumAge": "45 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Fernanda Luiza Ferraz, Physiotherapist / Therapist", "role": "CONTACT", "phone": "55 41 99971-1737", "email": "fernandaferraz88@gmail.com"}], "overallOfficials": [{"name": "Henrique Cunha Carvalho, PhD. Dr.", "affiliation": "UTFPR", "role": "STUDY_CHAIR"}], "locations": [{"facility": "Clínica Fernanda Ferraz - Fisioterapia Integrativa LTDA", "city": "Curitiba", "state": "Paraná", "zip": "80240-100", "country": "Brazil", "contacts": [{"name": "Fernanda Luiza Ferraz, Physiotherapist / Therapist", "role": "CONTACT", "phone": "55 41 999711737", "email": "fernandaferraz88@gmail.com"}], "geoPoint": {"lat": -25.42778, "lon": -49.27306}}]}, "referencesModule": {"references": [{"pmid": "36242631", "type": "BACKGROUND", "citation": "Pires MV, de Lima CJ, Carvalho HC, Moreira LH, Fernandes AB. Effectiveness of intravesical ozone in interstitial cystitis by the O'Leary-Sant symptom index. Int Urogynecol J. 2023 Jul;34(7):1437-1446. doi: 10.1007/s00192-022-05383-3. Epub 2022 Oct 15."}, {"pmid": "30257358", "type": "BACKGROUND", "citation": "Wei A, Feng H, Jia XM, Tang H, Liao YY, Li BR. Ozone therapy ameliorates inflammation and endometrial injury in rats with pelvic inflammatory disease. Biomed Pharmacother. 2018 Nov;107:1418-1425. doi: 10.1016/j.biopha.2018.07.137. Epub 2018 Sep 1."}, {"pmid": "31249259", "type": "BACKGROUND", "citation": "Merhi Z, Garg B, Moseley-LaRue R, Moseley AR, Smith AH, Zhang J. Ozone therapy: a potential therapeutic adjunct for improving female reproductive health. Med Gas Res. 2019 Apr-Jun;9(2):101-105. doi: 10.4103/2045-9912.260652."}, {"pmid": "18672121", "type": "BACKGROUND", "citation": "Gupta S, Goldberg JM, Aziz N, Goldberg E, Krajcir N, Agarwal A. Pathogenic mechanisms in endometriosis-associated infertility. Fertil Steril. 2008 Aug;90(2):247-57. doi: 10.1016/j.fertnstert.2008.02.093."}, {"pmid": "9341595", "type": "BACKGROUND", "citation": "Nisolle M, Donnez J. Peritoneal endometriosis, ovarian endometriosis, and adenomyotic nodules of the rectovaginal septum are three different entities. Fertil Steril. 1997 Oct;68(4):585-96. doi: 10.1016/s0015-0282(97)00191-x."}, {"pmid": "16256378", "type": "BACKGROUND", "citation": "Wright CI, Kroner CI, Draijer R. Non-invasive methods and stimuli for evaluating the skin's microcirculation. J Pharmacol Toxicol Methods. 2006 Jul-Aug;54(1):1-25. doi: 10.1016/j.vascn.2005.09.004. Epub 2005 Oct 25."}, {"pmid": "31951524", "type": "BACKGROUND", "citation": "Horne AW, Saunders PTK. SnapShot: Endometriosis. Cell. 2019 Dec 12;179(7):1677-1677.e1. doi: 10.1016/j.cell.2019.11.033. Epub 2019 Dec 12."}, {"pmid": "28189296", "type": "BACKGROUND", "citation": "Ahn SH, Singh V, Tayade C. Biomarkers in endometriosis: challenges and opportunities. Fertil Steril. 2017 Mar;107(3):523-532. doi: 10.1016/j.fertnstert.2017.01.009. Epub 2017 Feb 8."}, {"pmid": "34638893", "type": "BACKGROUND", "citation": "Smolarz B, Szyllo K, Romanowicz H. Endometriosis: Epidemiology, Classification, Pathogenesis, Treatment and Genetics (Review of Literature). Int J Mol Sci. 2021 Sep 29;22(19):10554. doi: 10.3390/ijms221910554."}, {"pmid": "34048704", "type": "BACKGROUND", "citation": "Saunders PTK, Horne AW. Endometriosis: Etiology, pathobiology, and therapeutic prospects. Cell. 2021 May 27;184(11):2807-2824. doi: 10.1016/j.cell.2021.04.041."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO", "description": "Ethical or Consent Restrictions: Participants may not have given explicit consent for their data to be shared beyond the original study.\n\nLegal or Institutional Policies: Data sharing may be restricted by Brazillian laws."}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D013817", "term": "Thermography"}, {"id": "D019220", "term": "High-Energy Shock Waves"}], "ancestors": [{"id": "D003952", "term": "Diagnostic Imaging"}, {"id": "D019937", "term": "Diagnostic Techniques and Procedures"}, {"id": "D003933", "term": "Diagnosis"}, {"id": "D062125", "term": "Thermometry"}, {"id": "D008919", "term": "Investigative Techniques"}, {"id": "D000069453", "term": "Ultrasonic Waves"}, {"id": "D013016", "term": "Sound"}, {"id": "D011840", "term": "Radiation, Nonionizing"}, {"id": "D011827", "term": "Radiation"}, {"id": "D055585", "term": "Physical Phenomena"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT00109512", "orgStudyIdInfo": {"id": "NBI-56418-0501"}, "organization": {"fullName": "Abbott", "class": "INDUSTRY"}, "briefTitle": "Endometriosis Trial: Study of NBI-56418 in Endometriosis", "officialTitle": "A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of NBI-56418 in Endometriosis"}, "statusModule": {"statusVerifiedDate": "2012-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2005-04"}, "primaryCompletionDateStruct": {"date": "2006-06", "type": "ACTUAL"}, "completionDateStruct": {"date": "2006-06", "type": "ACTUAL"}, "studyFirstSubmitDate": "2005-04-28", "studyFirstSubmitQcDate": "2005-04-28", "studyFirstPostDateStruct": {"date": "2005-04-29", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2012-02-21", "lastUpdatePostDateStruct": {"date": "2012-02-22", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "Sponsor"}, "leadSponsor": {"name": "Abbott", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "This is a Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study with subjects randomized to one of three treatment groups, placebo, 75 mg and 150 mg in a 1:1:1 ratio. Study drug was administered once daily for 12 weeks. After the last dose at the end of Week 12, follow-up continued every 4 weeks for 12 weeks."}, "conditionsModule": {"conditions": ["Endometriosis"], "keywords": ["endometriosis", "pelvic pain", "painful periods", "dysmenorrhea", "painful menstruation", "GnRH", "agonist", "antagonist", "menstrual pain"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 76, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "placebo", "type": "PLACEBO_COMPARATOR", "interventionNames": ["Drug: placebo"]}, {"label": "NBI-56418 75 mg", "type": "EXPERIMENTAL", "interventionNames": ["Drug: NBI-56418 (GnRH antagonist)"]}, {"label": "NBI-56418 150 mg", "type": "EXPERIMENTAL", "interventionNames": ["Drug: NBI-56418 (GnRH antagonist)"]}], "interventions": [{"type": "DRUG", "name": "NBI-56418 (GnRH antagonist)", "armGroupLabels": ["NBI-56418 150 mg", "NBI-56418 75 mg"]}, {"type": "DRUG", "name": "placebo", "armGroupLabels": ["placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Total Composite Pelvic Signs and Symptom Scale (CPSSS) scores", "description": "This scale is used to assess the signs (pelvic tenderness and induration) and symptoms (nonmenstrual pelvic pain, dysmenorrhea and dyspareunia) associated with endometriosis.", "timeFrame": "Every 4 weeks"}], "secondaryOutcomes": [{"measure": "Endometriosis Health Profile-5 (EHP-5)", "description": "The EHP-5 assesses quality of life.", "timeFrame": "Every 4 weeks"}, {"measure": "Visual Analog Scale (VAS) scores", "description": "VAS measures endometriosis pain.", "timeFrame": "Every 4 weeks"}, {"measure": "Number of Subjects with Adverse Events", "timeFrame": "Up to 24 weeks"}, {"measure": "Clinical Laboratory Tests", "timeFrame": "Up to 24 weeks"}, {"measure": "Vital Sign Measurements", "timeFrame": "Up to 24 weeks"}, {"measure": "Physical Examinations", "timeFrame": "Up to 24 weeks"}, {"measure": "Electrocardiogram (ECG) tracings", "timeFrame": "Up to 24 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria\n\n* Be female, aged 18 to 49 years, inclusive.\n* Have pelvic pain and dysmenorrhea resulting in a Composite Pelvic Sign and Symptoms Score (CPSSS) of ≥ 6.\n* Have had a diagnosis of endometriosis made following laparoscopic visualization of the disease within the last 5 years of the start of screening.\n* Have regular menstrual cycles (28 days ±5 days) for greater than or equal to 2 years. For the cycle that immediately precedes dosing, cycle length will be determined as part of the medical history.\n* Have a Body Mass Index between 18 and 30 kg/m2.\n* Agree to use two forms of non-hormonal contraception (unless sterilized by tubal ligation) for greater than or equal to 3 months prior to Screening through ovulation and return of menses after treatment.\n* Have a negative serum pregnancy test at Screening and a negative urine pregnancy test at prior to dosing at the beginning of Week 1.\n* Have a cervical smear negative for malignancy at Screening.\n* Be willing to comply with all study procedures and restrictions.\n* Be able to read, understand, and sign the ICF (informed consent form) before entering into the study.\n* Be willing to provide authorization for access to personal health information in conjunction with US Health Insurance Portability and Accountability Act (HIPAA).\n\nExclusion Criteria\n\n* Are currently receiving a GnRH agonist or GnRH antagonist, or have received any of these agents within 6 months of Screening.\n* Have been nonresponsive to GnRH agonist or antagonist therapy for the management of endometriosis.\n* Are currently receiving hormonal therapy including the oral contraceptive pill or have received any of these agents within 3 months of Screening.\n* Are on any concurrent medical treatment/medications or have had surgical or hormonal treatment other than oral contraceptives for endometriosis within 3 months of Screening.\n* Have uterine fibroids or any other pelvic lesions greater than or equal to 3 cm in diameter as verified by ultrasound.\n* Are currently breast-feeding an infant.\n* Are using any steroid preparation, taken by any route (e.g., oral, inhaled) on a chronic or regular basis within 3 months of Screening.\n* Have an unstable medical condition or chronic disease (including history of neurological \\[including cognitive\\], hepatic, renal, cardiovascular, gastrointestinal, pulmonary, or endocrine disease), or malignancy that could confound interpretation of the study outcomes.\n* Have chronic pelvic pain that is not caused by endometriosis.\n* Have any psychological disorder according to criteria indicated in the Diagnostics and Statistical Manual of Mental Disorders, 4th edition within one year before screening. Such disorders include, but are not limited to, alcohol and substance abuse/dependence.\n* Have a history of poor compliance in clinical research studies.\n* Have a medically significant illness in the 30 days before the beginning of Week 1.\n* Have a medically significant abnormality observed upon Screening or the beginning of Week 1 physical examination, or in any other baseline measurement. Findings outside the standard reference ranges will be jointly approved with NBI's (Neurocrine Biosciences) Medical Monitor before being considered eligible for the study.\n* Are using any investigational drug within 2 months of Screening.\n* Have a positive human immunodeficiency virus antibody (HIV Ab), hepatitis B surface antigen (HBsAg), or hepatitis C virus antibody (HCV-Ab) assay at Screening or have a history of a positive result.\n* Have an allergy, hypersensitivity, or intolerance to a GnRH agonist or antagonist.", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "49 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Laura Williams, MD", "affiliation": "Abbott", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Site Reference ID/Investigator# 56266", "city": "Phoenix", "state": "Arizona", "zip": "85032", "country": "United States", "geoPoint": {"lat": 33.44838, "lon": -112.07404}}, {"facility": "Site Reference ID/Investigator# 55210", "city": "San Diego", "state": "California", "zip": "92103", "country": "United States", "geoPoint": {"lat": 32.71571, "lon": -117.16472}}, {"facility": "Site Reference ID/Investigator# 55214", "city": "San Ramon", "state": "California", "zip": "94566", "country": "United States", "geoPoint": {"lat": 37.77993, "lon": -121.97802}}, {"facility": "Site Reference ID/Investigator# 56267", "city": "Clearwater", "state": "Florida", "zip": "33759", "country": "United States", "geoPoint": {"lat": 27.96585, "lon": -82.8001}}, {"facility": "Site Reference ID/Investigator# 56270", "city": "Champaign", "state": "Illinois", "zip": "61820", "country": "United States", "geoPoint": {"lat": 40.11642, "lon": -88.24338}}, {"facility": "Site Reference ID/Investigator# 56273", "city": "Chicago", "state": "Illinois", "zip": "60612", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Site Reference ID/Investigator# 56269", "city": "Oak Brook", "state": "Illinois", "zip": "60523", "country": "United States", "geoPoint": {"lat": 41.83281, "lon": -87.92895}}, {"facility": "Site Reference ID/Investigator# 56271", "city": "Peoria", "state": "Illinois", "zip": "61615", "country": "United States", "geoPoint": {"lat": 40.69365, "lon": -89.58899}}, {"facility": "Site Reference ID/Investigator# 56272", "city": "Louisville", "state": "Kentucky", "zip": "40291", "country": "United States", "geoPoint": {"lat": 38.25424, "lon": -85.75941}}, {"facility": "Site Reference ID/Investigator# 55213", "city": "Winston-Salem", "state": "North Carolina", "zip": "27103", "country": "United States", "geoPoint": {"lat": 36.09986, "lon": -80.24422}}, {"facility": "Site Reference ID/Investigator# 55211", "city": "Arlington", "state": "Texas", "zip": "76012", "country": "United States", "geoPoint": {"lat": 32.73569, "lon": -97.10807}}, {"facility": "Site Reference ID/Investigator# 56268", "city": "Sandy City", "state": "Utah", "zip": "84070", "country": "United States", "geoPoint": {"lat": 40.59161, "lon": -111.8841}}, {"facility": "Site Reference ID/Investigator# 56274", "city": "Richmond", "state": "Virginia", "zip": "23294", "country": "United States", "geoPoint": {"lat": 37.55376, "lon": -77.46026}}, {"facility": "Site Reference ID/Investigator# 55212", "city": "Virginia Beach", "state": "Virginia", "zip": "23451", "country": "United States", "geoPoint": {"lat": 36.85293, "lon": -75.97799}}, {"facility": "Site Reference ID/Investigator# 56275", "city": "Spokane", "state": "Washington", "zip": "99204", "country": "United States", "geoPoint": {"lat": 47.65966, "lon": -117.42908}}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}, {"id": "D017699", "term": "Pelvic Pain"}, {"id": "D004412", "term": "Dysmenorrhea"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}, {"id": "D010146", "term": "Pain"}, {"id": "D009461", "term": "Neurologic Manifestations"}, {"id": "D012816", "term": "Signs and Symptoms"}, {"id": "D013568", "term": "Pathological Conditions, Signs and Symptoms"}, {"id": "D008599", "term": "Menstruation Disturbances"}, {"id": "D010335", "term": "Pathologic Processes"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT03749109", "orgStudyIdInfo": {"id": "000295"}, "organization": {"fullName": "Ferring Pharmaceuticals", "class": "INDUSTRY"}, "briefTitle": "Quinagolide Vaginal Ring on Lesion Reduction Assessed by MRI in Women With Endometriosis/Adenomyosis", "officialTitle": "A Randomised, Double-blind, Placebo-controlled, Proof-of-mechanism Phase 2 Trial Investigating the Effect of Quinagolide Extended-release Vaginal Ring on Reduction of Lesions Assessed by High-resolution Magnetic Resonance Imaging in Women With Endometrioma, Deep Infiltrating Endometriosis, and/or Adenomyosis", "acronym": "QLARITY"}, "statusModule": {"statusVerifiedDate": "2023-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2019-08-19", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2021-06-21", "type": "ACTUAL"}, "completionDateStruct": {"date": "2021-07-18", "type": "ACTUAL"}, "studyFirstSubmitDate": "2018-11-19", "studyFirstSubmitQcDate": "2018-11-19", "studyFirstPostDateStruct": {"date": "2018-11-21", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2022-06-21", "resultsFirstSubmitQcDate": "2022-08-15", "resultsFirstPostDateStruct": {"date": "2022-09-07", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-08-04", "lastUpdatePostDateStruct": {"date": "2023-08-07", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Ferring Pharmaceuticals", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "This will be a randomized, double-blind, placebo-controlled, proof-of-mechanism phase 2 trial investigating the effect of quinagolide extended-release vaginal ring on reduction of lesions assessed by high-resolution magnetic resonance imaging in women with endometrioma, deep infiltrating endometriosis, and/or adenomyosis."}, "conditionsModule": {"conditions": ["Endometriosis"], "keywords": ["Endometrioma", "Adenomyosis", "Deep infiltrating endometriosis"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 67, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Quinagolide 1080 µg", "type": "EXPERIMENTAL", "description": "Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.", "interventionNames": ["Drug: Quinagolide 1080 µg"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Vaginal ring containing matching placebo", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Quinagolide 1080 µg", "description": "Vaginal ring containing Quinagolide 1080 µg for daily releases", "armGroupLabels": ["Quinagolide 1080 µg"], "otherNames": ["FE 999051"]}, {"type": "DRUG", "name": "Placebo", "description": "Matching placebo", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Changes in the Sizes (mm) of Endometrioma, Deep Infiltrating Endometriosis (DIE) and Adenomyosis Lesions Summed by Type on Magnetic Resonance (MR) Images at Cycle 4", "description": "The MRI examination was performed on a high resolution 3T machine at screening and at end-of-treatment / cycle 4.\n\nAt screening, every measurable lesion (defined as ≥10 mm in size) of any type was recorded and was summed up by type for primary analysis.", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)"}], "secondaryOutcomes": [{"measure": "Percentage of Changes in the Sizes of Endometrioma, DIE and Adenomyosis Lesions Summed by Type on MR Images at Cycle 4", "description": "The MRI examination was performed on a high resolution 3T machine at screening and at end-of-treatment / cycle 4.", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)"}, {"measure": "Proportion of Lesions by Type With a Decrease in a Size of ≥5 mm on MR Images at Cycle 4", "description": "The MRI examination was performed on a high resolution 3T machine at screening and at end-of-treatment / cycle 4.", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)"}, {"measure": "Proportion of Subjects With a Lesion of Any Type Decreased in a Size of ≥5 mm on MR Images at Cycle 4", "description": "The MRI examination was performed on a high resolution 3T machine at screening and at end-of-treatment / cycle 4.", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)"}, {"measure": "Number of New or Disappearing Endometrioma, DIE and Adenomyosis Lesions Summed by Type on MR Images at Cycle 4", "description": "The MRI examination was performed on a high resolution 3T machine at screening and at end-of-treatment / cycle 4.", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)"}, {"measure": "Changes in the Volumes (mm3) of Endometrioma and DIE Lesions Summed by Type on MR Images at Cycle 4", "description": "The MRI examination was performed on a high resolution 3T machine at screening and at end-of-treatment / cycle 4.", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)"}, {"measure": "Changes in the Sizes of Endometrioma Assessed by Transvaginal Ultrasound (TVU) at Cycle 4", "description": "Transvaginal ultrasound (TVU) will be performed, preferably by the same sonographer, at the screening visit and at end-of-treatment / cycle 4.", "timeFrame": "At baseline and at menstrual cycle 4 (around 4 months, each cycle is approximately 28 days)"}, {"measure": "Changes in the Mean Individual and Total Symptom and Sign Severity of Scores of the Biberoglu and Behrman (B&B) Scale at Cycle 4", "description": "B\\&B scale is a used scale for endometriosis that consists of two parts, with the first part evaluating symptoms (i.e. different types of pain) and the second part evaluating physical signs.\n\nIn the first part, the subject was asked to grade her pelvic pain (item A), dysmenorrhea (item B) and dyspareunia (item C) during the last menstrual cycle as none, mild, moderate or severe, corresponding to a score of 0-3.\n\nIn the second part, the investigator graded the subject's pelvic tenderness (item D) and induration (item E) based on findings from a pelvic examination as none, mild, moderate or severe, corresponding to a score of 0-3.\n\nThe total symptom and sign severity score was the sum of all five scores, i.e. A+B+C+D+E.\n\nThe score can be between 0 and 15.", "timeFrame": "At baseline and at menstrual cycle 4 (around 4 months, each cycle is approximately 28 days)"}, {"measure": "Changes in the Numerical Rating Scale (NRS) Pain Scores Per Cycle at Cycles 1, 2, 3 and 4", "description": "Assessed by Subjects. NRS is a 11-point scale, with 0 indicating no pain and 10 indicating the worst imaginable pain.\n\nSubjects were asked to score the worst pain in relation to endometriosis / adenomyosis on the NRS based on a recall of their experiences during the following timeframes:\n\n* during the last menstrual cycle\n* during the menstrual period of the last menstrual cycle\n* during the non-menstrual period of the last menstrual cycle", "timeFrame": "At baseline and at menstrual cycles 1 (~1 month), 2 (~2 months), 3 (~3 months) and 4 (~4 months)"}, {"measure": "Changes in the Endometriosis Health Profile-30 (EHP-30) Scores at Cycles 2 and 4", "description": "EHP-30 is a quality-of-life questionnaire. Score ranges from 0-100 and lower score denotes improvement.\n\nIt consists of 30 questions measuring the frequency of the endometriosis impact on their quality of life during the past four weeks, with five options of never, rarely, sometimes, often and always.", "timeFrame": "At baseline, at menstrual cycles 2 (~2 months) and 4 (~4 months)"}, {"measure": "Changes in the Menstrual Bleeding Pattern Over 4 Cycles (Menstrual Cycle Duration)", "description": "Assessed by subject self-reported answers to menstrual bleeding questions. The Menstrual Cycle Duration is shown.", "timeFrame": "At baseline and at menstrual cycles 1 (~1 month), 2 (~2 months), 3 (~3 months) and 4 (~4 months)"}, {"measure": "Changes in the Menstrual Bleeding Pattern Over 4 Cycles (Menstrual Bleeding Duration)", "description": "Assessed by subject self-reported answers to menstrual bleeding questions. The Menstrual Bleeding Duration is shown.", "timeFrame": "At baseline and at menstrual cycles 1 (~1 month), 2 (~2 months), 3 (~3 months) and 4 (~4 months)"}, {"measure": "Serum Levels of Prolactin During Cycle 1, at Cycles 2 and 4", "description": "Assessed by blood sample collection", "timeFrame": "Within 1-5 days post randomization, and at menstrual cycles 2 (~2 months) and 4 (~4 months)"}, {"measure": "Serum Levels of Thyroid-stimulating Hormone (TSH) During Cycle 1, at Cycles 2 and 4", "description": "Assessed by blood sample collection", "timeFrame": "Within 1-5 days post randomization, and at menstrual cycles 2 (~2 months) and 4 (~4 months)"}, {"measure": "Serum Levels of Insulin-like Growth Factor-1 (IGF-1) During Cycle 1, at Cycles 2 and 4", "description": "Assessed by blood sample collection", "timeFrame": "Within 1-5 days post randomization, and at menstrual cycles 2 (~2 months) and 4 (~4 months)"}, {"measure": "Plasma Concentrations of Quinagolide and Its Metabolites During Cycles 1 to 4", "description": "Assessed by blood sample collection", "timeFrame": "Within 1-5 days post randomization, within 7-14 days post randomization, and at menstrual cycles 1 (~1 month), 2 (~2 months), 3 (~3 months) and 4 (~4 months)"}, {"measure": "Changes in Clinical Chemistry and Hematology Parameters: Hematocrit", "description": "Assessed by blood sample collection", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)"}, {"measure": "Changes in Clinical Chemistry and Hematology Parameters: Hemaglobin", "description": "Assessed by blood sample collection", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)"}, {"measure": "Changes in Clinical Chemistry and Hematology Parameters: Ery. Mean Corpuscular Hemoglobin", "description": "Assessed by blood sample collection", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)"}, {"measure": "Changes in Clinical Chemistry and Hematology Parameters: Ery. Mean Corpuscular HGB Concentration", "description": "Assessed by blood sample collection", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)"}, {"measure": "Changes in Clinical Chemistry and Hematology Parameters: Ery. Mean Corpuscular Volume", "description": "Assessed by blood sample collection", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)"}, {"measure": "Changes in Clinical Chemistry and Hematology Parameters: Platelets", "description": "Assessed by blood sample collection", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)"}, {"measure": "Changes in Clinical Chemistry and Hematology Parameters: Erythrocytes", "description": "Assessed by blood sample collection", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)"}, {"measure": "Changes in Clinical Chemistry and Hematology Parameters: Leukocytes", "description": "Assessed by blood sample collection", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)"}, {"measure": "Changes in Clinical Chemistry and Hematology Parameters: Alanine Aminotransferase", "description": "Assessed by blood sample collection", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)"}, {"measure": "Changes in Clinical Chemistry and Hematology Parameters: Albumin", "description": "Assessed by blood sample collection", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)"}, {"measure": "Changes in Clinical Chemistry and Hematology Parameters: Alkaline Phosphatase", "description": "Assessed by blood sample collection", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)"}, {"measure": "Changes in Clinical Chemistry and Hematology Parameters: Aspartate Aminotransferase", "description": "Assessed by blood sample collection", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)"}, {"measure": "Changes in Clinical Chemistry and Hematology Parameters: Bicarbonate", "description": "Assessed by blood sample collection", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)"}, {"measure": "Changes in Clinical Chemistry and Hematology Parameters: Direct Bilirubin", "description": "Assessed by blood sample collection", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)"}, {"measure": "Changes in Clinical Chemistry and Hematology Parameters: Bilirubin", "description": "Assessed by blood sample collection", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)"}, {"measure": "Changes in Clinical Chemistry and Hematology Parameters: Calcium", "description": "Assessed by blood sample collection", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)"}, {"measure": "Changes in Clinical Chemistry and Hematology Parameters: Chloride", "description": "Assessed by blood sample collection", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)"}, {"measure": "Changes in Clinical Chemistry and Hematology Parameters: Cholesterol", "description": "Assessed by blood sample collection", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)"}, {"measure": "Changes in Clinical Chemistry and Hematology Parameters: Creatinine", "description": "Assessed by blood sample collection", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)"}, {"measure": "Changes in Clinical Chemistry and Hematology Parameters: Gamma Glutamyl Transferase", "description": "Assessed by blood sample collection", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)"}, {"measure": "Changes in Clinical Chemistry and Hematology Parameters: Glucose", "description": "Assessed by blood sample collection", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)"}, {"measure": "Changes in Clinical Chemistry and Hematology Parameters: Lactate Dehydrogenase", "description": "Assessed by blood sample collection", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)"}, {"measure": "Changes in Clinical Chemistry and Hematology Parameters: Phosphate", "description": "Assessed by blood sample collection", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)"}, {"measure": "Changes in Clinical Chemistry and Hematology Parameters: Potassium", "description": "Assessed by blood sample collection", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)"}, {"measure": "Changes in Clinical Chemistry and Hematology Parameters: Sodium", "description": "Assessed by blood sample collection", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)"}, {"measure": "Changes in Clinical Chemistry and Hematology Parameters: Protein", "description": "Assessed by blood sample collection", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)"}, {"measure": "Changes in Clinical Chemistry and Hematology Parameters: Urate", "description": "Assessed by blood sample collection", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)"}, {"measure": "Changes in Clinical Chemistry and Hematology Parameters: Urea Nitrogen", "description": "Assessed by blood sample collection", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)"}, {"measure": "Proportion of Subjects With Markedly Abnormal Changes in Clinical Chemistry and Hematology Parameters", "description": "Assessed by blood sample collection", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)"}, {"measure": "Frequency and Intensity of Adverse Events", "description": "Assessed by and Adverse Event Log completed by the Investigator", "timeFrame": "From obtaining the informed consent to end of trial (up to 6 menstrual cycles ~ around 6 months, each cycle is approximately 28 days)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Pre-menopausal women between the ages 18-45 years (both inclusive) at the time of signing the informed consent\n2. Body mass index (BMI) of 18-35 kg/m2 (both inclusive) at screening\n3. Confirmation of deep infiltrating endometriosis (DIE), endometrioma or adenomyosis by high-resolution MRI at screening\n4. Transvaginal ultrasound (TVU) documenting a uterus with no abnormalities of endometrium and presence of at least one ovary with no clinically significant abnormalities at screening. Note that presence of uterine fibroids are not exclusionary but presence of any submucosal fibroids or polyps are exclusionary\n5. Willing and able to use a non-hormonal single-barrier method (i.e. condom) for contraception from the start of screening to the end-of-treatment. This is not required if adequate contraception is achieved by vasectomy of the male sexual partner, surgical sterilisation (e.g. tubal ligation and blockage methods such as ESSURE) of the subject, or true abstinence of the subject (sporadic sexual intercourse with men requiring condom use)\n6. Willing to avoid the use of vaginal douches or any other intravaginally administered medications or devices (except for tampons) from randomization to the end of treatment\n\nExclusion Criteria:\n\n1. Use of depot medroxyprogesterone acetate (MPA) within 10 months prior to the screening visit.\n2. Use of gonadotropin-releasing (GnRH) agonists (3-month depot) or dopamine agonists within 6 months prior to the screening visit.\n3. Use of GnRH agonists (1-month depot or nasal spray), GnRH antagonists, aromatase inhibitors, danazol, birth control implants (e.g. NEXPLANON), progestogen or levonorgestrel releasing intrauterine device (IUD) within 3 months prior to the screening visit.\n4. Use of hormonal contraceptives (including combined oral contraceptive pill, transdermal patch, and contraceptive ring) within 1 menstrual cycle prior to the screening visit.\n5. Contraindications to MRI such as having internal/external metallic devices and/or accessories (e.g. cardiac pacemakers and leg braces)", "healthyVolunteers": false, "sex": "FEMALE", "genderBased": true, "minimumAge": "18 Years", "maximumAge": "45 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Global Clinical Compliance", "affiliation": "Ferring Pharmaceuticals", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Gyneacology Rigshospitalet", "city": "Copenhagen", "country": "Denmark", "geoPoint": {"lat": 55.67594, "lon": 12.56553}}, {"facility": "Charité Universitätsmedizin", "city": "Berlin", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Universitätsklinikum Carl Gustav Carus", "city": "Dresden", "country": "Germany", "geoPoint": {"lat": 51.05089, "lon": 13.73832}}, {"facility": "Universitätsklinikum Münster", "city": "Münster", "country": "Germany", "geoPoint": {"lat": 51.96236, "lon": 7.62571}}, {"facility": "Azienda Opsedaliera Universitaria Careggi", "city": "Florence", "country": "Italy", "geoPoint": {"lat": 43.77925, "lon": 11.24626}}, {"facility": "Università degli Studi di Roma La Sapienza", "city": "Rome", "country": "Italy", "geoPoint": {"lat": 41.89193, "lon": 12.51133}}, {"facility": "Azienda Ospedaliera Universitaria Senese", "city": "Siena", "country": "Italy", "geoPoint": {"lat": 43.31822, "lon": 11.33064}}, {"facility": "Azienda Ospedaliera Universitaria Integrata Verona", "city": "Verona", "country": "Italy", "geoPoint": {"lat": 45.43854, "lon": 10.9938}}, {"facility": "Centrum Medyczne PROMED", "city": "Krakow", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"facility": "Gabinet Lekarski Specjalistyczny SONUS", "city": "Warsaw", "country": "Poland", "geoPoint": {"lat": 52.22977, "lon": 21.01178}}, {"facility": "Specjalistyczny Gabinet Lekarski", "city": "Warsaw", "country": "Poland", "geoPoint": {"lat": 52.22977, "lon": 21.01178}}]}, "referencesModule": {"references": [{"pmid": "40188683", "type": "DERIVED", "citation": "Pellicer A, Taylor HS, Alberich-Bayarri A, Liu Y, Gamborg M, Barletta KE, Pinton P, Heiser PW, Bagger YZ. Quinagolide vaginal ring for reduction of endometriotic lesions: Results from the QLARITY trial. Eur J Obstet Gynecol Reprod Biol. 2025 Jun;310:113946. doi: 10.1016/j.ejogrb.2025.113946. Epub 2025 Mar 30."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "In total, 147 subjects were screened. Of these, 80 were screening failures and 67 were randomized and exposed to the investigational medicinal product (IMP): 35 to Quinagolide and 32 to Placebo.", "recruitmentDetails": "The trial was performed in 6 investigational sites in 3 countries between Aug 2019 to Jul 2021.", "groups": [{"id": "FG000", "title": "Quinagolide 1080 µg", "description": "Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.\n\nQuinagolide 1080 µg: Vaginal ring containing Quinagolide 1080 µg for daily releases"}, {"id": "FG001", "title": "Placebo", "description": "Vaginal ring containing matching placebo\n\nPlacebo: Matching placebo"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "35"}, {"groupId": "FG001", "numSubjects": "32"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "33"}, {"groupId": "FG001", "numSubjects": "32"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Quinagolide 1080 µg", "description": "Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.\n\nQuinagolide 1080 µg: Vaginal ring containing Quinagolide 1080 µg for daily releases"}, {"id": "BG001", "title": "Placebo", "description": "Vaginal ring containing matching placebo\n\nPlacebo: Matching placebo"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "35"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "67"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "35"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "67"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "36.9", "spread": "5.51"}, {"groupId": "BG001", "value": "35.2", "spread": "5.96"}, {"groupId": "BG002", "value": "36.1", "spread": "5.75"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "35"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "67"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "35"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "67"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "34"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "66"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Body Mass Index (BMI)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "23.91", "spread": "3.86"}, {"groupId": "BG001", "value": "23.30", "spread": "4.15"}, {"groupId": "BG002", "value": "23.62", "spread": "3.98"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Changes in the Sizes (mm) of Endometrioma, Deep Infiltrating Endometriosis (DIE) and Adenomyosis Lesions Summed by Type on Magnetic Resonance (MR) Images at Cycle 4", "description": "The MRI examination was performed on a high resolution 3T machine at screening and at end-of-treatment / cycle 4.\n\nAt screening, every measurable lesion (defined as ≥10 mm in size) of any type was recorded and was summed up by type for primary analysis.", "populationDescription": "All analyses for primary and secondary efficacy endpoints are presented by lesion type. This means one subject can be included in multiple lesion groups, depending on the type of lesion(s) with a size of ≥10 mm present at baseline. Thus, the FAS population by lesion type includes 47 subjects in the endometrioma group, 45 subjects in the DIE group, and 36 subjects in the adenomyosis group. The primary and secondary efficacy results are presented for these subjects unless otherwise specified.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)", "groups": [{"id": "OG000", "title": "Quinagolide 1080 µg", "description": "Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.\n\nQuinagolide 1080 µg: Vaginal ring containing Quinagolide 1080 µg for daily releases"}, {"id": "OG001", "title": "Placebo", "description": "Vaginal ring containing matching placebo\n\nPlacebo: Matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"title": "Endometrioma", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "22"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.20", "spread": "4.34"}, {"groupId": "OG001", "value": "-1.94", "spread": "4.48"}]}]}, {"title": "DIE", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "26"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.41", "spread": "2.52"}, {"groupId": "OG001", "value": "-0.94", "spread": "2.03"}]}]}, {"title": "Adenomyosis", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "16"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.10", "spread": "3.75"}, {"groupId": "OG001", "value": "-3.43", "spread": "3.87"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Endometrioma", "nonInferiorityType": "OTHER", "pValue": "0.78", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA adjusted for baseline lesion size.", "paramType": "Difference in LS mean", "paramValue": "1.74", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-10.45", "ciUpperLimit": "13.94"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "DIE", "nonInferiorityType": "OTHER", "pValue": "0.29", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA adjusted for baseline lesion size.", "paramType": "Difference in LS mean", "paramValue": "3.35", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.89", "ciUpperLimit": "9.59"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Adenomyosis", "nonInferiorityType": "OTHER", "pValue": "0.95", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA adjusted for baseline lesion size.", "paramType": "Difference in LS mean", "paramValue": "0.33", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-10.33", "ciUpperLimit": "10.99"}]}, {"type": "SECONDARY", "title": "Percentage of Changes in the Sizes of Endometrioma, DIE and Adenomyosis Lesions Summed by Type on MR Images at Cycle 4", "description": "The MRI examination was performed on a high resolution 3T machine at screening and at end-of-treatment / cycle 4.", "populationDescription": "All analyses for primary and secondary efficacy endpoints are presented by lesion type. This means one subject can be included in multiple lesion groups, depending on the type of lesion(s) with a size of ≥10 mm present at baseline. Thus, the FAS population by lesion type includes 47 subjects in the endometrioma group, 45 subjects in the DIE group, and 36 subjects in the adenomyosis group. The primary and secondary efficacy results are presented for these subjects unless otherwise specified.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage of changes in the size", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)", "groups": [{"id": "OG000", "title": "Quinagolide 1080 µg", "description": "Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.\n\nQuinagolide 1080 µg: Vaginal ring containing Quinagolide 1080 µg for daily releases"}, {"id": "OG001", "title": "Placebo", "description": "Vaginal ring containing matching placebo\n\nPlacebo: Matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"title": "Endometrioma", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "21"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "15.64", "spread": "70.12"}, {"groupId": "OG001", "value": "-6.83", "spread": "44.46"}]}]}, {"title": "DIE", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "25"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "7.67", "spread": "15.22"}, {"groupId": "OG001", "value": "5.81", "spread": "37.73"}]}]}, {"title": "Adenomyosis", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "16"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.04", "spread": "32.31"}, {"groupId": "OG001", "value": "-6.99", "spread": "25.48"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Endometrioma", "nonInferiorityType": "OTHER", "pValue": "0.65", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA adjusted for baseline lesion size.", "paramType": "Difference in LS mean", "paramValue": "-6.99", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-36.80", "ciUpperLimit": "22.82"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "DIE", "nonInferiorityType": "OTHER", "pValue": "0.92", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA adjusted for baseline lesion size.", "paramType": "Difference in LS mean", "paramValue": "-1.13", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-22.77", "ciUpperLimit": "20.51"}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "0.74", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA adjusted for baseline lesion size.", "paramType": "Difference in LS mean", "paramValue": "-5.92", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-40.94", "ciUpperLimit": "29.10"}]}, {"type": "SECONDARY", "title": "Proportion of Lesions by Type With a Decrease in a Size of ≥5 mm on MR Images at Cycle 4", "description": "The MRI examination was performed on a high resolution 3T machine at screening and at end-of-treatment / cycle 4.", "populationDescription": "All analyses for primary and secondary efficacy endpoints are presented by lesion type. This means one subject can be included in multiple lesion groups, depending on the type of lesion(s) with a size of ≥10 mm present at baseline. Thus, the FAS population by lesion type includes 47 subjects in the endometrioma group, 45 subjects in the DIE group, and 36 subjects in the adenomyosis group. The primary and secondary efficacy results are presented for these subjects unless otherwise specified.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of lesions", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)", "typeUnitsAnalyzed": "Lesions", "denomUnitsSelected": "Lesions", "groups": [{"id": "OG000", "title": "Quinagolide 1080 µg", "description": "Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.\n\nQuinagolide 1080 µg: Vaginal ring containing Quinagolide 1080 µg for daily releases"}, {"id": "OG001", "title": "Placebo", "description": "Vaginal ring containing matching placebo\n\nPlacebo: Matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "32"}]}, {"units": "Lesions", "counts": [{"groupId": "OG000", "value": "112"}, {"groupId": "OG001", "value": "108"}]}], "classes": [{"title": "Endometrioma", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "32"}]}, {"units": "Lesions", "counts": [{"groupId": "OG000", "value": "53"}, {"groupId": "OG001", "value": "46"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "18.9"}, {"groupId": "OG001", "value": "21.7"}]}]}, {"title": "DIE", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "32"}]}, {"units": "Lesions", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "33"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "12.1"}]}]}, {"title": "Adenomyosis", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "32"}]}, {"units": "Lesions", "counts": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "29"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "12.1"}, {"groupId": "OG001", "value": "24.1"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Endometrioma", "nonInferiorityType": "OTHER", "pValue": "0.95", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "1.04", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.38", "ciUpperLimit": "2.82"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Adenomyosis", "nonInferiorityType": "OTHER", "pValue": "0.39", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "0.55", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.14", "ciUpperLimit": "2.17"}]}, {"type": "SECONDARY", "title": "Proportion of Subjects With a Lesion of Any Type Decreased in a Size of ≥5 mm on MR Images at Cycle 4", "description": "The MRI examination was performed on a high resolution 3T machine at screening and at end-of-treatment / cycle 4.", "populationDescription": "All analyses for primary and secondary efficacy endpoints are presented by lesion type. This means one subject can be included in multiple lesion groups, depending on the type of lesion(s) with a size of ≥10 mm present at baseline. Thus, the FAS population by lesion type includes 47 subjects in the endometrioma group, 45 subjects in the DIE group, and 36 subjects in the adenomyosis group. The primary and secondary efficacy results are presented for these subjects unless otherwise specified.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of subjects", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)", "groups": [{"id": "OG000", "title": "Quinagolide 1080 µg", "description": "Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.\n\nQuinagolide 1080 µg: Vaginal ring containing Quinagolide 1080 µg for daily releases"}, {"id": "OG001", "title": "Placebo", "description": "Vaginal ring containing matching placebo\n\nPlacebo: Matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"title": "Endometrioma", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "22"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "24.0"}, {"groupId": "OG001", "value": "31.8"}]}]}, {"title": "DIE", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "26"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "11.5"}]}]}, {"title": "Adenomyosis", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "16"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "15.0"}, {"groupId": "OG001", "value": "37.5"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Endometrioma", "nonInferiorityType": "OTHER", "pValue": "0.60", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "0.70", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.19", "ciUpperLimit": "2.65"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Adenomyosis", "nonInferiorityType": "OTHER", "pValue": "0.21", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "0.35", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.07", "ciUpperLimit": "1.79"}]}, {"type": "SECONDARY", "title": "Number of New or Disappearing Endometrioma, DIE and Adenomyosis Lesions Summed by Type on MR Images at Cycle 4", "description": "The MRI examination was performed on a high resolution 3T machine at screening and at end-of-treatment / cycle 4.", "populationDescription": "All analyses for primary and secondary efficacy endpoints are presented by lesion type. This means one subject can be included in multiple lesion groups, depending on the type of lesion(s) with a size of ≥10 mm present at baseline. Thus, the FAS population by lesion type includes 47 subjects in the endometrioma group, 45 subjects in the DIE group, and 36 subjects in the adenomyosis group. The primary and secondary efficacy results are presented for these subjects unless otherwise specified.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Lesions", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)", "groups": [{"id": "OG000", "title": "Quinagolide 1080 µg", "description": "Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.\n\nQuinagolide 1080 µg: Vaginal ring containing Quinagolide 1080 µg for daily releases"}, {"id": "OG001", "title": "Placebo", "description": "Vaginal ring containing matching placebo\n\nPlacebo: Matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"title": "Endometrioma - Disappearing Lesions", "categories": [{"measurements": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "5"}]}]}, {"title": "DIE - Disappearing Lesions", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Adenomyosis - Disappearing Lesions", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "Endometrioma - New Lesions", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "3"}]}]}, {"title": "DIE - New Lesions", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Adenomyosis - New Lesions", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Endometrioma - Disappearing Lesions", "nonInferiorityType": "OTHER", "pValue": "0.13", "statisticalMethod": "Negative-binomial regression", "paramType": "Rate Ratio", "paramValue": "2.53", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.76", "ciUpperLimit": "8.39"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Adenomyosis - Disappearing Lesions", "nonInferiorityType": "OTHER", "pValue": "0.56", "statisticalMethod": "Negative-binomial regression", "paramType": "Rate Ratio", "paramValue": "0.49", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.04", "ciUpperLimit": "5.41"}]}, {"type": "SECONDARY", "title": "Changes in the Volumes (mm3) of Endometrioma and DIE Lesions Summed by Type on MR Images at Cycle 4", "description": "The MRI examination was performed on a high resolution 3T machine at screening and at end-of-treatment / cycle 4.", "populationDescription": "All analyses for primary and secondary efficacy endpoints are presented by lesion type. This means one subject can be included in multiple lesion groups, depending on the type of lesion(s) with a size of ≥10 mm present at baseline. Thus, the FAS population by lesion type includes 47 subjects in the endometrioma group, and 45 subjects in the DIE group. The primary and secondary efficacy results are presented for these subjects unless otherwise specified.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm^3", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)", "groups": [{"id": "OG000", "title": "Quinagolide 1080 µg", "description": "Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.\n\nQuinagolide 1080 µg: Vaginal ring containing Quinagolide 1080 µg for daily releases"}, {"id": "OG001", "title": "Placebo", "description": "Vaginal ring containing matching placebo\n\nPlacebo: Matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"title": "Endometrioma", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "22"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.12", "spread": "4.62"}, {"groupId": "OG001", "value": "1.89", "spread": "4.77"}]}]}, {"title": "DIE", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "26"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.15", "spread": "1.81"}, {"groupId": "OG001", "value": "-0.87", "spread": "1.25"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Endometrioma", "nonInferiorityType": "OTHER", "pValue": "0.97", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA adjusted for baseline lesion size.", "paramType": "Difference in LS mean", "paramValue": "0.23", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-12.78", "ciUpperLimit": "13.23"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "DIE", "nonInferiorityType": "OTHER", "pValue": "0.74", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA adjusted for baseline lesion size.", "paramType": "Difference in LS mean", "paramValue": "0.72", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.63", "ciUpperLimit": "5.07"}]}, {"type": "SECONDARY", "title": "Changes in the Sizes of Endometrioma Assessed by Transvaginal Ultrasound (TVU) at Cycle 4", "description": "Transvaginal ultrasound (TVU) will be performed, preferably by the same sonographer, at the screening visit and at end-of-treatment / cycle 4.", "populationDescription": "Subjects analyzed for this endpoint represent subjects who were evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm", "timeFrame": "At baseline and at menstrual cycle 4 (around 4 months, each cycle is approximately 28 days)", "groups": [{"id": "OG000", "title": "Quinagolide 1080 µg", "description": "Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.\n\nQuinagolide 1080 µg: Vaginal ring containing Quinagolide 1080 µg for daily releases"}, {"id": "OG001", "title": "Placebo", "description": "Vaginal ring containing matching placebo\n\nPlacebo: Matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "17"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "14.19", "spread": "8.70"}, {"groupId": "OG001", "value": "4.06", "spread": "9.02"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "0.42", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA adjusted for baseline lesion size.", "paramType": "Difference in LS mean", "paramValue": "10.13", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-14.74", "ciUpperLimit": "35.00"}]}, {"type": "SECONDARY", "title": "Changes in the Mean Individual and Total Symptom and Sign Severity of Scores of the Biberoglu and Behrman (B&B) Scale at Cycle 4", "description": "B\\&B scale is a used scale for endometriosis that consists of two parts, with the first part evaluating symptoms (i.e. different types of pain) and the second part evaluating physical signs.\n\nIn the first part, the subject was asked to grade her pelvic pain (item A), dysmenorrhea (item B) and dyspareunia (item C) during the last menstrual cycle as none, mild, moderate or severe, corresponding to a score of 0-3.\n\nIn the second part, the investigator graded the subject's pelvic tenderness (item D) and induration (item E) based on findings from a pelvic examination as none, mild, moderate or severe, corresponding to a score of 0-3.\n\nThe total symptom and sign severity score was the sum of all five scores, i.e. A+B+C+D+E.\n\nThe score can be between 0 and 15.", "populationDescription": "All analyses for primary and secondary efficacy endpoints are presented by lesion type. This means one subject can be included in multiple lesion groups, depending on the type of lesion(s) with a size of ≥10 mm present at baseline. Thus, the FAS population by lesion type includes 47 subjects in the endometrioma group, 45 subjects in the DIE group, and 36 subjects in the adenomyosis group. The primary and secondary efficacy results are presented for these subjects unless otherwise specified.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "At baseline and at menstrual cycle 4 (around 4 months, each cycle is approximately 28 days)", "groups": [{"id": "OG000", "title": "Quinagolide 1080 µg", "description": "Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.\n\nQuinagolide 1080 µg: Vaginal ring containing Quinagolide 1080 µg for daily releases"}, {"id": "OG001", "title": "Placebo", "description": "Vaginal ring containing matching placebo\n\nPlacebo: Matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"title": "Endometrioma", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "22"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.2", "spread": "2.26"}, {"groupId": "OG001", "value": "-2.1", "spread": "2.51"}]}]}, {"title": "DIE", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "26"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.3", "spread": "2.16"}, {"groupId": "OG001", "value": "-1.6", "spread": "2.21"}]}]}, {"title": "Adenomyosis", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "16"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.5", "spread": "2.33"}, {"groupId": "OG001", "value": "-1.9", "spread": "1.86"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Endometrioma", "nonInferiorityType": "OTHER", "pValue": "0.10", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA adjusted for baseline lesion size.", "paramType": "Difference in LS mean", "paramValue": "1.09", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.20", "ciUpperLimit": "2.38"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "DIE", "nonInferiorityType": "OTHER", "pValue": "0.67", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA adjusted for baseline lesion size.", "paramType": "Difference in LS mean", "paramValue": "0.28", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.02", "ciUpperLimit": "1.58"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Adenomyosis", "nonInferiorityType": "OTHER", "pValue": "0.64", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA adjusted for baseline lesion size.", "paramType": "Difference in LS mean", "paramValue": "0.32", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.06", "ciUpperLimit": "1.71"}]}, {"type": "SECONDARY", "title": "Changes in the Numerical Rating Scale (NRS) Pain Scores Per Cycle at Cycles 1, 2, 3 and 4", "description": "Assessed by Subjects. NRS is a 11-point scale, with 0 indicating no pain and 10 indicating the worst imaginable pain.\n\nSubjects were asked to score the worst pain in relation to endometriosis / adenomyosis on the NRS based on a recall of their experiences during the following timeframes:\n\n* during the last menstrual cycle\n* during the menstrual period of the last menstrual cycle\n* during the non-menstrual period of the last menstrual cycle", "populationDescription": "All analyses for primary and secondary efficacy endpoints are presented by lesion type. This means one subject can be included in multiple lesion groups, depending on the type of lesion(s) with a size of ≥10 mm present at baseline. Thus, the FAS population by lesion type includes 47 subjects in the endometrioma group, 45 subjects in the DIE group, and 36 subjects in the adenomyosis group. The primary and secondary efficacy results are presented for these subjects unless otherwise specified.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "At baseline and at menstrual cycles 1 (~1 month), 2 (~2 months), 3 (~3 months) and 4 (~4 months)", "groups": [{"id": "OG000", "title": "Quinagolide 1080 µg", "description": "Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.\n\nQuinagolide 1080 µg: Vaginal ring containing Quinagolide 1080 µg for daily releases"}, {"id": "OG001", "title": "Placebo", "description": "Vaginal ring containing matching placebo\n\nPlacebo: Matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"title": "Endometrioma at cycle 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "22"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.5", "spread": "1.96"}, {"groupId": "OG001", "value": "-0.7", "spread": "2.21"}]}]}, {"title": "Endometrioma at cycle 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "22"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.9", "spread": "2.17"}, {"groupId": "OG001", "value": "-1.1", "spread": "2.85"}]}]}, {"title": "Endometrioma at cycle 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "22"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.7", "spread": "2.73"}, {"groupId": "OG001", "value": "-1.1", "spread": "1.67"}]}]}, {"title": "Endometrioma at cycle 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "22"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.5", "spread": "3.11"}, {"groupId": "OG001", "value": "-2.0", "spread": "1.94"}]}]}, {"title": "DIE at cycle 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "26"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.6", "spread": "2.14"}, {"groupId": "OG001", "value": "-0.7", "spread": "2.19"}]}]}, {"title": "DIE at cycle 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "26"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.1", "spread": "2.20"}, {"groupId": "OG001", "value": "-1.4", "spread": "2.97"}]}]}, {"title": "DIE at cycle 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "26"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.7", "spread": "2.65"}, {"groupId": "OG001", "value": "-1.0", "spread": "1.97"}]}]}, {"title": "DIE at cycle 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "26"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.2", "spread": "2.27"}, {"groupId": "OG001", "value": "-2.1", "spread": "2.21"}]}]}, {"title": "Adenomyosis at cycle 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "16"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.3", "spread": "1.84"}, {"groupId": "OG001", "value": "-0.7", "spread": "2.24"}]}]}, {"title": "Adenomyosis at cycle 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "16"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.7", "spread": "2.37"}, {"groupId": "OG001", "value": "-0.9", "spread": "2.13"}]}]}, {"title": "Adenomyosis at cycle 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "16"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.8", "spread": "2.34"}, {"groupId": "OG001", "value": "-0.9", "spread": "1.78"}]}]}, {"title": "Adenomyosis at cycle 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "16"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.6", "spread": "2.91"}, {"groupId": "OG001", "value": "-1.9", "spread": "2.28"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Endometrioma at cycle 1", "nonInferiorityType": "OTHER", "pValue": "0.73", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA adjusted for baseline lesion size.", "paramType": "Difference in LS mean", "paramValue": "0.21", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.02", "ciUpperLimit": "1.44"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Endometrioma at cycle 2", "nonInferiorityType": "OTHER", "pValue": "0.54", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA adjusted for baseline lesion size.", "paramType": "Difference in LS mean", "paramValue": "0.42", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.97", "ciUpperLimit": "1.82"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Endometrioma at cycle 3", "nonInferiorityType": "OTHER", "pValue": "0.46", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA adjusted for baseline lesion size.", "paramType": "Difference in LS mean", "paramValue": "-0.50", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.86", "ciUpperLimit": "0.85"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Endometrioma at cycle 4", "nonInferiorityType": "OTHER", "pValue": "0.49", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA adjusted for baseline lesion size.", "paramType": "Difference in LS mean", "paramValue": "0.53", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.99", "ciUpperLimit": "2.05"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "DIE at cycle 1", "nonInferiorityType": "OTHER", "pValue": "0.99", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA adjusted for baseline lesion size.", "paramType": "Difference in LS mean", "paramValue": "-0.01", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.32", "ciUpperLimit": "1.30"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "DIE at cycle 2", "nonInferiorityType": "OTHER", "pValue": "0.83", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA adjusted for baseline lesion size.", "paramType": "Difference in LS mean", "paramValue": "0.17", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.38", "ciUpperLimit": "1.71"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "DIE at cycle 3", "nonInferiorityType": "OTHER", "pValue": "0.28", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA adjusted for baseline lesion size.", "paramType": "Difference in LS mean", "paramValue": "-0.74", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.11", "ciUpperLimit": "0.63"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "DIE at cycle 4", "nonInferiorityType": "OTHER", "pValue": "0.26", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA adjusted for baseline lesion size.", "paramType": "Difference in LS mean", "paramValue": "0.75", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.57", "ciUpperLimit": "2.07"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Adenomyosis at cycle 1", "nonInferiorityType": "OTHER", "pValue": "0.19", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA adjusted for baseline lesion size.", "paramType": "Difference in LS mean", "paramValue": "0.91", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.49", "ciUpperLimit": "2.31"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Adenomyosis at cycle 2", "nonInferiorityType": "OTHER", "pValue": "0.93", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA adjusted for baseline lesion size.", "paramType": "Difference in LS mean", "paramValue": "0.07", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.45", "ciUpperLimit": "1.58"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Adenomyosis at cycle 3", "nonInferiorityType": "OTHER", "pValue": "0.85", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA adjusted for baseline lesion size.", "paramType": "Difference in LS mean", "paramValue": "-0.13", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.58", "ciUpperLimit": "1.32"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Adenomyosis at cycle 4", "nonInferiorityType": "OTHER", "pValue": "0.99", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA adjusted for baseline lesion size.", "paramType": "Difference in LS mean", "paramValue": "0.01", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.68", "ciUpperLimit": "1.69"}]}, {"type": "SECONDARY", "title": "Changes in the Endometriosis Health Profile-30 (EHP-30) Scores at Cycles 2 and 4", "description": "EHP-30 is a quality-of-life questionnaire. Score ranges from 0-100 and lower score denotes improvement.\n\nIt consists of 30 questions measuring the frequency of the endometriosis impact on their quality of life during the past four weeks, with five options of never, rarely, sometimes, often and always.", "populationDescription": "All analyses for primary and secondary efficacy endpoints are presented by lesion type. This means one subject can be included in multiple lesion groups, depending on the type of lesion(s) with a size of ≥10 mm present at baseline. Thus, the FAS population by lesion type includes 47 subjects in the endometrioma group, 45 subjects in the DIE group, and 36 subjects in the adenomyosis group. The primary and secondary efficacy results are presented for these subjects unless otherwise specified.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Score on a scale", "timeFrame": "At baseline, at menstrual cycles 2 (~2 months) and 4 (~4 months)", "groups": [{"id": "OG000", "title": "Quinagolide 1080 µg", "description": "Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.\n\nQuinagolide 1080 µg: Vaginal ring containing Quinagolide 1080 µg for daily releases"}, {"id": "OG001", "title": "Placebo", "description": "Vaginal ring containing matching placebo\n\nPlacebo: Matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"title": "Endometrioma at cycle 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "22"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-46.6", "spread": "90.49"}, {"groupId": "OG001", "value": "-51.0", "spread": "71.60"}]}]}, {"title": "Endometrioma at cycle 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "22"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-56.6", "spread": "88.84"}, {"groupId": "OG001", "value": "-94.0", "spread": "85.14"}]}]}, {"title": "DIE at cycle 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "26"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-55.6", "spread": "91.14"}, {"groupId": "OG001", "value": "-41.7", "spread": "86.27"}]}]}, {"title": "DIE at cycle 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "26"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-54.8", "spread": "87.29"}, {"groupId": "OG001", "value": "-85.7", "spread": "98.96"}]}]}, {"title": "Adenomyosis at cycle 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "16"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-46.3", "spread": "102.92"}, {"groupId": "OG001", "value": "-33.2", "spread": "52.21"}]}]}, {"title": "Adenomyosis at cycle 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "16"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-64.9", "spread": "105.62"}, {"groupId": "OG001", "value": "-79.4", "spread": "90.04"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Endometrioma at cycle 2", "nonInferiorityType": "OTHER", "pValue": "0.75", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA adjusted for baseline lesion size.", "paramType": "Difference in LS mean", "paramValue": "-7.35", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-53.97", "ciUpperLimit": "39.27"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Endometrioma at cycle 4", "nonInferiorityType": "OTHER", "pValue": "0.42", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA adjusted for baseline lesion size.", "paramType": "Difference in LS mean", "paramValue": "17.31", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-25.41", "ciUpperLimit": "60.04"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "DIE at cycle 2", "nonInferiorityType": "OTHER", "pValue": "0.47", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA adjusted for baseline lesion size.", "paramType": "Difference in LS mean", "paramValue": "-17.66", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-66.30", "ciUpperLimit": "30.98"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "DIE at cycle 4", "nonInferiorityType": "OTHER", "pValue": "0.27", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA adjusted for baseline lesion size.", "paramType": "Difference in LS mean", "paramValue": "25.61", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-21.05", "ciUpperLimit": "72.27"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Adenomyosis at cycle 2", "nonInferiorityType": "OTHER", "pValue": "0.41", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA adjusted for baseline lesion size.", "paramType": "Difference in LS mean", "paramValue": "-20.95", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-71.83", "ciUpperLimit": "29.92"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Adenomyosis at cycle 4", "nonInferiorityType": "OTHER", "pValue": "0.93", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA adjusted for baseline lesion size.", "paramType": "Difference in LS mean", "paramValue": "2.25", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-49.57", "ciUpperLimit": "54.06"}]}, {"type": "SECONDARY", "title": "Changes in the Menstrual Bleeding Pattern Over 4 Cycles (Menstrual Cycle Duration)", "description": "Assessed by subject self-reported answers to menstrual bleeding questions. The Menstrual Cycle Duration is shown.", "populationDescription": "All analyses for primary and secondary efficacy endpoints are presented by lesion type. This means one subject can be included in multiple lesion groups, depending on the type of lesion(s) with a size of ≥10 mm present at baseline. Thus, the FAS population by lesion type includes 47 subjects in the endometrioma group, 45 subjects in the DIE group, and 36 subjects in the adenomyosis group. The primary and secondary efficacy results are presented for these subjects unless otherwise specified.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Days", "timeFrame": "At baseline and at menstrual cycles 1 (~1 month), 2 (~2 months), 3 (~3 months) and 4 (~4 months)", "groups": [{"id": "OG000", "title": "Quinagolide 1080 µg", "description": "Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.\n\nQuinagolide 1080 µg: Vaginal ring containing Quinagolide 1080 µg for daily releases"}, {"id": "OG001", "title": "Placebo", "description": "Vaginal ring containing matching placebo\n\nPlacebo: Matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"title": "Endometrioma at baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "22"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "31.9", "spread": "10.54"}, {"groupId": "OG001", "value": "32.6", "spread": "10.38"}]}]}, {"title": "Endometrioma at cycle 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "22"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "27.8", "spread": "2.92"}, {"groupId": "OG001", "value": "26.9", "spread": "2.39"}]}]}, {"title": "Endometrioma at cycle 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "22"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "28.1", "spread": "2.13"}, {"groupId": "OG001", "value": "27.4", "spread": "2.50"}]}]}, {"title": "Endometrioma at cycle 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "23"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "27.7", "spread": "2.12"}, {"groupId": "OG001", "value": "28.3", "spread": "2.65"}]}]}, {"title": "Endometrioma at cycle 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "23"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "28.2", "spread": "3.27"}, {"groupId": "OG001", "value": "26.9", "spread": "2.23"}]}]}, {"title": "DIE at baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "26"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "33.2", "spread": "11.80"}, {"groupId": "OG001", "value": "31.4", "spread": "9.45"}]}]}, {"title": "DIE at cycle 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "26"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "26.7", "spread": "2.66"}, {"groupId": "OG001", "value": "27.3", "spread": "2.78"}]}]}, {"title": "DIE at cycle 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "26"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "27.4", "spread": "1.98"}, {"groupId": "OG001", "value": "27.7", "spread": "2.52"}]}]}, {"title": "DIE at cycle 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "27"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "28.2", "spread": "2.86"}, {"groupId": "OG001", "value": "28.5", "spread": "2.29"}]}]}, {"title": "DIE at cycle 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "26"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "26.9", "spread": "2.23"}, {"groupId": "OG001", "value": "27.7", "spread": "2.59"}]}]}, {"title": "Adenomyosis at baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "16"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "33.5", "spread": "11.16"}, {"groupId": "OG001", "value": "32.4", "spread": "11.49"}]}]}, {"title": "Adenomyosis at cycle 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "16"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "27.7", "spread": "2.54"}, {"groupId": "OG001", "value": "26.8", "spread": "2.61"}]}]}, {"title": "Adenomyosis at cycle 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "16"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "28.3", "spread": "2.23"}, {"groupId": "OG001", "value": "27.4", "spread": "2.37"}]}]}, {"title": "Adenomyosis at cycle 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "17"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "27.8", "spread": "2.52"}, {"groupId": "OG001", "value": "27.9", "spread": "1.93"}]}]}, {"title": "Adenomyosis at cycle 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "17"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "27.2", "spread": "1.50"}, {"groupId": "OG001", "value": "27.4", "spread": "1.87"}]}]}]}, {"type": "SECONDARY", "title": "Changes in the Menstrual Bleeding Pattern Over 4 Cycles (Menstrual Bleeding Duration)", "description": "Assessed by subject self-reported answers to menstrual bleeding questions. The Menstrual Bleeding Duration is shown.", "populationDescription": "All analyses for primary and secondary efficacy endpoints are presented by lesion type. This means one subject can be included in multiple lesion groups, depending on the type of lesion(s) with a size of ≥10 mm present at baseline. Thus, the FAS population by lesion type includes 47 subjects in the endometrioma group, 45 subjects in the DIE group, and 36 subjects in the adenomyosis group. The primary and secondary efficacy results are presented for these subjects unless otherwise specified.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Days", "timeFrame": "At baseline and at menstrual cycles 1 (~1 month), 2 (~2 months), 3 (~3 months) and 4 (~4 months)", "groups": [{"id": "OG000", "title": "Quinagolide 1080 µg", "description": "Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.\n\nQuinagolide 1080 µg: Vaginal ring containing Quinagolide 1080 µg for daily releases"}, {"id": "OG001", "title": "Placebo", "description": "Vaginal ring containing matching placebo\n\nPlacebo: Matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"title": "Endometrioma at baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "22"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "5.1", "spread": "1.08"}, {"groupId": "OG001", "value": "5.1", "spread": "0.97"}]}]}, {"title": "Endometrioma at cycle 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "22"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "5.3", "spread": "1.71"}, {"groupId": "OG001", "value": "4.7", "spread": "0.77"}]}]}, {"title": "Endometrioma at cycle 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "22"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "5.3", "spread": "1.22"}, {"groupId": "OG001", "value": "5.1", "spread": "0.87"}]}]}, {"title": "Endometrioma at cycle 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "23"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.5", "spread": "1.61"}, {"groupId": "OG001", "value": "4.8", "spread": "0.89"}]}]}, {"title": "Endometrioma at cycle 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "24"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "5.0", "spread": "1.43"}, {"groupId": "OG001", "value": "4.7", "spread": "1.52"}]}]}, {"title": "DIE at baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "26"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.9", "spread": "0.99"}, {"groupId": "OG001", "value": "5.3", "spread": "1.01"}]}]}, {"title": "DIE at cycle 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "26"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "5.0", "spread": "1.60"}, {"groupId": "OG001", "value": "4.6", "spread": "0.70"}]}]}, {"title": "DIE at cycle 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "26"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "5.0", "spread": "1.82"}, {"groupId": "OG001", "value": "5.0", "spread": "1.04"}]}]}, {"title": "DIE at cycle 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "27"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.5", "spread": "1.22"}, {"groupId": "OG001", "value": "4.9", "spread": "0.93"}]}]}, {"title": "DIE at cycle 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "27"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "5.2", "spread": "1.04"}, {"groupId": "OG001", "value": "4.9", "spread": "1.60"}]}]}, {"title": "Adenomyosis at baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "16"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "5.2", "spread": "1.20"}, {"groupId": "OG001", "value": "5.4", "spread": "1.15"}]}]}, {"title": "Adenomyosis at cycle 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "16"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "5.0", "spread": "1.75"}, {"groupId": "OG001", "value": "4.9", "spread": "0.62"}]}]}, {"title": "Adenomyosis at cycle 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "16"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.6", "spread": "1.78"}, {"groupId": "OG001", "value": "4.8", "spread": "1.17"}]}]}, {"title": "Adenomyosis at cycle 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "17"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.3", "spread": "1.66"}, {"groupId": "OG001", "value": "4.7", "spread": "1.05"}]}]}, {"title": "Adenomyosis at cycle 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "17"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "5.0", "spread": "0.74"}, {"groupId": "OG001", "value": "5.0", "spread": "1.32"}]}]}]}, {"type": "SECONDARY", "title": "Serum Levels of Prolactin During Cycle 1, at Cycles 2 and 4", "description": "Assessed by blood sample collection", "populationDescription": "All analyses for primary and secondary efficacy endpoints are presented by lesion type. This means one subject can be included in multiple lesion groups, depending on the type of lesion(s) with a size of ≥10 mm present at baseline. Thus, the FAS population by lesion type includes 47 subjects in the endometrioma group, 45 subjects in the DIE group, and 36 subjects in the adenomyosis group. The primary and secondary efficacy results are presented for these subjects unless otherwise specified.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg/L", "timeFrame": "Within 1-5 days post randomization, and at menstrual cycles 2 (~2 months) and 4 (~4 months)", "groups": [{"id": "OG000", "title": "Quinagolide 1080 µg", "description": "Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.\n\nQuinagolide 1080 µg: Vaginal ring containing Quinagolide 1080 µg for daily releases"}, {"id": "OG001", "title": "Placebo", "description": "Vaginal ring containing matching placebo\n\nPlacebo: Matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"title": "Endometrioma at cycle 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "21"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "5.51", "spread": "3.604"}, {"groupId": "OG001", "value": "12.68", "spread": "4.618"}]}]}, {"title": "Endometrioma at cycle 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "22"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "9.30", "spread": "4.739"}, {"groupId": "OG001", "value": "12.79", "spread": "4.381"}]}]}, {"title": "Endometrioma at cycle 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "22"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "9.47", "spread": "4.081"}, {"groupId": "OG001", "value": "12.31", "spread": "6.648"}]}]}, {"title": "DIE at cycle 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "25"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "5.95", "spread": "3.258"}, {"groupId": "OG001", "value": "10.80", "spread": "4.201"}]}]}, {"title": "DIE at cycle 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "26"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "10.36", "spread": "5.118"}, {"groupId": "OG001", "value": "11.85", "spread": "5.029"}]}]}, {"title": "DIE at cycle 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "26"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "10.65", "spread": "4.465"}, {"groupId": "OG001", "value": "12.08", "spread": "6.739"}]}]}, {"title": "Adenomyosis at cycle 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "15"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "5.80", "spread": "4.017"}, {"groupId": "OG001", "value": "12.13", "spread": "4.563"}]}]}, {"title": "Adenomyosis at cycle 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "16"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "7.97", "spread": "2.608"}, {"groupId": "OG001", "value": "11.94", "spread": "4.150"}]}]}, {"title": "Adenomyosis at cycle 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "16"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "9.35", "spread": "3.418"}, {"groupId": "OG001", "value": "11.95", "spread": "4.395"}]}]}]}, {"type": "SECONDARY", "title": "Serum Levels of Thyroid-stimulating Hormone (TSH) During Cycle 1, at Cycles 2 and 4", "description": "Assessed by blood sample collection", "populationDescription": "All analyses for primary and secondary efficacy endpoints are presented by lesion type. This means one subject can be included in multiple lesion groups, depending on the type of lesion(s) with a size of ≥10 mm present at baseline. Thus, the FAS population by lesion type includes 47 subjects in the endometrioma group, 45 subjects in the DIE group, and 36 subjects in the adenomyosis group. The primary and secondary efficacy results are presented for these subjects unless otherwise specified.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mIU/L", "timeFrame": "Within 1-5 days post randomization, and at menstrual cycles 2 (~2 months) and 4 (~4 months)", "groups": [{"id": "OG000", "title": "Quinagolide 1080 µg", "description": "Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.\n\nQuinagolide 1080 µg: Vaginal ring containing Quinagolide 1080 µg for daily releases"}, {"id": "OG001", "title": "Placebo", "description": "Vaginal ring containing matching placebo\n\nPlacebo: Matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"title": "Endometrioma at cycle 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "21"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.672", "spread": "1.3376"}, {"groupId": "OG001", "value": "1.513", "spread": "0.6822"}]}]}, {"title": "Endometrioma at cycle 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "22"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.785", "spread": "1.0535"}, {"groupId": "OG001", "value": "1.509", "spread": "0.6746"}]}]}, {"title": "Endometrioma at cycle 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "22"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.692", "spread": "0.9489"}, {"groupId": "OG001", "value": "1.422", "spread": "0.6528"}]}]}, {"title": "DIE at cycle 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "25"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.706", "spread": "1.5550"}, {"groupId": "OG001", "value": "1.394", "spread": "0.8200"}]}]}, {"title": "DIE at cycle 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "26"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.726", "spread": "1.1633"}, {"groupId": "OG001", "value": "1.383", "spread": "0.6903"}]}]}, {"title": "DIE at cycle 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "26"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.375", "spread": "0.8953"}, {"groupId": "OG001", "value": "1.299", "spread": "0.6571"}]}]}, {"title": "Adenomyosis at cycle 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "15"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.067", "spread": "1.8100"}, {"groupId": "OG001", "value": "1.325", "spread": "0.7248"}]}]}, {"title": "Adenomyosis at cycle 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "16"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.722", "spread": "1.1557"}, {"groupId": "OG001", "value": "1.311", "spread": "0.5664"}]}]}, {"title": "Adenomyosis at cycle 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "16"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.801", "spread": "0.9463"}, {"groupId": "OG001", "value": "1.353", "spread": "0.5614"}]}]}]}, {"type": "SECONDARY", "title": "Serum Levels of Insulin-like Growth Factor-1 (IGF-1) During Cycle 1, at Cycles 2 and 4", "description": "Assessed by blood sample collection", "populationDescription": "All analyses for primary and secondary efficacy endpoints are presented by lesion type. This means one subject can be included in multiple lesion groups, depending on the type of lesion(s) with a size of ≥10 mm present at baseline. Thus, the FAS population by lesion type includes 47 subjects in the endometrioma group, 45 subjects in the DIE group, and 36 subjects in the adenomyosis group. The primary and secondary efficacy results are presented for these subjects unless otherwise specified.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "nmol/L", "timeFrame": "Within 1-5 days post randomization, and at menstrual cycles 2 (~2 months) and 4 (~4 months)", "groups": [{"id": "OG000", "title": "Quinagolide 1080 µg", "description": "Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.\n\nQuinagolide 1080 µg: Vaginal ring containing Quinagolide 1080 µg for daily releases"}, {"id": "OG001", "title": "Placebo", "description": "Vaginal ring containing matching placebo\n\nPlacebo: Matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"title": "Endometrioma at cycle 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "21"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "23.90", "spread": "8.002"}, {"groupId": "OG001", "value": "22.96", "spread": "6.721"}]}]}, {"title": "Endometrioma at cycle 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "22"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "19.9", "spread": "6.511"}, {"groupId": "OG001", "value": "21.81", "spread": "5.481"}]}]}, {"title": "Endometrioma at cycle 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "22"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "21.82", "spread": "5.450"}, {"groupId": "OG001", "value": "20.22", "spread": "5.786"}]}]}, {"title": "DIE at cycle 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "25"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "22.16", "spread": "8.099"}, {"groupId": "OG001", "value": "23.68", "spread": "6.135"}]}]}, {"title": "DIE at cycle 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "26"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "18.01", "spread": "5.484"}, {"groupId": "OG001", "value": "21.07", "spread": "6.526"}]}]}, {"title": "DIE at cycle 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "26"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "20.98", "spread": "5.678"}, {"groupId": "OG001", "value": "20.53", "spread": "6.083"}]}]}, {"title": "Adenomyosis at cycle 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "15"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "21.80", "spread": "7.763"}, {"groupId": "OG001", "value": "22.51", "spread": "4.580"}]}]}, {"title": "Adenomyosis at cycle 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "16"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "19.17", "spread": "6.497"}, {"groupId": "OG001", "value": "19.93", "spread": "5.233"}]}]}, {"title": "Adenomyosis at cycle 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "16"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "21.19", "spread": "6.331"}, {"groupId": "OG001", "value": "18.93", "spread": "4.836"}]}]}]}, {"type": "SECONDARY", "title": "Plasma Concentrations of Quinagolide and Its Metabolites During Cycles 1 to 4", "description": "Assessed by blood sample collection", "populationDescription": "Subjects analyzed for this endpoint represent subjects who were evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg/mL", "timeFrame": "Within 1-5 days post randomization, within 7-14 days post randomization, and at menstrual cycles 1 (~1 month), 2 (~2 months), 3 (~3 months) and 4 (~4 months)", "groups": [{"id": "OG000", "title": "Quinagolide 1080 μg", "description": "Vaginal ring containing Quinagolide 1080 μg, with daily target release rate of 13.5 μg.\n\nQuinagolide 1080 μg: Vaginal ring containing Quinagolide 1080 μg for daily releases"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "33"}]}], "classes": [{"title": "Within 1-5 days of randomization", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "30"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "11.66", "spread": "5.23"}]}]}, {"title": "Within 7-14 days of randomization", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "32"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "5.50", "spread": "2.59"}]}]}, {"title": "Cycle 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "32"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.90", "spread": "1.33"}]}]}, {"title": "Cycle 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "33"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.92", "spread": "1.68"}]}]}, {"title": "Cycle 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "32"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.78", "spread": "1.32"}]}]}, {"title": "Cycle 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "32"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.16", "spread": "3.03"}]}]}]}, {"type": "SECONDARY", "title": "Changes in Clinical Chemistry and Hematology Parameters: Hematocrit", "description": "Assessed by blood sample collection", "populationDescription": "Subjects analyzed for this endpoint represent subjects who were evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "% v/v", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)", "groups": [{"id": "OG000", "title": "Quinagolide 1080 µg", "description": "Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.\n\nQuinagolide 1080 µg: Vaginal ring containing Quinagolide 1080 µg for daily releases"}, {"id": "OG001", "title": "Placebo", "description": "Vaginal ring containing matching placebo\n\nPlacebo: Matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.007", "spread": "0.0181"}, {"groupId": "OG001", "value": "-0.005", "spread": "0.0259"}]}]}]}, {"type": "SECONDARY", "title": "Changes in Clinical Chemistry and Hematology Parameters: Hemaglobin", "description": "Assessed by blood sample collection", "populationDescription": "Subjects analyzed for this endpoint represent subjects who were evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "g/L", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)", "groups": [{"id": "OG000", "title": "Quinagolide 1080 µg", "description": "Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.\n\nQuinagolide 1080 µg: Vaginal ring containing Quinagolide 1080 µg for daily releases"}, {"id": "OG001", "title": "Placebo", "description": "Vaginal ring containing matching placebo\n\nPlacebo: Matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "34"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-3.6", "spread": "5.60"}, {"groupId": "OG001", "value": "-3.2", "spread": "8.69"}]}]}]}, {"type": "SECONDARY", "title": "Changes in Clinical Chemistry and Hematology Parameters: Ery. Mean Corpuscular Hemoglobin", "description": "Assessed by blood sample collection", "populationDescription": "Subjects analyzed for this endpoint represent subjects who were evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg/cell", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)", "groups": [{"id": "OG000", "title": "Quinagolide 1080 µg", "description": "Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.\n\nQuinagolide 1080 µg: Vaginal ring containing Quinagolide 1080 µg for daily releases"}, {"id": "OG001", "title": "Placebo", "description": "Vaginal ring containing matching placebo\n\nPlacebo: Matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "34"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.7", "spread": "0.71"}, {"groupId": "OG001", "value": "-0.6", "spread": "1.22"}]}]}]}, {"type": "SECONDARY", "title": "Changes in Clinical Chemistry and Hematology Parameters: Ery. Mean Corpuscular HGB Concentration", "description": "Assessed by blood sample collection", "populationDescription": "Subjects analyzed for this endpoint represent subjects who were evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "g/L", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)", "groups": [{"id": "OG000", "title": "Quinagolide 1080 µg", "description": "Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.\n\nQuinagolide 1080 µg: Vaginal ring containing Quinagolide 1080 µg for daily releases"}, {"id": "OG001", "title": "Placebo", "description": "Vaginal ring containing matching placebo\n\nPlacebo: Matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-3.1", "spread": "7.11"}, {"groupId": "OG001", "value": "-4.3", "spread": "8.76"}]}]}]}, {"type": "SECONDARY", "title": "Changes in Clinical Chemistry and Hematology Parameters: Ery. Mean Corpuscular Volume", "description": "Assessed by blood sample collection", "populationDescription": "Subjects analyzed for this endpoint represent subjects who were evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "fL", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)", "groups": [{"id": "OG000", "title": "Quinagolide 1080 µg", "description": "Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.\n\nQuinagolide 1080 µg: Vaginal ring containing Quinagolide 1080 µg for daily releases"}, {"id": "OG001", "title": "Placebo", "description": "Vaginal ring containing matching placebo\n\nPlacebo: Matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.2", "spread": "2.11"}, {"groupId": "OG001", "value": "-0.7", "spread": "3.10"}]}]}]}, {"type": "SECONDARY", "title": "Changes in Clinical Chemistry and Hematology Parameters: Platelets", "description": "Assessed by blood sample collection", "populationDescription": "Subjects analyzed for this endpoint represent subjects who were evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "10^9 cells/L", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)", "groups": [{"id": "OG000", "title": "Quinagolide 1080 µg", "description": "Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.\n\nQuinagolide 1080 µg: Vaginal ring containing Quinagolide 1080 µg for daily releases"}, {"id": "OG001", "title": "Placebo", "description": "Vaginal ring containing matching placebo\n\nPlacebo: Matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "34"}, {"groupId": "OG001", "value": "31"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4.9", "spread": "33.98"}, {"groupId": "OG001", "value": "11.6", "spread": "45.92"}]}]}]}, {"type": "SECONDARY", "title": "Changes in Clinical Chemistry and Hematology Parameters: Erythrocytes", "description": "Assessed by blood sample collection", "populationDescription": "Subjects analyzed for this endpoint represent subjects who were evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "10^12 cells/L", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)", "groups": [{"id": "OG000", "title": "Quinagolide 1080 µg", "description": "Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.\n\nQuinagolide 1080 µg: Vaginal ring containing Quinagolide 1080 µg for daily releases"}, {"id": "OG001", "title": "Placebo", "description": "Vaginal ring containing matching placebo\n\nPlacebo: Matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "34"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.02", "spread": "0.192"}, {"groupId": "OG001", "value": "-0.01", "spread": "0.228"}]}]}]}, {"type": "SECONDARY", "title": "Changes in Clinical Chemistry and Hematology Parameters: Leukocytes", "description": "Assessed by blood sample collection", "populationDescription": "Subjects analyzed for this endpoint represent subjects who were evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "10^9 cells/L", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)", "groups": [{"id": "OG000", "title": "Quinagolide 1080 µg", "description": "Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.\n\nQuinagolide 1080 µg: Vaginal ring containing Quinagolide 1080 µg for daily releases"}, {"id": "OG001", "title": "Placebo", "description": "Vaginal ring containing matching placebo\n\nPlacebo: Matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "34"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.43", "spread": "1.928"}, {"groupId": "OG001", "value": "0.18", "spread": "2.055"}]}]}]}, {"type": "SECONDARY", "title": "Changes in Clinical Chemistry and Hematology Parameters: Alanine Aminotransferase", "description": "Assessed by blood sample collection", "populationDescription": "Subjects analyzed for this endpoint represent subjects who were evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "U/L", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)", "groups": [{"id": "OG000", "title": "Quinagolide 1080 µg", "description": "Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.\n\nQuinagolide 1080 µg: Vaginal ring containing Quinagolide 1080 µg for daily releases"}, {"id": "OG001", "title": "Placebo", "description": "Vaginal ring containing matching placebo\n\nPlacebo: Matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "31"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.1", "spread": "5.88"}, {"groupId": "OG001", "value": "-0.2", "spread": "3.86"}]}]}]}, {"type": "SECONDARY", "title": "Changes in Clinical Chemistry and Hematology Parameters: Albumin", "description": "Assessed by blood sample collection", "populationDescription": "Subjects analyzed for this endpoint represent subjects who were evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "g/L", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)", "groups": [{"id": "OG000", "title": "Quinagolide 1080 µg", "description": "Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.\n\nQuinagolide 1080 µg: Vaginal ring containing Quinagolide 1080 µg for daily releases"}, {"id": "OG001", "title": "Placebo", "description": "Vaginal ring containing matching placebo\n\nPlacebo: Matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "31"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.0", "spread": "2.28"}, {"groupId": "OG001", "value": "0.7", "spread": "2.84"}]}]}]}, {"type": "SECONDARY", "title": "Changes in Clinical Chemistry and Hematology Parameters: Alkaline Phosphatase", "description": "Assessed by blood sample collection", "populationDescription": "Subjects analyzed for this endpoint represent subjects who were evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "IU/L", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)", "groups": [{"id": "OG000", "title": "Quinagolide 1080 µg", "description": "Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.\n\nQuinagolide 1080 µg: Vaginal ring containing Quinagolide 1080 µg for daily releases"}, {"id": "OG001", "title": "Placebo", "description": "Vaginal ring containing matching placebo\n\nPlacebo: Matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "31"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.1", "spread": "8.18"}, {"groupId": "OG001", "value": "4.2", "spread": "6.67"}]}]}]}, {"type": "SECONDARY", "title": "Changes in Clinical Chemistry and Hematology Parameters: Aspartate Aminotransferase", "description": "Assessed by blood sample collection", "populationDescription": "Subjects analyzed for this endpoint represent subjects who were evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "U/L", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)", "groups": [{"id": "OG000", "title": "Quinagolide 1080 µg", "description": "Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.\n\nQuinagolide 1080 µg: Vaginal ring containing Quinagolide 1080 µg for daily releases"}, {"id": "OG001", "title": "Placebo", "description": "Vaginal ring containing matching placebo\n\nPlacebo: Matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "31"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.0", "spread": "3.72"}, {"groupId": "OG001", "value": "0.5", "spread": "3.43"}]}]}]}, {"type": "SECONDARY", "title": "Changes in Clinical Chemistry and Hematology Parameters: Bicarbonate", "description": "Assessed by blood sample collection", "populationDescription": "Subjects analyzed for this endpoint represent subjects who were evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)", "groups": [{"id": "OG000", "title": "Quinagolide 1080 µg", "description": "Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.\n\nQuinagolide 1080 µg: Vaginal ring containing Quinagolide 1080 µg for daily releases"}, {"id": "OG001", "title": "Placebo", "description": "Vaginal ring containing matching placebo\n\nPlacebo: Matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "31"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-2.7", "spread": "2.59"}, {"groupId": "OG001", "value": "-2.9", "spread": "2.51"}]}]}]}, {"type": "SECONDARY", "title": "Changes in Clinical Chemistry and Hematology Parameters: Direct Bilirubin", "description": "Assessed by blood sample collection", "populationDescription": "Subjects analyzed for this endpoint represent subjects who were evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "umol/L", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)", "groups": [{"id": "OG000", "title": "Quinagolide 1080 µg", "description": "Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.\n\nQuinagolide 1080 µg: Vaginal ring containing Quinagolide 1080 µg for daily releases"}, {"id": "OG001", "title": "Placebo", "description": "Vaginal ring containing matching placebo\n\nPlacebo: Matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "31"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.0", "spread": "0.38"}, {"groupId": "OG001", "value": "0.0", "spread": "1.10"}]}]}]}, {"type": "SECONDARY", "title": "Changes in Clinical Chemistry and Hematology Parameters: Bilirubin", "description": "Assessed by blood sample collection", "populationDescription": "Subjects analyzed for this endpoint represent subjects who were evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "umol/L", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)", "groups": [{"id": "OG000", "title": "Quinagolide 1080 µg", "description": "Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.\n\nQuinagolide 1080 µg: Vaginal ring containing Quinagolide 1080 µg for daily releases"}, {"id": "OG001", "title": "Placebo", "description": "Vaginal ring containing matching placebo\n\nPlacebo: Matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "31"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.2", "spread": "2.84"}, {"groupId": "OG001", "value": "-0.8", "spread": "4.57"}]}]}]}, {"type": "SECONDARY", "title": "Changes in Clinical Chemistry and Hematology Parameters: Calcium", "description": "Assessed by blood sample collection", "populationDescription": "Subjects analyzed for this endpoint represent subjects who were evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)", "groups": [{"id": "OG000", "title": "Quinagolide 1080 µg", "description": "Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.\n\nQuinagolide 1080 µg: Vaginal ring containing Quinagolide 1080 µg for daily releases"}, {"id": "OG001", "title": "Placebo", "description": "Vaginal ring containing matching placebo\n\nPlacebo: Matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "31"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.009", "spread": "0.0896"}, {"groupId": "OG001", "value": "0.012", "spread": "0.0773"}]}]}]}, {"type": "SECONDARY", "title": "Changes in Clinical Chemistry and Hematology Parameters: Chloride", "description": "Assessed by blood sample collection", "populationDescription": "Subjects analyzed for this endpoint represent subjects who were evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)", "groups": [{"id": "OG000", "title": "Quinagolide 1080 µg", "description": "Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.\n\nQuinagolide 1080 µg: Vaginal ring containing Quinagolide 1080 µg for daily releases"}, {"id": "OG001", "title": "Placebo", "description": "Vaginal ring containing matching placebo\n\nPlacebo: Matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "31"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.2", "spread": "2.68"}, {"groupId": "OG001", "value": "-0.5", "spread": "2.49"}]}]}]}, {"type": "SECONDARY", "title": "Changes in Clinical Chemistry and Hematology Parameters: Cholesterol", "description": "Assessed by blood sample collection", "populationDescription": "Subjects analyzed for this endpoint represent subjects who were evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)", "groups": [{"id": "OG000", "title": "Quinagolide 1080 µg", "description": "Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.\n\nQuinagolide 1080 µg: Vaginal ring containing Quinagolide 1080 µg for daily releases"}, {"id": "OG001", "title": "Placebo", "description": "Vaginal ring containing matching placebo\n\nPlacebo: Matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "31"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.045", "spread": "0.5050"}, {"groupId": "OG001", "value": "0.244", "spread": "0.5219"}]}]}]}, {"type": "SECONDARY", "title": "Changes in Clinical Chemistry and Hematology Parameters: Creatinine", "description": "Assessed by blood sample collection", "populationDescription": "Subjects analyzed for this endpoint represent subjects who were evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "umol/L", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)", "groups": [{"id": "OG000", "title": "Quinagolide 1080 µg", "description": "Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.\n\nQuinagolide 1080 µg: Vaginal ring containing Quinagolide 1080 µg for daily releases"}, {"id": "OG001", "title": "Placebo", "description": "Vaginal ring containing matching placebo\n\nPlacebo: Matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "31"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-3.5", "spread": "8.21"}, {"groupId": "OG001", "value": "-4.3", "spread": "7.82"}]}]}]}, {"type": "SECONDARY", "title": "Changes in Clinical Chemistry and Hematology Parameters: Gamma Glutamyl Transferase", "description": "Assessed by blood sample collection", "populationDescription": "Subjects analyzed for this endpoint represent subjects who were evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "U/L", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)", "groups": [{"id": "OG000", "title": "Quinagolide 1080 µg", "description": "Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.\n\nQuinagolide 1080 µg: Vaginal ring containing Quinagolide 1080 µg for daily releases"}, {"id": "OG001", "title": "Placebo", "description": "Vaginal ring containing matching placebo\n\nPlacebo: Matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "31"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.1", "spread": "4.77"}, {"groupId": "OG001", "value": "1.0", "spread": "4.46"}]}]}]}, {"type": "SECONDARY", "title": "Changes in Clinical Chemistry and Hematology Parameters: Glucose", "description": "Assessed by blood sample collection", "populationDescription": "Subjects analyzed for this endpoint represent subjects who were evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)", "groups": [{"id": "OG000", "title": "Quinagolide 1080 µg", "description": "Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.\n\nQuinagolide 1080 µg: Vaginal ring containing Quinagolide 1080 µg for daily releases"}, {"id": "OG001", "title": "Placebo", "description": "Vaginal ring containing matching placebo\n\nPlacebo: Matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "31"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.07", "spread": "0.734"}, {"groupId": "OG001", "value": "-0.06", "spread": "0.866"}]}]}]}, {"type": "SECONDARY", "title": "Changes in Clinical Chemistry and Hematology Parameters: Lactate Dehydrogenase", "description": "Assessed by blood sample collection", "populationDescription": "Subjects analyzed for this endpoint represent subjects who were evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "U/L", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)", "groups": [{"id": "OG000", "title": "Quinagolide 1080 µg", "description": "Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.\n\nQuinagolide 1080 µg: Vaginal ring containing Quinagolide 1080 µg for daily releases"}, {"id": "OG001", "title": "Placebo", "description": "Vaginal ring containing matching placebo\n\nPlacebo: Matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "31"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.7", "spread": "12.30"}, {"groupId": "OG001", "value": "2.8", "spread": "8.42"}]}]}]}, {"type": "SECONDARY", "title": "Changes in Clinical Chemistry and Hematology Parameters: Phosphate", "description": "Assessed by blood sample collection", "populationDescription": "Subjects analyzed for this endpoint represent subjects who were evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)", "groups": [{"id": "OG000", "title": "Quinagolide 1080 µg", "description": "Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.\n\nQuinagolide 1080 µg: Vaginal ring containing Quinagolide 1080 µg for daily releases"}, {"id": "OG001", "title": "Placebo", "description": "Vaginal ring containing matching placebo\n\nPlacebo: Matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "31"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.013", "spread": "0.1452"}, {"groupId": "OG001", "value": "0.048", "spread": "0.1885"}]}]}]}, {"type": "SECONDARY", "title": "Changes in Clinical Chemistry and Hematology Parameters: Potassium", "description": "Assessed by blood sample collection", "populationDescription": "Subjects analyzed for this endpoint represent subjects who were evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)", "groups": [{"id": "OG000", "title": "Quinagolide 1080 µg", "description": "Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.\n\nQuinagolide 1080 µg: Vaginal ring containing Quinagolide 1080 µg for daily releases"}, {"id": "OG001", "title": "Placebo", "description": "Vaginal ring containing matching placebo\n\nPlacebo: Matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "31"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.07", "spread": "0.333"}, {"groupId": "OG001", "value": "0.06", "spread": "0.357"}]}]}]}, {"type": "SECONDARY", "title": "Changes in Clinical Chemistry and Hematology Parameters: Sodium", "description": "Assessed by blood sample collection", "populationDescription": "Subjects analyzed for this endpoint represent subjects who were evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)", "groups": [{"id": "OG000", "title": "Quinagolide 1080 µg", "description": "Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.\n\nQuinagolide 1080 µg: Vaginal ring containing Quinagolide 1080 µg for daily releases"}, {"id": "OG001", "title": "Placebo", "description": "Vaginal ring containing matching placebo\n\nPlacebo: Matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "31"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.7", "spread": "2.04"}, {"groupId": "OG001", "value": "0.4", "spread": "2.54"}]}]}]}, {"type": "SECONDARY", "title": "Changes in Clinical Chemistry and Hematology Parameters: Protein", "description": "Assessed by blood sample collection", "populationDescription": "Subjects analyzed for this endpoint represent subjects who were evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "g/L", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)", "groups": [{"id": "OG000", "title": "Quinagolide 1080 µg", "description": "Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.\n\nQuinagolide 1080 µg: Vaginal ring containing Quinagolide 1080 µg for daily releases"}, {"id": "OG001", "title": "Placebo", "description": "Vaginal ring containing matching placebo\n\nPlacebo: Matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "31"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.1", "spread": "3.82"}, {"groupId": "OG001", "value": "1.4", "spread": "3.19"}]}]}]}, {"type": "SECONDARY", "title": "Changes in Clinical Chemistry and Hematology Parameters: Urate", "description": "Assessed by blood sample collection", "populationDescription": "Subjects analyzed for this endpoint represent subjects who were evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "umol/L", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)", "groups": [{"id": "OG000", "title": "Quinagolide 1080 µg", "description": "Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.\n\nQuinagolide 1080 µg: Vaginal ring containing Quinagolide 1080 µg for daily releases"}, {"id": "OG001", "title": "Placebo", "description": "Vaginal ring containing matching placebo\n\nPlacebo: Matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "31"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "10.7", "spread": "56.36"}, {"groupId": "OG001", "value": "1.3", "spread": "37.59"}]}]}]}, {"type": "SECONDARY", "title": "Changes in Clinical Chemistry and Hematology Parameters: Urea Nitrogen", "description": "Assessed by blood sample collection", "populationDescription": "Subjects analyzed for this endpoint represent subjects who were evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)", "groups": [{"id": "OG000", "title": "Quinagolide 1080 µg", "description": "Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.\n\nQuinagolide 1080 µg: Vaginal ring containing Quinagolide 1080 µg for daily releases"}, {"id": "OG001", "title": "Placebo", "description": "Vaginal ring containing matching placebo\n\nPlacebo: Matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "31"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.180", "spread": "1.0184"}, {"groupId": "OG001", "value": "0.148", "spread": "1.2286"}]}]}]}, {"type": "SECONDARY", "title": "Proportion of Subjects With Markedly Abnormal Changes in Clinical Chemistry and Hematology Parameters", "description": "Assessed by blood sample collection", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of subjects", "timeFrame": "At baseline and at menstrual cycle 4 (around 5 months, each cycle is approximately 28 days)", "groups": [{"id": "OG000", "title": "Quinagolide 1080 µg", "description": "Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.\n\nQuinagolide 1080 µg: Vaginal ring containing Quinagolide 1080 µg for daily releases"}, {"id": "OG001", "title": "Placebo", "description": "Vaginal ring containing matching placebo\n\nPlacebo: Matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.86"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Frequency and Intensity of Adverse Events", "description": "Assessed by and Adverse Event Log completed by the Investigator", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of subjects", "timeFrame": "From obtaining the informed consent to end of trial (up to 6 menstrual cycles ~ around 6 months, each cycle is approximately 28 days)", "groups": [{"id": "OG000", "title": "Quinagolide 1080 µg", "description": "Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.\n\nQuinagolide 1080 µg: Vaginal ring containing Quinagolide 1080 µg for daily releases"}, {"id": "OG001", "title": "Placebo", "description": "Vaginal ring containing matching placebo\n\nPlacebo: Matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"title": "Mild adverse events", "categories": [{"measurements": [{"groupId": "OG000", "value": "28.6"}, {"groupId": "OG001", "value": "43.8"}]}]}, {"title": "Moderate adverse events", "categories": [{"measurements": [{"groupId": "OG000", "value": "42.9"}, {"groupId": "OG001", "value": "37.5"}]}]}, {"title": "Severe adverse events", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.9"}, {"groupId": "OG001", "value": "9.4"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Adverse events were recorded for each participant from the time of signed informed consent for participation in the trial to follow-up visit (approximately 1 month after visit 8 (month 4), up to 5 months).", "description": "All adverse events with onset after start of first administration of IMP and before the follow-up phone call were considered treatment-emergent.", "eventGroups": [{"id": "EG000", "title": "Quinagolide 1080 µg", "description": "Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.\n\nQuinagolide 1080 µg: Vaginal ring containing Quinagolide 1080 µg for daily releases", "deathsNumAffected": 0, "deathsNumAtRisk": 35, "seriousNumAffected": 1, "seriousNumAtRisk": 35, "otherNumAffected": 20, "otherNumAtRisk": 35}, {"id": "EG001", "title": "Placebo", "description": "Vaginal ring containing matching placebo\n\nPlacebo: Matching placebo", "deathsNumAffected": 0, "deathsNumAtRisk": 32, "seriousNumAffected": 0, "seriousNumAtRisk": 32, "otherNumAffected": 20, "otherNumAtRisk": 32}], "seriousEvents": [{"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 35}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}], "otherEvents": [{"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 35}, {"groupId": "EG001", "numEvents": 3, "numAffected": 2, "numAtRisk": 32}]}, {"term": "Abdominal distension", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 35}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 32}]}, {"term": "Rectal Haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 35}, {"groupId": "EG001", "numEvents": 4, "numAffected": 2, "numAtRisk": 32}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 35}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 32}]}, {"term": "Peripheral swelling", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 35}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 32}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 2, "numAtRisk": 35}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 35}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 32}]}, {"term": "Corona virus infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 35}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 32}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 9, "numAffected": 6, "numAtRisk": 35}, {"groupId": "EG001", "numEvents": 15, "numAffected": 8, "numAtRisk": 32}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 35}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 32}]}, {"term": "Somnolence", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 2, "numAtRisk": 35}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 32}]}, {"term": "Hypoaesthesia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 35}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 32}]}, {"term": "Ovarian cyst", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 35}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 32}]}, {"term": "Vulvovaginal pruritus", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 35}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Hot flush", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 35}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention."}, "pointOfContact": {"title": "Global Clinical Compliance", "organization": "Ferring Pharmaceuticals", "email": "DK0-Disclosure@ferring.com", "phone": "-"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2019-11-12", "uploadDate": "2022-06-21T10:26", "filename": "Prot_000.pdf", "size": 1003677}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2021-08-26", "uploadDate": "2022-06-21T10:27", "filename": "SAP_001.pdf", "size": 623547}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04", "removedCountries": ["Spain", "Switzerland"], "submissionTracking": {"firstMcpInfo": {"postDateStruct": {"date": "2022-07-15", "type": "ACTUAL"}}}}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}, {"id": "D062788", "term": "Adenomyosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}, {"id": "D014591", "term": "Uterine Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C046650", "term": "quinagolide"}]}}, "hasResults": true}, {"protocolSection": {"identificationModule": {"nctId": "NCT03125304", "orgStudyIdInfo": {"id": "jdzy2015065"}, "organization": {"fullName": "State Administration of Traditional Chinese Medicine of the People's Republic of China", "class": "OTHER_GOV"}, "briefTitle": "Acupuncture for Pain of Endometriosis", "officialTitle": "Acupuncture for Pain of Endometriosis: A Multicenter, Randomized, and Controlled Trial"}, "statusModule": {"statusVerifiedDate": "2021-10", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2017-05-21", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2021-03-26", "type": "ACTUAL"}, "completionDateStruct": {"date": "2021-06-23", "type": "ACTUAL"}, "studyFirstSubmitDate": "2017-04-17", "studyFirstSubmitQcDate": "2017-04-20", "studyFirstPostDateStruct": {"date": "2017-04-24", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2021-10-17", "lastUpdatePostDateStruct": {"date": "2021-10-19", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Liang Ruining", "investigatorTitle": "Professor", "investigatorAffiliation": "Jiangxi University of Traditional Chinese Medicine"}, "leadSponsor": {"name": "State Administration of Traditional Chinese Medicine of the People's Republic of China", "class": "OTHER_GOV"}, "collaborators": [{"name": "The Affiliated Hospital of JiangXi University of TCM", "class": "UNKNOWN"}, {"name": "The Qionghai Hospital of TCM", "class": "UNKNOWN"}, {"name": "The GanZhou Maternal and Child Health Hospital", "class": "UNKNOWN"}, {"name": "The Second Affiliated Hospital of JiangXi University TCM", "class": "UNKNOWN"}]}, "oversightModule": {"isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "This proposed trial is a multicenter,randomized and controlled clinical trial. The aim of this trial is to evaluate the efficacy and safety of acupuncture for treating pain of Endometriosis.The trial period will consist of three menstrual cycles of treatment, and three menstrual cycles in the follow-up period.We put forward the following hypothesis: the effect of acupuncture group is better than the control group on relieving pain.", "detailedDescription": "Endometriosis is a kind of chronic gynaecology disease that endometrial tissue appear outside the uterine cavity , the main symptoms include dysmenorrhea, dyspareunia, chronic pelvic pain, and infertility, etc. .The secondary progressive and aggravating dysmenorrhea is thought to be the most typical symptom of endometriosis.The epidemiology data shows that about 87.7% endometriosis patients accompany with dysmenorrhea, affecting majority of women's physical and mental health and quality of life seriously .The treatment for dysmenorrhea is still the key and pressing problem of endometriosis.Endometriotic lesions can be excised or ablated surgically, but the risk of recurrence is high. Drug therapy mainly involves the use of oral contraceptives, progesterone and androgen derivatives, gonadotropin-releasing hormone (GnRH) agonists and aromatase inhibitors, etc.,However, in some women the side effects may not be well tolerated or the pain relief provided may be inadequate. Therefore, a large number of patients with endometriosis are turning to complementary and alternative medicine such as acupuncture.Acupuncture, as an important component of traditional Chinese medicine is widely used in Asian countries,and it can treat different diseases, including endometriosis dysmenorrhea.The analgesia principle of acupuncture is based on the theory of holistic view of zang-fu organs and meridians.In traditional Chinese medicine, dysmenorrhea is etiologically caused by the stagnated blood or Qi circulation in the uterus. The pathological factors are mostly dampness, blood stasis,and Qi obstructions. Acupuncture stimulation, which involves thrusting or twisting needles,results in various biochemical reactions that can have effects throughout the body.When the running of blood and Qi is unobstructed, pain can be relieved.However, only some small trials considered to be lacking in quality or size to guide practice.So it is urgently necessary to design multicenter ,randomized controlled trial to prove it ."}, "conditionsModule": {"conditions": ["Endometriosis"], "keywords": ["Endometriosis", "acupuncture", "pain", "dysmenorrhea"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": "The participants assigned to the treatment groups will receive acupuncture at Sanyinjiao (SP 6), Zhaohai (KI 6) ,Taichong (LR 3) ,Qichong (ST 30) and Guanyuan (CV4), while the control group will receive acupuncture at non-acupoint.", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 106, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "treatment group", "type": "EXPERIMENTAL", "description": "Treatment group will receive acupuncture at Sanyinjiao (SP 6), Zhaohai (KI 6) ,Taichong (LR 3) ,Qichong (ST 30) and Guanyuan.", "interventionNames": ["Other: acupuncture"]}, {"label": "control group", "type": "PLACEBO_COMPARATOR", "description": "Control group will receive acupuncture at non-acupoints.", "interventionNames": ["Other: acupuncture"]}], "interventions": [{"type": "OTHER", "name": "acupuncture", "description": "They will be treated seven days before expected menstrual onset with once a day and three times a week for therapy. During the menstrual period,they will be treated everyday when they are having pain.Every treatment lasts 30 minutes. The trial period will consist of three menstrual cycles of treatment and three menstrual cycles in the follow-up period.", "armGroupLabels": ["control group", "treatment group"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Visual analogue scale", "description": "Pelvic pain", "timeFrame": "up to 24 weeks"}], "secondaryOutcomes": [{"measure": "Endometriosis Health Profile -30", "description": "Endometriosis-specific quality of life", "timeFrame": "up to 24 weeks"}, {"measure": "Multidimensional Pain Inventory", "description": "Physical functioning", "timeFrame": "up to 24 weeks"}, {"measure": "Beck Depression Inventory and Profile of Mood States", "description": "Emotional functioning", "timeFrame": "up to 24 weeks"}, {"measure": "Patient Global Impression of Change", "description": "Patient satisfaction", "timeFrame": "up to 24 weeks"}, {"measure": "Pain diary", "description": "the specific time and frequency of pain attacks, the duration of pain", "timeFrame": "up to 24 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion criteria\n\n1. Women age between 20 and 40.\n2. Endometriosis diagnosed according to the Endometriosis Consensus Guidelines (Chinese Medical Association, 2015): 1) symptomatic endometriosis detected by laparoscopy or laparotomy; or 2) ovarian endometrioma detected by ultrasound or magnetic resonance imaging with pelvic pain.\n3. Patients willing to receive acupuncture for pain relief.\n4. Pelvic pain score equal or over 4 cm on the Visual Analogue Scale (VAS).\n5. Regular menstrual cycle.\n6. Signed informed consent\n\nExclusion criteria\n\n1. Pelvic ultrasound demonstrates the endometrial cyst measures more than 5 cm in diameter and surgery is indicated.\n2. Imaging examination suspects pelvic genital malignancies.\n3. Cancer antigen-125 \\> 200 IU/L.\n4. Pelvic infectious diseases.\n5. Other severe disorders in heart, lung, liver, kidney, or mental disorders not able to cooperate in the study.\n6. Patients who have received any other treatment for endometriosis that may affect the observation of the curative effects of acupuncture these three months.\n7. Pregnancy or breastfeeding.\n8. Refusal to be randomized.", "healthyVolunteers": false, "sex": "FEMALE", "genderBased": true, "minimumAge": "20 Years", "maximumAge": "40 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Ruining Liang", "affiliation": "The Second Affiliated Hospital of Jiangxi University of TCM", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "the second affiliated hospital of Jiangxi University of TCM", "city": "Nanchang", "state": "Jiangxi", "country": "China", "geoPoint": {"lat": 28.68396, "lon": 115.85306}}]}, "referencesModule": {"references": [{"pmid": "21442808", "type": "BACKGROUND", "citation": "Xiang DF, Sun QZ, Liang XF. [Effect of abdominal acupuncture on pain of pelvic cavity in patients with endometriosis]. Zhongguo Zhen Jiu. 2011 Feb;31(2):113-6. Chinese."}, {"pmid": "20728977", "type": "BACKGROUND", "citation": "Rubi-Klein K, Kucera-Sliutz E, Nissel H, Bijak M, Stockenhuber D, Fink M, Wolkenstein E. Is acupuncture in addition to conventional medicine effective as pain treatment for endometriosis? A randomised controlled cross-over trial. Eur J Obstet Gynecol Reprod Biol. 2010 Nov;153(1):90-3. doi: 10.1016/j.ejogrb.2010.06.023. Epub 2010 Aug 21."}, {"pmid": "26054137", "type": "BACKGROUND", "citation": "Zhang X, Li W. [Efficacy on endometriosis treated with electroacupuncture]. Zhongguo Zhen Jiu. 2015 Apr;35(4):323-6. Chinese."}, {"pmid": "24346786", "type": "BACKGROUND", "citation": "Magalhaes J. Acupuncture for pain in endometriosis. Sao Paulo Med J. 2013;131(6):439. doi: 10.1590/1516-3180.20131316T1."}, {"pmid": "36716811", "type": "DERIVED", "citation": "Li PS, Peng XM, Niu XX, Xu L, Hung Yu Ng E, Wang CC, Dai JF, Lu J, Liang RN. Efficacy of acupuncture for endometriosis-associated pain: a multicenter randomized single-blind placebo-controlled trial. Fertil Steril. 2023 May;119(5):815-823. doi: 10.1016/j.fertnstert.2023.01.034. Epub 2023 Jan 27."}, {"pmid": "29880009", "type": "DERIVED", "citation": "Liang R, Li P, Peng X, Xu L, Fan P, Peng J, Zhou X, Xiao C, Jiang M. Efficacy of acupuncture on pelvic pain in patients with endometriosis: study protocol for a randomized, single-blind, multi-center, placebo-controlled trial. Trials. 2018 Jun 7;19(1):314. doi: 10.1186/s13063-018-2684-6."}]}, "ipdSharingStatementModule": {"ipdSharing": "UNDECIDED"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}, {"id": "D010146", "term": "Pain"}, {"id": "D004412", "term": "Dysmenorrhea"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}, {"id": "D009461", "term": "Neurologic Manifestations"}, {"id": "D012816", "term": "Signs and Symptoms"}, {"id": "D013568", "term": "Pathological Conditions, Signs and Symptoms"}, {"id": "D008599", "term": "Menstruation Disturbances"}, {"id": "D010335", "term": "Pathologic Processes"}, {"id": "D017699", "term": "Pelvic Pain"}]}, "interventionBrowseModule": {"meshes": [{"id": "D015670", "term": "Acupuncture Therapy"}], "ancestors": [{"id": "D000529", "term": "Complementary Therapies"}, {"id": "D013812", "term": "Therapeutics"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT03789123", "orgStudyIdInfo": {"id": "2018.11.1.01.082.r1.101"}, "organization": {"fullName": "Bagcilar Training and Research Hospital", "class": "OTHER_GOV"}, "briefTitle": "Effects of Dienogest and Dienogest Plus Estradiol Valerate in Ovarian Endometrioma", "officialTitle": "Effects of Dienogest and Dienogest Plus Estradiol Valerate on Ovarian Reserve and Endometrioma Size"}, "statusModule": {"statusVerifiedDate": "2018-12", "overallStatus": "UNKNOWN", "lastKnownStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2019-01-01", "type": "ESTIMATED"}, "primaryCompletionDateStruct": {"date": "2019-07-01", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2019-12-01", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2018-11-22", "studyFirstSubmitQcDate": "2018-12-27", "studyFirstPostDateStruct": {"date": "2018-12-28", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2018-12-27", "lastUpdatePostDateStruct": {"date": "2018-12-28", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Bagcilar Training and Research Hospital", "class": "OTHER_GOV"}, "collaborators": [{"name": "Kocaeli Derince Education and Research Hospital", "class": "OTHER"}, {"name": "Suleymaniye Birth And Women's Health Education And Research Hospital", "class": "OTHER_GOV"}]}, "oversightModule": {"isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false, "isUsExport": false}, "descriptionModule": {"briefSummary": "Progesterone resistance in endometriosis is a known fact. The progestin derivatives used in endometriosis cause decidualization and atrophy of ectopic foci. Moreover, they inhibit neo-angiogenesis, provide suppress expansile/destructive growth facilitated by matrix metalloproteinases, and implantation of ectopic foci. The effect of drugs containing the estrogen-progesterone combination is mainly based on the inhibition of ovulation, decidualization and atrophy of ectopic foci. In estrogen-progesterone mechanism, it is known that estrogen has a progesterone receptor-enhancing effect, which may make progesterone more potent. Based on this, the investigators hypothesized that estrogen added to progesterone could lead to a further reduction in endometrioma size by various mechanisms which probably include the increased progesterone sensitivity in endometriosis. In addition, the investigators hypothesized that this therapy can alleviate the destructive effect of endometriomas on the ovarian reserve."}, "conditionsModule": {"conditions": ["Ovarian Reserve"], "keywords": ["Endometrioma", "Estradiol valerate + dienogest", "Dienogest", "Ovarian reserve"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "SINGLE", "whoMasked": ["OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 710, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Study Group (patients with OMA)", "type": "EXPERIMENTAL", "description": "I) Untreated patients (n=142)\n\nII) Dienogest (n=142)\n\nIII) Dienogest/Estradiol valerate+Dienogest (n=142)", "interventionNames": ["Drug: Estradiol valerate/dienogest"]}, {"label": "Control Group(patients without OMA)", "type": "SHAM_COMPARATOR", "description": "I) Untreated patients (n=142)\n\nII) Dienogest/Estradiol valerate+Dienogest (n=142)", "interventionNames": ["Drug: Estradiol valerate/dienogest"]}], "interventions": [{"type": "DRUG", "name": "Estradiol valerate/dienogest", "description": "The effects of drugs given for endometrioma and contraception will be observed on ovarian reserve, endometrioma size and pain score.", "armGroupLabels": ["Control Group(patients without OMA)", "Study Group (patients with OMA)"], "otherNames": ["Dienogest"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Ovarian reserve", "description": "The investigators evaluate serum anti-Müllerian hormone (AMH) level(ng/mL) using commercial elisa kits and antral follicle count (number) using ultrasonography. The patients with higher ovarian reserve represent a better outcome.", "timeFrame": "up to 24 months"}], "secondaryOutcomes": [{"measure": "Endometrioma Size", "description": "The investigators evaluate endometrioma size (centimeter) using ultrasonography.", "timeFrame": "up to 24 months"}, {"measure": "Pain Score", "description": "Vas score (minimum score:0 and maximum score:10). The patients with lower pain scores represent a better outcome.", "timeFrame": "up to 24 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Study Group: At least one endometrioma greater than 3 cm, between 18-40 years of age, without surgical indication at the time of diagnosis, occasionally and intermittently controlled pain with NSAIDs or no pain symptom\n2. Control Group: Patients with reproductive age without any ovarian cysts\n\nExclusion Criteria:\n\n* suspicion of malignancy, irregular mentrual period, endocrine diseases, drug intake that may affect ovarian reserve in the last 6 months (i.e GnRH agonists), previous ovarian surgery, AMH levels under 2 ng/ml.", "healthyVolunteers": true, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "40 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Tolga Karacan, M.D", "role": "CONTACT", "phone": "05303638765", "email": "tolgakaracan84@gmail.com"}], "overallOfficials": [{"name": "Engin Oral, Prof.Dr. M.D", "affiliation": "Istanbul University Cerrahpasa Medical Faculty", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Tolga Karacan", "status": "RECRUITING", "city": "Istanbul", "state": "Bagcilar", "zip": "34100", "country": "Turkey (Türkiye)", "contacts": [{"name": "Tolga Karacan, M.D", "role": "CONTACT", "phone": "5303638765", "email": "tolgakaracan84@gmail.com"}, {"name": "Gulfem Basol, M.D", "role": "SUB_INVESTIGATOR"}, {"name": "Fatma V Ferit, Prof.Dr.M.D", "role": "SUB_INVESTIGATOR"}, {"name": "Eser Ozyurek, M.D", "role": "SUB_INVESTIGATOR"}], "geoPoint": {"lat": 41.01384, "lon": 28.94966}}]}, "ipdSharingStatementModule": {"ipdSharing": "UNDECIDED"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C454300", "term": "estradiol valerate-dienogest"}, {"id": "C023635", "term": "dienogest"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT02027142", "orgStudyIdInfo": {"id": "Sleep and endometriosis."}, "organization": {"fullName": "IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy", "class": "OTHER"}, "briefTitle": "Sleep Quality, Daytime Sleepiness and Insomnia in Patients With Endometriosis: a Case-control Study.", "officialTitle": "Symptomatic Endometriosis of the Posterior Cul-de-sac is Associated With Impaired Sleep Quality, Excessive Daytime Sleepiness and Insomnia: a Case-control Study."}, "statusModule": {"statusVerifiedDate": "2017-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-05"}, "primaryCompletionDateStruct": {"date": "2013-12", "type": "ACTUAL"}, "completionDateStruct": {"date": "2013-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-01-02", "studyFirstSubmitQcDate": "2014-01-02", "studyFirstPostDateStruct": {"date": "2014-01-03", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-05-01", "lastUpdatePostDateStruct": {"date": "2017-05-04", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Umberto Leone Roberti Maggiore", "investigatorTitle": "MD", "investigatorAffiliation": "IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy"}, "leadSponsor": {"name": "IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study included women referred to two academic centres for the diagnosis and treatment of endometriosis (cases) and women referred to our Institutions because of routine gynaecologic consultations (controls). In this age-matched case-control study, the aimdy was to assess quality of sleep, the average daytime sleepiness and insomnia in patients with endometriosis by using three different self-reported questionnaires."}, "conditionsModule": {"conditions": ["Endometriosis", "Sleep"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "CASE_CONTROL", "timePerspective": "CROSS_SECTIONAL"}, "enrollmentInfo": {"count": 290, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Cases", "description": "Women referred to two academic centres for the diagnosis and treatment of endometriosis.", "interventionNames": ["Other: Pittsburgh Sleep Quality Index.", "Other: Epworth sleepiness scale.", "Other: Insomnia Severity Index.", "Other: The Endometriosis Health Profile."]}, {"label": "Controls", "description": "Women referred to our Institutions because of routine gynaecologic consultations.", "interventionNames": ["Other: Pittsburgh Sleep Quality Index.", "Other: Epworth sleepiness scale.", "Other: Insomnia Severity Index."]}], "interventions": [{"type": "OTHER", "name": "Pittsburgh Sleep Quality Index.", "description": "Pittsburgh Sleep Quality Index is an effective instrument used to measure the quality and patterns of sleep of patients. It allows evaluating \"poor\" from \"good\" sleep by assessing seven domains. A total score ≤ 5 indicated good sleep quality while a total score \\> 5 was indicated poor sleep quality.", "armGroupLabels": ["Cases", "Controls"]}, {"type": "OTHER", "name": "Epworth sleepiness scale.", "description": "Epworth sleepiness scale is an 8-item questionnaire developed to measure average daytime sleepiness. A total score ≥ 10 indicates excessive daytime sleepiness.", "armGroupLabels": ["Cases", "Controls"]}, {"type": "OTHER", "name": "Insomnia Severity Index.", "description": "Insomnia Severity Index is a 7-item questionnaire developed to measure insomnia. A total score between 0 and 7 correspond to not clinically significant insomnia, between 8 and 14 to subthreshold insomnia, between 15 and 21 to clinical insomnia (moderate), between 22 and 28 to clinical insomnia (severe).", "armGroupLabels": ["Cases", "Controls"]}, {"type": "OTHER", "name": "The Endometriosis Health Profile.", "description": "The Endometriosis Health Profile is a patient generated instrument that evaluates disease-specific health-related quality of life in patients with endometriosis. The questionnaire is administrable to all patients with endometriosis and it consists in 30 items divided in 5 domains (pain, control and powerlessness, emotional well-being, social support and self-image). Each scale for each domain is comprised between 0 (indicating the best health status) and 100 (indicating the worst health status).", "armGroupLabels": ["Cases"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Quality of sleep.", "description": "Quality of sleep was assessed by using the Pittsburgh Sleep Quality Index.", "timeFrame": "Cases were administered and fulfilled the questionnaires at the moment of being scheduled for surgery (3-4 months before the operation). Controls were administered and fulfilled the questionnaires after routine gynaecologic consultation."}], "secondaryOutcomes": [{"measure": "Average daytime sleepiness.", "description": "Average daytime sleepiness was assessed by using the Epworth sleepiness scale.", "timeFrame": "Cases were administered and fulfilled the questionnaires at the moment of being scheduled for surgery (3-4 months before the operation). Controls were administered and fulfilled the questionnaires after routine gynaecologic consultation."}, {"measure": "Insomnia.", "description": "Insomnia was assessed by using the Insomnia Severity Index.", "timeFrame": "Cases were administered and fulfilled the questionnaires at the moment of being scheduled for surgery (3-4 months before the operation). Controls were administered and fulfilled the questionnaires after routine gynaecologic consultation."}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\nReproductive age Surgical and histological diagnosis of rectovaginal endometriosis\n\nExclusion Criteria:\n\nSuspicion of endometriosis (based on evaluation of symptoms, gynaecological examination and transvaginal ultrasonography) History of infertility Previous diagnosis of endometriosis Gynaecological, intestinal and urological diseases causing abdominal pain (e.g. pelvic congestion syndrome, bladder pain syndrome) Severe underlying comorbidities (cardiovascular, respiratory, renal, hematological, endocrine, hepatic, gastrointestinal, neurological, or psychiatric) Pregnancy at any gestational age Suspicion or diagnosis of oncological pathology Use of gonadotropin releasing hormone analogues (GnRH-a) Restless legs syndrome Shift work Use of antiallergic drugs Narcotics Refusal or inability to sign the informed consent form or complete the study questionnaires", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "50 Years", "stdAges": ["ADULT"], "studyPopulation": "In this study were recruited women referred to two academic centres for the diagnosis and treatment of endometriosis (cases) and women referred to our Institutions because of routine gynaecologic consultations (controls).", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"overallOfficials": [{"name": "Umberto Leone Roberti Maggiore, MD", "affiliation": "IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Simone Ferrero, PhD", "affiliation": "IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy", "role": "STUDY_DIRECTOR"}, {"name": "Stefano Salvatore, MD", "affiliation": "IRRCS San Raffaele Hospital and Vita-Salute San Raffaele University of Milan", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro", "city": "Genoa", "state": "Ligury", "zip": "16122", "country": "Italy", "geoPoint": {"lat": 44.40478, "lon": 8.94439}}, {"facility": "IRRCS San Raffaele Hospital and Vita-Salute San Raffaele University", "city": "Milan", "state": "Lombardy", "zip": "20132", "country": "Italy", "geoPoint": {"lat": 45.46427, "lon": 9.18951}}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT02253251", "orgStudyIdInfo": {"id": "Pro00009633"}, "organization": {"fullName": "MiraKind", "class": "OTHER"}, "briefTitle": "Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment", "officialTitle": "Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment"}, "statusModule": {"statusVerifiedDate": "2025-01", "overallStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2014-09"}, "primaryCompletionDateStruct": {"date": "2030-12", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2035-09", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2014-09-25", "studyFirstSubmitQcDate": "2014-09-26", "studyFirstPostDateStruct": {"date": "2014-10-01", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2025-01-21", "lastUpdatePostDateStruct": {"date": "2025-01-23", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "MiraKind", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The investigators will recruit and enroll individuals that may have the KRAS-variant or other microRNA binding site mutations to join registry studies. The investigators will allow individuals to obtain their results through a physician at the completion of the studies. The investigators current focus is cancer and autoimmunity.", "detailedDescription": "The investigators have identified germ-line microRNA binding site mutations that predict an increased risk of cancer, endometriosis and associated infertility, and unique tumor biology and response to treatment. The goal of this protocol is to further determine the mechanisms of these mutations, such as the KRAS-variant, and their associations with human health, such as cancer. The investigators will collect saliva samples from individual patients who are eligible and choose to enroll in these studies, to test for the KRAS-variant and/or other mutations under study. With specific permission, the investigators will keep excess DNA to further investigate and discover additional similar mutations. The investigators purpose is to have participants answer questionnaires about lifestyle factors in an ongoing manner, to understand the impact of different factors on cancer risk for patients with these mutations."}, "conditionsModule": {"conditions": ["Cancer"], "keywords": ["Breast Cancer", "Cancer Risk", "Family Breast and Ovarian Cancer", "Genetic Cancer Risk", "Cancer Treatment", "Familial multiple primary cancer risk", "Autoimmunity", "Endometriosis"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": true, "targetDuration": "10 Years", "designInfo": {"observationalModel": "COHORT", "timePerspective": "PROSPECTIVE"}, "bioSpec": {"retention": "SAMPLES_WITHOUT_DNA", "description": "DNA will be isolated from the submitted sample and kept with permission for additional studies."}, "enrollmentInfo": {"count": 15000, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Family Registry", "description": "For individuals identified with the KRAS-variant. Patients will be prospectively followed to determine the impact of lifestyle on disease risk.", "interventionNames": ["Genetic: KRAS-variant and microRNA binding site mutation testing"]}, {"label": "Double primary breast cancer", "description": "Women with multiple primary breast cancer will be tested for the KRAS-variant and compared between those with this mutation and those without.", "interventionNames": ["Genetic: KRAS-variant and microRNA binding site mutation testing"]}, {"label": "Autoimmunity", "description": "We have shown that the KRAS-variant and other members of this genetic class of mutations associate with altered immunity, leading to immunosuppression as well as autoimmunity.", "interventionNames": ["Genetic: KRAS-variant and microRNA binding site mutation testing"]}, {"label": "Cancer patients receiving certain treatments", "description": "We have found that microRNA binding site mutations are predictive biomarkers of outcomes from cancer therapy, including response and toxicity. We will enroll patients to further study and validate these findings.", "interventionNames": ["Genetic: KRAS-variant and microRNA binding site mutation testing"]}], "interventions": [{"type": "GENETIC", "name": "KRAS-variant and microRNA binding site mutation testing", "description": "Participant in these studies will be tested for the KRAS-variant", "armGroupLabels": ["Autoimmunity", "Cancer patients receiving certain treatments", "Double primary breast cancer", "Family Registry"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Measuring the prevalence of the KRAS-variant in certain populations Prevalence of the KRAS-variant in BRCA negative breast cancer patients", "description": "The Prevalence of the KRAS-variant will be determined in specific populations, such as women with drug resistant endometriosis, or BRCA negative breast cancer. The prevalence will be compared to extensive data on the expected and known prevalence of the KRAS-variant in non-diseased populations. Statistical significance will be determined by Chi-squared analysis.", "timeFrame": "1 year"}, {"measure": "Comparing the impact of interventions in KRAS-variant versus non-KRAS variant populations", "description": "We will compare the impact of specific treatment approaches for example in women with the KRAS-variant and double primary breast cancer, versus the interventions used in non-KRAS-variant double primary breast cancer patients.", "timeFrame": "1 year"}], "secondaryOutcomes": [{"measure": "The impact of lifestyle factors on cancer risk for KRAS-variant patients", "description": "Individuals with the KRAS-variant will be prospectively followed, and lifestyle factors will be associated with changes in health, including cancer development. Our goal is to compare baseline characteristics between individuals with the KRAS-variant who do, versus do not, develop cancer, for example.", "timeFrame": "10 years"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Personal or family history of cancer\n* Personal history of endometriosis, or autoimmunity\n\nExclusion Criteria:\n\n* Younger than 18\n* Non-english speaking and unable to understand and sign the consent", "healthyVolunteers": true, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"], "studyPopulation": "Breast and ovarian cancer patients and the family members of those that have the KRAS-variant from primarily the US. Those with Autoimmunity.", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"centralContacts": [{"name": "Joanne Weidhaas, MDPhD", "role": "CONTACT", "phone": "203-671-1308", "email": "joanne@mirakind.org"}, {"name": "Joanne Weidhaas", "role": "CONTACT", "phone": "424-387-8100", "email": "Joanne@miradx.com"}], "overallOfficials": [{"name": "Joanne Weidhaas, MDPhD", "affiliation": "MiraKind", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "MiraKind", "status": "RECRUITING", "city": "Los Angeles", "state": "California", "zip": "90025", "country": "United States", "contacts": [{"name": "Joanne Weidhaas, MDPhD", "role": "CONTACT", "phone": "203-671-1308", "email": "joanne@mirakind.org"}, {"name": "Joanne Weidhaas", "role": "CONTACT", "phone": "424-387-8100"}], "geoPoint": {"lat": 34.05223, "lon": -118.24368}}]}, "referencesModule": {"references": [{"pmid": "25183481", "type": "BACKGROUND", "citation": "Saridaki Z, Weidhaas JB, Lenz HJ, Laurent-Puig P, Jacobs B, De Schutter J, De Roock W, Salzman DW, Zhang W, Yang D, Pilati C, Bouche O, Piessevaux H, Tejpar S. A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy. Clin Cancer Res. 2014 Sep 1;20(17):4499-4510. doi: 10.1158/1078-0432.CCR-14-0348."}, {"pmid": "25081901", "type": "BACKGROUND", "citation": "Chung CH, Lee JW, Slebos RJ, Howard JD, Perez J, Kang H, Fertig EJ, Considine M, Gilbert J, Murphy BA, Nallur S, Paranjape T, Jordan RC, Garcia J, Burtness B, Forastiere AA, Weidhaas JB. A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2014 Nov;25(11):2230-2236. doi: 10.1093/annonc/mdu367. Epub 2014 Jul 31."}, {"pmid": "22662244", "type": "BACKGROUND", "citation": "Pilarski R, Patel DA, Weitzel J, McVeigh T, Dorairaj JJ, Heneghan HM, Miller N, Weidhaas JB, Kerin MJ, McKenna M, Wu X, Hildebrandt M, Zelterman D, Sand S, Shulman LP. The KRAS-variant is associated with risk of developing double primary breast and ovarian cancer. PLoS One. 2012;7(5):e37891. doi: 10.1371/journal.pone.0037891. Epub 2012 May 25."}, {"pmid": "22307873", "type": "BACKGROUND", "citation": "Grechukhina O, Petracco R, Popkhadze S, Massasa E, Paranjape T, Chan E, Flores I, Weidhaas JB, Taylor HS. A polymorphism in a let-7 microRNA binding site of KRAS in women with endometriosis. EMBO Mol Med. 2012 Mar;4(3):206-17. doi: 10.1002/emmm.201100200. Epub 2012 Feb 3."}, {"pmid": "22139083", "type": "BACKGROUND", "citation": "Ratner ES, Keane FK, Lindner R, Tassi RA, Paranjape T, Glasgow M, Nallur S, Deng Y, Lu L, Steele L, Sand S, Muller RU, Bignotti E, Bellone S, Boeke M, Yao X, Pecorelli S, Ravaggi A, Katsaros D, Zelterman D, Cristea MC, Yu H, Rutherford TJ, Weitzel JN, Neuhausen SL, Schwartz PE, Slack FJ, Santin AD, Weidhaas JB. A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. Oncogene. 2012 Oct 18;31(42):4559-66. doi: 10.1038/onc.2011.539. Epub 2011 Dec 5."}, {"pmid": "24732316", "type": "BACKGROUND", "citation": "Lee LJ, Ratner E, Uduman M, Winter K, Boeke M, Greven KM, King S, Burke TW, Underhill K, Kim H, Boulware RJ, Yu H, Parkash V, Lu L, Gaffney D, Dicker AP, Weidhaas J. The KRAS-variant and miRNA expression in RTOG endometrial cancer clinical trials 9708 and 9905. PLoS One. 2014 Apr 14;9(4):e94167. doi: 10.1371/journal.pone.0094167. eCollection 2014."}, {"pmid": "21994416", "type": "BACKGROUND", "citation": "Smits KM, Paranjape T, Nallur S, Wouters KA, Weijenberg MP, Schouten LJ, van den Brandt PA, Bosman FT, Weidhaas JB, van Engeland M. A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer. Clin Cancer Res. 2011 Dec 15;17(24):7723-31. doi: 10.1158/1078-0432.CCR-11-0990. Epub 2011 Oct 12."}, {"pmid": "21435948", "type": "BACKGROUND", "citation": "Paranjape T, Heneghan H, Lindner R, Keane FK, Hoffman A, Hollestelle A, Dorairaj J, Geyda K, Pelletier C, Nallur S, Martens JW, Hooning MJ, Kerin M, Zelterman D, Zhu Y, Tuck D, Harris L, Miller N, Slack F, Weidhaas J. A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis. Lancet Oncol. 2011 Apr;12(4):377-86. doi: 10.1016/S1470-2045(11)70044-4. Epub 2011 Mar 22."}, {"pmid": "20676756", "type": "BACKGROUND", "citation": "Hollestelle A, Pelletier C, Hooning M, Crepin E, Schutte M, Look M, Collee JM, Nieuwlaat A, Dorssers LC, Seynaeve C, Aulchenko YS, Martens JW, van den Ouweland AM, Weidhaas JB. Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families. Breast Cancer Res Treat. 2011 Jul;128(1):79-84. doi: 10.1007/s10549-010-1080-z. Epub 2010 Jul 30."}, {"pmid": "20647319", "type": "BACKGROUND", "citation": "Ratner E, Lu L, Boeke M, Barnett R, Nallur S, Chin LJ, Pelletier C, Blitzblau R, Tassi R, Paranjape T, Hui P, Godwin AK, Yu H, Risch H, Rutherford T, Schwartz P, Santin A, Matloff E, Zelterman D, Slack FJ, Weidhaas JB. A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk. Cancer Res. 2010 Aug 15;70(16):6509-15. doi: 10.1158/0008-5472.CAN-10-0689. Epub 2010 Jul 20."}, {"pmid": "18922928", "type": "BACKGROUND", "citation": "Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, Babar I, Muller RU, Straka E, Su L, Burki EA, Crowell RE, Patel R, Kulkarni T, Homer R, Zelterman D, Kidd KK, Zhu Y, Christiani DC, Belinsky SA, Slack FJ, Weidhaas JB. A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. Cancer Res. 2008 Oct 15;68(20):8535-40. doi: 10.1158/0008-5472.CAN-08-2129."}], "seeAlsoLinks": [{"label": "non-profit running the study", "url": "http://mirakind.org"}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D009369", "term": "Neoplasms"}, {"id": "D001943", "term": "Breast Neoplasms"}, {"id": "D010051", "term": "Ovarian Neoplasms"}, {"id": "D001327", "term": "Autoimmune Diseases"}, {"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D009371", "term": "Neoplasms by Site"}, {"id": "D001941", "term": "Breast Diseases"}, {"id": "D012871", "term": "Skin Diseases"}, {"id": "D017437", "term": "Skin and Connective Tissue Diseases"}, {"id": "D004701", "term": "Endocrine Gland Neoplasms"}, {"id": "D010049", "term": "Ovarian Diseases"}, {"id": "D000291", "term": "Adnexal Diseases"}, {"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D005833", "term": "Genital Neoplasms, Female"}, {"id": "D014565", "term": "Urogenital Neoplasms"}, {"id": "D000091662", "term": "Genital Diseases"}, {"id": "D004700", "term": "Endocrine System Diseases"}, {"id": "D006058", "term": "Gonadal Disorders"}, {"id": "D007154", "term": "Immune System Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT05331053", "orgStudyIdInfo": {"id": "STUDY00009584"}, "organization": {"fullName": "Penn State University", "class": "OTHER"}, "briefTitle": "MicroRNA Activation of LOX-1 Mechanisms in Endometriosis", "officialTitle": "MicroRNA Activation of LOX-1 Mechanisms in Endometriosis"}, "statusModule": {"statusVerifiedDate": "2025-01", "overallStatus": "TERMINATED", "whyStopped": "COVID halting human subjects research and preliminary data from this proposal were used to submit an NIH grant. The NIH grant was funded and 3 other protocols were launched.", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2018-05-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2022-06-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2024-08-31", "type": "ACTUAL"}, "studyFirstSubmitDate": "2022-04-08", "studyFirstSubmitQcDate": "2022-04-08", "studyFirstPostDateStruct": {"date": "2022-04-15", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2023-11-27", "resultsFirstSubmitQcDate": "2024-02-05", "resultsFirstPostDateStruct": {"date": "2024-02-28", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2025-01-15", "lastUpdatePostDateStruct": {"date": "2025-01-30", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Lacy Alexander", "investigatorTitle": "Professor of Kinesiology, Physiology", "investigatorAffiliation": "Penn State University"}, "leadSponsor": {"name": "Penn State University", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "Endometriosis is a disorder that occurs in women. With endometriosis, tissue that should be found in the womb is found in sites outside of the womb. This disorder impairs the function of the cells that line the body's blood vessels (endothelium). The endothelium helps to control blood flow in healthy vessels. Women with this disorder have an increased risk for high blood pressure and high cholesterol. They have a higher risk for cardiovascular disease, too. With this study, we will learn how endometriosis impairs the lining of blood vessels and increases the risk for disease.", "detailedDescription": "Epidemiologic data demonstrate a clear association between endometriosis, reproductive risk factors, inflammation and cardiovascular (CV) risk. Circulating factors, Low-density lipoprotein (LDL) and oxidized LDL (oxLDL), are two of many biomarkers of cardiovascular and inflammatory disease of endometriosis. An important signaling mechanism through which circulating LDL and oxLDL act is the lectin-like oxidized LDL receptor (LOX-1). LOX-1 signal transduction functionally results in pronounced endothelial dysfunction, a hallmark of CV. We hypothesis that one factor mediating the elevated risk of cardiovascular disease in endometriosis is microRNA (miRNA) activation of LOX-1 receptor mechanisms.\n\nSpecific Aim 1. To test the hypothesis that LOX-1 receptor activation is increased leading to endothelial dysfunction in endometriosis.\n\nSpecific Aim 2. To test the hypothesis that decreased microRNAs (i.e. let7-a, let7-b, let7-g, MiR98, Mi590-p) are driving increased LOX-1 receptor expression and function in endometriosis."}, "conditionsModule": {"conditions": ["Endometriosis"], "keywords": ["Skin blood flow", "Cholesterol", "Statin", "Intradermal Microdialysis"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "interventionModelDescription": "Only women with endometriosis will complete this study. Once consented and screened, each subject is asked to take Atorvastatin (Lipitor, 10mg/day) for seven days. Participants will undergo experimental testing before and after the seven day intervention.", "primaryPurpose": "BASIC_SCIENCE", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 6, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Atorvastatin", "type": "EXPERIMENTAL", "description": "Oral atorvastatin (Lipitor) therapy (10mg/day) for seven days.\n\nAtorvastatin acts as a systemic LOX inhibitor.", "interventionNames": ["Drug: Atorvastatin"]}], "interventions": [{"type": "DRUG", "name": "Atorvastatin", "description": "Simvastation acts as a systemic LOX inhibitor.", "armGroupLabels": ["Atorvastatin"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in Nitric Oxide Dependent Vasodilation in the Skin", "description": "area under the curve of laser Doppler flux/mean arterial pressure \\* log acetylcholine (mol/L)", "timeFrame": "before and after intervention (7 days)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Women between the ages of 18 and 45 years with endometriosis (diagnosis by prior laparoscopy by subject's own physician \\<5 years prior, and reported by the subject to the researchers)\n\nExclusion Criteria:\n\n* Use of nicotine-containing products (e.g. smoking, chewing tobacco, etc.)\n* Diabetes (HbA1C .6.5%)\n* BP\\>140/90\n* Taking pharmacotherapy that could alter peripheral vascular control (e.g. insulin sensitizing, cardiovascular medications)\n* Pregnancy\n* Breastfeeding\n* Taking illicit and/or recreational drugs\n* Abnormal liver function\n* Rash, skin disease, disorders of pigmentation, known skin allergies\n* Diagnosed or suspected metabolic or cardiovascular disease\n* Persistent unexplained elevations of serum transaminases\n* Known allergy to latex or investigative substances", "healthyVolunteers": true, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "45 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "The Pennsylvania State University", "city": "University Park", "state": "Pennsylvania", "zip": "16801", "country": "United States", "geoPoint": {"lat": 40.80201, "lon": -77.85639}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "6 enrolled", "recruitmentDetails": "All endometriosis patients had a confirmed diagnosis prior to enrollment via laparoscopy.", "groups": [{"id": "FG000", "title": "Atorvastatin", "description": "Oral atorvastatin (Lipitor) therapy (10mg/day) for seven days."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Atorvastatin", "description": "Oral atorvastatin (Lipitor) therapy (10mg/day) for seven days.\n\nAtorvastatin acts as a systemic LOX inhibitor.\n\nAtorvastatin: Simvastation acts as a systemic LOX inhibitor."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "6"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "33", "spread": "9"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "6"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "1"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "5"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "5"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "1"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "6"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in Nitric Oxide Dependent Vasodilation in the Skin", "description": "area under the curve of laser Doppler flux/mean arterial pressure \\* log acetylcholine (mol/L)", "populationDescription": "A subset (n = 6) of endometriosis patients participated in a seven-day oral atorvastatin (Lipitor®) therapy (10 mg/day). These subjects returned to the laboratory on day 7, having taken the final dose that morning.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "flux/MAP*logAch(mol/L)", "timeFrame": "before and after intervention (7 days)", "groups": [{"id": "OG000", "title": "Atorvastatin", "description": "Oral atorvastatin (Lipitor) therapy (10mg/day) for seven days.\n\nAtorvastatin acts as a systemic LOX inhibitor.\n\nAtorvastatin: Simvastation acts as a systemic LOX inhibitor."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "200", "spread": "80"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "2 weeks", "description": "other", "eventGroups": [{"id": "EG000", "title": "Atorvastatin", "description": "Oral atorvastatin (Lipitor) therapy (10mg/day) for seven days.\n\nAtorvastatin acts as a systemic LOX inhibitor.\n\nAtorvastatin: Simvastation acts as a systemic LOX inhibitor.", "deathsNumAffected": 0, "deathsNumAtRisk": 6, "seriousNumAffected": 0, "seriousNumAtRisk": 6, "otherNumAffected": 0, "otherNumAtRisk": 6}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Lacy M. Alexander, Ph.D.", "organization": "Penn State University", "email": "lma191@psu.edu", "phone": "8148671781"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2022-02-16", "uploadDate": "2023-11-27T14:40", "filename": "Prot_SAP_000.pdf", "size": 434932}, {"typeAbbrev": "ICF", "hasProtocol": false, "hasSap": false, "hasIcf": true, "label": "Informed Consent Form", "date": "2021-01-28", "uploadDate": "2023-11-27T14:41", "filename": "ICF_001.pdf", "size": 185455}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04", "submissionTracking": {"firstMcpInfo": {"postDateStruct": {"date": "2023-12-22", "type": "ACTUAL"}}}}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000069059", "term": "Atorvastatin"}], "ancestors": [{"id": "D011758", "term": "Pyrroles"}, {"id": "D001393", "term": "Azoles"}, {"id": "D006573", "term": "Heterocyclic Compounds, 1-Ring"}, {"id": "D006571", "term": "Heterocyclic Compounds"}, {"id": "D006538", "term": "Heptanoic Acids"}, {"id": "D005227", "term": "Fatty Acids"}, {"id": "D008055", "term": "Lipids"}]}}, "hasResults": true}, {"protocolSection": {"identificationModule": {"nctId": "NCT06445179", "orgStudyIdInfo": {"id": "2024-A00350-47"}, "organization": {"fullName": "GCS Ramsay Santé pour l'Enseignement et la Recherche", "class": "OTHER"}, "briefTitle": "ENDOmetriosis Robotic Assisted Surgery", "officialTitle": "Robot-Assisted Versus Standard Laparoscopic Approach of Total Hysterectomy for Deep Infiltrating Endometriosis and Adenomyosis: A Multicenter, Open-label Randomized Controlled Trial", "acronym": "ENDO-RAS"}, "statusModule": {"statusVerifiedDate": "2025-04", "overallStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2025-04-16", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2027-06", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2027-06", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2024-05-27", "studyFirstSubmitQcDate": "2024-05-31", "studyFirstPostDateStruct": {"date": "2024-06-06", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2025-04-18", "lastUpdatePostDateStruct": {"date": "2025-04-24", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "GCS Ramsay Santé pour l'Enseignement et la Recherche", "class": "OTHER"}, "collaborators": [{"name": "Euraxi Pharma", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to compare the robot-assisted approach with the laparoscopic approach in terms of reducing the rates of intraoperative and postoperative complications in patients undergoing total hysterectomy for DIE and adenomyosis without digestive tract involvement.", "detailedDescription": "The ENDO-RAS trial aims to evaluate the safety and effectiveness of robot-assisted laparoscopy compared to conventional laparoscopy for hysterectomy in patients with Deep infiltrating endometriosis and adenomyosis without digestive tract involvement, as verified by magnetic resonance imaging and classified using both the ENZIAN and Deep Pelvic Endometriosis Index classifications. These classifications are used to evaluate Deep infiltrating endometriosis and reproducibly predict the occurrence of postoperative complications.\n\nEligible patients will be recruited from the gynecological surgery department after meeting the inclusion and non-inclusion criteria and signed informed consent forms. Participants will then be randomly assigned to receive either robot-assisted total laparoscopic hysterectomy or total laparoscopic hysterectomy.\n\nThe ENDO-RAS Trial is a multicenter, randomized, controlled, and open-label study. Eligible patients will be randomized into two parallel groups."}, "conditionsModule": {"conditions": ["Endometriosis"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": "Eligible patients will be randomized into two parallel groups.", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE", "maskingDescription": "The ENDO-RAS Trial is a multicenter, randomized, controlled, and open-label study."}}, "enrollmentInfo": {"count": 224, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "without Robotic-Assisted", "type": "ACTIVE_COMPARATOR", "description": "In the control group, all patients will undergo a Total Laparoscopic Hysterectomy. The number of ports needed for the laparoscope and assistants will be reported.", "interventionNames": ["Procedure: Total Laparoscopic Hysterectomy", "Device: Ureterolysis"]}, {"label": "Robotic-Assisted", "type": "EXPERIMENTAL", "description": "All patients in the experimental group will undergo a Robotic-Assisted Total Laparoscopic Hysterectomy using either the HugoTM Robot-Assisted Surgery system (Medtronic©), the Da Vinci® Xi or X Surgical System, or CMR versus (if available). The number of ports required for the laparoscope, robotic arms, and assistants will be documented.", "interventionNames": ["Procedure: Total Laparoscopic Hysterectomy", "Device: Ureterolysis"]}], "interventions": [{"type": "PROCEDURE", "name": "Total Laparoscopic Hysterectomy", "description": "The standard procedure for performing total hysterectomy will also follow the Querleu and Morrow classification system, which divides the procedure into four types based on the extent of resection:\n\n* Type A: minimum resection of paracervix.\n* Type B: transection of the paracervix and the ureter.\n* Type C: Transection of paracervix at the junction with the internal iliac vascular system\n* Type D: Laterally extended resection. Furthermore, bilateral ureterolysis will be performed with the option of bilateral concomitant salpingo-oophorectomy.", "armGroupLabels": ["Robotic-Assisted", "without Robotic-Assisted"]}, {"type": "DEVICE", "name": "Ureterolysis", "description": "unilateral or bilateral ureterolysis with or without bilateral adnexectomy", "armGroupLabels": ["Robotic-Assisted", "without Robotic-Assisted"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Intra and post-operative complication rates", "description": "Rate of intra- and post-operative complications (Clavien-Dindo grade 2 or higher) following surgery (Total Laparoscopic Hysterectomy).", "timeFrame": "3 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* ≥ 18 years of age.\n* Diagnosed adenomyosis, either internal or external (magnetic resonance imaging) per the Enzian and dPEI classifications.\n* Diagnosed deep infiltrating endometriosis per the Enzian and dPEI classifications, without the involvement of the digestive tract.\n* Failure of first- and second-line medical treatment.\n* Eligibility for total hysterectomy with complete removal of endometriosis lesions.\n* Participants covered by entitled to social security.\n* All participants must provide written informed consent before undergoing the surgical procedure.\n\nExclusion Criteria:\n\n* Digestive tract involvement.\n* Adenomyosis only.\n* Contraindications to surgery.\n* Participants who are under guardianship, curatorship, or deprivation of liberty.", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Pierre MD COLLINET", "role": "CONTACT", "phone": "677707402", "phoneExt": "+33", "email": "pierre.collinet@hotmail.fr"}], "locations": [{"facility": "Hôpital Privé de Provence", "status": "RECRUITING", "city": "Aix-en-Provence", "zip": "13080", "country": "France", "contacts": [{"name": "Jean-Philippe ESTRADE, MD", "role": "CONTACT", "email": "jeanphilippeestrade@me.com"}], "geoPoint": {"lat": 43.5283, "lon": 5.44973}}, {"facility": "Hôpital Privé le Bois", "status": "NOT_YET_RECRUITING", "city": "Lille", "zip": "59000", "country": "France", "contacts": [{"name": "Pierre MD COLLINET", "role": "CONTACT", "email": "pierre.collinet@hotmail.fr"}], "geoPoint": {"lat": 50.63391, "lon": 3.05512}}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT05175248", "orgStudyIdInfo": {"id": "Pro00059650"}, "organization": {"fullName": "Physicians Committee for Responsible Medicine", "class": "OTHER"}, "briefTitle": "Nutritional Intervention for Endometriosis", "officialTitle": "A Randomized Controlled Trial of a Nutritional Intervention for Endometriosis"}, "statusModule": {"statusVerifiedDate": "2024-11", "overallStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2022-03-02", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2025-11", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2025-11", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2021-12-14", "studyFirstSubmitQcDate": "2021-12-14", "studyFirstPostDateStruct": {"date": "2022-01-03", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2024-11-04", "lastUpdatePostDateStruct": {"date": "2024-11-06", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Physicians Committee for Responsible Medicine", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false, "isUsExport": false}, "descriptionModule": {"briefSummary": "In a 12-week parallel study, women with a verified diagnosis of endometriosis will be randomly assigned to follow a low-fat plant-based diet or to stay on their usual diets for 12 weeks. Participants in both groups will be asked to make no changes to their exercise patterns for the study period. Changes in pain, quality of life, and inflammatory biomarkers from baseline to final will be the primary outcomes. Secondary outcomes will include changes in body weight, blood lipids, gut microbiome composition, and hormonal changes.", "detailedDescription": "Endometriosis is a chronic, painful condition that affects 5-10% of reproductive aged women. It is characterized by the presence of endometrial cells outside the uterus, causing pain and infertility. Current therapies to temporarily control symptoms include surgery and medical options with significant side effects. Women with endometriosis may have several surgeries by their mid-20s. The medical costs associated with endometriosis in the US alone are about $3.6 billion annually, and the total annual health care cost associated with endometriosis in 2002 was $22 billion, one-third of which is direct health care costs, with two-thirds attributed to loss of productivity.\n\nDiet may play important roles in endometriosis through its effect on circulating estrogen concentrations and inflammatory processes. Reduced fat intake and increased fiber intake have been shown to reduce estrogen levels, a key determinant of endometriosis activity. Some evidence suggests a pathogenic role for the gut microbiome, which influences the mucosal immune system and pelvic inflammation. The microbiome is responsive to short term dietary intervention, although long term changes have not been well characterized.\n\nTherefore, the investigators propose a novel intervention strategy using a plant-based diet to improve pain, inflammation, and quality of life.\n\nThe morbidity caused by endometriosis is substantial in terms of pain, reduced quality of life, lost productivity, and effects on relationships. Current medical therapies are limited in efficacy and have major side effects. Typical palliative surgery does not cure endometriosis. Better understanding of diet's ability to influence the disease process has the potential to improve quality of life and daily functioning without the cost and side effects of current therapies."}, "conditionsModule": {"conditions": ["Endometriosis"], "keywords": ["endometriosis", "plant-based", "vegan", "low-fat", "diet", "nutrition"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 120, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Plant-based Intervention Group", "type": "EXPERIMENTAL", "description": "Intervention group participants will adopt a low-fat, plant-based diet for 12 weeks. Participants will be provided with a commercially available supplement containing 100 micrograms of vitamin B12 and asked to take it daily during the study. Alcoholic beverages will be limited to 1 per day. Participants will be asked to keep their physical activity level constant.", "interventionNames": ["Behavioral: Plant-based Intervention Group"]}, {"label": "Control Group", "type": "NO_INTERVENTION", "description": "Control group participants will be asked to maintain their usual diet for the duration of the 12-week study period. Participants will be provided with a commercially available supplement containing 100 micrograms of vitamin B12 and asked to take it daily during the study. Alcoholic beverages will be limited to 1 per day. Participants will be asked to keep their physical activity level constant. At the conclusion of the 12 weeks, control group participants will be offered instruction in the plant-based diet."}], "interventions": [{"type": "BEHAVIORAL", "name": "Plant-based Intervention Group", "description": "Participants in the intervention group will be instructed in ways to adopt a plant-based diet, use appropriate methods of food preparation, and make meals enjoyable and appetizing. The plant-based diet primarily emphasizes whole grains, vegetables, beans and legumes, and fruits. Animal products and added oils will be proscribed and the use of ultra-processed foods, sugar, and sugar-sweetened beverages will be discouraged. Fat intake will be limited to 20-30 g/day.", "armGroupLabels": ["Plant-based Intervention Group"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Modified Biberoglu and Behrman Scale: change from baseline", "description": "Endometriosis-specific pain scale will be used. For inclusion in study, participants require a score of at least 5/9.", "timeFrame": "at baseline and at 12 weeks"}, {"measure": "Endometriosis Health Profile (EHP-30): change from baseline", "description": "The EHP-30 questionnaire is the only validated quality of life questionnaire for the use in endometriosis.", "timeFrame": "at baseline and at 12 weeks"}, {"measure": "Inflammatory biomarkers: change from baseline", "description": "Blood tests for biomarkers of inflammation (hsCRP, TNF-alpha, IL-1 beta and IL-6).", "timeFrame": "at baseline and at 12 weeks"}], "secondaryOutcomes": [{"measure": "Body weight: change from baseline", "description": "Weight will be measured using a self-calibrating scale (Renpho).", "timeFrame": "at baseline and at 12 weeks"}, {"measure": "Blood lipids: change from baseline", "description": "Change in blood lipids assessed via blood tests including lipid panels.", "timeFrame": "at baseline and at 12 weeks"}, {"measure": "Estrogen levels: change from baseline", "description": "Estradiol, free estradiol, and sex hormone binding globulin (SHBG) will be measured through blood tests.", "timeFrame": "at baseline and at 12 weeks"}, {"measure": "Gut microbiome composition: change from baseline", "description": "Participants will collect stool samples for microbiome analysis. Sample collection will be carried out using home collection procedures with samples returned through local post. The participants will apply a small smear to the tips of a swab from used toilet paper. The swab will, in turn, be used to transfer the smear to a fecal occult blood test (FOBT) card that will be returned by mail to a laboratory for analysis.", "timeFrame": "at baseline and at 12 weeks"}, {"measure": "Biomarkers of endometriosis and inflammation: change from baseline", "description": "Plasma levels of brain-derived neurotrophic factor (BDNF) and IL-10 will be measured through blood tests.", "timeFrame": "at baseline and at 12 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Women with a surgical, imaging, or clinical diagnosis of endometriosis\n2. Age 18-45 years\n3. Stable health condition and medications for past 3 months\n4. Modified Biberoglu and Behrman (B\\&B) pelvic pain score of at least 5/9\n5. Able to follow a plant-based diet for 12 weeks\n6. Willing to be randomly assigned to either a plant-based group or a control group that will not make any dietary changes for 12 weeks\n\nExclusion Criteria:\n\n1. Body mass index ≥ 40 kg/m2\n2. Smoking or drug abuse during the past six months\n3. Alcohol consumption of more than 2 drinks per day or the equivalent, episodic increased drinking (e.g., more than 2 drinks per day on weekends), or a history of alcohol abuse or dependency followed by any current use\n4. Unstable medical or psychiatric illness\n5. Already following a plant-based diet\n6. Pregnant or breastfeeding, or plans of pregnancy within the study period\n7. Hysterectomy or ovariectomy\n8. Fibroids, ovarian cysts, pelvic inflammatory disease\n9. Endocrine inflammatory conditions, such as Cushing's syndrome, Hashimoto's thyroiditis, Graves' disease, type 1 diabetes mellitus, and Addison's disease\n10. Lack of English fluency\n11. Unable or unwilling to participate in all components of the study\n12. Evidence of an eating disorder", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "45 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Macy Sutton, MS", "role": "CONTACT", "phone": "202-527-7385", "email": "msutton@pcrm.org"}, {"name": "Tatiana Znayenko-Miller, MS", "role": "CONTACT", "phone": "202-527-7317", "email": "tznayenkomiller@pcrm.org"}], "overallOfficials": [{"name": "Hana Kahleova, MD, PhD", "affiliation": "Physicians Committee for Responsible Medicine", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Neal Barnard, MD", "affiliation": "Physicians Committee for Responsible Medicine", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Physicians Committee for Responsible Medicine", "status": "RECRUITING", "city": "Washington D.C.", "state": "District of Columbia", "zip": "20016", "country": "United States", "contacts": [{"name": "Macy Sutton, MS", "role": "CONTACT", "phone": "2025277385", "email": "msutton@pcrm.org"}, {"name": "Danielle Holtz, BS", "role": "CONTACT", "phone": "2025277363", "email": "dholtz@pcrm.org"}, {"name": "Hana Kahleova, MD, PhD", "role": "CONTACT"}], "geoPoint": {"lat": 38.89511, "lon": -77.03637}}]}, "referencesModule": {"references": [{"pmid": "15980014", "type": "BACKGROUND", "citation": "Kennedy S, Bergqvist A, Chapron C, D'Hooghe T, Dunselman G, Greb R, Hummelshoj L, Prentice A, Saridogan E; ESHRE Special Interest Group for Endometriosis and Endometrium Guideline Development Group. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod. 2005 Oct;20(10):2698-704. doi: 10.1093/humrep/dei135. Epub 2005 Jun 24."}, {"pmid": "22562031", "type": "BACKGROUND", "citation": "Khanaki K, Nouri M, Ardekani AM, Ghassemzadeh A, Shahnazi V, Sadeghi MR, Darabi M, Mehdizadeh A, Dolatkhah H, Saremi A, Imani AR, Rahimipour A. Evaluation of the relationship between endometriosis and omega-3 and omega-6 polyunsaturated fatty acids. Iran Biomed J. 2012;16(1):38-43. doi: 10.6091/ibj.1025.2012."}, {"pmid": "9572232", "type": "BACKGROUND", "citation": "Marik JJ. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Obstet Gynecol. 1998 May;91(5 Pt 1):793-4. doi: 10.1097/00006250-199805000-00029. No abstract available."}, {"pmid": "18165396", "type": "BACKGROUND", "citation": "Stratton P, Sinaii N, Segars J, Koziol D, Wesley R, Zimmer C, Winkel C, Nieman LK. Return of chronic pelvic pain from endometriosis after raloxifene treatment: a randomized controlled trial. Obstet Gynecol. 2008 Jan;111(1):88-96. doi: 10.1097/01.AOG.0000297307.35024.b5."}, {"pmid": "23427182", "type": "BACKGROUND", "citation": "Rogers PA, D'Hooghe TM, Fazleabas A, Giudice LC, Montgomery GW, Petraglia F, Taylor RN. Defining future directions for endometriosis research: workshop report from the 2011 World Congress of Endometriosis In Montpellier, France. Reprod Sci. 2013 May;20(5):483-99. doi: 10.1177/1933719113477495. Epub 2013 Feb 20."}, {"pmid": "8039147", "type": "BACKGROUND", "citation": "Goldin BR, Woods MN, Spiegelman DL, Longcope C, Morrill-LaBrode A, Dwyer JT, Gualtieri LJ, Hertzmark E, Gorbach SL. The effect of dietary fat and fiber on serum estrogen concentrations in premenopausal women under controlled dietary conditions. Cancer. 1994 Aug 1;74(3 Suppl):1125-31. doi: 10.1002/1097-0142(19940801)74:3+3.0.co;2-5."}, {"pmid": "27541692", "type": "BACKGROUND", "citation": "Sender R, Fuchs S, Milo R. Revised Estimates for the Number of Human and Bacteria Cells in the Body. PLoS Biol. 2016 Aug 19;14(8):e1002533. doi: 10.1371/journal.pbio.1002533. eCollection 2016 Aug."}, {"pmid": "16741115", "type": "BACKGROUND", "citation": "Gill SR, Pop M, Deboy RT, Eckburg PB, Turnbaugh PJ, Samuel BS, Gordon JI, Relman DA, Fraser-Liggett CM, Nelson KE. Metagenomic analysis of the human distal gut microbiome. Science. 2006 Jun 2;312(5778):1355-9. doi: 10.1126/science.1124234."}, {"pmid": "26002030", "type": "BACKGROUND", "citation": "Longman RS, Littman DR. The functional impact of the intestinal microbiome on mucosal immunity and systemic autoimmunity. Curr Opin Rheumatol. 2015 Jul;27(4):381-7. doi: 10.1097/BOR.0000000000000190."}, {"pmid": "22674334", "type": "BACKGROUND", "citation": "Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. Science. 2012 Jun 8;336(6086):1268-73. doi: 10.1126/science.1223490. Epub 2012 Jun 6."}, {"pmid": "18854238", "type": "BACKGROUND", "citation": "Ivanov II, Frutos Rde L, Manel N, Yoshinaga K, Rifkin DB, Sartor RB, Finlay BB, Littman DR. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe. 2008 Oct 16;4(4):337-49. doi: 10.1016/j.chom.2008.09.009."}, {"pmid": "20620945", "type": "BACKGROUND", "citation": "Wu HJ, Ivanov II, Darce J, Hattori K, Shima T, Umesaki Y, Littman DR, Benoist C, Mathis D. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity. 2010 Jun 25;32(6):815-27. doi: 10.1016/j.immuni.2010.06.001."}, {"pmid": "16009137", "type": "BACKGROUND", "citation": "Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell. 2005 Jul 15;122(1):107-18. doi: 10.1016/j.cell.2005.05.007."}, {"pmid": "18509436", "type": "BACKGROUND", "citation": "Mazmanian SK, Round JL, Kasper DL. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature. 2008 May 29;453(7195):620-5. doi: 10.1038/nature07008."}, {"pmid": "16267321", "type": "BACKGROUND", "citation": "Fredricks DN, Fiedler TL, Marrazzo JM. Molecular identification of bacteria associated with bacterial vaginosis. N Engl J Med. 2005 Nov 3;353(18):1899-911. doi: 10.1056/NEJMoa043802."}, {"pmid": "20534435", "type": "BACKGROUND", "citation": "Ravel J, Gajer P, Abdo Z, Schneider GM, Koenig SS, McCulle SL, Karlebach S, Gorle R, Russell J, Tacket CO, Brotman RM, Davis CC, Ault K, Peralta L, Forney LJ. Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci U S A. 2011 Mar 15;108 Suppl 1(Suppl 1):4680-7. doi: 10.1073/pnas.1002611107. Epub 2010 Jun 3."}, {"pmid": "22719852", "type": "BACKGROUND", "citation": "Srinivasan S, Hoffman NG, Morgan MT, Matsen FA, Fiedler TL, Hall RW, Ross FJ, McCoy CO, Bumgarner R, Marrazzo JM, Fredricks DN. Bacterial communities in women with bacterial vaginosis: high resolution phylogenetic analyses reveal relationships of microbiota to clinical criteria. PLoS One. 2012;7(6):e37818. doi: 10.1371/journal.pone.0037818. Epub 2012 Jun 18."}, {"pmid": "24336217", "type": "BACKGROUND", "citation": "David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, Ling AV, Devlin AS, Varma Y, Fischbach MA, Biddinger SB, Dutton RJ, Turnbaugh PJ. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014 Jan 23;505(7484):559-63. doi: 10.1038/nature12820. Epub 2013 Dec 11."}, {"pmid": "30625295", "type": "BACKGROUND", "citation": "Agarwal SK, Chapron C, Giudice LC, Laufer MR, Leyland N, Missmer SA, Singh SS, Taylor HS. Clinical diagnosis of endometriosis: a call to action. Am J Obstet Gynecol. 2019 Apr;220(4):354.e1-354.e12. doi: 10.1016/j.ajog.2018.12.039. Epub 2019 Jan 6."}, {"pmid": "20567196", "type": "BACKGROUND", "citation": "Practice bulletin no. 114: management of endometriosis. Obstet Gynecol. 2010 Jul;116(1):223-236. doi: 10.1097/AOG.0b013e3181e8b073. No abstract available."}, {"pmid": "1786335", "type": "BACKGROUND", "citation": "Ridout MS. Testing for random dropouts in repeated measurement data. Biometrics. 1991 Dec;47(4):1617-9; discussion 1619-21."}, {"type": "BACKGROUND", "citation": "Paik, MC, Quasi-likelihood regression models with missing covariates, Biometrika 1996: Vol. 83, No. 4., 825-834"}, {"pmid": "3153505", "type": "BACKGROUND", "citation": "Gibbons RD, Hedeker D, Waternaux C, Davis JM. Random regression models: a comprehensive approach to the analysis of longitudinal psychiatric data. Psychopharmacol Bull. 1988;24(3):438-43. No abstract available."}, {"type": "BACKGROUND", "citation": "Hedeker D, Gibbons R, Waternaux C. Sample size estimation for longitudinal designs with attrition: Comparing time-related contrasts between two groups. Journal of Educational and Behavioral Statistics. 1999; 24:70-93."}, {"type": "BACKGROUND", "citation": "Westfall PH and Young SS. (1993). Resampling-based Multiple Testing: Examples and Methods for Multiple P-value Adjustment. John Wiley & Sons: New York."}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT06392997", "orgStudyIdInfo": {"id": "ZWG-24-01"}, "organization": {"fullName": "ZIWIG", "class": "INDUSTRY"}, "briefTitle": "Evaluation of Salivary RNA in Subjects Scheduled for Surgery for a Gynecologic Pathology", "officialTitle": "Evaluation of Salivary RNA in Subjects Scheduled for Surgery for a Gynecologic Pathology", "acronym": "GynRNA"}, "statusModule": {"statusVerifiedDate": "2025-01", "overallStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2024-12-05", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2026-12", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2026-12", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2024-04-09", "studyFirstSubmitQcDate": "2024-04-25", "studyFirstPostDateStruct": {"date": "2024-05-01", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2025-01-20", "lastUpdatePostDateStruct": {"date": "2025-01-23", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "ZIWIG", "class": "INDUSTRY"}, "collaborators": [{"name": "Monitoring Force Group", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false, "isUsExport": false}, "descriptionModule": {"briefSummary": "GynRAN is an international, multicentre, transversal, diagnostic and non-interventional study carried out in gynecology-obstetrics/gynecological oncology departments that aims to identify a diagnostic signature for gynecological pathologies by analyzing of coding and non-coding RNA contained in patients saliva.\n\nThe study population consists of patients with clinically symptomatic females with one or more of the gynecological pathologies (endometriosis, adenomyosis, ovarian cysts, fibroids, ovarian/cervical/uterine cancer) and asymptomatic females.\n\nThe patients concerned by the study will be managed without modification of the care pathway, nor modification of the therapeutic indications, nor modification of the diagnostic or follow-up examinations necessary according to the context, which are carried out according to the local recommendations."}, "conditionsModule": {"conditions": ["Gynecologic Disease", "Gynecologic Cancer", "Endometriosis", "Ovarian Cancer", "Cyst Ovary", "Fibroid", "Cervical Cancer", "Uterine Cancer"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "COHORT", "timePerspective": "PROSPECTIVE"}, "bioSpec": {"retention": "SAMPLES_WITHOUT_DNA", "description": "Salivary samples"}, "enrollmentInfo": {"count": 2500, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Symptomatic group", "description": "Clinically symptomatic females with one or more of the following gynecological pathology:\n\n* Endometriosis,\n* Adenomyosis,\n* Ovarian cysts,\n* Fibroids,\n* Ovarian cancer,\n* Cervical cancer\n* Uterine cancer.", "interventionNames": ["Diagnostic Test: Saliva sample"]}, {"label": "Asymptomatic group", "description": "Asymptomatic females with:\n\n* Cervical dysplasia or cancer\n* A normal pap-smear (control)", "interventionNames": ["Diagnostic Test: Saliva sample"]}], "interventions": [{"type": "DIAGNOSTIC_TEST", "name": "Saliva sample", "description": "Saliva sample", "armGroupLabels": ["Asymptomatic group", "Symptomatic group"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Area under the curve (AUC) of the Receiver Operating Curve (ROC)", "description": "Identify a diagnostic signature for each pathology (Endometriosis / Adenomyosis / Ovarian cysts / Fibroids / Cervical Displasia / Ovarian cancer / Cervical cancer /Uterine cancer) by analyzing of coding and non-coding RNA contained in the saliva.", "timeFrame": "Through the end of study inclusions, an average of 1 year"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Subject of legal age (according to local legislation) and at least 18 years old\n2. Subject (and if applicable her legal representative) having dated and signed the informed consent form\n3. Subject with a medical insurance policy\n4. Subject presenting to the department:\n\n   1. With Symptoms (bleeding and/or pain and/or clinically observed symptom) of one or more of the following pathologies (suspected undergoing diagnostic surgery/biopsy or diagnosed and before any curative treatment of the pathology):\n\n      * Endometriosis\n      * Adenomyosis,\n      * Ovarian cysts,\n      * Fibroids,\n      * Ovarian cancer,\n      * Cervical cancer,\n      * Uterine cancer.\n   2. Asymptomatic with pap smear positive for cervical dysplasia or cervical cancer and before any curative treatment.\n   3. Asymptomatic undergoing a pap smear for cervical cancer screening in a gynecological follow-up context.\n\nExclusion Criteria:\n\n1. Recent (\\<1 month) or ongoing bacterial or viral infection\n2. Known active oral or digestive mycosis\n3. Evolving oral pathology, symptomatic or obvious\n4. Known pregnancy\n5. Known current non-gynecological pelvic pathology\n6. Subject with a diagnosed breast cancer or cancer other than gynecological with the exception of basal cell carcinoma\n7. Subject with a history of treated cancer within the last 5 years with the exception of basal cell carcinoma\n8. Subject who has already received chemotherapy or radiotherapy or undergone complete or partial excision of the gynecological pathology of inclusion criterion\n9. Subject with significant difficulties reading or writing her language\n10. Subject unable to comply with study and/or follow-up procedures\n11. Participation in an interventional study with investigational drug or in the exclusion period of an interventional study.", "healthyVolunteers": true, "sex": "FEMALE", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"], "studyPopulation": "The study populations is constituted of s:\n\n1. Clinically symptomatic females with one or more of the following gynecological pathology:\n\n   * Endometriosis,\n   * Adenomyosis,\n   * Ovarian cysts,\n   * Fibroids,\n   * Ovarian cancer,\n   * Cervical cancer\n   * Uterine cancer.\n2. Asymptomatic females with:\n\n   * cervical dysplasia or cancer\n   * a normal pap-smear (control)", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"centralContacts": [{"name": "Sofiane Bendifallah, MD", "role": "CONTACT", "phone": "+33146412699", "email": "sofiane.bendifallah@yahoo.fr"}], "locations": [{"facility": "CHU d'Angers", "status": "NOT_YET_RECRUITING", "city": "Angers", "country": "France", "contacts": [{"name": "Léa DELBOS, Dr", "role": "CONTACT", "phone": "+33 2 41 76 28 62", "email": "lea.delbos@chu-angers.fr"}], "geoPoint": {"lat": 47.47156, "lon": -0.55202}}, {"facility": "Clinique Tivoli Ducos - IFEMENDO", "status": "RECRUITING", "city": "Bordeaux", "country": "France", "contacts": [{"name": "Horace ROMAN, Pr", "role": "CONTACT", "phone": "+33 5 64 10 09 45", "email": "horace.roman@gmail.com"}], "geoPoint": {"lat": 44.84124, "lon": -0.58046}}, {"facility": "Institut Bergonié", "status": "NOT_YET_RECRUITING", "city": "Bordeaux", "country": "France", "contacts": [{"name": "Frédéric GUYON, Dr", "role": "CONTACT", "phone": "+33 5 56 33 32 79", "email": "f.guyon@bordeaux.unicancer.fr"}], "geoPoint": {"lat": 44.84124, "lon": -0.58046}}, {"facility": "CHU Caen", "status": "RECRUITING", "city": "Caen", "zip": "14033", "country": "France", "contacts": [{"name": "Raffaèle Fauvet, Pr", "role": "CONTACT", "phone": "+33 2 31 27 23 36", "email": "fauvet-r@chu-caen.fr"}], "geoPoint": {"lat": 49.18585, "lon": -0.35912}}, {"facility": "CGFL", "status": "NOT_YET_RECRUITING", "city": "Dijon", "country": "France", "contacts": [{"name": "Hélène COSTAZ, Dr", "role": "CONTACT", "phone": "+33 6 66 35 55 33", "email": "hcostaz@cgfl.fr"}], "geoPoint": {"lat": 47.31344, "lon": 5.01391}}, {"facility": "CHU Lyon Sud", "status": "NOT_YET_RECRUITING", "city": "Lyon", "country": "France", "contacts": [{"name": "François GOLFIER, Pr", "role": "CONTACT", "phone": "+33 4 78 86 41 78", "email": "françois.golfier@chu-lyon.fr"}], "geoPoint": {"lat": 45.74906, "lon": 4.84789}}, {"facility": "American Hospital of Paris", "status": "NOT_YET_RECRUITING", "city": "Neuilly-sur-Seine", "country": "France", "contacts": [{"name": "Sofiane Bendifallah, MD", "role": "CONTACT", "phone": "+33146412699", "email": "sofiane.bendifallah@yahoo.fr"}], "geoPoint": {"lat": 48.8846, "lon": 2.26965}}, {"facility": "CHU de Rennes Site Hôpital Sud", "status": "NOT_YET_RECRUITING", "city": "Rennes", "country": "France", "contacts": [{"name": "Vincent LAVOUE, Pr", "role": "CONTACT", "phone": "+33 2 99 28 43 21", "email": "vincent.lavoue@chu-rennes.fr"}], "geoPoint": {"lat": 48.11109, "lon": -1.67431}}, {"facility": "Clinique La sagesse", "status": "NOT_YET_RECRUITING", "city": "Rennes", "country": "France", "contacts": [{"name": "Claire Marie ROGER, Dr", "role": "CONTACT", "phone": "+33 2 99 85 75 14", "email": "cmroger@lasagesse.fr"}], "geoPoint": {"lat": 48.11109, "lon": -1.67431}}, {"facility": "CHU Rouen", "status": "RECRUITING", "city": "Rouen", "country": "France", "contacts": [{"name": "Morgane PERRIN, Dr", "role": "CONTACT", "phone": "+33 2 32 88 89 90", "email": "Morganeperrin.mp@gmail.com"}], "geoPoint": {"lat": 49.44313, "lon": 1.09932}}, {"facility": "Clinique Pasteur", "status": "RECRUITING", "city": "Toulouse", "country": "France", "contacts": [{"name": "Ludivine Genre, Dr", "role": "CONTACT", "phone": "+33 5 62 21 39 49", "email": "lgenre@clinique-pasteur.com"}], "geoPoint": {"lat": 43.60426, "lon": 1.44367}}, {"facility": "CHU Bretonneau-Tours", "status": "RECRUITING", "city": "Tours", "country": "France", "contacts": [{"name": "Lobna OULDAMER, Pr", "role": "CONTACT", "phone": "+33 2 47 47 47 41", "email": "l.ouldamer@chu-tours.fr"}], "geoPoint": {"lat": 47.39484, "lon": 0.70398}}, {"facility": "Institut Gustave Roussy", "status": "NOT_YET_RECRUITING", "city": "Villejuif", "country": "France", "contacts": [{"name": "Alexandra LEARY, Dr", "role": "CONTACT", "phone": "+33 1 42 11 43 77", "email": "alexandra.leary@gustaveroussy.fr"}], "geoPoint": {"lat": 48.7939, "lon": 2.35992}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D004715", "term": "Endometriosis"}, {"id": "D010051", "term": "Ovarian Neoplasms"}, {"id": "D010048", "term": "Ovarian Cysts"}, {"id": "D007889", "term": "Leiomyoma"}, {"id": "D002583", "term": "Uterine Cervical Neoplasms"}, {"id": "D014594", "term": "Uterine Neoplasms"}], "ancestors": [{"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}, {"id": "D004701", "term": "Endocrine Gland Neoplasms"}, {"id": "D009371", "term": "Neoplasms by Site"}, {"id": "D009369", "term": "Neoplasms"}, {"id": "D010049", "term": "Ovarian Diseases"}, {"id": "D000291", "term": "Adnexal Diseases"}, {"id": "D005833", "term": "Genital Neoplasms, Female"}, {"id": "D014565", "term": "Urogenital Neoplasms"}, {"id": "D004700", "term": "Endocrine System Diseases"}, {"id": "D006058", "term": "Gonadal Disorders"}, {"id": "D003560", "term": "Cysts"}, {"id": "D009379", "term": "Neoplasms, Muscle Tissue"}, {"id": "D018204", "term": "Neoplasms, Connective and Soft Tissue"}, {"id": "D009370", "term": "Neoplasms by Histologic Type"}, {"id": "D002577", "term": "Uterine Cervical Diseases"}, {"id": "D014591", "term": "Uterine Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT05951452", "orgStudyIdInfo": {"id": "RECHMPL23_0057"}, "organization": {"fullName": "University Hospital, Montpellier", "class": "OTHER"}, "briefTitle": "The Developmental Origins of Endometriosis", "officialTitle": "The Developmental Origins of Endometriosis", "acronym": "ENDOHaD"}, "statusModule": {"statusVerifiedDate": "2025-01", "overallStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2024-01-08", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2026-01-08", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2026-01-08", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2023-06-29", "studyFirstSubmitQcDate": "2023-07-10", "studyFirstPostDateStruct": {"date": "2023-07-19", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2025-01-17", "lastUpdatePostDateStruct": {"date": "2025-01-22", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "University Hospital, Montpellier", "class": "OTHER"}, "collaborators": [{"name": "Centre National de la Recherche Scientifique, France", "class": "OTHER"}, {"name": "Fondation pour la Recherche sur l'Endométriose", "class": "UNKNOWN"}, {"name": "Fondation pour la Recherche Médicale", "class": "OTHER"}, {"name": "Université Montpellier", "class": "OTHER"}]}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "Introduction:\n\nEndometriosis is a common pathology affecting one in 10 women, characterized by the ectopic development of endometrium, which can cause pain and/or infertility. This pathology is primarily determined by hereditary factors, but it is also susceptible to environmental influences, such as the age of the onset of menstruation or exposure to chemical substances that modify the endocrine system. Recent studies have highlighted that endometriosis is more common in women with relatively short ano-genital distances (AGD), and that sensitivity to pain is closely linked to adult levels of testosterone (T) or oxytocin (OT).\n\nAim:\n\nThe main objective is to compare the anogenital distance (AGD) between two groups of women: one with stage III or IV endometriosis (ENDO +) and another group without endometriosis confirmed by laparoscopy (ENDO -).\n\nThe secondary objectives are to compare various factors between the 2 groups :\n\n* Basal testosterone levels in blood.\n* Variations in blood testosterone levels before and after a video stimulating empathy.\n* Basal oxytocin levels in saliva.\n* Variations in oxytocin levels in saliva before and after an empathy-stimulating video.\n* Pelvic pain, between D2 and D5 after the start of the menstrual cycle.\n\nFor the ENDO + group only:\n\n* Evaluate patients' quality of life, between D2 and D5 after the start of the menstrual cycle.\n* Correlate pain experienced over the last 4 weeks with hormonal markers (AGD, T, OT).\n\nMethods:\n\nParticipants in the ENDO+ group will fill in a questionnaire assessing the impact of pain experienced over the past 4 weeks on their quality of life. D0 is defined as the day when participants experience a menstrual bleed before 10 am. All participants will return for project-specific hospital appointment between D2 and D5 after the start of their menstrual cycle to measure T, Sex Hormone-Binding Globulin (SHBG) and OT.\n\nDuring this consultation, the following samples will be taken:\n\n* 10mL blood sample\n* 2mL saliva sample\n\nBoth samples will be taken at t0 (before watching the video) and t1 (20 minutes after watching the video)."}, "conditionsModule": {"conditions": ["Endometriosis"], "keywords": ["Endometriosis", "Testosterone", "Oxytocin", "DOHaD"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "CASE_CONTROL", "timePerspective": "PROSPECTIVE"}, "bioSpec": {"retention": "SAMPLES_WITHOUT_DNA", "description": "Serums and saliva extracts before and after wathching the empathy-inducing video"}, "enrollmentInfo": {"count": 40, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "ENDO +", "description": "Patients with endometriosis diagnosed by Magnetic Resonance Imaging (MRI) or laparoscopy", "interventionNames": ["Other: Blood samples for testosterone and SHBG measurements", "Other: Saliva samples for oxytocin measurements"]}, {"label": "ENDO -", "description": "Patients without endometriosis diagnosed by laparoscopy", "interventionNames": ["Other: Blood samples for testosterone and SHBG measurements", "Other: Saliva samples for oxytocin measurements"]}], "interventions": [{"type": "OTHER", "name": "Blood samples for testosterone and SHBG measurements", "description": "Several measurements of the testosterone concentration will be performed on serum from 10 mL of blood collected at:\n\n* t0 corresponding to the start of the hospital appointment and before watching the video\n* t1 which corresponds to 20 minutes after watching a 2 minutes empathy-inducing video", "armGroupLabels": ["ENDO +", "ENDO -"]}, {"type": "OTHER", "name": "Saliva samples for oxytocin measurements", "description": "Several measurements of the oxytocin concentration will be performed on 2 ml saliva samples:\n\n* t0 corresponding to 20 minutes after the start of the hospital appointment and before watching the video\n* t1 which corresponds to 20 minutes after watching a 2 minutes empathy-inducing video", "armGroupLabels": ["ENDO +", "ENDO -"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Measure of the anogenital distance (AGD)", "description": "AGD is measured at enrollment for patients already diagnosed by Magnetic resonance imaging (MRI), and it is measured during the laparoscopy once the diagnosis has been confirmed.\n\nAGD is measured by 2 different operators with a millimetric precision ruler according 2 validated methods :\n\n* measure of the distance from the clitoral surface to the anus (AGD-AC), and\n* measure of the distance from the posterior fourchette to the anus (AGD-AF). The method is described here: https://www.jove.com/v/57912/ Each operator will measure the AGD-AC and the AGD-AF 3 times. For each type of AGD, the final value will correspond to the mean of the 6 values.", "timeFrame": "At diagnosis or at inclusion"}], "secondaryOutcomes": [{"measure": "Basal total testosterone", "description": "The basal total testosterone (Ttotal(t0)) level is measured in blood", "timeFrame": "t0 : Between the second and the fifth day of the menstrual cycle, before wathching an empathy-inducing video"}, {"measure": "Basal bio-available testosterone", "description": "The basal bio-available testosterone (Tbio-available(t0)) level is measured in blood", "timeFrame": "t0 : Between the second and the fifth day of the menstrual cycle, before wathching an empathy-inducing video"}, {"measure": "Basal sex hormone-binding globulin", "description": "Basal sex hormone-binding globulin (SHBG(t0)) level is mesured in blood", "timeFrame": "t0 : Between the second and the fifth day of the menstrual cycle, before watching an empathy-inducing video"}, {"measure": "Basal Free Androgen Index", "description": "Basal Free Androgen Index (FAI(t0)) = (Ttotal(t0)/SHBG(t0))\\*100", "timeFrame": "t0 : Between the second and the fifth day of the menstrual cycle, before watching an empathy-inducing video"}, {"measure": "Total testosterone after empathy induction", "description": "The total testosterone level after empathy induction (Ttotal(t1)) is measured in blood", "timeFrame": "t1 : Between the second and the fifth day of the menstrual cycle, after wathching an empathy-inducing video"}, {"measure": "Bio-available testosterone after empathy induction", "description": "The bio-available testosterone level after empathy induction (Tbio-available(t1)) is measured in blood", "timeFrame": "t1 : Between the second and the fifth day of the menstrual cycle, after wathching an empathy-inducing video"}, {"measure": "Sex hormone-binding globulin after empathy induction", "description": "Sex hormone-binding globulin after empathy induction (SHBG(t1)) is mesured in blood", "timeFrame": "t1 : Between the second and the fifth day of the menstrual cycle, after wathching an empathy-inducing video"}, {"measure": "Free Androgen Index after empathy induction", "description": "Free Androgen Index after empathy induction (FAI(t1)) = (Ttotal(t1)/SHBG(t1))\\*100", "timeFrame": "t1 : Between the second and the fifth day of the menstrual cycle, after wathching an empathy-inducing video"}, {"measure": "Variation in total testosterone levels before and after an empathy-inducing video", "description": "The level of variation in total testosterone before (t0) and after watching empathy-inducing video (t1) is assessed according to: Ttotal(t1)-Ttotal(t0)", "timeFrame": "t1 : Between the second and the fifth day of the menstrual cycle, after wathching an empathy-inducing video"}, {"measure": "Variation in bio-available testosterone levels before and after an empathy-inducing video", "description": "The level of variation in bio-available testosterone before (t0) and after watching empathy-inducing video (t1) is assessed according to: Tbio-available(t1)-Tbio-available(t0)", "timeFrame": "t1 : Between the second and the fifth day of the menstrual cycle, after wathching an empathy-inducing video"}, {"measure": "Variation in Sex hormone-binding globulin levels before and after an empathy-inducing video", "description": "The level of variation in Sex hormone-binding globulin before (t0) and after watching empathy-inducing video (t1) is assessed according to: SHBG(t1)-SHBG(t0)", "timeFrame": "t1 : Between the second and the fifth day of the menstrual cycle, after wathching an empathy-inducing video"}, {"measure": "% of variation in Free Androgen Index before and after an empathy-inducing video", "description": "% of variation in Free Androgen Index before (t0) and after watching empathy-inducing video (t1) is assessed according to: \\[\\[FAI(t1)-FAI(t0)\\]/FAI(t0)\\] × 100", "timeFrame": "t1 : Between the second and the fifth day of the menstrual cycle, after wathching an empathy-inducing video"}, {"measure": "Basal oxytocin (OT) level", "description": "The basal OT level is measured by the dosage in the saliva of :\n\nTotal OT (OTtotal(t0))", "timeFrame": "t0 : Between the second and the fifth day of the menstrual cycle, before wathching an empathy-inducing video"}, {"measure": "Oxytocin (OT) level after empathy induction", "description": "The basal OT level is measured by the dosage in the saliva of :\n\nTotal OT (OTtotal(t1))", "timeFrame": "t1 : Between the second and the fifth day of the menstrual cycle, after wathching an empathy-inducing video"}, {"measure": "Variation in oxytocin (OT) level before and after an empathy-inducing video", "description": "Variation in OT level before (t0) and after watching an empathy-inducing video (t1) is assessed in the saliva according to:\n\n\\- OTtotal(t1)-OTtotal(t0)\n\n-% of variation of OT = \\[\\[OT(t1)-OT(t0)\\]/OT(t0)\\] × 100", "timeFrame": "t1 : Between the second and the fifth day of the menstrual cycle, after wathching empathy-inducing video"}, {"measure": "Area under the Receiving Operator Characteristic (ROC) curve for AGD", "description": "The ROC curve is a graphical representation that illustrates the performance of a binary classification model. It plots the true positive rate (sensitivity) against the false positive rate (1 - specificity) at various classification thresholds. In other words, the model's sensitivity corresponds to the model's ability to detect patients (ENDO+) while the model's specificity corresponds to the model's ability to detect a non-patient (ENDO-). The ROC curve helps assess the model's ability to correctly identify true positives while minimizing false positives.\n\nThe area under the ROC curve (AUC) can be interpreted as the probability that, among two randomly chosen subjects, a patient and a non-patient, the value of the marker is higher for the patient than for the non-sick. An AUC of 0.5 (50%) indicates that the marker is non-informative. An increase in AUC indicates an improvement in discriminatory abilities, with a maximum of 1.0 (100%).", "timeFrame": "At diagnosis (ENDO+) or at enrollment (ENDO-)"}, {"measure": "Pelvic pain intensity", "description": "Pelvic pain will be assessed using a Visual Analogue Scale (VAS). The visual analog scale (VAS) is a validated, unidimensional subjective measure for acute and chronic pain. Scores are recorded by making a handwritten mark on a 10-cm line that represents a continuum between \"no pain\" and \"worst pain.\"", "timeFrame": "t0 : Between the second and the fifth day of the menstrual cycle, before watching an empathy-inducing video"}], "otherOutcomes": [{"measure": "Quality of life (for the ENDO+ group only)", "description": "The quality of life of patients with endometriosis is assessed with the Endometriosis Health Profile questionnaire (EHP-30©)\n\nEHP-30 is a self-administered questionnaire validated in French to assess the effects that endometriosis can have on the quality of life of women. This questionnaire consists of 30 domains grouped into 5 areas:\n\nPain (11 items: n° 1 to 11), Control and helplessness (6 items: n°12 to 17), Emotional well-being (6 items: n°18 to 23), Social support (4 items: n°24 to 27), Self-image (3 items: n°28 to 30). Each item is rated on a Likert scale (Never=0, Rarely=1, Sometimes=2, Often=3, Always=4). Each domain is then represented by a score calculated on a scale from 0 (indicating the best possible state of health) to 100 (indicating the worst possible state of health): Domain score = \\[sum of responses to each item in the domain\\] / \\[4 (= maximum item response) × number domain items\\] × 100", "timeFrame": "t0 : Between the second and the fifth day of the menstrual cycle, before wathching an empathy-inducing video"}, {"measure": "Score of pain (for the ENDO+ group only)", "description": "The score of pain of patients with endometriosis is assessed with the French version of the Endometriosis Health Profile questionnaire (EHP-30©). The score of the first domain Pain consists of 11 items. Each item is rated on a Likert scale (Never=0, Rarely=1, Sometimes=2, Often=3, Always=4).", "timeFrame": "t0 : Between the second and the fifth day of the menstrual cycle, before wathching empathy-inducing video"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Nulliparous woman\n* No hormonal contraception for at least 3 months\n* Regular menstrual cycles (between 26 and 32 days) or proven ovulation (positive urine ovulation test ovulation test or progesterone level \\>3 ng/ml in the luteal phase)\n* Normal BMI (≥ 18,5 and \\< 30 kg/m²)\n\nSpecific criteria (ENDO+ group) :\n\n* Stage III or IV endometriosis confirmed by laparoscopy or by laparotomy or MRI\n* Painful symptoms\n\nSpecific criteria (ENDO- group) :\n\n• Patient without endometriosis confirmed by laparoscopy\n\nExclusion Criteria:\n\n* Ovarian stimulation planned within 3 months\n* Adenomyosis\n* Use of a copper coil\n* Polycystic ovary syndrome\n* Pudendal neuralgia\n* Episiotomy or lesion of the posterior perineum that may modify AGD\n* Diabetes or thyroid disease\n* Chronic liver failure, chronic renal failure, cardiac pathology, autoimmune disease\n* Autism\n* Diagnosis and/or treatment for psychiatric illness\n* Chronic exposure to cocaine, methamphetamine, morphine or ecstasy within 30 days before the inclusion visit\n* Chronic exposure to Tetrahydrocannabinol (THC) within 7 days prior to inclusion.\n* Patient on treatment(s) that vary oxytocin (e.g. atosiban), testosterone or GnRH\n* Pregnant or breast-feeding patient\n* Patients who have given birth or breastfed within 6 weeks before the inclusion visit\n* Patient unable to read French\n* Failure to obtain informed consent\n* Patient not affiliated with or not benefiting from a national health insurance scheme\n* Person under legal protection, guardianship or curatorship\n* Patient participating in other research involving the human person", "sex": "FEMALE", "minimumAge": "20 Years", "maximumAge": "38 Years", "stdAges": ["ADULT"], "studyPopulation": "Women with or without endometriosis", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"centralContacts": [{"name": "Alexandra ALVERGNE, PhD", "role": "CONTACT", "phone": "+334.67.14.46.15", "email": "alexandra.alvergne@umontpellier.fr"}, {"name": "Noémie RANISAVLJEVIC, MD", "role": "CONTACT", "phone": "+334.67.33.64.81", "email": "n-ranisavjlevic@chu-montpellier.fr"}], "overallOfficials": [{"name": "Alexandra ALVERGNE, PhD", "affiliation": "Centre National de la Recherche Scientifique, France", "role": "STUDY_CHAIR"}], "locations": [{"facility": "CHU de Montpellier", "status": "RECRUITING", "city": "Montpellier", "zip": "34295", "country": "France", "contacts": [{"name": "Noémie RANISAVLJEVIC, MD", "role": "CONTACT", "email": "n-ranisavljevic@chu-montpellier.fr"}, {"name": "Noémie RANISAVLJEVIC, MD", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Martha DURAES, MD", "role": "SUB_INVESTIGATOR"}], "geoPoint": {"lat": 43.61093, "lon": 3.87635}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}, {"id": "D000098845", "term": "Developmental Origins of Health and Disease"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}, {"id": "D011297", "term": "Prenatal Exposure Delayed Effects"}, {"id": "D049188", "term": "Prenatal Injuries"}, {"id": "D011248", "term": "Pregnancy Complications"}]}, "interventionBrowseModule": {"meshes": [{"id": "D001800", "term": "Blood Specimen Collection"}, {"id": "D013739", "term": "Testosterone"}], "ancestors": [{"id": "D013048", "term": "Specimen Handling"}, {"id": "D019411", "term": "Clinical Laboratory Techniques"}, {"id": "D019937", "term": "Diagnostic Techniques and Procedures"}, {"id": "D003933", "term": "Diagnosis"}, {"id": "D011677", "term": "Punctures"}, {"id": "D013514", "term": "Surgical Procedures, Operative"}, {"id": "D008919", "term": "Investigative Techniques"}, {"id": "D000737", "term": "Androstenols"}, {"id": "D000736", "term": "Androstenes"}, {"id": "D000731", "term": "Androstanes"}, {"id": "D013256", "term": "Steroids"}, {"id": "D000072473", "term": "Fused-Ring Compounds"}, {"id": "D011083", "term": "Polycyclic Compounds"}, {"id": "D045165", "term": "Testosterone Congeners"}, {"id": "D012739", "term": "Gonadal Steroid Hormones"}, {"id": "D042341", "term": "Gonadal Hormones"}, {"id": "D006728", "term": "Hormones"}, {"id": "D006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT02434640", "orgStudyIdInfo": {"id": "16742"}, "secondaryIdInfos": [{"id": "2014-005298-36", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Bayer", "class": "INDUSTRY"}, "briefTitle": "Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of BAY1128688 After Multiple Oral Administrations in Healthy Women", "officialTitle": "Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of BAY1128688 After Multiple Oral Administrations in Healthy Women"}, "statusModule": {"statusVerifiedDate": "2016-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2015-04"}, "primaryCompletionDateStruct": {"date": "2015-12", "type": "ACTUAL"}, "completionDateStruct": {"date": "2016-04", "type": "ACTUAL"}, "studyFirstSubmitDate": "2015-04-30", "studyFirstSubmitQcDate": "2015-04-30", "studyFirstPostDateStruct": {"date": "2015-05-05", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-05-18", "lastUpdatePostDateStruct": {"date": "2016-05-19", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Bayer", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The objective of this trial is to investigate the safety and tolerability of BAY1128688 and to determine the concentration of this substance in blood after repeated administration by the oral route. The investigational substance will be administered in tablet form to healthy women."}, "conditionsModule": {"conditions": ["Endometriosis"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 51, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "BAY1128688 [Dose1]", "type": "EXPERIMENTAL", "description": "BAY1128688 dose level 1", "interventionNames": ["Drug: BAY1128688"]}, {"label": "BAY1128688 [Dose2]", "type": "EXPERIMENTAL", "description": "BAY1128688 dose level 2", "interventionNames": ["Drug: BAY1128688"]}, {"label": "BAY1128688 [Dose3]", "type": "EXPERIMENTAL", "description": "BAY1128688 dose level 3", "interventionNames": ["Drug: BAY1128688"]}, {"label": "BAY1128688 [Dose4]", "type": "EXPERIMENTAL", "description": "BAY1128688 dose level 4", "interventionNames": ["Drug: BAY1128688"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo to match arm 1,2, 3 and 4", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "BAY1128688", "description": "Part A: Single dose and multiple dose for 14 days (postmenopausal women)", "armGroupLabels": ["BAY1128688 [Dose1]", "BAY1128688 [Dose2]", "BAY1128688 [Dose3]", "BAY1128688 [Dose4]"]}, {"type": "DRUG", "name": "Placebo", "description": "Part A: Single dose and multiple dose for 14 days (postmenopausal women)", "armGroupLabels": ["Placebo"]}, {"type": "DRUG", "name": "BAY1128688", "description": "Part B: Multiple dose for 28 days (premenopausal women)", "armGroupLabels": ["BAY1128688 [Dose2]", "BAY1128688 [Dose3]"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Frequency of Treatment Emergent Adverse Events (TEAEs) with severity grading", "timeFrame": "Up to 2 months"}, {"measure": "Cmax,md (maximum concentration) of BAY1128688 after multiple dose", "timeFrame": "0, 15, 30, 60, 90min, 2, 3, 4, 6, 8, 12, 24h (24h: QD only)"}, {"measure": "Cav,md (average steady state concentration) of BAY1128688 after multiple dose", "timeFrame": "0, 15, 30, 60, 90min, 2, 3, 4, 6, 8, 12, 24h (24h: QD only)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\nPART A\n\n* Postmenopausal state, revealed by\n\n  1. Medical history. One of the following:\n\n     * Natural menopause at least 12 months prior to first study drug administration,\n     * Surgical menopause by bilateral ovariectomy at least 3 months prior to first study drug administration) or\n     * Hysterectomy AND\n  2. Follicle-stimulating hormone (FSH) \\> 40 IU/L\n* Age 45 to 68 years\n\nPART B\n\n* Healthy female subjects\n\n  * Sterilized by tubal-ligation\n  * Pre-treatment menstrual cycle assessed as ovulatory\n* Completion of more than 3 menstrual cycles after delivery, abortion or lactation\n* Age 18 to 48 years\n\nExclusion Criteria:\n\n* Body mass index (kg/m2) greater or equal 32 (or less or equal 18)\n* Smoking: PART A: non-smoking; PART B: less than 10 cigarettes per day\n* Use of medicines including but not restricted to contraceptives and NSAIDs (details regarding previous use of medicines provided by the study center)\n* Ability and willingness to adhere to restrictions regarding diet (PART A and B) and to eat standardised meals (PART A only)\n* Significant diseases of the heart, gastrointestinal tract and/or liver and/or kidney and/or reproductive organs (present or in the past; details will be provided by the study center)\n* Recent infectious diseases (details will be provided by the study center)\n* Migraine or depression\n* Thyroid disease which requires treatment\n* Metabolic disorders, for example diabetes mellitus or hypertriglyceridemia\n* Drug or alcohol abuse; regular consumption of more than 800 ml of beer per day (or other drinks resembling 40 g of alcohol)", "healthyVolunteers": true, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "68 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Bayer Study Director", "affiliation": "Bayer", "role": "STUDY_DIRECTOR"}], "locations": [{"city": "Neu-Ulm", "state": "Bavaria", "zip": "89231", "country": "Germany", "geoPoint": {"lat": 48.39279, "lon": 10.01112}}, {"city": "Berlin", "state": "State of Berlin", "zip": "13353", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"city": "Berlin", "state": "State of Berlin", "zip": "14050", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}]}, "referencesModule": {"references": [{"pmid": "37306288", "type": "DERIVED", "citation": "Gashaw I, Reif S, Wiesinger H, Kaiser A, Zollmann FS, Scheerans C, Grevel J, Piraino P, Seidel H, Peters M, Rottmann A, Rohde B, Arlt W, Hilpert J. Novel aldo-keto reductase 1C3 inhibitor affects androgen metabolism but not ovarian function in healthy women: a phase 1 study. Eur J Endocrinol. 2023 Jul 10;188(7):578-591. doi: 10.1093/ejendo/lvad063."}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000729512", "term": "BAY1128688"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT03931915", "orgStudyIdInfo": {"id": "TAK-385/3-A"}, "organization": {"fullName": "ASKA Pharmaceutical Co., Ltd.", "class": "INDUSTRY"}, "briefTitle": "Clinical Study to Evaluate Efficacy and Safety of TAK-385 40 mg Compared With Leuprorelin in Patients With Endometriosis", "officialTitle": "Phase III Clinical Study to Evaluate Efficacy and Safety of TAK-385 40 mg Compared With Leuprorelin in Patients With Endometriosis"}, "statusModule": {"statusVerifiedDate": "2020-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2019-05-08", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2020-06-12", "type": "ACTUAL"}, "completionDateStruct": {"date": "2020-09-28", "type": "ACTUAL"}, "studyFirstSubmitDate": "2019-04-24", "studyFirstSubmitQcDate": "2019-04-26", "studyFirstPostDateStruct": {"date": "2019-04-30", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2020-12-10", "lastUpdatePostDateStruct": {"date": "2020-12-11", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "ASKA Pharmaceutical Co., Ltd.", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The objective is to evaluate the efficacy and safety of TAK-385 40 mg orally administrated once daily for 24 weeks compared with Leuprorelin \\[once/4 weeks, 3.75 or 1.88 mg subcutaneously (SC)/time\\] in patients with endometriosis.", "detailedDescription": "This study is a phase III, multicenter, randomized, double-blind, parallel-group study to investigate the efficacy and safety of TAK-385 40 mg once daily compared with leuprorelin (once/4 weeks, 3.75 or 1.88 mg SC/time) in premenopausal subjects ≥ 20 years of age with endometriosis. 320 women with endometriosis will be enrolled in the study. This study consists of screening of approximately 1 to 6 weeks, run-in of approximately 3 to 6 weeks, treatment of 24 weeks, and follow-up of 4 weeks. After signing the informed consent form, subjects should record their symptoms in the electronic patient diary every day. During run-in period, daily data will be collected in the electronic patient diary for calculation of the baseline values for the efficacy evaluation.Following run-in period, subjects will receive investigational products (TAK-385 + leuprorelin placebo or TAK-385 placebo + leuprorelin) under double blind. During this study, subjects will visit the study center to undergo the designated examinations and evaluations at each visit. Safety will be assessed throughout the study by monitoring adverse events, vital signs, physical examinations, clinical laboratory tests, 12-lead electrocardiograms (ECG), and assessments of bone mineral density.Subjects will visit the study center to undergo the designated examinations and evaluations at 28 days after final administration."}, "conditionsModule": {"conditions": ["Endometriosis"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 335, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "TAK-385", "type": "EXPERIMENTAL", "description": "TAK-385 40 mg administered orally once daily before breakfast + Leuprorelin placebo administered subcutaneously once every 4 weeks", "interventionNames": ["Drug: TAK-385"]}, {"label": "Leuprorelin acetate", "type": "ACTIVE_COMPARATOR", "description": "TAK-385 placebo administered orally once daily before breakfast + Leuprorelin acetate 1.88 mg / 3.75 mg administered subcutaneously once every 4 weeks", "interventionNames": ["Drug: Leuprorelin acetate"]}], "interventions": [{"type": "DRUG", "name": "TAK-385", "description": "TAK-385 40 mg tablets + Leuprorelin acetate placebo injection", "armGroupLabels": ["TAK-385"], "otherNames": ["relugolix"]}, {"type": "DRUG", "name": "Leuprorelin acetate", "description": "TAK-385 placebo tablets + Leuprorelin acetate 1.88 mg / 3.75 mg injection", "armGroupLabels": ["Leuprorelin acetate"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change of maximum Visual Analogue Scale (VAS) score for endometriosis associated pelvic pain", "description": "Pelvic pain will be assessed using the VAS (0 - 100) as pain evaluation scale", "timeFrame": "Baseline and the last 28 days of treatment period"}], "secondaryOutcomes": [{"measure": "Change of mean VAS score for endometriosis associated pelvic pain", "description": "Pelvic pain will be assessed using the VAS (0 - 100) as pain evaluation scale", "timeFrame": "Baseline and the last 28 days of treatment period"}, {"measure": "VAS score for endometriosis associated pelvic pain", "description": "Pelvic pain will be assessed using the VAS (0 - 100) as pain evaluation scale", "timeFrame": "Up to Week 24"}, {"measure": "Change of VAS score for endometriosis associated pelvic pain", "description": "Pelvic pain will be assessed using the VAS (0 - 100) as pain evaluation scale", "timeFrame": "Baseline and up to Week 24"}, {"measure": "VAS score for menstrual pain", "description": "Menstrual pain will be assessed using the VAS (0 - 100) as pain evaluation scale", "timeFrame": "Up to Week 24"}, {"measure": "Change of VAS score for menstrual pain", "description": "Menstrual pain will be assessed using the VAS (0 - 100) as pain evaluation scale", "timeFrame": "Baseline and up to Week 24"}, {"measure": "VAS score for endometriosis associated pelvic pain outside the menstruation period", "description": "Pelvic pain outside the menstruation period will be assessed using the VAS (0 - 100) as pain evaluation scale", "timeFrame": "Up to Week 24"}, {"measure": "Change of VAS score for endometriosis associated pelvic pain outside the menstruation period", "description": "Pelvic pain outside the menstruation period will be assessed using the VAS (0 - 100) as pain evaluation scale", "timeFrame": "Baseline and up to Week 24"}, {"measure": "VAS score for dyspareunia", "description": "Dyspareunia will be assessed using the VAS (0 - 100) as pain evaluation scale", "timeFrame": "Up to Week 24"}, {"measure": "Change of VAS score for dyspareunia", "description": "Dyspareunia will be assessed using the VAS (0 - 100) as pain evaluation scale", "timeFrame": "Baseline and up to Week 24"}, {"measure": "Adverse event", "timeFrame": "Up to Week 28"}, {"measure": "Bone mineral density", "timeFrame": "Up to Week 24"}, {"measure": "Serum concentrations of NTx (N-telopeptide)", "timeFrame": "Up to Week 24"}, {"measure": "Serum concentrations of BAP (Bone alkaline phosphatase)", "timeFrame": "Up to Week 24"}, {"measure": "Period from the last dose of study drug to return of menstrual cycles", "timeFrame": "From Week 24 to Week 28"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. The participant is a premenopausal Japanese woman aged 20 years or older at the time consent is obtained.\n2. The participant with endometriosis that falls under one of the following. However, in case of recurrence after surgery, it must be diagnosed again by either of the following.\n\n   * The participant who has been diagnosed with endometriosis by Laparotomy or Laparoscopy.\n   * The participant who has been confirmed ovarian chocolate cyst by Magnetic Resonance Imaging (MRI) or ultrasonic examination (vaginal, transabdominal or rectal).\n   * The participant who has been diagnosed with clinical endometriosis and has the symptom of either induration of Douglas cavum, restriction of uterine mobility or pelvic tenderness confirmed by internal or rectal examination.\n3. The participant must have dysmenorrhea or pelvic pain associated with endometriosis, of which either 1 or both should be at least \"moderate\" as determined by the investigator or subinvestigator using the B\\&B scale.\n4. The participant must have maximum VAS score \\> 30 for pelvic pain associated with endometriosis.\n5. The participant has experienced regular menstrual cycles (25 to 38 days) that should include menstrual bleeding of at least 3 consecutive days (at least 3 regular menstrual cycles to be confirmed).\n6. The participant agrees to use routinely adequate contraception from signing of informed consent throughout the duration of the study.\n\nExclusion Criteria:\n\n1. The participant has the following drug usage:\n\n   * Use of the following drugs within 24 weeks:bisphosphonate preparation or other investigational agent\n   * Use of the following drugs within 16 weeks (for 1-, 3- and 6-month sustained-release preparations, within 20, 28 and 40 weeks, respectively): gonadotropin-releasing hormone (GnRH) analogues, danazol, or aromatase inhibitors.\n   * Use of the following drugs within 8 weeks:dienogest, oral contraceptive or sex hormone preparations (norethindrone, norethisterone, medroxyprogesterone, estrogen, or other progestins, etc.)\n   * Use of the following drugs (excluding drugs for external use and supplements) within 4 weeks :anti-coagulant drugs, anti-platelet drugs, tranexamic acid, selective estrogen receptor modulators, activated vitamin D preparations, other vitamin D preparations, calcitonin, ipriflavone, steroid hormones, vitamin K preparations, teriparatide, or denosumab\n2. The participant has received TAK-385 (including placebo) in a previous clinical study.\n3. The participant has ovarian chocolate cyst of 10 cm or more and over 40 years old at the time imaging test is performed.\n4. The participant has a history of panhysterectomy or bilateral oophorectomy.\n5. The participant has had markedly abnormal uterine bleeding or anovulatory bleeding, as determined by the investigator or subinvestigator.\n6. The participant has nondiagnosable abnormal genital bleeding.\n7. The participant has a current history of thyroid gland disorder with irregular menstruation, or has a potential for irregular menstruation due to thyroid gland disorder, as determined by the investigator or subinvestigator.\n8. The participant has uterine fibroid requiring treatment.\n9. The participant has lower abdominal pain due to irritable bowel syndrome or severe interstitial cystitis.\n10. The participant has a previous or current history of pelvic inflammatory disease within 8 weeks.\n11. The participant has a previous or current history of osteoporosis, osteopenia, or other metabolic bone diseases.\n12. The participant has a positive cervical cytology result \\[other than Negative for Intraepithelial Lesion or Malignancy (NILM) in accordance with the 2014 Bethesda system\\]. However, the following participant may participate in this study; Atypical Squamous Cells of Undetermined Significance (ASC-US) and negative by high-risk Human Papillomavirus (HPV) test. And furthermore, regarding the participant with negative cervical cytology result conducted within 1 year, she may participate in this study without additional test.\n13. The participant has a malignant tumor or a history of a malignant tumor within 5 years.\n14. The participant has clinically significant cardiovascular disease or uncontrollable hypertension.\n15. The participant is inappropriate for participation in this study based on 12-lead ECG findings, as determined by the investigator or subinvestigator.\n16. The participant has active liver disease or jaundice, or has Alanine aminotransferase (ALT), Aspartate aminotransferase (AST) or total bilirubin \\> 1.5 times the upper limit of normal in the clinical laboratory tests.\n17. The participant has previous or current history of diseases considered to be inappropriate for participation in this study, including severe hepatic impairment, jaundice, renal impairment, cardiovascular disease, endocrine system disease, metabolic disorder, pulmonary disease, gastrointestinal disease, neural disease, urological disease, immune disease, or mental disorder (especially depression-like symptoms) or suicide attempt resulting from a mental disorder.\n18. The participant has a previous or current history of hypersensitivity to GnRH analogues, or has a previous or current history of severe hypersensitivity to other drugs.\n19. The participant is pregnant, lactating, or intending to become pregnant or to donate ova between the signing date of informed consent and 1 month after the end of the study.", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "20 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "Chubu Rosai Hospital", "city": "Aichi", "country": "Japan", "geoPoint": {"lat": 32.51879, "lon": 130.62158}}, {"facility": "Meitetsu Hospital", "city": "Aichi", "country": "Japan", "geoPoint": {"lat": 32.51879, "lon": 130.62158}}, {"facility": "Aiiku Ladies Clinic", "city": "Chiba", "country": "Japan", "geoPoint": {"lat": 35.6, "lon": 140.11667}}, {"facility": "Chiba Aoba Municipal Hospital", "city": "Chiba", "country": "Japan", "geoPoint": {"lat": 35.6, "lon": 140.11667}}, {"facility": "Tokyo Bay Urayasu Ichikawa Medical Center", "city": "Chiba", "country": "Japan", "geoPoint": {"lat": 35.6, "lon": 140.11667}}, {"facility": "Tsujinaka Hospital Kashiwanoha", "city": "Chiba", "country": "Japan", "geoPoint": {"lat": 35.6, "lon": 140.11667}}, {"facility": "Fujito Clinic", "city": "Hiroshima", "country": "Japan", "geoPoint": {"lat": 34.4, "lon": 132.45}}, {"facility": "Hashimoto Clinic", "city": "Hokkaido", "country": "Japan"}, {"facility": "Tokeidai Memorial Hospital", "city": "Hokkaido", "country": "Japan"}, {"facility": "Yoshio Obstetrics Gynecology Hospital", "city": "Hokkaido", "country": "Japan"}, {"facility": "Shinsuma Hospital", "city": "Hyōgo", "country": "Japan", "geoPoint": {"lat": 43.36667, "lon": 144.43333}}, {"facility": "Kagawa Prefectural Central Hospital", "city": "Kagawa", "country": "Japan", "geoPoint": {"lat": 34.06667, "lon": 131.03333}}, {"facility": "Takamatsu Red Cross Hospital", "city": "Kagawa", "country": "Japan", "geoPoint": {"lat": 34.06667, "lon": 131.03333}}, {"facility": "Fujisawa City Hospital", "city": "Kanagawa", "country": "Japan", "geoPoint": {"lat": 37.58333, "lon": 139.91667}}, {"facility": "Rinkan Clinic", "city": "Kanagawa", "country": "Japan", "geoPoint": {"lat": 37.58333, "lon": 139.91667}}, {"facility": "Second Kawasaki Saiwai Clinic", "city": "Kanagawa", "country": "Japan", "geoPoint": {"lat": 37.58333, "lon": 139.91667}}, {"facility": "Tawada Ladies Clinic", "city": "Kanagawa", "country": "Japan", "geoPoint": {"lat": 37.58333, "lon": 139.91667}}, {"facility": "Japanese Red Cross Kumamoto Hospital", "city": "Kumamoto", "country": "Japan", "geoPoint": {"lat": 32.80589, "lon": 130.69181}}, {"facility": "Kurashiki Medical Clinic", "city": "Okayama", "country": "Japan", "geoPoint": {"lat": 34.65, "lon": 133.93333}}, {"facility": "Chayamachi Ladies Clinic", "city": "Osaka", "country": "Japan", "geoPoint": {"lat": 34.69379, "lon": 135.50107}}, {"facility": "Hayakawa Clinic", "city": "Osaka", "country": "Japan", "geoPoint": {"lat": 34.69379, "lon": 135.50107}}, {"facility": "Minami-Morimachi Ladies Clinic", "city": "Osaka", "country": "Japan", "geoPoint": {"lat": 34.69379, "lon": 135.50107}}, {"facility": "Nomura Clinic Nanba", "city": "Osaka", "country": "Japan", "geoPoint": {"lat": 34.69379, "lon": 135.50107}}, {"facility": "Rikako Ladies Clinic", "city": "Osaka", "country": "Japan", "geoPoint": {"lat": 34.69379, "lon": 135.50107}}, {"facility": "Tanabe Ladies Clinic", "city": "Osaka", "country": "Japan", "geoPoint": {"lat": 34.69379, "lon": 135.50107}}, {"facility": "Yoshimura Ladies Clinic", "city": "Osaka", "country": "Japan", "geoPoint": {"lat": 34.69379, "lon": 135.50107}}, {"facility": "Dantsuka Clinic", "city": "Saitama", "country": "Japan", "geoPoint": {"lat": 35.90807, "lon": 139.65657}}, {"facility": "Kashiwazaki Ladies Clinic", "city": "Saitama", "country": "Japan", "geoPoint": {"lat": 35.90807, "lon": 139.65657}}, {"facility": "Maruyama Memorial General Hospital", "city": "Saitama", "country": "Japan", "geoPoint": {"lat": 35.90807, "lon": 139.65657}}, {"facility": "Kusatsu General Hospital", "city": "Shiga", "country": "Japan", "geoPoint": {"lat": 36.02247, "lon": 138.13005}}, {"facility": "Akasaka-Mitsuke Miyazaki Clinic", "city": "Tokyo", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}, {"facility": "Ginza Yoshida Hospital", "city": "Tokyo", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}, {"facility": "Hamada Hospital", "city": "Tokyo", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}, {"facility": "Ikebukuro Metroporitan Clinic", "city": "Tokyo", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}, {"facility": "NS Clinic", "city": "Tokyo", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}, {"facility": "Sei Women's Clinic", "city": "Tokyo", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}, {"facility": "Seijo Kinoshita Hospital", "city": "Tokyo", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}, {"facility": "Shimamura Memorial Hospital", "city": "Tokyo", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}, {"facility": "Toranomon Women's Clinic", "city": "Tokyo", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}, {"facility": "Yokokura Clinic", "city": "Tokyo", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}, {"facility": "Yukawa Women's Clinic", "city": "Tokyo", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}]}, "referencesModule": {"references": [{"pmid": "34895700", "type": "DERIVED", "citation": "Harada T, Osuga Y, Suzuki Y, Fujisawa M, Fukui M, Kitawaki J. Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain compared with leuprorelin in Japanese women: a phase 3, randomized, double-blind, noninferiority study. Fertil Steril. 2022 Mar;117(3):583-592. doi: 10.1016/j.fertnstert.2021.11.013. Epub 2021 Dec 8."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C561634", "term": "relugolix"}, {"id": "D016729", "term": "Leuprolide"}], "ancestors": [{"id": "D007987", "term": "Gonadotropin-Releasing Hormone"}, {"id": "D010906", "term": "Pituitary Hormone-Releasing Hormones"}, {"id": "D007028", "term": "Hypothalamic Hormones"}, {"id": "D036361", "term": "Peptide Hormones"}, {"id": "D006728", "term": "Hormones"}, {"id": "D006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D009479", "term": "Neuropeptides"}, {"id": "D010455", "term": "Peptides"}, {"id": "D000602", "term": "Amino Acids, Peptides, and Proteins"}, {"id": "D009842", "term": "Oligopeptides"}, {"id": "D009419", "term": "Nerve Tissue Proteins"}, {"id": "D011506", "term": "Proteins"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT00194233", "orgStudyIdInfo": {"id": "708870"}, "secondaryIdInfos": [{"id": "RRU008"}], "organization": {"fullName": "University of Pennsylvania", "class": "OTHER"}, "briefTitle": "Serum and Peritoneal Fluid Bank for Endometriosis Markers", "officialTitle": "Serum and Peritoneal Fluid Bank for Assessment of Markers of Endometriosis"}, "statusModule": {"statusVerifiedDate": "2016-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2003-11"}, "primaryCompletionDateStruct": {"date": "2007-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-06", "type": "ACTUAL"}, "studyFirstSubmitDate": "2005-09-13", "studyFirstSubmitQcDate": "2005-09-13", "studyFirstPostDateStruct": {"date": "2005-09-19", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-08-15", "lastUpdatePostDateStruct": {"date": "2016-08-16", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "Kurt T Barnhart, MD, MSCE", "oldOrganization": "University of Pennsylvania"}, "leadSponsor": {"name": "University of Pennsylvania", "class": "OTHER"}}, "descriptionModule": {"briefSummary": "The purpose of this study is to investigate differences in protein expression profiles of blood and peritoneal fluid samples obtained from patients who do, and those who do not, have endometriosis seen during laparoscopic surgery. These profiles may include both known and novel markers for diagnosing endometriosis."}, "conditionsModule": {"conditions": ["Endometriosis"], "keywords": ["Endometriosis"]}, "designModule": {"studyType": "OBSERVATIONAL", "designInfo": {"observationalModel": "CASE_CONTROL", "timePerspective": "PROSPECTIVE"}, "bioSpec": {"retention": "SAMPLES_WITH_DNA", "description": "Serum, Plasma, Peritoneal fluid"}, "enrollmentInfo": {"count": 300, "type": "ESTIMATED"}}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Undergoing laparoscopic surgery for one of the following indications:\n\n  1. infertility\n  2. pain\n  3. tubal sterilization\n* For cases, visualization of endometriosis\n* For controls, absence of endometriosis\n\nExclusion Criteria:\n\n* None", "healthyVolunteers": true, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "50 Years", "stdAges": ["ADULT"], "studyPopulation": "Women undergoing Laparoscopy at HUP", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"overallOfficials": [{"name": "Kurt T Barnhart, MD, MSCE", "affiliation": "University of Pennsylvania", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "University of Pennsylvania Reproductive Research Unit", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19104", "country": "United States", "geoPoint": {"lat": 39.95238, "lon": -75.16362}}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D004715", "term": "Endometriosis"}], "ancestors": [{"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000091662", "term": "Genital Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT06009640", "orgStudyIdInfo": {"id": "2022/514/220/8"}, "organization": {"fullName": "Dr. Lutfi Kirdar Kartal Training and Research Hospital", "class": "OTHER_GOV"}, "briefTitle": "Integration of Intraoperative Neuromonitoring Into Decompression Surgery", "officialTitle": "Integration of Intraoperative Neuromonitoring Into Laparoscopic Pelvic Nerve Decompression Surgery"}, "statusModule": {"statusVerifiedDate": "2023-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2021-12-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2022-02-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2022-03-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2023-08-11", "studyFirstSubmitQcDate": "2023-08-18", "studyFirstPostDateStruct": {"date": "2023-08-24", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-08-23", "lastUpdatePostDateStruct": {"date": "2023-08-25", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Elif Cansu Gundogdu", "investigatorTitle": "Specialist doctor", "investigatorAffiliation": "Dr. Lutfi Kirdar Kartal Training and Research Hospital"}, "leadSponsor": {"name": "Dr. Lutfi Kirdar Kartal Training and Research Hospital", "class": "OTHER_GOV"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "To describe a novel technique by integrating the intraoperative neurophysiological monitoring (IONM) into laparoscopy to protect pelvic nerves by continuously monitoring when they are at risk during surgery.", "detailedDescription": "We integrated intraoperative neuromonitoring system into laparoscopic lumbosacral plexus nerve decompression surgery and simultaneusly recorded nerve roots from lumbar 5 to sacral 4 during the operation. Diseases that cause pelvic nerve compression such as abnormal vascular conflict, aberrant priformis muscle, and endometriosis have settled in hard-to-reach deep areas of the pelvis. Sacral and sciatic nerves might be damaged when performing decompression surgery in these deep pelvic areas. We described a novel technique by integrating the intraoperative neurophysiological monitoring (IONM) into laparoscopy to protect pelvic nerves by continuously monitoring when they are at risk during surgery."}, "conditionsModule": {"conditions": ["Nerve Entrapments", "Pelvic Pain"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 10, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Intraoperative neurophysiological monitoring for decompression surgery", "type": "EXPERIMENTAL", "description": "we integrated intraoperative neuromonitoring system into laparoscopic lumbosacral plexus nerve decompression surgery and simultaneusly recorded nerve roots from lumbar 5 to sacral 4 during the operation. Diseases that cause pelvic nerve compression such as abnormal vascular conflict, aberrant priformis muscle, and endometriosis have settled in hard-to-reach deep areas of the pelvis. These areas can be accesed more easily with by laparoscopy, which provides better magnification and visualization. Sacral and sciatic nerves might be damaged when performing decompression surgery in these deep pelvic areas. Patients who gave informed consent and underwent surgical treatment for a proven diagnosis of lumbosacral plexus nerve entrapment were included in the study.", "interventionNames": ["Device: Intraoperative neurophysiological monitoring with Nicolet Endeavor IOM Machine"]}], "interventions": [{"type": "DEVICE", "name": "Intraoperative neurophysiological monitoring with Nicolet Endeavor IOM Machine", "description": "Integration of intraoperative neurophysiological monitoring (IONM) into laparoscopic decompression surgery to protect pelvic nerves by continuously monitoring when they are at risk during surgery.", "armGroupLabels": ["Intraoperative neurophysiological monitoring for decompression surgery"], "otherNames": ["Nicolet Endeavor IOM Machine"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Pain score assessment with visual Analogic Scale (VAS)", "description": "Pain symptoms (Dysmenorrhea, dyspareunia, dyschezia, sciatic pain, chronic pelvic pain) were evaluated preoperatively , and re-evaluated at the postoperative first month.", "timeFrame": "1 month"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with symptoms of chronic pelvic pain , dyspareunia, dysmenorrhea and severe, burning sharp pain on the lower extremity dermatomes, which had been present for at least one year were included.\n\nExclusion Criteria:\n\n* Patients who underwent laparoscopic decompression surgery but did not give informed consent were not included in the study.", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Elif Gundogdu, M.D.Dr", "affiliation": "Kartal Dr. Lutfi Kirdar City Hospital", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Kartal Dr. Lutfi Kirdar City Hospital", "city": "Istanbul", "state": "Kartal", "country": "Turkey (Türkiye)", "geoPoint": {"lat": 41.01384, "lon": 28.94966}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-11-04"}, "conditionBrowseModule": {"meshes": [{"id": "D009408", "term": "Nerve Compression Syndromes"}, {"id": "D017699", "term": "Pelvic Pain"}], "ancestors": [{"id": "D010523", "term": "Peripheral Nervous System Diseases"}, {"id": "D009468", "term": "Neuromuscular Diseases"}, {"id": "D009422", "term": "Nervous System Diseases"}, {"id": "D010146", "term": "Pain"}, {"id": "D009461", "term": "Neurologic Manifestations"}, {"id": "D012816", "term": "Signs and Symptoms"}, {"id": "D013568", "term": "Pathological Conditions, Signs and Symptoms"}]}, "interventionBrowseModule": {"meshes": [{"id": "D064795", "term": "Intraoperative Neurophysiological Monitoring"}], "ancestors": [{"id": "D016343", "term": "Monitoring, Intraoperative"}, {"id": "D008991", "term": "Monitoring, Physiologic"}, {"id": "D019937", "term": "Diagnostic Techniques and Procedures"}, {"id": "D003933", "term": "Diagnosis"}, {"id": "D064926", "term": "Neurophysiological Monitoring"}, {"id": "D013514", "term": "Surgical Procedures, Operative"}]}}, "hasResults": false}], "nextPageToken": "ZVNj7o2Elu8o3lptV96h6rb2mpOQJJxpYfSg3fIW"}